Authors,Author(s) ID,Title,Year,Source title,Volume,Issue,Art. No.,Page start,Page end,Page count,Cited by,DOI,Link,Affiliations,Authors with affiliations,Abstract,Author Keywords,Index Keywords,Molecular Sequence Numbers,Chemicals/CAS,Tradenames,Manufacturers,Funding Details,Funding Text 1,Funding Text 2,Funding Text 3,References,Correspondence Address,Editors,Sponsors,Publisher,Conference name,Conference date,Conference location,Conference code,ISSN,ISBN,CODEN,PubMed ID,Language of Original Document,Abbreviated Source Title,Document Type,Publication Stage,Access Type,Source,EID
"Aguirre-Plans J., Piñero J., Sanz F., Furlong L.I., Fernandez-Fuentes N., Oliva B., Guney E.","57200855561;55220852900;7102263897;34770469800;8557712800;35500780700;23477104200;","GUILDify v2.0: A Tool to Identify Molecular Networks Underlying Human Diseases, Their Comorbidities and Their Druggable Targets",2019,"Journal of Molecular Biology","431","13",,"2477","2484",,1,"10.1016/j.jmb.2019.02.027","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062913663&doi=10.1016%2fj.jmb.2019.02.027&partnerID=40&md5=56de97fe6d2836012b57685018cbddc6","Structural Bioinformatics Group, Research Programme on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia  08003, Spain; Integrative Biomedical Informatics Group, Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia  08003, Spain; Department of Biosciences, U Science Tech, Universitat de Vic-Universitat Central de Catalunya, Vic, Catalonia  08500, Spain; Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3EB, United Kingdom; Department of Pharmacology and Personalised Medicine, CARIM, FHML, Maastricht University, Universiteitssingel 50, Maastricht, ER  6229, Netherlands","Aguirre-Plans, J., Structural Bioinformatics Group, Research Programme on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia  08003, Spain; Piñero, J., Integrative Biomedical Informatics Group, Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia  08003, Spain; Sanz, F., Integrative Biomedical Informatics Group, Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia  08003, Spain; Furlong, L.I., Integrative Biomedical Informatics Group, Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia  08003, Spain; Fernandez-Fuentes, N., Department of Biosciences, U Science Tech, Universitat de Vic-Universitat Central de Catalunya, Vic, Catalonia  08500, Spain, Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3EB, United Kingdom; Oliva, B., Structural Bioinformatics Group, Research Programme on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia  08003, Spain; Guney, E., Integrative Biomedical Informatics Group, Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia  08003, Spain, Department of Pharmacology and Personalised Medicine, CARIM, FHML, Maastricht University, Universiteitssingel 50, Maastricht, ER  6229, Netherlands","The genetic basis of complex diseases involves alterations on multiple genes. Unraveling the interplay between these genetic factors is key to the discovery of new biomarkers and treatments. In 2014, we introduced GUILDify, a web server that searches for genes associated to diseases, finds novel disease genes applying various network-based prioritization algorithms and proposes candidate drugs. Here, we present GUILDify v2.0, a major update and improvement of the original method, where we have included protein interaction data for seven species and 22 human tissues and incorporated the disease–gene associations from DisGeNET. To infer potential disease relationships associated with multi-morbidities, we introduced a novel feature for estimating the genetic and functional overlap of two diseases using the top-ranking genes and the associated enrichment of biological functions and pathways (as defined by GO and Reactome). The analysis of this overlap helps to identify the mechanistic role of genes and protein–protein interactions in comorbidities. Finally, we provided an R package, guildifyR, to facilitate programmatic access to GUILDify v2.0 (http://sbi.upf.edu/guildify2) © 2019 Elsevier Ltd","disease comorbidity; drug repurposing; network analysis; systems medicine; target prioritization","access to information; Article; asthma; comorbidity; drug targeting; gene function; gene identification; genetic algorithm; genetic association; genetic disorder; human; Internet; non small cell lung cancer; priority journal; protein interaction; protein protein interaction; rheumatoid arthritis; software",,,,,"Ministry of Economy

116030, 777365

European Federation of Pharmaceutical Industries and Associations

H2020 Euratom, EURATOM: 676559, 634143

Ministerio de Economía y Competitividad: RYC-2015-17519, PRB2-ISCIII, PT13/0001/0023, MDM-2014-0370, BIO2017-85329-R

Federación Española de Enfermedades Raras: CP10/00524, CPII16/00026, PI13/00082","J.A.P. and E.G. would like to acknowledge the technical support from Research Programme on Biomedical Informatics IT team, in particular A. Gonzalez Pauner and M.A. Sánchez Gómez. The authors received support from the following: + D + i 2013-2016 funded by ISCIII–FEDER ( PI13/00082 , CP10/00524 , CPII16/00026 ); IMI-JU under grants agreements no. 116030 (TransQST) and no. 777365 (eTRANSAFE), resources of which are composed of financial contribution from the EU-FP7 ( FP7/2007- 2013 ) and EFPIA companies in kind contribution; the EU H2020 Programme 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate); the Spanish Ministry of Economy (MINECO) ( BIO2017-85329-R , RYC-2015-17519 ); and “Unidad de Excelencia María de Maeztu,” funded by the Spanish Ministry of Economy (ref.: MDM-2014-0370 ). The Research Programme on Biomedical Informatics is a member of the Spanish National Bioinformatics Institute, PRB2-ISCIII, and is supported by Grant PT13/0001/0023 of the PE I ISCIII and FEDER . Conflicts of Interest Statement: None declared. Appendix A",,,"Wangler, M.F., Yamamoto, S., Chao, H.-T., Posey, J.E., Westerfield, M., Postlethwait, J., Hieter, P., Bellen, H.J., Model organisms facilitate rare disease diagnosis and therapeutic research (2017) Genetics., 207, pp. 9-27; Bromberg, Y., Chapter 15: disease gene prioritization (2013) PLoS Comput. Biol., 9; Menche, J., Sharma, A., Kitsak, M., Ghiassian, S.D., Vidal, M., Loscalzo, J., Barabási, A.-L., Uncovering disease-disease relationships through the incomplete interactome (2014) Science (80-.), 347. , (1257601-1-1257601–8); Wang, X., Gulbahce, N., Yu, H., Network-based methods for human disease gene prediction (2011) Brief. Funct. Genomics, 10, pp. 280-293; Ghiassian, S.D., Menche, J., Barabási, A.L., A DIseAse MOdule Detection (DIAMOnD) algorithm derived from a systematic analysis of connectivity patterns of disease proteins in the human interactome (2015) PLoS Comput. Biol., 11; Nitsch, D., Tranchevent, L.C., Gonalves, J.P., Vogt, J.K., Madeira, S.C., Moreau, Y., PINTA: a web server for network-based gene prioritization from expression data (2011) Nucleic Acids Res., 39, pp. 334-338; Zuberi, K., Franz, M., Rodriguez, H., Montojo, J., Lopes, C.T., Bader, G.D., Morris, Q., GeneMANIA prediction server 2013 update (2013) Nucleic Acids Res., 41, pp. 115-122; Gottlieb, A., Magger, O., Berman, I., Ruppin, E., Sharan, R., Principle: a tool for associating genes with diseases via network propagation (2011) Bioinformatics., 27, pp. 3325-3326; Kacprowski, T., Doncheva, N.T., Albrecht, M., NetworkPrioritizer: a versatile tool for network-based prioritization of candidate disease genes or other molecules (2013) Bioinformatics., 29, pp. 1471-1473; Guney, E., García-garcía, J., Oliva, B., GUILDify: a web server for phenotypic characterization of genes through biological data integration and network-based prioritization algorithms (2014) Bioinformatics., 30, pp. 1789-1790; Guney, E., Oliva, B., Exploiting protein–protein interaction networks for genome-wide disease–gene prioritization (2012) PLoS One, 7; Rubio-Perez, C., Guney, E., Aguilar, D., Piñero, J., Garcia-Garcia, J., Iadarola, B., Sanz, F., Oliva, B., Genetic and functional characterization of disease associations explains comorbidity (2017) Sci. Rep., 7; Halakou, F., Sen Kilic, E., Cukuroglu, E., Keskin, O., Gursoy, A., Enriching traditional protein–protein interaction networks with alternative conformations of proteins (2017) Sci. Rep., 7; Kominakis, A., Hager-Theodorides, A.L., Zoidis, E., Saridaki, A., Antonakos, G., Tsiamis, G., Combined GWAS and ‘guilt by association’-based prioritization analysis identifies functional candidate genes for body size in sheep (2017) Genet. Sel. Evol., 49; Tejera, E., Cruz-Monteagudo, M., Burgos, G., Sánchez, M.E., Sánchez-Rodríguez, A., Pérez-Castillo, Y., Borges, F., Rebelo, I., Consensus strategy in genes prioritization and combined bioinformatics analysis for preeclampsia pathogenesis (2017) BMC Med. Genet., 10; Aguirre-Plans, J., Piñero, J., Menche, J., Sanz, F., Furlong, L.I., Schmidt, H.H.H.W., Oliva, B., Guney, E., Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology (2018) Pharmaceuticals., 11, p. 61; Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Wilson, M., DrugBank 5.0: a major update to the DrugBank database for 2018 (2018) Nucleic Acids Res., 46, pp. D1074-D1082; Cotto, K.C., Wagner, A.H., Feng, Y., Kiwala, S., Coffman, C., Spies, G., Wollam, A., Griffith, M., DGIdb 3.0: a redesign and expansion of the drug–gene interaction database (2018) Nucleic Acids Res., 46, pp. 1068-1073; Ursu, O., Holmes, J., Knockel, J., Bologa, C.G., Yang, J.J., Mathias, S.L., Nelson, S.J., Oprea, T.I., DrugCentral: online drug compendium (2017) Nucleic Acids Res., 45, pp. 932-939; Gaulton, A., Hersey, A., Patr, A., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Smit, I., The ChEMBL database in 2017 (2017) Nucleic Acids Res., 45, pp. 945-954; Kitsak, M., Sharma, A., Menche, J., Guney, E., Ghiassian, S.D., Loscalzo, J., Barabási, A.L., Tissue Specificity of human disease module (2016) Sci. Rep., 6; G. Consortium, Genetic effects on gene expression across human tissues (2017) Nature., 550, pp. 204-213; Piñero, J., Bravo, Á., Queralt-Rosinach, N., Gutiérrez-Sacristán, A., Deu-Pons, J., Centeno, E., García-García, J., Furlong, L.I., DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants (2017) Nucleic Acids Res., 45, pp. D833-D839; The UniProt Consortium, UniProt: the universal protein knowledgebase (2017) Nucleic Acids Res., 45, pp. D158-D169; Davis, A.P., Grondin, C.J., Johnson, R.J., Sciaky, D., King, B.L., McMorran, R., Wiegers, J., Mattingly, C.J., The comparative toxicogenomics database: update 2017 (2017) Nucleic Acids Res., 45, pp. D972-D978; Landrum, M.J., Lee, J.M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Maglott, D.R., ClinVar: public archive of interpretations of clinically relevant variants (2016) Nucleic Acids Res., 44, pp. D862-D868; Rath, A., Olry, A., Dhombres, F., Brandt, M.M., Urbero, B., Ayme, S., Representation of rare diseases in health information systems: the orphanet approach to serve a wide range of end users (2012) Hum. Mutat., 33, pp. 803-808; MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., Parkinson, H., The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog) (2017) Nucleic Acids Res., 45, pp. D896-D901; Gutiérrez-Sacristán, A., Bravo, À., Portero, M., Valverde, O., Armario, A., Blanco-Gandía, M.C., Farré, A., Furlong, L.I., Text mining and expert curation to develop a database on psychiatric diseases and their genes (2017) Database., 1650, pp. 48-55; Köhler, S., Vasilevsky, N.A., Engelstad, M., Foster, E., McMurry, J., Aymé, S., Baynam, G., Robinson, P.N., The human phenotype ontology in 2017 (2017) Nucleic Acids Res., 45, pp. D865-D876; Garcia-Garcia, J., Guney, E., Aragues, R., Planas-Iglesias, J., Oliva, B., Biana: a software framework for compiling biological interactions and analyzing networks (2010) BMC Bioinformatics., 11, p. 56; Kibbe, W.A., Arze, C., Felix, V., Mitraka, E., Bolton, E., Fu, G., Mungall, C.J., Schriml, L.M., Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data (2015) Nucleic Acids Res., 43, pp. 1071-1078; Franz, M., Lopes, C.T., Huck, G., Dong, Y., Sumer, O., Bader, G.D., Cytoscape.js: a graph theory library for visualisation and analysis (2015) Bioinformatics., 32, pp. 309-311; Rolfes, M.C., Juhn, Y.J., Wi, S.I., Sheen, Y.H., Asthma and the risk of rheumatoid arthritis: an insight into the heterogeneity and phenotypes of asthma (2017) Tuberc. Respir. Dis. (Seoul), 80, pp. 113-135; Sharma, A., Menche, J., Chris Huang, C., Ort, T., Zhou, X., Kitsak, M., Sahni, N., Barabási, A.L., A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma (2014) Hum. Mol. Genet., 24, pp. 3005-3020; Bethune, G., Bethune, D., Ridgway, N., Xu, Z., Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update (2010) J. Thorac. Dis., 2, pp. 48-51; Rubio-Perez, C., Tamborero, D., Schroeder, M.P., Antolín, A.A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Lopez-Bigas, N., In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities (2015) Cancer Cell, 27, pp. 382-396; Zhou, J., Zhang, S., Chen, X., Zheng, X., Yao, Y., Lu, G., Zhou, J., Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer (2017) Cancer Lett., 408, pp. 130-137","Oliva, B.; Structural Bioinformatics Group, Research Programme on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu FabraSpain; email: baldo.oliva@upf.edu",,,"Academic Press",,,,,00222836,,JMOBA,"30851278","English","J. Mol. Biol.",Article,"Final",,Scopus,2-s2.0-85062913663
"Gea J., Pascual S., Castro-Acosta A., Hernández-Carcereny C., Castelo R., Márquez-Martín E., Montón C., Palou A., Faner R., Furlong L.I., Seijo L., Sanz F., Torà M., Vilaplana C., Casadevall C., López-Campos J.L., Monsó E., Peces-Barba G., Cosío B.G., Agustí A., Admetlló M., Alvarez-Martínez C., Barreiro E., Casals F., Córdova R., García M., González-García J.G., Márquez E., Ormaza M.J., Puigdevall P., Seijó L., Torralba Y., en representacion del grupo BIOMEPOC, Anexo. Miembros del grupo BIOMEPOC","7004959809;54939778800;57204242583;36631973700;6601957393;8894975000;6603958638;25823362300;6507910788;34770469800;57202567045;7102263897;8739046800;38662075400;56029286000;32667948000;55041612300;6602094485;8527027300;7101749378;37020152700;6602791169;7005260014;6701339869;55964520500;56905844000;57190139169;16683670200;57204245100;57204243502;57202567045;8652429300;","The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease [Proyecto de biomarcadores y perfiles clínicos personalizados en la enfermedad pulmonar obstructiva crónica (proyecto BIOMEPOC)]",2019,"Archivos de Bronconeumologia","55","2",,"93","99",,3,"10.1016/j.arbres.2018.07.026","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060345388&doi=10.1016%2fj.arbres.2018.07.026&partnerID=40&md5=ff9a92f33df811785a5481cae2d31725","Servicio de Neumología, Hospital del Mar - IMIM. Departamento CEXS, Universitat Pompeu Fabra (UPF), Barcelona, Spain; Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Servicio de Neumología, Hospital 12 de Octubre, Madrid, Spain; Servicio de Neumología (Instituto Clínic de Respiratorio) y Dispositivo Transversal de Hospitalización a Domicilio (Dirección Médica y de Enfermería), Hospital ClínicFundació Clínic per la Recerca BiomèdicaUniversitat de Barcelona, IDIBAPS, Barcelona, Spain; Grup de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, Department CEXS, UPF, Barcelona, Spain; Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain; Servicio de Neumología, Consorci Sanitari Parc TaulíUniversitat Autònoma de Barcelona, Sabadell, Spain; Servicio de Neumología, Hospital Son Espases - Instituto de Investigación Sanitaria de Palma (IdISBa), Palma de Mallorca, Spain; Servicio de Neumología, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain; Clínica Universidad de Navarra, Madrid, Spain; Biobanco del IMIM - Hospital del Mar (MARBiobanc), Barcelona, Spain; Laboratorio de Referencia de Cataluña, El Prat de Llobregat, Spain; Hospital del Mar, CIBERES, Barcelona, Spain; Hospital Clínic, Universitat de Barcelona, CIBERES, Barcelona, Spain; Hospital 12 de Octubre, CIBERES, Madrid, Spain; Hospital del Mar, IMIM, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; IMIM, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain; Hospital Son Espases, CIBERES, Palma, Spain; Hospital Son Espases – Instituto de Investigación Sanitaria de Baleares (IdISBa), CIBERES, Palma de Mallorca, Spain; Fundació Clínic per la Recerca Biomédica, CIBERES, Barcelona, Spain; IMIM, Barcelona, Spain; Consorci Hospitalari de Parc Taulí, Universitat Autònoma de Barcelona, CIBERES, Sabadell, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Universidad de Sevilla, CIBERES, Sevilla, Spain; Consorci Sanitari Parc Taulí, Universitat Autònoma de Barcelona, CIBERES, Sabadell, Spain; Hospital Son Espases, CIBERES, Palma de Mallorca, Spain; Fundación Jiménez Díaz, Universidad Autónoma de Madrid, CIBERES, Madrid, Spain; IMIM, Universitat Pompeu Fabra, Barcelona, Spain; Fundación Jiménez Díaz, Universidad Autónoma de Madrid y Universidad de Navarra, CIBERES, Madrid, Spain; IMIM, Universidad Autónoma de Barcelona, Barcelona, Spain; Hospital Clínic, CIBERES, Barcelona, Spain; Laboratorio de Referencia de Catalunya, El Prat de Llobregat, Spain","Gea, J., Servicio de Neumología, Hospital del Mar - IMIM. Departamento CEXS, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Hospital del Mar, IMIM, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; Pascual, S., Servicio de Neumología, Hospital del Mar - IMIM. Departamento CEXS, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Hospital del Mar, IMIM, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; Castro-Acosta, A., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología, Hospital 12 de Octubre, Madrid, Spain, Hospital 12 de Octubre, CIBERES, Madrid, Spain; Hernández-Carcereny, C., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología (Instituto Clínic de Respiratorio) y Dispositivo Transversal de Hospitalización a Domicilio (Dirección Médica y de Enfermería), Hospital ClínicFundació Clínic per la Recerca BiomèdicaUniversitat de Barcelona, IDIBAPS, Barcelona, Spain, Hospital Clínic, Universitat de Barcelona, CIBERES, Barcelona, Spain; Castelo, R., Grup de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, Department CEXS, UPF, Barcelona, Spain, Universitat Pompeu Fabra, Barcelona, Spain; Márquez-Martín, E., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain; Montón, C., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología, Consorci Sanitari Parc TaulíUniversitat Autònoma de Barcelona, Sabadell, Spain, Consorci Sanitari Parc Taulí, Universitat Autònoma de Barcelona, CIBERES, Sabadell, Spain; Palou, A., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología, Hospital Son Espases - Instituto de Investigación Sanitaria de Palma (IdISBa), Palma de Mallorca, Spain, Hospital Son Espases, CIBERES, Palma de Mallorca, Spain; Faner, R., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología (Instituto Clínic de Respiratorio) y Dispositivo Transversal de Hospitalización a Domicilio (Dirección Médica y de Enfermería), Hospital ClínicFundació Clínic per la Recerca BiomèdicaUniversitat de Barcelona, IDIBAPS, Barcelona, Spain, Fundació Clínic per la Recerca Biomédica, CIBERES, Barcelona, Spain; Furlong, L.I., Grup de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, Department CEXS, UPF, Barcelona, Spain, IMIM, Barcelona, Spain; Seijo, L., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain, Clínica Universidad de Navarra, Madrid, Spain, Fundación Jiménez Díaz, Universidad Autónoma de Madrid y Universidad de Navarra, CIBERES, Madrid, Spain; Sanz, F., Grup de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, Department CEXS, UPF, Barcelona, Spain, IMIM, Universitat Pompeu Fabra, Barcelona, Spain; Torà, M., Biobanco del IMIM - Hospital del Mar (MARBiobanc), Barcelona, Spain, IMIM, Universidad Autónoma de Barcelona, Barcelona, Spain; Vilaplana, C., Laboratorio de Referencia de Cataluña, El Prat de Llobregat, Spain, Laboratorio de Referencia de Catalunya, El Prat de Llobregat, Spain; Casadevall, C., Servicio de Neumología, Hospital del Mar - IMIM. Departamento CEXS, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, IMIM, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; López-Campos, J.L., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, CIBERES, Sevilla, Spain; Monsó, E., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología, Consorci Sanitari Parc TaulíUniversitat Autònoma de Barcelona, Sabadell, Spain, Consorci Sanitari Parc Taulí, Universitat Autònoma de Barcelona, CIBERES, Sabadell, Spain; Peces-Barba, G., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, CIBERES, Madrid, Spain; Cosío, B.G., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología, Hospital Son Espases - Instituto de Investigación Sanitaria de Palma (IdISBa), Palma de Mallorca, Spain, Hospital Son Espases – Instituto de Investigación Sanitaria de Baleares (IdISBa), CIBERES, Palma de Mallorca, Spain; Agustí, A., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología (Instituto Clínic de Respiratorio) y Dispositivo Transversal de Hospitalización a Domicilio (Dirección Médica y de Enfermería), Hospital ClínicFundació Clínic per la Recerca BiomèdicaUniversitat de Barcelona, IDIBAPS, Barcelona, Spain, Hospital Clínic, Universitat de Barcelona, CIBERES, Barcelona, Spain; Admetlló, M., Hospital del Mar, CIBERES, Barcelona, Spain; Alvarez-Martínez, C., Hospital 12 de Octubre, CIBERES, Madrid, Spain; Barreiro, E., Hospital del Mar, IMIM, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; Casals, F., Universitat Pompeu Fabra, Barcelona, Spain; Córdova, R., Hospital Son Espases, CIBERES, Palma, Spain; García, M., Consorci Hospitalari de Parc Taulí, Universitat Autònoma de Barcelona, CIBERES, Sabadell, Spain; González-García, J.G., Hospital del Mar, Barcelona, Spain; Márquez, E., Hospital Universitario Virgen del Rocío, Universidad de Sevilla, CIBERES, Sevilla, Spain; Ormaza, M.J., Consorci Sanitari Parc Taulí, Universitat Autònoma de Barcelona, CIBERES, Sabadell, Spain; Puigdevall, P., Universitat Pompeu Fabra, Barcelona, Spain; Seijó, L., Centro de Investigación Biomédica en Red, Área de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain, Servicio de Neumología, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain, Clínica Universidad de Navarra, Madrid, Spain, Fundación Jiménez Díaz, Universidad Autónoma de Madrid y Universidad de Navarra, CIBERES, Madrid, Spain; Torralba, Y., Hospital Clínic, CIBERES, Barcelona, Spain; en representacion del grupo BIOMEPOC; Anexo. Miembros del grupo BIOMEPOC","Chronic obstructive pulmonary disease (COPD) is an entity with a heterogeneous presentation. For this reason, attempts have been made to characterize different phenotypes and endotypes to enable a more individualized approach. The aim of the Biomarkers in COPD (BIOMEPOC) project is to identify useful biomarkers in blood to improve the characterization of patients. Clinical data and blood samples from a group of patients and healthy controls will be analyzed. The project will consist of an exploration phase and a validation phase. Analytical parameters in blood will be determined using standard techniques and certain ‘omics’ (transcriptomics, proteomics, and metabolomics). The former will be hypothesis-driven, whereas the latter will be exploratory. Finally, a multilevel analysis will be conducted. Currently, 269 patients and 83 controls have been recruited, and sample processing is beginning. Our hope is to use the results to identify new biomarkers that, alone or combined, will allow a better characterization of patients. © 2018 SEPAR","Biological markers; COPD; Endotypes; Multilevel analysis; Personalized medicine","biological marker; protein; transcriptome; analytical parameters; Article; blood level; chronic obstructive lung disease; controlled study; exploratory research; human; major clinical study; metabolomics; proteomics; transcriptomics; validation study; aged; blood sampling; disease severity; female; forced expiratory volume; hypothesis; male; metabolite; molecular interaction; patient coding; screening test",,"protein, 67254-75-5",,,,,,,"Fletcher, C., Peto, R., The natural history of chronic airflow obstruction (1977) Br Med J., 1, pp. 1645-1648; Vogelmeier, C.F., Criner, G.J., Martínez, F.J., Anzueto, A., Barnes, P.J., Bourbeau, J., Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD executive summary (2017) Arch Bronconeumol., 53, pp. 128-149; Soriano, J.B., Lamprecht, B., Chronic obstructive pulmonary disease: A worldwide problem (2012) Med Clin North Am., 96, pp. 671-680; Orozco-Levi, M., Garcia-Aymerich, J., Villar, J., Ramírez-Sarmiento, A., Antó, J.M., Gea, J., Wood smoke exposure and risk of chronic obstructive pulmonary disease (2006) Eur Respir J., 27, pp. 542-546; Agustí, A., Faner, R., Systemic inflammation and comorbidities in chronic obstructive pulmonary disease (2012) Proc Am Thorac Soc., 9, pp. 43-46; Izquierdo, J.L., Comorbidities in chronic obstructive pulmonary disease (2016) Arch Bronconeumol., 52, pp. 547-548; Vestbo, J., COPD: Definition and phenotypes (2014) Clin Chest Med., 35, pp. 1-6; Plaza, V., Álvarez, F., Calle, M., Casanova, C., Cosío, B.G., López-Viña, A., Consensus on the asthma-COPD overlap syndrome (ACOS) Between the Spanish COPD guidelines (GesEPOC) and the Spanish guidelines on the management of asthma (GEMA) (2017) Arch Bronconeumol., 53, pp. 443-449; Miravitlles, M., Soler-Cataluña, J.J., Calle, M., Molina, J., Almagro, P., Quintano, J.A., Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017 Pharmacological Treatment of Stable Phase (2017) Arch Bronconeumol., 53, pp. 324-335; Garcia-Aymerich, J., Gómez, F.P., Benet, M., Farrero, E., Basagaña, X., Gayete, À., Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes (2011) Thorax., 66, pp. 430-437; Agustí, A., Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? (2013) Ann Am Thorac Soc., 10, pp. S125-S130; Agustí, A., Edwards, L.D., Rennard, S.I., MacNee, W., Tal-Singer, R., Miller, B.E., Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype (2012) PLoS One., 7, p. e37483; Agusti, A., MacNee, W., The COPD control panel: Towards personalised medicine in COPD (2013) Thorax., 68, pp. 687-690; Agusti, A., Gea, J., Faner, R., Biomarkers, the control panel and personalized COPD medicine (2016) Respirology., 21, pp. 24-33; http://ec.europa.eu/research/health/pdf/biomarkers-for-patient-stratification_en.pdf, Stratification biomarkers in personalised medicine [consultado Mar 2018]. Disponible en; www.cancer.gov/dictionary?cdrid=45618, NCI Dictionary of Cancer Terms [consultado Mar 2018]. Disponible en; Celli, B.R., Locantore, N., Yates, J., Tal-Singer, R., Miller, B.E., Bakke, P., Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease (2012) Am J Respir Crit Care Med., 185, pp. 1065-1072; Pinto-Plata, V.M., Livnat, G., Girish, M., Cabral, H., Masdin, P., Linacre, P., Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD (2007) Chest., 131, pp. 37-43; Zinellu, E., Zinellu, A., Fois, A.G., Carru, C., Pirina, P., Circulating biomarkers of oxidative stress in chronic obstructive pulmonary disease: A systematic review (2016) Respir Res., 17, p. 150; Deja, S., Porebska, I., Kowal, A., Zabek, A., Barg, W., Pawelczyk, K., Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease (2014) J Pharm Biomed Anal., 100, pp. 369-380; Verrills, N.M., Irwin, J.A., He, X.Y., Wood, L.G., Powell, H., Simpson, J.L., Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease (2011) Am J Respir Crit Care Med., 183, pp. 1633-1643; Loi, A.L.T., Hoonhorst, S., van Aalst, C., Langereis, J., Kamp, V., Sluis-Eising, S., Proteomic profiling of peripheral blood neutrophils identifies two inflammatory phenotypes in stable COPD patients (2017) Respir Res., 18, p. 100; Leung, J.M., Chen, V., Hollander, Z., Dai, D., Tebbutt, S.J., Aaron, S.D., COPD exacerbation biomarkers validated using multiple reaction monitoring mass spectrometry (2016) PLoS One., 11, p. e0161129; Naz, S., Kolmert, J., Yang, M., Reinke, S.N., Kamleh, M.A., Snowden, S., Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD (2017) Eur Respir J., 49, p. 1602322; Rana, G.S., York, T.P., Edmiston, J.S., Zedler, B.K., Pounds, J.G., Adkins, J.N., Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette smokers with COPD (2010) Anal Bioanal Chem., 397, pp. 1809-1819; Stolz, D., Meyer, A., Rakic, J., Boeck, L., Scherr, A., Tamm, M., Mortality risk prediction in COPD by a prognostic biomarker panel (2014) Eur Respir J., 44, pp. 1557-1570; Pinto-Plata, V., Toso, J., Lee, K., Park, D., Bilello, J., Mullerova, H., Profiling serum biomarkers in patients with COPD: Associations with clinical parameters (2007) Thorax., 62, pp. 595-601; Noell, G., Cosío, B.G., Faner, R., Monsó, E., Peces-Barba, G., de Diego, A., Multi-level differential network analysis of COPD exacerbations (2017) Eur Respir J., 50, p. 1700075; Grosdidier, S., Ferrer, A., Faner, R., Piñero, J., Roca, J., Cosío, B., Network medicine analysis of COPD multimorbidities (2014) Respir Res., 15, p. 111; Rudzka, D.A., Clark, W., Hedley, A., Kalna, G., Olson, M.F., Transcriptomic profiling of human breast and melanoma cells selected by migration through narrow constraints (2017) Sci Data., 4, p. 170172; Ashburner, M., Lewis, S., On ontologies for biologists: The Gene Ontology-untangling the web (2002) Novartis Found Symp., 247, pp. 66-80; Robinson, P.N., Mundlos, S., The human phenotype ontology (2010) Clin Genet., 77, pp. 525-534; Anapindi, K.D.B., Romanova, E.V., Southey, B.R., Sweedler, J.V., Peptide identifications and false discovery rates using different mass spectrometry platforms (2018) Talanta., 182, pp. 456-463; Subirana, I., Fitó, M., Diaz, O., Vila, J., Francés, A., Delpon, E., Prediction of coronary disease incidence by biomarkers of inflammation, oxidation, and metabolism (2018) Sci Rep., 8, p. 3191; Li, Y., Chen, M., Liu, C., Xia, Y., Xu, B., Hu, Y., Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study (2018) Int J Mol Med., 41, pp. 3006-3014; Gea, J., Pascual, S., Casals, F., Casadevall, C., Castro-Acosta, A., Córdoba, R., Gene expression profile in the blood of COPD patients (2017) Am J Respir Crit Care Med., 195, p. A6936; Pascual, S., Puigdevall, P., González-García, J.G., Castro-Acosta, A., Córdoba, R., Torralba, Y., Transcriptome of fragile and non-fragile COPD patients: Beyond clinical parameters? (2018) Chest., , (abstract, en prensa); Gea, J., Castelo, R., Pascual, S., Casadevall, C., Castro-Acosta, A., Córdoba, R., Endotipo eosinofílico de la EPOC: Perfil diferencial de expresión genética en sangre (2018) Arch Bronconeumol., 54 (sup C1), pp. 157-158","Gea, J.; Servicio de Neumología, Hospital del Mar - IMIM. Departamento CEXS, Universitat Pompeu Fabra (UPF)Spain; email: jgea@parcdesalutmar.cat",,,"Elsevier Doyma",,,,,03002896,,ARBRD,"30343952","English; Spanish","Arch. Bronconeumol.",Article,"Final",,Scopus,2-s2.0-85060345388
"Leis A., Ronzano F., Mayer M.A., Furlong L.I., Sanz F.","35072969800;42962270900;36971031500;34770469800;7102263897;","Detecting signs of depression in tweets in Spanish: Behavioral and linguistic analysis",2019,"Journal of Medical Internet Research","21","6", e14199,"","",,,"10.2196/14199","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068990815&doi=10.2196%2f14199&partnerID=40&md5=68000cff9b38b60c02ad93f70fb2780a","Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer Dr Aiguader 88, Barcelona, 08003, Spain","Leis, A., Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer Dr Aiguader 88, Barcelona, 08003, Spain; Ronzano, F., Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer Dr Aiguader 88, Barcelona, 08003, Spain; Mayer, M.A., Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer Dr Aiguader 88, Barcelona, 08003, Spain; Furlong, L.I., Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer Dr Aiguader 88, Barcelona, 08003, Spain; Sanz, F., Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer Dr Aiguader 88, Barcelona, 08003, Spain","Background: Mental disorders have become a major concern in public health, and they are one of the main causes of the overall disease burden worldwide. Social media platforms allow us to observe the activities, thoughts, and feelings of people’s daily lives, including those of patients suffering from mental disorders. There are studies that have analyzed the influence of mental disorders, including depression, in the behavior of social media users, but they have been usually focused on messages written in English. Objective: The study aimed to identify the linguistic features of tweets in Spanish and the behavioral patterns of Twitter users who generate them, which could suggest signs of depression. Methods: This study was developed in 2 steps. In the first step, the selection of users and the compilation of tweets were performed. A total of 3 datasets of tweets were created, a depressive users dataset (made up of the timeline of 90 users who explicitly mentioned that they suffer from depression), a depressive tweets dataset (a manual selection of tweets from the previous users, which included expressions indicative of depression), and a control dataset (made up of the timeline of 450 randomly selected users). In the second step, the comparison and analysis of the 3 datasets of tweets were carried out. Results: In comparison with the control dataset, the depressive users are less active in posting tweets, doing it more frequently between 23:00 and 6:00 (P<.001). The percentage of nouns used by the control dataset almost doubles that of the depressive users (P<.001). By contrast, the use of verbs is more common in the depressive users dataset (P<.001). The first-person singular pronoun was by far the most used in the depressive users dataset (80%), and the first- and the second-person plural pronouns were the least frequent (0.4% in both cases), this distribution being different from that of the control dataset (P<.001). Emotions related to sadness, anger, and disgust were more common in the depressive users and depressive tweets datasets, with significant differences when comparing these datasets with the control dataset (P<.001). As for negation words, they were detected in 34% and 46% of tweets in among depressive users and in depressive tweets, respectively, which are significantly different from the control dataset (P<.001). Negative polarity was more frequent in the depressive users (54%) and depressive tweets (65%) datasets than in the control dataset (43.5%; P<.001). Conclusions: Twitter users who are potentially suffering from depression modify the general characteristics of their language and the way they interact on social media. On the basis of these changes, these users can be monitored and supported, thus introducing new opportunities for studying depression and providing additional health care services to people with this disorder. ©Angela Leis, Francesco Ronzano, Miguel A Mayer, Laura I Furlong, Ferran Sanz.","Depression; Mental health; Social media; Text mining",,,,,,"FI2016

PRB2-ISCIII, PT17/0009/0014, 634143","We received support from the Agency for Management of University and Research Grants in Catalonia (Spain) for the incorporation of new research personnel (FI2016), the European Union H2020 Research and Innovation Programme 2014-2020 under grant agreement number 634143 (MedBioinformatics: Creating medically driven integrative bioinformatics applications focused on oncology and central nervous system disorders and their comorbidities). The Research Programme on Biomedical Informatics is a member of the Spanish National Bioinformatics Institute, PRB2-ISCIII, and it is supported by grant PT17/0009/0014.",,,"(2013) Mental Health Action Plan 2013-2020, , http://apps.who.int/iris/bitstream/10665/89966/1/9789241506021_eng.pdf?ua=1, accessed 2018-04-25 WebCite Cache ID 778TsWziL; Marcus, M., Yasamy, M.T., Van Ommeren, M., Chisholm, D., Saxena, S., (2012) Depression: A Global Public Health Concern, , http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf, WHO Department of Mental Health and Substance Abuse. World Health Organization. accessed 2018-04-25 WebCite Cache ID 778NmzRq1; Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the global burden of disease study 2013 (2015) Lancet, 386 (9995), pp. 743-800. , Aug 22; FREE Full text doi: Medline: 26063472; Trautmann, S., Rehm, J., Wittchen, H.U., The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? (2016) EMBO Rep, 17 (9), pp. 1245-1249. , FREE Full text doi: Medline: 27491723; Patel, V., Chisholm, D., Parikh, R., Charlson, F.J., Degenhardt, L., Dua, T., Global priorities for addressing the burden of mental, neurological,substance use disorders (2016) Disease Control Priorities: Mental, Neurological, and Substance Use Disorders,, 4, pp. 1-27. , Patel Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME, Vos T, editors. Third Edition Washington, DC: The World Bank; Whiteford, H.A., Degenhardt, L., Rehm, J., Baxter, A.J., Ferrari, A.J., Erskine, H.E., Global burden of disease attributable to mental and substance use disorders: Findings from the global burden of disease study 2010 (2013) Lancet, 382 (9904), pp. 1575-1586. , Nov 9; Medline: 23993280; Wongkoblap, A., Vadillo, M.A., Curcin, V., Researching mental health disorders in the era of social media: Systematic review (2017) J Med Internet Res, 19 (6), p. e228. , Dec 29; FREE Full text doi: Medline: 28663166; (2018) Depression: Key Facts, , https://www.who.int/news-room/fact-sheets/detail/depression, accessed 2018-04-23 WebCite Cache ID 778TC0BMP; Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030 (2006) PLoS Med, 3 (11). , Nov; FREE Full text doi: Medline: 17132052; Vigo, D., Thornicroft, G., Atun, R., Estimating the true global burden of mental illness (2016) Lancet Psychiatry, 3 (2), pp. 171-178. , Feb; Medline: 26851330; (2017) Depression and Other Common Mental Disorders: Global Health Estimates, , http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER-2017.2-eng.pdf?ua=1, accessed 2018-04-25 WebCite Cache ID 77CsSorTr; Ferrari, A.J., Charlson, F.J., Norman, R.E., Patten, S.B., Freedman, G., Murray, C.J., Burden of depressive disorders by country, sex, age, and year: Findings from the global burden of disease study 2010 (2013) PLoS Med, 10 (11). , Nov; FREE Full text doi: Medline: 24223526; Paul, M.J., Dredze, M., You are what you tweet: Analyzing twitter for public health (2011) Proceedings of the Fifth International AAAI Conference on Weblogs and Social Media, pp. 265-272. , AAAI'11; July 17-21, 2011; Barcelona, Spain; Park, M., Cha, C., Cha, M., Depressive moods of users portrayed in twitter (2012) Proceedings of the ACM SIGKDD Workshop on Health Informatics, pp. 1-8. , HI-KDD'12; August 12-16, 2012; Beijing, China; Nguyen, T., O’Dea, B., Larsen, M., Phung, D., Venkatesh, S., Christensen, H., Using linguistic and topic analysis to classify sub-groups of online depression communities (2015) Multimed Tools Appl, 76 (8), pp. 10653-10676. , Dec 21; Cavazos-Rehg, P.A., Krauss, M.J., Sowles, S., Connolly, S., Rosas, C., Bharadwaj, M., A content analysis of depression-related Tweets (2016) Comput Human Behav, 54, pp. 351-357. , FREE Full text doi: Medline: 26392678; Coppersmith, G., Dredze, M., Harman, C., Hollingshead, K., From ADHD to sad: Analyzing the language of mental health on Twitter through self-reported diagnoses (2015) Proceedings of the 2nd Workshop on Computational Linguistics and Clinical Psychology: From Linguistic Signal to Clinical Reality, pp. 1-10. , https://www.aclweb.org/anthology/W15-1201, CLPSYCH'15; June 5, 2015; Denver, Colorado; Naslund, J.A., Aschbrenner, K.A., McHugo, G.J., Unützer, J., Marsch, L.A., Bartels, S.J., Exploring opportunities to support mental health care using social media: A survey of social media users with mental illness (2019) Early Interv Psychiatry, 13 (3), pp. 405-413. , Jun; Medline: 29052947; Berry, N., Lobban, F., Belousov, M., Emsley, R., Nenadic, G., Bucci, S., #WhywetweetMH: Understanding why people use Twitter to discuss mental health problems (2017) J Med Internet Res, 19 (4), p. e107. , Dec 5; FREE Full text doi: Medline: 28381392; De Choudhury, M., Gamon, M., Counts, S., Horvitz, E., Predicting depression via social media (2013) Proceedings of the Seventh International Conference on Weblogs and Social Media. 2013, pp. 128-138. , AAAI'13; July 8-11, Cambridge, MA; Wilson, M.L., Ali, S., Valstar, M.F., Finding information about mental health in microblogging platforms: A case study of depression (2014) Proceedings of the 5th Information Interaction in Context Symposium, pp. 8-17. , IIiX'14; August 26-30, 2014; Regensburg, Germany; Coppersmith, G., Dredze, M., Harman, C., Quantifying mental health signals in twitter (2014) Proceedings of the 2nd Workshop on Computational Linguistics and Clinical Psychology: From Linguistic Signal to Clinical Reality, pp. 51-60. , CLPSYCH'14; June 5, 2014; Baltimore, Maryland; Radzikowski, J., Stefanidis, A., Jacobsen, K.H., Croitoru, A., Crooks, A., Delamater, P.L., The measles vaccination narrative in Twitter: A quantitative analysis (2016) JMIR Public Health Surveill, 2 (1), p. e1. , FREE Full text doi: Medline: 27227144; Stefanidis, A., Vraga, E., Lamprianidis, G., Radzikowski, J., Delamater, P.L., Jacobsen, K.H., Zika in Twitter: Temporal variations of locations, actors, and concepts (2017) JMIR Public Health Surveill, 3 (2), p. e22. , Apr 20; FREE Full text doi: Medline: 28428164; Finch, K.C., Snook, K.R., Duke, C.H., Fu, K., Tse, Z.T., Adhikari, A., Public health implications of social media use during natural disasters, environmental disasters, and other environmental concerns (2016) Nat Hazards, 83 (1), pp. 729-760. , Apr 19; Eysenbach, G., Infodemiology and infoveillance: Framework for an emerging set of public health informatics methods to analyze search, communication and publication behavior on the internet (2009) J Med Internet Res, 11 (1), p. e11. , Mar 27; FREE Full text doi: Medline: 19329408; Conway, M., O'Connor, D., Social media, big data, and mental health: Current advances and ethical implications (2016) Curr Opin Psychol, 9, pp. 77-82. , Jun; FREE Full text doi: Medline: 27042689; Jain, S.H., Powers, B.W., Hawkins, J.B., Brownstein, J.S., The digital phenotype (2015) Nat Biotechnol, 33 (5), pp. 462-463. , May; Medline: 25965751; (2018) Number of Monthly Active Twitter Users Worldwide from 1st Quarter 2010 to 2nd Quarter 2018 (in Millions), , https://www.statista.com/statistics/282087/number-of-monthly-active-twitter-users/, accessed 2018-10-20 WebCite Cache ID 778OhlXHI; Tausczik, Y.R., Pennebaker, J.W., The psychological meaning of words: LIWC and computerized text analysis methods (2009) J Lang Soc Psychol, 29 (1), pp. 24-54. , Dec 8; FREE Full text doi; Ramirez-Esparza, N., Chung, C.K., Kacewicz, E., Pennebaker, J.W., The psychology of word use in depression forums in Englishin Spanish: Texting two text analytic approaches (2008) Proceedings of the 2nd International Conference on Weblogs and Social Media, , https://www.aaai.org/Papers/ICWSM/2008/ICWSM08-020.pdf, AAAI'08; March 30–April 2, 2008; Seattle, Washington URL; Chung, C., Pennebaker, J., The psychological functions of function words (2007) Social Communication: Frontiers of Social Psychology, pp. 343-359. , Fiedler K, editor. First Edition. New York: Psychology Press; Prieto, V.M., Matos, S., Álvarez, M., Cacheda, F., Oliveira, J.L., Twitter: A good place to detect health conditions (2014) PLoS One, 9 (1). , FREE Full text doi: Medline: 24489699; Thackeray, R., Burton, S.H., Giraud-Carrier, C., Rollins, S., Draper, C.R., Using Twitter for breast cancer prevention: An analysis of breast cancer awareness month (2013) BMC Cancer, 13, p. 508. , Oct 29; FREE Full text doi: Medline: 24168075; Pavalanathan, U., De Choudhury, M., Identity management and mental health discourse in social media (2015) Proceedings of the 24th International Conference on World Wide Web, pp. 315-321. , WWW'15 Companion; May 18-22, 2015; Florence, Italy; De Choundhury, M., Counts, S., Horvitz, E., Social media as a measurement tool of depression in populations (2013) Proceedings of the 5th Annual ACM Web Science Conference. 2013, pp. 47-56. , https://dl.acm.org/citation.cfm?id=2464480, WebSci'13; May 2-4, Paris, France; Coppersmith, G., Harman, C., Dredze, M., Measuring post traumatic stress disorder in Twitter (2014) Proceedings of the 8th International Conference on Weblogs and Social Media, pp. 579-582. , https://www.aaai.org/ocs/index.php/ICWSM/ICWSM14/paper/viewFile/8079/8082, 2014 AAAI'14; June 1-4, Ann Arbor, Michigan; Birnbaum, M.L., Ernala, S.K., Rizvi, A.F., De Choudhury, M., Kane, J.M., A collaborative approach to identifying social media markers of schizophrenia by employing machine learning and clinical appraisals (2017) J Med Internet Res, 19 (8), p. e289. , Dec 14; FREE Full text doi: Medline: 28807891; Arseniev-Koehler, A., Lee, H., McCormick, T., Moreno, M.A., #Proana: Pro-eating disorder socialization on Twitter (2016) J Adolesc Health, 58 (6), pp. 659-664. , Medline: 27080731; (2019) Leading Countries Based on Number of Twitter Users as of January 2019 (in Millions), , https://www.statista.com/statistics/242606/number-of-active-twitter-users-in-selected-countries/, WebCite Cache ID 77Ctc6VPr; Twitter Developer, , https://developer.twitter.com/en.html, accessed 2018-11-10 WebCite Cache ID 778Qhq4Gu; (2013) Diagnostic and Statistical Manual of Mental Disorders, , American Psychiatric Association. Fifth Edition. Washington, DC: American Psychiatric Publishing; Natural Language Tool Kit, , https://www.nltk.org/api/nltk.tokenize.html, accessed 2018-10-10 WebCite Cache ID 778Rzo6pe; Padró, L., Stanilovsky, E., Freeling 3.0: Towards wider multilinguality (2012) Proceedings of the Eighth International Conference on Language Resources and Evaluation. 2012, pp. 2473-2479. , http://www.lrec-conf.org/proceedings/lrec2012/pdf/430_Paper.pdf, LREC'12; May 21-27, Istanbul, Turkey; Perez-Rosas, V., Banea, C., Mihalcea, R., Learning sentiment lexicons in Spanish (2012) Proceedings of the Eighth International Conference on Language Resources and Evaluation. 2012, pp. 3077-3081. , http://www.lrec-conf.org/proceedings/lrec2012/pdf/1081_Paper.pdf, LREC'12; May 21-27, Istanbul, Turkey; Cruz, F.L., Troyano, J.A., Pontes, B., Ortega, F.J., Building layered, multilingual sentiment lexicons at synset and lemma levels (2014) Expert Syst Appl, 41 (13), pp. 5984-5994. , Oct; FREE Full text doi; Ekman, P., Friesen, W.V., O'Sullivan, M., Chan, A., Diacoyanni-Tarlatzis, I., Heider, K., Universals and cultural differences in the judgments of facial expressions of emotion (1987) J Pers Soc Psychol, 53 (4), pp. 712-717. , Oct; Medline: 3681648; Sidorov, G., Miranda-Jiménez, S., Viveros-Jiménez, F., Gelbukh, A., Castro-Sánchez, N.A., Castillo, F., Empirical study of opinion mining in Spanish tweets (2012) Proceedings of the 11th Mexican International Conference on Artificial Intelligence, pp. 1-4. , 2012 MICAI'12; October 27-November 4, San Luis Potosí, Mexico; Nambisan, P., Luo, Z., Kapoor, A., Patrick, T.B., Cisler, R.A., Social media, big data, and public health informatics: Ruminating behavior of depression revealed through twitter (2015) Proceedings of the 2015 48th Hawaii International Conference on System Sciences, pp. 2906-2913. , 2015 HICSS'15; January 5-8, Kauai, Hawaii; Cassano, P., Fava, M., Depression and public health: An overview (2002) J Psychosom Res, 53 (4), pp. 849-857. , Oct; Medline: 12377293; Morris, D.W., Rush, A.J., Jain, S., Fava, M., Wisniewski, S.R., Balasubramani, G.K., Diurnal mood variation in outpatients with major depressive disorder: Implications for DSM-V from an analysis of the sequenced treatment alternatives to relieve depression study data (2007) J Clin Psychiatry, 68 (9), pp. 1339-1347. , Sep; Medline: 17915971; De Choudhury, M., Kiciman, E., Dredze, M., Coppersmith, G., Kumar, M., Discovering shifts to suicidal ideation from mental health content in social media (2016) Proceedings of the 2016 CHI Conference on Human Factors in Computing Systems, pp. 2098-2110. , http://europepmc.org/abstract/MED/29082385, CHI'16; May 7-12, 2016; San Jose, California; Bucci, W., Freedman, N., The language of depression (1981) Bull Menninger Clin, 45 (4), pp. 334-358. , Jul; Medline: 6176285; Rude, S., Gortner, E.M., Pennebaker, J., Language use of depressed and depression-vulnerable college students (2004) Cogn Emot, 18 (8), pp. 1121-1133; Pyszczynski, T., Greenberg, J., Self-regulatory perseveration and the depressive self-focusing style: A self-awareness theory of reactive depression (1987) Psychol Bull, 102 (1), pp. 122-138. , Jul; Medline: 3615702; Pennebaker, J.W., Mehl, M.R., Niederhoffer, K.G., Psychological aspects of natural language use: Our words, our selves (2003) Annu Rev Psychol, 54, pp. 547-577. , Medline: 12185209; Sonnenschein, A.R., Hofmann, S.G., Ziegelmayer, T., Lutz, W.L., Linguistic analysis of patients with mood and anxiety disorders during cognitive behavioral therapy (2018) Cogn Behav Ther, 47 (4), pp. 315-327. , Medline: 29345528; Painuly, N., Sharan, P., Mattoo, S.K., Relationship of anger and anger attacks with depression: A brief review (2005) Eur Arch Psychiatry Clin Neurosci, 255 (4), pp. 215-222. , Aug; Medline: 16133740; Neacsiu, A.D., Rompogren, J., Eberle, J.W., McMahon, K., Changes in problematic anger, shame, and disgust in anxious and depressed adults undergoing treatment for emotion dysregulation (2018) Behav Ther, 49 (3), pp. 344-359. , FREE Full text doi: Medline: 29704965; Bernard, J.D., Baddeley, J.L., Rodriguez, B.F., Burke, P.A., Depression, language, and affect: An examination of the influence of baseline depression and affect induction on language (2016) J Lang Soc Psychol, 35 (3), pp. 317-326; De Choudhury, M., Sharma, S.S., Logar, T., Eekhout, W., Nielsen, R.C., Gender and cross-cultural differences in social media disclosures of mental illness (2017) Proceedings of the 2017 ACM Conference on Computer Supported Cooperative Work and Social Computing, pp. 353-369. , 2017 CSCW'17; February 25-March 1, Portland, Oregon; De Choudhury, M., De, S., Mental health discourse on Reddit: Self-disclosure, social support, and anonymity (2014) Proceedings of the 8th International Conference on Weblogs and Social Media, pp. 71-80. , https://www.aaai.org/ocs/index.php/ICWSM/ICWSM14/paper/view/8075/8107, AAAI'14; June 1-4, 2014; Ann Arbor, Michigan; Mowery, D., Smith, H., Cheney, T., Stoddard, G., Coppersmith, G., Bryan, C., Understanding depressive symptoms and psychosocial stressors on Twitter: A corpus-based study (2017) J Med Internet Res, 19 (2), p. e48. , Dec 28; FREE Full text doi: Medline: 28246066; Eichstaedt, J.C., Schwartz, H.A., Kern, M.L., Park, G., Labarthe, D.R., Merchant, R.M., Psychological language on Twitter predicts county-level heart disease mortality (2015) Psychol Sci, 26 (2), pp. 159-169. , Feb; FREE Full text doi: Medline: 25605707; Yom-Tov, E., Johansson-Cox, I., Lampos, V., Hayward, A.C., Estimating the secondary attack rate and serial interval of influenza-like illnesses using social media (2015) Influenza Other Respir Viruses, 9 (4), pp. 191-199. , Jul; FREE Full text doi: Medline: 25962320; Paul, M.J., Dredze, M., Discovering health topics in social media using topic models (2014) PLoS One, 9 (8). , FREE Full text doi: Medline: 25084530; Chary, M., Genes, N., McKenzie, A., Manini, A.F., Leveraging social networks for toxicovigilance (2013) J Med Toxicol, 9 (2), pp. 184-191. , Jun; FREE Full text doi: Medline: 23619711; Seabrook, E.M., Kern, M.L., Fulcher, B.D., Rickard, N.S., Predicting depression from language-based emotion dynamics: Longitudinal analysis of Facebook and Twitter status updates (2018) J Med Internet Res, 20 (5), p. e168. , Dec 8; FREE Full text doi: Medline: 29739736; Reece, A.G., Reagan, A.J., Lix, K.L., Dodds, P.S., Danforth, C.M., Langer, E.J., Forecasting the onset and course of mental illness with Twitter data (2017) Sci Rep, 7 (1), p. 13006. , Dec 11; FREE Full text doi: Medline: 29021528; Alvarez-Mon, M.A., Asunsolo Del Barco, A., Lahera, G., Quintero, J., Ferre, F., Pereira-Sanchez, V., Increasing interest of mass communication media and the general public in the distribution of Tweets about mental disorders: Observational study (2018) J Med Internet Res, 20 (5), p. e205. , Dec 28; FREE Full text doi: Medline: 29807880","Sanz, F.; Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer Dr Aiguader 88, Spain; email: ferran.sanz@upf.edu",,,"Journal of Medical Internet Research",,,,,14388871,,,"31250832","English","J. Med. Internet Res.",Article,"Final",Open Access,Scopus,2-s2.0-85068990815
"Giannoula A., Gutierrez-Sacristán A., Bravo Á., Sanz F., Furlong L.I.","57201213356;56728807700;56374942700;7102263897;34770469800;","Identifying temporal patterns in patient disease trajectories using dynamic time warping: A population-based study",2018,"Scientific Reports","8","1", 4216,"","",,8,"10.1038/s41598-018-22578-1","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044003054&doi=10.1038%2fs41598-018-22578-1&partnerID=40&md5=180c30dcfd70e7a4fd43d85c39c5cdb2","Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), DCEXS, Universitat Pompeu Fabra, Barcelona, Spain","Giannoula, A., Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Gutierrez-Sacristán, A., Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Bravo, Á., Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Furlong, L.I., Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), DCEXS, Universitat Pompeu Fabra, Barcelona, Spain","Time is a crucial parameter in the assessment of comorbidities in population-based studies, as it permits to identify more complex disease patterns apart from the pairwise disease associations. So far, it has been, either, completely ignored or only, taken into account by assessing the temporal directionality of identified comorbidity pairs. In this work, a novel time-analysis framework is presented for large-scale comorbidity studies. The disease-history vectors of patients of a regional Spanish health dataset are represented as time sequences of ordered disease diagnoses. Statistically significant pairwise disease associations are identified and their temporal directionality is assessed. Subsequently, an unsupervised clustering algorithm, based on Dynamic Time Warping, is applied on the common disease trajectories in order to group them according to the temporal patterns that they share. The proposed methodology for the temporal assessment of such trajectories could serve as the preliminary basis of a disease prediction system. © 2018 The Author(s).",,"cluster analysis; comorbidity; epidemiology; female; human; male; medical informatics; procedures; register; time factor; Cluster Analysis; Comorbidity; Epidemiology; Female; Humans; Male; Medical Informatics; Registries; Time Factors",,,,,"CP10/00524, CPII16/00026, PI13/00082

115372

PRB2-ISCIII, PT13/0001/0023

European Federation of Pharmaceutical Industries and Associations

676559, 634143

Federación Española de Enfermedades Raras, FEDER","We received support from ISCIII-FEDER (PI13/00082, CP10/00524, CPII16/00026), IMI-JU under grants agreements no. 115372 (EMIF), resources composed of financial contribution from the EU-FP7 (FP7/2007–2013) and EFPIA companies in kind contribution, and the EU H2020 Programme 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (Elixir-Excelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D + i 2013–2016, funded by ISCIII and FEDER. Funding has been also received by the Marie-Curie UPFellowship Program.",,,"Valderas, J.M., Starfield, B., Sibbald, B., Salisbury, C., Ronald, M., Defining comorbidity: Implications for understanding health and health services (2009) Ann. Fam. Med., 7, pp. 357-363; Capobianco, E., Lio, P., Comorbidity: A multidimensional approach (2013) Trends Mol. Med., 19, pp. 515-521; Starfield, B., Threads and yarns: Weaving the tapestry of comorbidity (2006) Ann. Fam. Med., 4, pp. 101-103; Fortin, M., Bravo, G., Hudon, C., Vanasse, A., Lapointe, L., Prevalence of multimorbidity among adults seen in family practice (2005) Ann. Fam. Med., 3, pp. 223-228; Finlayson, S.G., LePendu, P., Shah, N.H., Building the graph of medicine from millions of clinical narratives (2014) Sci. Data, 1, p. 140032; Roque, F.S., Using electronic patient records to discover disease correlations and stratify patient cohorts (2011) PLoS Comput. Biol., 7, p. e1002141; Blair, D.R., A nondegenerate code of deleterious variants in Mendelian loci contributes to complex disease risk (2013) Cell, 155, pp. 70-80; Teno, J.M., Weitzen, S., Fennell, M.L., Mor, V., Dying trajectory in the last year of life: Does cancer trajectory fit other diseases? (2001) J. Palliat. Med., 4, pp. 457-464; Murtagh, F.E., Sheerin, N.S., Addington-Hall, J., Higginson, I.J., Trajectories of illness in stage 5 chronic kidney disease: A longitudinal study of patient symptoms and concerns in the last year of life (2011) Clin. J. Am. Soc. Nephrol., 6, pp. 1580-1590; Chmiel, A., Klimek, P., Thurner, S., Spreading of diseases through comorbidity networks across life and gender (2014) New J. Phys., 16, p. 115013; Hidalgo, C.A., Blum, N., Barabasi, A.L., Christakis, N.A., A dynamic network approach for the study of human phenotypes (2009) PLoS Comput. Biol., 5, p. e1000353; Jensen, A.B., Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients (2014) Nat. Commun., 5 (10), p. 1038; Hanauer, D.A., Ramakrishnan, N., Modeling temporal relationships in large scale clinical associations (2013) J. Am. Med. Inform. Assoc., 20, pp. 332-341; Sakoe, H., Chiba, S., Dynamic programming algorithm optimization for spoken word recognition (1978) IEEE Trans. Ac. Speach Sign. Proc., 26, pp. 43-49; Muller, M., Dynamic time warping (2007) Information Retrieval for Music and Motion, pp. 69-84. , Germany: Springer; Pinazo-Durán, M.D., Eclectic ocular comorbidities and systemic diseases with eye involvement: A review (2016) Biomed. Res. Int., 2016, p. 6215745; Javadi, M.A., Zarei-Ghanavati, S., Cataracts in diabetic patients: A review article (2008) J. Opthalm. Vis. Res., 3, pp. 52-65; Klein, B.E., Klein, R., Moss, M.S., Prevalence of cataracts in a population-based study of persons with diabetes mellitus (1985) Ophthalmology, 92, pp. 1191-1196; Abraham, A.G., Condon, N.G., West Gower, E., The new epidemiology of cataract (2006) Ophthalmol. Clin. North Am., 19, pp. 415-425; Nemet, A.Y., Vinker, S., Levartovsky, S., Kaiserman, I., Is cataract associated with cardiovascular morbidity? (2010) Eye, 24, pp. 1352-1358; Chiang, C.C., Lin, C.L., Peng, C.L., Sung, F.C., Tsai, Y.Y., Increased risk of cancer in patients with early-onset cataracts: A nationwide population-based study (2014) Cancer Sci., 105, pp. 431-436; Flynn, R.W., McDonald, T.M., Hapca, A., McKenzie, I.S., Schembri, S., Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis (2014) Respir. Res., 15, p. 141; Paganini-Hill, A., Clark, L.J., Eye problems in breast cancer patients treated with tamoxifen (2000) Breast Cancer Res. Treat., 60, pp. 167-172; Falk, J.A., Cardiac disease in chronic obstructive pulmonary disease (2008) Proc. Am. Thorac. Soc., 5, pp. 543-548; Finkelstein, J., Cha, E., Scharf, S.M., Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity (2009) Int. J. COPD, 4, pp. 337-349; Horstmann, M., Witthuhn, R., Falk, M., Stenzl, A., Gender-specific differences in bladder cancer: A retrospective analysis (2008) Gender Med., 5, pp. 385-394; Verneulen, S.H., Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study (2015) Br. J. Cancer, 112, pp. 594-600; Jhamb, M., Urinary tract diseases and bladder cancer risk: A case-control study (2007) Cancer Causes Control, 18, pp. 839-845; Darmon, M., Ciroldi, M., Thiery, G., Schlemmer, B., Azoulay, E., Clinical review: Specific aspects of acute renal failure in cancer patients (2006) Crit. Care, 10, p. 211; Kang, D., Benign prostatic hyperplasia and subsequent risk of bladder cancer (2007) Br. J. Cancer, 96, pp. 1475-1479; Divo, M., Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease (2012) Am. J. Respir. Crit. Care Med., 186, pp. 155-161; Hasin, T., Patients with heart failure have an increased risk of incident cancer (2013) J. Am. Coll. Cardiol., 62, pp. 881-886; Tashakkor, A.Y., Moghaddamjou, A., Chen, L., Cheung, W.Y., Predicting the risk of cardiovascular comorbidities in adult cancer survivors (2013) Curr. Oncol., 20, pp. e360-e370; Yusuf, S.W., Ilias-Khan, N.A., Durand, J.B., Chemotherapy-induced cardiomyopathy (2011) Expert Rev. Cardiovasc. Ther., 9, pp. 231-243; Breedveld, F.C., Osteoarthritis\-The impact of a serious disease (2004) Rheumatology, 43, pp. i4-i8; Woolf, A.D., Pfleger, B., Burden of major musculoskeletal conditions (2003) Bull. World Health Organ., 81, pp. 646-656; Suri, P., Morgenroth, D.C., Hunter, D.J., Epidemiology of osteoarthritis and associated comorbidities (2012) PM&R, 4, pp. S10-S19; Gabriel, S.E., Crowson, C.S., O'Fallon, W.M., Comorbidity in arthritis (1999) J. Rheumatol., 26, pp. 2475-2479; Rahman, M.M., Kopec, J.A., Cibere, J., Goldsmith, C.H., Anis, A.H., The relationship between osteoarthritis and cardiovascular disease in a population health survey: A cross-sectional study (2013) Epidemiol. Res., 3, p. e002624; Fernades, G.S., Valdes, A.M., Cardiovascular disease and osteoarthritis: Common pathways and patient outcomes (2015) Eur. J. Clin. Invest., 45, pp. 405-414; Wang, H., Bai, J., He, B., Hu, X., Liu, D., Osteoarthritis and the risk of cardiovascular disease: A meta-analysis of observational studies (2016) Sci. Reports, 6, p. 39672; Lane, N.E., Pain management in osteoarthritis: The role of COX-2inhibitors (1997) J. Rheumatol., 24, pp. 20-24; Bagley, S.C., Atman, R.B., Computing disease incidence, prevalence and comorbidity from electronic medical records (2016) J. Biomed. Inform., 63, pp. 108-111; Hersh, W.R., Caveats for the use of operational health record data in comparative effectiveness research (2013) Med. Care, 51, pp. S30-S37; (2015), http://www.icd9data.com, ICD-9-CM Diagnosis Codes; Agresti, A., A survey of exact inference for contingency tables (1992) Statist. Sci., 7, pp. 131-153; Aach, J., Church, G., Aligning gene expression time series with time warping algorithms (2001) Bioinformatics, 17, pp. 495-508; Huang, G., Zhang, D., Zheng, X., Zhu, X., An EMG-based handwriting recognition through dynamic time warping (2010) Proc. IEEE Eng. Med. Biol. Soc. Buenos Aires, Argentina, pp. 4902-54905; Kuzmanic, A., Zanchi, V., Hand shape classification using dtw and lcss as similarity measures for vision-based gesture recognition system (2007) Proc. Int. Conf. Computer As A Tool. Warsaw, Poland, pp. 264-269; Zhang, Z., Huang, K., Tan, T., Comparison of similarity measures for trajectory clustering in outdoor surveillance scenes (2006) Proc. Int. Conf. Patt. Recogn, pp. 1135-1138. , Washington, DC, USA; Banavas, G., Denham, S., Denham, M., Fast nonlinear deterministic forecasting of segmented stock indices using pattern matching and embedding techniques (2000) Comput. Econ. Finance, 64","Furlong, L.I.; Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), DCEXS, Universitat Pompeu FabraSpain; email: laura.furlong@upf.edu",,,"Nature Publishing Group",,,,,20452322,,,"29523868","English","Sci. Rep.",Article,"Final",Open Access,Scopus,2-s2.0-85044003054
"Pastor M., Quintana J., Sanz F.","7102415847;7102072362;7102263897;","Development of an infrastructure for the prediction of biological endpoints in industrial environments. Lessons learned at the eTOX project",2018,"Frontiers in Pharmacology","9","OCT", 1147,"","",,1,"10.3389/fphar.2018.01147","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055322462&doi=10.3389%2ffphar.2018.01147&partnerID=40&md5=16dd80ba8e9633128691fd687ec61861","Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain","Pastor, M., Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Quintana, J., Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain","In silico methods are increasingly being used for assessing the chemical safety of substances, as a part of integrated approaches involving in vitro and in vivo experiments. A paradigmatic example of these strategies is the eTOX project http://www.etoxproject.eu, funded by the European Innovative Medicines Initiative (IMI), which aimed at producing high quality predictions of in vivo toxicity of drug candidates and resulted in generating about 200 models for diverse endpoints of toxicological interest. In an industry-oriented project like eTOX, apart from the predictive quality, the models need to meet other quality parameters related to the procedures for their generation and their intended use. For example, when the models are used for predicting the properties of drug candidates, the prediction system must guarantee the complete confidentiality of the compound structures. The interface of the system must be designed to provide non-expert users all the information required to choose the models and appropriately interpret the results. Moreover, procedures like installation, maintenance, documentation, validation and versioning, which are common in software development, must be also implemented for the models and for the prediction platform in which they are implemented. In this article we describe our experience in the eTOX project and the lessons learned after 7 years of close collaboration between industrial and academic partners. We believe that some of the solutions found and the tools developed could be useful for supporting similar initiatives in the future. © 2007 - 2018 Frontiers Media S.A. All Rights Reserved.","Chemical safety; Computational toxicology; Drug safety; In silico toxicology; Industrial environments; Machine learning; Predictive models; Public-private partnership",,,,,,"Innovative Medicines Initiative

Innovative Medicines Initiative

Innovative Medicines Initiative

Seventh Framework Programme

European Federation of Pharmaceutical Industries and Associations

Innovative Medicines Initiative","In silico methods are increasingly being used for assessing the chemical safety of substances, as a part of integrated approaches involving in vitro and in vivo experiments. A paradigmatic example of these strategies is the eTOX project http://www.etoxproject.eu, funded by the European Innovative Medicines Initiative (IMI), which aimed at producing high quality predictions of in vivo toxicity of drug candidates and resulted in generating about 200 models for diverse endpoints of toxicological interest. In an industry-oriented project like eTOX, apart from the predictive quality, the models need to meet other quality parameters related to the procedures for their generation and their intended use. For example, when the models are used for predicting the properties of drug candidates, the prediction system must guarantee the complete confidentiality of the compound structures. The interface of the system must be designed to provide non-expert users all the information required to choose the models and appropriately interpret the results. Moreover, procedures like installation, maintenance, documentation, validation and versioning, which are common in software development, must be also implemented for the models and for the prediction platform in which they are implemented. In this article we describe our experience in the eTOX project and the lessons learned after 7 years of close collaboration between industrial and academic partners. We believe that some of the solutions found and the tools developed could be useful for supporting similar initiatives in the future.","In particular, the eTOX project, funded by the Innovative Medicines Initiative, constituted a pioneering exercise of extracting and integrating in vivo data from legacy resources at the pharmaceutical industry, and exploiting such data for read-across and the development of predictive models, since one of the aims of the eTOX project was to set up an integrated system for the prediction of toxicological endpoints, with a focus on organ and in vivo endpoints. The project faced many challenges, some of which have been described in previous publications (Cases et al., 2014; Sanz et al., 2015, 2017; Steger-Hartmann and Pognan, 2018). Here we wish to share our experiences in an aspect that is often overlooked in this kind of projects, which is how to translate predictive models generated by academia or by Small-Medium Enterprises (SMEs) into a production environment where they can be routinely applied. Irrespectively of the scientific quality of a model, it must meet several requirements to make it amenable for being used by the pharmaceutical industry. This requires building a common understanding between academic and industrial partners, identifying the end-user needs, and making significant efforts to incorporate into the models and the predictive system features that, in spite of their low scientific interest, make the difference between usable and not usable models. In the present article we describe the most significant lessons learned in eTOX, describing some of the problems we identified and describing the solutions applied to solve or mitigate them. Most of these solutions are the result of long hours of discussion, where we learned to understand each other’s points of view.","The eTOX project (Grant Agreement No. 115002), was developed under the Innovative Medicines Initiative Joint Undertaking (IMI), resources of which are composed of a financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contributions. The authors of this article are also involved in other related IMI projects, such as iPiE (no. 115735), TransQST (no. 116030) and eTRANSAFE (no. 777365), as well as the H2020 EU-ToxRisk project (no. 681002).","Amberg, A., Anger, L., Spirkl, H.-P., Guillon, J.-M., Ballet, V., Schmidt, F., Cardiosafety in silico prediction - Validation results of a multiscale simulation model (eTOX VII) (2016) Toxicol. Suppl. Toxicol. Sci., 150, p. 2647; Benfenati, E., Diaza, R.G., Cassano, A., Pardoe, S., Gini, G., Mays, C., The acceptance of in silico models for reach: Requirements, barriers, and perspectives (2011) Chem. Cent. J., 5, pp. 1-11; Bravo, À., Li, T.S., Su, I., Good, B.M., Furlong, I., Combining machine learning, crowdsourcing and expert knowledge to detect chemical-induced diseases in text (2016) Database, 2016, p. baw094; Capoferri, L., Verkade-Vreeker, M.C.A., Buitenhuis, D., Commandeur, J.N.M., Pastor, M., Vermeulen, N.P.E., Linear interaction energy based prediction of cytochrome P450 1A2 binding affinities with reliability estimation (2015) PLoS One, 10, p. e0142232; Carrió, P., López, O., Sanz, F., Pastor, M., ETOXlab, an open source modeling framework for implementing predictive models in production environments (2015) J. Cheminform., 7, p. 8; Carrió, P., Pinto, M., Ecker, G., Sanz, F., Pastor, M., Applicability domain analysis (ADAN): A robust method for assessing the reliability of drug property predictions (2014) J. Chem. Inf. Model., 54, pp. 1500-1511; Cases, M., Briggs, K., Steger-Hartmann, T., Pognan, F., Marc, P., Kleinöder, T., The eTOX data-sharing project to advance in Silico drug-induced toxicity prediction (2014) Int. J. Mol. Sci., 15, pp. 21136-21154; Daneshian, M., Kamp, H., Hengstler, J., Leist, M., Van De Water, B., Highlight report: Launch of a large integrated European in vitro toxicology project: EU-ToxRisk (2016) Arch. Toxicol., 90, pp. 1021-1024; Durán, Á., Martínez, G.C., Pastor, M., Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in molecular interaction fields (2008) J. Chem. Inf. Model., 48, pp. 1813-1823; (2009) Guidance on the Development, Evaluation, and Application of Environmental Models, , Environmental Protection Agency Technical Report EPA/100/K-09/003. Washington, DC: Environmental Protection Agency; Faulon, J.-L., Brown, W.M., Martin, S., Reverse engineering chemical structures from molecular descriptors: How many solutions? (2005) J. Comput. Aided. Mol. Des., 19, pp. 637-650; Fielding, R.T., (2000) Architectural Styles and the Design of Network-based Software Architectures, , https://www.ics.uci.edu/~fielding/pubs/dissertation/top.htm; Filimonov, D., Poroikov, V., Why relevant chemical information cannot be exchanged without disclosing structures (2005) J. Comput. Aided. Mol. Des., 19, pp. 705-713; (2007) GNU GPL v3, , http://www.gnu.org/copyleft/gpl.html; Hewitt, M., Ellison, C.M., Cronin, M.T.D., Pastor, M., Steger-Hartmann, T., Munoz-Muriendas, J., Ensuring confidence in predictions: A scheme to assess the scientific validity of in silico models (2015) Adv. Drug Deliv. Rev., 86, pp. 101-111; Lenselink, E.B., Ten Dijke, N., Bongers, B., Papadatos, G., Van Vlijmen, H.W.T., Kowalczyk, W., Beyond the hype: Deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set (2017) J. Cheminform., 9, p. 45; Liu, J., Patlewicz, G., Williams, A., Thomas, R.S., Shah, I., Predicting organ toxicity using in vitro bioactivity data and chemical structure (2017) Chem. Res. Toxicol., 30, pp. 2046-2059; Luechtefeld, T., Marsh, D., Rowlands, C., Hartung, T., Machine learning of toxicological big data enables read-across structure activity relationships (RASAR) outperforming animal test reproducibility (2018) Toxicol. Sci., 165, pp. 198-212; Maldonado, E.M., Leoncikas, V., Fisher, C.P., Moore, J.B., Plant, N.J., Kierzek, A.M., Integration of genome scale metabolic networks and gene regulation of metabolic enzymes with physiologically based pharmacokinetics (2017) CPT Pharmacometrics Syst. Pharmacol., 6, pp. 732-746; Masek, B.B., Shen, L., Smith, K.M., Pearlman, R.S., Sharing chemical information without sharing chemical structure (2008) J. Chem. Inf. Model., 48, pp. 256-261; Myatt, G.J., Ahlberg, E., Akahori, Y., Allen, D., Amberg, A., Anger, L.T., In silico toxicology protocols (2018) Regul. Toxicol. Pharmacol., 96, pp. 1-17; (2007) Guidance Document on the Validation of (Quantitative) Structure-Activity Relationships (QSAR) Models, , Organisation for Economic Co-operation and Development Technical Report ENV/JM/MONO. Paris: Organisation for Economic Co-operation and Development; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors (2000) J. Med. Chem., 43, pp. 3233-3243; Sakuratani, Y., Zhang, H.Q., Nishikawa, S., Yamazaki, K., Yamada, T., Yamada, J., Hazard Evaluation Support System (HESS) for predicting repeated dose toxicity using toxicological categories (2013) SAR QSAR Environ. Res., 24, pp. 351-363; Sanz, F., Carrió, P., López, O., Capoferri, L., Kooi, D.P., Vermeulen, N.P.E., Integrative modeling strategies for predicting drug toxicities at the eTox project (2015) Mol. Inform., 34, pp. 477-484; Sanz, F., Pognan, F., Steger-Hartmann, T., Díaz, C., Legacy data sharing to improve drug safety assessment: The eTOX project (2017) Nat. Rev. Drug Discov., 16, pp. 811-812; Steger-Hartmann, T., Pognan, F., Improving the safety assessment of chemicals and drug candidates by the integration of bioinformatics and chemoinformatics data (2018) Basic Clin. Pharmacol. Toxicol, , [Epub ahead of print]; Tetko, I.V., Abagyan, R., Oprea, T.I., Surrogate data - A secure way to share corporate data (2005) J. Comput. Aided. Mol. Des., 19, pp. 749-764","Pastor, M.; Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu FabraSpain; email: manuel.pastor@upf.edu",,,"Frontiers Media S.A.",,,,,16639812,,,,"English","Front. Pharmacol.",Article,"Final",Open Access,Scopus,2-s2.0-85055322462
"Piñero J., Furlong L.I., Sanz F.","55220852900;34770469800;7102263897;","In silico models in drug development: where we are",2018,"Current Opinion in Pharmacology","42",,,"111","121",,2,"10.1016/j.coph.2018.08.007","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053054924&doi=10.1016%2fj.coph.2018.08.007&partnerID=40&md5=48389ddcce912be6e987263df3ff48fb","Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Carrer Dr. Aiguader 88, Barcelona, 08003, Spain","Piñero, J., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Carrer Dr. Aiguader 88, Barcelona, 08003, Spain; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Carrer Dr. Aiguader 88, Barcelona, 08003, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Carrer Dr. Aiguader 88, Barcelona, 08003, Spain","The use and utility of computational models in drug development has significantly grown in the last decades, fostered by the availability of high throughput datasets and new data analysis strategies. These in silico approaches are demonstrating their ability to generate reliable predictions as well as new knowledge on the mode of action of drugs and the mechanisms underlying their side effects, altogether helping to reduce the costs of drug development. The aim of this review is to provide a panorama of developments in the field in the last two years. © 2018 Elsevier Ltd",,"messenger RNA; paracetamol; perfluorooctanesulfonic acid; phosphatidylinositol 3 kinase; phosphatidylinositol 3 kinase inhibitor; DNA microarray; drug industry; drug metabolism; drug sensitivity; drug transport; electrophysiology; enzyme inhibition; gene expression profiling; gene product; gene regulatory network; genetic model; genome scale metabolic modeling; genomics; human; machine learning; malignant neoplasm; neurotoxicity; nonhuman; prediction; pregnant woman; priority journal; Quantitative Systems Pharmacology model; Quantitative Systems Toxicology model; reliability; Review; signal transduction; simulation; systems biology; toxicogenomics; transcriptomics",,"paracetamol, 103-90-2; phosphatidylinositol 3 kinase, 115926-52-8",,,"CPII16/00026

681002

Instituto de Salud Carlos III

676559

116030, 777365

Ministerio de Economía y Competitividad: MDM-2014-0370

Federación Española de Enfermedades Raras","We acknowledge support from ISCIII-FEDER ( CPII16/00026 ), the EU H2020 Programme 2014-2020 under grant agreements no. 681002 (EU-ToxRisk) and no. 676559 (ELIXIR-EXCELERATE), and the IMI2-JU under grants agreements no. 116030 (TransQST) and no. 777365 (eTRANSAFE), resources of which are composed of financial contribution from the EU-H2020 and EFPIA companies in kind contribution. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and FEDER. The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the MINECO (ref: MDM-2014-0370).",,,"Sorger, P.K., Allerheiligen, S.R.B., Altmann, R.B., Shoichet, B., Lauffenburger, D.A., Iyengar, R., Califano, A., Emergence of quantitative and systems pharmacology: a white paper (2011) NIH QSP Work; Sturla, S.J., Boobis, A.R., FitzGerald, R.E., Hoeng, J., Kavlock, R.J., Schirmer, K., Whelan, M., Peitsch, M.C., Systems toxicology: from basic research to risk assessment (2014) Chem Res Toxicol, 27, pp. 314-329; Bloomingdale, P., Housand, C., Apgar, J.F., Millard, B.L., Mager, D.E., Burke, J.M., Shah, D.K., Quantitative systems toxicology (2017) Curr Opin Toxicol, 4, pp. 79-87; Cadoo, K.A., Gajria, D., Suh, E., Patil, S., Theodoulou, M., Norton, L., Hudis, C.A., Traina, T.A., Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review (2016) NPJ Breast Cancer, 2, p. 16006; Fang, L., Xin, W., Ding, H., Zhang, Y., Zhong, L., Luo, H., Li, J., Huang, P., Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis (2016) Sci Rep, 6, p. 25913; Schuck, E., Bohnert, T., Chakravarty, A., Damian-Iordache, V., Gibson, C., Hsu, C.-P., Heimbach, T., Lin, J., Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape (2015) AAPS J, 17, pp. 462-473; Kuepfer, L., Niederalt, C., Wendl, T., Schlender, J.-F., Willmann, S., Lippert, J., Block, M., Teutonico, D., Applied concepts in PBPK modeling: how to build a PBPK/PD model (2016) CPT Pharmacometrics Syst Pharmacol, 5, pp. 516-531; van der Graaf, P.H., Benson, N., Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development (2011) Pharm Res, 28, pp. 1460-1464; Ke, A.B., Greupink, R., Abduljalil, K., Drug dosing in pregnant women: challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations (2018) CPT Pharmacometrics Syst Pharmacol, 7, pp. 103-110; Xue, C., Zhang, X., Cai, W., Prediction of drug-drug interactions with bupropion and its metabolites as CYP2D6 inhibitors using a physiologically-based pharmacokinetic model (2017) Pharmaceutics, 10, p. 1; Moj, D., Hanke, N., Britz, H., Frechen, S., Kanacher, T., Wendl, T., Haefeli, W.E., Lehr, T., Clarithromycin, midazolam, and digoxin: application of PBPK modeling to gain new insights into drug–drug interactions and co-medication regimens (2017) AAPS J, 19, pp. 298-312; Pilla Reddy, V., Walker, M., Sharma, P., Ballard, P., Vishwanathan, K., Development, verification, and prediction of osimertinib drug-drug interactions using PBPK modeling approach to inform drug label (2018) CPT Pharmacometrics Syst Pharmacol; Gu, H., Dutreix, C., Rebello, S., Ouatas, T., Wang, L., Chun, D.Y., Einolf, H.J., He, H., Simultaneous physiologically based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin (2018) Drug Metab Dispos, 46, pp. 109-121; Marzolini, C., Rajoli, R., Battegay, M., Elzi, L., Back, D., Siccardi, M., Physiologically based pharmacokinetic modeling to predict drug–drug interactions with efavirenz involving simultaneous inducing and inhibitory effects on cytochromes (2017) Clin Pharmacokinet, 56, pp. 409-420; Duan, P., Zhao, P., Zhang, L., Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin and atorvastatin to predict drug-drug interactions (DDIs) (2017) Eur J Drug Metab Pharmacokinet, 42, pp. 689-705; Marsousi, N., Desmeules, J.A., Rudaz, S., Daali, Y., Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software (2018) Biopharm Drug Dispos, 39, pp. 3-17; Li, X., Shi, L., Tang, X., Wang, Q., Zhou, L., Song, W., Feng, Z., Yang, L., Mechanistic prediction of food effects for Compound A tablet using PBPK model (2017) Saudi J Biol Sci, 24, pp. 603-609; Rose, R.H., Turner, D.B., Neuhoff, S., Jamei, M., Incorporation of the time-varying postprandial increase in splanchnic blood flow into a PBPK model to predict the effect of food on the pharmacokinetics of orally administered high-extraction drugs (2017) AAPS J, 19, pp. 1205-1217; Cristofoletti, R., Patel, N., Dressman, J.B., Differences in food effects for 2 weak bases with similar BCS drug-related properties: what is happening in the intestinal lumen? (2016) J Pharm Sci, 105, pp. 2712-2722; Purohit, H.S., Trasi, N.S., Sun, D.D., Chow, E.C.Y., Wen, H., Zhang, X., Gao, Y., Taylor, L.S., Investigating the impact of drug crystallinity in amorphous tacrolimus capsules on pharmacokinetics and bioequivalence using discriminatory in vitro dissolution testing and physiologically based pharmacokinetic modeling and simulation (2018) J Pharm Sci, 107, pp. 1330-1341; Hens, B., Pathak, S.M., Mitra, A., Patel, N., Liu, B., Patel, S., Jamei, M., Turner, D.B., In silico modeling approach for the evaluation of gastrointestinal dissolution, supersaturation, and precipitation of posaconazole (2017) Mol Pharm, 14, pp. 4321-4333; Thiel, C., Schneckener, S., Krauss, M., Ghallab, A., Hofmann, U., Kanacher, T., Zellmer, S., Kuepfer, L., A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation (2015) J Pharm Sci, 104, pp. 191-206; Chen, Y., Zhao, K., Liu, F., Xie, Q., Zhong, Z., Miao, M., Liu, X., Liu, L., Prediction of deoxypodophyllotoxin disposition in mouse, rat, monkey, and dog by physiologically based pharmacokinetic model and the extrapolation to human (2016) Front Pharmacol, 7, p. 488; Campbell, J.L., Andersen, M.E., Hinderliter, P.M., Yi, K.D., Pastoor, T.P., Breckenridge, C.B., Clewell, H.J., PBPK model for atrazine and its chlorotriazine metabolites in rat and human (2016) Toxicol Sci, 150, pp. 441-453; Maldonado, E.M., Leoncikas, V., Fisher, C.P., Moore, J.B., Plant, N.J., Kierzek, A.M., Integration of genome scale metabolic networks and gene regulation of metabolic enzymes with physiologically based pharmacokinetics (2017) CPT pharmacometrics Syst Pharmacol, 6, pp. 732-746. , This review describes the current status of multiscale models combining PBPK, GSMN, and gene regulatory networks, and provides an example on how to build a multiscale model integrating HepatoNet1, (a liver GSMN), the gene regulatory network of cytochrome CYP3A4, and a whole body PBPK model, and two example applications; Thiel, C., Cordes, H., Conde, I., Castell, J.V., Blank, L.M., Kuepfer, L., Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients (2017) Arch Toxicol, 91, pp. 865-883. , The authors develop a multiscale approach that combines PBPK models with toxicogenomics data that is able to translate in vitro drug response data to thein vivo context. As example they use the approach to predict in vivo rat and patient responses to acute azathioprine overdose; Thiel, C., Cordes, H., Fabbri, L., Aschmann, H.E., Baier, V., Smit, I., Atkinson, F., Kuepfer, L., A comparative analysis of drug-induced hepatotoxicity in clinically relevant situations (2017) PLOS Comput Biol, 13, p. e1005280; Andersen, M.E., Black, M.B., Campbell, J.L., Pendse, S.N., Clewell, I.I.I.H.J., Pottenger, L.H., Bus, J.S., McMullen, P.D., Combining transcriptomics and PBPK modeling indicates a primary role of hypoxia and altered circadian signaling in dichloromethane carcinogenicity in mouse lung and liver (2017) Toxicol Appl Pharmacol, 332, pp. 149-158; Sharma, R.P., Schuhmacher, M., Kumar, V., Developing integrated PBPK/PD coupled mechanistic pathway model (miRNA-BDNF): an approach towards system toxicology (2017) Toxicol Lett, 280, pp. 79-91; Mason, C.L., Leedale, J., Tasoulis, S., Jarman, I., Antoine, D.J., Webb, S.D., Systems toxicology approach to identifying paracetamol overdose (2018) CPT Pharmacometrics Syst Pharmacol, , The authors propose anin silico paracetamol toxicity identification framework that uses a PBPK model of paracetamol and takes into account a panel of biomarkers of liver injury. The framework allows to predict the paracetamol dose, and time since administration, as well as the probability of DILI in mice models; Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Ross, K.N., The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease (2006) Science, 313, pp. 1929-1935; De Abrew, K.N., Kainkaryam, R.M., Shan, Y.K., Overmann, G.J., Settivari, R.S., Wang, X., Xu, J., Carney, E.W., Grouping 34 chemicals based on mode of action using connectivity mapping (2016) Toxicol Sci, 151, pp. 447-461; Chen, B., Ma, L., Paik, H., Sirota, M., Wei, W., Chua, M.-S., So, S., Butte, A.J., Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets (2017) Nat Commun, 8, p. 16022; Liu, X., Zeng, P., Cui, Q., Zhou, Y., Comparative analysis of genes frequently regulated by drugs based on connectivity map transcriptome data (2017) PLOS ONE, 12, p. e0179037; El-Hachem, N., Gendoo, D.M.A., Ghoraie, L.S., Safikhani, Z., Smirnov, P., Chung, C., Deng, K., Ho, C., Integrative cancer pharmacogenomics to infer large-scale drug taxonomy (2017) Cancer Res, 77, pp. 3057-3069. , The authors develop a computational method that combines different types of drug-centric data: structural information, toxicogenomics data, and growth inhibition profiles from cancer cell lines. From each type of data, drug–drug similarity matrices are built, which are combined using a network fusion algorithm to produce a drug taxonomy that succesfully classifies drugs in major classes, and predicts new drug targets; Rempel, E., Hoelting, L., Waldmann, T., Balmer, N.V., Schildknecht, S., Grinberg, M., Das Gaspar, J.A., Marchan, R., A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors (2015) Arch Toxicol, 89, pp. 1599-1618; Giordano, M., Tripathi, K.P., Guarracino, M.R., Ensemble of rankers for efficient gene signature extraction in smoke exposure classification (2018) BMC Bioinformatics, 19, p. 48; Wang, Z., Monteiro, C.D., Jagodnik, K.M., Fernandez, N.F., Gundersen, G.W., Rouillard, A.D., Jenkins, S.L., McDermott, M.G., Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd (2016) Nat Commun, 7, p. 12846; Darde, T.A., Gaudriault, P., Beranger, R., Lancien, C., Caillarec-Joly, A., Sallou, O., Bonvallot, N., Jégou, B., TOXsIgN: a cross-species repository for toxicogenomic signatures (2018) Bioinformatics; Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P., Haw, R., May, B., The reactome pathway knowledgebase (2018) Nucleic Acids Res, 46, pp. D649-D655; Slenter, D.N., Kutmon, M., Hanspers, K., Riutta, A., Windsor, J., Nunes, N., Mélius, J., Digles, D., WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research (2018) Nucleic Acids Res, 46, pp. D661-D667; Consortium, T.G.O., Expansion of the Gene Ontology knowledgebase and resources (2017) Nucleic Acids Res, 45, pp. D331-D338; Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., Mesirov, J.P., Molecular signatures database (MSigDB) 3.0 (2011) Bioinformatics, 27, pp. 1739-1740; Parmentier, C., Couttet, P., Wolf, A., Zaccharias, T., Heyd, B., Bachellier, P., Uteng, M., Richert, L., Evaluation of transcriptomic signature as a valuable tool to study drug-induced cholestasis in primary human hepatocytes (2017) Arch Toxicol, 91, pp. 2879-2893; Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Lander, E.S., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles (2005) Proc Natl Acad Sci U S A, 102, pp. 15545-15550; Yang, L., Allen, B.C., Thomas, R.S., BMDExpress: a software tool for the benchmark dose analyses of genomic data (2007) BMC Genomics, 8, p. 387; Dean, J.L., Jay Zhao, Q., Lambert, J.C., Hawkins, B.S., Thomas, R.S., Wesselkamper, S.C., Application of gene set enrichment analysis for identification of chemically-induced, biologically relevant transcriptomic networks and potential utilization in human health risk assessment (2017) Toxicol Sci, 157, p. kfx021; Sirci, F., Napolitano, F., Pisonero-Vaquero, S., Carrella, D., Medina, D.L., di Bernardo, D., Comparing structural and transcriptional drug networks reveals signatures of drug activity and toxicity in transcriptional responses (2017) NPJ Syst Biol Appl, 3, p. 23; Kohonen, P., Parkkinen, J.A., Willighagen, E.L., Ceder, R., Wennerberg, K., Kaski, S., Grafström, R.C., A transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injury (2017) Nat Commun, 8, p. 15932. , The authors apply an approach to reduce dimentionality of toxicogenomics data, and combine it with cytotoxicity data to produce the PTGS, a collection of 14 gene sets that can be used to predict liver toxicity, and group drugs by mode of action, among other examples; Hendrickx, D.M., Souza, T., Jennen, D.G.J., Kleinjans, J.C.S., DTNI: a novel toxicogenomics data analysis tool for identifying the molecular mechanisms underlying the adverse effects of toxic compounds (2017) Arch Toxicol, 91, pp. 2343-2352. , The authors develop an ODE-based method that infers gene regulatory networks using time and dose toxicogenomics data, and a set of genes belonging to a process of interest. The method is able to provide statistic significance for the interactions among the genes in the gene set, and to pinpoint compound affecting the process under study; Souza, T.M., Kleinjans, J.C.S., Jennen, D.G.J., Dose and time dependencies in stress pathway responses during chemical exposure: novel insights from gene regulatory networks (2017) Front Genet, 8, p. 142; Taškova, K., Fontaine, J.-F., Mrowka, R., Andrade-Navarro, M.A., Evaluation of in vivo and in vitro models of toxicity by comparison of toxicogenomics data with the literature (2018) Methods, 132, pp. 57-65; Csardi, G., Kutalik, Z., Bergmann, S., Modular analysis of gene expression data with R (2010) Bioinformatics, 26, pp. 1376-1377; AbdulHameed, M.D.M., Ippolito, D.L., Stallings, J.D., Wallqvist, A., Mining kidney toxicogenomic data by using gene co-expression modules (2016) BMC Genomics, 17, p. 790; Te, J.A., AbdulHameed, M.D.M., Wallqvist, A., Systems toxicology of chemically induced liver and kidney injuries: histopathology-associated gene co-expression modules (2016) J Appl Toxicol, 36, pp. 1137-1149; Pang, W., Lian, F.-Z., Leng, X., Wang, S., Li, Y., Wang, Z., Li, K., Jiang, Y., Microarray expression profiling and co-expression network analysis of circulating LncRNAs and mRNAs associated with neurotoxicity induced by BPA (2018) Environ Sci Pollut Res; Zhang, B., Horvath, S., A general framework for weighted gene co-expression network analysis (2005) Stat Appl Genet Mol Biol, 4. , Article17; Sutherland, J.J., Webster, Y.W., Willy, J.A., Searfoss, G.H., Goldstein, K.M., Irizarry, A.R., Hall, D.G., Stevens, J.L., Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity (2017) Pharmacogenomics J, , Using WGCNA to analyze gene expression data from rat liver, the authors produce the TGX map, a collection of modules of co-expressed genes, and show their utility to understand the mechanisms underlying specific liver toxicity phenotypes using several examples; Ivliev, A.E., ‘t Hoen, P.A.C., Borisevich, D., Nikolsky, Y., Sergeeva, M.G., Drug repositioning through systematic mining of gene coexpression networks in cancer (2016) PLOS ONE, 11. , e0165059; Vahle, J.L., Anderson, U., Blomme, E.A.G., Hoflack, J.-C., Stiehl, D.P., Use of toxicogenomics in drug safety evaluation: current status and an industry perspective (2018) Regul Toxicol Pharmacol; Fielden, M.R., Zacharewski, T.R., Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology (2001) Toxicol Sci, 60, pp. 6-10; Berger, S.I., Iyengar, R., Role of systems pharmacology in understanding drug adverse events (2011) Wiley Interdiscip Rev Syst Biol Med, 3, pp. 129-135; Noble, D., Cardiac action and pacemaker potentials based on the Hodgkin–Huxley equations (1960) Nature, 188, pp. 495-497; O'Hara, T., Virág, L., Varró, A., Rudy, Y., Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation (2011) PLoS Comput Biol, 7. , e1002061; Colatsky, T., Fermini, B., Gintant, G., Pierson, J.B., Sager, P., Sekino, Y., Strauss, D.G., Stockbridge, N., The comprehensive in vitro proarrhythmia assay (CiPA) initiative — update on progress (2016) J Pharmacol Toxicol Methods, 81, pp. 15-20; Yang, P.-C., Perissinotti, L.L., López-Redondo, F., Wang, Y., DeMarco, K.R., Jeng, M.-T., Vorobyov, I., Noskov, S.Y., A multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias (2017) J Physiol, 595, pp. 4695-4723; Li, Z., Dutta, S., Sheng, J., Tran, P.N., Wu, W., Chang, K., Mdluli, T., Colatsky, T., Improving the in silico assessment of proarrhythmia risk by combining hERG (Human ether-à-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology (2017) Circ Arrhythm Electrophysiol, 10, p. e004628; Passini, E., Britton, O.J., Lu, H.R., Rohrbacher, J., Hermans, A.N., Gallacher, D.J., Greig, R.J.H., Rodriguez, B., Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity (2017) Front Physiol, 8, p. 668. , The authors show thatin silico cardiac electrophysiological models exhibit more accurate risk prediction of clinical pro-arrhythmic cardiotoxicity compared to animal experiments and human induced pluripotent stem cell-derived cardiomyocytes; Romero, L., Cano, J., Gomis-Tena, J., Trenor, B., Sanz, F., Pastor, M., Saiz, J., In silico QT and APD prolongation assay for early screening of drug-induced proarrhythmic risk (2018) J Chem Inf Model, 58, pp. 867-878. , The authors show thatin silico simulations that combine drug concentration, and multiple channel–drug interactions in isolated endocardial, midmyocardial, and epicardial cells outperform the standard potassium hERG channels block test in the taks of predictiong drug-induced proarrhythmic risk; Bloomingdale, P., Nguyen, V.A., Niu, J., Mager, D.E., Boolean network modeling in systems pharmacology (2018) J Pharmacokinet Pharmacodyn, 45, pp. 159-180; Traynard, P., Tobalina, L., Eduati, F., Calzone, L., Saez-Rodriguez, J., Logic modeling in quantitative systems pharmacology (2017) CPT Pharmacometrics Syst Pharmacol, 6, pp. 499-511; Le Novère, N., Quantitative and logic modelling of molecular and gene networks (2015) Nat Rev Genet, 16, pp. 146-158; Tejeda Zañudo, G., J, S., M, A., R: a network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer (2017) Cancer Converg, 1, p. 5; Zhu, P., Aliabadi, H.M., Uludağ, H., Han, J., Identification of potential drug targets in cancer signaling pathways using stochastic logical models (2016) Sci Rep, 6, p. 23078; Poret, A., Guziolowski, C., Therapeutic target discovery using Boolean network attractors: improvements of kali (2018) R Soc Open Sci, 5, p. 171852; Vitali, F., Cohen, L.D., Demartini, A., Amato, A., Eterno, V., Zambelli, A., Bellazzi, R., A network-based data integration approach to support drug repurposing and multi-target therapies in triple negative breast cancer (2016) PLOS ONE, 11, p. e0162407; Morris, M., Clarke, D., Osimiri, L., Lauffenburger, D., Systematic analysis of quantitative logic model ensembles predicts drug combination effects on cell signaling networks (2016) CPT Pharmacometrics Syst Pharmacol, 5, pp. 544-553; Samaga, R., Klamt, S., Modeling approaches for qualitative and semi-quantitative analysis of cellular signaling networks (2013) Cell Commun Signal, 11, p. 43; Melas, I.N., Sakellaropoulos, T., Iorio, F., Alexopoulos, L.G., Loh, W.-Y., Lauffenburger, D.A., Saez-Rodriguez, J., Bai, J.P.F., Identification of drug-specific pathways based on gene expression data: application to drug induced lung injury (2015) Integr Biol (Camb), 7, pp. 904-920. , The authors develop a framework that combines toxicogenomics data, drug targets and transcription factor information, and a global signaling network to find specific pathways underlying the mode of action of a drug. As a proof of concept, they use drugs known to produce lung toxicity, and produce a signaling subnetwork capable of explaining the mechanisms underlying drug-induced lung injury; Messinis, D.E., Melas, I.N., Hur, J., Varshney, N., Alexopoulos, L.G., Bai, J.P.F., Translational systems pharmacology-based predictive assessment of drug-induced cardiomyopathy (2018) CPT Pharmacometrics Syst Pharmacol, 7, pp. 166-174; Gille, C., Bölling, C., Hoppe, A., Bulik, S., Hoffmann, S., Hübner, K., Karlstädt, A., Rother, K., HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology (2010) Mol Syst Biol, 6, p. 411; Thiele, I., Swainston, N., Fleming, R.M.T., Hoppe, A., Sahoo, S., Aurich, M.K., Haraldsdottir, H., Stobbe, M.D., A community-driven global reconstruction of human metabolism (2013) Nat Biotechnol, 31, pp. 419-425; Chang, R.L., Xie, L., Xie, L., Bourne, P.E., Palsson, B.Ø., Drug off-target effects predicted using structural analysis in the context of a metabolic network model (2010) PLoS Comput Biol, 6, p. e1000938; Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Uhlen, M., Nielsen, J., Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease (2014) Nat Commun, 5, p. 3083; Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Nookaew, I., Jacobson, P., Walley, A.J., Uhlen, M., Integration of clinical data with a genome-scale metabolic model of the human adipocyte (2013) Mol Syst Biol, 9, p. 649; Sahoo, S., Thiele, I., Predicting the impact of diet and enzymopathies on human small intestinal epithelial cells (2013) Hum Mol Genet, 22, pp. 2705-2722; Väremo, L., Scheele, C., Broholm, C., Mardinoglu, A., Kampf, C., Asplund, A., Nookaew, I., Nielsen, J., Proteome- and transcriptome-driven reconstruction of the human myocyte metabolic network and its use for identification of markers for diabetes (2015) Cell Rep, 11, pp. 921-933; Ravikrishnan, A., Raman, K., Critical assessment of genome-scale metabolic networks: the need for a unified standard (2015) Brief Bioinform, 16, pp. 1057-1068; Blais, E.M., Rawls, K.D., Dougherty, B.V., Li, Z.I., Kolling, G.L., Ye, P., Wallqvist, A., Papin, J.A., Reconciled rat and human metabolic networks for comparative toxicogenomics and biomarker predictions (2017) Nat Commun, 8, p. 14250; Carbonell, P., Lopez, O., Amberg, A., Pastor, M., Sanz, F., Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data (2016) ALTEX, 34, pp. 219-234; Sier, J.H., Thumser, A.E., Plant, N.J., Linking physiologically-based pharmacokinetic and genome-scale metabolic networks to understand estradiol biology (2017) BMC Syst Biol, 11, p. 141; Shaked, I., Oberhardt, M.A., Atias, N., Sharan, R., Ruppin, E., Metabolic network prediction of drug side effects (2016) Cell Syst, 2, pp. 209-213; Hoekstra, A., Chopard, B., Coveney, P., Multiscale modelling and simulation: a position paper (2014) Philos Trans A Math Phys Eng Sci, 372, p. 20130377; Vicini, P., Multiscale modeling in drug discovery and development: future opportunities and present challenges (2010) Clin Pharmacol Ther, 88, pp. 126-129; Sluka, J.P., Fu, X., Swat, M., Belmonte, J.M., Cosmanescu, A., Clendenon, S.G., Wambaugh, J.F., Glazier, J.A., A liver-centric multiscale modeling framework for xenobiotics (2016) PLOS ONE, 11, p. e0162428; Cordes, H., Thiel, C., Baier, V., Blank, L.M., Kuepfer, L., Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation (2018) npj Syst Biol Appl, 4, p. 10; Sahli Costabal, F., Yao, J., Kuhl, E., Predicting drug-induced arrhythmias by multiscale modeling (2018) Int J Numer Method Biomed Eng, 34, p. e2964; Ribba, B., Grimm, H.P., Agoram, B., Davies, M.R., Gadkar, K., Niederer, S., van Riel, N., van der Graaf, P.H., Methodologies for quantitative systems pharmacology (QSP) models: design and estimation (2017) CPT pharmacometrics Syst Pharmacol, 6, pp. 496-498; Breschi, A., Gingeras, T.R., Guigó, R., Comparative transcriptomics in human and mouse (2017) Nat Rev Genet, 18, pp. 425-440; El-Hachem, N., Grossmann, P., Blanchet-Cohen, A., Bateman, A.R., Bouchard, N., Archambault, J., Aerts, H.J.W.L., Haibe-Kains, B., Characterization of conserved toxicogenomic responses in chemically exposed hepatocytes across species and platforms (2016) Environ Health Perspect, 124, pp. 313-320; Sutherland, J.J., Jolly, R.A., Goldstein, K.M., Stevens, J.L., Assessing concordance of drug-induced transcriptional response in rodent liver and cultured hepatocytes (2016) PLOS Comput Biol, 12, p. e1004847; Shankaran, H., Cronin, A., Barnes, J., Sharma, P., Tolsma, J., Jasper, P., Mettetal, J.T., Systems pharmacology model of gastrointestinal damage predicts species differences and optimizes clinical dosing schedules (2018) CPT Pharmacometrics Syst Pharmacol, 7, pp. 26-33. , The authors build a matemathical model that describe the dynamics of different types of intestinal cells to predict gastrointestinal toxicity of irinotecan. The model was fit using measurements in rats, and was able to translate into quantitative predictions of enterocyte loss and recovery kinetics in humans; Mih, N., Brunk, E., Bordbar, A., Palsson, B.O., A multi-scale computational platform to mechanistically assess the effect of genetic variation on drug responses in human erythrocyte metabolism (2016) PLoS Comput Biol, 12, p. e1005039. , An example of how protein structural information can be integrated to GSMN models to predict the impact of genetic variation on drug metabolism; Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-Luria, A.H., Cummings, B.B., Analysis of protein-coding genetic variation in 60,706 humans (2016) Nature, 536, pp. 285-706291; Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Abecasis, G.R., Bentley, D.R., Chakravarti, A., Eichler, E.E., A global reference for human genetic variation (2015) Nature, 526, pp. 68-74; Turnbull, C., Scott, R.H., Thomas, E., Jones, L., Murugaesu, N., Pretty, F.B., Halai, D., Hamblin, A., The 100 000 Genomes Project: bringing whole genome sequencing to the NHS (2018) BMJ, 361, p. k1687; Sun, B.B., Maranville, J.C., Peters, J.E., Stacey, D., Staley, J.R., Blackshaw, J., Burgess, S., Surendran, P., Genomic atlas of the human plasma proteome (2018) Nature, 558, pp. 73-79; Sanz, F., Pognan, F., Steger-Hartmann, T., Díaz, C., eTOX, Cases, M., Pastor, M., Briggs, K., Legacy data sharing to improve drug safety assessment: the eTOX project (2017) Nat Rev Drug Discov, 1612, p. 2017. , The authors discuss their experience in building a collaborative model for sharing legacy pre-clinical safety data among pharmaceutical companies, leading to the development of the eTOX database and facilitating the development of predictive models; Fisel, P., Schaeffeler, E., Schwab, M., DNA methylation of ADME genes (2016) Clin Pharmacol Ther, 99, pp. 512-527; Koppel, N., Maini Rekdal, V., Balskus, E.P., Chemical transformation of xenobiotics by the human gut microbiota (2017) Science, 356, p. eaag2770; Wilson, I.D., Nicholson, J.K., Gut microbiome interactions with drug metabolism, efficacy, and toxicity (2017) Transl Res, 179, pp. 204-222; Magnúsdóttir, S., Heinken, A., Kutt, L., Ravcheev, D.A., Bauer, E., Noronha, A., Greenhalgh, K., Wilmes, P., Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota (2016) Nat Biotechnol, 35, pp. 81-89; Thiele, I., Clancy, C.M., Heinken, A., Fleming, R.M.T., Quantitative systems pharmacology and the personalized drug–microbiota–diet axis (2017) Curr Opin Syst Biol, 4, pp. 43-52; OECD, Guidance Document on the Validation of (Quantitative) Structure–Activity Relationship [(Q)SAR] Models (2014); Igarashi, Y., Nakatsu, N., Yamashita, T., Ono, A., Ohno, Y., Urushidani, T., Yamada, H., Open TG-GATEs: a large-scale toxicogenomics database (2015) Nucleic Acids Res, 43, pp. D921-D927; Subramanian, A., Narayan, R., Corsello, S.M., Peck, D.D., Natoli, T.E., Lu, X., Gould, J., Asiedu, J.K., A next generation connectivity map: L1000 Platform and the First 1,000,000 Profiles (2017) Cell, 171. , 1437–0001452.e17; Lamb, J., The Connectivity Map: a new tool for biomedical research (2007) Nat Rev Cancer, 7, pp. 54-60; Shoemaker, R.H., The NCI60 human tumour cell line anticancer drug screen (2006) Nat Rev Cancer, 6, pp. 813-823; Keenan, A.B., Jenkins, S.L., Jagodnik, K.M., Koplev, S., He, E., Torre, D., Wang, Z., Lachmann, A., The library of integrated network-based cellular signatures NIH program: system-level cataloging of human cells response to perturbations (2018) Cell Syst, 6, pp. 13-24; Lea, I.A., Gong, H., Paleja, A., Rashid, A., Fostel, J., CEBS: a comprehensive annotated database of toxicological data (2017) Nucleic Acids Res, 45, pp. D964-D971",,,,"Elsevier Ltd",,,,,14714892,,COPUB,"30205360","English","Curr. Opin. Pharmacol.",Review,"Final",,Scopus,2-s2.0-85053054924
"Aguirre-Plans J., Piñero J., Menche J., Sanz F., Furlong L.I., Schmidt H.H.H.W., Oliva B., Guney E.","57200855561;55220852900;14621838300;7102263897;34770469800;7404731233;35500780700;23477104200;","Proximal pathway enrichment analysis for targeting comorbid diseases via network endopharmacology",2018,"Pharmaceuticals","11","3", 61,"","",,4,"10.3390/ph11030061","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049754753&doi=10.3390%2fph11030061&partnerID=40&md5=ab0830b8d0689e012b46fc34fb978064","Hospital del Mar Medical Research Institute and Pompeu Fabra University, Dr. Aiguader 88, Barcelona, 08003, Spain; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, Vienna, A-1090, Austria; Department of Pharmacology and Personalised Medicine, CARIM, FHML, Maastricht University, Universiteitssingel 50, Maastricht, 6229 ER, Netherlands","Aguirre-Plans, J., Hospital del Mar Medical Research Institute and Pompeu Fabra University, Dr. Aiguader 88, Barcelona, 08003, Spain; Piñero, J., Hospital del Mar Medical Research Institute and Pompeu Fabra University, Dr. Aiguader 88, Barcelona, 08003, Spain; Menche, J., CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, Vienna, A-1090, Austria; Sanz, F., Hospital del Mar Medical Research Institute and Pompeu Fabra University, Dr. Aiguader 88, Barcelona, 08003, Spain; Furlong, L.I., Hospital del Mar Medical Research Institute and Pompeu Fabra University, Dr. Aiguader 88, Barcelona, 08003, Spain; Schmidt, H.H.H.W., Department of Pharmacology and Personalised Medicine, CARIM, FHML, Maastricht University, Universiteitssingel 50, Maastricht, 6229 ER, Netherlands; Oliva, B., Hospital del Mar Medical Research Institute and Pompeu Fabra University, Dr. Aiguader 88, Barcelona, 08003, Spain; Guney, E., Hospital del Mar Medical Research Institute and Pompeu Fabra University, Dr. Aiguader 88, Barcelona, 08003, Spain, Department of Pharmacology and Personalised Medicine, CARIM, FHML, Maastricht University, Universiteitssingel 50, Maastricht, 6229 ER, Netherlands","The past decades have witnessed a paradigm shift from the traditional drug discovery shaped around the idea of “one target, one disease” to polypharmacology (multiple targets, one disease). Given the lack of clear-cut boundaries across disease (endo)phenotypes and genetic heterogeneity across patients, a natural extension to the current polypharmacology paradigm is to target common biological pathways involved in diseases via endopharmacology (multiple targets, multiple diseases). In this study, we present proximal pathway enrichment analysis (PxEA) for pinpointing drugs that target common disease pathways towards network endopharmacology. PxEA uses the topology information of the network of interactions between disease genes, pathway genes, drug targets and other proteins to rank drugs by their interactome-based proximity to pathways shared across multiple diseases, providing unprecedented drug repurposing opportunities. Using PxEA, we show that many drugs indicated for autoimmune disorders are not necessarily specific to the condition of interest, but rather target the common biological pathways across these diseases. Finally, we provide high scoring drug repurposing candidates that can target common mechanisms involved in type 2 diabetes and Alzheimer’s disease, two conditions that have recently gained attention due to the increased comorbidity among patients. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.","Alzheimer’s disease; Autoimmune disorders; Comorbidity; Drug repurposing; Network endopharmacology; Proximal pathway enrichment analysis; Systems medicine; Type 2 diabetes","acetylsalicylic acid; amitriptyline; antidiabetic agent; arbutamine; azathioprine; balsalazide; betamethasone; bupranolol; celecoxib; chenodeoxycholic acid; clenbuterol; colecalciferol; crisaborole; cyclosporine; dexamethasone; erythrityl tetranitrate; esmolol; fampridine; fenoterol; gabapentin; magnesium sulfate; meloxicam; montelukast; obeticholic acid; practolol; prednisone; roflumilast; sildenafil; tetrahydrolipstatin; unindexed drug; allergic rhinitis; Alzheimer disease; Article; asthma; chronic obstructive lung disease; comorbidity; drug development; drug repositioning; drug targeting; endopharmacology; endophenotype; erectile dysfunction; genetic heterogeneity; human; hypertension; multiple sclerosis; non insulin dependent diabetes mellitus; nonhuman; obesity; polypharmacology; primary biliary cirrhosis; pulmonary hypertension",,"acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; amitriptyline, 50-48-6, 549-18-8; arbutamine, 125251-66-3, 128470-16-6; azathioprine, 446-86-6; balsalazide, 82101-18-6; betamethasone, 378-44-9; bupranolol, 14556-46-8, 15148-80-8; celecoxib, 169590-42-5; chenodeoxycholic acid, 474-25-9; clenbuterol, 21898-19-1, 37148-27-9; colecalciferol, 1406-16-2, 67-97-0; crisaborole, 906673-24-3; cyclosporine, 59865-13-3, 63798-73-2, 79217-60-0; dexamethasone, 50-02-2; erythrityl tetranitrate, 7297-25-8; esmolol, 81147-92-4, 81161-17-3; fampridine, 1003-40-3, 504-24-5; fenoterol, 13392-18-2, 1944-12-3; gabapentin, 60142-96-3; magnesium sulfate, 7487-88-9; meloxicam, 71125-38-7; montelukast, 151767-02-1, 158966-92-8; obeticholic acid, 459789-99-2; practolol, 6673-35-4; prednisone, 53-03-2; roflumilast, 162401-32-3; sildenafil, 139755-83-2; tetrahydrolipstatin, 96829-58-2",,,"Secretaría de Estado de Investigacion, Desarrollo e Innovacion

CPII16/00026

European Metrology Programme for Innovation and Research

777111

PRB2-ISCIII, PT13/0001/0023

European Federation of Pharmaceutical Industries and Associations

H2020 Euratom, EURATOM: 676559

Innovative Medicines Initiative: 116030

Ministerio de Economía y Competitividad: MDM-2014-0370

Federación Española de Enfermedades Raras","Funding: The authors received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116030. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. The authors also received support from EU H2020 Programme 2014–2020 under grant agreement No. 676559 (Elixir-Excelerate). E.G. was supported by EU-cofunded Beatriu de Pinós incoming fellowship from the Agency for Management of University and Research Grants (AGAUR) of Government of Catalunya and L.I.F. received support from ISCIII-FEDER (CPII16/00026). H.H.H.W.S. has received funding from from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 777111 (Repotrial). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013–2016, funded by ISCIII and FEDER. The DCEXS is a “Unidad de Excelencia María de Maeztu”, funded by the MINECO (ref: MDM-2014-0370).",,,"Strebhardt, K., Ullrich, A., Paul Ehrlich’s magic bullet concept: 100 years of progress (2008) Nat. Rev. Cancer, 8, pp. 473-480; Csermely, P., Korcsmáros, T., Kiss, H.J., London, G., Nussinov, R., Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review (2013) Pharmacol. Ther., 138, pp. 333-408; Allison, M., Reinventing clinical trials (2012) Nat. Biotechnol., 30, pp. 41-49; Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs (2014) Nat. Biotechnol., 32, pp. 40-51; Hopkins, A.L., Network pharmacology: The next paradigm in drug discovery (2008) Nat. Chem. Biol., 4, pp. 682-690; Pujol, A., Mosca, R., Farres, J., Aloy, P., Unveiling the role of network and systems biology in drug discovery (2010) Trends Pharmacol. Sci., 31, pp. 115-123; Guney, E., Menche, J., Vidal, M., Barábasi, A.L., Network-based in silico drug efficacy screening (2016) Nat. Commun., 7; Jaeger, S., Igea, A., Arroyo, R., Alcalde, V., Canovas, B., Orozco, M., Nebreda, A.R., Aloy, P., Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer (2017) Cancer Res, 77, pp. 459-469; Jin, G., Wong, S.T.C., Toward better drug repositioning: Prioritizing and integrating existing methods into efficient pipelines (2014) Drug Discov. Today, 19, pp. 637-644; Hodos, R.A., Kidd, B.A., Shameer, K., Readhead, B.P., Dudley, J.T., In silico methods for drug repurposing and pharmacology (2016) Wiley Interdiscip. Rev. Syst. Biol. Med., 8, pp. 186-210; Vilar, S., Hripcsak, G., The role of drug profiles as similarity metrics: Applications to repurposing, adverse effects detection and drug–drug interactions (2016) Brief. Bioinform., 18, pp. 670-681; Loscalzo, J., Kohane, I., Barabasi, A.L., Human disease classification in the postgenomic era: A complex systems approach to human pathobiology (2007) Mol. Syst. Biol., 3, p. 124; Duran-Frigola, M., Mateo, L., Aloy, P., Drug repositioning beyond the low-hanging fruits (2017) Curr. Opin. Syst. Biol., 3, pp. 95-102; Li, Y., Agarwal, P., Rajagopalan, D., A global pathway crosstalk network (2008) Bioinformatics, 24, pp. 1442-1447; Garcia-Garcia, J., Guney, E., Aragues, R., Planas-Iglesias, J., Oliva, B., Biana: A software framework for compiling biological interactions and analyzing networks (2010) BMC Bioinform, 11, p. 56; Menche, J., Sharma, A., Kitsak, M., Ghiassian, S.D., Vidal, M., Loscalzo, J., Barabási, A.L., Uncovering disease-disease relationships through the incomplete interactome (2015) Science, 347, p. 1257601. , Disease networks; Ko, Y., Cho, M., Lee, J.S., Kim, J., Identification of disease comorbidity through hidden molecular mechanisms (2016) Sci. Rep., 6, p. 39433; Rubio-Perez, C., Guney, E., Aguilar, D., Piñero, J., Garcia-Garcia, J., Iadarola, B., Sanz, F., Oliva, B., Genetic and functional characterization of disease associations explains comorbidity (2017) Sci. Rep., 7, p. 6207; Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M.J., Barbas, C., Daiber, A., Ghezzi, P., Oliva, B., Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach (2018) Pharmacol. Rev., 70, pp. 348-383; Toro-Domínguez, D., Carmona-Sáez, P., Alarcón-Riquelme, M.E., Shared signatures between rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome uncovered through gene expression meta-analysis (2014) Arthritis Res. Ther., 16, p. 489; Luan, M., Shang, Z., Teng, Y., Chen, X., Zhang, M., Lv, H., Zhang, R., The shared and specific mechanism of four autoimmune diseases (2017) Oncotarget, 8, pp. 108355-108374; Autoimmune Disease Statistics, , www.aarda.org/news-information/statistics, accessed on 13 June 2018; Baranzini, S.E., (2013) Chapter 70—Autoimmune Disorders, pp. 822-838. , Genomic and Personalized Medicine, 2nd ed.; Ginsburg, G.S., Willard, H.F., Eds.; Academic Press: Cambridge, MA, USA; Gottesman, I.I., Gould, T.D., The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions (2003) Am. J. Psychiatry, 160, pp. 636-645; Ghiassian, S.D., Menche, J., Chasman, D.I., Giulianini, F., Wang, R., Ricchiuto, P., Aikawa, M., Zeller, T., Endophenotype Network Models: Common Core of Complex Diseases (2016) Sci. Rep., 6, p. 27414; Glaab, E., Baudot, A., Krasnogor, N., Schneider, R., Valencia, A., EnrichNet: Network-based gene set enrichment analysis (2012) Bioinformatics, 28, pp. i451-i457; Himmelstein, D.S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S.L., Hadley, D., Green, A., Baranzini, S.E., Systematic integration of biomedical knowledge prioritizes drugs for repurposing (2018) Elife, p. 6; Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Ross, K.N., The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease (2006) Science, 313, pp. 1929-1935; Sims-Robinson, C., Kim, B., Rosko, A., Feldman, E.L., How does diabetes accelerate Alzheimer disease pathology? (2010) Nat. Rev. Neurol., 6, pp. 551-559; Hiltunen, M., Khandelwal, V.K.M., Yaluri, N., Tiilikainen, T., Tusa, M., Koivisto, H., Krzisch, M., Kemppainen, S., Increased risk of type 2 diabetes in Alzheimer disease (2012) J. Cell. Mol. Med, 16, pp. 1206-1222; Yarchoan, M., Arnold, S.E., Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease (2014) Diabetes, 63, pp. 2253-2261; Du, J., Wang, Z., Therapeutic potential of lipase inhibitor orlistat in Alzheimer’s disease (2009) Med. Hypotheses, 73, pp. 662-663; Mahmoudiandehkordi, S., Arnold, M., Nho, K., Ahmad, S., Jia, W., Xia, G., Louie, G., Thompson, J.W., Altered Bile Acid Profile Associates with Cognitive Impairment in Alzheimer’s Disease: An Emerging Role for Gut Microbiome (2018) Biorxiv; Guerciolini, R., Mode of action of orlistat (1997) Int. J. Obes. Relat. Metab. Disord., 21, pp. S12-S23. , PubMed; Snowden, S.G., Ebshiana, A.A., Hye, A., An, Y., Pletnikova, O., O’Brien, R., Troncoso, J., Thambisetty, M., Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study (2017) Plos Med, 14; Daugherty, D., Goldberg, J., Fischer, W., Dargusch, R., Maher, P., Schubert, D., A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism (2017) Alzheimers Res. Ther., 9, p. 50; Ramos, B.P., Colgan, L.A., Nou, E., Arnsten, A.F., β2 adrenergic agonist, clenbuterol, enhances working memory performance in aging animals (2008) Neurobiol. Aging, 29, pp. 1060-1069; Chai, G.S., Wang, Y.Y., Yasheng, A., Zhao, P., Beta 2-adrenergic receptor activation enhances neurogenesis in Alzheimer’s disease mice (2016) Neural Regener. Res., 11, pp. 1617-1624; Pan, S.J., Hancock, J., Ding, Z., Fogt, D., Lee, M., Ivy, J.L., Effects of clenbuterol on insulin resistance in conscious obese Zucker rats (2001) Am. J. Physiol. Endocrinol. Metab., 280, pp. E554-E561; Ceol, A., Aryamontri, A.C., Licata, L., Peluso, D., Briganti, L., Perfetto, L., Castagnoli, L., Cesareni, G., MINT, the molecular interaction database: 2009 update (2010) Nucleic Acids Res, 38, pp. D532-D539; Stark, C., Breitkreutz, B.J., Chatr-Aryamontri, A., Boucher, L., Oughtred, R., Livstone, M.S., Nixon, J., Shi, X., The BioGRID Interaction Database: 2011 update (2010) Nucleic Acids Res, 39, pp. D698-D704; Prasad, T.S.K., Goel, R., Kandasamy, K., Keerthikumar, S., Kumar, S., Mathivanan, S., Telikicherla, D., Venugopal, A., Human Protein Reference Database—2009 update (2009) Nucleic Acids Res., 37, pp. D767-D772; Kanehisa, M., Goto, S., Hattori, M., Aoki-Kinoshita, K.F., Itoh, M., Kawashima, S., Katayama, T., Hirakawa, M., From genomics to chemical genomics: New developments in KEGG (2006) Nucleic Acids Res, 34, pp. D354-D357; Duarte, N.C., Becker, S.A., Jamshidi, N., Thiele, I., Mo, M.L., Vo, T.D., Srivas, R., Palsson, B.O., Global reconstruction of the human metabolic network based on genomic and bibliomic data (2007) Proc. Natl. Acad. Sci. USA, 104, pp. 1777-1782; Ruepp, A., Brauner, B., Dunger-Kaltenbach, I., Frishman, G., Montrone, C., Stransky, M., Waegele, B., Stümpflen, V., CORUM: The comprehensive resource of mammalian protein complexes (2008) Nucleic Acids Res, 36, pp. D646-D650; Hornbeck, P.V., Kornhauser, J.M., Tkachev, S., Zhang, B., Skrzypek, E., Murray, B., Latham, V., Sullivan, M., PhosphoSitePlus: A comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse (2012) Nucleic Acids Res, 40, pp. D261-D270; Leskovec, J., Faloutsos, C., (2006) Sampling from Large Graphs, pp. 631-636. , Proceedings of the 12th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, Philadelphia, PA, USA, 20–23 August 2006; ACM: New York, NY, USA; Erten, S., Bebek, G., Ewing, R., Koyuturk, M., DADA: Degree-Aware Algorithms for Network-Based Disease Gene Prioritization (2011) Biodata Min, 4, p. 19; Guney, E., Oliva, B., Analysis of the Robustness of Network-Based Disease-Gene Prioritization Methods Reveals Redundancy in the Human Interactome and Functional Diversity of Disease-Genes (2014) Plos ONE, 9; Guney, E., Investigating Side Effect Modules in the Interactome and Their Use in Drug Adverse Effect Discovery (2017) Complex Networks VIII, pp. 239-250. , Springer: Cham, Switzerland; Guney, E., Oliva, B., Exploiting Protein-Protein Interaction Networks for Genome-Wide Disease-Gene Prioritization (2012) Plos ONE, 7; Piñero, J., Bravo, A., Queralt-Rosinach, N., Gutiérrez-Sacristán, A., Deu-Pons, J., Centeno, E., García-García, J., Furlong, L.I., DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants (2017) Nucleic Acids Res, 45, pp. D833-D839; UniProt: A hub for protein information (2015) Nucleic Acids Res, 43, pp. D204-D212; Landrum, M.J., Lee, J.M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Hoover, J., ClinVar: Public archive of interpretations of clinically relevant variants (2016) Nucleic Acids Res, 44, pp. D862-D868; Rath, A., Olry, A., Dhombres, F., Brandt, M.M., Urbero, B., Ayme, S., Representation of rare diseases in health information systems: The Orphanet approach to serve a wide range of end users (2012) Hum. Mutat., 33, pp. 803-808; Welter, D., Macarthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Hindorff, L., The NHGRI GWAS Catalog, a curated resource of SNP-trait associations (2014) Nucleic Acids Res, 42, pp. D1001-D1006; Davis, A.P., Grondin, C.J., Lennon-Hopkins, K., Saraceni-Richards, C., Sciaky, D., King, B.L., Wiegers, T.C., Mattingly, C.J., The Comparative Toxicogenomics Database’s 10th year anniversary: Update (2015) Nucleic Acids Res, 2015 (43), pp. D914-D920. , [CrossRef[PubMed; Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Sayeeda, Z., DrugBank 5.0: A major update to the DrugBank database for 2018 (2018) Nucleic Acids Res, 46, pp. D1074-D1082; Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., Mesirov, J.P., Molecular signatures database (MSigDB) 3 (2011) 0. Bioinformatics, 27, pp. 1739-1740; Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Kamdar, M.R., The Reactome pathway knowledgebase (2014) Nucleic Acids Res, 42, pp. D472-D477; Zhou, X., Menche, J., Barabási, A.L., Sharma, A., Human symptoms—Disease network (2014) Nat. Commun., 5, p. 4212; Hidalgo, C.A., Blumm, N., Barabási, A.L., Christakis, N.A., A Dynamic Network Approach for the Study of Human Phenotypes (2009) Plos Comput. Biol., 5; Kibbe, W.A., Arze, C., Felix, V., Mitraka, E., Bolton, E., Fu, G., Mungall, C.J., Vasant, D., Disease Ontology 2015 update: An expanded and updated database of human diseases for linking biomedical knowledge through disease data (2015) Nucleic Acids Res, 43, pp. D1071-D1078; Clark, N.R., Ma’Ayan, A., Introduction to statistical methods for analyzing large data sets: Gene-set enrichment analysis (2011) Sci. Signal., 4, p. 4; Benjamini, Y., Hochberg, Y., Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing (1995) J. R. Stat. Soc. Ser. B (Methodol.), 57, pp. 289-300; Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Ideker, T., Cytoscape: A software environment for integrated models of biomolecular interaction networks (2003) Genome Res, 13, pp. 2498-2504; Vanderplas, J., (2018) Python Data Science Handbook, , O’Reilly Media, Inc.: Sebastopol, CA, USA; Wickham, H., (2009) Ggplot2: Elegant Graphics for Data Analysis (Use R!), , Springer: New York, NY, USA","Guney, E.; Hospital del Mar Medical Research Institute and Pompeu Fabra University, Dr. Aiguader 88, Spain; email: emre.guney@upf.edu",,,"MDPI AG",,,,,14248247,,,,"English","Pharmaceuticals",Article,"Final",Open Access,Scopus,2-s2.0-85049754753
"Cano J., Gomis-Tena J., Amberg A., Anger L., Ballet V., Guillon J.-M., Pastor M., Sanz F., Romero L., Saiz J.","57201723574;6602304661;6602980607;36551889900;36999226200;57195608692;7102415847;7102263897;57201236528;7005152234;","Development and Validation of an in Silico Rabbit Purkinje Cell Action Potential Model: A Step Towards a Drug Safety Testing Tool",2018,"Computing in Cardiology","2018-September",, 8743649,"","",,,"10.22489/CinC.2018.304","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068767671&doi=10.22489%2fCinC.2018.304&partnerID=40&md5=a2c793d19a0edc714fd19904284e57d4","Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politécnica de Valéncia, Valencia, 46022, Spain; RD Preclinical Safety, SANOFI, Frankfurt, Germany; RD Preclinical Safety, SANOFI, Paris, France; Research Programme on Biomedical Informatics (GRIB), Dept. of Experimental and Health Sciences, Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, Spain","Cano, J., Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politécnica de Valéncia, Valencia, 46022, Spain; Gomis-Tena, J., Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politécnica de Valéncia, Valencia, 46022, Spain; Amberg, A., RD Preclinical Safety, SANOFI, Frankfurt, Germany; Anger, L., RD Preclinical Safety, SANOFI, Frankfurt, Germany; Ballet, V., RD Preclinical Safety, SANOFI, Paris, France; Guillon, J.-M., RD Preclinical Safety, SANOFI, Paris, France; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Dept. of Experimental and Health Sciences, Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Dept. of Experimental and Health Sciences, Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Romero, L., Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politécnica de Valéncia, Valencia, 46022, Spain; Saiz, J., Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politécnica de Valéncia, Valencia, 46022, Spain","Companies and regulators evaluate compounds' cardiac safety commonly through in-vitro assays involving cardiac cells. Rabbit cardiac Purkinje Cells (RPCs) are very sensitive to drug effects such as Action Potential Duration (APD) alteration by ion channel block. Our objective is to create a novel RPC model calibrated with the latest experimental data. We developed a new RPC model using Pan-Rudy's Canine Purkinje cell model as a framework. We adapted important parameters, namely, size, ion fluxes and conductances. We also included a sodium current Markovian formulation to account for its recently increased importance. Variables were adjusted to match the main experimentally observed RPCs features. Steady-state was reached by pacing the model for 1500 seconds at different Basic Cycle Lengths (BCLs). The model was validated by extracting data from experimental sources. Results show overall agreement with the literature with improvements to previous models. In conclusion, we improved and successfully validated an RPC model. This work paves the way towards a reliable in-silico tool for testing drug effects on RPCs. © 2018 Creative Commons Attribution.",,"Cardiology; Cells; Cytology; Neurons; Action potential durations; Action potentials; Drug effects; Drug safety testing; In-vitro assays; Purkinje cells; Sodium current; Steady state; Safety testing",,,,,"Generalitat Valenciana: 2016/088

European Regional Development Fund, FEDER: DPI2015-69125-R

Ministerio de Economía y Competitividad, MINECO","This work was partially supported by grants from the Ministerio de Economía y Competitividad and Fondo Europeo de Desarrollo Regional (FEDER) DPI2015-69125-R (MINECO/FEDER, UE) and from the ""Programa Prometeo"", Generalitat Valenciana, Award Number: 2016/088.",,,"Fermini, B., Hancox, J.C., Abi-Gerges, N., Bridgland-Taylor, M., Chaudhary, K.W., Colatsky, T., A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm (2016) J Biomol Screen, 21 (1), pp. 1-11. , Jan 1; Lu, H.R., Vlaminckx, E., Gallacher, D.J., Choice of cardiac tissue in vitro plays an important role in assessing the risk of drug-induced cardiac arrhythmias in human: Beyond QT prolongation (2008) J Pharmacol Toxicol Methods, 57 (1), pp. 1-8; Li, W., Yu, Y., Hou, J.-W., Zhou, Z.-W., Guo, K., Zhang, P.-P., Larger rate dependence of late sodium current in cardiac Purkinje cells: A potential link to arrhythmogenesis (2017) Hear Rhythm, 14 (3), pp. 422-431; Moreno, J.D., Lewis, T.J., Clancy, C.E., Parameterization for in-silico modeling of ion channel interactions with drugs (2016) Bondarenko VE, Editor. PLoS One, 11 (3), p. e0150761. , Mar 10; Li, P., Rudy, Y., A model of canine purkinje cell electrophysiology and ca2+ cycling: Rate dependence, triggered activity, and comparison to ventricular myocytes (2011) Circ Res, 109 (1), pp. 71-79. , Jun 24; Corrias, A., Giles, W., Rodriguez, B., Ionic mechanisms of electrophysiological properties and repolarization abnormalities in rabbit Purkinje fibers (2011) Am J Physiol Heart Circ Physiol, 300 (5), pp. H1806-H1813. , May; Moreno, J.D., Yang, P.-C., Bankston, J.R., Grandi, E., Bers, D.M., Kass, R.S., Ranolazine for congenital and acquired late INa-linked arrhythmias: In silico pharmacological screening (2013) Circ Res, 113 (7), pp. e50-61. , Sep 13; Aslanidi, O.V., Sleiman, R.N., Boyett, M.R., Hancox, J.C., Zhang, H., Ionic mechanisms for electrical heterogeneity between rabbit purkinje fiber and ventricular cells (2010) Biophys J, 98 (11), pp. 2420-2431. , Jun; Aubert, M., Osterwalder, R., Wagner, B., Parrilla, I., Cavero, I., Doessegger, L., Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans (2006) Drug Saf, 29 (3), pp. 237-254; Conlon, K., De Maeyer, J.H., Bruce, C., Schuurkes, J.A.J., Christie, L., McRedmond, J., Nonclinical cardiovascular studies of prucalopride, a highly selective 5-hydroxytryptamine 4 receptor agonist (2018) J Pharmacol Exp Ther, 364 (2), pp. 156-169. , Feb [cited 2018 Apr 13]; Ducroq, J., Printemps, R., Le Grand, M., Additive effects of ziprasidone and d,l-sotalol on the action potential in rabbit Purkinje fibres and on the hERG potassium current (2005) J Pharmacol Toxicol Methods, 52 (1), pp. 115-122. , Jul; Ducroq, J., Printemps, R., Guilbot, S., Gardette, J., Salvetat, C., Le Grand, M., Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies (2007) J Pharmacol Toxicol Methods, 56 (2), pp. 159-170. , Sep; Dumaine, R., Cordeiro, J.M., Comparison of K+ currents in cardiac Purkinje cells isolated from rabbit and dog (2007) J Mol Cell Cardiol, 42 (2), pp. 378-389. , Feb; Gluais, P., Bastide, M., Caron, J., Adamantidis, M., Risperidone prolongs cardiac action potential through reduction of K+ currents in rabbit myocytes (2002) Eur J Pharmacol, 444 (3), pp. 123-132. , May; Goineau, S., Castagné, V., Guillaume, P., Froget, G., The comparative sensitivity of three in vitro safety pharmacology models for the detection of lidocaine-induced cardiac effects (2012) J Pharmacol Toxicol Methods, 66 (1), pp. 52-58. , Jul; Hof, T., Sallé, L., Coulbault, L., Richer, R., Alexandre, J., Rouet, R., TRPM4 non-selective cation channels influence action potentials in rabbit Purkinje fibres (2016) J Physiol, 594 (2), pp. 295-306. , Jan 15; Lee, H.-A., Hyun, S.-A., Park, S.-G., Kim, K.-S., Kim, S.J., Comparison of electrophysiological effects of calcium channel blockers on cardiac repolarization (2016) Korean J Physiol Pharmacol, 20 (1), p. 119; Lu, H.R., Vlaminckx, E., Van Ammel, K., De Clerck, F., Drug-induced long QT in isolated rabbit Purkinje fibers: Importance of action potential duration, triangulation and early afterdepolarizations (2002) Eur J Pharmacol, 452 (2), pp. 183-192. , Oct; Roche, M., Renauleaud, C., Ballet, V., Doubovetzky, M., Guillon, J.-M., The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability (2010) J Pharmacol Toxicol Methods, 61 (3), pp. 238-250. , May; Cordeiro, J.M., Spitzer, K.W., Giles, W.R., Repolarizing K+ currents in rabbit heart Purkinje cells (1998) J Physiol, 508 (3), pp. 811-823; Lu, H.R., Vlaminckx, E., Teisman, A., Gallacher, D.J., Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit (2005) J Pharmacol Toxicol Methods, 52 (1), pp. 90-105; Yan, D., Cheng, L., Song, H.-Y., Turdi, S., Kerram, P., Electrophysiological effects of haloperidol on isolated rabbit Purkinje fibers and Guinea pigs papillary muscles under normal and simulated ischemia (2007) Acta Pharmacol Sin, 28 (8), pp. 1155-1160. , Aug; Masumiya, H., Saito, M., Ito, M., Matsuda, T., Noguchi, K., Iida-Tanaka, N., Lack of action potential-prolonging effect of terfenadine on rabbit myocardial tissue preparations (2004) Biol Pharm Bull, 27 (1), pp. 131-135; Schmidt, U., Hajjar, R.J., Helm, Pa., Kim, C.S., Doye, A., Gwathmey, J.K., Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure (1998) J Mol Cell Cardiol, 30 (10), pp. 1929-1937; Lu, H.R., Vlaminckx, E., Van De Water, A., Gallacher, D.J., Calmodulin antagonist W-7 prevents sparfloxacin-induced early afterdepolarizations (EADs) in isolated rabbit purkinje fibers: Importance of beat-to-beat instability of the repolarization (2006) J Cardiovasc Electrophysiol, 17 (4), pp. 415-422. , Apr; Lu, H.R., Vlaminckx, E., Cools, F., Tissues cardiac isolated in potentials action on trioxide arsenic of effects direct g.dj.of the choice of species i.of cardiac tissue t (2012) Methods Toxicol Pharmacol J. P.Time., 66 (2), pp. 135-144. , Sep",,,,"IEEE Computer Society","45th Computing in Cardiology Conference, CinC 2018","23 September 2018 through 26 September 2018",,149035,23258861,9781728109589,,,"English","Comput. Cardiol.",Conference Paper,"Final",Open Access,Scopus,2-s2.0-85068767671
"Romero L., Cano J., Gomis-Tena J., Trenor B., Sanz F., Pastor M., Saiz J.","57201236528;57201723574;6602304661;6603366726;7102263897;7102415847;7005152234;","In Silico QT and APD Prolongation Assay for Early Screening of Drug-Induced Proarrhythmic Risk",2018,"Journal of Chemical Information and Modeling","58","4",,"867","878",,1,"10.1021/acs.jcim.7b00440","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045956014&doi=10.1021%2facs.jcim.7b00440&partnerID=40&md5=d033edf8fa1d8da13b69d30004af72c6","Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, camino de Vera, s/n, Valencia, 46022, Spain; Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer del Dr. Aiguader 88, Barcelona, 08002, Spain","Romero, L., Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, camino de Vera, s/n, Valencia, 46022, Spain; Cano, J., Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, camino de Vera, s/n, Valencia, 46022, Spain; Gomis-Tena, J., Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, camino de Vera, s/n, Valencia, 46022, Spain; Trenor, B., Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, camino de Vera, s/n, Valencia, 46022, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer del Dr. Aiguader 88, Barcelona, 08002, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Carrer del Dr. Aiguader 88, Barcelona, 08002, Spain; Saiz, J., Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, camino de Vera, s/n, Valencia, 46022, Spain","Drug-induced proarrhythmicity is a major concern for regulators and pharmaceutical companies. For novel drug candidates, the standard assessment involves the evaluation of the potassium hERG channels block and the in vivo prolongation of the QT interval. However, this method is known to be too restrictive and to stop the development of potentially valuable therapeutic drugs. The aim of this work is to create an in silico tool for early detection of drug-induced proarrhythmic risk. The system is based on simulations of how different compounds affect the action potential duration (APD) of isolated endocardial, midmyocardial, and epicardial cells as well as the QT prolongation in a virtual tissue. Multiple channel-drug interactions and state-of-the-art human ventricular action potential models (O'Hara, T., PLos Comput. Biol. 2011, 7, e1002061) were used in our simulations. Specifically, 206.766 cellular and 7072 tissue simulations were performed by blocking the slow and the fast components of the delayed rectifier current (IKs and IKr, respectively) and the L-type calcium current (ICaL) at different levels. The performance of our system was validated by classifying the proarrhythmic risk of 84 compounds, 40 of which present torsadogenic properties. On the basis of these results, we propose the use of a new index (Tx) for discriminating torsadogenic compounds, defined as the ratio of the drug concentrations producing 10% prolongation of the cellular endocardial, midmyocardial, and epicardial APDs and the QT interval, over the maximum effective free therapeutic plasma concentration (EFTPC). Our results show that the Tx index outperforms standard methods for early identification of torsadogenic compounds. Indeed, for the analyzed compounds, the Tx tests accuracy was in the range of 87-88% compared with a 73% accuracy of the hERG IC50 based test. © 2018 American Chemical Society.",,"Drug interactions; Tissue; Action potential durations; Delayed rectifier; Drug concentration; Multiple channels; Pharmaceutical company; Plasma concentration; Therapeutic drugs; Tissue simulations; Electric rectifiers; action potential; biological model; chemically induced; computer simulation; drug effect; electrocardiography; heart arrhythmia; heart ventricle; human; pathology; pathophysiology; risk assessment; time factor; Action Potentials; Arrhythmias, Cardiac; Computer Simulation; Electrocardiography; Heart Ventricles; Humans; Models, Biological; Risk Assessment; Time Factors",,,,,"115002

DPI2015-69125-R

PROMETEU2016/088","L.R., J.C., J.G., B.T., J.S.: This work was partially supported by the Direccioń General de Politicá Cientifí ca de la Generalitat Valenciana (PROMETEU2016/088) as well as Ministerio de Economiá y Competitividad and Fondo Europeo de Desarrollo Regional (FEDER) DPI2015-69125-R (MINECO/FEDER, UE). F.S, M.P.: received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115002 (eTOX), resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contributions.",,,"Hammond, T.G., Carlsson, L., Davis, A.S., Lynch, W.G., Mackenzie, I., Redfern, W.S., Sullivan, A.T., Camm, A.J., Methods of Collecting and Evaluating Non-Clinical Cardiac Electrophysiology Data in the Pharmaceutical Industry: Results of an International Survey (2001) Cardiovasc. Res., 49 (4), pp. 741-750; Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., De Ponti, F., QT Prolongation through hERG K+ Channel Blockade: Current Knowledge and Strategies for the Early Prediction during Drug Development (2005) Med. Res. Rev., 25, pp. 133-166; Noble, D., Computational Models of the Heart and Their Use in Assessing the Actions of Drugs (2008) J. Pharmacol. Sci. (Tokyo, Jpn.), 107 (2), pp. 107-117; Valentin, J.-P., Hammond, T., Safety and Secondary Pharmacology: Successes, Threats, Challenges and Opportunities (2008) J. Pharmacol. Toxicol. Methods, 58 (2), pp. 77-87; Adams, C.P., Brantner, V.V., Estimating the Cost of New Drug Development: Is It Really 802 Million Dollars? (2006) Health Aff., 25 (2), pp. 420-428; (2005) ICH Harmonised Tripartite Guideline. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs E14, , http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf, Ste4 Version; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, May; (2005) E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs, , https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073153.pdf, U.S. Food and Drug Administration: Rockville, MD, October; Roden, D.M., Cellular Basis of Drug-Induced Torsades de Pointes (2008) Br. J. Pharmacol., 154 (7), pp. 1502-1507; Kramer, J., Obejero-Paz, C.A., Myatt, G., Kuryshev, Y.A., Bruening-Wright, A., Verducci, J.S., Brown, A.M., MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes (2013) Sci. Rep., 3 (1), p. 2100; Windley, M.J., Abi-Gerges, N., Fermini, B., Hancox, J.C., Vandenberg, J.I., Hill, A.P., Measuring Kinetics and Potency of hERG Block for CiPA (2017) J. Pharmacol. Toxicol. Methods, 88, p. 197; Pollard, C.E., Abi Gerges, N., Bridgland-Taylor, M.H., Easter, A., Hammond, T.G., Valentin, J.-P., An Introduction to QT Interval Prolongation and Non-Clinical Approaches to Assessing and Reducing Risk (2010) Br. J. Pharmacol., 159 (1), pp. 12-21; Mirams, G.R., Cui, Y., Sher, A., Fink, M., Cooper, J., Heath, B.M., McMahon, N.C., Noble, D., Simulation of Multiple Ion Channel Block Provides Improved Early Prediction of Compounds' Clinical Torsadogenic Risk (2011) Cardiovasc. Res., 91 (1), pp. 53-61; Obiol-Pardo, C., Gomis-Tena, J., Sanz, F., Saiz, J., Pastor, M., A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity (2011) J. Chem. Inf. Model., 51 (2), pp. 483-492; Davies, M.R., Mistry, H.B., Hussein, L., Pollard, C.E., Valentin, J.-P., Swinton, J., Abi-Gerges, N., An in Silico Canine Cardiac Midmyocardial Action Potential Duration Model as a Tool for Early Drug Safety Assessment (2012) Am. J. Physiol. Heart Circ. Physiol., 302 (7), pp. H1466-H1480; Beattie, K.A., Luscombe, C., Williams, G., Munoz-Muriedas, J., Gavaghan, D.J., Cui, Y., Mirams, G.R., Evaluation of an in Silico Cardiac Safety Assay: Using Ion Channel Screening Data to Predict QT Interval Changes in the Rabbit Ventricular Wedge (2013) J. Pharmacol. Toxicol. Methods, 68 (1), pp. 88-96; Mirams, G.R., Davies, M.R., Brough, S.J., Bridgland-Taylor, M.H., Cui, Y., Gavaghan, D.J., Abi-Gerges, N., Prediction of Thorough QT Study Results Using Action Potential Simulations Based on Ion Channel Screens (2014) J. Pharmacol. Toxicol. Methods, 70 (3), pp. 246-254; Yap, C.W., Cai, C.Z., Xue, Y., Chen, Y.Z., Prediction of Torsade-Causing Potential of Drugs by Support Vector Machine Approach (2004) Toxicol. Sci., 79 (1), pp. 170-177; He, Y., Lim, S.W.Y., Yap, C.W., Determination of Torsade-Causing Potential of Drug Candidates Using One-Class Classification and Ensemble Modelling Approaches (2012) Curr. Drug Saf., 7 (4), pp. 298-308; Mistry, H.B., Davies, M.R., Di Veroli, G.Y., A New Classifier-Based Strategy for in-Silico Ion-Channel Cardiac Drug Safety Assessment (2015) Front. Pharmacol., 6, p. 59; Lancaster, M.C., Sobie, E.A., Improved Prediction of Drug-Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms (2016) Clin. Pharmacol. Ther., 100 (4), pp. 371-379; Wiśniowska, B., Polak, S., Am i or Am i Not Proarrhythmic? Comparison of Various Classifications of Drug TdP Propensity (2017) Drug Discovery Today, 22 (1), pp. 10-16; Sager, P.T., Gintant, G., Turner, J.R., Pettit, S., Stockbridge, N., Rechanneling the Cardiac Proarrhythmia Safety Paradigm: A Meeting Report from the Cardiac Safety Research Consortium (2014) Am. Heart J., 167 (3), pp. 292-300; Redfern, W.S., Carlsson, L., Davis, A.S., Lynch, W.G., Mackenzie, I., Palethorpe, S., Siegl, P.K.S., Hammond, T.G., Relationships between Preclinical Cardiac Electrophysiology, Clinical QT Interval Prolongation and Torsade de Pointes for a Broad Range of Drugs: Evidence for a Provisional Safety Margin in Drug Development (2003) Cardiovasc. Res., 58 (1), pp. 32-45; Gintant, G., An Evaluation of hERG Current Assay Performance: Translating Preclinical Safety Studies to Clinical QT Prolongation (2011) Pharmacol. Ther., 129 (2), pp. 109-119; Rodriguez, B., Burrage, K., Gavaghan, D., Grau, V., Kohl, P., Noble, D., The Systems Biology Approach to Drug Development: Application to Toxicity Assessment of Cardiac Drugs (2010) Clin. Pharmacol. Ther., 88 (1), pp. 130-134; Romero, L., Trenor, B., Yang, P.-C., Saiz, J., Clancy, C.E., In Silico Screening of the Impact of hERG Channel Kinetic Abnormalities on Channel Block and Susceptibility to Acquired Long QT Syndrome (2015) J. Mol. Cell. Cardiol., 87, pp. 271-282; Trenor, B., Gomis-Tena, J., Cardona, K., Romero, L., Rajamani, S., Belardinelli, L., Giles, W.R., Saiz, J., In Silico Assessment of Drug Safety in Human Heart Applied to Late Sodium Current Blockers (2013) Channels, 7 (4), pp. 249-262; Okada, J.-I., Yoshinaga, T., Kurokawa, J., Washio, T., Furukawa, T., Sawada, K., Sugiura, S., Hisada, T., Screening System for Drug-Induced Arrhythmogenic Risk Combining a Patch Clamp and Heart Simulator (2015) Sci. Adv., 1 (4), p. e1400142; Mirams, G.R., Davies, M.R., Cui, Y., Kohl, P., Noble, D., Application of Cardiac Electrophysiology Simulations to pro-Arrhythmic Safety Testing (2012) Br. J. Pharmacol., 167 (5), pp. 932-945; O'Hara, T., Virág, L., Varró, A., Rudy, Y., Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental Validation (2011) PLoS Comput. Biol., 7 (5), p. e1002061; Woosley, R., Romero, K., (2013) QTdrugs List, , www.Crediblemeds.org, AZCERT, Inc.: 1822 Innovation Park Dr., Oro Valley, AZ 85755; Bottino, D., Penland, R.C., Stamps, A., Traebert, M., Dumotier, B., Georgieva, A., Helmlinger, G., Lett, G.S., Preclinical Cardiac Safety Assessment of Pharmaceutical Compounds Using an Integrated Systems-Based Computer Model of the Heart (2006) Prog. Biophys. Mol. Biol., 90 (1-3), pp. 414-443; Brennan, T., Fink, M., Rodriguez, B., Multiscale Modelling of Drug-Induced Effects on Cardiac Electrophysiological Activity (2009) Eur. J. Pharm. Sci., 36 (1), pp. 62-77; Elkins, R.C., Davies, M.R., Brough, S.J., Gavaghan, D.J., Cui, Y., Abi-Gerges, N., Mirams, G.R., Variability in High-Throughput Ion-Channel Screening Data and Consequences for Cardiac Safety Assessment (2013) J. Pharmacol. Toxicol. Methods, 68 (1), pp. 112-122; Hoffmann, P., Warner, B., Are hERG Channel Inhibition and QT Interval Prolongation All There Is in Drug-Induced Torsadogenesis? A Review of Emerging Trends (2006) J. Pharmacol. Toxicol. Methods, 53 (2), pp. 87-105; Cantilena, L., Jr., Koerner, J., Temple, R., Throckmorton, D., FDA Evaluation of Cardiac Repolarization Data for 19 Drugs and Drug Candidates (2006) Clin. Pharmacol. Ther., 79 (2), p. P29; Virág, L., Iost, N., Opincariu, M., Szolnoky, J., Szécsi, J., Bogáts, G., Szenohradszky, P., Papp, J.G., The Slow Component of the Delayed Rectifier Potassium Current in Undiseased Human Ventricular Myocytes (2001) Cardiovasc. Res., 49 (4), pp. 790-797; Romero, L., Carbonell, B., Trenor, B., Rodríguez, B., Saiz, J., Ferrero, J.M., Systematic Characterization of the Ionic Basis of Rabbit Cellular Electrophysiology Using Two Ventricular Models (2011) Prog. Biophys. Mol. Biol., 107 (1), pp. 60-73; Zicha, S., Moss, I., Allen, B., Varro, A., Papp, J., Dumaine, R., Antzelevich, C., Nattel, S., Molecular Basis of Species-Specific Expression of Repolarizing K+ Currents in the Heart (2003) Am. J. Physiol. Heart Circ. Physiol., 285 (4), pp. H1641-H1649; Cubeddu, L.X., Drug-Induced Inhibition and Trafficking Disruption of Ion Channels: Pathogenesis of QT Abnormalities and Drug-Induced Fatal Arrhythmias (2016) Curr. Cardiol. Rev., 12 (2), pp. 141-154; Damrongwatanasuk, R., Fradley, M.G., Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia (2017) Curr. Treat. Options Cardiovasc. Med., 19 (4), p. 24; Kanlop, N., Chattipakorn, S., Chattipakorn, N., Effects of Cilostazol in the Heart (2011) J. Cardiovasc. Med., 12 (2), pp. 88-95; Iram, F., Ali, S., Ahmad, A., Khan, S.A., Husain, A., A Review on Dronedarone: Pharmacological, Pharmacodynamic and Pharmacokinetic Profile (2016) J. Acute Dis., 5 (2), pp. 102-108; Zhang, X., Jordan, P., Cristea, L., Salgo, M., Farha, R., Kolis, S., Lee, L.S., Thorough QT/QTc Study of Ritonavir-Boosted Saquinavir Following Multiple-Dose Administration of Therapeutic and Supratherapeutic Doses in Healthy Participants (2012) J. Clin. Pharmacol., 52 (4), pp. 520-529; Poluzzi, E., Raschi, E., Motola, D., Moretti, U., De Ponti, F., Antimicrobials and the Risk of Torsades de Pointes: The Contribution from Data Mining of the US FDA Adverse Event Reporting System (2010) Drug Saf., 33 (4), pp. 303-314; Briasoulis, A., Agarwal, V., Pierce, W.J., QT Prolongation and Torsade de Pointes Induced by Fluoroquinolones: Infrequent Side Effects from Commonly Used Medications (2011) Cardiology, 120 (2), pp. 103-110; Adamantidis, M.M., Dumotier, B.M., Caron, J.F., Bordet, R., Sparfloxacin but Not Levofloxacin or Ofloxacin Prolongs Cardiac Repolarization in Rabbit Purkinje Fibers (1998) Fundam. Clin. Pharmacol., 12 (1), pp. 70-76; Briggs, K., Cases, M., Heard, D.J., Pastor, M., Pognan, F., Sanz, F., Schwab, C.H., Wichard, J.D., Inroads to Predict in Vivo Toxicology - An Introduction to the eTOX Project (2012) Int. J. Mol. Sci., 13, pp. 3820-3846; Sanz, F., Carrió, P., López, O., Capoferri, L., Kooi, D.P., Vermeulen, N.P.E., Geerke, D.P., Pastor, M., Integrative Modeling Strategies for Predicting Drug Toxicities at the eTOX Project (2015) Mol. Inf., 34, pp. 477-484","Saiz, J.; Centro de Investigación e Innovación en Bioingeniería (CI2B), Universitat Politècnica de València, camino de Vera, s/n, Spain; email: jsaiz@ci2b.upv.es",,,"American Chemical Society",,,,,15499596,,JCISD,"29547274","English","J. Chem. Inf. Model.",Article,"Final",,Scopus,2-s2.0-85045956014
"López-Massaguer O., Pinto-Gil K., Sanz F., Amberg A., Anger L.T., Stolte M., Ravagli C., Marc P., Pastor M.","57200183862;56543802500;7102263897;6602980607;36551889900;57189359384;57193556442;7004044863;7102415847;","Generating modeling data from repeat-dose toxicity reports",2018,"Toxicological Sciences","162","1",,"287","300",,1,"10.1093/toxsci/kfx254","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043513468&doi=10.1093%2ftoxsci%2fkfx254&partnerID=40&md5=443b8b73f65ec39ae457e085b556b03d","Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Institut Hospital del Mar d'Investigacions Médiques (IMIM), Universitat Pompeu Fabra, Barcelona, 08003, Spain; Sanofi, Preclinical Safety, Frankfurt am Main, 65926, Germany; Translational Medicine, Novartis Institute for Biomedical Research, Basel, CH-4002, Switzerland","López-Massaguer, O., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Institut Hospital del Mar d'Investigacions Médiques (IMIM), Universitat Pompeu Fabra, Barcelona, 08003, Spain; Pinto-Gil, K., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Institut Hospital del Mar d'Investigacions Médiques (IMIM), Universitat Pompeu Fabra, Barcelona, 08003, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Institut Hospital del Mar d'Investigacions Médiques (IMIM), Universitat Pompeu Fabra, Barcelona, 08003, Spain; Amberg, A., Sanofi, Preclinical Safety, Frankfurt am Main, 65926, Germany; Anger, L.T., Sanofi, Preclinical Safety, Frankfurt am Main, 65926, Germany; Stolte, M., Sanofi, Preclinical Safety, Frankfurt am Main, 65926, Germany; Ravagli, C., Translational Medicine, Novartis Institute for Biomedical Research, Basel, CH-4002, Switzerland; Marc, P., Translational Medicine, Novartis Institute for Biomedical Research, Basel, CH-4002, Switzerland; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Institut Hospital del Mar d'Investigacions Médiques (IMIM), Universitat Pompeu Fabra, Barcelona, 08003, Spain","Over the past decades, pharmaceutical companies have conducted a large number of high-quality in vivo repeat-dose toxicity (RDT) studies for regulatory purposes. As part of the eTOX project, a high number of these studies have been compiled and integrated into a database. This valuable resource can be queried directly, but it can be further exploited to build predictive models. As the studies were originally conducted to investigate the properties of individual compounds, the experimental conditions across the studies are highly heterogeneous. Consequently, the original data required normalization/standardization, filtering, categorization and integration to make possible any data analysis (such as building predictive models). Additionally, the primary objectives of the RDT studies were to identify toxicological findings, most of which do not directly translate to in vivo endpoints. This article describes a method to extract datasets containing comparable toxicological properties for a series of compounds amenable for building predictive models. The proposed strategy starts with the normalization of the terms used within the original reports. Then, comparable datasets are extracted from the database by applying filters based on the experimental conditions. Finally, carefully selected profiles of toxicological findings are mapped to endpoints of interest, generating QSAR-like tables. In this work, we describe in detail the strategy and tools used for carrying out these transformations and illustrate its application in a data sample extracted from the eTOX database. The suitability of the resulting tables for developing hazard-predicting models was investigated by building proof-of-concept models for in vivo liver endpoints. © The Author 2017.","In silico modeling; In vivo data; Ontologies; RDT; Toxicology databases","adult; animal experiment; Article; controlled study; data base; data processing; liver toxicity; mathematical model; mouse; nonhuman; partial least squares regression; proof of concept; quantitative structure activity relation; random forest; rat; repeat dose toxicity; toxicity; toxicity testing; adverse drug reaction; bioassay; data mining; factual database; forecasting; information dissemination; preclinical study; procedures; risk assessment; standards; statistics and numerical data; theoretical model; toxicity testing; Data Mining; Databases, Factual; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Forecasting; Information Dissemination; Models, Theoretical; Risk Assessment; Toxicity Tests",,,,,,,,,"Agrawal, R., Gupta, A., Sarawagi, S., Modeling multidimensional databases (1997) Proceedings 13th International Conference on Data Engineering, pp. 232-243. , IEEE Computer Society Press; Angermueller, C., Pärnamaa, T., Parts, L., Oliver, S., Deep learning for computational biology.Mol (2016) Syst. Biol, 12, p. 878; Atkinson, F., (2014) Standardiser, , https://github.com/flatkinson/standardiser, last accessed November 20, 2017; Baader, F., McGinness, D., Nardi, D., Patel-Schneider, P.F., (2010) The Description Logic Handbook: Theory, Implementation and Applications Cambridge University Press, , New York, NY, USA; Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Valigi, R., Clementi, S., Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems (1993) Quant. Struct. Relationships, 12, pp. 9-20; Carbonell, P., Lopez, O., Amberg, A., Pastor, M., Sanz, F., Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data (2017) ALTEX, 34, pp. 219-234; Carrió, P., Pinto, M., Ecker, G., Sanz, F., Pastor, M., Applicability domain analysis (ADAN): A robust method for assessing the reliability of drug property predictions (2014) J. Chem. Inf. Model, 54, pp. 1500-1511; Cases, M., Briggs, K., Steger-Hartmann, T., Pognan, F., Marc, P., Kleinöder, T., Schwab, C.H., Sanz, F., The eTOX Data-Sharing Project to Advance in Silico Drug-Induced Toxicity Prediction (2014) Int. J. Mol. Sci, 15, pp. 21136-21154; Codd, E.F., A relational model of data for large shared data banks (1970) Commun. ACM, 13, pp. 377-387; Date, C.J., An introduction to database systems (1995) An Introd. Database Syst, 1, p. 839; Durán, Á., Zamora, I., Pastor, M., Suitability of GRINDbased principal properties for the description of molecular similarity and ligand-based virtual screening (2009) J. Chem. Inf. Model, 49, pp. 2129-2138; (2007), GNU GENERAL PUBLIC LICENSE Version 3, 29 June 2007; Garcia-Molina, H., Ullman, J.D., Widom, J., (2008) Database systems: the complete book 2nd ed, , Pearson Prentice Hall, Upper Saddle River, NJ, USA; Gray, J., Chaudhuri, S., Bosworth, A., Layman, A., Reichart, D., Venkatrao, M., Pellow, F., Pirahesh, H., Data cube: A relational aggregation operator generalizing group-by, cross-tab, and sub-totals (1997) Data Min. Knowl. Discov, 1, pp. 29-53; (2007), http://www.gnu.org/licenses/gpl.html, last accessed November 20, 2017; Hayamizu, T.F., Mangan, M., Corradi, J.P., Kadin, J.A., Ringwald, M., The Adult Mouse Anatomical Dictionary: a tool for annotating and integrating data (2005) Genome Biol, 6, p. R29; Keenan, C.M., Baker, J., Bradley, A., Goodman, D.G., Harada, T., Herbert, R., Kaufmann, W., Meseck, E., International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) (2015) Toxicol. Pathol, 43, pp. 730-732; Kimball, R., Reeves, L., Ross, M., Thornthwaite, W., (2008) The Data Warehouse Lifecycle Toolkit Table of Contents Wiley Pub, , New York, NY, USA; Leffler, J.E., Grunwald, E., (1963) Rates and equilibria of organic reactions Wiley, , New York; López-Massaguer, O., (2017) eTOX in vivo data extraction tool v1.0, , https://github.com/phi-grib/etox-rdt-extraction-tool, last accessed November 20, 2017; López-Massaguer, O., (2017) Scoring tool v1.4.1, , https://github.com/phi-grib/Scoring, last accessed November 20, 2017; Martin, M.T., Judson, R.S., Reif, D.M., Kavlock, R.J., Dix, D.J., Profiling chemicals based on chronic toxicity results from the U.S (2009) EPA toxref database. Environ. Health Perspect, 117, pp. 392-399; Mayr, A., Klambauer, G., Unterthiner, T., Hochreiter, S., DeepTox: Toxicity prediction using deep learning (2016) Front. Environ. Sci, 3, pp. 17-31; Mernik, M., Heering, J., Sloane, A.M., When and how to develop domain-specific languages (2005) ACM Comput. Surv, 37, pp. 316-344; Milletti, F., Storchi, L., Sforna, G., Cruciani, G., New and original pKa prediction method using grid molecular interaction fields (2007) J. Chem. Inf. Model, 47, pp. 2172-2181; (2017) MoKa eTOX version 3.0, , http://www.moldiscovery.com/software/moka/; (2017) Pentacle 1.0.6, , http://www.moldiscovery.com/software/moka/, last accessed November 20, 2017; (2017) AdrianaCode, , https://www.mn-am.com/products/adrianacode, last accessed November 20, 2017; (2017), https://bioportal.bioontology.org/ontologies/MA, last accessed November 20, 2017; Mulliner, D., Schmidt, F., Stolte, M., Spirkl, H.P., Czich, A., Amberg, A., Computational models for human and animal hepatotoxicity with a global application scope (2016) Chem. Res. Toxicol, 29, pp. 757-767; Necib, C., Freytag, J., Using Ontologies for Database Query Reformulation (2004) Proceeding on the 18 th conference on Advances in Databases and Information Systems (ADBIS02004); Odersky, M., Altherr, P., Cremet, V., Emir, B., Maneth, S., Micheloud, S., Mihaylov, N., Zenger, M., (2004) An Overview of the Scala Programming Language, École Polytechnique Fédé rale de Lausanne, , https://infoscience.epfl.ch/record/52656/files/ScalaOverview.pdf, last accessed November 20, 2017; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors (2000) J. Med. Chem, 43, pp. 3233-3243; Pedregosa, F., Scikit-learn: Machine learning in python (2011) J. Mach. Learn. Res, 12, pp. 2825-2830; (2016), https://www.postgresql.org, 2016, last accessed November 20, 2017; Ravagli, C., Pognan, F., Marc, P., OntoBrowser: A collaborative tool for curation of ontologies by subject matter experts (2017) Bioinformatics, 33 (1), pp. 148-149; Sadowski, J., Gasteiger, J., Klebe, G., Comparison of automatic three-dimensional model builders using 639 X-ray structures (1994) J. Chem. Inf. Model, 34, pp. 1000-1008; Sanz, F., Carrió, P., López, O., Capoferri, L., Kooi, D.P., Vermeulen, N.P.E., Geerke, D.P., Schwab, C.H., Integrative modeling strategies for predicting drug toxicities at the eTOX project (2015) Mol. Inform, 34, pp. 477-484; Stonebraker, M., Rowe, L.A., Stonebraker, M., Rowe, L.A., The design of POSTGRES (1986) Proceedings of the 1986 ACM SIGMOD international conference onManagement of data-SIGMOD '86, pp. 340-355. , ACMPress. NewYork,NewYork, USA; Ullman, J.D., Widom, J., (2008) A first course in database systems, , 3rd ed. Pearson Prentice Hall, Upper Saddle River, NJ, USA; Wold, S., Sjöström, M., Eriksson, L., PLS-regression: a basic tool of chemometrics (2001) Chemom. Intell. Lab. Syst, 58, pp. 109-130; Wong, L., Kleisli, a Functional Query System (2000) J. Funct. Program, 10, pp. 19-56","Pastor, M.; Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Institut Hospital del Mar d'Investigacions Médiques (IMIM), Universitat Pompeu Fabra, C/Dr. Aiguader 88, Spain; email: manuel.pastor@upf.edu",,,"Oxford University Press",,,,,10966080,,TOSCF,"29155963","English","Toxicol. Sci.",Article,"Final",Open Access,Scopus,2-s2.0-85043513468
"López-Massaguer O., Sanz F., Pastor M.","57200183862;7102263897;7102415847;","An automated tool for obtaining QSAR-ready series of compounds using semantic web technologies",2018,"Bioinformatics","34","1",,"131","133",,1,"10.1093/bioinformatics/btx566","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040045670&doi=10.1093%2fbioinformatics%2fbtx566&partnerID=40&md5=2b7d98f985d2b83afc4737ab2705f309","Research Programme On Biomedical Informatics (GRIB), Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, 08003, Spain","López-Massaguer, O., Research Programme On Biomedical Informatics (GRIB), Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, 08003, Spain; Sanz, F., Research Programme On Biomedical Informatics (GRIB), Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, 08003, Spain; Pastor, M., Research Programme On Biomedical Informatics (GRIB), Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, 08003, Spain","We describe an application (Collector) for obtaining series of compounds annotated with bioactivity data, ready to be used for the development of quantitative structure-activity relationships (QSAR) models. The tool extracts data from the 'Open Pharmacological Space' (OPS) developed by the Open PHACTS project, using as input a valid name of the biological target. Collector uses the OPS ontologies for expanding the query using all known target synonyms and extracts compounds with bioactivity data against the target from multiple sources. The extracted data can be filtered to retain only drug-like compounds and the bioactivities can be automatically summarised to assign a single value per compound, yielding data ready to be used for QSAR modeling. The data obtained is locally stored facilitating the traceability and auditability of the process. Collector was used successfully for the development of models for toxicity endpoints within the eTOX project. © 2017 The Author.",,"biology; procedures; quantitative structure activity relation; semantic web; software; Computational Biology; Quantitative Structure-Activity Relationship; Semantic Web; Software",,,,,"Seventh Framework Programme

European Federation of Pharmaceutical Industries and Associations

Innovative Medicines Initiative: 115002, 115191","This project was developed under the Innovative Medicines Initiative Joint Undertaking Open PHACTS Project, grant agreement number 115191 and eTOX project, grant agreement n° 115002, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contributions.",,,"Allemang, D., Hendler, J., (2011) Semantic Web for the Working Ontologist: Effective Modeling in RDFS and OWL, , 2nd ed. Elsevier, Waltham, MA; Berners-Lee, T., The semantic web (2001) Sci. Am., 284, pp. 34-43; Carrio, P., ETOXlab, an open source modeling framework for implementing predictive models in production environments (2015) J. Cheminf., 7, p. 8; Gaulton, A., ChEMBL: A large-scale bioactivity database for drug discovery (2012) Nucleic Acids Res., 40, pp. D1100-D1107; Gray, A.J.G., Applying linked data approaches to pharmacology: Architectural decisions and implementation (2014) Semant.Web, 5, pp. 101-113; Groth, P., API-centric Linked Data integration: The Open PHACTS Discovery Platform case study (2014) Web Semant. Sci. Serv. Agents World WideWeb, 29, pp. 12-18; Hilton, P., (2014) Play for Scala: Covers Play 2 Manning; Kelder, T., WikiPathways: Building research communities on biological pathways (2012) Nucleic Acids Res., 40, pp. D1301-D1307; Lipinski, C.A., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings (2001) Adv. Drug Deliv. Rev., 46, pp. 3-26; Machina, H.K., Effective integration of informatics tools to enhance the drug discovery process (2013) Ind. Eng. Chem. Res., 52, pp. 16547-16554; Mons, B., The value of data (2011) Nat. Genet., 43, pp. 281-283; Odersky, M., An overview of the Scala programming language (2004) Technical Report IC/2004/640, EPFL Lausanne; Parsons, S., A semantic web primer (2009) Knowl. Eng. Rev., 24, p. 415. , Second Edition by Antoniou Grigoris and Harmelen Frank van, MIT Press; Ratnam, J., The application of the Open Pharmacological Concepts Triple Store (Open PHACTS) to support drug discovery research (2014) PLoS One, 9, p. e115460; Sanz, F., Integrative modeling strategies for predicting drug toxicities at the eTOX project (2015) Mol. Inf., 34, pp. 477-484; Stonebraker, M., The design of POSTGRES (1986) Proceedings of the 1986 ACM SIGMOD International Conference On Management of Data-SIGMOD '86, pp. 340-355. , ACM Press, New York, New York, USA; Update on activities at the Universal Protein Resource (UniProt) in 2013 (2013) Nucleic Acids Res., 41, pp. D43-D47. , The UniProt Consortium; Wilkinson, M.D., The FAIR Guiding Principles for scientific data management and stewardship (2016) Sci. Data, 3, p. 160018","Pastor, M.; Research Programme On Biomedical Informatics (GRIB), Institut Hospital Del Mar d'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu FabraSpain; email: manuel.pastor@upf.edu",,,"Oxford University Press",,,,,13674803,,BOINF,"28968713","English","Bioinformatics",Article,"Final",Open Access,Scopus,2-s2.0-85040045670
"López-Massaguer O., Pastor M., Sanz F., Carbonell P.","57200183862;7102415847;7102263897;36780066700;","Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data",2018,"Methods in Molecular Biology","1800",,,"505","518",,,"10.1007/978-1-4939-7899-1_23","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049005873&doi=10.1007%2f978-1-4939-7899-1_23&partnerID=40&md5=cfd4ce20a70ea24ee2b63bb98e077e86","Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Manchester Centre for Fine and Speciality Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, University of Manchester, Manchester, United Kingdom","López-Massaguer, O., Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Pastor, M., Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Carbonell, P., Manchester Centre for Fine and Speciality Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, University of Manchester, Manchester, United Kingdom","The present method describes a systems biology approach for the in silico predictive modeling of drug toxicity. The data from LINCS were used to determine the type and number of pathways disturbed by each compound and to estimate the extent of disturbance (network perturbation elasticity). Moreover, the most frequently disturbed metabolic pathways and reactions were determined across the studied toxicants. The process was exemplified by successful predictions on various statins. In conclusion, an entirely new approach linking gene expression alterations to the prediction of complex organ toxicity was developed. © Springer Science+Business Media, LLC, part of Springer Nature 2018.","Drug toxicity; Gene regulation; Hepatotoxicity; Predictive modeling; Systems biology","pravastatin; rosuvastatin; simvastatin; computer model; data base; gene expression; gene expression profiling; gene mapping; liver cell; liver toxicity; metabolism; systems biology; antibody specificity; chemical database; drug effect; elasticity; gene expression regulation; human; metabolism; procedures; systems biology; Databases, Chemical; Elasticity; Gene Expression Regulation; Hepatocytes; Humans; Metabolic Networks and Pathways; Organ Specificity; Systems Biology",,"pravastatin, 81093-37-0, 81131-70-6; rosuvastatin, 147098-18-8, 147098-20-2; simvastatin, 79902-63-9",,,,,,,"Duan, Q., Flynn, C., Niepel, M., LINCS Canvas Browser: Interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures (2014) Nucleic Acids Res, 42, pp. W449-W460; Thiele, I., Swainston, N., Fleming, R.M.T., A community-driven global reconstruction of human metabolism (2013) Nat Biotechnol, 31, pp. 419-425; Carbonell, P., Lopez, O., Amberg, A., Pastor, M., Sanz, F., Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data (2017) ALTEX, 34, pp. 219-234; Ebrahim, A., Lerman, J.A., Palsson, B.O., Hyduke, D.R., COBRApy: COnstraints-Based Reconstruction and Analysis for python (2013) BMC Syst Biol, 7, p. 74; Juty, N., Ali, R., Glont, M., BioModels: Content, features, functionality, and use (2015) CPT Pharmacometrics Syst Pharmacol, 4, pp. 55-68; Thiele, I., Palsson, B.Ø., A protocol for generating a high-quality genome-scale metabolic reconstruction (2010) Nat Protoc, 5, pp. 93-121; Orth, J.D., Thiele, I., Palsson, B.Ø., What is flux balance analysis? (2010) Nat Biotechnol, 28, pp. 245-248; Zhu, X., Kruhlak, N.L., Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data (2014) Toxicology, 321, pp. 62-72; Ahmed, M.H., Al-Atta, A., Hamad, M.A., The safety and effectiveness of statins as treatment for HIV-dyslipidemia: The evidence so far and the future challenges (2012) Expert Opin Pharmacother, 13, pp. 1901-1909; Liu, R., Abdulhameed, M.D.M., Wallqvist, A., Molecular structure-based large-scale prediction of chemical-induced gene expression changes (2017) J Chem Inf Model, 57, pp. 2194-2202; Larhlimi, A., Blachon, S., Selbig, J., Nikoloski, Z., Robustness of metabolic networks: A review of existing definitions (2011) Biosystems, 106, pp. 1-8; King, Z.A., Dräger, A., Ebrahim, A., Sonnenschein, N., Lewis, N.E., Palsson, B.O., Escher: A web application for building, sharing, and embedding data-rich visualizations of biological pathways (2015) Plos Comput Biol, 11","Carbonell, P.; Manchester Centre for Fine and Speciality Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, University of ManchesterUnited Kingdom; email: pablo.carbonell@manchester.ac.uk",,,"Humana Press Inc.",,,,,10643745,,,"29934908","English","Methods Mol. Biol.",Book Chapter,"Final",,Scopus,2-s2.0-85049005873
"Gutiérrez-Sacristán A., Bravo À., Giannoula A., Mayer M.A., Sanz F., Furlong L.I.","56728807700;56374942700;57201213356;36971031500;7102263897;34770469800;","comoRbidity: An R package for the systematic analysis of disease comorbidities",2018,"Bioinformatics","34","18",,"3228","3230",,2,"10.1093/bioinformatics/bty315","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060632235&doi=10.1093%2fbioinformatics%2fbty315&partnerID=40&md5=7ed2ed07c1e7d259ce7b0c17dc4e9f24","Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, 08003, Spain; Department of Biomedical Informatics, Harvard Medical School, Boston, MA  02115, United States; Large-Scale Text Understanding Systems Lab, TALN Research Group, Department of Information and Communication Technologies (DTIC), Universitat Pompeu Fabra, Barcelona, 08018, Spain","Gutiérrez-Sacristán, A., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, 08003, Spain, Department of Biomedical Informatics, Harvard Medical School, Boston, MA  02115, United States; Bravo, À., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, 08003, Spain, Large-Scale Text Understanding Systems Lab, TALN Research Group, Department of Information and Communication Technologies (DTIC), Universitat Pompeu Fabra, Barcelona, 08018, Spain; Giannoula, A., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, 08003, Spain; Mayer, M.A., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, 08003, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, 08003, Spain; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, 08003, Spain","Motivation: The study of comorbidities is a major priority due to their impact on life expectancy, quality of life and healthcare cost. The availability of electronic health records (EHRs) for data mining offers the opportunity to discover disease associations and comorbidity patterns from the clinical history of patients gathered during routine medical care. This opens the need for analytical tools for detection of disease comorbidities, including the investigation of their underlying genetic basis. Results: We present comoRbidity, an R package aimed at providing a systematic and comprehensive analysis of disease comorbidities from both the clinical and molecular perspectives. comoRbidity leverages from (i) user provided clinical data from EHR databases (the clinical comorbidity analysis) and (ii) genotype-phenotype information of the diseases under study (the molecular comorbidity analysis) for a comprehensive analysis of disease comorbidities. The clinical comorbidity analysis enables identifying significant disease comorbidities from clinical data, including sex and age stratification and temporal directionality analyses, while the molecular comorbidity analysis supports the generation of hypothesis on the underlying mechanisms of the disease comorbidities by exploring shared genes among disorders. The open-source comoRbidity package is a software tool aimed at expediting the integrative analysis of disease comorbidities by incorporating several analytical and visualization functions. © The Author(s) 2018. Published by Oxford University Press.",,"comorbidity; data mining; electronic health record; factual database; female; human; male; procedures; software; Comorbidity; Data Mining; Databases, Factual; Electronic Health Records; Female; Humans; Male; Software",,,,,"Harvard Medical School

2Department

MDM-2014-0370

CP10/00524, CPII16/00026, PI13/00082

American Geriatrics Society, AGS

115372, 115735

PRB2-ISCIII, PT13/0001/0023

European Federation of Pharmaceutical Industries and Associations, EFPIA

676559, 634143

Federación Española de Enfermedades Raras, FEDER","1Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF), Barcelona 08003, Spain, 2Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA and 3Large-Scale Text Understanding Systems Lab, TALN Research Group, Department of Information and Communication Technologies (DTIC), Universitat Pompeu Fabra, Barcelona 08018, Spain","The authors received support from ISCIII-FEDER (PI13/00082, CP10/00524, CPII16/00026), IMI-JU under grants agreements no. 115372 (EMIF), no. 115735 (iPiE), resources of which are composed of financial contribution from the EU-FP7 (FP7/2007-2013) and EFPIA companies in kind contribution and the EU H2020 Programme 2014–2020 under grant agreements no. 634143 (MedBioinformatics) and no. 676559 (ElixirExcelerate). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D+i 2013-2016, funded by ISCIII and FEDER. AGS acknowledges financial support from the Spanish Ministry of Economy and Competitiveness, through the ‘María de Maeztu’ Programme for Units of Excellence in R&D (MDM-2014-0370).",,"Backenroth, D., Using rich data on comorbidities in case-control study design with electronic health record data improves control of confounding in the detection of adverse drug reactions (2016) PLoS One, 11; Bagley, S.C., Constraints on biological mechanism from disease comorbidity using electronic medical records and database of genetic variants (2016) PLoS Comput. Biol., 12; Bonavita, V., De Simone, R., Towards a definition of comorbidity in the light of clinical complexity (2008) Neurol. Sci., 29, pp. 99-102; Doshi-Velez, F., Comorbidity clusters in autism spectrum disorders: An electronic health record time-series analysis (2014) Pediatrics, 133, pp. e54-e63; Fortin, M., Multimorbidity is common to family practice: Is it commonly researched? (2005) Can. Fam. Phys., 51, pp. 244-245; Gijsen, R., Causes and consequences of comorbidity: A review (2001) J. Clin. Epidemiol., 54, pp. 661-674; Hidalgo, C.A., A dynamic network approach for the study of human phenotypes (2009) PLoS Comput. Biol., 5; Holmes, A.B., Discovering disease associations by integrating electronic clinical data and medical literature (2011) PLoS One, 6; Jakovljević, M., Ostojić, L., Comorbidity and multimorbidity in medicine today: Challenges and opportunities for bringing separated branches of medicine closer to each other (2013) Psychiatr. Danub., 25, pp. 18-28; Jensen, P., Mining electronic health records: Towards better research applications and clinical care (2012) Nat. Rev. Genet., 13, pp. 395-405; Marengoni, A., Aging with multimorbidity: A systematic review of the literature (2011) Ageing Res. Rev., 10, pp. 430-439; McCormick, P., (2016) Medicalrisk: Medical Risk and Comorbidity Tools for ICD9-CM Data. R Package Version 1.2, , https://CRAN.R-project.org/package=medicalrisk; Mezzich, J.E., Salloum, I.M., Clinical complexity and person-centered integrative diagnosis (2008) World Psychiatry, 7, pp. 1-2; Moni, M., comoR: A software for disease comorbidity risk assessment (2014) J. Clin. Bioinform., 4, p. 8; Moni, M.A., CytoCom: A cytoscape app to visualize, query and analyse disease comorbidity networks (2015) Bioinformatics, 31, pp. 969-971; Piñero, J., DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants (2017) Nucleic Acids Res, 45, pp. D833-D839; Taylor, A.W., Multimorbidity–Not just an older person’s issue. Results from an Australian biomedical study (2010) BMC Public Health, 10, p. 718; Valderas, J.M., Defining comorbidity: Implications for understanding health and health services (2009) Ann. Fam. Med., 7, pp. 357-363; van den Akker, M., Comorbidity or multimorbidity (1996) Eur. J. Gen. Pract., 2, pp. 65-70","Furlong, L.I.; Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences (DCEXS), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra (UPF)Spain; email: laura.furlong@upf.edu",,,"Oxford University Press",,,,,13674803,,BOINF,"29897411","English","Bioinformatics",Article,"Final",Open Access,Scopus,2-s2.0-85060632235
"Rubio-Perez C., Guney E., Aguilar D., Piñero J., Garcia-Garcia J., Iadarola B., Sanz F., Fernandez-Fuentes N., Furlong L.I., Oliva B.","56355193100;23477104200;7003346290;55220852900;7102375601;57200070667;7102263897;8557712800;34770469800;35500780700;","Genetic and functional characterization of disease associations explains comorbidity",2017,"Scientific Reports","7","1", 6207,"","",,7,"10.1038/s41598-017-04939-4","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026419425&doi=10.1038%2fs41598-017-04939-4&partnerID=40&md5=b71cefe6ac46442e7c05fda2f6a46e55","Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, 08028, Spain; Structural Bioinformatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain; Center for Complex Network Research, Department of Physics, Northeastern University, Boston, MA  02115, United States; Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, 08003, Spain; Integrative Biomedical Informatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain; Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3EB, United Kingdom","Rubio-Perez, C., Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, 08028, Spain, Structural Bioinformatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain; Guney, E., Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, 08028, Spain, Center for Complex Network Research, Department of Physics, Northeastern University, Boston, MA  02115, United States; Aguilar, D., Structural Bioinformatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain, Barcelona Institute for Global Health (ISGlobal), Barcelona, Catalonia, 08003, Spain; Piñero, J., Integrative Biomedical Informatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain; Garcia-Garcia, J., Structural Bioinformatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain, Integrative Biomedical Informatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain; Iadarola, B., Structural Bioinformatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain; Sanz, F., Integrative Biomedical Informatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain; Fernandez-Fuentes, N., Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3EB, United Kingdom; Furlong, L.I., Integrative Biomedical Informatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain; Oliva, B., Structural Bioinformatics Group, GRIB, IMIM, Department of Experimental and Life Sciences, Universitat Pompeu Fabra, Barcelona, Catalonia, 08003, Spain, Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3EB, United Kingdom","Understanding relationships between diseases, such as comorbidities, has important socio-economic implications, ranging from clinical study design to health care planning. Most studies characterize disease comorbidity using shared genetic origins, ignoring pathway-based commonalities between diseases. In this study, we define the disease pathways using an interactome-based extension of known disease-genes and introduce several measures of functional overlap. The analysis reveals 206 significant links among 94 diseases, giving rise to a highly clustered disease association network. We observe that around 95% of the links in the disease network, though not identified by genetic overlap, are discovered by functional overlap. This disease network portraits rheumatoid arthritis, asthma, atherosclerosis, pulmonary diseases and Crohn's disease as hubs and thus pointing to common inflammatory processes underlying disease pathophysiology. We identify several described associations such as the inverse comorbidity relationship between Alzheimer's disease and neoplasms. Furthermore, we investigate the disruptions in protein interactions by mapping mutations onto the domains involved in the interaction, suggesting hypotheses on the causal link between diseases. Finally, we provide several proof-of-principle examples in which we model the effect of the mutation and the change of the association strength, which could explain the observed comorbidity between diseases caused by the same genetic alterations. © 2017 The Author(s).",,"biological marker; comorbidity; diseases; gene regulatory network; genetic predisposition; genetics; human; metabolism; protein analysis; signal transduction; single nucleotide polymorphism; Biomarkers; Comorbidity; Disease; Gene Regulatory Networks; Genetic Predisposition to Disease; Humans; Metabolic Networks and Pathways; Polymorphism, Single Nucleotide; Protein Interaction Maps; Signal Transduction",,"Biomarkers",,,"Instituto de Salud Carlos III

634143

BES2013063354

PRB2-ISCIII, PT13/0001/0023, 2013-2016

BIO2014-57518-R

Federación Española de Enfermedades Raras, FEDER: CP10/00524, PI13/00082","Authors acknowledge support of Spanish Ministry of Economy MINECO grant BIO2014-57518-R, Instituto Carlos III (ISCIII) FEDER grants CP10/00524 and PI13/00082, and EU H2020 Programme 2014-2020 under grant agreement no. 634143 (MedBioinformatics). We also acknowledge the support, helpful comments, and ideas of Dr. Lopez-Bigas, from the Biomedical Genomics Group at IRB Barcelona. CRP is supported by Spanish Ministry of Economy and Competitiveness FPI fellowship (BES2013063354). EG is supported by EU cofounded AGAUR Beatriu de Pinos fellowship from Government of Catalunya. The Research Programme on Biomedical Informatics (GRIB) is member of the Spanish National Bioinformatics Institute (INB) and PRB2-ISCIII, supported by grant PT13/0001/0023 of the PE I+D+I 2013-2016 funded by ISCII-FEDER.",,,"Park, J., Lee, D.S., Christakis, N.A., Barabasi, A.L., The impact of cellular networks on disease comorbidity (2009) Mol Syst Biol, 5, p. 262. , doi:1038/msb.2009.16; Roque, F.S., Using electronic patient records to discover disease correlations and stratify patient cohorts (2011) PLoS Comput Biol, 7, p. e1002141; Faner, R., Molecular and clinical diseasome of comorbidities in exacerbated COPD patients (2015) Eur Respir J; Agusti, A., Personalized respiratory medicine: Exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014 (2015) Am J Respir Crit Care Med, 191, pp. 391-401; Suthram, S., Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets (2010) PLoS Comput Biol, 6, p. e1000662; Van Driel, M.A., Bruggeman, J., Vriend, G., Brunner, H.G., Leunissen, J.A., A text-mining analysis of the human phenome (2006) Eur J Hum Genet, 14, pp. 535-542; Hu, J.X., Thomas, C.E., Brunak, S., Network biology concepts in complex disease comorbidities (2016) Nat Rev Genet, 17, pp. 615-629; Mosca, R., DSysMap: Exploring the edgetic role of disease mutations (2015) Nat Methods, 12, pp. 167-168; Sahni, N., Widespread macromolecular interaction perturbations in human genetic disorders (2015) Cell, 161, pp. 647-660; Rolland, T., A proteome-scale map of the human interactome network (2014) Cell, 159, pp. 1212-1226; Ideker, T., Sharan, R., Protein networks in disease (2008) Genome Res, 18, pp. 644-652; Garcia-Garcia, J., Guney, E., Aragues, R., Planas-Iglesias, J., Oliva, B., Biana: A software framework for compiling biological interactions and analyzing networks (2011) BMC Bioinformatics, 11, p. 56; Chang, L., Jones, Y., Ellisman, M.H., Goldstein, L.S., Karin, M., JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins (2003) Dev Cell, 4, pp. 521-533. , 1:CAS:528:DC%2BD3sXjtFSmtLY%3D 12689591; Messier, C., Diabetes, Alzheimer's disease and apolipoprotein genotype (2003) Exp Gerontol, 38, pp. 941-946. , 1:CAS:528:DC%2BD3sXmvVygtrs%3D 12954480; Menche, J., Disease networks. Uncovering disease-disease relationships through the incomplete interactome (2015) Science, 347, p. 1257601; Guney, E., Garcia-Garcia, J., Oliva, B., GUILDify: A web server for phenotypic characterization of genes through biological data integration and network-based prioritization algorithms (2014) Bioinformatics, 30, pp. 1789-1790; Planas-Iglesias, J., Extending signaling pathways with protein-interaction networks. Application to apoptosis (2012) OMICS, 16, pp. 245-256; Engin, H.B., Guney, E., Keskin, O., Oliva, B., Gursoy, A., Integrating structure to protein-protein interaction networks that drive metastasis to brain and lung in breast cancer (2013) PLoS One, 8, p. e81035; Wang, X., Three-dimensional reconstruction of protein networks provides insight into human genetic disease (2012) Nat Biotechnol, 30, pp. 159-164; Guney, E., Oliva, B., Exploiting protein-protein interaction networks for genome-wide disease-gene prioritization (2012) PLoS One, 7, p. e43557; Zhong, Q., Edgetic perturbation models of human inherited disorders (2009) Mol Syst Biol, 5, p. 321; Vidal, M., Cusick, M.E., Barabasi, A.L., Interactome networks and human disease (2011) Cell, 144, pp. 986-998; Barabasi, A.L., Gulbahce, N., Loscalzo, J., Network medicine: A network-based approach to human disease (2011) Nat Rev Genet, 12, pp. 56-68; Loscalzo, J., Barabasi, A.L., Systems biology and the future of medicine (2011) Wiley Interdiscip Rev Syst Biol Med, 3, pp. 619-627; Hidalgo, C.A., Blumm, N., Barabasi, A.L., Christakis, N.A., A dynamic network approach for the study of human phenotypes (2009) PLoS Comput Biol, 5, p. e1000353; Lipscomb, C.E., Medical Subject Headings (MeSH) (2000) Bull Med Libr Assoc, 88, pp. 265-266. , 1:STN:280:DC%2BD3M%2Fjs1Ggtg%3D%3D 10928714 35238; Michaud, K., Wolfe, F., Comorbidities in rheumatoid arthritis (2007) Best Pract Res Clin Rheumatol, 21, pp. 885-906; Enright, A.J., Van Dongen, S., Ouzounis, C.A., An efficient algorithm for large-scale detection of protein families (2002) Nucleic Acids Res, 30, pp. 1575-1584. , 1:CAS:528:DC%2BD38Xltlajsrk%3D 11917018 101833; Roe, C.M., Cancer linked to Alzheimer disease but not vascular dementia (2010) Neurology, 74, pp. 106-112; Roe, C.M., Behrens, M.I., Xiong, C., Miller, J.P., Morris, J.C., Alzheimer disease and cancer (2005) Neurology, 64, pp. 895-898; Ibanez, K., Boullosa, C., Tabares-Seisdedos, R., Baudot, A., Valencia, A., Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses (2014) PLoS Genet, 10, p. e1004173; Tabares-Seisdedos, R., No paradox, no progress: Inverse cancer comorbidity in people with other complex diseases (2011) Lancet Oncol, 12, pp. 604-608. , 21498115; Akhurst, R.J., TGF beta signaling in health and disease (2004) Nat Genet, 36, pp. 790-792; Xu, Y., Pasche, B., TGF-beta signaling alterations and susceptibility to colorectal cancer (2007) Hum Mol Genet 16 Spec No, 1, pp. R14-20; Raszeja-Wyszomirska, J., Miazgowski, T., Osteoporosis in primary biliary cirrhosis of the liver (2014) Prz Gastroenterol, 9, pp. 82-87; Gordon, K.J., Blobe, G.C., Role of transforming growth factor-beta superfamily signaling pathways in human disease (2008) Biochim Biophys Acta, 1782, pp. 197-228; Groppe, J., Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding (2008) Mol Cell, 29, pp. 157-168; Rose, P., The RCSB Protein Data Bank: Redesigned web site and web services (2011) Nucleic Acids Res, 39, pp. D392-401; Stranges, P.B., Kuhlman, B., A comparison of successful and failed protein interface designs highlights the challenges of designing buried hydrogen bonds (2013) Protein Sci, 22, pp. 74-82; Assi, S.A., Tanaka, T., Rabbitts, T.H., Fernandez-Fuentes, N., PCRPi: Presaging Critical Residues in Protein interfaces, a new computational tool to chart hot spots in protein interfaces (2010) Nucleic Acids Res, 38, p. e86; Sjoblom, T., The consensus coding sequences of human breast and colorectal cancers (2006) Science, 314, pp. 268-274; Gupta, S.K., Lamont, E.B., Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia (2004) J Am Geriatr Soc, 52, pp. 1681-1687. , 15450045; Baxter, N.N., Durham, S.B., Phillips, K.A., Habermann, E.B., Virning, B.A., Risk of dementia in older breast cancer survivors: A population-based cohort study of the association with adjuvant chemotherapy (2009) J Am Geriatr Soc, 57, pp. 403-411. , 19278395; Catala-Lopez, F., Alzheimer's disease and cancer: Current epidemiological evidence for a mutual protection (2014) Neuroepidemiology, 42, pp. 121-122; Catala-Lopez, F., Inverse and direct cancer comorbidity in people with central nervous system disorders: A meta-analysis of cancer incidence in 577,013 participants of 50 observational studies (2014) Psychother Psychosom, 83, pp. 89-105; Sorrentino, G., Comel, A., Mantovani, F., Del Sal, G., Regulation of mitochondrial apoptosis by Pin1 in cancer and neurodegeneration (2014) Mitochondrion, 19, pp. 88-96; Czabotar, P.E., Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis (2013) Cell, 152, pp. 519-531; Reed, J.C., Proapoptotic multidomain Bcl-2/Bax-family proteins: Mechanisms, physiological roles, and therapeutic opportunities (2006) Cell Death Differ, 13, pp. 1378-1386; Tanzi, R.E., Bertram, L., Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective (2005) Cell, 120, pp. 545-555; Tortosa, A., Lopez, E., Ferrer, I., Bcl-2 and Bax protein expression in Alzheimer's disease (1998) Acta Neuropathol, 95, pp. 407-412. , 1:CAS:528:DyaK1cXislWitLw%3D 9560019; Meijerink, J.P., Hematopoietic malignancies demonstrate loss-of-function mutations of BAX (1998) Blood, 91, pp. 2991-2997. , 1:CAS:528:DyaK1cXisVWlurc%3D 9531611; Meijerink, J.P., Smetsers, T.F., Sloetjes, A.W., Linders, E.H., Mensink, E.J., Bax mutations in cell lines derived from hematological malignancies (1995) Leukemia, 9, pp. 1828-1832. , 1:STN:280:DyaK28%2FntFWgsw%3D%3D 7475270; McCurrach, M.E., Connor, T.M., Knudson, C.M., Korsmeyer, S.J., Lowe, S.W., Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis (1997) Proc Natl Acad Sci USA, 94, pp. 2345-2349. , 1997PNAS.94.2345M 1:CAS:528:DyaK2sXhvF2lurk%3D 9122197 20090; Sax, J.K., BID regulation by p53 contributes to chemosensitivity (2002) Nat Cell Biol, 4, pp. 842-849; Mosca, R., Ceol, A., Stein, A., Olivella, R., Aloy, P., 3did: A catalog of domain-based interactions of known three-dimensional structure (2014) Nucleic Acids Res, 42, pp. D374-379; Berry, M., Brightling, C., Pavord, I., Wardlaw, A., TNF-alpha in asthma (2007) Curr Opin Pharmacol, 7, pp. 279-282; Catal, F., A human monoclonal anti-TNF alpha antibody (adalimumab) reduces airway inflammation and ameliorates lung histology in a murine model of acute asthma (2015) Allergol Immunopathol (Madr), 43, pp. 14-18; Sieberts, S.K., Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis (2016) Nat Commun, 7, p. 12460; Anecchino, C., Fanizza, C., Marino, V., Romero, M., Drug outcome survey to evaluate anti-TNF treatment in rheumatoid arthritis: An Italian observational study (the DOSE study) (2015) Clin Exp Rheumatol, 33, pp. 779-787. , 1:STN:280:DC%2BC28visVWitQ%3D%3D 26575614; Umicevic Mirkov, M., Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis (2013) Ann Rheum Dis, 72, pp. 1375-1381; De Punder, Y.M., The prevalence of clinical remission in RA patients treated with anti-TNF: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry (2012) Rheumatology (Oxford), 51, pp. 1610-1617; Lequerre, T., Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers (2015) Joint Bone Spine, 82, pp. 330-337; Keshava Prasad, T.S., Human Protein Reference Database-2009 update (2009) Nucleic Acids Res, 37, pp. D767-772. , 1:STN:280:DC%2BD1M%2FitVCluw%3D%3D 18988627; Salwinski, L., The Database of Interacting Proteins: 2004 update (2004) Nucleic Acids Res, 32, pp. D449-451. , 1:CAS:528:DC%2BD3sXhtVSrurnJ 14681454 308820; Mewes, H.W., MIPS: Curated databases and comprehensive secondary data resources in 2010 (2010) Nucleic Acids Res, 39, pp. D220-224; Chatr-Aryamontri, A., The BioGRID interaction database: 2015 update (2015) Nucleic Acids Res, 43, pp. D470-478; Bader, G.D., Betel, D., Hogue, C.W., BIND: The Biomolecular Interaction Network Database (2003) Nucleic Acids Res, 31, pp. 248-250. , 1:CAS:528:DC%2BD3sXhvFSnu7c%3D 12519993 165503; Kerrien, S., The IntAct molecular interaction database in 2012 (2012) Nucleic Acids Res, 40, pp. D841-846. , 1:CAS:528:DC%2BC3MXhs12htbvI 22121220; Licata, L., MINT, the molecular interaction database: 2012 update (2012) Nucleic Acids Res, 40, pp. D857-861. , 1:CAS:528:DC%2BC3MXhs12hurbE 22096227; Pinero, J., DisGeNET: A discovery platform for the dynamical exploration of human diseases and their genes (2015) Database (Oxford); Bauer-Mehren, A., Rautschka, M., Sanz, F., Furlong, L.I., DisGeNET: A Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks (2010) Bioinformatics, 26, pp. 2924-2926; Welter, D., The NHGRI GWAS Catalog, a curated resource of SNP-trait associations (2013) Nucleic Acids Res, 42, pp. D1001-1006; Rath, A., Representation of rare diseases in health information systems: The Orphanet approach to serve a wide range of end users (2012) Hum Mutat, 33, pp. 803-808; Davis, A.P., A CTD-Pfizer collaboration: Manual curation of 88,000 scientific articles text mined for drug-disease and drug-phenotype interactions (2013) Database (Oxford), 2013, p. bat080; Wu, C.H., The Universal Protein Resource (UniProt): An expanding universe of protein information (2006) Nucleic Acids Res, 34, pp. D187-191; Schaefer, C., Meier, A., Rost, B., Bromberg, Y., SNPdbe: Constructing an nsSNP functional impacts database (2012) Bioinformatics, 28, pp. 601-602; Landrum, M.J., ClinVar: Public archive of relationships among sequence variation and human phenotype (2014) Nucleic Acids Res, 42, pp. D980-985; Zhang, Y., Systematic analysis, comparison, and integration of disease based human genetic association data and mouse genetic phenotypic information (2010) BMC Med Genomics, 3, p. 1; Myers, E.W., Miller, W., Optimal alignments in linear space (1988) Comput Appl Biosci, 4, pp. 11-17. , 1:CAS:528:DyaL1cXitFyls7Y%3D 3382986; Eswar, N., Comparative protein structure modeling using Modeller (2006) Curr Protoc Bioinformatics, 5, p. Unit; Segura Mora, J., Assi, S.A., Fernandez-Fuentes, N., Presaging critical residues in protein interfaces-web server (PCRPi-W): A web server to chart hot spots in protein interfaces (2010) PLoS One, 5, p. e12352","Fernandez-Fuentes, N.; Institute of Biological, Environmental and Rural Sciences, Aberystwyth UniversityUnited Kingdom; email: naf4@aber.ac.uk",,,"Nature Publishing Group",,,,,20452322,,,"28740175","English","Sci. Rep.",Article,"Final",Open Access,Scopus,2-s2.0-85026419425
"Sanz F., Pognan F., Steger-Hartmann T., Díaz C.","7102263897;6602679901;6603592872;57197180745;","Legacy data sharing to improve drug safety assessment: The eTOX project",2017,"Nature Reviews Drug Discovery","16","12",,"811","812",,15,"10.1038/nrd.2017.177","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85035327690&doi=10.1038%2fnrd.2017.177&partnerID=40&md5=f6813272f1cea330cb17af5d023e4f12","Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, 08003, Spain; Novartis Institute for Biomedical Research, Basel, CH-4002, Switzerland; Bayer AG, Berlin, 13353, Germany; Synapse Research Management Partners, Barcelona, 08007, Spain","Sanz, F., Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, 08003, Spain; Pognan, F., Novartis Institute for Biomedical Research, Basel, CH-4002, Switzerland; Steger-Hartmann, T., Bayer AG, Berlin, 13353, Germany; Díaz, C., Synapse Research Management Partners, Barcelona, 08007, Spain","The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility. © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.",,"data base; drug approval; drug industry; drug information; drug safety; eTOX database; food and drug administration; incidence; information dissemination; liver toxicity; medical documentation; practice guideline; prediction; priority journal; quantitative structure activity relation; Review; software; standardization; statistical model; adverse drug reaction; human; preclinical study; procedures; risk assessment; Drug Evaluation, Preclinical; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Humans; Information Dissemination; Risk Assessment",,,,,,,,,"Obiol-Pardo, C., A multiscale simulation system for the prediction of drug-induced cardiotoxicity (2011) J. Chem. Inf. Model., 51, pp. 483-492; Carbonell, P., Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data (2017) ALTEX, 34, pp. 219-234; Harvey, J., Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development (2017) Regul. Toxicol. Pharmacol., 84, pp. 116-123; Carrió, P., Applicability Domain Analysis (ADAN): A robust method for assessing the reliability of drug property predictions (2014) J. Chem. Inf. Model., 54, pp. 1500-1511; Hewitt, M., Ensuring confidence in predictions: A scheme to assess the scientific validity of in silico models (2015) Adv. Drug Deliv. Rev., 86, pp. 101-111","Sanz, F.; Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Universitat Pompeu FabraSpain; email: ferran.sanz@upf.edu",,,"Nature Publishing Group",,,,,14741776,,NRDDA,"29026211","English","Nat. Rev. Drug Discov.",Review,"Final",,Scopus,2-s2.0-85035327690
"Leist M., Ghallab A., Graepel R., Marchan R., Hassan R., Bennekou S.H., Limonciel A., Vinken M., Schildknecht S., Waldmann T., Danen E., van Ravenzwaay B., Kamp H., Gardner I., Godoy P., Bois F.Y., Braeuning A., Reif R., Oesch F., Drasdo D., Höhme S., Schwarz M., Hartung T., Braunbeck T., Beltman J., Vrieling H., Sanz F., Forsby A., Gadaleta D., Fisher C., Kelm J., Fluri D., Ecker G., Zdrazil B., Terron A., Jennings P., van der Burg B., Dooley S., Meijer A.H., Willighagen E., Martens M., Evelo C., Mombelli E., Taboureau O., Mantovani A., Hardy B., Koch B., Escher S., van Thriel C., Cadenas C., Kroese D., van de Water B., Hengstler J.G.","7005865830;55205117800;57202771838;8340029300;57195233567;56500662300;39262110600;7801561545;6507007477;7102676761;6701788890;6603955128;24390838000;7103172164;23007942600;36972936700;14018887900;7102641522;35446506300;35608776700;8850441900;55696877900;7005429459;7003571748;6603786552;7004296072;7102263897;6701324942;55672411200;7402131226;56355379100;22333799600;24794675100;36088274100;57206840980;56537849200;7005336396;35402441200;57196097675;6507481906;57196088202;7003950754;35311585700;8857290100;55838510682;36113704700;56021540100;36946199300;6602736631;23981975500;6701428641;7003827454;7004358088;","Adverse outcome pathways: opportunities, limitations and open questions",2017,"Archives of Toxicology","91","11",,"3477","3505",,68,"10.1007/s00204-017-2045-3","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031799653&doi=10.1007%2fs00204-017-2045-3&partnerID=40&md5=ad64379b2fd8fa4add675cb147abfe99","In Vitro Toxicology and Biomedicine, Department inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Box 657, Universitaetsstr. 10, Konstanz, 78457, Germany; Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany; Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt; Research Division of Drug Discovery and Safety, Leiden University, Einsteinweg 55, Leiden, 2333 CC, Netherlands; The Danish EPA, Copenhagen, Denmark; Division of Physiology, Department of Physiology and Medical Physics, Medical University of Innsbruck, Innsbruck, 6020, Austria; Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, 1090, Belgium; BASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany; Simcyp (A Certara Company), Sheffield, United Kingdom; INERIS, DRC/VIVA/METO, Parc ALATA BP2, Verneuil en Halatte, 60550, France; Department of Food Safety, German Federal Institute for Risk Assessment, Max-Dohrn-Str. 8-10, Berlin, 10589, Germany; Institute of Toxicology, University of Mainz, Mainz, Germany; INRIA, Unit Rocquencourt, B.P.105, Le Chesnay Cedex, 78153, France; Laboratoire Jacques-Louis Lions, France Université of Paris 06, CNRS, UMR 7598, 4 pl. Jussieu, Paris, France; Institute for Computer Science, University of Leipzig, Haertelstraße 16-18, Leipzig, 04107, Germany; Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University, Tübingen, Germany; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Aquatic Ecology and Toxicology Section, Centre for Organismal Studies, University of Heidelberg, Im Neuenheimer Feld 504, Heidelberg, 69120, Germany; Department of Human Genetics, Leiden University Medical Center, Postal Zone S4-P, PO Box 9600, Leiden, 2300 RC, Netherlands; Research Programme on Biomedical Informatics (GRIB), Department of Health and Life Sciences, Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Unit of Toxicology Sciences, Swetox, Karolinska Institutet, Forskargatan 20, Södertälje, SE-151 36, Sweden; Laboratory of Environmental Chemistry and Toxicology, Department of Environmental Health Sciences, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via la Masa 19, Milano, 20156, Italy; InSphero AG, Wagistrasse 27, Schlieren, CH-8952, Switzerland; Pharmacoinformatics Research Group, Department of Pharmaceutical Chemistry, University of Vienna, Althanstraße 14, Vienna, 1090, Austria; European Food Safety Authority (EFSA), Pesticide Unit, via Carlo Magno 1 A, Parma, 43126, Italy; Division of Molecular and Computational Toxicology, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, De Boelelaan 1108, Amsterdam, 1081 HZ, Netherlands; BioDetection Systems b.v. (BDS), Science Park 406, Amsterdam, 1098 XH, Netherlands; Section Molekular Hepatology, II. Medical Clinic, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany; Institute of Biology, Leiden University, Leiden, 2333 CC, Netherlands; Department of Bioinformatics, BiGCaT, NUTRIM, Maastricht University, PO Box 616, Maastricht, 6200 MD, Netherlands; Open PHACTS Foundation, Cambridge, United Kingdom; Inserm UMR-S973, Molécules Thérapeutiques in silico, Paris Diderot University, Paris, France; Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Istituto Superiore di Sanità, Viale Regina Elena 299, Roma, 00161, Italy; Douglas Connect GmbH, Bärmeggenweg 14, Zeiningen, Aargau, 4314, Switzerland; Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM) Chemical Risk Assessment Group Manager Structure Activity Relationships/databases, and expert systems Nikolai-Fuchs-Strasse 1, Hannover, 30625, Germany; TNO (Department of Risk Analysis of Products in Development), Zeist, Netherlands; Department of Neurochemistry, Stockholm University, Svante Arrhenius väg 16, Stockholm, SE-106 91, Sweden","Leist, M., In Vitro Toxicology and Biomedicine, Department inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Box 657, Universitaetsstr. 10, Konstanz, 78457, Germany; Ghallab, A., Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany, Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt; Graepel, R., Research Division of Drug Discovery and Safety, Leiden University, Einsteinweg 55, Leiden, 2333 CC, Netherlands; Marchan, R., Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany; Hassan, R., Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany, Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt; Bennekou, S.H., The Danish EPA, Copenhagen, Denmark; Limonciel, A., Division of Physiology, Department of Physiology and Medical Physics, Medical University of Innsbruck, Innsbruck, 6020, Austria; Vinken, M., Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, 1090, Belgium; Schildknecht, S., In Vitro Toxicology and Biomedicine, Department inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Box 657, Universitaetsstr. 10, Konstanz, 78457, Germany; Waldmann, T., In Vitro Toxicology and Biomedicine, Department inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Box 657, Universitaetsstr. 10, Konstanz, 78457, Germany; Danen, E., Research Division of Drug Discovery and Safety, Leiden University, Einsteinweg 55, Leiden, 2333 CC, Netherlands; van Ravenzwaay, B., BASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany; Kamp, H., BASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany; Gardner, I., Simcyp (A Certara Company), Sheffield, United Kingdom; Godoy, P., Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany; Bois, F.Y., INERIS, DRC/VIVA/METO, Parc ALATA BP2, Verneuil en Halatte, 60550, France; Braeuning, A., Department of Food Safety, German Federal Institute for Risk Assessment, Max-Dohrn-Str. 8-10, Berlin, 10589, Germany; Reif, R., Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany; Oesch, F., Institute of Toxicology, University of Mainz, Mainz, Germany; Drasdo, D., INRIA, Unit Rocquencourt, B.P.105, Le Chesnay Cedex, 78153, France, Laboratoire Jacques-Louis Lions, France Université of Paris 06, CNRS, UMR 7598, 4 pl. Jussieu, Paris, France; Höhme, S., Institute for Computer Science, University of Leipzig, Haertelstraße 16-18, Leipzig, 04107, Germany; Schwarz, M., Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University, Tübingen, Germany; Hartung, T., Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Braunbeck, T., Aquatic Ecology and Toxicology Section, Centre for Organismal Studies, University of Heidelberg, Im Neuenheimer Feld 504, Heidelberg, 69120, Germany; Beltman, J., Research Division of Drug Discovery and Safety, Leiden University, Einsteinweg 55, Leiden, 2333 CC, Netherlands; Vrieling, H., Department of Human Genetics, Leiden University Medical Center, Postal Zone S4-P, PO Box 9600, Leiden, 2300 RC, Netherlands; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Health and Life Sciences, Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Forsby, A., Unit of Toxicology Sciences, Swetox, Karolinska Institutet, Forskargatan 20, Södertälje, SE-151 36, Sweden, Department of Neurochemistry, Stockholm University, Svante Arrhenius väg 16, Stockholm, SE-106 91, Sweden; Gadaleta, D., Laboratory of Environmental Chemistry and Toxicology, Department of Environmental Health Sciences, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via la Masa 19, Milano, 20156, Italy; Fisher, C., Simcyp (A Certara Company), Sheffield, United Kingdom; Kelm, J., InSphero AG, Wagistrasse 27, Schlieren, CH-8952, Switzerland; Fluri, D., InSphero AG, Wagistrasse 27, Schlieren, CH-8952, Switzerland; Ecker, G., Pharmacoinformatics Research Group, Department of Pharmaceutical Chemistry, University of Vienna, Althanstraße 14, Vienna, 1090, Austria; Zdrazil, B., Pharmacoinformatics Research Group, Department of Pharmaceutical Chemistry, University of Vienna, Althanstraße 14, Vienna, 1090, Austria; Terron, A., European Food Safety Authority (EFSA), Pesticide Unit, via Carlo Magno 1 A, Parma, 43126, Italy; Jennings, P., Division of Molecular and Computational Toxicology, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, De Boelelaan 1108, Amsterdam, 1081 HZ, Netherlands; van der Burg, B., BioDetection Systems b.v. (BDS), Science Park 406, Amsterdam, 1098 XH, Netherlands; Dooley, S., Section Molekular Hepatology, II. Medical Clinic, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany; Meijer, A.H., Institute of Biology, Leiden University, Leiden, 2333 CC, Netherlands; Willighagen, E., Department of Bioinformatics, BiGCaT, NUTRIM, Maastricht University, PO Box 616, Maastricht, 6200 MD, Netherlands, Open PHACTS Foundation, Cambridge, United Kingdom; Martens, M., Department of Bioinformatics, BiGCaT, NUTRIM, Maastricht University, PO Box 616, Maastricht, 6200 MD, Netherlands; Evelo, C., Department of Bioinformatics, BiGCaT, NUTRIM, Maastricht University, PO Box 616, Maastricht, 6200 MD, Netherlands, Open PHACTS Foundation, Cambridge, United Kingdom; Mombelli, E., INERIS, DRC/VIVA/METO, Parc ALATA BP2, Verneuil en Halatte, 60550, France; Taboureau, O., Inserm UMR-S973, Molécules Thérapeutiques in silico, Paris Diderot University, Paris, France, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Mantovani, A., Istituto Superiore di Sanità, Viale Regina Elena 299, Roma, 00161, Italy; Hardy, B., Douglas Connect GmbH, Bärmeggenweg 14, Zeiningen, Aargau, 4314, Switzerland; Koch, B., Institute of Biology, Leiden University, Leiden, 2333 CC, Netherlands; Escher, S., Fraunhofer Institute of Toxicology and Experimental Medicine (ITEM) Chemical Risk Assessment Group Manager Structure Activity Relationships/databases, and expert systems Nikolai-Fuchs-Strasse 1, Hannover, 30625, Germany; van Thriel, C., Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany; Cadenas, C., Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany; Kroese, D., TNO (Department of Risk Analysis of Products in Development), Zeist, Netherlands; van de Water, B., Research Division of Drug Discovery and Safety, Leiden University, Einsteinweg 55, Leiden, 2333 CC, Netherlands; Hengstler, J.G., Leibniz Research Centre for Working Environment and Human Factors, Technical University Dortmund, Dortmund, Germany","Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a formalized, transparent and quality-controlled way, mechanistic information to apical endpoints for regulatory purposes. AOP links a molecular initiating event (MIE) to the adverse outcome (AO) via key events (KE), in a way specified by key event relationships (KER). Although this approach to formalize mechanistic toxicological information only started in 2010, over 200 AOPs have already been established. At this stage, new requirements arise, such as the need for harmonization and re-assessment, for continuous updating, as well as for alerting about pitfalls, misuses and limits of applicability. In this review, the history of the AOP concept and its most prominent strengths are discussed, including the advantages of a formalized approach, the systematic collection of weight of evidence, the linkage of mechanisms to apical end points, the examination of the plausibility of epidemiological data, the identification of critical knowledge gaps and the design of mechanistic test methods. To prepare the ground for a broadened and appropriate use of AOPs, some widespread misconceptions are explained. Moreover, potential weaknesses and shortcomings of the current AOP rule set are addressed (1) to facilitate the discussion on its further evolution and (2) to better define appropriate vs. less suitable application areas. Exemplary toxicological studies are presented to discuss the linearity assumptions of AOP, the management of event modifiers and compensatory mechanisms, and whether a separation of toxicodynamics from toxicokinetics including metabolism is possible in the framework of pathway plasticity. Suggestions on how to compromise between different needs of AOP stakeholders have been added. A clear definition of open questions and limitations is provided to encourage further progress in the field. © 2017, Springer-Verlag GmbH Germany.","Binning of events; CCl4; Computational toxicology; Interspecies extrapolation; Liver fibrosis; Metabolism; Multi-scale integration; Multiple hit events; Paracetamol; Pathway unidirectionality; Prioritization of compounds; Proof of non-toxicity; Regulatory toxicology; Systems biology; Tumor promotion; Vinyl acetate","adverse outcome; adverse outcome pathway; Article; ecotoxicology; epidemiological data; human; metabolism; nonhuman; plasticity; priority journal; risk assessment; signal transduction; toxicity assay; toxicokinetics; adverse outcome pathway; animal; C57BL mouse; history; procedures; quality control; systems biology; vinyl acetate; vinyl derivative; Adverse Outcome Pathways; Animals; Ecotoxicology; History, 21st Century; Humans; Mice, Inbred C57BL; Quality Control; Risk Assessment; Systems Biology; Toxicokinetics; Vinyl Compounds",,"vinyl acetate, 108-05-4; vinyl derivative, 2669-89-8; vinyl acetate; Vinyl Compounds",,,"Horizon 2020 Framework Programme, H2020: 681002, 2020

European Commission

Bundesministerium für Bildung und Forschung","A second important novelty is that large regulatory agencies have adopted the concept of mechanistic toxicology (Leist et al. 2014; Edwards et al. 2016). The AOP concept is supported by the OECD, and this greatly facilitates its implementation into regulatory thinking. The consequence will be an integration of existing knowledge on toxic mechanisms into regulatory procedures. A secondary consequence is that the European Commission and other funding agencies have realized the need to support research projects that define and implement AOPs (Daneshian et al. 2016; Daston et al. 2015).","Acknowledgements This work was supported by the EU-ToxRisk project (An Integrated European “Flagship” Program Driving Mechanism-Based Toxicity Testing and Risk Assessment for the 21st Century) funded by the European Commission under the Horizon 2020 programme (Grant Agreement No. 681002). This review is a joint activity of members of the EU-ToxRisk project and additionally incorporates ideas and suggestions of several colleagues who are not members of this consortium. We thank in particular Brigitte Landesmann, Maurice Whelan, Anna Bal-Price, and Christian Desaintes for their valuable discussion. Some work on examples was funded by the German Federal Ministry of Education and Research (BMBF) (LiSyM, SysDT, Neuri-Tox, LivSys, Lebersimulator projects). We thank M. Turajski and B. Schanze for valuable bibliographic support, and B. Barton for excellent support in handling the manuscript.",,"Ames, B.N., Whitfield, H.J., Jr., Frameshift mutagenesis in Salmonella (1966) Cold Spring Harb Symp Quant Biol, 31, pp. 221-225. , COI: 1:CAS:528:DyaF2sXksl2qtrw%3D, PID: 4866378; Andersen, M.E., Krewski, D., Toxicity testing in the 21st century: bringing the vision to life (2009) Toxicol Sci, 107, pp. 324-330. , COI: 1:CAS:528:DC%2BD1MXhtVeht7g%3D, PID: 19074763; Andersen, M.E., Krewski, D., The vision of toxicity testing in the 21st century: moving from discussion to action (2010) Toxicol Sci, 117, pp. 17-24. , COI: 1:CAS:528:DC%2BC3cXhtVGrtLbI, PID: 20573784; Ankley, G.T., Bennett, R.S., Erickson, R.J., Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment (2010) Environ Toxicol Chem, 29, pp. 730-741. , COI: 1:CAS:528:DC%2BC3cXjt12ju7Y%3D, PID: 20821501; Ball, N., Cronin, M.T.D., Shen, J., Toward good read-across practice (GRAP) guidance (2016) ALTEX, 33, pp. 149-166. , PID: 26863606; Balmer, N.V., Leist, M., Epigenetics and transcriptomics to detect adverse drug effects in model systems of human development (2014) Basic Clin Pharmacol Toxicol, 115, pp. 59-68. , COI: 1:CAS:528:DC%2BC2cXpsVektr4%3D, PID: 24476462; Balmer, N.V., Weng, M., Zimmer, B., Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome (2012) Hum Mol Genet, 21, pp. 4104-4114. , COI: 1:CAS:528:DC%2BC38Xht1yntrrK, PID: 22723015; Balmer, N.V., Klima, S., Rempel, E., From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects (2014) Arch Toxicol, 88, pp. 1451-1468. , COI: 1:CAS:528:DC%2BC2cXpvVehtrY%3D, PID: 24935251; Bal-Price, A., Crofton, K., Leist, M., International STakeholder NETwork for developmental neurotoxicity (ISTNET): creating a developmental neurotoxicity (DNT) testing roadmap for regulatory purposes (2015) Arch Toxicol, 89, pp. 269-287. , COI: 1:CAS:528:DC%2BC2MXhsV2qur4%3D, PID: 25618548; Bal-Price, A., Crofton, K.M., Sachana, M., Putative adverse outcome pathways relevant to neurotoxicity (2015) Crit Rev Toxicol, 45, pp. 83-91. , COI: 1:CAS:528:DC%2BC2MXhsF2ltr4%3D, PID: 25605028; Bal-Price, A., Lein, P.J., Keil, K.P., Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity (2017) Neurotoxicology, 59, pp. 240-255. , COI: 1:CAS:528:DC%2BC28XptVGjsrs%3D, PID: 27212452; Basketter, D.A., Clewell, H., Kimber, I., A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing—t4 report (2012) ALTEX, 29, pp. 3-91. , PID: 22307314; Bataller, R., Brenner, D.A., Liver fibrosis (2005) J Clin Investig, 15, pp. 209-218; Baumann, J., Gassmann, K., Masjosthusmann, S., Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events (2016) Arch Toxicol, 90, pp. 1415-1427. , COI: 1:CAS:528:DC%2BC2MXht1ChtbbN, PID: 26216354; Becker, R.A., Ankley, G.T., Edwards, S.W., Increasing scientific confidence in adverse outcome pathways: application of tailored Bradford-Hill considerations for evaluating weight of evidence (2015) Regul Toxicol Pharmacol, 72, pp. 514-537. , PID: 25863193; Beliaeff, B., Burgeot, T., Integrated biomarkers response: a useful tool for ecological risk assessment (2002) Environ Toxicol Chem, 21, pp. 1316-1322. , COI: 1:CAS:528:DC%2BD38Xktleru7g%3D, PID: 12069320; Bhattacharya, S., A test for mutagenicity of methylcholanthrene (1948) Nature, 162, p. 573. , COI: 1:CAS:528:DyaH1MXhvVWktg%3D%3D, PID: 18886414; Blaauboer, B.J., Boekelheide, K., Clewell, H.J., The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans (2012) Altex, 29, pp. 411-425. , PID: 23138511; Bois, F.Y., Jamei, M., Clewell, H.J., PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals (2010) Toxicology, 278, pp. 256-267. , COI: 1:CAS:528:DC%2BC3cXhsFanurzM, PID: 20600548; Bolt, H.M., Foth, H., Hengstler, J.G., Degen, G.H., Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective (2004) Toxicol Lett, 151 (1), pp. 29-41. , COI: 1:CAS:528:DC%2BD2cXks1Wnsbc%3D, PID: 15177638; Bouhifd, M., Andersen, M.E., Baghdikian, C., The human toxome project (2015) ALTEX, 32, pp. 112-124. , PID: 25742299; Casey, W.M., Advances in the development and validation of test methods in the United States (2016) Toxicol Res, 32, pp. 9-14. , PID: 26977254; Carbonell, P., Lopez, O., Amberg, A., Pastor, M., Sanz, F., Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data (2017) ALTEX, 34 (2), pp. 219-234. , PID: 27690270; Clippinger, A.J., Hill, E., Curren, R., Bridging the gap between regulatory acceptance and industry use of non-animal methods (2016) ALTEX, 33, pp. 453-458. , PID: 27254273; Crawford, S.E., Hartung, T., Hollert, H., Green toxicology: a strategy for sustainable chemical and material development (2017) Environ Sci Eur, 29, p. 16. , PID: 28435767; Daneshian, M., Kamp, H., Hengstler, J., Highlight report: launch of a large integrated European in vitro toxicology project: EU-ToxRisk (2016) Arch Toxicol, 90, pp. 1021-1024. , COI: 1:CAS:528:DC%2BC28XkvVyqtrk%3D, PID: 27017488; Daston, G., Knight, D.J., Schwarz, M., SEURAT: safety evaluation ultimately replacing animal testing—recommendations for future research in the field of predictive toxicology (2015) Arch Toxicol, 89, pp. 15-23. , COI: 1:CAS:528:DC%2BC2cXitVSitb%2FN, PID: 25433540; Delrue, N., Sachana, M., Sakuratani, Y., The adverse outcome pathway concept: a basis for developing regulatory decision-making tools (2016) Altern Lab Anim, 44, pp. 417-429. , PID: 27805824; Depledge, M.H., The rational basis for the use of biomarkers as ecotoxicological tools (1994) Nondestructive biomarkers in vertebrates, pp. 271-295. , In:, Fossi, MC, Leonzio, C, (ed; Drasdo, D., Hoehme, S., Hengstler, J.G., How predictive quantitative modelling of tissue organisation can inform liver disease pathogenesis (2014) J Hepatol, 61, pp. 951-956. , PID: 24950483; Duffield, J.S., Forbes, S.J., Constandinou, C.M., Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair (2005) J Clin Invest, 115, pp. 56-65. , COI: 1:CAS:528:DC%2BD2MXis1eksw%3D%3D, PID: 15630444; Edwards, S.W., Tan, Y.M., Villeneuve, D.L., Adverse outcome pathways-organizing toxicological information to improve decision making (2016) J Pharmacol Exp Ther, 356 (1), pp. 170-181. , COI: 1:CAS:528:DC%2BC28Xhslelur0%3D, PID: 26537250; Fasbender, F., Widera, A., Hengstler, J.G., Natural killer cells and liver fibrosis (2016) Front Immunol, 7, p. 19. , PID: 26858722; Fehrenbacher, N., Gyrd-Hansen, M., Poulsen, B., Sensitization to the lysosomal cell death pathway upon immortalization and transformation (2004) Cancer Res, 64, pp. 5301-5310. , COI: 1:CAS:528:DC%2BD2cXmtF2murw%3D, PID: 15289336, PubMed PMID: 15289336; Fischer, F.C., Modeling exposure in the Tox21 in vitro bioassays (2017) Chem Res Toxicol, 30 (5), pp. 1197-1208. , COI: 1:CAS:528:DC%2BC2sXksVehu7Y%3D, PID: 28316234; Foghsgaard, L., Wissing, D., Mauch, D., Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor (2001) J Cell Biol, 153, pp. 999-1010. , COI: 1:CAS:528:DC%2BD3MXktVagsrw%3D, PID: 11381085; Gantner, F., Leist, M., Küsters, S., T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release (1996) Exp Cell Res, 229, pp. 137-146. , COI: 1:CAS:528:DyaK28Xntlegt7o%3D, PID: 8940257; Gassmann, K., Abel, J., Bothe, H., Species-specific differential AhR expression protects human neural progenitor cells against developmental neurotoxicity of PAHs (2010) Environ Health Perspect, 118, pp. 1571-1577. , COI: 1:CAS:528:DC%2BC3cXhsFyqu7zP, PID: 20570779; Gerhardt, E., Kügler, S., Leist, M., Cascade of caspase activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis (2001) Mol Cell Neurosci, 17, pp. 717-731. , COI: 1:CAS:528:DC%2BD3MXivVehs7Y%3D, PID: 11312607, PubMed PMID: 11312607; Ghallab, A., Cellière, G., Henkel, S.G., Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases (2016) J Hepatol, 64, pp. 860-871. , COI: 1:CAS:528:DC%2BC28Xltl2quw%3D%3D, PID: 26639393; Godoy, P., Hewitt, N.J., Albrecht, U., Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (2013) Arch Toxicol, 87, pp. 1315-1530. , COI: 1:CAS:528:DC%2BC3sXhtlahtr3N, PID: 23974980; Grinberg, M., Stöber, R.M., Edlund, K., Toxicogenomics directory of chemically exposed human hepatocytes (2014) Arch Toxicol, 88 (12), pp. 2261-2287. , COI: 1:CAS:528:DC%2BC2cXhvFCgurfP, PID: 25399406; Environment directorate joint meeting of the chemicals committee and the working party on chemicals, pesticides and biotechnology (2017) Series on Testing and Assessment No 184, , http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2013)6&doclanguage=en, Guidance document on developing and assessing adverse outcome pathways, Accessed 4 Sept 2017; Hamon, J., Jennings, P., Bois, F.Y., Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells (2014) BMC Syst Biol, 8, p. 76. , PID: 24964791; Hansson, O., Castilho, R.F., Kaminski Schierle, G.S., Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons (2000) Exp Neurol, 164, pp. 102-111. , COI: 1:CAS:528:DC%2BD3cXksVaqs78%3D, PID: 10877920; Hansson, O., Nylandsted, J., Castilho, R.F., Overexpression of heat shock protein 70 in R6/2 Huntington’s disease mice has only modest effects on disease progression (2003) Brain Res, 970, pp. 47-57. , COI: 1:CAS:528:DC%2BD3sXivFeqtL4%3D, PID: 12706247; Hartung, T., Food for thought… on evidence-based toxicology (2009) ALTEX, 26, pp. 75-82. , PID: 19565165; Hartung, T., Look back in anger—what clinical studies tell us about preclinical work (2013) ALTEX, 30, pp. 275-291. , PID: 23861075; Hartung, T., Making big sense from big data in toxicology by read-across (2016) ALTEX, 33, pp. 83-93. , PID: 27032088; Hartung, T., Utility of the adverse outcome pathway concept in drug development (2017) Expert Opin Drug Metab Toxicol, 13, pp. 1-3. , PID: 27718748; Hartung, T., McBride, M., Food for thought… on mapping the human toxome (2011) ALTEX, 28, pp. 83-93. , PID: 21625825; Hartung, T., van Vliet, E., Jaworska, J., Systems toxicology (2012) ALTEX, 29, pp. 119-128. , PID: 22562485; Hartung, T., Luechtefeld, T., Maertens, A., Integrated testing strategies for safety assessments (2013) ALTEX, 30, pp. 3-18. , PID: 23338803; Hartung, T., Stephens, M., Hoffmann, S., Mechanistic validation (2013) ALTEX, 30, pp. 119-130. , PID: 23665802; Hartung, T., FitzGerald, R., Paul, J., Systems toxicology—real world applications and opportunities (2017) Chem Res Toxicol, 30, pp. 870-882. , COI: 1:CAS:528:DC%2BC2sXltlSisbY%3D, PID: 28362102; Hengstler, J.G., Arand, M., Herrero, M.E., Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility (1998) Recent Results Cancer Res, 154, pp. 47-85. , COI: 1:CAS:528:DyaK1cXmvFyrs70%3D, PID: 10026993; Hengstler, J.G., Van der Burg, B., Steinberg, P., Interspecies differences in cancer susceptibility and toxicity (1999) Drug Metab Rev, 31, pp. 917-970. , COI: 1:CAS:528:DyaK1MXnvFCitrY%3D, PID: 10575555; Hengstler, J.G., Bogdanffy, M.S., Bolt, H.M., Challenging dogma: thresholds for genotoxic carcinogens? The case of vinyl acetate (2003) Annu Rev Pharmacol Toxicol, 43, pp. 485-520. , COI: 1:CAS:528:DC%2BD3sXitFWqtrY%3D, PID: 12415124; Hengstler, J.G., Marchan, R., Leist, M., Highlight report: towards the replacement of in vivo repeated dose systemic toxicity testing (2012) Arch Toxicol, 86, pp. 13-15. , COI: 1:CAS:528:DC%2BC3MXhs1GhtbnF, PID: 22187068; Hirt, U., Gantner, F., Leist, M., Phagocytosis of non-apoptotic cells dying by caspase-independent mechanisms (2000) J Immunol, 164, pp. 6520-6529. , COI: 1:CAS:528:DC%2BD3cXktFWltbg%3D, PID: 10843710; Hoehme, S., Hengstler, J.G., Brulport, M., Mathematical modelling of liver regeneration after intoxication with CCl(4) (2007) Chem Biol Interact, 168, pp. 74-93. , COI: 1:CAS:528:DC%2BD2sXkvFGls7w%3D; Hoehme, S., Brulport, M., Bauer, A., Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration (2010) Proc Natl Acad Sci USA, 107, pp. 10371-10376. , COI: 1:CAS:528:DC%2BC3cXnvV2is7o%3D, PID: 20484673; Hoffmann, S., Hartung, T., Towards an evidence-based toxicology (2006) Hum Exp Toxicol, 25, pp. 497-513. , COI: 1:STN:280:DC%2BD28roslWhtw%3D%3D, PID: 17017003; Hoffmann, S., de Vries, R.B.M., Stephens, M.L., A primer on systematic reviews in toxicology (2017) Arch Toxicol, 91 (7), pp. 2551-2575. , COI: 1:CAS:528:DC%2BC2sXnslKlu7g%3D, PID: 28501917; Horvat, T., Landesmann, B., Lostia, A., Adverse outcome pathway development from protein alkylation to liver fibrosis (2017) Arch Toxicol, 91, pp. 1523-1543. , COI: 1:CAS:528:DC%2BC28Xhtlyksr3I, PID: 27542122; Huggett, R.J., Kimerle, R.A., Mehrle, P.M., Bergman, H.L., (1992) Biomarkers. Biochemical, physiological, and histological markers of anthropogenic stress, p. 347. , Lewis Publishers, Boca Raton; Jacobs, M.N., Colacci, A., Louekari, K., International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances (2016) ALTEX, 33, pp. 359-392. , PID: 27120445; Jalan, R., Moreau, R., Kamath, P.S., Arroyo, V., Acute-on-chronic liver failure: a distinct clinical condition (2016) Semin Liver Dis, 36 (2), pp. 107-108. , PID: 27172350; Jansen, P.L., Ghallab, A., Vartak, N., The ascending pathophysiology of cholestatic liver disease (2017) Hepatology, 65 (2), pp. 722-738. , COI: 1:CAS:528:DC%2BC2sXhtlCnsrY%3D, PID: 27981592; Jennings, P., Stress response pathways, toxicity pathways and adverse outcome pathways (2013) Arch Toxicol, 87, pp. 13-14. , COI: 1:CAS:528:DC%2BC38Xhs1Kjt7zM, PID: 23149676; Jennings, P., Limonciel, A., Felice, L., An overview of transcriptional regulation in response to toxicological insult (2013) Arch Toxicol, 87, pp. 49-72. , COI: 1:CAS:528:DC%2BC38Xht1Grt7vN, PID: 22926699; Kim, K.H., Chen, C.C., Monzon, R.I., Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts (2013) Mol Cell Biol, 33, pp. 2078-2090. , COI: 1:CAS:528:DC%2BC3sXntFajtbc%3D, PID: 23508104; Kisseleva, T., Cong, M., Paik, Y., Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis (2012) Proc Natl Acad Sci USA, 109, pp. 9448-9453. , COI: 1:CAS:528:DC%2BC38Xptlahsr8%3D, PID: 22566629; Kleensang, A., Maertens, A., Rosenberg, M., Pathways of toxicity (2014) ALTEX, 31, pp. 53-61. , PID: 24127042; Kleinstreuer, N.C., Ceger, P.C., Allen, D.G., A curated database of rodent uterotrophic bioactivity (2016) Environ Health Perspect, 124, pp. 556-562. , PID: 26431337; Kleinstreuer, N.C., Ceger, P., Watt, E.D., Development and validation of a computational model for androgen receptor activity (2017) Chem Res Toxicol, 30, pp. 946-964. , COI: 1:CAS:528:DC%2BC28XitVajtrnK, PID: 27933809; Knapen, D., Vergauwen, L., Villeneuve, D.L., The potential of AOP networks for reproductive and developmental toxicity assay development (2015) Reprod Toxicol, 56, pp. 52-55. , COI: 1:CAS:528:DC%2BC2MXmslOrurw%3D, PID: 25889759; Krizhanovsky, V., Yon, M., Dickins, R.A., Senescence of activated stellate cells limits liver fibrosis (2008) Cell, 134, pp. 657-667. , COI: 1:CAS:528:DC%2BD1cXhtVGqtrbI, PID: 18724938; Krug, A.K., Balmer, N.V., Matt, F., Evaluation of a human neurite growth assay as specific screen for developmental neurotoxicants (2013) Arch Toxicol, 87, pp. 2215-2231. , COI: 1:CAS:528:DC%2BC3sXnsFSrsrk%3D, PID: 23670202; Krug, A.K., Kolde, R., Gaspar, J.A., Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach (2013) Arch Toxicol, 87, pp. 123-143. , COI: 1:CAS:528:DC%2BC38XhslWrsLbO, PID: 23179753; Krug, A.K., Gutbier, S., Zhao, L., Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+) (2014) Cell Death Dis, 5. , COI: 1:CAS:528:DC%2BC2cXntlOhsL8%3D, PID: 24810058; Kuegler, P.B., Zimmer, B., Waldmann, T., Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicitiy testing—a review by the Transatlantic Think Tank for toxicology (t4) (2010) ALTEX, 27, pp. 17-42. , PID: 20390237; Latta, M., Künstle, G., Leist, M., Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis (2000) J Exp Med, 191, pp. 1975-1985. , COI: 1:CAS:528:DC%2BD3cXjvFyntbo%3D, PID: 10839812; Leist, M., Hartung, T., Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice (2013) Arch Toxicol, 87, pp. 563-567. , COI: 1:CAS:528:DC%2BC3sXktFCgt7w%3D, PID: 23503654; Leist, M., Jäättelä, M., Four deaths and a funeral: from caspases to alternative mechanisms (2001) Nat Rev Mol Cell Biol, 2, pp. 589-598. , COI: 1:CAS:528:DC%2BD3MXlvVOqs78%3D, PID: 11483992; Leist, M., Nicotera, P., Calcium and neuronal death (1997) Rev Physiol Biochem Pharmacol, 132, pp. 79-125; Leist, M., Gantner, F., Künstle, G., The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure (1996) Mol Med, 2, pp. 109-124. , COI: 1:CAS:528:DyaK28Xitlamuro%3D, PID: 8900539; Leist, M., Fava, E., Montecucco, C., Nicotera, P., Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity (1997) Eur J Neurosci, 9, pp. 1488-1498. , COI: 1:STN:280:DyaK2szot1CjsA%3D%3D, PID: 9240406; Leist, M., Gantner, F., Naumann, H., Tumor necrosis factor-induced apoptosis during the poisoning of mice with hepatotoxins (1997) Gastroenterology, 112, pp. 923-934. , COI: 1:CAS:528:DyaK2sXhvFOlsL8%3D, PID: 9041255; Leist, M., Volbracht, C., Kühnle, S., Caspase-mediated apoptosis in neuronal excitotoxicity triggered by nitric oxide (1997) Mol Med, 3, pp. 750-764. , COI: 1:CAS:528:DyaK1cXhvVI%3D, PID: 9407551; Leist, M., Gantner, F., Künstle, G., Cytokine-mediated hepatic apoptosis (1998) Rev Physiol Biochem Pharmacol, 133, pp. 109-155. , COI: 1:CAS:528:DyaK1cXjsVWis70%3D, PID: 9600012; Leist, M., Volbracht, C., Fava, E., 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis (1998) Mol Pharmacol, 54, pp. 789-801. , COI: 1:CAS:528:DyaK1cXntlOntLo%3D, PID: 9804614; Leist, M., Hartung, T., Nicotera, P., The dawning of a new age of toxicology (2008) ALTEX, 25, pp. 103-114. , PID: 18551234; Leist, M., Efremova, L., Karreman, C., Food for thought on considerations and guidelines for basic test method descriptions in toxicology (2010) ALTEX, 27, pp. 309-317. , PID: 21240472; Leist, M., Hasiwa, N., Daneshian, M., Validation and quality control of replacement alternatives—current status and future challenges (2012) Toxicol Res, 1, pp. 8-22. , COI: 1:CAS:528:DC%2BC38Xos1ylsL8%3D; Leist, M., Hasiwa, N., Rovida, C., Consensus report on the future of animal-free systemic toxicity testing (2014) ALTEX, 31, pp. 341-356. , PID: 25061899; Lewin, L., (1885) Lehrbuch der Toxikologie: für Aerzte, Studierende und Apotheker (translation: textbook of Toxicology for physicians, students and pharmacists), , Urban & Schwarzenberg, Wien; Lewin, L., (1924) Phantastica. Die betäubenden und erregenden Genussmittel. Für Ärzte und Nichtärzte (translation: Phantastica. Anaesthetic and stimulating drugs for physicians and laymen). Verlag von Georg Stilke, , Berlin; Limonciel, A., Aschauer, L., Wilmes, A., Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes (2011) Toxicol In Vitro, 25, pp. 1855-1862. , COI: 1:CAS:528:DC%2BC3MXhsVKmt7%2FP, PID: 21635945; Maertens, A., Anastas, N., Spencer, P.J., Green Toxicology (2014) ALTEX, 31, pp. 243-249. , PID: 25061898; Matozzo, V., Gagné, F., Marin, M.G., Ricciardi, F., Blaise, C., Vitellogenin as a biomarker of exposure to estrogenic compounds in aquatic invertebrates: a review (2008) Environ Int, 34, pp. 531-545. , COI: 1:CAS:528:DC%2BD1cXmtlersb4%3D, PID: 18029015; McCarty, J.F., Shugart, L.R., (1990) Biomarkers of environmental contamination, p. 457. , Lewis Publishers, CRC Press, Boca Raton; Nicotera, P., Leist, M., Manzo, L., Neuronal cell death: a demise with different shapes (1999) Trends Pharmacol Sci, 20 (2), pp. 46-51. , COI: 1:CAS:528:DyaK1MXksVygu7s%3D, PID: 10101962; (2007) Toxicity testing in the 21st century: a vision and a strategy, , The National Academies Press, Washington; (2017), https://ntp.niehs.nih.gov/pubhealth/evalatm/test-method-evaluations/immunotoxicity/nonanimal/index.html, Accessed 4 Sept 2017; Nyffeler, J., Karreman, C., Leisner, H., Design of a high-throughput human neural crest cell migration assay to indicate potential developmental toxicants (2017) ALTEX, 34, pp. 7555-7594; Nylandsted, J., Wick, W., Hirt, U.A., Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion (2002) Cancer Res, 62, pp. 7139-7142. , COI: 1:CAS:528:DC%2BD3sXhtVyktA%3D%3D, PID: 12499245; Obiol-Pardo, C., Gomis-Tena, J., Sanz, F., Saiz, J., Pastor, M., A multiscale simulation system for the prediction of drug-induced cardiotoxicity (2011) J Chem Inf Model, 51, pp. 483-492. , COI: 1:CAS:528:DC%2BC3MXnvVSmsQ%3D%3D, PID: 21250697; Ockleford, C., EFSA panel on plant protection products and their residues (PPR) investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson’s disease and childhood leukaemia (2017) EFSA J, 15, p. 4691; Oesch, F., Herrero, M.E., Hengstler, J.G., Lohmann, M., Arand, M., Metabolic detoxification: implications for thresholds (2000) Toxicol Pathol, 28 (3), pp. 382-387. , COI: 1:CAS:528:DC%2BD3cXktlSqtL4%3D, PID: 10862554; Oesch, F., Herrero, M.E., Lohmann, M., Hengstler, J.G., Arand, M., Sequestration of biological reactive intermediates by trapping as covalent enzyme-intermediate complex (2001) Adv Exp Med Biol, 500, pp. 577-586. , COI: 1:CAS:528:DC%2BD38XjslGitLc%3D, PID: 11764999; Oki, N.O., Edwards, S.W., An integrative data mining approach to identifying adverse outcome pathway signatures (2016) Toxicology, 28 (350-352), pp. 49-61; Paparella, M., Colacci, A., Jacobs, M.N., Uncertainties of testing methods: What do we (want to) know about carcinogenicity? (2017) ALTEX, 34 (2), pp. 235-252. , PID: 27776202; Patlewicz, G., Ball, N., Becker, R.A., Read-across approaches—misconceptions, promises and challenges ahead (2014) ALTEX, 31, pp. 387-396. , PID: 25368965; Pelkonen, O., Terron, A., Hernandez, A.F., Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research (2017) Arch Toxicol, 91 (8), pp. 2763-2780. , COI: 1:CAS:528:DC%2BC2sXosVSrsL0%3D, PID: 28536863; Polasek, T.M., Patel, F., Jensen, B.P., Sorich, M.J., Wiese, M.D., Doogue, M.P., Predicted metabolic drug clearance with increasing adult age (2013) Br J Clin Pharmacol, 75 (4), pp. 1019-1028. , COI: 1:CAS:528:DC%2BC3sXktFOgsLY%3D, PID: 22924488; Poulin, P., Theil, F.P., Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution (2002) J Pharm Sci, 91, pp. 129-156. , COI: 1:CAS:528:DC%2BD38Xmslyhtg%3D%3D, PID: 11782904; Radaeva, S., Sun, R., Jaruga, B., Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners (2006) Gastroenterology, 130, pp. 435-452. , COI: 1:CAS:528:DC%2BD28Xit1aksr0%3D, PID: 16472598; Rahnenführer, J., Leist, M., From smoking guns to footprints: mining for critical events of toxicity pathways in transcriptome data (2015) Arch Toxicol, 89, pp. 813-817. , PID: 25851820; Ramachandran, P., Iredale, J.P., Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution (2012) J Hepatol, 56, pp. 1417-1419. , PID: 22314426; Ramachandran, P., Pellicoro, A., Vernon, M.A., Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis (2012) Proc Natl Acad Sci USA, 109, pp. E3186-E3195. , COI: 1:CAS:528:DC%2BC38Xhsl2itrrE, PID: 23100531; Rempel, E., Hoelting, L., Waldmann, T., A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors (2015) Arch Toxicol, 89, pp. 1599-1618. , COI: 1:CAS:528:DC%2BC2MXhtlChu7fM, PID: 26272509; Rostami-Hodjegan, A., Physiologically based pharmacokinetics joined with in vitro–in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology (2012) Clin Pharmacol Ther, 92 (1), pp. 50-61. , COI: 1:CAS:528:DC%2BC38XptVGmtbo%3D, PID: 22644330; Rovida, C., Alépée, N., Api, A.M., Integrated testing strategies (ITS) for safety assessment (2015) ALTEX, 32, pp. 171-181. , PID: 26168280; Samuel, G.O., Hoffmann, S., Wright, R., Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: a scoping review (2016) Environ Int, 92-93, pp. 630-646. , PID: 27039952; Sauer, J.M., Hartung, T., Leist, M., Systems toxicology: the future of risk assessment (2015) Int J Toxicol, 34, pp. 346-348. , PID: 25804424; Schierle, G.S., Hansson, O., Leist, M., Caspase inhibition reduces apoptosis and increases survival of nigral transplants (1999) Nat Med, 5, pp. 97-100. , COI: 1:CAS:528:DyaK1MXmtFOhug%3D%3D, PID: 9883846; Schildknecht, S., Pöltl, D., Nagel, D.M., Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells (2009) Toxicol Appl Pharmacol, 241, pp. 23-35. , COI: 1:CAS:528:DC%2BD1MXhtlWitL7O, PID: 19647008; Schildknecht, S., Pape, R., Müller, N., Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite (2011) J Biol Chem, 286, pp. 4991-5002. , COI: 1:CAS:528:DC%2BC3MXhvVeqtL4%3D, PID: 21081502; Schildknecht, S., Karreman, C., Pöltl, D., Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases (2013) ALTEX, 30, pp. 427-444. , PID: 24173167; Schildknecht, S., Pape, R., Meiser, J., Preferential extracellular generation of the active parkinsonian toxicant MPP+ by transporter-independent export of the intermediate MPDP+ (2015) Antioxid Redox Signal, 23, pp. 1001-1016. , COI: 1:CAS:528:DC%2BC2MXhslOks7fK, PID: 26413876; Schildknecht, S., Di Monte, D.A., Pape, R., Tipping points and endogenous determinants of nigrostriatal degeneration by MPTP (2017) Trends Pharmacol Sci, 38, pp. 541-555. , COI: 1:CAS:528:DC%2BC2sXlvFWgtrs%3D, PID: 28442167; Schliess, F., Hoehme, S., Henkel, S.G., Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration (2014) Hepatology, 60, pp. 2040-2051. , COI: 1:CAS:528:DC%2BC2cXitVCis73O, PID: 24677161; Shinde, V., Hoelting, L., Perumal, S.S., Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development—introduction of the STOP-Toxukn and STOP-Toxukk t (2016) Arch Toxicol, 91, pp. 839-864. , PID: 27188386; Smirnova, L., Hogberg, H.T., Leist, M., Developmental neurotoxicity—challenges in the 21st century and in vitro opportunities (2014) ALTEX, 31, pp. 129-156. , PID: 24687333; Stephens, M.L., Betts, K., Beck, N.B., The emergence of systematic review in toxicology (2016) Toxicol Sci, 152, pp. 10-16. , PID: 27208075; Stiegler, N., Krug, A., Matt, F., Assessment of chemical-induced impairment of human neurite outgrowth by multiparametric live cell imaging in high-density cultures (2011) Toxicol Sci, 121, pp. 73-87. , COI: 1:CAS:528:DC%2BC3MXlt1CltbY%3D, PID: 21342877; Tacke, F., Zimmermann, H.W., Macrophage heterogeneity in liver injury and fibrosis (2014) J Hepatol, 60, pp. 1090-1096. , COI: 1:CAS:528:DC%2BC2cXivFCru7c%3D, PID: 24412603; Tian, Z., Chen, Y., Gao, B., Natural killer cells in liver disease (2013) Hepatology, 57, pp. 1654-1662. , COI: 1:CAS:528:DC%2BC3sXlslygt7o%3D, PID: 23111952; Tollefsen, K.E., Scholz, S., Cronin, M.T., Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA) (2014) Reg Toxicol Pharmacol, 70, pp. 629-640; Trevan, J.W., The error of determination of toxicity (1927) Proc R Soc Lond B Biol Sci, 101 (712), pp. 483-514; Tsaioun, K., Blaauboer, B.J., Hartung, T., Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods (2016) ALTEX, 33, pp. 343-358. , PID: 27806179; (2017) Users’ handbook supplement to the guidance document for developing and assessing AOPs, , http://www.oecd-ilibrary.org/environment/users-handbook-supplement-to-the-guidance-document-for-developing-and-assessing-adverse-outcome-pathways_5jlv1m9d1g32-en, Accessed 4 Sept 2017; van der Burg, B., Pieterse, B., Buist, H., A high throughput screening system for predicting chemically-induced reproductive organ deformities (2015) Reprod Toxicol, 55, pp. 95-103. , PID: 25527862; van der Burg, B., Wedebye, E.B., Dietrich, D.R., The ChemScreen project to design a pragmatic alternative approach to predict reproductive toxicity of chemicals (2015) Reprod Toxicol, 55, pp. 114-123. , PID: 25656794; van Thriel, C., Westerink, R., Beste, C., Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts (2011) NeuroToxicol, 33, pp. 911-924; Vartak, N., Damle-Vartak, A., Richter, B., Cholestasis-induced adaptive remodeling of interlobular bile ducts (2016) Hepatology, 63, pp. 951-964. , COI: 1:CAS:528:DC%2BC28XjsFejtb8%3D, PID: 26610202; Villeneuve, D.L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T.H., LaLone, C.A., Landesmann, B., Whelan, M., Adverse outcome pathway (AOP) development I: strategies and principles (2014) Toxicol Sci, 142, pp. 312-320. , COI: 1:CAS:528:DC%2BC2MXitl2ntrY%3D, PID: 25466378; Villeneuve, D.L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T.H., LaLone, C.A., Landesmann, B., Whelan, M., Adverse outcome pathway development. II: best practices (2014) Toxicol Sci, 142, pp. 321-330. , COI: 1:CAS:528:DC%2BC2MXitl2ntrc%3D, PID: 25466379; Vinken, M., Adverse outcome pathways and drug-induced liver injury testing (2015) Chem Res Toxicol, 28, pp. 1391-1397. , COI: 1:CAS:528:DC%2BC2MXhtVOit7bI, PID: 26119269; Volbracht, C., Leist, M., Nicotera, P., ATP controls neuronal apoptosis triggered by microtubule breakdown or potassium deprivation (1999) Mol Med, 5, pp. 477-489. , COI: 1:CAS:528:DyaK1MXlvFWjt74%3D, PID: 10449809; Volbracht, C., Fava, E., Leist, M., Calpain inhibitors prevent nitric oxide-triggered excitotoxic apoptosis (2001) NeuroReport, 12, pp. 3645-3648. , COI: 1:CAS:528:DC%2BD3MXpt1Grsrk%3D, PID: 11726766; Volbracht, C., Leist, M., Kolb, S.A., Apoptosis in caspase-inhibited neurons (2001) Mol Med, 7, pp. 36-48. , COI: 1:CAS:528:DC%2BD3MXhtlKmsrk%3D, PID: 11474126; Wilmes, A., Limonciel, A., Aschauer, L., Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress (2013) J Proteomics, 79, pp. 180-194. , COI: 1:CAS:528:DC%2BC3sXivFymsrY%3D, PID: 23238060; Wilmes, A., Bielow, C., Ranninger, C., Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics (2015) Toxicol In Vitro, 30, pp. 117-127. , COI: 1:CAS:528:DC%2BC2cXhvVamsL7J, PID: 25450742; Wittwehr, C., Aladjov, H., Ankley, G., How adverse outcome pathways can aid the development and use of computational prediction models for regulatory toxicology (2017) Toxicol Sci, 155, pp. 326-336. , PID: 27994170; Wynn, T.A., Cellular and molecular mechanisms of fibrosis (2008) J Pathol, 214, pp. 199-210. , COI: 1:CAS:528:DC%2BD1cXhvFCkt7w%3D, PID: 18161745; Zhu, H., Bouhifd, M., Kleinstreuer, N., Supporting read-across using biological data (2016) ALTEX, 33, pp. 167-182. , PID: 26863516; Zimmer, B., Lee, G., Balmer, N.V., Evaluation of developmental toxicants and signaling pathways in a functional test based on the migration of human neural crest cells (2012) Environ Health Perspect, 120, pp. 1116-1122. , COI: 1:CAS:528:DC%2BC38XhtlCqtLbP, PID: 22571897; Zimmer, B., Pallocca, G., Dreser, N., Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery (2014) Arch Toxicol, 88, pp. 1109-1126. , COI: 1:CAS:528:DC%2BC2cXlt1CgsLk%3D, PID: 24691702","Leist, M.; In Vitro Toxicology and Biomedicine, Department inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Box 657, Universitaetsstr. 10, Germany; email: marcel.leist@uni-konstanz.de",,,"Springer Verlag",,,,,03405761,,ARTOD,"29051992","English","Arch. Toxicol.",Article,"Final",,Scopus,2-s2.0-85031799653
"Sanz F.","7102263897;","Data Integration and Sharing Supporting Drug R&D",2017,"Comprehensive Medicinal Chemistry III","1-8",,,"436","443",,,"10.1016/B978-0-12-409547-2.12297-8","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046128347&doi=10.1016%2fB978-0-12-409547-2.12297-8&partnerID=40&md5=95c04e4fdeb36a553233b36b76016b74","Universitat Pompeu Fabra, Barcelona, Spain","Sanz, F., Universitat Pompeu Fabra, Barcelona, Spain","Drug discovery and development is a knowledge-intensive process that implies the generation, management, and analysis of huge amounts of data from the initial target discovery research to the post-marketing pharmacovigilance studies, including central operations such as virtual screening and toxicological assessment. The integrative analysis of information from several types and sources (the biomedical Big Data) offers great opportunities for gaining a more complete and powerful view on the biology, the diseases, and their pharmacological treatment. The article presents a series of strategies and computational tools, most of them publicly available, which facilitate and enrich the tasks to be done along the drug discovery and development pipeline. © 2017 Elsevier Ltd. All rights reserved.","Biana; Big data; ChEMBL; ClinicalTrials.gov; Data integration; Data management; Databases; DisGeNET; DiXa; Drug Bank; DSSTox; EMIF; ETOX; EU-ADR; EudraCT; EudraPharm; HIPPIE; Human Interactome database; Open PHACTS; Reactome; STRING; SureChEMBL; Text-mining; Tox21; ToxCast",,,,,,,,,,"Cases, M., Furlong, L.I., Albanell, J., Altman, R.B., Bellazzi, R., Boyer, S., Brand, A., Sanz, F., Improving Data and Knowledge Management to Better Integrate Health Care and Research (2013) J. Intern. Med., 274 (4), pp. 321-328; Marti-Solano, M., Birney, E., Bril, A., Della Pasqua, O., Kitano, H., Mons, B., Xenarios, I., Sanz, F., Integrative Knowledge Management to Enhance Pharmaceutical R&D (2014) Nat. Rev. Drug Discov., 13 (4), pp. 239-240; https://www.openphacts.org/; Ratnam, J., Zdrazil, B., Digles, D., Cuadrado-Rodriguez, E., Neefs, J.M., Tipney, H., Siebes, R., Chichester, C., The Application of the Open Pharmacological Concepts Triple Store (open PHACTS) to Support Drug Discovery Research (2014) PLoS One, 9 (12); Chichester, C., Digles, D., Siebes, R., Loizou, A., Groth, P., Harland, L., Drug Discovery FAQs: Workflows for Answering Multidomain Drug Discovery Questions (2015) Drug Discov. Today, 20 (4), pp. 399-405; http://www.drugbank.ca/; Wishart, D.S., Knox, C., Guo, A.C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., Woolsey, J., DrugBank: A Comprehensive Resource for In Silico Drug Discovery and Exploration (2006) Nucleic Acids Res., 34, pp. D668-D672. , DATABASE ISSUE; http://www.disgenet.org/web/DisGeNET/; Piñero, J., Queralt-Rosinach, N., Bravo, A., Deu-Pons, J., Bauer-Mehren, A., Baron, M., Sanz, F., Furlong, L.I., DisGeNET: A Discovery Platform for the Dynamical Exploration of Human Diseases and Their Genes (2015) Database (Oxford); http://www.reactome.org/; Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., D'Eustachio, P., The Reactome Pathway Knowledgebase (2016) Nucleic Acids Res., 44 (1), pp. D481-D487; http://string-db.org/; Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., von Mering, C., STRING v10: Protein-Protein Interaction Networks, Integrated Over the Tree of Life (2015) Nucleic Acids Res., 43, pp. D447-D452. , DATABASE ISSUE; http://interactome.dfci.harvard.edu/H_sapiens/index.php?page=download; Rolland, T., Taşan, M., Charloteaux, B., Pevzner, S.J., Zhong, Q., Sahni, N., Yi, S., Vidal, M., A Proteome-Scale Map of the Human Interactome Network (2014) Cell, 159 (5), pp. 1212-1226; http://cbdm-01.zdv.uni-mainz.de/~mschaefer/hippie/; Schaefer, M.H., Fontaine, J.F., Vinayagam, A., Porras, P., Wanker, E.E., Andrade-Navarro, M.A., HIPPIE: Integrating Protein Interaction Networks With Experiment Based Quality Scores (2012) PLoS One, 7 (2); http://sbi.imim.es/web/index.php/research/servers/biana; Garcia-Garcia, J., Guney, E., Aragues, R., Planas-Iglesias, J., Oliva, B., Biana: A Software Framework for Compiling Biological Interactions and Analyzing Networks (2010) BMC Bioinformat., 11, p. 56; https://www.ebi.ac.uk/chembl/; Bento, A.P., Gaulton, A., Hersey, A., Bellis, L.J., Chambers, J., Davies, M., Krüger, F.A., Overington, J.P., The ChEMBL Bioactivity Database: An Update (2014) Nucleic Acids Res., 42, pp. D1083-D1090. , DATABASE ISSUE; Mestres, J., Gregori-Puigjané, E., Valverde, S., Solé, R.V., Data Completeness-The Achilles Heel of Drug-Target Networks (2008) Nat. Biotechnol., 26 (9), pp. 983-984; Mestres, J., Martín-Couce, L., Gregori-Puigjané, E., Cases, M., Boyer, S., Ligand-Based Approach to In Silico Pharmacology: Nuclear Receptor Profiling (2006) J. Chem. Inf. Model., 46 (6), pp. 2725-2736; https://www.surechembl.org/search/; Papadatos, G., Davies, M., Dedman, N., Chambers, J., Gaulton, A., Siddle, J., Koks, R., Overington, J.P., SureChEMBL: A Large-Scale, Chemically Annotated Patent Document Database (2016) Nucleic Acids Res., 44 (1), pp. D1220-D1228; Cases, M., Briggs, K., Steger-Hartmann, T., Pognan, F., Marc, P., Kleinöder, T., Schwab, C.H., Sanz, F., The eTOX Data-Sharing Project to Advance In Silico Drug-Induced Toxicity Prediction (2014) Int. J. Mol. Sci., 15, pp. 21136-21154; Briggs, K., Barber, C., Cases, M., Marc, P., Steger-Hartmann, T., Value of Shared Preclinical Safety Studies-The eTOX Database (2015) Tox. Rep., 2, pp. 210-221; Sanz, F., Carrió, P., López, O., Capoferri, L., Kooi, D.P., Vermeulen, N.P.E., Geerke, D.P., Pastor, M., Integrative Modeling Strategies for Predicting Drug Toxicities at the eTOX Project (2015) Mol. Inf., 34, pp. 477-484; http://www.epa.gov/chemical-research/toxicity-forecasting; http://ntp.niehs.nih.gov/results/hts/index.html; http://www.epa.gov/chemical-research/distributed-structure-searchable-toxicity-dsstox-database; Hendrickx, D.M., Aerts, H.J., Caiment, F., Clark, D., Ebbels, T.M., Evelo, C.T., Gmuender, H., Kleinjans, J.C., DiXa: A Data Infrastructure for Chemical Safety Assessment (2015) Bioinformatics, 31 (9), pp. 1505-1507; http://wwwdev.ebi.ac.uk/fg/dixa/index.html; https://clinicaltrials.gov/ct2/help/how-find/find-study-results#Overview; http://www.eudrapharm.eu/eudrapharm/selectLanguage.do?NOCOOKIE=NOCOOKIE&NEW_SESSION=true; https://eudract.ema.europa.eu/index.html; Coloma, P.M., Schuemie, M.J., Trifirò, G., Furlong, L., van Mulligen, E., Bauer-Mehren, A., Avillach, P., Sturkenboom, M., Drug-Induced Acute Myocardial Infarction: Identifying 'prime suspects' From Electronic Healthcare Records-Based Surveillance System (2013) PLoS One, 8 (8); http://www.emif.eu/; Rawlins, M.D., Spontaneous Reporting of Adverse Drug Reactions. I: The Data (1988) Br. J. Clin. Pharmacol., 26 (1), pp. 1-5; Bauer-Mehren, A., van Mullingen, E.M., Avillach, P., Carrascosa Mdel, C., Garcia-Serna, R., Piñero, J., Singh, B., Furlong, L.I., Automatic Filtering and Substantiation of Drug Safety Signals (2012) PLoS Comput. Biol., 8 (4)","Sanz, F.; Universitat Pompeu FabraSpain; email: ferran.sanz@upf.edu",,,"Elsevier Inc.",,,,,,9780128032008; 9780128032015,,,"English","Compr. Med. Chem. III",Book Chapter,"Final",,Scopus,2-s2.0-85046128347
"Guixà-González R., Albasanz J.L., Rodriguez-Espigares I., Pastor M., Sanz F., Martí-Solano M., Manna M., Martinez-Seara H., Hildebrand P.W., Martín M., Selent J.","55090002500;6602359915;56165211100;7102415847;7102263897;55090002400;35325177400;22433269800;8526042400;56712116500;55891371700;","Membrane cholesterol access into a G-protein-coupled receptor",2017,"Nature Communications","8",, 14505,"","",,40,"10.1038/ncomms14505","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013391445&doi=10.1038%2fncomms14505&partnerID=40&md5=ceab5a9ec69eb3af77baf2aa872abf2c","Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences of Pompeu Fabra University (UPF), Hospital Del Mar Medical Research Institute (IMIM), Barcelona, 08003, Spain; Institut für Medizinische Physik und Biophysik, AG ProteiInformatics, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin, D-10117, Germany; Department of Inorganic Chemistry, Organic Chemistry, and Biochemistry, Fac. of Sci. and Chem. Technol. and Fac. of Med. of Cd. Real. Regional Center of Biomedical Research, University of Castilla-La Mancha (UCLM), Ciudad Real, 13071, Spain; Department of Physics, Tampere University of Technology (TUT), PO Box 692, Tampere, FI-33101, Finland","Guixà-González, R., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences of Pompeu Fabra University (UPF), Hospital Del Mar Medical Research Institute (IMIM), Barcelona, 08003, Spain, Institut für Medizinische Physik und Biophysik, AG ProteiInformatics, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin, D-10117, Germany; Albasanz, J.L., Department of Inorganic Chemistry, Organic Chemistry, and Biochemistry, Fac. of Sci. and Chem. Technol. and Fac. of Med. of Cd. Real. Regional Center of Biomedical Research, University of Castilla-La Mancha (UCLM), Ciudad Real, 13071, Spain; Rodriguez-Espigares, I., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences of Pompeu Fabra University (UPF), Hospital Del Mar Medical Research Institute (IMIM), Barcelona, 08003, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences of Pompeu Fabra University (UPF), Hospital Del Mar Medical Research Institute (IMIM), Barcelona, 08003, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences of Pompeu Fabra University (UPF), Hospital Del Mar Medical Research Institute (IMIM), Barcelona, 08003, Spain; Martí-Solano, M., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences of Pompeu Fabra University (UPF), Hospital Del Mar Medical Research Institute (IMIM), Barcelona, 08003, Spain; Manna, M., Department of Physics, Tampere University of Technology (TUT), PO Box 692, Tampere, FI-33101, Finland; Martinez-Seara, H., Department of Physics, Tampere University of Technology (TUT), PO Box 692, Tampere, FI-33101, Finland; Hildebrand, P.W., Institut für Medizinische Physik und Biophysik, AG ProteiInformatics, Charité-Universitätsmedizin Berlin, Charitéplatz 1, Berlin, D-10117, Germany; Martín, M., Department of Inorganic Chemistry, Organic Chemistry, and Biochemistry, Fac. of Sci. and Chem. Technol. and Fac. of Med. of Cd. Real. Regional Center of Biomedical Research, University of Castilla-La Mancha (UCLM), Ciudad Real, 13071, Spain; Selent, J., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences of Pompeu Fabra University (UPF), Hospital Del Mar Medical Research Institute (IMIM), Barcelona, 08003, Spain","Cholesterol is a key component of cell membranes with a proven modulatory role on the function and ligand-binding properties of G-protein-coupled receptors (GPCRs). Crystal structures of prototypical GPCRs such as the adenosine A2A receptor (A2A R) have confirmed that cholesterol finds stable binding sites at the receptor surface suggesting an allosteric role of this lipid. Here we combine experimental and computational approaches to show that cholesterol can spontaneously enter the A2A R-binding pocket from the membrane milieu using the same portal gate previously suggested for opsin ligands. We confirm the presence of cholesterol inside the receptor by chemical modification of the A2A R interior in a biotinylation assay. Overall, we show that cholesterol's impact on A2A R-binding affinity goes beyond pure allosteric modulation and unveils a new interaction mode between cholesterol and the A2A R that could potentially apply to other GPCRs. © 2017 The Author(s).",,"adenosine A2a receptor; cholesterol; radioligand; adenosine A2a receptor; cholesterol; G protein coupled receptor; protein binding; amino acid; bioassay; cells and cell components; chemical binding; chemoreception; crystal structure; fat; ligand; lipid; membrane; protein; allosterism; animal cell; Article; binding affinity; binding assay; binding site; biotinylation; cell membrane; chemical modification; controlled study; ligand binding; molecular dynamics; nonhuman; rat; receptor binding; animal; binding competition; cell membrane; chemistry; metabolism; protein domain; tumor cell line; Animals; Binding Sites; Binding, Competitive; Cell Line, Tumor; Cell Membrane; Cholesterol; Molecular Dynamics Simulation; Protein Binding; Protein Domains; Rats; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled",,"cholesterol, 57-88-5; Cholesterol; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled",,,"Ministerio de Economía y Competitividad, MINECO: BFU2011-23034

Ministerio de Ciencia y Tecnología, MICYT: SAF2009-13609-C04-04

Ministerio de Ciencia y Tecnología, MICYT: 634143

PEII-2014-030-P

Academy of Finland

2015 FI-B00145

Deutsche Forschungsgemeinschaft, DFG: WO 1908/2-1

Deutsche Forschungsgemeinschaft, DFG: SFB 740) SFB70

Deutsche Forschungsgemeinschaft, DFG: DFG HI 1502/ 1-1

Instituto de Salud Carlos III, ISCIII: PI15/00460

Instituto de Salud Carlos III, ISCIII: CP12/03139","J.S. and R.G.-G. acknowledge support from Fundaci? La Marat? de TV3 (091010), Instituto de Salud Carlos III FEDER (CP12/03139 and PI15/00460), and the GLISTEN European Research Network. F.S., M.P., J.S. and R.G.-G. acknowledge support from Ministerio de Educaci?n y Ciencia (Grant Number: SAF2009-13609-C04-04) and H2020 Project MedBioinformatics under Grant Agreement Number 634143. P.W.H. and R.G.-G. acknowledge support from the Deutsche Forschungsgemeinschaft (DFG HI 1502/ 1-1, WO 1908/2-1, SFB 740) SFB70 and the Norddeutscher Verbund f?r Hoch- und H?chstleistungsrechner (HLRN). M.Mar. and J.L.A. acknowledge support from Ministerio de Econom?a y Competitividad (BFU2011-23034) and JCCM (PEII-2014-030-P). I.R.-E. acknowledges support from AGAUR and European Social Fund (2015 FI-B00145). H.M.-S. and M. Man acknowledge financial support from the Academy of Finland and thank the CSC-IT Center for Science (Espoo, Finland) for providing computational resources.",,,"Dawaliby, R., Allosteric regulation of G protein-coupled receptor activity by phospholipids (2015) Nat. Chem. Biol., 12, pp. 35-39; Guixà-González, R., Membrane omega-3 fatty acids modulate the oligomerisation kinetics of adenosine A2A and dopamine D2 receptors (2016) Sci. Rep., 6, p. 19839; Paila, Y.D., Chattopadhyay, A., The function of G-protein coupled receptors and membrane cholesterol: Specific or general interaction? (2009) Glycoconj. J., 26, pp. 711-720; Paila, Y.D., Chattopadhyay, A., Membrane cholesterol in the function and organization of G-protein coupled receptors (2010) Subcell. Biochem, 51, pp. 381-398; Oates, J., Watts, A., Uncovering the intimate relationship between lipids, cholesterol and GPCR activation (2011) Curr. Opin. Struct. Biol., 21, pp. 802-807; Gimpl, G., Interaction of G protein coupled receptors and cholesterol (2016) Chem. Phys. Lipids, 199, pp. 61-73; Gimpl, G., Burger, K., Fahrenholz, F., Cholesterol as modulator of receptor function (1997) Biochemistry, 36, pp. 10959-10974; Nguyen, D.H., Taub, D., CXCR4 function requires membrane cholesterol: Implications for HIV infection (2002) J. Immunol., 168, pp. 4121-4126; Nguyen, D.H., Taub, D.D., Inhibition of chemokine receptor function by membrane cholesterol oxidation (2003) Exp. Cell Res., 291, pp. 36-45; Harikumar, K.G., Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor (2005) J. Biol. Chem., 280, pp. 2176-2185; Huang, P., Cholesterol reduction by methyl-b-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells (2007) Biochem. Pharmacol., 73, pp. 534-549; Bari, M., Paradisi, A., Pasquariello, N., Maccarrone, M., Cholesteroldependent modulation of type 1 cannabinoid receptors in nerve cells (2005) J. Neurosci. Res., 81, pp. 275-283; Colozo, A.T., Park, P.S.H., Sum, C.S., Pisterzi, L.F., Wells, J.W., Cholesterol as a determinant of cooperativity in the M2 muscarinic cholinergic receptor (2007) Biochem. Pharmacol., 74, pp. 236-255; Michal, P., Rudajev, V., El-Fakahany, E.E., Dolezal, V., Membrane cholesterol content influences binding properties of muscarinic M2 receptors and differentially impacts activation of second messenger pathways (2009) Eur. J. Pharmacol., 606, pp. 50-60; Xu, W., Localization of the kappa opioid receptor in lipid rafts (2006) J. Pharmacol. Exp. Ther., 317, pp. 1295-1306; Rod, R., Segments, O., Albert, D., Cholesterol modulation of photoreceptor function in bovine retinal rod outer segments (1990) J. Biol. Chem., 265, pp. 20727-20730; Mitchell, D.C., Straume, M., Miller, J.L., Litman, B.J., Modulation of metarhodopsin formation by cholesterol-induced ordering of bilayer lipids? (1990) Biochemistry, 29, pp. 9143-9149; Albert, A.D., Boesze-Battaglia, K., Paw, Z., Watts, A., Epand, R.M., Effect of cholesterol on rhodopsin stability in disk membranes (1996) BBA-Protein Struct. Mol, 1297, pp. 77-82; Niu, S.L., Mitchell, D.C., Litman, B.J., Manipulation of cholesterol levels in rod disk membranes by methyl-b-cyclodextrin: Effects on receptor activation (2002) J. Biol. Chem., 277, pp. 20139-20145; Zocher, M., Zhang, C., Rasmussen, S.G.F., Kobilka, B.K., Müller, D.J., Cholesterol increases kinetic, energetic, and mechanical stability of the human b2-adrenergic receptor (2012) Proc. Natl Acad. Sci. USA, 109, pp. E3463-E3472; Khelashvili, G., Mondal, S., Andersen, O.S., Weinstein, H., Cholesterol modulates the membrane effects and spatial organization of membranepenetrating ligands for G-protein coupled receptors (2010) J. Phys. Chem. B, 114, pp. 12046-12057; Cherezov, V., High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor (2007) Science, 318, pp. 1258-1266; Hanson, M.A., A specific cholesterol binding site is established by the 2.8A structure of the human b2-adrenergic receptor (2008) Structure, 16, pp. 897-905; Liu, W., Structural basis for allosteric regulation of GPCRs by sodium ions (2012) Science, 337 (80), pp. 232-236; Wu, H., Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator (2014) Science, 344, pp. 58-64; Song, Y., Kenworthy, A.K., Sanders, C.R., Cholesterol as a co-solvent and a ligand for membrane proteins (2014) Protein Sci., 23, pp. 1-22; Benned-Jensen, T., Molecular characterization of oxysterol binding to the Epstein-Barr virus-induced gene 2 (GPR183) (2012) J. Biol. Chem., 287, pp. 35470-35483; Sensi, C., Oxysterols act as promiscuous ligands of class-A GPCRs: In silico molecular modeling and in vitro validation (2014) Cell Signal., 26, pp. 2614-2620; Nachtergaele, S., Oxysterols are allosteric activators of the oncoprotein Smoothened (2012) Nat. Chem. Biol., 8, pp. 211-220; Byrne, E.F.X., Structural basis of Smoothened regulation by its extracellular domains (2016) Nature, 535, pp. 517-522; Burnstock, G., Ralevic, V., Purinergic signaling and blood vessels in health and disease (2014) Pharmacol. Rev., 66, pp. 102-192; Popoli, P., Pepponi, R., Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system (2012) CNS Neurol. Disord. Drug Targets, 11, pp. 664-674; Cunha, R.A., Ferré, S., Vaugeois, J.-M., Chen, J.-F., Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders (2008) Curr. Pharm. des, 14, pp. 1512-1524; Morelli, M., Role of adenosine A2A receptors in Parkinsonian motor impairment and l-DOPA-induced motor complications (2007) Prog. Neurobiol., 83, pp. 293-309; Lyman, E., A role for a specific cholesterol interaction in stabilizing the Apo configuration of the human A2A adenosine receptor (2009) Structure, 17, pp. 1660-1668; Lee, J.Y.J., Lyman, E., Predictions for cholesterol interaction sites on the A2A adenosine receptor (2012) J. Am. Chem. Soc., 134, pp. 16512-16515; Park, J.H., Opsin, a structural model for olfactory receptors? (2013) Angew Chemie-Int. Ed, 52, pp. 11021-11024; Szczepek, M., Crystal structure of a common GPCR binding interface for G protein and arrestin (2014) Nat. Commun., 5, p. 4801; O'Malley, M.A., Helgeson, M.E., Wagner, N.J., Robinson, A.S., The morphology and composition of cholesterol-rich micellar nanostructures determine transmembrane protein (GPCR) activity (2011) Biophys. J., 100, pp. L11-L13; Jaakola, V., Griffith, M., Hanson, M., The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist (2008) Science, 322, pp. 1211-1217; Brannigan, G., Hénin, J., Law, R., Eckenhoff, R., Klein, M.L., Embedded cholesterol in the nicotinic acetylcholine receptor (2008) Proc. Natl. Acad. Sci. USA, 105, pp. 14418-14423; Javitch, J.A., Li, X., Kaback, J., Karlin, A., A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice (1994) Proc. Natl. Acad. Sci. USA, 91, pp. 10355-10359; Hanson, M.A., Crystal structure of a lipid G protein-coupled receptor (2012) Science, 335, pp. 851-855; Hurst, D.P., A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor (2010) J. Biol. Chem., 285, pp. 17954-17964; Park, J.H., Scheerer, P., Hofmann, K.P., Choe, H.-W., Ernst, O.P., Crystal structure of the ligand-free G-protein-coupled receptor opsin (2008) Nature, 454, pp. 183-187; Mustafi, D., Palczewski, K., Topology of class A G protein-coupled receptors: Insights gained from crystal structures of rhodopsins, adrenergic and adenosine receptors (2009) Mol. Pharmacol., 75, pp. 1-12; Hildebrand, P.W., A ligand channel through the G protein coupled receptor opsin (2009) PLoS ONE, 4, p. e4382; Piechnick, R., Effect of channel mutations on the uptake and release of the retinal ligand in opsin (2012) Proc. Natl. Acad. Sci. USA, 109, pp. 5247-5252; Petrek, M., CAVER: A new tool to explore routes from protein clefts, pockets and cavities (2006) BMC Bioinformatics, 7, p. 316; Wang, T., Duan, Y., Ligand entry and exit pathways in the beta2-adrenergic receptor (2009) J. Mol. Biol., 392, pp. 1102-1115; Luis Albasanz, J., Fernandez, M., Martín, M., Internalization of metabotropic glutamate receptor in C6 cells through clathrin-coated vesicles (2002) Brain Res. Mol. Brain Res., 99, pp. 54-66; Castillo, C.A., Albasanz, J.L., Fernández, M., Martín, M., Endogenous expression of adenosine A1A2 and A3 receptors in rat C6 glioma cells (2007) Neurochem. Res., 32, pp. 1056-1070; Gou-Fàbregas, M., 7-dehydrocholesterol efficiently supports Ret signaling in a mouse model of Smith-Opitz-Lemli syndrome (2016) Sci. Rep, 6, p. 28534; Jové, M., Lipidomic and metabolomic analyses reveal potential plasma biomarkers of early atheromatous plaque formation in hamsters (2013) Cardiovasc. Res., 97, pp. 642-652; Sandra, K., Pereira, A.D.S., Vanhoenacker, G., David, F., Sandra, P., Comprehensive blood plasma lipidomics by liquid chromatography/ quadrupole time-of-flight mass spectrometry (2010) J. Chromatogr. A, 1217, pp. 4087-4099; Sana, T.R., Roark, J.C., Li, X., Waddell, K., Fischer, S.M., Molecular formula and METLIN personal metabolite database matching applied to the identification of compounds generated by LC/TOF-MS (2008) J. Biomol. Tech, 19, pp. 258-266; Harvey, M.J., Giupponi, G., De Fabritiis, G., ACEMD: Accelerating biomolecular dynamics in the microsecond time scale (2009) J. Chem. Theory Comput., 5, pp. 1-9; Klauda, J.B., Update of the CHARMM all-atom additive force field for lipids: Validation on six lipid types (2010) J. Phys. Chem. B, 114, pp. 7830-7843; Lim, J.B., Rogaski, B., Klauda, J.B., Update of the cholesterol force field parameters in CHARMM (2012) J. Phys. Chem. B, 116, pp. 203-210; MacKerell, A., Bashford, D., All-atom empirical potential for molecular modeling and dynamics studies of proteins (1998) J. Phys. Chem. B, 5647, pp. 3586-3616; Jo, S., Lim, J.J.B., Klauda, J.J.B., Im, W., CHARMM-GUI membrane builder for mixed bilayers and its application to yeast membranes (2009) Biophys. J., 96, pp. 50-58; Humphrey, W., Dalke, A., Schulten, K., VMD: Visual molecular dynamics (1996) J. Mol. Graph., 14, pp. 33-38; McNamara, R.K., Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder (2007) Biol. Psychiatry, 62, pp. 17-24; McNamara, R.K., Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: Gender differences and partial normalization with antipsychotic medications (2007) Schizophr. Res., 91, pp. 37-50; McNamara, R.K., Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder (2008) Psychiatry Res., 160, pp. 285-299; Martín, V., Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex (2010) J. Alzheimers Dis., 19, pp. 489-502; Fabelo, N., Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease (2011) Mol. Med., 17, p. 1107; Taha, A.Y., Cheon, Y., Ma, K., Rapoport, S.I., Rao, J.S., Altered fatty acid concentrations in prefrontal cortex of schizophrenic patients (2013) J. Psychiatr. Res., 47, pp. 636-643; Berendsen, H.J.C., Postma, J.P.M., Van Gunsteren, W.F., DiNola, A., Haak, J.R., Molecular dynamics with coupling to an external bath (1984) J. Chem. Phys., 81, p. 3684; Grest, G., Kremer, K., Molecular dynamics simulation for polymers in the presence of a heat bath (1986) Phys. Rev. A, 33, pp. 3628-3631; Darden, T., York, D., Pedersen, L., Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems (1993) J. Chem. Phys., pp. 13-16. , 27709; Eswar, N., Eramian, D., Webb, B., Shen, M.-Y., Sali, A., Protein structure modeling with MODELLER (2008) Methods Mol. Biol., 426, pp. 145-159; Abraham, M.J., Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers (2015) SoftwareX, 1-2, pp. 19-25; Crowley, M.F., Williamson, M.J., Walker, R.C., CHAMBER: Comprehensive support for CHARMM force fields within the AMBER software (2009) Int. J. Quant. Chem., 109, pp. 3767-3772; Dahl, A.C.E., Chavent, M., Sansom, M.S.P., Bendix: Intuitive helix geometry analysis and abstraction (2012) Bioinformatics, 28, pp. 2193-2194","Martín, M.; Department of Inorganic Chemistry, Organic Chemistry, and Biochemistry, Fac. of Sci. and Chem. Technol. and Fac. of Med. of Cd. Real. Regional Center of Biomedical Research, University of Castilla-La Mancha (UCLM)Spain; email: mairena.martin@uclm.es",,,"Nature Publishing Group",,,,,20411723,,,"28220900","English","Nat. Commun.",Article,"Final",Open Access,Scopus,2-s2.0-85013391445
"Carbonell P., Lopez O., Amberg A., Pastor M., Sanz F.","36780066700;56556019000;6602980607;7102415847;7102263897;","Hepatotoxicity prediction by systems biology modeling of disturbed metabolic pathways using gene expression data",2017,"Altex","34","2",,"219","234",,8,"10.14573/altex.1602071","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018654791&doi=10.14573%2faltex.1602071&partnerID=40&md5=f74513aa622a1551077b73e15d31c579","Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Manchester Synthetic Biology Research Centre for Fine and Speciality Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, Faculty of Science and Engineering, University of Manchester, 131 Princess Street, Manchester, M1 7DN, United Kingdom; Sanofi Aventis Deutschland GmbH, Preclinical Safety, Frankfurt am Main, Germany","Carbonell, P., Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain, Manchester Synthetic Biology Research Centre for Fine and Speciality Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, Faculty of Science and Engineering, University of Manchester, 131 Princess Street, Manchester, M1 7DN, United Kingdom; Lopez, O., Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Amberg, A., Sanofi Aventis Deutschland GmbH, Preclinical Safety, Frankfurt am Main, Germany; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Institut Hospital Del Mar D'Investigacions Mèdiques (IMIM), Dept. of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain","The present study applies a systems biology approach for the in silico predictive modeling of drug toxicity on the basis of high-quality preclinical drug toxicity data with the aim of increasing the mechanistic understanding of toxic effects of compounds at different levels (pathway, cell, tissue, organ). The model development was carried out using 77 compounds for which gene expression data for treated primary human hepatocytes is available in the LINCS database and for which rodent in vivo hepatotoxicity information is available in the eTOX database. The data from LINCS were used to determine the type and number of pathways disturbed by each compound and to estimate the extent of disturbance (network perturbation elasticity), and were used to analyze the correspondence with the in vivo information from eTOX. Predictive models were developed through this integrative analysis, and their specificity and sensitivity were assessed. The quality of the predictions was determined on the basis of the area under the curve (AUC) of plots of true positive vs. false positive rates (ROC curves). The ROC AUC reached values of up to 0.9 (out of 1.0) for some hepatotoxicity endpoints. Moreover, the most frequently disturbed metabolic pathways were determined across the studied toxicants. They included, e.g., mitochondrial beta-oxidation of fatty acids and amino acid metabolism. The process was exemplified by successful predictions on various statins. In conclusion, an entirely new approach linking gene expression alterations to the prediction of complex organ toxicity was developed and evaluated.","Drug toxicity; Gene regulation; Hepatotoxicity; Predictive modeling; Systems biology","alanine aminotransferase; aspartate aminotransferase; bilirubin; gamma glutamyltransferase; pravastatin; rosuvastatin; simvastatin; amino acid metabolism; Article; citric acid cycle; elasticity; emotion; fatty acid oxidation; gene control; gene expression; hepatobiliary disease; histopathology; human; liver cell; liver cell damage; liver injury; liver toxicity; metabolism; nonhuman; simulation; systems biology; toxic dose; transcription regulation; upregulation; adverse drug reaction; animal; animal testing alternative; drug effects; factual database; gene expression regulation; genetics; in vitro study; liver; metabolism; preclinical study; procedures; rat; sensitivity and specificity; statistical model; Animal Testing Alternatives; Animals; Databases, Factual; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation; Hepatocytes; Humans; In Vitro Techniques; Liver; Metabolic Networks and Pathways; Models, Statistical; Rats; Sensitivity and Specificity",,"alanine aminotransferase, 9000-86-6, 9014-30-6; aspartate aminotransferase, 9000-97-9; bilirubin, 18422-02-1, 635-65-4; gamma glutamyltransferase, 85876-02-4; pravastatin, 81093-37-0, 81131-70-6; rosuvastatin, 147098-18-8, 147098-20-2; simvastatin, 79902-63-9",,,,,,,"Alsheikh-Ali, A.A., Ambrose, M.S., Kuvin, J.T., Karas, R.H., The safety of rosuvastatin as used in common clinical practice: A postmarketing analysis (2005) Circulation, 111, pp. 3051-3057. , https://doi.org/10.1161/CIRCULATIONAHA.105.555482; Barski, O.A., Tipparaju, S.M., Bhatnagar, A., The aldo-keto reductase superfamily and its role in drug metabolism and detoxification (2008) Drug Metab Rev, 40, pp. 553-624. , https://doi.org/10.1080/03602530802431439; Bordbar, A., Monk, J.M., King, Z.A., Palsson, B.Ø., Constraint-based models predict metabolic and associated cellular functions (2014) Nat Rev Genet, 15, pp. 107-120. , https://doi.org/10.1038/nrg3643; Carbonell, P., Lecointre, G., Faulon, J.L., Origins of specificity and promiscuity in metabolic networks (2011) J Biol Chem, 286, pp. 43994-44004. , https://doi.org/10.1074/jbc.m111.274050; Cases, M., Briggs, K., Steger-Hartmann, T., The eTOX data-sharing project to advance in silico drug-induced toxicity prediction (2014) Int J Mol Sci, 15, pp. 21136-21154. , https://doi.org/10.3390/ijms151121136; Chen, M., Bisgin, H., Tong, L., Toward predictive models for drug-induced liver injury in humans: Are we there yet? (2014) Biomark Med, 8, pp. 201-213. , https://doi.org/10.2217/bmm.13.146; Cheng, F., Theodorescu, D., Schulman, I.G., Lee, J.K., In vitro transcriptomic prediction of hepatotoxicity for early drug discovery (2011) J Theor Biol, 290, pp. 27-36. , https://doi.org/10.1016/j.jtbi.2011.08.009; D'Alessandro, L.A., Hoehme, S., Henney, Unraveling liver complexity from molecular to organ level: Challenges and perspectives (2015) Prog Biophys Mol Bio, 117, pp. 78-86. , https://doi.org/10.1016/j.pbiomolbio.2014.11.005; Dada, J.O., Mendes, P., Multi-scale modelling and simulation in systems biology (2011) Integr Biol, 3, pp. 86-96. , https://doi.org/10.1039/c0ib00075b; Duan, Q., Niepel, F.C., LINCS Canvas Browser: Interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures (2014) Nucleic Acids Res, 42, pp. W449-460. , https://doi.org/10.1093/nar/gku476; Ebbels, T.M.D., Keun, H.C., Beckonert, O.P., Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: The consortium on metabonomic toxicology screening approach (2007) J Proteome Res, 6, pp. 4407-4422. , https://doi.org/10.1021/pr0703021; Ebrahim, A., Lerman, J.A.J., Palsson, B.Ø., Hyduke, D.R., COBRApy: Constraints-based reconstruction and analysis for Python (2013) BMC Sys Biol, 7, p. 74. , https://doi.org/10.1186/1752-0509-7-74; Elowitz, M.B., Leibler, S., A synthetic oscillatory network of transcriptional regulators (2000) Nature, 403, pp. 335-338. , https://doi.org/10.1038/35002125; Famularo, G., Miele, L., Minisola, G., Grieco, A., Liver toxicity of rosuvastatin therapy (2007) World J Gastroentero, 13, pp. 1286-1288. , https://doi.org/10.3748/wjg.v13.i8.1286; Gille, C., Bolling, C., Hoppe, A., HepatoNet1: A comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology (2010) Mol Syst Biol, 6, p. 411. , https://doi.org/10.1038/msb.2010.62; Gleeson, M.P., Modi, S., Bender, A., The challenges involved in modeling toxicity data in silico: A review (2012) Curr Pharm Design, 18, pp. 1266-1291. , https://doi.org/10.2174/138161212799436359; Godoy, P., Hewitt, N.J., Albrecht, U., Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (2013) Arch Toxicol, 87, pp. 1315-1530. , https://doi.org/10.1007/s00204-013-1078-5; Greene, N., Fisk, L., Naven, R.T., Developing structure-activity relationships for the prediction of hepatotoxicity (2010) Chem Res Toxicol, 23, pp. 1215-1222. , https://doi.org/10.1021/tx1000865; Hoofnagle, J.H., Serrano, J., Knoben, J.E., Navarro, V.J., LiverTox: A website on drug-induced liver injury (2013) Hepatology, 57, pp. 873-874. , https://doi.org/10.1002/hep.26175; Hucka, M., Finney, A., Sauro, H.M., The systems biology markup language (SBML): A medium for representation and exchange of biochemical network models (2003) Bioinformatics, 19, pp. 524-531. , https://doi.org/10.1093/bioinformatics/btg015; Hwang, N.K., Park, J.S., Cha, K.S., Kang, J.S., Hepatotoxicity associated with a short course of rosuvastatin (2015) Chin Med J, 128, pp. 1693-1694. , https://doi.org/10.4103/0366-6999.158382; Juty, N., Ali, R., Glont, S., BioModels: Content, features, functionality, and use (2015) CPT Pharmacometrics Syst Pharmacol, 4, pp. 55-68. , https://doi.org/10.1002/psp4.3; King, Z.A., Drger, A., Ebrahim, A., Escher: A web application for building, sharing, and embedding data-rich visualizations of biological pathways (2015) PLoS Comput Biol, 11, p. e1004321. , https://doi.org/10.1371/journal.pcbi.1004321; Krewski, D., Andersen, A.D., Toxicity testing in the 21st century: A vision and a strategy (2010) J Toxicol Environ Health B Crit Rev, 13, pp. 51-138. , https://doi.org/10.1080/10937 404.2010.483176; Lazarou, J., Pomeranz, B.H., Corey, P.N., Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies (1998) JAMA, 279, pp. 1200-1205. , https://doi.org/10.1001/jama.279.15.1200; Liu, J., Mansouri, K., Judson, R.S., Predicting hepatotoxicity using ToxCast in vitro bioactivity and chemical structure (2015) Chem Res Toxicol, 28, pp. 738-751. , https://doi.org/10.1021/tx500501h; Low, Y., Uehara, T., Minowa, Y., Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics approaches (2011) Chem Res Toxicol, 24, pp. 1251-1262. , https://doi.org/10.1021/tx200148a; Low, Y., Sedykh, A., Fourches, D., Integrative chemical-biological read-across approach for chemical hazard classification (2013) Chem Res Toxicol, 26, pp. 1199-1208. , https://doi.org/10.1021/tx400110f; Myshkin, E., Brennan, R., Khasanova, T., Prediction of organ toxicity endpoints by QSAR modeling based on precise chemical-histopathology annotations (2012) Chem Biol Drug des, 80, pp. 406-416. , https://doi.org/10.1111/j.1747-0285.2012.01411.x; O'Boyle, N.M., Banck, M., James, C.A., Open Babel: An open chemical toolbox (2011) J Cheminform, 3, p. 33. , https://doi.org/10.1186/1758-2946-3-33; O'Brien, E.J., Lerman, J.A., Chang, R.L., Genome-scale models of metabolism and gene expression extend and refine growth phenotype prediction (2013) Mol Syst Biol, 9, p. 693. , https://doi.org/10.1038/msb.2013.52; O'Brien, P.J., Irwin, W., Diaz, D., High concordance of drug induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell based model using high content screening (2006) ArchToxicol, 80, pp. 580-604. , https://doi.org/10.1007/s00204-006-0091-3; Orth, J.D., Thiele, I., Palsson, B.O., What is flux balance analysis? (2010) Nat Biotechnol, 28, pp. 245-248. , https://doi.org/10.1038/nbt.1614; Payne, J.L., Moore, J.H., Wagner, A., Robustness, evolvability, and the logic of genetic regulation (2014) Artif Life, 20, pp. 111-126. , https://doi.org/10.1162/artl_a_00099; Planson, A.G., Paillard, C.P., Compound toxicity screening and structure-activity relationship modeling in Escherichia coli (2012) Biotechnol Bioeng, 109, pp. 846-850. , https://doi.org/10.1002/bit.24356; Planson, A.G., Carbonell, P., Grigoras, I., Faulon, J.L., A retrosynthetic biology approach to therapeutics: From conception to delivery (2012) Curr Opin Biotechnol, 23, pp. 948-956. , https://doi.org/10.1016/j.copbio.2012.03.009; Plant, N.J., An introduction to systems toxicology (2015) Toxicol Res, 4, pp. 9-22. , https://doi.org/10.1039/c4tx00058g; Rolfsson, O., Palsson, B.Ø., Thiele, I., The human metabolic reconstruction Recon 1 directs hypotheses of novel human metabolic functions (2011) BMC Syst Biol, 5, p. 155. , https://doi.org/10.1186/1752-0509-5-155; Russmann, S., Kullak-Ublick, G.A., Grattagliano, I., Current concepts of mechanisms in drug-induced hepatotoxicity (2009) Curr Med Chem, 16, pp. 3041-3053. , https://doi.org/10.2174/092986709788803097; Schellenberger, J., Que, R., Fleming, R.M.T., Quantitative prediction of cellular metabolism with constraint-based models: The COBRA Toolbox v2.0 (2011) Nat Protocols, 6, pp. 1290-1307. , https://doi.org/10.1038/nprot.2011.308; Schuetz, R., Zamboni, N., Zampieri, M., Multidimensional optimality of microbial metabolism (2012) Science, 336, pp. 601-604. , https://doi.org/10.1126/science.1216882; Shlomi, T., Cabili, M.N., Herrgard, M.J., Network-based prediction of human tissue-specific metabolism (2008) Nat Biotechnol, 26, pp. 1003-1010. , https://doi.org/10.1038/nbt.1487; Thiele, I., Palsson, B.Ø., A protocol for generating a high-quality genome-scale metabolic reconstruction (2010) Nat Protocols, 5, pp. 93-121. , https://doi.org/10.1038/nprot.2009.203; Thiele, I., Swainston, N., Fleming, R.M.T., A community-driven global reconstruction of human metabolism (2013) Nat Biotechnol, 31, pp. 419-425. , https://doi.org/10.1038/nbt.2488; Törnqvist, E., Annas, A., Granath, B., Strategic focus on 3R principles reveals major reductions in the use of animals in pharmaceutical toxicity testing (2014) PLoS One, 9. , https://doi.org/10.1371/journal.pone.0101638; Waring, M.J., Arrowsmith, J., Leach, A.R., An analysis of the attrition of drug candidates from four major pharmaceutical companies (2015) Nat Rev Drug Discov, 14, pp. 475-486. , https://doi.org/10.1038/nrd4609; De Van, W.H., Gifford, E., ADMET in silico modelling: Towards prediction paradise? (2003) Nat Rev Drug Discov, 2, pp. 192-204. , https://doi.org/10.1038/nrd1032; Zhu, X., Kruhlak, N.L., Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data (2014) Toxicology, 321, pp. 62-72. , https://doi.org/10.1016/j.tox.2014.03.009; Zhu, X.W., Sedykh, A., Liu, S.S., Hybrid in silico models for drug-induced liver injury using chemical descriptors and in vitro cell-imaging information (2014) J Appl Toxicol, 34, pp. 281-288. , https://doi.org/10.1002/jat.2879","Carbonell, P.; Manchester Synthetic Biology Research Centre for Fine and Speciality Chemicals (SYNBIOCHEM), Manchester Institute of Biotechnology, Faculty of Science and Engineering, University of Manchester, 131 Princess Street, United Kingdom; email: pablo.carbonell@manchester.ac.uk",,,"Elsevier GmbH",,,,,1868596X,,ALTEE,"27690270","English","Altex",Article,"Final",Open Access,Scopus,2-s2.0-85018654791
"Mayer M.A., Gutierrez-Sacristan A., Leis A., De La Peña S., Sanz F., Furlong L.I.","36971031500;56728807700;35072969800;57194139882;7102263897;34770469800;","Using Electronic Health Records to Assess Depression and Cancer Comorbidities",2017,"Studies in Health Technology and Informatics","235",,,"236","240",,1,"10.3233/978-1-61499-753-5-236","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018799269&doi=10.3233%2f978-1-61499-753-5-236&partnerID=40&md5=74bc64bbf041809f3fdb64f4cdb9cc7c","Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain","Mayer, M.A., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain; Gutierrez-Sacristan, A., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain; Leis, A., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain; De La Peña, S., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain","Comorbid diseases are an important concern in oncology since they can affect the choice and effectiveness of treatment. What is particularly relevant is the fact that the diagnosis of depression in cancer patients has an important impact on the quality of life of these patients. Although there is no consensus about a specific relationship of depression with certain cancer types, some authors have proposed that depression constitutes a risk factor for cancer. The objective of this study is to identify the presence of comorbidities in a massive EHR system, between depression and the 10 most common cancers in women and men and to determine if there is a preferred temporal ordering in the co-occurrence of these diseases. All the cancers studied showed a significant co-occurrence with depression, more specifically, twice more frequent than what could be expected by chance. A preferred directionality was identified between some of the comorbid diseases, such as breast cancer followed by depression, and depression followed by either stomach cancer, colorectal cancer or lung cancer. Future work will address other potential factors that have an influence on the likelihood of suffering from depression in patients with cancer, such as drug therapies received, exposure to substance of abuse or other comorbidities. © 2017 European Federation for Medical Informatics (EFMI) and IOS Press.","Cancer; Comorbidity; Depression; Electronic Health Records","comorbidity; complication; depression; electronic health record; female; human; male; Neoplasms; quality of life; risk factor; Spain; Comorbidity; Depression; Electronic Health Records; Female; Humans; Male; Neoplasms; Quality of Life; Risk Factors; Spain",,,,,,,,,"Geraci, J.M., Escalante, C.P., Freeman, J.L., Goodwin, J.S., Comorbid disease and cancer: The need for more relevant conceptual models in health services research (2005) Journal of Clinical Oncology, 23 (30), pp. 7399-7404; Torta, R.G., Ieraci, V., Pharmacological management of depression in patients with cancer: Practical considerations (2013) Drugs, 73 (11), pp. 1131-1145; Currier, M.B., Nemeroff, C.B., Depression as a risk factor for cancer: From pathophysiological advances to treatment implications (2014) Annual Review Medicine, 65, pp. 203-221; Reich, F.M., Depression and cancer: Recent data on clinical issues, research challenges and treatment approaches (2008) Current Opinion in Oncology, 20 (4), pp. 353-359; Williams, M.L., Depression-The hidden symptom in advanced cancer (2003) Journal of the Royal Society of Medicine, 96 (12), pp. 577-581; International Agency for Research on Cancer, , http://www.iarc.fr, World Health Organization; Mayer, M.A., Furlong, L.I., Torre, P., Reuse of EHRs to support clinical research in a hospital of reference (2015) Studies in Health Technology and Informatics, 66, pp. 856-890; Sancho, J.J., Planas, I., Domenech, D., Martin-Baranera, M., Palau, J., Sanz, F., IMASIS A multicenter hospital information system-experience in Barcelona (1998) Studies in Health Technology and Informatics, 56, pp. 35-42; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), , http://www.cdc.gov/nchs/icd/icd9cm.htm, Centers for Disease Control and Prevention; (2013) Diagnostic and Statistical Manual of Mental Disorders (Fith Edition), , American Psychiatric Association. DSM-5. Arlington, United States of America; https://bitbucket.org/ibi_group/comorbidity, A Gutiérrez-Sacristan. comoRbidity R package; Hidalgo, C., Blumm, N., Barabási, A., Christakis, N., A dynamic network approach for the study of human phenotype (2009) PLoS Computational Biology, 5 (4), p. e1000353; Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., Golani, I., Controlling the false discovery rate in behavior genetics research (2001) Behavioural Brain Research, 125, pp. 279-284","Mayer, M.A.; Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, Spain; email: miguelangel.mayer@upf.edu","Randell R.Cornet R.Scott P.J.Cornet R.Peek N.McCowan C.",,"IOS Press",,,,,09269630,9781614997528,,"28423789","English","Stud. Health Technol. Informatics",Article,"Final",,Scopus,2-s2.0-85018799269
"Piñero J., Bravo A., Queralt-Rosinach N., Gutiérrez-Sacristán A., Deu-Pons J., Centeno E., García-García J., Sanz F., Furlong L.I.","55220852900;56374942700;35766634600;56728807700;35603037000;36631601300;7102375601;7102263897;34770469800;","DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants",2017,"Nucleic Acids Research","45","D1",,"D833","D839",,253,"10.1093/nar/gkw943","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016126262&doi=10.1093%2fnar%2fgkw943&partnerID=40&md5=d376f25e3368cb0042c3c6dd9d6dd394","Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain; Department of Molecular and Experimental Medicine, Scripps Research Institute, San Diego, CA  92037, United States","Piñero, J., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain; Bravo, A., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain; Queralt-Rosinach, N., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain, Department of Molecular and Experimental Medicine, Scripps Research Institute, San Diego, CA  92037, United States; Gutiérrez-Sacristán, A., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain; Deu-Pons, J., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain; Centeno, E., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain; García-García, J., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Barcelona, E-08003, Spain","The information about the genetic basis of human diseases lies at the heart of precision medicine and drug discovery. However, to realize its full potential to support these goals, several problems, such as fragmentation, heterogeneity, availability and different conceptualization of the data must be overcome. To provide the community with a resource free of these hurdles, we have developed DisGeNET (http://www.disgenet.org), one of the largest available collections of genes and variants involved in human diseases. DisGeNET integrates data from expert curated repositories, GWAS catalogues, animal models and the scientific literature. DisGeNET data are homogeneously annotated with controlled vocabularies and community-driven ontologies. Additionally, several original metrics are provided to assist the prioritization of genotype-phenotype relationships. The information is accessible through a web interface, a Cytoscape App, an RDF SPARQL endpoint, scripts in several programming languages and an R package. DisGeNET is a versatile platform that can be used for different research purposes including the investigation of the molecular underpinnings of specific human diseases and their comorbidities, the analysis of the properties of disease genes, the generation of hypothesis on drug therapeutic action and drug adverse effects, the validation of computationally predicted disease genes and the evaluation of text-mining methods performance. © The Author(s) 2016.",,"access to information; Article; comorbidity; computer interface; data mining; disease association; disease model; disease ontology; diseases; drug mechanism; drug safety; genetic database; genetic variability; genome-wide association study; genotype phenotype correlation; information processing; molecular diagnostics; online system; validation process; biology; genetic association study; genetic predisposition; genetic variation; genomics; human; procedures; software; web browser; Computational Biology; Databases, Genetic; Genetic Association Studies; Genetic Predisposition to Disease; Genetic Variation; Genomics; Humans; Software; Web Browser",,,,,,,,,"Bauer-Mehren, A., Rautschka, M., Sanz, F., Furlong, L.I., DisGeNET: A Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks (2010) Bioinformatics, 26, pp. 2924-2926; Pi Ñero, J., Queralt-Rosinach, N., Bravo, A., Deu-Pons, J., Bauer-Mehren, A., Baron, M., Sanz, F., Furlong, L.I., DisGeNET: A discovery platform for the dynamical exploration of human diseases and their genes (2015) Database, p. bav028; Davis, A.P., Grondin, C.J., Lennon-Hopkins, K., Saraceni-Richards, C., Sciaky, D., King, B.L., Wiegers, T.C., Mattingly, C.J., The Comparative Toxicogenomics Database's 10th year anniversary: Update 2015 (2015) Nucleic Acids Res., 43, pp. D914-D920; UniProt: A hub for protein information (2014) Nucleic Acids Res., 43, pp. D204-D212. , The UniProt Consortium; Landrum, M.J., Lee, J.M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Hoover, J., ClinVar: Public archive of interpretations of clinically relevant variants (2016) Nucleic Acids Res., 44, pp. D862-D868; Rath, A., Olry, A., Dhombres, F., Brandt, M.M., Urbero, B., Ayme, S., Representation of rare diseases in health information systems: The Orphanet approach to serve a wide range of end users (2012) Hum. Mutat., 33, pp. 803-808; Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Hindorff, L., The NHGRI GWAS Catalog, a curated resource of SNP-trait associations (2014) Nucleic Acids Res., 42, pp. D1001-D1006; Shimoyama, M., De Pons, J., Hayman, G.T., Laulederkind, S.J.F., Liu, W., Nigam, R., Petri, V., Wang, S.-J., The Rat Genome Database 2015: Genomic, phenotypic and environmental variations and disease (2015) Nucleic Acids Res., 43, pp. D743-D750; Eppig, J.T., Blake, J.A., Bult, C.J., Kadin, J.A., Richardson, J.E., The Mouse Genome Database (MGD): Facilitating mouse as a model for human biology and disease (2015) Nucleic Acids Res., 43, pp. D726-D736; Becker, K.G., Barnes, K.C., Bright, T.J., Wang, S.A., The genetic association database (2004) Nat. Genet., 36, pp. 431-432; Bundschus, M., Dejori, M., Stetter, M., Tresp, V., Kriegel, H.-P., Extraction of semantic biomedical relations from text using conditional random fields (2008) BMC Bioinformatics, 9, p. 207; Bravo, A., Cases, M., Queralt-Rosinach, N., Sanz, F., Furlong, L.I., A knowledge-driven approach to extract disease-related biomarkers from the literature (2014) Biomed Res. Int., 2014, p. 253128; Bravo, À., Piñero, J., Queralt-Rosinach, N., Rautschka, M., Furlong, L.I., Extraction of relations between genes and diseases from text and large-scale data analysis: Implications for translational research (2015) BMC Bioinformatics, 16, p. 55; Bodenreider, O., The Unified Medical Language System (UMLS): Integrating biomedical terminology (2004) Nucleic Acids Res., 32, pp. D267-D2710; Kibbe, W.A., Arze, C., Felix, V., Mitraka, E., Bolton, E., Fu, G., Mungall, C.J., Vasant, D., Disease Ontology 2015 update: An expanded and updated database of human diseases for linking biomedical knowledge through disease data (2015) Nucleic Acids Res., 43, pp. D1071-D1078; Groza, T., Köhler, S., Moldenhauer, D., Vasilevsky, N., Baynam, G., Zemojtel, T., Schriml, L.M., Beck, T., The human phenotype ontology: Semantic unification of common and rare disease (2015) Am. J. Hum. Genet., 97, pp. 111-124; Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., McKay, S., The Reactome pathway Knowledgebase (2015) Nucleic Acids Res., 44, pp. D481-D487; Mi, H., Poudel, S., Muruganujan, A., Casagrande, J.T., Thomas, P.D., PANTHER version 10: Expanded protein families and functions, and analysis tools (2016) Nucleic Acids Res., 44, pp. D336-D342; Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, K., DbSNP: The NCBI database of genetic variation (2001) Nucleic Acids Res., 29, pp. 308-311; Lek, M., Karczewski, K.J., Minikel, E.V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-Luria, A.H., Cummings, B.B., Analysis of protein-coding genetic variation in 60, 706 humans (2016) Nature, 536, pp. 285-291; Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Abecasis, G.R., Bentley, D.R., Chakravarti, A., Eichler, E.E., A global reference for human genetic variation (2015) Nature, 526, pp. 68-74; McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R.S., Thormann, A., Flicek, P., Cunningham, F., The ensembl variant effect predictor (2016) Genome Biol., 17, p. 122; Queralt-Rosinach, N., Piñero, J., Bravo, À., Sanz, F., Furlong, L.I., DisGeNET-RDF: Harnessing the innovative power of the semantic web to explore the genetic basis of diseases (2016) Bioinformatics, 32, pp. 2236-2238; Queralt-Rosinach, N., Kuhn, T., Chichester, C., Dumontier, M., Sanz, F., Furlong, L.I., Publishing DisGeNET as nanopublications (2016) Semant. Web, 7, pp. 519-528; Wilkinson, M.D., Dumontier, M., Aalbersberg, I.J.J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Bourne, P.E., The FAIR Guiding Principles for scientific data management and stewardship (2016) Sci. Data, 3, p. 160018; Dumontier, M., Baker, C.J., Baran, J., Callahan, A., Chepelev, L., Cruz-Toledo, J., Del Rio, N.R., Keath, N., The Semanticscience Integrated Ontology (SIO) for biomedical research and knowledge discovery (2014) J. Biomed. Semantics, 5, p. 14; Kutmon, M., Riutta, A., Nunes, N., Hanspers, K., Willighagen, E.L., Bohler, A., Mélius, J., Miller, R., WikiPathways: Capturing the full diversity of pathway knowledge (2016) Nucleic Acids Res., 44, pp. D488-D494; Jupp, S., Malone, J., Bolleman, J., Brandizi, M., Davies, M., Garcia, L., Gaulton, A., Redaschi, N., The EBI RDF platform: Linked open data for the life sciences (2014) Bioinformatics, 30, pp. 1338-1339; Petryszak, R., Keays, M., Tang, Y.A., Fonseca, N.A., Barrera, E., Burdett, T., Füllgrabe, A., Koskinen, S., Expression Atlas update-an integrated database of gene and protein expression in humans, animals and plants (2016) Nucleic Acids Res., 44, pp. D746-D752; Hopkins, A.L., Groom, C.R., The druggable genome (2002) Nat. Rev. Drug Discov., 1, pp. 727-730; Nelson, M.R., Tipney, H., Painter, J.L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Wang, J., The support of human genetic evidence for approved drug indications (2015) Nat. Genet., 47, pp. 856-860; Amberger, J.S., Bocchini, C.A., Schiettecatte, F., Scott, A.F., Hamosh, A., OMIM.org: Online mendelian inheritance in man (OMIM®), an online catalog of human genes and genetic disorders (2015) Nucleic Acids Res., 43, pp. D789-D798; Plaisier, C.L., O'Brien, S., Bernard, B., Reynolds, S., Simon, Z., Toledo, C.M., Ding, Y., Baliga, N.S., Causal mechanistic regulatory network for glioblastoma deciphered using systems genetics network analysis (2016) Cell Syst., 3, pp. 172-186; Kishore, A., Žižková, V., Kocourková, L., Petrkova, J., Bouros, E., Nunes, H., Lǒstáková, V., Kolek, V., Association study for 26 candidate loci in idiopathic pulmonary fibrosis patients from four european populations (2016) Front. Immunol., 7, p. 274; Bhatnagar, M., Shorvon, S., Genetic mutations associated with status epilepticus (2015) Epilepsy Behav., 49, pp. 104-110; Abascal, M.F., Besso, M.J., Rosso, M., Mencucci, M.V., Aparicio, E., Szapiro, G., Furlong, L.I., Vazquez-Levin, M.H., CDH1/E-cadherin and solid tumors (2016) An Updated Gene-disease Association Analysis Using Bioinformatics Tools. Comput. Biol. Chem., 60, pp. 9-20; Breen, M.S., Uhlmann, A., Nday, C.M., Glatt, S.J., Mitt, M., Metsalpu, A., Stein, D.J., Illing, N., Candidate gene networks and blood biomarkers of methamphetamine-associated psychosis: An integrative RNA-sequencing report (2016) Transl. Psychiatry, 6, p. e802; Hansen, M.C., Nederby, L., Roug, A., Villesen, P., Kjeldsen, E., Nyvold, C.G., Hokland, P., Novel scripts for improved annotation and selection of variants from whole exome sequencing in cancer research (2015) MethodsX, 2, pp. 145-153; Lee, I.-H., Lee, K., Hsing, M., Choe, Y., Park, J.-H., Kim, S.H., Bohn, J.M., Green, R.C., Prioritizing disease-linked variants, genes, and pathways with an interactive whole-genome analysis pipeline (2014) Hum. Mutat., 35, pp. 347-537; Alaimo, S., Giugno, R., Pulvirenti, A., NcPred: NcRNA-disease association prediction through tripartite network-based inference (2014) Front. Bioeng. Biotechnol., 2, p. 71; Liu, M.-X., Chen, X., Chen, G., Cui, Q.-H., Yan, G.-Y., A computational framework to infer human disease-associated long noncoding RNAs (2014) PLoS One, 9, p. e84408; Srivastava, I., Gahlot, L.K., Khurana, P., Hasija, Y., DbAARD & AGP: A computational pipeline for the prediction of genes associated with age related disorders (2016) J. Biomed. Inform., 60, pp. 153-161; Pi Ñero, J., Berenstein, A., Gonzalez-Perez, A., Chernomoretz, A., Furlong, L.I., Uncovering disease mechanisms through network biology in the era of Next Generation Sequencing (2016) Sci. Rep., 6, p. 24570; Chagoyen, M., Pazos, F., Characterization of clinical signs in the human interactome (2016) Bioinformatics, 32, pp. 1761-1765; Vogt, I., Prinz, J., Worf, K., Campillos, M., Systematic analysis of gene properties influencing organ system phenotypes in mammalian perturbations (2014) Bioinformatics, 30, pp. 3093-3100; Bauer-Mehren, A., Van Mullingen, E.M., Avillach, P., Carrascosa, M.D.C., Garcia-Serna, R., Pi Ñero, J., Singh, B., Diallo, G., Automatic filtering and substantiation of drug safety signals (2012) PLoS Comput. Biol., 8, p. e1002457; Mullen, J., Cockell, S.J., Woollard, P., Wipat, A., An integrated data driven approach to drug repositioning using gene-disease associations (2016) PLoS One, 11, p. e0155811; Grosdidier, S., Ferrer, A., Faner, R., Pi Ñero, J., Roca, J., Cosío, B., Agustí, A., Furlong, L.I., Network medicine analysis of COPD multimorbidities (2014) Respir. Res., 15, p. 111; Faner, R., Gutiérrez-Sacristán, A., Castro-Acosta, A., Grosdidier, S., Gan, W., Sánchez-Mayor, M., Lopez-Campos, J.L., Mannino, D., Molecular and clinical diseasome of comorbidities in exacerbated COPD patients (2015) Eur. Respir. J., 46, pp. 1001-1010; Xu, D., Zhang, M., Xie, Y., Wang, F., Chen, M., Zhu, K.Q., Wei, J., DTMiner: Identification of potential disease targets through biomedical literature mining (2016) Bioinformatics; Mannil, D., Vogt, I., Prinz, J., Campillos, M., Organ system heterogeneity DB: A database for the visualization of phenotypes at the organ system level (2015) Nucleic Acids Res., 43, pp. D900-D906; Hamed, M., Spaniol, C., Nazarieh, M., Helms, V., TFmiR: A web server for constructing and analyzing disease-specific transcription factor and miRNA co-regulatory networks (2015) Nucleic Acids Res., 43, pp. W283-W288; Cornish, A.J., Filippis, I., David, A., Sternberg, M.J.E., Exploring the cellular basis of human disease through a large-scale mapping of deleterious genes to cell types (2015) Genome Med., 7, p. 95","Furlong, L.I.; Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Dr Aiguader 88, Spain; email: laura.furlong@upf.edu",,,"Oxford University Press",,,,,03051048,,NARHA,"27924018","English","Nucleic Acids Res.",Article,"Final",Open Access,Scopus,2-s2.0-85016126262
"Gutiérrez-Sacristán A., Bravo À., Portero-Tresserra M., Valverde O., Armario A., Blanco-Gandía M.C., Farré A., Fernández-Ibarrondo L., Fonseca F., Giraldo J., Leis A., Mané A., Mayer M.A., Montagud-Romero S., Nadal R., Ortiz J., Pavon F.J., Perez E.J., Rodríguez-Arias M., Serrano A., Torrens M., Warnault V., Sanz F., Furlong L.I.","56728807700;56374942700;55485063300;7003421046;7005836750;55879070500;57191034032;57191035028;11940519300;7003797712;35072969800;57191038566;36971031500;56012512400;6701731005;57191039800;24074833100;56803291800;6603913675;8854228600;7006681890;16837518000;7102263897;34770469800;","Text mining and expert curation to develop a database on psychiatric diseases and their genes",2017,"Database : the journal of biological databases and curation","2017",,,"","",,5,"10.1093/database/bax043","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040952116&doi=10.1093%2fdatabase%2fbax043&partnerID=40&md5=df95d7ad5c04f62ea9032f3494a42b65","Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Neurobiology of Behaviour Research Group (GReNeC), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), DCEXS, Universitat Pompeu Fabra (UPF), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Neurobiology of Behaviour Research Group (GReNeC), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), DCEXS, Universitat Pompeu Fabra (UPF), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Neurobiology of Behaviour Research Group (GReNeC), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), DCEXS, Universitat Pompeu Fabra (UPF), C/Dr. Aiguader 88, Barcelona, 08003, Spain","Gutiérrez-Sacristán, A., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Bravo, À., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Portero-Tresserra, M., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Valverde, O., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Armario, A., Neurobiology of Behaviour Research Group (GReNeC), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), DCEXS, Universitat Pompeu Fabra (UPF), C/Dr. Aiguader 88, Barcelona, 08003, Spain, Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Blanco-Gandía, M.C., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Farré, A., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Fernández-Ibarrondo, L., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Fonseca, F., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Giraldo, J., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain, Neurobiology of Behaviour Research Group (GReNeC), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), DCEXS, Universitat Pompeu Fabra (UPF), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Leis, A., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Mané, A., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain, Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Mayer, M.A., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Montagud-Romero, S., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Nadal, R., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain, Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Ortiz, J., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain, Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Pavon, F.J., Neurobiology of Behaviour Research Group (GReNeC), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), DCEXS, Universitat Pompeu Fabra (UPF), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Perez, E.J., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Rodríguez-Arias, M., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Serrano, A., Neurobiology of Behaviour Research Group (GReNeC), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), DCEXS, Universitat Pompeu Fabra (UPF), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Torrens, M., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Warnault, V., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Sanz, F., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain; Furlong, L.I., Institut de Neurociències and Animal Physiology Unit, Universitat Autònoma de Barcelona (UAB), C/Dr. Aiguader 88, Barcelona, 08003, Spain","Database URL: http://www.psygenet.org.PsyGeNET corpus: http://www.psygenet.org/ds/PsyGeNET/results/psygenetCorpus.tar.",,"data mining; genetic database; genetics; human; information processing; mental disease; procedures; software; Data Curation; Data Mining; Databases, Genetic; Humans; Mental Disorders; Software",,,,,,,,,,,,,,,,,,17580463,,,"29220439","English","Database (Oxford)",Article,"Final",Open Access,Scopus,2-s2.0-85040952116
"Jiménez R.C., Kuzak M., Alhamdoosh M., Barker M., Batut B., Borg M., Capella-Gutierrez S., Chue Hong N., Cook M., Corpas M., Flannery M., Garcia L., Gelpí J.L., Gladman S., Goble C., González Ferreiro M., Gonzalez-Beltran A., Griffin P.C., Grüning B., Hagberg J., Holub P., Hooft R., Ison J., Katz D.S., Leskošek B., López Gómez F., Oliveira L.J., Mellor D., Mosbergen R., Mulder N., Perez-Riverol Y., Pergl R., Pichler H., Pope B., Sanz F., Schneider M.V., Stodden V., Suchecki R., Svobodová Vařeková R., Talvik H.-A., Todorov I., Treloar A., Tyagi S., van Gompel M., Vaughan D., Via A., Wang X., Watson-Haigh N.S., Crouch S.","24481270200;14325240700;42760903200;57192395945;56176768300;57194974096;35335928400;57191382381;57207168831;24448006700;57194972163;50261456800;35517522400;55221967000;7004072716;57194977622;23396745000;26664597700;37088461600;57192404893;8935314200;6603607988;7005978055;49661664400;55599291600;57194976860;57193360895;57204300656;55612506500;7102238454;24598095700;26633154200;7005305909;7005597341;7102263897;7404064011;15623425400;36705161900;16235290700;35241373100;7102462913;22939397700;8099398400;55511076000;55249764800;6602979457;57194979102;26538313800;7006761235;","Four simple recommendations to encourage best practices in research software",2017,"F1000Research","6",, 876,"","",,13,"10.12688/f1000research.11407.1","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85024481292&doi=10.12688%2ff1000research.11407.1&partnerID=40&md5=20b68fb6104b9977f825f909fc34acaa","ELIXIR Hub, Wellcome Genome Campus, Hinxton, CB10 1SD, United Kingdom; Netherlands eScience Center, Science Park 140, Amsterdam, 1098 XG, Netherlands; CSL Limited, Bio21 Institute, 30 Flemington Road, Parkville, VIC  3010, Australia; National eResearch Collaboration Tools and ResourcesVIC  3010, Australia; ELIXIR-DE and de.NBI, Bioinformatics Group, Department of Computer Science, University of Freiburg, Freiburg, Germany; ELIXIR-SE, National Bioinformatics Infrastructure Sweden (NBIS), Scilifelab, Department of Biochemistry and Biophysics (DBB), Stockholm University, Stockholm, Sweden; ELIXIR-ES, Spanish National Bioinformatics Institute (INB), Spanish National Cancer Research Centre (CNIO), Calle de Melchor Fernández Almagro 3, Madrid, 28029, Spain; Software Sustainability Institute, JCMB, University of Edinburgh, Edinburgh, EH9 3FD, United Kingdom; Repositive Ltd, Future Business Centre, Cambridge, United Kingdom; EMBL Australia Bioinformatics Resource, Lab-14, The University of Melbourne, 700 Swanston St, Parkville, VIC  3053, Australia; EMBL-EBI, Wellcome Genome Campus, Hinxton, CB10 1SD, United Kingdom; Barcelona Supercomputing Center, Barcelona, 08034, Spain; Department of Biochemistry and Molecular Biomedicine, Universitat de Barcelona, Barcelona, 08028, Spain; ELIXIR-UK, Software Sustainability Institute, School of Computer Science, University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom; Oxford e-Research Centre, University of Oxford, Oxford, United Kingdom; BBMRI-ERIC, Neue Stiftingtalstraße 2/B/6, Graz, 8010, Austria; Dutch TechCenter for Life Sciences and ELIXIR-NL, Utrecht, Netherlands; ELIXIR-DK, Technical University of Denmark, Denmark, Denmark; National Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, Urbana, IL, United States; School of Information Sciences, University of Illinois Urbana Champaign, Urbana, IL, United States; Department of Electrical and Computer Engineering, University of Illinois Urbana Champaign, Urbana, IL, United States; Department of Computer Science, University of Illinois Urbana Champaign, Urbana, IL, United States; ELIXIR-SI, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; DETI/IEETA, University of Aveiro, Aveiro, Portugal; Center for Open Science, Charlottesville, VA, United States; Stemformatics, University of Melbourne, Melbourne, Australia; Computational Biology Division, Department of Integrative Biomedical Sciences, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; ELIXIR-CZ, Faculty of Information Technology, Czech Technical University in Prague, Prague, Czech Republic; BBMRI.at, Alpen-Adria-University Klagenfurt, Klagenfurt, Austria; GRIB, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; School of Agriculture, Food and Wine, University of Adelaide, Adelaide, Australia; Central European Institute of Technology (CEITEC), Brno, Czech Republic; National Centre for Biomolecular Research, Masaryk University, Brno, Czech Republic; ELIXIR-EE, Institute of Computer Science, University of Tartu, Tartu, Estonia; Science and Technologies Facilities Council, Swindon, United Kingdom; Australian National Data Service, Melbourne, Australia; Australian Genome Research Facility Ltd., Melbourne, Australia; Centre for Language and Speech Technology, Radboud University Nijmegen, Nijmegen, Netherlands; IBPM-CNR, Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy; Faculty of Information Technology, Monash UniversityVIC, Australia; Software Sustainability Institute, Web and Internet Science, University of Southampton, Southampton, United Kingdom","Jiménez, R.C., ELIXIR Hub, Wellcome Genome Campus, Hinxton, CB10 1SD, United Kingdom; Kuzak, M., Netherlands eScience Center, Science Park 140, Amsterdam, 1098 XG, Netherlands; Alhamdoosh, M., CSL Limited, Bio21 Institute, 30 Flemington Road, Parkville, VIC  3010, Australia; Barker, M., National eResearch Collaboration Tools and ResourcesVIC  3010, Australia; Batut, B., ELIXIR-DE and de.NBI, Bioinformatics Group, Department of Computer Science, University of Freiburg, Freiburg, Germany; Borg, M., ELIXIR-SE, National Bioinformatics Infrastructure Sweden (NBIS), Scilifelab, Department of Biochemistry and Biophysics (DBB), Stockholm University, Stockholm, Sweden; Capella-Gutierrez, S., ELIXIR-ES, Spanish National Bioinformatics Institute (INB), Spanish National Cancer Research Centre (CNIO), Calle de Melchor Fernández Almagro 3, Madrid, 28029, Spain; Chue Hong, N., Software Sustainability Institute, JCMB, University of Edinburgh, Edinburgh, EH9 3FD, United Kingdom; Cook, M., ELIXIR Hub, Wellcome Genome Campus, Hinxton, CB10 1SD, United Kingdom; Corpas, M., Repositive Ltd, Future Business Centre, Cambridge, United Kingdom; Flannery, M., EMBL Australia Bioinformatics Resource, Lab-14, The University of Melbourne, 700 Swanston St, Parkville, VIC  3053, Australia; Garcia, L., EMBL-EBI, Wellcome Genome Campus, Hinxton, CB10 1SD, United Kingdom; Gelpí, J.L., Barcelona Supercomputing Center, Barcelona, 08034, Spain, Department of Biochemistry and Molecular Biomedicine, Universitat de Barcelona, Barcelona, 08028, Spain; Gladman, S., EMBL Australia Bioinformatics Resource, Lab-14, The University of Melbourne, 700 Swanston St, Parkville, VIC  3053, Australia; Goble, C., ELIXIR-UK, Software Sustainability Institute, School of Computer Science, University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom; González Ferreiro, M., EMBL-EBI, Wellcome Genome Campus, Hinxton, CB10 1SD, United Kingdom; Gonzalez-Beltran, A., Oxford e-Research Centre, University of Oxford, Oxford, United Kingdom; Griffin, P.C., EMBL Australia Bioinformatics Resource, Lab-14, The University of Melbourne, 700 Swanston St, Parkville, VIC  3053, Australia; Grüning, B., ELIXIR-DE and de.NBI, Bioinformatics Group, Department of Computer Science, University of Freiburg, Freiburg, Germany; Hagberg, J., ELIXIR-SE, National Bioinformatics Infrastructure Sweden (NBIS), Scilifelab, Department of Biochemistry and Biophysics (DBB), Stockholm University, Stockholm, Sweden; Holub, P., BBMRI-ERIC, Neue Stiftingtalstraße 2/B/6, Graz, 8010, Austria; Hooft, R., Dutch TechCenter for Life Sciences and ELIXIR-NL, Utrecht, Netherlands; Ison, J., ELIXIR-DK, Technical University of Denmark, Denmark, Denmark; Katz, D.S., National Center for Supercomputing Applications, University of Illinois at Urbana-Champaign, Urbana, IL, United States, School of Information Sciences, University of Illinois Urbana Champaign, Urbana, IL, United States, Department of Electrical and Computer Engineering, University of Illinois Urbana Champaign, Urbana, IL, United States, Department of Computer Science, University of Illinois Urbana Champaign, Urbana, IL, United States; Leskošek, B., ELIXIR-SI, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; López Gómez, F., ELIXIR Hub, Wellcome Genome Campus, Hinxton, CB10 1SD, United Kingdom; Oliveira, L.J., DETI/IEETA, University of Aveiro, Aveiro, Portugal; Mellor, D., Center for Open Science, Charlottesville, VA, United States; Mosbergen, R., Stemformatics, University of Melbourne, Melbourne, Australia; Mulder, N., Computational Biology Division, Department of Integrative Biomedical Sciences, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Perez-Riverol, Y., EMBL-EBI, Wellcome Genome Campus, Hinxton, CB10 1SD, United Kingdom; Pergl, R., ELIXIR-CZ, Faculty of Information Technology, Czech Technical University in Prague, Prague, Czech Republic; Pichler, H., BBMRI.at, Alpen-Adria-University Klagenfurt, Klagenfurt, Austria; Pope, B., EMBL Australia Bioinformatics Resource, Lab-14, The University of Melbourne, 700 Swanston St, Parkville, VIC  3053, Australia; Sanz, F., GRIB, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Schneider, M.V., EMBL Australia Bioinformatics Resource, Lab-14, The University of Melbourne, 700 Swanston St, Parkville, VIC  3053, Australia; Stodden, V., School of Information Sciences, University of Illinois Urbana Champaign, Urbana, IL, United States; Suchecki, R., School of Agriculture, Food and Wine, University of Adelaide, Adelaide, Australia; Svobodová Vařeková, R., Central European Institute of Technology (CEITEC), Brno, Czech Republic, National Centre for Biomolecular Research, Masaryk University, Brno, Czech Republic; Talvik, H.-A., ELIXIR-EE, Institute of Computer Science, University of Tartu, Tartu, Estonia; Todorov, I., Science and Technologies Facilities Council, Swindon, United Kingdom; Treloar, A., Australian National Data Service, Melbourne, Australia; Tyagi, S., EMBL Australia Bioinformatics Resource, Lab-14, The University of Melbourne, 700 Swanston St, Parkville, VIC  3053, Australia, Australian Genome Research Facility Ltd., Melbourne, Australia; van Gompel, M., Centre for Language and Speech Technology, Radboud University Nijmegen, Nijmegen, Netherlands; Vaughan, D., EMBL-EBI, Wellcome Genome Campus, Hinxton, CB10 1SD, United Kingdom; Via, A., IBPM-CNR, Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy; Wang, X., Faculty of Information Technology, Monash UniversityVIC, Australia; Watson-Haigh, N.S., School of Agriculture, Food and Wine, University of Adelaide, Adelaide, Australia; Crouch, S., Software Sustainability Institute, Web and Internet Science, University of Southampton, Southampton, United Kingdom","Scientific research relies on computer software, yet software is not always developed following practices that ensure its quality and sustainability. This manuscript does not aim to propose new software development best practices, but rather to provide simple recommendations that encourage the adoption of existing best practices. Software development best practices promote better quality software, and better quality software improves the reproducibility and reusability of research. These recommendations are designed around Open Source values, and provide practical suggestions that contribute to making research software and its source code more discoverable, reusable and transparent. This manuscript is aimed at developers, but also at organisations, projects, journals and funders that can increase the quality and sustainability of research software by encouraging the adoption of these recommendations. © 2017 Jiménez RC et al.","Best practices; Code; FAIR; Guidelines; Open Science; Open Source; Quality; Recommendations; Software; Sustainability","adoption; organization; practice guideline; publication; reproducibility; software",,,,,,,,,"Artaza, H., Chue Hong, N., Manuel, C., Top 10 metrics for life science software good practices (2016) F1000Res, 5. , 27635232, 5007752, pii: ELIXIR-2000; Brase, J., Datacite - A Global Registration Agency for Research Data SSRN Electronic Journal, , n.d; Corpas, M., Jimenez, R., Carbon, S.J., BioJS: an open source standard for biological visualisation - its status in 2014 (2014) F1000Res, 3, p. 55. , 25075290, 4103492; Crouch, S., Chue Hong, N., Hettrick, S., The Software Sustainability Institute: Changing Research Software Attitudes and Practices (2013) Computing in Science & Engineering, 15 (6), pp. 74-80; DagstuhlEAS/draft-Manifesto (2017) GitHub, , Reference Source; Eijssen, L., Evelo, C., Kok, R., The Dutch Techcentre for Life Sciences: Enabling data-intensive life science research in the Netherlands [version 2; referees: 2 approved, 1 approved with reservations] (2016) F1000Res, 4, p. 33. , 26913186, 4743138; Fogel, K., Producing Open Source Software: How to Run a Successful Free Software Project (2005), Reference Source, O'Reilly Media, Inc; Gilb, T., Principles of Software Engineering Management (1988), Reference Source, Addison-Wesley Professional; Goble, C., Better Software, Better Research (2014) IEEE Internet Computing, 18 (5), pp. 4-8; Gómez, J., García, L.J., Salazar, G.A., BioJS: An Open Source JavaScript Framework for Biological Data Visualization (2013) Bioinformatics, 29 (8), pp. 1103-1104. , 23435069, 3624812; Hannay, J.E., MacLeod, C., Singer, J., How Do Scientists Develop and Use Scientific Software? (2009) 2009 ICSE Workshop on Software Engineering for Computational Science and Engineering; Henry, V.J., Bandrowski, A.E., Pepin, A.S., OMICtools: An Informative Directory for Multi-Omic Data Analysis (2014) Database (Oxford), 2014. , 25024350, 4095679, pii: bau069; Hettrick, S., Antonioletti, M., Carr, L., UK Research Software Survey 2014 (2016), Accessed November 27; Ince, D.C., Hatton, L., Graham-Cumming, J., The Case for Open Computer Programs (2012) Nature, 482 (7386), pp. 485-488. , 22358837; Ison, J., Rapacki, K., Ménager, H., Tools and Data Services Registry: A Community Effort to Document Bioinformatics Resources (2016) Nucleic Acids Res, 44 (D1), pp. D38-47. , 26538599, 4702812; Leprevost, F.V., Barbosar, V.C., Francisco, E.L., On best practices in the development of bioinformatics software (2014) Front Genet, 5, p. 199. , 25071829, 4078907; List, M., Ebert, P., Albrecht, F., Ten Simple Rules for Developing Usable Software in Computational Biology (2017) PLoS Comput Biol, 13 (1). , 28056032, 5215831; McKiernan, E.C., Bourne, P.E., Brown, C.T., How open science helps researchers succeed (2016) eLife, 5. , 27387362, 4973366, pii: e16800; Mulgan, G., Steinberg, T., Salem, O., Wide Open: Open Source Methods and Their Future Potential (2005), Reference Source, Demos Medical Publishing; Nosek, B.A., Alter, G., Banks, G.C., SCIENTIFIC STANDARDS. Promoting an open research culture (2015) Science. American Association for the Advancement of Science, 348 (6242), pp. 1422-1425. , 26113702, 4550299; Perez-Riverol, Y., Gatto, L., Wang, R., Ten Simple Rules for Taking Advantage of Git and GitHub (2016) PLoS Comput Biol, 12 (7). , 27415786, 4945047; Perez-Riverol, Y., Wang, R., Hermjakob, H., Open source libraries and frameworks for mass spectrometry based proteomics: a developer's perspective (2014) Biochim Biophys Acta, 1844 (1), pp. 63-76. , 23467006, 3898926; Popp, K.M., Best Practices for Commercial Use of Open Source Software: Business Models, Processes and Tools for Managing Open Source Software (2015) BoD - Books on Demand, , Reference Source; Prlić, A., Procter, J.B., Ten simple rules for the open development of scientific software (2012) PLoS Comput Biol, 8 (12). , 23236269, 3516539; Smith, A.M., Katz, D.S., Niemeyer, K.E., Software Citation Principles (2016) PeerJ Comput Sci, 2; Wilkinson, M.D., Dumontier, M., Aalbersberg, I.J., The FAIR Guiding Principles for scientific data management and stewardship (2016) Sci Data, 3, p. 160018. , 26978244, 4792175; Wilson, G., Aruliah, D.A., Brown, C.T., Best practices for scientific computing (2014) PLoS Biol, 12 (1). , 24415924, 3886731; Wilson, G., Bryan, J., Cranston, K., Good Enough Practices in Scientific Computing (2016), Reference Source; Wilson, G., Software Carpentry: lessons learned [version 1; referees: 3 approved] (2014) F1000Res, 3, p. 62. , 24715981, 3976103","Jiménez, R.C.; ELIXIR Hub, Wellcome Genome CampusUnited Kingdom; email: rafael.jimenez@elixir-europe.org",,,"Faculty of 1000 Ltd",,,,,20461402,,,,"English","F1000 Res.",Article,"Final",Open Access,Scopus,2-s2.0-85024481292
"Carrió P., Sanz F., Pastor M.","55227590800;7102263897;7102415847;","Toward a unifying strategy for the structure-based prediction of toxicological endpoints",2016,"Archives of Toxicology","90","10",,"2445","2460",,3,"10.1007/s00204-015-1618-2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946763147&doi=10.1007%2fs00204-015-1618-2&partnerID=40&md5=42f8f181b2de8966744c8bb5ff3ba409","Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Carrer Dr. Aiguader 88, Barcelona, 08003, Spain","Carrió, P., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Carrer Dr. Aiguader 88, Barcelona, 08003, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Carrer Dr. Aiguader 88, Barcelona, 08003, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Carrer Dr. Aiguader 88, Barcelona, 08003, Spain","Most computational methods used for the prediction of toxicity endpoints are based on the assumption that similar compounds have similar biological properties. This principle can be exploited using computational methods like read across or quantitative structure–activity relationships. However, there is no general agreement about which method is the most appropriate for quantifying compound similarity neither for exploiting the similarity principle in order to obtain reliable estimations of the compound properties. Moreover, optimal similarity metrics and modeling methods might depend on the characteristics of the endpoints and training series used in each case. This study describes a comparative analysis of the predictive performance of diverse similarity metrics and modeling methods in toxicological applications. A collection of two quantitative (n = 660, n = 1114) and three qualitative (n = 447, n = 905, n = 1220) datasets representing very different endpoints of interest in drug safety evaluation and rigorous methods were used to estimate the external predictive ability in each case. The results confirm that no single approach produces the best results in all instances, and the best predictions were obtained using different tools in different situations. The trends observed in this study were exploited to propose a unifying strategy allowing the use of the most suitable method for every compound. A comparison of the quality of the predictions obtained by the unifying strategy with those obtained by standard prediction methods confirmed the usefulness of the proposed approach. © 2015, Springer-Verlag Berlin Heidelberg.","Chemical domain; In silico toxicity prediction; QSAR; QSPR; Read across","accuracy; Article; controlled study; drug safety; finger dermatoglyphics; molecular weight; priority journal; quality control; quantitative structure activity relation; toxicology; animal; bioassay; biology; chemistry; factual database; forecasting; human; procedures; theoretical model; toxicology; drug; Animals; Computational Biology; Databases, Factual; Endpoint Determination; Forecasting; Humans; Models, Theoretical; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Toxicology",,"Pharmaceutical Preparations",,,,,,,"Alelyunas, Y.W., Empfield, J.R., McCarthy, D., Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate (2010) Bioorganic Med Chem Lett, 20, pp. 7312-7316. , COI: 1:CAS:528:DC%2BC3cXhsVKjtb%2FM; Aller, S.G., Yu, J., Ward, A., Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding (2009) Science, 323, pp. 1718-1722. , COI: 1:CAS:528:DC%2BD1MXjs1Kgtro%3D, PID: 19325113; Andersson, P.L., Maran, U., Fara, D., General and class specific models for prediction of soil sorption using various physicochemical descriptors (2002) J Chem Inf Comput Sci, 42, pp. 1450-1459. , COI: 1:CAS:528:DC%2BD38Xnt1Sjur8%3D, PID: 12444743; Aronov, A.M., Tuning out of hERG (2008) Curr Opin Drug Discov Devel, 11, pp. 128-140. , COI: 1:CAS:528:DC%2BD1cXhtFehsL4%3D, PID: 18175275; Bajorath, J., Computational chemistry in pharmaceutical research: at the crossroads (2012) J Comput Aided Mol Des, 26, pp. 11-12. , COI: 1:CAS:528:DC%2BC38XhsV2lsbs%3D, PID: 22083841; Bajorath, J., Exploring activity cliffs from a chemoinformatics perspective (2014) Mol Inform, 33, pp. 438-442. , COI: 1:CAS:528:DC%2BC2cXntVSnt7o%3D, PID: 27485979; Bajorath, J., Peltason, L., Wawer, M., Navigating structure-activity landscapes (2009) Drug Discov Today, 14, pp. 698-705. , COI: 1:CAS:528:DC%2BD1MXotFyktLY%3D, PID: 19410012; Bemis, G.W., Murcko, M.A., The properties of known drugs. 1. Molecular frameworks (1996) J Med Chem, 39, pp. 2887-2893. , COI: 1:CAS:528:DyaK28XjvVejtro%3D, PID: 8709122; Benet, L.Z., The drug transporter-metabolism alliance: uncovering and defining the interplay (2009) Mol Pharm, 6, pp. 1631-1643. , COI: 1:CAS:528:DC%2BD1MXhtlyhtL7J, PID: 19874004; Borst, P., Elferink, R.O., Mammalian ABC transporters in health and disease (2002) Annu Rev Biochem, 71, pp. 537-592. , COI: 1:CAS:528:DC%2BD38Xos1Clt74%3D, PID: 12045106; Breiman, L., Random Forests (2001) Mach Learn, 45, pp. 5-32; Broccatelli, F., Carosati, E., Cruciani, G., Oprea, T.I., Transporter-mediated efflux influences CNS side effects: ABCB1, from antitarget to target (2010) Mol Inform, 29, pp. 16-26. , COI: 1:CAS:528:DC%2BC3cXitVahtr8%3D, PID: 22347894; Broccatelli, F., Carosati, E., Neri, A., A novel approach for predicting p-glycoprotein (ABCB1) Inhibition using molecular interaction fields (2011) J Med Chem, 54, pp. 1740-1751. , COI: 1:CAS:528:DC%2BC3MXisVWms7Y%3D, PID: 21341745; Broccatelli, F., Mannhold, R., Moriconi, A., QSAR modeling and data mining link torsades de pointes risk to the interplay of extent of metabolism, active transport, and hERG liability (2012) Mol Pharm, 9, pp. 2290-2301. , COI: 1:CAS:528:DC%2BC38XptlWiur8%3D, PID: 22742658; Carrió, P., López, O., Sanz, F., Pastor, M., eTOXlab, an open source modeling framework for implementing predictive models in production environments (2015) J Cheminform, , PID: 25774224; Cherkasov, A., Muratov, E.N., Fourches, D., QSAR modeling: where have you been? where are you going to? (2014) J Med Chem, 57, pp. 4977-5010; Choudhuri, S., Klaassen, C.D., Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters (2006) Int J Toxicol, 25, pp. 231-259. , COI: 1:CAS:528:DC%2BD28XotVWnsLg%3D, PID: 16815813; Cortes, C., Vapnik, V., Support-vector networks (1995) Mach Learn, 20, pp. 273-297; Curigliano, G., Mayer, E.L., Burstein, H.J., Cardiac toxicity from systemic cancer therapy: a comprehensive review (2010) Prog Cardiovasc Dis, 53, pp. 94-104. , COI: 1:CAS:528:DC%2BC3cXhtVGmt7rP, PID: 20728696; Delaney, J.S., ESOL: estimating aqueous solubility directly from molecular structure (2004) J Chem Inf Comput Sci, 44, pp. 1000-1005. , COI: 1:CAS:528:DC%2BD2cXitVamurk%3D, PID: 15154768; Dimova, D., Bajorath, J., Extraction of SAR information from activity cliff clusters via matching molecular series (2014) Eur J Med Chem, 87, pp. 454-460. , COI: 1:CAS:528:DC%2BC2cXhs1Knsr7J, PID: 25282268; (2010) Durán Á, Pastor M Pentacle., , http://www.moldiscovery.com/software/pentacle; Durán, Á., Martínez, G.C., Pastor, M., Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in molecular interaction fields (2008) J Chem Inf Model, 48, pp. 1813-1823. , PID: 18693718; (2015) European Community Regulation on chemicals and their safe use., , http://ec.europa.eu/environment/chemicals/reach/reach_intro.htm, EC REACH; Eckert, H., Bajorath, J., Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches (2007) Drug Discov Today, 12, pp. 225-233. , COI: 1:CAS:528:DC%2BD2sXitl2htLw%3D, PID: 17331887; Ekins, S., Progress in computational toxicology (2014) J Pharmacol Toxicol Methods, 69, pp. 115-140. , COI: 1:CAS:528:DC%2BC2cXksVWks7s%3D, PID: 24361690; Enoch, S.J., Cronin, M.T.D., Madden, J.C., Hewitt, M., Formation of structural categories to allow for read-across for teratogenicity (2009) QSAR Comb Sci, 28, pp. 696-708. , COI: 1:CAS:528:DC%2BD1MXptFeit7o%3D; FDA, Guidance for industry starting dose in initial clinical trials guidance for industry estimating the maximum safe (2005) FDA; Fourches, D., Barnes, J.C., Day, N.C., Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species (2010) Chem Res Toxicol, 23, pp. 171-183. , COI: 1:CAS:528:DC%2BD1MXhsFGku7nN, PID: 20014752; Fung, M., Thornton, A., Mybeck, K., Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999 (2001) Drug Inf J, 35, pp. 293-317; Golbraikh, A., Muratov, E., Fourches, D., Tropsha, A., Data set modelability by QSAR (2014) J Chem Inf Model, 54, pp. 1-4. , COI: 1:CAS:528:DC%2BC3sXhsl2ns7bL, PID: 24251851; Guha, R., Exploring uncharted territories: predicting activity cliffs in structure-activity landscapes (2012) J Chem Inf Model, 52, pp. 2181-2191. , COI: 1:CAS:528:DC%2BC38XhtFKnsrzF, PID: 22873578; Guha, R., Dutta, D., Jurs, P.C., Chen, T., Local lazy regression: making use of the neighborhood to improve QSAR predictions (2006) J Chem Inf Model, 46, pp. 1836-1847. , COI: 1:CAS:528:DC%2BD28Xks1ymtr8%3D, PID: 16859315; Hancox, J.C., McPate, M.J., El Harchi, A., Zhang, Y.H., The hERG potassium channel and hERG screening for drug-induced torsades de pointes (2008) Pharmacol Ther, 119, pp. 118-132. , COI: 1:CAS:528:DC%2BD1cXhtVKntrnM, PID: 18616963; Helgee, E.A., Carlsson, L., Boyer, S., Norinder, U., Evaluation of quantitative structure-activity relationship modeling strategies: local and global models (2010) J Chem Inf Model, 50, pp. 677-689. , COI: 1:CAS:528:DC%2BC3cXivFGit7k%3D, PID: 20218538; Hewitt, M., Enoch, S.J., Madden, J.C., Hepatotoxicity: a scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action (2013) Crit Rev Toxicol, 43, pp. 537-558. , COI: 1:CAS:528:DC%2BC3sXhtFOisbvK, PID: 23875763; Hua, Y., Yongyan, W., Yiyu, C., Local and global quantitative structure-activity relationship modeling and prediction for the baseline toxicity (2007) J Chem Inf Model, 47, pp. 159-169; Juliano, R.L., Ling, V., A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants (1976) Biochim Biophys Acta, 455, pp. 152-162. , COI: 1:CAS:528:DyaE28XlvV2qs70%3D, PID: 990323; Klepsch, F., Ecker, G.F., Impact of the recent mouse p-glycoprotein structure for structure-based ligand design (2010) Mol Inform, 29, pp. 276-286. , COI: 1:CAS:528:DC%2BC3cXlt1Cjt7s%3D, PID: 27463054; Könemann, H., Structure-activity relationships and additivity in fish toxicities of environmental pollutants (1980) Ecotoxicol Environ Saf, 4, pp. 415-421. , PID: 7472245; Könemann, H., Musch, A., Quantitative structure-activity relationships in fish toxicity studies Part 2: the influence of pH on the QSAR of chlorophenols (1981) Toxicology, 19, pp. 223-228. , PID: 7233446; Kramer, N.I., Di Consiglio, E., Blaauboer, B.J., Testai, E., (2015) Biokinetics in repeated-dosing in vitro drug toxicity studies, , Toxicol, Vitr; Kruhlak, N.L., Choi, S.S., Contrera, J.F., Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models (2008) Toxicol Mech Methods, 18, pp. 217-227. , COI: 1:CAS:528:DC%2BD1cXjtlert7Y%3D, PID: 20020916; Kubinyi, H., Similarity and dissimilarity: a medicinal chemist’s view. Perspect Drug Discov Des 9-11:225–252 (1998) doi:10.1023/A:1027221424359; Landrum G RDKit: open-source cheminformatics., , http://www.rdkit.org; Leise, M.D., Poterucha, J.J., Talwalkar, J.A., Drug-induced liver injury (2014) Mayo Clin Proc, 89, pp. 95-106. , COI: 1:CAS:528:DC%2BC2cXlt1elsw%3D%3D, PID: 24388027; Li, Q., Jørgensen, F.S., Oprea, T., hERG classification model based on a combination of support vector machine method and GRIND descriptors (2008) Mol Pharm, 5, pp. 117-127. , COI: 1:CAS:528:DC%2BD1cXms1Ogsw%3D%3D, PID: 18197627; Liaw, A., Wiener, M., Classification and regression by randomForest (2002) R News, 2, pp. 18-22; Liebler, D.C., Guengerich, F.P., Elucidating mechanisms of drug-induced toxicity (2005) Nat Rev Drug Discov, 4, pp. 410-420. , COI: 1:CAS:528:DC%2BD2MXjs1OktL0%3D, PID: 15864270; Lin, Y., Jeon, Y., Random forests and adaptive nearest neighbors (2006) J Am Stat Assoc, 101, pp. 578-590. , COI: 1:CAS:528:DC%2BD2sXms1ymsA%3D%3D; Loo, T.W., Clarke, D.M., Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein (2002) J Biol Chem, 277, pp. 44332-44338. , COI: 1:CAS:528:DC%2BD38Xos1aktL0%3D, PID: 12223492; Structural Keys, M.A.C.C.S., Accelrys, San Diego (2011) CA; Maggiora, G.M., On outliers and activity cliffs—Why QSAR often disappoints (2006) J Chem Inf Model, 46, p. 1535. , COI: 1:CAS:528:DC%2BD28XntFeltbk%3D, PID: 16859285; Maggiora, G., Vogt, M., Stumpfe, D., Bajorath, J., Molecular similarity in medicinal chemistry (2014) J Med Chem, 57, pp. 3186-3204. , COI: 1:CAS:528:DC%2BC3sXhs1Kktb3E, PID: 24151987; Martens, H., Reliable and relevant modelling of real world data: a personal account of the development of PLS regression (2001) Chemometr Intell Lab Syst, 58, pp. 85-95. , COI: 1:CAS:528:DC%2BD3MXotF2mt7k%3D; Martin, Y.C., A practitioner’s perspective of the role of quantitative structure-activity analysis in medicinal chemistry (1981) J Med Chem, 24, pp. 229-237. , COI: 1:CAS:528:DyaL3MXpsFCmsw%3D%3D, PID: 7265109; Martin, Y.C., Kofron, J.L., Traphagen, L.M., Do structurally similar molecules have similar biological activity? (2002) J Med Chem, 45, pp. 4350-4358. , COI: 1:CAS:528:DC%2BD38XmtVCntLw%3D, PID: 12213076; Medina-Franco, J.L., Scanning structure−activity relationships with structure−activity similarity and related maps: from consensus activity cliffs to selectivity switches (2012) J Chem Inf Model, 52, pp. 2485-2493; Medina-Franco, J.L., Activity cliffs: facts or artifacts? (2013) Chem Biol Drug Des, 81, pp. 553-556. , COI: 1:CAS:528:DC%2BC3sXmvFSnsr8%3D, PID: 23375049; Mevik, B.-H., Wehrens, R., The pls package: principal component and partial least squares regression in R (2007) J Stat Softw, 18, pp. 1-24; (2014) Misc Functions of the Department of Statistics, , Meyer D, Dimitriadou E, Hornik K et al (2014) e1071:(e1071), TU Wien; Milletti, F., Storchi, L., Sforna, G., Cruciani, G., New and original pKa prediction method using grid molecular interaction fields (2007) J Chem Inf Model, 47, pp. 2172-2181. , COI: 1:CAS:528:DC%2BD2sXhtFSnsLrF, PID: 17910431; Milletti, F., Storchi, L., Sforna, G., Tautomer enumeration and stability prediction for virtual screening on large chemical databases (2009) J Chem Inf Model, 49, pp. 68-75. , COI: 1:CAS:528:DC%2BD1MXisVahug%3D%3D, PID: 19123923; Morgan, H.L., The generation of a unique machine description for chemical structures—a technique developed at chemical abstracts service (1965) J Chem Doc, 5, pp. 107-113. , COI: 1:CAS:528:DyaF2MXkt1Omtr0%3D; Muller, P.Y., Milton, M.N., Index in drug development (2012) Nat Rev Drug Discov, 11, pp. 751-761. , COI: 1:CAS:528:DC%2BC38Xht1ynt7vL, PID: 22935759; Muster, W., Breidenbach, A., Fischer, H., Computational toxicology in drug development (2008) Drug Discov Today, 13, pp. 303-310. , COI: 1:CAS:528:DC%2BD1cXkslart7Y%3D, PID: 18405842; Nikolova, N., Jaworska, J., Approaches to measure chemical similarity—a review (2003) QSAR Comb Sci, 22, pp. 1006-1026; NRC, (2007) Toxicity testing in the 21st century: a vision and a strategy, , The National Academies Press, Washington; Obiol-Pardo, C., Gomis-Tena, J., Sanz, F., A multiscale simulation system for the prediction of drug-induced cardiotoxicity (2011) J Chem Inf Model, 51, pp. 483-492. , COI: 1:CAS:528:DC%2BC3MXnvVSmsQ%3D%3D, PID: 21250697; Orogo, A.M., Choi, S.S., Minnier, B.L., Kruhlak, N.L., Construction and consensus performance of (Q)SAR models for predicting phospholipidosis using a dataset of 743 compounds (2012) Mol Inform, 31, pp. 725-739. , COI: 1:CAS:528:DC%2BC38XhtlajsbvI, PID: 27476455; Park, Y.C., Cho, M.H., A new way in deciding NOAEL based on the findings from GLP-toxicity test (2011) Toxicol Res, 27, pp. 133-135. , PID: 24278562; Pastor, M., Alignment-independent descriptors from molecular interaction fields (2006) Molecular interaction fields applications in drug discovery. ADME Predict, pp. 117-141. , Cruciani G, (ed), Wiley-VCH, London; Pastor, M., Cruciani, G., McLay, I., GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors (2000) J Med Chem, 43, pp. 3233-3243. , COI: 1:CAS:528:DC%2BD3cXltlOrur8%3D, PID: 10966742; Perkins, R., Fang, H., Tong, W., Welsh, W.J., Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology (2003) Environ Toxicol Chem, 22, pp. 1666-1679. , COI: 1:CAS:528:DC%2BD3sXotF2hu7c%3D, PID: 12924569; Przybylak, K.R., Alzahrani, A.R., Cronin, M.T.D., How does the quality of phospholipidosis data influence the predictivity of structural alerts? (2014) J Chem Inf Model, , PID: 25062434; Raunio, H., In silico toxicology—non-testing methods (2011) Front Pharmacol, 2, p. 33. , PID: 21772821; Reasor, M.J., Hastings, K.L., Ulrich, R.G., Drug-induced phospholipidosis: issues and future directions (2006) Expert Opin Drug Saf, 5, pp. 567-583. , COI: 1:CAS:528:DC%2BD28XmslSksL8%3D, PID: 16774494; Recanatini, M., Cavalli, A., Masetti, M., Modeling HERG and its interactions with drugs: recent advances in light of current potassium channel simulations (2008) ChemMedChem, 3, pp. 523-535. , COI: 1:CAS:528:DC%2BD1cXlsVSktrg%3D, PID: 18224703; Rogers, D., Hahn, M., Extended-connectivity fingerprints (2010) J Chem Inf Model, 50, pp. 742-754. , COI: 1:CAS:528:DC%2BC3cXlt1Onsbg%3D, PID: 20426451; Roy, K., Mitra, I., Kar, S., Comparative studies on some metrics for external validation of QSPR models (2012) J Chem Inf Model, 52, pp. 396-408. , COI: 1:CAS:528:DC%2BC3MXhs1OjtbnL, PID: 22201416; Sadowski, J., Gasteiger, J., From atoms and bonds to three-dimensional atomic coordinates: automatic model builders (1993) Chem Rev, 93, pp. 2567-2581. , COI: 1:CAS:528:DyaK3sXmt1GgsLs%3D; Sadowski, J., Gasteiger, J., Klebe, G., Comparison of automatic three-dimensional model builders using 639 X-ray structures (1994) J Chem Inf Model, 34, pp. 1000-1008. , COI: 1:CAS:528:DyaK2cXkvVajsbY%3D; Sanz, F., Carrió, P., López, O., Integrative modeling strategies for predicting drug toxicities at the eTOX project (2015) Mol Inform, 34, pp. 477-484. , COI: 1:CAS:528:DC%2BC2MXhtVaqtr3N, PID: 27490391; Sawada, H., Takami, K., Asahi, S., A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system (2005) Toxicol Sci, 83, pp. 282-292. , COI: 1:CAS:528:DC%2BD2MXisVWntg%3D%3D, PID: 15342952; Schultz, T.W., Amcoff, P., Berggren, E., A strategy for structuring and reporting a read-across prediction of toxicity (2015) Regul Toxicol Pharmacol, 72, pp. 586-601. , COI: 1:CAS:528:DC%2BC2MXpt1Kktbc%3D, PID: 26003513; Sheridan, R.P., Global quantitative structure–activity relationship models vs selected local models as predictors of off-target activities for project compounds (2014) J Chem Inf Model, 54, pp. 1083-1092. , COI: 1:CAS:528:DC%2BC2cXktlSrtbs%3D, PID: 24628044; Szakács, G., Paterson, J.K., Ludwig, J.A., Targeting multidrug resistance in cancer (2006) Nat Rev Drug Discov, 5, pp. 219-234. , PID: 16518375; Thai, K.-M., Windisch, A., Stork, D., The hERG potassium channel and drug trapping: insight from docking studies with propafenone derivatives (2010) ChemMedChem, 5, pp. 436-442. , COI: 1:CAS:528:DC%2BC3cXjslensL0%3D, PID: 20146282; Treinen-Moslen, M., Kanz, M.F., Intestinal tract injury by drugs: importance of metabolite delivery by yellow bile road (2006) Pharmacol Ther, 112, pp. 649-667. , COI: 1:CAS:528:DC%2BD28XhtFSksr7I, PID: 16842856; Tropsha, A., Best practices for QSAR model development, validation, and exploitation (2010) Mol Inform, 29, pp. 476-488. , COI: 1:CAS:528:DC%2BC3cXpslWktrw%3D, PID: 27463326; Vandenberg, J.I., Perry, M.D., Perrin, M.J., hERG K + channels: structure, function, and clinical significance (2012) Physiol Rev, 92, pp. 1393-1478. , COI: 1:CAS:528:DC%2BC38Xht1KmtbbM, PID: 22988594; Venables, W.N., Ripley, B.D., (2002) Modern applied statistics with S, , Springer, New York; Wilk-Zasadna, I., Bernasconi, C., Pelkonen, O., Coecke, S., Biotransformation in vitro: an essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data (2015) Toxicology, 332, pp. 8-19. , COI: 1:CAS:528:DC%2BC2cXhslOrt7bO, PID: 25456264; Willett, P., Barnard, J.M., Downs, G.M., Chemical similarity searching (1998) J Chem Inf Model, 38, pp. 983-996. , COI: 1:CAS:528:DyaK1cXks1ynu74%3D; Yoon, M., Blaauboer, B.J., Clewell, H.J., Quantitative in vitro to in vivo extrapolation (QIVIVE): an essential element for in vitro-based risk assessment (2015) Toxicology, 332, pp. 1-3. , COI: 1:CAS:528:DC%2BC2MXis1ejsrY%3D, PID: 25680635","Pastor, M.; Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Carrer Dr. Aiguader 88, Spain; email: manuel.pastor@upf.edu",,,"Springer Verlag",,,,,03405761,,ARTOD,"26553148","English","Arch. Toxicol.",Article,"Final",,Scopus,2-s2.0-84946763147
"Queralt-Rosinach N., Piñero J., Bravo À., Sanz F., Furlong L.I.","35766634600;55220852900;56374942700;7102263897;34770469800;","DisGeNET-RDF: Harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases",2016,"Bioinformatics","32","14",,"2236","2238",,21,"10.1093/bioinformatics/btw214","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84992396643&doi=10.1093%2fbioinformatics%2fbtw214&partnerID=40&md5=ae5b7f11d236ac655aacf18df9306232","Integrative Biomedical Informatics (IBI) Group, Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Doctor Aiguader 88, Barcelona, E-08003, Spain","Queralt-Rosinach, N., Integrative Biomedical Informatics (IBI) Group, Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Doctor Aiguader 88, Barcelona, E-08003, Spain; Piñero, J., Integrative Biomedical Informatics (IBI) Group, Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Doctor Aiguader 88, Barcelona, E-08003, Spain; Bravo, À., Integrative Biomedical Informatics (IBI) Group, Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Doctor Aiguader 88, Barcelona, E-08003, Spain; Sanz, F., Integrative Biomedical Informatics (IBI) Group, Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Doctor Aiguader 88, Barcelona, E-08003, Spain; Furlong, L.I., Integrative Biomedical Informatics (IBI) Group, Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Doctor Aiguader 88, Barcelona, E-08003, Spain","Motivation: DisGeNET-RDF makes available knowledge on the genetic basis of human diseases in the Semantic Web. Gene-disease associations (GDAs) and their provenance metadata are published as human-readable and machine-processable web resources. The information on GDAs included in DisGeNET-RDF is interlinked to other biomedical databases to support the development of bioinformatics approaches for translational research through evidence-based exploitation of a rich and fully interconnected linked open data. Availability and implementation: http://rdf.disgenet.org/ Contact: © 2016 The Author 2016. Published by Oxford University Press.",,"biology; diseases; factual database; genetics; human; Internet; semantics; Computational Biology; Databases, Factual; Disease; Humans; Internet; Semantics",,,,,,,,,"Altman, R.B., Translational bioinformatics: Linking the molecular world to the clinical world (2012) Clin. Pharmacol. Ther., 91, pp. 994-1000; Belleau, F., Bio2RDF: Towards a mashup to build bioinformatics knowledge systems (2008) J. Biomed. Inf., 41, pp. 706-716; Bravo, A., Extraction of relations between genes and diseases from text and large-scale data analysis: Implications for translational research (2015) BMC Bioinformatics, 16, p. 55; Digles, D., (2016) Open PHACTS Computational Protocols for in Silico Target Validation of Cellular Phenotypic Screens: Knowing the Knowns, , in press; Dumontier, M., The Semanticscience Integrated Ontology (SIO) for biomedical research and knowledge discovery (2014) J. Biomed. Seman., 5, p. 14; Gray, A.J.G., Applying linked data approaches to pharmacology: Architectural decisions and implementation (2014) Semant.Web, 5, pp. 101-113; Jupp, S., The EBI RDF platform: Linked open data for the life sciences (2014) Bioinformatics, 30, pp. 1338-1339; Juty, N., Identifiers.org and MIRIAM Registry: Community resources to provide persistent identification (2012) Nucleic Acids Res., 40, pp. D580-D586; Pinero, J., DisGeNET: A discovery platform for the dynamical exploration of human diseases and their genes (2015) Database, 2015. , bav028-bav028","Furlong, L.I.; Integrative Biomedical Informatics (IBI) Group, Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), C/Doctor Aiguader 88, Spain; email: support@disgenet.org",,,"Oxford University Press",,,,,13674803,,BOINF,"27153650","English","Bioinformatics",Article,"Final",Open Access,Scopus,2-s2.0-84992396643
"Queralt-Rosinach N., Kuhn T., Chichester C., Dumontier M., Sanz F., Furlong L.I.","35766634600;14056161100;7004994770;6701759312;7102263897;34770469800;","Publishing DisGeNET as nanopublications",2016,"Semantic Web","7","5",,"519","528",,9,"10.3233/SW-150189","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84976465112&doi=10.3233%2fSW-150189&partnerID=40&md5=77fcaab28bc1186f111d2105bf3b3af2","IBI group, Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Department of Humanities, Social and Political Sciences, ETH Zurich, Switzerland; CALIPHO group, Swiss Institute of Bioinformatics, CMU rue Michel Servet 1, Geneva 4, 1211, Switzerland; Stanford Center for Biomedical Informatics Research, Stanford University, United States","Queralt-Rosinach, N., IBI group, Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Kuhn, T., Department of Humanities, Social and Political Sciences, ETH Zurich, Switzerland; Chichester, C., CALIPHO group, Swiss Institute of Bioinformatics, CMU rue Michel Servet 1, Geneva 4, 1211, Switzerland; Dumontier, M., Stanford Center for Biomedical Informatics Research, Stanford University, United States; Sanz, F., IBI group, Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Furlong, L.I., IBI group, Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain","The increasing and unprecedented publication rate in the biomedical field is a major bottleneck for knowledge discovery in the Life Sciences. The manual curation of facts from published scientific papers is slow and inefficient, and therefore new approaches are needed that can enable the automatic, scalable and reliable extraction of assertions. While the publication of scientific assertions and datasets on the SemanticWeb is gaining traction, it also creates new challenges such as the proper representation of provenance and versioning. Here, we address these issues and describe our efforts to represent the DisGeNET database of human gene-disease associations as permanent, immutable, and provenance rich digital objects called nanopublications. Our nanopublications are the first instance of a Linked Data model that ensures stable interlinking of the assertion and its metadata by Trusty URIs. As DisGeNET integrates manually curated as well as text-mined data of different origins, the semantic description of the evidence for each assertion is important to provide trust and allow evidence-based hypothesis generation. Here, we describe our steps to ensure high quality and demonstrate the utility of linking our data to other datasets on the emerging Semantic Web. © 2016 - IOS Press and the authors. All rights reserved.","Gene-disease associations; Linked data; Nanopublication; Provenance; Trusty URIs",,,,,,,,,,"Bauer-Mehren, A., Rautschka, M., Sanz, F., Furlong, L.I., DisGeNET: A Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks (2010) Bioinformatics, 26, pp. 2924-2926; Beck, T., Free, R.C., Thorisson, G.A., Brookes, A.J., Semantically enabling a genome-wide association study database (2012) Journal of Biomedical Semantics, 3, p. 9; Belhajjame, K., Corcho, O., Garijo, D., Zhao, J., Missier, P., Newman, D., Palma, R., Goble, C., Workflow-centric research objects: First class citizens in scholarly discourse (2012) SePublica 2012 Semantic Publishing, Proc. of the 2nd Workshop on Semantic Publishing, , Hernissos, Crete, Greece, May 28th; García Castro, A., Lange, C., Van Harmelen, F., Good, B., (2012) CEURWorkshop Proceedings, 903, pp. 1-12; Bravo, A., Piñero, J., Queralt-Rosinach, N., Rautschka, M., Furlong, L.I., Extraction of relations between genes and diseases from text and large-scale data analysis: Implications for translational research (2015) BMC Bioinformatics, 16, p. 55; Callahan, A., Cruz-Toledo, J., Ansell, P., Dumontier, M., Bio2RDF Release 2: Improved coverage, interoperability and provenance of Life Science Linked Data (2013) The Semantic Web: Semantics and Big Data, Proc. of 10th International Conference, ESWC 2013, 7882, pp. 200-212. , Montpeiller, France, May 26-30, 2013, P. Cimiano, O. Corcho, V. Presutti, L. Hollink and S. Rudolph, eds, Lecture Notes in Computer Science, Springer, Berlin, Heidelberg; Chichester, C., Gaudet, P., Karch, O., Groth, P., Lane, L., Bairoch, A., Mons, B., Loizou, A., Querying neXtProt nanopublications and their value for insights on sequence variants and tissue expression (2014) Journal of Web Semantics, 29, p. 15; Chichester, C., Karch, O., Gaudet, P., Lane, L., Mons, B., Bairoch, A., Converting neXtProt into Linked Data and nanopublications (2015) Semantic Web, 6; Ciccarese, P., Soiland-Reyes, S., Belhajjame, K., Gray, A.J.G., Goble, C., Clark, T., PAV ontology: Provenance, authoring and versioning (2013) Journal of Biomedical Semantics, 4, p. 37; Dumontier, M., Baker, C.J.O., Baran, J., Callahan, A., Chepelev, L., Cruz-Toledo, J., Del Rio, N.R., Hoehndorf, R., The Semanticscience Integrated Ontology (SIO) for biomedical research and knowledge discovery (2014) Journal of Biomedical Semantics, 5, p. 14; Good, B.M., Clarke, E.L., De Alfaro, L., Su, A.I., The Gene Wiki in 2011: Community intelligence applied to human gene annotation (2012) Nucleic Acids Research, 40, pp. D1255-D1261; Good, B.M., Clarke, E.L., Loguercio, S., Su, A.I., Building a biomedical semantic network in Wikipedia with Semantic Wiki Links (2012) Database (Oxford), 2012, p. bar060; Gray, A., Groth, P., Loizou, A., Askjaer, S., Brenninkmeijer, C., Burger, K., Chichester, C., Williams, A.J., Applying Linked Data approaches to pharmacology: Architectural decisions and implementation (2014) Semantic Web Journal, 5, pp. 101-113; Juty, N., Le Novère, N., Hermjakob, H., Laibe, C., Towards the collaborative curation of the registry underlying identifiers. Org (2013) Database (Oxford), 2013, p. bat017; Kelder, T., Van Iersel, M.P., Hanspers, K., Kutmon, M., Conklin, B.R., Evelo, C., Pico, A.R., WikiPathways: Building research communities on biological pathways (2012) Nucleic Acids Research, 40, pp. D1301-D1307. , Database issue; Kuhn, T., Dumontier, M., Trusty URIs: Verifiable, immutable, and permanent digital artifacts for Linked Data (2014) The Semantic Web: Trends and Challenges, Proc. of 11th International Conference, ESWC 2014, 8465, pp. 395-410. , Anissaras, Crete, Greece, May 25-29, 2014, V. Presutti, C. d'Amato, F. Gandon, M. d'Aquin, S. Staab and A. Tordai, eds, Lecture Notes in Computer Science, Springer International Publishing, Switzerland; McCusker, J.P., Yan, R., Solanki, K., Erickson, J., Chang, C., Dumontier, M., Dordick, J., McGuinness, D., A nanopublication framework for systems biology and drug repurposing (2014) ICBO 2014 International Conference on Biomedical Ontology, Proc. of the 5th International Conference on Biomedical Ontology, 1327, pp. 90-92. , Houston, Texas, USA, October 8-9, 2014, W.R. Hogan, S. Arabandi and M. Brochhausen, eds, CEUR Workshop Proceedings; Mina, E., Thompson, M., Kaliyaperumal, R., Zhao, J., Horst, E., Tatum, Z., Hettne, K., Roos, M., Nanopublications for exposing experimental data in the life-sciences: A Huntington's disease case study (2015) Journal of Biomedical Semantics, 6, p. 5; Piñero, J., Queralt-Rosinach, N., Bravo, A., Deu-Pons, J., Bauer-Mehren, A., Baron, M., Sanz, F., Furlong, L.I., DisGeNET: A discovery platform for the dynamical exploration of human diseases and their genes (2015) Database (Oxford) (2015), p. bav028; Queralt-Rosinach, N., Furlong, L.I., DisGeNET RDF: A gene-disease association linked open data resource (2013) SWAT4LS 2013, Semantic Web Applications and Tools for Life Sciences, Proc. of the 6th International Workshop on Semantic Web Applications and Tools for Life Sciences, 1114. , http://rdf.disgenet.org/, Edinburgh, UK, December 10, 2013, A. Paschke, A. Burger, P. Romano, M.S. Marshall and A. Splendiani, eds, CEUR Workshop Proceedings, DisGeNET RDF Web site at; Razick, S., Magklaras, G., Donaldson, I.M., IRefIndex: A consolidated protein interaction database with provenance (2008) BMC Bioinformatics, 9, p. 405; Rebholz-Schuhmann, D., Oellrich, A., Hoehndorf, R., Textmining solutions for biomedical research: Enabling integrative biology (2012) Nature Reviews Genetics, 13, pp. 829-839; Rodríguez-González, A., Martinez-Romero, M., Egaña Aranguren, M., Wilkinson, M.D., Nanopublishing clinical diagnoses: Tracking diagnostic knowledge base content and utilization (2014) 2014 IEEE 27th International Symposium on Computer-Based Medical Systems (CBMS), pp. 335-340; Sernadela, P., Lopes, P., Oliveira, J.L., Exploring nanopublications integration in pharmacovigilance scenarios (2013) 2013 IEEE 15th International Conference on e-Health Networking, Applications and Services (IEEE Healthcom 2013), pp. 728-730. , Lisbon, Portugal, October 9-12th, 2013; The UniProt Consortium, UniProt: A hub for protein information (2015) Nucleic Acids Research, 43, pp. D204-D212. , Database issue","Furlong, L.I.; IBI group, Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu FabraSpain; email: lfurlong@imim.es",,,"IOS Press",,,,,15700844,,,,"English","Semantic Web",Article,"Final",,Scopus,2-s2.0-84976465112
"Guixà-González R., Javanainen M., Gómez-Soler M., Cordobilla B., Domingo J.C., Sanz F., Pastor M., Ciruela F., Martinez-Seara H., Selent J.","55090002500;37000949300;36622655600;15051755300;35994198300;7102263897;7102415847;7003683975;22433269800;55891371700;","Membrane omega-3 fatty acids modulate the oligomerisation kinetics of adenosine A2A and dopamine D2 receptors",2016,"Scientific Reports","6",, 19839,"","",,45,"10.1038/srep19839","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955489920&doi=10.1038%2fsrep19839&partnerID=40&md5=7f18e0aff44c688493d04f9f21f4b270","Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Department of Physics, Tampere University of Technology, Tampere, Finland; Facultat de Medicina, IDIBELL, Universitat de Barcelona, Barcelona, Spain; Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain; Faculty of Sciences, University of Ghent, Gent, Belgium","Guixà-González, R., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Javanainen, M., Department of Physics, Tampere University of Technology, Tampere, Finland; Gómez-Soler, M., Facultat de Medicina, IDIBELL, Universitat de Barcelona, Barcelona, Spain; Cordobilla, B., Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain; Domingo, J.C., Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Ciruela, F., Facultat de Medicina, IDIBELL, Universitat de Barcelona, Barcelona, Spain, Faculty of Sciences, University of Ghent, Gent, Belgium; Martinez-Seara, H., Department of Physics, Tampere University of Technology, Tampere, Finland; Selent, J., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain","Membrane levels of docosahexaenoic acid (DHA), an essential omega-3 polyunsaturated fatty acid (ω-3 PUFA), are decreased in common neuropsychiatric disorders. DHA modulates key cell membrane properties like fluidity, thereby affecting the behaviour of transmembrane proteins like G protein-coupled receptors (GPCRs). These receptors, which have special relevance for major neuropsychiatric disorders have recently been shown to form dimers or higher order oligomers, and evidence suggests that DHA levels affect GPCR function by modulating oligomerisation. In this study, we assessed the effect of membrane DHA content on the formation of a class of protein complexes with particular relevance for brain disease: adenosine A2A and dopamine D2 receptor oligomers. Using extensive multiscale computer modelling, we find a marked propensity of DHA for interaction with both A2A and D2 receptors, which leads to an increased rate of receptor oligomerisation. Bioluminescence resonance energy transfer (BRET) experiments performed on living cells suggest that this DHA effect on the oligomerisation of A2A and D2 receptors is purely kinetic. This work reveals for the first time that membrane ω-3 PUFAs play a key role in GPCR oligomerisation kinetics, which may have important implications for neuropsychiatric conditions like schizophrenia or Parkinson's disease.",,"adenosine A2a receptor; docosahexaenoic acid; dopamine 2 receptor; fatty acid; omega 3 fatty acid; phospholipid; protein aggregate; cell membrane; cell survival; diffusion; drug effects; HEK293 cell line; human; kinetics; metabolism; molecular dynamics; probability; protein multimerization; time factor; Cell Membrane; Cell Survival; Diffusion; Docosahexaenoic Acids; Fatty Acids; Fatty Acids, Omega-3; HEK293 Cells; Humans; Kinetics; Molecular Dynamics Simulation; Phospholipids; Probability; Protein Aggregates; Protein Multimerization; Receptor, Adenosine A2A; Receptors, Dopamine D2; Time Factors",,"docosahexaenoic acid, 25167-62-8, 32839-18-2; Docosahexaenoic Acids; Fatty Acids; Fatty Acids, Omega-3; Phospholipids; Protein Aggregates; Receptor, Adenosine A2A; Receptors, Dopamine D2",,,"Agentschap voor Innovatie door Wetenschap en Technologie: SBO-140028

European Commission

Academy of Finland

Royal Economic Society: 228398

Fundació la Marató de TV3: 091010, TV3

Ministerio de Educación y Cultura: SAF2009-13609-C04-04

Institució Catalana de Recerca i Estudis Avançats, ICREA: ICREA Academia-2010

Ministerio de Economía y Competitividad: SAF2014-55700-P, PCIN-2013-019-C03-03, PIE14/00034

Instituto de Salud Carlos III: CP12/03139","1Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 2Department of Physics, Tampere University of Technology, Tampere, Finland. 3Facultat de Medicina, IDIBELL, Universitat de Barcelona, Barcelona, Spain. 4Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain. 5Faculty of Sciences, University of Ghent, Gent, Belgium. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to H.M.-S. (email: hseara@gmail.com) or J.S. (email: jana.selent@upf.edu)","J.S. and R.G.-G. acknowledge support from Fundació La Marató de TV3 (091010)/Instituto de Salud Carlos III FEDER (CP12/03139)/Ministerio de Educación y Ciencia (Grant number: SAF2009-13609-C04-04) the GLISTEN European Research Network, and the computer resources, technical expertise and assistance provided by the Red Española de Supercomputación (RES). R.G.-G. was also supported by the HPC-Europa2 project (project number: 228398) with the support of the European Commission - Capacities Area - Research Infrastructures. R.G.-G., M.J. and H.M.-S. thank the CSC–IT Center for Science for the computational resources provided. H.M-S. and M.J. acknowledge financial support from the Academy of Finland through its Centre of Excellence Programme. F.C. acknowledges support from Ministerio de Economía y Competitividad/Instituto de Salud Carlos III (SAF2014-55700-P, PCIN-2013-019-C03-03 and PIE14/00034), Institució Catalana de Recerca i Estudis Avançats (ICREA Academia-2010) and Agentschap voor Innovatie door Wetenschap en Technologie (SBO-140028). Also, M.G.-S. and F.C. belong to the “Neuropharmacology” and “Pain” accredited research group (Generalitat de Catalunya, 2009 SGR 232). We thank Dr. Marti-Solano for reading this manuscript and giving critical insights.",,"Taha, A.Y., Cheon, Y., Ma, K., Rapoport, S.I., Rao, J.S., Altered fatty acid concentrations in prefrontal cortex of schizophrenic patients (2013) J. Psychiat. Res., 47, pp. 636-643; Martín, V., Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex (2010) J. Alzheimers Dis., 19, pp. 489-502; Fabelo, N., Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease (2011) Mol. Med., 17, pp. 1107-1118; Innis, S.M., Dietary omega 3 fatty acids and the developing brain (2008) Brain Res., 1237, pp. 35-43; Calon, F., Cole, G., Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: Evidence from animal studies (2007) Prostag. Leukotr. Ess., 77, pp. 287-293; Tanaka, K., Farooqui, A.A., Siddiqi, N.J., Alhomida, A.S., Ong, W.-Y., Effects of docosahexaenoic acid on neurotransmission (2012) Biomol. Ther., 20, pp. 152-157; Jeffrey, B.G., Weisinger, H.S., Neuringer, M., Mitchell, D.C., The role of docosahexaenoic acid in retinal function (2001) Lipids, 36, pp. 859-871; Pinot, M., Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins (2014) Science, 345, pp. 693-697; Wassall, S.R., Stillwell, W., Polyunsaturated fatty acid-cholesterol interactions: Domain formation in membranes (2009) BBABiomembranes, 1788, pp. 24-32; Salem, N., Litman, B., Kim, H.Y., Gawrisch, K., Mechanisms of action of docosahexaenoic acid in the nervous system (2001) Lipids, 36, pp. 945-959; Akter, K., A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia (2012) J. Clin. Pharm. Ther., 37, pp. 132-139; Bousquet, M., Calon, F., Cicchetti, F., Impact of omega-3 fatty acids in Parkinson's disease (2011) Ageing Res. Rev., 10, pp. 453-463; Mondal, S., Khelashvili, G., Johner, N., Weinstein, H., (2014) How the Dynamic Properties and Functional Mechanisms of GPCRs Are Modulated by Their Coupling to the Membrane Environment, Vol. 796 of Advances in Experimental Medicine and Biology, , (Springer Netherlands); Gawrisch, K., Soubias, O., Mihailescu, M., Insights from biophysical studies on the role of polyunsaturated fatty acids for function of G-protein coupled membrane receptors (2008) Prostag. Leukotr. Ess., 79, pp. 131-134; Catapano, L.A., Manji, H.K., G protein-coupled receptors in major psychiatric disorders (2007) Biochim. Biophys. Acta, 1768, pp. 976-993; Mitchell, D.C., Niu, S.-L., Litman, B.J., Enhancement of G protein-coupled signaling by DHA phospholipids (2003) Lipids, 38, pp. 437-443; Mitchell, D.C., Straume, M., Litman, B.J., Role of sn-1-saturated, sn-2-polyunsaturated phospholipids in control of membrane receptor conformational equilibrium: Effects of cholesterol and acyl chain unsaturation on the metarhodopsin I 虠 metarhodopsin II equilibrium (1992) Biochemistry-US, 31, pp. 662-670; Litman, B.J., Niu, S.L., Polozova, A., Mitchell, D.C., The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways: Visual transduction (2001) J. Mol. Neurosci., 16, pp. 237-242; Feller, S.E., Gawrisch, K., Woolf, T.B., Rhodopsin exhibits a preference for solvation by polyunsaturated docosohexaenoic acid (2003) J. Am. Chem. Soc., 125, pp. 4434-4435; Grossfield, A., Feller, S.E., Pitman, M.C., Contribution of omega-3 fatty acids to the thermodynamics of membrane protein solvation (2006) J. Phys. Chem. B, 110, pp. 8907-8909; Milligan, G., The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization (2013) Mol. Pharmacol., 84, pp. 158-169; Ferré, S., Ciruela, F., Woods, A.S., Lluis, C., Franco, R., Functional relevance of neurotransmitter receptor heteromers in the central nervous system (2007) Trends Neurosci., 30, pp. 440-446; Guixà-González, R., Bruno, A., Marti-Solano, M., Selent, J., Crosstalk within GPCR heteromers in schizophrenia and Parkinson's disease: Physical or just functional? (2012) Curr. Med. Chem., 19, pp. 1119-1134; Perreault, M.L., Hasbi, A., O'Dowd, B.F., George, S.R., Heteromeric dopamine receptor signaling complexes: Emerging neurobiology and disease relevance (2014) Neuropsychopharmacol, 39, pp. 156-168; Guidolin, D., Agnati, L.F., Marcoli, M., Borroto-Escuela, D.O., Fuxe, K., G-protein-coupled receptor type a heteromers as an emerging therapeutic target (2015) Expert Opin. Ther. Tar., pp. 1-19; Soriano, A., Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A- D2 receptor heteromers (2009) J. Med. Chem., 52, pp. 5590-5602; Joerg, M., Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease (2015) J. Med. Chem., 58, pp. 718-738; Canals, M., Homodimerization of adenosine A2A receptors: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer (2004) J. Neurochem., 88, pp. 726-734; Zawarynski, P., Dopamine D2 receptor dimers in human and rat brain (1998) FEBS Lett., 441, pp. 383-386; Vidi, P.-A., Chen, J., Irudayaraj, J.M., Watts, V.J., Adenosine A2A receptors assemble into higher-order oligomers at the plasma membrane (2008) FEBS Lett., 582, pp. 3985-3990; Guo, W., Dopamine D2 receptors form higher order oligomers at physiological expression levels (2008) EMBO J., 27, pp. 2293-2304; Ferré, S., Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders (2004) Parkinsonism R. D., 10, pp. 265-271; Jorg, M., Scammells, P., Capuano, B., The dopamine D2 and adenosine A2A receptors: Past, present and future trends for the treatment of Parkinson's disease (2014) Curr. Med. Chem., 21, pp. 3188-3210; Fuxe, K., Marcellino, D., Genedani, S., Agnati, L., Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease (2007) Movement Disord., 22, pp. 1990-2017; Pou, C., La Cour, C.M., Stoddart, L.A., Millan, M.J., Milligan, G., Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface (2012) J. Biol. Chem., 287, pp. 8864-8878; Marrink, S.J., Risselada, H.J., Yefimov, S., Tieleman, D.P., De Vries, A.H., The MARTINI force field: Coarse grained model for biomolecular simulations (2007) J. Phys. Chem. B, 111, pp. 7812-7824; Monticelli, L., The MARTINI Coarse-grained force field: Extension to proteins (2008) J. Chem. Theory Comput., 4, pp. 819-834; Javanainen, M., Universal method for embedding proteins into complex lipid bilayers for molecular dynamics simulations (2014) J. Chem. Theory Comput., 10, pp. 2577-2582; Canals, M., Adenosine A2A-dopamine D2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer (2003) J. Biol. Chem., 278, pp. 46741-46749; Casado, V., Detection of heteromerization of more than two proteins by sequential BRET-FRET (2008) Nat. Methods, 5, pp. 727-733; Romero-Fernandez, W., Agonist-induced formation of FGFR1 homodimers and signaling differ among members of the FGF family (2011) Biochem. Biophys. Res. Co., 409, pp. 764-768; Klauda, J.B., Update of the CHARMM all-atom additive force field for lipids: Validation on six lipid types (2010) J. Phys. Chem. B, 114, pp. 7830-7843; Lim, J.B., Rogaski, B., Klauda, J.B., Update of the cholesterol force field parameters in CHARMM (2012) J. Phys. Chem. B, 116, pp. 203-210; MacKerell, A., Bashford, D., All-atom empirical potential for molecular modeling and dynamics studies of proteins (1998) J. Phys. Chem. B, 5647, pp. 3586-3616; Harvey, M., Giupponi, G., Fabritiis, G., ACEMD: Accelerating biomolecular dynamics in the microsecond time scale (2009) J. Chem. Theory Comput., 5, pp. 1-9; Ayoub, M.A., Pfleger, K.D.G., Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization (2010) Curr. Opin. Pharmacol., 10, pp. 44-52; Lan, T.-H., Bret evidence that β2 adrenergic receptors do not oligomerize in cells (2015) Sci. Rep., p. 5; Percherancier, Y., Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homoand heterodimers (2005) J. Biol. Chem., 280, pp. 9895-9903; Marquer, C., Influence of MT7 toxin on the oligomerization state of the M1 muscarinic receptor (2010) Biol. Cell, 102, pp. 409-420; Periole, X., Knepp, A., Sakmar, T.P., Marrink, S.J., Huber, T., Structural determinants of the supramolecular organization of G protein-coupled receptors in bilayers (2012) J. Am. Chem. Soc., 134, pp. 10959-10965; Mondal, S., Membrane driven spatial organization of GPCRs (2013) Sci. Rep., 3, p. 2909; Ghosh, A., Sonavane, U., Joshi, R., Multiscale modelling to understand the self-assembly mechanism of human β2-adrenergic receptor in lipid bilayer (2014) Comput. Biol. Chem., 48, pp. 29-39; Provasi, D., Boz, M.B., Johnston, J.M., Filizola, M., MacKerell, A., Preferred supramolecular organization and dimer interfaces of opioid receptors from simulated self-association (2015) PLoS Comp. Biol., 11, pp. e1004148-e1004148; Javanainen, M., Anomalous and normal diffusion of proteins and lipids in crowded lipid membranes (2013) Faraday Discuss., 161, pp. 397-417; Niemelä, P., Membrane proteins diffuse as dynamic complexes with lipids (2010) J. Am. Chem. Soc., 132, pp. 7574-7575; Risselada, H.J., Marrink, S.J., The molecular face of lipid rafts in model membranes (2008) P. Natl. Acad. Sci. USA, 105, pp. 17367-17372; Domański, J., Marrink, S.J., Schäfer, L.V., Transmembrane helices can induce domain formation in crowded model membranes (2012) BBA-Biomembranes, 1818, pp. 984-994; Stark, A.C., Andrews, C.T., Elcock, A.H., Toward optimized potential functions for protein-protein interactions in aqueous solutions: Osmotic second virial coefficient calculations using the martini coarse-grained force field (2013) J. Chem. Theory Comput., 9, pp. 4176-4185; De Jong, D.H., Improved parameters for the martini coarse-grained protein force field (2012) J. Chem. Theory Comput., 9, pp. 687-697; Polozova, A., Litman, B.J., Cholesterol dependent recruitment of di22:6-PC by a G protein-coupled receptor into lateral domains (2000) Biophys. J., 79, pp. 2632-2643; Feller, S.E., Gawrisch, K., MacKerell, A.D., Polyunsaturated fatty acids in lipid bilayers: Intrinsic and environmental contributions to their unique physical properties (2002) J. Am. Chem. Soc., 124, pp. 318-326; Pitman, M.C., Grossfield, A., Suits, F., Feller, S.E., Role of cholesterol and polyunsaturated chains in lipid-protein interactions molecular dynamics simulation of rhodopsin in a realistic membrane environment (2005) J. Am. Chem. Soc., 127, pp. 4576-4577; Schöneberg, J., Heck, M., Hofmann, K.P., Noé, F., Explicit spatiotemporal simulation of receptor-G protein coupling in rod cell disk membranes (2014) Biophys. J., 107, pp. 1042-1053; Gunkel, M., Schöneberg, J., Alkhaldi, W., Irsen, S., Noé, F., Al-Amoudi, A., Higher-order architecture of rhodopsin in intact photoreceptors and its implication for phototransduction kinetics (2015) Structure, 23, pp. 628-638","Martinez-Seara, H.; Department of Physics, Tampere University of TechnologyFinland; email: hseara@gmail.com",,,"Nature Publishing Group",,,,,20452322,,,"26796668","English","Sci. Rep.",Article,"Final",Open Access,Scopus,2-s2.0-84955489920
"Mayer M.A., Furlong L.I., Sanz F.","36971031500;34770469800;7102263897;","MedBioinformatics: Developing integrative bioinformatics applications for personalized medicine",2016,"Studies in Health Technology and Informatics","221",,,"125","",,1,"10.3233/978-1-61499-633-0-125","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969548911&doi=10.3233%2f978-1-61499-633-0-125&partnerID=40&md5=ace3f6aa6248e65a1cce14c7910449b5","Research Programme on Biomedical Informatics (GRIB), IMIM-Universitat Pompeu Fabra, Barcelona, Spain","Mayer, M.A., Research Programme on Biomedical Informatics (GRIB), IMIM-Universitat Pompeu Fabra, Barcelona, Spain; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), IMIM-Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM-Universitat Pompeu Fabra, Barcelona, Spain",[No abstract available],"Biomedical informatics; Genotype-phenotype analysis; Health information technologies; Translational medical research","Bioinformatics applications; Biomedical informatics; Genotype-phenotype analysis; Health information technologies; Medical research; Personalized medicines; Bioinformatics; algorithm; biology; computer interface; database management system; factual database; information retrieval; medical record; organization and management; personalized medicine; procedures; software; system analysis; Algorithms; Computational Biology; Database Management Systems; Databases, Factual; Information Storage and Retrieval; Medical Record Linkage; Precision Medicine; Software; Systems Integration; User-Computer Interface",,,,,,,,,,"Mayer, M.A.; Research Programme on Biomedical Informatics (GRIB), IMIM-Universitat Pompeu FabraSpain","Lovis C.Ehrler F.Hercigonja-Szekeres M.Sieverink F.Ugon A.Hofdijk J.Seroussi B.",,"IOS Press","EFMI Special Topic Conference, STC 2016","17 April 2016 through 19 April 2016",,121412,09269630,9781614996323,,"27071899","English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-84969548911
"Al-Shorbaji N., Bellazzi R., de Quiros F.G.B., Koch S., Kulikowski C.A., Lovell N.H., Maojo V., Park H.-A., Sanz F., Sarkar I.N., Tanaka H.","25227306500;18343389900;8437483100;56975881200;7005149346;7006684228;55171738800;7601570174;7102263897;15124590700;55567208800;","Discussion of “the new role of biomedical informatics in the age of digital medicine”",2016,"Methods of Information in Medicine","55","5",,"403","421",,5,"10.3414/ME15-12-0005","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991632800&doi=10.3414%2fME15-12-0005&partnerID=40&md5=bc375615ee134d2b904a449cfc2e4f84","Knowledge, Research and Ethics, e-Marefa, P.O. Box 2351, Amman, 11953, Jordan; Department of Electrical, Computer and Biomedical Engineering, Centre for Health Technologies, University of Pavia, Pavia, Italy; IRCCS Fondazione S. Maugeri, Pavia, Italy; Hospital Italiano de Buenos Aires, Peron 4190, Ciudad Autonoma de Buenos Aires, 1199, Argentina; Department of Learning, Informatics, Management and Ethics, Health Informatics Centre, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science, The State University of New Jersey Rutgers, Hill Center, Busch Campus, New Brunswick, NJ, United States; Graduate School of Biomedical Engineering, The University of New South Wales, Sydney, Australia; Departamento de Inteligencia Artificial, Facultad de Informática, Universidad Politécnica de Madrid, Campus de Montegancedo s/n, Boadilla del Monte, Madrid, 28660, Spain; College of Nursing & Systems Biomedical Informatics Research Center, Seoul National University, 103 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea; Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona Biomedical Research Park, Carrer Dr. Aiguader 88, Barcelona, 08003, Spain; Center for Biomedical Informatics, Brown University, Box G-R, Providence, RI  02912, United States; Tohoku Medical Megabank, Tohoku University, 2–1 Seiryo-cho, Aoba-ku, Sendai, 980–8573, Japan; Dipartimento di Ingegneria Industriale e dell‘Informazione, Università degli Studi di Pavia, Via Ferrata 3, Pavia, 27100, Italy; Health Informatics Centre, LIME, Karolinska Institutet, Uppsala, SE 171 77, Sweden; Faculty of Engineering, UNSW, Samuels Building, Lower Ground, Sydney, NSW  2052, Australia","Al-Shorbaji, N., Knowledge, Research and Ethics, e-Marefa, P.O. Box 2351, Amman, 11953, Jordan; Bellazzi, R., Department of Electrical, Computer and Biomedical Engineering, Centre for Health Technologies, University of Pavia, Pavia, Italy, IRCCS Fondazione S. Maugeri, Pavia, Italy, Dipartimento di Ingegneria Industriale e dell‘Informazione, Università degli Studi di Pavia, Via Ferrata 3, Pavia, 27100, Italy; de Quiros, F.G.B., Hospital Italiano de Buenos Aires, Peron 4190, Ciudad Autonoma de Buenos Aires, 1199, Argentina; Koch, S., Department of Learning, Informatics, Management and Ethics, Health Informatics Centre, Karolinska Institutet, Stockholm, Sweden, Health Informatics Centre, LIME, Karolinska Institutet, Uppsala, SE 171 77, Sweden; Kulikowski, C.A., Department of Computer Science, The State University of New Jersey Rutgers, Hill Center, Busch Campus, New Brunswick, NJ, United States; Lovell, N.H., Graduate School of Biomedical Engineering, The University of New South Wales, Sydney, Australia, Faculty of Engineering, UNSW, Samuels Building, Lower Ground, Sydney, NSW  2052, Australia; Maojo, V., Departamento de Inteligencia Artificial, Facultad de Informática, Universidad Politécnica de Madrid, Campus de Montegancedo s/n, Boadilla del Monte, Madrid, 28660, Spain; Park, H.-A., College of Nursing & Systems Biomedical Informatics Research Center, Seoul National University, 103 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea; Sanz, F., Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona Biomedical Research Park, Carrer Dr. Aiguader 88, Barcelona, 08003, Spain; Sarkar, I.N., Center for Biomedical Informatics, Brown University, Box G-R, Providence, RI  02912, United States; Tanaka, H., Tohoku Medical Megabank, Tohoku University, 2–1 Seiryo-cho, Aoba-ku, Sendai, 980–8573, Japan","This article is part of a For-Discussion-Section of Methods of Information in Medicine about the paper “The New Role of Biomedical Informatics in the Age of Digital Medicine” written by Fernando J. Martin-Sanchez and Guillermo H. Lopez-Campos [1]. It is introduced by an editorial. This article contains the combined commentaries invited to in - dependently comment on the paper of Martin-Sanchez and Lopez-Campos. In subsequent issues the discussion can continue through letters to the editor. © Schattauer 2016.","Biomedical informatics; Digital medicine; Exposome; Participatory medicine; Precision medicine; Self-quantification; Social media","biology; human; medical informatics; medical research; nomenclature; preventive medicine; statistics; Biomedical Research; Computational Biology; Humans; Medical Informatics; Preventive Medicine; Statistics as Topic; Terminology as Topic",,,,,,,,,"Martin-Sanchez, F.J., Lopez-Campos, G.H., The New Role of Biomedical Informatics in the Age of Digital Medicine (2016) Methods Inf Med, 55 (5), pp. 392-402; Al-Shorbaji, N., EHealth to go beyond data processing in response to public and individual health challenges PAHO Ehealth Newsletter, 2 (1). , http://www.paho.org/ict4health/newsletter/eHealth_Newsletter_January13.html, January 2014; Scott, R.E., Mars, M., A globally accepted e-health terminology? (2015) Med-E-Tel: The International Ehealth, Telemedicine, and Health ICT Forum for Education, Networking and Business Luxexpo, , https://www.medetel.eu/download/2015/parallel_sessions/presentation/day3/Terminology.pdf, Luxembourg, Luxembourg 20–22 April; Oh, H., Rizo, C., Enkin, M., Jadad, A., What is eHealth (3): A Systematic Review of Published Definitions (2005) J Med Internet Res, 7 (1); Pagliari, C., Sloan, D., Gregor, P., Sullivan, F., Detmer, D., Kahan, J.P., What is eHealth (4): A scoping exercise to map the field (2005) J Med Internet Res, 7 (1). , http://www.ncbi.nlm.nih.gov/pubmed/15829481; WHA58.28 Ehealth, , http://apps.who.int/iris/bitstream/10665/20378/1/WHA58_28-en.pdf?ua=1; http://www.oxforddictionaries.com/definition/english/bioinformatics, Oxford Dictionaries; Hersh, W., Who are the Informaticians? What We Know and Should Know (2006) J am Med Inform Assoc, 13 (2), pp. 166-170; The Free Dictionary on the Internet, , http://encyclopedia.thefreedictionary.com/Interdisciplinarity; The Free Dictionary on the Internet, , http://encyclopedia.thefreedictionary.com/Interdisciplinarity; Bahagon, Y., Jacobson, O., EHealth, mHealth and healthier social media reform: The big scale view (2012) Int J Integr Care, 12. , http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571141; Van Velsen, L., Wentzel, J., Van Gemert-Pijnen, J.E., Designing eHealth that Matters via a Multidisciplinary Requirements Development Approach (2013) JMIR Res Protoc, 2 (1); RIO+, (2012), http://www.uncsd2012.org, United Nations Conference on Sustainable Development, Rio de Janeiro, Brazil, on June 20–22; (2015), http://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/1&Lang=E, September; Wild, C.P., Complementing the genome with an “exposome”: The outstanding challenge of environmental exposure measurement in molecular epidemiology (2005) Cancer Epidemiol Biomarkers Prev, 14 (8), pp. 1847-1850. , http://cebp.aacrjournals.org/content/14/8/1847; (2013) The World Health Report 2013: Research for Universal Health Coverage, 20p. , Geneva: World Health Organization; (2010) World Health Report 2010: “Health Systems Financing: The Path to Universal Coverage, , http://www.who.int/whr/2010/en, Geneva: World Health Organization; Universal Health Coverage, , https://documents-dds-ny.un.org/doc/UNDOC/LTD/N12/630/51/PDF/N1263051.pdf?, 2 December 2012, OpenElement; Bernstam, E.V., Smith, J.W., Johnson, T.R., What is biomedical informatics? (2010) J Biomed Inform, 43 (1), pp. 104-110; Coiera, R., (2015) Guide to Health Informatics, , 3rd ed. Boca Raton, FL: CRC Press; Elenko, E., Underwood, L., Zohar, D., Defining digital medicine (2015) Nat Biotechnol, 33 (5), pp. 456-461; Ohno-Machado, L., NIH‘s Big Data to Knowledge initiative and the advancement of biomedical informatics (2014) J am Med Inform Assoc, 21 (2), p. 193; Lopez-Campos, G.H., Lopez-Alonso, V., Martin-Sanchez, F., Is Precision Medicine different from Personalised Medicine? A Biomedical informatics perspective (2014) Stud Health Technol Inform, 202, pp. 20-23; Chisholm, R.L., At the Interface between Medical Informatics and Personalized Medicine: The eMERGE Network Experience (2013) Healthc Inform Res, 19 (2), pp. 67-68; Lopez-Campos, G., Ofoghi, B., Martin-Sanchez, F., Enabling Self-Monitoring Data Exchange in Participatory Medicine (2015) Stud Health Technol Inform, 216, p. 1102; Martin Sanchez, F., Gray, K., Bellazzi, R., Lopez-Campos, G., Exposome informatics: Considerations for the design of future biomedical research information systems (2014) J am Med Inform Assoc, 21 (3), pp. 386-390; Ückert, F., Ammenwerth, E., Dujat, C., Grant, A., Haux, R., Hein, A., Hochlehnert, A., Hasman, A., Past and next 10 years of medical informatics (2014) J Med Syst, 38 (7), p. 74; Bellazzi, R., Big data and biomedical informatics: A challenging opportunity (2014) Yearb Med Inform, 9, pp. 8-13; Williams, M.S., Ritchie, M.D., Payne, P.R., Interdisciplinary training to build an informatics workforce for precision medicine (2015) Appl Transl Genom, 6, pp. 28-30; Otero, P., Hersh, W., Jai Ganesh, A.U., Big Data: Are Biomedical and Health Informatics Training Programs Ready? Contribution of the IMIA Working Group for Health and Medical Informatics Education (2014) Yearb Med Inform, 9, pp. 177-181; Kulikowski, C.A., Shortliffe, E.H., Currie, L.M., Elkin, P.L., Hunter, L.E., Johnson, T.R., Kalet, I.J., Williamson, J.J., AMIA Board white paper: Definition of biomedical informatics and specification of core competencies for graduate education in the discipline (2012) J am Med Inform Assoc, 19 (6), pp. 931-938; Collins, F.S., Varmus, H., A new initiative on precision medicine (2015) N Engl J Med, 372 (9), pp. 793-795; Jameson, J.L., Longo, D.L., Precision medicine – personalized, problematic, and promising (2015) N Engl J Med, 372 (23), pp. 2229-2234; Alyass, A., Turcotte, M., Meyre, D., From big data analysis to personalized medicine for all: Challenges and opportunities (2015) BMC Med Genom, 8, p. 33; Topol, E.J., (2013) The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care, p. 319. , 1st pbk. ed. New York: Basic Books; Lefebvre, R.C., Bornkessel, A.S., Digital social networks and health (2013) Circulation, 127 (17), pp. 1829-1836; Valente, T.W., Network interventions (2012) Science, 337 (6090), pp. 49-53; Ortiz, E., Clancy, C.M., Use of Information Technology to Improve the Quality of Health Care in the United States (2003) Health Serv Res, 38 (2), pp. xi-xxii; Dolan, B., Healthcare still lags behind other industries in leveraging mobile, CIO survey finds Mobilehealthnews, , http://mobihealthnews.com/31404/healthcare-still-lags-behind-other-industries-in-leveraging-mobile-ciosurvey-finds, last accessed 2016–05–03; Eysenbach, G., What is e-health? (2001) J Med Internet Res, 3 (2); Hersh, W., A stimulus to define informatics and health information technology (2009) BMC Med Inf Dec Mak, 9, p. 24; Hasman, A., Ammenwerth, E., Dickhaus, H., Knaup, P., Lovis, C., Mantas, J., Maojo, V., Sarkar, I.N., Biomedical Informatics – A Confluence of Disciplines? (2011) Methods Inf Med, 50 (6), pp. 508-524; Maojo, V., Kulikowski, C.A., Note on Friedman’s ‘what informatics is and isn’t’ (2013) J am Med Inform Assoc, 20, pp. e365-e366; Koch, S., Vimarlund, V., Critical Advances in Brid - Ging Personal Health Informatics and Clinical Informatics (2012) Yearb Med Inform, 7 (1), pp. 48-55; Zakim, D., Fritz, C., Braun, N., Fritz, P., Alscher, M.D., Computerized history-taking as a tool to manage dyslipidemia (2010) Vasc Health Risk Manag, 6, pp. 1039-1045; http://www.pewinternet.org/2013/01/28/tracking-for-health, last accessed 2016–05–15; http://quantifiedself.com/symposium/Symposium-2014/QSPublicHealth2014_Report.pdf, (last accessed 2016–05–15); Kravitz, R.L., Duan, N., Vohra, S., Li, J., DEcIDE Methods Center N-of-1 Guidance Panel. Introduction to N-of-1 Trials: Indications and Barriers (2014) Design and Implementation of N-Of-1 Trials: A User’s Guide, pp. 1-11. , Kravitz RL, Duan N, editors, and the DEcIDE Methods Center N-of-1 Guidance Panel (Duan N, Eslick I, Gabler NB, Kaplan HC, Kravitz RL, Larson EB, Pace WD, Schmid CH, Sim I, Vohra S), AHRQ Publication No. 13(14)-EHC122-EF. Rockville, MD: Agency for Healthcare Research and Quality; Maojo, V., Kulikowski, C.A., Medical Informatics and Bioinformatics: Integration or Evolution through Scientific Crises? (2006) Methods Inf Med, 45 (5), pp. 474-482; Kulikowski, C.A., The Micro-Macro Spectrum of Medical Informatics Challenges: From Molecular Medicine to Transforming Health Care in a Globalizing Society (2002) Methods Inf Med, 41 (1), pp. 20-24; Coiera, E., Aarts, J., Kulikowski, C., The Dangerous Decade (2012) J am Med Inform Assoc, 19 (1), pp. 2-5; http://www.forbes.com/sites/jacobmorgan/2014/05/13/simple-explanation-internet-things-that-anyone-can-understand, last accessed 2016–04–18; http://www.forbes.com/sites/tjmccue/2015/04/22/117-billionmarket-for-internet-of-things-in-healthcareby-2020, (last accessed 2016–04–18); Zhang, Y.T., Poon, C.C., Editorial note on bio, medical, and health informatics (2010) IEEE Transactions on Information Technology in Biomedicine, 14 (3), pp. 543-545; http://www.meddeviceonline.com/doc/how-to-avoid-fda-regulationof-your-mobile-medical-app-0001, (last accessed 2016–04–22); Wachter, R., (2015) The Digital Doctor: Hope, Hype, and Harm at the Dawn of Medicine‘s Computer Age, , McGraw-Hill; Wiener, N., (1961) Cybernetics: Or Control and Communication in the Animal and the Machine, , 2nd ed. Cambridge, MA: The MIT Press; http://ipscience.thomsonreuters.com/product/web-of-science; Whitehead, A.N., Russell, B., (1910) Principia Mathematica, , 1st ed. Cambridge: Cambridge University Press; http://aleph0.clarku.edu/~djoyce/hilbert/problems.html; Levin, L.S., Idler, E.I., (1981) The Hidden Health Care System: Mediating Structures and Medicine, , Cambridge, MA; Ballinger Publishing Co; Ferguson, T., (2007) E-Patients: How they Can Help Us Heal Health Care, , http://e-patients.net/e-Patients_White_Paper.pdf; Kim, J.H., Health Avatar: An Informatics Platform for Personal and Private Big Data (2014) Healthc Inform Res, 20 (1), pp. 1-2; Jeon, E., Park, H.-A., Development of a Smartphone Application for Clinical-Guideline-Based Obesity Management (2015) Healthc Inform Res, 21 (1), pp. 10-20; Kang, H., Park, H.-A., A Mobile App for Hypertension Management Based on Clinical Practice Guidelines: Development and Deployment (2016) JMIR Mhealth Uhealth, 4 (1); Jo, S., Park, H.-A., Development and Evaluation of a Smartphone Application for Managing Gestational Diabetes Mellitus (2016) Healthc Inform Res, 22 (1), pp. 11-21. , http://dx.doi.org/10.4258/hir.2016.22.1.11; Lappalainen, I., Almeida-King, J., Kumanduri, V., Senf, A., Spalding, J.D., Ur-Rehman, S., The European Genome-phenome Archive of human data consented for biomedical research (2015) Nat Genet, 47 (7), pp. 692-695; http://www.medbioinformatics.eu, last accessed 2016–05–24; Cases, M., Furlong, L.I., Albanell, J., Altman, R.B., Bellazzi, R., Boyer, S., Improving data and knowl - Edge management to better integrate health care and research (2013) J Intern Med, 274 (4), pp. 321-328; http://www.disgenet.org, last accessed 2016–05–24; Queralt-Rosinach, N., Piñero, J., Bravo, À., Sanz, F., Furlong, L.I., DisGeNET-RDF: Harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases (2016) Bioinformatics, 32 (14), pp. 2236-2238; Marti-Solano, M., Birney, E., Bril, A., Della Pasqua, O., Kitano, H., Mons, B., Integrative knowledge management to enhance pharmaceutical R&D (2014) Nat Rev Drug Discov, 13 (4), pp. 239-240; Coloma, P.M., Schuemie, M.J., Trifirò, G., Furlong, L., Van Mulligen, E., Bauer-Mehren, A., EU-ADR consortium. Drug-induced acute myocardial infarction: Identifying ‘prime suspects’ from electronic healthcare records-based surveillance system (2013) Plos One, 8 (8); Maojo, V., Kulikowski, C.A., Bioinformatics and medical informatics: Collaborations on the road to genomic medicine? (2003) J am Med Inform Assoc, 10 (6), pp. 515-522; Martin-Sanchez, F., Iakovidis, I., Norager, S., Maojo, V., De Groen, P., Van Der Lei, J., Synergy between medical informatics and bioinformatics: Facilitating genomic medicine for future health care (2004) J Biomed Inform, 37 (1), pp. 30-42; Maojo, V., Martin-Sanchez, F., Billhardt, H., Iakovidis, I., Kulikowski, C., Establishing an agenda for biomedical informatics (2003) Methods Inf Med, 42 (2), pp. 121-125; Sarkar, I.N., Biomedical informatics and translational medicine (2010) J Transl Med, 8, p. 22; Butte, A.J., Translational bioinformatics: Coming of age (2008) J am Med Inform Assoc, 15 (6), pp. 709-714; Sarkar, I.N., Butte, A.J., Lussier, Y.A., Tarczy-Hornoch, P., Ohno-Machado, L., Translational bioinformatics: Linking knowledge across biological and clinical realms (2011) J am Med Inform Assoc, 18 (4), pp. 354-357; Embi, P.J., Payne, P.R., Clinical research informatics: Challenges, opportunities and definition for an emerging domain (2009) J am Med Inform Assoc, 16 (3), pp. 316-327; Embi, P.J., Payne, P.R., Kaufman, S.E., Logan, J.R., Barr, C.E., Identifying challenges and opportunities in clinical research informatics: Analysis of a facilitated discussion at the 2006 AMIA Annual Symposium (2007) AMIA Annu Symp Proc, pp. 221-225; Bernstam, E.V., Smith, J.W., Johnson, T.R., What is biomedical informatics? (2010) J Biomed Inform, 43 (1), pp. 104-110; Friedman, C.P., Ozbolt, J.G., Masys, D.R., American College of Medical I. Toward a new culture for biomedical informatics: Report of the 2001 ACMI symposium (2001) J am Med Inform Assoc, 8 (6), pp. 519-526; Kahn, M.G., The expanding informatics community: Blessing or curse? (2001) J am Med Inform Assoc, 8 (6), pp. 621-623; Moore, J.H., Holmes, J.H., The golden era of biomedical informatics has begun (2016) Biodata Min, 9, p. 15; Topol, E.J., The creative destruction of medicine: How the digital revolution will create better health care (2012) New York: Basic Books, 303p; Elenko, E., Underwood, L., Zohar, D., Defining digital medicine (2015) Nat Biotechnol, 33 (5), pp. 456-461; Steinberg, D., Horwitz, G., Zohar, D., Building a business model in digital medicine (2015) Nat Biotechnol, 33 (9), pp. 910-920; McDaniel, A.M., Schutte, D.L., Keller, L.O., Consumer health informatics: From genomics to population health (2008) Nurs Outlook, 56 (5), pp. 216-223; Selby, J.V., Beal, A.C., Frank, L., The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda (2012) JAMA, 307 (15), pp. 1583-1584; Hood, L., Flore, M., A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory (2012) N Biotechnol, 29 (6), pp. 613-624. , Epub 2012 Mar 18; Zerhouni, E., (2008) Strategic Vision for the Future: From Curative to Preemptive Medicine, , Bethesda, MD: National Institutes of Health; Worthey, E.A., Mayer, A.N., Syverson, G.D., Helbing, D., Bonacci, B.B., Decker, B., Et. Al., Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease (2011) Genet Med, 13 (3), pp. 255-262; Collins, R., What makes UK Biobank special? (2012) Lancet, 379 (9822), pp. 1173-1174; Zinovyev, A., Overcoming Complexity of Biological Systems: From Data Analysis to Modelling (2015) Math Model Nat Phenom, 10 (3), pp. 186-205; Xu, Z., Shi, Y., Exploring Big Data Analysis: Fundamental Scientific Problems (2015) Annals of Data Science, 2 (4), pp. 363-367; Hinton, G.E., Osindero, S.A., The YW. Fast Learning Algorithm for Deep Belief Nets (2006) Neural Comput, 18 (7), pp. 1527-1554; Aisner, D., Olsen, L.A., McGinnis, J.M., (2007) The Learning Healthcare System: Workshop Summary, , Institute of Medicine (US) Roundtable on Evidence- Based Medicine, Washington (DC): National Academies Press (US), The National Academies Collection: Reports funded by National Institutes of Health; Shortliffe, T., Cimino, J., (2013) Biomedical Informatics – Computer Applications in Health Care and Biomedicine, , editors, 4th ed. London: Springer","Al-Shorbaji, N.; Knowledge, Research and Ethics, e-Marefa, P.O. Box 2351, Jordan; email: shorbajin@gmail.com",,,"Schattauer GmbH",,,,,00261270,,MIMCA,"27524112","English","Methods Inf. Med.",Article,"Final",,Scopus,2-s2.0-84991632800
"Gutiérrez-Sacristán A., Bravo A., Portero M., Valverde O., Armario A., Blanco-Gandía M.C., Farré A., Fernández-Ibarrondo L., Fonseca F., Giraldo J., Leis A., Mané A., Mayer M.A., Montagud-Romero S., Nadal R., Ortiz J., Pavón F.J., Perez E., Rodríguez-Arias M., Serrano A., Torrens M., Warnault V., Sanz F., Furlong L.I.","56728807700;56374942700;57191037123;7003421046;7005836750;55879070500;57191034032;57191035028;11940519300;7003797712;35072969800;57191038566;36971031500;56012512400;6701731005;57191039800;24074833100;56803291800;6603913675;8854228600;7006681890;16837518000;7102263897;34770469800;","Text mining and expert curation to develop a database on psychiatric diseases and their genes",2016,"CEUR Workshop Proceedings","1650",,,"48","55",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-84985995034&partnerID=40&md5=515b96d66ec3054a0010f897ea18981c","GRIB, IMIM - UPF, Spain; GReNeC, IMIM - UPF, Spain; Universitat Autònoma de Barcelona, Spain; Universitat de Valencia, Spain; Parc de Salut Mar, UAB, Spain; Program in Cancer Research, IMIM, Spain; Institut de Neurociències, UAB, Spain; School of Medicine, UAB, Spain; Instituto de Investigación Biomédica de Málaga, Spain","Gutiérrez-Sacristán, A., GRIB, IMIM - UPF, Spain; Bravo, A., GRIB, IMIM - UPF, Spain; Portero, M., GReNeC, IMIM - UPF, Spain; Valverde, O., GReNeC, IMIM - UPF, Spain; Armario, A., Universitat Autònoma de Barcelona, Spain; Blanco-Gandía, M.C., Universitat de Valencia, Spain; Farré, A., Parc de Salut Mar, UAB, Spain; Fernández-Ibarrondo, L., Program in Cancer Research, IMIM, Spain; Fonseca, F., Parc de Salut Mar, UAB, Spain; Giraldo, J., Universitat Autònoma de Barcelona, Spain; Leis, A., GRIB, IMIM - UPF, Spain; Mané, A., Parc de Salut Mar, UAB, Spain; Mayer, M.A., GRIB, IMIM - UPF, Spain; Montagud-Romero, S., Universitat de Valencia, Spain; Nadal, R., Institut de Neurociències, UAB, Spain; Ortiz, J., School of Medicine, UAB, Spain; Pavón, F.J., Instituto de Investigación Biomédica de Málaga, Spain; Perez, E., Parc de Salut Mar, UAB, Spain; Rodríguez-Arias, M., Universitat de Valencia, Spain; Serrano, A., Instituto de Investigación Biomédica de Málaga, Spain; Torrens, M., Parc de Salut Mar, UAB, Spain; Warnault, V., GReNeC, IMIM - UPF, Spain; Sanz, F., GRIB, IMIM - UPF, Spain; Furlong, L.I., GRIB, IMIM - UPF, Spain","During the last years there has been a growing research in the genetics of psychiatric diseases. However, there is still a limited understanding of the cellular and molecular mechanisms leading to these diseases, which has hampered the application of this wealth of knowledge into the clinical practice to improve diagnosis and treatment of psychiatric patients. PsyGeNET (http:// www.psygenet.org/) has been developed to improve the understanding of psychiatric diseases, by facilitating the access to the vast amount of their genetic information in a structured manner, providing a set of analysis and visualization tools. In this communication we describe the protocol we put in place for the sustainable update of this knowledge resource. It includes the recruitment of a team of experts to perform the curation of the data previously extracted by text mining. Annotation guidelines and a webbased annotation tool were developed to support curators tasks. A curation workflow was designed including a pilot phase, and two rounds of curation and analysis phases. We report the results of the application of this workflow to the task of curation of gene-disease associations for PsyGeNET, including the analysis of the inter-annotator agreement, and suggest that this model is a suitable approach for the sustainable development and update of knowledge resources.",,"Diagnosis; Genes; Patient treatment; Semantics; Clinical practices; Gene-disease associations; Genetic information; Knowledge resource; Molecular mechanism; Psychiatric disease; Psychiatric patients; Visualization tools; Data mining",,,,,,,,,"Baldacchino, A., Groussard-Escaffre, N., Clancy, C., Lack, C., Sieroslavrska, K., C-L Hodges, L-B Merinder, Laijarvi, H., Epidemiological issues in comorbidity: Lessons learnt from a pan-european isadora project (2009) Mental Health and Substance Use: Dual Diagnosis, 2 (2), pp. 88-100. , [Baldacchino et al. 2009]; Bravo, A., Pinẽro, J., Queralt-Rosinach, N., Rautschka, M., Furlong, L.I., Extraction of relations between genes and diseases from text and large-scale data analysis: Implications for translational research (2015) BMC Bioinformatics, 16 (1), p. 1. , [Bravo et al. 2015]; Chun, H.-W., Tsuruoka, Y., Kim, J.-D., Shiba, R., Nagata, N., Hishiki, T., Tsujii, J., Automatic recognition of topic-classified relations between prostate cancer and genes using medline abstracts (2006) BMC Bioinformatics, 7 (3), p. 1. , [Chun et al. 2006]; Craven, M., Kumlien, J., Constructing biological knowledge bases by extracting information from text sources (1999) ISMB, 1999, pp. 77-86. , [Craven et al. 1999]; Gutiérrez-Sacristán, A., Grosdidier, S., Valverde, O., Torrens, M., Bravo, A., Pinẽro, J., Sanz, F., Furlong, L.I., Psygenet: A knowledge platform on psychiatric disorders and their genes (2015) Bioinformatics, p. btv301. , [Gutiérrez-Sacristán et al. 2015]; Kessler, R.C., Berglund, P., Demler, O., Jin, R., Merikangas, K.R., Walters, E.E., Lifetime prevalence and age-of-onset distributions of dsm-IV disorders in the national comorbidity survey replication (2005) Archives of General Psychiatry, 62 (6), pp. 593-602. , [Kessler et al. 2005]; Lee, H.-J., Shim, S.-H., Song, M.-R., Lee, H., Park, J.C., Comagc: A corpus with multi-faceted annotations of gene-cancer relations (2013) BMC Bioinformatics, 14 (1), p. 1. , [Lee et al. 2013]; Murray, C.J.L., Lopez, A.D., Measuring the global burden of disease (2013) New England Journal of Medicine, 369 (5), pp. 448-457. , [Murray and Lopez2013]; Neves, M., An analysis on the entity annotations in biological corpora (2014) F1000Research, 3. , [Neves2014]; Piñero, J., Queralt-Rosinach, N., Bravo, A., Deu-Pons, J., Bauer-Mehren, A., Baron, M., Sanz, F., Furlong, L.I., Disgenet: A discovery platform for the dynamical exploration of human diseases and their genes (2015) Database, , [Piñero et al. 2015] 2015: Bav028; Sullivan, P.F., Daly, M.J., O'Donovan, M., Genetic architectures of psychiatric disorders: The emerging picture and its implications (2012) Nature Reviews Genetics, 13 (8), pp. 537-551. , [Sullivan et al. 2012]; Van Mulligen, E.M., Fourrier-Reglat, A., Gurwitz, D., Molokhia, M., Nieto, A., Trifiro, G., Kors, J.A., Furlong, L.I., The eu-adr corpus: Annotated drugs, diseases, targets, and their relationships (2012) Journal of biomedical informatics, 45 (5), pp. 879-884. , [Van Mulligen et al. 2012]; Whiteford, H.A., Degenhardt, L., Rehm, J., Baxter, A.J., Ferrari, A.J., Erskine, H.E., Charlson, F.J., Johns, N., Global burden of disease attributable to mental and substance use disorders: Findings from the global burden of disease study 2010 (2013) The Lancet, 382, pp. 1575-1586; Wiegers, T.C., Davis, A.P., Cohen, K.B., Hirschman, L., Mattingly, C.J., Text mining and manual curation of chemical-gene-disease networks for the comparative toxicogenomics database (ctd) (2009) BMC Bioinformatics, 10 (1), p. 326. , [Wiegers et al. 2009]",,"Neves M.Nenadic G.Rebholz-Schuhmann D.Rinaldi F.","","CEUR-WS","7th International Symposium on Semantic Mining in Biomedicine, SMBM 2016","4 August 2016 through 5 August 2016",,122975,16130073,,,,"English","CEUR Workshop Proc.",Conference Paper,"Final",,Scopus,2-s2.0-84985995034
"Sanz F., Carriõ P., Lõpez O., Capoferri L., Kooi D.P., Vermeulen N.P.E., Geerke D.P., Montanari F., Ecker G.F., Schwab C.H., Kleinöder T., Magdziarz T., Pastor M.","7102263897;55227590800;56556019000;36996904700;56690502300;7101606504;7801379476;56085430000;24794675100;57202459522;15751017500;6508354909;7102415847;","Integrative Modeling Strategies for Predicting Drug Toxicities at the eTOX Project",2015,"Molecular Informatics","34","6-7",,"477","484",,12,"10.1002/minf.201400193","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84933520162&doi=10.1002%2fminf.201400193&partnerID=40&md5=2b3ad64bb5bb393d4e18c475b6b3614f","Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain; Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, Faculty of Sciences, De Boelelaan 1083, Amsterdam, HV  1081, Netherlands; University of Vienna, Department of Pharmaceutical Chemistry, Althanstrasse 14, Vienna, 1090, Austria; Molecular Networks GmbH, Medical Valley Center, Henkestrasse 91, Erlangen, 91052, Germany","Sanz, F., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain; Carriõ, P., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain; Lõpez, O., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain; Capoferri, L., Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, Faculty of Sciences, De Boelelaan 1083, Amsterdam, HV  1081, Netherlands; Kooi, D.P., Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, Faculty of Sciences, De Boelelaan 1083, Amsterdam, HV  1081, Netherlands; Vermeulen, N.P.E., Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, Faculty of Sciences, De Boelelaan 1083, Amsterdam, HV  1081, Netherlands; Geerke, D.P., Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, Faculty of Sciences, De Boelelaan 1083, Amsterdam, HV  1081, Netherlands; Montanari, F., University of Vienna, Department of Pharmaceutical Chemistry, Althanstrasse 14, Vienna, 1090, Austria; Ecker, G.F., University of Vienna, Department of Pharmaceutical Chemistry, Althanstrasse 14, Vienna, 1090, Austria; Schwab, C.H., Molecular Networks GmbH, Medical Valley Center, Henkestrasse 91, Erlangen, 91052, Germany; Kleinöder, T., Molecular Networks GmbH, Medical Valley Center, Henkestrasse 91, Erlangen, 91052, Germany; Magdziarz, T., Molecular Networks GmbH, Medical Valley Center, Henkestrasse 91, Erlangen, 91052, Germany; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Dr. Aiguader 88, Barcelona, E-08003, Spain","Early prediction of safety issues in drug development is at the same time highly desirable and highly challenging. Recent advances emphasize the importance of understanding the whole chain of causal events leading to observable toxic outcomes. Here we describe an integrative modeling strategy based on these ideas that guided the design of eTOXsys, the prediction system used by the eTOX project. Essentially, eTOXsys consists of a central server that marshals requests to a collection of independent prediction models and offers a single user interface to the whole system. Every of such model lives in a self-contained virtual machine easy to maintain and install. All models produce toxicity-relevant predictions on their own but the results of some can be further integrated and upgrade its scale, yielding in vivo toxicity predictions. Technical aspects related with model implementation, maintenance and documentation are also discussed here. Finally, the kind of models currently implemented in eTOXsys is illustrated presenting three example models making use of diverse methodology (3D-QSAR and decision trees, Molecular Dynamics simulations and Linear Interaction Energy theory, and fingerprint-based QSAR). © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.","AOP; Drug safety; Integrative modeling; Multi-scale models; Toxicity prediction","drug; Article; decision tree; drug safety; information model; lipidosis; priority journal; quantitative structure activity relation; adverse drug reaction; animal; biological model; human; molecular dynamics; Animals; Drug-Related Side Effects and Adverse Reactions; Humans; Models, Biological; Molecular Dynamics Simulation",,,,,,,,,"Sacks, L.V., Shamsuddin, H.H., Yasinskaya, Y.I., Bouri, K., Lanthier, M.L., Sherman, R.E., (2014) JAMA, 311, pp. 378-384; Kramer, J.A., Sagartz, J.E., Morris, D.L., (2007) Nat. Rev. Drug Discov., 6, pp. 636-649; DSSTox, , http://www.epa.gov/ncct/dsstox/; ACToR, , http://actor.epa.gov/actor/faces/ACToRHome.jsp; Kopp-Schneider, A., Prieto, P., Kinsner-Ovaskainen, A., Stanzel, S., (2013) Toxicol. in Vitro, 27, pp. 1395-1401; Shah, F., Greene, N., (2014) Chem. Res. Toxicol., 27, pp. 86-98; Kavlock, R., Chandler, K., Houck, K., Hunter, S., Judson, R., Kleinstreuer, N., Knudsen, T., Reif, D., (2012) Chem. Res. Toxicol., 25, pp. 1287-1302; Attene-Ramos, M.S., Miller, N., Huang, R., Michael, S., Itkin, M., Kavlock, R.J., Austin, C.P., Tice, R.R., (2013) Drug Discov. Today, 18, pp. 716-723; Hardy, B., Douglas, N., Helma, C., Rautenberg, M., Jeliazkova, N., Jeliazkov, V., Nikolova, I., Kramer, S., (2010) J. Cheminform., 2; Benigni, R., Battistelli, C.L., Bossa, C., Tcheremenskaia, O., Crettaz, P., (2013) Mutagenesis, 28, pp. 401-409; Tluczkiewicz, I., Batke, M., Kroese, D., Buist, H., Aldenberg, T., Pauné, E., Grimm, H., Mangelsdorf, I., (2013) Regul. Toxicol. Pharmacol., 67, pp. 157-169; Safe-T, , http://www.imi-safe-t.eu/; ETOX, , http://etoxproject.eu/; Briggs, K., Cases, M., Heard, D.J., Pastor, M., Pognan, F., Sanz, F., Schwab, C.H., Watson, D.K., (2012) Int. J. Mol. Sci., 13, pp. 3820-3846; Cases, M., Briggs, K., Steger-Hartmann, T., Pognan, F., Marc, P., Kleinöder, T., Schwab, C.H., Sanz, F., (2014) Int. J. Mol. Sci., 15, pp. 21136-21154; Meek, M.E.B., Barton, H.A., Bessems, J.G., Lipscomb, J.C., Krishnan, K., (2013) Regul. Toxicol. Pharmacol., 66, pp. 116-129; Vinken, M., (2013) Toxicology, 312, pp. 158-165; (2007) Organisation for Economic Co-Operation and Development (2007) Guidance Document on the Validation of (Quantitative) Structure-Activity Relationships [(Q)SAR] Models. Report Number ENV/JM/MONO; Carriõ, P., Lõpez, O., Sanz, F., Pastor, M., (2015) J. Cheminform., 7, p. 8; Atkinson, F.L., Standardiser, , https://github.com/flatkinson/standardiser; Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Valigi, R., Clementi, S., (1993) Quant. Struct. Relationships, 12, pp. 9-20; Carriõ, P., Pinto, M., Ecker, G., Sanz, F., Pastor, M., (2014) J. Chem. Inf. Model., 54, pp. 1500-1511; Berthold, M., Cebron, N., Dill, F., Gabriel, T., Kötter, T., Meinl, T., Ohl, P., Wiswedel, B., (2008) Data Anal. Mach. Learn. Appl. SE-38, pp. 319-326. , in (Eds: C. Preisach, H. Burkhardt, L. Schmidt-Thieme, R. Decker), Springer, Heidelberg; Pipeline Pilot, Http://accelrys.com/products/pipeline-pilot/., , http://accelrys.com/products/pipeline-pilot/; Obiol-Pardo, C., Gomis-Tena, J., Sanz, F., Saiz, J., Pastor, M., (2011) J. Chem. Inf. Model., 51, pp. 483-492; Tomizawa, K., Sugano, K., Yamada, H., Horii, I., (2006) J. Toxicol. Sci., 31, pp. 315-324; Hruban, Z., (1984) Environ. Health Perspect., 55, pp. 53-76; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., (2000) J. Med. Chem., 43, pp. 3233-3243; Durán Á., Martínez, G.C., Pastor, M., (2008) J. Chem. Inf. Model., 48, pp. 1813-1823; Kruhlak, N.L., Choi, S.S., Contrera, J.F., Weaver, J.L., Willard, J.M., Hastings, K.L., Sancilio, L.F., (2008) Toxicol. Mech. Methods, 18, pp. 217-227; Milletti, F., Storchi, L., Sforna, G., Cross, S., Cruciani, G., (2009) J. Chem. Inf. Model., 49, pp. 68-75; Milletti, F., Storchi, L., Sforna, G., Cruciani, G., (2007) J. Chem. Inf. Model., 47, pp. 2172-2181; Sutherland, J.J., O'Brien, L., Weaver, D.F., (2004) J. Med. Chem., 47, pp. 5541-5554; Durán Á., Pastor, M., Pentacle, , http://www.moldiscovery.com/software/pentacle; Aqvist, J., Medina, C., Samuelsson, J.E., (1994) Protein Eng., 7, pp. 385-391; Peric-Hassler, L., Stjernschantz, E., Oostenbrink, C., Geerke, D.P., (2013) Int. J. Mol. Sci., 14, pp. 24514-24530; Vosmeer, C.R., Pool, R., Van Stee, M.F., Peric-Hassler, L., Vermeulen, N.P.E., Geerke, D.P., (2014) Int. J. Mol. Sci., 15, pp. 798-816; Stjernschantz, E., Oostenbrink, C., (2010) Biophys. J., 98, pp. 2682-2691; Jakalian, A., Bush, B.L., Jack, D.B., Bayly, C.I., (2000) J. Comput. Chem., 21, pp. 132-146; Meier, R., Pippel, M., Brandt, F., Sippl, W., Baldauf, C., (2010) J. Chem. Inf. Model., 50, pp. 879-889; Hritz, J., De Ruiter, A., Oostenbrink, C., (2008) J. Med. Chem., 51, pp. 7469-7477; Vasanthanathan, P., Hritz, J., Taboureau, O., Olsen, L., Jørgensen, F.S., Vermeulen, N.P.E., Oostenbrink, C., (2009) J. Chem. Inf. Model., 49, pp. 43-52; Sousa, A.W., Vranken, W.F., (2012) BMC Res. Notes, 5, p. 367; Hess, B., Kutzner, C., Van Der Spoel, D., Lindahl, E., (2008) J. Chem. Theory Comput., 4, pp. 435-447; Vaz, R.J., Nayeem, A., Santone, K., Chandrasena, G., Gavai, A.V., (2005) Bioorganic Med. Chem. Lett., 15, pp. 3816-3820; Cohen, L.H., Remley, M.J., Raunig, D., Vaz, A.D.N., (2003) Drug Metab. Dispos., 31, pp. 1005-1015; Korhonen, L.E., Rahnasto, M., Mähönen, N.J., Wittekindt, C., Poso, A., Juvonen, R.O., Raunio, H., (2005) J. Med. Chem., 48, pp. 3808-3815; (2012) Guidance for Industry, Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling Recommendations, , Food and Drug Administration; Kruijtzer, C.M.F., Beijnen, J.H., Rosing, H., Ten Bokkel Huinink, W.W., Schot, M., Jewell, R.C., Paul, E.M., Schellens, J.H.M., (2002) J. Clin. Oncol., 20, pp. 2943-2950; Montanari, F., Ecker, G.F., (2014) Mol. Inform., 33, pp. 322-331; Landrum, G., RDKit: Open-source Cheminformatics, , http://www.rdkit.org; Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Dubourg, V., (2012) J. Mach. Learn. Res., 12, pp. 2825-2830; http://www.gnu.org/copyleft/gpl.html, GPL v3","Pastor, M.; Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Dr. Aiguader 88, Spain",,,"Wiley-VCH Verlag",,,,,18681743,,MIONB,"27490391","English","Mol. Informatics",Article,"Final",,Scopus,2-s2.0-84933520162
"Gutierrez-Sacristan A., Grosdidier S., Valverde O., Torrens M., Bravo A., Piñero J., Sanz F., Furlong L.I.","56728807700;23027796200;7003421046;7006681890;56374942700;55220852900;7102263897;34770469800;","PsyGeNET: A knowledge platform on psychiatric disorders and their genes",2015,"Bioinformatics","31","18",,"3075","3077",,21,"10.1093/bioinformatics/btv301","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941755300&doi=10.1093%2fbioinformatics%2fbtv301&partnerID=40&md5=258ab447e6ce45dc51ed12ab866627b3","Research Group on Integrative Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Spain; Neurobiology of Behaviour Research Group, IMIM, DCEXS, Spain; Institute of Neuropsychiatry and Addiction, Universitat Autonoma de Barcelona, Barcelona, 08003, Spain","Gutierrez-Sacristan, A., Research Group on Integrative Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Spain; Grosdidier, S., Research Group on Integrative Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Spain; Valverde, O., Neurobiology of Behaviour Research Group, IMIM, DCEXS, Spain; Torrens, M., Institute of Neuropsychiatry and Addiction, Universitat Autonoma de Barcelona, Barcelona, 08003, Spain; Bravo, A., Research Group on Integrative Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Spain; Piñero, J., Research Group on Integrative Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Spain; Sanz, F., Research Group on Integrative Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Spain; Furlong, L.I., Research Group on Integrative Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Spain","PsyGeNET (Psychiatric disorders and Genes association NETwork) is a knowledge platform for the exploratory analysis of psychiatric diseases and their associated genes. PsyGeNET is composed of a database and a web interface supporting data search, visualization, filtering and sharing. PsyGeNET integrates information from DisGeNET and data extracted from the literature by text mining, which has been curated by domain experts. It currently contains 2642 associations between 1271 genes and 37 psychiatric disease concepts. In its first release, PsyGeNET is focused on three psychiatric disorders: major depression, alcohol and cocaine use disorders. PsyGeNET represents a comprehensive, open access resource for the analysis of the molecular mechanisms underpinning psychiatric disorders and their comorbidities. © 2015 The Author.",,"biological marker; alcoholism; algorithm; animal; chromosomal mapping; cocaine dependence; data mining; disease model; factual database; gene regulatory network; genetics; human; knowledge base; major depression; mouse; publication; rat; software; Alcoholism; Algorithms; Animals; Biomarkers; Chromosome Mapping; Cocaine-Related Disorders; Data Mining; Databases, Factual; Depressive Disorder, Major; Disease Models, Animal; Gene Regulatory Networks; Humans; Knowledge Bases; Mice; Publications; Rats; Software",,"Biomarkers",,,,,,,"Becker, K.G., The genetic association database (2004) Nat. Genet, 36, pp. 431-432; Blake, J.A., The Mouse Genome Database: Integration of and access to knowledge about the laboratory mouse (2014) Nucleic Acids Res., 42, pp. D810-D817; Bravo, A., Extraction of relations between genes and diseases from text and large-scale data analysis: Implications for translational research (2015) BMC Bioinformatics, 16, p. 55; Collins, P.Y., Grand challenges in global mental health (2011) Nature, 475, pp. 27-30; Davis, A.P., The Comparative Toxicogenomics Database: Update 2013 (2013) Nucleic Acids Res., 41, pp. D1104-D1114; Laulederkind, S.J.F., The Rat Genome Database 2013-data, tools and users (2013) Brief. Bioinform., 14, pp. 520-526; Murray, C.J.L., Lopez, A.D., Measuring the global burden of disease (2013) N. Engl. J. Med., 369, pp. 448-457; Pettinati, H.M., Current status of co-occurring mood and substance use disorders: A new therapeutic target (2013) Am. J. Psychiatry, 170, pp. 23-30; Piñ Ero, J., DisGeNET: A discovery platform for the dynamical exploration of human diseases and their genes (2015) Database, , (Oxford)., pii: bav028; Sullivan, P.F., Genetic architectures of psychiatric disorders: The emerging picture and its implications (2012) Nat. Rev. Genet., 13, pp. 537-551; Whiteford, H.A., Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010 (2013) Lancet, 382, pp. 1575-1586; (2014) Global Status Report on Alcohol and Health, , World Health Organization World Health Organization","Furlong, L.I.; Research Group on Integrative Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu FabraSpain; email: lfurlong@imim.es",,,"Oxford University Press",,,,,13674803,,BOINF,"25964630","English","Bioinformatics",Article,"Final",Open Access,Scopus,2-s2.0-84941755300
"Agustí A., Antó J.M., Auffray C., Barbé F., Barreiro E., Dorca J., Escarrabill J., Faner R., Furlong L.I., Garcia-Aymerich J., Gea J., Lindmark B., Monsó E., Plaza V., Puhan M.A., Roca J., Ruiz-Manzano J., Sampietro-Colom L., Sanz F., Serrano L., Sharpe J., Sibila O., Silverman E.K., Sterk P.J., Sznajder J.I.","7101749378;56196020900;7005050330;7007035883;7005260014;7003615567;7003810466;6507910788;34770469800;6603421917;7004959809;56517842900;55041612300;7004891871;56365235600;24784609700;7003705264;6602320941;7102263897;57201877537;16305238700;8761639900;57203069737;7102794272;7006017243;","Personalized respiratory medicine: Exploring the horizon, addressing the issues: Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014",2015,"American Journal of Respiratory and Critical Care Medicine","191","4",,"391","401",,46,"10.1164/rccm.201410-1935PP","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84922895251&doi=10.1164%2frccm.201410-1935PP&partnerID=40&md5=5d4de2eac990de74308c8392e42b45f1","Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University Barcelona, Villarroel 170, Barcelona, 08036, Spain; Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain; Centre for Research in Environmental Epidemiology, Hospital Del Mar Medical Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; European Institute for Systems Biology and Medicine, Lyon, France; Institut de Recerca Biomèdica de Lleida, Lleida, Spain; Pulmonology Department, Hospital Del Mar-Hospital Del Mar Medical Research Institute, CEXS, Barcelona, Spain; Hospital University Bellvitge, University Barcelona, El Institut d'Investigació Biomèdica de Bellvitge, Spain; Research Programme on Biomedical Informatics, Hospital Del Mar Medical Research Institute, University Pompeu Fabra, Barcelona, Spain; Laboratorios Almirall, Barcelona, Spain; Hospital University Parc Taulí, Sabadell, Spain; Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, University Autonoma de Barcelona, Barcelona, Spain; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland; Hospital University Germans Trias i Pujol, University Autónoma Barcelona, Badalona, Spain; European Molecular Biology Laboratory/Centre for Genomic Regulation Systems Biology Research Unit, Centre for Genomic Regulation, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States; Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands; Northwestern University, Chicago, IL, United States","Agustí, A., Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University Barcelona, Villarroel 170, Barcelona, 08036, Spain, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain; Antó, J.M., Centre for Research in Environmental Epidemiology, Hospital Del Mar Medical Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; Auffray, C., European Institute for Systems Biology and Medicine, Lyon, France; Barbé, F., Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain, Institut de Recerca Biomèdica de Lleida, Lleida, Spain; Barreiro, E., Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain, Pulmonology Department, Hospital Del Mar-Hospital Del Mar Medical Research Institute, CEXS, Barcelona, Spain; Dorca, J., Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain, Hospital University Bellvitge, University Barcelona, El Institut d'Investigació Biomèdica de Bellvitge, Spain; Escarrabill, J., Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University Barcelona, Villarroel 170, Barcelona, 08036, Spain; Faner, R., Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University Barcelona, Villarroel 170, Barcelona, 08036, Spain, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain; Furlong, L.I., Research Programme on Biomedical Informatics, Hospital Del Mar Medical Research Institute, University Pompeu Fabra, Barcelona, Spain; Garcia-Aymerich, J., Centre for Research in Environmental Epidemiology, Hospital Del Mar Medical Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; Gea, J., Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain, Pulmonology Department, Hospital Del Mar-Hospital Del Mar Medical Research Institute, CEXS, Barcelona, Spain; Lindmark, B., Laboratorios Almirall, Barcelona, Spain; Monsó, E., Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain, Hospital University Parc Taulí, Sabadell, Spain; Plaza, V., Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, University Autonoma de Barcelona, Barcelona, Spain; Puhan, M.A., Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland; Roca, J., Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University Barcelona, Villarroel 170, Barcelona, 08036, Spain, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain; Ruiz-Manzano, J., Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain, Hospital University Germans Trias i Pujol, University Autónoma Barcelona, Badalona, Spain; Sampietro-Colom, L., Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University Barcelona, Villarroel 170, Barcelona, 08036, Spain; Sanz, F., Research Programme on Biomedical Informatics, Hospital Del Mar Medical Research Institute, University Pompeu Fabra, Barcelona, Spain; Serrano, L., European Molecular Biology Laboratory/Centre for Genomic Regulation Systems Biology Research Unit, Centre for Genomic Regulation, Barcelona, Spain, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain; Sharpe, J., European Molecular Biology Laboratory/Centre for Genomic Regulation Systems Biology Research Unit, Centre for Genomic Regulation, Barcelona, Spain, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain; Sibila, O., Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, University Autonoma de Barcelona, Barcelona, Spain; Silverman, E.K., Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States; Sterk, P.J., Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands; Sznajder, J.I., Northwestern University, Chicago, IL, United States","This Pulmonary Perspective summarizes the content and main conclusions of an international workshop on personalized respiratory medicine coorganized by the Barcelona Respiratory Network (www.brn.cat) and the AJRCCM in June 2014. It discusses (1) its definition and historical, social, legal, and ethical aspects; (2) the view from different disciplines, including basic science, epidemiology, bioinformatics, and network/systems medicine; (3) the bottlenecks and opportunities identified by some currently ongoing projects; and (4) the implications for the individual, the healthcare system and the pharmaceutical industry. The authors hope that, although it is not a systematic review on the subject, this document can be a useful reference for researchers, clinicians, healthcare managers, policy-makers, and industry parties interested in personalized respiratory medicine. Copyright © 2015 by the American Thoracic Society.",,"new drug; bioinformatics; clinical practice; diseases; drug development; drug industry; epidemiology; ethics; health care organization; health care system; human; legal aspect; medical history; pathology; personalized medicine; priority journal; respiratory system; Review; scientist; social aspect; workshop; biology; consensus development; personalized medicine; procedures; pulmonology; Spain; trends; Computational Biology; Humans; Precision Medicine; Pulmonary Medicine; Spain",,,,,"GlaxoSmithKline foundation, GSK

National Institutes of Health, NIH: P01 HL105339

National Institutes of Health, NIH: R01 HL111759

Novartis",,,,"Sznajder, J.I., Ciechanover, A., Personalized medicine: The road ahead (2012) Am J Respir Crit Care Med, 186, pp. 945-947; Agusti, A., The path to personalised medicine in COPD (2014) Thorax, 69, pp. 857-864; Annas, G.J., Elias, S., 23andMe and the FDA (2014) N Engl J Med, 370, pp. 985-988; Fairclough, S., Physiological data must remain confidential (2014) Nature, 505, p. 263; Holgate, S.T., Palotie, A., Prainsack, B., Brand, A., Lehrach, H., Steinhausen, K., Berghmans, S., Seewald, C., (2012) Personalized Medicine for the European Citizen, , Strasbourg France: European Science Foundation; Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Holt, R.A., The sequence of the human genome (2001) Science, 291, pp. 1304-1351; Barabási, A.L., Gulbahce, N., Loscalzo, J., Network medicine: A networkbased approach to human disease (2011) Nat Rev Genet, 12, pp. 56-68; Kim, M.S., Pinto, S.M., Getnet, D., Nirujogi, R.S., Manda, S.S., Chaerkady, R., Madugundu, A.K., Jain, S., A draft map of the human proteome (2014) Nature, 509, pp. 575-581; Kohl, P., Crampin, E.J., Quinn, T.A., Noble, D., Systems biology: An approach (2010) Clin Pharmacol Ther, 88, pp. 25-33; Balch, W.E., Sznajder, J.I., Budinger, S., Finley, D., Laposky, A.D., Cuervo, A.M., Benjamin, I.J., Postow, L., Malfolded protein structure and proteostasis in lung diseases (2014) Am J Respir Crit Care Med, 189, pp. 96-103; Diez, D., Agustí, A., Wheelock, C.E., Network analysis in the investigation of chronic respiratory diseases: From basics to application (2014) Am J Respir Crit Care Med, 190, pp. 981-988; Zhong, Q., Simonis, N., Li, Q.R., Charloteaux, B., Heuze, F., Klitgord, N., Tam, S., Mou, D., Edgetic perturbation models of human inherited disorders (2009) Mol Syst Biol, 5, p. 321; Periyasamy, S., Gray, A., Kille, P., The bottom-up approach to defining life: Deciphering the functional organization of biological cells via multiobjective representation of biological complexity from molecules to cells (2013) Front Physiol, 4, p. 369; Kiel, C., Serrano, L., Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations (2014) Mol Syst Biol, 10, p. 727; Kiel, C., Serrano, L., Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling (2009) Sci Signal, 2, p. ra38; Casanueva, M.O., Burga, A., Lehner, B., Fitness trade-offs and environmentally induced mutation buffering in isogenic C. Elegans (2012) Science, 335, pp. 82-85; Wheelock, C.E., Goss, V.M., Balgoma, D., Nicholas, B., Brandsma, J., Skipp, P.J., Snowden, S., Horvath, I., Application of 'omics technologies to biomarker discovery in inflammatory lung diseases (2013) Eur Respir J, 42, pp. 802-825; Zhang, H., Gustafsson, M., Nestor, C., Chung, K.F., Benson, M., Targeted omics and systems medicine: Personalising care (2014) Lancet Respir Med, 2, pp. 785-787; Gustafsson, M., Nestor, C., Zhang, H., Barabasi, A.L., Baranzini, S., Brunak, S., Chung, K., Meehan, R., Modules, networks and systems medicine for understanding disease and aiding diagnosis (2014) Genome Medicine, 6, p. 82; Smarr, L., Quantifying your body: A how-to guide from a systems biology perspective (2012) Biotechnol J, 7, pp. 980-991; Doll, R., Smoking and lung cancer (1953) BMJ, 1, pp. 505-506; Kauffmann, F., Postgenome respiratory epidemiology: A multidisciplinary challenge (2004) Eur Respir J, 24, pp. 471-480; Manolio, T.A., Genomewide association studies and assessment of the risk of disease (2010) N Engl J Med, 363, pp. 166-176; Ioannidis, J.P., Personalized genetic prediction: Too limited too expensive or too soon? (2009) Ann Intern Med, 150, pp. 139-141; Hall, I.P., Stratified medicine: Drugs meet genetics (2013) Eur Respir Rev, 22, pp. 53-57; Belsky, D.W., Sears, M.R., Hancox, R.J., Harrington, H., Houts, R., Moffitt, T.E., Sugden, K., Caspi, A., Polygenic risk and the development and course of asthma: An analysis of data from a four-decade longitudinal study (2013) Lancet Respir Med, 1, pp. 453-461; Schwartz, J., Bellinger, D., Glass, T., Expanding the scope of environmental risk assessment to better include differential vulnerability and susceptibility (2011) Am J Public Health, 101, pp. S88-S93; Khoury, M.J., Gwinn, M.L., Glasgow, R.E., Kramer, B.S., A population perspective on how personalized medicine can improve health (2012) Am J Prev Med, 42, pp. 639-645; Bauer-Mehren, A., Bundschus, M., Rautschka, M., Mayer, M.A., Sanz, F., Furlong, L.I., Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases (2011) PLoS ONE, 6; Schneeweiss, S., Learning from big health care data (2014) N Engl J Med, 370, pp. 2161-2163; Murdoch, T.B., Detsky, A.S., The inevitable application of big data to health care (2013) JAMA, 309, pp. 1351-1352; Cases, M., Furlong, L.I., Albanell, J., Altman, R.B., Bellazzi, R., Boyer, S., Brand, A., Clark, T.W., Improving data and knowledge management to better integrate health care and research (2013) J Intern Med, 274, pp. 321-328; Bauer-Mehren, A., Rautschka, M., Sanz, F., Furlong, L.I., DisGeNET: A Cytoscape plugin to visualize, integrate, search and analyze genedisease networks (2010) Bioinformatics, 26, pp. 2924-2926; Grosdidier, S., Ferrer, A., Faner, R., Piñero, J., Roca, J., Cosío, B., Agustí, A., Furlong, L.I., Network medicine analysis of COPD multimorbidities (2014) Respir Res, 15, p. 111; Pillai, S.G., Ge, D., Zhu, G., Kong, X., Shianna, K.V., Need, A.C., Feng, S., Gulsvik, A., A genome-wide association study in chronic obstructive pulmonary disease (COPD): Identification of two major susceptibility loci (2009) PLoS Genet, 5, p. e1000421; Pulkkinen, V., Bruce, S., Rintahaka, J., Hodgson, U., Laitinen, T., Alenius, H., Kinnula, V.L., Kere, J., ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses (2010) FASEB J, 24, pp. 1167-1177; Chen, H.Y., Yu, S.L., Chen, C.H., Chang, G.C., Chen, C.Y., Yuan, A., Cheng, C.L., Kaosf, T., A five-gene signature and clinical outcome in non-small-cell lung cancer (2007) N Engl J Med, 356, pp. 11-20; Armanios, M.Y., Chen, J.J., Cogan, J.D., Alder, J.K., Ingersoll, R.G., Markin, C., Lawson, W.E., Phillips, J.A., III, Telomerase mutations in families with idiopathic pulmonary fibrosis (2007) N Engl J Med, 356, pp. 1317-1326; Yang, I.V., Pedersen, B.S., Rabinovich, E., Hennessy, C.E., Davidson, E.J., Murphy, E., Guardela, B.J., Singh, M.K., Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis (IPF) (2014) Am J Respir Crit Care Med, 190, pp. 1263-1272; Molloy, K., McElvaney, N.G., Ivacaftor: From bench to bedside... and back again (2014) Am J Respir Crit Care Med, 190, pp. 128-129; Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haluska, F.G., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib (2004) N Engl J Med, 350, pp. 2129-2139; Lötvall, J., Akdis, C.A., Bacharier, L.B., Bjermer, L., Casale, T.B., Custovic, A., Lemanske, R.F., Jr., Greenberger, P.A., Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome (2011) J Allergy Clin Immunol, 127, pp. 355-360; Maher, T.M., Beyond the diagnosis of idiopathic pulmonary fibrosis; The growing role of systems biology and stratified medicine (2013) Curr Opin Pulm Med, 19, pp. 460-465; Barabási, A.L., Network medicine: From obesity to the ""diseasome."" (2007) N Engl J Med, 357, pp. 404-407; Castaldi, P.J., Dy, J., Ross, J., Chang, Y., Washko, G.R., Curran-Everett, D., Williams, A., Crapo, J.D., Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema (2014) Thorax, 69, pp. 415-422; Cho, M.H., McDonald, M.L., Zhou, X., Mattheisen, M., Castaldi, P.J., Hersh, C.P., Demeo, D.L., Laird, N.M., Risk loci for chronic obstructive pulmonary disease: A genome-wide association study and meta-analysis (2014) Lancet Respir Med, 2, pp. 214-225; Zhou, X., Qiu, W., Sathirapongsasuti, J.F., Cho, M.H., Mancini, J.D., Lao, T., Thibault, D.M., Gulsvik, A., Gene expression analysis uncovers novel hedgehog interacting protein (HHIP) effects in human bronchial epithelial cells (2013) Genomics, 101, pp. 263-272; Chu, J.H., Hersh, C.P., Castaldi, P.J., Cho, M.H., Raby, B.A., Laird, N., Bowler, R., Quackenbush, J., Analyzing networks of phenotypes in complex diseases: Methodology and applications in COPD (2014) BMC Syst Biol, 8, p. 78; Faner, R., Cruz, T., López-Giraldo, A., Agustí, A., Network medicine multimorbidity and the lung in the elderly (2014) Eur Respir J, 44, pp. 775-788; Silverman, E.K., Loscalzo, J., Developing new drug treatments in the era of network medicine (2013) Clin Pharmacol Ther, 93, pp. 26-28; Sorger, P.K., Allerheiligen, S.R.B., Abernethy, D.R., Altman, R.B., Brouwer, K.L.R., Califano, A., D'Arggenio, D.Z., Lalonde, R., Quantitative and systems pharmacology in the post-genomic era: New approaches to discovering drugs and understanding therapeutic mechanisms (2011) An NIH White Paper by the QSP Workshop Group, pp. 1-48; Lee, M.J., Ye, A.S., Gardino, A.K., Heijink, A.M., Sorger, P.K., Macbeath, G., Yaffe, M.B., Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks (2012) Cell, 149, pp. 780-794; Yelensky, R., Li, Y., Lewitzky, S., Leroy, E., Hurwitz, C., Rodman, D., Trifilieff, A., Paulding, C.A., A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients (2012) Pharmacogenomics J, 12, pp. 484-488; Loscalzo, J., Kohane, I., Barabasi, A.L., Human disease classification in the postgenomic era: A complex systems approach to human pathobiology (2007) Mol Syst Biol, 3, p. 124; Silverman, E.K., Loscalzo, J., Network medicine approaches to the genetics of complex diseases (2012) Discov Med, 14, pp. 143-152; Medical imaging in personalised medicine: A white paper of the research committee of the European Society of Radiology (ESR) (2011) Insights Imaging, 2, pp. 621-630. , European Society of Radiology; Vanfleteren, L.E.G.W., Kocks, J.W.H., Stone, I.S., Breyer-Kohansal, R., Greulich, T., Lacedonia, D., Buhl, R., Barnes, N., Moving from the Oslerian paradigm to the post-genomic era: Are asthma and COPD outdated terms? (2014) Thorax, 69, pp. 72-79; Bousquet, J., Anto, J., Auffray, C., Akdis, M., Cambon-Thomsen, A., Keil, T., Haahtela, T., Sunyer, J., MeDALL (Mechanisms of the Development of ALLergy): An integrated approach from phenotypes to systems medicine (2011) Allergy, 66, pp. 596-604; Antójm, Pinart, M., Akdis, M., Auffray, C., Bachert, C., Basagaña, X., Carlsen, K.H., Illi, S., Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: A Mechanisms of the Development of Allergy (MeDALL) seminar (2012) J Allergy Clin Immunol, 129, pp. 943-954. , WHO Collaborating Centre on Asthma and Rhinitis (Montpellier), e4; Pinart, M., Benet, M., Annesi-Maesano, I., Von Berg, A., Berdel, D., Carlsen, K.C., Carlsen, K.H., Fantini, M.P., Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: A population-based cohort study (2014) Lancet Respir Med, 2, pp. 131-140; Moore, W.C., Hastie, A.T., Li, X., Li, H., Busse, W.W., Jarjour, N.N., Wenzel, S.E., Bleecker, E.R., Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis (2014) J Allergy Clin Immunol, 133, pp. 1557-1563. , National Heart, Lung, and Blood Institute's Severe Asthma Research Program, e5; Turan, N., Kalko, S., Stincone, A., Clarke, K., Sabah, A., Howlett, K., Curnow, S.J., O'Neill, L., A systems biology approach identifies molecular networks defining skeletal muscle abnormalities in chronic obstructive pulmonary disease (2011) PLOS Comput Biol, 7; Bousquet, J., Addis, A., Adcock, I., Agache, I., Agusti, A., Alonso, A., Annesi- Maesano, I., Baena-Cagnani, C.E., Integrated care pathways for airway diseases (AIRWAYS-ICPs) (2014) Eur Respir J, 44, pp. 304-323. , European Innovation Partnership on Active and Healthy Ageing Action Plan B3; Mechanisms of the Development of Allergy WP 10; Global Alliance against Chronic Respiratory Diseases; Bousquet, J., Anto, J.M., Sterk, P.J., Adcock, I.M., Chung, K.F., Roca, J., Agusti, A., Cesario, A., Systems medicine and integrated care to combat chronic noncommunicable diseases (2011) Genome Med, 3, pp. 43-55; Evidence-based medicine: A new approach to teaching the practice of medicine (1992) JAMA, 268, pp. 2420-2425; Puhan, M.A., Singh, S., Weiss, C.O., Varadhan, R., Boyd, C.M., A framework for organizing and selecting quantitative approaches for benefit-harm assessment (2012) BMC Med Res Methodol, 12, pp. 173-185; Chong, J., Poole, P., Leung, B., Black, P.N., Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (2011) Cochrane Database Syst Rev, (5); Gail, M.H., Costantino, J.P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., Vogel, V., Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer (1999) J Natl Cancer Inst, 91, pp. 1829-1846; Gibert, K., García-Alonso, C., Salvador-Carulla, L., Integrating clinicians, knowledge and data: Expert-based cooperative analysis in healthcare decision support (2010) Health Res Policy Syst, 8, pp. 28-46; Yu, T., Fain, K., Boyd, C.M., Singh, S., Weiss, C.O., Li, T., Varadhan, R., Puhan, M.A., Benefits and harms of roflumilast in moderate to severe COPD (2014) Thorax, 69, pp. 616-622; Pharmacoepidemiological Research on Outcomes of Therapeutics by A European Consortium, , http://www.imi-protect.eu/benefit-risk, [accessed 2014 Jun 12]; Porter, M.E., A strategy for health care reform: Toward a value-based system (2009) N Engl J Med, 361, pp. 109-112; Henshall, C., Schuller, T., Health technology assessment, value-based decision making, and innovation (2013) Int J Technol Assess Health Care, 29, pp. 353-359. , HTAi Policy Forum; Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osińska, B., Herholz, H., Wendykowska, K., Laius, O., Zara, C., Risk sharing arrangements for pharmaceuticals: Potential considerations and recommendations for European payers (2010) BMC Health Serv Res, 10, pp. 153-169; Wennberg, J., Gittelsohn, A., Small area variations in health care delivery (1973) Science, 182, pp. 1102-1108; Garber, A.M., Tunis, S.R., Does comparative-effectiveness research threaten personalized medicine? (2009) N Engl J Med, 360, pp. 1925-1927; Cook, D., Thompson, J.E., Habermann, E.B., Visscher, S.L., Dearani, J.A., Roger, V.L., Borah, B.J., From 'solution shop' model to 'focused factory' in hospital surgery: Increasing care value and predictability (2014) Health Aff (Millwood), 33, pp. 746-755; Porter, M.E., Pabo, E.A., Lee, T.H., Redesigning primary care: A strategic vision to improve value by organizing around patients' needs (2013) Health Aff (Millwood), 32, pp. 516-525; Rabe, K.F., Ward, B., Uncovering and tackling Europe's hidden respiratory illness (2012) Lancet, 380, pp. 623-624; Barnett, K., Mercer, S.W., Norbury, M., Watt, G., Wyke, S., Guthrie, B., Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study (2012) Lancet, 380, pp. 37-43; Agusti, A., Macnee, W., The COPD control panel: Towards personalised medicine in COPD (2013) Thorax, 68, pp. 687-690; Auffray, C., Hood, L., Editorial: Systems biology and personalized medicine - The future is now (2012) Biotechnol J, 7, pp. 938-939; Galas, D.J., Hood, L., Systems biology and emerging technologies will catalyze the transition from reactive medicine to predictive personalized preventive and participatory (P4) medicine (2009) IBC, 1, pp. 1-4; Chen, R., Mias, G.I., Li-Pook-Than, J., Jiang, L., Lam, H.Y., Chen, R., Miriami, E., Dewey, F.E., Personal omics profiling reveals dynamic molecular and medical phenotypes (2012) Cell, 148, pp. 1293-1307; Mirnezami, R., Nicholson, J., Darzi, A., Preparing for precision medicine (2012) N Engl J Med, 366, pp. 489-491; Cowley, A.W., Jr., The elusive field of systems biology (2004) Physiol Genomics, 16, pp. 285-286; Di Ventura, B., Lemerle, C., Michalodimitrakis, K., Serrano, L., From in vivo to in silico biology and back (2006) Nature, 443, pp. 527-533; Winslow, R.L., Trayanova, N., Geman, D., Miller, M.I., Computational medicine: Translating models to clinical care (2012) Sci Transl Med, 4, p. 158rv11; Auffray, C., Chen, Z., Hood, L., Systems medicine: The future of medical genomics and healthcare (2009) Genome Med, 1, p. 2; Auffray, C., Adcock, I.M., Chung, K.F., Djukanovic, R., Pison, C., Sterk, P.J., An integrative systems biology approach to understanding pulmonary diseases (2010) Chest, 137, pp. 1410-1416; McShane, L.M., Cavenagh, M.M., Lively, T.G., Eberhard, D.A., Bigbeewlwilliams Pmmesirov, J.P., Polleymy Kim, K.Y., Tricoli, J.V., Criteria for the use of omics-based predictors in clinical trials (2013) Nature, 502, pp. 317-320; McShane, L.M., Cavenagh, M.M., Lively, T.G., Eberhard, D.A., Bigbee, W.L., Williams, P.M., Mesirov, J.P., Tricoli, J.V., Criteria for the use of omics-based predictors in clinical trials: Explanation and elaboration (2013) BMC Med, 11, pp. 220-242; Szalma, S., Koka, V., Khasanova, T., Perakslis, E.D., Effective knowledge management in translational medicine (2010) J Transl Med, 8, pp. 68-77; Celli, B.R., Cote, C.G., Marin, J.M., Casanova, C., Montes De Oca, M., Mendez, R.A., Pinto Plata, V., Cabral, H.J., The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease (2004) N Engl J Med, 350, pp. 1005-1012; Puhan, M.A., Garcia-Aymerich, J., Frey, M., Ter Riet, G., Antó, J.M., Agustí, A.G., Gómez, F.P., Kessels, A.G., Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: The updated BODE index and the ADO index (2009) Lancet, 374, pp. 704-711; Agustí, A., Edwards, L.D., Rennard, S.I., Macnee, W., Tal-Singer, R., Miller, B.E., Vestbo, J., Wouters, E., Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype (2012) PLoS ONE, 7; Thomsen, M., Ingebrigtsen, T.S., Marott, J.L., Dahl, M., Lange, P., Vestbo, J., Nordestgaard, B.G., Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease (2013) JAMA, 309, pp. 2353-2361; Gray, J.A., The shift to personalised and population medicine (2013) Lancet, 382, pp. 200-201; Epstein, R., Teagarden, J.R., Comparative effectiveness and personalized medicine: Evolving together or apart? (2010) Health Aff (Millwood), 29, pp. 1783-1787; Hussey, P.S., Wertheimer, S., Mehrotra, A., The association between health care quality and cost: A systematic review (2013) Ann Intern Med, 158, pp. 27-34; Butcher, E.C., Berg, E.L., Kunkel, E.J., Systems biology in drug discovery (2004) Nat Biotechnol, 22, pp. 1253-1259","Agustí, A.; Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University Barcelona, Villarroel 170, Spain; email: alvar.agusti@clinic.ub.es",,,"American Thoracic Society",,,,,1073449X,,AJCME,"25531178","English","Am. J. Respir. Crit. Care Med.",Review,"Final",,Scopus,2-s2.0-84922895251
"Carrió P., López O., Sanz F., Pastor M.","55227590800;56556019000;7102263897;7102415847;","ETOXlab, an open source modeling framework for implementing predictive models in production environments",2015,"Journal of Cheminformatics","7","1", 8,"","",,12,"10.1186/s13321-015-0058-6","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924953945&doi=10.1186%2fs13321-015-0058-6&partnerID=40&md5=e43e0b2147f01d295d3a71f170993336","Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM, Dr. Aiguader 88, Barcelona, E-08003, Spain","Carrió, P., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM, Dr. Aiguader 88, Barcelona, E-08003, Spain; López, O., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM, Dr. Aiguader 88, Barcelona, E-08003, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM, Dr. Aiguader 88, Barcelona, E-08003, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM, Dr. Aiguader 88, Barcelona, E-08003, Spain","Background: Computational models based in Quantitative-Structure Activity Relationship (QSAR) methodologies are widely used tools for predicting the biological properties of new compounds. In many instances, such models are used as a routine in the industry (e.g. food, cosmetic or pharmaceutical industry) for the early assessment of the biological properties of new compounds. However, most of the tools currently available for developing QSAR models are not well suited for supporting the whole QSAR model life cycle in production environments. Results: We have developed eTOXlab; an open source modeling framework designed to be used at the core of a self-contained virtual machine that can be easily deployed in production environments, providing predictions as web services. eTOXlab consists on a collection of object-oriented Python modules with methods mapping common tasks of standard modeling workflows. This framework allows building and validating QSAR models as well as predicting the properties of new compounds using either a command line interface or a graphic user interface (GUI). Simple models can be easily generated by setting a few parameters, while more complex models can be implemented by overriding pieces of the original source code. eTOXlab benefits from the object-oriented capabilities of Python for providing high flexibility: any model implemented using eTOXlab inherits the features implemented in the parent model, like common tools and services or the automatic exposure of the models as prediction web services. The particular eTOXlab architecture as a self-contained, portable prediction engine allows building models with confidential information within corporate facilities, which can be safely exported and used for prediction without disclosing the structures of the training series. Conclusions: The software presented here provides full support to the specific needs of users that want to develop, use and maintain predictive models in corporate environments. The technologies used by eTOXlab (web services, VM, object-oriented programming) provide an elegant solution to common practical issues; the system can be installed easily in heterogeneous environments and integrates well with other software. Moreover, the system provides a simple and safe solution for building models with confidential structures that can be shared without disclosing sensitive information. © 2015 Carrió et al.; licensee Springer.","Confidential compounds; Modeling; Open source; Predictive models; QSAR; Web services",,,,,,,,,,"Tropsha, A., Best practices for QSAR model development, validation, and exploitation (2010) Mol Inform, 29, pp. 476-488. , 1:CAS:528:DC%2BC3cXpslWktrw%3D; Warr, W.A., Scientific workflow systems: Pipeline Pilot and KNIME (2012) J Comput Aided Mol des, 26, pp. 801-804. , 1:CAS:528:DC%2BC38XhtFGltbzM; Stålring, J.C., Carlsson, L.A., Almeida, P., Boyer, S., AZOrange - High performance open source machine learning for QSAR modeling in a graphical programming environment (2011) J Cheminform, 3, p. 28; Cox, R., Green, D.V.S., Luscombe, C.N., Malcolm, N., Pickett, S.D., QSAR workbench: Automating QSAR modeling to drive compound design (2013) J Comput Aided Mol des, 27, pp. 321-336. , 1:CAS:528:DC%2BC3sXnvVWmsL4%3D; Sushko, I., Novotarskyi, S., Körner, R., Pandey, A., Rupp, M., Teetz, W., Online chemical modeling environment (OCHEM): Web platform for data storage, model development and publishing of chemical information (2011) J Comput Aided Mol des, 25, pp. 533-554. , 1:CAS:528:DC%2BC3MXosFCgsrg%3D; Hardy, B., Douglas, N., Helma, C., Rautenberg, M., Jeliazkova, N., Jeliazkov, V., Collaborative development of predictive toxicology applications (2010) J Cheminform, 2, p. 7; Demšar, J., Curk, T., Erjavec, A., Gorup, C., Hočevar, T., Milutinovič, M., Orange: Data mining toolbox in Python (2013) J Mach Learn Res, 14, pp. 2349-2353; Hall, M., Frank, E., Holmes, G., The WEKA data mining software: An update (2009) ACM SIGKDD, 11, pp. 10-18; Berthold, M., Cebron, N., Dill, F., Gabriel, T., Kötter, T., Meinl, T., KNIME: The Konstanz Information Miner (2008) Data Analysis, Machine Learning and Applications SE-38, pp. 319-326. , C. Preisach H. Burkhardt L. Schmidt-Thieme R. Decker (eds) Springer Berlin Heidelberg 10.1007/978-3-540-78246-9-38 [Studies in Classification, Data Analysis, and Knowledge Organization]; http://accelrys.com/products/pipeline-pilot/, Pipeline Pilot; Briggs, K., Cases, M., Heard, D.J., Pastor, M., Pognan, F., Sanz, F., Inroads to predict in vivo toxicology-an introduction to the eTOX Project (2012) Int J Mol Sci, 13, pp. 3820-3846. , 1:CAS:528:DC%2BC38XlsVagtbc%3D; Frey, J., Bird, C., Web-based services for drug design and discovery (2011) Expert Opin Drug Discov, 6, pp. 885-895; Prospect, P., ChemSpider: An online chemical information resource (2010) J Chem Educ, 87, pp. 10-11; Williams, A.J., Harland, L., Groth, P., Pettifer, S., Chichester, C., Willighagen, E.L., Open PHACTS: Semantic interoperability for drug discovery (2012) Drug Discov Today, 17, pp. 1188-1198; RDKit: Open-source Cheminformatics, , http://www.rdkit.org; Yap, C., Software News and Update PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints (2010) J Comput Chem, 32, pp. 1466-1474; Standardiser, , https://github.com/flatkinson/standardiser; (2013) R: A Language and Environment for Statistical Computing, , R Core Team; Carrió, P., Pinto, M., Ecker, G., Sanz, F., Pastor, M., Applicability Domain Analysis (ADAN): A robust method for assessing the reliability of drug property predictions (2014) J Chem Inf Model, 54, pp. 1500-1511; Milletti, F., Storchi, L., Sforna, G., Cross, S., Cruciani, G., Tautomer enumeration and stability prediction for virtual screening on large chemical databases (2009) J Chem Inf Model, 49, pp. 68-75. , 1:CAS:528:DC%2BD1MXisVahug%3D%3D; Milletti, F., Storchi, L., Sforna, G., Cruciani, G., New and original pKa prediction method using grid molecular interaction fields (2007) J Chem Inf Model, 47, pp. 2172-2181. , 1:CAS:528:DC%2BD2sXhtFSnsLrF; Sadowski, J., Gasteiger, J., Klebe, G., Comparison of automatic three-dimensional model builders using 639 X-ray structures (1994) J Chem Inf Comput Sci, 34, pp. 1000-1008. , 1:CAS:528:DyaK2cXkvVajsbY%3D; Sadowski, J., Gasteiger, J., From atoms and bonds to three-dimensional atomic coordinates: Automatic model builders (1993) Chem Rev, 93, pp. 2567-2581. , 1:CAS:528:DyaK3sXmt1GgsLs%3D; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors (2000) J Med Chem, 43, pp. 3233-3243. , 1:CAS:528:DC%2BD3cXltlOrur8%3D; Pastor, M., Alignment-independent Descriptors from Molecular Interaction Fields (2006) Molecular Interaction Fields. Applications in Drug Discovery and ADME Predictions, pp. 117-141. , G. Cruciani (eds) Wiley-VCH Weinheim 10.1002/3527607676.ch6; http://www.mol-net.com, ADRIANA.Code; Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Valigi, R., Clementi, S., Generating Optimal Linear PLS Estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems (1993) Quant Struct Relationships, 12, pp. 9-20. , 1:CAS:528:DyaK3sXkvVGntrs%3D; Masek, B.B., Shen, L., Smith, K.M., Pearlman, R.S., Sharing chemical information without sharing chemical structure (2008) Society, 48, pp. 256-261. , 1:CAS:528:DC%2BD1cXhsFGktr8%3D; Filimonov, D., Poroikov, V., Why relevant chemical information cannot be exchanged without disclosing structures (2005) J Comput Aided Mol des, 19, pp. 705-713. , 1:CAS:528:DC%2BD28XhslWnsL8%3D; Tetko, I.V., Abagyan, R., Oprea, T.I., Surrogate data-A secure way to share corporate data (2005) J Comput Aided Mol des, 19, pp. 749-764. , 1:CAS:528:DC%2BD28XhslWnsLs%3D; Aqvist, J., Medina, C., Samuelsson, J.E., A new method for predicting binding affinity in computer-aided drug design (1994) Protein Eng, 7, pp. 385-391. , 1:STN:280:DyaK2c3jtlSnsw%3D%3D","Pastor, M.; Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM, Dr. Aiguader 88, Spain",,,"BioMed Central Ltd.",,,,,17582946,,,,"English","J. Cheminformatics",Article,"Final",Open Access,Scopus,2-s2.0-84924953945
"Piñero J., Queralt-Rosinach N., Bravo À., Deu-Pons J., Bauer-Mehren A., Baron M., Sanz F., Furlong L.I.","55220852900;35766634600;56374942700;35603037000;35572639000;56888360600;7102263897;34770469800;","DisGeNET: A discovery platform for the dynamical exploration of human diseases and their genes",2015,"Database","2015",, bav028,"","",,279,"10.1093/database/bav028","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939221315&doi=10.1093%2fdatabase%2fbav028&partnerID=40&md5=39b720c14bd0a409783b60511a55878d","Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr Aiguader 88, Barcelona, E-08003, Spain; Roche Pharma Research and Early Development, PRED Informatics, Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, 82377, Germany; Scientific and Business Information Services, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, 82377, Germany","Piñero, J., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr Aiguader 88, Barcelona, E-08003, Spain; Queralt-Rosinach, N., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr Aiguader 88, Barcelona, E-08003, Spain; Bravo, À., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr Aiguader 88, Barcelona, E-08003, Spain; Deu-Pons, J., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr Aiguader 88, Barcelona, E-08003, Spain; Bauer-Mehren, A., Roche Pharma Research and Early Development, PRED Informatics, Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, 82377, Germany; Baron, M., Scientific and Business Information Services, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg, 82377, Germany; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr Aiguader 88, Barcelona, E-08003, Spain; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr Aiguader 88, Barcelona, E-08003, Spain","DisGeNET is a comprehensive discovery platform designed to address a variety of questions concerning the genetic underpinning of human diseases. DisGeNET contains over 380 000 associations between >16 000 genes and 13 000 diseases, which makes it one of the largest repositories currently available of its kind. DisGeNET integrates expert-curated databases with text-mined data, covers information on Mendelian and complex diseases, and includes data from animal disease models. It features a score based on the supporting evidence to prioritize gene-disease associations. It is an open access resource available through a web interface, a Cytoscape plugin and as a Semantic Web resource. The web interface supports user-friendly data exploration and navigation. DisGeNET data can also be analysed via the DisGeNET Cytoscape plugin, and enriched with the annotations of other plugins of this popular network analysis software suite. Finally, the information contained in DisGeNET can be expanded and complemented using Semantic Web technologies and linked to a variety of resources already present in the Linked Data cloud. Hence, DisGeNET offers one of the most comprehensive collections of human gene-disease associations and a valuable set of tools for investigating the molecular mechanisms underlying diseases of genetic origin, designed to fulfill the needs of different user profiles, including bioinformaticians, biologists and health-care practitioners. © The Author(s) 2015. Published by Oxford University Press.",,"animal; cloud computing; computer interface; disease model; gene regulatory network; genetic database; genetic disorder; genetics; human; human genome; Internet; Animals; Cloud Computing; Databases, Genetic; Disease Models, Animal; Gene Regulatory Networks; Genetic Diseases, Inborn; Genome, Human; Humans; Internet; User-Computer Interface",,,,,,,,,"Altman, R.B., Introduction to translational bioinformatics collection (2012) PLoS Comput. Biol, 8, p. e1002796; Sarkar, I.N., Butte, A.J., Lussier, Y.A., Translational bioinformatics: Linking knowledge across biological and clinical realms (2011) J. Am. Med. Inform. Assoc, 18, pp. 354-357; Topol, E.J., Individualized medicine from Prewomb to Tomb (2014) Cell, 157, pp. 241-253; Rappaport, N., Nativ, N., Stelzer, G., (2013) MalaCards: An Integrated Compendium for Diseases and Their Annotation, , Database (Oxford)., 2013, bat018; Lopes, P., Oliveira, J.L., An innovative portal for rare genetic diseases research: The semantic Diseasecard (2013) J. Biomed. Inform, 46, pp. 1108-1115; Amberger, J., Bocchini, C.A., Scott, A.F., McKusick's online mendelian inheritance in man (OMIM) (2009) Nucleic Acids Res, 37, pp. D793-D796; Davis, A.P., Murphy, C.G., Johnson, R., The comparative toxicogenomics database: Update 2013 (2013) Nucleic Acids Res, 41, pp. D1104-D1114; Becker, K.G., Barnes, K.C., Bright, T.J., The genetic association database (2004) Nat. Genet, 36, pp. 431-432; Mailman, M.D., Feolo, M., Jin, Y., The NCBI dbGaP database of genotypes and phenotypes (2007) Nat. Genet, 39, pp. 1181-1186; Tryka, K.A., Hao, L., Sturcke, A., NCBI's database of genotypes and phenotypes: DbGaP (2014) Nucleic Acids Res, 42, pp. D975-D979; Welter, D., MacArthur, J., Morales, J., The NHGRI GWAS Catalog, a curated resource of SNP-trait associations (2014) Nucleic Acids Res, 42, pp. D1001-D1006; Bauer-Mehren, A., Rautschka, M., Sanz, F., DisGeNET: A Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks (2010) Bioinformatics, 26, pp. 2924-2926; Bauer-Mehren, A., Bundschus, M., Rautschka, M., Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases (2011) PLoSOne, 6, p. e20284; Bravo, A., Pinero, J., Queralt, N., Extraction of relations between genes and diseases from text and large-scale data analysis: Implications for translational research. Cold Spring Harbor Labs Journals, 007443 (2015) BMC Bioinformatics, 16, p. 55; Chen, H., Yu, T., Chen, J.Y., Semantic web meets integrative biology: A survey (2013) Brief. Bioinform, 14, pp. 109-125; Almeida, J.S., Dress, A., Kühne, T., ICT for Bridging biology and medicine (Dagstuhl Perspectives Workshop 13342) (2014) Dagstuhl Manifestos, 3, p. 50; Activities at the universal protein resource (UniProt) (2014) Nucleic Acids Res, 42, pp. D191-D198; Laulederkind, S.J.F., Hayman, G.T., Wang, S.-J., The Rat Genome Database 2013-data, tools and users (2013) Brief. Bioinform, 14, pp. 520-526; Blake, J.A., Bult, C.J., Eppig, J.T., The Mouse Genome Database: Integration of and access to knowledge about the laboratory mouse (2014) Nucleic Acids Res, 42, pp. D810-D817; Mitchell, J.A., Aronson, A.R., Mork, J.G., Gene indexing: Characterization and analysis of NLM's GeneRIFs (2003) AMIA Annu. Symp. Proc., pp. 460-464; Bundschus, M., Dejori, M., Stetter, M., Extraction of semantic biomedical relations from text using conditional random fields (2008) BMC Bioinformatics, 9, p. 207; Mi, H., Dong, Q., Muruganujan, A., PANTHER version 7: Improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium (2010) Nucleic Acids Res, 38, pp. D204-D210; Thomas, P.D., PANTHER: A browsable database of gene products organized by biological function, using curated protein family and subfamily classification (2003) Nucleic Acids Res, 31, pp. 334-341; Croft, D., Mundo, A.F., Haw, R., The Reactome pathway knowledgebase (2014) Nucleic Acids Res, 42, pp. D472-D477; Ezkurdia, I., Juan, D., Rodriguez, J.M., Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes (2014) Hum. Mol. Genet, 23, pp. 5866-5878; Schriml, L.M., Arze, C., Nadendla, S., Disease ontology: A backbone for disease semantic integration (2012) Nucleic Acids Res, 40, pp. D940-D946; Köhler, S., Doelken, S.C., Mungall, C.J., The human phenotype ontology project: Linking molecular biology and disease through phenotype data (2014) Nucleic Acids Res, 42, pp. D966-D974; Wilson, S.A.K., Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver (1912) Brain, 34, pp. 295-507; Tanzi, R.E., Petrukhin, K., Chernov, I., The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene (1993) Nat. Genet, 5, pp. 344-350; Terada, K., Sugiyama, T., The Long-Evans Cinnamon rat: An animal model for Wilson's disease (1999) Pediatr. Int, 41, pp. 414-418; Lutsenko, S., Atp7b-/- mice as a model for studies of Wilson's disease (2008) Biochem. Soc. Trans, 36, pp. 1233-1238; Grosdidier, S., Ferrer, A., Faner, R., Network medicine analysis of COPD multimorbidities (2014) Respir. Res, 15, p. 111; Gray, A.J.G., Groth, P., Loizou, A., Applying linked data approaches to pharmacology: Architectural decisions and implementation (2014) Semant.Web, 5, pp. 101-113; Berger, J., Moller, D.E., The mechanisms of action of PPARs (2002) Annu. Rev. Med, 53, pp. 409-435; Cauchi, S., Nead, K.T., Choquet, H., The genetic susceptibility to type 2 diabetes may be modulated by obesity status: Implications for association studies (2008) BMC Med. Genet, 9, p. 45; Ben Ali, S., Ben Yahia, F., Sediri, Y., Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population (2009) Clin. Biochem, 42, pp. 1642-1647; Gallicchio, L., Chang, H.H., Christo, D.K., Single nucleotide polymorphisms in obesity-related genes and all-cause and cause-specific mortality: A prospective cohort study (2009) BMC Med. Genet, 10, p. 103; Prakash, J., Srivastava, N., Awasthi, S., Association of PPARc gene polymorphisms with obesity and obesity-associated phenotypes in North Indian population Am. J. Hum. Biol, 24, pp. 454-459; Francis, G.A., Li, G., Casey, R., Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3) (2006) BMC Med. Genet, 7, p. 3; Jeninga, E.H., Van Beekum, O., Van Dijk, A.D.J., Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy (2007) Mol. Endocrinol, 21, pp. 1049-1065; Wolford, J.K., Yeatts, K.A., Dhanjal, S.K., Sequence variation in PPARG may underlie differential response to troglitazone (2005) Diabetes, 54, pp. 3319-3325; Andrulionytè, L., Zacharova, J., Chiasson, J.-L., Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial (2004) Diabetologia, 47, pp. 2176-2184; Heald, M., Cawthorne, M.A., Dual acting and pan-PPAR activators as potential anti-diabetic therapies (2011) Handb. Exp. Pharmacol., pp. 35-51; Bravo, A., Cases, M., Queralt-Rosinach, N., A knowledge-driven approach to extract disease-related biomarkers from the literature (2014) Biomed Res. Int, 2014, p. 253128; Van Mulligen, E.M., Fourrier-Reglat, A., Gurwitz, D., The EU-ADR corpus: Annotated drugs, diseases, targets, and their relationships (2012) J. Biomed. Inform, 45, pp. 879-884; Thomas, P., Rocktäschel, T., Mayer, Y., Leser, U., (2014) SETH: SNP Extraction Tool for Human Variations, , http://rockt.github.io/SETH/2014; Dumontier, M., Baker, C.J., Baran, J., The Semanticscience Integrated Ontology (SIO) for biomedical research and knowledge discovery (2014) J. Biomed. Semantics, 5, p. 14; Belleau, F., Nolin, M.-A., Tourigny, N., Bio2RDF: Towards a mashup to build bioinformatics knowledge systems (2008) J. Biomed. Inform, 41, pp. 706-716; Momtchev, V., Peychev, D., Primov, T., Georgiev, G., Expanding the pathway and interaction knowledge in linked life data (2009) Proc. of International SemanticWeb Challenge","Furlong, L.I.; Research Programme on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr Aiguader 88, Spain",,,"Oxford University Press",,,,,17580463,,,"25877637","English","Database",Article,"Final",Open Access,Scopus,2-s2.0-84939221315
"Martí-Solano M., Iglesias A., De Fabritiis G., Sanz F., Brea J., Loza M.I., Pastor M., Selent J.","55090002400;56657189800;22134417700;7102263897;6603008588;7003766926;7102415847;55891371700;","Detection of new biased agonists for the serotonin 5-ht2a receptor: modeling and experimental validation",2015,"Molecular Pharmacology","87","4",,"740","746",,12,"10.1124/mol.114.097022","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929938672&doi=10.1124%2fmol.114.097022&partnerID=40&md5=2be3fb224873fe1bde101ec0c3d8605b","Department of Experimental and Health Sciences, Research Programme on Biomedical Informatics, Pompeu Fabra University, Barcelona, Spain; Department of Pharmacology, Institute of Industrial Pharmacy, Santiago de Compostela University, Santiago de Compostela, Spain","Martí-Solano, M., Department of Experimental and Health Sciences, Research Programme on Biomedical Informatics, Pompeu Fabra University, Barcelona, Spain; Iglesias, A., Department of Pharmacology, Institute of Industrial Pharmacy, Santiago de Compostela University, Santiago de Compostela, Spain; De Fabritiis, G., Department of Experimental and Health Sciences, Research Programme on Biomedical Informatics, Pompeu Fabra University, Barcelona, Spain; Sanz, F., Department of Experimental and Health Sciences, Research Programme on Biomedical Informatics, Pompeu Fabra University, Barcelona, Spain; Brea, J., Department of Pharmacology, Institute of Industrial Pharmacy, Santiago de Compostela University, Santiago de Compostela, Spain; Loza, M.I., Department of Pharmacology, Institute of Industrial Pharmacy, Santiago de Compostela University, Santiago de Compostela, Spain; Pastor, M., Department of Experimental and Health Sciences, Research Programme on Biomedical Informatics, Pompeu Fabra University, Barcelona, Spain; Selent, J., Department of Experimental and Health Sciences, Research Programme on Biomedical Informatics, Pompeu Fabra University, Barcelona, Spain","Detection of biased agonists for the serotonin 5-HT2A receptor can guide the discovery of safer and more efficient antipsychotic drugs. However, the rational design of such drugs has been hampered by the difficulty detecting the impact of small structural changes on signaling bias. To overcome these difficulties, we characterized the dynamics of ligand-receptor interactions of known biased and balanced agonists using molecular dynamics simulations. Our analysis revealed that interactions with residues S5.46 and N6.55 discriminate compounds with different functional selectivity. Based on our computational predictions, we selected three derivatives of the natural balanced ligand serotonin and experimentally validated their ability to act as biased agonists. Remarkably, our approach yielded compounds promoting an unprecedented level of signaling bias at the 5-HT2A receptor, which could help interrogate the importance of particular pathways in conditions like schizophrenia. © 2015 by The American Society for Pharmacology and Experimental Therapeutics.",,"neuroleptic agent; serotonin; serotonin 2A agonist; neuroleptic agent; serotonin; serotonin 2 agonist; serotonin 2A receptor; animal cell; Article; binding affinity; conformational transition; controlled study; drug design; drug determination; drug receptor binding; drug selectivity; EC50; female; hydrogen bond; ligand binding; lipid bilayer; molecular dynamics; nonhuman; priority journal; protein conformation; signal transduction; waste; analogs and derivatives; animal; binding competition; chemistry; CHO cell line; Cricetulus; drug design; human; metabolism; molecular docking; Animals; Antipsychotic Agents; Binding, Competitive; CHO Cells; Cricetulus; Drug Design; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Agonists",,"serotonin, 50-67-9; Antipsychotic Agents; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Agonists",,,,,,,"Ballesteros, J., Weinstein, H., Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein coupled receptor (1995) Methods Neurosci, 25, pp. 366-428; Berg, K.A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., Clarke, W.P., Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus (1998) Mol Pharmacol, 54, pp. 94-104; Berg, K.A., Stout, B.D., Cropper, J.D., Maayani, S., Clarke, W.P., Novel actions of inverse agonists on 5-HT2C receptor systems (1999) Mol Pharmacol, 55, pp. 863-872; Braden, M.R., Nichols, D.E., Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor (2007) Mol Pharmacol, 72, pp. 1200-1209; Case, D.A., (2012) AMBER 12, , University of California, San Francisco, CA; Dror, R.O., Arlow, D.H., Maragakis, P., Mildorf, T.J., Pan, A.C., Xu, H., Borhani, D.W., Shaw, D.E., Activation mechanism of the b2- Adrenergic receptor (2011) Proc Natl Acad Sci USA, 108, pp. 18684-18689; Ebersole, B.J., Visiers, I., Weinstein, H., Sealfon, S.C., Molecular basis of partial agonism: Orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy (2003) Mol Pharmacol, 63, pp. 36-43; Fowler, J.C., Bhattacharya, S., Urban, J.D., Vaidehi, N., Mailman, R.B., Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations (2012) Mol Pharmacol, 81, pp. 820-831; González-Maeso, J., Sealfon, S.C., Psychedelics and schizophrenia (2009) Trends Neurosci, 32, pp. 225-232; González-Maeso, J., Weisstaub, N.V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Zhou, Q., Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior (2007) Neuron, 53, pp. 439-452; Harvey, M.J., De Fabritiis, G., An implementation of the smooth particle mesh Ewald method on GPU hardware (2009) J Chem Theory Comput, 5, pp. 2371-2377; Humphrey, W., Dalke, A., Schulten, K., VMD: Visual molecular dynamics (1996) J Mol Graph, 14 (33-38), pp. 27-28; Jo, S., Lim, J.B., Klauda, J.B., Im, W., CHARMM-GUI Membrane Builder for mixed bilayers and its application to yeast membranes (2009) Biophys J, 97, pp. 50-58; Kurita, M., Holloway, T., García-Bea, A., Kozlenkov, A., Friedman, A.K., Moreno, J.L., Heshmati, M., Takahashi, N., HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity (2012) Nat Neurosci, 15, pp. 1245-1254; Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., PROCHECK: A program to check the stereochemical quality of protein structures (1993) J Appl Cryst, 26, pp. 283-291; Latek, D., Pasznik, P., Carlomagno, T., Filipek, S., Towards improved quality of GPCR models by usage of multiple templates and profile-profile comparison (2013) PLoS ONE, 8, p. e56742; Li, H., Robertson, A.D., Jensen, J.H., Very fast empirical prediction and rationalization of protein pKa values (2005) Proteins, 61, pp. 704-721; Martí-Solano, M., Guixà-González, R., Sanz, F., Pastor, M., Selent, J., Novel insights into biased agonism at G protein-coupled receptors and their potential for drug design (2013) Curr Pharm des, 19, pp. 5156-5166; Meltzer, H.Y., The role of serotonin in antipsychotic drug action (1999) Neuropsychopharmacology, 21 (2), pp. 106S-115S; Milletti, F., Vulpetti, A., Tautomer preference in PDB complexes and its impact on structure-based drug discovery (2010) J Chem Inf Model, 50, pp. 1062-1074; Moya, P.R., Berg, K.A., Gutiérrez-Hernandez, M.A., Sáez-Briones, P., Reyes-Parada, M., Cassels, B.K., Clarke, W.P., Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors (2007) J Pharmacol Exp Ther, 321, pp. 1054-1061; Nichols, D.E., Hallucinogens (2004) Pharmacol Ther, 101, pp. 131-181; Nygaard, R., Zou, Y., Dror, R.O., Mildorf, T.J., Arlow, D.H., Manglik, A., Pan, A.C., Bokoch, M.P., The dynamic process of b(2)- Adrenergic receptor activation (2013) Cell, 152, pp. 532-542; Obiol-Pardo, C., López, L., Pastor, M., Selent, J., Progress in the structural prediction of G protein-coupled receptors: D3 receptor in complex with eticlopride (2011) Proteins, 79, pp. 1695-1703; Park, P.S.H., Ensemble of G protein-coupled receptor active states (2012) Curr Med Chem, 19, pp. 1146-1154; Rajagopal, S., Ahn, S., Rominger, D.H., Gowen-MacDonald, W., Lam, C.M., Dewire, S.M., Violin, J.D., Lefkowitz, R.J., Quantifying ligand bias at seventransmembrane receptors (2011) Mol Pharmacol, 80, pp. 367-377; Rasmussen, S.G., Choi, H.J., Fung, J.J., Pardon, E., Casarosa, P., Chae, P.S., Devree, B.T., Kobilka, T.S., Structure of a nanobodystabilized active state of the b(2) adrenoceptor (2011) Nature, 469, pp. 175-180; Thanawala, V.J., Forkuo, G.S., Stallaert, W., Leff, P., Bouvier, M., Bond, R., Ligand bias prevents class equality among beta-blockers (2014) Curr Opin Pharmacol, 16, pp. 50-57; Tschammer, N., Bollinger, S., Kenakin, T., Gmeiner, P., Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor (2011) Mol Pharmacol, 79, pp. 575-585; Urban, J.D., Clarke, W.P., Von Zastrow, M., Nichols, D.E., Kobilka, B., Weinstein, H., Javitch, J.A., Sexton, P.M., Functional selectivity and classical concepts of quantitative pharmacology (2007) J Pharmacol Exp Ther, 320, pp. 1-13; Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., Improved protein-ligand docking using GOLD (2003) Proteins, 52, pp. 609-623; Wacker, D., Wang, C., Katritch, V., Han, G.W., Huang, X.P., Vardy, E., McCorvy, J.D., Siu, F.Y., Structural features for functional selectivity at serotonin receptors (2013) Science, 340, pp. 615-619; Whalen, E.J., Rajagopal, S., Lefkowitz, R.J., Therapeutic potential of b- Arrestin- And G protein-biased agonists (2011) Trends Mol Med, 17, pp. 126-139","Selent, J.; Department of Experimental and Health Sciences, Research Programme on Biomedical Informatics, Pompeu Fabra UniversitySpain; email: jana.selent@upf.edu",,,"American Society for Pharmacology and Experimental Therapy",,,,,0026895X,,MOPMA,"25661038","English","Mol. Pharmacol.",Article,"Final",Open Access,Scopus,2-s2.0-84929938672
"Mayer M.A., Furlong L.I., Torre P., Planas I., Cots F., Izquierdo E., Portabella J., Rovira J., Gutierrez-Sacristan A., Sanz F.","36971031500;34770469800;57209066802;6602265390;6602368727;56727815800;56728540300;56727851200;56728807700;7102263897;","Reuse of EHRs to Support Clinical Research in a Hospital of Reference",2015,"Studies in Health Technology and Informatics","210",,,"224","226",,3,"10.3233/978-1-61499-512-8-224","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937402103&doi=10.3233%2f978-1-61499-512-8-224&partnerID=40&md5=a65f248dc9b4ef3011bdefbdb8b1572c","Research Pogramme on Biomedical Informatics, IMIM - Universitat Pompeu Fabra, Barcelona, Spain; Parc de Salut MAR (PSMAR), Barcelona, Spain","Mayer, M.A., Research Pogramme on Biomedical Informatics, IMIM - Universitat Pompeu Fabra, Barcelona, Spain; Furlong, L.I., Research Pogramme on Biomedical Informatics, IMIM - Universitat Pompeu Fabra, Barcelona, Spain; Torre, P., Parc de Salut MAR (PSMAR), Barcelona, Spain; Planas, I., Parc de Salut MAR (PSMAR), Barcelona, Spain; Cots, F., Parc de Salut MAR (PSMAR), Barcelona, Spain; Izquierdo, E., Parc de Salut MAR (PSMAR), Barcelona, Spain; Portabella, J., Parc de Salut MAR (PSMAR), Barcelona, Spain; Rovira, J.; Gutierrez-Sacristan, A., Research Pogramme on Biomedical Informatics, IMIM - Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Pogramme on Biomedical Informatics, IMIM - Universitat Pompeu Fabra, Barcelona, Spain","Most hospitals have already implemented information systems and Electronic Health Records (EHRs), but the reuse of such data for research is still infrequent. We present a pilot project on the exploitation of clinical information from a Spanish hospital database in the context of the European Medical Information Framework project (EMIF). Specific use cases such as patients with diabetes mellitus type 2, obesity and dementia were assessed, by exploiting EHR data integrated from several separated clinical databases. The possibility to analyse the features of specific groups of patients based on their diagnosis codes can provide new data about relationships between different conditions that can contribute for decision-making, healthcare and research. © 2015 European Federation for Medical Informatics (EFMI).","clinical research; Electronic health records; hospitals; information systems","Decision making; Diagnosis; eHealth; Hospitals; Information systems; Information use; Medical computing; Records management; Clinical database; Clinical information; Diabetes mellitus type 2; Electronic health record; Electronic health record (EHRs); Medical information; Pilot projects; Clinical research; data mining; electronic health record; information retrieval; medical record; medical research; procedures; Spain; statistics and numerical data; utilization; Biomedical Research; Data Mining; Electronic Health Records; Information Storage and Retrieval; Medical Record Linkage; Spain",,,,,,,,,"Coorevits, P., Sundgren, M., Klein, G.O., Bahr, A., Claerhout, B., Daniel, C., Dugas, M., Kalra, D., Electronic health records: New opportunities for clinical research (2013) Journal of Internal Medicine, 274, pp. 547-560; Weng, C., Appelbaum, P., Hripcsak, G., Using EHRs to integrate research with patient care: Promises and challenges (2012) JAMIA, 19, pp. 684-687; Sancho, J.J., Planas, I., Domenech, D., Martín-Baranera, M., Palau, J., Sanz, F., (1998) Stud Health Technol Inform, 56, pp. 35-42; Coloma, P.M., Schuemie, M.J., Trifiró, G., Gini, R., Herings, R., Hippisley-Cox, J., Mazzaglia, G., Consortium, E., Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: The EU-ADR Project (2011) Pharmacoepidem Drug Safe, 20, pp. 1-11; Prokosch, H.U., Ganslandt, T., Reusing the electronic medical record for clinical research (2009) Methods Inf Med, 48, pp. 38-44; Holzer, K., Gall, W., Utilizing IHE-based electronic health record systems for secondary use (2011) Methods Inf Med, 50, pp. 1-7; Jensen, P.B., Jensen, L.J., Brunak, S., Mining electronic health records: Towards better research applications and clinical care (2012) Nature Reviews, 13, pp. 395-405",,"Cornet R.Stoicu-Tivadar L.Cornet R.Parra Calderon C.L.Andersen S.K.Horbst A.Hercigonja-Szekeres M.",,"IOS Press","26th Medical Informatics in Europe Conference, MIE 2015","27 May 2015 through 29 May 2015",,112963,09269630,9781614995111,,"25991136","English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-84937402103
"Faner R., Gutiérrez-Sacristán A., Castro-Acosta A., Grosdidier S., Gan W., Sánchez-Mayor M., Lopez-Campos J.L., Pozo-Rodriguez F., Sanz F., Mannino D., Furlong L.I., Agusti A.","6507910788;56728807700;44761037400;23027796200;7103165545;56891643600;32667948000;6603279847;7102263897;7005919220;34770469800;7101749378;","Molecular and clinical diseasome of comorbidities in exacerbated COPD patients",2015,"European Respiratory Journal","46","4",,"1001","1010",,17,"10.1183/13993003.00763-2015","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943226586&doi=10.1183%2f13993003.00763-2015&partnerID=40&md5=a5a7c2f76b092a5f7a89493904df2bec","Fundació Privada Clinic per A la Recerca Biomèdica, Barcelona, Spain; CIBER Enfermedades Respiratorias (CIBERES), Spain; Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Instituto de Investigación, Hospital 12 de Octubre, Madrid, Spain; Dept of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington, KY, United States; Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocio, Universidad de Sevilla, Sevilla, Spain; Thorax Institute, Hospital Clinic, IDIBAPS, Univ. Barcelona, Villarroel 170, Escala 3, Planta 5, Barcelona, 08036, Spain","Faner, R., Fundació Privada Clinic per A la Recerca Biomèdica, Barcelona, Spain, CIBER Enfermedades Respiratorias (CIBERES), Spain; Gutiérrez-Sacristán, A., Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Castro-Acosta, A., CIBER Enfermedades Respiratorias (CIBERES), Spain, Instituto de Investigación, Hospital 12 de Octubre, Madrid, Spain; Grosdidier, S., Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Gan, W., Dept of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington, KY, United States; Sánchez-Mayor, M., Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Lopez-Campos, J.L., CIBER Enfermedades Respiratorias (CIBERES), Spain, Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocio, Universidad de Sevilla, Sevilla, Spain; Pozo-Rodriguez, F., CIBER Enfermedades Respiratorias (CIBERES), Spain, Instituto de Investigación, Hospital 12 de Octubre, Madrid, Spain; Sanz, F., Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Mannino, D., Dept of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington, KY, United States; Furlong, L.I., Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Agusti, A., Fundació Privada Clinic per A la Recerca Biomèdica, Barcelona, Spain, CIBER Enfermedades Respiratorias (CIBERES), Spain, Thorax Institute, Hospital Clinic, IDIBAPS, Univ. Barcelona, Villarroel 170, Escala 3, Planta 5, Barcelona, 08036, Spain","The frequent occurrence of comorbidities in patients with chronic obstructive pulmonary disease (COPD) suggests that they may share pathobiological processes and/or risk factors. To explore these possibilities we compared the clinical diseasome and the molecular diseasome of 5447 COPD patients hospitalised because of an exacerbation of the disease. The clinical diseasome is a network representation of the relationships between diseases, in which diseases are connected if they co-occur more than expected at random; in the molecular diseasome, diseases are linked if they share associated genes or interaction between proteins. The results showed that about half of the disease pairs identified in the clinical diseasome had a biological counterpart in the molecular diseasome, particularly those related to inflammation and vascular tone regulation. Interestingly, the clinical diseasome of these patients appears independent of age, cumulative smoking exposure or severity of airflow limitation. These results support the existence of shared molecular mechanisms among comorbidities in COPD. Copyright © ERS 2015.",,"adult; age; airflow; blood vessel tone; chronic obstructive lung disease; clinical diseasome; comorbidity; Conference Paper; controlled study; disease association; disease exacerbation; disease severity; female; gene interaction; gene ontology; genetic analysis; genetic association; hospitalization; human; inflammation; major clinical study; male; molecular diseasome; priority journal; smoking; aged; algorithm; complication; computer program; information processing; medical audit; metabolism; middle aged; protein analysis; Pulmonary Disease, Chronic Obstructive; risk factor; Aged; Algorithms; Clinical Audit; Comorbidity; Data Collection; Female; Hospitalization; Humans; Inflammation; Male; Middle Aged; Protein Interaction Mapping; Pulmonary Disease, Chronic Obstructive; Risk Factors; Smoking; Software",,,,,,,,,"Mannino, D.M., Thorn, D., Swensen, A., Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD (2008) Eur Respir J, 32, pp. 962-969; Vestbo, J., Hurd, S.S., Agusti, A.G., Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary (2013) Am J Respir Crit Care Med, 187, pp. 347-365; Vanfleteren, L.E., Spruit, M.A., Groenen, M., Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease (2013) Am J Respir Crit Care Med, 187, pp. 728-735; Decramer, M., Janssens, W., Chronic obstructive pulmonary disease and comorbidities (2013) Lancet Respir Med, 1, pp. 73-83; Miller, J., Edwards, L.D., Agusti, A., Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort (2013) Respir Med, 107, pp. 1376-1384; Diez, D., Agusti, A., Wheelock, C.E., Network analysis in the investigation of chronic respiratory diseases: From basics to application (2014) Am J Respir Crit Care Med, 190, pp. 981-988; Faner, R., Cruz, T., López-Giraldo, A., Network medicine, multimorbidity and the lung in the elderly (2014) Eur Respir J, 44, pp. 775-788; Fabbri, L.M., Beghe, B., Agusti, A., COPD and the solar system (2012) Am J Respir Crit Care Med, 186, pp. 117-119; Agusti, A., Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? (2013) Ann Am Thorac Soc, 10, pp. S125-S130; Van Remoortel, H., Hornikx, M., Langer, D., Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease (2013) Am J Respir Crit Care Med, 189, pp. 30-38; Divo, M.J., Casanova, C., Marin, J.M., COPD comorbidities network (2015) Eur Respir J, 46, pp. 640-650; Faner, R., Agusti, A., Network analysis: A way forward to understand COPD multimorbidity (2015) Eur Respir J, 46, pp. 591-592; Grosdidier, S., Ferrer, A., Faner, R., Network medicine analysis of COPD multimorbidities (2014) Respir Res, 15, p. 111; Pozo-Rodriguez, F., Alvarez, C.J., Castro-Acosta, A., Clinical audit of patients admitted to hospital in Spain due to exacerbation of COPD (AUDIPOC study): Method and organisation (2010) Arch Bronconeumol, 46, pp. 349-357; Pozo-Rodriguez, F., López-Campos, J.L., Alvarez-Martínez, C.J., Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC Study (2012) PLoS ONE, 7, p. e42156; Lopez-Campos, J.L., Hartl, S., Pozo-Rodriguez, F., European COPD Audit: Design, organisation of work and methodology (2013) Eur Respir J, 41, pp. 270-276; Lopez-Campos, J.L., Hartl, S., Pozo-Rodriguez, F., Variability of hospital resources for acute care of COPD patients: The European COPD Audit (2014) Eur Respir J, 43, pp. 754-762; Hidalgo, C.A., Blumm, N., Barabasi, A.L., A dynamic network approach for the study of human phenotypes (2009) PLoS Comput Biol, 5, p. e1000353; Charlson, M., Szatrowski, T.P., Peterson, J., Validation of a combined comorbidity index (1994) J Clin Epidemiol, 47, pp. 1245-1251; Shannon, P., Markiel, A., Ozier, O., Cytoscape: A software environment for integrated models of biomolecular interaction networks (2003) Genome Res, 13, pp. 2498-2504; Bauer-Mehren, A., Rautschka, M., Sanz, F., DisGeNET: A Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks (2010) Bioinformatics, 26, pp. 2924-2926; Pinero, J., Queralt-Rosinach, N., Bravo, A., DisGeNET: A discovery platform for the dynamical exploration of human diseases and their genes (2015) Database (Oxford), 2015, p. bav028; Barabasi, A.L., Gulbahce, N., Loscalzo, J., Network medicine: A network-based approach to human disease (2011) Nat Rev Genet, 12, pp. 56-68; Schaefer, M.H., Fontaine, J.F., Vinayagam, A., HIPPIE: Integrating protein interaction networks with experiment based quality scores (2012) PLoS ONE, 7, p. e31826; Kaimal, V., Bardes, E.E., Tabar, S.C., ToppCluster: A multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems (2010) Nucleic Acids Res, 38, pp. W96-W102; Agusti, A., Calverley, P., Celli, B., Characterisation of COPD heterogeneity in the ECLIPSE cohort (2010) Respir Res, 11, pp. 122-136; Divo, M., Cote, C., De Torres, J.P., Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease (2012) Am J Respir Crit Care Med, 186, pp. 155-161; Sichelstiel, A., Yadava, K., Trompette, A., Targeting IL-1beta and IL-17A driven inflammation during influenza-induced exacerbations of chronic lung inflammation (2014) PLoS ONE, 9, p. e98440; Mortaz, E., Adcock, I.M., Shafei, H., Role of P2X7 receptors in release of IL-1beta: A possible mediator of pulmonary inflammation (2012) Tanaffos, 11, pp. 6-11; Oelsner, E.C., Pottinger, T.D., Burkart, K.M., Adhesion molecules, endothelin-1 and lung function in seven population-based cohorts (2013) Biomarkers, 18, pp. 196-203; Carratu, P., Scoditti, C., Maniscalco, M., Exhaled and arterial levels of endothelin-1 are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension (2008) BMC Pulm Med, 8, p. 20; Spiropoulos, K., Trakada, G., Nikolaou, E., Endothelin-1 levels in the pathophysiology of chronic obstructive pulmonary disease and bronchial asthma (2003) Respir Med, 97, pp. 983-989; Wedzicha, J.A., Donaldson, G.C., Rapid FEV1 decline, early COPD, and angiotensin-converting enzymes? (2014) Chest, 145, pp. 671-672; Petersen, H., Sood, A., Meek, P.M., Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use (2014) Chest, 145, pp. 695-703; Agusti, A., Barbera, J.A., Wouters, E.F., Lungs, bone marrow and adipose tissue: A network approach to the pathobiology of chronic obstructive pulmonary disease (2013) Am J Respir Crit Care Med, 188, pp. 1396-1406; Roca, M., Verduri, A., Corbetta, L., Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease (2013) Eur J Clin Invest, 43, pp. 510-521; McAllister, D.A., Maclay, J.D., Mills, N.L., Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD (2012) Eur Respir J, 39, pp. 1097-1103; Maier, D., Kalus, W., Wolff, M., Knowledge management for systems biology a general and visually driven framework applied to translational medicine (2011) BMC Syst Biol, 5, p. 38; Kohl, P., Crampin, E.J., Quinn, T.A., Systems biology: An approach (2010) Clin Pharmacol Ther, 88, pp. 25-33; Lam, T.K., Spitz, M., Schully, S.D., ""Drivers"" of translational cancer epidemiology in the 21st century: Needs and opportunities (2013) Cancer Epidemiol Biomarkers Prev, 22, pp. 181-188; Marshall, J.K., Myocardial infarction, peptic ulcer and acetylsalicylic acid: Of good and evil (2009) Can J Gastroenterol, 23, p. 618; Faner, R., Rojas, M., MacNee, W., Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (2012) Am J Respir Crit Care Med, 186, pp. 306-313; Sin, D.D., Anthonisen, N.R., Soriano, J.B., Mortality in COPD: Role of comorbidities (2006) Eur Respir J, 28, pp. 1245-1257; Burgel, P.R., Paillasseur, J.L., Roche, N., Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities (2014) Biomed Res Int, 2014, p. 420134; Barabasi, A.L., Network medicine - From obesity to the ""diseasome"" (2007) N Engl J Med, 357, pp. 404-407; Agusti, A., Sobradillo, P., Celli, B., Addressing the complexity of chronic obstructive pulmonary disease: From phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine (2011) Am J Respir Crit Care Med, 183, pp. 1129-1137; Agusti, A., The path to personalized medicine in COPD (2014) Thorax, 69, pp. 857-864; Frei, A., Muggensturm, P., Putcha, N., Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: The newly developed COMCOLD index (2014) J Clin Epidemiol, 67, pp. 904-911; Faner, R., Gonzalez, N., Cruz, T., Systemic inflammatory response to smoking in chronic obstructive pulmonary disease: Evidence of a gender effect (2014) PLoS ONE, 9, p. e97491; Agusti, A., Anto, J.M., Auffray, C., Personalized respiratory medicine: Exploring the horizon, addressing the issues (2015) Am J Respir Crit Care Med, 191, pp. 391-401","Agusti, A.; Thorax Institute, Hospital Clinic, IDIBAPS, Univ. Barcelona, Villarroel 170, Spain",,,"European Respiratory Society",,,,,09031936,,ERJOE,"26250499","English","Eur. Respir. J.",Conference Paper,"Final",Open Access,Scopus,2-s2.0-84943226586
"Cases M., Briggs K., Steger-Hartmann T., Pognan F., Marc P., Kleinöder T., Schwab C.H., Pastor M., Wichard J., Sanz F.","56251049800;23979276700;6603592872;6602679901;7004044863;15751017500;13205406700;7102415847;6506429877;7102263897;","The eTOX data-sharing project to advance in Silico drug-induced toxicity prediction",2014,"International Journal of Molecular Sciences","15","11",,"21136","21154",,31,"10.3390/ijms151121136","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84910109734&doi=10.3390%2fijms151121136&partnerID=40&md5=da2ec44c8ab59234959ec162bb24ccb8","Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr. Aiguader 88, Barcelona, E-08003, Spain; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, United Kingdom; Investigational Toxicology, Bayer HealthCare, Müllerstraße 178, Berlin, D-13353, Germany; PreClinical Safety, Novartis Institute for Biomedical Research, Klybeckstrasse 141, Basel, CH-4057, Switzerland; Molecular Networks GmbH, Medical Valley Center, Henke strasse 91, Erlangen, 91052, Germany","Cases, M., Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr. Aiguader 88, Barcelona, E-08003, Spain, Investigational Toxicology, Bayer HealthCare, Müllerstraße 178, Berlin, D-13353, Germany; Briggs, K., Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, United Kingdom; Steger-Hartmann, T., Investigational Toxicology, Bayer HealthCare, Müllerstraße 178, Berlin, D-13353, Germany; Pognan, F., PreClinical Safety, Novartis Institute for Biomedical Research, Klybeckstrasse 141, Basel, CH-4057, Switzerland; Marc, P., PreClinical Safety, Novartis Institute for Biomedical Research, Klybeckstrasse 141, Basel, CH-4057, Switzerland; Kleinöder, T., Molecular Networks GmbH, Medical Valley Center, Henke strasse 91, Erlangen, 91052, Germany; Schwab, C.H., Molecular Networks GmbH, Medical Valley Center, Henke strasse 91, Erlangen, 91052, Germany; Pastor, M., Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr. Aiguader 88, Barcelona, E-08003, Spain; Wichard, J., Investigational Toxicology, Bayer HealthCare, Müllerstraße 178, Berlin, D-13353, Germany; Sanz, F., Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr. Aiguader 88, Barcelona, E-08003, Spain","The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug development, which follows numerous strict guidelines, are mostly not available in the public domain. These safety data are sometimes published as a condensed summary for the few compounds that reach the market, but the majority of studies are never made public and are often difficult to access in an automated way, even sometimes within the owning company itself. It is evident from many academic and industrial examples, that useful data mining and model development requires large and representative data sets and careful curation of the collected data. In 2010, under the auspices of the Innovative Medicines Initiative, the eTOX project started with the objective of extracting and sharing preclinical study data from paper or pdf archives of toxicology departments of the 13 participating pharmaceutical companies and using such data for establishing a detailed, well-curated database, which could then serve as source for read-across approaches (early assessment of the potential toxicity of a drug candidate by comparison of similar structure and/or effects) and training of predictive models. The paper describes the efforts undertaken to allow effective data sharing intellectual property (IP) protection and set up of adequate controlled vocabularies) and to establish the database (currently with over 4000 studies contributed by the pharma companies corresponding to more than 1400 compounds). In addition, the status of predictive models building and some specific features of the eTOX predictive system (eTOXsys) are presented as decision support knowledge-based tools for drug development process at an early stage. © 2014 by the authors; licensee MDPI, Basel, Switzerland.","Data integration; Data sharing; Decision support system; In silico toxicity; In vitro toxicity; In vivo toxicity; Ontologies; Predictive models; QSAR; Read-across","Article; biological activity; chemical analysis; computer interface; computer model; data analysis; decision making; drug database; drug industry; eTOX database; legal aspect; methodology; patent; prediction; quantitative structure activity relation; toxicity testing; biological model; chemistry; computer simulation; controlled vocabulary; data mining; drug database; drug development; Drug-Related Side Effects and Adverse Reactions; human; drug; Computer Simulation; Data Mining; Databases, Pharmaceutical; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Humans; Models, Biological; Pharmaceutical Preparations; Vocabulary, Controlled",,"Pharmaceutical Preparations",,,,,,,"Sacks, L.V., Shamsuddin, H.H., Yasinskaya, Y.I., Bouri, K., Lanthier, M.L., Sherman, R.E., Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012 (2014) JAMA, 311, pp. 378-384; Kramer, J.A., Sagartz, J.E., Morris, D.L., The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates (2007) Nat. Rev. Drug Discov, 6, pp. 636-649; Fitzgerald, G.A., Testing cardiovascular drug safety and efficacy in randomized trials (2014) Circ. Res, 114, pp. 1156-1161; http://toxml.org, accessed on 31 August 2014; http://www.epa.gov/ncct/dsstox/, accessed on 31 August 2014; http://actor.epa.gov/actor/faces/ACToRHome.jsp, accessed on 31 August 2014; Kopp-Schneider, A., Prieto, P., Kinsner-Ovaskainen, A., Stanzel, S., Design of a testing strategy using non-animal based test methods: Lessons learnt from the ACuteTox project (2013) Toxicol. In Vitro, 27, pp. 1395-1401; Bushnell, P.J., Kavlock, R.J., Crofton, K.M., Weiss, B., Rice, D.C., Behavioral toxicology in the 21st century: Challenges and opportunities for 2 behavioral scientists (2010) Neurotoxicol. Teratol, 32, pp. 313-328; Knudsen, T.B., Houck, K.A., Sipes, N.S., Singh, A.V., Judson, R.S., Martin, M.T., Weissman, A., Reif, D.M., Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets (2011) Toxicology, 282, pp. 1-15; Kavlock, R., Chandler, K., Houck, K., Hunter, S., Judson, R., Kleinstreuer, N., Knudsen, T., Reif, D., Update on EPA’s ToxCast program: Providing high throughput decision support tools for chemical risk management (2012) Chem. Res. Toxicol, 25, pp. 1287-1302; Shah, F., Greene, N., Analysis of Pfizer compounds in EPA’s ToxCast chemicals-assay space (2014) Chem. Res. Toxicol, 27, pp. 86-98; Attene-Ramos, M.S., Miller, N., Huang, R., Michael, S., Itkin, M., Kavlock, R.J., Austin, C.P., Tice, R.R., The Tox21 robotic platform for the assessment of environmental chemicals—From vision to reality (2013) Drug Discov. Today, 18, pp. 716-723; Hardy, B., Douglas, N., Helma, C., Rautenberg, M., Jeliazkova, N., Jeliazkov, V., Nikolova, I., Kramer, S., Collaborative development of predictive toxicology applications (2010) J. Cheminform, 2, 7p; Kohonen, P., Benfenati, E., Bower, D., Ceder, R., Crump, M., Cross, K., Grafström, R.C., Jeliazkova, N., The ToxBank data warehouse: Supporting the replacement of in vivo repeated dose systemic toxicity testing (2013) Mol. Inf, 32, pp. 47-63; Benigni, R., Battistelli, C.L., Bossa, C., Tcheremenskaia, O., Crettaz, P., New perspectives in toxicological information management, and the role of ISSTOX databases in assessing chemical mutagenicity and carcinogenicity (2013) Mutagenesis, 28, pp. 401-409; Tluczkiewicz, I., Batke, M., Kroese, D., Buist, H., Aldenberg, T., Pauné, E., Grimm, H., Mangelsdorf, I., The OSIRIS Weight of Evidence approach: ITS for the endpoints repeated-dose toxicity (RepDose ITS) (2013) Regul. Toxicol. Pharmacol, 67, pp. 157-169; Williams, A.J., Harland, L., Groth, P., Pettifer, S., Chichester, C., Willighagen, E.L., Evelo, C.T., Goble, C., Open PHACTS: Semantic interoperability for drug discovery (2012) Drug Discov. Today, 17, pp. 1188-1198; http://www.imi-safe-t.eu/, accessed on 31 August 2014; http://www.cosmostox.eu/, accessed on 31 August 2014; Merlot, C., Computational toxicology―A tool for early safety evaluation (2010) Drug Discov. Today, 15, pp. 16-22; Richard, A.M., Yang, C., Judson, R.S., Toxicity data informatics: Supporting a new paradigm for toxicity prediction (2008) Toxicol. Mech. Methods, 18, pp. 103-118; Yang, C., Valerio, L.G., Jr., Arvidson, K.B., Computational toxicology approaches at the US Food and Drug Administration (2009) Altern. Lab. Anim, 37, pp. 523-531; IMI, http://imi.europa.eu/index_en.html, accessed on 31 August 2014; Bril, A., Canet, E., The innovative medicine initiative (IMI) (2008) Med. Sci, 24, pp. 885-890; http://www.e-TOX.net, eTOX official website, accessed on 31 August 2014; Briggs, K., Cases, M., Heard, D.J., Pastor, M., Pognan, F., Sanz, F., Schwab, C.H., Watson, D.K., Inroads to predict in vivo toxicology—An introduction to the eTOX project (2012) Int. J. Mol. Sci, 13, pp. 3820-3846; InnoMed PredTox, https://www.genedata.com/lp/innomed-predtox.html, accessed on 31 August 2014; http://toxico.nibio.go.jp/, accessed on 31 August 2014; https://ntp.niehs.nih.gov/drugmatrix/index.html, accessed on 31 August 2014; Li, Q., Cheng, T., Wang, Y., Bryant, S.H., PubChem as a public resource for drug discovery (2010) Drug Discov. Today, 15, pp. 1052-1057; Bento, A.P., Gaulton, A., Hersey, A., Bellis, L.J., Chambers, J., Davies, M., Krüger, F.A., McGlinchey, S., The ChEMBL bioactivity database: An update (2014) Nucleic Acids Res, 42, pp. D1083-D1090; https://www.ebi.ac.uk/chembl/, accessed on 31 August 2014; http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d125, accessed on 31 August 2014; http://dailymed.nlm.nih.gov/, accessed on 31 August 2014; http://www.drugbank.ca/, accessed on 31 August 2014; Cases, M., Pastor, M., Sanz, F., The eTOX library of public resources for in silico toxicity prediction (2013) Mol. Inform, 32, pp. 24-35; eTOXlibrary, http://cadd.imim.es/etox-library/, accessed on 31 August 2014; RepDose, http://fraunhofer-repdose.de/, accessed on 31 August 2014; Marchant, C., Briggs, K., Long, A., In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for windows, meteor, and vitic (2008) Toxicol. Mech. Methods, 18, pp. 177-187; InChi-IUPAC, http://www.iupac.org/home/publications/e-resources/inchi.html, accessed on 31 August 2014; Harland, L., Larminie, C., Sansone, S.A., Popa, S., Marshall, M.S., Braxenthaler, M., Cantor, M., Huang, E., Empowering industrial research with shared biomedical vocabularies (2011) Drug Discov. Today, 16, pp. 940-947; http://www.cdisc.org/SEND, accessed on 31 August 2014; http://www.cdisc.org/mission-and-principles, accessed on 31 August 2014; http://www.goreni.org/, accessed on 24 October 2014; Briggs, K., Barber, C., Cases, M., Steger-Hartmann, T. Value of shared preclinical safety studies— The eTOX database (2014) Toxicol. Rep, , Submitted; Hewitt, M., Enoch, S.J., Madden, J.C., Przybylak, K.R., Cronin, M., Hepatotoxicity: A scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action (2013) Crit. Rev. Toxicol, 43, pp. 537-558; Obiol-Pardo, C., Gomis-Tena, J., Sanz, F., Saiz, J., Pastor, M.A., Multiscale simulation system for the prediction of drug-induced cardiotoxicity (2011) J. Chem. Inform. Model, 51, pp. 483-492; Taboureau, O., Jørgensen, F.S., In silico predictions of hERG channel blockers in drug discovery: From ligand-based and target-based approaches to systems chemical biology (2011) Comb. Chem. High Throughput Screen, 14, pp. 375-387; Poongavanam, V., Haider, N., Ecker, G.F., Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors (2012) Bioorg. Med. Chem, 20, pp. 5388-5395; Pinto, M., Trauner, M., Ecker, G.F., An in silico classification model for putative ABCC2 substrates (2012) Mol. Inform, 31, pp. 547-553; Perić-Hassler, L., Stjernschantz, E., Oostenbrink, C., Geerke, D.P., CYP 2D6 binding affinity predictions using multiple ligand and protein conformations (2013) Int. J. Mol. Sci, 14, pp. 24514-24530; Vosmeer, C.R., Pool, R., Van Stee, M.F., Peric-Hassler, L., Vermeulen, N., Geerke, D.P., Towards automated binding affinity prediction using an iterative linear interaction energy approach (2014) Int. J. Mol. Sci, 15, pp. 798-816; Klepsch, F., Vasanthanathan, P., Ecker, G.F., Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors (2014) J. Chem. Inform. Model, 54, pp. 218-229; Carrió, P., Pinto, M., Ecker, G., Sanz, F., Pastor, M., Applicability domain aNalysis (ADAN): A robust method for assessing the reliability of drug property predictions (2014) J. Chem. Inform. Model, 54, pp. 1500-1511","Sanz, F.; Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr. Aiguader 88, Spain",,,"MDPI AG",,,,,16616596,,,"25405742","English","Int. J. Mol. Sci.",Article,"Final",Open Access,Scopus,2-s2.0-84910109734
"Martí-Solano M., Sanz F., Pastor M., Selent J.","55090002400;7102263897;7102415847;55891371700;","A dynamic view of molecular switch behavior at serotonin receptors: Implications for Functional selectivity",2014,"PLoS ONE","9","10", e109312,"","",,12,"10.1371/journal.pone.0109312","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84908031988&doi=10.1371%2fjournal.pone.0109312&partnerID=40&md5=258c89136fcd3fb0be9b7225e505fb8c","Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain","Martí-Solano, M., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Selent, J., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain","Functional selectivity is a property of G protein-coupled receptors that allows them to preferentially couple to particular signaling partners upon binding of biased agonists. Publication of the X-ray crystal structure of serotonergic 5-HT1B and 5-HT2B receptors in complex with ergotamine, a drug capable of activating G protein coupling and β-arrestin signaling at the 5-HT1B receptor but clearly favoring β-arrestin over G protein coupling at the 5-HT2B subtype, has recently provided structural insight into this phenomenon. In particular, these structures highlight the importance of specific residues, also called micro-switches, for differential receptor activation. In our work, we apply classical molecular dynamics simulations and enhanced sampling approaches to analyze the behavior of these micro-switches and their impact on the stabilization of particular receptor conformational states. Our analysis shows that differences in the conformational freedom of helix 6 between both receptors could explain their different G protein-coupling capacity. In particular, as compared to the 5-HT1B receptor, helix 6 movement in the 5-HT2B receptor can be constrained by two different mechanisms. On the one hand, an anchoring effect of ergotamine, which shows an increased capacity to interact with the extracellular part of helices 5 and 6 and stabilize them, hinders activation of a hydrophobic connector region at the center of the receptor. On the other hand, this connector region in an inactive conformation is further stabilized by unconserved contacts extending to the intracellular part of the 5-HT2B receptor, which hamper opening of the G protein binding site. This work highlights the importance of considering receptor capacity to adopt different conformational states from a dynamic perspective in order to underpin the structural basis of functional selectivity. Copyright: © 2014 Martí-Solano et al.",,"ergotamine; serotonin 1B receptor; serotonin 2B receptor; serotonin 1B receptor; serotonin 2B receptor; serotonin agonist; Article; binding site; controlled study; functional selectivity; hydrophobicity; molecular dynamics; molecular interaction; protein analysis; protein binding; protein conformation; protein function; protein stability; signal transduction; structure analysis; X ray analysis; chemical phenomena; chemistry; metabolism; protein database; protein tertiary structure; thermodynamics; Binding Sites; Databases, Protein; Ergotamine; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Protein Stability; Protein Structure, Tertiary; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2B; Serotonin Receptor Agonists; Thermodynamics",,"ergotamine, 113-15-5, 52949-35-6; Ergotamine; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2B; Serotonin Receptor Agonists",,,,,,,"Urban, J., Clarke, W., Von Zastrow, M., Nichols, D.E., Kobilka, B., Functional selectivity and classical concepts of quantitative pharmacology (2007) J Pharmacol Exp Ther, 320, pp. 1-13; Martí-Solano, M., Guixà-González, R., Sanz, F., Pastor, M., Selent, J., Novel insights into biased agonism at G protein-coupled receptors and their potential for drug design (2013) Curr Pharm Des, 19, pp. 5156-5166; Wisler, J.W., Xiao, K., Thomsen, A.R., Lefkowitz, R.J., Recent developments in biased agonism (2014) Curr Opin Cell Biol, 27 C, pp. 18-24; Kenakin, T., Christopoulos, A., Signalling bias in new drug discovery: Detection, quantification and therapeutic impact (2012) Nat Rev Drug Discov, 12, pp. 205-216; Allen, J.A., Yost, J.M., Setola, V., Chen, X., Sassano, M.F., Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy (2011) Proc Natl Acad Sci U S A., 108, pp. 2-7; Park, P.S.H., Ensemble of G protein-coupled receptor active states (2012) Curr Med Chem., 19, pp. 1146-1154; Kenakin, T., Miller, L.J., Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery (2010) Pharmacol Rev., 62, pp. 265-304; Preininger, A.M., Meiler, J., Hamm, H.E., Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: A perspective (2013) J Mol Biol., 425, pp. 2288-2298; Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Structural basis for molecular recognition at serotonin receptors (2013) Science, 340, pp. 610-614; Wacker, D., Wang, C., Katritch, V., Han, G., Structural features for functional selectivity at serotonin receptors (2013) Science, 340, pp. 615-619; Labruijere, S., Villalo, C.M., Vandenbrink, A.M., Activation of 5-hydrozytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs (2013) Expert Opin Pharmacother., 14, pp. 1599-1610; Roth, B., Drugs and valvular heart disease (2007) N Engl J Med, pp. 6-9; Nygaard, R., Frimurer, T.M., Holst, B., Rosenkilde, M.M., Schwartz, T.W., Ligand binding and micro-switches in 7TM receptor structures (2009) Trends Pharmacol Sci., 30, pp. 249-259; Harvey, M.J., De Fabritiis, G., High-throughput molecular dynamics: The powerful new tool for drug discovery (2012) Drug Discov Today., 17, pp. 1059-1062; Dror, R.O., Arlow, D.H., Maragakis, P., Mildorf, T.J., Pan, A.C., Activation mechanism of the b2-adrenergic receptor (2011) Proc Natl Acad Sci U S A., 108, pp. 1-6; Nygaard, R., Zou, Y., Dror, R.O., Mildorf, T.J., Arlow, D.H., The dynamic process of b2-adrenergic receptor activation (2013) Cell, 152, pp. 532-542; Kruse, A.C., Hu, J., Pan, A.C., Arlow, D.H., Rosenbaum, D.M., Structure and dynamics of the M3 muscarinic acetylcholine receptor (2012) Nature, 482, pp. 552-556; Dror, R.O., Pan, A.C., Arlow, D.H., Borhani, D.W., Maragakis, P., Pathway and mechanism of drug binding to G-protein-coupled receptors (2011) Proc Natl Acad Sci U S A, 108, pp. 13118-13123; Ballesteros, J., Weinstein, H., Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors (1995) Methods Neurosci., 25, pp. 366-428; Rasmussen, S.G.F., DeVree, B.T., Zou, Y., Kruse, A.C., Chung, K.Y., Crystal structure of the beta2 adrenergic receptor-Gs protein complex (2011) Nature, 477, pp. 549-555; Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G.F., Thian, F.S., High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor (2007) Science, 318, pp. 1258-1265; Ballesteros, J.A., Jensen, A.D., Liapakis, G., Rasmussen, S.G., Shi, L., Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6 (2001) J Biol Chem., 276, pp. 29171-29177; Yuan, S., Ghoshdastider, U., Trzaskowski, B., Latek, D., Debinski, A., The role of water in activation mechanism of human N-formyl peptide receptor 1 (FPR1) based on molecular dynamics simulations (2012) PLoS One, 7, p. e47114; Dror, R.O., Arlow, D.H., Maragakis, P., Mildorf, T.J., Pan, A.C., Activation mechanism of the b2-adrenergic receptor (2011) Proc Natl Acad Sci U S A, 108, pp. 18684-18689; Bock, A., Merten, N., Schrage, R., Dallanoce, C., Bätz, J., The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling (2012) Nat Commun., 3, p. 1044; Gregory, K.J., Hall, N.E., Tobin, A.B., Sexton, P.M., Christopoulos, A., Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias (2010) J Biol Chem., 285, pp. 7459-7474; Venkatakrishnan, A.J., Deupi, X., Lebon, G., Tate, C.G., Schertler, G.F., Molecular signatures of G-protein-coupled receptors (2013) Nature, 494, pp. 185-194; Katritch, V., Cherezov, V., Stevens, R., Structure-function of the G proteincoupled receptor superfamily (2013) Annu Rev Pharmacol Toxicol, pp. 531-556; Li, H., Robertson, A.D., Jensen, J.H., Very fast empirical prediction and rationalization of protein pKa values (2005) Proteins, 61, pp. 704-721; (2014) Molecular Operating Environment (MOE) Software, , http://www.chemcomp.com/software.htm, Accessed 2014 Sep. 25; Jo, S., Lim, J.B., Klauda, J.B., Im, W., CHARMM-GUI Membrane Builder for mixed bilayers and its application to yeast membranes (2009) Biophys J., 97, pp. 50-58; Humphrey, W., Dalke, A., Schulten, K., VMD: Visual molecular dynamics (1996) J Mol Graph., 14, pp. 33-38; Case, D., (2012) AMBER 12. Amber Molecular Dynamics Software, , http://ambermd.org, Accessed 2014 Sep. 25; Harvey, M.J., Giupponi, G., De Fabritiis, G., ACEMD: Accelerating biomolecular dynamics in the microsecond timescale (2009) J Chem Theory Comput., 5, pp. 1632-1639; Feenstra, K.A., Improving efficiency of large time-scale molecular dynamics simulations of hydrogen-rich systems (1999) J Comput Chem., 20, pp. 786-798; Bonomi, M., Branduardi, D., Bussi, G., Camilloni, C., Provasi, D., (2009) PLUMED: A Portable Plugin for Free-energy Calculations with Molecular Dynamics, pp. 1-15; Barducci, A., Bussi, G., Parrinello, M., Well-tempered metadynamics: A smoothly converging and tunable free-energy method (2008) Phys Rev Lett., 100, p. 020603; Raiteri, P., Laio, A., Gervasio, F.L., Micheletti, C., Parrinello, M., Efficient reconstruction of complex free energy landscapes by multiple walkers metadynamics (2006) J Phys Chem B., 110, pp. 3533-3539; (2014) R: A Language and Environment for Statistical Computing, , http://www.R-project.org, Vienna, Austria: R Foundation for Statistical Computing, Accessed 2014 Sep. 25; Williams, T., Kelly, C., (2014) Gnuplot 4.5: An Interactive Plotting Program, , http://www.gnuplot.info, Accessed 2014 Sep. 25; Mezei, M., Filizola, M., TRAJELIX: A computational tool for the geometric characterization of protein helices during molecular dynamics simulations (2006) J Comput Aided Mol Des., 20, pp. 97-107; Mezei, M., Simulaid: A simulation facilitator and analysis program (2010) J Comput Chem, pp. 2658-2668","Pastor, M.; Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu FabraSpain",,,"Public Library of Science",,,,,19326203,,POLNC,"25313636","English","PLoS ONE",Article,"Final",Open Access,Scopus,2-s2.0-84908031988
"Grosdidier S., Ferrer A., Faner R., Piñero J., Roca J., Cosío B., Agustí A., Gea J., Sanz F., Furlong L.I.","23027796200;56150886500;6507910788;55220852900;24784609700;8527027300;7101749378;7004959809;7102263897;34770469800;","Network medicine analysis of COPD multimorbidities",2014,"Respiratory Research","15","1", 111,"","",,26,"10.1186/s12931-014-0111-4","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84907400402&doi=10.1186%2fs12931-014-0111-4&partnerID=40&md5=4dd7e42ca3694258fcff43e5e796eda3","Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Servei de Pneumologia, IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; FISIB, CIBERES, Palma de Mallorca, Spain; Thorax Institute, Hospital Clínic, IDIBAPS, Universitat Barcelona, Barcelona, Spain; Hospital Universitari Son Espases-IdISPa, Ciberes, Palma de Mallorca, Spain","Grosdidier, S., Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Ferrer, A., Servei de Pneumologia, IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; Faner, R., FISIB, CIBERES, Palma de Mallorca, Spain; Piñero, J., Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Roca, J., Thorax Institute, Hospital Clínic, IDIBAPS, Universitat Barcelona, Barcelona, Spain; Cosío, B., Hospital Universitari Son Espases-IdISPa, Ciberes, Palma de Mallorca, Spain; Agustí, A., FISIB, CIBERES, Palma de Mallorca, Spain, Thorax Institute, Hospital Clínic, IDIBAPS, Universitat Barcelona, Barcelona, Spain; Gea, J., Servei de Pneumologia, IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; Sanz, F., Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Furlong, L.I., Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain","Background: Patients with chronic obstructive pulmonary disease (COPD) often suffer concomitant disorders that worsen significantly their health status and vital prognosis. The pathogenic mechanisms underlying COPD multimorbidities are not completely understood, thus the exploration of potential molecular and biological linkages between COPD and their associated diseases is of great interest.Methods: We developed a novel, unbiased, integrative network medicine approach for the analysis of the diseasome, interactome, the biological pathways and tobacco smoke exposome, which has been applied to the study of 16 prevalent COPD multimorbidities identified by clinical experts.Results: Our analyses indicate that all COPD multimorbidities studied here are related at the molecular and biological level, sharing genes, proteins and biological pathways. By inspecting the connections of COPD with their associated diseases in more detail, we identified known biological pathways involved in COPD, such as inflammation, endothelial dysfunction or apoptosis, serving as a proof of concept of the methodology. More interestingly, we found previously overlooked biological pathways that might contribute to explain COPD multimorbidities, such as hemostasis in COPD multimorbidities other than cardiovascular disorders, and cell cycle pathway in the association of COPD with depression. Moreover, we also observed similarities between COPD multimorbidities at the pathway level, suggesting common biological mechanisms for different COPD multimorbidities. Finally, chemicals contained in the tobacco smoke target an average of 69% of the identified proteins participating in COPD multimorbidities.Conclusions: The network medicine approach presented here allowed the identification of plausible molecular links between COPD and comorbid diseases, and showed that many of them are targets of the tobacco exposome, proposing new areas of research for understanding the molecular underpinning of COPD multimorbidities. © 2014 Grosdidier et al.; licensee BioMed Central Ltd.","Comorbidity; COPD; Diseasome; Multimorbidity; Network medicine; Systems biology; Tobacco chemicals","tobacco smoke; smoke; apoptosis; Article; cardiovascular disease; cell cycle; chronic obstructive lung disease; comorbidity; controlled study; depression; endothelial dysfunction; female; genetic association; hemostasis; human; inflammation; protein analysis; signal transduction; adverse effects; comorbidity; gene expression regulation; gene regulatory network; genetics; health status; metabolism; pathophysiology; prevalence; prognosis; protein protein interaction; Pulmonary Disease, Chronic Obstructive; risk factor; smoke; smoking; system analysis; systems biology; Comorbidity; Gene Expression Regulation; Gene Regulatory Networks; Health Status; Humans; Prevalence; Prognosis; Protein Interaction Maps; Pulmonary Disease, Chronic Obstructive; Risk Factors; Signal Transduction; Smoke; Smoking; Systems Biology; Systems Integration",,"Smoke",,,,,,,"Mannino, D.M., Kiriz, V.A., Changing the burden of COPD mortality (2006) Int J Chron Obstruct Pulmon Dis, 1, pp. 219-233. , 18046859; Agustí, A., Vestbo, J., Current controversies and future perspectives in chronic obstructive pulmonary disease (2011) Am J Respir Crit Care Med, 184, pp. 507-513. , 21680951; Agusti, A., Sobradillo, P., Celli, B., Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine (2011) Am J Respir Crit Care Med, 183, pp. 1129-1137. , 21169466; Fabbri, L.M., Beghé, B., Agustí, A., COPD and the solar system: introducing the chronic obstructive pulmonary disease comorbidome (2012) Am J Respir Crit Care Med, 186, pp. 117-119. , 22798411; Dm, M., Thorn, D., Swensen, A., Holguin, F., Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD (2008) Eur Respir J, 32, pp. 962-969; Barnes, P.J., Chronic obstructive pulmonary disease: effects beyond the lungs (2010) PLoS Med, 7, p. e1000220. , 20305715; Park, J., Lee, D.S., Christakis, N.A., Barabási, A.L., The impact of cellular networks on disease comorbidity (2009) Mol Syst Biol, 5, p. 262. , 19357641; Lee, D.S., Park, J., Kay, K.A., Christakis, N.A., Oltvai, Z.N., Barabási, A.L., The implications of human metabolic network topology for disease comorbidity (2008) Proc Natl Acad Sci USA, 105, pp. 9880-9885. , 18599447; Barabási, A.L., Gulbahce, N., Loscalzo, J., Network medicine: a network-based approach to human disease (2011) Nat Rev Genet, 12, pp. 56-68. , 21164525; Divo, M., Cote, C., De Torres, J.P., Casanova, C., Marin, J.M., Pinto-Plata, V., Zulueta, J., Celli, B., Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease (2012) Am J Respir Crit Care Med, 186, pp. 155-161. , 22561964; Furlong, L.I., Human diseases through the lens of network biology (2013) Trends Genet, 29, pp. 150-159. , 23219555; Cazzola, M., Bettoncelli, G., Sessa, E., Cricelli, C., Biscione, G., Prevalence of comorbidities in patients with chronic obstructive pulmonary disease (2010) Respiration, 80, pp. 112-119. , 20134148; Feary, J.R., Rodrigues, L.C., Smith, C.J., Hubbard, R.B., Gibson, J.E., Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care (2010) Thorax, 65, pp. 956-962. , 20871122; Schnell, K., Weiss, C.O., Lee, T., Krishnan, J.A., Leff, B., Wolff, J.L., Boyd, C., The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008 (2012) BMC Pulm Med, 12, p. 26. , 22695054; Bodenreider, O., The unified medical language system (UMLS): integrating biomedical terminology (2004) Nucleic Acids Res, 32, pp. D267-D270. , 14681409; Bauer-Mehren, A., Rautschka, M., Sanz, F., Furlong, L.I., DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks (2010) Bioinformatics, 26, pp. 2924-2926. , 20861032; Cerami, E.G., Gross, B.E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Sander, C., Pathway Commons, a web resource for biological pathway data (2011) Nucleic Acids Res, 39, pp. D685-D690. , 21071392; Schaefer, M.H., Fontaine, J.F., Vinayagam, A., Porras, P., Wanker, E.E., Andrade-Navarro, M.A., HIPPIE: Integrating protein interaction networks with experiment based quality scores (2012) PLoS One, 7, p. e31826. , 22348130; Croft, D., O'Kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., Caudy, M., Stein, L., Reactome: a database of reactions, pathways and biological processes (2011) Nucleic Acids Res, 39, pp. D691-D697. , 21067998; Yu, G., (2012) ReactomePA: Reactome Pathway Analysis R package version 2.15.2; Perez-Llamas, C., Lopez-Bigas, N., Gitools: analysis and visualisation of genomic data using interactive heat-maps (2011) PLoS One, 6, p. e19541. , 21602921; Rustemeier, K., Stabbert, R., Haussmann, H.J., Roemer, E., Carmines, E.L., Evaluation of the potential effects of ingredients added to cigarettes. Part 2: chemical composition of mainstream smoke (2002) Food Chem Toxicol, 40, pp. 93-104. , 11731039; Hoffmann, D., Hoffmann, I., Tobacco smoke components (1998) Beiträge zur Tabakforschung Int, 18, pp. 49-52; Barnes, P.J., Celli, B.R., Systemic manifestations and comorbidities of COPD (2009) Eur Respir J, 33, pp. 1165-1185. , 19407051; Corsonello, A., Incalzi, R.A., Pistelli, R., Pedone, C., Bustacchini, S., Lattanzio, F., Comorbidities of chronic obstructive pulmonary disease (2011) Curr Opin Pulm Med, 17, pp. S21-S28. , 22209926; Thomsen, M., Dahl, M., Tybjaerg-Hansen, A., Nordestgaard, B.G., β2 -adrenergic receptor Thr164IIe polymorphism, blood pressure and ischaemic heart disease in 66 750 individuals (2012) J Intern Med, 271, pp. 305-314. , 21883537; Prior, S.J., Goldberg, A.P., Ryan, A.S., ADRB2 haplotype is associated with glucose tolerance and insulin sensitivity in obese postmenopausal women (2011) Obesity (Silver Spring), 19, pp. 396-401; Lacey, R.J., Cable, H.C., James, R.F., London, N.J., Scarpello, J.H., Morgan, N.G., Concentration-dependent effects of adrenaline on the profile of insulin secretion from isolated human islets of Langerhans (1993) J Endocrinol, 138, pp. 555-563. , 8277227; Hersh, C.P., Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities (2010) Pharmacogenomics, 11, pp. 237-247. , 20136362; Papatheodorou, A., Makrythanasis, P., Kaliakatsos, M., Dimakou, A., Orfanidou, D., Roussos, C., Kanavakis, E., Tzetis, M., Development of novel microarray methodology for the study of mutations in the SERPINA1 and ADRB2 genes-their association with Obstructive Pulmonary Disease and Disseminated Bronchiectasis in Greek patients (2010) Clin Biochem., 43, pp. 43-50. , 19747908; Thomsen, M., Nordestgaard, B.G., Sethi, A.A., Tybjærg-Hansen, A., Dahl, M., β2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies (2012) Eur Respir J, 39, pp. 558-566. , 22075484; Zee, R.Y., Cook, N.R., Reynolds, R., Cheng, S., Ridker, P.M., Haplotype analysis of the beta2 adrenergic receptor gene and risk of myocardial infarction in humans (2005) Genetics, 169, pp. 1583-1587. , 15520258; Mattingly, C.J., Rosenstein, M.C., Davis, A.P., Colby, G.T., Forrest, J.N., Boyer, J.L., The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks (2006) Toxicol Sci, 92, pp. 587-595. , 16675512; Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P., Fukuchi, Y., Zielinski, J., Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary (2007) Am J Respir Crit Care Med, 176, pp. 532-555. , 17507545; DeMeo, D.L., Carey, V.J., Chapman, H.A., Reilly, J.J., Ginns, L.C., Speizer, F.E., Weiss, S.T., Silverman, E.K., Familial aggregation of FEF(25-75) and FEF(25-75)/FVC in families with severe, early onset COPD (2004) Thorax, 59, pp. 396-400. , 15115866; Pechnick, R.N., Zonis, S., Wawrowsky, K., Pourmorady, J., Chesnokova, V., P21Cip1 restricts neuronal proliferation in the subgranular zone of the dentate gyrus of the hippocampus (2008) Proc Natl Acad Sci U S A, 105, pp. 1358-1363. , 18172194; Snyder, J.S., Soumier, A., Brewer, M., Pickel, J., Cameron, H.A., Adult hippocampal neurogenesis buffers stress responses and depressive behaviour (2011) Nature, 476, pp. 458-461. , 21814201; Yoshida, T., Tuder, R.M., Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease (2007) Physiol Rev, 87, pp. 1047-1082. , 17615396; Bauer-Mehren, A., Furlong, L.I., Sanz, F., Pathway databases and tools for their exploitation: benefits, current limitations and challenges (2009) Mol Syst Biol, 5, p. 290. , 19638971","Furlong, L.I.; Integrative Biomedical Informatics Group, Research Program on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Barcelona, DCEXS, Universitat Pompeu FabraSpain",,,"BioMed Central Ltd.",,,,,14659921,,RREEB,"25248857","English","Respir. Res.",Article,"Final",Open Access,Scopus,2-s2.0-84907400402
"Carrió P., Pinto M., Ecker G., Sanz F., Pastor M.","55227590800;7202889875;24794675100;7102263897;7102415847;","Applicability domain analysis (ADAN): A robust method for assessing the reliability of drug property predictions",2014,"Journal of Chemical Information and Modeling","54","5",,"1500","1511",,33,"10.1021/ci500172z","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901642561&doi=10.1021%2fci500172z&partnerID=40&md5=a741752ee987fa084de8535f9b9565fa","Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Dr. Aiguader, 88, E-08003 Barcelona, Spain; Department of Medicinal Chemistry, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria","Carrió, P., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Dr. Aiguader, 88, E-08003 Barcelona, Spain; Pinto, M., Department of Medicinal Chemistry, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria; Ecker, G., Department of Medicinal Chemistry, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Dr. Aiguader, 88, E-08003 Barcelona, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Dr. Aiguader, 88, E-08003 Barcelona, Spain","We report a novel method called ADAN (Applicability Domain ANalysis) for assessing the reliability of drug property predictions obtained by in silico methods. The assessment provided by ADAN is based on the comparison of the query compound with the training set, using six diverse similarity criteria. For every criterion, the query compound is considered out of range when the similarity value obtained is larger than the 95th percentile of the values obtained for the training set. The final outcome is a number in the range of 0-6 that expresses the number of unmet similarity criteria and allows classifying the query compound within seven reliability categories. Such categories can be further exploited to assign simpler reliability classes using a traffic light schema, to assign approximate confidence intervals or to mark the predictions as unreliable. The entire methodology has been validated simulating realistic conditions, where query compounds are structurally diverse from those in the training set. The validation exercise involved the construction of more than 1000 models. These models were built using a combination of training set, molecular descriptors, and modeling methods representative of the real predictive tasks performed in the eTOX project (a project whose objective is to predict in vivo toxicological end points in drug development). Validation results confirm the robustness of the proposed assessment methodology, which compares favorably with other classical methods based solely on the structural similarity of the compounds. ADAN characteristics make the method well-suited for estimate the quality of drug predictions obtained in extremely unfavorable conditions, like the prediction of drug toxicity end points. © 2014 American Chemical Society.",,"Reliability; Assessment methodologies; Confidence interval; Molecular descriptors; Property predictions; Realistic conditions; Similarity criteria; Structural similarity; Validation results; Forecasting; adverse drug reaction; artificial intelligence; computer simulation; drug development; Internet; procedures; reproducibility; safety; theoretical model; Artificial Intelligence; Computer Simulation; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Internet; Models, Theoretical; Reproducibility of Results; Safety",,,,,,,,,"Stevens, J.L., Baker, T.K., The Future of Drug Safety Testing: Expanding the View and Narrowing the Focus (2009) Drug Discovery Today, 14, pp. 162-167; Modi, S., Hughes, M., Garrow, A., White, A., The Value of in Silico Chemistry in the Safety Assessment of Chemicals in the Consumer Goods and Pharmaceutical Industries (2012) Drug Discovery Today, 17, pp. 135-142; (2013) European Community Regulation on Chemicals and Their Safe Use, , http://ec.europa.eu/environment/chemicals/reach/reach_intro.htm, REACH. (accessed Sept. 9); Meanwell, N.A., Improving Drug Candidates by Design: A Focus on Physicochemical Properties as a Means of Improving Compound Disposition and Safety (2011) Chem. Res. Toxicol., 24, pp. 1420-1456; Bass, A.S., Cartwright, M.E., Mahon, C., Morrison, R., Snyder, R., McNamara, P., Bradley, P., Hunter, J., Exploratory Drug Safety: A Discovery Strategy to Reduce Attrition in Development (2009) J. Pharmacol. Toxicol. Methods, 60, pp. 69-78; Car, B., Enabling Technologies in Reducing Drug Attrition Due to Safety Failures (2006) Am. Drug Discovery, 1, pp. 53-56; Briggs, K., Cases, M., Heard, D.J., Pastor, M., Pognan, F., Sanz, F., Schwab, C.H., Wichard, J.D., Inroads to Predict in Vivo Toxicology - An Introduction to the eTOX Project (2012) Int. J. Mol. Sci., 13, pp. 3820-3846; Tetko, I.V., Bruneau, P., Mewes, H.-W., Rohrer, D.C., Poda, G.I., Can We Estimate the Accuracy of ADME-Tox Predictions? (2006) Drug Discovery Today, 11, pp. 700-707; Weaver, S., Gleeson, M.P., The Importance of the Domain of Applicability in QSAR Modeling (2008) J. Mol. Graph. Model., 26, pp. 1315-1326; Netzeva, T., Worth, A., Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships (2005) Altern. Lab. Anim., 33, pp. 155-173; Sahigara, F., Mansouri, K., Ballabio, D., Mauri, A., Consonni, V., Todeschini, R., Comparison of Different Approaches to Define the Applicability Domain of QSAR Models (2012) Molecules, 17, pp. 4791-4810; Sahigara, F., Ballabio, D., Todeschini, R., Consonni, V., Defining a Novel k-Nearest Neighbours Approach to Assess the Applicability Domain of a QSAR Model for Reliable Predictions (2013) J. Cheminform., 5, pp. 27-36; Jaworska, J., Nikolova-Jeliazkova, N., Aldenberg, T., QSAR Applicability Domain Estimation by Projection of the Training Set in Descriptor Space: A Review (2005) ATLA, Altern. Lab. Anim., 33, pp. 445-459; Keefer, C., Kauffman, G., Gupta, R., Interpretable, Probability-Based Confidence Metric for Continuous Quantitative Structure-Activity Relationship Models (2013) J. Chem. Inf. Model., 53, pp. 368-383; Briesemeister, S., Rahnenführer, J., Kohlbacher, O., No Longer Confidential: Estimating the Confidence of Individual Regression Predictions (2012) PLoS One, 7, p. 48723; Sheridan, R.P., Three Useful Dimensions for Domain Applicability in QSAR Models Using Random Forest (2012) J. Chem. Inf. Model., 52, pp. 814-823; Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings (2001) Adv. Drug Delivery Rev., 46, pp. 3-26; Eriksson, L., Jaworska, J., Worth, A.P., Cronin, M.T.D., McDowell, R.M., Gramatica, P., Methods for Reliability and Uncertainty Assessment and for Applicability Evaluations of Classification- and Regression-Based QSARs (2003) Environ. Health Perspect., 111, pp. 1361-1375; Sheridan, R.P., Using Random Forest to Model the Domain Applicability of Another Random Forest Model (2013) J. Chem. Inf. Model., 53, pp. 2837-2850; Sutherland, J.J., O'Brien, L.A., Weaver, D.F., Spline-Fitting with a Genetic Algorithm: A Method for Developing Classification Structure-Activity Relationships (2003) J. Chem. Inf. Comput. Sci., 43, pp. 1906-1915; Delaney, J.S., ESOL: Estimating Aqueous Solubility Directly from Molecular Structure (2004) J. Chem. Inf. Comput. Sci., 44, pp. 1000-1005; Obiol-Pardo, C., Gomis-Tena, J., Sanz, F., Saiz, J., Pastor, M., A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity (2011) J. Chem. Inf. Model., 51, pp. 483-492; O'Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., Hutchison, G.R., Open Babel: An Open Chemical Toolbox (2011) J. Cheminform., 3, pp. 33-47; Milletti, F., Storchi, L., Sforna, G., Cross, S., Cruciani, G., Tautomer Enumeration and Stability Prediction for Virtual Screening on Large Chemical Databases (2009) J. Chem. Inf. Model., 49, pp. 68-75; Milletti, F., Storchi, L., Sforna, G., Cruciani, G., New and Original p K a Prediction Method Using Grid Molecular Interaction Fields (2007) J. Chem. Inf. Model., 47, pp. 2172-2181; Sadowski, J., Gasteiger, J., From Atoms and Bonds to Three-Dimensional Atomic Coordinates: Automatic Model Builders (1993) Chem. Rev., 93, pp. 2567-2581; Sadowski, J., Gasteiger, J., Klebe, G., Comparison of Automatic Three-Dimensional Model Builders Using 639 X-Ray Structures (1994) J. Chem. Inf. Comput. Sci., 34, pp. 1000-1008; Yap, C.W.E.I., Software News and Update PaDEL-Descriptor: An Open Source Software to Calculate Molecular Descriptors and Fingerprints (2010) J. Comput. Chem., 32, pp. 1466-1474; Gasteiger, J., Of Molecules and Humans (2006) J. Med. Chem., 49, pp. 6429-6434; (2013) ADRIANA.Code, , http://www.mol-net.com, Molecular Networks GmbH: Erlangen, Germany, (accessed Sept. 9); Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent Descriptors (GRIND): A Novel Class of Alignment-Independent Three-Dimensional Molecular Descriptors (2000) J. Med. Chem., 43, pp. 3233-3243; Pastor, M., Alignment-Independent Descriptors from Molecular Interaction Fields (2006) Molecular Interaction Fields. Applications in Drug Discovery and ADME Predictions, pp. 117-141. , In; Cruciani, G. Wiley-VCH: Chichester, U.K; Mevik, B.-H., Wehrens, R., The Pls Package: Principal Component and Partial Least Squares Regression in R (2007) J. Stat. Software, 18, pp. 1-24; Liaw, A., Wiener, M., Classification and Regression by randomForest (2002) R News, 2, pp. 18-22; Breiman, L., Random Forests (2001) Mach. Learn., 45, pp. 5-32; Guha, R., Chemical Informatics Functionality in R (2007) J. Stat. Software, 18, pp. 1-16; Nikolova, N., Jaworska, J., Approaches to Measure Chemical Similarity - A Review (2003) QSAR Comb. Sci., 22, pp. 1006-1026; Maggiora, G., On Outliers and Activity Cliffs - Why QSAR Often Disappoints (2006) J. Chem. Inf. Model., 46, pp. 1535-1535; Martin, Y.C., Kofron, J.L., Traphagen, L.M., Do Structurally Similar Molecules Have Similar Biological Activity? (2002) J. Med. Chem., 45, pp. 4350-4358; Wold, S., Johansson, E.C.M., PLS - Partial Least Squares Projections to Latent Structures (1993) 3D-QSAR in Drug Design, Theory, Methods, and Applications, pp. 523-550. , In; Kubinyi, H. ESCOM: Leiden, The Netherlands","Pastor, M.; Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Dr. Aiguader, 88, E-08003 Barcelona, Spain; email: manuel.pastor@upf.edu",,,"American Chemical Society",,,,,15499596,,JCISD,"24821140","English","J. Chem. Inf. Model.",Article,"Final",,Scopus,2-s2.0-84901642561
"Selent J., Marti-Solano M., Rodríguez J., Atanes P., Brea J., Castro M., Sanz F., Loza M.I., Pastor M.","55891371700;55090002400;7404695962;56068173900;6603008588;13402994300;7102263897;7003766926;7102415847;","Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles",2014,"European Journal of Medicinal Chemistry","77",,,"91","95",,8,"10.1016/j.ejmech.2014.02.058","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896115809&doi=10.1016%2fj.ejmech.2014.02.058&partnerID=40&md5=e8ad459c61b74f392bed5ad4ec0f61bb","Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader, 88, E-08003 Barcelona, Spain; Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782, Spain","Selent, J., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader, 88, E-08003 Barcelona, Spain; Marti-Solano, M., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader, 88, E-08003 Barcelona, Spain; Rodríguez, J., Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782, Spain; Atanes, P., Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782, Spain; Brea, J., Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782, Spain; Castro, M., Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782, Spain; Sanz, F., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader, 88, E-08003 Barcelona, Spain; Loza, M.I., Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782, Spain; Pastor, M., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader, 88, E-08003 Barcelona, Spain","The clinical efficacy of antipsychotic drugs has been associated with a certain binding profile for a set of G protein-coupled receptors (GPCR)s. In this work, we use the structurally-related clozapine-olanzapine pair to progress in the understanding of the structural properties that determine their divergent binding profiles and, thereby, their differing therapeutic efficacy. First, we present novel site-directed mutagenesis results that confirm our previous hypothesis on the importance of ligand interaction with positions 5.42 and 5.46 in transmembrane helix 5. Then, we use refined models of ligand-receptor complexes, built from recently published GPCR crystal structures, to gain further insight into the molecular mechanisms responsible for the observed experimental outcomes. In particular, we observe that preventing or potentiating hydrogen bonding with position 5.46, could allow obtaining ligands with, respectively, clozapine or olanzapine-like affinities. Results presented in this study could guide the design of antipsychotic candidates with tailored binding profiles. © 2014 Elsevier Masson SAS. All rights reserved.","Antipsychotic drugs; Binding profile; GPCR; Molecular modelling; Multi-target; Site-directed mutagenesis","clozapine; G protein coupled receptor; hydrogen; ligand; membrane protein; olanzapine; benzodiazepine derivative; clozapine; dopamine 2 receptor; dopamine D2L receptor; neuroleptic agent; olanzapine; protein binding; serotonin 1A receptor; animal cell; article; binding affinity; crystal structure; drug efficacy; drug protein binding; drug selectivity; hydrogen bond; molecular model; nonhuman; protein expression; site directed mutagenesis; structure activity relation; binding competition; chemical phenomena; chemical structure; chemistry; dose response; genetics; human; metabolism; structure activity relation; Antipsychotic Agents; Benzodiazepines; Binding, Competitive; Clozapine; Dose-Response Relationship, Drug; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Protein Binding; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Structure-Activity Relationship",,"clozapine, 5786-21-0; hydrogen, 12385-13-6, 1333-74-0; olanzapine, 132539-06-1; Antipsychotic Agents; Benzodiazepines; Clozapine; dopamine D2L receptor; Ligands; olanzapine; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2",,,"Ministerio de Ciencia y Tecnología, MICYT: SAF2009-13609-C04-04

European Social Fund, ESF: 2012FI_B 00819

Xunta de Galicia: 10PXIB203056PR

091010

Instituto de Salud Carlos III: CP12/03139","This work was funded by the Ministerio de Educación y Ciencia , Grant number: SAF2009-13609-C04-04 ; XUNTA de Galicia , Grant number: 10PXIB203056PR and La MARATÓ de TV3 Foundation , Grant number: 091010 . M M-S is supported by a doctoral fellowship from the University and Research Secretariat of the Catalan Government and the European Social Fund ( 2012FI_B 00819 ). JS acknowledges support from the Instituto de Salud Carlos III FEDER ( CP12/03139 ). Appendix A",,,"Roth, B., Sheffler, D., Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia (2004) Nature Reviews Drug Discovery, 3, pp. 3-9; Kim, D.H., Maneen, M.J., Stahl, S.M., Building a better antipsychotic: Receptor targets for the treatment of multiple symptom dimensions of schizophrenia (2009) Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 6, pp. 78-85; Selent, J., Bauer-Mehren, A., López, L., Loza, M.I., Sanz, F., Pastor, M., A novel multilevel statistical method for the study of the relationships between multireceptorial binding affinity profiles and in vivo endpoints (2010) Molecular Pharmacology, 77, pp. 149-158; Wong, E.H.F., Tarazi, F.I., Shahid, M., The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action (2010) Pharmacology & Therapeutics, 126, pp. 173-185; Souza, J.S., Kayo, M., Tassell, I., Martins, C.B., Elkis, H., Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: Evidence from a systematic review and meta-analyses (2013) CNS Spectrums, 18, pp. 82-89; Nooijen, P.M.M., Carvalho, F., Flanagan, R.J., Haematological toxicity of clozapine and some other drugs used in psychiatry (2011) Human Psychopharmacology, 26, pp. 112-119; Attard, A., Taylor, D.M., Comparative effectiveness of atypical antipsychotics in schizophrenia: What have real-world trials taught us? (2012) CNS Drugs, 26, pp. 491-508; Selent, J., López, L., Sanz, F., Pastor, M., Multi-receptor binding profile of clozapine and olanzapine: A structural study based on the new beta2 adrenergic receptor template (2008) ChemMedChem, 3, pp. 1194-1198; Ballesteros, J., Weinstein, H., Integrated methods for the construction of three dimensional models and computational probing of structure function relations in Gprotein coupled receptor (1995) Methods in Neurosciences, 25, pp. 366-428; Chien, E.Y.T., Liu, W., Zhao, Q., Katritch, V., Han, G.W., Hanson, M.A., Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist (2010) Science, 330, pp. 1091-1095; Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Structural basis for molecular recognition at serotonin receptors (2013) Science, pp. 1-9; Milletti, F., Vulpetti, A., Tautomer preference in PDB complexes and its impact on structure-based drug discovery (2010) Journal of Chemical Information and Modeling, 50, pp. 1062-1074; Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G.F., Foon, S.T., Kobilka, T.S., Choi, H.-J., Stevens, R.C., High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor (2007) Science, 318 (5854), pp. 1258-1265. , DOI 10.1126/science.1150577; Cullen, B.R., Use of eukaryotic expression technology in the functional analysis of cloned genes (1987) Methods in Enzymology, 152, pp. 684-704; Software, , http://www.chemcomp.com/software.htm, Molecular Operating Environment (MOE); Sali, A., Blundell, T.L., Comparative protein modelling by satisfaction of spatial restraints (1993) Journal of Molecular Biology, 234 (3), pp. 779-815. , DOI 10.1006/jmbi.1993.1626; Case, D., (2012) AMBER 12, , University of California San Francisco; Gerber, P.R., Müller, K., MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry (1995) Journal of Computer-Aided Molecular Design, 9, pp. 251-268; Laskowski, R.A., Macarthur, M.W., Moss, D.S., Thornton, J.M., PROCHECK: A program to check the stereochemical quality of protein structures (1993) Journal of Applied Crystallography, 26, pp. 283-291; Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., Improved protein-ligand docking using GOLD (2003) Proteins: Structure, Function and Genetics, 52 (4), pp. 609-623. , DOI 10.1002/prot.10465","Selent, J.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader, 88, E-08003 Barcelona, Spain; email: Jana.selent@upf.edu",,,"Elsevier Masson SAS",,,,,02235234,,EJMCA,"24631727","English","Eur. J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-84896115809
"Bravo A., Cases M., Queralt-Rosinach N., Sanz F., Furlong L.I.","56374942700;56251049800;35766634600;7102263897;34770469800;","A knowledge-driven approach to extract disease-related biomarkers from the literature",2014,"BioMed Research International","2014",, 253128,"","",,24,"10.1155/2014/253128","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84900334705&doi=10.1155%2f2014%2f253128&partnerID=40&md5=9b6278c666b4fc862d2b15adbe9c308b","Department of Experimental and Health Sciences, Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, C/Dr Aiguader 88, E-08003 Barcelona, Spain","Bravo, A., Department of Experimental and Health Sciences, Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, C/Dr Aiguader 88, E-08003 Barcelona, Spain; Cases, M., Department of Experimental and Health Sciences, Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, C/Dr Aiguader 88, E-08003 Barcelona, Spain; Queralt-Rosinach, N., Department of Experimental and Health Sciences, Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, C/Dr Aiguader 88, E-08003 Barcelona, Spain; Sanz, F., Department of Experimental and Health Sciences, Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, C/Dr Aiguader 88, E-08003 Barcelona, Spain; Furlong, L.I., Department of Experimental and Health Sciences, Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, C/Dr Aiguader 88, E-08003 Barcelona, Spain","The biomedical literature represents a rich source of biomarker information. However, both the size of literature databases and their lack of standardization hamper the automatic exploitation of the information contained in these resources. Text mining approaches have proven to be useful for the exploitation of information contained in the scientific publications. Here, we show that a knowledge-driven text mining approach can exploit a large literature database to extract a dataset of biomarkers related to diseases covering all therapeutic areas. Our methodology takes advantage of the annotation of MEDLINE publications pertaining to biomarkers with MeSH terms, narrowing the search to specific publications and, therefore, minimizing the false positive ratio. It is based on a dictionary-based named entity recognition system and a relation extraction module. The application of this methodology resulted in the identification of 131,012 disease-biomarker associations between 2,803 genes and 2,751 diseases, and represents a valuable knowledge base for those interested in disease-related biomarkers. Additionally, we present a bibliometric analysis of the journals reporting biomarker related information during the last 40 years. © 2014 À. Bravo et al.",,"biological marker; brain derived neurotrophic factor; C reactive protein; CD34 antigen; CD4 antigen; CD8alpha antigen; dipeptidyl carboxypeptidase; intercellular adhesion molecule 1; interleukin 2; interleukin 6; Muellerian inhibiting factor; netrin 1; neutrophil gelatinase associated lipocalin; pentraxin; protein; protein moc 31; protein p53; troponin I; tumor necrosis factor; unclassified drug; vasculotropin A; biological marker; genetic marker; acute kidney failure; article; autism; Bowen disease; data base; disease association; genetic association; heart failure; human; information; knowledge base; lung adenocarcinoma; lupus vulgaris; medical information; Medline; methodology; publication; standardization; data mining; genetic marker; metabolism; Biological Markers; Data Mining; Genetic Markers; Humans; MEDLINE",,"brain derived neurotrophic factor, 218441-99-7; C reactive protein, 9007-41-4; dipeptidyl carboxypeptidase, 9015-82-1; intercellular adhesion molecule 1, 126547-89-5; interleukin 2, 85898-30-2; Muellerian inhibiting factor, 80497-65-0; protein, 67254-75-5; troponin I, 77108-40-8; vasculotropin A, 489395-96-2; Biological Markers; Genetic Markers",,,,,,,"Atkinson Jr., A.J., Colburn, W.A., DeGruttola, V.G., DeMets, D.L., Downing, G.J., Hoth, D.F., Oates, J.A., Zeger, S.L., Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework (2001) Clinical Pharmacology and Therapeutics, 69 (3), pp. 89-95. , DOI 10.1067/mcp.2001.113989; http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129296. pdf, Guidance for Industry-E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories; Anderson, D.C., Kodukula, K., Biomarkers in pharmacology and drug discovery (2014) Biochemical Pharmacology, 87 (1), pp. 172-188. , 10.1016/j.bcp.2013.08.026; Frank, R., Hargreaves, R., Clinical biomarkers in drug discovery and development (2003) Nature Reviews Drug Discovery, 2 (7), pp. 566-580; Dancey, J.E., Dobbin, K.K., Groshen, S., Jessup, J.M., Hruszkewycz, A.H., Koehler, M., Parchment, R., Grever, M.R., Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents (2010) Clinical Cancer Research, 16 (6), pp. 1745-1755. , 2-s2.0-77949667760 10.1158/1078-0432.CCR-09-2167; Oldenhuis, C.N.A.M., Oosting, S.F., Gietema, J.A., De Vries, E.G.E., Prognostic versus predictive value of biomarkers in oncology (2008) European Journal of Cancer, 44 (7), pp. 946-953. , 2-s2.0-42649085349 10.1016/j.ejca.2008.03.006; Poste, G., Bring on the biomarkers (2011) Nature, 469 (7329), pp. 156-157. , 2-s2.0-78651394465 10.1038/469156a; Prensner, J.R., Chinnaiyan, A.M., Srivastava, S., Systematic, evidence-based discovery of biomarkers at the NCI (2012) Clinical & Experimental Metastasis, 29 (7), pp. 645-652. , 10.1007/s10585-012-9507-z; Cases, M., Furlong, L.I., Albanell, J., Improving data and knowledge management to better integrate health care and research (2013) Journal of International Medicine, 274 (4), pp. 321-328. , 10.1111/joim.12105; http://www.nlm.nih.gov/bsd/pmresources.html, Medline; http://www.ncbi.nlm.nih.gov/mesh/?term=biological+marker, Biological Markers MeSH term; http://www.ncbi.nlm.nih.gov/mesh/?term=Biomarkers%2C+Pharmacological, Biomarkers, Pharmacological MeSH term; Hahn, U., Cohen, K.B., Garten, Y., Shah, N.H., Mining the pharmacogenomics literature - A survey of the state of the art (2012) Briefings in Bioinformatics, 13 (4), pp. 460-494. , 10.1093/bib/bbs018; Younesi, E., Toldo, L., Müller, B., Friedrich, C.M., Novac, N., Scheer, A., Hofmann-Apitius, M., Fluck, J., Mining biomarker information in biomedical literature (2012) BMC Medical Informatics & Decision Making; Hui, L., Chunmei, L., Biomarker identification using text mining (2012) Computational and Mathematical Methods in Medicine, 2012, p. 4. , 135780 10.1155/2012/135780; Jessen, W.J., Landschulz, K.T., Turi, T.G., Reams, R.Y., Mining PubMed for biomarker-disease associations to guide discovery (2012) Nature Precedings, , 10.1038/npre.2012.6941.1; ftp://ftp.ncbi.nih.gov/gene/DATA/gene_info.gz, Ncbi-Gene; http://www.genenames.org/cgi-bin/hgnc_downloads, Hgnc; ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/ knowledgebase/taxonomic_divisions/uniprot_sprot_human.dat.gz, UniProt human data; ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/ idmapping/by_organism/HUMAN_9606_idmapping_selected.tab.gz, UniProt IDmapping; http://www.nlm.nih.gov/research/umls/licensedcontent/ umlsknowledgesources.html, 2013AA UMLS Full Release Files, January 2013 version; http://biosemantics.org/index.php?page=casper, Casper; Huang, M., Zhu, X., Hao, Y., Payan, D.G., Qu, K., Li, M., Discovering patterns to extract protein-protein interactions from full texts (2004) Bioinformatics, 20 (18), pp. 3604-3612. , DOI 10.1093/bioinformatics/bth451; Lau, W.W., Johnson, C.A., Becker, K.G., Rule-based human gene normalization in biomedical text with confidence estimation Proceedings of the Life Sciences Society Computational Systems Bioinformatics Conference (CSB '07), 6, pp. 371-379. , August 2007 San Diego, Calif, USA; Bui, Q.C., Sloot, P.M., A robust approach to extract biomedical events from literature (2012) Bioinformatics, 28 (20), pp. 2654-2661. , 10.1093/bioinformatics/bts487; Salton, G., Buckley, C., Term-weighting approaches in automatic text retrieval (1988) Information Processing & Management, 24 (5), pp. 513-523. , 2-s2.0-45549117987 10.1016/0306-4573(88)90021-0; Bauer-Mehren, A., Rautschka, M., Sanz, F., Furlong, L.I., DisGeNET: A cytoscape plugin to visualize, integrate, search and analyze gene-disease networks (2010) Bioinformatics, 26 (22), pp. 2924-2926. , 2-s2.0-78149236787 10.1093/bioinformatics/btq538; http://ibi.imim.es/DisGeNET/, DisGeNET website; http://ibi.imim.es/DisGeNET-Dev/ontologies/GeneDiseaseAssociation_v4.owl, DisGeNET Gene-Disease Association Ontology (dgdao) 2012; http://code.google.com/p/semanticscience/wiki/SIO, Semantics Science Integrated Ontology or SIO Ontology; http://www.nlm.nih.gov/mesh/trees.html, MeSH Disease Tree; Xu, R., Wang, Q., A knowledge-driven conditional approach to extract pharmacogenomics specific drug-gene relationships from free text (2012) Journal of Biomedical Informatics, 45 (5), pp. 827-834. , 10.1016/j.jbi.2012.04.011; Bentzen, S.M., Buffa, F.M., Wilson, G.D., Multiple biomarker tissue microarrays: Bioinformatics and practical approaches (2008) Cancer and Metastasis Reviews, 27 (3), pp. 481-494. , 2-s2.0-47949085216 10.1007/s10555-008-9145-8; Rossi, D., IX. Chronic lymphocytic leukaemia: New genetic markers as prognostic factors (2013) Hematological Oncology, 31, pp. 57-59. , supplement 1 10.1002/hon.2068","Furlong, L.I.; Department of Experimental and Health Sciences, Hospital Del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, C/Dr Aiguader 88, E-08003 Barcelona, Spain; email: lfurlong@imim.es",,,"Hindawi Publishing Corporation",,,,,23146133,,,"24839601","English","BioMed Res. Int.",Article,"Final",Open Access,Scopus,2-s2.0-84900334705
"Marti-Solano M., Birney E., Bril A., Pasqua O.D., Kitano H., Mons B., Xenarios I., Sanz F.","55090002400;7004802904;55856361600;57191864487;7201618005;7004074338;6602760768;7102263897;","Integrative knowledge management to enhance pharmaceutical RandD",2014,"Nature Reviews Drug Discovery","13","4",,"239","240",,7,"10.1038/nrd4290","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897432350&doi=10.1038%2fnrd4290&partnerID=40&md5=1123771647127eaa121dac6bcb3c270d","IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridgeshire CB10 1SD, United Kingdom; Institut de Recherches Internationales Servier, 53 rue Carnot, 92284 Suresnes Cedex, France; GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT, United Kingdom; Systems Biology Institute, 5-6-9 Shirokanedai, Minato, Tokyo 108-0071, Japan; RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045, Japan; Netherlands Bioinformatics Centre, 260 NBIC, 6500 HB Nijmegen, Netherlands; Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands; Swiss Institute of Bioinformatics, Quartier Sorge-Batiment Genopode, 1015 Lausanne, Switzerland","Marti-Solano, M., IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain; Birney, E., European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridgeshire CB10 1SD, United Kingdom; Bril, A., Institut de Recherches Internationales Servier, 53 rue Carnot, 92284 Suresnes Cedex, France; Pasqua, O.D., GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT, United Kingdom; Kitano, H., Systems Biology Institute, 5-6-9 Shirokanedai, Minato, Tokyo 108-0071, Japan, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045, Japan; Mons, B., Netherlands Bioinformatics Centre, 260 NBIC, 6500 HB Nijmegen, Netherlands, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands; Xenarios, I., Swiss Institute of Bioinformatics, Quartier Sorge-Batiment Genopode, 1015 Lausanne, Switzerland; Sanz, F., IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain","Information technologies already have a key role in pharmaceutical research and development (R&D), but achieving substantial advances in their use and effectiveness will depend on overcoming current challenges in sharing, integrating and jointly analysing the range of data generated at different stages of the R&D process. © 2014 Macmillan Publishers Limited. All rights reserved An.",,"drug development; drug efficacy; drug research; drug use; information dissemination; information processing; information technology; integrative medicine; knowledge management; ontology development; priority journal; review; Cooperative Behavior; Drug Industry; Humans; Information Management; Knowledge Management; Research; Technology, Pharmaceutical",,,,,,,,,"Sansone, S.A., Toward interoperable bioscience data (2012) Nature Genet., 44, pp. 121-126; Cases, M., Improving data and knowledge management to better integrate health care and research (2013) J. Intern. Med., 274, pp. 321-328; Beck, T., Knowledge engineering for health: A new discipline required to bridge the ICT gap between research and healthcare (2012) Hum. Mutat., 33, pp. 797-802; Kitano, H., Social engineering for virtual 'big science' in systems biology (2011) Nature Chem. Biol., 7, pp. 323-326; Williams, A.J., Open PHACTS: Semantic interoperability for drug discovery (2012) Drug Discov. Today, 17, pp. 1188-1198","Sanz, F.; IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain; email: ferran.sanz@upf.edu",,,"Nature Publishing Group",,,,,14741776,,NRDDA,"24687050","English","Nat. Rev. Drug Discov.",Review,"Final",,Scopus,2-s2.0-84897432350
"Espinet B., Ferrer A., Bellosillo B., Nonell L., Salar A., Fernandez-Rodriguez C., Puigdecanet E., Gimeno J., Garcia-Garcia M., Carmen Vela M., Luno E., Collado R., Navarro J.T., De La Banda E., Abrisqueta P., Arenillas L., Serrano C., Lloreta J., Minana B., Cerutti A., Florensa L., Orfao A., Sanz F., Sole F., Dominguez-Sola D., Serrano S.","7004259456;7101848062;6603924332;25230430800;6701726712;55918623300;24467151600;7005858959;38861550800;56080018700;6601976385;14324236800;35390860500;16938921000;16303073300;8341481900;7005731962;7004089146;6507490965;7006118551;7006055618;7102602445;7102263897;35436144900;6506721771;55444168000;","Distinction between asymptomatic monoclonal b-cell lymphocytosis with cyclin d1 overexpression and mantle cell lymphoma: From molecular profiling to flow cytometry",2014,"Clinical Cancer Research","20","4",,"1007","1019",,18,"10.1158/1078-0432.CCR-13-1077","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896715588&doi=10.1158%2f1078-0432.CCR-13-1077&partnerID=40&md5=3c276aa4d71d673d729493c7fd47a4cb","Servei de Patologia, United States; Servei d'Hematologia, Hospital Del Mar, United States; Programa de Recerca en C ancer, United States; Servei d'An alisi de Microarrays, United States; Institut Catal a de Recerca i Estudis Avancats (ICREA), United States; Research Programmeon Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, PRBB, Spain; Servei d'Hematologia, ICO-Hospital Germans Trias i Pujol, United States; Servei d'Hematologia, IDIBELL-Hospital de Bellvitge, L'Hospitalet de Llobregat, United States; Servei d'Hematologia, Hospital Universitari Vall d'Hebron, Spain; Centre de Regulacio Gen omica, Barcelona, Spain; Servicio de Hematologia, Hospital Universitario Central de Asturias, Oviedo, Spain; Servicio de Hematologia, Hospital General Universitario de Valencia, Valencia, Spain; Laboratorio de Citometria de Flujo, Servicio de Hematologia, Fundacion Jimenez Diaz, Madrid, Spain; Servicio General de Citometria, Centro de Investigacion Del Cancer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain; Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 Saint Nicholas Avenue, NY, 10032, United States; Universitat Autònoma de Barcelona, Spain","Espinet, B., Servei de Patologia, United States, Programa de Recerca en C ancer, United States; Ferrer, A., Servei de Patologia, United States, Programa de Recerca en C ancer, United States; Bellosillo, B., Servei de Patologia, United States, Programa de Recerca en C ancer, United States; Nonell, L., Servei d'An alisi de Microarrays, United States; Salar, A., Servei d'Hematologia, Hospital Del Mar, United States, Programa de Recerca en C ancer, United States; Fernandez-Rodriguez, C., Programa de Recerca en C ancer, United States; Puigdecanet, E., Servei d'An alisi de Microarrays, United States; Gimeno, J., Servei de Patologia, United States; Garcia-Garcia, M., Servei de Patologia, United States, Programa de Recerca en C ancer, United States; Carmen Vela, M., Servei de Patologia, United States; Luno, E., Servicio de Hematologia, Hospital Universitario Central de Asturias, Oviedo, Spain; Collado, R., Servicio de Hematologia, Hospital General Universitario de Valencia, Valencia, Spain; Navarro, J.T., Servei d'Hematologia, ICO-Hospital Germans Trias i Pujol, United States; De La Banda, E., Servei d'Hematologia, IDIBELL-Hospital de Bellvitge, L'Hospitalet de Llobregat, United States; Abrisqueta, P., Servei d'Hematologia, Hospital Universitari Vall d'Hebron, Spain; Arenillas, L., Servei de Patologia, United States, Programa de Recerca en C ancer, United States; Serrano, C., Laboratorio de Citometria de Flujo, Servicio de Hematologia, Fundacion Jimenez Diaz, Madrid, Spain; Lloreta, J., Servei de Patologia, United States, Programa de Recerca en C ancer, United States; Minana, B., Centre de Regulacio Gen omica, Barcelona, Spain; Cerutti, A., Institut Catal a de Recerca i Estudis Avancats (ICREA), United States; Florensa, L., Servei de Patologia, United States, Programa de Recerca en C ancer, United States; Orfao, A., Servicio General de Citometria, Centro de Investigacion Del Cancer (IBMCC-CSIC/USAL and IBSAL) and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain; Sanz, F., Research Programmeon Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, PRBB, Spain; Sole, F., Servei de Patologia, United States, Programa de Recerca en C ancer, United States; Dominguez-Sola, D., Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 Saint Nicholas Avenue, NY, 10032, United States; Serrano, S., Servei de Patologia, United States, Universitat Autònoma de Barcelona, Spain","Purpose: According to current diagnostic criteria, mantle cell lymphoma (MCL) encompasses the usual, aggressive variants and rare, nonnodal cases with monoclonal asymptomatic lymphocytosis, cyclin D1- positive (MALD1). We aimed to understand the biology behind this clinical heterogeneity and to identify markers for adequate identification of MALD1 cases. Experimental Design: We compared 17 typical MCL cases with a homogeneous group of 13 untreated MALD1 cases (median follow-up, 71 months). We conducted gene expression profiling with functional analysis in five MCL and five MALD1. Results were validated in 12 MCL and 8 MALD1 additional cases by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in 24MCLand 13MALD1cases by flow cytometry. Classification and regression trees strategy was used to generate an algorithm based on CD38 and CD200 expression by flow cytometry. Results: We found 171 differentially expressed genes with enrichment of neoplastic behavior and cell proliferation signatures in MCL. Conversely, MALD1 was enriched in gene sets related to immune activation and inflammatory responses. CD38 and CD200 were differentially expressed betweenMCLandMALD1and confirmed by flow cytometry (median CD38, 89% vs. 14%; median CD200, 0% vs. 24%, respectively). Assessment of both proteins allowed classifying 85% (11 of 13) of MALD1 cases whereas 15% remained unclassified. SOX11 expression by qRT-PCR was significantly different between MCL and MALD1 groups but did not improve the classification. Conclusion: We show for the first time that MALD1, in contrast to MCL, is characterized by immune activation and driven by inflammatory cues. Assessment of CD38/CD200 by flow cytometry is useful to distinguish most cases of MALD1 from MCL in the clinical setting. MALD1 should be identified and segregated from the current MCL category to avoid overdiagnosis and unnecessary treatment. © 2014 American Association for Cancer Research.",,"CD200 receptor; CD38 antigen; cyclin D1; transcription factor Sox11; adult; article; asymptomatic disease; cell proliferation; clinical article; controlled study; female; flow cytometry; gene expression; gene expression profiling; gene overexpression; human; human cell; human tissue; immunoreactivity; inflammation; male; mantle cell lymphoma; monoclonal b cell lymphocytosis; neoplasm; priority journal; protein expression; quantitative analysis; reverse transcription polymerase chain reaction; Asymptomatic Diseases; B-Lymphocytes; Case-Control Studies; Cyclin D1; Diagnosis, Differential; Female; Flow Cytometry; Gene Expression Profiling; Humans; Lymphocytosis; Lymphoma, Mantle-Cell; Male; Middle Aged; Survival Analysis; Transcriptome",,,,,,,,,"Swerdlow, S.H., Campo, E., Seto, M., Müller-Hermelink, H.K., Mantle cell lymphoma (2008) World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, pp. 229-232. , Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. Lyon, France: IARC Press; Campo, E., Raffeld, M., Jaffe, E.S., Mantle-cell lymphoma (1999) Semin Hematol, 36, pp. 115-127; Hinds, P.W., Dowdy, S.F., Eaton, E.N., Arnold, A., Weinberg, R.A., Function of a human cyclin gene as an oncogene (1994) Proc Natl Acad Sci U S A, 91, pp. 709-713; Gladden, A.B., Woolery, R., Aggarwal, P., Wasik, M.A., Diehl, J.A., Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces Bcell lymphoma (2006) Oncogene, 25, pp. 998-1007; Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Improvement of overall survival in advanced stage mantle cell lymphoma (2009) J Clin Oncol, 27, pp. 511-518; Nodit, L., Bahler, D.W., Jacobs, S.A., Locker, J., Swerdlow, S.H., Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes (2003) Hum Pathol, 34, pp. 1030-1034; Orchard, J., Garand, R., Davis, Z., Babbage, G., Sahota, S., Matutes, E., A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease (2003) Blood, 101, pp. 4975-4981; Espinet, B., Sole, F., Pedro, C., Garcia, M., Bellosillo, B., Salido, M., Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: An early-stage event in the development or an indolent form of a mantle cell lymphoma? (2005) Hum Pathol, 36, pp. 1232-1237; Fernandez, V., Salamero, O., Espinet, B., Sole, F., Royo, C., Navarro, A., Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma (2010) Cancer Res, 70, pp. 1408-1418; Ondrejka, S.L., Lai, R., Kumar, N., Smith, S.D., Hsi, E.D., Indolent mantle cell leukemia: A clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis (2011) Haematologica, 96, pp. 1121-1127; Rule, S.A., Poplar, S., Evans, P.A., O'Connor, S.J., Owen, R.G., Indolent mantlecell lymphoma: Immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation (2011) J Clin Oncol, 29, pp. e437-e439; Del Giudice, I., Messina, M., Chiaretti, S., Santangelo, S., Tavolaro, S., De Propris, M.S., Behind the scenes of non-nodal MCL: Downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes (2012) Br J Haematol, 156, pp. 601-611; Royo, C., Navarro, A., Clot, G., Salaverria, I., Gine, E., Jares, P., Nonnodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease (2012) Leukemia, 26, pp. 1895-1898; Thieblemont, C., Nasser, V., Felman, P., Leroy, K., Gazzo, S., Callet-Bauchu, E., Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis (2004) Blood, 103, pp. 2727-2737; Navarro, A., Royo, C., Hernandez, L., Jares, P., Campo, E., Molecular pathogenesis of mantle cell lymphoma: New perspectives and challenges with clinical implications (2011) Semin Hematol, 48, pp. 155-165; Espinet, B., Sole, F., Woessner, S., Bosch, F., Florensa, L., Campo, E., Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma (1999) Cancer Genet Cytogenet, 111, pp. 92-98; Ventura, R.A., Martin-Subero, J.I., Jones, M., McParland, J., Gesk, S., Mason, D.Y., FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue (2006) J Mol Diagn, 8, pp. 141-151; Van Dongen, J.J., Langerak, A.W., Bruggemann, M., Evans, P.A., Hummel, M., Lavender, F.L., Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 (2003) Leukemia, 17, pp. 2257-2317; Wiestner, A., Tehrani, M., Chiorazzi, M., Wright, G., Gibellini, F., Nakayama, K., Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival (2007) Blood, 109, pp. 4599-4606; Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., ZAP-70 expression as a surrogate for immunoglobulin-variableregion mutations in chronic lymphocytic leukemia (2003) N Engl J Med, 348, pp. 1764-1775; Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U., Exploration, normalization, and summaries of high density oligonucleotide array probe level data (2003) Biostatistics, 4, pp. 249-264; Smyth, G.K., Linear models and empirical bayes methods for assessing differential expression in microarray experiments (2004) Stat Appl Genet Mol Biol, 3, pp. Article3; Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Bioconductor: Open software development for computational biology and bioinformatics (2004) Genome Biol, 5, pp. R80; Bengtsson, H., Simpson, K., Bullard, J., Hansen, K., (2008) Aroma.affymetrix: A Generic Framework in R for Analyzing Small to Very Large Affymetrix Data Sets in Bounded Memory, , http://www.aroma-project.org, Tech Report #745, Department of Statistics, University of California, Berkeley, February. [cited 2013 Sep 15]; Ingenuity Pathway Analysis (Ingenuity Systems), , www.ingenuity.com, cited 2013 Sep 15; Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles (2005) Proc Natl Acad Sci U S A, 102, pp. 15545-15550; Gene Expression Omnibus, A Public Functional Genomics Data Repository Supporting MIAME-compliant Data Submissions, , http://www.ncbi.nlm.nih.gov/geo, cited 2013 Sep 15; Breiman, L., Friedman, J., Stone, C.J., Olshen, R.A., (1984) Classification and Regression Trees, , Boca Raton, Florida: Chapman & Hall; The Confidence Interval of A Proportion Tool, , http://www.vassarstats.net/prop1.html, cited 2013Sep15; Pittaluga, S., Verhoef, G., Criel, A., Maes, A., Nuyts, J., Boogaerts, M., Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma (1996) Leuk Lymphoma, 21, pp. 115-125; Rawstron, A.C., Green, M.J., Kuzmicki, A., Kennedy, B., Fenton, J.A., Evans, P.A., Monoclonal B lymphocytes with the characteristics of ""indolent"" chronic lymphocytic leukemia are present in 3. 5% of adults with normal blood counts (2002) Blood, 100, pp. 635-639; Welzel, N., Le, T., Marculescu, R., Mitterbauer, G., Chott, A., Pott, C., Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: Implications for the mechanism of translocation and the origin of mantle cell lymphoma (2001) Cancer Res, 61, pp. 1629-1636; Salar, A., Juanpere, N., Bellosillo, B., Domingo-Domenech, E., Espinet, B., Seoane, A., Gastrointestinal involvement in mantle cell lymphoma: A prospective clinic, endoscopic, and pathologic study (2006) Am J Surg Pathol, 30, pp. 1274-1280; Kuppers, R., Klein, U., Hansmann, M.L., Rajewsky, K., Cellular origin of human B-cell lymphomas (1999) N Engl J Med, 341, pp. 1520-1529; Hadzidimitriou, A., Agathangelidis, A., Darzentas, N., Murray, F., Fau-Larue, M.H., Pedersen, L.B., Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases (2011) Blood, 118, pp. 3088-3095; Navarro, A., Clot, G., Royo, C., Jares, P., Hadzidimitriou, A., Agathangelidis, A., Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features (2012) Cancer Res, 72, pp. 5307-5316; Ek, S., Dictor, M., Jerkeman, M., Jirstrom, K., Borrebaeck, C.A., Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma (2008) Blood, 111, pp. 800-805; Thieblemont, C., Houlgatte, R., Felman, P., Traverse-Glehen, A., Baseggio, L., Rolland, D., Indolent Mantle Cell Lymphoma (MCL): A retrospective detailed clinical and morphological analysis of 21 patients, with histological, cytological, cytogenetic, interphase genetic, immunoglobulin gene, and gene expression profiling analysis (2008) ASH Annual Meeting Abstracts, 112, p. 1780; A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) N Engl J Med, 329, pp. 987-994; Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., Van Hoof, A., Kluin-Nelemans, H.C., A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma (2008) Blood, 111, pp. 558-565; Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R.R., Ruan, J., Outcome of deferred initial therapy in mantle-cell lymphoma (2009) J Clin Oncol, 27, pp. 1209-1213; Eve, H.E., Furtado, M.V., Hamon, M.D., Rule, S.A., Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma (2009) J Clin Oncol, 27, pp. e189-e190; Van Zelm, M.C., Szczepanski, T., Van Der, B.M., Van Dongen, J.J., Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion (2007) J Exp Med, 204, pp. 645-655; Hirt, C., Schuler, F., Dolken, L., Schmidt, C.A., Dolken, G., Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR (2004) Blood, 104, pp. 904-905; Nieto, W.G., Almeida, J., Romero, A., Teodosio, C., Lopez, A., Henriques, A.F., Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach (2009) Blood, 114, pp. 33-37; Jares, P., Colomer, D., Campo, E., Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics (2007) Nat Rev Cancer, 7, pp. 750-762; Landgren, O., Albitar, M., Ma, W., Abbasi, F., Hayes, R.B., Ghia, P., B-cell clones as early markers for chronic lymphocytic leukemia (2009) N Engl J Med, 360, pp. 659-667; Klein, U., Lia, M., Crespo, M., Siegel, R., Shen, Q., Mo, T., The DLEU2/ miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia (2010) Cancer Cell, 17, pp. 28-40; Nieto, W.G., Teodosio, C., Lopez, A., Rodriguez-Caballero, A., Romero, A., Barcena, P., Non-CLL-like monoclonal B-cell lymphocytosis in the general population: Prevalence and phenotypic/genetic characteristics (2010) Cytometry B Clin Cytom, 78 (SUPPL. 1), pp. S24-34; Vegliante, M.C., Palomero, J., Perez-Galan, P., Roue, G., Castellano, G., Navarro, A., SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma (2013) Blood, 121, pp. 2175-2185; Ferrando, A.A., SOX11 is a mantle cell lymphoma oncogene (2013) Blood, 121, pp. 2169-2170; Nygren, L., Baumgartner, W.S., Klimkowska, M., Christensson, B., Kimby, E., Sander, B., Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma (2012) Blood, 119, pp. 4215-4223; Van Dongen, J.J., Lhermitte, L., Bottcher, S., Almeida, J., Van Der Velden, V.H., Flores-Montero, J., EuroFlow antibody panels for standardized ndimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes (2012) Leukemia, 26, pp. 1908-1975; Malavasi, F., Deaglio, S., Damle, R., Cutrona, G., Ferrarini, M., Chiorazzi, N., CD38 and chronic lymphocytic leukemia: A decade later (2011) Blood, 118, pp. 3470-3478; Zucchetto, A., Benedetti, D., Tripodo, C., Bomben, R., Dal Bo, M., Marconi, D., CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/ vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival (2009) Cancer Res, 69, pp. 4001-4009; Dorfman, D.M., Shahsafaei, A., CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms (2010) Am J Clin Pathol, 134, pp. 726-733; Palumbo, G.A., Parrinello, N., Fargione, G., Cardillo, K., Chiarenza, A., Berretta, S., CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia (2009) Leuk Res, 33, pp. 1212-1216","Dominguez-Sola, D.; Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 Saint Nicholas Avenue, NY, 10032, United States; email: dd2115@columbia.edu",,,"American Association for Cancer Research Inc.",,,,,10780432,,CCREF,"24352646","English","Clin. Cancer Res.",Article,"Final",Open Access,Scopus,2-s2.0-84896715588
"Lopes P., Nunes T., Campos D., Furlong L.I., Bauer-Mehren A., Sanz F., Carrascosa M.C., Mestres J., Kors J., Singh B., Van Mulligen E., Van Der Lei J., Diallo G., Avillach P., Ahlberg E., Boyer S., Diaz C., Oliveira J.L.","55538753378;55508659200;36241209000;34770469800;35572639000;7102263897;46260981600;7004586125;7005293297;57199778724;7003307150;56592306600;24398462100;23972137300;55507820200;55913555400;57197180745;57193360895;","Gathering and exploring scientific knowledge in pharmacovigilance",2013,"PLoS ONE","8","12", e83016,"","",,8,"10.1371/journal.pone.0083016","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892404109&doi=10.1371%2fjournal.pone.0083016&partnerID=40&md5=f65c1529cc5a6cb20fb6336aca72fb2e","DETI/IEETA, University of Aveiro, Aveiro, Portugal; Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; Erasmus University Medical Center, Rotterdam, Netherlands; LESIM-ISPED, Université de Bordeaux, Bordeaux, France; LERTIM, Faculté de Médecine, Université de Aix-Marseille, Marseille, France; AstraZeneca, Molndal, Sweden; Synapse Research Management Partners, Barcelona, Spain","Lopes, P., DETI/IEETA, University of Aveiro, Aveiro, Portugal; Nunes, T., DETI/IEETA, University of Aveiro, Aveiro, Portugal; Campos, D., DETI/IEETA, University of Aveiro, Aveiro, Portugal; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; Bauer-Mehren, A., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; Carrascosa, M.C., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; Mestres, J., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; Kors, J., Erasmus University Medical Center, Rotterdam, Netherlands; Singh, B., Erasmus University Medical Center, Rotterdam, Netherlands; Van Mulligen, E., Erasmus University Medical Center, Rotterdam, Netherlands; Van Der Lei, J., Erasmus University Medical Center, Rotterdam, Netherlands; Diallo, G., LESIM-ISPED, Université de Bordeaux, Bordeaux, France; Avillach, P., LESIM-ISPED, Université de Bordeaux, Bordeaux, France, LERTIM, Faculté de Médecine, Université de Aix-Marseille, Marseille, France; Ahlberg, E., AstraZeneca, Molndal, Sweden; Boyer, S., AstraZeneca, Molndal, Sweden; Diaz, C., Synapse Research Management Partners, Barcelona, Spain; Oliveira, J.L., DETI/IEETA, University of Aveiro, Aveiro, Portugal","Pharmacovigilance plays a key role in the healthcare domain through the assessment, monitoring and discovery of interactions amongst drugs and their effects in the human organism. However, technological advances in this field have been slowing down over the last decade due to miscellaneous legal, ethical and methodological constraints. Pharmaceutical companies started to realize that collaborative and integrative approaches boost current drug research and development processes. Hence, new strategies are required to connect researchers, datasets, biomedical knowledge and analysis algorithms, allowing them to fully exploit the true value behind state-of-the-art pharmacovigilance efforts. This manuscript introduces a new platform directed towards pharmacovigilance knowledge providers. This system, based on a service-oriented architecture, adopts a plugin-based approach to solve fundamental pharmacovigilance software challenges. With the wealth of collected clinical and pharmaceutical data, it is now possible to connect knowledge providers' analysis and exploration algorithms with real data. As a result, new strategies allow a faster identification of high-risk interactions between marketed drugs and adverse events, and enable the automated uncovering of scientific evidence behind them. With this architecture, the pharmacovigilance field has a new platform to coordinate large-scale drug evaluation efforts in a unique ecosystem, publicly available at http://bioinformatics.ua.pt/euadr/. © 2013 Lopes et al.",,"algorithm; article; computer program; data base; drug surveillance program; knowledge; medical research; scoring system; web browser; computer program; drug interaction; female; human; Internet; male; Drug Interactions; Female; Humans; Internet; Male; Pharmacovigilance; Software",,,,,,,,,"McClure, D.L., Improving Drug Safety: Active Surveillance Systems Should be Paramount (2009) Pharmaceutical Medicine, 23, pp. 127-130. , doi:10.1007/BF03256760; Shibata, A., Hauben, M., Pharmacovigilance, signal detection and signal intelligence overview (2011) Proceedings of the 14th International Conference on Information Fusion (FUSION). Chicago, IL, pp. 1-7; (2010) Annual Report, , Ema Ema European Medicines Agency; Robb, M.A., Racoosin, J.A., Sherman, R.E., Gross, T.P., Ball, R., The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety (2012) Pharmacoepidemiol Drug Saf, 21, pp. 9-11. , doi:10.1002/pds.2311. PubMed: 22262587; Xu, L., Anchordoquy, T., Drug delivery trends in clinical trials and translational medicine: Challenges and opportunities in the delivery of nucleic acid-based therapeutics (2011) J Pharm Sci, 100, pp. 38-52. , doi:10.1002/jps.22243. PubMed: 20575003; Nelson, J.C., Cook, A.J., Yu, O., Dominguez, C., Zhao, S., Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data (2012) Pharmacoepidemiol Drug Saf, 21, pp. 62-71. , doi:10.1002/pds.2324. PubMed: 22262594; Staffa, J.A., Dal Pan, G.J., Regulatory Innovation in Postmarketing Risk Assessment and Management (2012) Clin Pharmacol Ther, 91, pp. 555-557. , doi:10.1038/clpt.2011.289. PubMed: 22297386; Stahl, M., Edwards, I.R., Bowring, G., Kiuru, A., Lindquist, M., Assessing the Impact of Drug Safety Signals from the WHO Database Presented inSIGNAL': Results from a Questionnaire of National Pharmacovigilance Centres (2003) Drug Safety, 26, pp. 721-727; Lazarou, J., Pomeranz, B.H., Corey, P.N., Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies (1998) JAMA, 279, pp. 1200-1205. , doi:10.1001/jama.279.15.1200. PubMed: 9555760; Meyboom, R.H.B., Lindquist, M., Egberts, A.C.G., Edwards, I.R., Signal Selection and Follow-Up in Pharmacovigilance (2002) Drug Safety, 25, pp. 459-465. , doi:10.2165/00002018-200225060-00011. PubMed: 12071784; Alvarez-Requejo, A., Carvajal, A., Bégaud, B., Moride, Y., Vega, T., Under-reporting of adverse drug reactions Estimate based on a spontaneous reporting scheme and a sentinel system (1998) Eur J Clin Pharmacol, 54, pp. 483-488. , doi:10.1007/s002280050498. PubMed: 9776440; Grootheest, V., Attitudinal survey of voluntary reporting of adverse drug reactions (1999) Br J Clin Pharmacol, 48, pp. 623-627. , PubMed: 10583035; De Bruin, M.L., Van Puijenbroek, E.P., Egberts, A.C., Hoes, A.W., Leufkens, H.G., Non-sedating antihistamine drugs and cardiac arrhythmias - Biased risk estimates from spontaneous reporting systems? (2002) Br J Clin Pharmacol, 53, pp. 370-374. , doi:10.1046/j.1365-2125.2002.01569.x. PubMed: 11966667; Coloma, P.M., Schuemie, M.J., Trifirò, G., Gini, R., Herings, R., Combining electronic healthcare databases in Europe to allow for largescale drug safety monitoring: The EU-ADR Project (2011) Pharmacoepidemiol Drug Saf, 20, pp. 1-11. , doi:10.1002/pds.2206. PubMed: 21182150; Härmark, L., Van Grootheest, A.C., Pharmacovigilance: Methods, recent developments and future perspectives (2008) Eur J Clin Pharmacol, 64, pp. 743-752. , doi:10.1007/s00228-008-0475-9. PubMed: 18523760; Trontell, A.E., The RADAR Project and the FDA (2005) JAMA, 294, p. 1206. , doi:10.1001/jama.294.10.1206-a. PubMed: 16160128; Platt, R., Carnahan, R., The US Food and Drug Administration's Mini-Sentinel Program (2012) Pharmacoepidemiology and Drug Safety, 21, pp. 1-303. , doi:10.1002/pds.3324; Trifiro, G., Fourrier-Reglat, A., Sturkenboom, M.C.J.M., Díaz Acedo, C., Van Der Lei, J., The EU-ADR project: Preliminary results and perspective (2009) Stud Health Technol Inform, 148, pp. 43-49. , PubMed: 19745234; Stang, P.E., Ryan, P.B., Racoosin, J.A., Overhage, J.M., Hartzema, A.G., Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership (2010) Ann Intern Med, 153, pp. 600-606. , doi: 10.7326/0003-4819-153-9-201011020-00010. PubMed: 21041580; Ryan, P.B., Madigan, D., Stang, P.E., Marc Overhage, J., Racoosin, J.A., Empirical assessment of methods for risk identification in healthcare data: Results from the experiments of the Observational Medical Outcomes Partnership (2012) Stat Med, 31, pp. 4401-4415. , doi:10.1002/sim.5620. PubMed: 23015364; Schuemie, M.J., Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD (2011) Pharmacoepidemiol Drug Saf, 20, pp. 292-299. , doi:10.1002/pds.2051. PubMed: 20945505; Platt, R., Wilson, M., Chan, K.A., Benner, J.S., Marchibroda, J., The New Sentinel Network - Improving the Evidence of Medical-Product Safety (2009) N Engl J Med, 361, pp. 645-647. , doi:10.1056/NEJMp0905338. PubMed: 19635947; Behrman, R.E., Benner, J.S., Brown, J.S., McClellan, M., Woodcock, J., Developing the Sentinel System - A National Resource for Evidence. Development (2011) New England Journal of Medicine, 364, pp. 498-499. , doi:10.1056/NEJMp1014427; Curtis, L.H., Weiner, M.G., Boudreau, D.M., Cooper, W.O., Daniel, G.W., Design considerations, architecture, and use of the Mini-Sentinel distributed data system (2012) Pharmacoepidemiol Drug Saf, 21, pp. 23-31. , doi:10.1002/pds.2336. PubMed: 22262590; Gini, R., Coppola, M., Ryan, P.B., Righetti, G., Peri, I., Frameworks for Data Extraction and Management from Electronic Healthcare Databases for Multi-Center Epidemiologic Studies: A Comparison among EU-ADR, MATRICE, and OMOP Strategies (2013) 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Montréal. Canada; Trifirò, G., Patadia, V., Schuemie, M.J., Coloma, P.M., Gini, R., EU-ADR healthcare database network vs. Spontaneous reporting system database: Preliminary comparison of signal detection (2011) Stud Health Technol Inform, 166, pp. 25-30. , PubMed: 21685607; Wilke, R.A., Xu, H., Denny, J.C., Roden, D.M., Krauss, R.M., The Emerging Role of Electronic Medical Records in Pharmacogenomics (2011) Clin Pharmacol Ther, 89, pp. 379-386. , doi:10.1038/clpt.2010.260. PubMed: 21248726; Coloma, P.M., Trifirò, G., Schuemie, M.J., Gini, R., Herings, R., Electronic healthcare databases for active drug safety surveillance: Is there enough leverage? (2012) Pharmacoepidemiol Drug Saf, 21, pp. 611-621. , doi: 10.1002/pds.3197. PubMed: 22315152; Chan, K.A., Hauben, M., Signal detection in pharmacovigilance: Empirical evaluation of data mining tools (2005) Pharmacoepidemiol Drug Saf, 14, pp. 597-599. , doi:10.1002/pds.1128. PubMed: 16134080; Wilson, A.M., Thabane, L., Holbrook, A., Application of data mining techniques in pharmacovigilance (2004) Br J Clin Pharmacol, 57, pp. 127-134. , PubMed: 14748811; Koh, H.C., Tan, G., Data mining applications in healthcare (2005) J Healthc Inf Manag, 19, pp. 64-72. , PubMed: 15869215; Fu, Y., Chen, Z., Koru, G., Gangopadhyay, A., A privacy protection technique for publishing data mining models and research data (2010) ACM Trans Manage Inf Syst, 1, pp. 1-20; Avillach, P., Coloma, P.M., Gini, R., Schuemie, M., Mougin, F., Harmonization process for the identification of medical events in eight European healthcare databases: The experience from the EU-ADR project (2012) Journal of the American Medical Informatics Association; Trifirò, G., Pariente, A., Coloma, P.M., Kors, J.A., Polimeni, G., Data mining on electronic health record databases for signal detection in pharmacovigilance: Which events to monitor? (2009) Pharmacoepidemiol Drug Saf, 18, pp. 1176-1184. , doi:10.1002/pds.1836. PubMed: 19757412; Oliveira, J.L., Lopes, P., Nunes, T., Campos, D., Boyer, S., The EU-ADR Web Platform: Delivering advanced pharmacovigilance tools (2012) Pharmacoepidemiology and Drug Safety; Hollingsworth, D., (1995) The Workflow Reference Model; Petkov, S., Oren, E., Haller, A., (2005) Aspects in Workflow Management, p. 20. , Galway, Ireland: DERI, Digital Enterprise Research Institute; Ludascher, B., Altintas, I., Berkley, C., Higgings, D., Jaeger, E., Taverna: Scientific Workflow Management and the Kepler System. Research Articles (2006) Concurrency-Computation: Practice and Experience, 18, pp. 1039-1065. , doi:10.1002/cpe.994; Goecks, J., Nekrutenko, A., Taylor, J., Galaxy: A comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences (2010) Genome Biol, 11, pp. R86. , doi: 10.1186/gb-2010-11-8-r86. PubMed: 20738864; Jamil, H., El-Hajj-Diab, B., BioFlow: A Web-Based Declarative Workflow Language for Life Sciences (2008) IEEE Congress on Services. Honolulu, HI, USA, pp. 453-460. , IEEE Computer Society; Lopes, P., Oliveira, J.L., COEUS:""Semantic web in a box"" for biomedical applications (2012) Journal of Biomedical Semantics, 3, pp. 1-19; Shucheng, Y., Cong, W., Kui, R., Wenjing, L., Achieving Secure, Scalable, and Fine-grained Data Access Control in Cloud Computing (2010) Proc. IEEE INFOCOM. San Diego, CA, USA, pp. 1-9; Cheung, K.-H., Yip, K.Y., Townsend, J.P., Scotch, M., HCLS 2.0/3.0: Health care and life sciences data mashup using Web 2.0/3.0 (2008) Journal of Biomedical Informatics, 41, pp. 694-705; Rui, Z., Ling, L., Security Models and Requirements for Healthcare Application Clouds (2010) Cloud Computing (CLOUD), 2010 IEEE 3rd International Conference on, pp. 268-275; Baker, A., Vega, L., DeHart, T., Harrison, S., Healthcare and Security: Understanding and Evaluating the Risks (2011) Ergonomics and Health Aspects of Work with Computers, pp. 99-108. , Robertson, M., editor editor. Berlin: Springer Berlin / Heidelberg; Coloma, P.M., Schuemie, M.J., Trifirò, G., Furlong, L., Van Mulligen, E., Drug-Induced Acute Myocardial Infarction: Identifying 'Prime Suspects' from Electronic Healthcare Records-Based Surveillance. System (2013) PLOS ONE, 8, pp. e72148. , doi:10.1371/journal.pone.0072148; Avillach, P., Mougin, F., Joubert, M., Thiessard, F., Pariente, A., A semantic approach for the homogeneous identification of events in eight patient databases: A contribution to the European eu-ADR project (2009) Stud Health Technol Inform, 150, pp. 190-194. , PubMed: 19745295; De Leon, J., Highlights of Drug Package Inserts and the Website DailyMed: The Need for Further Improvement in Package Inserts to Help Busy Prescribers (2011) J Clin Psychopharmacol; Wishart, D.S., Knox, C., Guo, A.C., Cheng, D., Shrivastava, S., DrugBank: A knowledgebase for drugs, drug actions and drug targets (2008) Nucleic Acids Res, 36, pp. D901-D906. , PubMed: 18048412; Bauher-Mehren, A., Mulligen, Ev., Avillach, P., Carrascosa, M., Singh, B., Automatic filtering and substantiation of drug safety signals (2012) PLOS Computational Biololgy, 8; Zadeh, L.A., A simple view of the Dempster-Shafer theory of evidence and its implication for the rule of combination (1986) AI Magazine, 7, p. 85; Vilar, S., Harpaz, R., Chase, H.S., Costanzi, S., Rabadan, R., Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: Application to rhabdomyolysis (2011) Journal of the American Medical Informatics Association; Papay, J., Yuen, N., Powell, G., Mockenhaupt, M., Bogenrieder, T., Spontaneous adverse event reports of Stevens - Johnson syndrome/toxic epidermal necrolysis: Detecting associations with medications (2012) Pharmacoepidemiol Drug Saf, 21, pp. 289-296. , doi:10.1002/pds.2276. PubMed: 22139991; Sommet, A., Durrieu, G., Lapeyre-Mestre, M., Montastruc, J.-L., A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006 (2012) Pharmacoepidemiology and Drug Safety, 21, pp. 285-288. , Association of French PharmacoVigilance Centres; Wang, K., Bai, X., Li, J., Ding, C., A service-based framework for pharmacogenomics data integration (2010) Enterprise - Information Systems, 4, pp. 225-245. , doi:10.1080/17517575.2010.498525; Dudley, J.T., Butte, A.J., In silico research in the era of cloud computing (2010) Nat Biotechnol, 28, pp. 1181-1185. , doi:10.1038/nbt1110-1181. PubMed: 21057489","DETI/IEETA, University of Aveiro, Aveiro, Portugal",,,,,,,,19326203,,POLNC,"24349421","English","PLoS ONE",Article,"Final",Open Access,Scopus,2-s2.0-84892404109
"Cases M., Furlong L.I., Albanell J., Altman R.B., Bellazzi R., Boyer S., Brand A., Brookes A.J., Brunak S., Clark T.W., Gea J., Ghazal P., Graf N., Guigó R., Klein T.E., López-Bigas N., Maojo V., Mons B., Musen M., Oliveira J.L., Rowe A., Ruch P., Shabo A., Shortliffe E.H., Valencia A., van der Lei J., Mayer M.A., Sanz F.","56251049800;34770469800;7003744711;7202798518;18343389900;55913555400;8626241100;7005962229;7005477388;36602278600;7004959809;7005878579;34975072100;7004339139;7202313665;6603569620;55171738800;7004074338;7005635736;57193360895;57196499480;57201506313;14049224500;7006598518;16308427600;56592306600;36971031500;7102263897;","Improving data and knowledge management to better integrate health care and research",2013,"Journal of Internal Medicine","274","4",,"321","328",,28,"10.1111/joim.12105","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883742021&doi=10.1111%2fjoim.12105&partnerID=40&md5=e9212f51db772149e4d693ef26a32a2f","Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Servei d'Oncologia, Hospital del Mar, IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Departments of Bioengineering, Genetics and Medicine, Stanford University, Stanford, CA, United States; Dipartimento di Ingegneria Industriale e dell'Informazione, Università di Pavia, Pavia, Italy; Safety Assessment, AstraZeneca, Mölndal, Sweden; Institute for Public Health Genomics, Maastricht University, Maastricht, Netherlands; Department of Genetics, University of Leicester, Leicester, United Kingdom; Center for Protein Research, University of Copenhagen, Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark; MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Cambridge, MA, United States; Servei de Pneumologia, Hospital del Mar - IMIM, DCEXS, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; Division of Pathway Medicine, Synthesys, University of Edinburgh, Edinburgh, United Kingdom; Department of Pediatric Oncology and Hematology, Saarland University, Homburg, Germany; Centre de Regulació Genòmica (CRG), Barcelona, Spain; Spanish Institute of Bioinformatics (INB), Madrid, Spain; Department of Genetics, Stanford University, Stanford, CA, United States; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Biomedical Informatics Group, Universidad Politécnica de Madrid, Madrid, Spain; Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands; Netherlands Bioinformatics Center, Nijmegen, Netherlands; Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, United States; DETI/IEETA, University of Aveiro, Aveiro, Portugal; Janssen Research and Development, Buckinghamshire, United Kingdom; BITEM, University of Applied Sciences, Geneva, Switzerland; IBM Research Laboratory, Haifa, Israel; Arizona State University, Phoenix, AZ, United States; Department of Biomedical Informatics, Columbia University, New York, NY, United States; Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands","Cases, M., Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Albanell, J., Servei d'Oncologia, Hospital del Mar, IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Altman, R.B., Departments of Bioengineering, Genetics and Medicine, Stanford University, Stanford, CA, United States; Bellazzi, R., Dipartimento di Ingegneria Industriale e dell'Informazione, Università di Pavia, Pavia, Italy; Boyer, S., Safety Assessment, AstraZeneca, Mölndal, Sweden; Brand, A., Institute for Public Health Genomics, Maastricht University, Maastricht, Netherlands; Brookes, A.J., Department of Genetics, University of Leicester, Leicester, United Kingdom; Brunak, S., Center for Protein Research, University of Copenhagen, Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark; Clark, T.W., MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Cambridge, MA, United States; Gea, J., Servei de Pneumologia, Hospital del Mar - IMIM, DCEXS, Universitat Pompeu Fabra, CIBERES, Barcelona, Spain; Ghazal, P., Division of Pathway Medicine, Synthesys, University of Edinburgh, Edinburgh, United Kingdom; Graf, N., Department of Pediatric Oncology and Hematology, Saarland University, Homburg, Germany; Guigó, R., Centre de Regulació Genòmica (CRG), Barcelona, Spain, Spanish Institute of Bioinformatics (INB), Madrid, Spain; Klein, T.E., Department of Genetics, Stanford University, Stanford, CA, United States; López-Bigas, N., Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain, Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Maojo, V., Biomedical Informatics Group, Universidad Politécnica de Madrid, Madrid, Spain; Mons, B., Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands, Netherlands Bioinformatics Center, Nijmegen, Netherlands; Musen, M., Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, United States; Oliveira, J.L., DETI/IEETA, University of Aveiro, Aveiro, Portugal; Rowe, A., Janssen Research and Development, Buckinghamshire, United Kingdom; Ruch, P., BITEM, University of Applied Sciences, Geneva, Switzerland; Shabo, A., IBM Research Laboratory, Haifa, Israel; Shortliffe, E.H., Arizona State University, Phoenix, AZ, United States, Department of Biomedical Informatics, Columbia University, New York, NY, United States; Valencia, A., Spanish Institute of Bioinformatics (INB), Madrid, Spain, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; van der Lei, J., Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands; Mayer, M.A., Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM, DCEXS, Universitat Pompeu Fabra, Barcelona, Spain, Spanish Institute of Bioinformatics (INB), Madrid, Spain",[No abstract available],,"environmental chemical; transcriptome; Alzheimer disease; artificial intelligence; assertiveness; automation; biomedical engineering; biomedicine; clinical study; computer program; computerized provider order entry; data analysis; decision support system; editorial; education; electronic medical record; health care; human; inclusion body myositis; knowledge discovery; knowledge management; medical information; medical research; priority journal; professional knowledge; quality control; questionnaire; register; reliability; scientist; standardization; systems biology; Biomedical Research; Databases, Factual; Delivery of Health Care; Humans; Knowledge Management",,,,,,,,,"Ruttenberg, A., Clark, T., Bug, W., Advancing translational research with the Semantic Web (2007) BMC Bioinformatics, 8 (SUPPL 3), pp. S2; Antezana, E., Kuiper, M., Mironov, V., Biological knowledge management: the emerging role of the Semantic Web technologies (2009) Brief Bioinform, 10, pp. 392-407; Butte, A.J., Translational Bioinformatics: coming of age (2008) J Am Med Inform Assoc, 15, pp. 709-714; (2012), http://www.bdebate.org/debat/beyond-omics-revolutions-integrative-knowledge-management, B-Debates. Accessed July 10, 2013; Mons, B., van Haagen, H., Chichester, C., The value of data (2011) Nat Genet, 43, pp. 281-283; Sansone, S.A., Rocca-Serra, P., Field, D., Toward interoperable bioscience data (2012) Nat Genet, 44, pp. 121-126; Wilffert, B., Swen, J., Mulder, H., Touw, D., Maitland-Van der Zee, A.H., Deneer, V., From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics (2011) Int J Clin Pharm, 33, pp. 3-9; Gottlieb, A., Stein, G.Y., Oron, Y., Ruppin, E., Sharan, R., INDI: a computational framework for inferring drug interactions and their associated recommendations (2012) Mol Syst Biol, 8, p. 592; Preissner, S., Kroll, K., Dunkel, M., SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions (2010) Nucleic Acids Res, 38, pp. D237-D243; Beck, T., Gollapudi, S., Brunak, S., Knowledge engineering for health: a new discipline required to bridge the ""ICT gap"" between research and healthcare (2012) Hum Mutat, 33, pp. 797-802; Warner, H.R., Sorenson, D.K., Bouhaddou, O., (1997) Knowledge Engineering in Health Informatics, , New York: Springer-Verlag; Hardy, J., Singleton, A., Genomewide association studies and human disease (2009) N Engl J Med, 360, pp. 1759-1768; Chen, R., Mias, G.I., Li-Pook-Than, J., Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes (2012) Cell, 148, pp. 1293-1307; Fernandes-Taylor, S., Hyun, J.K., Reeder, R.N., Harris, A.H.S., Common statistical and research design problems in manuscripts submitted to high-impact medical journals (2011) BMC Res Notes, 4, p. 304; Prinz, F., Schlange, T., Asadullah, K., Believe it or not: how much can we rely on published data on potential drug targets? (2011) Nat Rev Drug Discov, 10, p. 712; Greenberg, S.A., How citation distortions create unfounded authority: analysis of a citation network (2009) BMJ, 339, pp. b2680; Sparkes, A., Aubrey, W., Byrne, E., Towards Robot Scientists for autonomous scientific discovery (2010) Autom Exp, 2, p. 1; Riva, A., Nuzzo, A., Stefanelli, M., Bellazzi, R., An automated reasoning framework for translational research (2010) J Biomed Inform, 43, pp. 419-427; Ekins, S., Waller, C.L., Bradley, M.P., Clark, A.M., Williams, A.J., Four disruptive strategies for removing drug discovery bottlenecks (2013) Drug Discov Today, 18, pp. 265-271; Hudson, K.L., Genomics, Health Care, and Society (2011) N Engl J Med, 365, pp. 1033-1041; Jensen, P.B., Jensen, L.J., Brunak, S., Mining electronic health records: towards better research applications and clinical care (2012) Nat Genet, 13, pp. 395-405; http://ec.europa.eu/justice/data-protection/index_en.htm, European Parliament - Data protection Accessed July 10, 2013; http://www.bioontology.org/, National Center for Biomedical Ontology.Accessed July 10, 2013; http://www.obofoundry.org/, Open Biological and Biomedical Ontologies. Accessed July 10, 2013; http://www.ricordo.eu/, Ricordo project. Accessed July 10, 2013; Tabarés-Seisdedos, R., Dumont, N., Baudot, A., No paradox, no progress: inverse cancer comorbidity in people with other complex diseases (2011) Lancet Oncol, 12, pp. 604-608; http://www.independenthealthrecordbanks.blogspot.co.il/, Independent Health Record Banks. Accessed July 10, 2013; Hood, L., Friend, S.H., Predictive, personalized, preventive, participatory (P4) cancer medicine (2011) Nat Rev Clin Oncol, 8, pp. 184-187; http://altmetrics.org/manifesto/, Almetrics, Accessed July 10, 2013","Sanz, F.C/ Dr. Aiguader 88, 08003 Barcelona, Spain; email: ferran.sanz@upf.edu",,,,,,,,09546820,,JINME,"23808970","English","J. Intern. Med. (GBR)",Editorial,"Final",,Scopus,2-s2.0-84883742021
"Coloma P.M., Schuemie M.J., Trifirò G., Furlong L., van Mulligen E., Bauer-Mehren A., Avillach P., Kors J., Sanz F., Mestres J., Oliveira J.L., Boyer S., Helgee E.A., Molokhia M., Matthews J., Prieto-Merino D., Gini R., Herings R., Mazzaglia G., Picelli G., Scotti L., Pedersen L., van der Lei J., Sturkenboom M.","35572748100;35238890300;10140803400;34770469800;7003307150;35572639000;23972137300;7005293297;7102263897;7004586125;57193360895;55913555400;35304849300;7004121920;7402837621;24478918700;18433997300;7007013493;6603729200;14033193500;15729848200;7201717857;56592306600;21743803900;","Drug-Induced Acute Myocardial Infarction: Identifying 'Prime Suspects' from Electronic Healthcare Records-Based Surveillance System",2013,"PLoS ONE","8","8", e72148,"","",,25,"10.1371/journal.pone.0072148","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883144641&doi=10.1371%2fjournal.pone.0072148&partnerID=40&md5=b7235435f2faa502995e9e1d2454c063","Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands; Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, University of Messina, Messina, Italy; Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar - Universitat Pompeu Fabra, Barcelona, Spain; Laboratoire d'Epidémiologie, de Statistique et d'Informatique Médicales (LESIM), L'Institut de Santé Publique, d'Épidémiologie et de Developpement (ISPED), University Bordeaux Segalen, Bordeaux, France; Laboratoire d'Enseignement et de Recherche sur le Traitement de l'Information Medicale (LERTIM), Faculté de Médecine, Université Aix Marseille 2, Marseille, France; Instituto de Engenharia Electrónica e Telemática de Aveiro (IEETA), Universidade de Aveiro, Aveiro, Portugal; Safety Assessment, AstraZeneca Research and Development, Mölndal, Sweden; Department of Primary Care and Public Health Sciences, Kings College London, London, United Kingdom; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom; Agenzia Regionale di Sanità della Toscana, Florence, Italy; PHARMO Institute, Utrecht, Netherlands; Società Italiana di Medicina Generale, Florence, Italy; Pedianet-Società Servizi Telematici SRL, Padova, Italy; Department of Statistics, Università di Milano-Bicocca, Milan, Italy; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, Netherlands","Coloma, P.M., Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands; Schuemie, M.J., Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands; Trifirò, G., Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands, Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, University of Messina, Messina, Italy; Furlong, L., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar - Universitat Pompeu Fabra, Barcelona, Spain; van Mulligen, E., Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands; Bauer-Mehren, A., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar - Universitat Pompeu Fabra, Barcelona, Spain; Avillach, P., Laboratoire d'Epidémiologie, de Statistique et d'Informatique Médicales (LESIM), L'Institut de Santé Publique, d'Épidémiologie et de Developpement (ISPED), University Bordeaux Segalen, Bordeaux, France, Laboratoire d'Enseignement et de Recherche sur le Traitement de l'Information Medicale (LERTIM), Faculté de Médecine, Université Aix Marseille 2, Marseille, France; Kors, J., Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar - Universitat Pompeu Fabra, Barcelona, Spain; Mestres, J., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar - Universitat Pompeu Fabra, Barcelona, Spain; Oliveira, J.L., Instituto de Engenharia Electrónica e Telemática de Aveiro (IEETA), Universidade de Aveiro, Aveiro, Portugal; Boyer, S., Safety Assessment, AstraZeneca Research and Development, Mölndal, Sweden; Helgee, E.A., Safety Assessment, AstraZeneca Research and Development, Mölndal, Sweden; Molokhia, M., Department of Primary Care and Public Health Sciences, Kings College London, London, United Kingdom; Matthews, J., Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom; Prieto-Merino, D., Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom; Gini, R., Agenzia Regionale di Sanità della Toscana, Florence, Italy; Herings, R., PHARMO Institute, Utrecht, Netherlands; Mazzaglia, G., Società Italiana di Medicina Generale, Florence, Italy; Picelli, G., Pedianet-Società Servizi Telematici SRL, Padova, Italy; Scotti, L., Department of Statistics, Università di Milano-Bicocca, Milan, Italy; Pedersen, L., Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; van der Lei, J., Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands; Sturkenboom, M., Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands, Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, Netherlands","Background:Drug-related adverse events remain an important cause of morbidity and mortality and impose huge burden on healthcare costs. Routinely collected electronic healthcare data give a good snapshot of how drugs are being used in 'real-world' settings.Objective:To describe a strategy that identifies potentially drug-induced acute myocardial infarction (AMI) from a large international healthcare data network.Methods:Post-marketing safety surveillance was conducted in seven population-based healthcare databases in three countries (Denmark, Italy, and the Netherlands) using anonymised demographic, clinical, and prescription/dispensing data representing 21,171,291 individuals with 154,474,063 person-years of follow-up in the period 1996-2010. Primary care physicians' medical records and administrative claims containing reimbursements for filled prescriptions, laboratory tests, and hospitalisations were evaluated using a three-tier triage system of detection, filtering, and substantiation that generated a list of drugs potentially associated with AMI. Outcome of interest was statistically significant increased risk of AMI during drug exposure that has not been previously described in current literature and is biologically plausible.Results:Overall, 163 drugs were identified to be associated with increased risk of AMI during preliminary screening. Of these, 124 drugs were eliminated after adjustment for possible bias and confounding. With subsequent application of criteria for novelty and biological plausibility, association with AMI remained for nine drugs ('prime suspects'): azithromycin; erythromycin; roxithromycin; metoclopramide; cisapride; domperidone; betamethasone; fluconazole; and megestrol acetate.Limitations:Although global health status, co-morbidities, and time-invariant factors were adjusted for, residual confounding cannot be ruled out.Conclusion:A strategy to identify potentially drug-induced AMI from electronic healthcare data has been proposed that takes into account not only statistical association, but also public health relevance, novelty, and biological plausibility. Although this strategy needs to be further evaluated using other healthcare data sources, the list of 'prime suspects' makes a good starting point for further clinical, laboratory, and epidemiologic investigation. © 2013 Coloma et al.",,"amoxicillin; azithromycin; betamethasone; cefixime; ceftriaxone; cisapride; clarithromycin; clonidine; dexamethasone; domperidone; erythromycin; fenoterol; fentanyl; fluconazole; glibenclamide; ketobemidone; magaldrate; megestrol; metformin; metoclopramide; nifedipine; novel erythropoiesis stimulating protein; penicillin V; pivampicillin; prednisone; roxithromycin; salbutamol; sulfonamide; tramadol; unindexed drug; acute heart infarction; article; biological plausibility; clinical study; confounding variable; demography; Denmark; drug exposure; drug induced disease; Electronic Healthcare Records Based Surveillance System; electronic medical record; emergency health service; filtration; follow up; hospitalization; human; Italy; laboratory test; medical literature; Netherlands; novelty; prescription; public health; reimbursement; statistical analysis; three tier triage system; Acute Disease; Adverse Drug Reaction Reporting Systems; Azithromycin; Betamethasone; Cisapride; Domperidone; Electronic Health Records; Fluconazole; Humans; Megestrol Acetate; Metoclopramide; Myocardial Infarction",,"amoxicillin, 26787-78-0, 34642-77-8, 61336-70-7; azithromycin, 83905-01-5; betamethasone, 378-44-9; cefixime, 79350-37-1; ceftriaxone, 73384-59-5, 74578-69-1; cisapride, 81098-60-4; clarithromycin, 81103-11-9; clonidine, 4205-90-7, 4205-91-8, 57066-25-8; dexamethasone, 50-02-2; domperidone, 57808-66-9; erythromycin, 114-07-8, 70536-18-4; fenoterol, 13392-18-2, 1944-12-3; fentanyl, 437-38-7; fluconazole, 86386-73-4; glibenclamide, 10238-21-8; ketobemidone, 469-79-4; magaldrate, 1317-26-6, 74978-16-8; megestrol, 3562-63-8; metformin, 1115-70-4, 657-24-9; metoclopramide, 12707-59-4, 2576-84-3, 364-62-5, 7232-21-5; nifedipine, 21829-25-4; penicillin V, 87-08-1; pivampicillin, 26309-95-5, 33817-20-8; prednisone, 53-03-2; roxithromycin, 80214-83-1; salbutamol, 18559-94-9, 35763-26-9; tramadol, 27203-92-5, 36282-47-0",,,,,,,"Budnitz, D.S., Lovegrove, M.C., Shehab, N., Richards, C.L., Emergency hospitalizations for adverse drug events in older Americans (2011) N Engl J Med, 365, pp. 2002-2012; Hug, B.L., Keohane, C., Seger, D.L., Yoon, C., Bates, D.W., The costs of adverse drug events in community hospitals (2012) Jt Comm J Qual Patient Saf, 38, pp. 120-126; Wu, T.Y., Jen, M.H., Bottle, A., Molokhia, M., Aylin, P., Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009 (2010) J R Soc Med, 103, pp. 239-250; Black, N., Why we need observational studies to evaluate the effectiveness of health care (1996) BMJ, 312, pp. 1215-1218; Papanikolaou, P.N., Christidi, G.D., Ioannidis, J.P., Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies (2006) CMAJ, 174, pp. 635-641; Ray, W.A., Population-based studies of adverse drug effects (2003) N Engl J Med, 349, pp. 1592-1594; Platt, R., Wilson, M., Chan, K.A., Benner, J.S., Marchibroda, J., The new Sentinel Network-improving the evidence of medical-product safety (2009) N Engl J Med, 361, pp. 645-647; Coloma, P.M., Schuemie, M.J., Trifiro, G., Gini, R., Herings, R., Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project (2011) Pharmacoepidemiol Drug Saf, 20, pp. 1-11; Stang, P.E., Ryan, P.B., Racoosin, J.A., Overhage, J.M., Hartzema, A.G., Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership (2010) Ann Intern Med, 153, pp. 600-606; The Uppsala Monitoring Centre. WHO Global Database Reaches 7 Million; US Food and Drug Administration. Reports received and entered into AERS by year; Meyboom, R.H., Lindquist, M., Egberts, A.C., Edwards, I.R., Signal selection and follow-up in pharmacovigilance (2002) Drug Saf, 25, pp. 459-465; Waller, P., Heeley, E., Moseley, J., Impact analysis of signals detected from spontaneous adverse drug reaction reporting data (2005) Drug Saf, 28, pp. 843-850; Heeley, E., Waller, P., Moseley, J., Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study (2005) Drug Saf, 28, pp. 901-906; Levitan, B., Yee, C.L., Russo, L., Bayney, R., Thomas, A.P., A model for decision support in signal triage (2008) Drug Saf, 31, pp. 727-735; Lindquist, M., Use of triage strategies in the WHO signal-detection process (2007) Drug Saf, 30, pp. 635-637; Mazzaglia, G., Mantovani, L.G., Sturkenboom, M.C., Filippi, A., Trifiro, G., Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care (2005) J Hypertens, 23, pp. 2093-2100; Vlug, A.E., van der Lei, J., Mosseveld, B.M., van Wijk, M.A., van der Linden, P.D., Postmarketing surveillance based on electronic patient records: the IPCI project (1999) Methods Inf Med, 38, pp. 339-344; Sturkenboom, M., Nicolosi, A., Cantarutti, L., Mannino, S., Picelli, G., Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics (2005) Pediatrics, 116, pp. e26-e33; Christensen, S., Riis, A., Norgaard, M., Thomsen, R.W., Sorensen, H.T., Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcer (2007) Aliment Pharmacol Ther, 25, pp. 907-912; Goettsch, W.G., de Jong, R.B., Kramarz, P., Herings, R.M., Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study (2007) Pharmacoepidemiol Drug Saf, 16, pp. 166-172; Corrao, G., Zambon, A., Conti, V., Nicotra, F., La Vecchia, C., Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation (2008) Ann Oncol, 19, pp. 150-155; Barchielli, A., Balzi, D., Marchionni, N., Carrabba, N., Margheri, M., Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy (2007) Int J Cardiol, 114, pp. 57-63; Coloma, P.M., Trifiro, G., Schuemie, M.J., Gini, R., Herings, R., Electronic healthcare databases for active drug safety surveillance: is there enough leverage? (2012) Pharmacoepidemiol Drug Saf, 21, pp. 611-621; Avillach, P., Joubert, M., Thiessard, F., Trifiro, G., Dufour, J.C., Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project (2010) Stud Health Technol Inform, 160, pp. 1085-1089; Avillach, P., Coloma, P.M., Gini, R., Schuemie, M., Mougin, F., Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project (2013) J Am Med Inform Assoc, 20, pp. 184-192; Coloma, P.M., Valkhoff, V.E., Mazzaglia, G., Nielsson, M.S., Pedersen, L., Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries (2013) BMJ Open, 3; Schuemie, M.J., Coloma, P.M., Straatman, H., Herings, R.M., Trifiro, G., Using Electronic Health Care Records for Drug Safety Signal Detection: A Comparative Evaluation of Statistical Methods (2012) Med Care; Schuemie, M.J., Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD (2011) Pharmacoepidemiol Drug Saf, 20, pp. 292-299; Bauer-Mehren, A., van Mullingen, E.M., Avillach, P., Carrascosa Mdel, C., Garcia-Serna, R., Automatic filtering and substantiation of drug safety signals (2012) PLoS Comput Biol, 8, pp. e1002457; Oliveira, J.L., Lopes, P., Nunes, T., Campos, D., Boyer, S., The EU-ADR Web Platform: delivering advanced pharmacovigilance tools (2013) Pharmacoepidemiol Drug Saf, 22, pp. 459-467; Hauben, M., Aronson, J.K., Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions (2009) Drug Saf, 32, pp. 99-110; Hill, A.B., The Environment and Disease: Association or Causation? (1965) Proc R Soc Med, 58, pp. 295-300; Caster, O., Edwards, I.R., Reflections on attribution and decisions in pharmacovigilance (2010) Drug Saf, 33, pp. 805-809; Gurwitz, D., Motulsky, A.G., Drug reactions, enzymes, and biochemical genetics': 50 years later (2007) Pharmacogenomics, 8, pp. 1479-1484; Stricker, B.H., Psaty, B.M., Detection, verification, and quantification of adverse drug reactions (2004) BMJ, 329, pp. 44-47; Evans, M., Rees, A., Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? (2002) Drug Saf, 25, pp. 649-663; Kounis, N.G., Zavras, G.M., Histamine-induced coronary artery spasm: the concept of allergic angina (1991) Br J Clin Pract, 45, pp. 121-128; Biteker, M., Current understanding of Kounis syndrome (2010) Expert Rev Clin Immunol, 6, pp. 777-788; Kovanen, P.T., Kaartinen, M., Paavonen, T., Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction (1995) Circulation, 92, pp. 1084-1088; Ridella, M., Bagdure, S., Nugent, K., Cevik, C., Kounis syndrome following beta-lactam antibiotic use: review of literature (2009) Inflamm Allergy Drug Targets, 8, pp. 11-16; Araujo, L., Demoly, P., Macrolides allergy (2008) Curr Pharm Des, 14, pp. 2840-2862; Thong, B.Y., Update on the management of antibiotic allergy (2010) Allergy Asthma Immunol Res, 2, pp. 77-86; Demoly, P., Gomes, E.R., Drug hypersensitivities: definition, epidemiology and risk factors (2005) Eur Ann Allergy Clin Immunol, 37, pp. 202-206; Rubin, J.B., Borden, W.B., Coronary heart disease in young adults (2012) Curr Atheroscler Rep, 14, pp. 140-149; Chen, J.P., Hou, D., Pendyala, L., Goudevenos, J.A., Kounis, N.G., Drug-eluting stent thrombosis: the Kounis hypersensitivity-associated acute coronary syndrome revisited (2009) JACC Cardiovasc Interv, 2, pp. 583-593; Keller, G.A., Di Girolamo, G., Prokinetic agents and QT prolongation: a familiar scene with new actors (2010) Curr Drug Saf, 5, pp. 73-78; Quigley, E.M., Cisapride: what can we learn from the rise and fall of a prokinetic? (2011) J Dig Dis, 12, pp. 147-156; Hennessy, S., Leonard, C.E., Newcomb, C., Kimmel, S.E., Bilker, W.B., Cisapride and ventricular arrhythmia (2008) Br J Clin Pharmacol, 66, pp. 375-385; Collins, K.K., Sondheimer, J.M., Domperidone-induced QT prolongation: add another drug to the list (2008) J Pediatr, 153, pp. 596-598; Tonini, M., De Ponti, F., Di Nucci, A., Crema, F., Review article: cardiac adverse effects of gastrointestinal prokinetics (1999) Aliment Pharmacol Ther, 13, pp. 1585-1591; Mosca, L., Banka, C.L., Benjamin, E.J., Berra, K., Bushnell, C., Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update (2007) J Am Coll Cardiol, 49, pp. 1230-1250; Stone, N., Secondary causes of hyperlipidemia (1994) Med Clin North Am, 78, pp. 117-141; Sarnes, E., Crofford, L., Watson, M., Dennis, G., Kan, H., Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review (2011) Clin Ther, 33, pp. 1413-1432; Weeke, P., Folke, F., Gislason, G.H., Lippert, F.K., Olesen, J.B., Pharmacotherapy and hospital admissions before out-of-hospital cardiac arrest: a nationwide study (2010) Resuscitation, 81, pp. 1657-1663; Gisondi, P., Girolomoni, G., Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors (2009) Semin Thromb Hemost, 35, pp. 313-324; Szekanecz, Z., Kerekes, G., Der, H., Sandor, Z., Szabo, Z., Accelerated atherosclerosis in rheumatoid arthritis (2007) Ann N Y Acad Sci, 1108, pp. 349-358; Panwalker, A.P., Hyperglycemia induced by megestrol acetate (1992) Ann Intern Med, 116, p. 878; Henry, K., Rathgaber, S., Sullivan, C., McCabe, K., Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia (1992) Ann Intern Med, 116, pp. 53-54; Kilby, J.M., Tabereaux, P.B., Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus (1998) J Acquir Immune Defic Syndr Hum Retrovirol, 17, pp. 46-50; Khazan, M., Mathis, A.S., Probable case of torsades de pointes induced by fluconazole (2002) Pharmacotherapy, 22, pp. 1632-1637; McMahon, J.H., Grayson, M.L., Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis (2008) Am J Health Syst Pharm, 65, pp. 619-623; Sharkey, P.K., Rinaldi, M.G., Dunn, J.F., Hardin, T.C., Fetchick, R.J., High-dose itraconazole in the treatment of severe mycoses (1991) Antimicrob Agents Chemother, 35, pp. 707-713; Ahmad, S.R., Singer, S.J., Leissa, B.G., Congestive heart failure associated with itraconazole (2001) Lancet, 357, pp. 1766-1767; Groll, A.H., Piscitelli, S.C., Walsh, T.J., Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development (1998) Adv Pharmacol, 44, pp. 343-500; Brüggemann, R.J.A.J., Blijlevens, N.M., Billaud, E.M., Kosterink, J.G., Verweij, P.E., Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents (2009) Clin Infect Dis, 48, pp. 1441-1458; Edwards, I.R., Aronson, J.K., Adverse drug reactions: definitions, diagnosis, and management (2000) Lancet, 356, pp. 1255-1259; Park, B.K., Kitteringham, N.R., Powell, H., Pirmohamed, M., Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity (2000) Toxicology, 153, pp. 39-60","Coloma, P. M.; Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands; email: p.coloma@erasmusmc.nl",,,,,,,,19326203,,POLNC,"24015213","English","PLoS ONE",Article,"Final",Open Access,Scopus,2-s2.0-84883144641
"Martí-Solano M., Guixà-González R., Sanz F., Pastor M., Selent J.","55090002400;55090002500;7102263897;7102415847;55891371700;","Novel insights into biased agonism at G protein-coupled receptors and their potential for drug design",2013,"Current Pharmaceutical Design","19","28",,"5156","5166",,19,"10.2174/1381612811319280014","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881334295&doi=10.2174%2f1381612811319280014&partnerID=40&md5=ad75194420192f3d1a8430d6f0e389e1","Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader, 88, E- 08003 Barcelona, Spain","Martí-Solano, M., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader, 88, E- 08003 Barcelona, Spain; Guixà-González, R., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader, 88, E- 08003 Barcelona, Spain; Sanz, F., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader, 88, E- 08003 Barcelona, Spain; Pastor, M., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader, 88, E- 08003 Barcelona, Spain; Selent, J., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader, 88, E- 08003 Barcelona, Spain","G-protein coupled receptors (GPCRs) are the most important class of current pharmacological targets. However, it is now widely acknowledged that their regulation is more complex than previously thought: the evidence that GPCRs can couple to several effector pathways, and the existence of biased agonists able to activate them differentially, has introduced a new level of complexity in GPCR drug research. Considering bias represents a challenge for the research of new GPCR modulators, because it demands a detailed characterization of compound properties for several effector pathways. Still, biased ligands could provide an opportunity to modulate GPCR function in a finer way and to separate therapeutic from side effects. Nowadays, a variety of agonists for GPCRs have been described, which differ in their ability to promote receptor coupling to different Gprotein families or even subunits, recruit signal transducers such as arrestins, activate a variety of downstream molecular pathways and induce certain phosphorylation signatures or gene expression patterns. In this review, we will cover some of the experimental techniques currently used to understand and characterize biased agonism and discuss their strengths and limitations. Additionally, we will comment on the computational efforts that are being devoted to study ligand-induced bias and on the potential they hold for rationalizing its structural determinants. Finally, we will discuss which of these strategies could be used for the rational design of biased ligands and give some examples of the potential therapeutic value of this class of compounds. © 2013 Bentham Science Publishers.","Biased agonism; Drug discovery; Functional selectivity; GPCR","6 chloro 2,3,4,5 tetrahydro 7,8 dihydroxy 1 phenyl 1h 3 benzazepine; alprenolol; fenoterol; G protein coupled receptor; G protein coupled receptor stimulating agent; oxprenolol; retina S antigen; skf 82957; unclassified drug; agonist; drug activity; drug design; drug mechanism; drug receptor binding; drug research; drug structure; drug targeting; gene expression; human; nonhuman; priority journal; protein phosphorylation; review; Animals; Binding Sites; Computational Biology; Drug Agonism; Drug Design; Humans; Ligands; Models, Biological; Molecular Conformation; Receptors, G-Protein-Coupled; Signal Transduction",,"6 chloro 2,3,4,5 tetrahydro 7,8 dihydroxy 1 phenyl 1h 3 benzazepine, 71636-61-8; alprenolol, 13655-52-2, 13707-88-5, 39405-98-6, 58615-82-0; fenoterol, 13392-18-2, 1944-12-3; oxprenolol, 22972-97-0, 6452-71-7, 6452-73-9; retina S antigen, 113315-03-0","skf 81297; skf 82957",,,,,,"Lagerström, M.C., Schiöth, H.B., Structural diversity of G proteincoupled receptors and significance for drug discovery (2008) Nat Rev Drug Discov, 7 (4), pp. 339-357; Overington, J.P., Al-Lazikani, B., Hopkins, A.L., How many drug targets are there? (2006) Nat Rev Drug Discov, 5 (12), pp. 993-996; Maudsley, S., Martin, B., Luttrell, L.M., The origins of diversity and specificity in G protein-coupled receptor signaling (2005) J Pharmacol Exp Ther, 314 (2), pp. 485-494; Urban, J., Clarke, W., Von Zastrow, M., Functional selectivity and classical concepts of quantitative pharmacology (2007) J Pharmacol Exp Ther, 320 (1), pp. 1-13; Christopoulos, A., Kenakin, T., G protein-coupled receptor allosterism and complexing (2002) Pharmacol Rev, 54 (2), pp. 323-374; Milligan, G., G protein-coupled receptor hetero-dimerization: Contribution to pharmacology and function (2009) Br J Pharmacol, 158 (1), pp. 5-14; Marsh, D., Protein modulation of lipids, and vice-versa, in membranes (2008) Biochim Biopshys Acta, 1778 (7-8), pp. 1545-1575; Whalen, E.J., Rajagopal, S., Lefkowitz, R.J., Therapeutic potential of α-arrestin-and G protein-biased agonists (2011) Trends Mol Med, 17 (3), pp. 126-139; Smith, N.J., Bennett, K.A., Milligan, G., When simple agonism is not enough: Emerging modalities of GPCR ligands (2011) Mol Cell Endocrinol, 331 (2), pp. 241-247; Neubig, R., Missing links: Mechanisms of protean agonism (2007) Mol Pharmacol, 71 (5), pp. 1200-1202; Kenakin, T., Christopoulos, A., Signalling bias in new drug discovery: Detection, quantification and therapeutic impact. Nature reviews (2012) Drug discovery, 12 (3), pp. 205-216; Galandrin, S., Oligny-Longpré, G., Bouvier, M., The evasive nature of drug efficacy: Implications for drug discovery (2007) Trends Pharmacol Sci, 28 (8), pp. 423-430; Mailman, R.B., GPCR functional selectivity has therapeutic impact (2007) Trends Pharmacol Sci, 28 (8), pp. 390-396; Hermans, E., Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors (2003) Pharmacol Ther, 99 (1), pp. 25-44; Goupil, E., Laporte, S.A., Hebert, T.E., Functional Selectivity in GPCR Signaling: Understanding the Full Spectrum of Receptor Conformations (2012) Mini-Rev Med Chem, 12, pp. 817-830; Zhang, L., Brass, L.F., Manning, D.R., The Gq and G12 Families of Heterotrimeric G Proteins Report Functional Selectivity (2009) Mol Pharmacol, 75 (1), pp. 235-241; Violin, J.D., Dewire, S.M., Yamashita, D., Selectively Engaging Beta-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance (2010) J Pharmacol Exp Ther, 335 (3), pp. 572-579; Rives, M.-L., Rossillo, M., Liu-Chen, L.-Y., Javitch, J.A., 6'GNTI is a G protein-biased kappa-opioid receptor agonist that inhibits arrestin recruitment (2012) J Biol Chem, 287 (32), pp. 27050-27054; Blättermann, S., Peters, L., Ottersbach, P.A., A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer (2012) Nat Chem Biol, 8 (7), pp. 631-638; Rajagopal, S., Kim, J., Ahn, S., Beta-arrestin-but not G proteinmediated signaling by the ""decoy"" receptor CXCR7 (2010) Proc Natl Acad Sci USA, 107 (2), pp. 628-632; Park, P.S., Ensemble of G Protein-Coupled Receptor Active States (2012) Curr Med Chem, 19 (8), pp. 1146-1154; De Lean, A., Stadel, J.M., Lefkowitz, R.J., A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor (1980) J Biol Chem, 255 (15), pp. 7108-7117; Samama, P., Cotecchia, S., A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model (1993) J Biol Chem, 268 (7), pp. 4625-4636; Kenakin, T., Miller, L.J., Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery (2010) Pharmacol Rev, 62 (2), pp. 265-304; Niesen, M.J.M., Bhattacharya, S., Vaidehi, N., The role of conformational ensembles in ligand recognition in G-protein coupled receptors (2011) J Am Chem Soc, 133 (33), pp. 13197-13204; Liapakis, G., Cordomi, A., Pardo, L., The G-protein Coupled Receptor Family: Actors with Many Faces (2012) Curr Pharm Des, 18 (2), pp. 175-185; Hoffmann, C., Zürn, A., Bünemann, M., Lohse, M.J., Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open (2008) Br J Pharmacol, 153 (SUPPL.), pp. S358-S366; Kenakin, T., Christopoulos, A., Analytical pharmacology: The impact of numbers on pharmacology (2011) Trends Pharmacol Sci, 32 (4), pp. 189-196; Galandrin, S., Bouvier, M., Signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogenactivated protein kinase reveals the pluridimensionality of efficacy (2006) Mol Pharmacol, 70 (5), pp. 1575-1584; Stallaert, W., Christopoulos, A., Bouvier, M., Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors (2011) Expert Opin Drug Discov, 6 (8), pp. 811-825; Kenakin, T.P., '7TM receptor allostery: Putting numbers to shapeshifting proteins (2009) Trends Pharmacol Sci, 30 (9), pp. 460-469; Black, J., Leff, P., Operational models of pharmacological agonism (1983) Proc R Soc London, 220, pp. 141-162; Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., Novick, S., A simple method for quantifying functional selectivity and agonist bias (2012) ACS Chemical Neuroscience, 3 (3), pp. 193-203; Rajagopal, S., Ahn, S., Rominger, D.H., Quantifying ligand bias at seven-transmembrane receptors (2011) Mol Pharmacol, 80 (3), pp. 367-377; Denis, C., Saulière, A., Galandrin, S., Sénard, J.-M., Galés, C., Probing heterotrimeric G protein activation: Applications to biased ligands (2012) Curr Pharm Des, 18 (2), pp. 128-144; Lohse, M.J., Nikolaev, V.O., Hein, P., Hoffmann, C., Vilardaga, J.-P., Bünemann, M., Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors (2008) Trends Pharmacol Sci, 29 (3), pp. 159-165; Saulière, A., Bellot, M., Paris, H., Deciphering biased-agonism complexity reveals a new active AT1 receptor entity (2012) Nat Chem Biol, 8 (7), pp. 622-630; Charest, P.G., Terrillon, S., Bouvier, M., Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET (2005) EMBO reports, 6 (4), pp. 334-340; Shukla, A.K., Violin, J.D., Whalen, E.J., Gesty-Palmer, D., Shenoy, S.K., Lefkowitz, R.J., Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors (2008) Proc Natl Acad Sci USA, 105 (29), pp. 9988-9993; Christensen, G.L., Kelstrup, C.D., Lyngsø, C., Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists (2010) Mol Cell Proteomics, 9 (7), pp. 1540-1553; Xiao, K., McClatchy, D.B., Shukla, A.K., Functional specialization of beta-arrestin interactions revealed by proteomic analysis (2007) Proc Natl Acad Sci USA, 104 (29), pp. 12011-12016; González-Maeso, J., Weisstaub, N.V., Zhou, M., Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior (2007) Neuron, 53 (3), pp. 439-452; Stewart, G.D., Sexton, P.M., Christopoulos, A., Detection of Novel Functional Selectivity at M3 Muscarinic Acetylcholine Receptors Using a Saccharomyces cerevisiae Platform (2010) ACS Chem Biol, 5 (4), pp. 365-375; Ghanouni, P., Gryczynski, Z., Steenhuis, J.J., Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor (2001) The Journal of biological chemistry, 276 (27), pp. 24433-24436; Audet, N., Galés, C., Archer-Lahlou, E., Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing deltaopioid receptors and heterotrimeric G proteins (2008) J Biol Chem, 283 (22), pp. 15078-15088; Yao, X., Parnot, C., Deupi, X., Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor (2006) Nat Chem Biol, 2 (8), pp. 417-422; West, G.M., Chien, E.Y.T., Katritch, V., Ligand-Dependent Perturbation of the Conformational Ensemble for the GPCR 2 Adrenergic Receptor Revealed by HDX (2011) Structure, 19 (10), pp. 1424-1432; Zocher, M., Fung, J.J., Kobilka, B.K., Müller, D.J., Ligand-Specific Interactions Modulate Kinetic, Energetic, and Mechanical Properties of the Human 2 Adrenergic Receptor (2012) Structure, pp. 1391-1402; Rahmeh, R., Damian, M., Cottet, M., Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy (2012) Proc Natl Acad Sci USA, 109 (17), pp. 6733-6738; Liu, J.J., Horst, R., Katritch, V., Stevens, R.C., Wüthrich, K., Biased Signaling Pathways in α2-Adrenergic Receptor Characterized by 19FNMR (2012) Science, 335 (6072), pp. 1106-1110; Audet, M., Bouvier, M., Restructuring G-Protein-Coupled Receptor Activation (2012) Cell, 151 (1), pp. 14-23; Park, S.H., Das, B.B., Casagrande, F., Structure of the chemokine receptor CXCR1 in phospholipid bilayers (2012) Nature, 491 (7426), pp. 779-783; Scheerer, P., Park, J., Hildebrand, P., Crystal structure of opsin in its G-protein-interacting conformation (2008) Nature, 455 (7212), pp. 2-8; Rasmussen, S.G.F., Choi, H.-J., Fung, J.J., Structure of a nanobodystabilized active state of the α(2) adrenoceptor (2011) Nature, 469 (7329), pp. 175-180; Rasmussen, S., DeVree, B., Zou, Y., Crystal structure of the α2 adrenergic receptor-Gs protein complex (2011) Nature, 477 (7366), pp. 549-555; Warne, T., Edwards, P.C., Leslie, A.G.W., Tate, C.G., Crystal structures of a stabilized α1-adrenoceptor bound to the biased agonists bucindolol and carvedilol (2012) Structure, 20 (5), pp. 841-849; Galandrin, S., Oligny-Longpré, G., Bonin, H., Ogawa, K., Galés, C., Bouvier, M., Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor (2008) Mol Pharmacol, 74 (1), pp. 162-172; Wisler, J.W., DeWire, S.M., Whalen, E.J., A unique mechanism of beta-blocker action: Carvedilol stimulates beta-arrestin signaling (2007) Proc Natl Acad Sci USA, 104 (42), pp. 16657-16662; Wang, C., Jiang, Y., Ma, J., Structural Basis for Molecular Recognition at Serotonin Receptors (2013) Science, 340 (6132), pp. 610-614; Wacker, D., Wang, C., Katritch, V., Han, G., Structural Features for Functional Selectivity at Serotonin Receptors (2013) Science, 469 (7329), pp. 175-180; Granier, S., Kobilka, B., A new era of GPCR structural and chemical biology (2012) Nat Chem Biol, 8 (8), pp. 670-673; De Graaf, C., Rognan, D., Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor (2008) Journal of medicinal chemistry, 51 (16), pp. 4978-4985; Katritch, V., Reynolds, K., Cherezov, V., Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes (2009) Journal of molecular recognition: JMR, 22 (4), pp. 307-318; Bhattacharya, S., Hall, S.E., Li, H., Vaidehi, N., Ligand-Stabilized Conformational States of Human Beta2 Adrenergic Receptor: Insight into G-Protein-Coupled Receptor Activation (2008) Biophys J, 94 (6), pp. 2027-2042; Bhattacharya, S., Vaidehi, N., Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor (2010) J Am Chem Soc, 132 (14), pp. 5205-5214; Fowler, J.C., Bhattacharya, S., Urban, J.D., Vaidehi, N., Mailman, R.B., Receptor conformations involved in dopamine D2L receptor functional selectivity induced by selected transmembrane-5 serine mutations (2012) Mol Pharmacol, 81 (6), pp. 820-831; Feng, Z., Hou, T., Li, Y., Studies on the interactions between beta2 adrenergic receptor and Gs protein by molecular dynamics simulations (2012) J Chem Inf Model, 52 (4), pp. 1005-1014; Dror, R.O., Arlow, D.H., Maragakis, P., Activation mechanism of the α2-adrenergic receptor (2011) Proc Natl Acad Sci USA, 108 (46), pp. 18684-18689; Provasi, D., Artacho, M.C., Negri, A., Mobarec, J.C., Filizola, M., Ligand-Induced Modulation of the Free-Energy Landscape of G Protein-Coupled Receptors Explored by Adaptive Biasing Techniques (2011) PLoS Comput Biol, 7 (10), pp. e1002193. , Nussinov R, editor; Goetz, A., Lanig, H., Gmeiner, P., Clark, T., Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the α2-adrenergic receptor (2011) J Mol Biol, 414 (4), pp. 611-623; Kim, I.-M., Tilley, D.G., Chen, J., Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation (2008) Proc Natl Acad Sci USA, 105 (38), pp. 14555-14560; Jozwiak, K., Toll, L., Jimenez, L., Woo, A.Y.-H., Xiao, R.-P., Wainer, I.W., The effect of stereochemistry on the thermodynamic characteristics of the binding of fenoterol stereoisomers to the beta2-adrenoceptor (2010) Biochem Pharmacol, 79 (11), pp. 1610-1615; Raehal, K.M., Bohn, L.M., The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics (2011) Neuropharmacology, 60 (1), pp. 58-65; Neubig, R., Spedding, M., Kenakin, T., Christopoulos, A., Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology (2003) Pharmacol Rev, 55 (4), pp. 597-606; Bridges, T.M., Lindsley, C.W., G-protein-coupled receptors: From classical modes of modulation to allosteric mechanisms (2008) ACS Chem Biol, 3 (9), pp. 530-541; Leach, K., Sexton, P.M., Christopoulos, A., Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology (2007) Trends Pharmacol Sci, 28 (8), pp. 382-389; Mathiesen, J.M., Ulven, T., Martini, L., Gerlach, L.O., Heinemann, A., Kostenis, E., Identification of Indole Derivatives Exclusively Interfering with a G Protein-Independent Signaling Pathway of the Prostaglandin D2 Receptor CRTH2 (2005) Mol Pharmacol, 68 (2), pp. 393-402; Maillet, E., Pellegrini, N., Valant, C., A novel, conformationspecific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties (2007) FASEB J, 21 (9), pp. 2124-2134; Valant, C., Maillet, E., Bourguignon, J.J., Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: Structural exploration (2009) J Med Chem, 52 (19), pp. 5999-6011; Burford, N.T., Watson, J., Bertekap, R., Alt, A., Strategies for the identification of allosteric modulators of G-protein-coupled receptors (2011) Biochem Pharmacol, 81 (6), pp. 691-702; Gesty-Palmer, D., Flannery, P., Yuan, L., A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation (2009) Science Translational Medicine, 1 (1), pp. 1ra1; Allen, J., Yost, J.M., Setola, V., Discovery of beta-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy (2011) Proc Natl Acad Sci USA, 108 (45), pp. 2-7; Rocheville, M., Jerman, J.C., 7TM pharmacology measured by labelfree: A holistic approach to cell signalling (2009) Curr Opin Pharmacol, 9 (5), pp. 643-649; Fang, Y., Ferrie, A.M., Label-free optical biosensor for ligand-directed functional selectivity acting on beta2 adrenoceptor in living cells (2008) FEBS letters, 582 (5), pp. 558-564; Stallaert, W., Dorn, J.F., Van der Westhuizen, E., Audet, M., Bouvier, M., Impedance responses reveal αα-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles (2012) PloS One, 7 (1), pp. e29420; Beyermann, M., Heinrich, N., Fechner, K., Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain (2007) Br J Pharmacol, 151 (6), pp. 851-859; Tschammer, N., Bollinger, S., Kenakin, T., Gmeiner, P., Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor (2011) Mol Pharmacol, 79 (3), pp. 575-585; Chen, X., Sassano, M.F., Zheng, L., Structure-Functional Selectivity Relationship Studies of α-Arrestin-Biased Dopamine D2 Receptor Agonists (2012) J Med Chem, 55 (16), pp. 7141-7153; Valant, C., Aurelio, L., Devine, S.M., Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor (2012) Journal of medicinal chemistry, 55 (5), pp. 2367-2375; Weiss, D.R., Ahn, S., Sassano, M.F., Conformation Guides Molecular Efficacy in Docking Screens of Activated α-2 Adrenergic G Protein Coupled Receptor (2013) ACS chemical biology; Seifert, R., Schneider, E.H., Dove, S., Paradoxical Stimulatory Effects of the ""Standard"" Histamine H4-Receptor Antagonist JNJ7777120: The H4 Receptor Joins the Club of 7 Transmembrane Domain Receptors Exhibiting Functional Selectivity (2011) Mol Pharmacol, 79 (4), pp. 631-638; Nijmeijer, S., Vischer, H.F., Rosethorne, E.M., Charlton, S.J., Leurs, R., Analysis of Multiple Histamine H4 Receptor Compound Classes Uncovers Gi and α-Arrestin2 Biased Ligands (2012) Mol Pharmacol, 82 (6), pp. 1174-1182; Nijmeijer, S., Vischer, H.F., Sirci, F., Detailed analysis of biased histamine H(4) receptor signalling by JNJ 7777120 analogues (2013) Br J Pharmacol, , [ahead of print]; Guixa-Gonzalez, R., Bruno, A., Marti-Solano, M., Selent, J., Crosstalk within GPCR Heteromers in Schizophrenia and Parkinson's Disease: Physical or Just Functional? (2012) Curr Med Chem, 19 (8), pp. 1119-1134; Fiorentini, C., Busi, C., Gorruso, E., Gotti, C., Spano, P., Missale, C., Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization (2008) Mol Pharmacol, 74 (1), pp. 59-69; Strömberg, I., Popoli, P., Müller, C.E., Ferré, S., Fuxe, K., Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum (2000) Eur J Neurosci, 12 (11), pp. 4033-4037; Rashid, A.J., So, C.H., Kong, M.M.C., D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum (2007) Proc Natl Acad Sci USA, 104 (2), pp. 654-659; Mitchell, D.C., Niu, S.L., Litman, B.J., Optimization of receptor-G protein coupling by bilayer lipid composition I: Kinetics of rhodopsintransducin binding (2001) J Biol Chem, 276 (46), pp. 42801-42806; Niu, S.L., Mitchell, D.C., Litman, B.J., Optimization of receptor-G protein coupling by bilayer lipid composition II: Formation of metarhodopsin II-transducin complex (2001) J Biol Chem, 276 (46), pp. 42807-42811; Sadiq, S.K., Guixà-González, R., Dainese, E., Pastor, M., De Fabritiis, G., Selent, J., Molecular Modeling and Simulation of Membrane Lipid-Mediated Effects on GPCRs (2013) Curr Med Chem, 20 (1), pp. 22-38; Blanpain, C., Wittamer, V., Vanderwinden, J.M., Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways (2001) J Biol Chem, 276 (26), pp. 23795-23804; O'Dowd, B., Hnatowich, M., Caron, M.G., Lefkowitz, R.J., Bouvier, M., Palmitoylation of the human beta2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor (1989) J Biol Chem, 264 (13), pp. 7564-7569; Reid, H.M., Kinsella, B.T., Palmitoylation of the TPbeta isoform of the human thromboxane A2 receptor. Modulation of G protein: Effector coupling and modes of receptor internalization (2007) Cell Signal, 19 (5), pp. 1056-1070; Ballesteros, J., Weinstein, H., Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors (1995) Methods Neurosci, 25, pp. 366-428; Woo, A.Y., Wang, T., Zeng, X., Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes (2009) Mol Pharmacol, 75 (1), pp. 158-165; Ryman-Rasmussen, J., Nichols, D., Mailman, R.B., Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists (2005) Mol Pharmacol, 68 (4), pp. 1039-1048","Pastor, M.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader, 88, E- 08003 Barcelona, Spain; email: manuel.pastor@upf.edu",,,,,,,,13816128,,CPDEF,"23621547","English","Curr. Pharm. Des.",Review,"Final",,Scopus,2-s2.0-84881334295
"Kaczor A.A., Selent J., Sanz F., Pastor M.","57201126216;55891371700;7102263897;7102415847;","Modeling complexes of transmembrane proteins: Systematic analysis of protein-protein docking tools",2013,"Molecular Informatics","32","8",,"717","733",,19,"10.1002/minf.201200150","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882454897&doi=10.1002%2fminf.201200150&partnerID=40&md5=ad58855eca28c90d5cea382c8132bd3e","Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, Spain; Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy with Division for Medical Analytics, Medical University of Lublin, 4A Chodźki St., PL-20059 Lublin, Poland","Kaczor, A.A., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, Spain, Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy with Division for Medical Analytics, Medical University of Lublin, 4A Chodźki St., PL-20059 Lublin, Poland; Selent, J., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, Spain; Sanz, F., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, Spain; Pastor, M., Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, Spain","Protein-protein docking methodology is frequently used to model complexes of transmembrane proteins, in particular oligomers of G protein-coupled receptors (GPCRs), even if its applicability for these systems has never been fully validated. The aim of this work is to perform a systematic study on the suitability of some widely-used protein-protein docking software for modeling complexes of transmembrane proteins. In this study we tested the programs ZDOCK, ClusPro, HEX, GRAMM-X, PatchDock, SymmDock, and HADDOCK, using a set of membrane protein oligomers for which the 3D structure has been obtained experimentally, including opsin dimer, the recently published chemokine CXCR4 and kappa opioid receptor dimers. The results show that the docking success depends on the applied docking algorithm and scoring functions, but also on inherent structural features of the transmembrane proteins. Thus, proteins with large interface surfaces, rich in surface cavities, high-order symmetry, and small conformational change upon complex formation are well predicted more often than proteins without these features. The results of this systematic analysis provide guidelines that can be used for obtaining reliable models of transmembrane proteins, including GPCRs. Therefore they can be useful for the application of structure-based methods in drug discovery projects involving these targets. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.","Docking algorithms; G protein-coupled receptor dimers; Protein complexes; Protein-protein docking; Transmembrane proteins","chemokine receptor CXCR4; docking protein; ion channel; kappa opiate receptor; membrane protein; potassium channel; algorithm; article; automation; binding site; complex formation; computer program; conformational transition; gap junction; genetic conservation; hydrophobicity; molecular docking; molecular recognition; practice guideline; priority journal; protein conformation; protein secondary structure",,"chemokine receptor CXCR4, 188900-71-2",,,,,,,"Méndez, R., Leplae, R., Maria, L.D., Wodak, S.J., (2003) Proteins, 52, pp. 51-67; Chung, S., Funakoshi, T., Civelli, O., (2008) Br. J. Pharmacol., pp. 339-346. , 153 Suppl 1, S; Heilker, R., Wolff, M., Tautermann, C.S., Bieler, M., (2009) Drug Discov. Today, 14, pp. 231-240; Mohr, K., Tränkle, C., Kostenis, E., Barocelli, E., De Amici, M., Holzgrabe, U., (2010) Br. J. Pharmacol., 159, pp. 997-1008; Klabunde, T., Hessler, G., (2002) Chembiochem, 3, pp. 928-944; Fotiadis, D., Liang, Y., Filipek, S., Saperstein, D.A., Engel, A., Palczewski, K., (2003) Nature, 421, pp. 127-128; Fotiadis, D., Liang, Y., Filipek, S., Saperstein, D.A., Engel, A., Palczewski, K., (2004) FEBS Lett., 564, pp. 281-288; Liang, Y., Fotiadis, D., Filipek, S., Saperstein, D.A., Palczewski, K., Engel, A., (2003) J. Biol. Chem., 278, pp. 21655-21662; Wu, B., Chien, E.Y.T., Mol, C.D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Stevens, R.C., (2010) Science, 330, pp. 1066-1071; Kaczor, A.A., Selent, J., (2011) Curr. Med. Chem., 18, pp. 4606-4634; Filizola, M., (2010) Life Sci., 86, pp. 590-597; Selent, J., Kaczor, A.A., (2011) Curr. Med. Chem., 18, pp. 4588-4605; Dean, M.K., Higgs, C., Smith, R.E., Bywater, R.P., Snell, C.R., Scott, P.D., Upton, G.J., Reynolds, C.A., (2001) J. Med. Chem., 44, pp. 4595-4614; Gouldson, P.R., Bywater, R.P., Reynolds, C.A., (1997) Biochem. Soc. Trans., 25, pp. 529S; Nemoto, W., Toh, H., (2005) Proteins, 58, pp. 644-660; Sutcliffe, M.J., Smeeton, A.H., Wo, Z.G., Oswald, R.E., (1998) Faraday Discuss., 259-272, pp. 331-343. , discussion; Patargias, G., Zitzmann, N., Dwek, R., Fischer, W.B., (2006) J. Med. Chem., 49, pp. 648-655; Pedretti, A., Marconi, C., Bolchi, C., Fumagalli, L., Ferrara, R., Pallavicini, M., Valoti, E., Vistoli, G., (2008) Biochem. Biophys. Res. Commun., 369, pp. 648-653; Casciari, D., Dell'Orco, D., Fanelli, F., (2008) J. Chem. Inf. Model., 48, pp. 1669-1678; Liu, X., Kai, M., Jin, L., Wang, R., (2009) J. Comput. Aided Mol. Des., 23, pp. 321-332; Bruno, A., Guadix, A.E., Costantino, G., (2009) J. Chem. Inf. Model., 49, pp. 1602-1616; Periole, X., Huber, T., Marrink, S.-J., Sakmar, T.P., (2007) J. Am. Chem. Soc., 129, pp. 10126-10132; Wodak, S.J., Janin, J., (1978) J. Mol. Biol., 124, pp. 323-342; Janin, J., Wodak, S.J., (1985) Biopolymers, 24, pp. 509-526; Lesk, V.I., Sternberg, M.J.E., (2008) Bioinformatics, 24, pp. 1137-1144; Halperin, I., Ma, B., Wolfson, H., Nussinov, R., (2002) Proteins, 47, pp. 409-443; Méndez, R., Leplae, R., Lensink, M.F., Wodak, S.J., (2005) Proteins, 60, pp. 150-169; Ritchie, D.W., (2008) Curr. Protein Pept. Sci., 9, pp. 1-15; Gray, J.J., Moughon, S., Wang, C., Schueler-Furman, O., Kuhlman, B., Rohl, C.A., Baker, D., (2003) J. Mol. Biol., 331, pp. 281-299; Vajda, S., Kozakov, D., (2009) Curr. Opin. Struct. Biol., 19, pp. 164-170; Casciari, D., Seeber, M., Fanelli, F., (2006) BMC Bioinformatics, 7, p. 340; Wiehe, K., Pierce, B., Mintseris, J., Tong, W.W., Anderson, R., Chen, R., Weng, Z., (2005) Proteins, 60, pp. 207-213; Fanelli, F., (2007) Mol. Cell. Endocrinol., 260-262, pp. 59-64; Fanelli, F., Mauri, M., Capra, V., Raimondi, F., Guzzi, F., Ambrosio, M., Rovati, G.E., Parenti, M., (2011) Cell. Mol. Life Sci., 68, pp. 3109-3120; Fanelli, F., Felline, A., (2011) Biochim. Biophys. Acta, 1808, pp. 1256-1266; Vajda, S., (2005) Proteins, 60, pp. 176-180; Moreira, I.S., Fernandes, P.A., Ramos, M.J., (2010) J. Comput. Chem., 31, pp. 317-342; Comeau, S.R., Gatchell, D.W., Vajda, S., Camacho, C.J., (2004) Nucleic Acids Res., 32, pp. 96-99. , W; Comeau, S.R., Kozakov, D., Brenke, R., Shen, Y., Beglov, D., Vajda, S., (2007) Proteins, 69, pp. 781-785; Ritchie, D.W., (2003) Proteins, 52, pp. 98-106; Tovchigrechko, A., Vakser, I.A., (2006) Nucleic Acids Res., 34, pp. 310-314. , W; Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., Wolfson, H.J., (2005) Nucleic Acids Res., 33, pp. 363-367. , W; Dominguez, C., Boelens, R., Bonvin, A.M.J.J., (2003) J. Am. Chem. Soc., 125, pp. 1731-1737; De Vries, S.J., Van Dijk, A.D.J., Krzeminski, M., Van Dijk, M., Thureau, A., Hsu, V., Wassenaar, T., Bonvin, A.M.J.J., (2007) Proteins, pp. 726-733. , 69; Molecular Operating Environment Software Package, V. 2009.10, , MOE; Krissinel, E., Henrick, K., (2007) J. Mol. Biol., 372, pp. 774-797; Humphrey, W., Dalke, A., Schulten, K., (1996) J. Mol. Graph., 14, pp. 33-38. , 27-28; Lyskov, S., Gray, J.J., (2008) Nucleic Acids Res., 36, p. 233. , WW 238; Dutzler, R., Campbell, E.B., Cadene, M., Chait, B.T., Mackinnon, R., (2002) Nature, 415, pp. 287-294; Locher, K.P., Lee, A.T., Rees, D.C., (2002) Science, 296, pp. 1091-1098; Salom, D., Lodowski, D.T., Stenkamp, R.E., Le Trong, I., Golczak, M., Jastrzebska, B., Harris, T., Palczewski, K., (2006) Proc. Natl. Acad. Sci. USA, 103, pp. 16123-16128; Park, J.H., Scheerer, P., Hofmann, K.P., Choe, H.-W., Ernst, O.P., (2008) Nature, 454, pp. 183-187; Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G.W., Vardy, E., Liu, W., Stevens, R.C., (2012) Nature, 485, pp. 327-332; Essen, L., Siegert, R., Lehmann, W.D., Oesterhelt, D., (1998) Proc. Natl. Acad. Sci. USA, 95, pp. 11673-11678; Doyle, D.A., Cabral, J.M., Pfuetzner, R.A., Kuo, A., Gulbis, J.M., Cohen, S.L., Chait, B.T., Mackinnon, R., (1998) Science, 280, pp. 69-77; Steinbacher, S., Bass, R., Strop, P., Rees, D.C., (2007) Mechanosensitive Ion Channels, Part A, pp. 1-24. , in, 58, Academic Press, New York; Unwin, N., (2005) J. Mol. Biol., 346, pp. 967-989; Maeda, S., Nakagawa, S., Suga, M., Yamashita, E., Oshima, A., Fujiyoshi, Y., Tsukihara, T., (2009) Nature, 458, pp. 597-602; Tusnády, G.E., Dosztányi, Z., Simon, I., (2005) Nucleic Acids Res., 33, pp. 275-278. , D; Guex, N., Peitsch, M.C., (1997) Electrophoresis, 18, pp. 2714-2723; The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC; Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin, T.E., (2004) J. Comput. Chem., 25, pp. 1605-1612; Pedretti, A., Villa, L., Vistoli, G., (2004) J. Comput. Aided Mol. Des., 18, pp. 167-173; (2010) R: A Language and Environment for Statistical Computing, , R Development Core Team R Foundation for Statistical Computing, Vienna, Austria; The PyMOL Molecular Graphics System, , Version 1.5.0.4 Schrödinger, LLC; Li, C.H., Ma, X.H., Chen, W.Z., Wang, C.X., (2003) Protein Eng., 16, pp. 265-269; Yu, Y.H., Lu, B.Z., Han, J.G., Zhang, P.F., (2004) J. Comput. Aided Mol. Des., 18, pp. 251-260; Kozakov, D., Hall, D.R., Beglov, D., Brenke, R., Comeau, S.R., Shen, Y., Li, K., Vajda, S., (2010) Proteins, 78, pp. 3124-3130; Goldenberg, O., Erez, E., Nimrod, G., Ben-Tal, N., (2009) Nucleic Acids Res., 37, pp. 323-327. , D; Lanyi, J.K., Schobert, B., (2007) J. Mol. Biol., 365, pp. 1379-1392","Kaczor, A.A.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital Del Mar Medical Research Institute), Dr. Aiguader 88, Barcelona, Spain; email: agnieszka.kaczor@umlub.pl",,,,,,,,18681743,,MIONB,,"English","Mol. Informatics",Article,"Final",,Scopus,2-s2.0-84882454897
"de la Iglesia D., García-Remesal M., de la Calle G., Kulikowski C., Sanz F., Maojo V.","35242106300;6507216549;23495177000;7005149346;7102263897;55171738800;","The impact of computer science in molecular medicine: Enabling high-throughput research",2013,"Current Topics in Medicinal Chemistry","13","5",,"526","575",,8,"10.2174/1568026611313050002","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878572474&doi=10.2174%2f1568026611313050002&partnerID=40&md5=27762d021607e6699be1402a49bf1dee","Biomedical Informatics Group, Universidad Politecnica de Madrid, Spain; Department of Computer Science, Rutgers-The State University of New Jersey, United States; Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain","de la Iglesia, D., Biomedical Informatics Group, Universidad Politecnica de Madrid, Spain; García-Remesal, M., Biomedical Informatics Group, Universidad Politecnica de Madrid, Spain; de la Calle, G., Biomedical Informatics Group, Universidad Politecnica de Madrid, Spain; Kulikowski, C., Department of Computer Science, Rutgers-The State University of New Jersey, United States; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Maojo, V., Biomedical Informatics Group, Universidad Politecnica de Madrid, Spain","The Human Genome Project and the explosion of high-throughput data have transformed the areas of molecular and personalized medicine, which are producing a wide range of studies and experimental results and providing new insights for developing medical applications. Research in many interdisciplinary fields is resulting in data repositories and computational tools that support a wide diversity of tasks: genome sequencing, genome-wide association studies, analysis of genotype-phenotype interactions, drug toxicity and side effects assessment, prediction of protein interactions and diseases, development of computational models, biomarker discovery, and many others. The authors of the present paper have developed several inventories covering tools, initiatives and studies in different computational fields related to molecular medicine: medical informatics, bioinformatics, clinical informatics and nanoinformatics. With these inventories, created by mining the scientific literature, we have carried out several reviews of these fields, providing researchers with a useful framework to locate, discover, search and integrate resources. In this paper we present an analysis of the state-of-the-art as it relates to computational resources for molecular medicine, based on results compiled in our inventories, as well as results extracted from a systematic review of the literature and other scientific media. The present review is based on the impact of their related publications and the available data and software resources for molecular medicine. It aims to provide information that can be useful to support ongoing research and work to improve diagnostics and therapeutics based on molecular-level insights. © 2013 Bentham Science Publishers.","Biomedical informatics; Computational resources; Data sources; Genotype-phenotype; Medicinal chemistry; Molecular medicine; Personalized medicine","amino acid sequence; clinical data repository; computer; data analysis software; data base; drug design; gene expression; genomics; high throughput sequencing; journal impact factor; medical literature; Medical Subject Headings; metabolism; metabolomics; microarray analysis; molecular docking; molecular medicine; personalized medicine; pharmacophore; phylogeny; priority journal; protein domain; protein interaction; proteomics; publication; publishing; review; RNA sequence; scientific literature; simulation; single nucleotide polymorphism; transcriptomics; web browser; Biomedical Research; Chemistry, Pharmaceutical; Computational Biology; High-Throughput Screening Assays; Humans; Individualized Medicine; Medical Informatics; Molecular Medicine; Software",,,,,,,,,"Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Elkin, C., International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome (2001) Nature, 409, pp. 860-921. , Frazier, M.; Gibbs, R.A.; Muzny, D.M.; Scherer, S.E.; Bouck, J.B.; Sodergren, E.J.; Worley, K.C.; Rives, C.M.; Gorrell, J.H.; Metzker, M.L.; Naylor, S.L.; Kucherlapati, R.S.; Nelson, D.L.; Weinstock, G.M.; Sakaki, Y.; Fujiyama, A.; Hattori, M.; Ya-da, T.; Toyoda, A.; Itoh, T.; Kawagoe, C.; Watanabe, H.; Totoki, Y.; Taylor, T.; Weissenbach, J.; Heilig, R.; Saurin, W.; Artiguena-ve, F.; Brottier, P.; Bruls, T.; Pelletier, E.; Robert, C.; Wincker, P.; Smith, D.R.; Doucette-Stamm, L.; Rubenfield, M.; Weinstock, K.; Lee, H.M.; Dubois, J.; Rosenthal, A.; Platzer, M.; Nyakatura, G.; Taudien, S.; Rump, A.; Yang, H.; Yu, J.; Wang, J.; Huang, G.; Gu, J.; Hood, L.; Rowen, L.; Madan, A.; Qin, S.; Davis, R.W.; Feders-piel, N.A.; Abola, A.P.; Proctor, M.J.; Myers, R. M.; Schmutz, J.; Dickson, M.; Grimwood, J.; Cox, D.R.; Olson, M.V, Kaul, R.; Shimizu, N.; Kawasaki, K.; Minoshima, S.; Evans, G.A.; Athana-siou, M.; Schultz, R.; Roe, B.A.; Chen, F.; Pan, H.; Ramser, J.; Lehrach, H.; Reinhardt, R; Trelles, O., Prins, P., Snir, M., Jansen, R.C., Big data, but are we ready? (2011) Nat Rev Genet, 12 (3), p. 224; Kumpulainen, S., Jarvelin, K., Barriers to Task-Based Information Access in Molecular Medicine (2012) Journal of the American Society For Information Science and Technology, 63 (1), pp. 86-97; Benson, D.A., Cavanaugh, M., Clark, K., Karsch-Mizrachi, I., Lipman, D.J., Ostell, J., Sayers, E.W., GenBank (2013) Nucleic Acids Res, 41 (D1), pp. D36-D42; Fernández-Suárez, X.M., Galperin, M.Y., The 2013 Nucleic Acids Research Database Issue and the online Molecular Biology Database Collection (2013) Nucleic Acids Res, 41 (D1), pp. D1-D7; Lathe, W., Williams, J., Mangan, M., Karolchik, D., Genomic Data Resources: Challenges and Promises (2008) Nature Education, 1 (3); Scriver, C.R., Sly, W.S., Childs, B., Beaudet, A.L., Valle, D., Kin-Zler, K.W., Vogelstein, B., (2001) The Metabolic and Molecular Basis of Inherited Disease, , 8th ed.; McGraw-Hill:New York; Pauling, L., Itano, H.A., Sickle cell anemia, a molecular disease (2835) Science, 1949 (109), p. 443; Williams, R.J., (1956) Biochemical Individuality: The Basis For the Gene-totrophic Concept, , John Wiley & Sons: New York; Perutz, M.F., Lehmann, H., Molecular pathology of human haemoglobin (1968) Nature, 219 (5157), pp. 902-909; Schechter, A.N., Hemoglobin research and the origins of molecular medicine (2008) Blood, 112 (10), pp. 3927-3938; Weatherall, D.J., Molecular medicine: The road to the better integration of the medical sciences in the twenty-first century (2010) Notes Rec R Soc Lond, 64 (SUPPL. 1), pp. S5-S15; Vallance, P., Levick, M., Drug discovery and development in the age of molecular medicine (2007) Clin Pharmacol Ther, 82 (4), pp. 363-366; Davidson, E., Levin, M., Gene regulatory networks (2005) Proc Natl Acad Sci USA, 102, p. 4935; Liang, M., MicroRNA: A new entrance to the broad paradigm of systems molecular medicine (2009) Physiol Genomics, 38 (2), pp. 113-115; Nesse, R.M., Ganten, D., Gregory, T.R., Omenn, G.S., Evolutionary molecular medicine (2012) J Mol Med, 90 (5), pp. 509-522; A map of human genome variation from population-scale sequencing (2010) Nature, 467 (7319), pp. 1061-1073. , 1000 Genomes Project Consortium; Gerstein, M., Genomics: ENCODE leads the way on big data (2012) Nature, 489 (7415), p. 208; Massoud, T.F., Gambhir, S.S., Integrating noninvasive molecular imaging into molecular medicine: An evolving paradigm (2007) Trends Mol Med, 13 (5), pp. 183-191; Hoffman, E.P., Skipping toward personalized molecular medicine (2007) N Engl J Med, 357 (26), pp. 2719-2722; Sotiriou, C., Piccart, M.J., Taking gene-expression profiling to the clinic: When will molecular signatures become relevant to patient care? (2007) Nat Rev Cancer, 7 (7), pp. 545-553; Dunn, B.K., Jegalian, K., Greenwald, P., Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: Issues and opportunities (2011) Recent Results Cancer Res, 188, pp. 21-47; Waldman, S.A., Terzic, M.R., Terzic, A., Molecular medicine hones therapeutic arts to science (2007) Clin Pharmacol Ther, 82 (4), pp. 343-347; Schneider, M.V., Orchard, S., Omics technologies, data and bioin-formatics principles (2011) Methods Mol Biol, 719, pp. 3-30; Rivero, D., Rabuñal, J., Dorado, J., Pazos, A., Automatic Design of ANNs by Means of GP for Data Mining Tasks: Iris Flower Classification Problem. Adaptive and Natural Computing Algorithms (2007) Lecture Notes In Computer Science, 4431, pp. 276-285; Tan, K.C., Yu, Q., Heng, C.M., Lee, T.H., Evolutionary computing for knowledge discovery in medical diagnosis (2003) Artif Intell Med, 27 (2), pp. 129-154; Porto-Pazos, A.B., Veiguela, N., Mesejo, P., Navarrete, M., Alva-Rellos, A., Ibáñez, O., Pazos, A., Araque, A., Artificial astrocytes improve neural network performance (2011) PLoS One, 6 (4), pp. e19109; Cooper, J., Cervenansky, F., de Fabritiis, G., Fenner, J., Friboulet, D., Giorgino, T., Manos, S., Coveney, P.V., The Virtual Physiological Human ToolKit (2010) Philos Transact a Math Phys Eng Sci, 368 (1925), pp. 3925-3936; Sarachan, B.D., Simmons, M.K., Subramanian, P., Temkin, J.M., Combining medical informatics and bioinformatics toward tools for personalized medicine (2003) Methods Inf Med, 42 (2), pp. 111-115; Altman, R.B., Translational bioinformatics: Linking the molecular world to the clinical world (2012) Clin Pharmacol Ther, 91 (6), pp. 994-1000; Maojo, V., Herrero, C., Valenzuela, F., Crespo, J., Lázaro, P., Pazos, A., A JAVA-based multimedia tool for clinical practice guidelines (1997) Studies In Health Technology and Informatics, 43, p. 348; Aldridge, S., Biobanking Emerging as a Key Growth Area (2005) Genetic Engineering News, 25, p. 1; Cannata, N., Merelli, E., Altman, R.B., Time to organize the bioin-formatics Resourceome (2005) PLoS Comput Biol, 1 (7), pp. e20; (2013) Online Molecular Biology Database Collection, , http://www.oxfordjournals.org/nar/database/a/, Accessed March 3; (2013) ORBIT, , http://orbit.nlm.nih.gov/, Accessed March 3; (2013) ITools, , http://cms.loni.ucla.edu/iTools/index.aspx, Accessed March 3; (2013) Data Sources and Tools At the EBI, , http://www.ebi.ac.uk/, Accessed March 3; de la Calle, G., García-Remesal, M., Chiesa, S., de la Iglesia, D., Maojo, V., BIRI: A new approach for automatically discovering and indexing available public bioinformatics resources from the literature (2009) BMC Bioinformatics, 10, p. 320; de la Calle, G., Garcia-Remesal, M., Nkumu-Mbomio, N., Kuli-Kowski, C., Maojo, V., e-MIR2: A public online inventory of medical informatics resources (2012) BMC Med Inform Decis Mak, 12, p. 82; Maojo, V., Fritts, M., de la Iglesia, D., Cachau, R.E., Garcia-Remesal, M., Mitchell, J.A., Kulikowski, C., Nanoinformatics: A new area of research in nanomedicine (2012) Int J Nanomedicine, 7, pp. 3867-3890; Webb, A.J., Thorisson, G.A., Brookes, A.J., An informatics project and online ""Knowledge Centre"" supporting modern genotype-to-phenotype research (2011) Human Mutation, 32 (5), pp. 543-550; STATegra (FP7), , http://stategra.eu/; (2013) The ACTION-Grid Project, , http://www.action-grid.eu/, Accessed March 3; (2013) Linked Data, , http://linkeddata.org/, Accessed March 3; Butte, A.J., Kohane, I.S., Creation and implications of a phenome-genome network (2006) Nature Biotechnology, 24 (1), pp. 55-62; Giorgetti, A., Ruggerone, P., Pantano, S., Carloni, P., Advanced computational methods in molecular medicine (2012) J Biomed Biotech-nol, 2012, p. 709085; Fischer, H.P., Towards quantitative biology: Integration of biological information to elucidate disease pathways and to guide drug discovery (2005) Biotechnol Annu Rev, 11, pp. 1-68; Rivero, D., Rabuñal, J., Dorado, J., Pazos, A., Time series forecast with anticipation using genetic programming (2005) Computational Intelligence and Bioinspired Systems, 3512, pp. 968-975; Guo, L., Rivero, D., Dorado, J., Munteanu, C.R., Pazos, A., Automatic feature extraction using genetic programming: An application to epileptic EEG classification (2011) Expert Systems With Applications, 38 (8), pp. 10425-10436; Liao, C., Sitzmann, M., Pugliese, A., Nicklaus, M.C., Software and resources for computational medicinal chemistry (2011) Future Med Chem, 3 (8), pp. 1057-1085; Geldenhuys, W.J., Gaasch, K.E., Watson, M., Allen, D.D., van der Schyf, C.J., Optimizing the use of open-source software applications in drug discovery (2006) Drug Discov Today, 11 (3-4), pp. 127-132; Vizcaíno, J.A., Foster, J.M., Martens, L., Proteomics data repositories: Providing a safe haven for your data and acting as a springboard for further research (2010) J Proteomics, 73 (11), pp. 2136-2146; Martens, L., Proteomics databases and repositories (2011) Methods Mol Biol, 694, pp. 213-227; Mead, J.A., Bianco, L., Bessant, C., Recent developments in public proteomic MS repositories and pipelines (2009) Proteomics, 9 (4), pp. 861-881; Wright, J.C., Hubbard, S.J., Recent developments in proteome informatics for mass spectrometry analysis (2009) Comb Chem High Throughput Screen, 12 (2), pp. 194-202; Harrison, R., Protecting innovation in bioinformatics and in-silico biology (2003) BioDrugs, 17 (4), pp. 227-231; Duardo-Sánchez, A., Patlewicz, G., López-Díaz, A., Current topics on software use in medicinal chemistry: Intellectual property, taxes, and regulatory issues (2008) Current Topics In Medicinal Chemistry, 8 (18), pp. 1666-1675; (2013) INBIOMED Vision (FP7-270107), , http://www.inbiomedvision.eu, Accessed March 3; (2013) PubMed, , http://www.ncbi.nlm.nih.gov/pubmed/, Accessed March 3; (2013) Embase, , http://www.embase.com, Accessed March 3; (2013) Scopus, , http://www.scopus.com, Accessed March 3; (2013) ISI Web of Knowledge, , http://www.webofknowledge.com, Accessed March 3; Press, W.H., Teukolsky, S.A., Vetterling, W.T., Flannery, B.P., (2007) Numerical Recipes: The Art of Scientific Computing, , 3rd ed. Section 16.4., Hierarchical Clustering by Phylogenetic Trees. Cambridge University Press: New York; Debouck, C., Integrating genomics across drug discovery and development (2009) Toxicol Lett, 186 (1), pp. 9-12; George, R.A., Smith, T.D., Callaghan, S., Hardman, L., Pierides, C., Horaitis, O., Wouters, M.A., Cotton, R.G., General mutation databases: Analysis and review (2008) J Med Genet, 45 (2), pp. 65-70; Williams, H.E., Zobel, J., Indexing and Retrieval for Genomic Databases (2002) IEEE Transactions On Knowledge and Data Engineering, pp. 63-78; Williams-Devane, C.R., Wolf, M.A., Richard, A.M., Toward a public toxicogenomics capability for supporting predictive toxicology: Survey of current resources and chemical indexing of experiments in GEO and ArrayExpress (2009) Toxicol Sci, 109 (2), pp. 358-371; Kanehisa, M., Goto, S., KEGG: Kyoto encyclopedia of genes and genomes (2000) Nucleic Acids Res, 28 (1), pp. 27-30; Kuhn, R.M., Haussler, D., Kent, W.J., The UCSC genome browser and associated tools (2012) Brief Bioinform, , Oct 31. [Epub ahead of print]; Benson, D.A., Karsch-Mizrachi, I., Lipman, D.J., Ostell, J., Rapp, B.A., Wheeler, D.L., GenBank (2000) Nucleic Acids Res, 28 (1), pp. 15-18; Flicek, P., Amode, M.R., Barrell, D., Beal, K., Brent, S., Carvalho-Silva, D., Clapham, P., Searle, S.M., Ensembl 2012 (2012) Nucleic Acids Res, 40, pp. D84-D90; Database resources of the National Center for Biotechnology Information (2013) Nucleic Acids Res, 41 (D1), pp. D8-D20. , NCBI Resource Coordinators; Katoh, K., Standley, D.M., MAFFT multiple sequence alignment software version 7: Improvements in performance and usability (2013) Mol Biol Evol, , Jan 16. [Epub ahead of print]; Notredame, C., Higgins, D.G., Heringa, J., T-Coffee: A novel method for fast and accurate multiple sequence alignment (2000) J Mol Biol, 302 (1), pp. 205-217; Kent, W.J., BLAT--the BLAST-like alignment tool (2002) Genome Res, 12 (4), pp. 656-664; Chen, V.B., Arendall, W.B., Headd, J.J., Keedy, D.A., Im-Mormino, R.M., Kapral, G.J., Murray, L.W., Richardson, D.C., MolProbity: All-atom structure validation for macromolecular crystallography (2010) Acta Crystallogr D Biol Crystal-logr, 66 (Pt 1), pp. 12-21; Dennis, G., Sherman, B.T., Hosack, D.A., Yang, J., Gao, W., Lane, H.C., Lempicki, R.A., DAVID: Database for Annotation, Visualization, and Integrated Discovery (2003) Genome Biol, 4 (5), pp. P3; Robinson, J., Marsh, S.G., The IMGT/HLA database (2007) Methods Mol Biol, 409, pp. 43-60; Tatusova, T.A., Madden, T.L., BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences (1999) FEMS Microbiol Lett, 174 (2), pp. 247-250; Dunham, I., Kundaje, A., Aldred, S.F., Collins, P.J., Davis, C.A., Doyle, F., An integrated encyclopedia of DNA elements in the human genome (2012) Nature, 489 (7414), pp. 57-74. , ENCODE Project Consortium; Kulikova, T., Aldebert, P., Althorpe, N., Baker, W., Bates, K., Browne, P., van den Broek, A., Apweiler, R., The EMBL Nucleotide Sequence Database (2004) Nucleic Acids Res, 32, pp. D27-D30; Zheng, G., Lu, X.J., Olson, W.K., Web 3DNA--a web server for the analysis, reconstruction, and visualization of three-dimensional nucleic-acid structures (2009) Nucleic Acids Res, 37, pp. W240-W246; Maglott, D., Ostell, J., Pruitt, K.D., Tatusova, T., Entrez Gene: Gene-centered information at NCBI (2011) Nucleic Acids Res, 39, pp. D52-D57; Jenssen, T.K., Laegreid, A., Komorowski, J., Hovig, E., A literature network of human genes for high-throughput analysis of gene expression (2001) Nat Genet, 28 (1), pp. 21-28; Thomas-Chollier, M., Sand, O., Turatsinze, J.V., Janky, R., De-France, M., Vervisch, E., Brohée, S., van Helden, J., RSAT: Regulatory sequence analysis tools (2008) Nucleic Acids Res, 36, pp. W119-W127; Ning, Z., Cox, A.J., Mullikin, J.C., SSAHA: A fast search method for large DNA databases (2001) Genome Res, 11 (10), pp. 1725-1729; Miyazaki, S., Sugawara, H., Gojobori, T., Tateno, Y., DNA Data Bank of Japan (DDBJ) in XML (2003) Nucleic Acids Res, 31 (1), pp. 13-16; Zhang, B., Kirov, S., Snoddy, J., WebGestalt: An integrated system for exploring gene sets in various biological contexts (2005) Nucleic Acids Res, 33, pp. W741-W748; Wu, C., Orozco, C., Boyer, J., Leglise, M., Goodale, J., Batalov, S., Hodge, C.L., Su, A.I., BioGPS: An extensible and customizable portal for querying and organizing gene annotation resources (2009) Genome Biol, 10 (11), pp. R130; Wallace, I.M., O'Sullivan, O., Higgins, D.G., Notredame, C., M-Coffee: Combining multiple sequence alignment methods with T-Coffee (2006) Nucleic Acids Res, 34 (6), pp. 1692-1699; Hsu, F., Kent, W.J., Clawson, H., Kuhn, R.M., Diekhans, M., Haussler, D., The UCSC Known Genes (2006) Bioinformatics, 22 (9), pp. 1036-1046; Wilming, L.G., Gilbert, J.G., Howe, K., Trevanion, S., Hubbard, T., Harrow, J.L., The vertebrate genome annotation (Vega) database (2008) Nucleic Acids Res, 36, pp. D753-D760; Pruess, M., Kersey, P., Apweiler, R., The Integr8 project--a resource for genomic and proteomic data (2005) In Silico Biol, 5 (2), pp. 179-185; Reimand, J., Kull, M., Peterson, H., Hansen, J., Vilo, J., g:Profiler--a web-based toolset for functional profiling of gene lists from large-scale experiments (2007) Nucleic Acids Res, 35, pp. W193-W200; Harrow, J., Denoeud, F., Frankish, A., Reymond, A., Chen, C.K., Chrast, J., Lagarde, J., Guigo, R., GENCODE: Producing a reference annotation for ENCODE (2006) Genome Biol, 7 (SUPPL. 1), pp. S4+1-9; Backes, C., Keller, A., Kuentzer, J., Kneissl, B., Comtesse, N., Elnakady, Y.A., Müller, R., Lenhof, H.P., GeneTrail--advanced gene set enrichment analysis (2007) Nucleic Acids Res, 35, pp. W186-W192; Guigó, R., Flicek, P., Abril, J.F., Reymond, A., Lagarde, J., De-Noeud, F., Antonarakis, S., Reese, M.G., EGASP: The human ENCODE Genome Annotation Assessment Project (2006) Genome Biol, S2 (SUPPL. 1), pp. 1-31; Leinonen, R., Akhtar, R., Birney, E., Bower, L., Cerdeno-Tárraga, A., Cheng, Y., Cleland, I., Cochrane, G., The European Nucleotide Archive (2011) Nucleic Acids Res, 39, pp. D28-D31; Warde-Farley, D., Donaldson, S.L., Comes, O., Zuberi, K., Badra-Wi, R., Chao, P., Franz, M., Morris, Q., The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function (2010) Nucleic Acids Res, 38, pp. W214-W220; Beisvag, V., Jünge, F.K., Bergum, H., Jølsum, L., Lydersen, S., Günther, C.C., Ramampiaro, H., Lae-Greid, A., GeneTools--application for functional annotation and statistical hypothesis testing (2006) BMC Bioinformatics, 7, p. 470; Allen, J.E., Salzberg, S.L., JIGSAW: Integration of multiple sources of evidence for gene prediction (2005) Bioinformatics, 21 (18), pp. 3596-3603; Bult, C.J., From information to understanding: The role of model organism databases in comparative and functional genomics (2006) Anim Genet, 37 (SUPPL. 1), pp. 28-40; Tendolkar, P.M., Baghdayan, A.S., Shankar, N., Pathogenic entero-cocci: New developments in the 21st century (2003) Cell Mol Life Sci, 60 (12), pp. 2622-2636; Blake, J.A., Bult, C.J., Eppig, J.T., Kadin, J.A., Richardson, J.E., The Mouse Genome Database genotypes: Phenotypes (2009) Nucleic Acids Res, 37, pp. 712-719; Sprague, J., Clements, D., Conlin, T., Edwards, P., Frazer, K., Schaper, K., Segerdell, E., Westerfield, M., The Zebrafish Information Network (ZFIN): The zebrafish model organism database (2003) Nucleic Acids Res, 31 (1), pp. 241-243; Twigger, S.N., Shimoyama, M., Bromberg, S., Kwitek, A.E., Jacob, H.J., Team, R.G.D., The Rat Genome Database, update 2007--easing the path from disease to data and back again (2007) Nucleic Acids Res, 35, pp. D658-D662; Logan-Klumpler, F.J., de Silva, N., Boehme, U., Rogers, M.B., Velarde, G., McQuillan, J.A., Carver, T., Berriman, M., GeneDB--an annotation database for pathogens (2012) Nucleic Acids Res, 40, pp. D98-D108; Ploger, R., Zhang, J., Bassett, D., Reeves, R., Hieter, P., Boguski, M., Spencer, F., XREFdb: Cross-referencing the genetics and genes of mammals and model organisms (2000) Nucleic Acids Res, 28 (1), pp. 120-122; Alm, E.J., Huang, K.H., Price, M.N., Koche, R.P., Keller, K., Dubchak, I.L., Arkin, A.P., The MicrobesOnline Web site for comparative genomics (2005) Genome Res, 15 (7), pp. 1015-1022; Basu, S., Fey, P., Pandit, Y., Dodson, R., Kibbe, W.A., Chisholm, R.L., DictyBase 2013: Integrating multiple Dictyostelid species (2013) Nucleic Acids Res, 41 (D1), pp. D676-D683; Wang, J., Xia, Q., He, X., Dai, M., Ruan, J., Chen, J., Yu, G., Yu, J., SilkDB: A knowledge-base for silkworm biology and genomics (2005) Nucleic Acids Res, 33, pp. D399-D402; Chan, P.P., Holmes, A.D., Smith, A.M., Tran, D., Lowe, T.M., The UCSC Archaeal Genome Browser: 2012 update (2012) Nucleic Acids Res, 40, pp. D646-D652; Kapranov, P., Willingham, A.T., Gingeras, T.R., Genome-wide transcription and the implications for genomic organization (2007) Nat Rev Genet, 8 (6), pp. 413-423; Sultan, M., Schulz, M.H., Richard, H., Magen, A., Klingenhoff, A., Scherf, M., Seifert, M., Yaspo, M.L., A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome (2008) Science, 321 (5891), pp. 956-960; Barrett, T., Edgar, R., Mining microarray data at NCBI's Gene Expression Omnibus (GEO)* (2006) Methods Mol Biol, 338, pp. 175-190; Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smi-Gielski, E.M., Sirotkin, K., dbSNP: The NCBI database of genetic variation (2001) Nucleic Acids Res, 29 (1), pp. 308-311; Parkinson, H., Kapushesky, M., Shojatalab, M., Abeygunawarde-Na, N., Coulson, R., Farne, A., Holloway, E., Brazma, A., ArrayExpress--a public database of mi-croarray experiments and gene expression profiles (2007) Nucleic Acids Res, 35, pp. D747-D750; Dahlquist, K.D., Salomonis, N., Vranizan, K., Lawlor, S.C., Conk-Lin, B.R., GenMAPP, a new tool for viewing and analyzing microar-ray data on biological pathways (2002) Nat Genet, 31 (1), pp. 19-20; Liu, G., Loraine, A.E., Shigeta, R., Cline, M., Cheng, J., Valmeekam, V., Sun, S., Siani-Rose, M.A., NetAffx: Af-fymetrix probesets and annotations (2003) Nucleic Acids Res, 31, pp. 82-86; Spandidos, A., Wang, X., Wang, H., Seed, B., PrimerBank: A resource of human and mouse PCR primer pairs for gene expression detection and quantification (2010) Nucleic Acids Res, 38, pp. D792-D799; Koscielny, G., Le Texier, V., Gopalakrishnan, C., Kumanduri, V., Riethoven, J.J., Nardone, F., Stanley, E., Gautheret, D., ASTD: The Alternative Splicing and Transcript Diversity database (2009) Genomics, 93 (3), pp. 213-220; Salgado, H., Peralta-Gil, M., Gama-Castro, S., Santos-Zavaleta, A., Muñiz-Rascado, L., García-Sotelo, J.S., Weiss, V., Collado-Vides, J., RegulonDB v8.0: Omics data sets, evolutionary conservation, regulatory phrases, cross-validated gold standards and more (2013) Nucleic Acids Res, 41 (D1), pp. D203-D213; Desmet, F.O., Hamroun, D., Lalande, M., Collod-Béroud, G., Claustres, M., Béroud, C., Human Splicing Finder: An online bioin-formatics tool to predict splicing signals (2009) Nucleic Acids Res, 37 (9), pp. e67; Durinck, S., Moreau, Y., Kasprzyk, A., Davis, S., de Moor, B., Brazma, A., Huber, W., BioMart and Bioconductor: A powerful link between biological databases and microarray data analysis (2005) Bioin-formatics, 21 (16), pp. 3439-3440; Ho Sui, S.J., Mortimer, J.R., Arenillas, D.J., Brumm, J., Walsh, C.J., Kennedy, B.P., Wasserman, W.W., oPOSSUM: Identification of over-represented transcription factor binding sites in co-expressed genes (2005) Nucleic Acids Res, 33 (10), pp. 3154-3164; Shamir, R., Maron-Katz, A., Tanay, A., Linhart, C., Steinfeld, I., Sharan, R., Shiloh, Y., Elkon, R., EXPANDER--an integrative program suite for microarray data analysis (2005) BMC Bioinformatics, 6, p. 232; Lee, H.K., Braynen, W., Keshav, K., Pavlidis, P., ErmineJ: Tool for functional analysis of gene expression data sets (2005) BMC Bioinformat-ics, 6, p. 269; Al-Shahrour, F., Minguez, P., Tárraga, J., Medina, I., Alloza, E., Montaner, D., Dopazo, J., FatiGO +: A functional profiling tool for genomic data. Integration of functional annotation, regulatory motifs and interaction data with microarray experiments (2007) Nucleic Acids Res, 35, pp. W91-W96; Maragkakis, M., Reczko, M., Simossis, V.A., Alexiou, P., Papado-Poulos, G.L., Dalamagas, T., Giannopoulos, G., Hatzigeorgiou, A.G., DIANA-microT web server: Elucidating microRNA functions through target prediction (2009) Nucleic Acids Res, 37, pp. W273-W276; Griffith, O.L., Montgomery, S.B., Bernier, B., Chu, B., Kasaian, K., Aerts, S., Mahony, S., Jones, S.J., Open Regulatory Annotation Consortium. ORegAnno: An open-access community-driven resource for regulatory annotation (2008) Nucleic Acids Res, 36, pp. D107-D113; Thierry-Mieg, D., Thierry-Mieg, J., AceView: A comprehensive cDNA-supported gene and transcripts annotation (2006) Genome Biol, 7 (SUPPL. 1), pp. S12+1-14; Ernst, J., Bar-Joseph, Z., STEM: A tool for the analysis of short time series gene expression data. BMC (2006) Bioinformatics, 7, p. 191; Boorsma, A., Foat, B.C., Vis, D., Klis, F., Bussemaker, H.J., T-profiler: Scoring the activity of predefined groups of genes using gene expression data (2005) Nucleic Acids Res, 33, pp. W592-W595; Siebert, S., Backofen, R., MARNA: Multiple alignment and consensus structure prediction of RNAs based on sequence structure comparisons (2005) Bioinformatics, 21 (16), pp. 3352-3359; Vadigepalli, R., Chakravarthula, P., Zak, D.E., Schwaber, J.S., Gonye, G.E., PAINT: A promoter analysis and interaction network generation tool for gene regulatory network identification (2003) OMICS, 7 (3), pp. 235-252; Rainer, J., Sanchez-Cabo, F., Stocker, G., Sturn, A., Trajanoski, Z., CARMAweb: Comprehensive R-and bioconductor-based web service for microarray data analysis (2006) Nucleic Acids Res, 34, pp. W498-W503; Kim, S.K., Nam, J.W., Rhee, J.K., Lee, W.J., Zhang, B.T., miTar-get: MicroRNA target gene prediction using a support vector machine (2006) BMC Bioinformatics, 7, p. 411; Cho, S., Jun, Y., Lee, S., Choi, H.S., Jung, S., Jang, Y., Park, C., Kim, W., miRGator v2.0: An integrated system for functional investigation of microRNAs (2011) Nucleic Acids Res, 39, pp. D158-D162; Zhong, S., Li, C., Wong, W.H., ChipInfo: Software for extracting gene annotation and gene ontology information for microarray analysis (2003) Nucleic Acids Res, 31 (13), pp. 3483-3486; Aerts, S., Thijs, G., Coessens, B., Staes, M., Moreau, Y., de Moor, B., Toucan: Deciphering the cis-regulatory logic of coregulated genes (2003) Nucleic Acids Res, 31, pp. 1753-1764; Montaner, D., Tárraga, J., Huerta-Cepas, J., Burguet, J., Vaqueri-Zas, J.M., Conde, L., Minguez, P., Dopazo, J., Next station in microarray data analysis: GEPAS (2006) Nucleic Acids Res, 34, pp. W486-W491; Abbas, A.R., Baldwin, D., Ma, Y., Ouyang, W., Gurney, A., Martin, F., Fong, S., Clark, H.F., Immune response in silico (IRIS): Immune-specific genes identified from a compendium of microarray expression data (2005) Genes Immun, 6 (4), pp. 319-331; Lardenois, A., Gattiker, A., Collin, O., Chalmel, F., Primig, M., GermOnline 4.0 is a genomics gateway for germline development, meiosis and the mitotic cell cycle (2010) Database (Oxford), , 2010, baq030; Leipzig, J., Pevzner, P., Heber, S., The Alternative Splicing Gallery (ASG): Bridging the gap between genome and transcriptome (2004) Nucleic Acids Res, 32 (13), pp. 3977-3983; Sarver, M., Zirbel, C.L., Stombaugh, J., Mokdad, A., Leontis, N.B., FR3D: Finding local and composite recurrent structural motifs in RNA 3D structures (2008) J Math Biol, 56 (1-2), pp. 215-252; Dieterich, C., Wang, H., Rateitschak, K., Luz, H., Vingron, M., CORG: A database for COmparative Regulatory Genomics (2003) Nucleic Acids Res, 31 (1), pp. 55-57; Hsiao, A., Ideker, T., Olefsky, J.M., Subramaniam, S., VAMPIRE microarray suite: A web-based platform for the interpretation of gene expression data (2005) Nucleic Acids Res, 33, pp. W627-W632; Huang, H.Y., Chien, C.H., Jen, K.H., Huang, H.D., RegRNA: An integrated web server for identifying regulatory RNA motifs and elements (2006) Nucleic Acids Res, 34, pp. W429-W434; Sethupathy, P., Corda, B., Hatzigeorgiou, A.G., TarBase: A comprehensive database of experimentally supported animal mi-croRNA targets (2006) RNA, 12 (2), pp. 192-197; Bakheet, T., Williams, B.R., Khabar, K.S., ARED 3.0: The large and diverse AU-rich transcriptome (2006) Nucleic Acids Res, 34, pp. 111-114; Megraw, M., Sethupathy, P., Corda, B., Hatzigeorgiou, A.G., miR-Gen: A database for the study of animal microRNA genomic organization and function (2007) Nucleic Acids Res, 35, pp. D149-D155; Machnicka, M.A., Milanowska, K., Osman Oglou, O., Purta, E., Kurkowska, M., Olchowik, A., Januszewski, W., Grosjean, H., MODOMICS: A database of RNA modification path-ways--2013 update (2013) Nucleic Acids Res, 41 (D1), pp. D262-D267; Chan, P.P., Lowe, T.M., GtRNAdb: A database of transfer RNA genes detected in genomic sequence (2009) Nucleic Acids Res, 37, pp. D93-D97; Shahi, P., Loukianiouk, S., Bohne-Lang, A., Kenzelmann, M., Küffer, S., Maertens, S., Eils, R., Brors, B., Argonaute--a database for gene regulation by mammalian microR-NAs (2006) Nucleic Acids Res, 34, pp. D115-D118; James, P., Protein identification in the post-genome era: The rapid rise of proteomics (1997) Q Rev Biophys, 30 (4), pp. 279-331; Joosten, R.P., te Beek, T.A., Krieger, E., Hekkelman, M.L., Hooft, R.W., Schneider, R., Sander, C., Vriend, G., A series of PDB related databases for everyday needs (2011) Nucleic Acids Res, 39, pp. D411-D419; Apweiler, R., Bairoch, A., Wu, C.H., Protein sequence databases (2004) Curr Opin Chem Biol, 8 (1), pp. 76-80; Arauzo-Bravo, M.J., Ahmad, S., Protein sequence and structure databases: A review (2005) Current Analytical Chemistry, 1 (3), pp. 355-371; Pavlopoulou, A., Michalopoulos, I., State-of-the-art bioinformatics protein structure prediction tools (Review) (2011) Int J Mol Med, 28 (3), pp. 295-310; Shoemaker, B.A., Panchenko, A.R., Deciphering protein-protein interactions. Part II. Computational methods to predict protein and domain interaction partners (2007) PLoS Comput Biol, 3 (4), pp. e43; Obenauer, J.C., Yaffe, M.B., Computational prediction of protein-protein interactions (2004) Methods In Molecular Biology, 261, pp. 445-468; Rodriguez-Soca, Y., Munteanu, C.R., Dorado, J., Rabuñal, J., Pazos, A., González-Díaz, H., Plasmod-PPI: A web-server predicting complex biopolymer targets in plasmodium with entropy measures of protein-protein interactions (2010) Polymer, 51 (1), pp. 264-273; Dhingra, V., Gupta, M., Andacht, T., Fu, Z.F., New frontiers in proteomics research: A perspective (2005) Int J Pharm, 299 (1-2), pp. 1-18; Mulder, N.J., Kersey, P., Pruess, M., Apweiler, R., In silico characterization of proteins: UniProt, InterPro and Integr8 (2008) Mol Biotech-nol, 38, pp. 165-177; Reorganizing the protein space at the Universal Protein Resource (UniProt) (2012) Nucleic Acids Res, 40, pp. D71-D75. , UniProt Consortium; Hunter, S., Jones, P., Mitchell, A., Apweiler, R., Attwood, T.K., Bateman, A., Bernard, T., Yong, S.Y., InterPro in 2011: New developments in the family and domain prediction database (2012) Nucleic Acids Res, 40, pp. D306-D312; Vizcaíno, J.A., Côté, R., Reisinger, F., Barsnes, H., Foster, J.M., Rameseder, J., Hermjakob, H., Martens, L., The Proteomics Identifications database: 2010 update (2010) Nucleic Acids Res, 38, pp. D736-D742; Wang, G., Dunbrack Jr., R.L., PISCES: A protein sequence culling server (2003) Bioinformatics, 19 (12), pp. 1589-1591; Kersey, P.J., Duarte, J., Williams, A., Karavidopoulou, Y., Birney, E., Apweiler, R., The International Protein Index: An integrated database for proteomics experiments (2004) Proteomics, 4 (7), pp. 1985-1988; Deutsch, E.W., Lam, H., Aebersold, R., PeptideAtlas: A resource for target selection for emerging targeted proteomics workflows (2008) EMBO Rep, 9 (5), pp. 429-434; Dinkel, H., Chica, C., Via, A., Gould, C.M., Jensen, L.J., Gibson, T.J., Diella, F., Phospho.ELM: A database of phosphorylation sites--update 2011 (2011) Nucleic Acids Res, 39, pp. D261-D267; Gromiha, M.M., Sarai, A., Thermodynamic database for proteins: Features and applications (2010) Methods Mol Biol, 609, pp. 97-112; Sadreyev, R., Grishin, N., COMPASS: A tool for comparison of multiple protein alignments with assessment of statistical significance (2003) J Mol Biol, 326 (1), pp. 317-336; Suzek, B.E., Huang, H., McGarvey, P., Mazumder, R., Wu, C.H., UniRef: Comprehensive and non-redundant UniProt reference clusters (2007) Bioinformatics, 23 (10), pp. 1282-1288; Dodge, C., Schneider, R., Sander, C., The HSSP database of protein structure-sequence alignments and family profiles (1998) Nucleic Acids Res, 26 (1), pp. 313-315; Pruess, M., Fleischmann, W., Kanapin, A., Karavidopoulou, Y., Kersey, P., Kriventseva, E., Mittard, V., Apweiler, R., The Proteome Analysis database: A tool for the in silico analysis of whole proteomes (2003) Nucleic Acids Res, 31 (1), pp. 414-417; Boutet, E., Lieberherr, D., Tognolli, M., Schneider, M., Bairoch, A., UniProtKB/Swiss-Prot (2007) Methods Mol Biol, 406, pp. 89-112; Chen, L., Oughtred, R., Berman, H.M., Westbrook, J., TargetDB: A target registration database for structural genomics projects (2004) Bioin-formatics, 20 (16), pp. 2860-2862; Cotter, D., Guda, P., Fahy, E., Subramaniam, S., MitoProteome: Mitochondrial protein sequence database and annotation system (2004) Nucleic Acids Res, 32, pp. D463-D467; Dellaire, G., Farrall, R., Bickmore, W.A., The Nuclear Protein Database (NPD): Sub-nuclear localisation and functional annotation of the nuclear proteome (2003) Nucleic Acids Res, 31 (1), pp. 328-330; Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E., The Protein Data Bank (2000) Nucleic Acids Res, 28 (1), pp. 235-242; Lo Conte, L., Ailey, B., Hubbard, T.J., Brenner, S.E., Murzin, A.G., Chothia, C., SCOP: A structural classification of proteins database (2000) Nucleic Acids Res, 28 (1), pp. 257-259; Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Ponten, F., Towards a knowledge-based Human Protein Atlas (2010) Nat Biotechnol, 28 (12), pp. 1248-1250; Pieper, U., Webb, B.M., Barkan, D.T., Schneidman-Duhovny, D., Schlessinger, A., Braberg, H., Yang, Z., Sali, A., ModBase, a database of annotated comparative protein structure models, and associated resources (2011) Nucleic Acids Res, 39, pp. D465-D474; Laskowski, R.A., PDBsum: Summaries and analyses of PDB structures (2001) Nucleic Acids Res, 29 (1), pp. 221-222; Dundas, J., Ouyang, Z., Tseng, J., Binkowski, A., Turpaz, Y., Liang, J., CASTp: Computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues (2006) Nucleic Acids Res, 34, pp. W116-W118; Wang, R., Fang, X., Lu, Y., Wang, S., The PDBbind database: Collection of binding affinities for protein-ligand complexes with known three-dimensional structures (2004) J Med Chem, 47 (12), pp. 2977-2980; Velankar, S., McNeil, P., Mittard-Runte, V., Suarez, A., Barrell, D., Apweiler, R., Henrick, K., E-MSD: An integrated data resource for bioinformatics (2005) Nucleic Acids Res, 33, pp. D262-D265; Lomize, M.A., Lomize, A.L., Pogozheva, I.D., Mosberg, H.I., OPM: Orientations of proteins in membranes database (2006) Bioinforma-tics, 22 (5), pp. 623-625; Natarajan, P., Lander, G.C., Shepherd, C.M., Reddy, V.S., Brooks, C.L., Johnson, J.E., Exploring icosahedral virus structures with VIPER (2005) Nat Rev Microbiol, 3 (10), pp. 809-817; Castagnetto, J.M., Hennessy, S.W., Roberts, V.A., Getzoff, E.D., Tainer, J.A., Pique, M.E., MDB: The Metalloprotein Database and Browser at The Scripps Research Institute (2002) Nucleic Acids Res, 30 (1), pp. 379-382; Nederveen, A.J., Doreleijers, J.F., Vranken, W., Miller, Z., Spronk, C.A., Nabuurs, S.B., Güntert, P., Bonvin, A.M., RECOORD: A recalculated coordinate database of 500+ proteins from the PDB using restraints from the BioMagResBank (2005) Proteins, 59 (4), pp. 662-672; Tusnády, G.E., Dosztányi, Z., Simon, I., PDB_TM: Selection and membrane localization of transmembrane proteins in the protein data bank (2005) Nucleic Acids Res, 33, pp. D275-D278; Michalopoulos, I., Torrance, G.M., Gilbert, D.R., Westhead, D.R., TOPS: An enhanced database of protein structural topology (2004) Nucleic Acids Res, 32, pp. D251-D254; Gold, N.D., Jackson, R.M., SitesBase: A database for structure-based protein-ligand binding site comparisons (2006) Nucleic Acids Res, 34, pp. D231-D234; Ahmad, Y., Boisvert, F.M., Gregor, P., Cobley, A., Lamond, A.I., NOPdb: Nucleolar Proteome Database--2008 update (2009) Nucleic Acids Res, 37, pp. D181-D184; Noguchi, T., Matsuda, H., Akiyama, Y., PDB-REPRDB: A database of representative protein chains from the Protein Data Bank (PDB) (2001) Nucleic Acids Res, 29 (1), pp. 219-220; Kouranov, A., Xie, L., de la Cruz, J., Chen, L., Westbrook, J., Bourne, P.E., Berman, H.M., The RCSB PDB information portal for structural genomics (2006) Nucleic Acids Res, 34, pp. D302-D305; Ivanciuc, O., Schein, C.H., Braun, W., SDAP: Database and computational tools for allergenic proteins (2003) Nucleic Acids Res, 31 (1), pp. 359-362; Raman, P., Cherezov, V., Caffrey, M., The Membrane Protein Data Bank (2006) Cell Mol Life Sci, 63 (1), pp. 36-51; Glaser, F., Rosenberg, Y., Kessel, A., Pupko, T., Ben-Tal, N., The ConSurf-HSSP database: The mapping of evolutionary conservation among homologs onto PDB structures (2005) Proteins, 58 (3), pp. 610-617; Nabuurs, S.B., Nederveen, A.J., Vranken, W., Doreleijers, J.F., Bonvin, A.M., Vuister, G.W., Vriend, G., Spronk, C.A., DRESS: A database of REfined solution NMR structures (2004) Proteins, 55 (3), pp. 483-486; Velankar, S., Alhroub, Y., Best, C., Caboche, S., Conroy, M.J., Dana, J.M., Fernandez Montecelo, M.A., Kleywegt, G.J., PDBe: Protein Data Bank in Europe (2012) Nucleic Acids Res, 40, pp. D445-D452; Pattin, K.A., Moore, J.H., Role for protein-protein interaction databases in human genetics (2009) Expert Rev Proteomics, 6 (6), pp. 647-659; Lehne, B., Schlitt, T., Protein-protein interaction databases: Keeping up with growing interactomes (2009) Hum Genomics, 3 (3), pp. 291-297; Salwinski, L., Miller, C.S., Smith, A.J., Pettit, F.K., Bowie, J.U., Eisenberg, D., The Database of Interacting Proteins: 2004 update (2004) Nucleic Acids Res, 32, pp. D449-D451; von Mering, C., Jensen, L.J., Kuhn, M., Chaffron, S., Doerks, T., Krüger, B., Snel, B., Bork, P., STRING 7--recent developments in the integration and prediction of protein interactions (2007) Nucleic Acids Res, 35, pp. D358-D362; Peri, S., Navarro, J.D., Amanchy, R., Kristiansen, T.Z., Jonnala-Gadda, C.K., Surendranath, V., Niranjan, V., Pandey, A., Development of human protein reference database as an initial platform for approaching systems biology in humans (2003) Genome Res, 13 (10), pp. 2363-2371; Chatr-Aryamontri, A., Breitkreutz, B.J., Heinicke, S., Boucher, L., Winter, A., Stark, C., Nixon, J., Tyers, M., The BioGRID interaction database: 2013 update (2013) Nucleic Acids Res, 41 (D1), pp. D816-D823; Licata, L., Briganti, L., Peluso, D., Perfetto, L., Iannuccelli, M., Galeota, E., Sacco, F., Cesareni, G., MINT, the molecular interaction database: 2012 update (2012) Nucleic Acids Res, 40, pp. D857-D861; Kerrien, S., Aranda, B., Breuza, L., Bridge, A., Broackes-Carter, F., Chen, C., Duesbury, M., Hermjakob, H., The IntAct molecular interaction database in 2012 (2012) Nucleic Acids Res, 40, pp. D841-D846; Hendlich, M., Bergner, A., Günther, J., Klebe, G., Relibase: Design and development of a database for comprehensive analysis of pro-tein-ligand interactions (2003) J Mol Biol, 326 (2), pp. 607-620; Brown, K.R., Jurisica, I., Online predicted human interaction database (2005) Bioinformatics, 21 (9), pp. 2076-2082; Liu, T., Lin, Y., Wen, X., Jorissen, R.N., Gilson, M.K., BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities (2007) Nucleic Acid Res, 35, pp. D198-D201; Finn, R.D., Marshall, M., Bateman, A., iPfam: Visualization of protein-protein interactions in PDB at domain and amino acid resolutions (2005) Bioinformatics, 21 (3), pp. 410-412; (2013) IPfam, , http://ipfam.sanger.ac.uk/, Accessed March 3; Stein, A., Céol, A., Aloy, P., 3did: Identification and classification of domain-based interactions of known three-dimensional structure (2011) Nucleic Acids Res, 39, pp. D718-D723; Güldener, U., Münsterkötter, M., Oesterheld, M., Pagel, P., Ruepp, A., Mewes, H.W., Stümpflen, V., MPact: The MIPS protein interaction resource on yeast (2006) Nucleic Acids Res, 34, pp. D436-D441; Prabakaran, P., An, J., Gromiha, M.M., Selvaraj, S., Uedaira, H., Kono, H., Sarai, A., Thermodynamic database for protein-nucleic acid interactions (ProNIT) (2001) Bioinformatics, 17 (11), pp. 1027-1034; Razick, S., Magklaras, G., Donaldson, I.M., iRefIndex: A consolidated protein interaction database with provenance (2008) BMC Bioinforma-tics, 9, p. 405; Huang, T.W., Tien, A.C., Huang, W.S., Lee, Y.C., Peng, C.L., Tseng, H.H., Kao, C.Y., Huang, C.Y., POINT: A database for the prediction of protein-protein interactions based on the orthologous interactome (2004) Bioinformatics, 20 (17), pp. 3273-3276; Gong, S., Yoon, G., Jang, I., Bolser, D., Dafas, P., Schroeder, M., Choi, H., Bhak, J., PSIbase: A database of Protein Structural Interac-tome map (PSIMAP) (2005) Bioinformatics, 21, pp. 2541-2543; Punta, M., Coggill, P.C., Eberhardt, R.Y., Mistry, J., Tate, J., Boursnell, C., Pang, N., Finn, R.D., The Pfam protein families database (2012) Nucleic Acids Res, 40, pp. 290-301; Hulo, N., Bairoch, A., Bulliard, V., Cerutti, L., de Castro, E., Langendijk-Genevaux, P.S., Pagni, M., Sigrist, C.J., The PROSITE database (2006) Nucleic Acids Res, 34, pp. 227-230; Marchler-Bauer, A., Lu, S., Anderson, J.B., Chitsaz, F., Derbyshire, M.K., Deweese-Scott, C., Fong, J.H., Bryant, S.H., CDD: A Conserved Domain Database for the functional annotation of proteins (2011) Nucleic Acids Res, 39, pp. 225-229; Dietmann, S., Park, J., Notredame, C., Heger, A., Lappe, M., Holm, L., A fully automatic evolutionary classification of protein folds: Dali Domain Dictionary version 3 (2001) Nucleic Acids Res, 29, pp. 55-57; Haft, D.H., Selengut, J.D., Richter, R.A., Harkins, D., Basu, M.K., Beck, E., TIGRFAMs and Genome Properties in 2013 (2013) Nucleic Acids Res, 41, pp. 387-395; Mi, H., Lazareva-Ulitsky, B., Loo, R., Kejariwal, A., Vandergriff, J., Rabkin, S., Guo, N., Thomas, P.D., The PANTHER database of protein families, subfamilies, functions and pathways (2005) Nucleic Acids Res, 33, pp. D284-D288; Servant, F., Bru, C., Carrère, S., Courcelle, E., Gouzy, J., Peyruc, D., Kahn, D., ProDom: Automated clustering of homologous domains (2002) Brief Bioinform, 3 (3), pp. 246-251; Henikoff, S., Henikoff, J.G., Pietrokovski, S., Blocks+: A non-redundant database of protein alignment blocks derived from multiple compilations (1999) Bioinformatics, 15 (6), pp. 471-479; Kriventseva, E.V., Fleischmann, W., Zdobnov, E.M., Apweiler, R., CluSTr: A database of clusters of SWISS-PROT+TrEMBL proteins (2001) Nucleic Acids Res, 29, pp. 33-36; Rappoport, N., Karsenty, S., Stern, A., Linial, N., Linial, M., Pro-toNet 6.0: Organizing 10 million protein sequences in a compact hierarchical family tree (2012) Nucleic Acids Res, 40, pp. D313-D320; Davis, F.P., Sali, A., PIBASE: A comprehensive database of structurally defined protein interfaces (2005) Bioinformatics (Oxford, England), 21, pp. 1901-1907; Ng, S.K., Zhang, Z., Tan, S.H., Lin, K., InterDom: A database of putative interacting protein domains for validating predicted protein interactions and complexes (2003) Nucleic Acids Res, 31, pp. 251-254; Winter, C., Henschel, A., Kim, W.K., Schroeder, M., SCOPPI: A structural classification of protein-protein interfaces (2006) Nucleic Acids Res, 34, pp. D310-D314; Pearl, F.M., Lee, D., Bray, J.E., Buchan, D.W., Shepherd, A.J., Orengo, C.A., The CATH extended protein-family database: Providing structural annotations for genome sequences (2002) Protein Sci, 11 (2), pp. 233-244; Qi, G., Lee, R., Hayward, S., A comprehensive and non-redundant database of protein domain movements (2005) Bioinformatics, 21, pp. 2832-2838; Whelan, S., de Bakker, P.I., Quevillon, E., Rodriguez, N., Goldman, N., PANDIT: An evolution-centric database of protein and associated nucleotide domains with inferred trees (2006) Nucleic Acids Res, 34, pp. 327-331; Huang, H., Barker, W.C., Chen, Y., Wu, C.H., iProClass: An integrated database of protein family, function and structure information (2003) Nucleic Acids Res, 31, pp. 390-392; Klimke, W., Agarwala, R., Badretdin, A., Chetvernin, S., Ciufo, S., Fedorov, B., Kiryutin, B., Tatusova, T., The National Center for Biotechnology Information's Protein Clusters Database (2009) Nucleic Acids Res, 37, pp. 216-223; Dunbrack Jr., R.L., Sequence comparison and protein structure prediction (2006) Curr Opin Struct Biol, 16 (3), pp. 374-384; Edgar, R.C., MUSCLE: Multiple sequence alignment with high accuracy and high throughput (2004) Nucleic Acids Res, 32 (5), pp. 1792-1797; Wheeler, D.L., Church, D.M., Federhen, S., Lash, A.E., Madden, T.L., Pontius, J.U., Schuler, G.D., Wagner, L., Database resources of the National Center for Biotechnology (2003) Nucleic Acids Res, 31, pp. 28-33; Falkner, J.A., Hill, J.A., Andrews, P.C., Proteomics FASTA archive and reference resource (2008) Proteomics, 8 (9), pp. 1756-1757; Zdobnov, E.M., Apweiler, R., InterProScan--an integration platform for the signature-recognition methods in InterPro (2001) Bioinformatics, 17 (9), pp. 847-848; Kelley, L.A., Maccallum, R.M., Sternberg, M.J., Enhanced genome annotation using structural profiles in the program 3D-PSSM (2000) J Mol Biol, 299, pp. 499-520; Gouet, P., Robert, X., Courcelle, E., ESPript/ENDscript: Extracting and rendering sequence and 3D information from atomic structures of proteins (2003) Nucleic Acids Res, 31, pp. 3320-3323; Mizuguchi, K., Deane, C.M., Blundell, T.L., Johnson, M.S., Over-Ington, J.P., JOY: Protein sequence-structure representation and analysis (1998) Bioinformatics, 14 (7), pp. 617-623; Schäffer, A.A., Wolf, Y.I., Ponting, C.P., Koonin, E.V., Aravind, L., Altschul, S.F., IMPALA: Matching a protein sequence against a collection of PSI-BLAST-constructed position-specific score matrices (1999) Bioinformatics, 15 (12), pp. 1000-1011; Cai, C.Z., Han, L.Y., Ji, Z.L., Chen, X., Chen, Y.Z., SVM-Prot: Web-based support vector machine software for functional classification of a protein from its primary sequence (2003) Nucleic Acids Res, 31 (13), pp. 3692-3697; de Castro, E., Sigrist, C.J., Gattiker, A., Bulliard, V., Langendijk-Genevaux, P.S., Gasteiger, E., Bairoch, A., Hulo, N., ScanProsite: Detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins (2006) Nucleic Acids Res, 34, pp. 362-365; Ferrer-Costa, C., Gelpí, J.L., Zamakola, L., Parraga, I., de la Cruz, X., Orozco, M., PMUT: A web-based tool for the annotation of pathological mutations on proteins (2005) Bioinformatics, 21 (14), pp. 3176-3178; O'Sullivan, O., Suhre, K., Abergel, C., Higgins, D.G., Notredame, C., 3DCoffee: Combining protein sequences and structures within multiple sequence alignments (2004) J Mol Biol, 340, pp. 385-395; Cox, J., Matic, I., Hilger, M., Nagaraj, N., Selbach, M., Olsen, J.V., Mann, M., A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics (2009) Nat Protoc, 4, pp. 698-705; Pei, J., Kim, B.H., Grishin, N.V., PROMALS3D: A tool for multiple protein sequence and structure alignments (2008) Nucleic Acids Res, 36 (7), pp. 2295-2300; Maiti, R., van Domselaar, G.H., Zhang, H., Wishart, D.S., SuperPose: A simple server for sophisticated structural superposition (2004) Nucleic Acids Res, 32, pp. 590-594; Pei, J., Kim, B.H., Tang, M., Grishin, N.V., PROMALS web server for accurate multiple protein sequence alignments (2007) Nucleic Acids Res, 35, pp. 649-652; Pei, J., Sadreyev, R., Grishin, N.V., PCMA: Fast and accurate multiple sequence alignment based on profile consistency (2003) Bioinfor-matics, 19 (3), pp. 427-428; Farrah, T., Deutsch, E.W., Aebersold, R., Using the Human Plasma PeptideAtlas to study human plasma proteins (2011) Methods Mol Biol, 728, pp. 349-374; Simossis, V.A., Heringa, J., PRALINE: A multiple sequence alignment toolbox that integrates homology-extended and secondary structure information (2005) Nucleic Acids Res, 33, pp. W289-W294; Roshan, U., Livesay, D.R., Probalign: Multiple sequence alignment using partition function posterior probabilities (2006) Bioinformatics, 22 (22), pp. 2715-2721; Guda, C., Lu, S., Scheeff, E.D., Bourne, P.E., Shindyalov, I.N., CE-MC: A multiple protein structure alignment server (2004) Nucleic Acids Res, 32, pp. 100-103; Eswar, N., John, B., Mirkovic, N., Fiser, A., Ilyin, V.A., Pieper, U., Stuart, A.C., Sali, A., Tools for comparative protein structure modeling and analysis (2003) Nucleic Acids Res, 31, pp. 3375-3380; Standley, D.M., Kinjo, A.R., Kinoshita, K., Nakamura, H., Protein structure databases with new web services for structural biology and biomedical research (2008) Brief Bioinform, 9 (4), pp. 276-285; Arnold, K., Bordoli, L., Kopp, J., Schwede, T., The SWISS-MODEL workspace: A web-based environment for protein structure homology modeling (2006) Bioinformatics, 22, pp. 195-201; McGuffin, L.J., Bryson, K., Jones, D.T., The PSIPRED protein structure prediction server (2000) Bioinformatics, 16 (4), pp. 404-405; Cole, C., Barber, J.D., Barton, G.J., The Jpred 3 secondary structure prediction server (2008) Nucleic Acids Res, 36, pp. 197-201; Holm, L., Park, J., DaliLite workbench for protein structure comparison (2000) Bioinformatics, 16 (6), pp. 566-567; McGuffin, L.J., Jones, D.T., Improvement of the GenTHREADER method for genomic fold recognition (2003) Bioinformatics, 19 (7), pp. 874-881; Shi, J., Blundell, T.L., Mizuguchi, K., FUGUE: Sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties (2001) J Mol Biol, 310, pp. 243-257; Rost, B., Yachdav, G., Liu, J., The PredictProtein server (2004) Nucleic Acids Res, 32, pp. W321-W326; Fiser, A., Sali, A., ModLoop: Automated modeling of loops in protein structures (2003) Bioinformatics, 19, pp. 2500-2501; Dolinsky, T.J., Czodrowski, P., Li, H., Nielsen, J.E., Jensen, J.H., Klebe, G., Baker, N.A., PDB2PQR: Expanding and upgrading automated preparation of biomolecular structures for molecular simulations (2007) Nucleic Acids Res, 35, pp. 522-525; Söding, J., Biegert, A., Lupas, A.N., The HHpred interactive server for protein homology detection and structure prediction (2005) Nucleic Acids Res, 33, pp. 244-248; Roy, A., Kucukural, A., Zhang, Y., I-TASSER: A unified platform for automated protein structure and function prediction (2010) Nat Pro-toc, 5 (4), pp. 725-738; Stebbings, L.A., Mizuguchi, K., HOMSTRAD: Recent developments of the Homologous Protein Structure Alignment Database (2004) Nucleic Acids Res, 32, pp. 203-207; Holm, L., Rosenström, P., Dali server: Conservation mapping in 3D (2010) Nucleic Acids Res, 38, pp. W545-W549; Lambert, C., Léonard, N., de Bolle, X., Depiereux, E., ESyPred3D: Prediction of proteins 3D structures (2002) Bioinformatics, 18 (9), pp. 1250-1256; Ulrich, E.L., Akutsu, H., Doreleijers, J.F., Harano, Y., Ioannidis, Y.E., Lin, J., Livny, M., Markley, J.L., BioMagResBank (2008) Nucleic Acids Res, 36, pp. 402-408; Ye, Y., Godzik, A., FATCAT: A web server for flexible structure comparison and structure similarity searching (2004) Nucleic Acids Res, 32, pp. W582-W585; Jaroszewski, L., Rychlewski, L., Li, Z., Li, W., Godzik, A., FFAS03: A server for profile--profile sequence alignments (2005) Nucleic Acids Res, 33, pp. 284-288; Long, F., Vagin, A.A., Young, P., Murshudov, G.N., BALBES: A molecular-replacement pipeline (2008) Acta Crystallogr D Biol Crysta-llogr, 64, pp. 125-132; Lu, G.G., TOP: A new method for protein structure comparisons and similarity searches (2000) Journal of Applied Crystallography, 33, pp. 176-183; Suhre, K., Sanejouand, Y.H., ElNemo: A normal mode web server for protein movement analysis and the generation of templates for molecular replacement (2004) Nucleic Acids Res, 32, pp. W610-W614; Willard, L., Ranjan, A., Zhang, H., Monzavi, H., Boyko, R.F., Sykes, B.D., Wishart, D.S., VADAR: A web server for quantitative evaluation of protein structure quality (2003) Nucleic Acids Res, 31, pp. 3316-3319; Jiang, W., Baker, M.L., Ludtke, S.J., Chiu, W., Bridging the information gap: Computational tools for intermediate resolution structure interpretation (2001) J Mol Biol, 308, pp. 1033-1044; Fiser, A., Sali, A., ModLoop: Automated modeling of loops in protein structures (2003) Bioinformatics, 19 (18), pp. 2500-2501; Eyrich, V.A., Martí-Renom, M.A., Przybylski, D., Madhusudhan, M.S., Fiser, A., Pazos, F., Valencia, A., Rost, B., EVA: Continuous automatic evaluation of protein structure prediction servers (2001) Bioinformatics, 17 (12), pp. 1242-1243; Kawabata, T., MATRAS: A program for protein 3D structure comparison (2003) Nucleic Acids Res, 31 (13), pp. 3367-3369; Heinig, M., Frishman, D., STRIDE: A web server for secondary structure assignment from known atomic coordinates of proteins (2004) Nucleic Acids Res, 32, pp. W500-W502; Contreras-Moreira, B., Bates, P.A., Domain fishing: A first step in protein comparative modelling (2002) Bioinformatics, 18 (8), pp. 1141-1142; Parthiban, V., Gromiha, M.M., Schomburg, D., CUPSAT: Prediction of protein stability upon point mutations (2006) Nucleic Acids Res, 34, pp. 239-242; Gille, C., Frömmel, C., STRAP: Editor for STRuctural Alignments of Proteins (2001) Bioinformatics, 17 (4), pp. 377-378; Berjanskii, M.V., Neal, S., Wishart, D.S., PREDITOR: A web server for predicting protein torsion angle restraints (2006) Nucleic Acids Res, 34, pp. 63-69; Persico, M., Ceol, A., Gavrila, C., Hoffmann, R., Florio, A., Cesa-Reni, G., HomoMINT: An inferred human network based on ortholo-gy mapping of protein interactions discovered in model organisms (2005) BMC Bioinformatics, 6 (SUPPL. 4), pp. S21; Meiler, J., Peti, W., Griesinger, C., DipoCoup: A versatile program for 3D-structure homology comparison based on residual dipolar couplings and pseudocontact shifts (2000) J Biomol NMR, 17 (4), pp. 283-294; Claude, J.B., Suhre, K., Notredame, C., Claverie, J.M., Abergel, C., CaspR: A web server for automated molecular replacement using homology modelling (2004) Nucleic Acids Res, 32, pp. W606-W609; Wishart, D.S., Arndt, D., Berjanskii, M., Tang, P., Zhou, J., Lin, G., CS23D: A web server for rapid protein structure generation using NMR chemical shifts and sequence data (2008) Nucleic Acids Res, 36, pp. W496-W502; Schultz, J., Milpetz, F., Bork, P., Ponting, C.P., SMART, a simple modular architecture research tool: Identification of signaling domains (1998) Proc Natl Acad Sci U S A, 95 (11), pp. 5857-5864; Ashkenazy, H., Erez, E., Martz, E., Pupko, T., Ben-Tal, N., Con-Surf 2010: Calculating evolutionary conservation in sequence and structure of proteins and nucleic acids (2010) Nucleic Acids Res, 38, pp. W529-W533; Obenauer, J.C., Cantley, L.C., Yaffe, M.B., Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs (2003) Nucleic Acids Res, 31 (13), pp. 3635-3641; Lensink, M.F., Méndez, R., Wodak, S.J., Docking and Scoring Protein Complexes: CAPRI 3rd Edition. Proteins, 2007, 69, pp. 704-718; Puntervoll, P., Linding, R., Gemünd, C., Chabanis-Davidson, S., Mattingsdal, M., Cameron, S., Martin, D.M., Gibson, T.J., ELM server: A new resource for investigating short functional sites in modular eukaryotic proteins (2003) Nucleic Acids Res, 31, pp. 3625-3630; Porter, C.T., Bartlett, G.J., Thornton, J.M., The Catalytic Site Atlas: A resource of catalytic sites and residues identified in enzymes using structural data (2004) Nucleic Acids Res, 32, pp. 129-133; Bailey, T.L., Boden, M., Buske, F.A., Frith, M., Grant, C.E., Clementi, L., Ren, J., Noble, W.S., MEME SUITE: Tools for motif discovery and searching (2009) Nucleic Acids Res, 37, pp. W202-W208; Yang, Z.R., Thomson, R., McNeil, P., Esnouf, R.M., RONN: The bio-basis function neural network technique applied to the detection of natively disordered regions in proteins (2005) Bioinformatics, 21 (16), pp. 3369-3376; Aerts, S., Thijs, G., Coessens, B., Staes, M., Moreau, Y., de Moor, B., Toucan: Deciphering the cis-regulatory logic of coregulated genes (2003) Nucleic Acids Res, 31 (6), pp. 1753-1764; Laskowski, R.A., Watson, J.D., Thornton, J.M., ProFunc: A server for predicting protein function from 3D structure (2005) Nucleic Acids Res, 33, pp. W89-W93; Walshaw, J., Woolfson, D.N., Socket: A program for identifying and analysing coiled-coil motifs within protein structures (2001) J Mol Biol, 307, pp. 1427-1450; Wang, L., Brown, S.J., BindN: A web-based tool for efficient prediction of DNA and RNA binding sites in amino acid sequences (2006) Nucleic Acids Res, 34, pp. W243-W248; Lu, L., Lu, H., Skolnick, J., MULTIPROSPECTOR: An algorithm for the prediction of protein-protein interactions by multimeric threading (2002) Proteins, 49, pp. 350-364; Tuncbag, N., Gursoy, A., Nussinov, R., Keskin, O., Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM (2011) Nat Protoc, 6, pp. 1341-1354; Flannick, J., Novak, A., Srinivasan, B.S., McAdams, H.H., Batzo-Glou, S., Graemlin: General and robust alignment of multiple large interaction networks (2006) Genome Res, 16 (9), pp. 1169-1181; Aloy, P., Russell, R.B., InterPreTS: Protein interaction prediction through tertiary structure (2003) Bioinformatics, 19 (1), pp. 161-162; Pagni, M., Ioannidis, V., Cerutti, L., Zahn-Zabal, M., Jongeneel, C.V., Falquet, L., MyHits: A new interactive resource for protein annotation and domain identification (2004) Nucleic Acids Res, 32, pp. 332-335; Tina, K.G., Bhadra, R., Srinivasan, N.P.I.C., Protein Interactions Calculator (2007) Nucleic Acids Res, 35, pp. 473-476; Garavelli, J.S., The RESID Database of Protein Modifications as a resource and annotation tool (2004) Proteomics, 4 (6), pp. 1527-1533; Ahmad, S., Gromiha, M., Fawareh, H., Sarai, A., ASAView: Database and tool for solvent accessibility representation in proteins (2004) BMC Bioinformatics, 5, p. 51; Hooper, S.D., Bork, P., Medusa: A simple tool for interaction graph analysis (2005) Bioinformatics, 21, pp. 4432-4433; Berger, S.I., Posner, J.M., Ma'ayan, A., Genes2Networks: Connecting lists of gene symbols using mammalian protein interactions databases (2007) BMC Bioinformatics, 8, p. 372; Han, D.S., Kim, H.S., Jang, W.H., Lee, S.D., Suh, J.K., PreSPI: A domain combination based prediction system for protein-protein interaction (2004) Nucleic Acids Res, 32 (21), pp. 6312-6320; Chou, K.C., Shen, H.B., Hum-PLoc: A novel ensemble classifier for predicting human protein subcellular localization (2006) Biochem Biophys Res Commun, 347, pp. 150-157; Horton, P., Park, K.J., Obayashi, T., Fujita, N., Harada, H., Adams-Collier, C.J., Nakai, K., WoLF PSORT: Protein localization predictor (2007) Nucleic Acids Res, 35, pp. 585-587; Chou, K.C., Shen, H.B., Hum-PLoc: A novel ensemble classifier for predicting human protein subcellular localization (2006) Biochem Biophys Res Commun, 347 (1), pp. 150-157; Shen, H.B., Chou, K.C., Gpos-PLoc: An ensemble classifier for predicting subcellular localization of Gram-positive bacterial proteins (2007) Protein Eng Des Sel, 20 (1), pp. 39-46; Shen, H.B., Chou, K.C., Virus-PLoc: A fusion classifier for predicting the subcellular localization of viral proteins within host virus-infected cells (2007) Biopolymers, 85, pp. 233-240; Shen, H.B., Yang, J., Chou, K.C., Euk-PLoc: An ensemble classifier for large-scale eukaryotic protein subcellular location prediction (2007) Amino Acids, 33 (1), pp. 57-67; Andreoli, C., Prokisch, H., Hörtnagel, K., Mueller, J.C., Müns-Terkötter, M., Scharfe, C., Meitinger, T., MitoP2, an integrated database on mitochondrial proteins in yeast and man (2004) Nucleic Acids Res, 32, pp. 459-462; Szafron, D., Lu, P., Greiner, R., Wishart, D.S., Poulin, B., Eisner, R., Lu, Z., Meeuwis, D., Pro-teome Analyst: Custom predictions with explanations in a web-based tool for high-throughput proteome annotations (2004) Nucleic Acids Res, 32, pp. 365-371; Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R.D., Bairoch, A., ExPASy: The proteomics server for in-depth protein knowledge and analysis (2003) Nucleic Acids Res, 31 (13), pp. 3784-3788; Brenner, S.E., Koehl, P., Levitt, M., The ASTRAL compendium for protein structure and sequence analysis (2000) Nucleic Acids Res, 28 (1), pp. 254-256; Rauch, A., Bellew, M., Eng, J., Fitzgibbon, M., Holzman, T., Hussey, P., Igra, M., McIntosh, M.W., Computational Proteomics Analysis System (CPAS): An extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments (2006) J Proteome Res, 5 (1), pp. 112-121; Côté, R.G., Jones, P., Martens, L., Kerrien, S., Reisinger, F., Lin, Q., Leinonen, R., Hermjakob, H., The Protein Identifier Cross-Referencing (PICR) service: Reconciling protein identifiers across multiple source databases (2007) BMC Bioinformatics, 8, p. 401; Bertone, P., Kluger, Y., Lan, N., Zheng, D., Christendat, D., Yee, A., Edwards, A.M., Gerstein, M., SPINE: An integrated tracking database and data mining approach for identifying feasible targets in high-throughput structural proteomics (2001) Nucleic Acids Res, 29, pp. 2884-2898; Go, E.P., Database resources in metabolomics: An overview (2010) J Neu-roimmune Pharmacol, 5 (1), pp. 18-30; Chagoyen, M., Pazos, F., Tools for the functional interpretation of metabolomic experiments (2012) Brief Bioinform, , Oct 14. [Epub ahead of print]; Schomburg, D., Schomburg, I., Enzyme databases (2010) Methods Mol Biol, 609, pp. 113-128; Schaefer, C.F., Pathway databases (2004) Applications of Bioinformatics In Cancer Detection. Annals of the New York Academy of Sciences, 1020, pp. 77-91. , Umar, A; Kapetanovic, I; Khan, J (Eds.); Henderson-Maclennan, N.K., Papp, J.C., Talbot Jr., C.C., McCabe, E.R., Presson, A.P., Pathway analysis software: Annotation errors and solutions (2010) Mol Genet Metab, 101 (2-3), pp. 134-140; Khatri, P., Sirota, M., Butte, A.J., Ten years of pathway analysis: Current approaches and outstanding challenges PLoS Comput Biol, 2012 (8), pp. e1002375; Alfarano, C., Andrade, C.E., Anthony, K., Bahroos, N., Bajec, M., Bantoft, K., Betel, D., Hogue, C.W., The Bio-molecular Interaction Network Database and related tools 2005 update (2005) Nucleic Acids Res, 33, pp. D418-D424; Caspi, R., Altman, T., Dreher, K., Fulcher, C.A., Subhraveti, P., Keseler, I.M., Kothari, A., Karp, P.D., The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases (2012) Nucleic Acids Res, 40, pp. 742-753; Croft, D., O'Kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., Caudy, M., Stein, L., Reactome:A database of reactions, pathways and biological processes (2011) Nucleic Acids Res, 39, pp. D691-D697; Wishart, D.S., Jewison, T., Guo, A.C., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Scalbert, A., HMDB 3.0--The Human Metabolome Database in (2013) Nucleic Acids Res, 2013 (41), pp. D801-D807; Latendresse, M., Paley, S., Karp, P.D., Browsing metabolic and regulatory networks with BioCyc (2012) Methods Mol Biol, 804, pp. 197-1216; Bairoch, A., The ENZYME database in 2000 (2000) Nucleic Acids Res, 28 (1), pp. 304-305; Goto, S., Nishioka, T., Kanehisa, M., LIGAND: Chemical database of enzyme reactions (2000) Nucleic Acids Res, 28 (1), pp. 380-382; Ren, Q., Chen, K., Paulsen, I.T., TransportDB: A comprehensive database resource for cytoplasmic membrane transport systems and outer membrane channels (2007) Nucleic Acids Res, 35, pp. 274-279; Schomburg, I., Chang, A., Ebeling, C., Gremse, M., Heldt, C., Huhn, G., Schomburg, D., BRENDA, the enzyme database: Updates and major new developments (2004) Nucleic Acids Res, 32, pp. D431-D433; Smith, C.A., O'Maille, G., Want, E.J., Qin, C., Trauger, S.A., Brandon, T.R., Custodio, D.E., Siuzdak, G., METLIN: A metabolite mass spectral database (2005) Ther Drug Monit, 27 (6), pp. 747-751; Moriya, Y., Itoh, M., Okuda, S., Yoshizawa, A.C., Kanehisa, M., KAAS: An automatic genome annotation and pathway reconstruction server (2007) Nucleic Acids Res, 35, pp. 182-185; Schaefer, C.F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Han-Nay, T., Buetow, K.H., PID: The Pathway Interaction Database (2009) Nucleic Acids Res, 37, pp. D674-D679; Romero, P., Wagg, J., Green, M.L., Kaiser, D., Krummenacker, M., Karp, P.D., Computational prediction of human metabolic pathways from the complete human genome (2005) Genome Biol, 6 (1), pp. R2; Claudel-Renard, C., Chevalet, C., Faraut, T., Kahn, D., Enzyme-specific profiles for genome annotation: PRIAM (2003) Nucleic Acids Res, 31 (22), pp. 6633-6639; Junker, B.H., Klukas, C., Schreiber, F., VANTED: A system for advanced data analysis and visualization in the context of biological networks (2006) BMC Bioinformatics, 7, p. 109; Lynn, D.J., Winsor, G.L., Chan, C., Richard, N., Laird, M.R., Barsky, A., Gardy, J.L., Brinkman, F.S., InnateDB: Facilitating systems-level analyses of the mammalian innate immune response (2008) Mol Syst Biol, 4, p. 218; Nair, R., Carter, P., Rost, B., NLSdb: Database of nuclear localization signals (2003) Nucleic Acids Res, 31, pp. 397-399; Papadopoulos, G.L., Alexiou, P., Maragkakis, M., Reczko, M., Hatzigeorgiou, A.G., DIANA-mirPath: Integrating human and mouse microRNAs in pathways (2009) Bioinformatics, 25 (15), pp. 1991-1993; Schellenberger, J., Park, J.O., Conrad, T.M., Palsson, B.Ø., BiGG: A Biochemical Genetic and Genomic knowledgebase of large scale metabolic reconstructions (2010) BMC Bioinformatics, 11, p. 213; Kind, T., Wohlgemuth, G., do Lee, Y., Lu, Y., Palazoglu, M., Shahbaz, S., Fiehn, O., FiehnLib: Mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry (2009) Anal Chem, 81 (24), pp. 10038-10048; Wu, J., Mao, X., Cai, T., Luo, J., Wei, L., KOBAS server: A web-based platform for automated annotation and pathway identification (2006) Nucleic Acids Res, 34, pp. 720-724; Yi, M., Horton, J.D., Cohen, J.C., Hobbs, H.H., Stephens, R.M., Whole Pathway Scope: A comprehensive pathway-based analysis tool for high-throughput data (2006) BMC Bioinformatics, 7, p. 30; Mlecnik, B., Scheideler, M., Hackl, H., Hartler, J., Sanchez-Cabo, F., Trajanoski, Z., PathwayExplorer: Web service for visualizing high-throughput expression data on biological pathways (2005) Nucleic Acids Res, 33, pp. 633-637; Nagasaki, M., Doi, A., Matsuno, H., Miyano, S., Genomic Object Net: I. A platform for modelling and simulating biopathways (2003) Appl Bioinformatics, 2 (3), pp. 181-184; Kumar, S., Tamura, K., Nei, M., MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment (2004) Brief Bioinform, 5 (2), pp. 150-163; Chen, F., Mackey, A.J., Stoeckert, C.J., Roos, D.S., OrthoMCL-DB: Querying a comprehensive multi-species collection of ortholog groups (2006) Nucleic Acids Res, 34, pp. 363-368; O'Brien, K.P., Remm, M., Sonnhammer, E.L., Inparanoid: A comprehensive database of eukaryotic orthologs (2005) Nucleic Acids Res, 33, pp. D476-D480; Ruan, J., Li, H., Chen, Z., Coghlan, A., Coin, L.J., Guo, Y., Héri-Ché, J.K., Durbin, R., TreeFam: 2008 Update (2008) Nucleic Acids Res, 36, pp. 735-740; Bowers, P.M., Pellegrini, M., Thompson, M.J., Fierro, J., Yeates, T.O., Eisenberg, D., Prolinks: A database of protein functional linkages derived from coevolution (2004) Genome Biol, 5, pp. R35; Krause, A., Stoye, J., Vingron, M., The SYSTERS protein sequence cluster set (2000) Nucleic Acids Res, 28 (1), pp. 270-272; Vilella, A.J., Severin, J., Ureta-Vidal, A., Heng, L., Durbin, R., Birney, E., EnsemblCompara GeneTrees: Complete, duplication-aware phylogenetic trees in vertebrates (2009) Genome Res, 19 (2), pp. 327-335; Ruepp, A., Waegele, B., Lechner, M., Brauner, B., Dunger-Kaltenbach, I., Fobo, G., Frishman, G., Mewes, H.W., CORUM: The comprehensive resource of mammalian protein complexes--2009 (2010) Nucleic Acids Res, 38, pp. 497-501; Howe, K., Bateman, A., Durbin, R., QuickTree: Building huge Neighbour-Joining trees of protein sequences (2002) Bioinformatics, 18 (11), pp. 1546-1547; Wilson, D., Pethica, R., Zhou, Y., Talbot, C., Vogel, C., Madera, M., Chothia, C., Gough, J., SUPERFAMILY--sophisticated comparative genomics, data mining, visualization and phylogeny (2009) Nucleic Acids Res, 37, pp. 380-386; Yang, L.W., Liu, X., Jursa, C.J., Holliman, M., Rader, A.J., Kari-Mi, H.A., Bahar, I., iGNM: A database of protein functional motions based on Gaussian Network Model (2005) Bioinformatics, 21, pp. 2978-2987; Waterhouse, R.M., Tegenfeldt, F., Li, J., Zdobnov, E.M., Krivent-Seva, E.V., OrthoDB: A hierarchical catalog of animal, fungal and bacterial orthologs (2013) Nucleic Acids Res, 41, pp. 358-365; Gurwitz, D., Lunshof, J.E., Altman, R.B., A call for the creation of personalized medicine databases (2006) Nat Rev Drug Discov, 5 (1), pp. 23-26; Vázquez, J.M., Aguiar, V., Seoane, J.A., Freire, A., Serantes, J.A., Dorado, J., Pazos, A., Munteanu, C.R., Star graphs of protein sequences and proteome mass spectra in cancer prediction (2009) Current Proteomics, 6 (4), p. 275; Walker, L., Starks, H., West, K.M., Fullerton, S.M., dbGaP data access requests: A call for greater transparency (2011) Sci Transl Med, 3, p. 113; Integrating common and rare genetic variation in diverse human populations (2010) Nature, 467, pp. 52-58. , The International HapMap Consortium; Lefranc, M.P., IMGT, the international ImMunoGeneTics database (2001) Nucleic Acids Res, 29 (1), pp. 207-209; Hamosh, A., Scott, A.F., Amberger, J.S., Bocchini, C.A., McKusick, V.A., Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders (2005) Nucleic Acids Res, 33, pp. 514-517; Stenson, P.D., Mort, M., Ball, E.V., Howells, K., Phillips, A.D., Thomas, N.S., Cooper, D.N., The Human Gene Mutation Database: 2008 update (2009) Genome Med, 1 (1), p. 13; Becker, K.G., Barnes, K.C., Bright, T.J., Wang, S.A., The genetic association database (2004) Nat Genet, 36 (5), pp. 431-432; Mailman, M.D., Feolo, M., Jin, Y., Kimura, M., Tryka, K., Bagoutdinov, R., Hao, L., Sherry, S.T., The NCBI dbGaP database of genotypes and phenotypes (2007) Nat Genet, 39 (10), pp. 1181-1186; Robinson, J., Halliwell, J.A., McWilliam, H., Lopez, R., Marsh, S.G., IPD--the Immuno Polymorphism Database (2013) Nucleic Acids Res, 41, pp. 1234-1240; van Driel, M.A., Bruggeman, J., Vriend, G., Brunner, H.G., Le-Unissen, J.A., A text-mining analysis of the human phenome (2006) Eur J Hum Genet, 14 (5), pp. 535-542; Firth, H.V., Richards, S.M., Bevan, A.P., Clayton, S., Corpas, M., Rajan, D., van Vooren, S., Carter, N.P., DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources (2009) Am J Hum Genet, 84 (4), pp. 524-533; Blumenfeld, O.O., Patnaik, S.K., Allelic genes of blood group antigens: A source of human mutations and cSNPs documented in the Blood Group Antigen Gene Mutation Database (2004) Hum Mutat, 23 (1), pp. 8-16; Nelson, M.R., Bryc, K., King, K.S., Indap, A., Boyko, A.R., No-Vembre, J., Briley, L.P., Lai, E.H., The Population Reference Sample, POPRES: A resource for population, disease, and pharmacological genetics research (2008) Am J Hum Genet, 83 (3), pp. 347-358; Reumers, J., Schymkowitz, J., Ferkinghoff-Borg, J., Stricher, F., Serrano, L., Rousseau, F., SNPeffect: A database mapping molecular phenotypic effects of human non-synonymous coding SNPs (2005) Nucleic Acids Res, 33, pp. 527-532; Conde, L., Vaquerizas, J.M., Santoyo, J., Al-Shahrour, F., Ruiz-Llorente, S., Robledo, M., Dopazo, J., PupaSNP Finder: A web tool for finding SNPs with putative effect at transcriptional level (2004) Nucleic Acids Res, 32, pp. W242-W248; McCarty, C.A., Chisholm, R.L., Chute, C.G., Kullo, I.J., Jarvik, G.P., Larson, E.B., Li, R., Wolf, W.A., eMERGE Team. The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies (2011) BMC Med Genomics, 4, p. 13; O'Dushlaine, C., Kenny, E., Heron, E.A., Segurado, R., Gill, M., Morris, D.W., Corvin, A., The SNP ratio test: Pathway analysis of genome-wide association datasets (2009) Bioinformatics, 25, pp. 2762-2763; Groth, P., Pavlova, N., Kalev, I., Tonov, S., Georgiev, G., Pohlenz, H.D., Weiss, B., PhenomicDB: A new cross-species genoty-pe/phenotype resource (2007) Nucleic Acids Res, 35, pp. 696-699; Amberger, J., Bocchini, C., Hamosh, A., A new face and new challenges for Online Mendelian Inheritance in Man (OMIM®) (2011) Hum Mutat, 32 (5), pp. 564-567; Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., Jia, M., Futreal, P.A., COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer (2011) Nucleic Acids Res, 39, pp. D945-D950; Packer, B.R., Yeager, M., Burdett, L., Welch, R., Beerman, M., Qi, L., Sicotte, H., Chanock, S.J., SNP500Cancer: A public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes (2006) Nucleic Acids Res, 34, pp. D617-D621; Oster, S., Langella, S., Hastings, S., Ervin, D., Madduri, R., Phillips, J., Kurc, T., Saltz, J., caGrid 1.0: An enterprise Grid infrastructure for biomedical research (2008) J Am Med Inform Assoc, 15 (2), pp. 138-149; Kemball-Cook, G., Tuddenham, E.G., Wacey, A.I., The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4 (1998) Nucleic Acids Res, 26 (1), pp. 216-219; Milhavet, F., Cuisset, L., Hoffman, H.M., Slim, R., El-Shanti, H., Aksentijevich, I., Lesage, S., Touitou, I., The infevers autoinflammatory mutation online registry: Update with new genes and functions (2008) Hum Mutat, 29 (6), pp. 803-808; Higgins, M.E., Claremont, M., Major, J.E., Sander, C., Lash, A.E., CancerGenes: A gene selection resource for cancer genome projects (2007) Nucleic Acids Res, 35, pp. 721-726; Winnenburg, R., Urban, M., Beacham, A., Baldwin, T.K., Holland, S., Lindeberg, M., Hansen, H., Köhler, J., PHI-base update: Additions to the pathogen host interaction database (2008) Nucleic Acids Res, 36, pp. D572-D576; Nicola, G., Liu, T., Gilson, M.K., Public domain databases for medicinal chemistry (2012) J Med Chem, 55, pp. 6987-7002; Zhang, Y.J., In silico technologies in drug design, discovery and development (2010) Curr Top Med Chem, 10 (6), pp. 617-618; Khan, F., Yadav, D.K., Maurya, A., Srivastava, S.K., Modern Methods & Web Resources in Drug Design & Discovery (2011) Letters In Drug Design & Discovery, 8 (5), pp. 469-490; Lagoumintzis, G., Poulas, K., Patrinos, G.P., Genetic databases and their potential in pharmacogenomics (2010) Curr Pharm Des, 16, pp. 2224-2231; Marsh, S., Kwok, P., McLeod, H.L., SNP databases and pharmaco-genetics: Great start, but a long way to go (2002) Hum Mutat, 20 (3), pp. 174-179; Yang, G.F., Huang, X., Development of quantitative structure-activity relationships and its application in rational drug design (2006) Curr Pharm Des, 12 (35), pp. 4601-4611; Cross, J.B., Thompson, D.C., Rai, B.K., Baber, J.C., Fan, K.Y., Hu, Y., Humblet, C., Comparison of several molecular docking programs: Pose prediction and virtual screening accuracy (2009) J Chem Inf Model, 49 (6), pp. 1455-1474; Khedkar, S.A., Malde, A.K., Coutinho, E.C., Srivastava, S., Phar-macophore modeling in drug discovery and development: An overview (2007) Med Chem, 3 (2), pp. 187-197; Kirkpatrick, D.L., Watson, S., Ulhaq, S., Structure-based drug design: Combinatorial chemistry and molecular modeling (1999) Comb Chem High Throughput Screen, 2 (4), pp. 211-221; Hendlich, M., Rippmann, F., Barnickel, G., LIGSITE: Automatic and efficient detection of potential small molecule-binding sites in proteins (1997) J Mol Graph Model, 15, pp. 359-363; Karelson, M., Maran, U., Wang, Y.L., Katritzky, A.R., QSPR and QSAR models derived using large molecular descriptor spaces. A review of CODESSA applications (1999) COLLECTION of CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 64 (10), pp. 1551-1571; Wolber, G., Langer, T., LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters (2005) J Chem Inf Model, 45 (1), pp. 160-169; Dixon, S.L., Smondyrev, A.M., Rao, S.N., PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching (2006) Chem. Biol. Drug Des, 67, pp. 370-372; Lagunin, A., Stepanchikova, A., Filimonov, D., Poroikov, V., PASS: Prediction of activity spectra for biologically active substances (2000) Bioinformatics, 16 (8), pp. 747-748; Zhang, H., Neal, S., Wishart, D.S., RefDB: A database of uniformly referenced protein chemical shifts (2003) J Biomol NMR, 25 (3), pp. 173-195; Kuhn, M., von Mering, C., Campillos, M., Jensen, L.J., Bork, P., STITCH: Interaction networks of chemicals and proteins (2008) Nucleic Acids Res, 36, pp. D684-D688; Meslamani, J., Rognan, D., Kellenberger, E., sc-PDB: A database for identifying variations and multiplicity of 'druggable' binding sites in proteins (2011) Bioinformatics, 27 (9), pp. 1324-1326; Kaufmann, K.W., Meiler, J., Using RosettaLigand for small molecule docking into comparative models (2012) PLoS One, 7 (12), pp. e50769; Benson, M.L., Smith, R.D., Khazanov, N.A., Dimcheff, B., Beaver, J., Dresslar, P., Nerothin, J., Carlson, H.A., Binding MOAD, a high-quality protein-ligand database (2008) Nucleic Acids Res, 36, pp. D674-D678; Hendlich, M., Rippmann, F., Barnickel, G., LIGSITE: Automatic and efficient detection of potential small molecule-binding sites in proteins (1997) J Mol Graph Model, 15 (6), pp. 359-363. , 389; Sharman, J.L., Benson, H.E., Pawson, A.J., Lukito, V., Mpamhan-Ga, C.P., Bombail, V., Davenport, A.P., Harmar, A.J., NC-IUPHAR. IUPHAR-DB: Updated database content and new features (2013) Nucleic Acids Res, 41, pp. 1083-1088; Weisel, M., Proschak, E., Schneider, G., PocketPicker: Analysis of ligand binding-sites with shape descriptors (2007) Chem Cent J, 1, p. 7; Brylinski, M., Skolnick, J., FINDSITE: A threading-based approach to ligand homology modeling (2009) PLoS Comput Biol, 5 (6), pp. e1000405; Paul, N., Rognan, D., ConsDock: A new program for the consensus analysis of protein-ligand interactions (2002) Proteins, 47 (4), pp. 521-533; Miller, M.D., Sheridan, R.P., Kearsley, S.K., SQ: A program for rapidly producing pharmacophorically relevent molecular superpositions (1999) J Med Chem, 42 (9), pp. 1505-1514; Hecker, N., Ahmed, J., von Eichborn, J., Dunkel, M., Macha, K., Eckert, A., Gilson, M.K., Preissner, R., SuperTarget goes quantitative: Update on drug-target interactions (2012) Nucleic Acids Res, 40, pp. 1113-1117; Günther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Preissner, R., SuperTarget and Matador: Resources for exploring drug-target relationships (2008) Nucleic Acids Res, 36, pp. D919-D922; Liu, S., Gao, Y., Vakser, I.A., DOCKGROUND protein-protein docking decoy set (2008) Bioinformatics, 24, pp. 2634-2635; Gao, Z., Li, H., Zhang, H., Liu, X., Kang, L., Luo, X., Zhu, W., Jiang, H., PDTD: A web-accessible protein database for drug target identification (2008) BMC Bioinformatics, 9, p. 104; Li, H., Gao, Z., Kang, L., Zhang, H., Yang, K., Yu, K., Luo, X., Jiang, H., TarFisDock: A web server for identifying drug targets with docking approach (2006) Nucleic Acids Res, 34, pp. W219-W224; Golovin, A., Dimitropoulos, D., Oldfield, T., Rachedi, A., Henrick, K., MSDsite: A database search and retrieval system for the analysis and viewing of bound ligands and active sites (2005) Proteins, 58, pp. 190-199; Stuart, A.C., Ilyin, V.A., Sali, A., LigBase: A database of families of aligned ligand binding sites in known protein sequences and structures (2002) Bioinformatics, 18 (1), pp. 200-201; Vilar, S., Cozza, G., Moro, S., Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery (2008) Curr Top Med Chem, 8, pp. 1555-1572; Vagin, A.A., Steiner, R.A., Lebedev, A.A., Potterton, L., McNi-Cholas, S., Long, F., Murshudov, G.N., REFMAC5 dictionary: Organization of prior chemical knowledge and guidelines for its use (2004) Acta Crystallogr D Biol Crystallogr, 60, pp. 2184-2195; Hewett, M., Oliver, D.E., Rubin, D.L., Easton, K.L., Stuart, J.M., Altman, R.B., Klein, T.E., PharmGKB: The Pharmacogenetics Knowledge Base (2002) Nucleic Acids Res, 30 (1), pp. 163-165; Wishart, D.S., Knox, C., Guo, A.C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., Woolsey, J., DrugBank: A comprehensive resource for in silico drug discovery and exploration (2006) Nucleic Acids Res, 34, pp. 668-672; Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A., Light, Y., Overington, J.P., ChEMBL: A large-scale bioactivity database for drug discovery (2012) Nucleic Acids Res, 40, pp. 1100-1107; Kuhn, M., Campillos, M., Letunic, I., Jensen, L.J., Bork, P., A side effect resource to capture phenotypic effects of drugs (2010) Mol Syst Biol, 6, p. 343; Bolton, E., Wang, Y., Thiessen, P.A., Bryant, S.H., PubChem: Integrated Platform of Small Molecules and Biological Activities (2008) Annual Reports In Computational Chemistry, 4. , American Chemical Society: Washington D.C, Chapter 12; Laskowski, R.A., Thornton, J.M., Understanding the molecular machinery of genetics through 3D structures (2008) Nat Rev Genet, 9 (2), pp. 141-151; Goddard, T.D., Ferrin, T.E., Visualization software for molecular assemblies (2007) Curr Opin Struct Biol, 17 (5), pp. 587-595; Alves, R., Antunes, F., Salvador, A., Tools for kinetic modeling of biochemical networks (2006) Nat Biotechnol, 24 (6), pp. 667-672; Milanesi, L., Romano, P., Castellani, G., Remondini, D., Liò, P., Trends in modeling Biomedical Complex Systems (2009) BMC Bioinfor-matics, 10 (SUPPL. 12), pp. I1; Alter, O., Genomic signal processing: From matrix algebra to genetic networks (2007) Methods Mol Biol, 377, pp. 17-60; Karr, J.R., Sanghvi, J.C., Macklin, D.N., Gutschow, M.V., Jacobs, J.M., Bolival, B., Assad-Garcia, N., Covert, M.W., A whole-cell computational model predicts phenotype from genotype (2012) Cell, 150, pp. 389-401; Hassan, S.A., Gracia, L., Vasudevan, G., Steinbach, P.J., Computer simulation of protein-ligand interactions: Challenges and applications (2005) Methods Mol Biol, 305, pp. 451-492; Henkel, R., Endler, L., Peters, A., Le Novère, N., Waltemath, D., Ranked retrieval of Computational Biology models (2010) BMC Bioin-formatics, 11, p. 423; Brooks, B.R., Brooks, C.L., Mackerell Jr., A.D., Nilsson, L., Pet-Rella, R.J., Roux, B., Won, Y., Karplus, M., CHARMM: The bio-molecular simulation program (2009) J Comput Chem, 30 (10), pp. 1545-1614; Schmidt, M.W., Baldridge, K.K., Boatz, J.A., Elbert, S.T., Gordon, M.S., Jensen, J.H., Koseki, S., Matsunaga, N., General atomic and molecular electronic structure system (1993) Journal of Computational Chemistry, 14 (11), pp. 1347-1363; van der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A.E., Berendsen, H.J., GROMACS: Fast, flexible, and free (2005) J Com-put Chem, 26 (16), pp. 1701-1718; Segall, M.D., Lindan, P.J.D., Probert, M.J., Pickard, C.J., Hasnip, P.J., Clark, S.J., Paynel, M.C., First-principles simulation: Ideas, illustrations and the CASTEP code (2002) J. Phys.: Condens. Matter, 14 (11), p. 2717; Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Schulten, K., Scalable molecular dynamics with NAMD (2005) J Comput Chem, 26 (16), pp. 1781-1802; First-principles computation of the electronic and dynamical properties of solids and nanostructures with ABINIT (2008) Journal of Physics Condensed Matter, 20 (6). , Internet; Stewart, J.J., MOPAC: A semiempirical molecular orbital program (1990) J Comput Aided Mol Des, 4 (1), pp. 1-105; Case, D.A., Cheatham, T.E., Darden, T., Gohlke, H., Luo, R., Merz Jr., K.M., Onufriev, A., Woods, R.J., The Amber biomolecular simulation programs (2005) J Comput Chem, 26 (16), pp. 1668-1688; Schaftenaar, G., Noordik, J.H., Molden: A pre-and post-processing program for molecular and electronic structures (2000) J Comput Aided Mol Des, 14 (2), pp. 123-134; Bruno, I.J., Cole, J.C., Edgington, P.R., Kessler, M., Macrae, C.F., McCabe, P., Pearson, J., Taylor, R., New software for searching the Cambridge Structural Database and visualizing crystal structures (2002) Acta Crystallogr B, 58 (Pt 3), pp. 389-397. , Pt 1; Drouin, D., Couture, A.R., Joly, D., Tastet, X., Aimez, V., Gauvin, R., CASINO V2.42: A fast and easy-to-use modeling tool for scanning electron microscopy and microanalysis users (2007) Scanning, 29 (3), pp. 92-101; Shepard, R., Shavitt, I., Pitzer, R.M., Comeau, D.C., Pepper, M., Lischka, H., Szalay, P.G., Zhao, J.G., A Progress Report on the Status of the COLUMBUS MRCI Program System (1988) Int. J. Quantum Chem. Symp, 22 (149); Vandevondele, J., Krack, M., Mohamed, F., Parrinello, M., Chas-Saing, T., Hutter, J., QUICKSTEP: Fast and accurate density functional calculations using a mixed Gaussian and plane waves approach (2005) Computer Physics Communications, 167 (2), pp. 103-128; Cline, M.S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N., Workman, C., Christmas, R., Bader, G.D., Integration of biological networks and gene expression data using Cytoscape (2007) Nat Protoc, 2, pp. 2366-2382; Valiev, M., Bylaska, E.J., Govind, N., Kowalski, K., Straatsma, T.P., van Dam, H.J.J., Wang, D., de Jong, W., NWChem: A comprehensive and scalable open-source solution for large scale molecular simulations (2010) Computer Physics Communications, 181 (9), pp. 1477-1489; Li, C., Donizelli, M., Rodriguez, N., Dharuri, H., Endler, L., Chel-Liah, V., Li, L., Laibe, C., BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models (2010) BMC Syst Biol, 4, p. 92; Moraru, I.I., Schaff, J.C., Slepchenko, B.M., Blinov, M.L., Morgan, F., Lakshminarayana, A., Gao, F., Loew, L.M., Virtual Cell modelling and simulation software environment (2008) IET Syst Biol, 2 (5), pp. 352-362; Schmidt, H., Jirstrand, M., Systems Biology Toolbox for MA-TLAB: A computational platform for research in systems biology (2006) Bioinformatics, 22, pp. 514-515; Representing structural information with RasMol (2005) Curr Protoc Bioinformatics, , Chapter 5, Unit 5.4. doi: 10.1002/0471250953.bi0504s11; Petrey, D., Honig, B., GRASP2: Visualization, surface properties, and electrostatics of macromolecular structures and sequences (2003) Methods Enzymol, 374, pp. 492-509; Hu, Z., Mellor, J., Wu, J., Yamada, T., Holloway, D., Delisi, C., VisANT: Data-integrating visual framework for biological networks and modules (2005) Nucleic Acids Res, 33, pp. 352-357; Flores, S., Echols, N., Milburn, D., Hespenheide, B., Keating, K., Lu, J., Wells, S., Gerstein, M., The Database of Macromolecular Motions: New features added at the decade mark (2006) Nucleic Acids Res, 34, pp. 296-301; Funahashi, A., Matsuoka, Y., Jouraku, A., Morohashi, M., Kiku-Chi, N., Kitano, H., CellDesigner 3.5: A versatile modeling tool for biochemical networks (2008) Proceedings of the IEEE, 96 (8), pp. 1254-1265; Kaznessis, Y.N., SynBioSS-aided design of synthetic biological constructs (2011) Methods Enzymol, 498, pp. 137-152; Azuaje, F., Al-Shahrour, F., Dopazo, J., Ontology-driven approaches to analyzing data in functional genomics (2006) Methods Mol Biol, 316, pp. 67-86; Beissbarth, T., Interpreting experimental results using gene ontologies (2006) Methods Enzymol, 411, pp. 340-352; Bodenreider, O., Biomedical ontologies in action: Role in knowledge management, data integration and decision support (2008) Yearb Med Inform, pp. 67-79; Antezana, E., Kuiper, M., Mironov, V., Biological knowledge management: The emerging role of the Semantic Web technologies (2009) Brief Bioinform, 10 (4), pp. 392-407; Alterovitz, G., Xiang, M., Hill, D.P., Lomax, J., Liu, J., Cherkassky, M., Dreyfuss, J., Ramoni, M.F., Ontology engineering (2010) Nat Bio-technol, 28 (2), pp. 128-130; Jensen, L.J., Bork, P., Ontologies in quantitative biology: A basis for comparison, integration, and discovery (2010) PLoS Biol, 8 (5), pp. e1000374; Bard, J.B., Rhee, S.Y., Ontologies in biology: Design, applications and future challenges (2004) Nat Rev Genet, 5 (3), pp. 213-222; Rubin, D.L., Shah, N.H., Noy, N.F., Biomedical ontologies: A functional perspective (2008) Brief Bioinform, 9 (1), pp. 75-90; Lambrix, P., Habbouche, M., Pérez, M., Evaluation of ontology development tools for bioinformatics (2003) Bioinformatics, 19, pp. 1564-1571; Maojo, V., Crespo, J., García-Remesal, M., de la Iglesia, D., Perez-Rey, D., Kulikowski, C., Biomedical ontologies: Toward scientific debate (2011) Methods Inf Med, 50, pp. 203-216; Arp, R., Smith, B., Function, Role, and Disposition in Basic Formal Ontology (2008) Nature Precedings, , http://hdl.handle.net/10101/npre.2008.1941.1, Available from, Accessed March 3; (2013) Basic Formal Ontology (BFO), , http://www.ifomis.org/bfo, Accessed March 3; Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Sherlock, G., Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium (2000) Nat Genet, 25 (1), pp. 25-29; Conesa, A., Götz, S., Garcia-Gómez, J.M., Terol, J., Talón, M., Robles, M., Blast2GO: A universal tool for annotation, visualization and analysis in functional genomics research (2005) Bioinformatics, 21, pp. 3674-3676; Camon, E., Magrane, M., Barrell, D., Lee, V., Dimmer, E., Mas-Len, J., Binns, D., Apweiler, R., The Gene Ontology Annotation (GOA) Database: Sharing knowledge in Uniprot with Gene Ontology (2004) Nucleic Acids Res, 32, pp. 262-266; Zeeberg, B.R., Feng, W., Wang, G., Wang, M.D., Fojo, A.T., Sunshine, M., Narasimhan, S., Weinstein, J.N., GoMi-ner: A resource for biological interpretation of genomic and pro-teomic data (2003) Genome Biol, 4, pp. R28; Maere, S., Heymans, K., Kuiper, M., BiNGO: A Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks (2005) Bioinformatics, 21, pp. 3448-3449; Beissbarth, T., Speed, T.P., GOstat: Find statistically overrepre-sented Gene Ontologies within a group of genes (2004) Bioinformatics, 20 (9), pp. 1464-1465; Doniger, S.W., Salomonis, N., Dahlquist, K.D., Vranizan, K., Lawlor, S.C., Conklin, B.R., MAPPFinder: Using Gene Ontology and GenMAPP to create a global gene-expression profile from mi-croarray data (2003) Genome Biol, 4, pp. R7; Al-Shahrour, F., Díaz-Uriarte, R., Dopazo, J., FatiGO: A web tool for finding significant associations of Gene Ontology terms with groups of genes (2004) Bioinformatics, 20 (4), pp. 578-580; Boyle, E.I., Weng, S., Gollub, J., Jin, H., Botstein, D., Cherry, J.M., Sherlock, G., GO ::TermFinder--open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes (2004) Bioinformatics, 20 (18), pp. 3710-3715; Rosse, C., Mejino, J.V.L., A reference ontology for biomedical informatics: The Foundational Model of Anatomy (2003) J Biomed Inform, 36, pp. 478-500; Zhang, B., Schmoyer, D., Kirov, S., Snoddy, J., GOTree Machine (GOTM): A web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies (2004) BMC Bioinformatics, 5, p. 16; Berriz, G.F., King, O.D., Bryant, B., Sander, C., Roth, F.P., Characterizing gene sets with FuncAssociate (2003) Bioinformatics, 19, pp. 2502-2504; Carbon, S., Ireland, A., Mungall, C.J., Shu, S., Marshall, B., Lewis, S., AmiGO Hub; Web Presence Working Group. AmiGO: Online access to ontology and annotation data (2009) Bioinformatics, 25, pp. 288-289; Müller, H.M., Kenny, E.E., Sternberg, P.W., Textpresso: An ontology-based information retrieval and extraction system for biological literature (2004) PLoS Biol, 2 (11), pp. e309; Martin, D., Brun, C., Remy, E., Mouren, P., Thieffry, D., Jacq, B., GOToolBox: Functional analysis of gene datasets based on Gene Ontology (2004) Genome Biol, 5, pp. R101; Eilbeck, K., Lewis, S.E., Mungall, C.J., Yandell, M., Stein, L., Durbin, R., Ashburner, M., The Sequence Ontology: A tool for the unification of genome annotations (2005) Genome Biol, 6, pp. R44; Smith, C.L., Goldsmith, C.A., Eppig, J.T., The Mammalian Pheno-type Ontology as a tool for annotating, analyzing and comparing phenotypic information (2005) Genome Biol, 6 (1), pp. R7; Ye, J., Fang, L., Zheng, H., Zhang, Y., Chen, J., Zhang, Z., Wang, J., Bolund, L., WEGO: A web tool for plotting GO annotations (2006) Nucleic Acids Res, 34, pp. 293-297; Zheng, Q., Wang, X.J., GOEAST: A web-based software toolkit for Gene Ontology enrichment analysis (2008) Nucleic Acids Res, 36, pp. W358-W363; Eden, E., Navon, R., Steinfeld, I., Lipson, D., Yakhini, Z., GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists (2009) BMC Bioinformatics, 10, p. 48; Khan, S., Situ, G., Decker, K., Schmidt, C.J., GoFigure: Automated Gene Ontology annotation (2003) Bioinformatics, 19, pp. 2484-2485; Khatri, P., Bhavsar, P., Bawa, G., Draghici, S., Onto-Tools: An ensemble of web-accessible, ontology-based tools for the functional design and interpretation of high-throughput gene expression experiments (2004) Nucleic Acids Res, 32, pp. 449-456; Bauer, S., Grossmann, S., Vingron, M., Robinson, P.N., Ontologi-zer 2.0--a multifunctional tool for GO term enrichment analysis and data exploration (2008) Bioinformatics, 24, pp. 1650-1651; Chou, K.C., Cai, Y.D., Prediction of protein subcellular locations by GO-FunD-PseAA predictor (2004) Biochem Biophys Res Commun, 320 (4), pp. 1236-1239; Martin, D.M., Berriman, M., Barton, G.J., GOtcha: A new method for prediction of protein function assessed by the annotation of seven genomes (2004) BMC Bioinformatics, 5, p. 178; Robinson, P.N., Köhler, S., Bauer, S., Seelow, D., Horn, D., Mundlos, S., The Human Phenotype Ontology: A tool for annotating and analyzing human hereditary disease (2008) Am J Hum Genet, 83 (5), pp. 610-615; Noy, N.F., Shah, N.H., Whetzel, P.L., Dai, B., Dorf, M., Griffith, N., Jonquet, C., Musen, M.A., BioPortal: Ontologies and integrated data resources at the click of a mouse (2009) Nucleic Acids Res, 37, pp. W170-W173; Levy, E.D., Pereira-Leal, J.B., Chothia, C., Teichmann, S.A., 3D complex: A structural classification of protein complexes (2006) PLoS Comput Biol, 2 (11), pp. e155; Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.H., Galon, J., ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks (2009) Bioinformatics, 25, pp. 1091-1093; Day-Richter, J., Harris, M.A., Haendel, M., Gene Ontology OBO-Edit Working Group; Lewis, S. OBO-Edit--an ontology editor for biologists (2007) Bioinformatics, 23, pp. 2198-2200; Giudicelli, V., Lefranc, M.P., IMGT-ONTOLOGY 2012 (2012) Front Genet, 3, p. 79; Cheng, J., Sun, S., Tracy, A., Hubbell, E., Morris, J., Valmeekam, V., Kimbrough, A., Siani-Rose, M.A., NetAffx Gene Ontology Mining Tool: A visual approach for microarray data analysis (2004) Bioinformatics, 20, pp. 1462-1463; Zhong, S., Storch, K.F., Lipan, O., Kao, M.C., Weitz, C.J., Wong, W.H., GoSurfer: A graphical interactive tool for comparative analysis of large gene sets in Gene Ontology space (2004) Appl Bioinformatics, 3, pp. 261-264; Pérez-Rey, D., Maojo, V., García-Remesal, M., Alonso-Calvo, R., Billhardt, H., Martin-Sánchez, F., Sousa, A., ONTOFUSION: Ontology-based integration of genomic and clinical databases (2006) Comput Biol Med, 36 (7-8), pp. 712-730; Zehetner, G., OntoBlast function: From sequence similarities directly to potential functional annotations by ontology terms (2003) Nucleic Acids Res, 31 (13), pp. 3799-3803; Krause, F., Schulz, M., Swainston, N., Liebermeister, W., Sustainable model building the role of standards and biological semantics (2011) Methods Enzymol, 500, pp. 371-395; Courtot, M., Juty, N., Knüpfer, C., Waltemath, D., Zhukova, A., Dräger, A., Dumontier, M., Le Novère, N., Controlled vocabularies and semantics in systems biology (2011) Molecular Systems Biology, 7, p. 543; Brazma, A., Krestyaninova, M., Sarkans, U., Standards for systems biology (2006) Nat Rev Genet, 7 (8), pp. 593-605; Robinson, J., Waller, M.J., Fail, S.C., McWilliam, H., Lopez, R., Parham, P., Marsh, S.G., The IMGT/HLA database (2009) Nucleic Acids Res, 37, pp. 1013-1017; Lindberg, D.A., Humphreys, B.L., McCray, A.T., The Unified Medical Language System (1993) Methods Inf Med, 32 (4), pp. 281-291; Hucka, M., Finney, A., Sauro, H.M., Bolouri, H., Doyle, J.C., Kitano, H., Arkin, A.P., Wang, J., SBML Forum. The systems biology markup language (SBML): A medium for representation and exchange of biochemical network models (2003) Bioinformatics, 19 (4), pp. 524-531; Spackman, K.A., Campbell, K.E., Côté, R.A., SNOMED RT: A reference terminology for health care (1997) Proc AMIA Annu Fall Symp, p. 640; HL7 version 3--an object-oriented methodology for collaborative standards development (1998) Int J Med Inform, 48 (1-3), pp. 151-161; Seal, R.L., Gordon, S.M., Lush, M.J., Wright, M.W., Bruford, E.A., Genenames.org: The HGNC resources in 2011 (2011) Nucleic Acids Res, 39, pp. 514-519; Orchard, S., Binz, P.A., Borchers, C., Gilson, M.K., Jones, A.R., Nicola, G., Vizcaino, J.A., Hermjakob, H., Ten years of standardizing proteomic data: A report on the HUPO-PSI Spring Workshop: April 12-14th, 2012, San Diego, USA (2012) Pro-teomics, 12 (18), pp. 2767-2772; Forrey, A.W., McDonald, C.J., Demoor, G., Huff, S.M., Leavelle, D., Leland, D., Fiers, T., Baenziger, J., Logical observation identifier names and codes (LOINC) database: A public use set of codes and names for electronic reporting of clinical laboratory test results (1996) Clin Chem, 42 (1), pp. 81-90; Juty, N., Le Novère, N., Laibe, C., Identifiers.org and MIRIAM Registry: Community resources to provide persistent identification (2012) Nucleic Acids Res, 40, pp. D580-D586; Brown, E.G., Wood, L., Wood, S., The medical dictionary for regulatory activities (MedDRA) (1999) Drug Saf, 20 (2), pp. 109-117; Wain, H.M., Lush, M.J., Ducluzeau, F., Khodiyar, V.K., Povey, S., Genew: The Human Gene Nomenclature Database, 2004 updates (2004) Nucleic Acids Res, 32, pp. D255-D257; Mao, X., Cai, T., Olyarchuk, J.G., Wei, L., Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary (2005) Bioinformatics, 21, pp. 3787-3793; Belleau, F., Nolin, M.A., Tourigny, N., Rigault, P., Morissette, J., Bio2RDF: Towards a mashup to build bioinformatics knowledge systems (2008) J Biomed Inform, 41 (5), pp. 706-716; Wildeman, M., van Ophuizen, E., den Dunnen, J.T., Taschner, P.E., Improving sequence variant descriptions in mutation databases and literature using the Mutalyzer sequence variation nomenclature checker (2008) Hum Mutat, 29 (1), pp. 6-13; Demir, E., Cary, M.P., Paley, S., Fukuda, K., Lemer, C., Vastrik, I., Wu, G., Bader, G.D., The BioPAX community standard for pathway data sharing (2010) Nat Biotechnol, 28 (9), pp. 935-942; Bornstein, B.J., Keating, S.M., Jouraku, A., Hucka, M., LibSBML: An API library for SBML (2008) Bioinformatics, 24, pp. 880-881; Westbrook, J., Ito, N., Nakamura, H., Henrick, K., Berman, H.M., PDBML: The representation of archival macromolecular structure data in XML (2005) Bioinformatics, 21, pp. 988-992; Alibés, A., Yankilevich, P., Cañada, A., Diaz-Uriarte, R., IDconver-ter and IDClight: Conversion and annotation of gene and protein IDs (2007) BMC Bioinformatics, 8, p. 9; Liu, H., Hu, Z.Z., Zhang, J., Wu, C., BioThesaurus: A web-based thesaurus of protein and gene names (2006) Bioinformatics, 22, pp. 103-105; Kasprzyk, A., Keefe, D., Smedley, D., London, D., Spooner, W., Melsopp, C., Hammond, M., Birney, E., (2004) Genome Res, 14 (1), pp. 160-169; Biology Browser, , http://www.biologybrowser.org/; Lee, T.J., Pouliot, Y., Wagner, V., Gupta, P., Stringer-Calvert, D.W., Tenenbaum, J.D., Karp, P.D., BioWarehouse: A bioinformat-ics database warehouse toolkit (2006) BMC Bioinformatics, 7, p. 170; Shah, S.P., Huang, Y., Xu, T., Yuen, M.M., Ling, J., Ouellette, B.F., Atlas-a data warehouse for integrative bioinformatics (2005) BMC Bioinformatics, 6, p. 34; Zdobnov, E.M., Lopez, R., Apweiler, R., Etzold, T., The EBI SRS server-recent developments (2002) Bioinformatics, 18 (2), pp. 368-373; Stajich, J.E., Block, D., Boulez, K., Brenner, S.E., Chervitz, S.A., Dagdigian, C., Fuellen, G., Birney, E., The Bioperl toolkit: Perl modules for the life sciences (2002) Genome Res, 12 (10), pp. 1611-1618; Roberts, R.J., Varmus, H.E., Ashburner, M., Brown, P.O., Eisen, M.B., Khosla, C., Kirschner, M., Wold, B., Information access. Building a ""GenBank"" of the published literatura (2001) Science, 291, pp. 2318-2319; Hokamp, K., Wolfe, K., What's new in the library? What's new in GenBank? Let PubCrawler tell you (1999) Trends Genet, 15 (11), pp. 471-472; Garcia-Remesal, M., Cuevas, A., Pérez-Rey, D., Martin, L., Angui-Ta, A., de la Iglesia, D., de la Calle, G., Maojo, V., PubDNA Finder: A web database linking full-text articles to sequences of nucleic acids (2010) Bioinformatics, 26, pp. 2801-2802; Hoffmann, R., Valencia, A., Implementing the iHOP concept for navigation of biomedical literatura (2005) Bioinformatics, 21 (SUPPL. 2), pp. 252-258; Doms, A., Schroeder, M., GoPubMed: Exploring PubMed with the Gene Ontology (2005) Nucleic Acids Res, 33, pp. 783-786; Rebholz-Schuhmann, D., Kirsch, H., Arregui, M., Gaudan, S., Riethoven, M., Stoehr, P., EBIMed--text crunching to gather facts for proteins from Medline (2007) Bioinformatics, 23, pp. 237-244; Tsuruoka, Y., Tsujii, J., Ananiadou, S., FACTA: A text search engine for finding associated biomedical concepts (2008) Bioinformatics, 24 (21), pp. 2559-2560; Garcia-Remesal, M., Garcia-Ruiz, A., Perez-Rey, D., de la Iglesia, D., Maojo, V., Using Nanoinformatics Methods for Automatically Identifying Relevant Nanotoxicology Entities from the Literature (2013) BioMed Research International, p. 9. , 2013(410294), doi:10.1155/2013/410294; Jelier, R., Schuemie, M.J., Veldhoven, A., Dorssers, L.C., Jenster, G., Kors, J.A., Anni 2.0: A multipurpose text-mining tool for the life sciences (2008) Genome Biol, 9 (6), pp. R96; Cohen, C., Fischel, O., Cohen, E., Molecular conceptor for training in medicinal chemistry, drug design, and cheminformatics (2007) Chem Biol Drug Des, 69 (1), pp. 75-82; (2013) NanoHUB, , https://www.nanohub.org/, Accessed March 3; Finding correlations in big data (2012) Nat Biotechnol, 30 (4), pp. 334-335. , doi: 10.1038/nbt.2182; Paylor, R., Questioning standardization in science (2009) Nat Methods, 6 (4), pp. 253-254; Smith, B., Ashburner, M., Rosse, C., Bard, J., Bug, W., Ceusters, W., Goldberg, L.J., Lewis, S., The OBO Foundry: Coordinated evolution of ontologies to support biomedical data integration (2007) Nat Biotechnol, 25 (11), pp. 1251-1255; (2013) Open Biological and Biomedical Ontologies, the OBO Foundry, , http://www.obofoundry.org/, Accessed March 3; Kuchinke, W., Aerts, J., Semler, S.C., Ohmann, C., CDISC standard-based electronic archiving of clinical trials (2009) Methods Inf Med, 48 (5), pp. 408-413; (2013) Clinical Data Interchange Standards Consortium (CDISC), , http://www.cdisc.org/, Accessed March 3; Jonnalagadda, S., Peeler, R., Topham, P., Discovering opinion leaders for medical topics using news articles (2012) J Biomed Semantics, 3, p. 2; Patel, C.J., Bhattacharya, J., Butte, A.J., An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus (2010) PLoS One, 5 (5), pp. e10746; Fingerman, I.M., McDaniel, L., Zhang, X., Ratzat, W., Hassan, T., Jiang, Z., Cohen, R.F., Schuler, G.D., NCBI Epigenomics: A new public resource for exploring epigenomic data sets (2011) Nucleic Acids Res, 39, pp. 908-912; Introducing Kuhn et al.'s paper Informatics and medicine: From molecules to populations and invited papers on this special topic (2008) Methods Inf Med, 47 (4), pp. 279-282; Kuhn, K.A., Knoll, A., Mewes, H.W., Schwaiger, M., Bode, A., Broy, M., Daniel, H., Ziegler, S., Informatics and medicine--from molecules to populations (2008) Methods Inf Med, 47, pp. 283-295; Altman, R.B., Balling, R., Brinkley, J.F., Coiera, E., Consorti, F., Dhansay, M.A., Geissbuhler, A., Wiederhold, G., Commentaries on Informatics and medicine: From molecules to populations (2008) Methods Inf Med, 47, pp. 296-317; Waldman, S.A., Terzic, A., The value proposition of molecular medicine (2012) Clin Transl Sci, 5 (1), pp. 108-110; What informatics is and isn't (2012) J Am Med Inform Assoc, , Oct 11. [Epub ahead of print]","de la Iglesia, D.; Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politécnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; email: diglesia@infomed.dia.fi.upm.es",,,,,,,,15680266,,CTMCC,"23548020","English","Curr. Top. Med. Chem.",Review,"Final",,Scopus,2-s2.0-84878572474
"Oliveira J.L., Lopes P., Nunes T., Campos D., Boyer S., Ahlberg E., van Mulligen E.M., Kors J.A., Singh B., Furlong L.I., Sanz F., Bauer-Mehren A., Carrascosa M.C., Mestres J., Avillach P., Diallo G., Díaz Acedo C., van der Lei J.","57193360895;55538753378;55508659200;36241209000;55913555400;55507820200;7003307150;7005293297;57199778724;34770469800;7102263897;35572639000;46260981600;7004586125;23972137300;24398462100;55939181800;56592306600;","The EU-ADR Web Platform: Delivering advanced pharmacovigilance tools",2013,"Pharmacoepidemiology and Drug Safety","22","5",,"459","467",,29,"10.1002/pds.3375","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84877591332&doi=10.1002%2fpds.3375&partnerID=40&md5=e5a5c5fa430a10f175d4b8011fd96d90","DETI/IEETA, University of Aveiro, Aveiro, Portugal; AstraZeneca, Molndal, Sweden; Erasmus University Medical Center, Rotterdam, Netherlands; Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute and Universitat Pompeu Fabra, Barcelona, Catalonia, Spain; LERTIM, EA 3283, Faculté de Médecine, Université de Aix-Marseille, Marseille, France; LESIM-ISPED, Université de Bordeaux, Bordeaux, France; Synapse Research Management Partners, Barcelona, Spain","Oliveira, J.L., DETI/IEETA, University of Aveiro, Aveiro, Portugal; Lopes, P., DETI/IEETA, University of Aveiro, Aveiro, Portugal; Nunes, T., DETI/IEETA, University of Aveiro, Aveiro, Portugal; Campos, D., DETI/IEETA, University of Aveiro, Aveiro, Portugal; Boyer, S., AstraZeneca, Molndal, Sweden; Ahlberg, E., AstraZeneca, Molndal, Sweden; van Mulligen, E.M., Erasmus University Medical Center, Rotterdam, Netherlands; Kors, J.A., Erasmus University Medical Center, Rotterdam, Netherlands; Singh, B., Erasmus University Medical Center, Rotterdam, Netherlands; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute and Universitat Pompeu Fabra, Barcelona, Catalonia, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute and Universitat Pompeu Fabra, Barcelona, Catalonia, Spain; Bauer-Mehren, A., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute and Universitat Pompeu Fabra, Barcelona, Catalonia, Spain; Carrascosa, M.C., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute and Universitat Pompeu Fabra, Barcelona, Catalonia, Spain; Mestres, J., Research Programme on Biomedical Informatics (GRIB), IMIM Hospital del Mar Research Institute and Universitat Pompeu Fabra, Barcelona, Catalonia, Spain; Avillach, P., LERTIM, EA 3283, Faculté de Médecine, Université de Aix-Marseille, Marseille, France, LESIM-ISPED, Université de Bordeaux, Bordeaux, France; Diallo, G., LESIM-ISPED, Université de Bordeaux, Bordeaux, France; Díaz Acedo, C., Synapse Research Management Partners, Barcelona, Spain; van der Lei, J., Erasmus University Medical Center, Rotterdam, Netherlands","Purpose: Pharmacovigilance methods have advanced greatly during the last decades, making post-market drug assessment an essential drug evaluation component. These methods mainly rely on the use of spontaneous reporting systems and health information databases to collect expertise from huge amounts of real-world reports. The EU-ADR Web Platform was built to further facilitate accessing, monitoring and exploring these data, enabling an in-depth analysis of adverse drug reactions risks. Methods: The EU-ADR Web Platform exploits the wealth of data collected within a large-scale European initiative, the EU-ADR project. Millions of electronic health records, provided by national health agencies, are mined for specific drug events, which are correlated with literature, protein and pathway data, resulting in a rich drug-event dataset. Next, advanced distributed computing methods are tailored to coordinate the execution of data-mining and statistical analysis tasks. This permits obtaining a ranked drug-event list, removing spurious entries and highlighting relationships with high risk potential. Results: The EU-ADR Web Platform is an open workspace for the integrated analysis of pharmacovigilance datasets. Using this software, researchers can access a variety of tools provided by distinct partners in a single centralized environment. Besides performing standalone drug-event assessments, they can also control the pipeline for an improved batch analysis of custom datasets. Drug-event pairs can be substantiated and statistically analysed within the platform's innovative working environment. Conclusions: A pioneering workspace that helps in explaining the biological path of adverse drug reactions was developed within the EU-ADR project consortium. This tool, targeted at the pharmacovigilance community, is available online at https://bioinformatics.ua.pt/euadr/. © 2013 John Wiley & Sons, Ltd.","Adverse drug reactions; Drug safety; in silico pharmacology; Pharmacoepidemiology; Pharmacovigilance","access to information; article; data mining; drug surveillance program; electronic medical record; human; medical information; medical literature; pharmacoepidemiology; postmarketing surveillance; priority journal; public health problem; work environment; Adverse Drug Reaction Reporting Systems; Data Mining; Databases, Factual; Europe; Humans; Internet; Pharmaceutical Preparations; Pharmacovigilance; Software",,"Pharmaceutical Preparations",,,,,,,"Giacomini, K.M., Krauss, R.M., Roden, D.M., Eichelbaum, M., Hayden, M.R., Nakamura, Y., When good drugs go bad (2007) Nature, 446, pp. 975-977; (2010), EMA. Annual Report. European Medicines Agency; Robb, M.A., Racoosin, J.A., Sherman, R.E., The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety (2012) Pharmacoepidemiol Drug Saf, 21, pp. 9-11; Xu, L., Anchordoquy, T., Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics (2011) J Pharm Sci, 100 (1), pp. 38-52; Nelson, J.C., Cook, A.J., Yu, O., Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data (2012) Pharmacoepidemiol Drug Saf, 21, pp. 62-71; Staffa, J.A., Dal Pan, G.J., Regulatory innovation in postmarketing risk assessment and management (2012) Clin Pharmacol Ther, 91 (3), pp. 555-557; Shibata, A., Hauben, M., (2011), pp. 1-7. , Pharmacovigilance, signal detection and signal intelligence. Proceedings of the 14th International Conference on Information Fusion (FUSION), 5-8 July; McClure, D.L., Improving drug safety: active surveillance systems should be paramount (2009) Pharmaceutical Medicine, 23 (3), pp. 127-130; Stahl, M., Edwards, I.R., Bowring, G., Kiuru, A., Lindquist, M., Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of national pharmacovigilance centres (2003) Drug Saf, 26 (10), pp. 721-727; Meyboom, R.H.B., Lindquist, M., Egberts, A.C.G., Edwards, I.R., Signal selection and follow-up in pharmacovigilance (2002) Drug Saf, 25 (6), pp. 459-465; Lazarou, J., Pomeranz, B.H., Corey, P.N., Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies (1998) JAMA, 279 (15), pp. 1200-1205; Alvarez-Requejo, A., Carvajal, A., Begaud, B., Moride, Y., Vega, T., Arias, L.H.M., Under-reporting of adverse drug reactions estimate based on a spontaneous reporting scheme and a sentinel system (1998) Eur J Clin Pharmacol, 54 (6), pp. 483-488; Grootheest, V., Attitudinal survey of voluntary reporting of adverse drug reactions (1999) Br J Clin Pharmacol, 48 (4), pp. 623-627; De Bruin, M., Van Puijenbroek, E., Egberts, A., Hoes, A., Leufkens, H., Non-sedating antihistamine drugs and cardiac arrhythmias-biased risk estimates from spontaneous reporting systems? (2002) Br J Clin Pharmacol, 53 (4), pp. 370-374; Wadman, M., Experts call for active surveillance of drug safety (2007) Nature, 446 (7134), pp. 358-359; Bauer-Mehren, A., van Mullingen, E.M., Avillach, P., Automatic filtering and substantiation of drug safety signals (2012) PLoS Comput Biol, 8 (4), pp. e1002457; Härmark, L., Van Grootheest, A.C., Pharmacovigilance: methods, recent developments and future perspectives (2008) Eur J Clin Pharmacol, 64 (8), pp. 743-752; Garcia-Serna, R., Mestres, J., Anticipating drug side effects by comparative pharmacology (2010) Expert Opin Drug Metab Toxicol, 6 (10), pp. 1253-1263; Mestres, J., Seifert, S.A., Oprea, T.I., Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome (2011) Clin Pharmacol Ther, 90 (5), pp. 662-665; Trifirò, G., Pariente, A., Coloma, P.M., Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? (2009) Pharmacoepidemiol Drug Saf, 18 (12), pp. 1176-1184; Ruttenberg, A., Clark, T., Bug, W., Advancing translational research with the Semantic Web (2007) BMC Bioinformatics, 8 (SUPPL 3), pp. S2-SS; Trifiro, G., Fourrier-Reglat, A., Sturkenboom, M.C.J.M., Diaz Acedo, C., Van Der Lei, J., Díaz Acedo, C., The EU-ADR project: preliminary results and perspective (2009) Stud Health Tech Informat, 148, pp. 43-49; Trontell, A.E., The RADAR Project and the FDA (2005) JAMA, 294 (10), p. 1206; Coloma, P.M., Trifirò, G., Schuemie, M.J., Electronic healthcare databases for active drug safety surveillance: is there enough leverage? (2012) Pharmacoepidemiol Drug Saf, 21 (6), pp. 611-621; Parkinson, J., Davis, S., Tv, S., The general practice research database: now and the future (2006) Pharmacovigilance, pp. 341-348. , RD Mann, amp; EB Andrews (eds.). John Wiley & Sons, Ltd: Chichester, UK; Wood, L., Martinez, C., The general practice research database: role in pharmacovigilance (2004) Drug Saf, 27 (12), pp. 871-881; Stark, R.G., John, J., Leidl, R., Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach (2011) BMC Health Serv Res, 11, p. 9; Chan, K.A., Hauben, M., Signal detection in pharmacovigilance: empirical evaluation of data mining tools (2005) Pharmacoepidemiol Drug Saf, 14 (9), pp. 597-599; Avillach, P., Mougin, F., Joubert, M., A semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project (2009) Stud Health Technol Inform, 150 (PART 2), pp. 190-194; Coloma, P.M., Schuemie, M.J., Trifirò, G., Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project (2011) Pharmacoepidemiol Drug Saf, 20, pp. 1-11; Trifirò, G., Patadia, V., Schuemie, M.J., EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection (2011) Stud Health Tech Informat, 166, pp. 25-30; McPhillips, T., Bowers, S., Zinn, D., Ludäscher, B., Scientific workflow design for mere mortals (2009) Future Generat Comput Syst, 25 (5), pp. 541-551; Oinn, T., Addis, M., Ferris, J., Taverna: a tool for the composition and enactment of bioinformatics workflows (2004) Bioinformatics, 20 (17), pp. 3045-3054; Avillach, P., Joubert, M., Thiessard, F., Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project (2010) Stud Health Technol Inform, 160 (PART 2), pp. 1085-1089; de Leon, J., Highlights of drug package inserts and the website DailyMed: the need for further improvement in package inserts to help busy prescribers (2011) J Clin Psychopharmacol, 31 (3), pp. 263-265; Wishart, D.S., Knox, C., Guo, A.C., DrugBank: a knowledgebase for drugs, drug actions and drug targets (2008) Nucleic Acids Res, 36 (SUPPL 1), pp. D901-D906; Ludascher, B., Altintas, I., Berkley, C., Taverna: scientific workflow management and the Kepler system (2006) Concurrency Comput Pract Ex, 18 (10), pp. 1039-1065; Zadeh, L.A., A simple view of the Dempster-Shafer theory of evidence and its implication for the rule of combination (1986) AI Mag, 7 (2), p. 85; Dudley, J.T., Butte, A.J., In silico research in the era of cloud computing (2010) Nat Biotechnol, 28 (11), pp. 1181-1185; Papay, J., Yuen, N., Powell, G., Mockenhaupt, M., Bogenrieder, T., Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications (2012) Pharmacoepidemiol Drug Saf, 21 (3), pp. 289-296; Sommet, A., Durrieu, G., Lapeyre-Mestre, M., Montastruc, J.-L., A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006 (2012) Pharmacoepidemiol Drug Saf, 21 (3), pp. 285-288. , The Association of French PharmacoVigilance C; Vilar, S., Harpaz, R., Chase, H.S., Costanzi, S., Rabadan, R., Friedman, C., Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis (2011) J Am Med Inform Assoc, 18, pp. i73-i80","Oliveira, J.L.; DETI/IEETA, University of Aveiro, 3810-193 Aveiro, Portugal; email: jlo@ua.pt",,,,,,,,10538569,,PDSAE,"23208789","English","Pharmacoepidemiol. Drug Saf.",Article,"Final",,Scopus,2-s2.0-84877591332
"Cases M., Pastor M., Sanz F.","56251049800;7102415847;7102263897;","The eTOX library of public resources for in silico toxicity prediction",2013,"Molecular Informatics","32","1",,"24","35",,7,"10.1002/minf.201200099","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873048924&doi=10.1002%2fminf.201200099&partnerID=40&md5=70f65a9838885e56fbefb2352f0d2248","Research Programme on Biomedical Informatics (GRIB), Dep. of Experimental and Health Sciences, Universitat Pompeu Fabra, C/ Dr. Aiguader 88, Barcelona, Spain","Cases, M., Research Programme on Biomedical Informatics (GRIB), Dep. of Experimental and Health Sciences, Universitat Pompeu Fabra, C/ Dr. Aiguader 88, Barcelona, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Dep. of Experimental and Health Sciences, Universitat Pompeu Fabra, C/ Dr. Aiguader 88, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Dep. of Experimental and Health Sciences, Universitat Pompeu Fabra, C/ Dr. Aiguader 88, Barcelona, Spain","(1000-1500 characters) In spite of the increasing amount of public access resources that offer original data related to drug toxicology, the successful exploitation of such data for the development of in silico predictive models is still limited by the quality of the data available, its integrability and its coverage for each toxicity endpoint. This work describes the strategy developed by the IMI eTOX consortium for identifying and compiling data and other related resources from the biomedical literature and a wide spectrum of public on-line sources. The main result of this effort is a large web-based structured library containing links to articles of toxicological relevance (data that can be used for modeling purposes, computational models, and toxicity mechanisms), public databases, standardized vocabularies and modeling tools. All this material has been manually reviewed, systematically evaluated and grouped into different categories. The library has been made public at the eTOX website (http://www.etoxproject.eu/), where it is updated on a monthly basis, constituting a useful resource for affording the in silico toxicity prediction of novel drug candidates. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.","Computational models; Data quality; Predictive models; Public resources; Toxicology data","computer model; data base; eTOX; linguistics; online system; prediction; priority journal; review; toxicology",,,"eTOX",,,,,,"http://www.ncbi.nlm.nih.gov/pubmed/, PubMed last accessed on October 31st; Hansen, K., (2009) J. Chem. Inf. Model., 499, pp. 2077-2081; http://www.emea.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/ epar_search.jsp&mid=WC0b01ac058001d124, EPAR last accessed on October 31st; http://www.ebi.ac.uk/, EMBL; http://www.chemspider.com/, last accessed on October 31st; http://www.openphacts.org/, last accessed on October 31st; http://www.caesar-project.eu/, Last accessed on October 31st; Hardy, B., (2010) J Cheminform, 2 (1), p. 7; http://pharmacogenetics.ucsf.edu, PMT last accessed on October 31st; http://www.imi.europa.eu, last accessed on October 31st; http://www.etoxproject.eu, last accessed on October 31st; Briggs, K., (2012) Int. J. Mol. Sci., 133, pp. 3820-3846; http://cadd.imim.es/etox-library, eTOX LIBRARY last accessed on October 31st; http://thomsonreuters.com/products_services/science/science_products/a-z/ isi_web_of_knowledge/, Thomson Reuters Web of Knowledge SM (formerly ISI Web of Knowledge) last accessed on October 31st; http://bioinformatics.oxfordjournals.org/, last accessed on October 31st; J. Chem. Inf. Model., , http://pubs.acs.org/journal/jcisd8/, last accessed on October 31st; http://www.nlm.nih.gov/bsd/pubmed_subsets/tox, PubMed Subset Strategies last accessed on October 31st; http://www.epa.gov/ncct/dsstox/index.html, DSSTox last accessed on October 31st; http://reni.item.fraunhofer.de/reni/public/rita/, RITA last accessed on October 31st; http://www.opentox.org/, last accessed on October 31st; http://www.acutetox.org/, last accessed on October 31st; http://www.cdisc.org/, last accessed on October 31st; http://www.caesar-project.eu/, last accessed on October 31st; http://www.ebi.ac.uk/chembl/, ChEMBL last accessed on October 31st; http://www.drugbank.ca/, last accessed on October 31st; http://www.cbs.dtu.dk/services/ChemProt, ChemProt last accessed on October 31st; http://cgl.imim.es/iphace/iPHACEdir/web/BCNcontents.html, iPHACE last accessed on October 31st; http://www.ncbi.nlm.nih.gov/geo/, Gene Expression Omnibus last accessed on October 31st; http://bioinf.xmu.edu.cn/databases/TiSGeD/index.html, TISGED last accessed on October 31st; https://ilab.acdlabs.com/iLab2/, ADME/Tox Web last accessed on October 31st; http://www.lmmd.org/database/, last accessed on October 31st; http://www.hmdb.ca/, last accessed on October 31st; http://prime.psc.riken.jp/?action=metabolites_index, KNApSAcK last accessed on October 31st; Williams, A.J., (2012) Drug Discov. Today, 17 (13-14), pp. 685-701; Fu, X., (2011) J. Cheminform., 31, pp. 24-39; http://www.cas.org/, last accessed on October 31st; http://www.iupac.org/home/publications/e-resources/inchi.html, InChiKey last accessed on October 31st; http://www.nlm.nih.gov/research/umls/, UMLS last accessed on October 31st; https://opentox.org/data/documents/development/tutorialfiles/toxpredict, ToxPredict last accessed on October 31st; http://insilicofirst.com/, last accessed on October 31st; https://www.lhasalimited.org/index.php/derek/, Derek last accessed on October 31st; http://www.biograf.ch/index.php?id=projects&subid=virtualtoxlab, VirtualToxLab last accessed on October 31st; http://uranus.fiehnlab.ucdavis.edu:8080/cts/homePage/index, Chemical Translation Service last accessed on October 31st; http://www.knime.org/introduction, last accessed on October 31st; http://www.whocc.no/atc_ddd_index/, ATC index last accessed on October 31st; http://www.ebi.ac.uk/chebi/, ChEBI last accessed on October 31st; http://www.scai.fraunhofer.de/en/business-research-areas/bioinformatics/ research-development/information-extraction-semantic-text-analysis/ named-entity-recognition/chem-corpora.html, CORPORA last accessed on October 31st; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc. htm, last accessed on October 31st; http://www.biosemantics.org/index.php?page=Jochem, Jochem last accessed on October 31st; http://bioportal.bioontology.org/, NCBO Bioportal last accessed on October 31st; http://www.obofoundry.org/; https://www.informatik.hu-berlin.de/forschung/gebiete/wbi/resources/ chemspot/chemspot/, ChemSpot last accessed on October 31st; http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/Demo/PubTator/, PubTator last accessed on October 31st; http://code.google.com/p/annotare/, Annotare last accessed on October 31st; http://www.oecd.org/dataoecd/33/37/37849783.pdf, last accessed on October 31st","Sanz, F.; Research Programme on Biomedical Informatics (GRIB), Dep. of Experimental and Health Sciences, Universitat Pompeu Fabra, C/ Dr. Aiguader 88, Barcelona, Spain; email: fsanz@imim.es",,,,,,,,18681743,,MIONB,,"English","Mol. Informatics",Review,"Final",,Scopus,2-s2.0-84873048924
"Maojo V., Fritts M., Martin-Sanchez F., De La Iglesia D., Cachau R.E., Garcia-Remesal M., Crespo J., Mitchell J.A., Anguita A., Baker N., Barreiro J.M., Benitez S.E., De La Calle G., Facelli J.C., Ghazal P., Geissbuhler A., Gonzalez-Nilo F., Graf N., Grangeat P., Hermosilla I., Hussein R., Kern J., Koch S., Legre Y., Lopez-Alonso V., Lopez-Campos G., Milanesi L., Moustakis V., Munteanu C., Otero P., Pazos A., Perez-Rey D., Potamias G., Sanz F., Kulikowski C.","55171738800;57206255066;6603119155;35242106300;7004318817;6507216549;36855359400;7406516978;23466228100;7201670001;7005345873;36647302900;23495177000;7006079736;7005878579;34769924200;6603635113;34975072100;57204413124;6507347158;55327482800;7202880832;56975881200;27171957700;6505807345;6507907876;7003682778;7003503719;35230297200;8437483200;7006526793;6506245444;6602507577;7102263897;7005149346;","Nanoinformatics: Developing new computing applications for nanomedicine",2012,"Computing","94","6",,"521","539",,16,"10.1007/s00607-012-0191-2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864573115&doi=10.1007%2fs00607-012-0191-2&partnerID=40&md5=1b2139f2dadf6fadc1d7d25f8c7aa274","Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; SAIC-Frederick Inc., National Cancer Institute at Frederick, Frederick, MD, United States; Health and Biomedical Informatics Research Laboratory Medical School-IBES, University of Melbourne, Parkville, VIC, Australia; Advanced Biomedical Computing Center, National Cancer Institute, SAIC-Frederick Inc., Frederick, MD, United States; Biomedical Informatics Department, University of Utah, Salt Lake City, UT, United States; Pacific Northwest National Laboratory, Richland, WA, United States; Department of Medical Informatics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Division of Pathway Medicine, Centre for Systems Biology Edinburgh, University of Edinburgh, Edinburgh, United Kingdom; Division of Medical Informatics, University Hospitals of Geneva, Geneva, Switzerland; Center for Bioinformatics and Molecular Simulation, Universidad de Talca, Talca, Chile; Department of Pediatric Oncology and Hematology, University of the Saarland, Homburg, Germany; Laboratoire d'Electronique et de Technologie de l'Information (LETI), MINATEC Campus, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Grenoble, France; Department of Medical Bioinformatics, Institute of Health Carlos III, Madrid, Spain; Information Technology Institute, Ministry of Communications and Information Technology, Cairo, Egypt; Department of Medical Statistics, Andrija Stampar School of Public Health, Zagreb University Medical School, Zagreb, Croatia; Health Informatics Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden; Health Grid Organization, Clermont-Ferrand, France; Institute of Biomedical Technology, National Research Council, Milan, Italy; Technical University of Crete, Chania, Crete, Greece; Institute of Computer Science, FORTH, Heraklion, Crete, Greece; Department of Information and Communication Technologies, University of A Coruña, A Coruna, Spain; Biomedical Informatics Research Programme (GRIB), IMIM, Universitat Pompeu Fabra, Barcelona, Spain; Department of Computer Science, Rutgers, State University of New Jersey, Newark, United States","Maojo, V., Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; Fritts, M., SAIC-Frederick Inc., National Cancer Institute at Frederick, Frederick, MD, United States; Martin-Sanchez, F., Health and Biomedical Informatics Research Laboratory Medical School-IBES, University of Melbourne, Parkville, VIC, Australia; De La Iglesia, D., Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; Cachau, R.E., Advanced Biomedical Computing Center, National Cancer Institute, SAIC-Frederick Inc., Frederick, MD, United States; Garcia-Remesal, M., Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; Crespo, J., Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; Mitchell, J.A., Biomedical Informatics Department, University of Utah, Salt Lake City, UT, United States; Anguita, A., Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; Baker, N., Pacific Northwest National Laboratory, Richland, WA, United States; Barreiro, J.M., Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; Benitez, S.E., Department of Medical Informatics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; De La Calle, G., Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; Facelli, J.C., Biomedical Informatics Department, University of Utah, Salt Lake City, UT, United States; Ghazal, P., Division of Pathway Medicine, Centre for Systems Biology Edinburgh, University of Edinburgh, Edinburgh, United Kingdom; Geissbuhler, A., Division of Medical Informatics, University Hospitals of Geneva, Geneva, Switzerland; Gonzalez-Nilo, F., Center for Bioinformatics and Molecular Simulation, Universidad de Talca, Talca, Chile; Graf, N., Department of Pediatric Oncology and Hematology, University of the Saarland, Homburg, Germany; Grangeat, P., Laboratoire d'Electronique et de Technologie de l'Information (LETI), MINATEC Campus, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Grenoble, France; Hermosilla, I., Department of Medical Bioinformatics, Institute of Health Carlos III, Madrid, Spain; Hussein, R., Information Technology Institute, Ministry of Communications and Information Technology, Cairo, Egypt; Kern, J., Department of Medical Statistics, Andrija Stampar School of Public Health, Zagreb University Medical School, Zagreb, Croatia; Koch, S., Health Informatics Centre, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden; Legre, Y., Health Grid Organization, Clermont-Ferrand, France; Lopez-Alonso, V., Department of Medical Bioinformatics, Institute of Health Carlos III, Madrid, Spain; Lopez-Campos, G., Department of Medical Bioinformatics, Institute of Health Carlos III, Madrid, Spain; Milanesi, L., Institute of Biomedical Technology, National Research Council, Milan, Italy; Moustakis, V., Technical University of Crete, Chania, Crete, Greece, Institute of Computer Science, FORTH, Heraklion, Crete, Greece; Munteanu, C., Department of Information and Communication Technologies, University of A Coruña, A Coruna, Spain; Otero, P., Department of Medical Informatics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Pazos, A., Department of Information and Communication Technologies, University of A Coruña, A Coruna, Spain; Perez-Rey, D., Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; Potamias, G., Institute of Computer Science, FORTH, Heraklion, Crete, Greece; Sanz, F., Biomedical Informatics Research Programme (GRIB), IMIM, Universitat Pompeu Fabra, Barcelona, Spain; Kulikowski, C., Department of Computer Science, Rutgers, State University of New Jersey, Newark, United States","Nanoinformatics has recently emerged to address the need of computing applications at the nano level. In this regard, the authors have participated in various initiatives to identify its concepts, foundations and challenges. While nanomaterials open up the possibility for developing new devices in many industrial and scientific areas, they also offer breakthrough perspectives for the prevention, diagnosis and treat- ment of diseases. In this paper, we analyze the different aspects of nanoinformatics and suggest five research topics to help catalyze new research and development in the area, particularly focused on nanomedicine.We also encompass the use of informatics to further the biological and clinical applications of basic research in nanoscience and nanotechnology, and the related concept of an extended ""nanotype"" to coalesce information related to nanoparticles. We suggest how nanoinformatics could accelerate developments in nanomedicine, similarly to what happened with the Human Genome and other -omics projects, on issues like exchanging modeling and simulationmethods and tools, linking toxicity information to clinical and personal databases or developing new approaches for scientific ontologies, among many others. © The Author(s) 2012.","Bioinformatics; Computing; Medical Informatics; Nanoinformatics; Nanomedicine; Nanotechnology","Basic research; Clinical application; Computing; Computing applications; Human genomes; Informatics; Medical informatics; Nanoinformatics; Nanoscience and nanotechnologies; New devices; Research and development; Research topics; Bioinformatics; Diagnosis; Information science; Nanoscience; Nanotechnology; Research; Medical nanotechnology",,,,,,,,,"Altman, R.B., Bioinformatics in support of molecular medicine (1998) Rev Proc AMIA Symp, 1998, pp. 53-61; Kulikowski, C.A., The micro-macro spectrum of medical informatics challenges: From molecular medicine to transforming health care in a globalizing society (2002) Methods Inf Med, 41 (1), pp. 20-24; Kohane, I.S., Bioinformatics and clinical informatics: The imperative to collaborate (2000) J Am Med Inform Assoc, 7 (5), pp. 512-516; Maojo, V., Kulikowski, C.A., Bioinformatics and medical informatics: Collaborations on the road to genomic medicine? (2003) J Am Med Inform Assoc, 10 (6), pp. 515-522; Maojo, V., Iakovidis, I., Martin-Sanchez, F., Medical informatics and bioinformatics: European efforts to facilitate synergy (2001) J Biomed Inform, 34 (6), pp. 423-427; Martin-Sanchez, F., Iakovidis, I., Nørager, S., Maojo, V., DeGroen, P., Van Der Lei, J., Jones, T., Vicente, F.J., Synergy between medical informatics and bioinformatics: Facilitating genomic medicine for future health care (2004) J Biomed Inform, 37 (1), pp. 30-42; Kulikowski, C., Weiss, S., (1971) Computer-based Models of Glaucoma, , Report no. 3, Department of Computer Science, Computers in Biomedicine. Rutgers University, New Brunswick; Kim, B.Y., Rutka, J.T., Chan, W.C., Nanomedicine (2010) N Engl J Med, 363 (25), pp. 2434-2443; Doms A Schroeder, M., Gopubmed: Exploring pubmed with the gene ontology (2005) Nucleic Acids Res, 33, pp. W783-W786. , http://www.gopubmed.org/, Accessed 14 November 2011; Maojo, V., Garcia-Remesal, M., De La Iglesia, D., Crespo, J., Perez-Rey, D., Chiesa, S., Fritts, M., Kulikowski, C.A., Nanoinformatics: Developing advanced informatics applications for nanomedicine (2011) Intracellular Delivery: Fundamentals and Applications (Fundamental Biomedical Technologies), , In: Prokov A (ed) Springer, NY; Maojo, V., Martin-Sanchez, F., Kulikowski, C., Nanoinformatics and dna-based computing: Catalyzing nanomedicine (2010) Pediatr Res, 67 (5), pp. 481-489; Freitas, R.A., (1999) Nanomedicine, , http://www.nanomedicine.com/NMI.htm, Basic Capabilities, vol I. Landes Bioscience, Georgetown Accessed June 2011; Freitas, R.A., (2003) Nanomedicine, , http://www.nanomedicine.com/NMIIA.htm, Biocompatibility, vol IIA. Landes Bioscience, Georgetown Accessed June 2011; Jain, K., (2008) The handbook of Nanomedicine, pp. 161-192. , Humana Press, NJ; Thomas, D.G., Pappu, R.V., Baker, N.A., Nanoparticle ontology for cancer nanotechnology research (2011) J Biomed Inform, 44 (1), pp. 59-74; Rosse, C., Mejino, J.V.L., Areference ontology for biomedical informatics: The foundationalmodel of anatomy (2003) J Biomed Inform, 36, pp. 478-500; (2007), http://128.119.56.118/~nnn01/Workshop.html, Workshop on Nanoinformatics Strategies. National Science Foundation. Arlington, Virginia Last access June 2011. Accessed Feb 2011; (2010) Nanoinformatics 2010: A Collaborative Roadmaping Workshop, , http://nanotechinformatics.org/, National Science Foundation November 3-5, 2010. Arlington, Virginia (USA). Accessed Feb 2011; Baker, N.A., Fritts, M., Guccione, S., (2009) Nanotechnology Informatics White Paper, , US National Cancer Institute, Bethesda; Dela Iglesia, D., Maojo, V., Chiesa, S., International efforts in nanoinformatics research applied to nanomedicine (2011) Methods Inf Med, 50 (1), pp. 84-95; Kiberstis, P., Roberts, L., It's not just the genes (2002) Science, 296 (5568), p. 685; Green, E.D., Guyer, M.S., Charting a course for genomic medicine from base pairs to bedside (2011) Nature, 470 (7333), pp. 204-213. , National Human Genome Research Institute; (2011), http://www.ncbi.nlm.nih.gov/sites/entrez, PubMed. U.S. National Library of Medicine. National Institutes of Health. Accessed Nov; Gordon N Sagman, U., (2003) Nanomedicine Taxonomy, , Canadian Institute of Health Research&Canadian NanoBusiness Alliance, Canada; Smith, B., Ashburner, M., Rosse, C., The obo foundry: Coordinated evolution of ontologies to support biomedical data integration (2007) Nat Biotechnol, 25 (11), pp. 1251-1255; De La Calle, G., García-Remesal, M., Chiesa, S., Biri: A new approach for automatically discovering and indexing available public bioinformatics resources from the literature (2009) BMC Bioinform, 10, p. 320; (2011), http://www.elsevier.com/wps/find/journaldescription.cws_home/622857/ description, Accessed Nov; Viceconti, M., Clapworthy, G., Van Sint Jan, S., The virtual physiological human-A european initiative for in silico human modelling (2008) J Physiol Sci, 58 (7), pp. 441-446; (2009), http://nanohub.org/, Network for Computational Nanotechnology, National Science Foundation NanoHub. Accessed June 2011; (2011), https://cananolab.nci.nih.gov/caNanoLab/, CaNanoLab. National Cancer Institute. National Institutes of Health. Accessed Mar; (2011) Collaboratory for Structural Nanobiology (CSN), , http://csn.ncifcrf.gov/, Accessed June; Munteanu, C.R., Convergence of bioinformatics with nanotechnology and artificial intelligence technologies (2011) Current Bioinformatics, 6 (2), p. 144. , In: Munteanu CR (ed) special issue, Bentham Science Publishers Ltd., Sharjah; Gerstein, M., Seringhaus, M., Fields, S., Structured digital abstract makes text mining easy (2007) Nature, 447 (7141), p. 142; Maojo, V., Crespo, J., García-Remesal, M., Biomedical ontologies: Toward scientific debate (2011) Methods Inf Med, 50 (3), pp. 203-216; Bewick, S., Yang R ZhangM, Complex mathematical models of biology at the nanoscale (2009) Wileyi Interdiscipl Rev Nanomed Nanobiotechnol, 1 (6), pp. 650-659; O'Donoghue, S.I., Goodsell, D.S., Frangakis, A.S., Visualization of macromolecular structures (2010) Nat Methods, 7 (3), pp. S42-S55; Berman, H., Henrick, K., Nakamura, H., Announcing the worldwide protein data bank (2003) Nat Struct Biol, 10 (12), p. 980; Maojo, V., Martín-Sánchez, F., (2010) The ACTION-Grid White Paper: Linking Biomedical Informatics, Grid Computing and Nanomedicine, , http://www.action-grid.eu/index.php?url=whitepaper, Accessed Nov 2011","Maojo, V.; Biomedical Informatics Group, Departamento de Inteligencia Artificial, Universidad Politècnica de Madrid, Boadilla del Monte, 28660 Madrid, Spain; email: vmaojo@fi.upm.es",,,,,,,,0010485X,,CMPTA,,"English","Comput.",Article,"Final",Open Access,Scopus,2-s2.0-84864573115
"Beck T., Gollapudi S., Brunak S., Graf N., Lemke H.U., Dash D., Buchan I., D́iaz C., Sanz F., Brookes A.J.","56344946200;55173896100;7005477388;34975072100;24565412500;7005335003;35594260500;57197180745;7102263897;7005962229;","Knowledge engineering for health: A new discipline required to bridge the ""ICT Gap"" between research and healthcare",2012,"Human Mutation","33","5",,"797","802",,19,"10.1002/humu.22066","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864340298&doi=10.1002%2fhumu.22066&partnerID=40&md5=4c3976e85a77aba3c58d2c6a76a95cc4","Department of Genetics, University of Leicester, Leicester, United Kingdom; Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark; Department of Disease Systems Biology, The Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark; Department of Pediatric Oncology, University of Saarland Medical School, Homburg, Saar, Germany; International Foundation for Computer-Assisted Radiology and Surgery, Kuessaberg, Germany; GNR Knowledge Center for Genome Informatics, Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, Delhi, India; North West Institute for BioHealth Informatics, University of Manchester, Manchester, United Kingdom; European Projects Management and Coordination Office, FundaciÓ IMIM, Barcelona, Spain; Research Programme on Biomedical Informatics, IMIM-Hospital del Mar, Pompeu Fabra University, Barcelona, Spain","Beck, T., Department of Genetics, University of Leicester, Leicester, United Kingdom; Gollapudi, S., Department of Genetics, University of Leicester, Leicester, United Kingdom; Brunak, S., Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark, Department of Disease Systems Biology, The Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark; Graf, N., Department of Pediatric Oncology, University of Saarland Medical School, Homburg, Saar, Germany; Lemke, H.U., International Foundation for Computer-Assisted Radiology and Surgery, Kuessaberg, Germany; Dash, D., GNR Knowledge Center for Genome Informatics, Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, Delhi, India; Buchan, I., North West Institute for BioHealth Informatics, University of Manchester, Manchester, United Kingdom; D́iaz, C., European Projects Management and Coordination Office, FundaciÓ IMIM, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics, IMIM-Hospital del Mar, Pompeu Fabra University, Barcelona, Spain; Brookes, A.J., Department of Genetics, University of Leicester, Leicester, United Kingdom","Despite vast amount of money and research being channeled toward biomedical research, relatively little impact has been made on routine clinical practice. At the heart of this failure is the information and communication technology ""chasm"" that exists between research and healthcare. A new focus on ""knowledge engineering for health"" is needed to facilitate knowledge transmission across the research-healthcare gap. This discipline is required to engineer the bidirectional flow of data: processing research data and knowledge to identify clinically relevant advances and delivering these into healthcare use; conversely, making outcomes from the practice of medicine suitably available for use by the research community. This system will be able to self-optimize in that outcomes for patients treated by decisions that were based on the latest research knowledge will be fed back to the research world. A series of meetings, culminating in the ""I-Health 2011"" workshop, have brought together interdisciplinary experts to map the challenges and requirements for such a system. Here, we describe the main conclusions from these meetings. An ""I4Health"" interdisciplinary network of experts now exists to promote the key aims and objectives, namely ""integrating and interpreting information for individualized healthcare,"" by developing the ""knowledge engineering for health"" domain. © 2012 Wiley Periodicals, Inc.","Biomedical research; Healthcare; I-Health 2011; ICT; Personalized medicine","article; bioinformatics; cooperation; data processing; health care; information processing; information technology; interdisciplinary communication; knowledge; knowledge engineering for health; medical research; personalized medicine; priority journal; standardization; consensus development; data base; electronic medical record; human; information system; medical informatics; personalized medicine; Consensus Development Conferences as Topic; Databases as Topic; Humans; Individualized Medicine; Information Management; Interdisciplinary Communication; Medical Informatics; Medical Records Systems, Computerized",,,,,,,,,"Adamusiak, T., Parkinson, H., Muilu, J., Roos, E., van der Velde, K.J., Thorisson, G.A., Byrne, M., Swertz, M.A., Observ-OM and Observ-TAB: Universal Syntax Solutions for the Integration, Search, and Exchange of Phenotype And Genotype Information (2012) Hum Mut, 33, pp. 867-873; Coloma, P.M., Schuemie, M.J., Trifiro, G., Gini, R., Herings, R., Hippisley-Cox, J., Mazzaglia, G., Sturkenboom, M., Combining electronic healthcare databases in europe to allow for large-scale drug safety monitoring: the EU-ADR project (2011) Pharmacoepidemiol Drug Saf, 20, pp. 1-11. , EU-ADR Consortium; Feigenbaum, E.A., Mc Corduck, P., The fifth generation: artificial intelligence and Japan's computer challenge to the world (1983), Reading, MA.: Addison-Wesley; Fortier, I., Burton, P.R., Robson, P.J., Ferretti, V., Little, J., L'Heureux, F., Deschenes, M., Harris, J.R., Quality, quantity and harmony: the Data SHa PER approach to integrating data across bioclinical studies (2010) Int J Epidemiol, 39, pp. 1383-1393; Hamilton, C.M., Strader, L.C., Pratt, J.G., Maiese, D., Hendershot, T., Kwok, R.K., Hammond, J.A., Beaty, T.H., The Phen X toolkit: get the most from your measures (2011) Am J Epidemiol, 174, pp. 253-260; Seven days: 2-8 December 2011 (2011) Nature, 480, pp. 156-157. , Nature; Poste, G., Bring on the biomarkers (2011) Nature, 469, pp. 156-157; Rayner, T.F., Rocca-Serra, P., Spellman, P.T., Causton, H.C., Farne, A., Holloway, E., Irizarry, R.A., Quackenbush, J., A simple spreadsheet-based, MIAME-supportive format for microarray data: MAGE-TAB BMC Bioinformatics, 7, p. 489","Brookes, A.J.; Department of Genetics, University of Leicester, University Road, Leicester LE1 7RH, United Kingdom; email: ajb97@le.ac.uk",,,,,,,,10597794,,HUMUE,"22392843","English","Hum. Mutat.",Article,"Final",,Scopus,2-s2.0-84864340298
"Bauer-Mehren A., van Mullingen E.M., Avillach P., del Carmen Carrascosa M., Garcia-Serna R., Piñero J., Singh B., Lopes P., Oliveira J.L., Diallo G., Ahlberg Helgee E., Boyer S., Mestres J., Sanz F., Kors J.A., Furlong L.I.","35572639000;55220180500;23972137300;55220179400;8680442600;55220852900;57199778724;55538753378;57193360895;24398462100;48361046900;55913555400;7004586125;7102263897;7005293297;34770469800;","Automatic filtering and substantiation of drug safety signals",2012,"PLoS Computational Biology","8","4", e1002457,"","",,28,"10.1371/journal.pcbi.1002457","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84861122386&doi=10.1371%2fjournal.pcbi.1002457&partnerID=40&md5=bbdd29964e3adc0818e460ccee8b593d","Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain; Erasmus University Medical Center, Rotterdam, Netherlands; LESIM-ISPED, Université de Bordeaux, Bordeaux, France; LERTIM, EA 3283, Faculté de Médecine, Université de Aix-Marseille, Marseille, France; DETI/IEETA, Universidade de Aveiro, Aveiro, Portugal; AstraZeneca, Mölndal, Sweden","Bauer-Mehren, A., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain; van Mullingen, E.M., Erasmus University Medical Center, Rotterdam, Netherlands; Avillach, P., LESIM-ISPED, Université de Bordeaux, Bordeaux, France, LERTIM, EA 3283, Faculté de Médecine, Université de Aix-Marseille, Marseille, France; del Carmen Carrascosa, M., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain; Garcia-Serna, R., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain; Piñero, J., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain; Singh, B., Erasmus University Medical Center, Rotterdam, Netherlands; Lopes, P., DETI/IEETA, Universidade de Aveiro, Aveiro, Portugal; Oliveira, J.L., DETI/IEETA, Universidade de Aveiro, Aveiro, Portugal; Diallo, G., LESIM-ISPED, Université de Bordeaux, Bordeaux, France; Ahlberg Helgee, E., AstraZeneca, Mölndal, Sweden; Boyer, S., AstraZeneca, Mölndal, Sweden; Mestres, J., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain; Kors, J.A., Erasmus University Medical Center, Rotterdam, Netherlands; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain","Drug safety issues pose serious health threats to the population and constitute a major cause of mortality worldwide. Due to the prominent implications to both public health and the pharmaceutical industry, it is of great importance to unravel the molecular mechanisms by which an adverse drug reaction can be potentially elicited. These mechanisms can be investigated by placing the pharmaco-epidemiologically detected adverse drug reaction in an information-rich context and by exploiting all currently available biomedical knowledge to substantiate it. We present a computational framework for the biological annotation of potential adverse drug reactions. First, the proposed framework investigates previous evidences on the drug-event association in the context of biomedical literature (signal filtering). Then, it seeks to provide a biological explanation (signal substantiation) by exploring mechanistic connections that might explain why a drug produces a specific adverse reaction. The mechanistic connections include the activity of the drug, related compounds and drug metabolites on protein targets, the association of protein targets to clinical events, and the annotation of proteins (both protein targets and proteins associated with clinical events) to biological pathways. Hence, the workflows for signal filtering and substantiation integrate modules for literature and database mining, in silico drug-target profiling, and analyses based on gene-disease networks and biological pathways. Application examples of these workflows carried out on selected cases of drug safety signals are discussed. The methodology and workflows presented offer a novel approach to explore the molecular mechanisms underlying adverse drug reactions. © 2012 Bauer-Mehren et al.",,"cisapride; drug metabolite; haloperidol; neuroleptic agent; olanzapine; pimozide; potassium channel hEAG1; potassium channel HERG; quetiapine; sulpiride; unclassified drug; voltage gated calcium channel; ziprasidone; article; ATP binding cassette subfamily B member 1 gene; bioinformatics; calcium channel voltage dependent L type alpha 1C subunit gene; cardiovascular risk; computer model; data base; data mining; drug activity; drug mechanism; drug metabolism; drug safety; gene; heart muscle potential; human; intracellular signaling; mathematical model; medical literature; molecular interaction; pharmacogenetics; potassium voltage gated channel subfamily H eag related member 1 gene; potassium voltage gated channel subfamily H eag related member 2 gene; protein interaction; QT prolongation; signal filtering; signal processing; signal substantiation; torsade des pointes; biological model; classification; computer simulation; data base; documentation; drug toxicity; factual database; information retrieval; methodology; register; Computer Simulation; Database Management Systems; Databases, Factual; Documentation; Drug Toxicity; Humans; Information Storage and Retrieval; Models, Biological; Registries",,"cisapride, 81098-60-4; haloperidol, 52-86-8; olanzapine, 132539-06-1; pimozide, 2062-78-4; quetiapine, 111974-72-2; sulpiride, 15676-16-1; ziprasidone, 118289-78-4, 122883-93-6, 138982-67-9, 199191-69-0",,,,,,,"Giacomini, K.M., Krauss, R.M., Roden, D.M., Eichelbaum, M., Hayden, M.R., When good drugs go bad (2007) Nature, 446, pp. 975-977; Lazarou, J., Pomeranz, B.H., Corey, P.N., Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies (1998) JAMA, 279, pp. 1200-1205; van der Hooft, C.S., Sturkenboom, M.C., van Grootheest, K., Kingma, H.J., Stricker, B.H., Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands (2006) Drug Saf, 29, pp. 161-168; Stark, R.G., John, J., Leidl, R., Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach (2011) BMC Health Serv Res, 11, p. 9; Wu, T.Y., Jen, M.H., Bottle, A., Molokhia, M., Aylin, P., Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009 (2010) J R Soc Med, 103, pp. 239-250; Härmark, L., Grootheest, A.C., Pharmacovigilance: methods, recent developments and future perspectives (2008) Eur J Clin Pharmacol, 64, pp. 743-752; Trifiro, G., Fourrier-Réglat, A., Sturkenboom, M.C., Diaz Acedo, C., van der Lei, J., The EU-ADR project: preliminary results and perspective (2009) Stud Health Technol Inform, 148, pp. 43-49; Coloma, P.M., Schuemie, M.J., Trifiro, G., Gini, R., Herings, R., Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project (2011) Pharmacoepidemiol Drug Saf, 20, pp. 1-11; Gurwitz, D., Motulsky, A.G., Drug reactions, enzymes, and biochemical genetics': 50 years later (2007) Pharmacogenomics, 8, pp. 1479-1484; Beutler, E., Drug-induced hemolytic anemia (1969) Pharmacol Rev, 21, pp. 73-103; Ekins, S., Predicting undesirable drug interactions with promiscuous proteins in silico (2004) Drug Discov Today, 9, pp. 276-285; Vane, J.R., Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs (1971) Nat New Biol, 231, pp. 232-235; Kawai, S., Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: A clinical consideration (1998) Inflamm Res, 47, pp. 102-106; Higashi, M.K., Veenstra, D.L., Kondo, L.M., Wittkowsky, A.K., Srinouanprachanh, S.L., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy (2002) JAMA, 287, pp. 1690-1698; Chiang, A.P., Butte, A.J., Data-Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events (2009) Clin Pharmacol Ther, 85, pp. 259-268; Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose (2009) PLoS Genet, 5, pp. e1000433; Howard, L.A., Miksys, S., Hoffmann, E., Mash, D., Tyndale, R.F., Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics (2003) Br J Pharmacol, 138, pp. 1376-1386; Ruttenberg, A., Clark, T., Bug, W., Samwald, M., Bodenreider, O., Advancing translational research with the Semantic Web (2007) BMC Bioinformatics, 8, pp. S2; Louie, B., Mork, P., Martin-Sanchez, F., Halevy, A., Tarczy-Hornoch, P., Data integration and genomic medicine (2007) J Biomed Inf, 40, pp. 5-16; Philippi, S., Kohler, J., Addressing the problems with life-science databases for traditional uses and systems biology (2006) Nat Rev Genet, 7, pp. 482-488; Antezana, E.Z., Kuiper, M., Mironov, V., Biological knowledge management: the emerging role of the Semantic Web technologies (2009) Brief Bioinform, 10, pp. 392-407; Mestres, J., Gregori-Puigjane, E., Valverde, S., Sole, R.V., Data completeness-the Achilles heel of drug-target networks (2008) Nat Biotechnol, 26, pp. 983-984; Gil, Y., Deelman, E., Ellisman, M., Fahringer, T., Fox, G., Examining the Challenges of Scientific Workflows (2007) Computer, 40, pp. 24-32; Oinn, T., Addis, M., Ferris, J., Marvin, D., Greenwood, M., Taverna: a tool for the composition and enactment of bioinformatics workflows (2004) Bioinformatics, 20, pp. 3045-3054; Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L.J., Bork, P., Drug target identification using side-effect similarity (2008) Science, 321, pp. 263-266; Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Cytoscape: a software environment for integrated models of biomolecular interaction networks (2003) Genome Res, 13, pp. 2498-2504; Wishart, D.S., Knox, C., Guo, A.C., Cheng, D., Shrivastava, S., DrugBank: a knowledgebase for drugs, drug actions and drug targets (2008) Nucleic Acids Res, 36, pp. D901-D906; Ray, W.A., Chung, C.P., Murray, K.T., Hall, K., Stein, C.M., Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death (2009) New Engl J Med, 360, pp. 225-235; Montout, C., Casadebaig, F., Lagnaoui, R., Verdoux, H., Philippe, A., Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients (2002) Schizophr Res, 57, pp. 147-156; Abdelmawla, N., Mitchell, A.J., Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms (2006) Adv Psychiatr Treat, 12, pp. 35-44; Hoffmann, P., Warner, B., Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends (2006) J Pharmacol Toxicol Methods, 53, pp. 87-105; Berger, S.I., Ma'ayan, A., Iyengar, R., Systems pharmacology of arrhythmias (2010) Science Signaling, 3, pp. ra30; Sicouri, S., Antzelevitch, C., Sudden cardiac death secondary to antidepressant and antipsychotic drugs (2008) Expert Opin Drug Saf, 7, pp. 181-194; Ocorr, K., Reeves, N.L., Wessells, R.J., Fink, M., Chen, H.S., KCNQ potassium channel mutations cause cardiac arrhythmias in Drosophila that mimic the effects of aging (2007) Proc Natl Acad Sci U S A, 104, pp. 3943-3948; Xie, L., Wang, J., Bourne, P.E., In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators (2007) PLoS Comp Biol, 3, pp. e217; Bodenreider, O., The Unified Medical Language System (UMLS): integrating biomedical terminology (2004) Nucl Acids Res, 32, pp. D267-D270; Swanson, D.R., Fish oil, Raynaud's syndrome, and undiscovered public knowledge (1986) Perspect Biol Med, 30, pp. 7-18; Garcia-Serna, R., Mestres, J., Anticipating drug side effects by comparative pharmacology (2010) Expert Opin Drug Metab Toxicol, 6, pp. 1253-1263; Bauer-Mehren, A., Rautschka, M., Sanz, F., Furlong, L.I., DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks (2010) Bioinformatics, 26, pp. 2924-2926; Lenz, W., Phenocopy (1970) Hum Genet, 9, pp. 227-229; Hedley, P.L., Jorgensen, P., Schlamowitz, S., Wangari, R., Moolman-Smook, J., The genetic basis of long QT and short QT syndromes: a mutation update (2009) Hum Mutat, 30, pp. 1486-1511; Kannankeril, P.J., Roden, D.M., Drug-induced long QT and torsade de pointes: recent advances (2007) Curr Opin Cardiol, 22, pp. 39-43; Borda, T.G., Cremaschi, G., Sterin-Borda, L., Haloperidol-mediated phosphoinositide hydrolysis via direct activation of alpha1-adrenoceptors in frontal cerebral rat cortex (1999) Can J Physiol Pharmacol, 77, pp. 22-28; Furberg, C.D., Pitt, B., Withdrawal of cerivastatin from the world market (2001) Curr Control Trials Cardiovasc Med, 2, pp. 205-207; Taniguchi, C.M., Armstrong, S.R., Green, L.C., Golan, D.E., Tashjian Jr., A.H., (2007) Drug Toxicity. Pharmacology: The Pathophysiologic Basis of Drug Therapy, , Philadelphia, PA, Lippincott Williams & Wilkins, 2 Ed; Avillach, P., Joubert, M., Thiessard, F., Trifirò, G., Dufour, J.-C., Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project (2010) Stud Health Technol Inform, 160, pp. 1085-1090; Schuemie, M.J., Jelier, R., Kors, J.A., Peregrine: Lightweight gene name normalization by dictionary lookup (2007) Second BioCreative Challenge Evaluation Workshop, pp. 131-133; Vastrik, I., D'Eustachio, P., Schmidt, E., Joshi-Tope, G., Gopinath, G., Reactome: a knowledge base of biologic pathways and processes (2007) Genome Biol, 8, pp. R39; Bauer-Mehren, A., Furlong, L.I., Sanz, F., Pathway databases and tools for their exploitation: benefits, current limitations and challenges (2009) Mol Syst Biol, 5, p. 290; Uhlén, M., Björling, E., Agaton, C., Szigyarto, C.A.-K., Amini, B., A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics (2005) Mol Cell Proteomics, 4, pp. 1920-1932; Trifiro, G., Pariente, A., Coloma, P.M., Kors, J.A., Polimeni, G., Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? (2009) Pharmacoepidemiol Drug Saf, 18, pp. 1176-1184; Avillach, P., Mougin, F., Joubert, M., Thiessard, F., Pariente, A., A semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European eu-ADR project (2009) Stud Health Technol Inform, 150, pp. 190-194; Cases, M., García-Serna, R., Hettne, K., Weeber, M., van der Lei, J., Chemical and biological profiling of an annotated compound library directed to the nuclear receptor family (2005) Curr Top Med Chem, 5, pp. 763-772","Furlong, L. I.; Research Programme on Biomedical Informatics (GRIB), IMIM-Hospital del Mar Research Institute, DCEX, Universitat Pompeu Fabra, Barcelona, Spain; email: lfurlong@imim.es",,,,,,,,1553734X,,,"22496632","English","PLoS Comput. Biol.",Article,"Final",Open Access,Scopus,2-s2.0-84861122386
"Briggs K., Cases M., Heard D.J., Pastor M., Pognan F., Sanz F., Schwab C.H., Steger-Hartmann T., Sutter A., Watson D.K., Wichard J.D.","23979276700;56251049800;54583427800;7102415847;6602679901;7102263897;13205406700;6603592872;36942617100;55143373500;6506429877;","Inroads to predict in vivo toxicology-an introduction to the eTOX project",2012,"International Journal of Molecular Sciences","13","3",,"3820","3846",,45,"10.3390/ijms13033820","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858976293&doi=10.3390%2fijms13033820&partnerID=40&md5=dddaac4f1c5cde5c9701525b43d55ff6","Woodhouse Lane Lhasa Ltd., 22-23 Blenheim Terrace, Leeds, LS2 9HD, United Kingdom; Research Programme on Biomedical Informatics (GRIB), Fundació IMIM, Universitat Pompeu Fabra PRBB, Dr. Aiguader 88, 08003 Barcelona, Spain; Department of Preclinical Safety, Novartis Institutes for Biomedical Research (NIBR), Postfach CH-4002, Basel, Switzerland; Molecular Networks GmbH, IZMP, Henkestr. 91, 91052 Erlangen, Germany; Bayer HealthCare, Investigational Toxicology, Müllerstr. 178, 13353 Berlin, Germany","Briggs, K., Woodhouse Lane Lhasa Ltd., 22-23 Blenheim Terrace, Leeds, LS2 9HD, United Kingdom; Cases, M., Research Programme on Biomedical Informatics (GRIB), Fundació IMIM, Universitat Pompeu Fabra PRBB, Dr. Aiguader 88, 08003 Barcelona, Spain; Heard, D.J., Department of Preclinical Safety, Novartis Institutes for Biomedical Research (NIBR), Postfach CH-4002, Basel, Switzerland; Pastor, M., Research Programme on Biomedical Informatics (GRIB), Fundació IMIM, Universitat Pompeu Fabra PRBB, Dr. Aiguader 88, 08003 Barcelona, Spain; Pognan, F., Department of Preclinical Safety, Novartis Institutes for Biomedical Research (NIBR), Postfach CH-4002, Basel, Switzerland; Sanz, F., Research Programme on Biomedical Informatics (GRIB), Fundació IMIM, Universitat Pompeu Fabra PRBB, Dr. Aiguader 88, 08003 Barcelona, Spain; Schwab, C.H., Molecular Networks GmbH, IZMP, Henkestr. 91, 91052 Erlangen, Germany; Steger-Hartmann, T., Bayer HealthCare, Investigational Toxicology, Müllerstr. 178, 13353 Berlin, Germany; Sutter, A., Bayer HealthCare, Investigational Toxicology, Müllerstr. 178, 13353 Berlin, Germany; Watson, D.K., Woodhouse Lane Lhasa Ltd., 22-23 Blenheim Terrace, Leeds, LS2 9HD, United Kingdom; Wichard, J.D., Bayer HealthCare, Investigational Toxicology, Müllerstr. 178, 13353 Berlin, Germany","There is a widespread awareness that the wealth of preclinical toxicity data that the pharmaceutical industry has generated in recent decades is not exploited as efficiently as it could be. Enhanced data availability for compound comparison (""read-across""), or for data mining to build predictive tools, should lead to a more efficient drug development process and contribute to the reduction of animal use (3Rs principle). In order to achieve these goals, a consortium approach, grouping numbers of relevant partners, is required. The eTOX (""electronic toxicity"") consortium represents such a project and is a public-private partnership within the framework of the European Innovative Medicines Initiative (IMI). The project aims at the development of in silico prediction systems for organ and in vivo toxicity. The backbone of the project will be a database consisting of preclinical toxicity data for drug compounds or candidates extracted from previously unpublished, legacy reports from thirteen European and European operation-based pharmaceutical companies. The database will be enhanced by incorporation of publically available, high quality toxicology data. Seven academic institutes and five small-to-medium size enterprises (SMEs) contribute with their expertise in data gathering, database curation, data mining, chemoinformatics and predictive systems development. The outcome of the project will be a predictive system contributing to early potential hazard identification and risk assessment during the drug development process. The concept and strategy of the eTOX project is described here, together with current achievements and future deliverables. copy; 2012 by the authors; licensee MDPI, Basel, Switzerland.","Computational models; Data integration; Data sharing; Decision support system; Expert systems; Histopathology; In silico toxicity; In vitro toxicity; In vivo toxicity; Knowledge management; Manual curation; Ontology; Predictive toxicology; QSAR","animal testing reduction; awareness; computer model; data base; data extraction; data mining; drug development; drug industry; electronic toxicity consortium; eTOX project; hazard; in vivo study; in vivo toxicity; information science; prediction; public-private partnership; review; risk assessment; toxicity; toxicology; adverse drug reaction; animal; drug screening; expert system; factual database; human; information dissemination; knowledge base; Animalia; Animals; Data Mining; Databases, Factual; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Expert Systems; Humans; Information Dissemination; Knowledge Bases; Risk Assessment",,,,,,,,,"Non-Clinical Safety Studies For the Conduct of Human Clinical Trials and Marketing Authorization For Pharmaceuticals CPMP/ICH/286/95, , http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf, ICH Topic M 3 (R2), accessed on 19 September 2011; Federsel, H.J., Handing Over the Baton: Connecting Medicinal Chemistry with Process R&D (2008) Drug News Perspect, 21, pp. 193-199; Car, B., Enabling Technologies in Reducing Drug Attrition Due to Safety Failures (2006) Int. Drug Disc, 1, pp. 53-56; Morelli, J.K., Buehrle, M., Pognan, F., Barone, L., Fieles, W., Ciaccio, P.J., Validation of an in vitro screen for phopholipidosis using a high content biology platform (2006) Cell Biol. Toxicol, 22, pp. 15-27; Hancox, J.C., McPate, M.J., el Harchi, A., Zhang, Y.H., The hERG potassium channel and hERG screening for drug-induced Torsades de Pointes (2008) Pharmacol. Ther, 119, pp. 118-132; Naven, R.T., Louise-May, S., Greene, N., The computational prediction of genotoxicity (2010) Expert Opin. Drug Metab. Toxicol, 6, pp. 797-807; Mekenyan, O., Patlewicz, G., Dimitrova, G., Kuseva, C., Todorov, M., Stoeva, S., Kotov, S., Donner, E.M., Use of Genotoxicity Information in the Development of Integrated Testing Strategies (ITS) for Skin Sensitization (2010) Chem. Res. Toxicol, 23, pp. 1519-1540; Obiol-Pardo, C., Gomis-Tena, J., Sanz, F., Saiz, J., Pastor, M., A multiscale simulation system for the prediction of drug-induced cardiotoxicity (2011) J. Chem. Inf. Model, 51, pp. 483-492; Benz, R.D., Toxicological and clinical computational analysis and the US FDA/CDER (2007) Expert Opin. Drug Metab. Toxicol, 3, pp. 109-124; Gubbels-Van, H.W.M., Blaauboer, B.J., Barentsen, H.M., Hoitink, M.A., Meerts, I.A., van der Hoeven, J.C., An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing (2005) Regul. Toxicol. Pharmacol, 42, pp. 284-295; Zhu, H., Martin, T.M., Ye, L., Sedykh, A., Young, D.M., Tropsha, A., Quantitative structureactivity relationship modeling of rat acute toxicity by oral exposure (2009) Chem. Res. Toxicol, 22, pp. 1913-1921; Bhhatarai, B., Gramatica, P., Oral LD50 toxicity modeling and prediction of per- and polyfluorinated chemicals on rat and mouse (2011) Mol. Divers, 15, pp. 467-476; Russell, W.M.S., Burch, R.L., (1959) The Principles of Humane Experimental Technique, , 1st ed.; Methuen: London, UK; The Innovative Medicines Initiative (IMI) Homepage, , http://www.imi.europa.eu, accessed on 19 September 2011; The ETOX Project Website, , http://www.e-TOX.net, accessed on 19 September 2011; Kramer, J.A., Sagartz, J.E., Morris, D.L., The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates (2007) Nat. Rev. Drug Discov, 6, pp. 636-649; Richard, A.M., Yang, C., Judson, R.S., Toxicity Data Informatics: Supporting a New Paradigm for Toxicity Prediction (2008) Toxicol. Mech. Method, 18, pp. 103-118; Hardy, B., Douglas, N., Helma, C., Rautenberg, M., Jeliazkova, N., Jeliazkov, V., Nikolova, I., Kramer, S., Collaborative development of predictive toxicology applications (2010) J. Cheminform, 2, p. 7; The OSIRIS Project Homepage, , http://www.osiris-reach.eu, accessed on 20 March 2012; Searls, D.B., Data integration: Challenges for drug discovery (2005) Nat. Rev. Drug Discov, 4, pp. 45-58; Bologa, C., Allu, T.K., Olah, M., Kappler, M.A., Oprea, T.I., Descriptor collision and confusion: Toward the design of descriptors to mask chemical structures (2005) J. Comput. Aided Mol. Des, 19, pp. 625-635; Krallinger, M., Erhardt, R.A., Valencia, A., Text-mining approaches in molecular biology and biomedicine (2005) Drug Discov. Today, 10, pp. 439-445; Bender, A., Scheiber, J., Glick, M., Davies, J.W., Azzaoui, K., Hamon, J., Urban, L., Jenkins, J.L., Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure (2007) Chem Med Chem, 2, pp. 861-873; Szakács, G., Váradi, A., Özvegy-Laczka, C., Sarkadi, B., The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) (2008) Drug Discov. Today, 13, pp. 379-393; Funk, C., The role of hepatic transporters in drug elimination (2008) Expert Opin. Drug Metab. Toxicol, 4, pp. 363-379; Marchant, C.A., Briggs, K.A., Long, A., In silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic (2008) Toxicol. Mech. Methods, 18, pp. 177-187; Cruciani, G., Carosati, E., de Boeck, B., Ethirajulu, K., Mackie, C., Howe, T., Vianello, R., MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist (2005) J. Med. Chem, 48, pp. 6970-6979; (2010) Methods and Applications Series: Challenges and Advances In Computational Chemistry and Physics, 8, pp. 1-414. , Recent Advances in QSAR Studies, 1st ed.; Puzyn, T., Leszczynski, J., Cronin, M.T., Eds.; Springer Verlag: Heidelberg, Germany; Pitluk, Z., Khalil, I., Achieving confidence in mechanism for drug discovery and development (2007) Drug Discov. Today, 12, pp. 924-930; Derek Nexus, General Information, , https://www.lhasalimited.org/derek_nexus/, accessed on 19 September 2011, authorisation required; OECD Principles For the Validation, For Regulatory Purposes, of (quantitative) Structure- Activity Relationship Models, , http://www.oecd.org/dataoecd/33/37/37849783.pdf, November 2004, accessed on 19 September 2011; ChOX Database, a Subset of Data Extracted From ChEMBL, , https://www.ebi.ac.uk/chembl/etox, accessed on 19 September 2011, authorisation required; ChEMBL Database, , https://www.ebi.ac.uk/chembldb/, accessed on 19 September 2011; Gene Expression Omnibus Database, , http://www.ncbi.nlm.nih.gov/geo/, accessed on 19 September 2011; The Open Biological and Biomedical Ontologies: Mouse Adult Gross Anatomy, , http://obofoundry.org/cgi-bin/detail.cgi?id=adult_mouse_anatomy, accessed on 19 September 2011; Standard of Exchange of Nonclinical Data (SEND) Homepage, , http://www.cdisc.org/send, accessed on 19 September 2011; The Open Biological and Biomedical Ontologies: Cell Type, , http://obofoundry.org/cgi-bin/detail.cgi?id=cell, accessed on 19 September 2011; The BioPortal: MedDRA, , http://bioportal.bioontology.org/ontologies/42280, accessed on 19 September 2011; The NCBI Taxonomy Homepage, , http://www.ncbi.nlm.nih.gov/Taxonomy/taxonomyhome.html/, accessed 19 September 2011; Halliwell, W.H., Cationic amphiphilic drug-induced phospholipidosis (1997) Toxicol. Pathol, 2, pp. 53-60; Kruhlak, N., Choi, S.S., Contrera, J.F., Weaver, J.L., Willard, J.M., Hastings, K.L., Sancilio, L.F., Development of a Phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models (2008) Toxicol. Mech. Methods, 18, pp. 217-227; Kodavanti, U.P., Mehendale, H.M., Cationic amphiphilic drugs and phospholipid storage disorder (1990) Pharmacol. Rev, 42, pp. 327-354; Schneider, P., Korolenko, T.A., Busch, U., A review of drug induced lysosomal 751 disorders of the liver in man and laboratory animals (1997) Microsc. Res. Tech, 36, pp. 752253-752275; Jaeschke, H., Gores, G.J., Cederbaum, A.I., Hinson, J.A., Pessayre, D., Lemasters, J.J., Mechanisms of hepatotoxicity (2002) Toxicol. Sci, 65, pp. 166-176; Boelsterli, U.A., Lim, P.L., Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? (2007) Toxicol. Appl. Pharmacol, 220, pp. 92-107; Giri, S., Nieber, K., Bader, A., Hepatotoxicity and hepatic metabolism of available drugs: Current problems and possible solutions in preclinical stages (2010) Expert Opin. Drug Metab. Toxicol, 6, pp. 895-917; Zollnera, G., Wagnera, M., Trauner, M., Nuclear receptors as drug targets in cholestasis and druginduced hepatotoxicity (2010) Pharmacol. Ther, 126, pp. 228-243; Greene, N., Fisk, L., Naven, R.T., Note, R.R., Patel, M.L., Pelletier, D.J., Developing structureactivity relationships for the prediction of hepatotoxicity (2010) Chem. Res. Toxicol, 23, pp. 1215-1222; Low, Y., Uehara, T., Minowa, Y., Yamada, H., Ohno, Y., Urushidani, T., Sedykh, A., Fourches, D., Predicting Drug-Induced Hepatotoxicity Using QSAR and Toxicogenomics Approaches (2011) Chem. Res. Toxicol, 24, pp. 1251-1262; Garcia-Serna, R., Mestres, J., Anticipating drug side effects by comparative pharmacology (2010) Expert Opin. Drug Metab. Toxicol, 6, pp. 1253-1263; Button, W.G., Judson, P.N., Long, A., Vessey, J.D., Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics (2003) J. Chem. Inf. Comput. Sci, 43, pp. 1371-1377; Judson, P.N., Marchant, C.A., Vessey, J.D., Using argumentation for absolute reasoning about the potential toxicity of chemicals (2003) J. Chem. Inf. Comput. Sci, 43, pp. 1364-1370; Ellison, C.M., Madden, J.C., Judson, P., Cronin, M.T., Using In silico Tools in a Weight of Evidence Approach to Aid Toxicological Assessment (2010) Mol. Inf, 29, pp. 97-110; Mudd Jr., P.N., Groenendaal, H., Bush, M.A., Schmith, V.D., Probabilistic Risk Analysis: Improving Early Drug Development Decision Making (2010) Clin. Pharmacol. Ther, 88, pp. 871-875","Pognan, F.; Department of Preclinical Safety, Novartis Institutes for Biomedical Research (NIBR), Postfach CH-4002, Basel, Switzerland; email: francois.pognan@novartis.com",,,,,,,,14220067,,,"22489185","English","Int. J. Mol. Sci.",Review,"Final",Open Access,Scopus,2-s2.0-84858976293
"Flachner B., Lörincz Z., Carotti A., Nicolotti O., Kuchipudi P., Remez N., Sanz F., Tóvári J., Szabó M.J., Bertók B., Cseh S., Mestres J., Dormán G.","7801345317;6603188135;7102635316;6603050960;55356881700;55357761000;7102263897;6602573151;35171477600;55357721900;7004676186;7004586125;7004277673;","A chemocentric approach to the identification of cancer targets.",2012,"PloS one","7","4",,"","",,11,"10.1371/journal.pone.0035582","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866177839&doi=10.1371%2fjournal.pone.0035582&partnerID=40&md5=71370bf82c7229de962fb67ebd6257d5","TargetEx, Dunakeszi, Hungary","Flachner, B., TargetEx, Dunakeszi, Hungary; Lörincz, Z.; Carotti, A.; Nicolotti, O.; Kuchipudi, P.; Remez, N.; Sanz, F.; Tóvári, J.; Szabó, M.J.; Bertók, B.; Cseh, S.; Mestres, J.; Dormán, G.","A novel chemocentric approach to identifying cancer-relevant targets is introduced. Starting with a large chemical collection, the strategy uses the list of small molecule hits arising from a differential cytotoxicity screening on tumor HCT116 and normal MRC-5 cell lines to identify proteins associated with cancer emerging from a differential virtual target profiling of the most selective compounds detected in both cell lines. It is shown that this smart combination of differential in vitro and in silico screenings (DIVISS) is capable of detecting a list of proteins that are already well accepted cancer drug targets, while complementing it with additional proteins that, targeted selectively or in combination with others, could lead to synergistic benefits for cancer therapeutics. The complete list of 115 proteins identified as being hit uniquely by compounds showing selective antiproliferative effects for tumor cell lines is provided.",,"antineoplastic agent; tumor protein; article; biological model; cell line; cell strain HCT116; cell survival; chemistry; computer simulation; drug antagonism; drug effect; drug screening; gene expression profiling; gene expression regulation; genetics; high throughput screening; human; IC 50; molecular library; oncogene; Antineoplastic Agents; Cell Line; Cell Survival; Computer Simulation; Drug Screening Assays, Antitumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Models, Biological; Neoplasm Proteins; Oncogenes; Small Molecule Libraries",,"Antineoplastic Agents; Neoplasm Proteins; Small Molecule Libraries",,,,,,,,"Flachner, B.",,,,,,,,19326203,,,"22558171","English","PLoS ONE",Article,"Final",Open Access,Scopus,2-s2.0-84866177839
"Bauer-Mehren A., Bundschus M., Rautschka M., Mayer M.A., Sanz F., Furlong L.I.","35572639000;24279398100;34168330800;36971031500;7102263897;34770469800;","Gene-disease network analysis reveals functional modules in mendelian, complex and environmental diseases",2011,"PLoS ONE","6","6", e20284,"","",,102,"10.1371/journal.pone.0020284","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79958795334&doi=10.1371%2fjournal.pone.0020284&partnerID=40&md5=338b023c81d6048767c1d71a07e89c6b","Research Programme on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Universitat Pompeu Fabra, Barcelona, Spain; Institute for Computer Science, Ludwig-Maximilians-University Munich, Munich, Germany; Roche Diagnostics GmbH, Penzberg, Germany","Bauer-Mehren, A., Research Programme on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Universitat Pompeu Fabra, Barcelona, Spain; Bundschus, M., Institute for Computer Science, Ludwig-Maximilians-University Munich, Munich, Germany, Roche Diagnostics GmbH, Penzberg, Germany; Rautschka, M., Research Programme on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Universitat Pompeu Fabra, Barcelona, Spain; Mayer, M.A., Research Programme on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Universitat Pompeu Fabra, Barcelona, Spain; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Universitat Pompeu Fabra, Barcelona, Spain","Background: Scientists have been trying to understand the molecular mechanisms of diseases to design preventive and therapeutic strategies for a long time. For some diseases, it has become evident that it is not enough to obtain a catalogue of the disease-related genes but to uncover how disruptions of molecular networks in the cell give rise to disease phenotypes. Moreover, with the unprecedented wealth of information available, even obtaining such catalogue is extremely difficult. Principal Findings: We developed a comprehensive gene-disease association database by integrating associations from several sources that cover different biomedical aspects of diseases. In particular, we focus on the current knowledge of human genetic diseases including mendelian, complex and environmental diseases. To assess the concept of modularity of human diseases, we performed a systematic study of the emergent properties of human gene-disease networks by means of network topology and functional annotation analysis. The results indicate a highly shared genetic origin of human diseases and show that for most diseases, including mendelian, complex and environmental diseases, functional modules exist. Moreover, a core set of biological pathways is found to be associated with most human diseases. We obtained similar results when studying clusters of diseases, suggesting that related diseases might arise due to dysfunction of common biological processes in the cell. Conclusions: For the first time, we include mendelian, complex and environmental diseases in an integrated gene-disease association database and show that the concept of modularity applies for all of them. We furthermore provide a functional analysis of disease-related modules providing important new biological insights, which might not be discovered when considering each of the gene-disease association repositories independently. Hence, we present a suitable framework for the study of how genetic and environmental factors, such as drugs, contribute to diseases. Availability: The gene-disease networks used in this study and part of the analysis are available at http://ibi.imim.es/DisGeNET/DisGeNETweb.html#Download. © 2011 Bauer-Mehren et al.",,"perhexiline; angina pectoris; article; cluster analysis; controlled study; disease classification; environmental disease; environmental factor; gene cluster; gene expression; gene regulatory network; gene structure; genetic analysis; genetic association; genetic disorder; human; immune complex disease; molecular genetics; rhabdomyolysis; environment; gene regulatory network; general aspects of disease; genetics; multigene family; phenotype; Cluster Analysis; Disease; Environment; Gene Regulatory Networks; Genetic Association Studies; Humans; Multigene Family; Phenotype",,"perhexiline, 6621-47-2",,,,,,,"Botstein, D., Risch, N., Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease (2003) Nat Genet, 33, pp. 228-237; Kann, M.G., Advances in translational bioinformatics: computational approaches for the hunting of disease genes (2010) Brief Bioinform, 11, pp. 96-110; Scriver, C.R., Waters, P.J., Monogenic traits are not simple: lessons from phenylketonuria (1999) Trends Genet, 15, pp. 267-272; Hirschhorn, J.N., Daly, M.J., Genome-wide association studies for common diseases and complex traits (2005) Nat Rev Genet, 6, pp. 95-108; Cokol, M., Iossifov, I., Weinreb, C., Rzhetsky, A., Emergent behavior of growing knowledge about molecular interactions (2005) Nat Biotechnol, 23, pp. 1243-1247; Hamosh, A., Scott, A.F., Amberger, J.S., Bocchini, C.A., McKusick, V.A., Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders (2005) Nucleic Acids Res, 33, pp. 514-517; Klein, T.E., Chang, J.T., Cho, M.K., Easton, K.L., Fergerson, R., Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base (2001) Pharmacogenomics J, 1, pp. 167-170; Mattingly, C.J., Rosenstein, M.C., Davis, A.P., Colby, G.T., Forrest, J.N., The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks (2006) Toxicol Sci, 92, pp. 587-595; Ananiadou, S., Pyysalo, S., Tsujii, J., Kell, D.B., Event extraction for systems biology by text mining the literature (2010) Trends Biotechnol, 28, pp. 381-390; Snead, M.P., Yates, J.R.W., Clinical and molecular genetics of Stickler syndrome (1999) J Med Genet, 36, pp. 353-359; Ahmad, N.N., Ala-Kokko, L., Knowlton, R.G., Jimenez, S.A., Weaver, E.J., Stop codon in the procollagen II gene (COL2A1) in a family with the Stickler syndrome (arthro-ophthalmopathy) (1991) Proc Natl Acad Sci, 88, pp. 6624-6627; Melkoniemi, M., Brunner, H., Manouvrier, S., Hennekam, R., Supertifurga, A., Autosomal Recessive Disorder Otospondylomegaepiphyseal Dysplasia Is Associated with Loss-of-Function Mutations in the COL11A2 Gene (2000) Am J Hum Genet, 66, pp. 368-377; Lim, J., Hao, T., Shaw, C., Patel, A.J., Szabó, G., A Protein-Protein Interaction Network for Human Inherited Ataxias and Disorders of Purkinje Cell Degeneration (2006) Cell, 125, pp. 801-814; Jones, S., Zhang, X., Parsons, D.W., Lin, J.C.-H., Leary, R.J., Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses (2008) Science, 321, pp. 1801-1806; D'Andrea, A.D., Grompe, M., The Fanconi anaemia/BRCA pathway (2003) Nat Rev Cancer, 3, pp. 23-34; Reeuwijk, J., Brunner, H.G., Bokhoven, H., Glyc-O-genetics of Walker-Warburg syndrome (2005) Clin Genet, 67, pp. 281-289; Hartwell, L.H., Hopfield, J.J., Leibler, S., Murray, A.W., From molecular to modular cell biology (1999) Nature, 402, pp. 47-52; Oti, M., Brunner, H.G., The modular nature of genetic diseases (2007) Clin Genet, 71, pp. 1-11; Suthram, S., Dudley, J.T., Chiang, A.P., Chen, R., Hastie, T.J., Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets (2010) PLoS Comp Biol, 6; Zaghloul, N.A., Katsanis, N., Functional modules, mutational load and human genetic disease (2010) Trends Genet, 26, pp. 168-176; Barabasi, A.-L., Gulbahce, N., Loscalzo, J., Network medicine: a network-based approach to human disease (2011) Nat Rev Genet, 12, pp. 56-68; Goh, K.-I., Cusick, M.E., Valle, D., Childs, B., Vidal, M., The human disease network (2007) Proc Natl Acad Sci, 104, pp. 8685-8690; Przulj, N., Wigle, D.A., Jurisica, I., Functional topology in a network of protein interactions (2004) Bioinformatics, 20, pp. 340-348; Yildirim, M.A., Goh, K.-I., Cusick, M.E., Barabasi, A.-L., Vidal, M., Drug-target network (2007) Nat Biotechnol, 25, pp. 1119-1126; Butts, C.T., Revisiting the Foundations of Network Analysis (2009) Science, 325, pp. 414-416; Barabási, A.-L., Oltvai, Z.N., Network biology: understanding the cell's functional organization (2004) Nat Rev Genet, 5, pp. 101-113; Sharan, R., Ulitsky, I., Shamir, R., Network-based prediction of protein function (2007) Mol Syst Biol, 3; Bauer-Mehren, A., Rautschka, M., Sanz, F., Furlong, L.I., DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks (2010) Bioinformatics, 26, pp. 2924-2926; Carreira, S., Goodall, J., Denat, L., Rodriguez, M., Nuciforo, P., Mitf regulation of Dia1 controls melanoma proliferation and invasiveness (2006) Genes Dev, 20, pp. 3426-3439; Garraway, L.A., Sellers, W.R., From integrated genomics to tumor lineage dependency (2006) Cancer Res, 66, pp. 2506-2508; Dipple, K.M., McCabe, E.R., Modifier genes convert ""simple"" Mendelian disorders to complex traits (2000) Mol Genet Metab, 71, pp. 43-50; Lima-Mendez, G., Helden, J., The powerful law of the power law and other myths in network biology (2009) Mol Biosyst, 5, pp. 1482-1493; López García de Lomana, A., Beg, Q.K., de Fabritiis, G., Villà-Freixa, J., Statistical analysis of global connectivity and activity distributions in cellular networks (2010) J Comput Biol, 17, pp. 869-878; Freudenberg, J., Propping, P., A similarity-based method for genome-wide prediction of disease-relevant human genes (2002) Bioinformatics, 18, pp. 110-115; van Driel, M.A., Bruggeman, J., Vriend, G., Brunner, H.G., Leunissen, J.A.M., A text-mining analysis of the human phenome (2006) Eur J Hum Genet, 14, pp. 535-542; Cerami, E., Demir, E., Schultz, N., Taylor, B.S., Sander, C., Automated Network Analysis Identifies Core Pathways in Glioblastoma (2010) PLoS ONE, 5; Li, Y., Agarwal, P., A Pathway-Based View of Human Diseases and Disease Relationships (2009) PLoS ONE, 4, pp. e4346; Margadant, C., Sonnenberg, A., Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing (2010) EMBO Reports, 11, pp. 97-105; Chavali, S., Barrenas, F., Kanduri, K., Benson, M., Network properties of human disease genes with pleiotropic effects (2010) BMC Systems Biology, 4, p. 78; Huberts, D.H.E.W., van der Klei, I.J., Moonlighting proteins: an intriguing mode of multitasking (2010) Biochim Biophys Acta, 1803, pp. 520-525; Fernández, A., Sessel, S., Selective antagonism of anticancer drugs for side-effect removal (2009) Trends Pharmacol Sci, 30, pp. 403-410; Berger, S.I., Iyengar, R., Network analyses in systems pharmacology (2009) Bioinformatics, 25, pp. 2466-2472; Bauer-Mehren, A., Furlong, L.I., Sanz, F., Pathway databases and tools for their exploitation: benefits, current limitations and challenges (2009) Mol Syst Biol, 5, p. 290; de Luca, L., Mebazaa, A., Filippatos, G., Parissis, J.T., Böhm, M., Overview of emerging pharmacologic agents for acute heart failure syndromes (2008) Eur J Heart Fail, 10, pp. 201-213; Kennedy, J.A., Kiosoglous, A.J., Murphy, G.A., Pelle, M.A., Horowitz, J.D., Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart (2000) J Cardiovasc Pharmacol, 36, pp. 794-801; Celik, I., Gallicchio, L., Boyd, K., Lam, T.K., Matanoski, G., Arsenic in drinking water and lung cancer: a systematic review (2008) Environ Res, 108, pp. 48-55; Chiou, H.Y., Hsueh, Y.M., Liaw, K.F., Horng, S.F., Chiang, M.H., Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan (1995) Cancer Res, 55, pp. 1296-1300; Radosavljević, V., Jakovljević, B., Arsenic and bladder cancer: observations and suggestions (2008) J Environ Health, 71, pp. 40-42; Smith, A.H., Hopenhayn-Rich, C., Bates, M.N., Goeden, H.M., Hertz-Picciotto, I., Cancer risks from arsenic in drinking water (1992) Environ Health Perspect, 97, pp. 259-267; Tsuda, T., Babazono, A., Yamamoto, E., Kurumatani, N., Mino, Y., Ingested arsenic and internal cancer: a historical cohort study followed for 33 years (1995) Am J Epidemiol, 141, pp. 198-209; Yang, C.-Y., Chang, C.-C., Chiu, H.-F., Does arsenic exposure increase the risk for prostate cancer? (2008) J Toxicol Environ Health A, 71, pp. 1559-1563; Park, S., Bae, J., Nam, B.-H., Yoo, K.-Y., Aetiology of cancer in Asia (2008) Asian Pac J Cancer Prev, 9, pp. 371-380; Sankaranarayanan, R., Boffetta, P., Research on cancer prevention, detection and management in low- and medium-income countries (2010) Ann Oncol; Thun, M.J., DeLancey, J.O., Center, M.M., Jemal, A., Elizabeth, M.W., The global burden of cancer: priorities for prevention (2010) Carcinogenesis, 31, pp. 100-110; Navarro Silvera, S.A., Rohan, T.E., Trace elements and cancer risk: a review of the epidemiologic evidence (2007) Cancer Causes Control, 18, pp. 7-27; Argos, M., Kibriya, M.G., Parvez, F., Jasmine, F., Rakibuz-Zaman, M., Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population (2006) Cancer Epidemiol Biomarkers Prev, 15, pp. 1367-1375; Bau, D.-T., Wang, T.-S., Chung, C.-H., Wang, A.S.S., Jan, K.-Y., Oxidative DNA adducts and DNA-protein cross-links are the major DNA lesions induced by arsenite (2002) Environ Health Perspect, 110 (SUPPL. 5), pp. 753-756; Duerr, R.H., Update on the genetics of inflammatory bowel disease (2003) J Clin Gastroenterol, 37, pp. 358-367; Scaldaferri, F., Fiocchi, C., Inflammatory bowel disease: progress and current concepts of etiopathogenesis (2007) J Dig Dis, 8, pp. 171-178; The Universal Protein Resource (UniProt) in 2010 (2010) Nucleic Acids Res, 38, pp. 142-148. , The UniProt C; Altman, R.B., PharmGKB: a logical home for knowledge relating genotype to drug response phenotype (2007) Nat Genet, 39, p. 426; Bundschus, M., Dejori, M., Stetter, M., Tresp, V., Kriegel, H.-P., Extraction of semantic biomedical relations from text using conditional random fields (2008) BMC Bioinformatics, 9, p. 207; Bauer-Mehren, A., Furlong, L., Rautschka, M., Sanz, F., From SNPs to pathways: integration of functional effect of sequence variations on models of cell signalling pathways (2009) BMC Bioinformatics, 10, pp. S6; Mitchell, J.A., Aronson, A.R., Mork, J.G., Folk, L.C., Humphrey, S.M., Gene Indexing: Characterization and Analysis of NLM's GeneRIFs (2003) AMIA Annu Symp Pro, 2003, pp. 460-464; Lu, Z., Cohen, K.B., Hunter, L., GeneRIF QUALITY ASSURANCE AS SUMMARY REVISION (2007) Pac Symp Biocomput, pp. 269-280; Rubinstein, R., Simon, I., MILANO - custom annotation of microarray results using automatic literature searches (2005) BMC Bioinformatics, 6, p. 12; Newman, M.E.J., The structure and function of complex networks (2003) SIAM Review, 45, pp. 167-256; Gabor, C., Tamas, N., The igraph Software Package for Complex Network Research (2006) InterJournal Complex Systems; van Dongen, S., Graph Clustering by Flow Simulation (2000), Centers for Mathematics and Computer Science, University of Utrecht; Enright, A.J., van Dongen, S., Ouzounis, C.A., An efficient algorithm for large-scale detection of protein families (2002) Nucl Acids Res, 30, pp. 1575-1584; Ravasz, E., Somera, A.L., Mongru, D.A., Oltvai, Z.N., Barabási, A.L., Hierarchical organization of modularity in metabolic networks (2002) Science (New York, NY), 297, pp. 1551-1555","Furlong, L. I.; Research Programme on Biomedical Informatics (GRIB), IMIM (Hospital del Mar Research Institute), Universitat Pompeu Fabra, Barcelona, Spain; email: lfurlong@imim.es",,,,,,,,19326203,,,"21695124","English","PLoS ONE",Article,"Final",Open Access,Scopus,2-s2.0-79958795334
"Obiol-Pardo C., Gomis-Tena J., Sanz F., Saiz J., Pastor M.","15842357500;6602304661;7102263897;7005152234;7102415847;","A multiscale simulation system for the prediction of drug-induced cardiotoxicity",2011,"Journal of Chemical Information and Modeling","51","2",,"483","492",,70,"10.1021/ci100423z","https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952159586&doi=10.1021%2fci100423z&partnerID=40&md5=6aedc32b451e569448b72e8390ecbaba","Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Grupo Bioelectronica I3BH, Universitat Politecnica de Valencia, Camino de Vera s/n, E-46022 Valencia, Spain","Obiol-Pardo, C., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Gomis-Tena, J., Grupo Bioelectronica I3BH, Universitat Politecnica de Valencia, Camino de Vera s/n, E-46022 Valencia, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Saiz, J., Grupo Bioelectronica I3BH, Universitat Politecnica de Valencia, Camino de Vera s/n, E-46022 Valencia, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain","The preclinical assessment of drug-induced ventricular arrhythmia, a major concern for regulators, is typically based on experimental or computational models focused on the potassium channel hERG (human ether-a-go-go-related gene, Kv11.1). Even if the role of this ion channel in the ventricular repolarization is of critical importance, the complexity of the events involved make the cardiac safety assessment based only on hERG has a high risk of producing either false positive or negative results. We introduce a multiscale simulation system aiming to produce a better cardiotoxicity assessment. At the molecular scale, the proposed system uses a combination of docking simulations on two potassium channels, hERG and KCNQ1, plus three-dimensional quantitative structure-activity relationship modeling for predicting how the tested compound will block the potassium currents IKr and IKs. The obtained results have been introduced in electrophysiological models of the cardiomyocytes and the ventricular tissue, allowing the direct prediction of the drug effects on electrocardiogram simulations. The usefulness of the whole method is illustrated by predicting the cardiotoxic effect of several compounds, including some examples in which classic hERG-based models produce false positive or negative results, yielding correct predictions for all of them. These results can be considered a proof of concept, suggesting that multiscale prediction systems can be suitable for being used for preliminary screening in lead discovery, before the compound is physically available, or in early preclinical development when they can be fed with experimentally obtained data. © 2011 American Chemical Society.",,"Cardiomyocytes; Cardiotoxicity; Computational model; Direct prediction; Docking simulations; Drug effects; Electrophysiological models; False positive; Ion channel; Molecular scale; Multi-scale simulation; Multiscales; Potassium channels; Potassium currents; Preclinical development; Prediction systems; Proof of concept; Safety assessments; System use; Three-dimensional quantitative structure-activity relationship; Ventricular arrhythmias; Ventricular repolarization; Electrophysiology; Ethers; Forecasting; Lead compounds; Rating; Three dimensional; drug; ERG1 potassium channel; potassium channel blocking agent; potassium channel HERG; potassium channel KCNQ1; article; biology; chemical structure; chemistry; drug antagonism; drug effect; electrophysiology; heart; human; methodology; physiology; protein conformation; quantitative structure activity relation; reproducibility; Computational Biology; Electrophysiological Processes; Ether-A-Go-Go Potassium Channels; Heart; Humans; KCNQ1 Potassium Channel; Models, Molecular; Pharmaceutical Preparations; Potassium Channel Blockers; Protein Conformation; Quantitative Structure-Activity Relationship; Reproducibility of Results",,"ERG1 potassium channel; Ether-A-Go-Go Potassium Channels; KCNQ1 Potassium Channel; Pharmaceutical Preparations; Potassium Channel Blockers",,,,,,,"Hammond, T.G., Carlsson, L., Davis, A.S., Lynch, W.G., MacKenzie, I., Redfern, W.S., Sullivan, A.T., Camm, A.J., Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey (2001) Cardiovascular Research, 49 (4), pp. 741-750. , DOI 10.1016/S0008-6363(00)00310-2, PII S0008636300003102; Yap, Y.G., Camm, A.J., Drug induced QT prolongation and torsades de pointes (2003) Heart, 89 (11), pp. 1363-1372; Hancox, J.C., McPate, M.J., Ei Harchi, A., Zhang, Y.H., The hERG potassium channel and hERG screening for drug-induced torsades de pointes (2008) Pharmacol. Ther., 119, pp. 118-132; Yao, X., Anderson, D.L., Ross, S.A., Lang, D.G., Desai, B.Z., Cooper, D.C., Wheelan, P., Hashim, M.A., Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model (2008) Br. J. Pharmacol., 154, pp. 1446-1456; Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., De Ponti, F., QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development (2005) Medicinal Research Reviews, 25 (2), pp. 133-166. , DOI 10.1002/med.20019; Inanobe, A., Kamiya, N., Murakami, S., Fukunishi, Y., Nakamura, H., Kurachi, Y., In silico prediction of the chemical block of human ether-a-go-go related gene (hERG) K+ current (2008) J. Physiol. Sci., 58, pp. 459-470; Li, Q., Jorgensen, F.S., Oprea, T., Brunak, S., Taboureau, O., HERG classification model based on a combination of support vector machine method and GRIND descriptors (2008) Molecular Pharmaceutics, 5 (1), pp. 117-127. , DOI 10.1021/mp700124e; Christ, T., Wettwer, E., Wuest, M., Braeter, M., Donath, F., Champeroux, P., Richard, S., Ravens, U., Electrophysiological profile of propiverine - Relationship to cardiac risk (2008) Naunyn Schmiedebergs Arch. Pharmacol., 376, pp. 431-440; Lee, H., Kim, K.S., Park, S.J., Kim, E.J., Cellular mechanism of the QT prolongation induced by sulpiride (2009) Int. J. Toxicol., 28, pp. 207-212; Curtis, M.J., Is cardiac IKs a relevant drug target? (2004) Cardiovascular Research, 61 (4), pp. 651-652. , DOI 10.1016/j.cardiores.2004.01.001; Jost, N., Papp, J.Gy., Varro, A., Slow delayed rectifier potassium current (IKs) and the repolarization reserve (2007) Annals of Noninvasive Electrocardiology, 12 (1), pp. 64-78. , DOI 10.1111/j.1542-474X.2007.00140.x; Lengyel, C., Varro, A., Tabori, K., Papp, J.G., Baczko, I., Combined pharmacological block of IKr and IKs increases short-term QT interval variability and provokes torsades de pointes (2007) British Journal of Pharmacology, 151 (7), pp. 941-951. , DOI 10.1038/sj.bjp.0707297, PII 0707297; Michael, G., Kane, K.A., Coker, S.J., Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs (2008) Br. J. Pharmacol., 154, pp. 1414-1426; So, P.P., Backx, P.H., Dorian, P., Slow delayed rectifier K+ current block by HMR 1556 increases dispersion of repolarization and promotes Torsades de Pointes in rabbit ventricles (2008) Br. J. Pharmacol., 155, pp. 1185-1194; Towart, R., Linders, J.T.M., Hermans An, H., Rohrbacher, J., Van Der Linde, H.J., Ercken, M., Cik, M., Gallacher, D.J., Blockade of the IKs potassium channel: An overlooked cardiovascular liability in drug safety screening? (2009) J. Pharmacol. Toxicol. Methods, 60, pp. 1-10; Luo, C.-H., Rudy, Y., A dynamic model of the cardiac ventricular action potential: I. Simulations of ionic currents and concentration changes (1994) Circulation Research, 74 (6), pp. 1071-1096; Suzuki, S., Murakami, S., Tsujimae, K., Findlay, I., Karachi, Y., In silico risk assessment for drug-induction of cardiac arrhythmia (2008) Prog. Biophys. Mol. Biol., 98, pp. 52-60; Silva, J.R., Pan, H., Wu, D., Nekouzadeh, A., Decker, K.F., Cui, J., Baker, N.A., Rudy, Y., A multiscale model linking ion-channel molecular dynamics and electrostatics to the cardiac action potential (2009) Proc. Natl. Acad. Sci. U.S.A., 106, pp. 11102-11106; Bottino, D., Penland, R.C., Stamps, A., Traebert, M., Dumotier, B., Georgieva, A., Helmlinger, G., Lett, G.S., Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart (2006) Progress in Biophysics and Molecular Biology, 90 (1-3), pp. 414-443. , DOI 10.1016/j.pbiomolbio.2005.06.006, PII S0079610705000544, From Funny Current to Current Physiome; Gasteiger, J., Rudolph, C., Sadowski, J., Automatic generation of 3D-atomic coordinates for organic molecules (1990) Tetrahedron Comput. Methodol., 3, pp. 537-547; Milletti, F., Storchi, L., Sforna, G., Cruciani, G., New and original pKa prediction method using grid molecular interaction fields (2007) Journal of Chemical Information and Modeling, 47 (6), pp. 2172-2181. , DOI 10.1021/ci700018y; Milletti, F., Storchi, L., Sforna, G., Cross, S., Cruciani, G., Tautomer enumeration and stability prediction for virtual screening on large chemical databases (2009) J. Chem. Inf. Model., 49, pp. 68-75; Farid, R., Day, T., Friesner, R.A., Pearlstein, R.A., New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies (2006) Bioorg. Med. Chem., 14, pp. 3160-3173; Lerche, C., Bruhova, I., Lerche, H., Steinmeyer, K., Wei, A.D., Strutz-Seebohm, N., Lang, F., Seebohm, G., Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter (2007) Molecular Pharmacology, 71 (6), pp. 1503-1511. , http://molpharm.aspetjournals.org/cgi/reprint/71/6/1503, DOI 10.1124/mol.106.031682; Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., Improved protein-ligand docking using GOLD (2003) Proteins: Structure, Function and Genetics, 52 (4), pp. 609-623. , DOI 10.1002/prot.10465; Mooij, W.T.M., Verdonk, M.L., General and targeted statistical potentials for protein-ligand interactions (2005) Proteins: Structure, Function and Genetics, 61 (2), pp. 272-287. , DOI 10.1002/prot.20588; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors (2000) J. Med. Chem., 43, pp. 3233-3243; Durán, A., Martínez, G.C., Pastor, M., Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in Molecular Interaction Fields (2008) J. Chem. Inf. Model., 48, pp. 1813-1823; Faber, G.M., Rudy, Y., Action potential and contractility changes [Na+](i) overloaded cardiac myocytes: A simulation study (2000) Biophysical Journal, 78 (5), pp. 2392-2404; Gima, K., Rudy, Y., Ionic current basis of electrocardiographic waveforms: A model study (2002) Circulation Research, 90 (8), pp. 889-896. , DOI 10.1161/01.RES.0000016960.61087.86; Brennan, T., Fink, M., Rodríguez, B., Multiscale modelling of drug-induced effects on cardiac electrophysiological activity (2009) Eur. J. Pharm. Sci., 36, pp. 62-77; Drouin, E., Charpentier, F., Gauthier, C., Laurent, K., Le Marec, H., Electrophysiologic characteristics of cells spanning the left ventricular wall of human heart: Evidence for presence of M cells (1995) J. Am. Coll. Cardiol., 26, pp. 185-192; Yan, G.-X., Shimizu, W., Antzelevitch, C., Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations (1998) Circulation, 98 (18), pp. 1921-1927; Clayton, R.H., Holden, A.V., Propagation of normal beats and re-entry in a computational model of ventricular cardiac tissue with regional differences in action potential shape and duration (2004) Progress in Biophysics and Molecular Biology, 85 (2-3), pp. 473-499. , DOI 10.1016/j.pbiomolbio.2003.12.002, PII S0079610703001135; Snyders, D.J., Chaudhary, A., High affinity open channel block by dofetilide of HERG expressed in a human cell line (1996) Molecular Pharmacology, 49 (6), pp. 949-955; Jurkiewicz, N.K., Sanguinetti, M.C., Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide (1993) Circ. Res., 72, pp. 75-83; Gögelein, H., Brüggermann, A., Gerlach, U., Brendel, J., Busch, A.E., Inhibition of IKs channels by HMR 1556 (2000) Naunyn Schmiedebergs Arch. Pharmacol., 362, pp. 480-488; Gerlach, U., Brendel, J., Lang, H.-J., Paulus, E.F., Weidmann, K., Bruggemann, A., Busch, A.E., Greger, R., Synthesis and activity of novel and selective Iks-channel blockers (2001) Journal of Medicinal Chemistry, 44 (23), pp. 3831-3837. , DOI 10.1021/jm0109255; Ko, C.M., Ducic, I., Fan, J., Shuba, Y.M., Morad, M., Suppression of mammalian K+ channel family by ebastine (1997) Journal of Pharmacology and Experimental Therapeutics, 281 (1), pp. 233-244; Rico, S., Antonijoan, R.M., Barbanoj, M.J., Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines (2009) J. Asthma Allergy, 2, pp. 73-92; Polak, S., Wiśniowska, B., Brandys, J., Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs cardiotoxic properties (2009) J. Appl. Toxicol., 29, pp. 183-206; Kohl, P., Noble, D., Systems biology and the virtual physiological human (2009) Mol. Syst. Biol., 5, p. 292","Pastor, M.; Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; email: manuel.pastor@upf.edu",,,,,,,,15499596,,,"21250697","English","J. Chem. Inf. Model.",Article,"Final",,Scopus,2-s2.0-79952159586
"Bauer-Mehren A., Rautschka M., Sanz F., Furlong L.I.","35572639000;34168330800;7102263897;34770469800;","DisGeNET: A Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks",2010,"Bioinformatics","26","22", btq538,"2924","2926",,105,"10.1093/bioinformatics/btq538","https://www.scopus.com/inward/record.uri?eid=2-s2.0-78149236787&doi=10.1093%2fbioinformatics%2fbtq538&partnerID=40&md5=fe6e1139d7658f8f07f66c057c55fd3a","Research Programme on Biomedical Informatics (GRIB) IMIM, DCEXS, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain","Bauer-Mehren, A., Research Programme on Biomedical Informatics (GRIB) IMIM, DCEXS, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain; Rautschka, M., Research Programme on Biomedical Informatics (GRIB) IMIM, DCEXS, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB) IMIM, DCEXS, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain; Furlong, L.I., Research Programme on Biomedical Informatics (GRIB) IMIM, DCEXS, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain","Summary: DisGeNET is a plugin for Cytoscape to query and analyze human gene-disease networks. DisGeNET allows user-friendly access to a new gene-disease database that we have developed by integrating data from several public sources. DisGeNET permits queries restricted to (i) the original data source, (ii) the association type, (iii) the disease class or (iv) specific gene(s)/disease(s). It represents gene-disease associations in terms of bipartite graphs and provides gene centric and disease centric views of the data. It assists the user in the interpretation and exploration of the genetic basis of human diseases by a variety of built-in functions. Moreover, DisGeNET permits multicolouring of nodes (genes/diseases) according to standard disease classification for expedient visualization. © The Author 2010. Published by Oxford University Press. All rights reserved.",,"article; biology; computer program; gene regulatory network; general aspects of disease; genetic database; genetics; human; methodology; Computational Biology; Databases, Genetic; Disease; Gene Regulatory Networks; Humans; Software",,,,,"Innovative Medicines Initiative: 115002

European Commission: ICT-215847

Agència de Gestió d’Ajuts Universitaris i de Recerca, AGAUR","Funding: This work was supported by the European Commission [EU-ADR, ICT-215847]; Innovative Medicines Initiative [eTOX, 115002]; and the AGAUR [to A.B.M.]. The GRIB is a node of the Spanish National Institute of Bioinformatics and the COMBIOMED network.",,,"Altman, R.B., PharmGKB: a logical home for knowledge relating genotype to drug response phenotype (2007) Nat. Genet., 39, p. 426; Botstein, D., Risch, N., Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease (2003) Nat. Genet., 33, pp. 228-237; Butts, C.T., Revisiting the foundations of network analysis (2009) Science, 325, pp. 414-416; Goh, K.-I., The human disease network (2007) Proc. Natl Acad. Sci, USA. USA, 104, pp. 8685-8690; Hamosh, A., Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders (2005) Nucleic Acids Res., 33, pp. D514-D517; Hirschhorn, J.N., Daly, M.J., Genome-wide association studies for common diseases and complex traits (2005) Nat. Rev. Genet., 6, pp. 95-108; Kann, M.G., Advances in translational bioinformatics: computational approaches for the hunting of disease genes (2010) Brief. Bioinform., 11, pp. 96-110; Mattingly, C.J., The comparative toxicogenomics database: a crossspecies resource for building chemical-gene interaction networks (2006) Toxicol. Sci., 92, pp. 587-595; Newman, M.E.J., The structure and function of complex networks (2003) SIAM Rev., 45, pp. 167-256; Shannon, P., Cytoscape: a software environment for integrated models of biomolecular interaction networks (2003) Genome Res., 13, pp. 2498-2504; Yildirim, M.A., Drug-target network (2007) Nat. Biotech., 25, pp. 1119-1126","Furlong, L.I.; Research Programme on Biomedical Informatics (GRIB) IMIM, DCEXS, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain; email: lfurlong@imim.es",,,,,,,,13674803,,BOINF,"20861032","English","Bioinformatics",Article,"Final",Open Access,Scopus,2-s2.0-78149236787
"López L., Selent J., Ortega R., Masaguer C.F., Domínguez E., Areias F., Brea J., Loza M.I., Sanz F., Pastor M.","56948275300;55891371700;57196694775;6701715235;15838786400;6602594095;6603008588;7003766926;7102263897;7102415847;","Synthesis, 3D-QSAR, and structural modeling of benzolactam derivatives with binding affinity for the D2and D3 receptors",2010,"ChemMedChem","5","8",,"1300","1317",,21,"10.1002/cmdc.201000101","https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955101547&doi=10.1002%2fcmdc.201000101&partnerID=40&md5=1d89a151da304edabe3747405915dd0e","Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain; Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Departamento de Farmacología, Instituto de Farmacia Industrial, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain","López, L., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain; Selent, J., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain; Ortega, R., Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Masaguer, C.F., Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Domínguez, E., Departamento de Farmacología, Instituto de Farmacia Industrial, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Areias, F., Departamento de Farmacología, Instituto de Farmacia Industrial, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Brea, J., Departamento de Farmacología, Instituto de Farmacia Industrial, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Loza, M.I., Departamento de Farmacología, Instituto de Farmacia Industrial, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Sanz, F., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain; Pastor, M., Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain","A series of 37 benzolactam derivatives were synthesized, and their respective affinities for the dopamine D2 and D3 receptors evaluated. The relationships between structures and binding affinities were investigated using both ligand-based (3D-QSAR) and receptor-based methods. The results revealed the importance of diverse structural features in explaining the differences in the observed affinities, such as the location of the benzolactam carbonyl oxygen, or the overall length of the compounds. The optimal values for such ligand properties are slightly different for the D2 and D 3 receptors, even though the binding sites present a very high degree of homology. We explain these differences by the presence of a hydrogen bond network in the D2 receptor which is absent in the D3 receptor and limits the dimensions of the binding pocket, causing residues in helix 7 to become less accessible. The implications of these results for the design of more potent and selective benzolactam derivatives are presented and discussed. © 2010 Wiley-VCH Verlag GmbH &amp; Co. KGaA.","3D-QSAR; Antipsychotics; Benzolactams; D2/D3 selectivity; Dopamine receptors","2 [4 (4 (2 chlorophenyl) piperazin 1 yl) butyl) 3,4 dihydroisoquinolin 1(2h) one; 2,3,4,5 tetrahydro n [4 (4 (2 methoxyphenyl) piperazin 1 yl) butyl] benzo [c] azepin 1 one; 2,3,4,5 tetrahydro n [4 (4 (2 pyridyl) piperazin 1 yl) butyl] benzo [c] azepin 1 one; 2,3,4,5 tetrahydro n [4 (4 (2 pyrimidyl) piperazin 1 yl) butyl] benzo [c] azepin 1 one; 2,3,4,5 tetrahydro n [4 (4 (2,3 dichlorophenyl) piperazin 1 yl) butyl] benzo [c] azepin 1 one; 2,3,4,5 tetrahydro n [4 (4 (4 methoxyphenyl) piperazin 1 yl) butyl] benzo [c] azepin 1 one; 3,4 Ddhydro n [4 (4 (4 methoxyphenyl) piperazin 1 yl) butyl]isoquinolin 1(2h) one; 3,4 dihydro n [4 (4 (2 methoxyphenyl) piperazin 1 yl) butyl] isoquinolin 1(2h) one; 3,4 dihydro n [4 (4 (2 methoxyphenyl) piperazin 1 yl) butyl] quinolin 2(1h) one; 3,4 dihydro n [4 (4 (2 pyridyl) piperazin 1 yl) butyl] isoquinolin 1(2h) one; 3,4 dihydro n [4 (4 (2 pyridyl) piperazin 1 yl) butyl] quinolin 2(1h) one; 3,4 dihydro n [4 (4 (2 pyrimidyl) piperazin 1 yl) butyl] isoquinolin 1(2h) one; 3,4 dihydro n [4 (4 (2 pyrimidyl) piperazin 1 yl) butyl] quinolin 2(1h) one; 3,4 dihydro n [4 (4 (2,3 dichlorophenyl) piperazin 1 yl) butyl] isoquinolin 1(2h) one; 3,4 dihydro n [4 (4 (2,3 dichlorophenyl) piperazin 1 yl) butyl] quinolin 2(1h) one; 3,4 dihydro n [4 (4 (3 methoxyphenyl) piperazin 1 yl) butyl] isoquinolin 1(2h) one; 3,4 dihydro n [4 (4 (4 methoxyphenyl) piperazin 1 yl) butyl] quinolin 2(1h) one; 3,4 dihydro n [5 (4 (2 methoxyphenyl) piperazin 1 yl) pentyl] isoquinolin 1(2h) one; benzolactam derivative; dopamine 2 receptor; dopamine 3 receptor; lactam derivative; unclassified drug; article; binding affinity; binding site; drug synthesis; hydrogen bond; ligand binding; molecular model; priority journal; quantitative structure activity relation; receptor affinity; receptor binding; structural homology; Binding Sites; Computer Simulation; Humans; Lactams; Protein Binding; Quantitative Structure-Activity Relationship; Receptors, Dopamine D2; Receptors, Dopamine D3",,"Lactams; Receptors, Dopamine D2; Receptors, Dopamine D3",,,,,,,"Jackson, D.M., Westlind-Danielsson, A., (1994) Pharmacol. Ther., 64, pp. 291-370; Missale, C., Nash, S.R., Robinson, S.W., Jaber, M., Caron, M.G., (1998) Physiol. Rev., 78, pp. 189-225; Sokoloff, P., Giros, B., Martres, M.P., Bouthenet, M.L., Schwartz, J.C., (1990) Nature, 347, pp. 146-151; Boeckler, F., Lanig, H., Gmeiner, P., (2005) J. Med. Chem., 48, pp. 694-709; Levant, B., (1997) Pharmacol. Rev., 49, pp. 231-252; Gurevich, E.V., Bordelon, Y., Shapiro, R.M., Arnold, S.E., Gur, R.E., Joyce, J.N., (1997) Arch. Gen. Psychiatry, 54, pp. 225-232; Schmauss, C., Haroutunian, V., Davis, K.L., Davidson, M., (1993) Proc. Natl. Acad. Sci. USA, 90, pp. 8942-8946; Schwartz, J.C., Diaz, J., Pilon, C., Sokoloff, P., (2000) Brain Res. Rev., 31, pp. 277-287; Joyce, J.N., Millan, M.J., (2005) Drug Discovery Today, 10, pp. 917-925; Marcus, M.M., Jardemark, K.E., Wadenberg, M., Langlois, X., Hertel, P., Svensson, T.H., (2005) Int. J. Neuropsychopharmacol., 8, pp. 315-327; Millan, M.J., Loiseau, F., Dekeyne, A., Gobert, A., Flik, G., Cremers, T.I., Rivet, J., Brocco, M., (2007) J. Pharmacol. Exp. Ther., 324, pp. 1212-1226; Kiss, B., Laszlovszky, I., Horváth, A., Némethy, Z., Schmidt, E., Bugovics, G., Fazekas, K., Szombathelyi, Z., (2008) Naunyn-Schmiedeberg's Arch. Pharmacol., 378, pp. 515-528; Bettinetti, L., Schlotter, K., Hübner, H., Gmeiner, P., (2002) J. Med. Chem., 45, pp. 4594-4597; Ortega, R., Raviña, E., Masaguer, C.F., Areias, F., Brea, J., Loza, M.I., López, L., Sanz, F., (2009) Bioorg. Med. Chem. Lett., 19, pp. 1773-1778; Tomita, M., Minami, S., Uyeo, S., (1969) J. Chem. Soc. C, pp. 183-188; Conley, R., (1958) J. Org. Chem., 23, pp. 1330-1333; Evans, D., Lockhart, I., (1965) J. Chem. Soc., pp. 4806-4812; Grunewald, G., Dahanukar, V., (1994) J. Heterocycl. Chem., 31, pp. 1609-1617; Mach, U.R., Hackling, A.E., Perachon, S., Ferry, S., Wermuth, C.G., Schwartz, J., Sokoloff, P., Stark, H., (2004) ChemBioChem, 5, pp. 508-518; Hackling, A., Ghosh, R., Perachon, S., Mann, A., Höltje, H., Wermuth, C.G., Schwartz, J., Stark, H., (2003) J. Med. Chem., 46, pp. 3883-3899; Norman, M.H., Rigdon, G.C., Navas, F., Cooper, B.R., (1994) J. Med. Chem., 37, pp. 2552-2563; Selent, J., López, L., Sanz, F., Pastor, M., (2008) ChemMedChem, 3, pp. 1194-1198; Durán, A., Martínez, G.C., Pastor, M., (2008) J. Chem. Inf. Model., 48, pp. 1813-1823; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., (2000) J. Med. Chem., 43, pp. 3233-3243; Ehrlich, K., Götz, A., Bollinger, S., Tschammer, N., Bettinetti, L., Härterich, S., Hübner, H., Gmeiner, P., (2009) J. Med. Chem., 52, pp. 4923-4935; Parker, E.M., Grisel, D.A., Iben, L.G., Shapiro, R.A., (1993) J. Neurochem., 60, pp. 380-383; Glennon, R.A., Dukat, M., Westkaemper, R.B., Ismaiel, A.M., Izzarelli, D.G., Parker, E.M., (1996) Mol. Pharmacol., 49, pp. 198-206; Fu, D., Ballesteros, J.A., Weinstein, H., Chen, J., Javitch, J.A., (1996) Biochemistry, 35, pp. 11278-11285; Arakawa, M., Yanamala, N., Upadhyaya, J., Halayako, A., Klein-Seetharaman, J., Chelikani, P., (2010) Protein Sci., 19, pp. 85-93; Sugimoto, Y., Fujisawa, R., Tanimura, R., Lattion, A.L., Cotecchia, S., Tsujimoto, G., Nagao, T., Kurose, H., (2002) J. Pharmacol. Exp. Ther., 301, pp. 51-58; Lundstrom, K., Turpin, M.P., Large, C., Robertson, G., Thomas, P., Lewell, X.Q., (1998) J. Recept. Signal Transduction Res., 18, pp. 133-150; Newman, A.H., Grundt, P., Cyriac, G., Deschamps, J.R., Taylor, M., Kumar, R., Ho, D., Luedtke, R.R., (2009) J. Med. Chem., 52, pp. 2559-2570; Lee, B., Chu, S., Lee, I., Lee, B., Song, C., Chi, D., (2000) Bull. Korean Chem. Soc., 21, pp. 860-866; Malinka, W., Sieklucka-Dziuba, M., Rajtar, G., Rubaj, A., Kleinrok, Z., (1999) Farmaco, 54, pp. 390-401; Malinka, W., Kaczmarz, M., Filipek, B., Sapa, J., Glod, B., (2002) Farmaco, 57, pp. 737-746; Santana, L., Uriarte, E., Fall, Y., Teijeira, M., Terán, C., García-Martínez, E., Tolf, B., (2002) Eur. J. Med. Chem., 37, pp. 503-510; Mokrosz, J.L., Duszyńska, B., Paluchowska, M.H., (1994) Arch. Pharm., 327, pp. 529-531; Geneste, H., Backfisch, G., Braje, W., Delzer, J., Haupt, A., Hutchins, C.W., King, L.L., Wernet, W., (2006) Bioorg. Med. Chem. Lett., 16, pp. 658-662; Ballesteros, J., Weinstein, H., (1995) Methods Neurosci., 25, pp. 366-428; Boeckmann, B., Bairoch, A., Apweiler, R., Blatter, M., Estreicher, A., Gasteiger, E., Martin, M.J., Schneider, M., (2003) Nucleic Acids Res., 31, pp. 365-370; Thompson, J.D., Higgins, D.G., Gibson, T.J., (1994) Nucleic Acids Res., 22, pp. 4673-4680; Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., Higgins, D.G., (1997) Nucleic Acids Res., 25, pp. 4876-4882; Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G.F., Thian, F.S., Kobilka, T.S., Choi, H., Stevens, R.C., (2007) Science, 318, pp. 1258-1265; Rasmussen, S.G.F., Choi, H., Rosenbaum, D.M., Kobilka, T.S., Thian, F.S., Edwards, P.C., Burghammer, M., Kobilka, B.K., (2007) Nature, 450, pp. 383-387; Baldwin, J.M., Schertler, G.F., Unger, V.M., (1997) J. Mol. Biol., 272, pp. 144-164; Sali, A., Blundell, T.L., (1993) J. Mol. Biol., 234, pp. 779-815; Cornell, W., Cieplak, P., Bayly, C., Gould, I., Merz, K., Ferguson, D., Sepellmeyer, D., (1995) J. Am. Chem. Soc., 117, pp. 5179-5197; Laskowski, R., MacArthur, M., Moss, D., Thornton, J., (1993) J. Appl. Crystallogr., 26, pp. 283-291; Ballesteros, J.A., Jensen, A.D., Liapakis, G., Rasmussen, S.G., Shi, L., Gether, U., Javitch, J.A., (2001) J. Biol. Chem., 276, pp. 29171-29177; Bissantz, C., (2003) J. Recept. Signal Transduction Res., 23, pp. 123-153; Shapiro, D.A., Kristiansen, K., Weiner, D.M., Kroeze, W.K., Roth, B.L., (2002) J. Biol. Chem., 277, pp. 11441-11449; Sylte, I., Bronowska, A., Dahl, S.G., (2001) Eur. J. Pharmacol., 416, pp. 33-41; Shi, L., Liapakis, G., Xu, R., Guarnieri, F., Ballesteros, J.A., Javitch, J.A., (2002) J. Biol. Chem., 277, pp. 40989-40996; Gasteiger, J., Rudolph, C., Sadowski, J., (1990) Tetrahedron Comp. Method., 3, pp. 537-547; Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., (2003) Proteins, 52, pp. 609-623; Mansour, A., Meng, F., Meador-Woodruff, J.H., Taylor, L.P., Civelli, O., Akil, H., (1992) Eur. J. Pharmacol., 227, pp. 205-214; Wang, C.D., Gallaher, T.K., Shih, J.C., (1993) Mol. Pharmacol., 43, pp. 931-940; (2009) Pentacle, , v. 1.05, Molecular Discovery Ltd., UK; Durán, A., López, L., Pastor, M., unpublished results; Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Valigi, R., Clementi, S., (1993) Quant. Struct-Act. Relat., 12, pp. 9-20","Pastor, M.; Research Programme on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, 08003 Barcelona, Spain; email: manuel.pastor@upf.edu",,,,,,,,18607179,,,"20544783","English","ChemMedChem",Article,"Final",,Scopus,2-s2.0-77955101547
"Selent J., Sanz F., Pastor M., de Fabritiis G.","55891371700;7102263897;7102415847;22134417700;","Induced effects of sodium ions on dopaminergic G-protein coupled receptors",2010,"PLoS Computational Biology","6","8", e1000884,"","",,70,"10.1371/journal.pcbi.1000884","https://www.scopus.com/inward/record.uri?eid=2-s2.0-78049415021&doi=10.1371%2fjournal.pcbi.1000884&partnerID=40&md5=cbd864bcc6b2c951c3dbf724cc40c29e","Computer-Assisted Drug Design Laboratory, Research Unit on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, Barcelona, Spain; Integrative Biomedical Informatics Laboratory, Research Unit on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, Barcelona, Spain; Computational Biochemistry and Biophysics Laboratory, Research Unit on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, Barcelona, Spain","Selent, J., Computer-Assisted Drug Design Laboratory, Research Unit on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Integrative Biomedical Informatics Laboratory, Research Unit on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, Barcelona, Spain; Pastor, M., Computer-Assisted Drug Design Laboratory, Research Unit on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, Barcelona, Spain; de Fabritiis, G., Computational Biochemistry and Biophysics Laboratory, Research Unit on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, Barcelona, Spain","G-protein coupled receptors, the largest family of proteins in the human genome, are involved in many complex signal transduction pathways, typically activated by orthosteric ligand binding and subject to allosteric modulation. Dopaminergic receptors, belonging to the class A family of G-protein coupled receptors, are known to be modulated by sodium ions from an allosteric binding site, although the details of sodium effects on the receptor have not yet been described. In an effort to understand these effects, we performed microsecond scale all-atom molecular dynamics simulations on the dopaminergic D2 receptor, finding that sodium ions enter the receptor from the extracellular side and bind at a deep allosteric site (Asp2.50). Remarkably, the presence of a sodium ion at this allosteric site induces a conformational change of the rotamer toggle switch Trp6.48 which locks in a conformation identical to the one found in the partially inactive state of the crystallized human β2 adrenergic receptor. This study provides detailed quantitative information about binding of sodium ions in the D2 receptor and reports a possibly important sodium-induced conformational change for modulation of D2 receptor function. © 2010 Selent et al.",,"beta 2 adrenergic receptor; dopamine 2 receptor; G protein coupled receptor; membrane protein; sodium ion; article; binding site; conformational transition; controlled study; crystallization; extracellular space; molecular dynamics; protein conformation; protein function; protein localization; receptor affinity; receptor binding; signal transduction; structure analysis; Allosteric Regulation; Allosteric Site; Humans; Molecular Dynamics Simulation; Protein Conformation; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Receptors, G-Protein-Coupled; Sodium",,"sodium ion, 17341-25-2; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2; Receptors, G-Protein-Coupled; Sodium, 7440-23-5",,,,,,,"Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G., Thian, F.S., High-resolution crystal structure of an engineered human beta2- adrenergic G protein-coupled receptor (2007) Science, 318, pp. 1258-1265; Hanson, M.A., Cherezov, V., Griffith, M.T., Roth, C.B., Jaakola, V., A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor (2008) Structure, 16, pp. 897-905; Warne, T., Serrano-Vega, M.J., Baker, J.G., Moukhametzianov, R., Edwards, P.C., Structure of a beta1-adrenergic G-protein-coupled receptor (2008) Nature, 454, pp. 486-491; Jaakola, V., Griffith, M.T., Hanson, M.A., Cherezov, V., Chien, E.Y.T., The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist (2008) Science, 322, pp. 1211-1217; Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Crystal structure of rhodopsin: A G protein-coupled receptor (2000) Science, 289, pp. 739-745; Granier, S., Kim, S., Fung, J.J., Bokoch, M.P., Parnot, C., FRET-based measurement of GPCR conformational changes (2009) Methods Mol Biol, 552, pp. 253-268; Hoffmann, C., Zürn, A., Bünemann, M., Lohse, M.J., Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open (2008) Br J Pharmacol 153 Suppl, 1, pp. 358-366; Ericksen, S.S., Cummings, D.F., Weinstein, H., Schetz, J.A., Ligand Selectivity of D2 Dopamine Receptors Is Modulated by Changes in Local Dynamics Produced by Sodium Binding (2009) J Pharmacol Exp Ther, 328, pp. 40-54; Schetz, J.A., Allosteric modulation of dopamine receptors (2005) Mini Rev Med Chem, 5, pp. 555-561; Neve, K.A., Cox, B.A., Henningsen, R.A., Spanoyannis, A., Neve, R.L., Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase (1991) Mol Pharmacol, 39, pp. 733-739; Javitch, J.A., Ballesteros, J.A., Chen, J., Chiappa, V., Simpson, M.M., Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: Contributions of the second membrane-spanning segment (1999) Biochemistry, 38, pp. 7961-7968; Ceresa, B., Limbird, L., Mutation of an aspartate residue highly conserved among G-protein- coupled receptors results in nonreciprocal disruption of alpha 2- adrenergic receptor-G-protein interactions. A negative charge at amino acid residue 79 forecasts alpha 2A-adrenergic receptor sensitivity to allosteric modulation by monovalent cations and fully effective receptor/G-protein coupling (1994) J Biol Chem, 269, pp. 29557-29564; Neve, K., Regulation of dopamine D2 receptors by sodium and pH (1991) Mol Pharmacol, 39, pp. 570-578; Ballesteros, J., Weinstein, H., Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G-protein coupled receptor (1995) Methods Neurosci, 25, pp. 366-428; Schetz, J.A., Sibley, D.R., The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation (2001) J Pharmacol Exp Ther, 296, pp. 359-363; Neve, K.A., Cumbay, M.G., Thompson, K.R., Yang, R., Buck, D.C., Modeling and Mutational Analysis of a Putative Sodium-Binding Pocket on the Dopamine D2 Receptor (2001) Mol Pharmacol, 60, pp. 373-381; Laio, A., Parrinello, M., Escaping free-energy minima (2002) Proc Natl Acad Sci U S A, 99, pp. 12562-12566; Laio, A., Gervasio, F.L., Metadynamics: A method to simulate rare events and reconstruct the free energy in biophysics, chemistry and material science (2008) Rep Prog Phys, 71, p. 126601; Scheerer, P., Park, J.H., Hildebrand, P.W., Kim, Y.J., Krauss, N., Crystal structure of opsin in its G-protein-interacting conformation (2008) Nature, 455, pp. 497-502; Park, J.H., Scheerer, P., Hofmann, K.P., Choe, H., Ernst, O.P., Crystal structure of the ligand-free G-protein-coupled receptor opsin (2008) Nature, 454, pp. 183-187; Ruprecht, J.J., Mielke, T., Vogel, R., Villa, C., Schertler, G.F.X., Electron crystallography reveals the structure of metarhodopsin I (2004) EMBO J, 23, pp. 3609-3620; Yao, X., Parnot, C., Deupi, X., Ratnala, V.R.P., Swaminath, G., Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor (2006) Nat Chem Biol, 2, pp. 417-422; Swaminath, G., Deupi, X., Lee, T.W., Zhu, W., Thian, F.S., Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists (2005) J Biol Chem, 280, pp. 22165-22171; Mobarec, J.C., Sanchez, R., Filizola, M., Modern Homology Modeling of GProtein Coupled Receptors: Which Structural Template to Use? (2009) J Med Chem, 52, pp. 5207-5216; Forrest, L.R., Tang, C.L., Honig, B., On the Accuracy of Homology Modeling and Sequence Alignment Methods Applied to Membrane Proteins (2006) Biophys J, 91, pp. 508-517; McKerell, B.D., Bellott, Dunbrack, Evanseck, J.D., All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins{ (1998) J Phys Chem B, 102, pp. 3586-3616; Motulsky, H.J., Insel, P.A., Influence of sodium on the alpha 2-adrenergic receptor system of human platelets. Role for intraplatelet sodium in receptor binding (1983) J Biol Chem, 258, pp. 3913-3919; Huber, T., Menon, S., Sakmar, T.P., Structural Basis for Ligand Binding and Specificity in Adrenergic Receptors: Implications for GPCR-Targeted Drug Discovery{ (2008) Biochemistry, 47, pp. 11013-11023; Dror, R.O., Arlow, D.H., Borhani, D.W., Jensen, M.O., Piana, S., Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations (2009) Proc Natl Acad Sci U S A, 106, pp. 4689-4694; http://www.vimeo.com/7900216; Bhattacharya, S., Hall, S.E., Vaidehi, N., Agonist-induced conformational changes in bovine rhodopsin: Insight into activation of G-protein-coupled receptors (2008) J Mol Biol, 382, pp. 539-555; Bonomi, M., Branduardi, D., Bussi, G., Camilloni, C., Provasi, D., PLUMED: A portable plugin for free-energy calculations with molecular dynamics (2009) Comput Phys Commun, 180, pp. 1961-1972; Wilson, M.H., Highfield, H.A., Limbird, L.E., The role of a conserved intertransmembrane domain interface in regulating alpha(2a)-adrenergic receptor conformational stability and cell-surface turnover (2001) Mol Pharmacol, 59, pp. 929-938; Selent, J., López, L., Sanz, F., Pastor, M., Multi-receptor binding profile of clozapine and olanzapine: A structural study based on the new beta2 adrenergic receptor template (2008) Chem Med Chem, 3, pp. 1194-1198; Humphrey, W., Dalke, A., Schulten, K., VMD: Visual molecular dynamics (1996) J Mol Graph, 14, pp. 33-38+27-28; Harvey, M.J., Giupponi, G., De Fabritiis, G., ACEMD: Accelerating Biomolecular Dynamics in the Microsecond Time Scale (2009) J Chem Theory Comput, 5, pp. 1632-1639; Harvey, M.J., De Fabritiis, G., An Implementation of the Smooth Particle Mesh Ewald Method on GPU Hardware (2009) J Chem Theory Comput, 5, pp. 2371-2377; Buch, I., Harvey, M.J., Giorgino, T., Anderson, D.P., De Fabritiis, G., Highthroughput all-atom molecular dynamics simulations using distributed computing (2010) J Chem Inf and Mod, 50, pp. 397-403; Giupponi, G., Harvey, M.J., De Fabritiis, G., The impact of accelerator processors for high-throughput molecular modeling and simulation (2008) Drug Discov Today, 13, pp. 1052-1058","de Fabritiis, G.; Computational Biochemistry and Biophysics Laboratory, Research Unit on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, Barcelona, Spain; email: gianni.defabritiis@upf.edu",,,,,,,,1553734X,,,"20711351","English","PLoS Comput. Biol.",Article,"Final",Open Access,Scopus,2-s2.0-78049415021
"Selent J., Bauer-Mehren A., López L., Loza M.I., Sanz F., Pastor M.","55891371700;35572639000;56948275300;7003766926;7102263897;7102415847;","A novel multilevel statistical method for the study of the relationships between multireceptorial binding affinity profiles and in vivo endpoints",2010,"Molecular Pharmacology","77","2",,"149","158",,10,"10.1124/mol.109.060103","https://www.scopus.com/inward/record.uri?eid=2-s2.0-74549202822&doi=10.1124%2fmol.109.060103&partnerID=40&md5=f9cc00118b761b21f59e3a4c5fe4f110","Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, Spain","Selent, J., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Bauer-Mehren, A., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; López, L., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Loza, M.I., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Pastor, M., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain","The present work introduces a novel method for drug research based on the sequential building of linked multivariate statistical models, each one introducing a different level of drug description. The use of multivariate methods allows us to overcome the traditional one-target assumption and to link in vivo endpoints with drug binding profiles, involving multiple receptors. The method starts with a set of drugs, for which in vivo or clinical observations and binding affinities for potentially relevant receptors are known, and allows obtaining predictions of the in vivo endpoints highlighting the most influential receptors. Moreover, provided that the structure of the receptor binding sites is known (experimentally or by homology modeling), the proposed method also highlights receptor regions and ligand-receptor interactions that are more likely to be linked to the in vivo endpoints, which is information of high interest for the design of novel compounds. The method is illustrated by a practical application dealing with the study of the metabolic side effects of antipsychotic drugs. Herein, the method detects related receptors confirmed by experimental results. Moreover, the use of structural models of the receptor binding sites allows identifying regions and ligand-receptor interactions that are involved in the discrimination between antipsychotic drugs that show metabolic side effects and those that do not. The structural results suggest that the topology of a hydrophobic sandwich involving residues in transmembrane helices (TM) 3, 5, and 6, as well as the assembling of polar residues in TM5, are important discriminators between target/antitarget receptors. Ultimately, this will provide useful information for the design of safer compounds inducing fewer side effects. Copyright © 2010 The American Society for Pharmacology and Experimental Therapeutics.",,"aripiprazole; bromperidol; chlorpromazine; chlorprothixene; clozapine; dopamine receptor; fluphenazine; haloperidol; loxapine; melperone; mesoridazine; molindone; neuroleptic agent; olanzapine; perphenazine; pimozide; prochlorperazine; quetiapine; remoxipride; risperidone; serotonin 1A receptor; serotonin receptor; sertindole; sulpiride; thioridazine; tiotixene; trifluoperazine; unindexed drug; ziprasidone; zotepine; adverse outcome; article; drug binding site; drug receptor binding; drug research; drug structure; experimental model; human; hydrophobicity; hyperglycemia; in vivo study; metabolic disorder; molecular interaction; non insulin dependent diabetes mellitus; priority journal; receptor affinity; side effect; statistical model; weight gain; Amino Acid Sequence; Antipsychotic Agents; Binding Sites; Endpoint Determination; Ligands; Models, Chemical; Models, Statistical; Molecular Sequence Data; Protein Binding; Receptors, Cell Surface",,"aripiprazole, 129722-12-9; bromperidol, 10457-90-6; chlorpromazine, 50-53-3, 69-09-0; chlorprothixene, 113-59-7, 6469-93-8; clozapine, 5786-21-0; fluphenazine, 146-56-5, 69-23-8; haloperidol, 52-86-8; loxapine, 1977-10-2; melperone, 1622-79-3, 3575-80-2; mesoridazine, 5588-33-0; molindone, 15622-65-8, 7416-34-4; olanzapine, 132539-06-1; perphenazine, 58-39-9; pimozide, 2062-78-4; prochlorperazine, 58-38-8; quetiapine, 111974-72-2; remoxipride, 78810-02-3, 80125-14-0, 82935-42-0; risperidone, 106266-06-2; sertindole, 106516-24-9; sulpiride, 15676-16-1; thioridazine, 130-61-0, 50-52-2; tiotixene, 5591-45-7; trifluoperazine, 117-89-5, 440-17-5; ziprasidone, 118289-78-4, 122883-93-6, 138982-67-9, 199191-69-0; zotepine, 26615-21-4; Antipsychotic Agents; Ligands; Receptors, Cell Surface",,,,,,,"Altar, C.A., Vawter, M.P., Ginsberg, S.D., Target identification for CNS diseases by transcriptional profiling (2009) Neuropsychopharmacology, 34, pp. 18-54; Farwell, W.R., Stump, T.E., Wang, J., Tafesse, E., L'Italien, G., Tierney, W.M., Weight gain and new onset diabetes associated with olanzapine and risperidone (2004) J Gen Intern Med, 19, pp. 1200-1205; Filizola, M., Weinstein, H., The study of G-protein coupled receptor oligomerization with computational modeling and bioinformatics (2005) FEBS J, 272, pp. 2926-2938; González-Maeso, J., Ang, R.L., Yuen, T., Chan, P., Weisstaub, N.V., López-Giménez, J.F., Zhou, M., Milligan, G., Identification of a serotonin/glutamate receptor complex implicated in psychosis (2008) Nature, 452, pp. 93-97; Gottfries, J., The drug designer's guide to selectivity (2006) Chemometrics Intellig Lab Syst, 83, pp. 148-156; Gurevich, V.V., Gurevich, E.V., How and why do GPCRs dimerize? (2008) Trends Pharmacol Sci, 29, pp. 234-240; Hwa, J., Gaivin, R., Porter, J.E., Perez, D.M., Synergism of constitutive activity in alpha 1-adrenergic receptor activation (1997) Biochemistry, 36, pp. 633-639; Kim, S.F., Huang, A.S., Snowman, A.M., Teuscher, C., Snyder, S.H., From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase (2007) Proc Natl Acad Sci U S A, 104, pp. 3456-3459; Kobilka, B., Agonist binding: A multistep process (2004) Mol Pharmacol, 65, pp. 1060-1062; Kota, P., Reeves, P.J., Rajbhandary, U.L., Khorana, H.G., Opsin is present as dimers in COS1 cells: Identification of amino acids at the dimeric interface (2006) Proc Natl Acad Sci U S A, 103, pp. 3054-3059; Lange, J.H., Reinders, J.H., Tolboom, J.T., Glennon, J.C., Coolen, H.K., Kruse, C.G., Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs (2007) J Med Chem, 50, pp. 5103-5108; Lieberman, J.A., Mailman, R.B., Duncan, G., Sikich, L., Chakos, M., Nichols, D.E., Kraus, J.E., Serotonergic basis of antipsychotic drug effects in schizophrenia (1998) Biol Psychiatry, 44, pp. 1099-1117; Liu, K.G., Robichaud, A.J., 5-HT6 antagonists as potential treatment for cognitive dysfunction (2009) Drug Dev Res, 70, pp. 145-168; Lu, Z.L., Hulme, E.C., The functional topography of transmembrane domain 3 of the M1 muscarinic acetylcholine receptor, revealed by scanning mutagenesis (1999) J Biol Chem, 274, pp. 7309-7315; Millan, M.J., Dekeyne, A., Gobert, A., Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo (1998) Neuropharmacology, 37, pp. 953-955; O'Neill, M.F., Unusual suspect for antipsychotic-induced diabetes (2005) Drug Discov Today, 10, pp. 1338-1338; Porter, J.E., Hwa, J., Perez, D.M., Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint (1996) J Biol Chem, 271, pp. 28318-28323; Reynolds, G.P., Hill, M.J., Kirk, S.L., The 5-HT2C receptor and antipsychoticinduced weight gain-mechanisms and genetics (2006) J Psychopharmacol, 20, pp. 15-18; Reynolds, G.P., Templeman, L.A., Zhang, Z.J., The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment (2005) Prog Neuropsychopharmacol Biol Psychiatry, 29, pp. 1021-1028; Roth, B.L., Meltzer, H.Y., Khan, N., Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors (1998) Adv Pharmacol, 42, pp. 482-485; Roth, B.L., Sheffler, D.J., Kroeze, W.K., Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia (2004) Nat Rev Drug Discov, 3, pp. 353-359; Selent, J., López, L., Sanz, F., Pastor, M., Multi-receptor binding profile of clozapine and olanzapine: A structural study based on the new beta2 adrenergic receptor template (2008) ChemMedChem, 3, pp. 1194-1198; Silvestre, J.S., Prous, J., Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes (2005) Methods Find Exp Clin Pharmacol, 27, pp. 289-304; Surgand, J.S., Rodrigo, J., Kellenberger, E., Rognan, D., A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors (2006) Proteins, 62, pp. 509-538; Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., Improved protein-ligand docking using GOLD (2003) Proteins, 52, pp. 609-623; Wang, X.S., Tang, H., Golbraikh, A., Tropsha, A., Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F (2008) J Chem Inf Model, 48, pp. 997-1013; Waters, M.L., Aromatic interactions in model systems (2002) Curr Opin Chem Biol, 6, pp. 736-741; Wold, S., Esbensen, K., Geladi, P., Principal component analysis (1987) Chemometrics Intell Lab Syst, 2, pp. 37-52; Wold, S., Sjöström, M., Eriksson, L., PLS-regression: A basic tool of chemometrics (2001) Chemometrics Intell Lab Syst, 58, pp. 109-130","Pastor, M.; Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; email: manuel.pastor@upf.edu",,,,,,,,0026895X,,MOPMA,"19903829","English","Mol. Pharmacol.",Article,"Final",,Scopus,2-s2.0-74549202822
"Furlong L.I., Sanz F.","34770469800;7102263897;","Identification of sequence variants of genes from biomedical literature: The OSIRIS approach",2009,"Information Retrieval in Biomedicine: Natural Language Processing for Knowledge Integration",,,,"289","300",,,"10.4018/978-1-60566-274-9.ch015","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901542974&doi=10.4018%2f978-1-60566-274-9.ch015&partnerID=40&md5=bb22c2f6447a93db2ed55def2066b902","Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra (UPF), Spain","Furlong, L.I., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra (UPF), Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra (UPF), Spain","SNPs constitute key elements in genetic epidemiology and pharmacogenomics. While data about genetic variation is found at sequence databases, functional and phenotypic information on consequences of the variations resides in literature. Literature mining is mainly hampered by the terminology problem. Thus, automatic systems for the identification of citations of allelic variants of genes in biomedical texts are required. We have reported the development of OSIRIS, aimed at retrieving literature about allelic variants of genes, a system that evolved towards a new version incorporating a new entity recognition module. The new version is based on a terminology of variations and a pattern-based search algorithm for the identification of variation terms and their disambiguation to dbSNP identifiers. OSIRISv1.2 can be used to link literature references to dbSNP database entries with high accuracy, and is suitable for collecting current knowledge on gene sequence variations for supporting the functional annotation of variation databases. © 2009, IGI Global.",,,,,,,,,,,"Ananiadou, S., Kell, D.B., Tsujii, J., Text mining and its potential applications in systems biology (2006) Trends Biotechnol, 24 (12), pp. 571-579; Ananiadou, S., McNaught, J., (2006) Text Mining for Biology and Biomedicine, , Boston, Artech House; Bonis, J., Furlong, L.I., Sanz, F., OSIRIS: A tool for retrieving literature about sequence variants (2006) Bioinformatics, 22 (20), pp. 2567-2569; Brookes, A.J., The essence of SNPs (1999) Gene, 234 (2), pp. 177-186; Burton, P.R., Tobin, M.D., Hopper, J.L., Key concepts in genetic epidemiology (2005) Lancet, 366 (9489), pp. 941-951; Caporaso, J.G., Baumgartner Jr., W.A., Randolph, D.A., Cohen, K.B., Hunter, L., Mutationfinder: A high-performance system for extracting point mutation mentions from text (2007) Bioinformatics, 23 (14), pp. 1862-1865; den Dunnen, J.T., Antonarakis, S.E., Nomenclature for the description of human sequence variations (2001) Hum Genet, 109 (1), pp. 121-124; Erdogmus, M., Sezerman, O.U., Application of automatic mutation-gene pair extraction to diseases (2007) J Bioinform Comput Biol, 5 (6), pp. 1261-1275; Furlong, L.I., Dach, H., Hofmann-Apitius, M., Sanz, F., OSIRISv1.2: A named entity recognition system for sequence variants of genes in biomedical literature (2008) BMC Bioinformatics, 9 (1), p. 84; Hanisch, D., Fundel, K., Mevissen, H.T., Zimmer, R., Fluck, J., Prominer: Rule-based protein and gene entity recognition (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S14; Horn, F., Lau, A.L., Cohen, F.E., Automated extraction of mutation data from the literature: Application of mutext to G proteincoupled receptors and nuclear hormone receptors (2004) Bioinformatics, 20 (4), pp. 557-568; Jensen, L.J., Saric, J., Bork, P., Literature mining for the biologist: From information retrieval to biological discovery (2006) Nat Rev Genet, 7 (2), pp. 119-129; Kanagasabai, R., Choo, K.H., Ranganathan, S., Baker, C.J., A workflow for mutation extraction and structure annotation (2007) J Bioinform Comput Biol, 5 (6), pp. 1319-1337; Kimchi-Sarfaty, C., Oh, J.M., Kim, I.W., Sauna, Z.E., Calcagno, A.M., Ambudkar, S.V., A ""silent"" polymorphism in the MDR1 gene changes substrate specificity (2007) Science, 315 (5811), pp. 525-528; Klinger, R., Friedrich, C.M., Mevissen, H.T., Fluck, J., Hofmann-Apitius, M., Furlong, L.I., Identifying gene-specific variations in biomedical text (2007) J Bioinform Comput Biol, 5 (6), pp. 1277-1296; Lee, L.C., Horn, F., Cohen, F.E., Automatic extraction of protein point mutations using a graph bigram association (2007) PLoS Comput Biol, 3 (2), pp. e16; Levy, S., Sutton, G., Ng, P.C., Feuk, L., Halpern, A.L., Walenz, B.P., The diploid genome sequence of an individual human (2007) PLoS Biol, 5 (10), pp. e254; McDonald, R.T., Winters, R.S., Mandel, M., Jin, Y., White, P.S., Pereira, F., An entity tagger for recognizing acquired genomic variations in cancer literature (2004) Bioinformatics, 20 (17), pp. 3249-3251; Park, J.C., Kim, J.-J., Named entity recognition (2006) Text Mining for Biology and Biomedicine, pp. 121-142. , In S. Ananiadou & J. McNaught (Eds.), London: Artech House Books; Rebholz-Schuhmann, D., Marcel, S., Albert, S., Tolle, R., Casari, G., Kirsch, H., Automatic extraction of mutations from medline and cross-validation with OMIM (2004) Nucleic Acids Res, 32 (1), pp. 135-142; Shastry, B.S., Snps in disease gene mapping, medicinal drug development and evolution (2007) J Hum Genet, 52 (11), pp. 871-880; Shatkay, H., Feldman, R., Mining the biomedical literature in the genomic era: An overview (2003) J Comput Biol, 10 (6), pp. 821-855; Sherry, S.T., Ward, M., Sirotkin, K., Dbsnp-database for single nucleotide polymorphisms and other classes of minor genetic variation (1999) Genome Res, 9 (8), pp. 677-679","Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra (UPF)Spain",,,"IGI Global",,,,,,9781605662749,,,"English","Info. Retr. in Biomed.: Nat. Lang. Proc. for Knowledge Intgn.",Book Chapter,"Final",,Scopus,2-s2.0-84901542974
"Mayer M.A., Leis Á., Sanz F.","36971031500;35072969800;7102263897;","Health information on the internet and trust marks as quality indicators: Vaccines case study [Información sobre salud en internet y sellos de confianza como indicadores de calidad: El caso de las vacunas]",2009,"Atencion Primaria","41","10",,"534","542",,21,"10.1016/j.aprim.2009.02.003","https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349592390&doi=10.1016%2fj.aprim.2009.02.003&partnerID=40&md5=f933075f42e623dec50aa2566db745a7","Departamento de Web Médica Acreditada, Colegio Oficial de Médicos de Barcelona, Barcelona, Spain; IMIM-Hospital del Mar, Departamento de Ciencias Experimentales Y de la Salud, Universidad Pompeu Fabra, Barcelona, Spain","Mayer, M.A., Departamento de Web Médica Acreditada, Colegio Oficial de Médicos de Barcelona, Barcelona, Spain, IMIM-Hospital del Mar, Departamento de Ciencias Experimentales Y de la Salud, Universidad Pompeu Fabra, Barcelona, Spain; Leis, Á., Departamento de Web Médica Acreditada, Colegio Oficial de Médicos de Barcelona, Barcelona, Spain; Sanz, F., IMIM-Hospital del Mar, Departamento de Ciencias Experimentales Y de la Salud, Universidad Pompeu Fabra, Barcelona, Spain","Objectives: To find out the prevalence of quality trust marks present in websites and to analyse the quality of these websites displaying trust marks compared with those that do not display them, in order to put forward these trust marks as a quality indicator. Design: Cross-sectional study. Setting: Internet. Participants: Websites on vaccines. Main measures: Using ""vacunas OR vaccines"" as key words, the features of 40 web pages were analysed. These web pages were selected from the page results of two search engines, Google and Yahoo! Results: Based on a total of 9 criteria, the average score of criteria fulfilled was 7 (95% CI 3.96-10.04) points for the web pages offered by Yahoo! and 7.3 (95% CI 3.86-10.74) offered by Google. Amongst web pages offered by Yahoo!, there were three with clearly inaccurate information, while there were four in the pages offered by Google. Trust marks were displayed in 20% and 30% medical web pages, respectively, and their presence reached statistical significance (P=0.033) when fulfilling the quality criteria compared with web pages where trust marks were not displayed. Conclusions: A wide variety of web pages was obtained by search engines and a large number of them with useless information. Although the websites analysed had a good quality, between 15% and 20% showed inaccurate information. Websites where trust marks were displayed had more quality than those that did not display one and none of them were included amongst those where inaccurate information was found. © 2008 Elsevier España, S.L. All rights reserved.","Health information; Internet; Quality assurance; Vaccines","vaccine; article; confidence interval; cross-sectional study; Internet; medical information; prevalence; quality control; statistical significance; trust; web browser; Cross-Sectional Studies; Internet; Quality Control; Vaccines",,"Vaccines",,,,,,,"(2008) 10.o Encuesta General de Medios (EGM). Datos Generales de Usuarios de Internet en España, , http://download.aimc.es/aimc/03internet/macro2007.pdf, Asociación de Usuarios de Internet. Febrero [actualizado 28 febrero 2008] [citado 3 Oct 2008]. Disponible en:; Mayer, M.A., Leis, A., El correo electrónico en la relación médico- paciente: uso y recomendaciones generales (2006) Aten Primaria, 37, pp. 413-417; Martín-Sánchez, F., Carnicero, J., La información de salud en Internet. Cómo mejorar su calidad desde la perspectiva de los principales agentes implicados (2002) Luces Y Sombras de la Información de Salud en Internet, pp. 37-54. , Informe SEIS. Madrid: Editorial SEIS;; Rosenvinge, J.H., Laugerud, S., Hjortdahl, P., Trust in health Websites: A survey among Norwegian Internet users (2003) Journal of Telemedicine and Telecare, 9 (3), pp. 161-166. , DOI 10.1258/135763303767149979; Grocco, A.G., Villacís-Keever, M., Jadad, A.R., Analysis of cases of harm associated with use of health information on the Internet (2002) JAMA, 287, pp. 2869-2871; Mayer, M.A., Pareras, L.G., Leis, A., La Web 2.0 se presenta como una nueva plataforma de gestión de la información médica (2008) Aten Primaria, 40, pp. 39-42; Wilson, P., How to find the good and avoid the bad or ugly: A short guide to tools for rating quality of health information on the internet (2002) British Medical Journal, 324 (7337), pp. 598-600; Baur, C., Deering, M.J., Proposed frameworks to improve the quality of health web sites: Review (2000) MedGenMed [Serial Online], , http://medscape.com/Medscape/GeneralMedicine/journal/2000/v02.n05/ mgm0926.baur/mgm0926.baur-01.html, [citado 5 Sep 2008]. Disponible en; Gagliardi, A., Jadad, A.R., Examination of instruments used to rate quality of health information on the internet: Chronicle of a voyage with an unclear destination (2002) British Medical Journal, 324 (7337), pp. 569-573; Eysenbach, G., Powell, J., Kuss, O., Sa, E.-R., Empirical studies assessing the quality of health information for consumers on the World Wide Web: A systematic review (2002) Journal of the American Medical Association, 287 (20), pp. 2691-2700; Delamothe, T., Quality of websites: Kitemarking the west wind (2000) British Medical Journal, 321 (7265), pp. 843-844; Walji, M., Sagaram, S., Sagaram, D., Meric-Bernstam, F., Johnson, C., Mirza, N.Q., Bernstam, E.V., Efficacy of quality criteria to identify potentially harmful information: A cross-sectional survey of complementary and alternative medicine Web sites (2004) Journal of Medical Internet Research, 6 (2). , http://www.jmir.org/2004/2/e21/; Mayer, M.A., Acreditar webs de contenido sanitario, ¿necesidad imposible? (2001) Med Clin, 116, pp. 496-497. , (Barc); Risk, A., Dzenowagis, J., Review of Internet health information quality initiatives (2001) Journal of Medical Internet Research, 3 (4), pp. 17-45. , http://www.jmir.org/2001/4/e28/; eEurope 2002: Criterios de Calidad para Los Sitios Web Relacionados Con la Salud, , http://europa.eu.int/information_society/eeurope/ehealth/doc/ communication_acte_es_fin.pdf, Comisión de las comunidades europeas. [citado 7 Sep 2008]. Disponible en:; HONCode, , http://www.hon.ch, [citado 20 Sep 2008]. Disponible en:; Programa de Calidad Web del Colegio Oficial de Médicos de Barcelona, , http://wma.comb.es, [citado 20 Sep 2008]. Disponible en:; Jacobson, R.M., Targonsky, P.V., Poland, G.A., A taxonomy of reasoning flaws in the anti-vaccine movement (2007) Vaccine, 25, pp. 3146-3152; Wolfe, R.M., Sharp, L.K., Lipsky, M.S., Content and design attributes of antivaccination Web sites (2002) Journal of the American Medical Association, 287 (24), pp. 3245-3248; Fallows, D., (2005) Search Engines Users. Internet Searchers Are Confident, Satisfied and Trusting -but They Are Also Unaware and Naïve, , http://www.pewinternet.org/pdfs/PIP_Searchengine_users.pdf, Pew Internet & American Life Project. [citado 15 Ene 2008]. Disponible en:; Giustini, D., How Web 2.0 is changing medicine (2006) British Medical Journal, 333 (7582), pp. 1283-1284. , DOI 10.1136/bmj.39062.555405.80; http://www.google.es, [citado 2 May 2006]. Disponible en:; http://es.yahoo.com, [citado 2 May 2006]. Disponible en:; Babio, G.O., Bermúdez, C., García, J.F., Márquez, S., Selección Y Evaluación de Sitios Web Dirigidos a Pacientes Referidos Al Campo de la Salud. Informe 1/2006, , http://www.juntadeandalucia.es/salud/contenidos/aetsa/pdf/ Informe%20sitios%20web%20sobre%20salud_DEF.pdf, Consejería de Salud. [citado 9 Sep 2008]. Disponible en:; Chatterjee, A., Vaccine and immunization resources on the World Wide Web (2003) Clin Infect Dis, 36, pp. 355-362; Cline, R.J.W., Haynes, K.M., Consumer health information seeking on the Internet: The state of the art (2001) Health Edu Res, 16, pp. 671-692; Ernst, E., Schmidt, K., 'Alternative' cancer cures via the Internet? (2002) British Journal of Cancer, 87 (5), pp. 479-480. , DOI 10.1038/sj.bjc.6600513; Programa de Vacunación en Adultos, , http://www.msc.es/profesionales/saludPublica/prevPromocion/vacunaciones/ vacunasProfesionales.htm, Salud Pública. [actualizado 29 Sep 2004] [citado 20 Mar 2008]. Disponible en:; Vaccines & Immunizations. Recommendations and Guidelines, , http://www.cdc.gov/vaccines/recs/default.htm, Centros para el Control y la Prevención de Enfermedades. Departamento de Salud y Servicios Humanos. [actualizado 27 Mar 2008] [citado 30 Abr 2008]. Disponible en:; Berland, G.K., Elliott, M.N., Morales, L.S., Algazy, J.I., Kravitz, R.L., Broder, M.S., Kanouse, D.E., McGlynn, E.A., Health information on the internet: Accessibility, quality, and readability in English and Spanish (2001) Journal of the American Medical Association, 285 (20), pp. 2612-2621; Mayer, M.A., (2006) Evaluación de Los Sistemas de Acreditación de Webs Sanitarias. La Experiencia de Web Médica Acreditada, , [tesis doctoral] Universitat Pompeu Fabra Barcelona; Alvárez Pasquín, M.J., (2006) Recursos Sobre Vacunas e Inmunización, , http://www.vacunas.org/images/stories/recursos/profesionales/ temasactuales/2006/tema_mes_septiembre06.pdf, Internet [actualizado 30 septiembre] [citado 16 Jun 2008]. Disponible en:; Vaccine Safety Net, , http://www.who.int/immunization_safety/safety_quality/ vaccine_safety_websites/en/, Organización Mundial de la Salud (OMS) [citado 20 Jun 2008]. Disponible en:; http://www.vacsatc.eu, [citado 20 Jun 2008]. Disponible en:; Villarroel, D., Mayer, M.A., Leis, A., Karkaletsis, V., Stamatakis, K., Metsis, V., AQUA (Assisting Quality Assessment): A system based on semantic web and information extraction technologies to support medical quality labelling agencies (2007) Technol Health Care, 15, pp. 368-369; Mayer, M.A., Leis, A., Ruiz, P., Label validation and user notification based on semantic web technologies: A quality step further on the internet (2007) Proceedings of the EFMI Jun 2007; Brijuni, Croatia, pp. 168-173. , Bryden JS, De Lusignan S, Blobel B, Perovecki M, editores. Medical informatics in enlarged Europe","Mayer, M. A.; Departamento de Web Médica Acreditada, Colegio Oficial de Médicos de Barcelona, Barcelona, Spain; email: mmayer.wma@comb.es",,,,,,,,02126567,,ATEPE,"19428147","Spanish","Aten. Prim.",Article,"Final",Open Access,Scopus,2-s2.0-70349592390
"Pulido M., Manresa J.M., Mojal S., Sanz F.","7006383312;54379636500;26433700400;7102263897;","Analysis of knowledge of international criteria for authorship by the Spanish researchers [Análisis del conocimiento de los criterios internacionales de autoría por parte de los investigadores españoles]",2009,"Medicina Clinica","133","10",,"381","389",,4,"10.1016/j.medcli.2009.05.001","https://www.scopus.com/inward/record.uri?eid=2-s2.0-69949150614&doi=10.1016%2fj.medcli.2009.05.001&partnerID=40&md5=f043b7cb6410ed4d7f464d0d6aeb89cf","Editora Médica Independiente, Barcelona, Spain; Asesoramiento en Edición Y Publicaciones Biomédicas, Servicios Científicos-Técnicos, Hospital del Mar, Barcelona, Spain; Asesoramiento Metodológico en Bioestadística (AMIB), Servicios Científico-técnicos, Hospital del Mar, Barcelona, Spain; Unidad de Soporte a la Investigación (USR) Metropolitana Nord, Idiap Jordi Gol, Mataró, Barcelona, Spain; Unidad de Investigación en Informática Biomédica (GRIB-IMIM/UPF), Barcelona, Spain","Pulido, M., Editora Médica Independiente, Barcelona, Spain, Asesoramiento en Edición Y Publicaciones Biomédicas, Servicios Científicos-Técnicos, Hospital del Mar, Barcelona, Spain; Manresa, J.M., Asesoramiento Metodológico en Bioestadística (AMIB), Servicios Científico-técnicos, Hospital del Mar, Barcelona, Spain, Unidad de Soporte a la Investigación (USR) Metropolitana Nord, Idiap Jordi Gol, Mataró, Barcelona, Spain; Mojal, S., Asesoramiento Metodológico en Bioestadística (AMIB), Servicios Científico-técnicos, Hospital del Mar, Barcelona, Spain; Sanz, F., Unidad de Investigación en Informática Biomédica (GRIB-IMIM/UPF), Barcelona, Spain",[No abstract available],,"author; biotechnology; knowledge; MEDLINE; public health; publication; questionnaire; research; review; scientific literature; Spain; statistical analysis",,,,,,,,,"Huth, E.J., Irresponsible authorship and wasteful publication (1986) Ann Intern Med, 104, pp. 257-259; Bennett, D.M., Taylor, D.M., Unethical practices in authorship of scientific papers (2003) Emerg Med (Fremantle), 15, pp. 263-270; Grieger, M.C., Authorship: An ethical dilemma of science (2005) Sao Paulo Med J, 123, pp. 242-246; Fye, W.B., Medical authorship: Traditions, trends and tribulations (1990) Ann Intern Med, 113, pp. 317-325; Smith, J., Gift authorship: A poisoned chalice? (1994) BMJ, 309, pp. 1456-1457; Flanagin, A., Carey, L.A., Fontanarosa, P.B., Phillips, S.G., Pace, B.P., Lundberg, G.D., Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals (1998) JAMA, 280, pp. 222-224; Relman, A.S., Publish or perish-or both (1977) N Engl J Med, 297, pp. 724-725; Angell, M., Publish or perish: A proposal (1986) Ann Intern Med, 104, pp. 261-262; Guidelines on authorship (1985) BMJ, 291, p. 722. , International Committee of Medical Journal Editors; (2008) Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication, , http://www.icmje.org, International Committee of Medical Journal Editors. Actualizado Oct [citado 10 Sep 2008]. Disponible en:; Reisenberg, D., Lundberg, G.D., The order of authorship: Who's on first (1990) JAMA, 264, p. 1857; Rennie, D., Yank, V., Emanuel, L., When authorship fails: A proposal to make contributors accountable (1997) JAMA, 278, pp. 579-585; Smith, R., Authorship is dying: Long live contributorship (1997) BMJ, 315, p. 686; Yank, V., Rennie, D., Disclosure of research contributions: A study of original research articles in the Lancet (1999) Ann Intern Med, 130, pp. 661-670; White, A.H., Coudret, N.A., Goodwin, C.S., From authorship to contributorship. Promoting integrity in research publication (1998) Nurse Educ, 23, pp. 26-32; Friedman, P.J., (2008) A New Standard for Authorship, , http://www.councilscienceeditors.org/services/friedman_article.cfm, [citado 11 Sep]. Disponible en:; Shapiro, D.W., Wenger, N.S., Spahiro, M.F., The contribution of authors to multiauthored biomedical research papers (1994) JAMA, 271, pp. 438-442; Goodman, N.W., Survey of fulfillment of criteria for authorship in published medical research (1994) BMJ, 309, p. 1482; Eastwood, S., Derish, P., Leash, E., Ordway, S., Ethical issues in biomedical research: Perceptions and practices of postdoctoral research fellows responding to a survey (1996) Sci Eng Ethics, 2, pp. 89-114; Marusić, M., Bozikov, J., Katavić, V., Hren, D., Kljaković-Gaspić, M., Marusić, A., Authorship in a small medical journal: A study of contributorship statements by corresponding authors (2004) Sci Eng Ethics, 10, pp. 493-502; Consensus Statement on Surgery Journal Authorship - 2006 (2006) Ann Surg Oncol, 13, pp. 757-758; (2006) Metodología para la Búsqueda de Información Médica. Manual de Estudio del Curso MEBIM Elaborado Por El Personal del Centro de Información GlaxoSmithKline, , Fundación de Ciencias de la Salud, Madrid; Tobin, M.J., Authors, authors, authors-follow instructions or expected delay (2000) Am J Crit Care Med, 162, pp. 1193-1194; Schriger, D.L., Arora, S., Altman, D.G., The content of medical journal instructions for authors (2006) Ann Emerg Med, 48, pp. 743-749; Wager, E., Do medical journals provide clear and consistent guidelines on authorship? (2007) MedGenMed, 9, p. 16; Dhaliwal, U., Singh, N., Bhatia, A., Awareness of authorship criteria and conflict: Survey in a medical institution in India (2006) MedGenMed, 8, p. 52; Pignatelli, B., Maisonneuve, H., Chapuis, F., Authorship: Views of researchers in French clinical settings (2005) J Med Ethics, 10, pp. 578-581; Bates, T., Anić, A., Marusić, M., Marusić, A., Authorship criteria and disclosure of contributions: Comparison of 3 general medical journals with different author contribution forms (2004) JAMA, 292, pp. 86-88; Marusić, A., Bates, T., Anić, A., Marusić, M., How the structure of contribution disclosure statements affects validity of authorship: A randomized study in a general medical journal (2006) Curr Med Res Opin, 22, pp. 1035-1044; Ilakovac, V., Fister, K., Marusic, M., Marusic, A., Reliability of disclosure forms of authors' contributions (2007) CMAJ, 176, pp. 41-46; Slone, R.M., Coauthors' contributions to major papers published in the AJR: Frequency of undeserved coauthorship (1996) AJR Am J Roentgenol, 167, pp. 571-579; Hwang, S.S., Song, H.H., Baik, J.H., Jung, S.L., Park, S.H., Choi, K.H., Researcher contributions and fulfillment of ICMJE authorship criteria: Analysis of author contribution lists in research articles with multiple authors published in radiology (2003) Radiology, 226, pp. 16-23. , International Committee of Medical Journal Editors; Jacard, M., Herskovic, V., Hernández, I., Reyes, H., An analysis of authorship in articles published in Revista Médica de Chile (2002) Rev Med Chile, 130, pp. 1391-1398; Baerlocher, M.O., Newton, M., Gautam, T., Tomlinson, G., Detsky, A.S., The meaning of author order in medical research (2007) J Investig Med, 55, pp. 174-180; Davies, H.D., Langley, J.M., Speert, D.P., Rating authors' contributions to collaborative research: The PICNIC survey of university departments of pediatrics (1996) CMAJ, 155, pp. 877-882. , Pediatric Investigators' Collaborative Network on Infections in Canada; Fotion, N., Conrad, C.C., Authorship and other credits (1984) Ann Intern Med, 100, pp. 592-594; Paneth, N., Separating authorship responsibility and authorship credit: A proposal for biomedical journals (1998) Am J Public Health, 88, pp. 824-826; Drenth, J.P., Multiple authorship: The contribution of senior authors (1998) JAMA, 280, pp. 219-221; Weeks, W.B., Wallace, A.E., Kimberly, B.C., Changes in authorship patterns in prestigious US medical journals (2004) Soc Sci Med, 59, pp. 1949-1954; Mainous III, A.G., Bowman, M.A., Zoller, J.S., The importance of interpersonal relationship factors in decisions regarding authorship (2002) Fam Med, 34, pp. 462-467; Hoen, W.P., Walvoort, H.C., Overbeke, A.J., What are the factors determining authorship and the order of the authors' names? A study among authors of the Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine) (1998) JAMA, 280, pp. 217-218","Pulido, M.; Editora Médica Independiente, Barcelona, Spain; email: mpulido@imim.es",,,"Ediciones Doyma, S.L.",,,,,00257753,,MCLBA,"19596367","Spanish","Med. Clin.",Article,"Final",,Scopus,2-s2.0-69949150614
"Bauer-Mehren A., Furlong L.I., Rautschka M., Sanz F.","35572639000;34770469800;34168330800;7102263897;","From SNPs to pathways: Integration of functional effect of sequence variations on models of cell signalling pathways",2009,"BMC Bioinformatics","10","SUPPL. 8", S6,"","",,21,"10.1186/1471-2105-10-S8-S6","https://www.scopus.com/inward/record.uri?eid=2-s2.0-69549108299&doi=10.1186%2f1471-2105-10-S8-S6&partnerID=40&md5=610b358041f4e85b1266d46b3faade71","Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain","Bauer-Mehren, A., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain; Furlong, L.I., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain; Rautschka, M., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain","Background: Single nucleotide polymorphisms (SNPs) are the most frequent type of sequence variation between individuals, and represent a promising tool for finding genetic determinants of complex diseases and understanding the differences in drug response. In this regard, it is of particular interest to study the effect of non-synonymous SNPs in the context of biological networks such as cell signalling pathways. UniProt provides curated information about the functional and phenotypic effects of sequence variation, including SNPs, as well as on mutations of protein sequences. However, no strategy has been developed to integrate this information with biological networks, with the ultimate goal of studying the impact of the functional effect of SNPs in the structure and dynamics of biological networks. Results: First, we identified the different challenges posed by the integration of the phenotypic effect of sequence variants and mutations with biological networks. Second, we developed a strategy for the combination of data extracted from public resources, such as UniProt, NCBI dbSNP, Reactome and BioModels. We generated attribute files containing phenotypic and genotypic annotations to the nodes of biological networks, which can be imported into network visualization tools such as Cytoscape. These resources allow the mapping and visualization of mutations and natural variations of human proteins and their phenotypic effect on biological networks (e.g. signalling pathways, protein-protein interaction networks, dynamic models). Finally, an example on the use of the sequence variation data in the dynamics of a network model is presented. Conclusion: In this paper we present a general strategy for the integration of pathway and sequence variation data for visualization, analysis and modelling purposes, including the study of the functional impact of protein sequence variations on the dynamics of signalling pathways. This is of particular interest when the SNP or mutation is known to be associated to disease. We expect that this approach will help in the study of the functional impact of disease-associated SNPs on the behaviour of cell signalling pathways, which ultimately will lead to a better understanding of the mechanisms underlying complex diseases. © 2009 Bauer-Mehren et al; licensee BioMed Central Ltd.",,"Analysis and modelling; Biological networks; Network visualization; Protein-protein interaction networks; Sequence variations; Signalling pathways; Single nucleotide polymorphisms; Structure and dynamics; Complex networks; Data visualization; Dynamics; Integration; Proteins; Tools; Visualization; Integral equations; amino acid sequence; article; computer program; data analysis; data extraction; gene mutation; gene sequence; genetic association; genetic database; genetic variability; genotype phenotype correlation; protein protein interaction; signal transduction; single nucleotide polymorphism; biological model; chemistry; computer interface; computer simulation; information retrieval; methodology; phenotype; physiology; sequence analysis; signal transduction; systems biology; epidermal growth factor receptor; protein; Computer Simulation; Information Storage and Retrieval; Models, Biological; Phenotype; Polymorphism, Single Nucleotide; Proteins; Receptor, Epidermal Growth Factor; Sequence Analysis, Protein; Signal Transduction; Systems Biology; User-Computer Interface","SWISSPROT: Q07889","protein, 67254-75-5; Proteins; Receptor, Epidermal Growth Factor, 2.7.1.112","Cytoscape",,,,,,"Levy, S., Sutton, G., Ng, P.C., Feuk, L., Halpern, A.L., Walenz, B.P., Axelrod, N., Denisov, G., The diploid genome sequence of an individual human (2007) PLoS Biol, 5 (10), pp. e254. , 1964779 17803354 10.1371/journal.pbio.0050254; Jegga, A.G., Gowrisankar, S., Chen, J., Aronow, B.J., PolyDoms: A whole genome database for the identification of non-synonymous coding SNPs with the potential to impact disease (2007) Nucl Acids Res, 35, pp. D700-D706. , Database issue 10.1093/nar/gkl826 17142238 1669724; Cavallo, A., Martin, A.C., Mapping SNPs to protein sequence and structure data (2005) Bioinformatics, 21 (8), pp. 1443-1450. , 10.1093/bioinformatics/bti220 15613399; Reumers, J., Maurer-Stroh, S., Schymkowitz, J., Rousseau, F., SNPeffect v2.0: A new step in investigating the molecular phenotypic effects of human non-synonymous SNPs (2006) Bioinformatics, 22 (17), pp. 2183-2185. , 10.1093/bioinformatics/btl348 16809394; Kim, B.-C., Kim, W.-Y., Park, D., Chung, W.-H., Shin, K.-S., Bhak, J., SNPΠromoter: A database of human SNPs (Single Nucleotide Polymorphisms) within the putative promoter regions (2008) BMC Bioinformatics, 9 (SUPPL. 1), pp. S2. , 2259403 18315851 10.1186/1471-2105-9-S1-S2; Ryan, M., Diekhans, M., Lien, S., Liu, Y., Karchin, R., LS-SNP/PDB: Annotated non-synonymous SNPs mapped to Protein Data Bank structures (2009) Bioinformatics, 25 (11), pp. 1431-1432. , 10.1093/bioinformatics/btp242 19369493; (2005) Systems Biology in Practice. Concepts, Implementation, and Application, , KGaA, Weinheim: Wiley-VCH Verlag GmbH & Co 1; Kimchi-Sarfaty, C., Oh, J.M., Kim, I.W., Sauna, Z.E., Calcagno, A.M., Ambudkar, S.V., Gottesman, M.M., A ""silent"" polymorphism in the MDR1 gene changes substrate specificity (2007) Science, 315 (5811), pp. 525-528. , 10.1126/science.1135308 17185560; De Gobbi, M., Viprakasit, V., Hughes, J.R., Fisher, C., Buckle, V.J., Ayyub, H., Gibbons, R.J., de Jong, P., A Regulatory SNP Causes a Human Genetic Disease by Creating a New Transcriptional Promoter (2006) Science, 312 (5777), pp. 1215-1217. , 10.1126/science.1126431 16728641; Capon, F., Allen, M.H., Ameen, M., Burden, A.D., Tillman, D., Barker, J.N., Trembath, R.C., A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups (2004) Hum Mol Genet, 13 (20), pp. 2361-2368. , 10.1093/hmg/ddh273 15333584; Cartegni, L., Chew, S.L., Krainer, A.R., Listening to silence and understanding nonsense: Exonic mutations that affect splicing (2002) Nat Rev Genet, 3 (4), pp. 285-298. , 10.1038/nrg775 11967553; Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, K., dbSNP: The NCBI database of genetic variation (2001) Nucleic Acids Res, 29 (1), pp. 308-311. , 29783 11125122 10.1093/nar/29.1.308; Altshuler, D., Brooks, L.D., Chakravarti, A., Collins, F.S., Daly, M.J., Donnelly, P., A haplotype map of the human genome (2005) Nature, 437 (7063), pp. 1299-1320. , 1880871 16255080 10.1038/nature04226; Fredman, D., Siegfried, M., Yuan, Y.P., Bork, P., Lehvaslaiho, H., Brookes, A.J., HGVbase: A human sequence variation database emphasizing data quality and a broad spectrum of data sources (2002) Nucleic Acids Res, 30 (1), pp. 387-391. , 99093 11752345 10.1093/nar/30.1.387; Amberger, J., Bocchini, C.A., Scott, A.F., Hamosh, A., McKusick's Online Mendelian Inheritance in Man (OMIM) (2009) Nucleic Acids Res, 37, pp. D793-D796. , Database 2686440 18842627 10.1093/nar/gkn665; The Universal Protein Resource (UniProt) (2008) Nucleic Acids Res, 36, pp. D190-D195. , The UniProt Consortium Database issue 2238893 18045787; Description of the Annotation Process in UniProt, , http://www.uniprot.org/docs/annbioch.txt; Yip, Y.L., Scheib, H., Diemand, A.V., Gattiker, A., Famiglietti, L.M., Gasteiger, E., Bairoch, A., The Swiss-Prot variant page and the ModSNP database: A resource for sequence and structure information on human protein variants (2004) Hum Mutat, 23 (5), pp. 464-470. , 10.1002/humu.20021 15108278; Bader, G.D., Cary, M.P., Sander, C., Pathguide: A pathway resource list (2006) Nucleic Acids Res, 34, pp. D504-D506. , Database 1347488 16381921 10.1093/nar/gkj126; Matthews, L., Gopinath, G., Gillespie, M., Caudy, M., Croft, D., de Bono, B., Garapati, P., Jassal, B., Reactome knowledgebase of human biological pathways and processes (2009) Nucleic Acids Res, 37, pp. D619-D622. , Database 2686536 18981052 10.1093/nar/gkn863; Le Novere, N., Bornstein, B., Broicher, A., Courtot, M., Donizelli, M., Dharuri, H., Li, L., Shapiro, B., BioModels Database: A free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems (2006) Nucleic Acids Res, 34, pp. D689-D691. , Database issue 10.1093/nar/gkj092 16381960 1347454; Uzun, A., Leslin, C.M., Abyzov, A., Ilyin, V., Structure SNP (StSNP): A web server for mapping and modeling nsSNPs on protein structures with linkage to metabolic pathways (2007) Nucleic Acids Res, 35, pp. W384-W392. , Web server issue 10.1093/nar/gkm232 17537826 1933130; Song, Y.C., Kawas, E., Good, B.M., Wilkinson, M.D., Tebbutt, S.J., DataBiNS: A BioMoby-based data-mining workflow for biological pathways and non-synonymous SNPs (2007) Bioinformatics, 23 (6), pp. 780-782. , 10.1093/bioinformatics/btl648 17237074; Wang, P., Dai, M., Xuan, W., McEachin, R.C., Jackson, A.U., Scott, L.J., Athey, B., Meng, F., SNP Function Portal: A web database for exploring the function implication of SNP alleles (2006) Bioinformatics, 22 (14), pp. e523-e529. , 10.1093/bioinformatics/btl241 16873516; Chen, L., Zhang, L., Zhao, Y., Xu, L., Shang, Y., Wang, Q., Li, W., Li, X., Prioritizing risk pathways: A novel association approach to searching for disease pathways fusing SNPs and pathways (2009) Bioinformatics, 25 (2), pp. 237-242. , 10.1093/bioinformatics/btn613 19029127; BioPAX, , http://www.biopax.org/; SBML.org, , http://sbml.org/Main_Page; Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Ideker, T., Cytoscape: A software environment for integrated models of biomolecular interaction networks (2003) Genome Res, 13 (11), pp. 2498-2504. , 403769 14597658 10.1101/gr.1239303; The Gene Ontology, , http://www.geneontology.org/; Tartaglia, M., Pennacchio, L.A., Zhao, C., Yadav, K.K., Fodale, V., Sarkozy, A., Pandit, B., Schackwitz, W., Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome (2007) Nat Genet, 39 (1), pp. 75-79. , 10.1038/ng1939 17143282; OWL Web Ontology Language Guide, , http://www.w3.org/TR/owl-guide/; Noy, N.F., Semantic integration: A survey of ontology-based approaches SIGMOD Rec, 33 (4), pp. 65-70. , 10.1145/1041410.1041421; Ruttenberg, A., Clark, T., Bug, W., Samwald, M., Bodenreider, O., Chen, H., Doherty, D., Kashyap, V., Advancing translational research with the Semantic Web (2007) BMC Bioinformatics, 8 (SUPPL. 3), pp. S2. , 1892099 17493285 10.1186/1471-2105-8-S3-S2; Luciano, J., Stevens, R., E-Science and biological pathway semantics (2007) BMC Bioinformatics, 8 (SUPPL. 3), pp. S3. , 1892100 17493286 10.1186/1471-2105-8-S3-S3; Birtwistle, M.R., Hatakeyama, M., Yumoto, N., Ogunnaike, B.A., Hoek, J.B., Kholodenko, B.N., Ligand-dependent responses of the ErbB signaling network: Experimental and modeling analyses (2007), 3. , 2132449 18004277; Citri, A., Yarden, Y., EGF-ERBB signalling: Towards the systems level (2006), 7 (7), pp. 505-516. , 16829981; Oda, K., Kim, J.-D., Ohta, T., Okanohara, D., Matsuzaki, T., Tateisi, Y., Tsujii, Ji., New challenges for text mining: Mapping between text and manually curated pathways (2008) BMC Bioinformatics, 9 (SUPPL. 3), pp. S5. , 2352872 18426550 10.1186/1471-2105-9-S3-S5; Kim, J.D., Ohta, T., Tsujii, J., Corpus annotation for mining biomedical events from literature (2008) BMC Bioinformatics, 9, p. 10. , 2267702 18182099 10.1186/1471-2105-9-10; Hermjakob, H., Fleischmann, W., Apweiler, R., Swissknife - 'Lazy parsing' of SWISS-PROT entries (1999) Bioinformatics, 15 (9), pp. 771-772. , 10.1093/bioinformatics/15.9.771 10498781; Entrez Gene, , http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene; HUGO Gene Nomenclature Comittee, , http://www.genenames.org/; DbSNP Home Page, , http://www.ncbi.nlm.nih.gov/projects/SNP/; Yip, Y.L., Lachenal, N., Pillet, V., Veuthey, A.L., Retrieving mutation-specific information for human proteins in UniProt/ Swiss-Prot Knowledgebase (2007) J Bioinform Comput Biol, 5 (6), pp. 1215-1231. , 10.1142/S021972000700320X 18172926; Rebholz-Schuhmann, D., Kirsch, H., Arregui, M., Gaudan, S., Riethoven, M., Stoehr, P., EBIMed - Text crunching to gather facts for proteins from Medline (2007) Bioinformatics, 23 (2), pp. e237-e244. , 10.1093/bioinformatics/btl302 17237098; Rebholz-Schuhmann, D., Arregui, M., Gaudan, S., Kirsch, H., Jimeno, A., Text processing through Web services: Calling Whatizit (2008) Bioinformatics, 24 (2), pp. 296-298. , 10.1093/bioinformatics/btm557 18006544; Hoops, S., Sahle, S., Gauges, R., Lee, C., Pahle, J., Simus, N., Singhal, M., Kummer, U., COPASI - A COmplex PAthway SImulator (2006) Bioinformatics, 22 (24), pp. 3067-3074. , 10.1093/bioinformatics/btl485 17032683; The R Project for Statistical Computing, , http://www.r-project.org/; Frazer, K.A., Murray, S.S., Schork, N.J., Topol, E.J., Human genetic variation and its contribution to complex traits (2009) Nat Rev Genet, 10 (4), pp. 241-251. , 10.1038/nrg2554 19293820","Furlong, L.I.; Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital del Mar, Universitat Pompeu Fabra, C/Dr. Aiguader 88, 08003 Barcelona, Spain; email: lfurlong@imim.es",,,,,,,,14712105,,BBMIC,"19758470","English","BMC Bioinform.",Article,"Final",Open Access,Scopus,2-s2.0-69549108299
"Ortega R., Raviña E., Masaguer C.F., Areias F., Brea J., Loza M.I., López L., Selent J., Pastor M., Sanz F.","57196694775;56264803900;6701715235;6602594095;6603008588;7003766926;56948275300;55891371700;7102415847;7102263897;","Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands",2009,"Bioorganic and Medicinal Chemistry Letters","19","6",,"1773","1778",,28,"10.1016/j.bmcl.2009.01.067","https://www.scopus.com/inward/record.uri?eid=2-s2.0-61349150703&doi=10.1016%2fj.bmcl.2009.01.067&partnerID=40&md5=cf67f29b39876133ac48ceb124d709be","Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain","Ortega, R., Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Raviña, E., Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Masaguer, C.F., Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Areias, F., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Brea, J., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Loza, M.I., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; López, L., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Selent, J., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Pastor, M., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain","A series of new benzolactam derivatives was synthesized and the derivatives were evaluated for their affinities at the dopamine D1, D2, and D3 receptors. Some of these compounds showed high D2 and/or D3 affinity and selectivity over the D1 receptor. The SAR study of these compounds revealed structural characteristics that decisively influenced their D2 and D3 affinities. Structural models of the complexes between some of the most representative compounds of this series and the D2 and D3 receptors were obtained with the aim of rationalizing the observed experimental results. Moreover, selected compounds showed moderate binding affinity on 5-HT2A which could contribute to reducing the occurrence of extrapyramidal side effects as potential antipsychotics. © 2009 Elsevier Ltd. All rights reserved.","Antipsychotics; Arylpiperazines; Benzolactams; Dopamine receptors; Structure-activity relationship","agents interacting with transmitter, hormone or drug receptors; benzolactam derivative; dopamine 1 receptor; dopamine 2 receptor; dopamine 3 receptor; lactam derivative; serotonin; unclassified drug; article; binding affinity; complex formation; controlled study; drug receptor binding; drug structure; drug synthesis; structure activity relation; Antipsychotic Agents; Benzodiazepinones; Chemistry, Pharmaceutical; Drug Design; Humans; Kinetics; Lactams; Ligands; Models, Chemical; Molecular Conformation; Molecular Structure; Piperazines; Receptors, Dopamine D2; Receptors, Dopamine D3; Structure-Activity Relationship",,"serotonin, 50-67-9; Antipsychotic Agents; Benzodiazepinones; Lactams; Ligands; Piperazines; Receptors, Dopamine D2; Receptors, Dopamine D3",,,"Comisión Interministerial de Ciencia y Tecnología: SAF2005-08025-C03

Xunta de Galicia: PIDIT06PXIB203173PR

Instituto de Salud Carlos III","This work was supported in part by grants from the CICYT (Spain, SAF2005-08025-C03) and by the Xunta de Galicia (Spain, PIDIT06PXIB203173PR), as well as by the HERACLES and COMBIOMED networks from Instituto de Salud Carlos III. J. Brea received financial support from the Programa Isabel Barreto (Xunta de Galicia, Spain).",,,"Missale, C., Nash, S.R., Robinson, S.W., Jaber, M., Caron, M.G., (1998) Physiol. Rev., 78, p. 189; Sokoloff, P., Giros, B., Martres, M.P., Bouthenet, M.L., Schwartz, J.C., (1990) Nature, 347, p. 146; Levant, B., (1997) Pharmacol. Rev., 49, p. 231; Joyce, J.N., Miador-Woodruff, J.H., (1997) Neuropsychopharmacology, 16, p. 375; Shafer, R.A., Levant, B., (1998) Psychopharmacology, 135, p. 1; Joyce, J.N., (2001) Pharmacol. Ther., 90, p. 231; Joyce, J.N., Millan, M.J., (2005) Drug Discov. Today, 10, p. 917; Strange, P.G., (1996) Adv. Drug Res., 28, p. 313; Kapur, S., Mamo, D., (2003) Prog. Neuro-Psychopharm. Biol. Psychiatry, 27, p. 1081; Leriche, L., Scharz, J.-C., Sokoloff, P., (2003) Neuropharmacology, 45, p. 174; Roth, B.L., Sheffler, D.J., Kroeze, W.K., (2004) Nat. Rev. Drug Discov., 3, p. 353; Spedding, M., Jay, T., Costa e Silva, J., Perret, L., (2005) Nat. Rev. Drug Discov., 4, p. 467; Nasrallah, H.A., (2008) Mol. Psychiatry, 13, p. 27; Meltzer, H.Y., (2004) CNS Spectrosc., 9, p. 15; Bezard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., Gross, C., Sokoloff, P., (2003) Nat. Med., 9, p. 762; Boeckler, F., Gmeiner, P., (2006) Pharmacol. Ther., 112, p. 281; Luedtkea, R.R., Mach, R.H., (2003) Curr. Pharm. Des., 9, p. 643; Crider, A.M., Scheideler, M.A., (2001) Mini Rev. Med. Chem., 1, p. 89; Pilla, M., Perachon, S., Sautel, F., Garridol, F., Mann, A., Wermuth, C.G., Schwartz, J.-C., Sokoloff, P., (1999) Nature, 400, p. 371; Wicke, K., Garcia-Ladona, J., (2001) Eur. J. Pharmacol., 424, p. 85; Bettinetti, L., Schlotter, K., Huebner, H., Gmeiner, P., (2002) J. Med. Chem., 45, p. 459; Millan, M.J., Loiseau, F., Dekeyne, A., Gobert, A., Flik, G., Cremers, T.I., Rivet, J.-M., Brocco, M., (2008) J. Pharmacol. Exper. Ther., 324, p. 1212; Hacling, A.E., Stark, H., (2002) ChemBioChem, 3, p. 946; Tomita, M., Minami, S., Uyeo, S., (1969) J. Chem. Soc., p. 183; Conley, R.T., (1958) J. Org. Chem., 23, p. 1330; Evans, D., Lockhart, I.M., (1965) J. Chem. Soc., p. 4806; Grunewald, G.L., Dahanukar, V.H., (1994) J. Heterocyclic Chem., 31, p. 1609; Mach, U.R., Hackling, A.E., Perachon, S., Ferry, S., Wermuth, C.G., Schwartz, J.-C., Sokoloff, P., Stark, H., (2004) ChemBioChem, 5, p. 508; Hackling, A., Ghosh, R., Perachon, S., Mann, A., Höltje, H.-D., Wermuth, C.G., Schwartz, J.-C., Stark, H., (2003) J. Med. Chem., 46, p. 3883; Norman, M.H., Rigdon, G.C., Navas III, F., Cooper, B.R., (1994) J. Med. Chem., 37, p. 2552; Brea, J., Castro, M., Loza, M.I., Masaguer, C.F., Raviña, E., Dezi, C., Pastor, M., Robledo, P., (2006) Neuropharmacology, 51, p. 261; Cheng, Y., Prusoff, W.H., (1973) Biochem. Pharmacol., 22, p. 3099; Selent, J., López, L., Sanz, F., Pastor, M., (2008) ChemMedChem, 3, p. 1194; Ballesteros, J., Weinstein, H., (1995) Methods Neurosci., 25, p. 366; Simpson, M.M., Ballesteros, J.A., Chiappa, V., Chen, J., Suehiro, M., Hartman, D.S., Godel, T., Javitch, J.A., (1999) Mol. Pharmacol., 56, p. 1116; Shi, L., Javitch, J.A., (2004) Proc. Natl. Acad. Sci. USA, 101, p. 440; Boeckler, F., Gmeiner, P., (2007) Biochim. Biophys. Acta, 1768, p. 871; Ceulemans, D.L.S., Gelders, Y.G., Hoppenbrouwers, M.-L.J.A., Reyntjens, A.J.M., Janssen, P.A.J., (1985) Psychopharmacology, 85, p. 329; Sokoloff, P., Diaz, J., Le Foll, B., Guillin, O., Leriche, L., Bezard, E., Gross, C., (2006) CNS Neurol. Disord. Drug Targets, 5, p. 25; note; Meltzer, H.Y., Matsubara, S., Lee, J.C., (1989) Psychopharmacol. Bull., 25, p. 390; Roth, B.L., Tandra, S., Burgess, L.H., Sibley, D.R., Meltzer, H.Y., (1995) Psychopharmacology, 120, p. 365; Roth, B.L., Meltzer, H.Y., Khan, N., (1998) Adv. Pharmacol., 42, p. 482","Masaguer, C.F.; Departamento de Química Orgánica, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; email: christianf.masaguer@usc.es",,,,,,,,0960894X,,BMCLE,"19217777","English","Bioorg. Med. Chem. Lett.",Article,"Final",,Scopus,2-s2.0-61349150703
"Bauer-Mehren A., Furlong L.I., Sanz F.","35572639000;34770469800;7102263897;","Pathway databases and tools for their exploitation: Benefits, current limitations and challenges",2009,"Molecular Systems Biology","5",, 290,"","",,124,"10.1038/msb.2009.47","https://www.scopus.com/inward/record.uri?eid=2-s2.0-68749099453&doi=10.1038%2fmsb.2009.47&partnerID=40&md5=dba11b73d63b230b37b23a8e4e416146","Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital Del Mar, Universitat Pompeu Fabra, Dr Aiguader 88, Barcelona, Spain; Research Unit on Biomedical Informatics, Universitat Pompeu Fabra, IMIM-Hospital Del Mar, Dr. Aiguader 88, 08003 Barcelona, Spain","Bauer-Mehren, A., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital Del Mar, Universitat Pompeu Fabra, Dr Aiguader 88, Barcelona, Spain; Furlong, L.I., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital Del Mar, Universitat Pompeu Fabra, Dr Aiguader 88, Barcelona, Spain, Research Unit on Biomedical Informatics, Universitat Pompeu Fabra, IMIM-Hospital Del Mar, Dr. Aiguader 88, 08003 Barcelona, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM-Hospital Del Mar, Universitat Pompeu Fabra, Dr Aiguader 88, Barcelona, Spain","In past years, comprehensive representations of cell signalling pathways have been developed by manual curation from literature, which requires huge effort and would benefit from information stored in databases and from automatic retrieval and integration methods. Once a reconstruction of the network of interactions is achieved, analysis of its structural features and its dynamic behaviour can take place. Mathematical modelling techniques are used to simulate the complex behaviour of cell signalling networks, which ultimately sheds light on the mechanisms leading to complex diseases or helps in the identification of drug targets. A variety of databases containing information on cell signalling pathways have been developed in conjunction with methodologies to access and analyse the data. In principle, the scenario is prepared to make the most of this information for the analysis of the dynamics of signalling pathways. However, are the knowledge repositories of signalling pathways ready to realize the systems biology promise? In this article we aim to initiate this discussion and to provide some insights on this issue. © 2009 EMBO and Macmillan Publishers Limited All rights reserved.","Biological pathways; Cell signalling; Network models; Pathway databases; Systems biology","epidermal growth factor receptor; G protein coupled receptor; mitogen activated protein kinase; calcium signaling; cell cycle; data extraction; factual database; information processing; information retrieval; knowledge base; mathematical model; methodology; molecular dynamics; molecular mechanics; online system; priority journal; protein database; protein protein interaction; review; signal transduction; structure analysis; article; biology; human; Internet; signal transduction; Computational Biology; Databases, Factual; Humans; Internet; Signal Transduction",,"mitogen activated protein kinase, 142243-02-5",,,,,,,"Adriaens, M.E., Jaillard, M., Waagmeester, A., Coort, S.L.M., Pico, A.R., Evelo, C.T.A., The public road to high-quality curated biological pathways (2008) Drug Discov Today, 13, pp. 856-862; Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P., (2007) Molecular Biology of the Cell, , New York, USA: Garland Science; Alves, R., Antunes, F., Salvador, A., Tools for kinetic modeling of biochemical networks (2006) Nat Biotechol, 24, pp. 667-672; Amit, I., Citri, A., Shay, T., Lu, Y., Katz, M., Zhang, F., Tarcic, G., Yarden, Y., A module of negative feedback regulators defines growth factor signaling (2007) Nat Genet, 39, pp. 503-512; Aoki-Kinoshita, K., Kanehisa, M., KEGG Primer: An introduction to pathway analysis using KEGG, doi:10.1038/pid.2007.2 (2007) NCI-Nature Pathway Interaction Database; Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Sherlock, G., Gene Ontology: Tool for the unification of biology (2000) Nat Genet, 25, pp. 25-29; Bader, G.D., Cary, M.P., Sander, C., Pathguide: A pathway resource list (2006) Nucleic Acids Res, 34, pp. D504-D506; Birtwistle, M.R., Hatakeyama, M., Yumoto, N., Ogunnaike, B.A., Hoek, J.B., Kholodenko, B.N., Ligand-dependent responses of the ErbB signaling network: Experimental and modeling analyses (2007) Mol Syst Biol, 3, p. 144; Borisov, N., Aksamitiene, E., Kiyatkin, A., Legewie, S., Berkhout, J., Maiwald, T., Kaimachnikov, N.P., Kholodenko, B.N., Systems-level interactions between insulin-EGF networks amplify mitogenic signaling (2009) Mol Syst Biol, 5, p. 256; Bornstein, B.J., Keating, S.M., Jouraku, A., Hucka, M., LibSBML: An API library for SBML (2008) Bioinformatics, 24, pp. 880-881; Buteau, J., Foisy, S., Joly, E., Prentki, M., Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor (2003) Diabetes, 52, pp. 124-132; Calzone, L., Gelay, A., Zinovyev, A., Radvanyi, F., Barillot, E., A comprehensive modular map of molecular interactions in RB/E2F pathway (2008) Mol Syst Biol, 4, p. 173; Chaumont, S., Compan, V., Toulme, E., Richler, E., Housley, G.D., Rassendren, F., Khakh, B.S., Regulation of P2X2 receptors by the neuronal calcium sensor VILIP1 (2008) Sci Signal, 1, pp. ra8; Citri, A., Yarden, Y., EGF-ERBB signalling: Towards the systems level (2006) Nat Rev Mol Cell Biol, 7, pp. 505-516; Evelo, C., (2009) Community curation on WikiPathways: How we assist knowledge collection, , http://dx.doi.org/10.1038/npre.2009.3115.1, Available from Nature Precedings, Berlin, Germany; Fisher, J., Henzinger, T.A., Executable cell biology (2007) Nat Biotechnol, 25, pp. 1239-1249; Giles, J., Key biology databases go wiki (2007) Nature, 445, p. 691; Herrgard, M.J., Swainston, N., Dobson, P., Dunn, W.B., Arga, K.Y., Arvas, M., Buthgen, N., Smallbone, K., A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology (2008) Nat Biotechnol, 26, pp. 1155-1160; Hoops, S., Sahle, S., Gauges, R., Lee, C., Pahle, J., Simus, N., Singhal, M., Kummer, U., COPASI - a COmplex PAthway SImulator (2006) Bioinformatics, 22, pp. 3067-3074; Hornberg, J.J., Bruggeman, F.J., Binder, B., Geest, C.R., de Vaate, A.J.M.B., Lankelma, J., Heinrich, R., Westerhoff, H.V., Principles behind the multifarious control of signal transduction. ERK phosphorylation and kinase/phosphatase control (2005) FEBS J, 272, pp. 244-258; Hu, J.C., Aramayo, R., Bolser, D., Conway, T., Elsik, C.G., Gribskov, M., Kelder, T., Welch, R.D., The emerging world of wikis (2008) Science, 320, pp. 1289-1290; Hu, Z., Snitkin, E.S., DeLisi, C., VisANT: An integrative framework for networks in systems biology (2008) Brief Bioinform, 9, pp. 317-325; Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, the rest of the SBML Forum, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr J-H et al (2003) The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19: 524-531; Joshi-Tope, G., Gillespie, M., Vastrik, I., D'Eustachio, P., Schmidt, E., de Bono, B., Jassal, B., Stein, L., Reactome: A knowledgebase of biological pathways (2005) Nucleic Acids Res, 33, pp. D428-D432; Kanehisa, M., Araki, M., Goto, S., Hattori, M., Hirakawa, M., Itoh, M., Katayama, T., Yamanishi, Y., KEGG for linking genomes to life and the environment (2008) Nucleic Acids Res, 36, pp. D480-D484; Kanehisa, M., Goto, S., KEGG: Kyoto encyclopedia of genes and genomes (2000) Nucleic Acids Res, 28, pp. 27-30; Karlebach, G., Shamir, R., Modelling and analysis of gene regulatory networks (2008) Nat Rev Mol Cell Biol, 9, pp. 770-780; Karp, P.D., Paley, S., Romero, P., The Pathway Tools software (2002) Bioinformatics, 18, pp. S225-S232; Kerrien, S., Alam-Faruque, Y., Aranda, B., Bancarz, I., Bridge, A., Derow, C., Dimmer, E., Roechert, B., IntAct - open source resource for molecular interaction data (2007) Nucl Acids Res, 35, pp. D561-D565; Kerrien, S., Orchard, S., Montecchi-Palazzi, L., Aranda, B., Quinn, A., Vinod, N., Bader, G., Cerami, E., Broadening the horizon - level 2.5 of the HUPO-PSI format for molecular interactions (2007) BMC Biol, 5, p. 44; Kholodenko, B.N., Demin, O.V., Moehren, G., Hoek, J.B., Quantification of short term signaling by the epidermal growth factor receptor (1999) J Biol Chem, 274, pp. 30169-30181; Kitano, H., A robustness-based approach to systems-oriented drug design (2007) Nat Rev Drug Discov, 6, pp. 202-210; Kitano, H., Towards a theory of biological robustness (2007) Mol Syst Biol, 3, p. 137; Li, H., Ung, C.Y., Ma, X.H., Li, B.W., Low, B.C., Cao, Z.W., Chen, Y.Z., Simulationof crosstalk between small GTPase RhoA and EGFR-ERK signaling pathway via MEKK1 (2009) Bioinformatics, 25, pp. 358-364; Maglott, D., Ostell, J., Pruitt, K.D., Tatusova, T., Entrez Gene: Genecentered information at NCBI (2007) Nucleic Acids Res, 35, pp. D26-D31; Matthews L, D'Eustachio P, Gillespie M, Croft D, de Bono B, Gopinath G, Jassal B, Lewis S, Schmidt E, Vastrik I, Wu G, Birney E, Stein L (2007) An introduction to the reactome knowledgebase of human biological pathways and processes. doi.10.1038/pid.2007.3. NCI-Nature Pathway Interaction Database; Matthews, L., Gopinath, G., Gillespie, M., Caudy, M., Croft, D., de Bono, B., Garapati, P., D'Eustachio, P., Reactome knowledgebase of human biological pathways and processes (2009) Nucleic Acids Res, 37, pp. D619-D622; Mishra, G.R., Suresh, M., Kumaran, K., Kannabiran, N., Suresh, S., Bala, P., Shivakumar, K., Arun, K.S., Human protein reference database - 2006 update (2006) Nucleic Acids Res, 34, pp. D411-D414; Oda, K., Kitano, H., A comprehensive map of the toll-like receptor signaling network (2006) Mol Syst Biol, 2, p. 0015; Oda, K., Matsuoka, Y., Funahashi, A., Kitano, H., A comprehensive pathway map of epidermal growth factor receptor signaling (2005) Mol Syst Biol, 1, p. 0010; Pico, A.R., Kelder, T., Iersel, M.P., Hanspers, K., Conklin, B.R., Evelo, C., WikiPathways: Pathway editing for the people (2008) PLoS Biol, 6, pp. e184; Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., Ullrich, A., EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF (1999) Nature, 402, pp. 884-888; Salomonis, N., Hanspers, K., Zambon, A., Vranizan, K., Lawlor, S., Dahlquist, K., Doniger, S., Pico, A., GenMAPP 2: New features and resources for pathway analysis (2007) BMC Bioinformatics, 8, pp. 21-27; Schaefer CF, AnthonyK, Krupa S,BuchoffJ, Day M,Hannay T,Buetow KH (2009) PID: the pathway interaction database. Nucleic Acids Res 37: D674-D679; Schoeberl, B., Eichler-Jonsson, C., Gilles, E.D., Muller, G., Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors (2002) Nat Biotechnol, 20, pp. 370-375; Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Ideker, T., Cytoscape: A software environment for integrated models of biomolecular interaction networks (2003) Genome Res, 13, pp. 2498-2504; Stromback, L., Jakoniene, V., Tan, H., Lambrix, P., Representing, storing and accessing molecular interaction data: A review of models and tools (2006) Brief Bioinform, 7, pp. 331-338; Stromback, L., Lambrix, P., Representations of molecular pathways: An evaluation of SBML, PSI MI and BioPAX (2005) Bioinformatics, 21, pp. 4401-4407; Suderman, M., Hallett, M., Tools for visually exploring biological networks (2007) Bioinformatics, 23, pp. 2651-2659; Tarbell, J.M., Ebong, E.E., The endothelial glycocalyx: A mechanosensor and -transducer (2008) Sci Signal, 1 (PT8); The universal protein resource (UniProt) (2008) Nucleic Acids Res, 36, pp. D190-D195. , The UniProt Consortium; van Iersel, M., Kelder, T., Pico, A., Hanspers, K., Coort, S., Conklin, B., Evelo, C., Presenting and exploring biological pathways with PathVisio (2008) BMC Bioinformatics, 9, p. 399; Vastrik, I., D'Eustachio, P., Schmidt, E., Joshi-Tope, G., Gopinath, G., Croft, D., de Bono, B., Stein, L., Reactome: A knowledge base of biologic pathways and processes (2007) Genome Biol, 8, pp. R39; Waldrop, M., Wikiomics (2008) Nature, 455 (22), p. 25; Wang, C.-C., Cirit, M., Haugh, J.M., PI3K-dependent cross-talk interactions converge with Ras as quantifiable inputs integrated by Erk (2009) Mol Syst Biol, 5, p. 246; Yaffe, M.B., Signaling networks and mathematics (2008) Sci Signal, 1, pp. eg7; Zanzoni, A., Montecchi-Palazzi, L., Quondam, M., Ausiello, G., Helmer-Citterich, M., Cesareni, G., MINT: A molecular INTeraction database (2002) FEBS Lett, 513, pp. 135-140; Zinovyev, A., Viara, E., Calzone, L., Barillot, E., BiNoM: A Cytoscape plugin for manipulating and analyzing biological networks (2008) Bioinformatics, 24, pp. 876-877","Furlong, L. I.; Research Unit on Biomedical Informatics, Universitat Pompeu Fabra, IMIM-Hospital Del Mar, Dr. Aiguader 88, 08003 Barcelona, Spain; email: lfurlong@imim.es",,,,,,,,17444292,,,"19638971","English","Mol. Syst. Biol.",Review,"Final",Open Access,Scopus,2-s2.0-68749099453
"Friedrich C.M., Hofmann-Apitius M., Dunlop R., Chronakis I., Sturkenboom M.C.J.M., Risselada R., Oliva B., Sanz F.","35232936500;57204494354;7005871079;57159477300;21743803900;25825410800;35500780700;7102263897;","Initial results on knowledge discovery and decision support for intracranial aneurysms",2008,"HEALTHINF 2008 - 1st International Conference on Health Informatics, Proceedings","1",,,"265","272",,1,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-57349177054&partnerID=40&md5=36ad9fdf6da3b1b398149f3e85efd9b0","Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Department of Bioinformatics, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; Infermed Ltd., 25 Bedford Square, London, United Kingdom; Department of Engineering, Oxford University, United Kingdom; Department of Academic Oncology, UCL, United Kingdom; Erasmus MC, Medical Informatics, 3000 CA Rotterdam, Netherlands; Research Unit on Biomedical Informatics (GRIB), IMIM/UPF, C/Dr. Aiguader, 88, 08003-Barcelona, Spain","Friedrich, C.M., Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Department of Bioinformatics, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; Hofmann-Apitius, M., Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Department of Bioinformatics, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; Dunlop, R., Infermed Ltd., 25 Bedford Square, London, United Kingdom; Chronakis, I., Department of Engineering, Oxford University, United Kingdom, Department of Academic Oncology, UCL, United Kingdom; Sturkenboom, M.C.J.M., Erasmus MC, Medical Informatics, 3000 CA Rotterdam, Netherlands; Risselada, R., Erasmus MC, Medical Informatics, 3000 CA Rotterdam, Netherlands; Oliva, B., Research Unit on Biomedical Informatics (GRIB), IMIM/UPF, C/Dr. Aiguader, 88, 08003-Barcelona, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM/UPF, C/Dr. Aiguader, 88, 08003-Barcelona, Spain","Intracranial Aneurysms are bulbous expansions of the intracranial vessels, that may rupture and lead to sub-arachnoid haemorrhage, which can result in severe disability or death of the affected person. The prediction of the individual rupture risk of a patient based on information from images, haemodynamic simulations, clinical parameters and genetic markers is one of the aims of the European Integrated Project @neurlST. The predicted rupture risk is meant to support decision making on clinical treatment. We will present initial results on Knowledge Discovery through a combination of text-mining, data integration from public bioinformatics data sources, and database mining. Additionally, we provide first results for decision support through knowledge based clinical guidelines and Bayesian networks.","Decision support; Intracranial aneurysm; Knowledge discovery","Bayesian networks; Bioinformatics; Decision support systems; Handicapped persons; Health risks; Inference engines; Bioinformatics datums; Clinical guidelines; Clinical parameters; Clinical treatments; Data integrations; Database minings; Decision support; Europeans; Genetic markers; Haemodynamic; Haemorrhage; Intracranial aneurysm; Knowledge discovery; Knowledge-based; Rupture risks; Severe disabilities; Support decision makings; Knowledge based systems",,,,,,,,,"Alfarano, C, Andrade, C. E, Anthony, K, Bahroos, N, Bajec, M, Bantoft, K, Betel, D, Bobechko, B, Boutilier, K, Burgess, E, Buzadzija, K, Cavero, R, D'Abreo, C, Donaldson, I, Dorairajoo, D, Dumontier, M. J, Dumontier, M. R, Earles, V, Farrall, R, Feldman, H, Garderman, E, Gong, Y, Gonzaga, R, Grytsan, V, Gryz, E, Gu, V, Haldorsen, E, Halupa, A, Haw, R, Hrvojic, A, Hurrell, L, Isserlin, R, Jack, F, Juma, F, Khan, A, Kon, T, Konopinsky, S, Le, V, Lee, E, Ling, S, Magidin, M, Moniakis, J, Montojo, J, Moore, S, Muskat, B, Ng, I, Paraiso, J. P, Parker, B, Pintilie, G, Pirone, R, Salama, J. J, Sgro, S, Shan, T, Shu, Y, Siew, J, Skinner, D, Snyder, K, Stasiuk, R, Strumpf, D, Tuekam, B, Tao, S, Wang, Z, White, M, Willis, R, Wolting, C, Wong, S, Wrong, A, Xin, C, Yao, R, Yates, B, Zhang, S, Zheng, K, Pawson, T, Ouellette, B. F. F, and Hogue, C. W. V, 2005, The biomolecular interaction network database and related tools 2; Aragues, R., Jaeggi, D., Oliva, B., Piana: Protein interactions and network analysis (2006) Bioinformatics, 22 (8), pp. 1015-1017; Arbona, A., Benkner, S., Engelbrecht, G., Fingberg, J., Hofmann, M., Kumpf, K., Lonsdale, G., Woehrer, A., A service-oriented grid infrastructure for biomedical data and compute services (2007) IEEE Trans Nanobioscience, 6 (2), pp. 136-141; Bonis, J., Furlong, L.I., Sanz, F., OSIRIS: A tool for retrieving literature about sequence variants (2006) Bioinformatics, pp. 2567-2569; Chatr-aryamontri, A., Ceol, A., Palazzi, L.M., Nardelli, G., Schneider, M.V., Castagnoli, L., Cesareni, G., Mint: The molecular interaction database (2007) Nucleic Acids Res, , 35(Database issue):D572-D574; Clarke, M. (2007). Cochrane literature review snapshot v2.0 - aneurysm analysis rupture risk review. Deliverable of the @neurlST project D18, University of Oxford; Cockell, S.J., Oliva, B., Jackson, R.M., Structure-based evaluation of in silico predictions of protein-protein interactions using comparative docking (2007) Bioinformatics, 23 (5), pp. 573-581; Druzdzel, M.J., GeNIe: A development environment for graphical decision-analytic models (1999) Proceedings of the 1999 Annual Symposium of the American Medical Informatics Association (AMIA-1999), p. 1206; Efron, B., Tibshirani, R.J., (1993) An Introduction to the Bootstrap, , Chapman & Hall/CRC; Espadaler, J., Romero-Isart, O., Jackson, R.M., Oliva, B., Prediction of protein-protein interactions using distant conservation of sequence patterns and structure relationships (2005) Bioinformatics, 21 (16), pp. 3360-3368; Fayyad, U.M., Piatetsky-Shapiro, G., Smyth, P., Knowledge Discovery and Data Mining: Towards a Unifying Framework (1996) Knowledge Discovery and Data Mining, pp. 82-88; Fluck, J., Mevissen, H. T., Dach, H., Oster, M., and Hofmann-Apitius, M. (2007). ProMiner: recognition of human gene and protein names using regularly updated dictionaries. In (Hirschmann et al., 2007), pages 149-151; Fox, J., Das, S., Safe and sound: Artificial intelligence in hazardous applications (2000) Proceedings of AAAI 2000; Fox, J., Johns, N., Rahmanzadeh, A., Thomsen, R., PROforma: A method and language for specifying clinical guidelines and protocols (1996) Proceedings of the Medical Informatics Europe, pp. 516-520. , Brender, J, Christensen, J, Scherrer, J.-R, and McNair, P, editors, IOS Press; Fox, J., Patkar, V., Thomson, R., Decision support for health care: The proforma evidence base (2006) Inform Prim Care, 14 (1), pp. 49-54; Gattermayer, T., (2007) SCAIView: Annotation and visualization system for knowledge discovery, , Master's thesis, Life Science Informatics at Bonn-Aachen International Center for Information Technology B-IT, Germany; Ghinea, N., van Gelder, J.M., A probabilistic and interactive decision-analysis system for unruptured intracranial aneurysms (2004) Neurosurg Focus, 17 (5), pp. E9; Glasspool, D.W., Fox, J., Oettinger, A., Smith-Spark, J.H., Argumentation in decision support for medical care planning for patients and clinicians (2006) Proceedings of the AAAI Spring Symposium Series, 2006; Han, B., Friedrich, C.M., Manthey, R., HofmannApitius, M., Bayesian network modeling for the prediction of treatment outcomes of intracranial aneurysms (2006) Short Papers and Poster Abstracts of the German Conference on Bioinformatics (GCB2006), p. 122. , Huson, D, Kohlbacher, O, Lupas, A, Nieselt, K, and Zell, A, editors; Hanisch, D., Fundel, K., Mevissen, H.-T., Zimmer, R., and Fluck, J. (2005). ProMiner: rule-based protein and gene entity recognition. BMC Bioinformatics, 6 (Suppl 1)(S14); (2007) Proceedings of the Second BioCreative Challenge Evaluation Workshop, , Hirschmann, L, Krallinger, M, and Valencia, A, editors , Centro Nacional de Investigaciones Oncologicas, CNIO; Hurt, C., Fox, J., Bury, J., Saha, V., Computerised advice on drug dosage decisions in childhood leukaemia: A method and a safety strategy (2003) LNAI, 2780, pp. 158-163. , Dojat, M, Keravnou, E, and Barahona, P, editors, Proceedings of the 9th Conference on Artificial Intelligence in Medicine in Europe AIME'03, Springer Verlag; Jensen, L.J., Saric, J., Bork, P., Literature mining for the biologist: From information retrieval to biological discovery (2006) Nature Reviews; Genetics, 7, pp. 119-129; Kerrien, S., Alam-Faruque, Y., Aranda, B., Bancarz, I., Bridge, A., Derow, C., Dimmer, E., Feuermann, M., Friedrichsen, A., Huntley, R., Köhler, C., Khadake, J., Leroy, C., Liban, A., Lieftink, C., Montecchi-Palazzi, L., Orchard, S., Risse, J., Robbe, K., Roechert, B., Thorneycroft, D., Zhang, Y., Apweiler, R., and Hermjakob, H. (2007). Intact-open source resource for molecular interaction data. Nucleic Acids Res, 35(Database issue):D561-D565; Klinger, R., Furlong, L. I., Friedrich, C. M., Mevissen, H. T., Fluck, J., Sanz, F., and Hofmann-Apitius, M. (2007). Identifying gene specific variants in biomedical text. Journal of Bioinformatics and Computational Biology, 5(6):in print; Krischek, B., Inoue, I., The genetics of intracranial aneurysms (2006) JHum Genet, 51 (7), pp. 587-594; Kullback, S., Leibler, R., On information and sufficiency (1951) Ann. Math. Stat, 22, pp. 79-86; Lafferty, J., McCallum, A., Pereira, F.C.N., Conditional Random Fields: Probabilistic Models for Segmenting and Labeling Sequence Data (2001) Proceedings of the Eighteenth International Conference on Machine Learning (ICML 2001), pp. 282-289. , Morgan Kaufmann Publishers; Maglott, D., Ostell, J., Pruitt, K.D., Tatusova, T., Entrez Gene: Gene-centered information at NCBI (2005) Nucleic Acids Research, 0, pp. D1-D6; Molyneux, A.J., Kerr, R.S.C., Yu, L., Clarke, M., Sneade, M., Yarnold, J.A., Sandercock, P., International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion (2005) Lancet, 366, pp. 809-817; Morgan, A.A., Hirschmann, L., (2007) Overview of BioCreative II gene normalization, pp. 17-27. , Hirschmann et al; Nahed, B.V., Bydon, M., Ozturk, A.K., Bilguvar, K., Bayrakli, F., Gunel, M., Genetics of intracranial aneurysms (2007) Neurosurgery, 60 (2), pp. 213-225. , discussion 225-6; Pagel, P., Kovac, S., Oesterheld, M., Brauner, B., DungerKaltenbach, I., Frishman, G., Montrone, C., Frishman, D., The mips mammalian protein-protein interaction database (2005) Bioinformatics, 21 (6), pp. 832-834; Patkar, V., Hurt, C., Steele, R., Love, S., Purushotham, A., Williams, M., Thomson, R., Fox, J., Evidence-based guidelines and decision support services: A discussion and evaluation in triple assessment of suspected breast cancer (2006) Br J Cancer, 95 (11), pp. 1490-1496; Peri, S, Navarro, J. D, Amanchy, R, Kristiansen, T. Z, Jonnalagadda, C. K, Surendranath, V, Niranjan, V, Muthusamy, B, Gandhi, T. K. B, Gronborg, M, Ibarrola, N, Deshpande, N, Shanker, K, Shivashankar, H. N, Rashmi, B. P, Ramya, M. A, Zhao, Z, Chandrika, K. N, Padma, N, Harsha, H. C, Yatish, A. J, Kavitha, M. P, Menezes, M, Choudhury, D. R, Suresh, S, Ghosh, N, Saravana, R, Chandran, S, Krishna, S, Joy, M, Anand, S. K, Madavan, V, Joseph, A, Wong, G. W, Schiemann, W. P, Constantinescu, S. N, Huang, L, Khosravi-Far, R, Steen, H, Tewari, M, Ghaffari, S, Blobe, G. C, Dang, C. V, Garcia, J. G. N, Pevsner, J, Jensen, O. N, Roepstorff, P, Deshpande, K. S, Chinnaiyan, A. M, Hamosh, A, Chakravarti, A, and Pandey, A, 2003, Development of human protein reference database as an initial platform for approaching systems biology in humans. GenomeRes, 13(10):2363-2371; Rinkel, G.J., Djibuti, M., Algra, A., van Gijn, J., Prevalence and risk of rupture of intracranial aneurysms (1998) Stroke, 29, pp. 251-256; Risselada, R., van der Lugt, A., Niessen, W. J., and Sturkenboom, M. C. J. M. (2007). Hormonal contraceptives and risk of aneurysmatic subarachnoid haemorrhage. Basic & Clinical Pharmacology & Toxicology, Special Issue on 8th Congress of the European Association for Clinical Pharmacology and Therapeutics, 101 (Suppl.):40; Rual, J.-F., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., Berriz, G. F., Gibbons, F. D., Dreze, M., Ayivi-Guedehoussou, N., Klitgord, N., Simon, C., Boxem, M., Milstein, S., Rosenberg, J., Goldberg, D. S., Zhang, L. V., Wong, S. L., Franklin, G., Li, S., Albala, J. S., Lim, J., Fraughton, C., Llamosas, E., Cevik, S., Bex, C., Lamesch, P., Sikorski, R. S., Vandenhaute, J., Zoghbi, H. Y., Smolyar, A., Bosak, S., Sequerra, R., Doucette-Stamm, L., Cusick, M. E., Hill, D. E., Roth, F. P., and Vidal, M. (2005). Towards a proteome-scale map of the human proteinprotein interaction network. Nature, 437(7062): 1173-1178; Russel, S., Norvig, P., (2003) Artificial Intelligence a modern Approach, , Prentince Hall, 2nd edition; Salwinski, L., Miller, C.S., Smith, A.J., Pettit, F.K., Bowie, J.U., Eisenberg, D., The database of interacting proteins: 2004 update (2004) Nucleic Acids Res, , 32(Database issue):D449-D451; Smigielski, E.M., Sirotkin, K., Ward, M., Sherry, S.T., dbSNP: A database of single nucleotide polymorphisms (2000) Nucleic Acids Research, 28 (1), pp. 352-355; Stark, C., Breitkreutz, B.-J., Reguly, T., Boucher, L., Breitkreutz, A., Tyers, M., Biogrid: A general repository for interaction datasets (2006) Nucleic Acids Res, , 34(Database issue):D535-D539; Stelzl, U., Worm, U., Lalowski, M., Haenig, C., Brembeck, F.H., Goehler, H., Stroedicke, M., Wanker, E.E., A human protein-protein interaction network: A resource for annotating the proteome (2005) Cell, 122 (6), pp. 957-968; Sutton, D.R., Fox, J., The syntax and semantics of the proforma guideline modeling language (2003) J Am Med Inform Assoc, 10 (5), pp. 433-443; van der Lei, J., Duisterhout, J.S., Westerhof, H.P., van der Does, E., Cromme, P.V., Boon, W.M., van Bemmel, J.H., The introduction of computer-based patient records in the netherlands (1993) Ann Intern Med, 119 (10), pp. 1036-1041; von Mering, C., Jensen, L. J., Snel, B., Hooper, S. D., Krupp, M., Foglierini, M., Jouffre, N., Huynen, M. A., and Bork, P. (2005). String: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res, 33(Database issue):D433-D437; Wiebers, D., Whisnant, J., Huston, J., Meissner, I., Brown, RD, J., Piepgras, G., Torner, J., Unruptured intracranial aneurysms: Natural history, clinical outcome, and risks of surgical and endovascular treatment (2003) Lancet, 362, pp. 103-110","Friedrich, C. M.; Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Department of Bioinformatics, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; email: friedrich@scai.fraunhofer.de",,,,"1st International Conference on Health Informatics, HEALTHINF 2008","28 January 2008 through 31 January 2008","Funchal, Madeira",74232,,9789898111166,,,"English","HEALTHINF - Int. Conf. Health Informatics, Proc.",Conference Paper,"Final",,Scopus,2-s2.0-57349177054
"Aranda R., Villalba K., Raviña E., Masaguer C.F., Brea J., Areias F., Domínguez E., Selent J., López L., Sanz F., Pastor M., Loza M.I.","25225412300;57208968349;56264803900;6701715235;6603008588;6602594095;15838786400;55891371700;56948275300;7102263897;7102415847;7003766926;","Synthesis, binding affinity, and molecular docking analysis of new benzofuranone derivatives as potential antipsychotics",2008,"Journal of Medicinal Chemistry","51","19",,"6085","6094",,20,"10.1021/jm800602w","https://www.scopus.com/inward/record.uri?eid=2-s2.0-53549089366&doi=10.1021%2fjm800602w&partnerID=40&md5=6a2408e21c8f089c0cce2441e9bcba5c","Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain","Aranda, R., Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Villalba, K., Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Raviña, E., Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Masaguer, C.F., Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Brea, J., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Areias, F., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Domínguez, E., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Selent, J., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; López, L., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Pastor, M., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Loza, M.I., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain","The complex etiology of schizophrenia has prompted researchers to develop clozapine-related multitarget strategies to combat its symptoms. Here we describe a series of new 6-aminomethylbenzofuranones in an effort to find new chemical structures with balanced affinities for 5-HT2 and dopamine receptors. Through biological and computational studies of 5-HT2A and D2 receptors, we identified the receptor serine residues S3.36 and S5.46 as the molecular keys to explaining the differences in affinity and selectivity between these new compounds for this group of receptors. Specifically, the ability of these compounds to establish one or two H-bonds with these key residues appears to explain their difference in affinity. In addition, we describe compound 2 (QF1004B) as a tool to elucidate the role of 5-HT2C receptors in mediating antipsychotic effects and metabolic adverse events. The compound 16a (QF1018B) showed moderate to high affinities for D2 and 5-HT2A receptors, and a 5-HT 2A/D2 ratio was predictive of an atypical antipsychotic profile. © 2008 American Chemical Society.",,"4 (4 fluorobenzoyl) 1 [(4,5,6,7 tetrahydro 4 oxobenzo[b]furan 6 yl)methyl]piperidine; 4 (6 fluorobenzisoxazol 3 yl) 1 [(4,5,6,7 tetrahydro 4 oxobenzo[b]furan 6 yl)methyl]piperidine; 6 [[4 (4 fluorobenzoyl)piperidin 1 yl]methyl] 2 phenyl 4,5,6,7 tetrahydro 1 benzofuran 4 one; 6 [[4 (4 fluorobenzoyl)piperidin 1 yl]methyl] 4,5,6,7 tetrahydro 1 benzofuran 4 one; 6 [[4 (6 fluorobenzisoxazol 3 yl)piperidin 1 yl]methyl] 4,5,6 tetrahydro 1 benzofuran 4 one; atypical antipsychotic agent; benzofuran derivative; clozapine; dopamine 2 receptor; ethyl 6 [[4 (4 fluorobenzoyl)piperidin 1 yl]methyl] 3 methyl 4 oxo 4,5,6,7 tetrahydro 1 benzofuran 2 carboxylate; ethyl 6 [[4 (6 fluorobenzisoxazol 3 yl)piperidin 1 yl]methyl] 3 methyl 4 oxo 4,5,6,7 tetrahydro 1 benzofuran 2 carboxylate; haloperidol; methyl 6 [[4 (4 fluorobenzoyl)piperidin 1 yl]methyl] 4 oxo 4,5,6,7 tetrahydro 1 benzofuran 3 carboxylate; methyl 6 [[4 (6 fluorobenzisoxazol 3 yl)piperidin 1 yl]methyl] 4 oxo 4,5,6,7 tetrahydro 1 benzofuran 3 carboxylate; neuroleptic agent; qf 0702b; qf 0703b; qf 1014b; qf 1018b; qf 1034b; qf 1038b; qf 1064b; qf 1068b; serine; serotonin 2 receptor; serotonin 2A receptor; serotonin 2C receptor; unclassified drug; article; binding affinity; drug receptor binding; drug selectivity; drug synthesis; hydrogen bond; molecular docking; stereochemistry; Antipsychotic Agents; Benzofurans; Binding, Competitive; Cloning, Molecular; Computer Simulation; Crystallography, X-Ray; Humans; Hydrogen Bonding; Models, Chemical; Models, Molecular; Molecular Structure; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D2; Sequence Alignment; Structure-Activity Relationship",,"clozapine, 5786-21-0; haloperidol, 52-86-8; serine, 56-45-1, 6898-95-9; Antipsychotic Agents; Benzofurans; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D2","qf 0702b; qf 0703b; qf 1003b; qf 1004b; qf 1014b; qf 1018b; qf 1034b; qf 1038b; qf 1064b; qf 1068b",,,,,,"(2001) WHO Fact Sheet Number 265, , The World Health Organization: Geneva, Switzerland; Altar, C.A., Martin, A.R., Thurkauf, A., Antipsychotic Agents (2003) Burger's Medicinal Chemistry and Drug Discovery, 6, pp. 599-672. , 6th ed, Abraham, D. J, Ed, Wiley: Hoboken, NJ; Seeman, P., Chou-Wong, M., Tadesco, J., Wong, K., Antipsychotic drug doses and neuroleptic/dopamine receptors (1976) Nature, 261, pp. 717-719; Hartman, D.S., Civelli, O., Dopamine receptor diversity: Molecular and pharmacological perspectives (1997) Prog. Drug Res, 48, pp. 173-194; Seeman, P., Targeting the dopamine D2 receptor in schizophrenia (2006) Expert Opin. Ther. Targets, 10, pp. 515-531; Sanberg, P.R., Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors (1980) Nature, 284, pp. 472-473; Casey, D.E., Pathophysiology of antipsychotic drug-induced movement disorders (2004) J. Clin. Psychiatry, 9, pp. 25-28; Filton, A.; Heel, R. C. Clozapine. A review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990, 40, 722-747; Schwarz, J.T., Brotman, A.W., A clinical guide to antipsychotic drugs (1992) Drugs, 44, pp. 981-992; Marino, M.J., Knutsen, L.J.S., Williams, M., Emerging opportunities for antipsychotic drug discovery in the postgenomic era (2008) J. Med. Chem, 51, pp. 1077-1107; Roth, B.L., Sheffler, D.J., Kroeze, W.K., Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia (2004) Nat. Rev. Drug Discov, 3, pp. 353-359; Richelson, E., Souder, T., Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds (2000) Life Sci, 68, pp. 29-39; Meltzer, H.Y., Matsubara, S., Lee, J.C., The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs (1989) Psychopharmacol. Bull, 25, pp. 390-392; Roth, B.L., Tandra, S., Burgess, L.H., Sibley, D.R., Meltzer, H.Y., D4 receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs (1995) Psychopharmacology, 120, pp. 365-368; Roth, B.L., Meltzer, H.Y., Khan, N., Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors (1998) Adv. Pharmacol, 42, pp. 482-485; Lowe, J.A., Atypical antipsychotics based on the D2/5-HT2 ratio hypothesis (1994) Curr. Med. Chem, 1, pp. 50-60; Van Oekelen, D., Luyten, W.H.M.L., Leysen, J.E., 5-HT2A and 5-HT2C receptors and their atypical regulation properties (2003) Life Sci, 72, pp. 2429-2449; Sipes, T.E., Geyer, M.A., DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum (1997) Brain Res, 761, pp. 97-104; Okuyama, S., Chaki, S., Kawashima, N., Suzuki, Y., Ogawa, S., Kumagai, T., Nakazato, A., Tomisawa, K., The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats (1997) Br. J. Pharmacol, 121, pp. 515-525; Payne, A., A superior antipsychotic: Rational design or irrational dream (2006) Drugs Future, 31, p. 16; Reavill, C., Kettle, A., Holland, V., Riley, G., Blackburn, T.P., Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist (1999) Br. J. Pharmacol, 126, pp. 572-574; Wood, M.D., Heidbreder, C., Reavill, C., Ashby Jr., C.R., Middlemiss, D.N., 5-HT2C receptor antagonists: Potential in schizophrenia (2001) Drug Dev. Res, 54, pp. 88-94; Richtand, N.M., Welge, J.A., Logue, A.D., Keck Jr., P.E., Strakowski, S.M., McNamara, R.K., Dopamine and serotonin receptor binding and antipsychotic efficacy (2007) Neuropsychopharmacology, 32, pp. 1715-1726; Lieberman, J.A., Hohn, C.A., Mikane, J., Rai, K., Pisciotta, A.V., Salz, B.L., Howard, A., Clozapine-induced agranulocytosis: Non-crossreactivity with other antipsychotic drugs (1988) J. Clin. Psychiatry, 49, pp. 271-277; Cortizo, L., Santana, L., Ravina, E., Orallo, F., Fontenla, J.A., Castro, E., de Ceballos, M., Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogs of butyrophenone (1991) J. Med. Chem, 34, pp. 2242-2247; Fontenla, J.A., Osuna, J.A., Rosa, E., Castro, M.E., Loza-García, I., G-Ferreiro, T., Calleja, J.M., de Ceballos, M.L., Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl)benzocycloalkanones as analogues of butyrophenone (1994) J. Med. Chem, 37, pp. 2564-2573; Ravina, E., Masaguer, C.F., Conformationally constrained butyrophenones. Synthesis and evaluation as antipsychotics (2001) Curr. Med. Chem.: Cent. Nerv. Syst. Agents, 1, pp. 43-62; Brea, J., Rodrigo, J., Carrieri, A., Sanz, F., Cadavid, M.I., Enguix, M.J., Villazon, M., Loza, M.I., New serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonists: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones (2002) J. Med. Chem, 45, pp. 54-71; Brea, J., Masaguer, C.F., Villazón, M., Cadavid, M.I., Raviña, E., Fontaine, F., Dezi, C., Loza, M.I., Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT2A and 5-HT2C receptor behaviors (2003) Eur. J. Med. Chem, 38, pp. 433-140; Raviña, E., Casariego, I., Masaguer, C.F., Fontenla, J.A., Montenegro, G.Y., Rivas, M.E., Loza, M.I., Demontis, G.C., Conformationally constrained butyrophenones with affinity for dopamine (D1, D2, D4) and serotonin (5-HT2A, 5-HT2B, 5-HT2C) receptors. Synthesis of aminomethylbenzo[b]furanones, and their evalution as antipsychotics (2000) J. Med. Chem, 43, pp. 4678-1693; Schelkun, R. M.; Yuen, P.-W.; Wustrow, D. J.; Kinsora, J.; Su, T.-Z.; Vartanian, M. G. Heteroaromatic side-chain analogs of pregabalin. Bioorg. Med. Chem. Lett. 2006, 16, 23292332; Pita, B., Masaguer, C.F., Raviña, E., A simple, efficient method for regioselective synthesis of 7-aminomethyl-7,8-dihydro-6H-quinolin-5-ones, new potential CNS agents (2000) Tetrahedron Lett, 41, pp. 9829-9833; Yilmaz, M., Pekel, A.T., Synthesis of benzofuran derivatives using manganese(III) acetate mediated addition of β-dicarbonyl compounds to alkyne and alkenes: A comparative study (2001) Synth. Commun, 31, pp. 3871-3876; Alagoz, O., Yilmaz, M., Pekel, A.T., Free radical cyclization of 1,3-dicarbonyl compounds mediated by manganese(III) acetate with alkynes and synthesis of tetrahydrobenzofurans, naphthalene, and trifluoroacetyl substituted aromatic compounds (2006) Synth. Commun, 36, pp. 1005-1013; Stetter, H., Lauterbach, R., Synthesis of evodone and menthofuran (1960) Chem. Ber, 93, pp. 603-607; Dezi, C., Brea, J., Alvarado, M., Raviña, E., Masaguer, C.F., Loza, M.I., Sanz, F., Pastor, M., Multistructure 3D-QSAR studies on a series of conformationally constrained butyrophenones docked into a new homology model of the 5-HT2A receptor (2007) J. Med. Chem, 50, pp. 3242-3255; Nielsen, B.B., Pickering, D.S., Greenwood, J.R., Brehm, L., Gajhede, M., Schousboe, A., Kastrup, J.S., Exploring the GluR2 ligand-binding core in complex with the bicyclical AMPA analogue (S)-4-AHCP (2005) FEBS J, 272, pp. 1639-1648; Hogner, A., Kastrup, J.S., Jin, R., Liljefors, T., Mayer, M.L., Egebjerg, J., Larsen, I.K., Gouaux, E., Structural basis for AMPA receptor activation and ligand selectivity: Crystal structures of five agonist complexes with the GluR2 ligand-binding core (2002) J. Mol. Biol, 322, pp. 93-109; Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, K. J.; Collins, I.; Davies, N. G. M.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51, 196-218; Selent, J., López, L., Sanz, F., Pastor, M., Multi-receptor binding profile of clozapine and olanzapine: A structural study based on the new β2 adrenergic receptor template (2008) ChemMedChem, 3, pp. 1194-1198; Raviña, E.; Negreira, J.; Cid, J.; Masaguer, C. F.; Rosa, E.; Rivas, M. E.; Fontenla, J. A.; Loza, M. I.; Tristan, H.; Cadavid, M. I.; Sanz, F.; Lozoya, E.; Carotti, A.; Carrieri, A. Conformationally constrained butyrophenones with mixed dopaminergic (D2) and serotoninergic (5-HT2A, 5-HT2C) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics. J. Med. Chem. 1999, 42, 2774-2797; Duncan, R. L., Jr.; Helsley, G. C.; Welstead, W. J., Jr.; Da Vanzo, J. P.; Funderburk, W. H.; Lunsford, C. D. Aroylpiperidines and pyrrolidines. New class of potent central nervous system depressants. J. Med. Chem. 1970, 13, 1-6; Ismaiel, A.M., Arruda, K., Teitler, M., Glennon, R.A., Ketanserin analogues: The effect of structural modification on 5-HT2 serotonin receptor binding (1995) J. Med. Chem, 38, pp. 1196-1202; Vogel, A.I., (1989) Vogel's Textbook of Practical Organic Chemistry, , 5th ed, Longman: Harlow, U.K; Cheng, Y., Prusoff, W.H., Relation between the inhibition constant (K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction (1973) Biochem. Pharmacol, 22, pp. 3099-3108; Ballesteros, J., Weinstein, H., Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors (1995) Methods Neurosci, 25, p. 366428; Boeckmann, B., Bairoch, A., Apweiler, R., Blatter, M.C., Estreicher, A., Gasteiger, E., Martin, M.J., Schneider, M., The SWISS-PROT protein knowledge-base and its supplement TrEMBL in 2003 (2003) Nucleic Acids Res, 31, pp. 365-370; Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G.F., Thian, F.S., Kobilka, T.S., Choi, H.-J., Stevens, R.C., High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor (2007) Science, 318, pp. 1258-1265; Rosenbaum, D.M., Cherezov, V., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., Choi, H.J., Kobilka, B.K., GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function (2007) Science, 318, pp. 1266-1273; Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties, and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673-1680; Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., Higgins, D.G., The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools (1997) Nucleic Acids Res, 25, pp. 4876-1882; Baldwin, J.M., Schertler, G.F., Unger, V.M., An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors (1997) J. Mol. Biol, 272, pp. 144-164; Sali, A., Blundell, T.L., Comparative protein modelling by satisfaction of spatial restraints (1993) J. Mol. Biol, 234, pp. 779-815; Cornell, W. D.; Cieplak, P.; Bayly, I. R.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeir, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197; Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., PROCHECK: A program to check the stereochemical quality of protein structures (1993) J. Appl. Crystallogr, 26, pp. 283-291; Sylte, I., Bronowska, A., Dahl, S.G., Ligand induced conformational states of the 5-HT(1A) receptor (2001) Eur. J. Pharmacol, 416, pp. 33-41; Shapiro, D.A., Kristiansen, K., Weiner, D.M., Kroeze, W.K., Roth, B.L., Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6 (2002) J. Biol. Chem, 277, pp. 11441-11449; Bissantz, C., Conformational changes of G protein-coupled receptors during their activation by agonist binding (2003) J. Recept. Signal Transduction, 23, pp. 123-153; Ballesteros, J.A., Jensen, A.D., Liapakis, G., Rasmussen, S.G.F., Shi, L., Gether, U., Javitch, J.A., Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6 (2001) J. Biol. Chem, 276, pp. 29171-29177; Shi, L., Liapakis, G., Xu, R., Guarnieri, F., Ballesteros, J.A., Javitch, J.A., Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch (2002) J. Biol. Chem, 277, pp. 40989-10996; Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., Improved protein-ligand docking using GOLD (2003) Proteins, 52, pp. 609-623; Mansour, A., Meng, F., Meador-Woodru, J.H., Taylor, L.P., Civelli, O., Akil, H., Site-directed mutagenesis of the human dopamine D2 receptor (1992) Eur. J. Pharmacol, 227, pp. 205-214; Wang, C.D., Gallaher, T.K., Shih, J.C., Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: Identification of amino acids necessary for ligand binding and receptor activation (1993) Mol. Pharmacol, 43, pp. 931-940","Masaguer, C. F.; Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; email: qojcfm@usc.es",,,,,,,,00222623,,JMCMA,"18783204","English","J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-53549089366
"Stefanachi A., Brea J.M., Cadavid M.I., Centeno N.B., Esteve C., Loza M.I., Martinez A., Nieto R., Raviña E., Sanz F., Segarra V., Sotelo E., Vidal B., Carotti A.","22235816900;6603008588;6603422293;6701440183;11239993500;7003766926;26436355500;23980774800;56264803900;7102263897;6603951720;6701728812;7005797173;7102635316;","Corrigendum to ""1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor"" [Bioorg. Med. Chem. 16 (2008) 2852-2869] (DOI:10.1016/j.bmc.2008.01.002)",2008,"Bioorganic and Medicinal Chemistry","16","18",,"8766","",,,"10.1016/j.bmc.2008.08.044","https://www.scopus.com/inward/record.uri?eid=2-s2.0-51449100360&doi=10.1016%2fj.bmc.2008.08.044&partnerID=40&md5=959909a130a7f8e07c00b554ee628f12","Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Unitat de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Almirall Research Center, Laboratorios Almirall S.A., Ctra. Laurea Miro 408, E-08980 St. Feliu Llobregat, Barcelona, Spain","Stefanachi, A., Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; Brea, J.M., Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Cadavid, M.I., Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Centeno, N.B., Unitat de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Esteve, C., Almirall Research Center, Laboratorios Almirall S.A., Ctra. Laurea Miro 408, E-08980 St. Feliu Llobregat, Barcelona, Spain; Loza, M.I., Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Martinez, A., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Nieto, R., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Raviña, E., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Sanz, F., Unitat de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Segarra, V., Almirall Research Center, Laboratorios Almirall S.A., Ctra. Laurea Miro 408, E-08980 St. Feliu Llobregat, Barcelona, Spain; Sotelo, E., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Vidal, B., Almirall Research Center, Laboratorios Almirall S.A., Ctra. Laurea Miro 408, E-08980 St. Feliu Llobregat, Barcelona, Spain; Carotti, A., Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy",[No abstract available],,"erratum; error",,,,,,,,,,"Carotti, A.; Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; email: carotti@farmchim.uniba.it",,,,,,,,09680896,,BMECE,,"English","Bioorg. Med. Chem.",Erratum,"Final",,Scopus,2-s2.0-51449100360
"Hofmann-Apitius M., Fluck J., Furlong L., Fornes O., Kolářik C., Hanser S., Boeker M., Schulz S., Sanz F., Klinger R., Mevissen T., Gattermayer T., Oliva B., Friedrich C.M.","57204494354;6603558627;34770469800;24483021600;8677178200;23496437800;24331040500;7201851157;7102263897;23134979000;6506592645;24483297600;35500780700;35232936500;","Knowledge environments representing molecular entities for the virtual physiological human",2008,"Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences","366","1878",,"3091","3110",,20,"10.1098/rsta.2008.0099","https://www.scopus.com/inward/record.uri?eid=2-s2.0-48349143152&doi=10.1098%2frsta.2008.0099&partnerID=40&md5=99d556bf56952c638a96eeba4bb51c34","Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, Dahlmannstrasse 2, 53113 Bonn, Germany; Institut Municipal d'Investigació Mèdica (IMIM), Universitat Pompeu Fabra, C/Doctor Aiguader 88, Barcelona 08003, Catalonia, Spain; Universitätsklinikum Freiburg, Hugstetter Straße 49, 79095 Freiburg, Germany; Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Institutszentrum Birlinghoven, 53754 Sankt Augustin, Germany","Hofmann-Apitius, M., Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, Dahlmannstrasse 2, 53113 Bonn, Germany, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Institutszentrum Birlinghoven, 53754 Sankt Augustin, Germany; Fluck, J., Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Institutszentrum Birlinghoven, 53754 Sankt Augustin, Germany; Furlong, L., Institut Municipal d'Investigació Mèdica (IMIM), Universitat Pompeu Fabra, C/Doctor Aiguader 88, Barcelona 08003, Catalonia, Spain; Fornes, O., Institut Municipal d'Investigació Mèdica (IMIM), Universitat Pompeu Fabra, C/Doctor Aiguader 88, Barcelona 08003, Catalonia, Spain; Kolářik, C., Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Institutszentrum Birlinghoven, 53754 Sankt Augustin, Germany; Hanser, S., Universitätsklinikum Freiburg, Hugstetter Straße 49, 79095 Freiburg, Germany; Boeker, M., Universitätsklinikum Freiburg, Hugstetter Straße 49, 79095 Freiburg, Germany; Schulz, S., Universitätsklinikum Freiburg, Hugstetter Straße 49, 79095 Freiburg, Germany; Sanz, F., Institut Municipal d'Investigació Mèdica (IMIM), Universitat Pompeu Fabra, C/Doctor Aiguader 88, Barcelona 08003, Catalonia, Spain; Klinger, R., Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Institutszentrum Birlinghoven, 53754 Sankt Augustin, Germany; Mevissen, T., Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Institutszentrum Birlinghoven, 53754 Sankt Augustin, Germany; Gattermayer, T., Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Institutszentrum Birlinghoven, 53754 Sankt Augustin, Germany; Oliva, B., Institut Municipal d'Investigació Mèdica (IMIM), Universitat Pompeu Fabra, C/Doctor Aiguader 88, Barcelona 08003, Catalonia, Spain; Friedrich, C.M., Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Institutszentrum Birlinghoven, 53754 Sankt Augustin, Germany","In essence, the virtual physiological human (VPH) is a multiscale representation of human physiology spanning from the molecular level via cellular processes and multicellular organization of tissues to complex organ function. The different scales of the VPH deal with different entities, relationships and processes, and in consequence the models used to describe and simulate biological functions vary significantly. Here, we describe methods and strategies to generate knowledge environments representing molecular entities that can be used for modelling the molecular scale of the VPH. Our strategy to generate knowledge environments representing molecular entities is based on the combination of information extraction from scientific text and the integration of information from biomolecular databases. We introduce @neuLink, a first prototype of an automatically generated, disease-specific knowledge environment combining biomolecular, chemical, genetic and medical information. Finally, we provide a perspective for the future implementation and use of knowledge environments representing molecular entities for the VPH. © 2008 The Royal Society.","Data mining; Information extraction; Virtual physiological human","Chlorine compounds; Physiology; Automatically generated; Bio-molecular; Biological functions; Biomolecular databases; Cellular processes; Chemical-; Data mining; Different scales; Human physiology; Information extraction; Medical information; Molecular entities; Molecular levels; Molecular scales; Multi-scale representation; Multicellular organization; Organ functions; Specific knowledge; Virtual physiological human; Virtual reality; allele; article; artificial intelligence; biological model; computer interface; computer simulation; human; knowledge base; metabolism; physiology; single nucleotide polymorphism; Alleles; Artificial Intelligence; Computer Simulation; Humans; Knowledge Bases; Metabolic Networks and Pathways; Models, Biological; Physiology; Polymorphism, Single Nucleotide; User-Computer Interface",,,,,,,,,"Alfarano, C., The biomolecular interaction network database and related tools 2005 update (2005) Nucleic Acids Res, 33, pp. D418-D424. , doi:10.1093/nar/gki051; Ananiadou, S., Mcnaught, J., (2005) Text mining for biology and biomedicine, , London, UK: Artech House, Inc; Aragues, R., Jaeggi, D., Oliva, B., PIANA: Protein interactions and network analysis (2006) Bioinformatics, 22, pp. 1015-1017. , doi:10.1093/bioinformatics/btl072; Aragues, R., Sali, A., Bonet, J., Marti-Renom, M.A., Oliva, B., Characterization of protein hubs by inferring interacting motifs from protein interactions (2007) PLoS Comput. Biol, 3, pp. 1761-1771. , doi:10.1371/journal.pcbi.0030178; Aragues, R., Sander, C., Oliva, B., Predicting cancer involvement of genes from heterogeneous data (2008) BMC Bioinform, 9, p. 172. , doi:10.1186/1471-2105-9-172; Berman, H., Henrick, K., Nakamura, H., Markley, J.L., The worldwide Protein Data Bank (wwPDB): Ensuring a single, uniform archive of PDB data (2007) Nucleic Acids Res, 35, pp. D301-D303. , doi:10.1093/nar/gkl971; Bertram, L., McQueen, M.B., Mullin, K., Blacker, D., Tanzi, R.E., Systematic metaanalyses of Alzheimer disease genetic association studies: The AlzGene database (2007) Nat. Genet, 39, pp. 17-23. , doi:10.1038/ng1934; Bodenreider, O., The unified medical language system (UMLS): Integrating biomedical terminology (2004) Nucleic Acids Res, 32, pp. D267-D270. , doi:10.1093/nar/gkh061; Butcher, E.C., Berg, E.L., Kunkel, E.J., Systems biology in drug discovery (2004) Nat. Biotechnol, 22, pp. 1253-1259. , doi:10.1038/nbt1017; Chatr-aryamontri, A., Ceol, A., Palazzi, L.M., Nardelli, G., Schneider, M.V., Castagnoli, L., Cesareni, G., MINT: The Molecular INTeraction database (2007) Nucleic Acids Res, 35, pp. D572-D574. , doi:10.1093/nar/ gkl950; Cockell, S.J., Oliva, B., Jackson, R.M., Structure-based evaluation of in silico predictions of protein-protein interactions using comparative docking (2007) Bioinformatics, 23, pp. 573-581. , doi:10. 1093/bioinformatics/btl661; Eigner-Pitto, V., 2007 In ICIC Conference in Sitges, Spain, 21-23 October 2007, , http://www.infonortics.com/chemical/ch07/07chempro-post.html; Espadaler, J., Romero-Isart, O., Jackson, R.M., Oliva, B., Prediction of protein - protein interactions using distant conservation of sequence patterns and structure relationships (2005) Bioinformatics, 21, pp. 3360-3368. , doi:10.1093/bioinformatics/btl522; Espadaler, J., Aragues, R., Eswar, N., Marti-Renom, M.A., Querol, E., Aviles, F.X., Sali, A., Oliva, B., Detecting remotely related proteins by their interactions and sequence similarity (2005) Proc. Natl Acad. Sci. USA, 102, pp. 7151-7156. , doi:10.1073/pnas.0500831102; Espana, L., Fernandez, Y., Rubio, N., Torregrosa, A., Blanco, J. & Sierra, A. 2004 Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res. Treat. 87, 33-44. (doi:10.1023/B:BREA.0000041579.51902.89); Fluck, J., Mevissen, T.H., Dach, H., Oster, M., Hofmann-Apitius, M., ProMiner: Recognition of human gene and protein names using regularly updated dictionaries (2006) Second BioCreAtIvE Challenge Workshop, Critical Assessment of Information Extraction in Molecular Biology, , Madrid, Spain; Furlong, L.I., Dach, H., Hofmann-Apitius, M., Sanz, F., OSIRIS v. 1.2: A named entity recognition system for sequence variants of genes in biomedical literature (2008) BMC Bioinform, 9, p. 84. , doi:10.1186/1471- 2105-9-84; Gattermayer, T., (2007) SCAIView: Annotation and visualization system for knowledge discovery, , Masters thesis, Life Science Informatics at Bonn-Aachen International Center for Information Technology B-IT, Germany; Gough, N.R., Science's signal transduction knowledge environment: The connections maps database (2002) Ann. NY Acad. Sci, 971, pp. 585-587; Han, B., Friedrich, C.M., Manthey, R., Hofmann-Apitius, M., Bayesian network modelling for the prodiction of treatment outcomes of intracranial aneurysms (2006) Short Papers and Poster Abstracts of the German Conference on Bioinformatics (GCB 2006), p. 122. , eds D. Huson, O. Kohlbacher, A. Lupas, K. Nieselt & A. Zell, p; Hanisch, D., Fundel, K., Mevissen, H.T., Zimmer, R., Fluck, J., ProMiner: Rule based protein and gene entity recognition (2005) BMC Bioinform, 6 (SUPPL. 1), pp. S14. , doi:10.1186/1471-2105-6-S1-S14; Hearst, M.A., Automatic acquisition of hyponyms from large text corpora (1992) Proc. 14th Int. Conf. on Computational Linguistics, pp. 539-545. , Nantes, France, 23-28 August; Heinemann, M., Panke, S., Synthetic biology - putting engineering into biology (2006) Bioinformatics, 22, pp. 2790-2799. , doi:10.1093/bioinformatics/btl469; Hirschman, L., Yeh, A., Blaschke, C., Valencia, A., Overview of BioCreAtIvE: Critical assessment of information extraction for biology (2005) BMC Bioinform, 6, pp. S1. , doi:10.1186/1471-2105-6-S1-S1; Jensen, L.J., Saric, J., Bork, P., Literature mining for the biologist: From information retrieval to biological discovery (2006) Nat. Rev. Genet, 7, pp. 119-129. , doi:10.1038/nrg1768; Jin, Y., Automated recognition of malignancy mentions in biomedical literature (2006) BMC Bioinform, 7, p. 492. , doi:10.1186/1471-2105-7-492; Kerrien, S., INTACT - open source resource for molecular interaction data (2007) Nucleic Acids Res, 35, pp. D561-D565. , doi:10.1093/nar/gkl958; Klinger, R., Furlong, L.I., Friedrich, C.M., Mevissen, H.T., Fluck, J., Sanz, F., Hofmann-Apitius, M., Identifying gene specific variations in biomedical text (2007) J. Bioinform. Comput. Biol, 5, pp. 1277-1296. , doi:10.1142/S0219720007003156; Klinger, R., Kolarik, C., Fluck, J., Hofmann-Apitius, M., Friedrich, C.M., In press. Detection of IUPAC and IUPAC-like chemical names Sixteenth Annual Int. Conf. Intelligent Systems for Molecular Biology; Kolářik, C., Hofmann-Apitius, C., Zimmermann, M., Fluck, J., Identification of new drug classification terms in textual resources (2007) Bioinformatics, 23, pp. 264-272. , doi:10.1093/bioinfor- matics/btm196; Krischek, B., Inoue, I., The genetics of intracranial aneurysms (2006) J. Hum. Genet, 51, pp. 587-594. , doi:10.1007/s10038-006-0407-4; Lafferty, J.D., McCallum, A., Pereira, F.C.N., Conditional random fields: Probabilistic models for segmenting and labeling sequence data (2001) Proc. Eighteenth Int. Conf. on Machine Learning, pp. 282-289; Maere, S., Heymans, K., Kuiper, M., BiNGO: A cytoscape plugin to assess over-representation of gene ontology categories in biological networks (2005) Bioinformatics, 21, pp. 3448-3449. , doi:10.1093/bioinformatics/bti551; Masolo, C., Borgo, S., Gangemi, A., Guarino, N., Oltramari, A. & Schneider, L. 2007 The WonderWeb Library of Foundational Ontologies. WonderWeb Deliverables 17 and 18. See http://wonderweb. semanticweb.org/index.shtml and also http://www.loa-cnr.it/DOLCE.html; McDonald, R., Pereira, R., Identifying gene and protein mentions in text using conditional random fields (2005) BMC Bioinform, 6, pp. S6. , doi:10.1186/1471-2105-6-S1-S6; Mewes, H.W., MIPS: Analysis and annotation of proteins from whole genomes in 2005 (2006) Nucleic Acids Res, 34, pp. D169-D172. , doi:10.1093/nar/gkj148; Michener, W.K., Beach, J.H., Jones, M.B., Ludäscher, B., Pennington, D.D., Pereira, R.S., Rajasekar, A., Schildhauer, M., A knowledge environment for the biodiversity and ecological sciences (2007) J. Intel. Inf. Syst, 29, pp. 111-126. , doi:10.1007/s10844-006-0034-8; Murray-Rust, P., 2008 In Dagstuhl Workshop on Text Mining and Ontologies, 24-28 March 2008, , http://www.dagstuhl.de/en/program/calendar/semhp/?semnrZ08131; Peri, S., Human protein reference database as a discovery resource for proteomics (2004) Nucleic Acids Res, 32, pp. D497-D501. , doi:10.1093/nar/gkh070; Plake, C., Schiemann, T., Pankalla, M., Hakenberg, J., Leser, U., AliBaba: PubMed as a graph (2006) Bioinformatics, 22, pp. 2444-2445. , doi:10.1093/bioinformatics/btl408; Radeke, H.H., Ludwig, R.J., Boehncke, W.H., Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo (2005) Exp. Dermatol, 14, pp. 641-666. , doi:10.1111/j.0906-6705.2005.00350.x; Rebholz-Schuhmann, D., Kirsch, H., Arregui, M., Gaudan, S., Rynbeek, M., Stoehr, P., Protein annotation by EBIMed (2006) Nat. Biotechnol, 24, pp. 902-903. , doi:10.1038/nbt0806-902; Salwinski, L., Miller, C., Smith, A., Pettit, F., Bowie, J., Eisenberg, D., The database of interacting proteins: 2004 update (2004) Nucleic Acids Res, 32, pp. D449-D451. , doi:10.1093/nar/gkh086; Sanz, R., Aragues, R., Stresing, V., Martin, B., Landemaine, T., Oliva, B., Driouch, K., Sierra, A., Functional pathways shared by liver and lung metastases: A mitochondrial chaperone machine is up-regulated in soft-tissue breast cancer metastasis (2007) Clin. Exp. Metastasis, 24, pp. 673-683. , doi:10.1007/s10585-007-9124-4; Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, K., dbSNP: The NCBI database of genetic variation (2001) Nucleic Acids Res, 29, pp. 308-311. , doi:10. 1093/nar/29.1.308; Stark, C., Breitkreutz, B.J., Reguly, T., Boucher, L., Breitkreutz, A., Tyers, M., Bi-oGRID: A general repository for interaction datasets (2006) Nucleic Acids Res, 34, pp. D535-D539. , doi:10.1093/ nar/gkj109; The UniProt Consortium 2007 The universal protein resource (UniProt). Nucleic Acids Res. 35, D193-D197. (doi:10.1093/nar/gkl929); Uramoto, N., Matsuzawa, H., Nagano, T., Murakami, A., Takeuchi, H., Takeda, K., A text-mining system for knowledge discovery from biomedical documents (2004) IBM Syst. J, 43, pp. 516-533; Wishart, D.S., Knox, C., Guo, A.C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., Woolsey, J., DrugBank: A comprehensive resource for in silico drug discovery and exploration (2006) Nucleic Acids Res, 1, pp. D668-D672. , doi:10.1093/nar/gkj067; Wren, J.D., A scalable machine-learning approach to recognize chemical names within large text databases (2006) BMC Bioinform, 7, pp. S3. , doi:10.1186/1471-2105-7-S2-S3","Hofmann-Apitius, M.; Bonn-Aachen International Center for Information Technology (B-IT), University of Bonn, Dahlmannstrasse 2, 53113 Bonn, Germany; email: martin.hofmann-apitius@scai.fraunhofer.de",,,"Royal Society",,,,,1364503X,,,"18559317","English","Philos. Trans. R. Soc. A Math. Phys. Eng. Sci.",Article,"Final",,Scopus,2-s2.0-48349143152
"Selent J., Pez L.L., Sanz F., Pastor M.","55891371700;25626406600;7102263897;7102415847;","Multi-receptor binding profile of clozapine and olanzapine: A structural study based on the new β2 adrenergic receptor template",2008,"ChemMedChem","3","8",,"1194","1198",,45,"10.1002/cmdc.200800074","https://www.scopus.com/inward/record.uri?eid=2-s2.0-53549107953&doi=10.1002%2fcmdc.200800074&partnerID=40&md5=fdf1e167239ee8e490f60b4d25fade40","Research Unit on Biomedical Informatics (GRIB), IMIM/Universitat Pompeu Fabra, Avinguda Dr. Aiguader 88, 08003 Barcelona, Spain","Selent, J., Research Unit on Biomedical Informatics (GRIB), IMIM/Universitat Pompeu Fabra, Avinguda Dr. Aiguader 88, 08003 Barcelona, Spain; Pez, L.L., Research Unit on Biomedical Informatics (GRIB), IMIM/Universitat Pompeu Fabra, Avinguda Dr. Aiguader 88, 08003 Barcelona, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM/Universitat Pompeu Fabra, Avinguda Dr. Aiguader 88, 08003 Barcelona, Spain; Pastor, M., Research Unit on Biomedical Informatics (GRIB), IMIM/Universitat Pompeu Fabra, Avinguda Dr. Aiguader 88, 08003 Barcelona, Spain","The relationships between the multi-receptor binding profile of clozapine and olanzapine and their therapeutic properties were analyzed by using novel complexes built from the recently solved β2 adrenergic receptor structure. While interactions with position 3.36 determine the binding profile of clozapine-like ligands, diversity in TM5 and TM6 is responsible for subtle differences between clozapine and olanzapine. (Chemical Equation Presented) © 2008 Wiley-VCH Verlag GmbH &amp; Co. KGaA.","Antipsychotic agents; Binding selectivity; G-protein-coupled receptors; Homology modeling; Multi-receptor profile","adrenergic receptor; benzodiazepine derivative; clozapine; olanzapine; article; binding site; chemical structure; chemistry; metabolism; molecular genetics; nucleotide sequence; protein binding; sequence alignment; Benzodiazepines; Binding Sites; Clozapine; Conserved Sequence; Models, Molecular; Molecular Sequence Data; Molecular Structure; Protein Binding; Receptors, Adrenergic; Sequence Alignment",,"clozapine, 5786-21-0; olanzapine, 132539-06-1; Benzodiazepines; Clozapine, 5786-21-0; olanzapine, 132539-06-1; Receptors, Adrenergic",,,,,,,"Wu, E.Q., Birnbaum, H.G., Shi, L., Ball, D.E., Kessler, R.C., Moulis, M., Aggarwal, J., (2005) J. Clin. Psychiatry, 66, pp. 1122-1129; Roth, B.L., Sheffler, D.J., Kroeze, W.K., (2004) Nat. Rev. Drug Discovery, 3, pp. 353-359; Garzya, V., Forbes, I.T., Gribble, A.D., Hadley, M.S., Lightfoot, A.P., Payne, A.H., Smith, A.B., Ratti, E.A., (2007) Bioorg. Med. Chem. Lett, 17, pp. 400-405; Hjerde, E., Dahl, S.G., Sylte, I., (2005) Eur. J. Med. Chem, 40, pp. 185-194; Kalani, M.Y., Vaidehi, N., Hall, S.E., Trabanino, R.J., Freddolino, P.L., Kalani, M.A., Floriano, W.B., Goddard III, W.A., (2004) Proc. Natl. Acad. Sci. USA, 101, pp. 3815-3820; Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., Choi, H.J., Stevens, R.C., (2007) Science, 318, pp. 1258-1265; Rosenbaum, D.M., Cherezov, V., Hanson, M.A., Rasmussen, S.G., Thian, F.S., Kobilka, T.S., Choi, H.J., Kobilka, B.K., (2007) Science, 318, pp. 1266-1273; Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Miyano, M., (2000) Science, 289, pp. 739-745; Almaula, N., Ebersole, B.J., Zhang, D., Weinstein, H., Sealfon, S.C., (1996) J. Biol. Chem, 271, pp. 14672-14675; Kobilka, B., (2004) Mol. Pharmacol, 65, pp. 1060-1062; Lundstrom, K., Turpin, M.P., Large, C., Robertson, G., Thomas, P., Lewell, X.Q., (1998) J. Recept. Signal Transduction Res, 18, pp. 133-150; Woodward, R., Daniell, S.J., Strange, P.G., Naylor, L.H., (1994) J. Neurochem, 62, pp. 1664-1669; Lange, J.H., Reinders, J.H., Tolboom, J.T., Glennon, J.C., Coolen, H.K., Kruse, C.G., (2007) J. Med. Chem, 50, pp. 5103-5108; KARTINFSTARTiARTINFEND, P.D.S.P., Database, , http://pdsp.med.unc.edu, National Institutes of Mental Health Psychoactive Drug Screening Program, access to this interactive links box is free; Meltzer, H.Y., Li, Z., Kaneda, Y., Ichikawa, J., (2003) Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 27, pp. 1159-1172; Braden, M.R., Parrish, J.C., Naylor, J.C., Nichols, D.E., (2006) Mol. Pharmacol, 70, pp. 1956-1964; Cox, B.A., Henningsen, R.A., Spanoyannis, A., Neve, R.L., Neve, K.A., (1992) J. Neurochem, 59, pp. 627-635; Javitch, J.A., Ballesteros, J.A., Weinstein, H., Chen, J., (1998) Biochemistry, 37, pp. 998-1006; Javitch, J.A., Fu, D., Chen, J., Karlin, A., (1995) Neuron, 14, pp. 825-831; Mansour, A., Meng, F., Meador-Woodruff, J.H., Taylor, L.P., Civelli, O., Akil, H., (1992) Eur. J. Pharmacol, 227, pp. 205-214; Muntasir, H.A., Bhuiyan, M.A., Ishiguro, M., Ozaki, M., Nagatomo, T., (2006) J. Pharmacol. Sci, 102, pp. 189-195; Gregoret, L.M., Rader, S.D., Fletterick, R.J., Cohen, F.E., (1991) Proteins Struct. Funct. Genet, 9, pp. 99-107; Dezi, C., Brea, J., Alvarado, M., Ravina, E., Masaguer, C.F., Loza, M.I., Sanz, F., Pastor, M., (2007) J. Med. Chem, 50, pp. 3242-3255; Sali, A., Blundell, T.L., (1993) J. Mol. Biol, 234, pp. 779-815; Cornell, W.D., Cieplak, P., Bayly, C.I., Gould, I.R., Merz, K.M., Ferguson, D.M., Spellmeyer, D.C., (1995) J. Am. Chem. Soc, 117, pp. 5179-5197; Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., (1993) J. Appl. Crystallogr, 26, pp. 283-291; Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., (2003) Proteins Struct. Funct. Genet, 52, pp. 609-623","Pastor, M.; Research Unit on Biomedical Informatics (GRIB), IMIM/Universitat Pompeu Fabra, Avinguda Dr. Aiguader 88, 08003 Barcelona, Spain; email: manuel.pastor@upf.edu",,,,,,,,18607179,,,"18465762","English","ChemMedChem",Article,"Final",,Scopus,2-s2.0-53549107953
"Stefanachi A., Brea J.M., Cadavid M.I., Centeno N.B., Esteve C., Loza M.I., Martinez A., Nieto R., Raviña E., Sanz F., Segarra V., Sotelo E., Vidal B., Carotti A.","22235816900;6603008588;6603422293;6701440183;11239993500;7003766926;26436355500;23980774800;56264803900;7102263897;6603951720;6701728812;7005797173;7102635316;","1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor",2008,"Bioorganic and Medicinal Chemistry","16","6",,"2852","2869",,25,"10.1016/j.bmc.2008.01.002","https://www.scopus.com/inward/record.uri?eid=2-s2.0-40949148593&doi=10.1016%2fj.bmc.2008.01.002&partnerID=40&md5=c2a119684785e02adbf425d2d9b53ca1","Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Unitat de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Almirall Research Center, Laboratorios Almirall S.A., Ctra. Laurea Miro 408, E-08980 St. Feliu Llobregat, Barcelona, Spain","Stefanachi, A., Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; Brea, J.M., Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Cadavid, M.I., Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Centeno, N.B., Unitat de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Esteve, C., Almirall Research Center, Laboratorios Almirall S.A., Ctra. Laurea Miro 408, E-08980 St. Feliu Llobregat, Barcelona, Spain; Loza, M.I., Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Martinez, A., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Nieto, R., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Raviña, E., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Sanz, F., Unitat de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Segarra, V., Almirall Research Center, Laboratorios Almirall S.A., Ctra. Laurea Miro 408, E-08980 St. Feliu Llobregat, Barcelona, Spain; Sotelo, E., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Vidal, B., Almirall Research Center, Laboratorios Almirall S.A., Ctra. Laurea Miro 408, E-08980 St. Feliu Llobregat, Barcelona, Spain; Carotti, A., Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy","A large series of piperazin-, piperidin- and tetrahydroisoquinolinamides of 4-(1,3-dialkyl-9-deazaxanthin-8-yl)phenoxyacetic acid were prepared through conventional or multiple parallel syntheses and evaluated for their binding affinity at the recombinant human adenosine receptors, chiefly at the hA2B and hA2A receptor subtypes. Several ligands endowed with high binding affinity at hA2B receptors, excellent selectivity over hA2A and hA3 and a significant, but lower, selectivity over hA1 were identified. Among them, piperazinamide derivatives 23 and 52, and piperidinamide derivative 69 proved highly potent at hA2B (Ki = 11, 2 and 5.5 nM, respectively) and selective towards hA2A (hA2A/hA2B SI = 912, 159 and 630, respectively), hA3 (hA3/hA2B SI = &gt; 100, 3090 and &gt;180, respectively) and hA1 (hA1/hA2B SI = &gt; 100, 44 and 120, respectively), SI being the selectivity index. A number of selected ligands tested in functional assays in vitro showed very interesting antagonist activities and efficacies at both A2A and A2B receptor subtypes, with pA2 values close to the corresponding pKis. Structure-affinity and structure-selectivity relationships suggested that the binding potency at the hA2B receptor may be increased by lipophilic substituents at the N4-position of piperazinamides and that an ortho-methoxy substituent at the 8-phenyl ring and alkyl groups at N1 larger than the ones at N3, in the 9-deazaxanthine ring, may strongly enhance the hA2A/hA2B SI. © 2008 Elsevier Ltd. All rights reserved.","1,3-Dialkyl-6-substituted-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-diones; 9-Deazaxanthines; Adenosine receptor antagonists; hA2A/hA2B selectivity; hA2B and hA2A binding affinities; Structure-affinity relationships; Structure-selectivity relationships","acetic acid derivative; adenosine A1 receptor; adenosine A2 receptor; adenosine A3 receptor; amide; piperazine derivative; piperidine derivative; xanthine derivative; animal cell; animal tissue; article; binding affinity; controlled study; drug receptor binding; drug selectivity; drug structure; drug synthesis; embryo; human; human cell; nonhuman; structure activity relation",,"amide, 17655-31-1",,,"Ministero dell’Istruzione, dell’Università e della Ricerca, MIUR","The authors thanks the MIUR (Ministero dell’Università e della Ricerca Scientifica, Rome (Italy)), for partial financial support.",,,"Jacobson, K.A., Gao, Z.-G., (2006) Nat. Rev. Drug Discov., 5, p. 247; Moro, S., Gao, Z.-G., Jacobson, K.A., Spalluto, G., (2006) Med. Res. Rev., 26, p. 131; Akkari, R., Burbiel, J.C., Hockemeyer, J., Müller, C.E., (2006) Curr. Top. Med. Chem., 6, p. 1375; Fredholm, B.B., IJzerman, A.P., Jacobson, K.A., Klotz, K.N., Linden, J., (2001) Pharmacol. Rev., 53, p. 527; Volpini, R., Costanzi, S., Vittori, S., Cristalli, G., Klotz, K.-N., (2003) Curr. Top. Med. Chem., 3, p. 427; Baraldi, P.G., Romagnoli, R., Preti, D., Fruttarolo, F., Carrion, M.D., Tabrizi, M.A., (2006) Curr. Med. Chem., 13, p. 3467; Strohmeier, G.R., Reppert, S.M., Lencer, W.I., Madara, J.L., (1995) J. Biol. Chem., 270, p. 2387; Papassotiropoulos, A., Hock, C., Nitsch, R.M., (2001) Neurobiol. Aging, 22, p. 903; Harada, H., Osamu Asano, O., Hoshino, Y., Yoshikawa, S., Matsukura, M., Kabasawa, Y., Nijima, J., Abe, S., (2001) J. Med. Chem., 44, p. 170; Linden, J., (2005) Mol. Pharmacol., 67, p. 1385; Jacobson, K.A., Hoffman, C., Cattabeni, F., Abbracchio, M.P., (1999) Apoptosis, 4, p. 197; Xaus, J., Valledor, A.F., Cardo, M., Marques, L., Beleta, J., Palacios, J.M., Celada, A., (1999) J. Immunol., 163, p. 4140; Fozard, J.R., McCarthy, C., (2002) Curr. Opin. Invest. Drugs, 3, p. 69; Feoktistov, I., Biaggioni, I., (1995) J. Clin. Invest., 96, p. 1979; Wolber, C., Fozard, J.R., (2005) Naunyn Schmiedeberg's Arch. Pharmacol., 371, p. 158; Holgate, S.T., (2005) Br. J. Pharmacol., 145, p. 1009; Feokistov, I., Murray, J.J., Biaggioni, I., (1994) Mol. Pharmacol., 45, p. 1160; Peyot, M.-L., Gadeau, A.-P., Dandré, F., Belloc, I., Dupuch, F., Desgranges, C., (2000) Circ. Res., 86, p. 76; Robeva, A.S., Woodward, R., Jin, X., Gao, Z.-J., Bhattacharya, S., Taylor, H.E., Rosin, D.L., Linden, J., (1996) Drug Dev. Res., 39, p. 243; Jacobson, K.A., Ukena, D., Padgett, W., Daly, J.W., Kirk, K.L., (1987) J. Med. Chem., 30, p. 211; Müller, C.E., Shi, D., Manning, M., Daly, J.W., (1993) J. Med. Chem., 36, p. 3341; Carotti, A., Stefanachi, A., Ravina, E., Sotelo, E., Loza, M.I., Cadavid, M.I., Centeno, N.B., Nicolotti, O., (2004) Eur. J. Med. Chem., 39, p. 879; Kim, S.A., Marshall, M.A., Melman, N., Kim, H.S., Müller, C.E., Linden, J., Jacobson, K.A., (2002) J. Med. Chem., 45, p. 2131; Grahner, B., Winiwarter, S., Lanzer, W., Müller, C.E., (1994) J. Med. Chem., 37, p. 1526; Hayallah, A., Sandoval-Ramirez, J., Reith, U., Schobert, U., Preiss, B., Schumacher, B., Daly, J.W., Müller, C.E., (2002) J. Med. Chem., 45, p. 1500; Vidal, B. J.; Esteve Trias, C.; Segarra Matamoros, V.; Ravina Rubira, E.; Fernandez Gonzales, F.; Loza Garcia, M. I.; Sanz Carreras, F. 6-WO Patent 03/000694, 2003; Kalla, R.; Perry, T.; Elzein, E.; Varkhedkar, V.; Li, X.; Ibrahin, P.; Palle, V.; Xiao, D.; Zablocki, J. US Patent 6825349, 2004; Palle, V.; Elzein, E.; Ibrahim, P.; Kalla, R.; Li X.; Perry T.; Varkhedkar, V.; Xiao, D.; Zablocki, J. WO Patent 05042534, 2005; Wang, G.; Rieger, J. M.; Thompson, R. D. WO Patent 05021548, 2005; Kim, Y.C., Ji, X., Melman, N., Linden, J., Jacobson, K.A., (1999) Drug Dev. Res., 47, p. 178; Kim, Y.C., Ji, X., Melman, N., Linden, J., Jacobson, K.A., (2000) J. Med. Chem., 43, p. 1165; Baraldi, P.G., Tabrizi, M.A., Preti, D., Bovero, A., Romagnoli, R., Fruttarolo, F., Abdel Zaid, N., Borea, P.A., (2004) J. Med. Chem., 47, p. 1434; Zablocki, J., Kalla, R., Perry, T., Palle, V., Varkhedkar, V., Xiao, D., Piscopio, A., Zeng, D., (2005) Bioorg. Med. Chem. Lett., 15, p. 609; Almirall Prodesfarma S. A.; Vidal, B.; Esteve, C. WO 03082873, 2003; Carotti, A., Cadavid, M.I., Centeno, N.B., Esteve, C., Loza, M.I., Martinez, A., Nieto, R., Vidal, B., (2006) J. Med. Chem., 49, p. 282; Lago, J., Alfonso, A., Vieytes, M.R., Botana, L.M., (2001) Cell Signal., 13, pp. 515-524; Hannon, J.P., Tigani, B., Williams, I., Mazzoni, L., Fozard, J.R., (2001) Br. J. Pharmacol., 132, p. 1509; Touchstone, J., (1982) Advances in Thin-Layer Chromatography, , Wiley, New York; Salomon, Y., (1979) Adv. Cyclic Nucleotide Res., 10, p. 35; Prentice, D.J., Hourani, S.M.O., (1996) Br. J. Pharmacol., 118, p. 1509; Alexander, S.P., Losinsky, A., Kendall, D.A., Hill, S.J.A., (1994) Br. J. Pharmacol., 111, p. 185","Carotti, A.; Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; email: carotti@farmchim.uniba.it",,,"Elsevier Ltd",,,,,09680896,,BMECE,"18226909","English","Bioorg. Med. Chem.",Article,"Final",,Scopus,2-s2.0-40949148593
"Martínez A., Gutiérrez-de-Terán H., Brea J., Raviña E., Loza M.I., Cadavid M.I., Sanz F., Vidal B., Segarra V., Sotelo E.","26436355500;6507897412;6603008588;56264803900;7003766926;6603422293;7102263897;7005797173;6603951720;6701728812;","Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2′-furyl)-1,2,4-triazolo[1,5-a]quinoxalines",2008,"Bioorganic and Medicinal Chemistry","16","4",,"2103","2113",,10,"10.1016/j.bmc.2007.10.103","https://www.scopus.com/inward/record.uri?eid=2-s2.0-39049143861&doi=10.1016%2fj.bmc.2007.10.103&partnerID=40&md5=de553f6936aea33fb21a7b2e5fca3d0a","Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain; Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain; Unitat de Recerca en Informática Médica (GRIB), IMIM, Dep. CEXS, Dr. Aiguader 88, Barcelona, E-08003, Spain; Medicinal Chemistry Department, Almirall, Treball 2-4, St. Just Desvern, Barcelona E-08960, Spain","Martínez, A., Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain; Gutiérrez-de-Terán, H., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain; Brea, J., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain; Raviña, E., Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain; Loza, M.I., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain; Cadavid, M.I., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain; Sanz, F., Unitat de Recerca en Informática Médica (GRIB), IMIM, Dep. CEXS, Dr. Aiguader 88, Barcelona, E-08003, Spain; Vidal, B., Medicinal Chemistry Department, Almirall, Treball 2-4, St. Just Desvern, Barcelona E-08960, Spain; Segarra, V., Medicinal Chemistry Department, Almirall, Treball 2-4, St. Just Desvern, Barcelona E-08960, Spain; Sotelo, E., Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain","A collection of 25 2-(2′-furyl)-1,2,4-triazolo[1,5-a]quinoxalines incorporating different substitution patterns at position 4 have been synthesized and their binding affinity towards human adenosine receptors (hA1, hA2A, hA2B and hA3) was determinated. The biological data show that several potent at hA1, but lightly selective, adenosine ligands were identified. Moreover, these results confirmed the hypothesis that the structural modifications carried out on the 4-position of the tricyclic system produces a remarkable modification of the adenosine receptorial profile. A 3D-QSAR modelling study (GRIND/ALMOND methodology) performed on the hA1 data gave further support to the pharmacological results, and it is presented as a useful tool for the future design of ligands with better pharmacological profiles. © 2008 Elsevier Ltd. All rights reserved.","1,2,4-Triazolo[1,5-a]quinoxalines; 3D-QSAR; Adenosine receptor binding","4 amino 2 (2' furyl) 1,2,4 triazolo[1,5 a]quinoxaline; adenosine A1 receptor; adenosine A2a receptor; adenosine A2b receptor; adenosine A3 receptor; adenosine receptor; quinoxaline derivative; unclassified drug; animal cell; article; binding affinity; controlled study; data analysis; drug potency; drug receptor binding; drug selectivity; drug structure; drug synthesis; embryo; female; human; human cell; nonhuman; quantitative structure activity relation; substitution reaction; Humans; Ligands; Protein Binding; Quantitative Structure-Activity Relationship; Quinoxalines; Receptors, Purinergic P1",,"Ligands; Quinoxalines; Receptors, Purinergic P1",,,,"Financial support from Almirall Laboratories (Barcelona) is gratefully acknowledged.",,,"Von Lubitz, D.K.J.E., Jacobson, K.A., Behavioral Effects of Adenosine Receptors Stimulation (1995) Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology, pp. 489-498. , Bellardinelli L., and Pelleg A. (Eds), Kluwer, Norwell; Ralevic, V., Burnstock, G., (1998) Pharmacol. Rev., 50, p. 413; Hess, S., (2001) Expert Opin. Ther. Pat., 11, p. 1533; Fredholm, B.B., Arslan, G., Haldner, L., Kull, G., Schulte, G., Wasserman, W., Nauyn-Schmied, A., (2000) Arch. Pharmacol., 362, p. 364; Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.N., Linden, J., (2001) Pharm. Rev., 53, p. 527; Baraldi, P.G., Cacciari, B., Romagnoli, R., Spalluto, G., (1999) Expert Opin. Ther. Pat., 9, p. 515; Muller, C.E., (2003) Curr. Top. Med. Chem., 3, p. 445; Muller, C.E., (2000) Curr. Med. Chem., 7, p. 1269; Merighi, S., Mirandola, P., Varani, K., Gessi, S., Leung, E., Baraldi, P.G., Tabrizi, M.A., Borea, P.A., (2003) Pharmacol. Ther., 100, p. 31; Baraldi, P.G., Borea, P.A., (2000) Trends Pharmacol. Sci., 21, p. 456; Baraldi, P.G., Cacciari, B., Romagnoli, R., Meringhi, S., Verani, K., Borea, P.A., Spalluto, P., (2000) Med. Res. Rev., 20, p. 103; Baraldi, P.G., Bovero, A., Fruttarolo, F., Romagnoli, R., Tabrizi, M., Aghazadeh, P., Delia, V., Moorman, A.R., (2003) Bioorg. Med. Chem., 11, p. 4161; Beukers, M.W., Chang, L.C.W., von Kuenzel, J.K., Mulder-Krieger, Th., Spanjersberg, R.F., Brussee, J., IJzerman, A.P., (2004) J. Med. Chem., 47, p. 3707; Harada, H., Asano, O., Hoshino, Y., Yoshikawa, S., Matsukura, M., Kabasawa, Y., Niijima, J., Abe, S., (2001) J. Med. Chem., 44, p. 170; Ozola, V., Thorand, M., Diekmann, M., Qurishi, R., Schumacher, B., Jacobson, K.A., Muller, C.E., (2003) Bioorg. Med. Chem., 11, p. 347; Sato, H., Nagashima, K., Nomura, H., Karasawa, A., Nishikawa, S., (1999) J. Toxicol. Path., 12, p. 21; Kozo, Y., Hideaki, K., Kiyoshi, S., Akira, K., (1994) Jpn. J. Pharmacol., 65, p. 167; Hideaki, M., Akira, K., Kazuhiro, K., (1993) J. Pharmacol. Exp. Ther., 266, p. 200; Ochi, M., Shiozaki, S., Kase, H., (2004) Neuroscience, 127, p. 223; Kim, J.S., Sohn, Y.H., (2002) Adv. Behav. Biol., 51, p. 365; Jacobson, K.A., Ijzerman, A.P., Linden, J., (1999) Drug Dev. Res., 47, p. 45; Fozard, J.R., (2003) Curr. Opin. Pharmacol., 3, p. 264; Feostikov, I., Baggioni, I., (1997) Pharmacol. Rev., 49, p. 381; Martinez-Tica, J.F., Zornow, M.H., (2000) Brain Res., 872, p. 110; Di Napoli, P., Contegiacomo, G., Taccardi, A.A., Maggi, A., Di Muzio, M., Statile, D., Giuliani, P., Barsotti, A., (1999) J. Clin. Basic Cardiol., 2, p. 99; Hamilton, H.W., Ortwine, D.F., Worth, D.F., Badger, E.W., Bristol, J.A., Bruns, R.F., Haleen, S.J., Steffen, R.P., (1985) J. Med. Chem., 28, p. 1071; Doichinova, I.A., Natcheva, R.N., Mihailova, D.N., (1994) Eur. J. Med. Chem., 29, p. 133; Hayallah, A.M., Sandoval-Ramírez, J., Reith, U., Schobert, U., Preiss, B., Schumacher, B., Daly, J.W., Müller, C.E., (2002) J. Med. Chem., 45, p. 1500; Baraldi, P.G., Tabrizi, M.A., Preti, D., Bovero, A., Romagnoli, R., Fruttarolo, F., Zaid, N.A., Borea, P.A., (2004) J. Med. Chem., 47, p. 1434; Kim, S.A., Marshall, M.A., Melman, N., Kim, H.S., Müller, C.E., Linden, J., Jacobson, K.A., (2002) J. Med. Chem., 45, p. 2131; Pastorin, G., Das Ros, T., Spatullo, G., Deflorian, F., Moro, S., Cacciari, B., Saraldi, P.G., Borea, P.A., (2003) J. Med. Chem., 46, p. 4278; Maconi, A., Pastorin, G., Da Ros, T., Spatullo, G., Gao, Z.G., Jacobson, K.A., Baraldi, P.G., Borea, P.A., (2002) J. Med. Chem., 45, p. 3579; Colotta, V., Catarzi, D., Varano, F., Cecchi, L., Filacchioni, G., Martini, C., (1999) Arch. Pharm. Pharm. Med. Chem., 332, p. 39; Muller, C.E., Dieckman, M., Thorand, M., Ozola, V., (2002) Bioorg. Med. Chem. Lett., 12, p. 501; Bertelli, L., Biagi, G., Giorgi, I., Manera, C., Livi, O., Scartoni, V., Betti, L., Barili, P.L., (1998) Eur. J. Med. Chem., 33, p. 113; Colotta, V., Cecchi, L., Catarzi, D., Conti, G., Filacchioni, G., (1993) Farmaco, 48, p. 1051; Calotta, V., Catarzi, D., Varano, F., Cecchi, L., Filacchioni, G., Galli, A., Costagli, C., (1997) Arch. Pharm., 330, p. 387; Catarzi, D., Cecchi, L., Colotta, V., Melani, F., Filacchioni, G., (1993) Farmaco, 48, p. 1065; Colotta, V., Cecchi, L., Filacchioni, G., Martini, C., Tacchi, P., Lucacchini, A., (1995) Eur. J. Med. Chem., 30, p. 133; Colotta, V., Catarzi, D., Varano, F., Cecchi, L., Filacchioni, G., Martini, C., Trincavelli, L., Lucacchini, A., (2000) J. Med. Chem., 43, p. 1158; Catarzi, D., Cecchi, L., Colotta, V., Filacchioni, G., Martini, C., Tacchi, P., (1995) J. Med. Chem., 38, p. 1330; Colotta, V., Catarzi, D., Varano, F., Cechi, L., Filacchioni, G., Martini, C., Trincavelli, L., Lucacchini, A., (2000) J. Med. Chem., 43, p. 3118; Catarzi, D., Colotta, V., Varano, C., Filacchioni, G., Martini, C., Trincavelli, L., Lucacchini, A., (2004) Farmaco, 59, p. 71; Colotta, V., Catarzi, D., Varano, C., Romana, F., Lenzi, O., Filacchioni, G., Trincavelli, L., Moro, S., (2004) J. Med. Chem., 47, p. 3580; Catarzi, D., Colotta, V., Varano, C., Lenzi, O., Filacchioni, G., Trincavelli, L., Martini, C., Moro, S., (2005) J. Med. Chem., 48, p. 7932; Lenzi, O., Colotta, V., Catarzi, D., Varano, C., Filacchioni, G., Martini, C., Trincavelli, L., Moro, S., (2006) J. Med. Chem., 49, p. 3916; Carotti, A., Stefanacchi, A., Raviña, E., Sotelo, E., Loza, M.I., Cadavid, M.I., Centeno, N.B., Nicolotti, O., (2004) Eur. J. Med. Chem., 39, p. 879; Carotti, A., Cadavid, M.I., Centeno, N.B., Esteve, C., Loza, M.I., Martínez, A., Nieto, R., Vidal, B., (2006) J. Med. Chem., 49, p. 282; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., (2000) J. Med. Chem., 43, p. 3233; Fontaine, F., Pastor, M., Sanz, F., (2004) J. Med. Chem., 47, p. 2805; Afzelius, L., Masimirembwa, C.M., Karlen, A., Andersson, T.B., Zamora, I., (2002) J. Comput. Aided Mol. Des., 16, p. 443; Carosati, E., Lemoine, H., Spogli, R., Grittner, D., Mannhold, R., Tabarrini, O., Sabatini, S., Cecchetti, V., (2005) Bioorg. Med. Chem., 13, p. 5581; Bosch, M.P., Campos, F., Niubo, I., Rosell, G., Diaz, J.L., Brea, J., Loza, M.I., Guerrero, A., (2004) J. Med. Chem., 47, p. 4041; Cruciani, G., Fontaine, F., Pastor, M. Almond 3.3.0. Molecular Discovery, Ltd: Perugia, Italy; Goodford, P.J., (1985) J. Med. Chem., 28, p. 849; Gasteiger, J.C., Rudolph, C., Sadowski, J., (1990) Tetrahedron Comp. Method, 3, p. 537; Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, Jr., J. A.; Stratmann, R. E.; Burant, J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Baboul, A. G.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Andres, J. L.; Gonzalez, C.; Head-Gordon, M.; Replogle, E. S.; Pople, J.A. Gaussian 98, Revision A.7, Gaussian: Pittsburgh PA, 1998; Carey, R.N., Wold, S., Westgard, J.O., (1975) Anal. Chem., 47, p. 1824; Hoskuldsson, A., (1988) J. Chemom., 2, p. 211","Raviña, E.; Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, E-15782, Spain",,,,,,,,09680896,,BMECE,"18249548","English","Bioorg. Med. Chem.",Article,"Final",,Scopus,2-s2.0-39049143861
"Furlong L.I., Dach H., Hofmann-Apitius M., Sanz F.","34770469800;23990154100;57204494354;7102263897;","OSIRISv1.2: A named entity recognition system for sequence variants of genes in biomedical literature",2008,"BMC Bioinformatics","9",, 84,"","",,25,"10.1186/1471-2105-9-84","https://www.scopus.com/inward/record.uri?eid=2-s2.0-41549167185&doi=10.1186%2f1471-2105-9-84&partnerID=40&md5=a0240e1b341448a4869c3a08fd1276f1","Research Unit on Biomedical Informatics (GRIB), IMIM, UPF, c/Dr. Aiguader 88, E-08003 Barcelona, Spain; Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, Germany","Furlong, L.I., Research Unit on Biomedical Informatics (GRIB), IMIM, UPF, c/Dr. Aiguader 88, E-08003 Barcelona, Spain; Dach, H., Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, Germany; Hofmann-Apitius, M., Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, Germany; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM, UPF, c/Dr. Aiguader 88, E-08003 Barcelona, Spain","Background: Single Nucleotide Polymorphisms, among other type of sequence variants, constitute key elements in genetic epidemiology and pharmacogenomics. While sequence data about genetic variation is found at databases such as dbSNP, clues about the functional and phenotypic consequences of the variations are generally found in biomedical literature. The identification of the relevant documents and the extraction of the information from them are hampered by the large size of literature databases and the lack of widely accepted standard notation for biomedical entities. Thus, automatic systems for the identification of citations of allelic variants of genes in biomedical texts are required. Results: Our group has previously reported the development of OSIRIS, a system aimed at the retrieval of literature about allelic variants of genes http://ibi.imim.es/osirisform.html. Here we describe the development of a new version of OSIRIS (OSIRISv1.2, http://ibi.imim.es/ OSIRISv1.2.html) which incorporates a new entity recognition module and is built on top of a local mirror of the MEDLINE collection and HgenetInfoDB: a database that collects data on human gene sequence variations. The new entity recognition module is based on a pattern-based search algorithm for the identification of variation terms in the texts and their mapping to dbSNP identifiers. The performance of OSIRISv1.2 was evaluated on a manually annotated corpus, resulting in 99% precision, 82% recall, and an F-score of 0.89. As an example, the application of the system for collecting literature citations for the allelic variants of genes related to the diseases intracranial aneurysm and breast cancer is presented. Conclusion: OSIRISv1.2 can be used to link literature references to dbSNP database entries with high accuracy, and therefore is suitable for collecting current knowledge on gene sequence variations and supporting the functional annotation of variation databases. The application of OSIRISv1.2 in combination with controlled vocabularies like MeSH provides a way to identify associations of biomedical interest, such as those that relate SNPs with diseases. © 2008 Furlong et al; licensee BioMed Central Ltd.",,"Biomedical literature; Functional annotation; Genetic epidemiologies; Intracranial aneurysms; Literature database; Named entity recognition; Relevant documents; Single nucleotide polymorphisms; Database systems; Diseases; Genes; accuracy; allele; article; automated pattern recognition; bioinformatics; breast cancer; computer interface; computer program; data analysis; gene mapping; gene sequence; genetic database; genetic variability; HgenetInfoDB; information retrieval; intracranial aneurysm; medical literature; MEDLINE; sensitivity and specificity; sequence analysis; sequence database; single nucleotide polymorphism; artificial intelligence; genetics; information retrieval; MEDLINE; MeSH heading; methodology; natural language processing; publication; single nucleotide polymorphism; United States; Artificial Intelligence; Information Storage and Retrieval; Medical Subject Headings; MEDLINE; Natural Language Processing; Pattern Recognition, Automated; Periodicals as Topic; Polymorphism, Single Nucleotide; United States",,,"OSIRISv1.2",,,,,,"Ananiadou, S., Kell, D.B., Tsujii, J., Text mining and its potential applications in systems biology (2006) Trends Biotechnol, 24, pp. 571-579. , 10.1016/j.tibtech.2006.10.002 17045684; Jensen, L.J., Saric, J., Bork, P., Literature mining for the biologist: From information retrieval to biological discovery (2006) Nat Rev Genet, 7, pp. 119-129. , 10.1038/nrg1768 16418747; Park, J.C., Kim, J., Named Entity Recognition (2006) Text Mining for Biology and Biomedicine, pp. 121-142. , London, Artech House Books Ananiadou S and McNaught J; Sherry, S.T., Ward, M.H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, K., dbSNP: The NCBI database of genetic variation (2001) Nucleic Acids Res, 29, pp. 308-311. , 29783 11125122 10.1093/nar/29.1.308; Fukuda, K., Tamura, A., Tsunoda, T., Takagi, T., Toward information extraction: Identifying protein names from biological papers (1998) Pac Symp Biocomput, pp. 707-718. , 9697224; Tanabe, L., Wilbur, W.J., Tagging gene and protein names in biomedical text (2002) Bioinformatics, 18, pp. 1124-1132. , 10.1093/bioinformatics/18.8.1124 12176836; Chang, J.T., Schutze, H., Altman, R.B., GAPSCORE: Finding gene and protein names one word at a time (2004) Bioinformatics, 20, pp. 216-225. , 10.1093/bioinformatics/btg393 14734313; McDonald, R., Pereira, F., Identifying gene and protein mentions in text using conditional random fields (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S6. , 1869020 15960840 10.1186/1471-2105-6-S1-S6; Settles, B., ABNER: An open source tool for automatically tagging genes, proteins and other entity names in text (2005) Bioinformatics, 21, pp. 3191-3192. , 10.1093/bioinformatics/bti475 15860559; Zhou, G., Shen, D., Zhang, J., Su, J., Tan, S., Recognition of protein/gene names from text using an ensemble of classifiers (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S7. , 1869021 15960841 10.1186/1471-2105-6-S1-S7; Krauthammer, M., Rzhetsky, A., Morozov, P., Friedman, C., Using BLAST for identifying gene and protein names in journal articles (2000) Gene, 259, pp. 245-252. , 10.1016/S0378-1119(00)00431-5 11163982; Leonard, J.E., Colombe, J.B., Levy, J.L., Finding relevant references to genes and proteins in Medline using a Bayesian approach (2002) Bioinformatics, 18, pp. 1515-1522. , 10.1093/bioinformatics/18.11.1515 12424124; Finkel, J., Dingare, S., Manning, C.D., Nissim, M., Alex, B., Grover, C., Exploring the boundaries: Gene and protein identification in biomedical text (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S5. , 1869019 15960839 10.1186/1471-2105-6-S1-S5; Fundel, K., Guttler, D., Zimmer, R., Apostolakis, J., A simple approach for protein name identification: Prospects and limits (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S15. , 1869007 15960827 10.1186/1471-2105-6-S1-S15; Hanisch, D., Fundel, K., Mevissen, H.T., Zimmer, R., Fluck, J., ProMiner: Rule-based protein and gene entity recognition (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S14. , 1869006 15960826 10.1186/1471-2105-6-S1-S14; Crim, J., McDonald, R., Pereira, F., Automatically annotating documents with normalized gene lists (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S13. , 1771968 15960825 10.1186/1471-2105-6-S1-S13; Mika, S., Rost, B., Protein names precisely peeled off free text (2004) Bioinformatics, 20 (SUPPL. 1), pp. I241-I247. , 10.1093/bioinformatics/bth904 15262805; Horn, F., Lau, A.L., Cohen, F.E., Automated extraction of mutation data from the literature: Application of MuteXt to G protein-coupled receptors and nuclear hormone receptors (2004) Bioinformatics, 20, pp. 557-568. , 10.1093/bioinformatics/btg449 14990452; Rebholz-Schuhmann, D., Marcel, S., Albert, S., Tolle, R., Casari, G., Kirsch, H., Automatic extraction of mutations from Medline and cross-validation with OMIM (2004) Nucleic Acids Res, 32, pp. 135-142. , 373272 14704350 10.1093/nar/gkh162; McDonald, R.T., Winters, R.S., Mandel, M., Jin, Y., White, P.S., Pereira, F., An entity tagger for recognizing acquired genomic variations in cancer literature (2004) Bioinformatics, 20, pp. 3249-3251. , 10.1093/bioinformatics/bth350 15180929; Bonis, J., Furlong, L.I., Sanz, F., OSIRIS: A tool for retrieving literature about sequence variants (2006) Bioinformatics, 22, pp. 2567-2569. , 10.1093/bioinformatics/btl421 16882651; PubMed, , http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed; Entrez Gene, , http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene; DbSNP, , http://www.ncbi.nlm.nih.gov/SNP/; OSIRISv1.2, , http://ibi.imim.es/OSIRISv1.2.html; Kim, J.D., Tsujii, J., Corpora and their Annotation (2006) Text Mining for Biology and Biomedicine, pp. 179-211. , 46 Gillingham Street, London SW1V 1AH UK, Artech House Ananiadou S and McNaught J; Rinkel, G.J.E., Djibuti, M., Algra, A., van Gijn, J., Prevalence and Risk of Rupture of Intracranial Aneurysms: A Systematic Review (1998) Stroke, 29, pp. 251-256. , 9445359; Krischek, B., Inoue, I., The genetics of intracranial aneurysms (2006) J Hum Genet, 51, pp. 587-594. , 16736093 10.1007/s10038-006-0407-4 16736093; Ruigrok, Y.M., Rinkel, G.J., Wijmenga, C., Genetics of intracranial aneurysms (2005) Lancet Neurol, 4, pp. 179-189. , 15721828; Khurana, V.G., Sohni, Y.R., Mangrum, W.I., McClelland, R.L., O'Kane, D.J., Meyer, F.B., Meissner, I., Endothelial nitric oxide synthase T-786C single nucleotide polymorphism: A putative genetic marker differentiating small versus large ruptured intracranial aneurysms (2003) Stroke, 34, pp. 2555-2559. , 10.1161/01.STR.0000096994.53810.59 14576373; Khurana, V.G., Sohni, Y.R., Mangrum, W.I., McClelland, R.L., O'Kane, D.J., Meyer, F.B., Meissner, I., Endothelial nitric oxide synthase gene polymorphisms predict susceptibility to aneurysmal subarachnoid hemorrhage and cerebral vasospasm (2004) J Cereb Blood Flow Metab, 24, pp. 291-297. , 10.1097/01.WCB.0000110540.96047.C7 15091109; Akagawa, H., Kasuya, H., Onda, H., Yoneyama, T., Sasahara, A., Kim, C.J., Lee, J.C., Inoue, I., Influence of endothelial nitric oxide synthase T-786C single nucleotide polymorphism on aneurysm size (2005) J Neurosurg, 102, pp. 68-71. , 15658098; Khurana, V.G., Meissner, I., Sohni, Y.R., Bamlet, W.R., McClelland, R.L., Cunningham, J.M., Meyer, F.B., The presence of tandem endothelial nitric oxide synthase gene polymorphisms identifying brain aneurysms more prone to rupture (2005) J Neurosurg, 102, pp. 526-531. , 15796389; Harrod, C.G., Batjer, H.H., Bendok, B.R., Deficiencies in estrogen-mediated regulation of cerebrovascular homeostasis may contribute to an increased risk of cerebral aneurysm pathogenesis and rupture in menopausal and postmenopausal women (2006) Med Hypotheses, 66, pp. 736-756. , 10.1016/j.mehy.2005.09.051 16356655; Casas, J.P., Cavalleri, G.L., Bautista, L.E., Smeeth, L., Humphries, S.E., Hingorani, A.D., Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: A HuGE review (2006) Am J Epidemiol, 164, pp. 921-935. , 10.1093/aje/kwj302 10.1093/aje/kwj302 17018701; Hirschman, L., Yeh, A., Blaschke, C., Valencia, A., Overview of BioCreAtIvE: Critical assessment of information extraction for biology (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S1. , 1869002 15960821 10.1186/1471-2105-6-S1-S1; Fluck, J., Mevissen, H.T., Dach, H., Oster, M., Hofmann-Apitius, M., ProMiner: Recognition of Human Gene and Protein names using regularly updated dictionaries (2007) Proceedings of the Second BioCreative Challenge Workshop, pp. 149-151. , Centro Nacional de Investigaciones Oncologicas Hirschman L, Krallinger M and Valencia A; Swiss-Prot, , http://ca.expasy.org/sprot/; Kitts, A., Sherry, S., NCBI Handbook. DbSNP. Rules and Methodology for Mapping, , http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=handbook.section.ch5.ch5-s8; Medical Subject Headings, , http://www.nlm.nih.gov/mesh/; Shatkay, H., Feldman, R., Mining the biomedical literature in the genomic era: An overview (2003) J Comput Biol, 10, pp. 821-855. , 10.1089/106652703322756104 14980013; Kim, J.D., Ohta, T., Tateisi, Y., Tsujii, J., GENIA corpus -- A semantically annotated corpus for bio-textmining10.1093/bioinformatics/btg1023 (2003) Bioinformatics, 19, pp. i180-i182. , 10.1093/bioinformatics/btg1023 12855455; Kulick, S., Bies, A., Liberman, M., Mandel, M., McDonald, R., Palmer, M., Schein, A., Ungar, L., Integrated Annotation for Biomedical Information Extraction (2004) HLT-NAACL Workshop: Biolink 2004, Linking Biological Literature, Ontologies and Databases, pp. 61-68; Kitts, A., Sherry, S., NCBI Handbook. DbSNP.dbSNP Resource Integration, , http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=handbook.section.ch5.ch5-s5; Vex Editor, , http://vex.sourceforge.net/; Eclipse Platform, , http://www.eclipse.org/","Furlong, L.I.; Research Unit on Biomedical Informatics (GRIB), IMIM, UPF, c/Dr. Aiguader 88, E-08003 Barcelona, Spain; email: lfurlong@imim.es",,,,,,,,14712105,,BBMIC,"18251998","English","BMC Bioinform.",Article,"Final",Open Access,Scopus,2-s2.0-41549167185
"Klinger R., Friedrich C.M., Mevissen H.T., Fluck J., Hofmann-apitius M., Furlong L.I., Sanz F.","23134979000;35232936500;6506120095;6603558627;57204494354;34770469800;7102263897;","Identifying gene-specific variations in biomedical text",2007,"Journal of Bioinformatics and Computational Biology","5","6",,"1277","1296",,17,"10.1142/S0219720007003156","https://www.scopus.com/inward/record.uri?eid=2-s2.0-37849003196&doi=10.1142%2fS0219720007003156&partnerID=40&md5=66e9096d3aef9c6002681f011274aa2c","Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; Research Unit on Biomedical Informatics (GRIB), IMIM, UPF, PRBB, c/ Dr. Aiguader 88, E-08003 Barcelona, Spain","Klinger, R., Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; Friedrich, C.M., Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; Mevissen, H.T., Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; Fluck, J., Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; Hofmann-apitius, M., Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; Furlong, L.I., Research Unit on Biomedical Informatics (GRIB), IMIM, UPF, PRBB, c/ Dr. Aiguader 88, E-08003 Barcelona, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM, UPF, PRBB, c/ Dr. Aiguader 88, E-08003 Barcelona, Spain","The influence of genetic variations on diseases or cellular processes is the main focus of many investigations, and results of biomedical studies are often only accessible through scientific publications. Automatic extraction of this information requires recognition of the gene names and the accompanying allelic variant information. In a previous work, the OSIRIS system for the detection of allelic variation in text based on a query expansion approach was communicated. Challenges associated with this system are the relatively low recall for variation mentions and gene name recognition. To tackle this challenge, we integrate the ProMiner system developed for the recognition and normalization of gene and protein names with a conditional random field (CRF)-based recognition of variation terms in biomedical text. Following the newly developed normalization of variation entities, we can link textual entities to Single Nucleotide Polymorphism database (dbSNP) entries. The performance of this novel approach is evaluated, and improved results in comparison to state-of-the-art systems are reported. © 2007 Imperial College Press.","Conditional random field; Named entity recognition; Normalization; Single nucleotide polymorphism; SNP; Variants","article; data base; gene identification; genetic variability; information retrieval; medical information system; methodology; protein analysis; recognition; single nucleotide polymorphism; Algorithms; Alleles; Computational Biology; Databases, Nucleic Acid; Humans; Information Storage and Retrieval; MEDLINE; Models, Statistical; Polymorphism, Single Nucleotide; Terminology as Topic; Variation (Genetics)",,,,,"European Commission","This work was partially funded by the MPG-FhG Machine Learning Collaboration (see http://lip.fml.tuebingen.mpg.de/) and is within the framework of the European integrated project @neurIST, which is cofinanced by the European Commission through contract no. IST-027703 (see http://www.aneurist.org).",,,"Smigielski, E.M., Sirotkin, K., Ward, M., Sherry, S.T., dbSNP, A database of single nucleotide polymorphisms (2000) Nucleic Acids Res, 28 (1), pp. 352-355; A haplotype map of the human genome (2005) Nature, 437 (7063), pp. 1241-12421. , International HapMap Consortium; McDonald, R., Winters, R.S., Ankuda, C.K., Murphy, J.A., Rogers, A.E., Pereira, F., Greenblatt, M.S., White, P.S., An automated procedure to identify biomedical articles that contain cancer-associated gene variants (2006) Hum Mutat, 27 (9), pp. 957-964; Jensen, L.J., Saric, J., Bork, P., Literature mining for the biologist: From information retrieval to biological discovery (2006) Nat Rev Genet, 7, pp. 119-129; Shatkay, H., Feldman, R., Mining the biomedical literature in the genomic era: An overview (2003) J Comput Biol, 10 (6), pp. 821-855; Hirschman, L., Yeh, A., Blaschke, C., Valencia, A., Overview of BioCreAtIvE: Critical assessment of information extraction for biology (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S1; Hirscbmann L, Krallinger M, Valencia A (eds.),Proceedings of the Second BioCreative Challenge Evaluation Workshop, Centro Nacional de Investigaciones Oncologicas, CNIO, 2007; Lafferty, J.D., McCallum, A., Pereira, F.C.N., Conditional random fields: Probabilistic models for segmenting and labeling sequence data (2001) Proceedings of the Eighteenth International Conference on Machine Learning (ICML 2001), pp. 282-289. , Morgan Kaufmann, San Francisco, CA, pp; Klinger, R., Friedrich, C.M., Fluck, J., Hofmann-Apitius, M., Named entity recognition with combinations of conditional random fields (2007) Proceedings of the Second BioCreative Challenge Evaluation Workshop, Centro Nacional de Investigaciones Oncologicas, CNIO, pp. 89-91. , Hirschmarm L, Krallinger M, Valencia A eds; Fluck, J., Mevissen, H.T., Dach, H., Oster, M., Hofmann-Apitius, M., ProMiner: Recognition of human gene and protein names using regularly updated dictionaries (2007) Proceedings of the Second BioCreative Challenge Evaluation Workshop, Centro Nacional de Investigaciones Oncologicas, CNIO, pp. 149-151. , Hirschmann L, Krallinger M, Valencia A eds; den Dunnen, J.T., Antonarakis, S.E., Nomenclature for the description of human sequence variations (2001) Hum Genet, 109 (1), pp. 121-124; Horn, F., Lau, A.L., Cohen, F.E., Automated extraction of mutation data from the literature: Applicatioq of MuteXt to G protein-coupled receptors and nuclear hormone receptors (2004) Bioinformatics, 20 (4), pp. 557-568; Lee, L.C., Horn, F., Cohen, F.E., Autornatic extraction of protein point mutations using a graph bigram association (2007) PLoS Comput Biol, 3 (2), pp. 184-198; Rebholz-Schuhmann, D., Marcel, S., Albert, S., Tolle, R., Casari, G., Kirsch, H., Automatic extraction of mutations from Medline and cross-validation with OMIM (2004) Nucleic Acids Res, 32 (1), pp. 135-142; McDonald, R.T., Winters, R.S., Mandel, M., Jin, Y., White, P.S., Pereira, F., An entity tagger for recognizing acquired genomic variations in cancer literature (2004) Bioinformatics, 20, pp. 3249-3251; Bonis, J., Furlong, L.I., Sanz, F., OSIRIS: A tool for retrieving literature about sequence variants (2006) Bioinformatics, 22 (20), pp. 2567-2569; Hanisch, D., Fundel, K., Mevissen, H.T., Zimmer, R., Fluck, J., ProMiner: Rule-based protein and gene entity recognition (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S14; Morton, T., LaCivita, J., WordFreak: An open tool for linguistic annotation (2003) HLT/NAACL 2003: Demonstrations, pp. 17-18; Hanisch, D., Fluck, J., Mevissen, H.T., Zimmer, R., Playing biology's name game: Identifying protein names in scientific text (2003) Pac Symp Biocomput, 8, pp. 403-414; Maglott, D., Ostell, J., Pruitt, K.D., Tatusova, T., Entrez Gene: Gene-centered information at NCBI (2005) Nucleic Acids Res, 33. , Database issue:D54-D58; The Universal Protein Resource (UniProt) (2006) Nucleic Acids Res, 35, pp. D193-D197. , The UniProt Consortium; McDonald R, Pereira F, Identifying gene and protein mentions in text using conditional random fields, BMC Bioinformatics 6(Suppl (1):S6, 2005; Kschischang, U., Frey, B.J., Loeliger, H.A., Factor graphs and the sum-product algorithm (2001) IEEE Trans Inf Theory, 47 (2), pp. 498-519; Settles, B., ABNER: An open source tool for automatically tagging genes, proteins and other entity names in text (2005) Bioinformatics, 21 (14), pp. 3191-3192; Rabiner, L.R., A tutorial on hidden Markov models and selected applications in speech recognition (1989) Proc IEEE, 77 (2), pp. 257-2861; Nocedal, J., Updating quasi-Newton matrices with limited storage (1980) Math Comput, 35 (151), pp. 773-782; McCallum, A.K., (2002) MALLET: A machine learning for language toolkit, , http://mallet.cs.umass.edu; Efron, B., Tibshirani, R.J., (1993) An Introduction to the Bootstrap, , Chapman & Hall/CRC, Boca Raton, FL","Klinger, R.; Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing, Schloss Birlinghoven, 53754 Sankt Augustin, Germany; email: roman.klinger@scai.fhg.de",,,,,,,,02197200,,JBCBB,"18172929","English","J. Bioinformatics Comput. Biol.",Article,"Final",,Scopus,2-s2.0-37849003196
"Dezi C., Brea J., Alvarado M., Raviña E., Masaguer C.F., Loza M.I., Sanz F., Pastor M.","6507203451;6603008588;8160457000;56264803900;6701715235;7003766926;7102263897;7102415847;","Multistructure 3D-QSAR studies on a series of conformationally constrained butyrophenones docked into a new homology model of the 5-HT2A receptor",2007,"Journal of Medicinal Chemistry","50","14",,"3242","3255",,19,"10.1021/jm070277a","https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447530682&doi=10.1021%2fjm070277a&partnerID=40&md5=2167968d0eecbc90dda1b9465bf335f3","Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Department of Pharmacology, Faculty of Pharmacy, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Department of Organic Chemistry, Faculty of Pharmacy, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain","Dezi, C., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Brea, J., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain, Department of Pharmacology, Faculty of Pharmacy, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Alvarado, M., Department of Organic Chemistry, Faculty of Pharmacy, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Raviña, E., Department of Organic Chemistry, Faculty of Pharmacy, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Masaguer, C.F., Department of Organic Chemistry, Faculty of Pharmacy, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Loza, M.I., Department of Pharmacology, Faculty of Pharmacy, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; Pastor, M., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain","The present study is part of a long-term research project aiming to gain insight into the mechanism of action of atypical antipsychotics. Here we describe a 3D-QSAR study carried out on a series of butyrophenones with affinity for the serotonin-2A receptor, aligned by docking into the binding site of a receptor model. The series studied has two peculiarities: (i) all the compounds have a chiral center and can be represented by two enantiomeric structures, and (ii) many of the structures can bind the receptor in two alternative orientations, posing the problem of how to select a single representative structure for every compound. We have used an original solution consisting of the simultaneous use of multiple structures, representing different configurations, binding conformations, and positions. The final model showed good statistical quality (n = 426, r2 = 0.84, q2 LOO = 0.81) and its interpretation provided useful information, not obtainable from the simple inspection of the ligand-receptor complexes. © 2007 American Chemical Society.",,"butyrophenone derivative; serotonin 2A receptor; article; binding affinity; binding site; conformational transition; drug conformation; drug receptor binding; drug structure; enantiomer; human; model; molecular docking; nonhuman; quantitative structure activity relation; Binding Sites; Butyrophenones; Models, Molecular; Quantitative Structure-Activity Relationship; Receptor, Serotonin, 5-HT2A",,"Butyrophenones; Receptor, Serotonin, 5-HT2A",,,,,,,"Horacek, J., Novel antipsychotics and extrapyramidal side effects. Theory and reality (2000) Pharmacopsychiatry, 33 (SUPPL. 1), pp. 34-42; Aghajanian, G.K., Marek, G.J., Serotonin model of schizophrenia: Emerging role of glutamate mechanisms (2000) Brain Res. Rev, 31, pp. 302-312; Reynolds, G.P., Receptor mechanisms in the treatment of schizophrenia (2004) J. Psychopharmacol, 18, pp. 340-345; Meltzer, H.Y., Matsubara, S., Lee, J.C., Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pKi values (1989) J. Pharmacol Exp. Ther, 251, pp. 238-246; Meltzer, H.Y., Li, Z., Kaneda, Y., Ichikawa, J., Serotonin receptors: Their key role in drugs to treat schizophrenia (2003) Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, pp. 1159-1172; Roth, B.L., Sheffler, D.J., Kroeze, W.K., Magic shotguns versus magic bullets: Selectively nonselective drugs for mood disorders and schizophrenia (2004) Nat. Rev. Drug Discovery, 3, pp. 353-359; Ravina, E.; Negreira, J.; Cid, J.; Masaguer, C. F.; Rosa, E.; Rivas, M. E.; Fontenla, J. A.; Loza, M. I.; Tristan, H.; Cadavid, M. I.; Sanz, F.; Lozoya, E.; Carotti, A.; Carrieri, A. Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thieno-cycloalkanones as putative atypical antipsychotics. J. Med. Chem. 1999, 42, 2774-2797; Brea, J., Rodrigo, J., Carrieri, A., Sanz, F., Cadavid, M.I., Enguix, M.J., Villazon, M., Loza, M.I., New serotonin 5-HT-(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)-benzo and heterocycloalkanones (2002) J. Med. Chem, 45, pp. 54-71; Brea, J., Masaguer, C.F., Villazon, M., Cadavid, M.I., Ravina, E., Fontaine, F., Dezi, C., Loza, M.I., Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT 2A and 5-HT 2C receptor behaviours (2003) Eur. J. Med. Chem, 38, pp. 433-440; Brea, J., Castro, M., Loza, M.I., Masaguer, C.F., Ravina, E., Dezi, C., Pastor, M., QF, P., a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine (2004) Neuropharmacology, 2006 (51), pp. 251-262; Waller, C.L., Oprea, T.I., Giolitti, A., Marshall, G.R., Three-dimensional QSAR of human immunodeficiency virus (l) protease inhibitors. 1. A CoMFA study employing experimentally determined alignment rales (1993) J. Med. Chem, 36, pp. 4152-4160; Waller, C.L., Marshall, G.R., Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and complementary-receptor-field alignment rules (1993) J. Med. Chem, 36, pp. 2390-2403; Cho, S.J., Garsia, M.L., Bier, J., Tropsha, A., Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors (1996) J. Med. Chem, 39, pp. 5064-5071; Pastor, M.; Cruciani, G.; Watson, K. A. A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. 1997, 40, 4089-4102; Lozano, J.J., Pastor, M., Craciani, G., Gaedt, K., Centeno, N.B., Gago, F., Sanz, F., 3D-QSAR methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands (2000) J. Comput.-Aided Mol. Des, 14, pp. 341-353; Sippl, W., Receptor-based 3D QSAR analysis of estrogen receptor ligands-merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods (2000) J. Comput.-Aided Mol. Des, 14, pp. 559-572; Sippl, W., Contreras, J.M., Parrot, I., Rival, Y.M., Wermuth, C.G., Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors (2001) J. Comput.-Aided Mol. Des, 15, pp. 395-410; Sippl, W., Binding affinity prediction of novel estrogen receptor ligands using receptor-based 3-D QSAR methods (2002) Bioorg. Med. Chem, 10, pp. 3741-3755; Pastor, M., Perez, C., Gago, F., Simulation of alternative binding modes in a structure-based QSAR study of HIV-1 protease inhibitors (1997) J. Mol. Graphics Modell, 15 (364-371), p. 389; Mewshaw, R.E., Silverman, L.S., Mathew, R.M., Kaiser, C., Sherrill, R.G., Cheng, M., Tiffany, C.W., Borosky, S.A., Bridged gamma-carbolines and derivatives possessing selective and combined affinity for 5-HT2 and D2 receptors (1993) J. Med. Chem, 36, pp. 1488-1495; Repke, D.B., Clark, R.D., Kluge, A.F., Muchowski, J.M., Strosberg, A.M., Lee, C.H., Whiting, R.L., Syntheses and hypotensive properties of substituted 2-aminotetralins (1985) J. Pharm. Sci, 74, pp. 37-39; Julia, S., Bonnet, Y., Etude des cétones avec noyau cyclopropane I. Les benzo- et naphtho- bicyclo- (0,1,4) hepténones (1957) Bull. Soc. Chim. Fr, pp. 1340-1347; Caro, Y., Torrado, M., Masaguer, C.F., Ravina, E., Padin, F., Brea, J., Loza, M.I., Chemoenzymatic synthesis and binding affinity of novel (R)- and (S)-3-aminomethyl-1-tetralones, potential atypical antipsychotics (2004) Bioorg. Med. Chem. Lett, 14, pp. 585-589; Metwally, K. A.; Dukat, M.; Egan, C. T.; Smith, C.; DuPre, A.; Gauthier, C. B.; Herrick-Davis, K.; Teitler, M.; Glennon, R. A. Spiperone: Influence of spiro ring substituents on 5-HT2A serotonin receptor binding. J. Med. Chem. 1998, 41, 5084-5093; Wysong, C.L., Yokum, T.S., Morales, G.A., Gundry, R.L., McLaughlin, M.L., Hammer, R.P., 4-Aminopiperidine-4-carboxylic acid: A cyclic alpha,alpha-disubstituted amino acid for preparation of water-soluble highly helical peptides (1996) J. Org. Chem, 61, pp. 7650-7651; Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Miyano, M., Crystal structure of rhodopsin: A G protein-coupled receptor (2000) Science, 289, pp. 739-745; Sali, A., Blundell, T.L., Comparative protein modelling by satisfaction of spatial restraints (1993) J. Mol. Biol, 234, pp. 779-815; Egan, C., Herrick-Davis, K., Teitler, M., Creation of a constitutively activated state of the 5-HT2A receptor by site-directed mutagenesis: Revelation of inverse agonist activity of antagonists (1998) Ann. N. Y. Acad. Sci, 861, pp. 136-139; Berg, K.A., Harvey, J.A., Spampinato, U., Clarke, W.P., Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors (2005) Trends Pharmacol. Sci, 26, pp. 625-630; Roth, B.L., McLean, S., Zhu, X.Z., Chuang, D.M., Characterization of two [3H]ketanserin recognition sites in rat striatum (1987) J. Neurochem, 49, pp. 1833-1838; Choudhary, M.S., Craigo, S., Roth, B.L., A single point mutation (Phe340- &gt;Leu340) of a conserved phenylalanine abolishes 4-[ 125I]-iodo-(2,5-dimethoxy) phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors (1993) Mol. Pharmacol, 43, pp. 755-761; Wurch, T., Colpaert, F.C., Pauwels, P.J., Chimeric receptor analysis of the ketanserin binding site in the human 5-hydroxytryptamineID receptor: Importance of the second extracellular loop and fifth transmembrane domain in antagonist binding (1998) Mol. Pharmacol, 54, pp. 1088-1096; Wurch, T., Palmier, C., Pauwels, P.J., Induction of a high-affinity ketanserin binding site at the 5-hydroxytryptamine(1B) receptor by modification of its carboxy-terminal intracellular portion (2000) Biochem. Pharmacol, 59, pp. 1117-1121; Ballesteros, J.A., Jensen, A.D., Liapakis, G., Rasmussen, S.G., Shi, L., Gether, U., Javitch, J.A., Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6 (2001) J. Biol. Chem, 276, pp. 29171-29177; Bissantz C Conformational changes of G protein-coupled receptors during their activation by agonist binding. J. Recept. Signal Transduct. Res. 2003, 23, 123-153; Shapiro, D.A., Kristiansen, K., Weiner, D.M., Kroeze, W.K., Roth, B.L., Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6 (2002) J. Biol. Chem, 277, pp. 11441-11449; Sylte, I.B.A., Dahl, S.G., Ligand induced conformational states of the 5-HT(1A) receptor (2001) Eur. J. Pharmacol, 416, pp. 33-41; Almaula, N., Ebersole, B.J., Ballesteros, J.A., Weinstein, H., Sealfon, S.C., Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: Direct and indirect effects on ligand affinity mediated by the same locus (1996) Mol. Pharmacol, 50, pp. 34-42; Shapiro, D.A., Kristiansen, K., Kroeze, W.K., Roth, B.L., Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5 (2000) Mol. Pharmacol, 58, pp. 877-886; Cortizo, L., Santana, L., Ravina, E., Orallo, F., Fontenla, J.A., Castro, E., Calleja, J.M., De Ceballos, M.L., Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogs of butyrophenone (1991) J. Med. Chem, 34, pp. 2242-2247; Alvarado, M., Coelho, A., Masaguer, C.F., Raviña, E., Brea, J., Padín, J.F., Loza, M.I., Synthesis and binding affinity of novel 3-aminoethyl-1-tetralones, potential atypical antipsychotics (2005) Bioorg. Med. Chem. Lett, 15, pp. 3063-3066; Loza, M.I., Ferreiro, T.G., Sanz, F., Lozoya, E., Rodriguez, J., Manaut, F., Verde, I., Cadavid, I., Antiserotoninergic activity of 2-aminoethylbenzocyclanones in rat aorta: Structure-activity relationships (1993) J. Pharm. Sci, 82, pp. 513-517; Fontenla, J.A., Osuna, J., Rosa, E., Castro, M.E., G-Ferreiro, T., Loza-Garcia, I., Calleja, J.M., Rodriguez, J., Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl)-benzocycloalkanones as analogs of butyrophenone (1994) J. Med. Chem, 37, pp. 2564-2573; Ravina, E., Fueyo, J., Masaguer, C.F., Negreira, J., Cid, J., Loza, I., Honrubia, A., De Ceballos, M.L., Synthesis and affinities for dopamine (D2) and 5-hydroxytryptamine (5-HT2A) receptors of 1-(benzoylpropyl)-4-(1 -oxocycloalkyl-2-ethyl)-piperazines as cyclic butyrophenone derivatives (1996) Chem. Pharm. Bull. (Tokyo), 44, pp. 534-541; Masaguer, C.F., Casariego, I., Ravina, E., Conformationally restricted butyrophenones with mixed dopaminergic (D[2]) and serotoninergic (5-HT[2A]) affinities. Synthesis of 5-aminoethyl-and 6-aminomethyl-4-oxotetrahydroindoles as potential atypical antipsychotics (1999) Chem. Pharm. Bull, 47, pp. 621-632; Masaguer, C.F., Formoso, E., Raviña, E., Tristán, H., Loza, M.I., Rivas, E., Fontenla, J., Butyrophenone analogues in the carbazole series: Synthesis and determination of affinities at D2 and 5-HT2A receptors (1998) Bioorg. Med. Chem. Lett, 8, pp. 3571-3576; Pita, B., Masaguer, C.F., Ravina, E., A simple, efficient method for regioselective synthesis of 7-aminomethyl-7,8-dihydro-6H-quinolin-5-ones, new potential CNS agents (2000) Tetrahedron Lett, 41, pp. 9829-9833; Ravina, E., Casariego, I., Masaguer, C.F., Fontenla, J.A., Montenegro, G.Y., Rivas, M.E., Loza, M.I., Demontis, G.C., Conformationally constrained butyrophenones with affinity for dopamine (D1, D2, D4) and serotonin (5-HT2A, 5-HT2B, 5-HT2C) receptors: Synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics (2000) J. Med. Chem, 43, pp. 4678-4693; Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., Improved protein-ligand docking using GOLD (2003) Proteins, 52, pp. 609-623; Gasteiger, J., Rudolph, C., Sadowski, J., Automatic generation of 3D-atomic coordinates for organic molecules (1990) Tetrahedron Comput. Methodol, 3, pp. 537-547; Jones, G., Willett, P., Glen, R.C., Leach, A.R., Taylor, R., Development and validation of a genetic algorithm for flexible docking (1997) J. Mol. Biol, 267, pp. 727-748; GRID 22; Molecular Discovery, Ltd.: London, U.K., 2006; (2003) GOLPE 4.6.0, , Multivariate Infometric Analysis: Srl. Perugia, Italy; Pastor, M., Craciani, G., Clementi, S., Smart region definition: A new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships (1997) J. Med. Chem, 40, pp. 1455-1464; Hudson, B.D., Hyde, R.M., Rah, E.R., Wood, J., Osman, J., Parameter based methods for compound selection from chemical databases (2006) Quant. Struct.-Act. Relat, 15, pp. 285-289; Cramer III, R.D., Patterson, D.E., Bunce, J.D., Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins (1988) J. Am. Chem. Soc, 110, pp. 5959-5967; Doweyko, A.M., 3D-QSAR illusions (2004) J. Comput.-Aided Mol. Des, 18, pp. 587-596; Ballesteros, J., Weinstein, H., Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors (1995) Methods Neurosci, 25, pp. 366-428; Boeckmann, B., Bairoch, A., Apweiler, R., Blatter, M.C., Estreicher, A., Gasteiger, E., Martin, M.J., Schneider, M., The SWISS-PROT protein knowledge-base and its supplement TrEMBL in 2003 (2003) Nucleic Acids Res, 31, pp. 365-370; Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., Higgins, D.G., The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools (1997) Nucleic Acids Res, 25, pp. 4876-4882; Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties, and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673-4680; Baldwin, J.M., Schertler, G.F., Unger, V.M., An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors (1997) J. Mol. Biol, 272, pp. 144-164; Persson, B., Argos, P., Prediction of membrane protein topology utilizing multiple sequence alignments (1997) J. Protein Chem, 16, pp. 453-457; Zhang, D., Weinstein, H., Polarity conserved positions in transmembrane domains of G-protein coupled receptors and bacteriorhodopsin (1994) FEBS Lett, 337, pp. 207-212; Cuff, J. A.; Clamp, M. E.; Siddiqui, A. S.; Finlay, M.; Barton, G. J. JPred: A consensus secondary structure prediction server. Bioinformatics 1998, 14, 892-893; White, S.H., Wimley, W.C., Membrane protein folding and stability: Physical principles (1999) Annu. Rev. Biophys. Biomol. Struct, 28, pp. 319-365; Russell, R.B., Barton, G.J., Multiple protein sequence alignment from tertiary structure comparison: Assignment of global and residue confidence levels (1992) Proteins, 14, pp. 309-323; Espadaler, J.; Fernandez-Fuentes, N.; Hermoso, A.; Querol, E.; Aviles, F. X.; Sternberg, M. J.; Oliva, B. ArchDB: Automated protein loop classification as a tool for structural genomics. Nucleic Acids Res. 2004, 32, D185-D188; Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J., PROCHECK, M., A program to check the stereochemical quality of protein structures (1993) J. Appl. Crystallogr, 26, pp. 283-291; Case, D.A., Pearlman, D.A., Caldwell, J.M., Cheatman III, T.E., Ross, W.S., Simmerling, C.L., Darden, T.A., Singh, U.C., (1999) AMBER 6.0, , University of California, San Francisco, San Francisco, CA; Cornell, W. D.; Cieplak, P.; Bayly, I. R.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeir, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197; Frisch, M. J.; et al. Gaussian 98, revision A.7; Gaussian, Inc.; Pittsburgh, PA, 1998; Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for determining atom-centered charges: The resp model. J. Phys. Chem. 1993, 97, 10269; Miyamoto, S., Kollman, P.A., An analytical version of the SHAKE and RATTLE algorithm for rigid water molecules (1992) J. Comput. Chem, 13, pp. 952-962; Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996, 14, 33-8, 27-8","Pastor, M.; Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, Dr. Aiguader 88, E-08003 Barcelona, Spain; email: manuel.pastor@upf.edu",,,,,,,,00222623,,JMCMA,"17579386","English","J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-34447530682
"Bonis J., Furlong L.I., Sanz F.","56728136000;34770469800;7102263897;","OSIRIS: A tool for retrieving literature about sequence variants",2006,"Bioinformatics","22","20",,"2567","2569",,15,"10.1093/bioinformatics/btl421","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33749853613&doi=10.1093%2fbioinformatics%2fbtl421&partnerID=40&md5=dd948bdda8a38b410ff0a10646cf898d","Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, carrer Dr Aiguader 88, E-08003 Barcelona, Spain","Bonis, J., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, carrer Dr Aiguader 88, E-08003 Barcelona, Spain; Furlong, L.I., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, carrer Dr Aiguader 88, E-08003 Barcelona, Spain; Sanz, F., Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, carrer Dr Aiguader 88, E-08003 Barcelona, Spain","Summary: Sequence variants, in particular single nucleotide polymorphisms (SNPs), are key elements for the identification of genes associated with complex diseases and with particular drug responses. The search for literature about sequence variation is hampered by the large number of allelic variants reported for many genes and by the variability in both gene and sequence variants nomenclatures. We describe OSIRIS, a search tool that integrates different sources of information with the aim to retrieve literature about sequence variation of a gene. In addition, it provides a method to link a dbSNP entry with the articles referring to it. © 2006 Oxford University Press.",,"allele; article; drug response; gene identification; gene sequence; genetic association; genetic disorder; genetic variability; MEDLINE; priority journal; single nucleotide polymorphism; Abstracting and Indexing; Base Sequence; Database Management Systems; Information Storage and Retrieval; Molecular Sequence Data; Natural Language Processing; Periodicals; Polymorphism, Single Nucleotide; PubMed; Sequence Analysis, DNA; Software; Variation (Genetics); Vocabulary, Controlled",,,"OSIRIS",,,"The authors acknowledge the financial support provided by the networks INBIOMED and INFOBIOMED.",,,"Chang, J.T., GAPSCORE: Finding gene and protein names one word at a time (2004) Bioinformatics, 20, pp. 216-225; Fundel, K., A simple approach for protein name identification: Prospects and limits (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S15; Hanisch, D., ProMiner: Rule-based protein and gene entity recognition (2005) BMC Bioinformatics, 6 (SUPPL. 1), pp. S14; Horn, F., Automated extraction of mutation data from the literature: Application of MuteXt to G protein-coupled receptors and nuclear hormone receptors (2004) Bioinformatics, 20, pp. 557-568; Jensen, L.J., Literature mining for the biologist: From information retrieval to biological discovery (2006) Nat. Rev. Genet., 7, pp. 119-129; McCarthy, J., Turning SNPs into Useful Markers of Drug Response (2002) Pharmacogenomics: The Search for Individualized Therapies, pp. 35-55. , In Licinio,J. and Wong,M.L. (eds), Wiley-VCH, Weinheim; Rebholz-Schuhmann, D., Automatic extraction of mutations from Medline and cross-validation with OMIM (2004) Nucleic Acids Res., 32, pp. 135-142; Sherry, S.T., dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation (1999) Genome Res., 9, pp. 677-679","Sanz, F.; Research Unit on Biomedical Informatics (GRIB), IMIM, Universitat Pompeu Fabra, carrer Dr Aiguader 88, E-08003 Barcelona, Spain; email: fsanz@imim.es",,,,,,,,13674803,,BOINF,"16882651","English","Bioinformatics",Article,"Final",Open Access,Scopus,2-s2.0-33749853613
"Brea J., Castro M., Loza M.I., Masaguer C.F., Raviña E., Dezi C., Pastor M., Sanz F., Cabrero-Castel A., Galán-Rodríguez B., Fernández-Espejo E., Maldonado R., Robledo P.","6603008588;13402994300;7003766926;6701715235;56264803900;6507203451;7102415847;7102263897;14038705000;6506621668;55663467100;26643254500;6603952623;","QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine",2006,"Neuropharmacology","51","2",,"251","262",,21,"10.1016/j.neuropharm.2006.03.021","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745957973&doi=10.1016%2fj.neuropharm.2006.03.021&partnerID=40&md5=ed2050b237d6a8807db84bc69c51ee30","Departamento de Farmacología, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Departamento de Química Orgánica, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Computer-Assisted Drug Design Laboratory, Research Group on Biomedical Informatics (GRIB)-IMIM, UPF, Barcelona, Spain; Laboratorio de Neurofarmacología, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), Calle Dr. Aiguader 80, 08003 Barcelona, Spain; Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain; Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain","Brea, J., Departamento de Farmacología, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Castro, M., Departamento de Farmacología, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Loza, M.I., Departamento de Farmacología, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Masaguer, C.F., Departamento de Química Orgánica, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Raviña, E., Departamento de Química Orgánica, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Dezi, C., Computer-Assisted Drug Design Laboratory, Research Group on Biomedical Informatics (GRIB)-IMIM, UPF, Barcelona, Spain; Pastor, M., Computer-Assisted Drug Design Laboratory, Research Group on Biomedical Informatics (GRIB)-IMIM, UPF, Barcelona, Spain; Sanz, F., Computer-Assisted Drug Design Laboratory, Research Group on Biomedical Informatics (GRIB)-IMIM, UPF, Barcelona, Spain; Cabrero-Castel, A., Laboratorio de Neurofarmacología, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), Calle Dr. Aiguader 80, 08003 Barcelona, Spain; Galán-Rodríguez, B., Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain; Fernández-Espejo, E., Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain; Maldonado, R., Laboratorio de Neurofarmacología, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), Calle Dr. Aiguader 80, 08003 Barcelona, Spain; Robledo, P., Laboratorio de Neurofarmacología, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), Calle Dr. Aiguader 80, 08003 Barcelona, Spain, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain","The aim of the present work was to characterize a lead compound displaying relevant multi-target interactions, and with an in vivo behavioral profile predictive of atypical antipsychotic activity. Synthesis, molecular modeling and in vitro and in vivo pharmacological studies were carried out for 2-[4-(6-fluorobenzisoxazol-3-yl)piperidinyl]methyl-1,2,3,4-tetrahydro-carbazol-4-one (QF2004B), a conformationally constrained butyrophenone analogue. This compound showed a multi-receptor profile with affinities similar to those of clozapine for serotonin (5-HT2A, 5-HT1A, and 5-HT2C), dopamine (D1, D2, D3 and D4), alpha-adrenergic (α1, α2), muscarinic (M1, M2) and histamine H1 receptors. In addition, QF2004B mirrored the antipsychotic activity and atypical profile of clozapine in a broad battery of in vivo tests including locomotor activity (ED50 = 1.19 mg/kg), apomorphine-induced stereotypies (ED50 = 0.75 mg/kg), catalepsy (ED50 = 2.13 mg/kg), apomorphine- and DOI (2,5-dimethoxy-4-iodoamphetamine)-induced prepulse inhibition (PPI) tests. These results point to QF2004B as a new lead compound with a relevant multi-receptor interaction profile for the discovery and development of new antipsychotics. © 2006 Elsevier Ltd. All rights reserved.","Atypical profile; Atypicality; Butyrophenone analogue; Prepulse inhibition test; Schizophrenia; Typical antipsychotics","2 [2 (6 fluorobenzisoxazol 3 yl)piperidinyl]methyl 1,2,3,4 tetrahydro carbazol 4 one; 4 iodo 2,5 dimethoxyamphetamine; alpha 1 adrenergic receptor; alpha 2 adrenergic receptor; apomorphine; atypical antipsychotic agent; butyrophenone derivative; clozapine; dopamine 1 receptor; dopamine 2 receptor; dopamine 3 receptor; dopamine 4 receptor; dopamine receptor blocking agent; haloperidol; histamine H1 receptor; muscarinic M1 receptor; muscarinic M2 receptor; qf 2004b; serotonin 1A receptor; serotonin 2A receptor; serotonin 2C receptor; serotonin antagonist; unclassified drug; animal cell; animal experiment; animal tissue; article; catalepsy; controlled study; drug activity; drug conformation; drug receptor binding; drug synthesis; female; in vitro study; in vivo study; locomotion; male; molecular model; mouse; nonhuman; prepulse inhibition; priority journal; receptor affinity; stereotypy; Animals; Antipsychotic Agents; Butyrophenones; Carbazoles; Catalepsy; CHO Cells; Clozapine; Cricetinae; Cricetulus; Humans; Isoxazoles; Male; Mice; Models, Molecular; Motor Activity; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Histamine H1; Receptors, Muscarinic; Receptors, Serotonin; Startle Reaction; Stereotyped Behavior",,"4 iodo 2,5 dimethoxyamphetamine, 64584-34-5; apomorphine, 314-19-2, 58-00-4; clozapine, 5786-21-0; dopamine 4 receptor, 137750-34-6; haloperidol, 52-86-8; Antipsychotic Agents; Butyrophenones; Carbazoles; Clozapine, 5786-21-0; Isoxazoles; QF 2004B; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Histamine H1; Receptors, Muscarinic; Receptors, Serotonin","qf 2004b","Sigma","Fundació la Marató de TV3: TV3

Instituto de Salud Carlos III: G03/05

SAF2002-04195-C03","This work was supported by grants from Fundació La Marató de TV3, Spanish Government (SAF2002-04195-C03), and Instituto de Investigación Sanitaria Carlos III (Red de Trastornos Adictivos G03/05 y Red CIEN).",,,"Ballesteros, J.A., Weinstein, H., Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptor (1994) Methods in Neurosciences, pp. 366-428. , Conn P.M., and Sealfon S.C. (Eds), Academic Press, San Diego; Barrett, J., Anti-psychotic drug effect on the behavior of squirrel monkeys differentially controlled by noxious stimuli (1982) Psychopharmacology, 77, pp. 1-6; Berg, K.A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., Clarke, W.P., Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus (1998) Mol. Pharmacol., 54, pp. 94-104; Brea, J., Rodrigo, J., Carrieri, A., Sanz, F., Cadavid, M.I., Enguix, M.J., Villazón, M., Loza, M.I., New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones (2002) J. Med. Chem., 45, pp. 54-71; Case, D.A., Pearlman, D.A., Caldwell, J.M., Cheatman III, T.E., Ross, W.S., Simmerling, C.L., Darden, T.A., Kollman, P.A., (1999) AMBER6, , University of California, San Francisco; Curzon, P., Decker, M.W., Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice (1998) Prog. Neuropsychopharmacol. Biol. Psychiatry, 22 (1), pp. 129-146; Dulawa, S.C., Geyer, M.A., Psychopharmacology of prepulse inhibition in mice (1996) Chin. J. Physiol., 39, pp. 139-146; Ellenbroek, B.A., Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs (1993) Pharmacol. Ther., 57, pp. 1-78; Elz, S., Kramer, K., Pertz, H.H., Detert, H., ter Laak, A.M., Kuhne, R., Schunack, W., Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists (2000) J. Med. Chem., 43, pp. 1071-1084; Espadaler, J., Fernandez-Fuentes, N., Hermoso, A., Querol, E., Aviles, F.X., Sternberg, M.J., Oliva, B., ArchDB: automated protein loop classification as a tool for structural genomics (2004) Nucleic Acids Res., 32, pp. D185-D188; Fernandez-Espejo, E., Galan-Rodriguez, B., Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor (2004) Psychopharmacology, 175, pp. 220-224; Geddes, J., Prevention of relapse in schizophrenia (2002) N. Engl. J. Med., 346, pp. 56-58; Geyer, M.A., Krebs-Thomson, K., Braff, D.L., Swerdlow, N.R., Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review (2001) Psychopharmacology, 156, pp. 117-154; Geyer, M.A., McIlwain, K.L., Paylor, R., Mouse genetic models for prepulse inhibition: an early review (2002) Mol. Psychiatry, 7, pp. 1039-1053; Giuliani, D., Ferrari, F., Involvement of dopamine receptors in the antipsychotic profile of (-) eticlopride (1997) Physiol. Behav., 61, pp. 563-567; Gonzalez-Gomez, J.C., Santana, L., Uriarte, E., Brea, J., Villazon, M., Loza, M.I., De Luca, M., Fontenla, J.A., New arylpiperazine derivatives with high affinity for alpha1A, D2 and 5-HT2A receptors (2003) Bioorg. Med. Chem. Lett., 13, pp. 175-178; Hauber, W., Impairments of movement initiation and execution induced by a blockade of dopamine D1 or D2 receptors are reversed by a blockade of N-methyl-d-aspartate receptors (1996) Neuroscience, 73, pp. 121-130; Herrick-Davis, K., Grinde, E., Teitler, M., Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors (2000) J. Pharmacol. Exp. Ther., 295, pp. 226-232; Knable, M.B., Weinberger, D.R., Dopamine, the prefrontal cortex and schizophrenia (1997) J. Psychopharmacol., 11, pp. 123-131; Leucht, S., Wahlbeck, K., Hamann, J., Kissling, W., New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis (2003) Lancet, 361, pp. 1581-1589; Lynch, M.R., Schizophrenia and the D1 receptor: focus on negative symptoms (1992) Prog. Neuropsychopharmacol. Biol. Psychiatry, 16, pp. 797-832; Malone, D.T., Long, L.E., Taylor, D.A., The effect of SR141716 and apomorphine on sensiromotor gating in Swiss mice (2004) Pharmacol. Biochem. Behav., 77, pp. 839-845; Masaguer, C.F., Raviña, E., Fontenla, J.A., Brea, J., Tristan, H., Loza, M.I., Butyrophenone analogues in the carbazole series as potential atypical antipsychotics: synthesis and determination of affinities at D2, 5-HT2A, 5-HT2B, and 5-HT2C receptors (2000) Eur. J. Med. Chem., 35, pp. 83-95; McCaughran Jr., J., Mahjubi, E., Decena, E., Hitzemann, R., Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition (1997) Psychopharmacology, 134, pp. 131-139; Meltzer, H.Y., Matsubara, S., Lee, J.C., Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values (1989) J. Pharmacol. Exp. Ther., 251, pp. 238-246; Meltzer, H.Y., Li, Z., Kaneda, Y., Ichikawa, J., Serotonin receptors: their key role in drugs to treat schizophrenia (2003) Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, pp. 1159-1172; Meschler, J.P., Conley, T.J., Howlett, A.C., Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol (2000) Biochem. Behav., 67, pp. 567-573; Miyamoto, S., Duncan, G.E., Marx, C.E., Lieberman, J.A., Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs (2005) Mol. Psychiatry, 10, pp. 79-104; Morimoto, T., Hashimoto, K., Yasumatsu, H., Tanaka, H., Fujimura, M., Kuriyama, M., Kimura, K., Yamagami, K., Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H- [1] benzothieno [2,3-b] [1, 5]benzodiazepine maleate) (2002) Neuropsychopharmacology, 26, pp. 456-467; Olivier, B., Leahy, C., Mullen, T., Paylor, R., Groppi, V.E., Sarnyai, Z., Brunner, D., The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? (2001) Psychopharmacology, 156, pp. 284-290; Ouagazzal, A.M., Jenck, F., Moreau, J.L., Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? (2001) Psychopharmacology, 156, pp. 273-283; Owen, J.M., O'Donovan, M.C., Gottesman, I.I., Schizophrenia (2002) Psychiatric Genetics and Genomics. first ed., pp. 247-266. , McGuffin P., Owen M.J., and Gottesman I.I. (Eds), Oxford University Press, Oxford; Owens, D.G., Adverse effects of antipsychotic agents. Do newer agents offer advantages? (1996) Drugs, 51, pp. 895-930; Palczewski, K., Crystal structure of rhodopsin: a G protein-coupled receptor (2000) Science, 278, pp. 739-745; Ralph-Williams, R.J., Lehmann-Masten, V., Otero-Corchon, V., Low, M.J., Geyer, M.A., Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice (2002) J. Neurosci., 22, pp. 9604-9611; Ralph-Williams, R.J., Lehmann-Masten, V., Geyer, M.A., Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice (2003) Neuropsychopharmacology, 28, pp. 108-118; Rauser, L., Savage, J.E., Meltzer, H.Y., Roth, B.L., Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor (2001) J. Pharmacol. Exp. Ther., 299, pp. 83-89; Raviña, E., Negreira, J., Cid, J., Masaguer, C.F., Rosa, E., Rivas, M.E., Fontenla, J.A., Carrieri, A., Conformationally constrained butyrophenones with mixed dopaminergic (D2) and serotoninergic 5-HT2A, 5-HT2C) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics (1999) J. Med. Chem., 42, pp. 2774-2797; Raviña, E., Casariego, I., Masaguer, C.F., Fontenla, J.A., Montenegro, G.Y., Rivas, M.E., Loza, M.I., Desmontis, G.C., Conformationally constrained butyrophenones with affinity for dopamine (D1, D2, D4) and serotonin (5-HT2A, 5-HT2B, 5-HT2C) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics (2000) J. Med. Chem., 43, pp. 4678-4693; Roth, B.L., Willins, D.L., Kristiansen, K., Kroeze, W.K., 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function (1998) Pharmacol. Ther., 79, pp. 231-257; Roth, B.L., Hanizavareh, S.M., Blum, A.E., Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders (2004) Psychopharmacology (Berl.), 174, pp. 17-24; Roth, B.L., Sheffler, D.J., Kroeze, W.K., Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia (2004) Nat. Rev. Drug Discov., 3, pp. 353-359; Russig, H., Spooren, W., Durkin, S., Feldon, J., Yee, B.K., Apomorphine-induced disruption of prepulse inhibition that can be normalised by systemic haloperidol is insensitive to clozapine pretreatment (2004) Psychopharmacology, 175, pp. 143-147; Sali, A., Blundell, T.L., Comparative protein modeling by satisfaction of spatial restraints (1993) J. Mol. Biol., 234, pp. 779-815; Serretti, A., De Ronchi, D., Lorenzi, C., Berardi, D., New antipsychotics and schizophrenia: a review on efficacy and side effects (2004) Curr. Med. Chem., 11, pp. 343-358; Sipes, T.E., Geyer, M.A., DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT2A and not by 5-HT2C receptors (1995) Behav. Pharmacol., 6, pp. 839-842; Valverde, O., Maldonado, R., Valjent, E., Zimmer, A.M., Zimmer, A., Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice (2000) J. Neurosci., 20, pp. 9284-9289; Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., Taylor, R.D., Improved protein-ligand docking using GOLD. Proteins Struct (2003) Funct. Genet., 52, pp. 609-623","Robledo, P.; Laboratorio de Neurofarmacología, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra (UPF), Calle Dr. Aiguader 80, 08003 Barcelona, Spain; email: patricia.robledo@upf.edu",,,,,,,,00283908,,NEPHB,"16697427","English","Neuropharmacology",Article,"Final",,Scopus,2-s2.0-33745957973
"Carotti A., Cadavid M.I., Centeno N.B., Esteve C., Loza M.I., Martinez A., Nieto R., Raviña E., Sanz F., Segarra V., Sotelo E., Stefanachi A., Vidal B.","7102635316;6603422293;6701440183;11239993500;7003766926;26436355500;23980774800;56264803900;7102263897;6603951720;6701728812;22235816900;7005797173;","Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor",2006,"Journal of Medicinal Chemistry","49","1",,"282","299",,37,"10.1021/jm0506221","https://www.scopus.com/inward/record.uri?eid=2-s2.0-30444448197&doi=10.1021%2fjm0506221&partnerID=40&md5=087d544fcd8776a70b14b2b0973b332f","Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Unitat de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Almirall Prodesfarma S.A., General Mitre, 151, E-08022 Barcelona, Spain","Carotti, A., Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; Cadavid, M.I., Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Centeno, N.B., Unitat de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Esteve, C., Almirall Prodesfarma S.A., General Mitre, 151, E-08022 Barcelona, Spain; Loza, M.I., Departamento de Farmacologia, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Martinez, A., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Nieto, R., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Raviña, E., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Sanz, F., Unitat de Recerca en Informàtica Biomèdica (GRIB), IMIM-UPF, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Segarra, V., Almirall Prodesfarma S.A., General Mitre, 151, E-08022 Barcelona, Spain; Sotelo, E., Departamento de Quimica Organica, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Stefanachi, A., Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; Vidal, B., Almirall Prodesfarma S.A., General Mitre, 151, E-08022 Barcelona, Spain","Over two hundred 1-, 3-, 8-, and 9-substituted-9-deazaxanthines were prepared and evaluated for their binding affinity at the recombinant human adenosine receptors, in particular at the hA2B and hA2A subtypes. Several ligands endowed with sub-micromolar to low nanomolar binding affinity at hA2B receptors, good selectivity over hA2A and hA3, but a relatively poor selectivity over hA1 were obtained. Good antagonistic potencies and efficacies, with pA2 values close to the corresponding pKis, were observed in functional assays in vitro performed on a selected series of compounds. 1,3-Dimethyl-8-phenoxy-(N- p-halogenophenyl)-acetamido-9-deazaxanthine derivatives appeared as the most interesting leads, some of them showing outstanding hA2B affinities, high selectivity over hA2A and hA3, but low selectivity over hA1. Structure-affinity relationships suggested that the binding potency at the hA2B receptor was mainly modulated by the steric (lipophilic) properties of the substituents at positions 1 and 3 and by the electronic and lipophilic characteristics of the substituents at position 8. A comparison among affinity and selectivity profiles of 9-deazaxanthines with the corresponding xanthines suggested some possible differences in their binding mode. © 2006 American Chemical Society.",,"acetamide derivative; adenosine A2 receptor antagonist; adenosine A2a receptor; adenosine A2b receptor; adenosine A3 receptor; halogen; receptor subtype; recombinant receptor; xanthine derivative; article; binding affinity; drug design; drug efficacy; drug potency; drug receptor binding; drug selectivity; drug synthesis; human; in vitro study; ligand binding; lipophilicity; nonhuman; rat; reaction analysis; stereospecificity; structure activity relation; Animals; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Drug Design; Hela Cells; Humans; Molecular Structure; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptor, Adenosine A3; Receptors, Adenosine A2; Stereoisomerism; Structure-Activity Relationship; Xanthines",,"Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptor, Adenosine A3; Receptors, Adenosine A2; Xanthines",,,,,,,"Cohn, L., Elias, J.A., Chupp, G.L., Asthma: Mechanisms of disease persistence and progression (2004) Annu. Rev. Immunol., 22, pp. 789-815; Frieri, M., Asthma concepts in the new millennium: Update in asthma pathophysiology (2005) Allergy Asthma Proc., 26, pp. 83-88; Szeleny, I., Pahal, A., Drug therapy in asthma bronchiale in the new millennium (2002) Pharmazie, 57, pp. 83-86; Drazen, J.M., Israel, E., O'Byrne, P.M., Treatment of asthma with drugs modifying the leukotriene pathway (1999) N. Engl. J. Med., 340, pp. 197-206; Kemp, J.P., Recent advances in the management of asthma using leukotriene modifiers (2003) Am. J. Respir. Med., 2, pp. 139-156; Holgate, S.T., Peters-Golden, M., Introduction: The antiinflammatory role of cysteinyl leukotriene receptor antagonists in asthma (2003) Allergy Clin. Immunol., 111, pp. S1-4; Stokes, J., Casale, T.B., Rationale for new treatments aimed at IgE immunomodulation (2004) Ann. Allergy Asthma Immunol., 93, pp. 212-217; Babu, K.S., Holgate, S.T., The role of anti-IgE therapies in the treatment of asthma (2002) Hosp. Med., 63, pp. 483-486; Marx, D., Ezeamuzie, C.I., Nieber, K., Szelenyi, I., Therapy of bronchial asthma with adenosine receptor agonists or antagonists (2001) Drug News Perspect., 14, pp. 89-100; Holgate, S.T., The identification of the adenosine A2B receptor as a novel therapeutic target in asthma (2005) Br. J. Pharmacol., 145, pp. 1009-1015; Jacobson, K.A., Ijzerman, Ad.P., Linden, J., 1,3-Dialkylxanthine derivatives having high potency as Antagonist at human A2B adenosine receptor (1999) Drug. Dev. Res., 47, pp. 45-53; Klinger, M., Freissmuth, M., Nanoff, C., Adenosine receptors: G protein-mediated signalling and the role of accessory proteins (2002) Cell Signal., 14, pp. 99-108; Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.N., Linden, J., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors (2001) Pharmacol. Rev., 55, pp. 527-552; Baraldi, P.G., Tabrizi, M.A., Preti, D., Bovero, A., Romagnoli, R., Fruttarolo, F., Zaid, N.A., Borea, P.A., Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists (2004) J. Med. Chem., 47, pp. 1434-1447; Volpini, R., Costanzi, S., Vittori, S., Cristalli, G., Klotz, K.N., Medicinal chemistry and pharmacology of A2B adenosine receptors (2003) Curr. Top. Med. Chem., 3, pp. 427-443; Cristalli, G., Lambertucci, C., Taffi, S., Vittori, S., Volpini, R., Medicinal chemistry of adenosine A2A receptor agonists (2003) Curr. Top. Med. Chem., 3, pp. 387-401; Müller, C.E., Stein, B., Adenosine receptor antagonists: Structure and potential therapeutic applications (1996) Curr. Pharm. Des., 2, pp. 501-530; Baraldi, P.G., Borea, P.A., New potent and selective human adenosine A3 receptor antagonists (2000) Trends Pharmacol. Sci., 27, pp. 456-459; Baraldi, P.G., Cacciari, B., Romagnoli, R., Merighi, S., Varani, K., Borea, P.A., Spalluto, G., A3 adenosine receptor ligands: History and perspectives (2000) Med. Res. Rev., 20, pp. 103-128; Van Der Wenden, E.M., Ijzerman, A.P., Soudijn, W.A., Steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptor (1992) J. Med. Chem., 55, pp. 629-635; Kim, Y.C., Ji, X., Melman, N., Linden, J., Jacobson, K.A., Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors (2000) J. Med. Chem., 43, pp. 1165-1172; Baraldi, P.G., Cacciari, B., Moro, S., Spalluto, G., Pastorin, G., Da Ros, T., Klotz, K.-N., Borea, P.A., Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A 3 adenosine receptor antagonists (2002) J. Med. Chem., 45, pp. 770-780; Soudijn, W., Van Weden, I., Ijzerman, A.P., Medicinal chemistry of adenosine A1 receptor ligands (2003) Curr. Top. Med. Chem., 3, pp. 355-367; Müller, C.E., Medicinal chemistry of adenosine A3 receptor ligands (2003) Curr. Top. Med. Chem., 3, pp. 445-462; DeNinno, M.P., Masamune, H., Chenard, L.K., DiRico, K.J., Eller, C., Etienne, J.B., Tickner, J.E., Hill, R.J., 3′-Aminoadenosine-5′-uronamides: Discovery of the first highly selective agonist at the human adenosine A3 receptor (2003) J. Med. Chem., 46, pp. 353-355; Kim, Y.C., Ji, X., Melman, N., Linden, J., Jacobson, K.A., Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors (2000) J. Med. Chem., 43, pp. 1165-1172; Hayallah, A.M., Sandoval-Ramirez, J., Reith, U., Schobert, U., Preiss, B., Schumacher, B., Daly, J.W., Müller, C.E., 1,8-Disubstituted xanthine derivatives: Synthesis of potent A2B-selective adenosine receptor antagonists (2002) J. Med. Chem., 45, pp. 1500-1510; Kim, S.A., Marshall, M.A., Melman, N., Kim, H.S., Müller, C.E., Linden, J., Jacobson, K.A., Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions (2002) J. Med. Chem., 45, pp. 2131-2138; Baraldi, P.G., Tabrizi, M.A., Preti, D., Bovero, A., Fruttarolo, F., Romagnoli, R., Moorman, A.R., Borea, P.A., [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors (2004) Bioorg. Med. Chem. Lett., 14, pp. 3607-3610; Hansel, T.T., Tennant, R.C., Tan, A.J., Higgins, L.A., Neighbour, H., Erin, E.M., Barnes, P.J., Theophylline: Mechanism of action and use in asthma and chronic obstructive pulmonary disease (2004) Drugs Today (Barc.), 40, pp. 55-69; Maconi, A., Pastorin, G., Da Ros, T., Spalluto, G., Gao, Z.G., Jacobson, K.A., Baraldi, P.G., Borea, P.A., Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A3 adenosine receptor antagonist (2002) J. Med. Chem., 45, pp. 3579-3582; Ongini, E., Monopoli, A., Cacciari, B., Baraldi, P.G., Selective adenosine A2A receptor antagonists (2001) Farmaco, 56, pp. 87-90; Müller, C.E., A1 adenosine receptors and their ligands: Overview and recent developments (2001) Farmaco, 56, pp. 77-80; Hayallah, A.M., Sandoval-Ramirez, J., Reith, U., Schobert, U., Preiss, B., Schumacher, B., Daly, J.W., Müller, C.E., 1,8-Disubstituted xanthine derivatives: Synthesis of potent A2B-selective adenosine receptor antagonists (2002) J. Med. Chem., 45, pp. 1500-1510; Baraldi, P.G., Romagnoli, R., Tabrizi, M.A., Bovero, A., Preti, D., Fruttarolo, F., Moorman, A.R., Borea, P.A., New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2 (2005) Farmaco, 60, pp. 185-202; Grahner, B., Winiwarter, S., Lanzner, W., Müller, C.E., Synthesis and structure-activity relationships of deazaxanthines: Analogues of potent A1- and A2-adenosine receptor antagonists (1994) J. Med. Chem., 37, pp. 1526-1534; Stefanachi, A., Leonetti, F., Cappa, A., Carotti, A., Fast and highly efficient one-pot synthesis of 9-deazaxanthines (2003) Tetrahedron Lett., 44, pp. 2121-2123; Carotti, A., Stefanachi, A., Raviña, E., Sotelo, E., Loza, M.I., Cadavid, M.I., Centeno, N.B., Nicolotti, O., 8-Substituted-9-deazaxanthines as adenosine receptor ligands: Design, synthesis and structure-affinity relationships at A2B (2004) Eur. J. Med. Chem., 39, pp. 879-887; Vidal, B.J., Esteve Trias, C., Segarra Matamoros, V., Ravina Rubira, E., Fernandez Gonzales, F., Loza Garcia, M.I., Sanz Carreras, F., 6-Phenyldihydropyrrolo pyrimidinedione, 2003, WO 033694; Senda, S., Suzui, A., Honda, M., Fujimura, H., Uracil derivatives and related compounds. III. 5-Amino-1,3,6- trialkyluracil derivatives (1958) Chem. Pharm. Bull., 6, pp. 482-487; Papesch, V., Dodson, R.M.G.D., Pyrimido[5,4-d][1,2,3]triazines (1963) J. Org. Chem., 28, p. 1329; Bicking, J.B., Robb, C.M., Watson, L.S., Cragoe Jr., E.J., (Vinylaryloxy)acetic acids. A new class of diuretic agents. 2. (4-(3-Oxo-1-alkenyl)phenoxy)acetic acids (1976) J. Med. Chem., 19, pp. 544-547; Agarwal, R., Chaudray, C., Singh, C.J., Misra, V.S., Synthesis of 2-methoxy-4-(3-methyl-5-oxo-1-phenyl-4-pyrazolylidenemethyl) phenoxyacetic acid and its ethyl ester (1982) Indian J. Med Chem Sect. B Org. Chem. Includ. Med Chem, 21 B, pp. 152-153; Albericio, F., Barany, G., An acid-labile anchoring linkage for solid-phase synthesis of C-terminal peptide amides under mild conditions (1987) Int. J. Pept. Protein Res., 30, pp. 206-216; Tipson, R.S., Antiviral activity of 2,2-dichloro-4′-formylacetoanilide thiosemicarbazone (1963) J. Med. Chem., 35, pp. 216-217; Cheng, M.F., Fang, J.M., Liquid-phase combinatorial synthesis of 1,4-benzodiazepine-2,5-diones as the candidates of endothelin receptor antagonism (2004) J. Comb. Chem., 6, pp. 99-104; Behrens, G., Hildenbrand, K., Schulte-Frohlinde, D., Herak, J.N., Reaction of sulfate radical anion with methylated uracils. An electron spin resonance study in aqueous solution (1988) J. Chem. Soc., Perkin Trans. 2, 3, pp. 305-307; Aichner, J., Egg, H., Gapp, D., Haller, S., Rakowitz, D., Ramspacher, U., Insight into novel cyclization reactions using acetic anhydride in the presence of 4-dimethylaminopyridine (1993) Heterocycles, 36, pp. 307-311; Senda, S., Suzui, A., Uracil derivatives and related compounds. I. Condensation of monosubstituted urea and ethyl acetoacetate (1958) Chem. Pharm. Bull., 6, pp. 476-479; Boese, A., B. 4-methyluracil and its homologs, US patent, 1938, 2,138,758; Senda, S., Hirota, K., Banno, K., Pyrimidine derivatives and related compounds. 15. Synthesis and analgetic and antiinflammatory activities of 1,3-substituted 5-amino-6-methyluracil derivatives (1972) J. Med. Chem., 15, pp. 471-476; Tipson, R.S., Antiviral activity of 2,2-dichloro-4′-formylacetoanilide thiosemicarbazone (1963) J. Med. Chem., 35, pp. 216-217; Tani, M., Ikegami, H., Tashiro, M., Hiura, T., Tsuikioka, H., Kaneko, C., Notoya, T., Uchida, M., Regioselective bromination of methoxy derivatives of ethyl indole-2-carboxylate [Synthetic studies of indoles and related compounds] (1992) Heterocycles, 34, pp. 2349-2362; Högberg, T., Ström, P., Ebner, M., Rämsby, S., Cyanide as an efficient and mild catalyst in the aminolysis of esters (1987) J. Org. Chem., 52, pp. 2033-2036; Jacobson, K.A., Ukena, D., Padgett, W., Daly, J.W., Kirk, K.L., Xanthine functionalized congeners as potent ligands at A2-adenosine receptors (1987) J. Med. Chem., 30, pp. 211-214; Touchstone, J., (1982) Advances in Thin-Layer Chromatography, , Wiley: New York; Nieto, R.M., Coelho, A., Martinez, A., Stefanachi, A., Sotelo, E., Ravina, E., Synthesis of 1-substituted-6-methyluracils (2003) Chem. Pharm. Bull., 51, pp. 1025-1028; Salomon, Y., Adenylate cyclase assay (1979) Adv. Cyclic Nucleotide. Res., 10, pp. 35-55; Prentice, D.J., Hourani, S.M.O., Activation of multiple sites by adenosine analogues in the rat isolated aorta (1996) Br. J. Pharmacol., 118, pp. 1509-1517; Alexander, S.P., Losinsky, A., Kendall, D.A., Hill, S.J., A comparison of A2 adenosine receptor induced cyclic AMP generation in cerebral cortex and relaxation of pre-contracted aorta (1994) Br. J. Pharmacol., 111, pp. 185-190","Carotti, A.; Dipartimento Farmaco-chimico, Università di Bari, via Orabona 4, I-70125 Bari, Italy; email: carotti@farmchim.uniba.it",,,,,,,,00222623,,JMCMA,"16392813","English","J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-30444448197
"Heredia J.A., Estruch A., Coltell O., Del Rey D.P., De La Calle G., Sánchez J.P., Sanz F.","11039731100;14021110200;6603090571;14021088600;23495177000;8570979000;7102263897;","Service oriented architecture for biomedical collaborative research",2005,"Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)","3745 LNBI",,,"252","261",,1,"10.1007/11573067_26","https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745312326&doi=10.1007%2f11573067_26&partnerID=40&md5=fcab89511dc1d19cafd976e076e1c76c","Departamento de Tecnología, Universitat Jaume I, Castellón, Spain; Systems Integration and Re-Engineering Research Group, Universitat Jaume I, Spain; Biomedical Informatics Group, Department of Artificial Intelligence, Universidad Politécnica de Madrid, Spain; Area de Bioinformática y Salud Pública, Institute de Salud Carlos III, Ministerio de Sanidad y Consumo, Madrid, Spain; GRIB, IMIM, UPF Barcelona, Spain","Heredia, J.A., Departamento de Tecnología, Universitat Jaume I, Castellón, Spain; Estruch, A., Departamento de Tecnología, Universitat Jaume I, Castellón, Spain; Coltell, O., Systems Integration and Re-Engineering Research Group, Universitat Jaume I, Spain; Del Rey, D.P., Biomedical Informatics Group, Department of Artificial Intelligence, Universidad Politécnica de Madrid, Spain; De La Calle, G., Biomedical Informatics Group, Department of Artificial Intelligence, Universidad Politécnica de Madrid, Spain; Sánchez, J.P., Area de Bioinformática y Salud Pública, Institute de Salud Carlos III, Ministerio de Sanidad y Consumo, Madrid, Spain; Sanz, F., GRIB, IMIM, UPF Barcelona, Spain","Following a systems engineering approach we have identified the information system requirements for biomedical collaborative research. We have designed a Service Oriented Architecture following a dynamic and adaptable to change approach, using technology and specifications that are being developed in an open way, utilizing industry partnerships and broad consortia such as W3C and the Organization for the Advancement of Structured Information Standards (OASIS), and based on standards and technology that are the foundation of the Internet. The design has been translated in a pilot implementation infrastructure (INBIOMED) that is now been populated with web services for data and images analysis and collaborative management. © Springer-Verlag Berlin Heidelberg 2005.",,"Information system; Organization for the Advancement of Structured Information Standards (OASIS); Service Oriented Architecture; Systems engineering approach; Biomedical engineering; Computer supported cooperative work; Image analysis; Information science; Specifications; Standards; World Wide Web; Computer architecture",,,,,,,,,"Buetow, K.H., Cyberinfrastructure: Empowering a ""third way"" in biomedical research (2005) Science, 308, pp. 821-824. , 6 May; Oliveira, I.C., Oliveira, J.L., Sanchez, J.P., Lopez-Alonso, V., Martin-Sanchez, F., Maojo, V., Sousa Pereira, A., Grid requirements for the integration of biomedical information resources for health applications (2005) Methods Inf Med., 44 (2), pp. 161-167; Murray, J.C., A comprehensive human linkage map with centimorgan density (1994) Science, 265, pp. 2049-2054; Booth, D., Web services architecture (2003) Working Draft, , www.w3.org/TR/ws-arch/, WC; Weerawarana, S., Curbera, F., Leymann, F., Storey, T., Ferguson, D., Web services platform architecture: SOAP, WSDL, WS-policy, WS-addressing, WS-BPEL (2005) WS-reliable Messaging, and More, , Prentice Hall PTR; Vogels, W., Web services are not distributed objects (2003) IEEE Internet Computing, pp. 59-66. , Nov-Dec; Haas, H., Web Services Glossary, , http://www.w3.org/TR/2004/NOTE-ws-gloss-20040211/, W3C Web services Working Group; Foster, I., The grid: Computing without bounds (2003) Sei Am., 288 (4), pp. 78-85. , Apr; Pastor, M., Benedetti, P., Carotti, A., Carrieri, A., Diaz, C., Herraiz, C., Höltje, H.-D., Stoll, F., Distant collaboration in drug discovery: The LINK3D project (2002) Journal of Computer-aided Molecular Design, 16, pp. 809-818; http://ncicb.nci.nih.gov/NCICB/core; www.lionbioscience.com; Heredia, J.A., Plataforma inbiomed: Objetivos y arquitectura (2004) Informática Biomédica, pp. 21-31. , Madrid. Editorial: Inbiomed; Austin, D., Barbir, A., Ferris, C., Garg, S., Web Services Architecture Requeriments, , http://www.w3.org/TR/wsa-reqs; Estruch, A., Heredia, J.A., Technological platform to aid the exchange of information and applications using web services (2004) Lecture Notes in Computer Science, 3337, pp. 458-468. , Nov; DataSet Class, , http://msdn.microsoft.com/library/default.asp?url=/library/en-us/cpref/ html/frlrfsystemdatadatasetclasstopic.asp; www.mged.org; Heredia, J.A., Modelo de información de los procesos de análisis en la investigación de patologías (2004) Informática Biomédica, pp. 223-247. , Madrid. Editorial: Inbiomed; Stead, W.W., Miller, R.A., Musen, M.A., Hersh, W.R., Integration and beyond: Linking information from disparate sources and into workflow (2000) J Am Med Inform Assoc., 7 (2), pp. 135-145. , Mar-Apr","Heredia, J.A.; Departamento de Tecnología, Universitat Jaume I, Castellón, Spain",,,,"6th International Symposium on Biological and Medical Data Analysis, ISBMDA 2005","10 November 2005 through 11 November 2005","Aveiro",67559,03029743,3540296743; 9783540296744,,,"English","Lect. Notes Comput. Sci.",Conference Paper,"Final",,Scopus,2-s2.0-33745312326
"Llargués E., Díaz C., Fitó R., Sanz F.","6506167086;57197180745;6507918242;7102263897;","Assessing the implementation of the VisualCor software in medical practice [Evaluación de la puesta en marcha del programa VisualCor en la práctica clínica]",2005,"Medicina Clinica","124","16", 78.478,"627","629",,1,"10.1157/13074394","https://www.scopus.com/inward/record.uri?eid=2-s2.0-20344374192&doi=10.1157%2f13074394&partnerID=40&md5=7b2a27b59714b641f67124a835bc20ea","Unitat de Recerca en Informàtica Biomèdica (GRIB), Institut Municipal d'Investigació Mèdica (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; Unitat de Recerca en Informàtica Biomèdica (GRIB), Institut Municipal d'Investigació Mèdica (IMIM), Universität Pompeu Fabra, C/ Dr. Aiguader, 80, 08003 Barcelona, Spain","Llargués, E., Unitat de Recerca en Informàtica Biomèdica (GRIB), Institut Municipal d'Investigació Mèdica (IMIM), Universitat Pompeu Fabra, Barcelona, Spain, Hospital General de Granollers, Granollers, Barcelona, Spain; Díaz, C., Unitat de Recerca en Informàtica Biomèdica (GRIB), Institut Municipal d'Investigació Mèdica (IMIM), Universitat Pompeu Fabra, Barcelona, Spain; Fitó, R., Hospital General de Granollers, Granollers, Barcelona, Spain; Sanz, F., Unitat de Recerca en Informàtica Biomèdica (GRIB), Institut Municipal d'Investigació Mèdica (IMIM), Universitat Pompeu Fabra, Barcelona, Spain, Unitat de Recerca en Informàtica Biomèdica (GRIB), Institut Municipal d'Investigació Mèdica (IMIM), Universität Pompeu Fabra, C/ Dr. Aiguader, 80, 08003 Barcelona, Spain",[No abstract available],,"adult; aged; article; computer program; consultation; data analysis; female; human; major clinical study; male; medical informatics; medical information system; medical practice; statistical significance",,,"VisualCor",,,,,,"Martínez De Aragón, M.V., Llàcer, A., Mortalidad en España 1995 (1998) Bol Epidemiol Sem, 6, pp. 105-116; Andersen, J.D., Increasing the acceptance of clinical information systems (1999) MD Comput, 16, pp. 62-65; Martin-Baranera, M., Planas, I., Palau, J., Miralles, M., Sancho, J.J., Sanz, F., Assessing physician's expectations and attitudes toward hospital information systems (1999) MD Comput, 16, pp. 73-76; Mitchell, E., Sullivan, F., A descriptive feast but an evaluative famine: Systematic review of published articles on primary care computing during 1980-97 (2001) BMJ, 322, pp. 279-282; Hingorani, A.D., Vallance, P., A simple computer program for guiding management of cardiovascular risk factors and prescribing (1999) BMJ, 318, pp. 101-105; Montgomery, A.A., Fahey, T., Peters, T.J., Macintosh, C., Sharp, D.J., Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: Randomised controlled trial (2000) BMJ, 320, pp. 686-690; Teich, J.M., Wrinn, M.M., Clinical decision support systems come of age (2000) MD Comput, 17, pp. 43-46; Haughton, J., A paradigm shift in healthcare. From disease management to patient-centered systems (2000) MD Comput, 17, pp. 34-38; Amatayakul, M., The race to standardize medical record information (2000) MD Comput, 17, pp. 22-24; Trickel, B., Ambulatory care. Implementing an integrated clinical and practice management system (2001) MD Comput, 18, pp. 37-39","Sanz, F.; Unitat de Recerca en Informàtica Biomèdica (GRIB), Institut Municipal d'Investigació Mèdica (IMIM), Universität Pompeu Fabra, C/ Dr. Aiguader, 80, 08003 Barcelona, Spain",,,"Ediciones Doyma, S.L.",,,,,00257753,,MCLBA,"15871781","Spanish","Med. Clin.",Article,"Final",,Scopus,2-s2.0-20344374192
"Fontaine F., Pastor M., Zamora I., Sanz F.","24755291000;7102415847;7003590293;7102263897;","Anchor-GRIND: Filling the gap between standard 3D QSAR and the GRid-INdependent descriptors",2005,"Journal of Medicinal Chemistry","48","7",,"2687","2694",,68,"10.1021/jm049113+","https://www.scopus.com/inward/record.uri?eid=2-s2.0-17144398395&doi=10.1021%2fjm049113%2b&partnerID=40&md5=0dcb94bb030e5316a16ab913649f0bc5","Res. U. on Biomed. Info. (GRIB), IMIM/Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain","Fontaine, F., Res. U. on Biomed. Info. (GRIB), IMIM/Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; Pastor, M., Res. U. on Biomed. Info. (GRIB), IMIM/Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; Zamora, I., Res. U. on Biomed. Info. (GRIB), IMIM/Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; Sanz, F., Res. U. on Biomed. Info. (GRIB), IMIM/Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain","The aim of this work is to present the anchor-GRIND methodology. Anchor-GRIND efficiently combines a priori chemical and biological knowledge about the studied compounds with alignment-independent molecular descriptors derived from molecular interaction fields. Such descriptors are particularly useful for series of ligands sharing a common scaffold but with very diverse substituents. The method uses a specific position of the molecular structure (the ""anchor point"") to compare the spatial distribution of the molecular interaction fields of the substituents. The descriptors produced are more detailed and specific than the original GRIND while still avoiding the bias introduced by the alignment. Three data sets have been studied to demonstrate the usefulness of the anchor-GRIND methodology for 3D-QSAR modeling. The two first data sets respectively include congeneric series of the hepatitis C virus NS3 protease and of the acetylcholinesterase inhibitors. The third data set discriminates between factor Xa inhibitors of high and low affinity. In all the series presented, the models obtained with the anchor-GRIND are statistically sound and easy to interpret. © 2005 American Chemical Society.",,"cholinesterase inhibitor; proteinase inhibitor; proteinase ns3 inhibitor; unclassified drug; analytic method; anchor grind model; article; chemical structure; grid independent descriptor method; Hepatitis C virus; ligand binding; methodology; molecular interaction; molecular model; quantitative structure activity relation; three dimensional imaging; Acetylcholinesterase; Cholinesterase Inhibitors; Drug Design; Factor Xa; Hydrogen Bonding; Hydrophobicity; Models, Molecular; Quantitative Structure-Activity Relationship; Serine Proteinase Inhibitors; Viral Nonstructural Proteins",,"proteinase inhibitor, 37205-61-1; Acetylcholinesterase, EC 3.1.1.7; Cholinesterase Inhibitors; Factor Xa, EC 3.4.21.6; NS3 protein, hepatitis C virus; Serine Proteinase Inhibitors; Viral Nonstructural Proteins",,,,,,,"Cramer, R.D., Patterson, D.E., Bunce, J.D., Comparative Molecular Field Analysis (CoMPA): 1. Effect of shape on binding of steroids to carrier proteins (1988) J. Am. Chem. Soc., 110, pp. 5959-5967; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors (2000) J. Med. Chem., 43, pp. 3233-3243; Cruciani, G., Pastor, M., Guba, W., VolSurf: A new tool for the pharmacokinetic optimization of lead compounds (2000) Eur. J. Pharm. Sci., 11 (SUPPL. 2), pp. S29-S39; Mason, J.S., Morize, I., Menard, P.R., Cheney, D.L., Hulme, C., New 4-point pharmacophore method for molecular similarity and diversity applications: Overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures (1999) J. Med. Chem., 42, pp. 3251-3264; Zamora, I., Afzelius, L., Cruciani, G., Predicting drug metabolism: A site of metabolism prediction tool applied to the cytochrome P450 2C9 (2003) J. Med. Chem., 46, pp. 2313-2324; Poupart, M.A., Cameron, D.R., Chabot, C., Ghiro, E., Goudreau, N., Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease (2001) J. Org. Chem., 66, pp. 4743-4751; Carbonell, T., Masip, I., Sanchez-Baeza, F., Delgado, M., Araya, E., Identification of selective inhibitors of acetylcholinesterase from a combinatorial library of 2,5-piperazinediones (2000) Mol. Divers., 5, pp. 131-143; Cruciani, G., Fontaine, F., Pastor, M., (2004) Almond, , 3.3.0; Molecular Discovery Ltd.: Perugia, Italy; Weininger, D., Smiles, a chemical language and information-system 0.1. Introduction to methodology and encoding rules (1988) J. Chem. Inf. Comput. Sci., 28, pp. 31-36; Gasteiger, J., Rudolph, C., Sadowski, J., Automatic generation of 3D atomic coordinates for organic molecules (1990) Tetrahedron Comput. Methodol., 3, pp. 537-547; http://www.daylight.com/dayhtml/doc/theory/theory.smarts.html; http://openbabel.sourceforge.net/; Goodford, P.J., A computational procedure for determining energetically favorable binding sites on biologically important macromolecules (1985) J. Med. Chem., 28, pp. 849-857; Fontaine, F., Pastor, M., Sanz, F., Incorporating molecular shape into the alignment-free GRid-INdependent Descriptors (2004) J. Med. Chem., 47, pp. 2805-2815; Llinas-Brunet, M., Bailey, M., Deziel, R., Fazal, G., Gorys, V., Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease (1998) Bioorg. Med. Chem. Lett., 8, pp. 2719-2724; Di Marco, S., Rizzi, M., Volpari, C., Walsh, M.A., Narjes, F., Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes (2000) J. Biol. Chem., 275, pp. 7152-7157; Pastor, M., Barroni, M., (2005) GOLPE 4.5.11, , Multivariate Infometric Analysis: Perugia, Italy","Pastor, M.; Res. U. on Biomed. Info. (GRIB), IMIM/Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; email: mpastor@imim.es",,,,,,,,00222623,,JMCMA,"15801859","English","J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-17144398395
"Maojo V., de la Calle G., Martín-Sánchez F., Díaz C., Sanz F.","55171738800;23495177000;6603119155;57197180745;7102263897;","INFOBIOMED: European Network of Excellence on Biomedical Informatics to support individualised healthcare.",2005,"AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium",,,,"1041","",,2,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-34249308940&partnerID=40&md5=be554669ecd24b6d1fed77a608191b9d","Biomedical Informatics Group, Artificial Intelligence Lab./Facultad de Informática, Universidad Politécnica de Madrid, Spain","Maojo, V., Biomedical Informatics Group, Artificial Intelligence Lab./Facultad de Informática, Universidad Politécnica de Madrid, Spain; de la Calle, G., Biomedical Informatics Group, Artificial Intelligence Lab./Facultad de Informática, Universidad Politécnica de Madrid, Spain; Martín-Sánchez, F., Biomedical Informatics Group, Artificial Intelligence Lab./Facultad de Informática, Universidad Politécnica de Madrid, Spain; Díaz, C., Biomedical Informatics Group, Artificial Intelligence Lab./Facultad de Informática, Universidad Politécnica de Madrid, Spain; Sanz, F., Biomedical Informatics Group, Artificial Intelligence Lab./Facultad de Informática, Universidad Politécnica de Madrid, Spain","INFOBIOMED is an European Network of Excellence (NoE) funded by the Information Society Directorate-General of the European Commission (EC). A consortium of European organizations from ten different countries is involved within the network. Four pilots, all related to linking clinical and genomic information, are being carried out. From an informatics perspective, various challenges, related to data integration and mining, are included.",,"article; chemistry; Europe; genomics; health care delivery; human; medical informatics; medical research; microbiology; organization and management; pilot study; Biomedical Research; Chemistry, Pharmaceutical; Delivery of Health Care; Europe; Genomics; Humans; Medical Informatics; Microbiology; Pilot Projects",,,,,,,,,,"Maojo, V.",,,,,,,,15594076,,,"16779328","English","AMIA Annu Symp Proc",Article,"Final",,Scopus,2-s2.0-34249308940
"Maojo V., Martin-Sánchez F., Barreiro J.M., Diaz C., Sanz F.","55171738800;6603119155;7005345873;57197180745;7102263897;","Biomedical informatics: From past experiences to the infobiomed network of excellence",2004,"Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)","3337",,,"418","426",,1,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-35048876255&partnerID=40&md5=ceefbb2cb92832a9b19fcf176313c13b","Biomedical Informatics Group, Artificial Intelligence Lab., Polytechnical University of Madrid, Spain; Bioinformatics Unit, Institute of Health Carlos III, Majadahonda, Madrid, Spain; Biomedical Informatics Research Group, Municipal Institue of Medical Research, IMIM, Barcelona, Spain","Maojo, V., Biomedical Informatics Group, Artificial Intelligence Lab., Polytechnical University of Madrid, Spain; Martin-Sánchez, F., Bioinformatics Unit, Institute of Health Carlos III, Majadahonda, Madrid, Spain; Barreiro, J.M., Biomedical Informatics Group, Artificial Intelligence Lab., Polytechnical University of Madrid, Spain; Diaz, C., Biomedical Informatics Research Group, Municipal Institue of Medical Research, IMIM, Barcelona, Spain; Sanz, F., Biomedical Informatics Research Group, Municipal Institue of Medical Research, IMIM, Barcelona, Spain","Medical Informatics (MI) and Bioinformatics (BI) are now facing, after various decades of ongoing research and activities, a crucial time, where both disciplines could merge, increase collaboration or follow separate roads. In this paper, we provide a vision of past experiences in both areas, pointing out significant achievements in both fields. Then, scientific and technological aspects are considered, following an ACM report on computing. Following this approach, both MI and BI are analyzed, from three perspectives: design, abstraction, and theories, showing differences between them. An overview of training experiences in Biomedical Informatics is also included, showing current trends. In this regard, we present the INFOBIOMED network of excellence, funded by the European Commission, as an example of a systematic effort to support a synergy between both disciplines, in the new area of Biomedical Informatics. © Springer-Verlag Berlin Heidelberg 2004.",,"Bioinformatics; Computation theory; Biomedical informatics; European Commission; Medical informatics; Technological aspects; Training experiences; Information science",,,,,,,,,"Ledley, R.S., Lusted, L., Reasoning Foundations of Medical Diagnosis (1959) Science, 130 (3366), pp. 9-21; (1984) Readings in Medical Artificial Intelligence: The First Decade, , Clancey, W. and E.H. Shortliffe (Eds). Reading: Addison Wesley; (1990) A History of Medical Informatics, , Blum, B. and K. Duncan. (Eds). Reading: Addison Wesley Pub; Maojo, V., Kulikowski, C.A., Bioinformatics and Medical Informatics: Collaborations on the Road to Genomic Medicine? (2003) J Am Med Inform Assoc., 10 (6), pp. 515-522. , Nov-Dec; Maojo, V., Crespo, J., Challenges for future intelligent systems in biomedicine (2002) Journal of Intelligent and Fuzzy Systems, 12 (1), pp. 1-3; Altman, R., The Interactions between Clinical Informatics and Bioinformatics (2000) JAMIA, 7 (5), pp. 439-443; Martín-Sanchez, F., Maojo, V., López-Campos, G., Integrating genomics into health information systems (2002) Methods of Information in Medicine, 41, pp. 25-30; Hagen, J., The origins of bioinformatics (2000) Nat. Rev. Genetics, 1, pp. 231-236; (2001) Medical Informatics. Computer Applications in Health Care, , Shortiffe, E.H., L. Perreault, L. Fagan, and G. Wiederhold (Eds). 2nd Edition. New York: Springer Verlag; Kassirer, J., Kopelman, R., (1991) Learning Clinical Reasoning, , Baltimore: Williams and Wilkins; Denning, P., Comer, D., Gries, D., Mulder, Tucker, A., Young, P., Computing as a discipline (1989) Communications of the ACM, 32 (1), pp. 9-23; Maojo, V., Martín-Sanchez, F., Crespo, J., Billhardt, H., Theory, Abstraction and Design in Medical Informatics (2002) Methods of Information in Medicine, 41, pp. 44-50; Kulikowski, C., Weiss, S., (1971) Computer-based Models of Glaucoma, , Report no. 3, Department of Computer Science, Computers in Biomedicine, Rutgers University; Blois, M., (1984) Information and Medicine: The Nature of Medical Descriptions, , Berkeley CA: Univ. of California Press; Musen, (2001) IMIA Satellite Working Conference. Challenges in Medical Informatics. Successes and Failures, , March 29-31. Madrid; Anderson, J., (1999) Cognitive Psychology and Its Implications (5th Ed), , Worth Publishing","Biomedical Informatics Group, Artificial Intelligence Lab., Polytechnical University of MadridSpain",,,,,,,,03029743,,,,"English","Lect. Notes Comput. Sci.",Article,"Final",,Scopus,2-s2.0-35048876255
"Sanz F., Díaz C., Martin-Sanchez F., Bonis J.","7102263897;57197180745;6603119155;56728136000;","European support to biomedical informatics development: In pursue of genomic medicine",2004,"Proceedings - Fourth IEEE Symposium on Bioinformatics and Bioengineering, BIBE 2004",,,,"215","221",,,"10.1109/BIBE.2004.1317345","https://www.scopus.com/inward/record.uri?eid=2-s2.0-4544262013&doi=10.1109%2fBIBE.2004.1317345&partnerID=40&md5=0fbccea16734404c1e6516a4dec470af","Biomed. Informatics Research Group, Munic. Inst. of Medical Research, IMIM, Barcelona, Spain; Bioinformatics Unit, Institute of Health Carlos III, Majadahonda, Madrid, Spain","Sanz, F., Biomed. Informatics Research Group, Munic. Inst. of Medical Research, IMIM, Barcelona, Spain; Díaz, C., Biomed. Informatics Research Group, Munic. Inst. of Medical Research, IMIM, Barcelona, Spain; Martin-Sanchez, F., Bioinformatics Unit, Institute of Health Carlos III, Majadahonda, Madrid, Spain; Bonis, J., Biomed. Informatics Research Group, Munic. Inst. of Medical Research, IMIM, Barcelona, Spain","Analyses of the relationships and synergy between Bioinformatics (BI) and Medical Informatics (MI) show that there is a great potential for synergy between both disciplines with a view on continuity and individualisation of healthcare, but that a collaborative effort is needed to bridge the current gap between them. Biomedical Informatics (BMI) is the emerging discipline that aims to put these two worlds together so that the discovery and creation of novel diagnostic and therapeutic methods is fostered. The INFOBIOMED network is a new approach that aims to set a durable structure for this collaborative strategy in Europe, mobilising the critical mass of resources necessary for enabling the consolidation of BMI as a crucial scientific discipline for future healthcare. The specific objectives of INFOBIOMED aim at enabling systematic progress in clinical and genetic data interoperability and integration and advancing the exchange and interfacing of methods, tools and technologies used in both MI and BI. Moreover, it intends to enable pilot applications in particular fields that demonstrate the benefits of a synergetic approach in BMI, as well as to create a robust framework for education, training and mobility of involved researchers in BMI for the creation of a solid European BMI research capacity.",,"Bioinformatics; Genomics; Medical informatics; Proteomics; Disease control; Genetic engineering; Health care; Information retrieval; Information technology; Interoperability; Knowledge based systems; Medical applications; Robustness (control systems); Biomedical engineering",,,,,,,,,"Liebman, M., Bioinformatics to biomedical informatics (2001) Genome Technology, 11, p. 64; Rindfleisch, T.C., Brutlag, D.L., Directions for clinical research and genomic research into the next decade: Implications for informatics (1998) J Am Med Inform Assoc, 5, pp. 404-411; Maojo, V., Iakovidis, I., Martin-Sanchez, F., Crespo, J., Kulikowski, C., Medical informatics and bioinformatics: European efforts to facilitate synergy (2001) J Biomed Inform, 34, pp. 423-427; Martin-Sanchez, F., Maojo, V., Lopez-Campos, G., Integrating genomics into health information systems (2002) Method Inform Med, 41, pp. 25-30; Kohane, I.S., Bioinformatics and clinical informatics: The imperative to collaborate (2000) J Am Med Inform Assoc, 7, pp. 512-516; Altman, R.B., The interactions between clinical informatics and bioinformatics: A case study (2000) J Am Med Inform Assoc, 7, pp. 439-443; Guttmacher, E., Collins, S.F., Genomic medicine, a primer (2002) N Engl J Med, 347, pp. 1512-1520; Synergy between medical informatics and bioinformatics: Facilitating genomic medicine for future healthcare (2003) BIOINFOMED White Paper, , BIOINFOMED Study EC-IST 2001-35024: Prospective Analysis of the Relationships and Synergy Between Medical Informatics and Bioinformatics. European Commission - Directorate General: Information Society, Brussels; Ford II, J.H., Turner, A., Yoshii, A., Information requirements of genomics researchers from the patient clinical record (2002) J Healthc Inf Manag, 16, pp. 56-61; Ibarrola, N., Maojo, V., Lopez-Campos, G., Martin-Sanchez, F., Integration of genetic information in the computerized clinical record (1999) EUROREC 99, III European Congress on Computerized Clinical Records; Cheah, Y.N., Abidi, S.S., Healthcare knowledge acquisition: An ontology-based approach using the extensible markup language (XML) (2000) Stud Health Technol Inform, 77, pp. 827-831; Sujansky, W., Heterogeneous database integration in biomedicine (2001) J Biomed Inform, 34, pp. 285-298; Katehakis, D.G., Sfakianakis, S., Tsiknakis, M., Orphanoudakis, S.C., An infrastructure for integrated electronic health record services: The role of XML (extensible markup language) (2001) J Med Internet Res, 3, pp. E7; Foster, I., Kesselman, C., (1999) The Grid, Blueprint for A New Computing Infrastructure, , San Francisco: Morgan Kaufman; Foster, I., Kesselman, C., Tuecke, S., The anatomy of the Grid: Enabling scalable virtual organizations (2001) Int J High Perform Comp Appl, 15, pp. 200-222; Wylie, J.E., Mineau, G.P., Biomedical databases: Protecting privacy and promoting research (2003) Trends Biotech, 21, pp. 113-116; De Moor, G.J.E., Iakovidis, I., Norager, S., Martin-Sanchez, F., Special issue on synergy Between research in medical informatics, bio informatics and neuro informatics (2003) Methods Inf Med, 42, pp. 111-189; Baud, R., Ruch, P., The future of natural language processing for biomedical applications (2002) Int J Med Inf, 67, pp. 1-5; Argen, J., The evolving role of information technology in the drug discovery process (2002) Drug Discov Today, 7, pp. 315-323; Pastor, M., Benedetti, P., Carotti, A., Carrieri, A., Diaz, C., Herráiz, C., Höltje, H.D., Stoll, F., Distant collaboration in drug discovery: The LINK3D project (2002) J Comput Aid Mol Des, 16, pp. 809-818. , LINK3D Consortium","Sanz, F.; Biomed. Informatics Research Group, Munic. Inst. of Medical Research, IMIM, Barcelona, Spain; email: fsanz@imim.es",,"IEEE Computer Society;IEEE Neural Networks Society;Taichung Healthcare and Management University, Taiwan;Ministry of Education, Taiwan;National Sciences Council, Taiwan;Institute for Information Industry, Taiwan",,"Proceedings - Fourth IEEE Symposium on Bioinformatics and Bioengineering, BIBE 2004","19 May 2004 through 21 May 2004","Taichung",63491,,0769521738; 9780769521732,,,"English","Proc. Fourth IEEE Symp. Bioinformatics Bioeng. BIBE",Conference Paper,"Final",,Scopus,2-s2.0-4544262013
"Barbany M., Gutiérrez-De-Terán H., Sanz F., Villà-Freixa J.","57193913809;6507897412;7102263897;7005142038;","Towards a MIP-based alignment and docking in computer-aided drug design",2004,"Proteins: Structure, Function and Genetics","56","3",,"585","594",,8,"10.1002/prot.20153","https://www.scopus.com/inward/record.uri?eid=2-s2.0-3142759982&doi=10.1002%2fprot.20153&partnerID=40&md5=a4308b9b9df2b55ed8e4db740c48dbab","Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Barcelona, Spain; Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim de Barceloneta 37-49, E-08003 Barcelona, Spain","Barbany, M., Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Barcelona, Spain; Gutiérrez-De-Terán, H., Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Barcelona, Spain; Sanz, F., Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Barcelona, Spain, Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim de Barceloneta 37-49, E-08003 Barcelona, Spain; Villà-Freixa, J., Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Barcelona, Spain, Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim de Barceloneta 37-49, E-08003 Barcelona, Spain","Structural alignment of ligands in their biological conformation is a crucial step in the building of pharmacophoric models in structure-based drug design. In addition, docking algorithms are limited in some cases by the quality of the scoring functions and the limited flexibility of the environment that the different programs allow. On the other hand, GRID molecular interaction potentials (MIPs) have been used for a long time in 3D-QSAR studies. However, in most of these studies the alignment of the molecules is performed on the basis of geometrical or physico-chemical criteria that differ from the MIPs used in the partial least squares statistical analysis. We have previously developed a method to use the same scoring function for the molecular alignment and for 3D-QSAR studies. This methodology, based on the use of GRID potentials, consists in the weighted averaging of similarities of the relevant MIPs of the molecules to be aligned. Here we present a method to obtain the weights for the different GRID probes in the average based on the structural information on protein-ligand complexes for relevant systems. The method, implemented in MIPSIM, is shown to yield good accuracy in the prediction of the alignments for two systems: a set of three inhibitors of dihydrofolate reductase and a set of fifteen non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs). The smooth GRID potentials are shown to capture the flexible character of the active site, as opposed to traditional docking scoring energy functions. © 2004 Wiley-Liss, Inc.",,"capravirine; carboxanilide; dihydrofolate reductase; efavirenz; methotrexate; RNA directed DNA polymerase inhibitor; tnk 6123; tnk 651; unclassified drug; article; computer aided design; conformation; drug design; energy; enzyme active site; geometry; molecular interaction; pharmacophore; physical chemistry; priority journal; quantitative structure activity relation; regression analysis; Binding Sites; Computer-Aided Design; Drug Design; Folic Acid Antagonists; HIV-1 Reverse Transcriptase; Ligands; Models, Chemical; Models, Molecular; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Software; Tetrahydrofolate Dehydrogenase; Thermodynamics; Human immunodeficiency virus 1",,"capravirine, 178979-85-6; dihydrofolate reductase, 9002-03-3; efavirenz, 154598-52-4; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; Folic Acid Antagonists; HIV-1 Reverse Transcriptase, EC 2.7.7.-; Ligands; Reverse Transcriptase Inhibitors; Tetrahydrofolate Dehydrogenase, EC 1.5.1.3",,,,,,,"Liljefors, T., Pettersson, I., Computer-aided development of three dimensional pharmacofore models (1996) A Textbook of Drug Design and Development, , Harwood Academic Publishers. Krogsgaard-Larsen P, Madsen U, eds; Perez, C., Ortiz, A., Evaluation of docking functions for protein-ligand docking (2001) J Med Chem, 44, pp. 3768-3785; Kubinyi, H., (1993) 3D QSAR in Drug Design: Theory, Methods and Applications, , Lenden: ESCOM; Murray, J., Brinck, T., Grice, M., Politzer, P., Correlations between molecular electrostatic potentials and some experimentally-based indices of reactivity (1992) J Mol Struct (Theochem), 256, pp. 29-45; Goodford, P., A computational procedure for determining energetically favourable binding sites on biologically important macromolecules (1985) J Med Chem, 28, pp. 849-857; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent Descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors (2000) J Med Chem, 43, pp. 3233-3243; Rodrigo, J., Barbany, M., Gutiérrez-De Terán, H., Centeno, N.B., De Càceres, M., Dezi, C., Fontaine, F., Sanz, F., Comparison of biomolecules on the basis of molecular interaction potentials (2002) J Braz Chem Soc, 13, pp. 795-799; Barbany, M., Gutiérrez-De Terán, H., Sanz, F., Villà-Freixa, J., Warshel, A., Pharmacophore approach for hapten design in catalytic antibodies generation (2003) ChemBioChem, 4, pp. 277-285; Berman, H., The Protein Data Bank (2002) Acta Crystallogr D Biol Crystallogr, 58, pp. 899-907; De Cáceres, M., Villà, J., Lozano, J.J., Sanz, F., MIPSIM: Similarity analysis of molecular interaction potentials (2000) Bioinformatics, 16, pp. 568-569; Bagdassarian, C.K., Schramm, V.L., Schwartz, S.D., Molecular electrostatic potential analysis for enzymatic substrates, competitive inhibitors, and transition-state inhibitors (1996) J Am Chem Soc, 118, pp. 8825-8836; Sanz, F., Manaut, F., Rodríguez, J., Lozoya, E., López De Briñas, E., MEPSIM: A computational package for analysis and comparison of molecular electrostatic potentials (1993) J Comput Aid Mol Des, 7, pp. 337-347; (2003) GRID v. 21. Molecular Discovery, , London; Russell, R.B., Barton, G.J., Multiple protein sequence alignment from tertiary structure comparison (1992) Proteins, 14, pp. 309-323; Zhou, J., Tits, A., Lawrence, C., (1997) FFSQP Program, Version 3.7, , Maryland: AEM Design, University of Maryland; Morris, G., Goodsell, D., Halliday, R., Huey, R., Hart, W., Belew, R., Olson, A., Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function (1998) J Comput Chem, 19, pp. 1639 FS-1662 FS; Huennekens, F., (1994) Adv Enzyme Regul, 34, pp. 397-419; Roth, B., Stammers, D., (1992) The Design of Drugs to Macromolecular Targets, , New York: John Wiley & Sons, Inc; Manaut, F., Lozoya, E., Sanz, F., Automatic determination of maximum electrostatic alignment between methotrexate and dihydrofolic acid (1991) QSAR: Rational Approaches to the Design of Bioactive Compounds, , Silipo C, Vittoria A, editors. Amsterdam: Elsevier Science; Lemmen, C., Lengauer, T., Klebe, G., Flexs: A method for fast flexible ligand superposition (1998) J Med Chem, 41, pp. 4502-4520; De Clercq, E., The role of non-nucleoside reverse transcriptase inhibitors (NNRTI) in the therapy of HIV-1 infection (1998) Antivir Res, 38, pp. 153-179; Kohlstaedt, L., Wang, J., Friedman, J., Rice, P., Steitz, T., Crystal structure at 3.5A resolution of HIV-1 reverse transcriptase complexed with an inhibitor (1992) Science, 256, pp. 1783-1790; Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Stammers, D., High resolution structures of HIV-1 RT from four RT-inhibitor complexes (1995) Nat Struct Biol, 2, pp. 293-302; Esnouf, R., Ren, J.S., Ross, C., Jones, Y., Stammers, D., Stuart, D., Mechanism of inhibition of HIV-1 reverse-transcriptase by nonnucleoside inhibitors (1995) Nat Struct Biol, 2, pp. 303-308; Hopkins, A.L., Ren, J.S., Esnouf, R.M., Wilcox, B.E., Jones, E.Y., Ross, C., Miyasaka, T., Tanaka, H., Complexes of HIV-1 reverse-transcriptase with inhibitors of the hept series reveal conformational-changes relevant to the design of potent nonnucleoside inhibitors (1996) J Med Chem, 39, pp. 1589-1600; Ren, J.S., Esnouf, R., Hopkins, A., Ross, C., Jones, Y., The structure of HIV-1 reverse-transcriptase complexed with 9-chloro-tibo-lessons for inhibitor design (1995) Structure, 3, pp. 915-926; Chimirri, A., Grasso, S., Molica, C., Monforte, A., Monforte, P., Zapplà, M., Bruno, G., De Clercq, E., (1997) Antiviral Chem Chemother, 8, p. 363; Matthews, B., Comparison of the predicted and observed secondary structure of t4 phage lysozyme (1975) Biochim Biophys Acta, 405, pp. 442-451; Åqvist, J., Medina, C., Samuelsson, J.E., A new method for predicting binding affinity in computer-aided drug design (1994) Prot Eng, 7, pp. 385-391; Sham, Y., Chu, Z.T., Tao, H., Warshel, A., Examining methods for calculations of binding free energies: LRA, LIE, PDLD-LRA and PDLD/S-LRA calculations of ligands binding to an HIV protease (2000) Proteins, 39, pp. 393-407; Dunn, W.J., Wold, S., Edlund, U., Hellberg, S., Gasteiger, J., Multivariate structure-activity relationship between data from a battery of biological tests and an ensemble of chemical descriptors: The pls methodol (1973) Quant Struct Act Relat, 3, pp. 131-137; Cocco, L., Roth, B., Temple Jr., C., Montgomery, J., London, R., Blakley, R., (1983) Protonated State of Methotrexate, Trimethoprim, and Pyrimethamine Bound to Dihydrofolate Reductase, 226 (2), pp. 567-577; Cody, V., Galitsky, N., Luft, J., Pangborn, W., Blakley, R., Gangjee, A., Comparison of ternary crystal complexes of f31 variants of human dihydrofolate reductase with nadph and a classical antitumor furopyrimidine (1998) Anticancer Drug Des, 13 (4), pp. 307-315; Davies, J.F., Delcamp, T., Prendergast, N., Ashford, V., Freisheim, J., Kraut, J., Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate (1990) Biochemistry, 29 (40), pp. 9467-9479; Chan, J., 2-Amino-6-arylsulfonylbenzonitriles as nonnucleoside reverse transcriptase inhibitors of HIV-1 (2001) J Med Chem, 44, pp. 1866-1882; Ren, J., Diprose, J., Warren, J., Esnouf, R., Bird, L., Ikemizu, S., Slater, M., Stammers, D., High resolution structures of HIV-1 RT from four RT-inhibitor complexes (2000) J Biol Chem, 275, pp. 5633-5639; Hopkins, A.L., Ren, J., Tanaka, H., Baba, M., Okamato, M., Stuart, D., Stammers, D., Design of MKC-442 (Emivirine) analogues with improved activity against drug-resistant HIV mutants (1999) J Med Chem, 42, pp. 4500-4505; Baba, M., Shigeta, S., Yuasa, S., Takashima, H., Sehila, K., Ubasaka, M., Tanaka, H., De Clercq, E., Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro (1994) Antimicrob Agents Chemother, 38, pp. 688-692; Mertens, A., Zilch, H., Zonig, B., Schafer, W., Poll, T., Kampe, W., Seidel, H., Leinert, H., Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV activity (1993) J Med Chem, 36, pp. 2526-2535; Young, S., Emini, E., L-743, 726 (DMP-266): A novel, highly potent non-nucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase (1995) Antimicrob Agents Chemother, 39, pp. 2609-2605; Fujiwara, T., Sato, A., El-Farrash, M., Miki, S., Abe, K., Isaka, Y., Kodama, M., Hinuma, Y., S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1 (1998) Antimicrob Agents Chemother, 42, pp. 1340-1345","Sanz, F.; Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim de Barceloneta 37-49, E-08003 Barcelona, Spain; email: fsanz@imim.es",,,,,,,,08873585,,PSFGE,"15229890","English","Proteins Struct. Funct. Genet.",Article,"Final",,Scopus,2-s2.0-3142759982
"Gutiérrez-De-Terán H., Pastor M., Centeno N.B., Åqvist J., Sanz F.","6507897412;7102415847;6701440183;7005059911;7102263897;","Comparative analysis of putative agonist-binding modes in the human A 1 adenosine receptor",2004,"ChemBioChem","5","6",,"841","849",,15,"10.1002/cbic.200300817","https://www.scopus.com/inward/record.uri?eid=2-s2.0-4544278494&doi=10.1002%2fcbic.200300817&partnerID=40&md5=4090124008c2e45d8e610c170c11be44","Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, 08003 Barcelona, Spain; Dept. of Cell and Molecular Biology, Uppsala University, BMC, 751 24 Uppsala, Sweden","Gutiérrez-De-Terán, H., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, 08003 Barcelona, Spain; Pastor, M., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, 08003 Barcelona, Spain; Centeno, N.B., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, 08003 Barcelona, Spain; Åqvist, J., Dept. of Cell and Molecular Biology, Uppsala University, BMC, 751 24 Uppsala, Sweden; Sanz, F., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, 08003 Barcelona, Spain","A recent study reported a model of the human A1 adenosine receptor and its agonist binding site, proposing two putative binding modes in the same binding site for the natural agonist, adenosine. The present work investigates the flexibility of this binding site by exhaustive exploration with the natural agonist and with three other adenosine derivatives: N6-cyclopentyladenosine (CPA), 2-chloro-N6-cydopentyladenosine (CCPA), and 5′-N-ethylcarboxamidoadenosine (NECA). Our aim was to find a common binding mode for agonists that would explain the role in the binding process of the different substitutions allowed at the 2, N6, and 5′ positions of adenosine. This problem was addressed through docking simulations, molecular dynamics studies, and estimations of the ligand-binding free energy with both the AUTODOCK scoring function and the linear interaction energy (LIE) approach. The results point to a single receptor-binding position that explains the effects of the different chemical modifications on the adenosine derivatives considered here.","Adenosine receptors; Binding free energy; Density functional calculations; Docking exploration; Homology modeling; Molecular dynamics","2 chloro 6 n cyclopentyladenosine; 6 n cyclopentyladenosine; adenosine; adenosine 5' (n ethylcarboxamide); adenosine A1 receptor; adenosine A1 receptor agonist; article; binding site; chemical modification; comparative study; energy; ligand binding; molecular dynamics; molecular interaction; molecular model; priority journal; scoring system; simulation; Adenosine; Adenosine-5'-(N-ethylcarboxamide); Binding Sites; Humans; Mathematics; Models, Molecular; Receptor, Adenosine A1; Thermodynamics",,"2 chloro 6 n cyclopentyladenosine, 37739-05-2; 6 n cyclopentyladenosine, 41552-82-3; adenosine 5' (n ethylcarboxamide), 35920-39-9; adenosine, 58-61-7; 2-chloro-N(6)cyclopentyladenosine, 37739-05-2; Adenosine, 58-61-7; Adenosine-5'-(N-ethylcarboxamide), 35920-39-9; N(6)-cyclopentyladenosine, 41552-82-3; Receptor, Adenosine A1",,,,,,,"Müller, C.E., (2001) Farmaco, 56, pp. 77-80; Müller, C., Stein, B., (1996) Curr. Pharm. Design., 2, pp. 501-530; Poulsen, S.A., Quinn, R.J., (1998) Bioorg. Med. Chem., 6, pp. 619-641; Haas, H.L., Selbach, O., (2000) Naunyn Schmiedebergs. Arch. Pharmacol., 362, pp. 375-381; Downey, J.M., Liu, G.S., Thornton, J.D., (1993) Cardiovasc. Res., 27, pp. 3-8; Müller, C.E., (2000) Curr. Med. Chem., 7, pp. 1269-1288; Vittori, S., Lorenzen, A., Stannek, C., Costanzi, S., Volpini, R., Ap, I.J., Kunzel, J.K., Cristalli, G., (2000) J. Med. Chem., 43, pp. 250-260; Van Der Wenden, E.M., Von Frijtag Drabbe Kunzel, J.K., Mathot, R.A.A., Danhof, M., Uzerman, A.P., Soudijn, W., (1995) J. Med. Chem., 38, pp. 4000-4006; Lohse, M.J., Klotz, K.N., Diekmann, E., Friedrich, K., Schwabe, U., (1988) Eur. J. Pharmacol., 156, pp. 157-160; Daly, J.W., Padgett, W.L., (1992) Biochem. Pharmacol., 43, pp. 1089-1093; Lohse, M.J., Klotz, K.N., Schwabe, U., Cristalli, G., Vittori, S., Grifantini, M., (1988) Naunyn Schmiedebergs Arch. Pharmacol., 337, pp. 687-689; Klotz, K.N., Messung, J., Hegler, J., Owman, C., Kull, B., Fredholm, B.B., Lohse, M.J., (1998) Naunyn Schmiedebergs Arch. Pharmacol., 357, pp. 1-9; Klotz, K.N., (2000) Naunyn Schmiedebergs Arch. Pharmacol., 562, pp. 382-391; Gutiérrez-De-Terán, H., Centeno, N.B., Pastor, M., Sanz, F., (2004) Proteins, 54, pp. 705-715; Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., LeTrong, I., Miyano, M., (2000) Science, 289, pp. 739-745; Goodford, P.J., (1985) J. Med. Chem., 28, pp. 849-857; Kristiansen, K., Kroeze, W.K., Willins, D.L., Gelber, E.I., Savage, J.E., Glennon, R.A., Roth, B.L., (2000) J. Pharmacol. Exp. Ther., 293, pp. 735-746; Rivkees, S.A., Barbhaiya, H., Ijzerman, A.P., (1999) J. Biol. Chem., 274, pp. 3617-3621; Klotz, K., Lohse, M., Schwabe, U., (1988) J. Biol. Chem., 263, pp. 17522-17526; Olah, M.E., Ren, H., Ostrowski, J., Jacobson, K.A., Stiles, G.L., (1992) J. Biol. Chem., 267, pp. 10764-10770; Ballesteros, J.A., Weinstein, H., (1994) Methods in Neurosciences, pp. 366-428. , (Eds.: P. M. Conn, S. C. Sealfon), Academic Press, San Diego; Allen, F.H., Kennard, O., (1993) Chem. Des. Autom. News., 8, pp. 31-37; (2000) Insight II, , Molecular Simulations Inc., San Diego; Stewart, J.J., (1990) J. Comput Aided. Mol. Des., 4, pp. 1-105; Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Zakrzewski, V.G., Pople, J.A., (1998) Gaussian 98 (Revision A.7), , Gaussian, Inc., Pittsburgh, PA; Bayly, C.I., Cieplak, P., Cornell, W.D., Kollman, P.A., (1993) J. Phys. Chem., 97, pp. 10 269-10 280; Cornell, W.D., Cieplak, P., Bayly, C.I., Gould, I.R., Merz, K.M., Ferguson, D.M., Spellmeyer, D.C., Kollman, P.A., (1995) J. Am. Chem. Soc., 117, pp. 5179-5197; Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., Olson, A.J., (1998) J. Comp. Chem., 19, pp. 1639-1662; Åqvist, J., Medina, C., Samuelsson, J.E., (1994) Protein. Eng., 7, pp. 385-391; Hansson, T., Marelius, J., Åqvist, J., (1998) J. Comput. Aided. Mol. Des., 12, pp. 27-35; Lee, F.S., Chu, Z.T., Bolger, M.B., Warshel, A., (1992) Prot. Eng., 5, pp. 215-228; Åqvist, J., Hansson, T., (1996) J. Phys. Chem., 100, pp. 9512-9521; Åqvist, J., Marelius, J., (2001) Comb. Chem. High Throughput. Screen., 4, pp. 613-626; Marelius, J., Kolmodin, K., Feierberg, I., Åqvist, J., (1999) J. Mol. Graph. Modelling, 16, pp. 213-225; Jorgensen, W., Chrandrasekhar, J., Madura, J.D., Impey, R.W., Klein, M.L., (1983) J. Chem. Phys., 79, pp. 926-935; Essex, J., Jorgensen, W., (1995) J. Comp. Chem., 16, pp. 951-972; King, G., Warshel, A., (1989) J. Chem. Phys., 91, pp. 3647-3661; Allende, G., Casado, V., Mallol, J., Franco, R., Lluis, C., Canela, E.I., (1993) J. Neurochem., 60, pp. 1525-1533; Lee, F.S., Warshel, A., (1992) J. Chem. Phys., 97, pp. 3100-3107; Humphrey, W., Dalke, A., Schulten, K., (1996) J. Mol. Graph. Model., 14, pp. 33-38; Van Der Wenden, E., Price, S.L., Apaya, R.P., Uzerman, A.P., Soudijn, W., (1995) J. Comp. Aid. Mol. Des., 9, pp. 44-54; Rashid, M., Manivet, P., Nishio, H., Pratuangdejkul, J., Rajab, M., Ishiguro, M., Launay, J.M., Nagatomo, T., (2003) Life Sci., 73, pp. 193-207; Mahmoudian, M., (1997) J. Mol. Graph. Model., 15, pp. 149-153; Gieldon, A., Kazmierkiewicz, R., Slusarz, R., Ciarkowski, J., (2001) J. Comput. Aided. Mol. Des., 15, pp. 1085-1104; Almlöf, M., Brandsdal, B.O., Åqvist, J., (2004) J. Comput. Chem., 25. , in press; Franchetti, P., Cappellacci, L., Marchetti, S., Trincavelli, L., Martini, C., Mazzoni, M.R., Lucacchini, A., Grifantini, M., (1998) J. Med. Chem., 41, pp. 1708-1715; De Zwart, M., Kourounakis, A., Kooijman, H., Spek, A.L., Link, R., Von Frijtag Drabbe Kunzel, J.K., Uzerman, A.P., (1999) J. Med. Chem., 42, pp. 1384-1392; Jiang, Q., Lee, B.X., Glashofer, M., Van Rhee, A.M., Jacobson, K.A., (1997) J. Med. Chem., 40, pp. 2588-2595; Gao, Z.-G., Chen, A., Barak, D., Kim, S.-K., Muller, C.E., Jacobson, K.A., (2002) J. Biol. Chem., 277, pp. 19056-19063; Javitch, J.A., Ballesteros, J.A., Weinstein, H., Chen, J., (1998) Biochemistry, 37, pp. 998-1006; Marie, J., Richard, E., Pruneau, D., Paquet, J.L., Siatka, C., Larguier, R., Ponce, C., Bonnafous, J.C., (2001) J. Biol. Chem., 276, pp. 41 100-41 111; Linden, J., Thai, T., Figler, H., Jin, X., Robeva, A.S., (1999) Mol. Pharmacol., 56, pp. 705-713; Tucker, A.L., Robeva, A.S., Taylor, H.E., Holeton, D., Bockner, M., Lynch, K.R., Linden, J., (1994) J. Biol. Chem., 269, pp. 27 900-27 906; Almlöf, M., (2003), July, personal communication; Luzhkov, V.B., Åqvist, J., (2001) FEBS Lett., 495, pp. 191-196; Sham, Y., Chu, Z.T., Tao, H., Warshel, A., (2000) Proteins, 39, pp. 393-407; Kim, S.-K., Gao, Z.-G., Rompaey, P.V., Gross, A.S., Chen, A., Calenbergh, S.V., Jacobson, K.A., (2003) J. Med. Chem., 46, pp. 4847-4859; Colquhoun, D., (1998) Br. J. Pharmacol., 125, pp. 924-947","Sanz, F.; Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, 08003 Barcelona, Spain; email: fsanz@imim.es",,,,,,,,14394227,,CBCHF,"15174168","English","ChemBioChem",Article,"Final",,Scopus,2-s2.0-4544278494
"Cordero L., Cadavid M.I., Fernández-Llimós F., Díaz C., Sanz F., Loza M.I.","7006028467;6603422293;56366491700;57197180745;7102263897;7003766926;","Continuing education and community pharmacists in Galicia: A study of opinions",2004,"Pharmacy World and Science","26","3",,"173","177",,11,"10.1023/B:PHAR.0000026807.59766.ae","https://www.scopus.com/inward/record.uri?eid=2-s2.0-3543046131&doi=10.1023%2fB%3aPHAR.0000026807.59766.ae&partnerID=40&md5=beb4fe2700ca4e85d47f9f2a9dbf2f62","Department of Pharmacology, School of Pharmacy, University of Santiago de Compostela, Spain; Munic. Institute of Medical Research, Pompeu Fabra University, Barcelona, Spain","Cordero, L., Department of Pharmacology, School of Pharmacy, University of Santiago de Compostela, Spain; Cadavid, M.I., Department of Pharmacology, School of Pharmacy, University of Santiago de Compostela, Spain; Fernández-Llimós, F., Munic. Institute of Medical Research, Pompeu Fabra University, Barcelona, Spain; Díaz, C., Munic. Institute of Medical Research, Pompeu Fabra University, Barcelona, Spain; Sanz, F., Munic. Institute of Medical Research, Pompeu Fabra University, Barcelona, Spain; Loza, M.I., Department of Pharmacology, School of Pharmacy, University of Santiago de Compostela, Spain","Aim of the study: To determine the opinions of a volunteer group of community pharmacists concerning general and specific issues related to continuing education. Methods: Participants were required to complete questionnaires before and after attendance at a refresher course, and score the relevant options provided on a scale from 0 to 10. The responses of the survey were analyzed to identify preferences and to detect any possible changes in opinion. Main outcome measure: Arithmetic means of pharmacists' opinions. Results: The teaching methods preferred by the community pharmacists were workshops for resolution of practical cases (9 ± 0.25 and 8.88 ± 0.13) and the distance-learning computer programmes (6.74 ± 0.25 and 8.18 ± 0.20). In selecting which topics that should be taught, the participants gave the highest ratings to healthcare needs (8.75 ± 0.14 and 8.57 ± 0.15) and the demands of the pharmacists (8.15 ± 0.16 and 8.40 ± 0.16), with pharmaceutical care being the most requested topic (29 points). Participants preferred courses lasting 20 to 50 hours (6.94 ± 0.26 and 7.89 ± 0.16), without preference for schedule. Conclusion: Community pharmacists in Galicia show a great interest in the provision and organization of continuing education activities that meet their needs and expectations. © 2004 Kluwer Academic Publishers.","Community pharmacy; Continuing pharmacy education; Educational models; Educational technology; Spain; Survey","adult; arithmetic; article; community; computer program; continuing education; controlled study; female; health care need; human; learning; male; pharmacist; questionnaire; teaching; Adult; Attitude of Health Personnel; Common Cold; Curriculum; Data Collection; Education, Distance; Education, Pharmacy, Continuing; Female; Humans; Influenza, Human; Male; Pharmacies; Pharmacists; Questionnaires; Spain; Teaching",,,,,"European Commission: HC 4022, HC 1114","The authors are grateful for the generous collaboration of the official Colleges of Pharmacists of Galicia and to the community pharmacists who participated in the educational survey. This work was partly funded by European Union projects TESEMED (HC 1114) and TESE-MED-II (HC 4022).",,,"Pharmaceutical Education. A commentary from the American College of Clinical Pharmacy (1992) Pharmacotherapy, 12, pp. 419-427; The role of the pharmacists in self-care and in self-medication (1998) Report of a 4th WHO Consultative Group on the Role of the Pharmacists, , The Hague, The Netherlands, 26-28 August 1998. Geneva: World Health Organization; Code of ethics for pharmacists (1996) Am J Health Syst Pharm, 53, p. 1805; (1997) FIP Statement of Professional Standards. Code of Ethics for Pharmacists. FIP Council Meeting, , Vancouver, September 1997. The Hague, The Netherlands: International Pharmaceutical Federation; Hanson, A.L., DeMuth, J.E., Facilitators and barriers to pharmacists' participation in lifelong learning (1991) Am J Pharm Educ, 55, pp. 20-29; Richards, W., Blank, J.W., Need analysis of practicing pharmacist in drug utilization review and patient counselling (1997) Am J Pharm Educ, 61, pp. 26-33; Scott, V.G., Amonkar, M.M., Madhavan, S.S., Pharmacists' preferences for continuing education and certificate programs (2001) Ann Pharmacother, 35, pp. 289-299; Hoyle, M., Mottram, D.R., Williamson, P.M., Hart, A., A study into how community pharmacists update their pharmaceutical knowledge (1990) Pharm J, 245, pp. E8-9; Pitts, J., Vincent, S., General practitioners' reasons for not attending a higher professional course (1994) Br J Gen Pract, 44, pp. 271-273; Keene, J.M., Cervetto, S., Health promotion in community pharmacy: A qualitative study (1995) Health Educ J, 54, pp. 285-293; Savela, E., Enlund, H., Kostiainen, E., In-house training as part of an activity campaign in Finnish pharmacies (1997) J Cont Educ Health Professions, 17, pp. 56-61; Cordero, L., (2001) Validation and Evaluation of Continuing Education Models for Community Pharmacists, , [Thesis]. University of Santiago de Compostela, Spain; Loza, M.I., Cordero, L., Fernández-Llimós, F., Cadavid, M.I., Calleja, J.M., Sanz, F., El proyecto TESEMED: Aprender en las farmacias comunitarias utilizando la telemática (2000) Pharm Care Esp, 2, pp. 440-443; (1999) SPSS [Informatic/COMPUTER Program]. Version 10.0 for Windows, , Chicago, Illinois: SPSS Inc; Mehra, I.V., Muller, C.A., Evaluation of a pilot clinical skills workshop series for community pharmacists (1998) Am J Pharm Educ, 62, pp. 136-141; Sinclair, H., Bond, C., Lennox, A.C., Silcock, J., Winfield, A., An evaluation of a training workshop for pharmacists based on the stages of change model of smoking cessation (1997) Health Educ J, 56, pp. 296-312; Vainio, K.K., Korhonen, M.J.H., Hirvonen, A.M., Enlund, K.H., The perceived role and skills of pharmacists in asthma management after in-house training (2001) Pharm World Sc, 23, pp. 6-12; Loza, M.I., Cordero, L., Fernández-Llimós, F., Corral, P., Cadavid, M.I., Sanz, F., Drug information sources used by community pharmacists in Galicia (2000) Pharm Care Esp, 2, pp. 108-122; Janke, K.K., Anderson, T.L., Continuing education needs assessment of Minnesota pharmacists (2000) American Association of Colleges of Pharmacy - Annual Meeting, 101, p. 9; Hepler, C.D., Strand, L.M., Opportunities and responsibilities in the pharmaceutical care (1990) Am J Hosp Pharm, 47, pp. 533-543; Hanson, A.L., Pharmacists' attitudes toward continuing education: Implications for planning curricular CE programs (1989) J Cont Educ Health Professions, 9, pp. 95-113","Department of Pharmacology, School of Pharmacy, University of Santiago de CompostelaSpain; email: ffmabel@usc.es",,,,,,,,09281231,,PWSCE,"15230366","English","Pharm. World Sci.",Article,"Final",,Scopus,2-s2.0-3543046131
"Fontaine F., Pastor M., Sanz F.","24755291000;7102415847;7102263897;","Incorporating molecular shape into the alignment-free GRid-INdependent descriptors",2004,"Journal of Medicinal Chemistry","47","11",,"2805","2815",,65,"10.1021/jm0311240","https://www.scopus.com/inward/record.uri?eid=2-s2.0-2442659094&doi=10.1021%2fjm0311240&partnerID=40&md5=80501072e9dc79f6910bdf57eefef660","Res. U. on Biomed. Info. (GRIB), IMIM, Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain","Fontaine, F., Res. U. on Biomed. Info. (GRIB), IMIM, Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; Pastor, M., Res. U. on Biomed. Info. (GRIB), IMIM, Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; Sanz, F., Res. U. on Biomed. Info. (GRIB), IMIM, Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain","The recently introduced GRid-INdependent Descriptors (GRIND) were designed to provide a suitable description of a series of ligands for 3D-QSAR studies not requiring the spatial superimposition of their structures. Despite the proven usefulness of the method, it was recognized that the original GRIND failed to describe appropriately the shape of the ligand molecules, which in some cases plays a major role in ligand-receptor binding. For this reason, the original descriptors have been enhanced with the addition of a molecular shape description based on the local curvature of the molecular surface. The integration of this description into the GRIND allows the generation of 3D-QSAR models able to identify both favorable and unfavorable shape complementarity in a simple and alignment-independent way. The usefulness of the new GRIND-shape description in 3D-QSAR is illustrated using two structure-activity studies: one performed on a set of xanthine-like antagonists of the A1 adenosine receptor; another performed on a series of Plasmodium falciparum plasmepsin II inhibitors.",,"adenosine A1 receptor antagonist; ligand; plasmepsin II; xanthine; analytic method; article; chemical structure; molecule; nonhuman; Plasmodium falciparum; quantitative structure activity relation; Animals; Aspartic Endopeptidases; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Plasmodium falciparum; Quantitative Structure-Activity Relationship; Receptor, Adenosine A1; Xanthines",,"plasmepsin II, 159447-18-4; xanthine, 69-89-6; Aspartic Endopeptidases, EC 3.4.23.-; Ligands; plasmepsin II, EC 3.4.23.39; Receptor, Adenosine A1; Xanthines",,,,,,,"Hansch, C., A quantitative approach to biochemical structure-activity relationships (1969) Acc. Chem. Res., 2, pp. 232-239; Cramer, R.D., Patterson, D.E., Bunce, J.D., Comparative Molecular Field Analysis (CoMFA): 1. Effect of shape on binding of steroids to carrier proteins (1988) J. Am. Chem. Soc., 110, pp. 5959-5967; Klebe, G., Abraham, U., Mietzner, T., Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity (1994) J. Med. Chem., 37, pp. 4130-4146; Cruciani, G., Watson, K.A., Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b (1994) J. Med. Chem., 37, pp. 2589-2601; Cramer, R.D., Topomer CoMFA: A design methodology for rapid lead optimization (2003) J. Med. Chem., 46, pp. 374-388; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors (2000) J. Med. Chem., 43, pp. 3233-3243; Goodford, P.J., A computational procedure for determining energetically favorable binding sites on biologically important macromolecules (1985) J. Med. Chem., 28, pp. 849-857; Carey, R.N., Wold, S., Westgard, J.O., Principal component analysis: An alternative to ""referee"" methods in method comparison studies (1975) Anal. Chem., 47, pp. 1824-1829; Hoskuldsson, A., PLS regression methods (1988) J Chemom., 2, pp. 211-228; Benedetti, P., Mannhold, R., Cruciani, G., Pastor, M., GBR compounds and mepyramines as cocaine abuse therapeutics: Chemometric studies on selectivity using grid independent descriptors (GRIND) (2002) J. Med. Chem., 45, pp. 1577-1584; Afzelius, L., Masimirembwa, C.M., Karlen, A., Andersson, T.B., Zamora, I., Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors (2002) J. Comput.-Aided Mol. Des., 16, pp. 443-458; Brea, J., Masaguer, C.F., Villazon, M., Cadavid, M.I., Ravina, E., Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT 2A and 5-HT 2C receptor behaviours (2003) Eur. J. Med. Chem., 38, pp. 433-440; Cruciani, G., Pastor, M., Mannhold, R., Suitability of molecular descriptors for database mining. A comparative analysis (2002) J. Med. Chem., 45, pp. 2685-2694; Fontaine, F., Pastor, M., Gutierrez-De-Teran, H., Lozano, J.J., Sanz, F., Use of alignment-free molecular descriptors in diversity analysis and optimal sampling of molecular libraries (2003) Mol. Diversity, 6, pp. 135-147; Ajay, Murcko, M.A., Computational methods to predict binding free energy in ligand-receptor complexes (1995) J. Med. Chem., 38, pp. 4953-4967; Hall, L.H., Kier, L.B., The molecular connectivity Chi indexes and Kappa shape indexes in structure-property modeling (1991) Reviews in Computational Chemistry, pp. 367-422. , VCH Publishers: New York; Lemmen, C., Lengauer, T., Computational methods for the structural alignment of molecules (2000) J. Comput.-Aided Mol. Des., 14, pp. 215-232; Good, A.C., Kuntz, I.D., Investigating the extension of pairwise distance pharmacophore measures to triplet-based descriptors (1995) J. Comput.-Aided Mol. Des., 9, pp. 373-379; Nilakantan, R., Bauman, N., Venkataraghavan, R., New method for rapid characterization of molecular shapes: Applications in drug design (1993) J. Chem. Inf. Comput. Sci., 33, pp. 79-85; Kotani, T., Higashiura, K., Rapid evaluation of molecular shape similarity index using pairwise calculation of the nearest atomic distances (2002) J. Chem. Inf. Comput. Sci., 42, pp. 58-63; Cosgrove, D.A., Bayada, D.M., Johnson, A.P., A novel method of aligning molecules by local surface shape similarity (2000) J. Comput.-Aided Mol. Des., 14, pp. 573-591; Kearsley, S., An alternative method for the alignment of molecular structures: Maximizing electrostatic and steric overlap (1990) Tetrahedron Comput. Methodol., 3, pp. 615-633; Waller, C.L., Oprea, T.I., Chae, K., Park, H.-K., Korach, K.S., Ligand-based identification of environmental estrogens (1996) Chem. Res. Toxicol., 9, pp. 1240-1248; Strappaghetti, G., Corsano, S., Barbaro, R., Giannaccini, G., Betti, L., Structure-activity relationships in a series of 8-substituted xanthines as A1-adenosine receptor antagonists (2001) Bioorg. Med. Chem., 9, pp. 575-583; Carroll, C.D., Patel, H., Johnson, T.O., Guo, T., Orlowski, M., Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library (1998) Bioorg. Med. Chem. Lett., 8, pp. 2315-2320; Lee, B., Richards, F.M., The interpretation of protein structures: Estimation of static accessibility (1971) J. Mol. Biol., 55, pp. 379-400; Greer, J., Bush, B.L., Macromolecular shape and surface maps by solvent exclusion (1978) Proc. Natl. Acad. Sci. U.S.A., 75, pp. 303-307; Richards, F.M., Areas, volumes, packing and protein structure (1977) Annu. Rev. Biophys. Bioeng., 6, pp. 151-176; Connolly, M.L., Analytical molecular surface calculation (1983) J. Appl. Crystallogr., 16, pp. 548-558; Walker, P.D., Arteca, G.A., Mezey, P.G., A complete shape characterization for molecular charge densities represented by Gaussian-type functions (1991) J. Comput. Chem., 12, pp. 220-230; Cruciani, G., Fontaine, F., Pastor, M., Almond, 3.2.0, , Molecular Discovery Ltd.: Perugia, Italy; Gasteiger, J., Rudolph, C., Sadowski, J., Automatic generation of 3D atomic coordinates for organic molecules (1990) Tetrahedron Comput. Methodol., 3, pp. 537-547; Fontaine, F., Pastor, M., Sanz, F., Potential usefulness of the GRIND descriptors for obtaining 3D-QSAR models without supervision (2001) XIIth National Congress of the Spanish Society of Medicinal Chemistry, , Sevilla, Spain; Poster; Müller, C., Stein, B., Adenosine receptor antagonists: Structures and potential therapeutic applications (1996) Curr. Pharm. Des., 2, pp. 501-530; Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.N., Linden, J., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors (2001) Pharmacol. Rev., 53, pp. 527-552; Poulsen, S.A., Quinn, R.J., Adenosine receptors: New opportunities for future drugs (1998) Bioorg. Med. Chem., 6, pp. 619-641; Haas, H.L., Selbach, O., Functions of neuronal adenosine receptors (2000) Naunyn-Schmiedeberg's Arch Pharmacol., 362, pp. 375-381; Suzuki, F., Shimada, J., Mizumoto, H., Karasawa, A., Kubo, K., Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure (1992) J. Med. Chem., 35, pp. 3066-3075; Nezami, A., Luque, I., Kimura, T., Kiso, Y., Freire, E., Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target (2002) Biochemistry, 41, pp. 2273-2280; Coombs, G.H., Goldberg, D.E., Klemba, M., Berry, C., Kay, J., Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets (2001) Trends Parasitol., 17, pp. 532-537; Nezami, A., Kimura, T., Hidaka, K., Kiso, A., Liu, J., High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor (2003) Biochemistry, 42, pp. 8459-8464; Silva, A.M., Lee, A.Y., Gulnik, S.V., Maier, P., Collins, J., Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum (1996) Proc. Natl. Acad. Sci. U.S.A., 93, pp. 10034-10039; Baldwin, E.T., Bhat, T.N., Gulnik, S., Hosur, M.V., Sowder II, R.C., Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design (1993) Proc. Natl. Acad. Sci. U.S.A., 90, pp. 6796-6800","Pastor, M.; Res. U. on Biomed. Info. (GRIB), IMIM, Universitat Pompeu Fabra, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; email: mpastor@imim.es",,,,,,,,00222623,,JMCMA,"15139758","English","J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-2442659094
"Bonis J., Sancho J.J., Sanz F.","56728136000;7201937083;7102263897;","Computer-assisted clinical decision support systems [Sistemas informáticos de soporte a la decisión clínica]",2004,"Medicina Clinica","122","SUPPL. 1",,"39","44",,3,"10.1157/13057545","https://www.scopus.com/inward/record.uri?eid=2-s2.0-1642274611&doi=10.1157%2f13057545&partnerID=40&md5=e39b7303f2b24064bde0f5355a454616","Grup de Rec. en Info. Biomed. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu i Fabra, Barcelona, Spain; Servei de Cirurgia, Hospital del Mar, Inst. Munic. d'Asistencia Sanitaria, Barcelona, Spain; Grup de Rec. en Info. Biomedica, GRIB (IMIM-UPF), Dr. Aiguader, 80, 08003 Barcelona, Spain","Bonis, J., Grup de Rec. en Info. Biomed. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu i Fabra, Barcelona, Spain; Sancho, J.J., Grup de Rec. en Info. Biomed. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu i Fabra, Barcelona, Spain, Servei de Cirurgia, Hospital del Mar, Inst. Munic. d'Asistencia Sanitaria, Barcelona, Spain; Sanz, F., Grup de Rec. en Info. Biomed. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu i Fabra, Barcelona, Spain, Grup de Rec. en Info. Biomedica, GRIB (IMIM-UPF), Dr. Aiguader, 80, 08003 Barcelona, Spain","This review deals with the historical evolution and methodological basis of computerized medical decision support tools. It also reviews the verification, validation and impact evaluation methods of these systems. The acceptability of them from the health professionals depends on the pro-activity and usefulness of the systems, between other factors. The clinical impact evaluation methods are described in deep detail and the Hunt et al review of 1998 is updated.","Clinical decision support systems; Evaluation studies; Review","automation; clinical impact evaluation method; clinical research; computer assisted diagnosis; evaluation; medical decision making; methodology; review; validation process; Decision Making, Computer-Assisted; Decision Support Systems, Clinical; Humans; Reproducibility of Results",,,,,,,,,"Ledley, R.S., Lusted, L.B., Reasoning foundations of medical diagnosis (1959) Science, 130, pp. 9-21; Joseph, G.M., Patel, V.L., Domain knowledge and hypothesis generation in diagnostic reasoning (1990) Med Decis Making, 10, pp. 31-46; Kohn, L.T., Corrigan, J.M., Donaldson, M.S., (2000) To Err is Human: Building a Safer Health System, , Washington DC: Committee on Quality of Health Care in America, Institute of Medicine; Bleich, H.L., Computer evaluation of acid-base disorders (1969) J Clin Invest, 48, pp. 1689-1696; Warner, H.R., Toronto, A.F., Veasey, L.G., Stephenson, R.A., Mathematical approach to medical diagnosis (1961) JAMA, 177, pp. 75-81; De Dombal, F.T., Hartley, J.R., Sleeman, D.H., A computer-assisted system for learning clinical diagnosis (1969) Lancet, 1, pp. 145-148; Ben-Bassat, M., Carlson, R.W., Puri, V.K., Davenport, M.D., Schriver, J.A., Pattern-based interactive diagnosis of multiple disorders: The MEDAS system (1980) IEEE Trans Pattern Anal Mach Intel, PAM1-2, pp. 148-160; Lipkin, M., Hardy, J.D., Differential diagnosis of hematological diseases aided by mechanical correlation of data (1957) Science, 125, pp. 551-552; Pople, H.E., Heuristic methods for imposing structure on ill-structured problems: The structuring of medical diagnostics (1982) Artificial Intelligence in Medicine, pp. 119-190. , Szolovits P, editor. Boulder: Westview Press; Shortliffe, E.H., (1976) Computer-based Medical Consultations: MYCIN Adifical Artifical Intelligence Series, , New York: Elsevier Computer Science Library; Gardner, R.M., Pryor, T.A., Warner, H.R., The HELP hospital information system: Update 1998 (1999) Int J Med Inf, 54, pp. 169-182; Miller, R.A., Medical diagnostic decision support systems-past, present, and future: A threaded bibliography and brief commentary (1994) J Am Med Inform Assoc, 1, pp. 8-27; Bates, D.W., Leape, L.L., Cullen, D.J., Laird, N., Petersen, L.A., Teich, J.M., Effect of computerized physician order entry and a team intervention on prevention of serious medication errors (1998) JAMA, 280, pp. 1311-1316; Hripcsak, G., The Arden Syntax for medical logic modules: Introduction (1994) Computers in Biology and Medicine, 24, pp. 329-330; Grimm Jr., R.H., Shimoni, K., Harlan Jr., W.R., Estes Jr., E.H., Evaluation of patient-care protocol use by various providers (1975) N Engl J Med, 292, pp. 507-511; Montgomery, A.A., Fahey, T., Peters, T.J., MacIntosh, C., Sharp, D.J., Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: Randomised controlled trial (2000) BMJ, 320, pp. 686-690; Heathfield, H., Pitty, D., Hanka, R., Evaluating information technology in health care: Barriers and challenges (1998) BMJ, 316, pp. 1959-1961; Carbó, J.M., Sancho, J.J., Miravitlles, M.J., González, J.C., Sanz, F., A new approach to computerized medical knowledge assessment (1991) Medical Informatics Europe 1991. Lecture Notes in Medical Informatics, 45, pp. 615-619. , K.-P. Adlassnig, Grabner G, Bensgton S, Hansen R, editors. Berlin: Springer-Verlag; Kuilboer, M.M., Van Wijk, M.A., Mosseveld, M., Van Der Does, E., Ponsioen, B.P., De Jongste, J.C., Feasibility of asthma critic, a decision-support system for asthma and COPD which generates patient-specific feedback on routinely recorded data in general practice (2002) Fam Pract, 19, pp. 442-447; Verdaguer, A., Patak, A., Sancho, J.J., Sierra, C., Sanz, F., Validation of the medical expert system PNEUMON-IA (1992) Comp Biom Res, 25, pp. 511-526; Hernández, C., Sancho, J.J., Belmonte, M.A., Sierra, C., Sanz, F., Validation of the medical expert system RENOIR (1994) Comp Biomed Res, 27, pp. 456-471; Eccles, M., McColl, E., Steen, N., Rousseau, N., Grimshaw, J., Parkin, D., Effect of computerised evidence based guidelines on management of asthma and angina in adults in primary care: Cluster randomised controlled trial (2002) BMJ, 325, p. 941; Carroll, C., Marsden, P., Soden, P., Naylor, E., New, J., Dornan, T., Involving users in the design and usability evaluation of a clinical decision support system (2002) Comput Methods Programs Biomed, 69, pp. 123-135; Jungk, A., Thull, B., Hoeft, A., Rau, G., Evaluation of two new ecological interface approaches for the anesthesia workplace (2000) J Clin Monit Comput, 16, pp. 243-258; Kaplan, B., Evaluating informatics applications-clinical decision support systems literature review (2001) Int J Med Inf, 64, pp. 15-37; Kaplan, B., Evaluating informatics applications-some alternative approaches: Theory, social interactionism, and call for methodological pluralism (2001) Int J Med Inf, 64, pp. 39-56; Friedman, C.P., Wyatt, J.C., (1997) Evaluation Methods in Medical Informatics, , New York: Springer-Verlag; Sacks, H., Randomised vs historical controls for clinical trials (1982) Am J Med, 72, pp. 233-240; Chuang, J.H., Hripcsak, G., Jenders, R.A., Considering clustering: A methodological review of clinical decision support system studies (2000) Proc AMIA Symp, pp. 146-150; Ukoumunne, O.C., Gulliford, M.C., Chinn, S., Sterne, J.A., Burney, P.G., Methods for evaluating area-wide and organisation-based interventions in health and health care: A systematic review (1999) Health Technol Assess, 3, pp. 111-192; Hunt, D.L., Haynes, R.B., Hanna, S.E., Smith, K., Effects of computer-based clinical decision support systems on physician performance and patient outcomes: A systematic review (1998) JAMA, 280, pp. 1339-1346; Lee, F., Implementation of physician order entry: User satisfaction and self-reported usage patterns (1996) J Am Med Inf Assoc, 3, pp. 42-55; Frijling, B.D., Lobo, C.M., Hulscher, M.E., Akkermans, R.P., Braspenning, J.C., Prins, A., Multifaceted support to improve clinical decision making in diabetes care: A randomised controlled trial in general practice (2002) Diabet Med, 19, pp. 836-842; Rousseau, N., McColl, E., Newton, J., Grimshaw, J., Eccles, M., Practice based, longitudinal, qualitative interview study of computerised evidence based guidelines in primary care (2003) BMJ, 326, p. 314; Pell, I., Dowie, J., Clarke, A., Kennedy, A., Bhavnani, V., Development and preliminary evaluation of a clinical guidance programme for the decision about prophylactic oophorectomy in women undergoing a hysterectomy (2002) Qual Saf Health Care, 11, pp. 32-38; Lee, T.T., Yeh, C.H., Ho, L.H., Application of a computerized nursing care plan system in one hostpial: Experiences of ICU nurses in Taiwan (2002) J Adv Nurs, 39, pp. 61-67; Junger, A., Michel, A., Benson, M., Quinzio, L.A., Hafer, J., Hartmann, B., Evaluation of the suitability of a patient data management system for ICUs on a general ward (2001) Int J Med Inf, 64, pp. 57-66; Porcelli, P.J., Lobach, D.F., Integration of clinical decision support with online encounter documentation for well child care at the point of care (1999) Proc AMIA Symp, pp. 599-603; Gadd, C.S., Baskaran, P., Lobach, D.F., Identification of design features to enhance utilization and acceptance of systems for Internet-based decision support at the point of care (1998) Proc AMIA Symp, pp. 91-95; Farand, L., Lafrance, J.P., Arocha, J.F., Collaborative problem-solving in tele-medicine and evidence interpretation on a complex clinical case (1998) Int J Med Inf, 51, pp. 153-167; Lau, F., Penn, A., Wilson, D., Noseworthy, T., Vincent, D., Doze, S., The diffusion of an evidence-based disease guidance system for managing stroke (1998) Int J Med Inf, 51, pp. 107-116; Jousimaa, J., Makela, M., Kunnamo, I., MacLennan, G., Grimshaw, J.M., Primary care guidelines on consultation practices: The effectiveness of computerized versus paper-based versions. A cluster randomized controlled trial among newly qualified primary care physicians (2002) Int J Technol Assess Health Care, 18, pp. 586-596; McCowan, C., Neville, R.G., Ricketts, I.W., Warner, F.C., Hoskins, G., Thomas, G.E., Lessons from a randomized controlled trial designed to evaluate computer decision support software to improve the management of asthma (2001) Med Inform Internet Med, 26, pp. 191-201; Dexter, P.R., Perkins, S., Overhage, J.M., Maharry, K., Kohler, R.B., McDonald, C.J., A computerized reminder system to increase the use of preventive care for hospitalized patients (2001) N Engl J Med, 345, pp. 965-970; Christakis, D.A., Zimmerman, F.J., Wright, J.A., Garrison, M.M., Rivara, F.P., Davis, R.L., A randomized controlled trial of point-of-care evidence to improve the antibiotic prescribing practices for otitis media in children (2001) Pediatrics, 107, pp. E15; Hetlevik, I., Holmen, J., Kruger, O., Kristensen, P., Iversen, H., Furuseth, K., Implementing clinical guidelines on the treatment of diabetes mellitus in general practice. Evaluation of effort, process, and patient outcome related to implementation of a computer-based decision support system (2000) Int J Technol Assess Health Care, 16, pp. 210-227; East, T.D., Heermann, L.K., Bradshaw, R.L., Lugo, A., Sailors, R.M., Ershler, L., Efficacy of computerized decision support for mechanical ventilation: Restuls of a prospective multi-center randomized trial (1999) Proc AMIA Symp, pp. 251-255; Flatley-Brennan, P., Computer network home care demonstration: A randomized trial in persons living with AIDS (1998) Comput Biol Med, 28, pp. 489-508; Mekhjian, H.S., Kumar, R.R., Kuehn, L., Bentley, T.D., Teater, P., Thomas, A., Inmediate benefits realized following implementation of physician order entry at an academic medical center (2002) J Am Med Inform Assoc, 9, pp. 529-539; Ruland, C.M., Handheld technology to improve patient care: Evaluating a support system for preference-based care planning at the bedside (2002) J Am Med Inform Assoc, 9, pp. 192-201; Sanders, D.L., Miller, R.A., The effects on clinician ordering patterns of a computerized decision support system for neuroradiology imaging studies (2001) Proc AMIA Symp, pp. 583-587; Bouaud, J., Seroussi, B., Antoine, E.C., Zelek, L., Spielmann, M., A before-after study using OncoDoc, a guideline-based decision support-system on breast cancer management: Impact upon physician prescribing behaviour (2001) Medinfo, 10, pp. 420-424; Rocha, B.H., Christenson, J.C., Evans, R.S., Gardner, R.M., Clinicians' response to computerized detection of infections (2001) J Am Med Inform Assoc, 8, pp. 117-125; Chang, P.L., Li, Y.C., Wang, T.M., Huang, S.T., Hsieh, M.L., Tsui, K.H., Evaluation of a decision-support system for preoperative staging of prostate cancer (1999) Med Decis Making, 19, pp. 419-427","Sanz, F.; Grup de Rec. en Info. Biomedica, GRIB (IMIM-UPF), Dr. Aiguader, 80, 08003 Barcelona, Spain",,,,,,,,00257753,,MCLBA,"14980159","Spanish","Med. Clin.",Review,"Final",,Scopus,2-s2.0-1642274611
"Gutiérrez-De-Terán H., Centeno N.B., Pastor M., Sanz F.","6507897412;6701440183;7102415847;7102263897;","Novel Approaches for Modeling of the A1 Adenosine Receptor and Its Agonist Binding Site",2004,"Proteins: Structure, Function and Genetics","54","4",,"705","715",,28,"10.1002/prot.10617","https://www.scopus.com/inward/record.uri?eid=2-s2.0-1542316348&doi=10.1002%2fprot.10617&partnerID=40&md5=56f0387da145aa1861d41d054dbd8e4f","Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona, Spain; Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, E-08003 Barcelona, Spain","Gutiérrez-De-Terán, H., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona, Spain; Centeno, N.B., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona, Spain; Pastor, M., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona, Spain, Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, E-08003 Barcelona, Spain","The present work describes the building of a human A1, adenosine receptor (hA1AR) model, based on the X-ray crystal structure of bovine rhodopsin, and its use as a basis for the investigation of some important structural characteristics of the receptor. One of the issues investigated was the protonation position of two histidine residues known to influence ligand binding, with protonation of His251 (6.52) in epsilon position and His278 (7.43) in delta position showing the best agreement with experimental evidence. The model was also used to study the position and structural role of water molecules present in the helical bundle. Finally, the binding site location and the ligand docking were investigated using an objective strategy. A suitable site for the binding of the ribose moiety of adenosine was first postulated and further confirmed by means of a novel chemometric strategy based on GRIND descriptors. Using this position as an anchor point, the binding of adenosine was studied by docking and molecular dynamics simulations obtaining two putative binding positions in good agreement with experimental data. © 2004 Wiley-Liss, Inc.","Adenosine; Docking exploration; G-protein coupled receptors; GRIND; Histidine protonation; Homology modeling; Human A1 receptor; Molecular dynamics; Structural water","adenosine; adenosine A1 receptor; G protein coupled receptor; rhodopsin; article; chemometrics; drug binding site; hydrogen bond; ligand binding; molecular dynamics; priority journal; proton transport; sequence alignment; X ray crystallography; Adenosine; Amino Acid Sequence; Animals; Binding Sites; Cattle; Computer Simulation; Crystallography, X-Ray; Histidine; Humans; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Sequence Data; Protein Structure, Secondary; Protons; Receptor, Adenosine A1; Water; Bovinae",,"adenosine, 58-61-7; rhodopsin, 60383-01-9, 9009-81-8; Adenosine, 58-61-7; Histidine, 71-00-1; Ligands; Protons; Receptor, Adenosine A1; Water, 7732-18-5",,,,,,,"Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.N., Linden, J., International Union of Pharmacology: XXV. Nomenclature and classification of adenosine receptors (2001) Pharmacol Rev, 53, pp. 527-552; Horn, F., Van Der Wenden, E.M., Oliveira, L., Vriend, G., Receptors coupling to G proteins: Is there a signal behind the sequence? (2000) Proteins, 41, pp. 448-459; Müller, C., Stein, B., Adenosine receptor antagonists: Structures and potential therapeutic applications (1996) Curr Pharm Design, 2, pp. 501-530; Müller, C.E., A1 adenosine receptors and their ligands: Overview and recent developments (2001) II Farmaco, 56, pp. 77-80; Poulsen, S.A., Quinn, R.J., Adenosine receptors: New opportunities for future drugs (1998) Bioorg Med Chem, 6, pp. 619-641; Haas, H.L., Selbach, O., Functions of neuronal adenosine receptors (2000) Naunyn-Schmiedebergs Arch Pharmakol, 362, pp. 375-381; Downey, J.M., Liu, G.S., Thornton, J.D., Adenosine and the anti-infarct effects of preconditioning (1993) Cardiovasc Res, 27, pp. 3-8; Neely, C.F., DiPierro, F.V., Kong, M., Greelish, J.P., Gardner, T.J., A1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart (1996) Circulation, 94, pp. 11376-11380; Suzuki, F., Shimada, J., Mizumoto, H., Karasawa, A., Kubo, K., Nonaka, H., Ishii, A., Kawakita, T., Adenosine A1 antagonists: 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure (1992) J Med Chem, 35, pp. 3066-3075; Bianucci, A.-M., Bigi, M.U., Biagi, G., Giorgi, I., Livi, O., Scartoni, V., A 3D model of the human A1 adenosine receptor: An evaluation of the binding free-energy with ligands (1998) Drug Des Discov, 15, pp. 149-156; Da Settimo, F., Primofiore, G., Taliani, S., Marini, A.M., Motta, C.L., Novellino, E., Greco, G., Martini, C., 3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: A new class of selective A1 adenosine receptor antagonists (2001) J Med Chem, 44, pp. 316-327; Rivkees, S.A., Barbhaiya, H., Ijzerman, A.P., Identification of the adenine binding site of the human A1 adenosine receptor (1999) J Biol Chem, 274, pp. 3617-3621; Dudley, M.W., Peet, N.P., Demeter, D.A., Weintraub, J.R., Ijzerman, A., Nordvall, G., Van Galen, P.J.M., Jacobson, K.A., Adenosine A1 receptor and ligand molecular modelling (1993) Drug Dev Res, 28, pp. 237-243; Ijzerman, A., Van Galen, P.J.M., Jacobson, K.A., Molecular modeling of adenosine receptors: I. The ligand binding site on the A1 receptor (1992) Drug Des Discov, 9, pp. 49-67; Moro, S., Li, A.H., Jacobson, K.A., Molecular modeling studies of human A3 adenosine antagonists: Structural homology and receptor docking (1998) J Chem InfComput Sci, 38, pp. 1239-1248; Jiang, Q., Van Rhee, A., Kim, J., Yehle, S., Wess, J., Jacobson, K., Hydrophilic side-chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition (1996) Mol Pharmacol, 50, pp. 512-521; Kim, J., Wess, J., Van Rhee, A.M., Schöneberg, T., Jacobson, K.A., Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2A adenosine receptor (1995) J Biol Chem, 270, pp. 13987-13997; Ijzerman, A., Van Der Wenden, E.M., Van Galen, P.J.M., Jacobson, K.A., Molecular modelling of adenosine receptors: The ligand binding site on the rat adenosine A2A receptor (1994) Eur J Pharmacol, 268, pp. 95-104; Henderson, R., Baldwin, J.M., Ceska, T.A., Zemlin, F., Beckmann, E., Downing, K.H., Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy (1990) J Mol Biol, 213, pp. 899-929; Baldwin, J.M., Schertler, G.F., Unger, V.M., An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors (1997) J Mol Biol, 272, pp. 144-164; Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Miyano, M., Crystal structure of rhodopsin: A G protein-coupled receptor (2000) Science, 289, pp. 739-745; Filipek, S., Teller, D.C., Palczewski, K., Stenkamp, R., The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors (2003) Annu Rev Biophys Biomol Struct, 32, pp. 375-397; Baraldi, P.G., Cacciari, B., Moro, S., Romagnoli, R., Ji, X., Jacobson, K.A., Gessi, S., Spalluto, G., Fluorosulfonyl- and bis- (beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: Irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies (2001) J Med Chem, 44, pp. 2735-2742; Jacobson, K.A., Gao, Z.G., Chen, A., Barak, D., Kim, S.A., Lee, K., Link, A., Liang, B.T., Neoceptor concept based on molecular complementarity in GPCRs: A mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides (2001) J Med Chem, 44, pp. 4125-4136; Barbhaiya, H., McClain, R., Ijzerman, A., Rivkees, S.A., Site-directed mutagenesis of the human A1 adenosine receptor: Influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding (1996) Mol Pharmacol, 50, pp. 1635-1642; Olah, M.E., Ren, H., Ostrowski, J., Jacobson, K.A., Stiles, G.L., Cloning, expression, and characterization of the unique bovine A 1 adenosine receptor: Studies on the ligand binding site by site-directed mutagenesis (1992) J Biol Chem, 267, pp. 10764-10770; Townsend-Nicholson, A., Schofield, P.R., A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding (1994) J Biol Chem, 269, pp. 2373-2376; Colquhoun, D., Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors (1998) Br J Pharmacol, 125, pp. 924-947; Olah, M.E., Stiles, G.L., The role of receptor structure in determining adenosine receptor activity (2000) Pharmacol Ther, 85, pp. 55-75; Dawson, E.S., Wells, J.N., Determination of amino acid residues that are accessible from the ligand binding crevice in the seventh transmembrane-spanning region of the human A 1 adenosine receptor (2001) Mol Pharmacol, 59, pp. 1187-1195; Kennedy, A., Mangum, K., Linden, J., Wells, J., Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe (1996) Mol Pharmacol, 50, pp. 789-798; Allende, G., Casado, V., Mallol, J., Franco, R., Lluis, C., Canela, E.I., Role of histidine residues in agonist and antagonist binding sites of A1 adenosine receptor (1993) J Neurochem, 60, pp. 1525-1533; Gao, Z.G., Jiang, Q., Jacobson, K.A., Ijzerman, A.P., Site-directed mutagenesis studies of human A(2A) adenosine receptors: Involvement of Glu(13) and His(278) in ligand binding and sodium modulation (2000) Biochem Pharmacol, 60, pp. 661-668; Ijzerman, A.P., Kunzel, J.K.V.F.D., Kim, J., Qiaoling, J., Jacobson, K.A., Site-directed mutagenesis of the human adenosine A2A receptor: Critical involvement of Glu13 in agonist recognition (1996) Eur J Pharmacol, 310, pp. 269-272; Ballesteros, J.A., Weinstein, H., Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors (1994) Methods in Neurosciences, pp. 366-428. , Conn PM, Sealfon SC, editors. San Diego: Academic Press; Bairoch, A., Apweiler, R., The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000 (2000) Nucleic Acids Res, 28, pp. 45-48; Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., Higgins, D.G., The CLUSTAL:X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools (1997) Nucleic Acids Res, 25, pp. 4876-4882; Thompson, J.D., Higgins, D.G., Gibson, T.J., CLUSTAL W improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice (1994) Nucleic Acids Res, 22, pp. 4673-4680; Persson, B., Argos, P., Prediction of membrane protein topology utilizing multiple sequence alignments (1997) J Protein Chem, 16, pp. 453-457; Swiss-Prot, , http://us.expasy.org; TMPRED, , http://www.ch.embnet.org; Rost, B., Sander, C., Prediction of protein secondary structure at better than 70% accuracy (1993) J Mol Biol, 232, pp. 584-599; Carrieri, A., Centeno, N.B., Rodrigo, J., Sanz, F., Carotti, A., Theoretical evidence of a salt bridge disfuption as the initiating process for the ald-adrenergic receptor activation: A molecular dynamics and docking study (2001) Proteins, 43, pp. 382-394; Blundell, T., Barlow, D., Borkakoti, N., Thornton, J., Solvent-induced distortions and the curvature of alpha-helices (1983) Nature, 306, pp. 281-283; (2000) Insight II, Version 2000, , San Diego: Simulations IM; Cornell, W.D., Cieplak, P., Bayly, C.I., Gould, I.R., Merz, K.M., Ferguson, D.M., Spellmeyer, D.C., Kollman, P.A., A second generation force field for the simulation of proteins, nucleic acids, and organic molecules (1995) J Am Chem Soc, 117, pp. 5179-5197; Case, D.A., Pearlman, D.A., Caldwell, J.W., (1999) AMBER, Version 6, , University of California, San Francisco; Scheer, A., Fanelli, F., Costa, T., De Benedetti, P., Cotecchia, S., Constitutively active mutants of the alpha 1B-adrenergic receptor: Role of highly conserved polar amino acids in receptor activation (1996) EMBO J, 15, pp. 3566-3578; Sealfon, S.C., Chi, L., Ebersole, B.J., Rodic, V., Zhang, D., Ballesteros, J.A., Weinstein, H., Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor (1995) J Biol Chem, 270, pp. 16683-16688; Zhou, W., Flanagan, C., Ballesteros, J., Konvicka, K., Davidson, J., Weinstein, H., Millar, R., Sealfon, S., A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor (1994) Mol Pharmacol, 45, pp. 165-170; Govaerts, C., Lefort, A., Costagliola, S., Wodak, S.J., Ballesteros, J.A., Van Sande, J., Pardo, L., Vassart, G., A conserved Asn in transmembrane helix 7 Is an on/off switch in the activation of the thyrotropin receptor (2001) J Biol Chem, 276, pp. 22991-22999; Ryckaert, J.P., Ciccotti, G., Berendsen, H.J.C., Numerical integration of the Cartesian equation of motion of a system constraints: Molecular dynamics of N-alkanes (1977) J Compt Phys, 23, pp. 327-341; Humphrey, W., Dalke, A., Schulten, K., VMD-visual molecular dynamics (1996) J Mol Graph Model, 14, pp. 33-38; Marengo, E., Todeschini, R., A new algorithm for optimal, distance-based experimental design (1992) Chemom Intell Lab Sys, 16, pp. 37-44; (2000) GOLPE, Version 4.5, , Perugia (Italy): Multivariate Infometric Analysis Srl. MIA; Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., PROCHECK a program to check the stereochemical quality of protein structures (1993) J Appl Crystallogr, 26, pp. 283-291; Hooft, R.W., Vriend, G., Sander, C., Abola, E.E., Errors in protein structures (1996) Nature, 381, p. 272; Goodford, P.J., A computational procedure for determining energetically favorable binding sites of biological important macromolecules (1985) J Med Chem, 28, pp. 849-857; Wade, R.C., Solvation of the active site of cytochrome P450-cam (1990) J Comput-Aided Mol Des, 4, pp. 199-204; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors (2000) J Med Chem, 43, pp. 3233-3243; (2001) ALMOND, Version 3.0, , Perugia (Italy): Multivariate Infometric Analysis Srl. MIA; Hodgkin, E., Richards, W., Molecular similarity based on electrostatic potential and electric field (1987) Int J Quan Chem, 14, pp. 105-110; Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., Olson, A.J., Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function (1998) J Comp Chem, 19, pp. 1639-1662; Gao, Z.G., Kim, S.K., Biadatti, T., Chen, W., Lee, K., Barak, D., Kim, S.G., Jacobson, K.A., Structural determinants of A3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary (2002) J Med Chem, 45, pp. 4471-4484; Kenakin, T., Onaran, O., The ligand paradox between affinity and efficacy: Can you be there and not make a difference? (2002) Trends Pharmacol Sci, 23, pp. 275-280; Olah, M., Jacobson, K., Stiles, G., Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding: Analysis of chimeric A1/A3 adenosine receptors (1994) J Biol Chem, 269, pp. 24692-24698; Kim, J., Jiang, Q., Glashofer, M., Yehle, S., Wess, J., Jacobson, K., Glutamate residues in the second extracellular loop of the human A 2A adenosine receptor are required for ligand recognition (1996) Mol Pharmacol, 49, pp. 683-691; Gao, Z.-G., Chen, A., Barak, D., Kim, S.-K., Muller, C.E., Jacobson, K.A., Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor (2002) J Biol Chem, 277, pp. 19056-19063; Lomize, A.L., Pogozheva, I.D., Mosberg, H.I., Structural organization of G-protein-coupled receptors (1999) J Comp Aid Mol Des, 13, pp. 325-353; Gao, Z.G., Ijzerman, A.P., Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions (2000) Biochem Pharmacol, 60, pp. 669-676; Klotz, K., Lohse, M., Schwabe, U., Chemical modification of A1 adenosine receptors in rat brain membranes: Evidence for histidine in different domains of the ligand binding site (1988) J Biol Chem, 263, pp. 17522-17526; Engh, R., Huber, R., Accurate bond and angle parameters for X-ray protein structure refinement (1991) Acta Crystallogr A, 47, pp. 392-400; Okada, T., Fujiyoshi, Y., Silow, M., Navarro, J., Landau, E.M., Shichida, Y., Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography (2002) Proc Natl Acad Sci USA, 99, pp. 5982-5987; Kristiansen, K., Kroeze, W.K., Willins, D.L., Gelber, E.I., Savage, J.E., Glennon, R.A., Roth, B.L., A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT2A serotonin receptor but does not participate in activation via a ""salt-bridge disruption"" mechanism (2000) J Pharmacol Exp Ther, 293, pp. 735-746; Müller, C.E., Adenosine receptor ligands-recent developments: Part I. Agonists (2000) Curr Med Chem, 7, pp. 1269-1288; Klotz, K.N., Adenosine receptors and their ligands (2000) Naunyn Schmiedebergs Arch Pharmacol, 362, pp. 382-391; http://relibase.ebi.ac.uk; Mahmoudian, M., The cannabinoid receptor: Computer-aided molecular modeling and docking of ligand (1997) J Mol Graph Model, 15, pp. 149-153; Gieldon, A., Kazmierkiewicz, R., Slusarz, R., Ciarkowski, J., Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin Vla, V2 receptors and with oxytocin receptors (2001) J Comput Aided Mol Des, 15, pp. 1085-1104; Reeves, D.C., Sayed, M.F., Chau, P.L., Price, K.L., Lummis, S.C., Prediction of 5-HT(3) receptor agonist-binding residues using homology modeling (2003) Biophys J, 84, pp. 2338-2334; Cavasotto, C.N., Orry, A.J., Abagyan, R.A., Structure-based identification of binding sites, native ligands and potential inhibitors for G-protein coupled receptors (2003) Proteins, 51, pp. 423-433; Javitch, J.A., Ballesteros, J.A., Weinstein, H., Chen, J., A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice (1998) Biochemistry, 37, pp. 998-1006; Marie, J., Richard, E., Pruneau, D., Paquet, J.L., Siatka, C., Larguier, R., Ponce, C., Bonnafous, J.C., Control of conformational equilibria in the human B2 bradykinin receptor: Modeling of nonpeptidic ligand action and comparison to the rhodopsin structure (2001) J Biol Chem, 276, pp. 41100-41111","Sanz, F.; Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, E-08003 Barcelona, Spain; email: fsanz@imim.es",,,,,,,,08873585,,PSFGE,"14997566","English","Proteins Struct. Funct. Genet.",Article,"Final",,Scopus,2-s2.0-1542316348
"Barreiro J.M., Maojo V., Martin-Sanchez F., Sanz F.","7005345873;55171738800;6603119155;7102263897;","Preface",2004,"Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)","3337",,,"","",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-84974667626&partnerID=40&md5=63c1369fedb64095b246f563ed7e8966","Polytechnical University of Madrid, School of Computer Science, Artificial Intelligence Department, Campus de Montegancedo s/n, Boadilla del Monte, Madrid  28660, Spain; Polytechnical University of Madrid, School of Computer Science, Artificial Intelligence Lab, Boadilla del Monte, Madrid  28660, Spain; Institute of Health Carlos III, Department of Medical Bioinformatics, Ctra. Majadahonda a Pozuelo, km. 2, Majadahonda, Madrid  28220, Spain; University Pompeu Fabra, Municipal Institute of Medical Research (IMIM), Research Unit on Biomedical Informatics (GRIB), Passeig Marítim de la Barceloneta 37-49, Barcelona, 08003, Spain","Barreiro, J.M., Polytechnical University of Madrid, School of Computer Science, Artificial Intelligence Department, Campus de Montegancedo s/n, Boadilla del Monte, Madrid  28660, Spain; Maojo, V., Polytechnical University of Madrid, School of Computer Science, Artificial Intelligence Lab, Boadilla del Monte, Madrid  28660, Spain; Martin-Sanchez, F., Institute of Health Carlos III, Department of Medical Bioinformatics, Ctra. Majadahonda a Pozuelo, km. 2, Majadahonda, Madrid  28220, Spain; Sanz, F., University Pompeu Fabra, Municipal Institute of Medical Research (IMIM), Research Unit on Biomedical Informatics (GRIB), Passeig Marítim de la Barceloneta 37-49, Barcelona, 08003, Spain",[No abstract available],,,,,,,,,,,,,"Martin-Sanchez F.Sanz F.Barreiro J.M.Maojo V.","","Springer Verlag","5th International Symposium on Biological and Medical Data Analysis, ISBMDA 2004","18 November 2004 through 19 November 2004",,144559,03029743,9783540305477,,,"English","Lect. Notes Comput. Sci.",Editorial,"Final",,Scopus,2-s2.0-84974667626
"Sanz F., Díaz C., Martin-Sanchez F., Maojo V.","7102263897;57197180745;6603119155;55171738800;","Structuring European biomedical informatics to support individualized healthcare: Current issues and future trends",2004,"Studies in Health Technology and Informatics","107",,,"803","807",,,"10.3233/978-1-60750-949-3-803","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887042945&doi=10.3233%2f978-1-60750-949-3-803&partnerID=40&md5=dec5aa387ef75a56b8dd7fc354c2128d","Biomedical Informatics Research Group, Institut Municipal d'Investigació Mèdica-IMIM, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; Bioinformatics Unit, Institute of Health Carlos III, Majadahonda, Madrid, Spain; Biomedical Informatics Group, Artificial Intelligence Lab, Polytechnical University of Madrid, Spain","Sanz, F., Biomedical Informatics Research Group, Institut Municipal d'Investigació Mèdica-IMIM, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; Díaz, C., Biomedical Informatics Research Group, Institut Municipal d'Investigació Mèdica-IMIM, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain; Martin-Sanchez, F., Bioinformatics Unit, Institute of Health Carlos III, Majadahonda, Madrid, Spain; Maojo, V., Biomedical Informatics Group, Artificial Intelligence Lab, Polytechnical University of Madrid, Spain","Bioinformatics and Medical Informatics are disciplines that up to now have followed separate development with few contacts and synergies between them in Europe. The elucidation of the human genome has however evidenced the need and the possibilities for a strong synergy between the two. Classical epidemiological and clinical research on the one hand, and genomic research on the other, separately considered, are no longer enough for advancing in the so-called genomic medicine, and a new integrative approach is required. Biomedical Informatics is the emerging discipline that aims to put these two worlds together so that the discovery and creation of novel diagnostic and therapeutic methods is fostered. On the basis of the results of the European Commission-funded BIOINFOMED Study, an INFOBIOMED Network of Excellence has been recently constituted with the main objective of setting a durable structurefor the described collaborative approach at a European level. Initially formed by fifteen renowned European organisations, the main objective of the INFOBIOMED network is therefore to enable the reinforcement of European BMIas an integrative discipline. © 2004 IMIA. All rights reserved.","Bioinformatics; Biomedical Informatics; Genomic Medicine; Medical Informatics; Research networks","Clinical research; Diagnosis; Genes; Mergers and acquisitions; Biomedical informatics; Collaborative approach; European Commission; Genomic research; Medical informatics; Novel diagnostics; Research networks; Therapeutic method; Bioinformatics",,,,,,,,,"Guttmacher, E., Collins, S.F., Genomic medicine a primer (2002) N EngUMed, 347 (19), pp. 1512-1520; Martin-Sanchez, F., Maojo, V., Lopez-Campos, G., Integrating genomics into health information systems (2002) Methods InfMed, 41 (1), pp. 25-30; Liebman, M., From bioinformatics to biomedical informatics (2001) Genome Technology, p. 64. , Nil; De Moor, G.J.E., Iakovidis, I., Norager, S., Martin-Sanchez, F., Special issue on synergy between research in medical informatics, bio informatics and neuro informatics (2003) Methods InfMed, 42, pp. 111-189; Maojo, V., Iakovidis, I., Martin-Sanchez, F., Crespo, J., Kulikowski, C., Medical informatics and bioinformatics: European efforts to facilitate synergy (2001) J Biomed Inform, 34 (6), pp. 423-427; Kohane, I.S., Bioinformatics and clinical informatics: The imperative to collaborate (2000) J Am Med Inform Assoc, 7 (5), pp. 512-516","Sanz, F.; Biomedical Informatics Research Group, Institut Municipal d'Investigació Mèdica-IMIM, C/Dr. Aiguader, 80, E-08003 Barcelona, Spain",,,"IOS Press",,,,,09269630,,,"15360923","English","Stud. Health Technol. Informatics",Article,"Final",,Scopus,2-s2.0-84887042945
"Fontaine F., Pastor M., Gutiérrez-De-Terán H., Lozano J.J., Sanz F.","24755291000;7102415847;6507897412;7103062769;7102263897;","Use of alignment-free molecular descriptors in diversity analysis and optimal sampling of molecular libraries",2003,"Molecular Diversity","6","2",,"135","147",,10,"10.1023/B:MODI.0000006840.89805.e1","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0347088831&doi=10.1023%2fB%3aMODI.0000006840.89805.e1&partnerID=40&md5=dc5a9ad7a2091b05ecd24dba3d68da34","Res. Grp. on Biomed. Info. (GRIB), IMAM, Universitas Pump Fabry, C/Dr. Aiguader 80, Barcelona, Spain","Fontaine, F., Res. Grp. on Biomed. Info. (GRIB), IMAM, Universitas Pump Fabry, C/Dr. Aiguader 80, Barcelona, Spain; Pastor, M., Res. Grp. on Biomed. Info. (GRIB), IMAM, Universitas Pump Fabry, C/Dr. Aiguader 80, Barcelona, Spain; Gutiérrez-De-Terán, H., Res. Grp. on Biomed. Info. (GRIB), IMAM, Universitas Pump Fabry, C/Dr. Aiguader 80, Barcelona, Spain; Lozano, J.J., Res. Grp. on Biomed. Info. (GRIB), IMAM, Universitas Pump Fabry, C/Dr. Aiguader 80, Barcelona, Spain; Sanz, F., Res. Grp. on Biomed. Info. (GRIB), IMAM, Universitas Pump Fabry, C/Dr. Aiguader 80, Barcelona, Spain","The selection of a sample of diverse compounds is a common strategy for exploring large molecular libraries. However, the success of such approach depends on the selection of relevant molecular descriptors and the use of appropriate sampling methods. In the context of pharmaceutical research, the molecular descriptors should be based on physicochemical properties related with the pharmacological behaviour of the compounds. In this sense, the alignment-free GRIND and VolSurf molecular descriptors are promising candidates since they have been successfully used in the modelling of both pharmacodynamic and pharmacokinetic properties of drugs. This work describes the use of such descriptors in the diversity sampling of a library of primary amines and compares the results with those obtained in a previous study that used quantum-mechanical descriptors. As in the previous work, principal component (PC) analysis was applied to reduce the dimensionality and remove redundant information of the original descriptors, and the compounds were sampled on the basis of k-means clustering on the space of the selected PCs. The results of the present study show that VolSurf and GRIND provide similar quality sampling regarding global features of the molecules such as hydrophilicity, however the topology of the compounds is considered differently. The similarity between particular compounds strongly depends on the original descriptors used. However all the sample selections done in the PC space after k-means clustering provide the same apparent diversity in comparison to the whole dataset. The results indicate that there is no best set of descriptors on a diversity basis. The selection of descriptors must be based on the drug features to be investigated.","Almond; Diversity; GRIND; K-means clustering; Molecular descriptors; Molecular library sampling; Principal component analysis; Quantum-mechanical descriptors; VolSurf","article; chemistry; hydrophilicity; molecular interaction; molecular library; principal component analysis; priority journal; quantitative structure activity relation; quantum mechanics; sampling; Combinatorial Chemistry Techniques; Computers, Molecular; Databases",,,,,"FIS 01/1330","We are grateful to the Fondo de Investigaciones San-itarias for the partial financial support to this research (Grant No.: FIS 01/1330).",,,"Potter, T., Matter, H., Random or rational design? Evaluation of diverse compound subsets from chemical structure databases (1998) J. Med. Chem., 41, pp. 478-488; Zheng, W., Cho, S.J., Waller, C.L., Tropsha, A., Rational combinatorial library design. 3. Simulated annealing guided evaluation (SAGE) of molecular diversity: A novel computational tool for universal library design and database mining (1999) J. Chem. Inf. Comput. Sci., 39, pp. 738-746; Blaney, J.M., Martin, E.J., Computational approaches for combinatorial library, design and molecular diversity analysis (1997) Curr. Opin. Chem. Biol., 1, pp. 54-59; Bures, M.G., Martin, Y.C., Computational methods in molecular diversity and combinatorial chemistry (1998) Curr. Opin. Chem. Biol., 2, pp. 376-380; Gorse, D., Lahana, R., Functional diversity of compound libraries (2000) Curr. Opin. Chem. Biol., 4, pp. 287-294; Willett, P., Chemoinformatics - Similarity and diversity in chemical libraries (2000) Curr. Opin. Biotechnol., 11, pp. 85-88; Tropsha, A., Zheng, W., Rational principles of compound selection for combinatorial library design (2002) Comb. Chem. High Throughput Screen., 5, pp. 111-123; Beavers, M.P., Chen, X., Structure-based combinatorial library design: Methodologies and applications (2002) J. Mol. Graph. Model., 20, pp. 463-468; Martin, Y.C., Diverse viewpoints on computational aspects of molecular diversity (2001) J. Comb. Chem., 3, pp. 231-250; Gutiérrez-de-Terán, H., Lozano, J.J., Segarra, V., Sanz, F., Molecular diversity, sample generation on the basis of quantum-mechanical computations and principal component analysis (2002) Comb. Chem. High Throughput Screen., 5, pp. 49-57; Gillet, V.J., Background theory, of molecular diversity (1999) Molecular Diversity in Drug Design, pp. 43-65. , Dean, P. M. and Lewis, R. A. (eds.), Kluwer Academic Publishers, Dordrecht; Xue, L., Bajorath, J., Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening (2000) Comb. Chem. High Throughput Screen., 3, pp. 363-372; Mason, J.S., Beno, B.R., Library design using BCUT chemistry-space descriptory and multiple four-point pharmacophore fingerprints: Simultaneous optimization and structure-based diversity (2000) J. Mol. Graph. Model., 18, pp. 438-451; Dixon, S.L., Villar, H.O., Bioactive diversity and screening library selection via affinity fingerprinting (1998) J. Chem. Inf. Comput. Sci., 38, pp. 1192-1203; Lipkus, A.H., Exploring chemical rings in a simple topological-descriptor space (2001) J. Chem. Inf. Comput. Sci., 41, pp. 430-438; Barnard, J.M., Downs, G.M., Von Scholley-Pfab, A., Brown, R.D., Use of Markush structure analysis techniques for descriptor generation and clustering of large combinatorial libraries (2000) J. Mol. Graph. Model., 18, pp. 452-463; Ivanciuc, O., Klein, D.J., Computing wiener-type indices for virtual combinatorial libraries generated from heteroatom-containing building blocks (2002) J. Chem. Inf. Comput. Sci., 42, pp. 8-22; Rarey, M., Stahl, M., Similarity searching in large combinatorial chemistry spaces (2001) J. Comput. Aided Mol. Des., 15, pp. 497-520; Consonni, V., Todeschini, R., Pavan, M., Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. I. Theory of the novel 3-D molecular descriptors (2002) J. Chem. Inf. Comput. Sci., 42, pp. 682-692; Makara, G.M., Measuring molecular similarity and diversity: Total pharmacophore diversity (2001) J. Med. Chem., 44, pp. 3563-3571; Goodford, P.J., A computational procedure for determining energetically favorable binding sites on biologically important macromolecules (1985) J. Med. Chem., 28, pp. 849-857; Cramer, R.D., Patterson, D.E., Bunce, J.D., Comparative Molecular Field Analysis (CoMFA): I. Effect of shape on binding of steroids to carrier proteins (1988) J. Am. Chem. Soc., 110, pp. 5959-5967; Cruciani, G., Watson, K.A., Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b (1994) J. Med. Chem., 37, pp. 2589-2601; Cruciani, G., Pastor, M., Guba, W., VolSurf: A new tool for the pharmacokinetic optimization of lead compounds (2000) Eur. J. Pharm. Sci., 11 (SUPPL. 2), pp. S29-S39; Crivori, P., Cruciani, G., Carrupt, P.A., Testa, B., Predicting blood-brain barrier permeation from three-dimensional molecular structure (2000) J. Med. Chem., 43, pp. 2204-2216; Zamora, I., Oprea, T., Cruciani, G., Pastor, M., Ungell, A.L., Surface descriptors for protein-ligand affinity prediction (2003) J. Med. Chem., 46, pp. 25-33; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., GRid-INdependent descriptors (GRIND): A.a novel class of alignment-independent three-dimensional molecular descriptors (2000) J. Med. Chem., 43, pp. 3233-3243; Benedetti, P., Mannhold, R., Cruciani, G., Pastor, M., GBR compounds and mepyramines as cocaine abuse therapeutics: Chemometric studies on selectivity using grid independent descriptors (GRIND) (2002) J. Med. Chem., 45, pp. 1577-1584; Afzelius, L., Masimirembwa, C.M., Karlen, A., Andersson, T.B., Zamora, I., Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitory using alignment independent GRIND descriptors (2002) J. Comput. Aided Mol. Des., 16, pp. 443-458; Cruciani, G., Pastor, M., Mannhold, R., Suitability of molecular descriptors for database mining. A comparative analysis (2002) J. Med. Chem., 45, pp. 2685-2694; Oprea, T.I., Zamora, I., Ungell, A.L., Pharmacokinetically based mapping device for chemical space navigation (2002) J. Comb. Chem., 4, pp. 258-266; Gasteiger, J., Rudolph, C., Sadowski, J., Automatic generation of 3-D atomic coordinates for organic molecules (1990) Tetrahedron Comp. Method., 3, pp. 537-547; Giesen, D.J., Gu, M.Z., Cramer, C.J., Truhlar, D.G., Universal, A., Organic Solvation Model (1996) J. Org. Chem., 61, pp. 8720-8721; Hawkins, G.D., Giesen, D.J., Chambers, C.C., Rossi, I., Storer, J.W., Rinaldi, D., Liotard, D.A., Truhlar, D.G., (1997) AMSOL 6.5.2, , University of Minnesota, Minneapolis; Cruciani, G., Pastor, M., Mecucci, S., (2002) VolSurf 3.0.7c, , Molecular Discovery Ltd., Perugia; Cruciani, G., Fontaine, F., Pastor, M., (2003) Almond 3.2.0, , Molecular Discovery Ltd., Perugia; Carey, R.N., Wold, S., Westgard, J.O., Principal component analysis: An alternative to 'referee' methods in method comparison studies (1975) Anal. Chem., 47, pp. 1824-1829; SPSS 11.0.1, SPSS inc. Chicago, 2001; Downs, G.M., Barnard, J.M., Clustering methods and their uses in computational chemistry (2002) Reviews in Computational Chemistry, pp. 1-40. , Lipkowitz, K. B. and Boyd, D. B. (eds.), Wiley-VCH, John Wiley & Sons, Inc","Sanz, F.; Res. Grp. on Biomed. Info. (GRIB), IMAM, Universitas Pump Fabry, C/Dr. Aiguader 80, Barcelona, Spain; email: fsanz@imim.es",,,,,,,,13811991,,MODIF,"14761163","English","Mol. Diversity",Article,"Final",,Scopus,2-s2.0-0347088831
"Barbany M., Gutiérrez-de-Terán H., Sanz F., Villà-Freixa J., Warshel A.","57193913809;6507897412;7102263897;7005142038;7006840601;","On the generation of catalytic antibodies by transition state analogues",2003,"ChemBioChem","4","4",,"277","285",,30,"10.1002/cbic.200390048","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0242515838&doi=10.1002%2fcbic.200390048&partnerID=40&md5=beaf5b65de07965cfd10b655372e1833","Compl. Structural Biology Laboratory, Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim Barceloneta 37-49, 08003 Barcelona, Spain; Department of Chemistry, University of Southern California, Los Angeles, CA 90089-1062, United States","Barbany, M., Compl. Structural Biology Laboratory, Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim Barceloneta 37-49, 08003 Barcelona, Spain; Gutiérrez-de-Terán, H., Compl. Structural Biology Laboratory, Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim Barceloneta 37-49, 08003 Barcelona, Spain; Sanz, F., Compl. Structural Biology Laboratory, Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim Barceloneta 37-49, 08003 Barcelona, Spain; Villà-Freixa, J., Compl. Structural Biology Laboratory, Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim Barceloneta 37-49, 08003 Barcelona, Spain; Warshel, A., Department of Chemistry, University of Southern California, Los Angeles, CA 90089-1062, United States","The effective design of catalytic antibodies represents a major conceptual and practical challenge. It is implicitly assumed that a proper transition state analogue (TSA) can elicit a catalytic antibody (CA) that will catalyze the given reaction in a similar way to an enzyme that would evolve (or was evolved) to catalyze this reaction. However, in most cases it was found that the TSA used produced CAs with relatively low rate enhancement as compared to the corresponding enzymes, when these exist. The present work explores the origin of this problem, by developing two approaches that examine the similarity of the TSA and the corresponding transition state (TS). These analyses are used to assess the proficiency of the CA generated by the given TSA. Both approaches focus on electrostatic effects that have been found to play a major role in enzymatic reactions. The first method uses molecular interaction potentials to look for the similarity between the TSA and the TS and, in principle, to help in designing new haptens by using 3D quantitative struture-activity relationships. The second and more quantitative approach generates a grid of Langevin dipoles, which are polarized by the TSA, and then uses the grid to bind the TS. Comparison of the resulting binding energy with the binding energy of the TS to the grid that was polarized by the TS provides an estimate of the proficiency of the given CA. Our methods are used in examining the origin of the difference between the catalytic power of the 1F7 CA and chorismate mutase. It is demonstrated that the relatively small changes in charge and structure between the TS and TSA are sufficient to account for the difference in proficiency between the CA and the enzyme. Apparently the environment that was preorganized to stabilize the TSA charge distribution does not provide a sufficient stabilization to the TS. The general implications of our findings and the difficulties in designing a perfect TSA are discussed. Finally, the possible use of our approach in screening for an optimal TSA is pointed out.","Catalytic antibodies; Langevin dipoles; Molecular interaction potentials; Structure-activity relationships; Transition states","catalytic antibody; catalytic antibody 1f7; chorismate mutase; enzyme; unclassified drug; analytic method; antibody detection; article; catalysis; concept formation; diagnostic approach route; dipole; drug design; electricity; energy; enzyme release; langevin dipole; mathematical analysis; molecular interaction; molecular stability; phase transition; polarization; priority journal; problem solving; quantitative structure activity relation; reaction analysis; surface charge; three dimensional imaging; transition state analog; Antibodies, Catalytic; Chemistry, Physical; Drug Stability; Models, Molecular; Molecular Structure; Structure-Activity Relationship",,"chorismate mutase, 9068-30-8; Antibodies, Catalytic",,,,,,,"Jencks, W.P., (1969) Catalysis in Chemistry and Enzymology, , McGraw-Hill, New York; Pauling, L., (1946) Chem. Eng. News, 24, pp. 1375-1377; Tramontano, A., Janda, K.D., Lerner, R.A., (1986) Science, 234, pp. 1566-1570; Pollack, S.J., Jacobs, J.W., Schultz, P.G., (1986) Science, 234, pp. 1570-1573; Powell, M., Hansen, D., (1989) Prot. Eng., 3, pp. 69-75; Larsen, N.A., Heine, A., Crane, L., Cravatt, B.F., Lerner, R.A., Wilson, I.A., (2001) J. Mol. Biol., 314, pp. 93-102; Mader, M.M., Bartlett, P.A., (1997) Chem. Rev., 97, pp. 1281-1301; Ulrich, H.D., Schultz, P.G., (1998) J. Mol. Biol., 275, pp. 95-111; Hilvert, D., (2000) Annu. Rev. Biochem., 69, pp. 751-793; Pohnert, G., (2001) Chem. Bio. Chem., 2, pp. 873-875; note; Warshel, A., (1991) Computer Modeling of Chemical Reactions in Enzymes and Solutions, , John Wiley & Sons, New York; Radzicka, A., Wolfenden, R., (1995) Science, 267, pp. 90-93; Warshel, A., (1998) J. Biol. Chem., 273, pp. 27035-27038; Villà, J., Warshel, A., (2001) J. Phys. Chem. B, 10 S, pp. 7887-7907; Tantillo, D.J., Houk, K.N., (1999) J. Org. Chem., 64, pp. 3066-3076; Villà, J., Štrajbl, M., Glennon, T.M., Sham, Y.Y., Chu, Z.T., Warshel, A., (2000) Proc. Natl. Acad. Sci. USA, 97, pp. 11899-11904; Warshel, A., (1978) Proc. Natl. Acad. Sci. USA, 75, pp. 5250-5254; Blundell, T.L., Jhoti, H., Abell, C., (2002) Nat. Rev. Drug Discovery, 1, pp. 45-54; Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Zakrzewski, V.G., Pople, J.A., (1998) Gaussian 98 (Revision A.7), , Gaussian, Inc., Pittsburgh PA; Sherer, E.C., Yang, G., Turner, G.M., Shields, G.C., Landry, D.W., (1997) J. Phys. Chem. A, 101, pp. 8526-8529; Schmidt, M., Baldridge, K., Boatz, J., Elbert, S., Gordon, J., Jensen, M.S., Koseki, S., Montgomery, J.A., (1993) J. Comput. Chem., 14, pp. 1347-1363; Goodford, P., (1985) J. Med. Chem., 28, pp. 849-857; De Cáceres, M., Villà, J., Lozano, J.J., Sanz, F., (2000) Bioinformatics, 16, pp. 568-569; Bagdassarian, C.K., Schramm, V.L., Schwartz, S.D., (1996) J. Am. Chem. Soc., 118, pp. 8825-8836; Andrews, P.R., Smith, G.D., Young, I.G., (1973) Biochemistry, 12, pp. 3492-3498; Haslam, E., (1993) Shikimic Acid: Metabolism and Metabolites, , John Wiley & Sons, New York; Lee, A., Stewart, J., Clardy, J., Ganem, B., (1995) Chem. Biol., 2, pp. 195-203; Schultz, P.G., (1988) Science, 240, pp. 426-433; Hilvert, D., Carpenter, S.H., Nared, K.D., Auditor, M.-T., (1988) Proc. Natl. Acad. Sci. USA, 85, pp. 4953-4955; Jackson, D.Y., Liang, M.N., Bartlett, P.A., Schultz, P.G., (1992) Angew. Chem., 104, pp. 196-198; (1992) Angew. Chem. Int. Ed. Engl., 31, pp. 182-183; Chook, Y.M., Ke, H., Lipscomb, W.N., (1993) Proc. Natl. Acad. Sci. USA, 90, pp. 8600-8603; Lee, A.Y., Karplus, A., Ganem, B., Clardy, J., (1995) J. Am. Chem. Soc., 117, pp. 3267-3628; Stater, N., Schnappauf, G., Braus, G., Lipscomb, W.N., (1997) Structure, 5, pp. 1437-1452; Haynes, M.R., Stura, E.A., Hilvert, D., Wilson, I.A., (1994) Science, 263, pp. 646-652; Kast, P., Asif-Ullah, M., Hilvert, D., (1996) Tetrahedron Lett., 37, pp. 2691-2694; Galopin, C.C., Zhang, S., Wilson, D.B., Ganem, B., (1996) Tetrahedron Lett., 37, pp. 8675-8678; Gustin, D.J., Mattei, P., Kast, P., Wiest, O., Lee, L., Cleland, W.W., Hilvert, D., (1999) J. Am. Chem. Soc., 121, pp. 1756-1757; Lee, Y.S., Hodoscek, M., Brooks, B.R., Kador, P.F., (1998) Biophys. Chem., 70, pp. 203-216; Martí, S., Andrés, J., Moliner, V., Silla, E., Tuñon, I., Bertrán, J., Field, M.J., (2001) J. Am. Chem. Soc., 123, pp. 1709-1712; Wiest, O., Houk, K.N., (1995) J. Am. Chem. Soc., 117, pp. 11628-11639; Hilvert, D., (1993) Acc. Chem. Res., 26, pp. 552-558; Levy, R.M., Gallicchio, E., (1998) Annu. Rev. Phys. Chem., 49, pp. 531-567; Sanz, F., Manaut, F., Rodríguez, J., Lozoya, E., López de Briñas, E., (1993) J. Comput.Aided Mol. Des., 7, pp. 337-347; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., (2000) J. Med. Chem., 43, pp. 3233-3243; Von Itzstein, M., Dyason, I.C., Oliver, S.W., White, H.F., Wu, W.Y., Kok, G.B., Pegg, M.S., (1996) J. Med. Chem., 39, pp. 388-391; Štrajbl, M., Florián, J., Warshel, A., (2000) J. Am. Chem. Soc., 122, pp. 5354-5366; Åqvist, J., Fothergill, M., (1996) J. Biol. Chem., 271, pp. 10010-10016; Janda, K.D., (1990) Biotechnol. Prog., 6, pp. 178-181; Asada, T., Gouda, H., Kollman, P.A., (2002) J. Am. Chem. Soc., 124, pp. 12535-12542; Gao, C., Lavey, B.J., Lo, C.-H.L., Datta, A., Wentworth, P., Janda, K.D., (1997) J. Am. Chem. Soc., 120, pp. 2211-2217; DeSilva, B., Orosz, G., Egodage, K., Carlson, R., Schowen, R., Wilson, G., (2000) Appl. Biochem. Biotechnol., 83, pp. 195-206; note; Warshel, A., Štrajbl, M., Villà, J., Florián, J., (2000) Biochemistry, 39, pp. 14728-14738; Suresh, C.H., Koga, N., (2002) J. Am. Chem. Soc., 124, pp. 1790-1797; Bader, R.F.W., (1991) Chem. Rev., 91, pp. 893-928","Sanz, F.; Compl. Structural Biology Laboratory, Res. Grp. on Biomed. Info. (GRIB), IMIM/UPF, Passeig Maritim Barceloneta 37-49, 08003 Barcelona, Spain; email: fsanz@imim.es",,,,,,,,14394227,,CBCHF,"12672107","English","ChemBioChem",Article,"Final",,Scopus,2-s2.0-0242515838
"Sanz F.","7102263897;","European Journal of Medicinal Chemistry: Preface",2003,"European Journal of Medicinal Chemistry","38","4",,"327","",,,"10.1016/S0223-5234(03)00084-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038731367&doi=10.1016%2fS0223-5234%2803%2900084-9&partnerID=40&md5=a274805f1779feedb62273bbc5706d8d","Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, 08003 Barcelona, Spain","Sanz, F., Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, 08003 Barcelona, Spain",[No abstract available],,"beta adrenergic receptor blocking agent; statin; tricyclic antidepressant agent; combinatorial chemistry; computer program; conference paper; cost; Europe; genetics; medical literature; molecular biology; molecular library; musculoskeletal disease; organization; physical chemistry; productivity; publishing; Spain; symposium",,,,,,,,,,"Sanz, F.; Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, 08003 Barcelona, Spain; email: fsanz@imim.es",,,"Elsevier Masson SAS",,,,,02235234,,EJMCA,,"English","Eur. J. Med. Chem.",Conference Paper,"Final",,Scopus,2-s2.0-0038731367
"Brea J., Masaguer C.F., Villazón M., Isabel Cadavid M., Raviña E., Fontaine F., Dezi C., Pastor M., Sanz F., Isabel Loza M.","6603008588;6701715235;6507618078;6504610483;56264803900;24755291000;6507203451;7102415847;7102263897;7801542386;","Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT2A and 5-HT2C receptor behaviours",2003,"European Journal of Medicinal Chemistry","38","4",,"433","440",,9,"10.1016/S0223-5234(03)00054-0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-12444331013&doi=10.1016%2fS0223-5234%2803%2900054-0&partnerID=40&md5=f4b3a36caf73b6accdfd9e8fe994bdb7","Facultad de Farmacia, Departamentos de Farmacología, Univ. de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Facultad de Farmacia, Lab. de Quim. Farmaceut., Univ. de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/Doctor Aiguader 80, 08003 Barcelona, Spain","Brea, J., Facultad de Farmacia, Departamentos de Farmacología, Univ. de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Masaguer, C.F., Facultad de Farmacia, Lab. de Quim. Farmaceut., Univ. de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Villazón, M., Facultad de Farmacia, Departamentos de Farmacología, Univ. de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Isabel Cadavid, M., Facultad de Farmacia, Departamentos de Farmacología, Univ. de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Raviña, E., Facultad de Farmacia, Lab. de Quim. Farmaceut., Univ. de Santiago de Compostela, 15782 Santiago de Compostela, Spain; Fontaine, F., Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/Doctor Aiguader 80, 08003 Barcelona, Spain; Dezi, C., Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/Doctor Aiguader 80, 08003 Barcelona, Spain; Pastor, M., Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/Doctor Aiguader 80, 08003 Barcelona, Spain; Sanz, F., Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/Doctor Aiguader 80, 08003 Barcelona, Spain; Isabel Loza, M., Facultad de Farmacia, Departamentos de Farmacología, Univ. de Santiago de Compostela, 15782 Santiago de Compostela, Spain","This study presents new pharmacological and molecular modelling studies on a recently described series of conformationally constrained butyrophenones. Alignment-free three-dimensional quantitative structure-activity relationship models developed on the basis of GRid Independent descriptors and partial least squares regression analysis, allow feasible predictions of activity of new compounds and reveal structural requirements for optimal affinity, particularly in the case of the 5-HT2A receptor. The requirements for the 5-HT2A affinity consist in a precise distance between hydrogen bond donor (protonated amino group) and hydrogen bond acceptor groups, as well as an optimal distance between the protonated amino group and the farthest extreme of the compounds. Another significant result has been the characterisation of two structurally similar compounds as interesting pharmacological tools (1-[(4-Oxo-4,5,6,7-tetrahydrobenzo[b]furan-5-yl)ethyl]-4-(6- fluorobenzisoxazol-3-yl)piperidine and 1-[(4-Oxo-4,5,6,7-tetrahydrobenzo[b]furan-6-yl)methyl]-4-(6- fluorobenzisoxazol-3-yl)piperidine). In spite of their structural similarity, the first compound shows clearly higher affinity for the 5-HT2C receptor (about 100 fold) and higher Meltzer ratio (1.17 vs. 0.99) than the second. Moreover, the first compound inhibits arachidonic acid release in a biphasic concentration-dependent way in functional experiments at the 5-HT2A receptor and it acts as inverse agonist at the 5-HT2C receptor, behaviours that are not shown by the second compound. © 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.","3D-QSAR models; 5-HT2A; 5-HT2C; Butyrophenone; GRIND; In verse agonism; Receptor conformations","1 [(4 oxo 4,5,6,7 tetrahydrobenzo[b]furan 5 yl)ethyl] 4 (6 fluorobenzisoxazol 3 yl)piperidine; 1 [(4 oxo 4,5,6,7 tetrahydrobenzo[b]furan 6 yl)methyl] 4 (6 fluorobenzisoxazol 3 yl)piperidine; 4 (6 fluorobenzisoxazol 3 yl) 1 [(4,5,6,7 tetrahydro 4 oxobenzo[b]furan 6 yl)methyl]piperidine; arachidonic acid; butyrophenone derivative; functional group; qf 0104b; qf 0108b; qf 0307b; qf 0510b; qf 0603b; qf 0703b; qf 0902b; qf 2001b; qf 2004b; serotonin 2A receptor; serotonin 2C receptor; unclassified drug; animal cell; arachidonic acid metabolism; binding competition; conference paper; controlled study; drug activity; drug conformation; drug receptor binding; genetic transfection; hydrogen bond; molecular model; nonhuman; prediction; proton transport; quantitative structure activity relation; receptor affinity; regression analysis; structural homology",,"arachidonic acid, 506-32-1, 6610-25-9, 7771-44-0","qf 0104b; qf 0108b; qf 0307b; qf 0510b; qf 0603b; qf 0703b; qf 0902b; qf 1004b; qf 2004b",,"Fundació la Marató de TV3: TV3

Ministerio de Ciencia y Tecnología, MICYT: SAF2002-04195-C03","This work was supported in part by grants from the Spanish Ministry of Science and Technology (SAF2002-04195-C03), the Galician Government and the Fundació La Marató de TV3.",,,"Meltzer, H.Y., (1994) J. Clin. Psychiatry, 55 (SUPPL. B), pp. 47-52; Horacek, J., (2000) Pharmacopsychiatry, 33 (SUPPL.), pp. 134-142; Aghajanian, G.K., Marek, G.J., (2000) Brain Res. Rev., 31, pp. 302-312; Green, M.F., Marshall-BD, J., Wirshing, W.C., Ames, D., Marder, S.R., McGurk, S., Kern, R.S., Mintz, J., (1997) Am. J. Psychiatry, 154, pp. 799-804; Sipes, T.E., Geyer, M.A., (1997) Brain Res., 761, pp. 97-104; Gleason, S.D., Shannon, H.E., (1997) Psychopharmacology, 129, pp. 79-84; Okuyama, S., Chaki, S., Kawashima, N., Suzuki, Y., Ogawa, S., Kumagai, T., Nakazato, A., Tomisawa, K., (1997) Br. J. Pharmacol., 121, pp. 515-525; Ereshefsky, L., Riesenman, C., True, J.E., Javors, M., (1996) Psychopharmacol. Bull., 32, pp. 101-106; Schmidt, C.J., (1996) IBS's International Conference on: Serotonin Receptors. Targets for New Therapeutic Agents; Padich, R.A., McCloskey, T.C., Kehne, J.H., (1996) Psychopharmacology, 124, pp. 107-116; Martin, P., Waters, N., Carlsson, A., Carlsson, M.L., (1997) J. Neural Transm., 104, pp. 561-564; Meltzer, H.C., Matsubara, S., Lee, J.C., (1989) Psychopharmacol. Bull., 253, pp. 390-392; Roth, B.L., Meltzer, H.Y., The role of serotonin in schizophrenia (1995) Psychopharmacology: The fourth generation of progress, Raven Press, pp. 1215-1227. , F.E. Bloom, & D.J. Kupfer; Herrick-Davis, K., Grinde, E., Teitler, M., (2000) J. Pharmacol. Exp. Ther., 295, pp. 226-232; Meltzer, H.Y., McGurk, S.R., (1999) Schizophrenia Bull., 25, pp. 233-255; Reavill, C., Kettle, A., Holland, V., Riley, G., Blackburn, T.P., (1999) Br. J. Pharmacol., 126, pp. 572-574; Knable, M.B., Weinberger, D.R., (1997) J. Psychopharmacol., 11, pp. 123-131; Cussac, D., Newman, T.A., Nicolas, J.P., Boutin, J.A., Millan, M.J., (2000) Naunyn Schmiedebergs Arch. Pharmacol., 361, pp. 549-554; Niswender, C.M., Herrick-Davis, K., Dilley, G.E., Meltzer, H.Y., Overholser, J.C., Stockmeier, C.A., Emeson, R.B., Sanders-Bush, E., (2001) Neuropsychopharmacology, 24, pp. 478-491; Kenakin, T., (2002) Nature Rev. Drug Discov., 1, pp. 103-110; Hilser, V.J., Freire, E., (1996) J. Mol. Biol., 262, pp. 756-772; Berg, K.A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., Clarke, W.P., (1998) Mol. Pharmacol., 54, pp. 94-104; De Ligt, R.A., Kourounakis, A.P., IJzerman, A.P., (2000) Br. J. Pharmacol., 130, pp. 1-12; Kenakin, T., (1995) Trends Pharmacol. Sci., 16, pp. 232-238; Strange, P.G., (2002) Trends Pharmacol. Sci., 23, pp. 89-95; Brea, J., Rodrigo, J., Carrieri, A., Sanz, F., Cadavid, M.I., Enguix, M.J., Villazón, M., Loza, M.I., (2002) J. Med. Chem., 45, pp. 54-71; Gasteiger, J., Rudolph, C., Sadowski, J., (1990) Tetrahedron Comp. Method, 3, pp. 537-547; (2002) ALMOND 3.0.3, Multivariate Infometric Analysis S.r.l, , Perugia, Italy; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., (2000) J. Med. Chem., 43, pp. 3233-3242; Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Valigi, R., Clementi, S., (1993) Quant. Struct. Act. Relat., 12, pp. 9-20; Raviña, E., Negreira, J., Cid, J., Masaguer, C.F., Rosa, E., Rivas, M.E., Fontenla, J.A., Carrieri, A., (1999) J. Med. Chem., 42, pp. 2774-2797; Masaguer, C.F., Raviña, E., Fontenla, J.A., Brea, J., Tristan, H., Loza, M.I., (2000) Eur. J. Med. Chem., 35, pp. 83-95; Masaguer, C.F., Casariego, I., Raviña, E., (1999) Chem. Pharm. Bull., 47, pp. 621-632; Masaguer, C.F., Formoso, E., Raviña, E., Tristan, H., Loza, M.I., Rivas, E., Fontenla, J.A., (1998) Bioorg. Med. Chem. Lett., 8, pp. 3571-3576; Raviña, E., Casariego, I., Masaguer, C.F., Fontenla, J.A., Montenegro, G.Y., Rivas, M.E., Loza, M.I., Demontis, G.C., (2000) J. Med. Chem., 43, pp. 4678-4693; Lopez-Gimenez, J.F., Villazon, M., Brea, J., Loza, M.I., Palacios, J.M., Mengod, G., Vilaro, M.T., (2001) Mol. Pharmacol., 60, pp. 690-699; Niswender, C.M., Copeland, S.C., Herrick-Davis, K., Emeson, R.B., Sanders-Bush, E., (1999) J. Biol. Chem., 274, pp. 9472-9478; Berg, K.A., Stout, B.D., Cropper, J.D., Maayani, S., Clarke, W.P., (1999) Mol. Pharmacol., 55, pp. 863-872","Isabel Loza, M.; Facultad de Farmacia, Departamentos de Farmacología, Univ. de Santiago de Compostela, 15782 Santiago de Compostela, Spain; email: ffmabel@usc.es",,,"Elsevier Masson SAS",,,,,02235234,,EJMCA,"12750032","English","Eur. J. Med. Chem.",Conference Paper,"Final",,Scopus,2-s2.0-12444331013
"Robles F., Sanz F., Beltrán de la Ascensión M., López-Arrieta J.M.","7004623007;7102263897;6506451043;6701748304;","Subclinical thyroid dysfunction in the elderly [Hipotiroidismo e hipertiroidismo subelínicos en el anciano]",2003,"Revista Espanola de Geriatria y Gerontologia","38","2",,"110","115",,2,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038039157&partnerID=40&md5=e630461af3172171ff0a65ec785cf09f","Geriatría, Hospital de Cantoblanco, Madrid, Spain; La Baneza, 43C, esc. 1. , 2. C., 28035 Madrid, Spain","Robles, F., Geriatría, Hospital de Cantoblanco, Madrid, Spain, La Baneza, 43C, esc. 1. , 2. C., 28035 Madrid, Spain; Sanz, F., Geriatría, Hospital de Cantoblanco, Madrid, Spain; Beltrán de la Ascensión, M., Geriatría, Hospital de Cantoblanco, Madrid, Spain; López-Arrieta, J.M., Geriatría, Hospital de Cantoblanco, Madrid, Spain","Thyroid dysfunction, both overt and subclinical, is frequent in the elderly. Diagnosis is difficult since many of the symptoms may mimic the effects of aging and other processes. Therefore, systematic screening is often used. The results of thyroid function tests are frequently abnormal but their clinical importance and the need for treatment vary widely. Symptomatic hypo- and hyperthyroidism always require treatment but what should be done in cases of subclinical thyroid function abnormalities is unclear.","Elderly; Guidelines; Screening; Thyroid dysfunction","iodine 131; levothyroxine; liothyronine; low density lipoprotein; thyroid antibody; thyroid hormone; thyrotropin; thyroxine; aged; aging; cardiovascular disease; human; hyperthyroidism; hypothyroidism; lipoprotein blood level; practice guideline; prevalence; review; risk factor; screening test; thyroid disease; thyroid function test",,"iodine 131, 10043-66-0, 15124-39-7; levothyroxine, 51-48-9; liothyronine, 6138-47-2, 6893-02-3; thyrotropin, 9002-71-5; thyroxine, 7488-70-2",,,,,,,"Cooper, D.S., Subclinical hypothyroidism (2001) N Engl J Med, 345, pp. 260-265; Sawin, C.T., Castelli, W.P., Hershman, J.M., McNamara, P., Bacharach, P., The aging thyroid: Thyroid deficiency in the Framingham study (1985) Arch Intern Med, 145, pp. 1386-1388; Díez, J.J., Hipotiroidismo en el anciano: Importancia clínica y dificultades en el diagnóstico y tratamiento (1998) Med Clin (Barc), 111, pp. 742-750; Attia, J., Margetts, P., Guyatt, S., Diagnosis of thyroid disease in hospitalised patients: A systematic review (1999) Arch Intern Med, 159, pp. 658-665; Anía, B.J., Suárez, J.L., Fernández-Burriel, M., Guerra, L., Betancort, C., Función tiroidea en ancianos al ingreso en una residencia (2000) An Med Interna, 17, pp. 5-8; Ayala, C., Cózar, M.V., Rodríguez, J.R., Silva, H., Pereira, J.L., Garcia-Luna, P.P., Enfermedad tiroidea subclínica en la población anciana sana institucionalizada (2001) Med Clin (Barc), 117, pp. 534-535; Wallace, K., Hofmann, M.T., Thyroid dysfunction: How to manage overt and subclinical disease in older patients (1998) Geriatrics, 53, pp. 32-41; Hak, A.E., Pols, H.A., Visser, T.J., Drexhage, H.A., Hofman, A., Witteman, J., Subclinical hypotiroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study (2000) Ann Intern Med, 132, pp. 270-278; Goldberg, T.H., Chavin, S.I., Preventive medicine and screening in older adults (1997) J Am Geriatr Soc, 45, pp. 344-354; Ladenson, P.W., Singer, P.A., Ain, K.B., Bagchi, N., Bigos, S.T., Levy, E.G., American Thyroid Association guidelines for detection of thyroid dysfunction (2000) Arch Intern Med, 160, pp. 1573-1575; Escobar-Morreale, H.F., Tratamiento actual del hipatiroidismo: Una revisión critica (2001) Endocrinol y Nutr, 48, pp. 78-81; Danese, M.D., Powe, N.R., Sawin, C.T., Ladenson, P.W., Screening for mild thyroid failure at the periodic health examination: A decision and cost-effectiveness analysis (1996) JAMA, 276, pp. 285-292; Danese, M.D., Ladenson, P.W., Meinert, C.L., Powe, N.R., Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: A quantitative review of the literature (2000) J Clin Endocrinol Metab, 85, pp. 2993-3001; Klein, I., Ojamaa, K., Thyroid hormone and the cardiovascular system (2001) N Engl J Med, 344, pp. 501-509; Toft, A.D., Clinical practice. Subclinical hyperthyroidism (2001) N Engl J Med, 345, pp. 512-516; Real, J.T., Ascaso, J.F., Hipertiroidismo en el anciano (2002) Med Clin (Barc), 118, pp. 784-787; Fatourechi, V., Adverse effects of subclinical hyperthyroidism (2001) Lancet, 358, pp. 856-857; Parle, J.V., Franklyn, K.W., Cross, K.W., Jones, S.C., Sheppard, M.C., Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom (1991) Clin Endocrinol, 34, pp. 77-83; Sawin, C.T., Séller, A., Wolf, P.A., Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons (1994) N Engl J Med, 331, pp. 1249-1252; Bauer, D.C., Ettinger, B., Nevitt, M.C., Stone, K.L., Risk for fracture in women with low serum levels of thyroid-stimulating hormone (2001) Ann Intern Med, 134, pp. 561-568; Parle, J.V., Misonneuve, P., Sheppard, M.C., Boyle, P., Franklyn, J.A., Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study (2001) Lancet, 358, pp. 861-865","Robles, F.La Baneza, 43C, esc. 1. , 2. C., 28035 Madrid, Spain; email: ROBLESAGUDO@terra.es",,,"Ediciones Doyma, S.L.",,,,,0211139X,,REGGD,,"Spanish","Rev. Esp. Geriatr. Gerontol.",Review,"Final",,Scopus,2-s2.0-0038039157
"Sanz F., Gago F.","7102263897;7006338269;","Current perspective of information technologies in drug discovery",2002,"Journal of Computer-Aided Molecular Design","16","11",,"767","768",,,"10.1023/A:1023821300566","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037837260&doi=10.1023%2fA%3a1023821300566&partnerID=40&md5=09c87a954d0c18a0d74fed2a115d3d12","Res. Grp. Biomed. Info. (GRIB), IMIM, Universitat Pompeu Fabra, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Departamento de Farmacologia, Universidad de Alcalá, E-28871 Madrid, Spain","Sanz, F., Res. Grp. Biomed. Info. (GRIB), IMIM, Universitat Pompeu Fabra, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Gago, F., Departamento de Farmacologia, Universidad de Alcalá, E-28871 Madrid, Spain",[No abstract available],,"drug; ligand; protein; article; bioinformatics; clinical chemistry; combinatorial chemistry; computer aided design; computer analysis; computer system; drug design; drug screening; drug targeting; genomics; information processing; Internet; medical research; molecular library; pharmacogenomics; pharmacophore; priority journal; protein structure; proteomics; three dimensional imaging; virtual reality; Computational Biology; Drug Design; Spain",,"protein, 67254-75-5",,,,,,,"Bjerrum, O.J., New Safe Medicines Faster: A proposition for a pan-European research effort (2002) Nature Rev. Drug Discov., 1, pp. 395-398; Richards, W.G., Virtual screening using grid computing: The screensaver project (2002) Nature Rev. Drug Discov., 1, pp. 551-555","Sanz, F.; Res. Grp. Biomed. Info. (GRIB), IMIM, Universitat Pompeu Fabra, C/Dr. Aiguader 80, E-08003 Barcelona, Spain",,,,,,,,0920654X,,JCADE,"12825787","English","J. Comp.-Aided Mol. Des.",Article,"Final",,Scopus,2-s2.0-0037837260
"Pastor M., Benedetti P., Carotti A., Carrieri A., Díaz C., Herráiz C., Höltje H.-D., Loza M.I., Oprea T., Padín F., Pubill F., Sanz F., Stoll F.","7102415847;57189020227;7102635316;7003355704;57197180745;35814533600;7004481780;7003766926;7003532941;55924930100;6504403310;7102263897;7004711172;","Distant collaboration in drug discovery: The LINK3D project",2002,"Journal of Computer-Aided Molecular Design","16","11",,"809","818",,5,"10.1023/A:1023884712617","https://www.scopus.com/inward/record.uri?eid=2-s2.0-12444338957&doi=10.1023%2fA%3a1023884712617&partnerID=40&md5=27cc5a30a9dca69b26f9c58a69da2dee","GRIB, IMIM/UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Università degli Studi, Bari, Italy; Heinrich-Heine-Universität, Düsseldorf, Germany; Univ. de Santiago de Compostela, Santiago de Compostela, Spain; ASTRAZENECA AB, Mölndal, Sweden; LACER SA, Barcelona, Spain","Pastor, M., GRIB, IMIM/UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Benedetti, P.; Carotti, A., Università degli Studi, Bari, Italy; Carrieri, A., Università degli Studi, Bari, Italy; Díaz, C., GRIB, IMIM/UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Herráiz, C., GRIB, IMIM/UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Höltje, H.-D., Heinrich-Heine-Universität, Düsseldorf, Germany; Loza, M.I., Univ. de Santiago de Compostela, Santiago de Compostela, Spain; Oprea, T., ASTRAZENECA AB, Mölndal, Sweden; Padín, F., Univ. de Santiago de Compostela, Santiago de Compostela, Spain; Pubill, F., LACER SA, Barcelona, Spain; Sanz, F., GRIB, IMIM/UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Stoll, F., Heinrich-Heine-Universität, Düsseldorf, Germany","The work describes the development of novel software supporting synchronous distant collaboration between scientists involved in drug discovery and development projects. The program allows to visualize and share data as well as to interact in real time using standard intranets and Internet resources. Direct visualization of 2D and 3D molecular structures is supported and original tools for facilitating remote discussion have been integrated. The software is multiplatform (MS-Windows, SGI-IRIX, Linux), allowing for a seamless integration of heterogeneous working environments. The project aims to support collaboration both within and between academic and industrial institutions. Since confidentiality is very important in some scenarios, special attention has been paid to security aspects. The article presents the research carried out to gather the requirements of collaborative software in the field of drug discovery and development and describes the features of the first fully functional prototype obtained. Real-world testing activities carried out on this prototype in order to guarantee its adequacy in diverse environments are also described and discussed.","Drug discovery; E-work; Internet; Knowledge sharing; Synchronous telecollaboration","article; chemical structure; computer interface; computer program; computer system; confidentiality; controlled study; drug design; information processing; Internet; intranet; medical research; priority journal; standardization; three dimensional imaging; Computer Graphics; Computer Simulation; Computer Systems; Cooperative Behavior; Drug Design; Internet; Models, Molecular; Remote Consultation; Software; User-Computer Interface",,,"MS-Windows, Linux; MS-Windows, SGI-IRIX","Linux; SGI-IRIX","European Commission: IST-2000-26338","The LINK3D project is partially funded by the European Commission (Contract IST-2000-26338). We are also grateful to all the professionals who voluntarily answered our surveys, providing us with a source of highly valuable information.",,,"Frivold, T.J., Lang, R.E., Fong, M.W., (1994), The Second International WWW Conference'94: Mosaic and the Web. Chicago, IL, U.S.A., October; Teasley, S., Wolinsky, S., (2001) Science, 292, p. 2254; LINK3D: Linking organizations through a secure environment for distributed drug discovery. EU-funded project IST-2000-26338; Cockburn, A., (2002), Agile Software Development. Addison-Wesley, Boston; (2001), http://www.trolltech.com, Qt 3.0, Trolltech AS; (2001), http://www.sgi.com, OpenInventor 2.1, Silicon Graphics Inc; http://mice.sdsc.edu, MICE, San Diego Supercomputer Center","Pastor, M.; GRIB, IMIM/UPF, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; email: mpastor@imim.es",,,,,,,,0920654X,,JCADE,"12825793","English","J. Comp.-Aided Mol. Des.",Article,"Final",,Scopus,2-s2.0-12444338957
"Nicolotti O., Pellegrini-Calace M., Altomare C., Carotti A., Carrieri A., Sanz F.","6603050960;13404393700;7005856522;7102635316;7003355704;7102263897;","Erratum: Ligands of neuronal nicotinic acetylcholine receptor (nAChR): Inferences from the hansch and 3D quantitative structure-activity relationship (QSAR) models (Current Medicinal Chemistry (2002) vol. 9 (1-29))",2002,"Current Medicinal Chemistry","9","8",,"899","",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036253496&partnerID=40&md5=935a0d682575b1ea5872a9063c3ecd2c","Dipartimento Farmaco-chimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy","Nicolotti, O., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Pellegrini-Calace, M., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Altomare, C., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Carotti, A., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Carrieri, A., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Sanz, F., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy",[No abstract available],,"erratum; error",,,,,,,,,,"Carotti, A.; Dipartimento Farmaco-chimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy",,,,,,,,09298673,,CMCHE,,"English","Curr. Med. Chem.",Erratum,"Final",,Scopus,2-s2.0-0036253496
"Honrubia M.-A., Rodrigo J., Cadavid M.-I., Calleja J.M., Sanz F., Loza M.-I.","7003365960;7103382103;6603422293;36832962500;7102263897;7003766926;","Influence of pH on the binding of diphenylmethylenepiperidines by 5-HT 2B receptors in rat stomach fundus",2002,"Chemical and Pharmaceutical Bulletin","50","3",,"395","398",,,"10.1248/cpb.50.395","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036515236&doi=10.1248%2fcpb.50.395&partnerID=40&md5=440f398fe763ff056d246468094519e8","Departments of Pharmacology, University of Santiago, E-15782 Santiago de Compostela, Spain; Research Group on Biomedical Informatics, Institut Municipal d'Investigació Mèdica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, E-08003 Barcelona, Spain","Honrubia, M.-A., Departments of Pharmacology, University of Santiago, E-15782 Santiago de Compostela, Spain; Rodrigo, J., Research Group on Biomedical Informatics, Institut Municipal d'Investigació Mèdica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, E-08003 Barcelona, Spain; Cadavid, M.-I., Departments of Pharmacology, University of Santiago, E-15782 Santiago de Compostela, Spain; Calleja, J.M., Departments of Pharmacology, University of Santiago, E-15782 Santiago de Compostela, Spain; Sanz, F., Research Group on Biomedical Informatics, Institut Municipal d'Investigació Mèdica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, E-08003 Barcelona, Spain; Loza, M.-I., Departments of Pharmacology, University of Santiago, E-15782 Santiago de Compostela, Spain","Cyproheptadine is one of the compounds exhibiting the highest activity at 5-HT2B receptors. In a previous work we analysed the relevance of the amino group in diphenylmethylenepiperidines (DPMP), which are open cyproheptadine analogues. Only compounds containing N-H or N-methyl motifs, showed significant 5-HT2B activity. Surprisingly, the corresponding quaternary ammonium salt demonstrated a total lack of activity. Therefore, the question arises whether protonation favours the interaction of these compounds with 5-HT2B receptors. Consequently, we studied the protonation influence (by varying the pH of the medium) on the antagonism of serotonin by some cyproheptadine analogues in rat stomach fundus. The main results were: 1) N-protonation increases the activity of DPMPs. 2) Alkaline pH facilitates the occurrence of a non-surmountable antagonism. 3) The contrast between the activity of protonated DPMPs and the lack of activity of the corresponding quaternary ammonium cation, suggests either that the latter is prevented from acting by steric hindrance, or that the mechanism by which protonation may increase the activity depends not only on the charge of the proton, but also on its ability to form hydrogen bonds. © 2002 Pharmaceutical Society of Japan.","5-HT2B receptor; Binding mechanism; Cyproheptadine; Diphenylmethylenepiperidines; pH influence; Protonation","alkaline earth metal; ammonium derivative; cyproheptadine; piperidine derivative; proton; serotonin 2B receptor; piperidine derivative; serotonin 2B receptor; serotonin receptor; animal tissue; article; chemical binding; controlled study; hydrogen bond; hydrolysis; nonhuman; pH; proton transport; rat; stereospecificity; stomach fundus; animal; male; metabolism; pH; protein binding; Sprague Dawley rat; stomach; Animals; Hydrogen-Ion Concentration; Male; Piperidines; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2B; Receptors, Serotonin; Stomach",,"cyproheptadine, 129-03-3, 969-33-5; proton, 12408-02-5, 12586-59-3; Piperidines; Receptor, Serotonin, 5-HT2B; Receptors, Serotonin",,,,,,,"Barnes, N.M., Sharp, T., (1999) Neuropharmacol., 38, pp. 1083-1152; Roth, B.L., Willins, D.L., Kristiansen, K., Kroeze, W.K., (1998) Pharmacol. Ther., 79, pp. 231-257; Vane, J.R., (1959) Br. J. Pharmacol. Chemother., 14, pp. 87-98; Foguet, M., Hoyer, D., Pardo, L.A., Parekh, A., Kluxen, F.W., Kalkman, H.O., Stuhmer, W., Lübbert, H., (1992) EMBO J., 11, pp. 3481-3487; Kursar, J.D., Nelson, D.L., Wainscott, D.B., Cohen, M., Baez, M., (1992) Mol. Pharmacol., 42, pp. 549-557; Kursar, J.D., Nelson, D.L., Wainscott, D.B., Baez, M., (1994) Mol. Pharmacol., 46, pp. 227-234; Schmuck, K., Christoph, U., Engels, P., Lübbert, H., (1994) FEBS Lett., 342, pp. 85-90; Wang, H.Y., Eberle-Wang, K., Simansky, K.J., Friedman, E., (1993) J. Pharmacol. Exp. Ther., 267, pp. 1002-1011; Wainscott, D.B., Cohen, M.L., Schenck, K.W., Audia, J.E., Nissen, J.S., Baez, M., Kursar, J.D., Nelson, D.L., (1993) Mol. Pharmacol., 43, pp. 419-426; Tournois, C., Mutel, V., Manivet, P., Launay, J.M., Kellermann, O., (1998) J. Biol. Chem., 273, pp. 17498-17503; Ellis, E.S., Byrne, C., Murphy, O.E., Tilford, N.S., Baxter, G.S., (1995) Br. J. Pharmacol., 114, pp. 400-404; Glusa, E., Pertz, H.H., (2000) Br. J. Pharmacol., 130, pp. 692-698; Launay, J.B., Bondoux, D., Callebert, J., Choi, D.S., Loric, S., Maroteaux, L., (1996) J. Biol. Chem., 271, pp. 3141-3147; Rothman, R.B., Baumann, M.H., Savage, J.E., Rauser, L., McBride, A., Hufeisen, S.J., Roth, B.L., (2000) Circulation, 102, pp. 2836-2841; Fitzgerald, L.W., Burn, T.C., Brown, B.S., Patterson, J.P., Corjay-M, H., Valentine, P.A., Sun, J.H., Robertson, D.W., (2000) Mol. Pharmacol., 57, pp. 75-81; Loza, M.I., Sanz, F., Cadavid, M.I., Honrubia, M., Orallo, F., Fontenla, J.A., Calleja, J.M., Villaverde, M.C., (1993) J. Pharm. Sci., 82, pp. 1090-1093; Kristiansen, K., Kroeze, W.K., Willins, D.L., Gelber, E.I., Savage, J.E., Glennon, R.A., Roth, B.L., (2000) J. Pharmacol. Exp. Therap., 293, pp. 735-746; Benveniste, M., Mayer, M.L., (1992) Mol. Pharmacol., 42, pp. 679-686; Loutzenhiser, R., Matsumoto, Y., Okawa, W., Epstein, M., (1990) Cir. Res., 67, pp. 426-439; Osman, R., Topiol, S., Rubenstein, L., Weinstein, H.A., (1987) Mol. Pharmacol., 32, pp. 699-705; Frankhuijzen, A.L., Bonta, I.L., (1974) Eur. J. Pharmacol., 26, pp. 220-230; Glennon, R.A., Peroutka, S.J., Dukat, M., (1991) Serotonin: Molecular Biology, Receptors and Functional Effects, pp. 186-191. , ed. by Fozard J. R., Saxena P. R., Birkhäuser Verlag, Basel; Vane, J.R., (1957) Br. J. Pharmacol., 12, pp. 344-349; Van Rossum, J.M., (1963) Arch. Int. Pharmacodyn., 143, pp. 299-330; Arunlaksana, O., Shild, H.O., (1959) Br. J. Pharmacol., 14, pp. 48-58; Tallarida, R.J., Murray, R.B., (1978) Manual of Pharmacologic Calculations with Computer Programs, , Spriger-Verlag, New York","Loza, M.-I.; Departments of Pharmacology, University of Santiago, E-15782 Santiago de Compostela, Spain; email: ffmabel@usc.es",,,,,,,,00092363,,CPBTA,"11911205","English","Chem. Pharm. Bull.",Article,"Final",Open Access,Scopus,2-s2.0-0036515236
"Brea J., Rodrigo J., Carrieri A., Sanz F., Cadavid M.I., Enguix M.J., Villazón M., Mengod G., Caro Y., Masaguer C.F., Raviña E., Centeno N.B., Carotti A., Loza M.I.","6603008588;7103382103;7003355704;7102263897;6603422293;6508152843;6507618078;7007000921;7005273736;6701715235;56264803900;6701440183;7102635316;7003766926;","New serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonists: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones",2002,"Journal of Medicinal Chemistry","45","1",,"54","71",,54,"10.1021/jm011014y","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037011897&doi=10.1021%2fjm011014y&partnerID=40&md5=f39380b8498b5ffdd6e0b61b36a4d145","Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Research Group on Biomedical Informatics, IMI, Universitat Pompeu Fabra, C/Drive Aiguader 80, E-08003, Barcelona, Spain; Dipartimento Farmacochimico, University of Bari, Via Orabona, 4, I-70126, Bari, Italy; Departamento de Neuroquímica, Instituto de Investigaciones Biomédicas de Barcelona, CSIC-IDIBAPS, C/Rosselló, 161 Bis, E-08036, Barcelona, Spain; Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782, Santiago de Compostela, Spain","Brea, J., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Rodrigo, J., Research Group on Biomedical Informatics, IMI, Universitat Pompeu Fabra, C/Drive Aiguader 80, E-08003, Barcelona, Spain; Carrieri, A., Dipartimento Farmacochimico, University of Bari, Via Orabona, 4, I-70126, Bari, Italy; Sanz, F., Research Group on Biomedical Informatics, IMI, Universitat Pompeu Fabra, C/Drive Aiguader 80, E-08003, Barcelona, Spain; Cadavid, M.I., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Enguix, M.J., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Villazón, M., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; Mengod, G., Departamento de Neuroquímica, Instituto de Investigaciones Biomédicas de Barcelona, CSIC-IDIBAPS, C/Rosselló, 161 Bis, E-08036, Barcelona, Spain; Caro, Y., Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782, Santiago de Compostela, Spain; Masaguer, C.F., Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782, Santiago de Compostela, Spain; Raviña, E., Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782, Santiago de Compostela, Spain; Centeno, N.B., Research Group on Biomedical Informatics, IMI, Universitat Pompeu Fabra, C/Drive Aiguader 80, E-08003, Barcelona, Spain; Carotti, A., Dipartimento Farmacochimico, University of Bari, Via Orabona, 4, I-70126, Bari, Italy; Loza, M.I., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago de Compostela, E-15782 Santiago de Compostela, Spain","A series of 52 conformationally constrained butyrophenones have been synthesized and pharmacologically tested as antagonists at 5-HT2A, 5-HT2B, and 5-HT2C serotonin receptors, useful for dissecting the role of each 5-HT2 subtype in pathophysiology. These compounds were also a consistent set for the identification of structural features relevant to receptor recognition and subtype discrimination. Six compounds were found highly active (pKi &gt; 8.76) and selective at the 5-HT2A receptor vs 5-HT2B and/or 5-HT2C receptors. Piperidine fragments confer high affinity at the 5-HT2A receptor subtype, with benzofuranone- and thiotetralonepiperidine as the most selective derivatives over 5-HT2C and 5-HT2B receptors, respectively; Ki 2A/2C and/or KB 2A/2B ratios greater than 100 were obtained. Compounds showing a more pronounced selectivity at 5-HT2A/5-HT2C than at 5-HT2A/5-HT2B bear 6-fiuorobenzisoxazolyl- and pfluorobenzoylpiperidine moieties containing one methylene bridging the basic piperidine to the alkanone moiety. An ethylene bridge between the alkanone and the amino moieties led to ligands with higher affinities for the 5-HT2B receptor. Significant selectivity at the 5-HT2B receptor vs 5-HT2C was observed with 1-1[(1-oxo-1,2,3,4-tetrahydro-3-naphthyl)methyl]-4-[3(p-fluorobenzoyl) propyl]piperazine (more than 100-fold higher). Although piperidine fragments also confer higher affinity at 5-HT2C receptors, only piperazine-containing ligands were selective over 5-HT2A. Moderate selectivity was observed at 5-HT2C vs 5-HT2B (10-fold) with some compounds bearing a 4-[3-(6-fiuorobenzisoxazolyl)]piperidine moiety in its structure. Molecular determinants for antagonists acting at 5-HT2A receptors were identified by 3D-QSAR (GRIDGOLPE) studies. Docking simulations at 5-HT2A and 5-HT2C receptors suggest a binding site for the studied type of antagonists (between transmembrane helices 2, 3, and 7) different to that of the natural agonist serotonin (between 3, 5, and 6).",,"1 1[(1 oxo 1,2,3,4 tetrahydro 3 naphthyl)methyl] 4 [3 (2 fluorobenzoyl)propyl]piperazine; alkanone derivative; benzofuran derivative; butyrophenone derivative; methysergide; mianserin; piperidine derivative; serotonin; serotonin 2 antagonist; serotonin 2A antagonist; serotonin 2A receptor; serotonin 2B antagonist; serotonin 2B receptor; serotonin 2C antagonist; serotonin 2C receptor; unclassified drug; animal cell; animal tissue; aorta; article; CHO cell; choroid plexus; controlled study; drug binding site; drug receptor binding; drug selectivity; drug synthesis; frontal cortex; human; human cell; male; molecular model; nonhuman; quantitative structure activity relation; rat; receptor affinity; serotoninergic system; stomach fundus; Animals; Aorta; Butyrophenones; CHO Cells; Cricetinae; Cycloparaffins; Frontal Lobe; Heterocyclic Compounds; Humans; Ligands; Male; Models, Molecular; Muscle, Smooth, Vascular; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Antagonists; Stomach",,"methysergide, 16509-15-2, 361-37-5, 62288-72-6; mianserin, 21535-47-7, 24219-97-4; serotonin, 50-67-9; Butyrophenones; Cycloparaffins; Heterocyclic Compounds; Ligands; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Antagonists",,"Sigma, Spain",,,,,"Martin, G.R., Humphrey, P.P., Receptors for 5-hydroxytryptamine: Current perspectives on classification and nomenclature (1994) Neuropharmacology, 33, pp. 261-273; Roth, B.L., Craigo, S.C., Choudhary, M.S., Uluer, A., Monsma, F.J.J., Shen, Y., Meltzer, H.Y., Sibley, D.R., Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors (1994) J. Pharmacol. Exp. Ther., 268, pp. 1403-1410; Hoyer, D., Clarke, D.E., Fozard, J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J., Saxena, P.R., Humphrey, P.P., International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin) (1994) Pharmacol. Rev., 46, pp. 157-203; Uphouse, L., Multiple serotonin receptors: Too many, not enough, or just the right number? (1997) Neurosci. Biobehav. Rev., 21, pp. 679-698; Cowen, P.J., Serotonin receptor subtypes: Implications for psychopharmacology (1991) Br. J. Psychiatry Suppl., pp. 7-14; Roth, B.L., Willins, D.L., Kristiansen, K., Kroeze, W.K., 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): Where structure meets function (1998) Pharmacol. Ther., 79, pp. 231-257; Martin, G.R., 5-Hydroxytryptamine receptors (1998) The IUPHAR compendium of r eceptor characterization and classification, pp. 167-185; Felder, C.C., Kanterman, R.Y., Ma, A.L., Axelrod, J., Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis (1990) Proc. Natl. Acad. Sci. U.S.A., 87, pp. 2187-2191; Thellung, S., Barzizza, A., Maura, G., Raiteri, M., Serotonergic inhibition of the mossy fibre-granule cell glutamate transmission in rat cerebellar slices (1993) Naunyn-Schmiedebergs Arch. Pharmacol., 348, pp. 347-351; Loric, S., Maroteaux, L., Kellermann, O., Launay, J.M., Functional serotonin-2B receptors are expressed by a teratocarcinoma-derived cell line during serotoninergic differentiation (1995) Mol. Pharmacol., 47, pp. 458-466; Tournois, C., Mutel, V., Manivet, P., Launay, J.M., Kellermann, O., Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line. Involvement of arachidonic acid metabolism (1998) J. Biol. Chem., 273, pp. 17498-17503; Manivet, P., Mouillet, R.S., Callebert, J., Nebigil, C.G., Maroteaux, L., Hosoda, S., Kellermann, O., Launay, J.M., PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor (2000) J. Biol. Chem., 275, pp. 9324-9331; Kaufman, M.J., Hartig, P.R., Hoffman, B.J., Serotonin 5-HT2C receptor stimulates cyclic GMP formation in choroid plexus (1995) J. Neurochem., 64, pp. 199-205; Pazos, A., Cortes, R., Palacios, J.M., Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors (1985) Brain Res., 346, pp. 231-249; Roth, B.L., McLean, S., Zhu, X.Z., Chuang, D.M., Characterization of two [3H]ketanserin recognition sites in rat striatum (1987) J. Neurochem., 49, pp. 1833-1838; Willins, D.L., Deutch, A.Y., Roth, B.L., Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex (1997) Synapse, 27, pp. 79-82; Maayani, S., Wilkinson, C.W., Stollak, J.S., 5-Hydroxytryptamine receptor in rabbit aorta: Characterization by butyrophenone analogues (1984) J. Pharmacol. Exp. Ther., 229, pp. 346-350; Ullmer, C., Schmuck, K., Kalkman, H.O., Lubbert, H., Expression of serotonin receptor mRNAs in blood vessels (1995) FEBS Lett., 370, pp. 215-221; Pazos, A., Hoyer, D., Palacios, J.M., The binding of serotonergic ligands to the porcine choroid plexus: Characterization of a new type of serotonin recognition Site (1984) Eur. J. Pharmacol., 106, pp. 539-546; Pazos, A., Probst, A., Palacios, J.M., Serotonin receptors in the human brain-III. Autoradiographic mapping of serotonin-1 receptors (1987) Neuroscience, 21, pp. 97-122; Molineaux, S.M., Jessell, T.M., Axel, R., Julius, D., 5-HT1C receptor is a prominent serotonin receptor subtype in the central nervous system (1989) Proc. Natl. Acad. Sci. U.S.A., 86, pp. 6793-6797; Pompeiano, M., Palacios, J.M., Mengod, G., Distribution of the serotonin 5-HT2 receptor family mRNAs: Comparison between 5-HT2A and 5-HT2C receptors (1994) Brain Res. Mol. Brain Res., 23, pp. 163-178; Bradley, P.B., Engel, G., Feniuk, W., Fozard, J.R., Humphrey, P.P., Middlemiss, D.N., Mylecharane, E.J., Saxena, P.R., Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine (1986) Neuropharmacology, 25, pp. 563-576; Mengod, G., Pompeiano, M., Martinez-Mir, M.I., Palacios, J.M., Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites (1990) Brain Res., 524, pp. 139-143; Lopez-Gimenez, J.F., Mengod, G., Palacios, J.M., Vilaro, M.T., Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100, 907 (1997) Naunyn-Schmiedebergs Arch. Pharmacol., 356, pp. 446-454; Kursar, J.D., Nelson, D.L., Wainscott, D.B., Cohen, M.L., Baez, M., Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus (1992) Mol. Pharmacol., 42, pp. 549-557; Cohen, M.L., Fludzinski, L.A., Contractile serotonergic receptor in rat stomach fundus (1987) J. Pharmacol. Exp. Ther., 243, pp. 264-269; Foguet, M., Hoyer, D., Pardo, L.A., Parekh, A., Kluxen, F.W., Kalkman, H.O., Stuhmer, W., Lubbert, H., Cloning and functional characterization of the rat stomach fundus serotonin receptor (1992) EMBO J., 11, pp. 3481-3487; Baxter, G., Kennett, G., Blaney, F., Blackburn, T., 5-HT2 receptor subtypes: A family re-united? (1995) Trends Pharmacol. Sci., 16, pp. 105-110; Schmuck, K., Ullmer, C., Engels, P., Lubbert, H., Cloning and functional characterization of the human 5-HT2B serotonin receptor (1994) FEBS Lett., 342, pp. 85-90; Bonhaus, D.W., Bach, C., DeSouza, A., Salazar, F.H., Matsuoka, B.D., Zuppan, P., Chan, H.W., Eglen, R.M., The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene Products: Comparison with 5-HT2A and 5-HT2C receptors (1995) Br. J. Pharmacol., 115, pp. 622-628; Kursar, J.D., Nelson, D.L., Wainscott, D.B., Baez, M., Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor (1994) Mol. Pharmacol., 46, pp. 227-234; Duxon, M.S., Flanigan, T.P., Reavley, A.C., Baxter, G.S., Blackburn, T.P., Fone, K.C., Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system (1997) Neuroscience, 76, pp. 323-329; Meltzer, H.Y., An overview of the mechanism of action of clozapine (1994) J. Clin. Psychiatry, 55 (SUPPL. B), pp. 47-52; Wainscott, D.B., Lucaites, V.L., Kursar, J.D., Baez, M., Nelson, D.L., Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: Evidence for species differences (1996) J. Pharmacol. Exp. Ther., 276, pp. 720-727; Barker, E.L., Westphal, R.S., Schmidt, D., Sanders, B.E., Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands (1994) J. Biol. Chem., 269, pp. 11687-11690; Ward, R.P., Hamblin, M.W., Lachowicz, J.E., Hoffman, B.J., Sibley, D.R., Dorsa, D.M., Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry (1995) Neuroscience, 64, pp. 1105-1111; Monsma, F.J.J., Shen, Y., Ward, R.P., Hamblin, M.W., Sibley, D.R., Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs (1993) Mol. Pharmacol., 43, pp. 320-327; Blake, T.J., Tillery, C.E., Reynolds, G.P., Antipsychotic drug affinities at alpha2-adrenoceptor subtypes in post-mortem human brain (1998) J. Psychopharmacol. (London), 12, pp. 151-154; Bymaster, F.P., Nelson, D.L., DeLapp, N.W., Falcone, J.F., Eckols, K., Truex, L.L., Foreman, M.M., Calligaro, D.O., Antagonism by olanzapine of dopamine DI, serotonin(2), muscarinic, histamine H-1 and alpha(1)-adrenergic receptors in vitro (1999) Schizophr. Res., 37, pp. 107-122; Michal, P., Lysíkova, M., El-Fakahany, E.E., Tucek, S., Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors (1999) Eur. J. Pharmacol., 376, pp. 119-125; Seeman, P., Corbett, R., Van-Tol, H.H., Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors (1997) Neuropsychopharmacology, 16, pp. 93-110; Creese, I., Burt, D.R., Snyder, S.H., Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs (1976) Science, 192, pp. 481-483; Seeman, P., Van-Tol, H.H., Dopamine receptor pharmacology (1994) Trends Pharmacol. Sci., 15, pp. 264-270; Horacek, J., Novel antipsychotics and extrapyramidal side effects. Theory and reality (2000) Pharmacopsychiatry, 33 (SUPPL.), pp. 134-142; Aghajanian, G.K., Marek, G.J., Serotonin model of Schizophrenia: Emerging role of glutamate mechanisms (2000) Brain Res. Rev., 31, pp. 302-312; Green, M.F., Marshall, B.D.J., Wirshing, W.C., Ames, D., Marder, S.R., McGurk, S., Kern, R.S., Mintz, J., Does risperidone improve verbal working memory in treatment-resistant Schizophrenia? (1997) Am. J. Psychiatry, 154, pp. 799-804; Sipes, T.E., Geyer, M.A., DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum (1997) Brain Res., 761, pp. 97-104; Gleason, S.D., Shannon, H.E., Blockade of phencyclidine induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice (1997) Psychopharmacology, 129, pp. 79-84; Okuyama, S., Chaki, S., Kawashima, N., Suzuki, Y., Ogawa, S., Kumagai, T., Nakazato, A., Tomisawa, K., The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor Antagonist, in Rats (1997) Br. J. Pharmacol., 121, pp. 515-525; Ereshefsky, L., Riesenman, C., True, J.E., Javors, M., Serotonin mediated increase in cytosolic [Ca++] in platelets of risperidone-treated Schizophrenia patients (1996) Psychopharmacol. Bull., 32, pp. 101-106; Schmidt, C.J., (1996) Development of a Selective 5-HT2A Receptor Antagonist for the Treatment of Schizophrenia, , Presented at IBS's International Conference on Serotonin Receptors. Targets for New Therapeutic Agents; Padich, R.A., McCloskey, T.C., Kehne, J.H., 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100, 907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in wistar rats (1996) Psychopharmacology, 124, pp. 107-116; Martin, P., Waters, N., Carlsson, A., Carlsson, M.L., The apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 in a mouse model of Schizophrenia is counteracted by ritanserin (1997) J. Neural Transm., 104, pp. 561-564; Herrick-Davis, K., Grinde, E., Teitler, M., Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors (2000) J. Pharmacol. Exp. Ther., 295, pp. 226-232; Meltzer, H.Y., McGurk, S.R., The effects of clozapine, risperidone, and olanzapine on cognitive function in Schizophrenia (1999) Schizophr. Bull., 25, pp. 233-255; Reavill, C., Kettle, A., Holland, V., Riley, G., Blackburn, T.P., Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist (1999) Br. J. Pharmacol., 126, pp. 572-574; Knable, M.B., Weinberger, D.R., Dopamine, the prefrontal cortex and Schizophrenia (1997) J. Psychopharmacol., 11, pp. 123-131; Cussac, D., Newman, T.A., Nicolas, J.P., Boutin, J.A., Millan, M.J., Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: A parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol (2000) Naunyn-Schmiedebergs Arch. Pharmacol., 361, pp. 549-554; Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Miyano, M., Crystal structure of rhodopsin: A G protein-coupled receptor (2000) Science, 289, pp. 739-745; Wang, C.D., Gallaher, T.K., Shih, J.C., Site-directed mutagenesis of the serotonin 5-hydroxytryptamine2 receptor: Identification of amino acids necessary for ligand binding and receptor activation (1993) Mol. Pharmacol., 43, pp. 931-940; Baldwin, J.M., Schertler, G.F., Unger, V.M., An alpha-carbon template for the transmembrane Helices in the Rhodopsin family of G-protein-coupled receptors (1997) J. Mol. Biol., 272, pp. 144-164; Sealfon, S.C., Chi, L., Ebersole, B.J., Rodic, V., Zhang, D., Ballesteros, J.A., Weinstein, H., Related contribution of specific helix 2 And 7 residues to conformational activation of the serotonin 5-HT2A receptor (1995) J. Biol. Chem., 270, pp. 16683-16688; Almaula, N., Ebersole, B.J., Zhang, D., Weinstein, H., Sealfon, S.C., Mapping The Binding Site Pocket of the Serotonin 5-Hydroxytryptamine2A Receptor. Ser3.36(159) Provides a Second Interaction Site for the Protonated Amine of Serotonin but not of Lysergic Acid Diethylamide or Bufotenin (1996) J. Biol. Chem., 271, pp. 14672-14675; Kristiansen, K., Dahl, S.G., Edvardsen, Ø., A database of mutants and effects of site-directed mutagenesis experiments on G-protein coupled receptors (1996) Proteins: Struct., Funct., Genet., 26, pp. 81-94; Kristiansen, K., Kroeze, W.K., Willins, D.L., Gelber, E.I., Savage, J.E., Glennon, R.A., Roth, B.L., A Highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT2A serotonin receptor but does not participate in activation via a ""salt-bridge disruption"" mechanism (2000) J. Pharmacol. Exp. Ther., 293, pp. 735-746; Raviña, E., Negreira, J., Cid, J., Masaguer, C.F., Rosa, E., Rivas, M.E., Fontenla, J.A., Carrieri, A., Conformationally constrained butyrophenones with mixed dopaminergic (D2) and serotoninergic (5-HT2A, 5-HT2C) affinities: Synthesis, pharmacology, 3D-QSAR, and molecular Modeling of (Aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics (1999) J. Med. Chem., 42, pp. 2774-2797; Konvicka, K., Guarnieri, F., Ballesteros, J.A., Weinstein, H., A proposed structure for transmembrane segment 7 of G protein coupled receptors incorporating an Asn-Pro/Asp-Pro motif (1998) Biophys. J., 75, pp. 601-611; Forbes, I.T., Dabbs, S., Duckworth, D.M., Ham, P., Jones, G.E., King, F.D., Saunders, D.V., Wood, M.D., Synthesis, Biological Activity, and Molecular Modeling of Selective 5-HT(2C/2B) Receptor Antagonists (1996) J. Med. Chem., 39, pp. 4966-4977; Kennett, G.A., Wood, M.D., Bright, F., Cilia, J., Piper, D.C., Gager, T., Thomas, D., Blackburn, T.P., In Vitro And In Vivo Profile of SB 206553, a Potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties (1996) Br. J. Pharmacol., 117, pp. 427-434; Bromidge, S.M., Dabbs, S., Davies, D.T., Duckworth, D.M., Forbes, I.T., Ham, P., Jones, G.E., Wood, M.D., Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: Synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines (1998) J. Med. Chem., 41, pp. 1598-1612; Bromidge, S.M., Dabbs, S., Davies, D.T., Davies, S., Duckworth, D.M., Forbes, I.T., Gaster, L.M., Wood, M.D., Biarylcarbamoylindolines are novel and selective 5-HT2C receptor inverse agonists: Identification of 5-methyl1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl] carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/ anxiolytic agent (2000) J. Med. Chem., 43, pp. 1123-1134; Weinhardt, K.K., Bonhaus, D.W., De Souza, A., Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT2C receptor (1996) Bioorg. Med. Chem. Lett., 6, p. 2692; Bonhaus, D.W., Flippin, L.A., Greenhouse, R.J., Jaime, S., Rocha, C., Dawson, M., Van Natta, K., Martin, G.R., RS127445: A selective, high affinity, orally bioavailable 5-HT2B receptor antagonist (1999) Br. J. Pharmacol., 127, pp. 1075-1082; Nozulak, J., Kalkman, H.O., Floersheim, P., Hoyer, D., Schoeffter, P., Buerki, H.R., (+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H10-methylindolo[1,7-bc] [2,6]naphthyridine: A 5-HT2C/2B receptor antagonist with low 5-HT2A receptor affinity (1995) J. Med. Chem., 38, pp. 28-33; Bös, M., Stadler, H., Wichmann, J., Jenck, F., Martin, J.R., Moreau, J.L., Sleight, A.J., Synthesis of O-methylasparvenonederived serotonin-receptor antagonists (1998) Helv. Chim. Acta, 91, pp. 525-538; Claudi, F., Scoccia, L., Giorgioni, G., Accorroni, B., Marucci, G., Gessi, S., Siniscalchi, A., Borea, P.A., 4-(4-fluorobenzoyl)-1-[2(4-iodo-2,5-dimethoxyphenyl)ethyl]piperidine and its derivatives: Synthesis and affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors (1999) Eur. J. Med. Chem., 34, pp. 843-852; Forbes, I.T., Ham, P., Booth, D.H., Martin, R.T., Thompson, M., Baxter, G.S., Blackburn, T.P., Wood, M.D., 5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-flindole: A novel 5-HT2c/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity (1995) J. Med. Chem., 38, pp. 2524-2530; Cortizo, L., Santana, L., Raviña, E., Orallo, F., Fontenla, J.A., Castro, E., Calleja, J.M., De Ceballos, M.L., Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogues of butyrophenone (1991) J. Med. Chem., 34, pp. 2242-2247; Fontenla, J.A., Osuna, J., Rosa, E., Castro, M.E., Ferreiro, T., Loza, M.I., Calleja, J.M., De Ceballos, M.L., Synthesis and atypical antipsychotic profile of some 2-(2piperidinoethyl)benzocycloalkanones as analogues of butyrophenone (1994) J. Med. Chem., 37, pp. 2564-2573; Loza, M.I., Verde, I., Castro, M.E., Orallo, F., Fontenla, J.A., Calleja, J.M., Raviña, E., De Ceballos, M.L., 5-HT2 antagonist activity of 2-aminomethyltetralones (1991) Bioorg. Med. Chem. Lett., 1, pp. 717-720; Loza, M.I., Ferreiro, T.G., Sanz, F., Lozoya, E., Rodriguez, J., Manaut, F., Verde, I., Raviña, E., Antiserotoninergic activity of 2-aminoethylbenzocyclanones in rat aorta: Structure-activity relationships (1993) J. Pharrn. Sci., 82, pp. 513-517; Raviña, E., Fueyo, J., Masaguer, C.F., Negreira, J., Cid, J., Loza, I., Honrubia, A., De Ceballos, M.L., Synthesis And affinities for dopamine (D2) and 5-hydroxytryptamine (5-HT2A) receptors of 1-(benzoylpropyl)-4-(1-oxocycloalkyl-2-ethyl)-piperazines as cyclic butyrophenone derivatives (1996) Chem. Pharm. Bull., 44, pp. 534-541; Masaguer, C.F., Raviña, E., Fontenla, J.A., Brea, J., Tristan, H., Loza, M.I., Butyrophenone analogues in the Carbazole series as potential atypical antipsychotics: Synthesis and determination of affinities at D2, 5-HT2A, 5-HT2B and 5-HT2C receptors (2000) Eur. J. Med. Chem., 35, pp. 83-95; Masaguer, C.F., Casariego, I., Raviña, E., Conformationally restricted butyrophenones with mixed dopaminergic (D2) and serotoninergic (5-HT2A) affinities. Synthesis of 5-aminoethyl- and 6-aminomethyl-4-oxotetrahydroindoles as potential atypical antipsychotics (1999) Chem. Pharm. Bull., 47, pp. 621-632; Masaguer, C.F., Formoso, E., Raviña, E., Tristan, H., Loza, M.I., Rivas, E., Fontenla, J.A., Butyrophenone analogues in the Carbazole series: Synthesis and determination of affinities at D2 and 5-HT2A receptors (1998) Bioorg. Med. Chem. Lett., 8, pp. 3571-3576; Ravina, E., Casariego, I., Masaguer, C.F., Fontenla, J.A., Montenegro, G.Y., Rivas, M.E., Loza, M.I., Demontis, G.C., Conformationally constrained butyrophenones with affinity for dopamine (D1, D2, D4) and serotonin (5-HT2A, 5-HT2B, 5-HT2C) receptors. Synthesis of aminomethylbenzoy[b]furanones, and their evalution as antipsychotics (2000) J. Med. Chem., 43, pp. 4678-4693; Julia, S., Bonnet, Y., Etude des cétones avec noyau cyclopropane I. Les benzo- et naphtho- bicyclo- (0,1,4) hepténones (1957) B. Soc. Chim. Fr., pp. 1340-1347; Cramer, R.D., Patterson, D., Bunce, J.D., Comparative molecular field analysis (COMFA).1. Effects of shape on binding of steroids to carrier protein (1988) J. Am. Chem. Soc., 110, pp. 5959-5967; Baroni, M., Constantine, G., Cruciani, G., Valigi, R., Clementi, S., Generating Optimal Linear PLS estimation (GOLPE): An advanced chemometric tool for handling 3D QSAR problems (1993) Quant. Struct.-Act. Relat., 12, pp. 9-20; Dunn III, W.J., Wold, S., Edlund, U., Hellberg, S., Gasteiger, J., Multivariate structure-activity relationships between data from a battery of biological tests and an ensemble of chemical descriptors: The PLS methodol (1984) Quant. Struct.-Act. Relat., 3, pp. 131-137; Goodford, P.J., A computational procedure for determining energetically favorable binding sites on biologically important macromolecules (1985) J. Med. Chem., 28, pp. 849-857; Pastor, M., Cruciani, G., Clementi, S., Smart region definition: A new way to improve the predective ability and interpretability of three-dimensional quantitative structure-activity relationships (1997) J. Med. Chem., 40, pp. 1455-1464; Galliard, P., Carrupt, P.A., Testa, B., Boudon, A., Molecular lipophilicity pontential, a tool in 3D QSAR: Method and applications (1994) J. Comput.-Aided Mol. Des., 8, pp. 83-96; Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., PROCHECK: A program to check the stereochemical quality of protein structures (1993) J. Appl. Crystallogr., 26, pp. 283-291; McMartin, C., Bohacek, R.S., QXP: Powerful rapid computer algorithms for structure-based drug design (1997) J. Comput.-Aided Mol. Des., 11, pp. 333-344; Johnson, M.P., Wainscott, D.B., Lucaites, V.L., Baez, M., Nelson, D.L., Mutations of transmembrane IV and V serines indicate that all tryptamines do not bind to the rat 5-HT2A receptor in the same manner (1997) Mol. Brain Res., 49, pp. 1-6; Wang, C.D., Gallaher, T.K., Shih, J.C., Site-directed mutagenesis of the serotonin 5-hydroxytryptamine 2 receptor: Identification of amino acids necessary for ligand binding and receptor activation (1993) Mol. Pharmacol., 43, pp. 931-940; Almaula, N., Ebersole, B.J., Ballesteros, J.A., Weinstein, H., Sealfon, S.C., Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: Direct and indirect effects on ligand affinity mediated by the same locus (1996) Mol. Pharmacol., 50, pp. 34-42; Vogel, A.I., (1989) Vogel's Textbook of Practical Organic Chemistry, 5th ed., , Longman: Harlow, U.K; Cheng, Y., Prusoff, W.H., Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction (1973) Biochem. Pharmacol., 22, pp. 3099-3108; Hoyer, D., Martin, G.R., Classification and nomenclature of 5-HT receptors: A comment on current issues (1996) Behav. Brain Res., 73, pp. 263-268; Gruetter, C.A., Lemke, S.M., Anestis, D.K., Szarek, J.L., Valentovic, M.A., Potentiation of 5-hydroxytryptamine-induced contraction in rat aorta by chlorpheniramine, citalopram and fluoxetine (1992) Eur.J. Pharmacol., 217, pp. 109-118; Fukuda, S., Su, C., Lee, T.J., Mechanisms of extraneuronal serotonin uptake in the rat aorta (1986) J. Pharmacol. Exp. Ther., 239, pp. 264-269; Cohen, M.L., Fuller, R.W., Wiley, K.S., Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle (1981) J. Pharmacol. Exp. Ther., 218, pp. 421-425; Van Rossum, J.M., Cumulative dose-response curves II. Technique for the making of dose-response curves in the isolated organs and the evaluation of drug parameters (1963) Arch. Intern. Med., pp. 143-299; Mackay, D., How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? (1978) J. Pharm. Pharmacol., 30, pp. 312-313; Vane, J.R., A sensitive method for the assay of 5-hydroxytryptamine (1957) Br. J. Pharmacol., 12, pp. 344-349; SYBYL 6.5, , Tripos Association, St. Louis, MO; Stewart, J.J.P., MOPAC: A semiempirical orbital program (1990) J. Comput.-Aided Mol. Des., 4, pp. 1-103; Holtje, H.D., Folkers, G., (1997) Molecular modeling: Basic principles and applications, , VCH: Weinheim; Ballesteros, J.A., Weinstein, H., Integrated methods for the construction of three-dimensional models and computacional probing of structure-function relations in G protein coupled receptors (1995) Methods Neurosci., 25, pp. 366-428; Carrieri, A., Centeno, N.B., Rodrigo, J., Sanz, F., Carotti, A., Theoretical evidence of a salt bridge disruption as the initiating process for the α1d-adrenergic receptor activation: A molecular dynamics and docking study (2001) Proteins, 43, pp. 382-394; Attwood, T.K., Beck, M.E., Flower, D.R., Scordis, P., Selley, J.N., The PRINTS protein fingerprint database in its fifth year (1998) Nucleic Acids Res., 26, pp. 304-308; (1998) Insight II, 98.0, , Molecular Simulation Inc.: San Diego; Pearlman, D.A., Case, D.A., Caldwell, J.W., Ross, W.S., Cheatham III, T.E., Ferguson, D.M., Seibel, G.L., Kollman, P.A., (1995) AMBER, version 4.1","Loza, M.I.; Departamento de Farmacología, Facultad de Farmacia, Univ. de Santiago de Compostela, E-15782 Santiago de Compostela, Spain; email: ffmabel@usc.es",,,,,,,,00222623,,JMCMA,"11754579","English","J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-0037011897
"Gutiérrez-De-Terán H., Lozano J.J., Segarra V., Sanz F.","6507897412;7103062769;6603951720;7102263897;","Molecular diversity sample generation on the basis of quantum-mechanical computations and principal component analysis",2002,"Combinatorial Chemistry and High Throughput Screening","5","1",,"49","57",,2,"10.2174/1386207023330543","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036213553&doi=10.2174%2f1386207023330543&partnerID=40&md5=16e241e89f2632ca9ec6865b8d349a23","Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain","Gutiérrez-De-Terán, H., Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Lozano, J.J., Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Segarra, V., Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Sanz, F., Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain","The present study introduces a new strategy of selection of a maximum diversity sample of n compounds from N available in a molecular database. This strategy can be useful in pharmacological screening, combinatorial chemistry or parallel synthesis planning. It consists of first describing the compounds by means of parameters derived from quantum mechanical computations (water solvation ΔG, benzene solvation ΔG, octanol solvation ΔG, dipolar moment), as well as standard molecular parameters such as solvent-accessible surface area and molecular weight. Solvation parameters are used because of the importance of this phenomenon in the pharmacological behaviour. Redundant information in the description of the compounds is eliminated by using principal components (PC) instead of the original descriptors. Based on the similarity between the N compounds in the PC space, they are classified into n groups by k-means cluster analysis. The compounds that are nearest to the centroid of each cluster constituted the maximum diversity sample. When practical difficulties exist for the use of one of the proposed compounds, another also close to the cluster centroid can substitute for it. This strategy has been tested in the selection of a sample of 50 amines from the 923 available in the Aldrich catalogue. The results have been contrasted with those obtained from an optimal, distance-based experimental design, resulting in an 86% of agreement between both approaches. An R2-like diversity coefficient has been used to assess the quality of the proposed solutions.",,"solvent; article; cluster analysis; combinatorial chemistry; mathematical computing; molecular weight; principal component analysis; priority journal; quantum mechanics; solvation; surface property; synthesis",,,,,,,,,"Special issue on ""Computational methods for the analysis of molecular diversity"" (1997) Perspect. Drug Discov. Design, 7-8; Newton, C.G., (1999) Molecular diversity in drug design, pp. 23-42. , Dean, P. M.; Lewis, R. A. Eds.; Kluwer Academic Publishers: Dordrecht; Ch 2; Gund, P., Sigal, N.H., (1999) Immunol. Today, 2 (SUPPL. 1), p. 25; SPSS 9.0, SPSS Inc. Chicago; Polanski, J., Jarzembek, K., Gasteiger, J., (2000) Comb. Chem. High Throughput Screen, 3, p. 481; Ros, F., Audouze, K., Pintore, M., Chretien, J.R., (2000) SAR QSAR Environ. Res., 11, p. 281; Spellmeyer, D.C., Grootenhuis, P.D.J., (1999) Ann. Rep. Med. Chem., 34, p. 287; Gillet, V.J., (1999) Molecular diversity in drug design, pp. 43-65. , Dean P. M.; Lewis, R. A. Eds.; Kluwer Academic Publishers: Dordrecht; Ch 3. And references there in; Downs, G.M., Willett, P., (1994) J. Chem. Inf. Comput. Sci., 34, p. 1094; Kubinyi, H., (1993) QSAR: Hansch analysis and related approaches, , VCH: Weinheim; Gibson, S., McGuire, R., Rees, D.C., (1996) J. Med. Chem., 39, p. 4065; Joliffe, I.T., Morgan, B.J.T., (1992) Stat. Methods Med. Res., 1, p. 69; Langer, T., Hoffman, R.D., (1998) Quant. Struct. -Act. Relat., 17, p. 211; Eriksson, L., Johansson, E., (1996) Chemom. Intell. Lab. Sys., 34, p. 1; Oprea, T., Gottfries, T., ChemGPS, A chemical space navigation tool (2000) 13th European Symposium on QSAR, , Düsseldorf; Voght, W., Nagen, D., Sator, H., (1987) Cluster analysis in clinical chemistry: A model, , J Wiley & Sons, Ltd.: Chichester; Sheridan, R.P., SanFeliciano, S.G., Kearsley, S.K., (2000) J. Mol. Graph., 18, p. 320; Gardiner, E.J., Holliday, J.D., Willet, P., Wilton, D.J., Artymiuk, P.J., (1998) Quant. Struct.-Act. Relat., 17, p. 232; Hudson, B.D., Hyde, R.M., Rahr, E., Wood, J., (1996) Quant. Struct.-Act. Relat., 15, p. 285; Späth, H., (1977) Cluster-Analyse-Algorithm zur Objektklassifizierung und Datenreduction, 2nd revised Ed., , R. Oldenbourg Verlag: Munich; Marengo, E., Todeschini, R., (1992) Chemom. Intell. Lab. Sys., 16, p. 37; Gasteiger, J., Rudolph, C., Sadowski, J., (1990) Tetrahedron Comp. Method., 3, p. 537; Sadowski, J., Gasteiger, J., Klebe, G., (1994) J. Chem. Inf. Comput. Sci., 34, p. 1000; Hawkins, G.D., Giesen, D.J., Lynch, G.C., Chambers, C.C., Rossi, I., Storer, J.W., Li, J., Truhlar, D.G., (1997) AMSOL-version 6.5.2, , University of Minnesota, Minneapolis; Chambers, C.C., Hawkins, G.D., Cramer, C.J., Truhlar, D.G., (1996) J. Org. Chem., 61, p. 8720; (1999) Q2 4.5. Multivariate Infometric Analisis srl, , Perugia, Italy; Hassan, M., Bielawski, J.P., Hempel, J.C., Waldman, M., (1996) Mol. Divers, 2, p. 64; Cummins, D.J., Andrews, C.W., Bentley, J.A., Cory, M., (1996) J. Chem. Inf. Comput. Sci., 36, p. 750; Patterson, D.E., Cramer, D.E., Ferguson, A.M., Clark, R.D., Weinberger, L.E., (1996) J. Med. Chem., 39, p. 3049; Bailey, D.S., Furness, L.M., Dean, P.M., (1999) Immunol. Today, 2 (SUPPL. 1), p. 6","Sanz, F.; Res. Group on Biomedical Informatics, IMIM, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; email: fsanz@IMIM.ES",,,"Bentham Science Publishers B.V.",,,,,13862073,,CCHSF,"11860339","English","Comb. Chem. High Throughput Screen.",Article,"Final",,Scopus,2-s2.0-0036213553
"Nicolotti O., Pellegrini-Calace M., Altomare C., Carotti A., Carrieri A., Sanz F.","6603050960;13404393700;7005856522;7102635316;7003355704;7102263897;","Ligands of neuronal nicotinic acetylcholine receptor (nAChR): Inferences from the Hansch and 3-D quantitative structure-activity relationship (QSAR) models",2002,"Current Medicinal Chemistry","9","1",,"1","29",,36,"10.2174/0929867023371463","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036230488&doi=10.2174%2f0929867023371463&partnerID=40&md5=a4b3a92cdf9e637ff4052de756ae56b8","Dipartimento Farmacochimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy","Nicolotti, O., Dipartimento Farmacochimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Pellegrini-Calace, M., Dipartimento Farmacochimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Altomare, C., Dipartimento Farmacochimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Carotti, A., Dipartimento Farmacochimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Carrieri, A., Dipartimento Farmacochimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; Sanz, F., Dipartimento Farmacochimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy","Neuronal acetylcholine ion channel receptors (nAChRs), that exist in several subtypes resulting from a different organisation of various subunits around the central ion channel, are involved in a variety of functions and disorders of the central nervous system. There is evidence to implicate a deficit of nAChRs in the symptomatology of severe neurologic pathologies, such as Alzheimer's and Parkinson's diseases. Reliable three-dimensional structures of nAChRs are not available yet, and this hampers adopting structure-based approaches in designing new ligands. Also pharmacophore models are not reliable enough to be used in ligand-based approaches to drug design and little structure-activity work has been reported so far. This paper deals with structure-activity relationships of a wide series of nicotinic ligands. It provides results from a study of the quantitative structure activity relationships (QSARs) based on literature data of about 270 nicotinic agonists, belonging to various chemical classes. The QSAR study was carried out by using either a classical Hansch approach or a Comparative Molecular Field Analysis (CoMFA). Within each congeneric series, Hansch-type equations revealed detrimental steric effects as the factors mainly modulating the receptor affinity, whereas CoMFA allowed us to merge progressively models obtained for each class of congeners into a more general one that showed good crossvalidation statistics. The CoMFA coefficient isocontour maps illustrated, at the 3-D level, the most relevant interactions responsible for a high receptor affinity, whereas the robustness of the global three-dimensional QSAR/CoMFA (n = 206, q2 = 0.749, r2 = 0.847, s= 0.600) model was supported by the high value of the prediction statistics (r2 pred = 0.961) and confirmed by the satisfactory predictions of the affinity data of an external set of 18 recently published ligands with chemical structures even quite diverse from those included in the training set.",,"3 dimethylaminomethylpyridine; anatoxin; anatoxin derivative; arecolone derivative; arylocymethylazacyclic derivative; azetidine derivative; cystisine derivative; cytisine; epibatidine derivative; ion channel; isoarecolone derivative; isonicotine; isoxazole derivative; ligand; napthyridine derivative; nicotine; nicotine derivative; nicotinic agent; nicotinic receptor; nitrogen policyclic derivative; phenoxymethylazacyclic derivative; phenylpyrrolidine derivative; protein subunit; pyrido[3,4 d]azepine derivative; pyridyloxymethylazetidine derivative; pyridyloxymethylpyrrolidine derivative; pyrrolidine derivative; pyrrolo[3,2 h]isoquinoline derivative; pyrrolo[3,4 c]pyridine derivative; receptor subtype; unclassified drug; unindexed drug; Alzheimer disease; article; calculation; central nervous system disease; controlled study; disease severity; drug design; drug structure; molecular model; nerve cell; Parkinson disease; pharmacophore; prediction; protein structure; quantitative structure activity relation; receptor affinity; statistical analysis; stereospecificity; symptomatology",,"cytisine, 485-35-8; nicotine, 54-11-5",,,,,,,"McDonald, I.A., Cosford, N., Vernier, J.M., (1995) Ann. Rep. in Med. Chem, 5, p. 41; Holladay, M.W., Lebold, S.A., Lin, N.-H., (1995) Drug Dev. Res, 35, p. 191; Holladay, M.W., Dart, M.J., Lynch, J.K., (1997) J. Med. Chem, 40, p. 4169; Levin, E.D., (1996) Drug Dev. Res, 38, p. 188; Stolerman, I.P., Mirza, N.R., Shoaib, M., (1995) Med. Chem. Rev, 15, p. 47; Gualtieri, F., (2000) Pharm. Acta Helvet, 74, p. 85; Newhouse, P.A., Kelton, M., (2000) Pharm. Acta Helvet, 74, p. 91; Schmitt, J.D., (2000) Curr. Med. Chem, 7, p. 749; Shacka, J.J., Robinson, S.E., (1996) Med. Chem. Res, 6, p. 444; Unwin, N., (1993) J. Mol. Bio, 229, p. 1101; Miyazawa, A., Fujiyoshi, Y., Stowell, M., Unwin, N., (1999) Mol. Biol, 288, p. 765; Lugovskoy, A.A., Maslennikov, I.V., Utkin, Y., Tsetlin, V.I., Cohen, J.B., Arseniev, A.S., (1998) Eur. J. Bioche, 255, p. 455; Dart, M.J., Wasicak, K.B., Ryther, K.B., Schrimpf, M., Kim, K.H., Anderson, D.J., Sullivan, J.P., Meyer, M., (2000) Pharm. Acta Helvet, 74, p. 115; Edelstein, S.J., Changeux, J.P., (1996) Experientia, 5, p. 1083; Arneric, S.P., Brioni, J.D., (1999) Neuronal Nicotin Receptors, , Wiley-Liss:. New York; Hansch, C., Maloney, P.P., Fujita, T., Muir, R.M., (1962) Nature, 194, p. 178; Beers, W.H., Reich, E., (1970) Nature, 225, p. 917; Sheridan, R.P., Nilakantan, R., Dixon, J.S., Venkataraghavan, R.J., (1986) J. Med. Chem, 29, p. 899; Barlow, R.B., Johnson, O., (1989) Br. J. Pharmacol, 98, p. 799; Glennon, R.A., Maarouf, A., Fahmy, S., Martin, B., Fan, F., Yousif, Y., Shafik, R.M., Dukat, M., (1993) Med. Chem. Res, 2, p. 546; Glennon, R.A., Dukat, M., (1996) Med. Chem. Res, 6, p. 465; Dukat, M., (1994) Med. Chem. Res, 4, p. 433; Glennon, R.A., Herndon, J.L., Dukat, M., (1994) Med. Chem. Res, 4, p. 461; Glennon, R.A., Dukat, M., , pp. 271-284. , in ref. 15; Manallack, D.T., Gallagher, T., Livingstone, D.J., (1995) Neural networks in QSAR and Drug Design, , James Devillers, Ed.: Rillieux la Pape, France; Damaj, M.I., Glassco, W., Dukat, M., May, E.L., Glennon, R.A., Martin, B.R., (1996) Drug Dev. Res, 38, p. 177; Glennon, R.A., Herndon, J.L., Dukat, M., (1994) Med. Chem. Res, 4, p. 461; Lin, N.-H., Carrera, G.M., Anderson, D.J., (1994) J. Med. Chem, 37, p. 3542; Cosford, N.D.P., Bleicher, L., Herbaut, A., McCallum, S., Vernier, J.-M., Dawson, H., Whitten, J.P., McDonald, I.A., (1996) J. Med. Chem, 39, p. 3235; Dukat, M., Dowd, M., Damaj, M.I., Martin, B., El-Zahabi, M.A., Glennon, R.A., (1999) Eur. J. Med. Chem, 34, p. 31; Lin, N., Gunn, D.E., Li, Y., He, Y., Bai, H., Ryther, K.B., Keith, B., Holladay, M.W., (1998) Bioorg. Med. Chem. Lett, 8, p. 249; Holladay, M.W., Bai, H., Li, Y., Lin, N.-H., Daanen, J.F., Ryther, K.B., Wasicak, J.T., Arneric, S.P., (1998) Bioorg. Med. Chem. Lett, 8, p. 2797; Elliott, R.L., Kopecka, H., Gunn, D.E., Lin, N., Garvey, D.S., Ryther, K.B., Holladay, M.W., Arneric, S.P., (1996) Bioorg. Med. Chem. Lett, 6, p. 2283; Ward, J.S., Merritt, L., Bymaster, F.P., Calligaro, D.O., (1994) Bioorg. Med. Chem. Lett, 4, p. 573; Thomas, P., Brough, P.A., Gallagher, T., Wonnacott, S., (1994) Drug Dev. Res, 31, p. 147; Kanne, D., Abood, L., (1988) J. Med. Chem, 31, p. 506; Canu Boido, C., Sparatore, F., (1999) Il Farmaco, 54, p. 438; Cheng, Y.X., Dukat, M., Dowd, M., Fiedler, W.M., Martin, B., Damaj, M.I., Glennon, R.A., (1999) Eur. J. Med. Chem, 34, p. 177; Hansch, C., Leo, A., (1995) Exploring QSAR, 1. , ACS, Prof. Ref. Book: USA; Hansch, C., Leo, A., Hoekman, D., (1995) Exploring QSAR, 2. , ACS Prof. Ref. Book: USA; Verloop, A., (1985) QSAR and strategy in Drug Design of bioactive Compounds, , Seydel, J. Ed. VCH: Berlin; ClogP for Windows ver. 4.0, Biobyte Corp., Claremont, CA; Christensen, S.B., Schaumburg, K., (1983) J. Org. Chem, 48, p. 396; SYBYL, TRIPOS Inc., St. Louis, MO-USA; Cramer R.D. III, Patterson, D.E., Bunce, V., (1988) J. Amer. Chem. Soc, 110, p. 5959; Altomare, C., Carrupt, P.A., Gaillard, P., El Tayar, N., Testa, B., Carotti, A., (1992) Chem. Res. Toxicol, 5, p. 366; Altomare, C., Campagna, F., Carta, V., Cellamare, S., Carotti, A., Genchi, G., De Sarro, G., (1994) Il Farmaco, 49, p. 313; Carrieri, A., Altomare, C., Barreca, M.L., Contento, A., Carotti, A., Hansch, C., (1994) Il Farmaco, 49, p. 573; Thull, U., Kneubühler, S., Gaillard, P., Carrupt, P.A., Testa, B., Altomare, C., Carotti, A., McNaught, K., (1995) Biochem. Pharmacol, 50, p. 869; Kneubühler, S., Thull, U., Altomare, C., Carta, V., Gaillard, P., Carrupt, P.A., Carotti, A., Testa, B., (1995) J. Med. Chem, 38, p. 3874; McNaught, K.St.P., Thull, U., Carrupt, P.A., Testa, B., Altomare, C., Cellamare, S., Carotti, A., Marsden, C.D., (1995) Biochem. Pharmacol, 50, p. 1903; Carrieri, A., Brasili, L., Leonetti, F., Pigini, M., Giannella, M., Bousquet, P., Carotti, A., (1997) Bioorg. Med. Chem, 5, p. 843; Barreca, M.L., Carrieri, A., Carotti, A., Chimirri, A., Monforte, A.M., Pellegrini Calace, M., Rao, A., (1999) Bioorg. Med. Chem, 7, p. 2283; Cinone, N., Carrieri, A., Strappaghetti, G., Corsano, S., Barbaro, R., Carotti, A., (1999) Bioorg. Med. Chem, 7, p. 2615; Ravina, E., Negreira, J., Cid, J., Masaguer, C.F., Rosa, E., Rivas, M.E., Fontenla, J.A., Carrieri, A., (1999) J. Med. Chem, 42, p. 2774; Roma, G., Cinone, N., Di Braccio, M., Grossi, G., Leoncini, G., Signorello, M.G., Carotti, A., (2000) Bioorg. Med. Chem, 8, p. 751; Altomare, C., Carotti, A., Cellamare, S., Fanelli, F., Gasparrini, F., Villani, C., Carrupt, P.A., Testa, B., (1993) Chirality, 5, p. 527; Carotti, A., Altomare, C., Cellamare, S., Monforte, A.M., Bettoni, G., Loiodice, F., Tangari, N., Tortorella, V., (1995) J. Comp.-Aided Mol. Des, 9, p. 131; Altomare, C., Cellamare, S., Carotti, A., Barreca, M.L., Chimirri, A., Monforte, A.M., Gasparrini, F., Mazza, F., (1996) Chirality, 8, p. 556; Goodford, P.J., (1985) J. Med. Chem, 28, p. 849; Goodford, P., (1998), GRID v.17, Molecular discovery, Ltd.: Oxford, UK; Cruciani, G., Watson, K.A., (1994) J. Med. Chem, 37, p. 2589; GOLPE 4.5 Multivariate Infometric Analysis S.r.l, Perugia, (Italy); Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Valigi, R., Clementi, S., (1993) Quant. Struct.-Act. Relat, 12, p. 9; Barlow, R.B., Howard, J.A., Johnson, O., (1986) Acta Cryst. (Sect. C), 42, p. 853; Koskinen, A.M.P., Rapoport, H., (1985) J. Med. Chem, 28, p. 1301; Barlow, R.B., Johnson, O., (1989) Br. J. Pharmacol, 98, p. 799; McMartin, C., Bohacek, R.S., (1997) J. Comp.-Aided Mol. Des, 11, p. 333; Lin, N.H., Gunn, D.E., Li, Y., Bai, H., Ryther, K.B., Kuntzweiler, T., Donnelly-Roberts, D.L., Holladay, M.W., (1998) Bioorg. Med. Chem. Lett, 8, p. 249; Gaillard, P., Carrupt, P.A., Testa, B., Bouron, A., (1994) J. Comp.-Aided Mol. Des, 8, p. 83; Pastor, M., Cruciani, G., Clementi, S., (1997) J Med Chem, 40, p. 1455; Box, G.E.P., Hunter, W.G., Hunter, J.S., (1978) Statistics for Experimenters, , Wiley: New York; Elliott, R.L., Ryther, K.B., Anderson, D.J., Raszkiewicz, J.L., Campbell, J.E., Sullivan, J.P., Garvey, D.S., (1995) Bioorg. Med. Chem. Lett, 5, p. 991; Dukat, M., Fiedler, M., Dumas, D., Damaj, I., Martin, B.R., Rosecrans, J.A., James, J.R., Glennon, R.A., (1996) Eur. J. Med. Chem, 31, p. 875; Badio, B., Daly, A., (1994) J. Mol. Pharm, 45, p. 563; Tonder, J.E., Hansen, J.B., Begtrup, M., Petterson, I., Rimvall, K., Christensen, B., Ehrbar, U., Olesen, P.H., (1999) J. Med. Chem, 42, p. 4970; Gubernator, K., Böhm, H.J., (1998) Stucture-based Ligand Design, , Wiley-VCH: Weinheim; Gaillard, P., Carrupt, P.A., Testa, B., Schambel, P.J., (1996) J. Med. Chem, 39, p. 126; Pigini, M., Bousquet, P., Brasili, L., Carrieri, A., Cavagna, R., Dontenwill, M., Gentili, F., Carotti, A., (1998) Bioorg. Med. Chem, 6, p. 2245; Kubinyi, H., Folkers, G., Martin, Y.C., (1998) 3D QSAR in Drug Design: Recent Advances, , Kluwer/Escom: Dordrecht (ND); Anderson, D.J., Arneric, S.P., (1994) Eur. J. Pharmac, 253, p. 261; Badio, B., Garraffo, H.M., Plummerm, C.V., Padgett, W.L., Daly, J.W., (1997) Eur. J. Pharm, 321, p. 189; Glennon, R.A., Dukat, M., (2000) Pharm. Acta Helvet, 74, p. 103; Ferretti, G., Dukat, M., Giannella, M., Piergentili, A., Pigini, M., Quaglia, W., Damai, M.I., Glennon, R.A., (2000) Bioorg. Med. Chem. Lett, 10, pp. 2665-2668; Savini, L., Chiasserini, L., Pellerano, C., Biggio, G., Maciocco, E., Serra, M., Cinone, N., Carotti, A., (2001) Bioorg. Med. Chem, 9, pp. 431-444","Carotti, A.; Dipartimento Farmacochimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; email: carotti@farmchim.uniba.it",,,"Bentham Science Publishers B.V.",,,,,09298673,,CMCHE,"11864064","English","Curr. Med. Chem.",Article,"Final",,Scopus,2-s2.0-0036230488
"Rodrigo J., Barbany M., Gutiérrez-de-Terán H., Centeno N.B., De-Càceres M., Dezi C., Fontaine F., Lozano J.J., Pastor M., Villà J., Sanz F.","7103382103;57193913809;6507897412;6701440183;6507318524;6507203451;24755291000;7103062769;7102415847;7005142038;7102263897;","Comparison of biomolecules on the basis of molecular interaction potentials",2002,"Journal of the Brazilian Chemical Society","13","6",,"795","799",,12,"10.1590/S0103-50532002000600010","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036985383&doi=10.1590%2fS0103-50532002000600010&partnerID=40&md5=21f668ec55808bff5b2b171c9d3daba5","Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Unidad de Bioinformática, Ctro. de Biol. Molec. Severo Ochoa, CSIC-UAM, E-28049 Canto Blanco (Madrid), Spain","Rodrigo, J., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Barbany, M., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Gutiérrez-de-Terán, H., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Centeno, N.B., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; De-Càceres, M., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Dezi, C., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Fontaine, F., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Lozano, J.J., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain, Unidad de Bioinformática, Ctro. de Biol. Molec. Severo Ochoa, CSIC-UAM, E-28049 Canto Blanco (Madrid), Spain; Pastor, M., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Villà, J., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Sanz, F., Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain","Molecular Interaction Potentials (MIP) are frequently used for the comparison of series of compounds displaying related biological behaviors. These potentials are interaction energies between the considered compounds and relevant probes. The interaction energies are computed in the nodes of grids defined around the compounds. There is a need of detailed and objective comparative analyses of MIP distributions in the framework of structure-activity studies. On the other hand, MIP-based studies do not have to be restricted to series of small ligands, since such studies present also interesting possibilities for the analysis and comparison of biological macromolecules. Such analyses can benefit from the application of new methods and computational approaches. The new software MIPSim (Molecular Interaction Potentials Similarity analysis) has recently been introduced with the purpose of analyzing and comparing MIP distributions of series of biomolecules. This program is transparently integrated with other programs, like GAMESS or GRID, which can be used for the computation of the potentials to be analyzed or compared. MIPSim incorporates several definitions of similarity coefficients, and is capable of combining several similarity measures into a single one. On the other hand, MIPSim can perform automatic explorations of the maximum similarity alignments between pairs of molecules.","MIPSim; Molecular alignment; Molecular Electrostatic Potential (MEP); Molecular Interaction Fields (MIF); Molecular Interaction Potentials (MIP); Molecular similarity","ligand; serotonin 2A antagonist; serotonin 2A receptor; serotonin 2B receptor; serotonin 2C receptor; serotonin agonist; analytic method; computer program; conference paper; drug receptor binding; electric potential; macromolecule; molecular interaction; structure activity relation",,,,,,,,,"Goodford, P., (1985) J. Med. Chem., 28, p. 849; López-de-Briñas, E., Lozano, J.J., Centeno, N.B., Segura, J., González, M., De La Torre, R., Sanz, F., (2000) Molecular Modelling and Prediction of Bioactivity, p. 141. , Gundertofte, K.; Jørgensen, F.S., eds.; Kluwer Academic/Plenum Publishers: New York; Lozano, J.J., Pastor, M., Cruciani, G., Gaedt, K., Centeno, N.B., Gago, F., Sanz, F., (2000) J. Comput. Aided Mol. Des., 14, p. 341; Cramer, R.D., Patterson, D., Bunce, J.D., (1988) J. Am. Chem. Soc., 110, p. 5959; Baroni, M., Constantino, G., Cruciani, G., Valigi, R., Clementi, S., (1993) Quant. Struct-Act. Rel., 12, p. 9; Cruciani, G., Pastor, M., Guba, W., (2000) Eur. J. Pharm. Sci., 11, pp. S29; Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S., (2000) J. Med. Chem., 43, p. 3233; Sanz, F., Manaut, F., José, J., Segura, J., Carbó, M., De La Torre, R., (1988) J. Mol. Struc. - Theochem, 170, p. 171; Sanz, F., Manaut, F., Rodríguez, J., Lozoya, E., López-de-Briñas, E., (1993) J. Comput. Aided Mol. Des., 7, p. 337; De Càceres, M., Villà, J., Lozano, J.J., Sanz, F., (2000) Bioinformatics, 16, p. 568; Manaut, F., Sanz, F., José, J., Milesi, M., (1991) J. Comput. Aided Mol. Des., 5, p. 371; Schmidt, M.W., Baldridge, K.K., Boatz, J.A., Elbert, S.T., Gordon, M.S., Jensen, J.H., Koseki, S., Montgomery, J.A., (1993) J. Comput. Chem., 14, p. 1347; Kaersley, S.K., Smith, G.M., (1990) Tetrahedron Comput. Methodol., 3, p. 615; Klebe, G., Mietzner, T., Weber, F., (1994) J. Comput. Aided Mol. Des., 8, p. 751; Kastenholz, M.A., Pastor, M., Cruciani, G., Haaksma, E.E., Fox, T., (2000) J. Med. Chem., 43, p. 3033; Brea, J., Rodrigo, J., Carrieri, A., Sanz, F., Cadavid, M.I., Enguix, M.J., Villazón, M., Loza, M.I., (2002) J. Med. Chem., 45, p. 54","Rodrigo, J.; Res. Grp. on Biomed. Info. (GRIB), Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; email: grib@imim.es",,,"Sociedade Brasileira de Quimica",,,,,01035053,,JOCSE,,"English","J. Braz. Chem. Soc.",Conference Paper,"Final",Open Access,Scopus,2-s2.0-0036985383
"Nicolotti O., Pellegrini-Calace M., Carrieri A., Altomare C., Centeno N.B., Sanz F., Carotti A.","6603050960;13404393700;7003355704;7005856522;6701440183;7102263897;7102635316;","Neuronal nicotinic receptor agonists: A multi-approach development of the pharmacophore",2001,"Journal of Computer-Aided Molecular Design","15","9",,"859","872",,22,"10.1023/A:1013115717587","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035211319&doi=10.1023%2fA%3a1013115717587&partnerID=40&md5=5df2cbc163c90f24ca099bf59802f5c2","Dipartimento Farmacochimico, Universitá di Bari, Via Orabona, 4, 70125 Bari, Italy; Research Group on Biomedical Informatics, Institut Municipal d'Investigació Mèdica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, E-08003 Barcelona, Spain","Nicolotti, O., Dipartimento Farmacochimico, Universitá di Bari, Via Orabona, 4, 70125 Bari, Italy; Pellegrini-Calace, M., Dipartimento Farmacochimico, Universitá di Bari, Via Orabona, 4, 70125 Bari, Italy; Carrieri, A., Dipartimento Farmacochimico, Universitá di Bari, Via Orabona, 4, 70125 Bari, Italy; Altomare, C., Dipartimento Farmacochimico, Universitá di Bari, Via Orabona, 4, 70125 Bari, Italy; Centeno, N.B., Research Group on Biomedical Informatics, Institut Municipal d'Investigació Mèdica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, E-08003 Barcelona, Spain; Sanz, F., Research Group on Biomedical Informatics, Institut Municipal d'Investigació Mèdica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, E-08003 Barcelona, Spain; Carotti, A., Dipartimento Farmacochimico, Universitá di Bari, Via Orabona, 4, 70125 Bari, Italy","Based on the results obtained with different automated computational approaches as applied to the study of eleven high-affinity agonists of the neuronal nicotine acetylcholine receptor (nAChR), belonging to different chemical classes, new relevant features were detected which complement the existing pharmacophores. Convergent results from DISCO (Distance Comparison), QXP (Quick Explore), Catalyst/HipHop, and MIPSIM (Molecular Interaction Potential Similarity) allowed us to identify and locate, in a well defined spatial arrangement, three geometrically independent key structural features: (i) a positively charged nitrogen atom for ionic or hydrogen bond interactions, (ii) a lone pair of the pyridine nitrogen or a specific lone pair of a carbonyl oxygen, as a hydrogen bond acceptor, and (iii) a centre of a hydrophobic area generally occupied by aliphatic cycles. The pharmacophore presented herein, along with predictive 2D and 3D QSAR models recently developed in our group, could represent valuable computational tools for the design of new nAChR agonists having therapeutical potential.","Catalyst; CoMFA; DISCO; Nicotinic agonists; Pharmacophore model; QXP","hydrogen; nicotinic agent; nitrogen; oxygen; pyridine; article; binding affinity; catalyst; chemical bond; controlled study; drug design; drug receptor binding; drug structure; hydrogen bond; hydrophobicity; pharmacophore; priority journal; quantitative structure activity relation; structure analysis; Animals; Computer Simulation; Drug Design; Ligands; Models, Chemical; Neurons; Nicotinic Agonists; Rats; Receptors, Nicotinic",,"Ligands; Nicotinic Agonists; Receptors, Nicotinic","Catalyst/HipHop, Molecular Simulations, United States; DISCO, Tripos, United States; Molecular Interaction Potential Similarity; Quick Explore; QXP","Molecular Simulations, United States; Tripos, United States","Consiglio Nazionale delle Ricerche","We are very grateful to Professor Peter Goodford (University of Cambridge), Professor Roberto Todeschini (University ‘La Bicocca’, Milan), Professor Maur-izio Botta (University of Siena), Dr. Colin McMartin and Professor Luisa Mosti (University of Genoa) for providing a free access to Grid, Dragon 1.0, Catalyst/HipHop, QXP and DISCO softwares, respectively. Financial support by MURST (Rome) and CNR (Rome) are gratefully acknowledged.",,,"McDonald, I.A., Cosford, N., Vernier, J.M., (1995) Ann. Rep. in Med. Chem., 5, p. 41; Holladay, M.W., Lebold, S.A., Lin, N.H., (1995) Drug Dev. Res., 35, p. 191; Holladay, M.W., Dart, M.J., Lynch, J.K., (1997) J. Med. Chem., 40, p. 4169; Arneric, P., Brioni, J.D., (1999) Neuronal Nicotinic Receptors, , Wiley-Liss, New York, NY; Levin, E.D., (1996) Drug Dev. Res, 38, p. 188; Gualtieri, F., (2000) Pharm. Acta Helvet., 74, p. 85; Newhouse, P.A., Kelton, M., (2000) Pharm. Acta Helvet., 74, p. 91; Shacka, J.J., Robinson, S.E., (1996) Med. Chem. Res., 6, p. 444; Miyazawa, A., Fujiyoshi, Y., Stowell, M., Unwin, N., (1999) J. Mol. Biol., 288, p. 765; Dart, M.J., Wasicak, K.B., Ryther, K.B., Schrimpf, M.R., Kim, K.H., Anderson, D.J., Sullivan, J.P., Meyer, M.D., (2000) Pharm. Acta Helvet., 74, p. 115; Beers, W.H., Reich, E., (1970) Nature, 225, p. 917; Sheridan, R.P., Nilakantan, R., Dixon, J.S., Venkataraghavan, R.J., (1986) J. Med. Chem, 29, p. 899; Barlow, R.B., Johnson, O., (1989) Br. J. Pharmacol., 98, p. 799; Manallack, D.T., Gallagher, T., Livingstone, D.J., (1996) Neural Networks in QSAR and Drug Design, , Deviller, James (Ed.) Rillieux la Pape, France; Barreiro, E.J., Barreiro, G., Guimarães, C.R.W., Bicca de Alencastro, R., (2000) J. Mol. Str: Theochem., 532, p. 11; Tonder, J.E., Olesen, P., Hansen, J.B., Begtrup, M., Petterson, I., (2001) J. Comput. Aid. Mol. Des., 15, p. 247; Van de Waterbeemd, H., (1995) Chemometric Methods in Molecular Design, , Wiley-VCH, Weinheim; Damaj, M.I., Glassco, W., Dukat, M., May, L.M., Glennon, R.A., Martin, B.R., (1996) Drug Dev. Res, 38, p. 177; Nicolotti, O., Pellegrini-Calace, M., Altomare, C., Carotti, A., Sanz, F., Curr. Med Chem., , in press; (2000), DRAGON1.0, Talete srl, Todeschini, R. and Consonni, V; Allen, F.H., Kennard, O., (1993) Chem. Des. Autom News, 8, p. 31; Stewart, J.J.P., MOPAC: A semiempirical orbital program (1990) J. Comput Aid. Mol. Des., 4, p. 1; SYBYL, TRIPOS Inc., St. Louis, MO, USA; Vedani, A., Duniz, J.D., (1985) J. Am. Chem. Soc., 107, p. 7653; Ippolito, J.A., Alexander, R.S., Christianson, D.W., (1990) J. Mol. Biol., 215, p. 457; Kollman, P.A., Case, D., Singh, U.C., Alagona, G., Profeta, S., Weiner, P., (1984) J. Am. Chem. Soc., 106, p. 765; Polak, E., Ribiere, G., (1969) Rev. Fran. Infor.Rech. Oper., 16, p. 35; Thompson, P.E., Manallack, D.T., Blaney, F.E., Gallagher, T., (1992) J. Comput. Aid. Mol. Des., 6, p. 287; (1986), MacroModel 6.0; Copyright Columbia University; Jorgensen, W.L., Tirado-Rives, J., (1988) J. Am. Chem. Soc., 110, p. 1657; McMartin, C., Bohacek, R.S., (1995) J Comput. Aid. Mol. Des., 9, p. 237; McMartin, C., Bohacek, R.S., (1997) J Comput. Aid. Mol. Des., 11, p. 333; Martin, Y.C., Bures, M., Dahaner, E., DeLazzer, J., Lico, I., Pavlik, P., (1993) J. Comput. Aid. Mol. Des., 7, p. 83; Brint, A., Willett, P., (1987) J. Chem. Inf. Comput. Sci., 27, p. 152; Molecular Simulations Inc, 9865, Scranton Road, San Diego, CA 92121, USA; Barnum, D., Greene, J., Smellie, A., Sprague, P., (1996) J. Chem. Inf. Comput. Sci., 36, p. 563; Smellie, A., Teig, S., Towbin, P., (1995) J. Comp. Chem., 16, p. 171; Smellie, A., Kahn, S.D., Teig, S., (1995) J. Chem. Inf. Comput. Sci., 35, p. 295; Greene, J., Kahn, S., Savoj, H., Sprague, P., Teig, S., (1994) J. Chem. Inf. Comput. Sci., 34, p. 1297; Orozco, M., Luque, F.J., (1996) Molecular Electrostatic Potentials: Concepts and Applications. Theoretical and Computational Chemistry, 3, pp. 181-218. , Murray, J.S. and Sen, K. (Eds.), Elsevier, Amsterdam; Schmidt, M.W., Baldridge, K.K., Boatz, J.A., Elbert, S.T., Gordon, M.S., Jensen, J.H., Koseki, S., Montgomery, J.A., (1993) J. Comput. Chem., 14, p. 1347; De Càceres, M., Villà, J., Lozano, J.J., Sanz, F., (2000) Bioinformatics, 16, p. 568; Sanz, F., Manaut, F., Rodriguez, J., Lozoya, E., Lopez-de-Brinas, E., (1993) J. Comput. Aid. Mol. Des., 7, p. 337; Goodford, P.J., (1985) Med. Chem., 28, p. 849; Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Vagli, R., Clementi, S., (1993) Quant. Struct.-Act. Rel., 12, p. 9; Wermouth, C.G., Ganellin, C.R., Lindberg, P., Mitscher, L.A., (1998) Ann. Rep. Med. Chem., 36, p. 385","Carotti, A.; Dipartimento Farmacochimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy; email: carotti@farmchim.uniba.it",,,,,,,,0920654X,,JCADE,"11776295","English","J. Comp.-Aided Mol. Des.",Article,"Final",,Scopus,2-s2.0-0035211319
"Nicolotti O., Pellegrini-Calace M., Carrieri A., Altomare C., Centeno N.B., Sanz F., Carotti A.","6603050960;13404393700;7003355704;7005856522;6701440183;7102263897;7102635316;","Erratum: Neuronal nicotinic receptor agonists: A multi-approach development of the pharmacophore (Journal of Computer-Aided Molecular Design (2001) vol. 15 (859))",2001,"Journal of Computer-Aided Molecular Design","15","12",,"1153","",,,"10.1023/A:1015947323579","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035555780&doi=10.1023%2fA%3a1015947323579&partnerID=40&md5=1e499cb35de81ed80c52f01a56b2619a","Dipartimento Farmaco-chimico, Università di Bari, Via Orabona, 4, Bari 70125, Italy; Research Group on Biomedical Informatics, Institut Municipal d'Investigaciò Mèdica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, Barcelona E-08003, Spain","Nicolotti, O., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona, 4, Bari 70125, Italy; Pellegrini-Calace, M., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona, 4, Bari 70125, Italy; Carrieri, A., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona, 4, Bari 70125, Italy; Altomare, C., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona, 4, Bari 70125, Italy; Centeno, N.B., Research Group on Biomedical Informatics, Institut Municipal d'Investigaciò Mèdica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, Barcelona E-08003, Spain; Sanz, F., Research Group on Biomedical Informatics, Institut Municipal d'Investigaciò Mèdica, Universitat Pompeu Fabra, Carrer Dr. Aiguader 80, Barcelona E-08003, Spain; Carotti, A., Dipartimento Farmaco-chimico, Università di Bari, Via Orabona, 4, Bari 70125, Italy",[No abstract available],,"erratum; error; priority journal",,,,,,,,,,"Carotti, A.; Dipartimento Farmaco-Chimico, Università di Bari, Via Orabona 4, 70125 Bari, Italy",,,,,,,,0920654X,,JCADE,,"English","J. Comp.-Aided Mol. Des.",Erratum,"Final",,Scopus,2-s2.0-0035555780
"Carrieri A., Centeno N.B., Rodrigo J., Sanz F., Carotti A.","7003355704;6701440183;7103382103;7102263897;7102635316;","Theoretical evidence of a salt bridge disruption as the initiating process for the α1d-adrenergic receptor activation: A molecular dynamics and docking study",2001,"Proteins: Structure, Function and Genetics","43","4",,"382","394",,17,"10.1002/prot.1051","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035371114&doi=10.1002%2fprot.1051&partnerID=40&md5=0cc4b6d0c96d3d174c141648a00f50f3","Dipartimento Farmaco-Chimico, Università di Bari, Bari, Italy; Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona, Spain; Dipartimento Farmaco-Chimico, Università di Bari, Via Orabona 4, 70125- Bari, Italy","Carrieri, A., Dipartimento Farmaco-Chimico, Università di Bari, Bari, Italy; Centeno, N.B., Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona, Spain; Rodrigo, J., Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona, Spain; Sanz, F., Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Barcelona, Spain; Carotti, A., Dipartimento Farmaco-Chimico, Università di Bari, Bari, Italy, Dipartimento Farmaco-Chimico, Università di Bari, Via Orabona 4, 70125- Bari, Italy","This study reports the building of the three-dimensional structure of the rat α1d-adrenergic receptor through a topology approach based on the structure of the rhodopsin receptor from cryoelectron microscopy. The validity and reliability of the receptor model were assessed through exhaustive molecular dynamics and docking studies. Some interesting ligand-receptor interactions were identified along with significant differences between the binding mode of agonists and antagonists. The importance of the disruption of a salt bridge as a possible initial event leading to receptor activation is discussed on the basis of data from mutagenesis and molecular dynamics studies. © 2001 Wiley-Liss, Inc.","Conformational analysis; Discretamine; G protein-coupled receptors; Molecular modeling; Noradrenaline","alpha 1D adrenergic receptor; discretamine; G protein coupled receptor; noradrenalin; rhodopsin; article; binding site; cryoelectron microscopy; molecular dynamics; molecular model; mutagenesis; nonhuman; priority journal; protein analysis; protein structure; rat; receptor binding; receptor intrinsic activity; structure analysis; three dimensional imaging; Amino Acid Sequence; Animals; Berberine Alkaloids; Binding Sites; Ligands; Models, Molecular; Molecular Sequence Data; Norepinephrine; Protein Binding; Protein Conformation; Rats; Receptors, Adrenergic, alpha-1; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Saccharomyces cerevisiae Proteins; Salts; Solubility",,"adrenergic receptor alpha(1d); Berberine Alkaloids; discretamine, 605-34-5; GPR1 protein, S cerevisiae; Ligands; Norepinephrine, 51-41-2; Receptors, Adrenergic, alpha-1; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Saccharomyces cerevisiae Proteins; Salts",,,,,,,"Hieble, J.P., Bondinell, W.E., Ruffolo R.R., Jr., α-and β-adrenoceptors: From gene to the clinic. 1. Molecular biology and adrenoceptor subclassification (1998) J Med Chem, 28, pp. 3415-3444; Ruffolo R.R., Jr., Bondinell, W.E., Hieble, J.P., α-and β-adrenoceptors: From gene to the clinic. 2. Structure activity relationships and therapeutic applications (1998) J Med Chem, 28, pp. 3682-3716; Hirasawa, A., Horie, K., Tanaka, T., Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor (1993) Biochem Biophys Res Commun, 195, pp. 902-909; Ramarao, C.S., Denker, J.M., Perez, D.M., Gaivin, R.J., Riek, R.P., Graham, R.M., Genomic organisation and expression of the human alpha 1B-adrenergic receptor (1992) J Biol Chem, 267, pp. 21936-21945; Bruno, J.F., Whittaker, J., Song, J.F., Berelowitz, M., Molecular cloning and sequencing of a cDNA encoding a human alpha 1A adrenergic receptor (1991) Biochem Biophys Res Commun, 179, pp. 1485-1490; Farahbackhsh, Z.T., Ridge, K.D., Khorana, H.G., Hofmann, K.P., Mapping light-dependent structural changes in the cytoplasmic loop connecting helices C and D in rhodopsin: A site-directed spin labelling study (1995) Biochemistry, 34, pp. 8812-8819; Fanelli, F., Menziani, C., Scheer, A., Cotecchia, S., De Benedetti, P.G., Theoretical study of the electrostatically driven step of receptor-G protein recognition (1999) Proteins, 37, pp. 145-156; Schertler, G.F., Villa, C., Henderson, R., Projection structure of rhodopsin (1993) Nature, 362, pp. 770-772; Unger, V.M., Hargrave, P.A., Baldwin, J.M., Schertler, G.F., Arrangement of rhodopsin transmembrane α-helices (1997) Nature, 389, pp. 203-206; Palczewski, K., Kumasaka, T., Hori, T., Crystal structure of rhodopsin: A G protein-coupled receptor (2000) Science, 289, pp. 739-745; Kristiansen, K., Dahl, S.G., Ø, E., A database of mutants and effects of site-directed mutagenesis experiments on G-protein coupled receptors (1996) Proteins, 26, pp. 81-94; Porter, J.E., Hwa, J., Perez, D.M., Activation of the α1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint (1996) J Biol Chem, 271, pp. 28318-28323; Robinson, P.R., Cohen, G.B., Zhukovsky, E.A., Oprian, A.A., Constitutively active mutants of rhodopsin (1992) Neuron, 9, pp. 719-725; Hamaguchi, N., True, T.A., Saussy D.L., Jr., Jeffs, P.W., Phenylalanine in the second membrane-spanning domain of alpha 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists (1996) Biochemistry, 35, pp. 14312-14317; Cotecchia, S., Scheer, A., Diviani, D., Fanelli, F., De Benedetti, P.G., Molecular mechanisms involved in the activation and regulation of the α1-adrenergic receptor subtype (1998) II Farmaco, 53, pp. 273-277; Ballesteros, J.A., Weinstein, H., Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors (1995) Methods Neurosci, 25, pp. 366-428; Bairoch, A., Apweiler, R., The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000 (2000) Nucleic Acids Res, 28, pp. 45-48; Burkhard, R., Casadio, R., Fariselli, P., Chris, S., Prediction of helical transmembrane segments at 95% accuracy (1995) Protein Sci, 4, pp. 521-533; Persson, B., Argos, P., Prediction of transmembrane segments in proteins utilising multiple sequence alignments (1994) J Mol Biol, 237, pp. 182-191; Insight, 2. , Molecular Simulations Inc., San Diego, CA, USA; Weiner, S.J., Kollman, P.A., Case, D.A., A new force field for molecular mechanical simulation of nucleic acids and proteins (1984) J Amer Chem Soc, 106, pp. 765-784; Baldwin, J.M., Schertler, G.F., Unger, V.M., An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors (1997) J Mol Biol, 272, pp. 144-164; Ryckaert, J.P., Ciccotti, G., Berendsen, H.J.C., Numerical integration of the cartesian equation of motion of a system constraints: Molecular dynamics of N-alkanes (1977) J Comput Phys, 23, pp. 327-341; Srinivasan, B.N., Blundell, T.L., An evaluation of the performance of an automated procedure for comparative modelling of protein tertiary structure (1993) Prot Eng, 6, pp. 501-512; Savarese, T.M., Fraser, C.M., In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors (1992) Biochem J, 283, pp. 1-19; Perez, J.J., Villar, H.O., Loew, G.H., Characterisation of the low-energy domains for met-enkephalin (1992) J Comp Aided Mol Des, 6, pp. 175-190; Perez, J.J., Sanchez, Y.M., Centeno, N.B., Characterization of the conformational domains of bradykinin by computational methods (1995) J Peptide Sci, 1, pp. 227-235; Laskowski, R.A., Macarthur, M.W., Moss, D.S., Thornton, J.M., PRO-CHECK: A program to check the stereochemical quality of protein structures (1993) J Appl Cryst, 26, pp. 283-291; Allen, F.H., Kennard, O., 3D search and research using the Cambridge Structural Database (1993) Chem Des Autom News, 8, pp. 31-37; Goodford, P.J., A computational procedure for determining energetically favourable binding sites on biologically important macromolecules (1985) J Med Chem, 28, pp. 849-857; McMartin, C., Bohacek, R.S., QXP: Powerful, rapid computer algorithms for structure-based drug design (1997) J Comput Aided Mol Des, 11, pp. 333-344; Mohamadi, F., Richards, N.G.J., Guida, W.C., MacroModel - An integrated software system for modeling organic and bioorganic molecules using molecular mechanics (1990) J Comp Chem, 11, p. 440; Scheer, A., Fanelli, F., Costa, T., De Benedetti, P.G., Cotecchia, S., Constitutively active mutants of the α1b-adrenergic receptor: Role of highly conserved polar amino acids in receptor activation (1996) EMBO J, 15, pp. 3566-3578; Zhou, W., Flanagan, C., Ballesteros, J.A., A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin releasing hormone receptor (1994) Mol Pharmacol, 45, pp. 165-170; Zhang, D., Weinstein, H., Polarity conserved positions in transmembrane domains of G-protein coupled receptors and bacteriorhodopsin (1994) FEBS Lett, 334, pp. 207-212; Strader, C.D., Candelore, M.R., Hill, W.S., Sigal, I.S., Dixon, R.A., Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor (1989) J Biol Chem, 264, pp. 13572-13578; Hwa, J., Perez, D.M., The unique nature of the serine interactions for α1-adrenergic receptor agonist binding and activation (1996) J Biol Chem, 271, pp. 6322-6327; Cavalli, A., Fanelli, F., Taddei, C., De Benedetti, P.G., Cotecchia, S., Amino acids of the α1B-adrenergic receptor involved in agonist binding: Differences in docking catecholamines to receptor subtypes (1996) FEBS Lett, 399, pp. 9-13; Oefner, C., Bingelli, A., Brue, V., Renin inhibition by substituted piperidines: A novel paradigm for the inhibition of monomeric aspartic proteinases? (2000) Chem Biol, 6, pp. 127-131. , and reference therein; Perez, D.M., Hwa, J., Gaivin, R., Mathur, M., Brown, F., Graham, R.M., Constitutive activation of a single effector pathway: Evidence for multiple activation states of a G protein-coupled receptor (1996) Mol Pharmacol, 49, pp. 112-122; Hunter, C.A., Sounders, J.K.M., The nature of π-π interactions (1990) J Amer Chem Soc, 112, pp. 5525-55334; Ko, F.N., Guhl, H., Yu, S.M., Hou, Y.S., Wu, Y.C., Teng, C.M., (-)-Discretamine, a selective alpha 1D-adrenoceptor antagonist, isolated from Fisostigma glaucescens (1994) Br J Pharmacol, 112, pp. 1174-1180; Leopardi, A., Testa, R., Motta, G., De Benedetti, P.G., Hieble, P., Giardinà, D., α1-Adrenoceptors: Subtype and organoselectivity of different agents (1996) Perspective in Receptor Research, pp. 135-152. , Giardinà D, Piergentili A, Pigini M, Editors. New York: Elsevier Sci;B.V;; Zhao, M.M., John, H., Perez, D.M., Identification of critical extracellular loop residues involved in α 1-adrenergic receptor subtype-selective antagonist binding (1996) Mol Pharmacol, 50, pp. 1118-1126; Yeagle, P.L., Salloum, A., Chopra, A., Structures of the intradiskal loops and amino terminus of the G-protein receptor, rhodopsin (2000) Pept Res, 55, pp. 455-465; Kraulis, P.J., MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures (1991) J App Cryst, 24, pp. 946-950; Frishman, D., Argos, P., Knowledge-based secondary structure assignment (1995) Proteins, 23, pp. 566-579; Thompson, J.D., Higgins, D.G., Gibson, T.J., CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice (1994) Nucleic Acids Res, 22, pp. 4673-4680","Carotti, A.; Dipartimento Farmaco-Chimico, Università di Bari, Via Orabona 4, 70125-Bari, Italy; email: carotti@farmchim.uniba.it",,,,,,,,08873585,,PSFGE,"11340655","English","Proteins Struct. Funct. Genet.",Article,"Final",,Scopus,2-s2.0-0035371114
"López-Arrieta J.M., Rodríguez J.L., Sanz F.","6701748304;57199093141;7102263897;","Efficacy and safety of nicotine on Alzheimer's disease patients.",2001,"Cochrane database of systematic reviews (Online)",,"2",,"","",,19,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035235815&partnerID=40&md5=3c0780b824e86711b9f5be25d1466d22","Hospital de Cantoblanco, Consejería de Sanidad, Carretera de Colmenar km 14.500, Madrid, Madrid  28049., Spain","López-Arrieta, J.M., Hospital de Cantoblanco, Consejería de Sanidad, Carretera de Colmenar km 14.500, Madrid, Madrid  28049., Spain; Rodríguez, J.L., Hospital de Cantoblanco, Consejería de Sanidad, Carretera de Colmenar km 14.500, Madrid, Madrid  28049., Spain; Sanz, F., Hospital de Cantoblanco, Consejería de Sanidad, Carretera de Colmenar km 14.500, Madrid, Madrid  28049., Spain","BACKGROUND: Nicotine is a cholinergic agonist that also has a presynaptic effect in releasing acetylcholine. In animal model has been shown to reverse spatial memory deficits produced by lesions in the medial septal nucleus of rats, and in aged monkeys nicotine administration improves memory and alertness to visual stimuli. Observational studies have claimed a protective effect of smoking against Alzheimer's disease (AD), but recent studies have called this into question. Smoking is a risk factor for stroke and so, possibly, for vascular dementia. Because nicotine has adverse effects, it is important to conduct a systematic review to assess the clinical efficacy and safety of nicotine for patients with AD OBJECTIVES: To evaluate the efficacy and safety of nicotine, administered in any way or form, for people with Alzheimer's disease. SEARCH STRATEGY: The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 24 January 2001 using the term nicotine. SELECTION CRITERIA: All unconfounded, double-blind, randomized trials in which treatment with nicotine patches or administration of nicotine intravenously or in any other way or form was administered for more than a day and compared with placebo for people with Alzheimer's disease. DATA COLLECTION AND ANALYSIS: The one included trial did not present results suitable for inclusion in the review. MAIN RESULTS: The poor quality of trials did not allow any synthesis of data across studies. REVIEWER'S CONCLUSIONS: This review is not able to provide any evidence that nicotine is a useful treatment for Alzheimer's disease.",,"nicotine; nicotinic agent; Alzheimer disease; clinical trial; controlled clinical trial; double blind procedure; human; randomized controlled trial; review; Alzheimer Disease; Double-Blind Method; Humans; Nicotine; Nicotinic Agonists; Randomized Controlled Trials",,"nicotine, 54-11-5; Nicotine, 54-11-5; Nicotinic Agonists",,,,,,,,"López-Arrieta, J.M.email: med013440@nacom.es",,,,,,,,1469493X,,,"11406005","English","Cochrane Database Syst Rev",Review,"Final",,Scopus,2-s2.0-0035235815
"De Càceres M., Villà J., Lozano J.J., Sanz F.","6507318524;7005142038;7103062769;7102263897;","MIPSIM: Similarity analysis of molecular interaction potentials",2000,"Bioinformatics","16","6",,"568","569",,11,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033828444&partnerID=40&md5=b94f88ab2558f3dfb3c3d91e98aaae52","R.G. on Medical Informatics, IMIM, UPF, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Department of Chemistry, University of Southern California, Los Angeles, CA 90089, United States; School of Medicine, Universitat Autònoma de Barcelona, Spain","De Càceres, M., R.G. on Medical Informatics, IMIM, UPF, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Villà, J., R.G. on Medical Informatics, IMIM, UPF, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain, Department of Chemistry, University of Southern California, Los Angeles, CA 90089, United States; Lozano, J.J., R.G. on Medical Informatics, IMIM, UPF, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain, School of Medicine, Universitat Autònoma de Barcelona, Spain; Sanz, F., R.G. on Medical Informatics, IMIM, UPF, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain","MIPSIM is a computational package designed to analyse and compare 3D distributions of molecular interaction potentials (MIP) of series of biomolecules.",,"theophylline; article; chemical structure; computer program; controlled study; drug structure; information processing; Internet; molecular interaction; molecule; priority journal; structure analysis; three dimensional imaging; Computational Biology; Internet; Models, Molecular; Quantitative Structure-Activity Relationship; Software",,,"GAMESS; GRID; MIPSIM",,"Comisión Interministerial de Ciencia y Tecnología: SAF98-0148-C04-02","MIPSIM development has been partly funded by CESCA and CICYT (SAF98-0148-C04-02) grants. We thank previous developers of MEPSIM (F.Manaut, M.Bergés and J.Rodríguez), as well as J.Rodrigo, M.Pastor, G.Cruciani and P.Goodford for helpful discussions.",,,"Bagdassarian, C.K., Schramm, V.L., Schwartz, D., Molecular electrostatic potential analysis for enzymatic substrates, competitive inhibitors, and transition-state inhibitors (1996) J. Am. Chem. Soc., 118, pp. 8825-8836; Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Vagli, R., Clementi, S., Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3DQSAR problems (1993) Quant Struct.-Act. Rel., 12, pp. 9-20; Goodford, P., A computational procedure for determining energetically favourable binding sites on biologically important macromolecules (1985) J. Med. Chem., 28, pp. 849-857; (1995), InsightII Biosym/MSI Inc., San Diego; Laaksonen, L., (1999), gOpenMol. Helsinki, Finland; Lozano, J.J., Pastor, M., Cruciani, G., Gaedt, K., Centeno, N.B., Gago, F., Sanz, F., 3D-QSAR Methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands (1999) J. Comput.-Aided Mol. Des., , In press; Murray, J.S., Brinck, T., Grice, M.E., Politzer, P., Correlations between molecular electrostatic potentials and some experimentally-based indices of reactivity (1992) J. Mol. Struc., 256, pp. 29-45. , (Theochem); Sanz, F., Manaut, F., Rodriguez, J., Lozoya, E., Lopez de Brinas, E., MEPSIM: A computational package for analysis and comparison of molecular electrostatic potentials (1993) J. Comput.-Aided Mol. Des., 7, pp. 337-347; Schmidt, M.W., Baldridge, K.K., Boatz, J.A., Elbert, S.T., Gordon, M.S., Jensen, J.H., Koseki, S., Montgomery, J.A., GAMESS (1993) J. Comput. Chem, 14, pp. 1347-1363","Sanz, F.; R.G. on Medical Informatics, IMIM, UPF, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain",,,,,,,,13674803,,BOINF,"10980158","English","Bioinformatics",Article,"Final",,Scopus,2-s2.0-0033828444
"Sanz F., Silveira C., Díaz C., Alonso A., Loza M.I., Cordero L., Fernández-Llimós F., Cadavid M.I., Tiddens L., Giorgio F., Cranz H., Henderson K., Mircheva J., Fernández J.L.","7102263897;7006744959;57197180745;56228341600;7003766926;7006028467;56366491700;6603422293;6507831854;6506547621;6602171667;16026382200;6603711833;57198958254;","Information technology in community pharmacies for supporting responsible self-medication",2000,"American Journal of Health-System Pharmacy","57","17",,"1601","1603",,13,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034284585&partnerID=40&md5=cc4550d168a3264632d6a5c96b2a3728","Res. Group of Medical Informatics, University Pompeu Fabra, Barcelona, Spain; Department of Pharmacology, Uniersity of Santiago de Compostela, Santiago de Compostela, Spain; Pharmaceutical Grp. Europ. Union, Brussels, Belgium; Assoc. Europ. Self-Medication I., Brussels, Belgium; SEMA Group S.A., Madrid, Spain","Sanz, F., Res. Group of Medical Informatics, University Pompeu Fabra, Barcelona, Spain; Silveira, C., Res. Group of Medical Informatics, University Pompeu Fabra, Barcelona, Spain; Díaz, C., Res. Group of Medical Informatics, University Pompeu Fabra, Barcelona, Spain; Alonso, A., Res. Group of Medical Informatics, University Pompeu Fabra, Barcelona, Spain; Loza, M.I., Department of Pharmacology, Uniersity of Santiago de Compostela, Santiago de Compostela, Spain; Cordero, L., Department of Pharmacology, Uniersity of Santiago de Compostela, Santiago de Compostela, Spain; Fernández-Llimós, F., Department of Pharmacology, Uniersity of Santiago de Compostela, Santiago de Compostela, Spain; Cadavid, M.I., Department of Pharmacology, Uniersity of Santiago de Compostela, Santiago de Compostela, Spain; Tiddens, L., Pharmaceutical Grp. Europ. Union, Brussels, Belgium; Giorgio, F., Pharmaceutical Grp. Europ. Union, Brussels, Belgium; Cranz, H., Assoc. Europ. Self-Medication I., Brussels, Belgium; Henderson, K., Assoc. Europ. Self-Medication I., Brussels, Belgium; Mircheva, J., Assoc. Europ. Self-Medication I., Brussels, Belgium; Fernández, J.L., SEMA Group S.A., Madrid, Spain",[No abstract available],,"article; drug information; European Union; information science; microcomputer; pharmacist; pharmacy; priority journal; responsibility; self medication; staff training; Community Pharmacy Services; Drug Information Services; Humans; Pharmacists; Self Medication; Statistics, Nonparametric",,,,,,,,,"Bradley, C., Blenkinsopp, A., Over the counter drugs. The future for self medication (1996) BMJ, 312, pp. 835-837; Blenkinsopp, A., Bradley, C., Patients, society and the increase in self medication (1996) BMJ, 312, pp. 629-632; Bond, C.M., Bradley, C., Over the counter drugs. The interface between the community pharmacist and patients (1996) BMJ, 312, pp. 758-760; Thomas, D.H., Noyce, P.R., The interface between self medication and the NHS (1996) BMJ, 312, pp. 688-691; (1998) The Role of the Pharmacist in Self-care and Self-medication, , Report of the 4th WHO Consultative Group on the Role of the Pharmacist. The Hague, Netherlands: World Health Organization; Baker, D.E., Smith, G.H., Abate, M.A., Selected topics in drug information access and practice: An update (1994) Ann Pharmacother, 28, pp. 1389-1394; (1994) Communication from the Commission Concerning Health Promotion, Information, Education and Training Within the Framework for Community Action in the Field of Public Health, , Brussels, Belgium: European Commission; Jun 1; Asscher, A.W., Parr, G.D., Whitmarsh, V.B., Towards the safer use of medicines (1995) BMJ, 311, pp. 1003-1006; Stork, M.W., Freene, R.J., Balon, D.J., RESPOND: Realistic Expert Simulation for Pharmacists on Diagnosis (1995) Pharm J, 254, pp. 295-298; D'Emanuele, A., The communications revolution (1996) Int Pharm J, 10 (4), pp. 129-134; Pankaskie, M., Sullivan, J., On-line learning: Trends in continuing education (1998) J Am Pharm Assoc, 38, p. 382; Felkey, B.G., Health system informatics (1997) Am J Health-Syst Pharm, 54, pp. 274-280; Sanz, F., Loza, M.I., Ahlgrimm, E.D., Over the counter drugs. Telematics will be useful in providing information (1996) BMJ, 313, p. 116. , Letter; Sanz, F., Loza, M.I., Ahlgrimm, E.D., (1996) Telematics in Community Pharmacies to Support Responsible Self-medication. The TESEMED Project, pp. 141-145. , Brender J, Christensen JP, Scherrer J-R et al., eds. Amsterdam: IOS Press; Sanz, F., Sosa-Iudicissa, M., Caston, O.L., Telematics and medicines: From rational design to rational utilisation (1997) Internet, Telematics and Health, pp. 389-392. , Oliveri N, Sosa-Iudicissa M, Gamboa C, eds. Amsterdam: IOS Press; Jones, R.B., Edgerton, E., Baxter, I., Where should a public access health information system be sited? (1993) Interact Comput, 5, pp. 413-421","Res. Group of Medical Informatics, University Pompeu Fabra, Barcelona, Spain",,,,,,,,10792082,,AHSPE,"10984812","English","Am. J. Health-Syst. Pharm.",Article,"Final",,Scopus,2-s2.0-0034284585
"Lozano J.J., Pastor M., Cruciani G., Gaedt K., Centeno N.B., Gago F., Sanz F.","7103062769;7102415847;7005031076;6504246432;6701440183;7006338269;7102263897;","3D-QSAR methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands",2000,"Journal of Computer-Aided Molecular Design","14","4",,"341","353",,71,"10.1023/A:1008164621650","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034050042&doi=10.1023%2fA%3a1008164621650&partnerID=40&md5=e817c3daa19e0bf3ab131d50bb9640a3","Res. Group on Medical Informatics, IMIM, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain; School of Medicine, Univ. Autònoma de Barcelona, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain; Laboratory on Chemometrics, Department of Chemistry, Università di Perugia, I-06123 Perugia, Italy; Department of Pharmacology, Universidad de Alcalá, E-28871 Alcala de Henares, Madrid, Spain; School of Health and Life Sciences, Universitat Pompeu Fabra, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain","Lozano, J.J., Res. Group on Medical Informatics, IMIM, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain, School of Medicine, Univ. Autònoma de Barcelona, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain; Pastor, M., Laboratory on Chemometrics, Department of Chemistry, Università di Perugia, I-06123 Perugia, Italy; Cruciani, G., Laboratory on Chemometrics, Department of Chemistry, Università di Perugia, I-06123 Perugia, Italy; Gaedt, K., Res. Group on Medical Informatics, IMIM, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain; Centeno, N.B., Res. Group on Medical Informatics, IMIM, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain, School of Medicine, Univ. Autònoma de Barcelona, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain; Gago, F., Department of Pharmacology, Universidad de Alcalá, E-28871 Alcala de Henares, Madrid, Spain; Sanz, F., Res. Group on Medical Informatics, IMIM, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain, School of Health and Life Sciences, Universitat Pompeu Fabra, C/ Dr. Aiguader, 80, E-08003 Barcelona, Spain","Many heterocyclic amines (HCA) present in cooked food exert a genotoxic activity when they are metabolised (N-oxidated) by the human cytochrome P450 1A2 (CYP1A2h). In order to rationalize the observed differences in activity of this enzyme on a series of 12 HCA, 3D-QSAR methods were applied on the basis of models of HCA-CYP1A2h complexes. The CYP1A2h enzyme model has been previously reported and was built by homology modeling based on cytochrome P450 BM3. The complexes were automatically generated applying the AUTODOCK software and refined using AMBER. A COMBINE analysis on the complexes identified the most important enzyme-ligand interactions that account for the differences in activity within the series. A GRID/GOLPE analysis was then performed on just the ligands, in the conformations and orientations found in the modeled complexes. The results from both methods were concordant and confirmed the advantages of incorporating structural information from series of ligand-receptor complexes into 3D-QSAR methodologies.","3D-QSAR; AUTODOCK; COMBINE; Cooked food heterocyclic amines; Cytochrome P450 1A2; Docking simulation; GRID/GOLPE","heterocyclic amine; ligand; phenacetin o deethylase; receptor; article; chemical analysis; chemical structure; computer program; conformation; controlled study; enzyme activity; human; intermethod comparison; ligand binding; molecular model; orientation; priority journal; quantitative structure activity relation; receptor binding; Binding Sites; Computer Simulation; Cytochrome P-450 CYP1A2; Drug Design; Electrostatics; Humans; Hydrogen Bonding; Ligands; Models, Molecular; Structure-Activity Relationship",,"Cytochrome P-450 CYP1A2, EC 1.14.14.1; Ligands",,,,,,,"Black, S.D., Coon, M.J., (1987) Adv. Enzymol. Relat. Areas Mol. Biol., 60, p. 35; Peterson, J.A., Graham, S.E., (1998) Structure, 6, p. 1079; Sugimura, T., (1997) Mutat. Res., 376, p. 211; Segura, J., Roberts, D.J., Tarrús, E.J., (1989) J. Pharm. Pharmacol., 41, p. 129; Fuhr, U., Strobl, G., Manaut, F., Anders, E., Sörgel, F., López De Brinñas, E., Chu, D.T.W., Staib, H., (1993) Mol. Pharmacol., 43, p. 191; Shimada, T., Iwasaki, M., Martin, M.V., Guengerich, F.P., (1989) Cancer Res., 49, p. 3218; Wakabayashi, K., Nagao, M., Esumi, H., Sugimura, T., (1992) Cancer Res. (Suppl.), 52, p. 2092; Chang, Y.T., Stiffelman, O.B., Vakser, I.A., Loew, G.H., Bridges, A., Waskell, L., (1997) Protein Eng., 10, p. 119; Szklarz, G.D., Halpert, J.R., (1997) Life Sci., 61, p. 2507; Lozano, J.J., Lopez-de-Brinas, E., Centeno, N.B., Guido, R., Sanz, F., (1997) J. Comput.-aided Mol. Design, 11, p. 395; Poulos, T.L., Finzel, B.C., Howard, A.J., (1986) Biochemistry, 25, p. 5314; Ravichandran, K.G., Boddupalli, S.S., Hasemann, C.A., Peterson, J.A., Deisenhofer, J., (1993) Science, 261, p. 731; Hasemann, C.A., Ravichandran, K.G., Peterson, J.A., Deisenhofer, J., (1994) J. Mol. Biol., 236, p. 1169; Cupp-Vickery, J.R., Poulos, T.L., (1995) Nat. Struct. Biol., 2, p. 144; Uno, T., Michell, E., Aida, K., Lambert, M.H., Darden, T.A., Pedersen, L.G., Negishi, M., (1997) Biochemistry, 36, p. 3193; Helms, V., Wade, R.C., (1998) J. Am. Chem. Soc., 120, p. 2710; Paulsen, M.D., Ornstein, R.L., (1996) Protein Eng., 9, p. 567; Kollman, P., (1993) Chem. Rev., 93, p. 2395; Ortiz, A.R., Pisabarro, M.T., Gago, F., Wade, R.C., (1995) J. Med. Chem., 36, p. 2681; Ortiz, A.R., Pastor, M., Palomer, A., Cruciani, G., Gago, F., Wade, R.C., (1997) J. Med. Chem., 40, p. 1136; Perez, C., Pastor, M., Ortiz, A.R., Gago, F., (1998) J. Med. Chem., 41, p. 836; Wade, R.C., Ortiz, A.R., Gago, F., (1998) 3D QSAR in Drug Design, 2, p. 19. , Kubinyi, H., Folkers, G. and Martin, Y.C. (Eds.), Kluwer/Escom, Dordrecht; Goodford, P., (1996) J. Chemometr, 10, p. 107; Cramer, R.D., Patterson, D.E., Bunce, J.D., (1988) J. Am. Chem. Soc., 110, p. 5959; (1998) Multivariate Infometric Analysis, , Perugia, Italy; Cruciani, G., Watson, K.A., (1994) J. Med. Chem., 37, p. 2589; Sugimura, T., (1985) Mutat. Res., 150, p. 33; Eisenbrand, G., Tang, W., (1993) Toxicology, 84, p. 1; GRID v. 15, Molecular Discovery Ltd., Oxford, 1997; Wild, D., Feser, W., Michel, S., Lord, H.L., Josephy, P.D., (1995) Carcinogesis, 16, p. 643; Shimada, T., Guengerich, F.P., (1991) Cancer Res., 51, p. 5284; Morris, G.M., Goodsell, D.S., Huey, R., Olson, A.J., (1996) J. Comput-aided Mol. Design, 10, p. 293; Raag, R., Li, H., Jones, B.C., Poulos, T.L., (1993) Biochemistry, 32, p. 4571; (1995) AMBER (UCSF): Assisted Model Building with Energy Refinement, Version 4.1, , Department of Pharmaceutical Chemistry, University of California, San Francisco, CA; Weiner, S.J., Kollman, P.A., Nguyen, D.T., Case, D.A., (1986) J. Comput. Chem., 7, p. 230; Poulos, T.L., Howard, A.J., (1987) Biochemistry, 26, p. 8165; Frisch, M.J., Trucks, G.W., Schlegel, H.B., Gill, P.M.W., Johnson, B.G., Robb, M.A., Cheeseman, J.R., Pople, J.A., (1995) Gaussian 94, Revision E.1, , Gaussian, Inc., Pittsburgh, PA; Bayly, C.I., Cieplak, P., Cornell, W.D., Kollman, P.A., (1993) J. Phys. Chem., 97, p. 10269; Pastor, M., Cruciani, G., Clementi, S., (1997) J. Med. Chem., 40, p. 1455; Gotoh, O., (1993) J. Biol. Chem., 267, p. 83; Furuya, H., Shimizu, T., Hirano, K., Hatano, M., Fujii-Kuriyama, Y., (1989) Biochemistry, 28, p. 6848; Shimizu, T., Sadeque, A.J.M., Sadeque, G.N., Hatano, M., Fujii-Kuriyama, Y., (1991) Biochemistry, 30, p. 1490; Tuck, P.S., Hiroya, K., Shimizu, T., Hatano, M., Ortiz De Montellano, P.R., (1993) Biochemistry, 32, p. 2548; Krainev, A.G., Shimizu, T., Ishigooka, M., Hiroya, K., Hatano, M., (1993) Biochemistry, 32, p. 1951; Poulos, T.L., (1995) Curr. Opin. Struct. Biol., 5, p. 767; Oprea, T.I., Hummer, G., Garcia, A.E., (1997) Proc. Natl. Acad. Sci. USA, 94, p. 2133","Sanz, F.; Res. Group on Medical Informatics, School of Health and Life Sciences, Universitat Pompea Fabra, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; email: ferran@imim.es",,,,,,,,0920654X,,JCADE,"10815771","English","J. Comp.-Aided Mol. Des.",Article,"Final",,Scopus,2-s2.0-0034050042
"Sancho J.J., Sanz F.","7201937083;7102263897;","Learning just-in-time in medical informatics",2000,"Studies in Health Technology and Informatics","72",,,"79","87",,1,"10.3233/978-1-60750-916-5-79","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033642908&doi=10.3233%2f978-1-60750-916-5-79&partnerID=40&md5=173ce87c92d22213f70455edf9a6762f","Department of Medical Informatics, IMIM, Aiguader 80, Barcelona, Spain","Sancho, J.J., Department of Medical Informatics, IMIM, Aiguader 80, Barcelona, Spain; Sanz, F., Department of Medical Informatics, IMIM, Aiguader 80, Barcelona, Spain","Just-in-time learning (JITL) methodology has been applied to many areas of knowledge acquisition and dissemination. The paradigm is a challenge to the traditional classroom course-oriented approach with the aim to shorten the learning time, increasing the efficiency of the learning process, improve availability and save money. The information technology tools and platforms have been heavily involved to develop and deliver JITL. This paper discusses the main characteristics of JITL with regard to its implementation to teaching Medical Informatics.",,"Health; Just in time production; Course-oriented; Information technology tools; Just in time; Just-in-time learning; Learning process; Learning time; Medical informatics; Wireless telecommunication systems; article; audiovisual equipment; curriculum; education; European Union; in service training; medical informatics; organization and management; teaching; Audiovisual Aids; Competency-Based Education; Computer-Assisted Instruction; Efficiency, Organizational; European Union; Inservice Training; Medical Informatics",,,,,,,,,"Beare, P.L., The comparative effectiveness of videotape, audiotape, and telelectures in delivering continuing teacher education (1989) The American Journal of Distance Education, 3 (2), pp. 57-66; Bloom, S.B., Krathwohl, D.R., (1956) Taxonomy of Educational Objectives: Handbook 1: Cognitive Domain, , Longman, 10 Bank St., White Plains, NY 10606; Capell, P., (1995) Report on Distance Learning Technologies, , Technical Report CMU/SEI-95-TR-004, Carnegie Mellon University Software Engineering Institute, September; Dannenberg, B.R., Sanchez, M., Joseph, A., Capell, P., Joseph, R., Saul, R., A computer-based multi-media tutor for beginning piano students (1990) Interface, 19 (2-3), pp. 155-173; Fletcher, J.D., (1990) Effectiveness and Cost of Interactive Videodisc Instruction in Defense Training and Education, , Technical Report ADA 228 387, Defense Technical Information Center (DTIC); (1959) Teaching by Television, , Ford Foundation .Technical Report, Fund for the Advancement of Education and Ford Foundation; Moore, M., Kearsley, G., (1996) Distance Education: A Systems View, , Wadsworth Publishing Company, Belmont; Moore, M., Thompson, M., (1997) The Effects of Distance Learning, Revised Edition, , Technical Report ACSDE Research Monograph (Number 15), American Center for the Study of Distance Education, The Pennsylvania State University, 110 Rackley Building, University Park, PA 16802-3202; Goodyear, P., Steeples, C., IT based open learning: Tasks and tools (1992) Journal of Computer Assisted Learning, 8, pp. 163-176",,,"'European People's Party'","IOS Press","2nd European Workshop on Acceptance of Telematics Applications by Healthcare Professionals, Education and Training in Health Telematics","11 December 1998 through 12 December 1998","Thessaloniki",,09269630,1586030337; 9781586030339,,"11010339","English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-0033642908
"López-Arrieta J.M., Rodríguez J.L., Sanz F.","6701748304;57199093141;7102263897;","Nicotine for Alzheimer's disease.",2000,"Cochrane database of systematic reviews (Online)",,"2",,"","",,18,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-84921430741&partnerID=40&md5=f7ccf4827d42055b7f5a7346a68c04d4","Hospital de Cantoblanco, Consejería de Sanidad, Carretera de Colmenar km 14.500, Madrid, Madrid  28049., Spain","López-Arrieta, J.M., Hospital de Cantoblanco, Consejería de Sanidad, Carretera de Colmenar km 14.500, Madrid, Madrid  28049., Spain; Rodríguez, J.L., Hospital de Cantoblanco, Consejería de Sanidad, Carretera de Colmenar km 14.500, Madrid, Madrid  28049., Spain; Sanz, F., Hospital de Cantoblanco, Consejería de Sanidad, Carretera de Colmenar km 14.500, Madrid, Madrid  28049., Spain","BACKGROUND: Nicotine is a cholinergic agonist that acts, not only post-synaptically, but also releases pre-synaptic acetylcholine, and in animal models has been shown to reverse spatial memory decline in rats with lesion in the medial septal nucleus and to show recovery on memory in aged monkeys. Nicotine also has effects on other transmitters like serotonin (5HT), dopamine, or GABA. On the other hand, because nicotine has serious adverse effects, especially concerning cardiovascular risks in elderly people, and also on sleep and behavior, there are several important reasons to conduct a systematic review to assess the clinical efficacy and safety of nicotine in patients with AD. OBJECTIVES: The aim of this review is to determine whether there is evidence of beneficial effect, and to assess its safety profile, when nicotine is used for Alzheimer's disease. SEARCH STRATEGY: The Cochrane Controlled Trials Register (Issue 2, 99) was searched using the terms nicotin* and alzheimer*. Three references to trials were deemed suitable for inclusion but are awaiting consideration while the investigators are contacted. SELECTION CRITERIA: All unconfounded, double-blind, randomized trials in which treatment with nicotine patches or administration of nicotine intravenously was administered for more than a day and compared to placebo in people with Alzheimer's disease. DATA COLLECTION AND ANALYSIS: As no trials were suitable for inclusion, no data have been extracted or pooled in a meta-analysis. One trial is awaiting consideration, and if included in an update of this review, any available data will be incorporated. MAIN RESULTS: The poor quality of the trials did not allow any synthesis of results across studies. However, the data available in trials considered are compatible with nicotine producing harm, no change or improvement. REVIEWER'S CONCLUSIONS: This review is not able to provide reliable evidence that nicotine is a useful treatment for Alzheimer's disease.",,"nicotine; nicotinic agent; Alzheimer disease; cognitive defect; human; psychological aspect; review; Alzheimer Disease; Cognition Disorders; Humans; Nicotine; Nicotinic Agonists",,"nicotine, 54-11-5; Nicotine, 54-11-5; Nicotinic Agonists",,,,,,,,"López-Arrieta, J.M.email: med013440@nacom.es",,,,,,,,1469493X,,,"10796667","English","Cochrane Database Syst Rev",Review,"Final",,Scopus,2-s2.0-84921430741
"Martín-Baranera M., Sancho J.J., Sanz F.","6603145514;7201937083;7102263897;","Controlling for chance agreement in the validation of medical expert systems with no gold standard: PNEUMON-IA and RENOIR revisited",2000,"Computers and Biomedical Research","33","6",,"380","397",,6,"10.1006/cbmr.2000.1552","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034518727&doi=10.1006%2fcbmr.2000.1552&partnerID=40&md5=4d7410b0dec6b4b941b35d5770615f23","Department of Medical Informatics, Institut Municipal d'Investigaci Medica (IMIM), Universitat Autònoma de Barcelona, Dr. Aiguader 80, E-08003 Barcelona, Spain","Martín-Baranera, M., Department of Medical Informatics, Institut Municipal d'Investigaci Medica (IMIM), Universitat Autònoma de Barcelona, Dr. Aiguader 80, E-08003 Barcelona, Spain; Sancho, J.J., Department of Medical Informatics, Institut Municipal d'Investigaci Medica (IMIM), Universitat Autònoma de Barcelona, Dr. Aiguader 80, E-08003 Barcelona, Spain; Sanz, F., Department of Medical Informatics, Institut Municipal d'Investigaci Medica (IMIM), Universitat Autònoma de Barcelona, Dr. Aiguader 80, E-08003 Barcelona, Spain","In the validation of medical expert systems, agreement among different human specialists on a random sample of cases may be taken as a substitute to a missing gold standard. Distance measures between pairs of experts, extensively described in previous studies, do not take into account the influence of chance-expected agreement. A weighted kappa index, with three different weighting schemes, is proposed as an alternative to be applied in the general situation of N cases assessed by E experts about K possible diagnoses, each of them qualified with one of G ordinal categories. A hierarchical cluster analysis, applied to the kappa matrices generated, allows for the classification of the expert system among clinical specialists, providing a relative assessment of its diagnostic ability. The above methodology is applied to the validation of two medical expert systems, PNEUMON-IA and RENOIR. © 2000 Academic Press.",,"article; cluster analysis; computer program; expert system; information science; medical expert; medical specialist; priority journal; quality control; standardization; validation process",,,"PNEUMON-IA; RENOIR",,"HC1115HC","This study was funded in part by the EU TAP Project VATAM (HC1115HC).",,,"Wyatt, J.C., Clinical data systems. 3. Development and evaluation (1994) Lancet, 344, pp. 1682-1688; Clayton, P.D., Hripcsak, G., Decision support in healthcare (1995) Int.J. Biomed. Compuf., 39 (1), pp. 59-66; Miller, R.A., Gardner, R.M., Summary recommendations for responsible monitoring and regulation of clinical software systems (1997) Ann. Intern. Med, 127, pp. 842-845. , The American Medical Informatics Association, the Computer-Based Patient Record Institute, the Medical Library Association, the Association of Academic Health Science Libraries, the American Health Information Management Association, and the American Nurses Association; Rushby, J., (1988) Validation and Testing of Knowledge-Based Systems. How Bad Can It Get?, , AAAI-88 Workshop on Validation and Verification of Expert Systems; Hunt, D.L., Haynes, R.B., Hanna, S.E., Smith, K., Effects of computer-based clinical decision support systems on physician performance and patient outcomes. A systematic review (1998) JAMA, 280, pp. 1339-1346; O'Leary, D.E., Validation of expert systems - With applications to auditing and accounting expert systems (1987) Decision Sci., 18, pp. 468-486; Engelbretch, R., Rector, A., Moser, W., Verification and validation (1995), ""Assessment and Evaluation of Information Technologies"" (E.M.S.J. van Gennip and J. L. Talmon, Eds.) IOS Press; Nykänen, P., Chowdhury, S., Wigertz, O., Evaluation of decision support systems in medicine (1991) Comput. Methods Programs Biomed., 34, pp. 229-238; Wyatt, J., Speigelhalter, D., Evaluating medical expert systems: What to test and how? (1990) Med. Inform., 15, pp. 205-217; Indurkhya, N., Weiss, S.M., Models for measuring performance of medical expert systems (1989) Artificial Intelligence Med., 1, pp. 61-70; Miller, P.L., The evaluation of artificial intelligence systems in medicine (1986) Comput. Methods Programs Biomed., 22, pp. 5-11; Ohmann, C., D Dombal, F.T., Winding, O., Evaluation procedure in the TELEGASTRO project (1994) Theor. Surg., 9, pp. 90-103; O'Keefe, R.M., Balci, O., Smith, E.P., Validating expert system performance (1987) IEEE Expert., 2 (4), pp. 81-90; Reproducibility of the histologic diagnosis of pneumonia among a panel of four pathologists. Analysis of a gold standard (1997) Chest, 112, pp. 458-465; Shortliffe, E.H., Barnett, O., Medical data: Their acquisition, storage and use (1990), Shortliffe E. H., ""Medical Informatics: Computer Applications in Health Care"" E. H. Shortliffe and L. E. Perrault, Eds. Addison-Wesley, Reading, MA; Adlassnig, K.P., Scheithauer, W., Performance evaluation of Medical Expert Systems using ROC curves (1989) Comput. Biomed. Res., 22, pp. 297-313; Coughlin, S.S., Trock, B., Criqui, M.H., Pickle, L.W., Browner, D., Tefft, M.C., The logistic modeling of sensitivity, specificity and predictive value of a diagnostic test (1992) J. Clin. Epidemiol., 45, pp. 1-7; Campbell, G., General methodology. 1. Advances in statistical methodology for the evaluation of diagnostic and laboratory tests (1994) Stat. Med., 13, pp. 499-508; Wacholder, S., Armstrong, B., Hartge, P., Validation studies using an alloyed gold standard (1993) Am. J. Epidemiol, 137, pp. 1251-1258; Reid, M.C., Laachs, M.S., Feinstein, A.R., Use of methodological standards in diagnostic test research. Getting better but still not good (1995) JAMA, 274, pp. 645-651; Yu, V., Buchanan, B., Shortliffe, E., Evaluating the performance of a computer-based consultant (1979) Comput. Programs Biomed., 9, pp. 95-102; Quaglini, S., Stefanelli, M., Barosi, G., Berzuini, A., A performance evaluation of the expert system ANEMIA (1988) Comput. Biomed. Res., 21, pp. 307-323; Van der Lei, J., Musen, M.A., Van der Does, E., Man in't Veld, A.J., Van Bemmel, J.H., Comparison of computer-aided and human review of general practitioners' management of hypertension (1991) Lancet, 338, pp. 1504-1508; Plugge, L.A., Verhey, F.R.J., Jolles, J., Differential diagnosis of dementia: A comparison between the expert system EVINCE and clinicians (1991) J. Neuropsychiatry Clin. Neurosci., 3, pp. 398-404; Korpinen, L., Pietila, T., Peltola, J., Nissila, M., Keranen, T., Touvinen, T., Falck, B., Frey, H., Evaluation of Epilepsy Expert - A decision support system (1994) Comput. Methods Programs Biomed., 45 (3), pp. 223-231; Verdaguer, A., Patak, A., Sancho, J.J., Sierra, C., Sanz, F., Validation of the medical expert system PNEUMON-IA (1992) Comput. Biomed. Res., 25, pp. 511-526; Hernández, C., Sancho, J.J., Belmonte, M.A., Sierra, C., Sanz, F., Validation of the medical expert system RENOIR (1994) Comput. Biomed. Res., 27 (6), pp. 456-471; Verdaguer, A., (1989) PNEUMON-IA: Desenvolupament d'un sistema expert d'ajuda al diagǹostic m̀edic, , Tesis doctoral. Universitat Aut́onoma de Barcelona. Barcelona; Belmonte Serrano, M.A., (1990) RENOIR: Un sistema experto para la ayuda en el diagńostico de colagenosis y artropat́iaas inflamatorias, , Tesis doctoral. Universidad Aut́onoma de Barcelona. Barcelona; Singer, P.A., Feinstein, A.R., Graphical display of categorical data (1993) J. Clin. Epidemiol., 46, pp. 231-236; Kramer, M.S., Feinstein, A.R., Clinical biostatistics. L.V.I. The biostatistics of concordance (1981) Clin. Pharmacol. Ther., 29, pp. 111-123; Wolfe, C.D.A., Taub, N.A., Woodrow, E.J., Burney, P.G.J., Assessment of scales of disability and handicap for stroke patients (1991) Stroke, 22, pp. 1242-1244; De Vet, H.C.W., Knipschild, P.G., Schouten, H.J.A., Sources of interobserver variation in histopathological grading of cervical dysplasia (1992) J. Clin. Epidemiol, 45, pp. 785-790; Emberton, M., Challands, A., Styles, R.E., Wightman, J.A., Black, N., Recollected versus contemporary patient reports of pre-operative symptoms in men undergoing transurethral porstatic resection for benign disease (1995) J. Clin. Epidemiol., 48 (6), pp. 749-756; Ioannidis, J.P.A., Cappelleri, J.C., Lau, J., Issues in comparison between meta-analyses and large trials (1998) JAMA, 279, pp. 1089-1093; Gjorup, T., Kelbaek, H., Sorensen, F., Stenbygard, L., Reliability in the interpretation of the course of serum enzyme concentration changes in suspected acute myocardial infarction (1992) Int. J. Cardiol., 35, pp. 43-47; Serraino, D., Franceschi, S., Dal Maso, L., Lepri, A.C., Tirelli, U., Rezza, G., The classification of AIDS cases: Concordance between two AIDS surveillance systems in Italy (1995) Am. J. Public Health, 85, pp. 1112-1114; Wells, P.S., Hirsh, J., Anderson, D.R., Lensing, A.W., Foster, G., Kearon, C., Weitz, J., Prandoni, P., Accuracy of clinical assessment of deep-vein thrombosis (1995) Lancet, 345 (8961), pp. 1326-1330; Holmvang, L., Hasback, P., Clemmensen, P., Wagner, G., Grande, P., Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a thrombin inhibition in myocardial ischemia [TRIM] substudy) (1998) Am. J. Cardiol., 82, pp. 54-60; Kraemer, H.C., Bloch, D.A., Kappa coefficients in epidemiology: An appraisal of a reappraisal (1988) J. Clin. Epidemiol., 41, pp. 959-968; Feinstein, A.R., Cicchetti, D.V., High agreement but low kappa. 1. The problems of two paradoxes (1990) J. Clin. Epidemiol., 43, pp. 543-549; Feinstein, A.R., Cicchetti, D.V., High agreement but low kappa. 1I. Resolving the paradoxes (1990) J. Clin. Epidemiol., 43, pp. 551-558; Byrt, T., Bishop, J., Carlin, J.B., Bias prevalence kappa (1993) J. Clin. Epidemiol., 46, pp. 423-429; Lantz, C.A., Nebenzahl, E., Behavior and interpretation of the statistic: Resolution of the two paradoxes (1996) J. Clin. Epidemiol., 49, pp. 431-434; Thompson, W.D., Walter, S.D., (1988) J. Clin. Epidemiol., 41, pp. 969-970; Maclure, M., Willett, W.C., Misinterpretation and misuse of the kappa statistic (1987) Am. J. Epidemiol., 126, pp. 161-169; Dubes, R.C., Jain, A.K., Validity studies in clustering methodologies (1979) Pattern Recognition, 11, pp. 235-254; Mojena, R., Hierarchical grouping methods and stopping rules: An evaluation (1976) Comput. J., 20, pp. 359-363; Afifi, A., Clark, V., Cluster analysis (1990), ""Computer-Aided Multivariate Analysis."" 2nd ed., Chap. 6. Van Nostrand Reinhold, New York; Cohen, J., A coefficient of agreement for nominal scales (1960) Educ. Psychol. Meas., 20, pp. 37-46; Fleiss, J.L., (1981) Statistical Methods for Rates and Proportions, , Wiley, New York","Martín-Baranera, M.; Unit of Clinical Epidemiology, Consorci Sanit. Creu Roja Catalunya, Av. Josep Molins 29-41, E-08906 L'Hosp. Llobregat, Barcelona, Spain; email: Montse.Martin@chcr.scs.es",,,"Academic Press Inc.",,,,,00104809,,CBMRB,"11150233","English","Comput. Biomed. Res.",Article,"Final",,Scopus,2-s2.0-0034518727
"Raviña E., Negreira J., Cid J., Masaguer C.F., Rosa E., Rivas M.E., Fontenla J.A., Loza M.I., Tristán H., Cadavid M.I., Sanz F., Lozoya E., Carotti A., Carrieri A.","56264803900;6507782405;7005013558;6701715235;7004952752;8066265000;7004054862;7003766926;6603250999;6603422293;7102263897;6603260860;7102635316;7003355704;","Conformationally constrained butyrophenones with mixed dopaminergic (D2) and serotoninergic (5-HT2(A), 5-HT2(C)) affinities: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and - thienocycloalkanones as putative atypical antipsychotics",1999,"Journal of Medicinal Chemistry","42","15",,"2774","2797",,34,"10.1021/jm981094e","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033614954&doi=10.1021%2fjm981094e&partnerID=40&md5=4ded5738f5ff3e9ad489df17684e3496","Depto. de Quimica Organica, Lab. de Quimica Farmaceutica, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Depto. d'Informatica Medica, Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Dr. Aiguader 80, E-08003 Barcelona, Spain; Dipartimento Farmaco Chimico, Università di Bari, I-70126 Bari, Italy","Raviña, E., Depto. de Quimica Organica, Lab. de Quimica Farmaceutica, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Negreira, J., Depto. de Quimica Organica, Lab. de Quimica Farmaceutica, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Cid, J., Depto. de Quimica Organica, Lab. de Quimica Farmaceutica, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Masaguer, C.F., Depto. de Quimica Organica, Lab. de Quimica Farmaceutica, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Rosa, E., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Rivas, M.E., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Fontenla, J.A., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Loza, M.I., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Tristán, H., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Cadavid, M.I., Departamento de Farmacología, Facultad de Farmacia, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Sanz, F., Depto. d'Informatica Medica, Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Dr. Aiguader 80, E-08003 Barcelona, Spain; Lozoya, E., Depto. d'Informatica Medica, Inst. Munic. d'Investigacio Medica, Universitat Pompeu Fabra, Dr. Aiguader 80, E-08003 Barcelona, Spain; Carotti, A., Dipartimento Farmaco Chimico, Università di Bari, I-70126 Bari, Italy; Carrieri, A., Dipartimento Farmaco Chimico, Università di Bari, I-70126 Bari, Italy","A series of novel conformationally restricted butyrophenones (2- (aminoethyl)- and 3-(aminomethyl)thieno- or benzocycloalkanones bearing (6- fluorobenzisoxazolyl)piperidine, (p-fluorobenzoyl)piperidine, (o- methoxyphenyl)piperazine, or linear butyrophenone fragments) were prepared and evaluated as atypical antipsychotic agents by in vitro assays of affinity for dopamine receptors (D1, D2) and serotonin receptors (5-HT2(A), 5- HT2(C)) and by in vivo assays of antipsychotic potential and the risk of inducing extrapyramidal side effects. Potency and selectivity depended mainly on the amine fragment connected to the cycloalkanone structure. As a group, compounds with a benzisoxazolyl fragment had the highest 5-HT2(A) activities, followed by the benzoylpiperidine derivatives; in general, α- substituted cycloalkanone derivatives were more active than the corresponding β-substituted congeners. CoMFA (comparative molecular field analysis) and docking studies showed electrostatic, steric, and lipophilic determinants of 5-HT2(A) and D2 affinities and 5-HT2(A)/D2 selectivity. The in vitro and in vivo pharmacological profiles of N-[(4-oxo-4H-5,6- dihydrocyclopenta[b]thiophene-5-yl)ethyl]-4-(6-fluorobenzisoxazol-3- yl)piperidine (23b, QF 0510B), N-[(4-oxo-4,5,6,7- tetrahydrobenzo[b]thiophene-5-yl)ethyl]-4-(6-fluorobenzisoxazol-3- yl)piperidine (24b, QF 0610B), and N-[(7-oxo-4,5,6,7- tetrahydrobenzo[b]thiophene-6-yl)ethyl]4-(6-fluorobenzisoxazol-3- yl)piperidine (29b, QF 0902B) suggest that they may be effective antipsychotic drugs with low propensity to induce extrapyramidal side effects.",,"amine; butyrophenone derivative; cycloalkanone; dopamine receptor; neuroleptic agent; piperazine derivative; piperidine derivative; serotonin receptor; article; drug conformation; drug receptor binding; drug synthesis; electricity; extrapyramidal symptom; lipophilicity; molecular model; pharmacology; quantitative structure activity relation; schizophrenia; stereochemistry; Animals; Antipsychotic Agents; Aorta, Thoracic; Brain; Catalepsy; Cattle; Dopamine Agents; Isoxazoles; Male; Mice; Models, Molecular; Motor Activity; Muscle Contraction; Muscle, Smooth, Vascular; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Agents; Structure-Activity Relationship; Thiophenes",,"Antipsychotic Agents; Dopamine Agents; Isoxazoles; QF 0510B; QF 0610B; QF 0902B; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Agents; Thiophenes",,,,,,,"Howard, H.R., Seeger, T.F., Novel antipsychotics (1993) Annual Reports in Medicinal Chemistry, 28, p. 39. , Bristol, J. A., Ed.; Academic Press: New York; Schaus, J.M., Bymaster, F.P., Dopaminergic approachesto antipsychotic agents (1998) Annual Reports in Medicinal Chemistry, 33, p. 1. , Bristol, J. A., Ed.; Academic Press: New York; Seeman, P., Dopamine receptors and dopamine hypothesis of schizophrenia (1987) Synapse, 192, pp. 481-483; Sitsen, A., Current trends in antipsychotic agents (1990) Script Report, p. 57. , PJB Publications: Richmond, U.K; Seeman, P., Chou-Wong, M., Tadesco, J., Wong, K., Antipsychotic drug doses and neuroleptic/dopamine receptors (1976) Nature, 261, pp. 717-719; Kennedy, J.L., Billett, E.A., Macciardi, F.M., Verga, M., Parsons, T.J., Meltzer, H.Y., Lieberman, J., Buchanan, J.A., Association study of dopamine D3 receptor gene and schizophrenia (1995) Am. J. Med. Genet., 60, pp. 558-562; Bristow, L.J., Kramer, M.S., Kulagowski, J., Patel, S., Ragan, C.I., Seabrook, G.R., Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist (1997) Trends Pharmacol. Sci., 18, pp. 186-187; Filton, A., Heel, R., Clozapine, C., A review of its pharmacological properties and therapeutic use in schizophrenia (1990) Drugs, 40, pp. 722-747; Schwarz, J.T., Brotman, A.W., A clinical guide to antipsychotic drugs (1992) Drugs, 44, pp. 981-992; Rosenheck, R., Cramer, J., Xu, W., Henderson, W., Frismann, L., A comparison of clozapine and haloperidol in hospitalized patients (1997) N. Engl. J. Med., 337, pp. 809-815; Megens, A.H.P., Kennis, L.E.J., Risperidone and related 5-HT2/D2 antagonists: A new type of antipsychotic agent (1996) Progress in Medicinal Chemistry, 33, p. 186. , Ellis, G. P., Luscombe, D. K., Eds.; Elsevier Sci.: Amsterdam; Beasley, C.M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., Hamilton, S., Olanzapine versus placebo and haloperidol: Acute phase results of the North American Double-blind Olanzapine Trial (1996) Neuropsychopharmacology, 14, pp. 111-123; Conley, R.R., Buchanan, R.W., Evaluation of treatment-resistant schizophrenia (1997) Schizophrenia Bull., 23, pp. 663-674; Sanders-Bush, E., Mayer, S.E., 5-Hydroxytryptamine (Serotonin) receptor agonists and antagonists (1996) The Pharmacological Basis of Therapeutics, 9th Ed., pp. 249-263. , Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W., Goodman, A., Eds.; McGraw-Hill: New York; Meltzer, H.Y., Matsubara, S., Lee, J.C., Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values (1989) J. Pharmacol. Exp. Ther., 251, pp. 238-246; Roth, B.L., Meltzer, H.Y., The role of Serotonin in Schizophenia (1995) Psychopharmacology: The Fourth Generation of Progress, pp. 1215-1227. , Bloom, F. E., Kupfer, D. J., Eds.; Raven Press: New York; Meltzer, H.Y., Matsubara, S., Lee, J.C., The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs (1989) Psychopharmacol. Bull., 25, pp. 390-392; Roth, B.L., Tandra, S., Burgess, L.H., Sibley, D.R., Meltzer, H.Y., D4 receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs (1995) Psychopharmacology, 120, pp. 365-368; Kapur, S., Remington, G., Serotonin-dopamine interaction and its relevance to schizophrenia (1996) Am. J. Psychiatry, 153, pp. 466-476; Lowe J.A. III, Atypical antipsychotics based on the D2/5-HT2 ratio hypothesis (1994) Curr. Med. Chem., 1, p. 50; Gleason, S.D., Shannon, H.E., Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice (1997) Psychopharmacology (Berlin), 129, pp. 79-84; Sipes, T.E., Geyer, M.A., DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum (1997) Brain Res., 761, pp. 97-104; Okuyama, S., Chaki, S., Kawashima, N., Suzuki, Y., Ogawa, S., Kumagai, T., Nakazato, A., Tomisawa, K., The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats (1997) Br. J. Pharmacol., 121, pp. 515-525; Green, M.F., Marshall B.D., Jr., Wirshing, W.C., Ames, D., Marder, S.R., McGurk, S., Kern, R.S., Mintz, J., Does risperidone improve verbal working memory in treatment-resistant schizophrenia? (1997) Am. J. Psychiatry, 154, pp. 799-804; Martin, P., Waters, N., Carlsson, A., Carlsson, M.L., The apparent antipsychotic action of the 5-HT2A receptor antagonist MDL 100907 in a mouse model of schizophrenia is counteracted by ritanserin (1997) J. Neural. Transm., 104, pp. 561-564; Padich, R.A., McCloskey T, C., Kehne, J.H., 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100, 907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats (1996) Psychopharmacology, 124, pp. 107-116; Schmidt, C.J., Development of a selective 5-HT2A receptor antagonist for the treatment of schizophrenia (1996) IBS's International Conference on Serotonin Receptors, , Central Nervous System. Targets for New Therapeutic Agents, Philadelphia, PA; Meltzer, H.Y., Atypical antipsychotic drugs: Which receptors are relevant? (1996) IBS's International Conference on Serotonin Receptors, , Central Nervous System. Targets for New Therapeutic Agents, Philadelphia, PA; Meltzer, H.Y., Multiple serotonin/dopamine receptor interactions contribute to atypical antipsychotic drug action (1996) Eur. Neuropsychopharmacol., 6, pp. S32-2; Roth, B.L., Craigo, S.C., Choudhary, S., Uluer, A., Monsma F.J., Jr., Shen, Y., Meltzer, H.Y., Sibley, D.R., Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-7 receptors (1994) J. Pharmacol. Exp. Ther., 268, pp. 1403-1410; Monsma, F.J., Shen, Y., Ward, R.P., Hamblin, M.W., Sibley, D.R., Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs (1992) Mol. Pharmacol., 43, pp. 320-327; Ward, R.P., Hamblin, M.W., Lachowicz, J.E., Hoffman, B.J., Sibley, D.R., Dorsa, D.M., Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry (1995) Neuroscience, pp. 1105-1111; Hoyer, D., Martin, G.R., Classification and nomenclature of 5-HT receptors: A comment on current issues (1996) Behav. Brain Res., 73, pp. 263-268; Hoyer, D., Clarke, D.E., Fozard, J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J., Saxena, P.R., Humphrey, P.P.A., VII international union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin) (1994) Pharmacol. Rev., 46, pp. 157-203; Erdmann, J., Nothen, M.M., Shimron-Abarbanell, D., Rietschel, M., Albus, M., Borrmann, M., Maier, W., Propping, P., The human serotonin 7 (5-HT7) receptor gene: Genomic organization and systematic mutation screening in schizophrenia and bipolar affective disorder (1996) Mol. Psychiatry, 1, pp. 392-397; Largent, B.L., Wikstrom, H., Snowman, A.M., Snyder, S.H., Novel antipsychotic drugs share high affinity for sigma receptors (1988) Eur. J. Pharmacol., 155, pp. 345-347; Janssen, P.A.J., Niemegeers, C.J.E., Awouters, F., Schelekens, K.H.L., Megens, A.A.H.P., Meert, T.F., Pharmacology of risperidone (R 64 766). A new antipsychotic with serotonin S2 and dopamine D2 antagonistic properties (1988) J. Pharmacol. Exp. Ther., 244, pp. 685-693; Megens, A.A.H.P., Niemegeers, C.J.E., Awouters, F.H.L., Behavioral disinhibition and depression in amphetaminized rats: A comparison of risperidone, ocaperidone and haloperidol (1992) J. Pharmacol. Exp. Ther., 260, pp. 160-167; Hyttel, J., Arnt, J., Costall, B., Domeney, A., Dragsted, N., Lembol, H.L., Meier, E., Starsfeldt, T., Pharmacological profile of the atypical neuroleptic sertindol (1992) Clin. Neuropharmacol., 15 (SUPPL. 1 PART A), pp. 267A-268A; Lieberman, J.A., Hohn, C.A., Mikane, J., Rai, K., Pisciotta, A.V., Salz, B.L., Howard, A., Clozapine-induced agranulocytosis: Non cross-reactivity with other antipsychotic drugs (1988) J. Clin. Psychiatry, 49, pp. 271-277; Cortizo, L., Santana, L., Raviña, E., Orallo, F., Fontenla, J.A., Castro, E., Calleja, J.M., De Ceballos, M.L., Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogues of butyrophenone (1991) J. Med. Chem., 34, pp. 2242-2247; Loza, M.I., Verde, I., Castro, E., Orallo, F., Fontenla, J.A., Calleja, J.M., Raviña, E., Cortizo, L., 5-HT2 antagonist activity of 3-aminomethyl tetralones (1991) Bioorg. Med. Chem. Lett., 1, pp. 717-720; Duncan R.L., Jr., Helsey, G.C., Welstead W.J., Jr., Da Vanzo, J.P., Funderburk, W.H., Lunsford, C.D., Aroylpiperidines and pyrrolidines. A new class of potent central nervous system depressants (1970) J. Med. Chem., 13, pp. 1-6; Ismaiel, A.M., Arruda, K., Teitler, M., Glennon, R.A., Ketanserin analogues: The effect of structural modifications on 5-HT2 serotonin receptor binding (1995) J. Med. Chem., 38, pp. 1196-1202; Loza, I., Ferreiro, T.G., Sanz, F., Lozoya, E., Rodriguez, J., Manaut, F., Verde, I., Raviña, E., Antiserotoninergic activity of 2-aminoethyl benzocyclanones in rat aorta: Structure-activity relationships (1993) J. Pharm. Sci., 82, pp. 513-517; Fontenla, J.A., Osuna, J., Rosa, E., Castro, E., Ferreiro, T.G., Loza García, I., Calleja, J.M., De Ceballos, M.L., Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl) benzocycloalkanones as analogues of butyrophenone (1994) J. Med. Chem., 37, pp. 2564-2573; Raviña, E., Fueyo, J., Masaguer, C.F., Negreira, J., Cid, J., Loza, I., Honrubia, A., De Ceballos, M.L., Synthesis and affinities for dopamine (D2) and 5-hydroxytryptamine (5-HT2a) receptors of 1-(benzoylpropyl)-4-(1-oxocycloalkyl-2-ethyl)piperazines as cyclic butyrophenone derivatives (1996) Chem. Pharm. Bull., 44, pp. 534-541; Raviña, E., Masaguer, C.F., Cid, J., Fontenla, J.A., Ferreiro, T.G., Cadavid, M.I., Loza, I., De Ceballos, M.L., Butyrophenone analogues: Synthesis of 2-methyl-3-ethyl-5-aminomethyl-4,5,6,7-tetrahydroindol-4-ones and their affinities for D1, D2 and 5-HT2A receptors (1995) Bioorg. Med. Chem. Lett., 5, pp. 579-584; Masaguer, C.F., Raviña, E., A practical and efficient route for synthesis of 6-aminomethyl-4-oxo-4,5,6,7-tetrahydroindoles as new CNS precursors (1996) Tetrahedron Lett., 37, pp. 5171-5174; Masaguer, C.F., Casariego, I., Raviña, E., Conformationally restricted butyrophenones with mixed dopaminergic (D2) and serotoninergic (5-HT2A) affinities. Synthesis of 5-aminoethyl-and 6-aminomethyl-4-oxotetrahydroindoles as potential atypical antipsychotics (1999) Chem. Pharm. Bull., p. 47; Masaguer, C.F., Formoso, E., Raviña, E., Tristán, H., Loza, I., Rivas, E., Fontenla, J.A., Butyrophenone analogues in the carbazole series: Synthesis and determination of affinities at D2 and 5-HT2A receptors (1998) Bioorg. Med. Chem. Lett., 8, pp. 3571-3576; Shutske, G.M., Setescak, L.L., Allen, R.C., Davis, L., Effland, R.C., Ranbom, K., Kitzen, J.M., Novick W.J., Jr., [(3-Aryl-1,2-benzisoxazol-6-yl)oxy]acetic acids. A new diuretic series (1982) J. Med. Chem., 25, pp. 36-44; Strupczewski, J.T., Allen, R.C., Gardner, B.A., Schmid, B.L., Stache, U., Glamkowski, E.J., Jones, M.C., Dunn, R.W., Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles (1985) J. Med. Chem., 28, pp. 761-769; Mewshaw, R.E., Silversman, L.S., Mathew, R.M., Kaiser, C., Sherrill, R.G., Cheng, M., Tiffanny, C.W., Abreu, M.E., Bridged γ-carbolines and derivatives possessing selective and combined affinity for 5-HT2A and D2 receptors (1993) J. Med. Chem., 36, pp. 1488-1495; Palermo, M.G., Corbett, R., Hartman, H.B., Hrib, N.J., Kafka, S., Kongsamut, S., Nmeoto, P.A., Martin, L.L., Synthesis and evaluation of 3-(4-piperazmyl)-6-hydroxy-benzisoxazoles and depot analogues as potential atypical neuroleptic compounds (1997) 214th National Meeting of the American Chemical Society, , Abstracts of Papers; Division of Medicinal Chemistry, Las Vegas, NV; Hashimoto, I., Takatsuka, R., Friedel-crafts reaction of benzene with 2-Phenylbutanedioic anhydride (1977) Bull. Chem. Soc. Jpn., 50, pp. 2495-2496; Diago-Meseguer, J., Palomo-Coll, A.L., Fernández-Lizarbe, J.R., Zugaza-Bilbao, A., A new reagent for activating carboxyl groups; preparation and reactions of N,N-bis[2-oxo-3-oxazolidinyl]phosphorodiamidic chloride (1980) Synthesis, pp. 547-551; Waldmann, H., Der phenylacetyl-(PhAc-)rest als enzymatisch ablösbare schutzgruppe für peptide und kohlenhydrate: Selektrive schutzgruppenabspaltungen mit penicillin-acylase (1998) Liebigs Ann. Chem., pp. 1175-1180; Tsunada, T., Suzuki, M., Noyori, R., A facile procedure for acetalization under aprotic conditions (1980) Tetrahedron Lett., 21, pp. 1357-1358; note; note; note; note; note; Cramer, R.D., Patterson, D.E., Bunce, J.D., Comparative Molecular Field Analysis (CoMFA). 1. Effects of shape on binding of steroids to carrier protein (1988) J. Am. Chem. Soc., 110, pp. 5959-5967; Cramer, R.D., De Prierst, S.A., Patterson, D.E., Hect, P., The developing practice of Comparative Molecular Field Analysis (1993) Drug Design: Theory, Methods and Applications, pp. 443-485. , Kubinyi, H., Ed.; Escom: Leiden; Thibaut, U., Applications of CoMFA and related 3D-QSAR approaches (1993) Drug Design: Theory, Methods and Applications, pp. 661-696. , Kubinyi, H., Ed.; Escom: Leiden; Gaillard, P., Carrupt, P.-A., Testa, B., Boudon, A., Molecular lipophilicity potential, a tool in 3D-QSAR: Method and applications (1994) J. Comput.-aided Mol. Des., 8, pp. 83-96; Testa, B., Carrupt, P.-A., Gaillard, P., Tsai, R.S., Intramolecular interactions encoded in lipophilicity (1997) Lipophilicity in Drug Action and Toxicology, pp. 49-71. , Pliska, V., Testa, B., van der Waterbeemd, H., Eds.; VCH: Weinheim; Wold, S., Johansson, E., Cocchi, M., PLS - Partial Least Squares Projections to Latent Structures (1993) Drug Design: Theory, Methods and Applications, pp. 523-549. , Kubinyi, H., Ed.; Escom: Leiden; Cramer R.D. III, Bunce, J.D., Patterson, D.E., Crossvalidation, bootstrapping and Partial Least Squares compared with multiple regression analysis (1988) Quant. Struct.-act. Relat., 7, pp. 18-25; note; note; Holtje, H.D., Folkers, G., (1996) Molecular Modeling, Basic Principles and Applications, , Mannhold, R., Kubyi, H., Timmerman, H., Eds.; VCH: Weinheim, Chapter 3; Stewart, J.J.P., MOPAC: A semiempirical molecular orbital program (1990) J. Comput.-aided Mol. Des., 4, pp. 1-103; Carrieri, A., Brasili, L., Leonetti, F., Pigini, M., Giannella, M., Bousquet, P., Carotti, A., 2-D and 3-D modeling of imidazoline receptor liganda: Insights into pharmacophore (1997) Bioorg. Med. Chem., 5, pp. 843-856; Still, W.C., Tempczyk, A., Hawley, R.C., Hendrickson, T., Semianalytical treatment of solvation for molecular mechanics and dynamics (1990) J. Am. Chem. Soc., 112, pp. 6127-6129; Wold, S., Eriksson, L., Statistical validation of QSAR results (1996) Chemometric Methods in Molecular Design, pp. 309-318. , van de Waterbeemd, H., Ed.; VCH: Weinheim; Folkers, G., Merz, A., Rognan, D., CoMFA scope and limitations (1993) Drug Design: Theory, Methods and Applications, pp. 583-618. , Kubinyi, H., Ed.; Escom: Leiden; Lozoya, E., Berger, M., Rodríguez, J., Sanz, F., Loza, M.I., Moldes, V., Masaguer, C.F., Comparison of electrostatic similarity approaches applied to a series of ketanserin analogues with 5-HT2A antagonist activity (1998) Quant. Struct.-act. Relat., 17, pp. 199-204; Baldwin, J.M., The probable arrangement of the helices in G protein-coupled receptors (1993) EMBO J., 12, pp. 1693-1703; Pearlman, D.A., Case, D.A., Caldwell, J.W., Ross, W.S., Cheatham, T.E., Ferguson, D.M., Seibel, G.L., Kollman, P.A., (1995) AMBER 4.1, , University of California: San Francisco, CA; Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., Procheck: A program to check the stereochemical quality of protein structures (1993) J. Appl. Crystallogr., 26, pp. 283-291; Hooft, R.W.W., Vriend, G., Sander, C., Abola, E.E., Errors in protein structures (1996) Nature, 381, p. 272; Fraser, C.M., Wang, C.D., Robinson, D.A., Gocayne, J.D., Venter, J.C., Site-directed mutagenesis of m1 muscarinic receptors: Conserved aspartic acids play important roles in receptor function (1989) Mol. Pharmacol., 36, pp. 840-847; Strader, C.D., Sigal, I.S., Dixon, R.A.F., Structural basis of α-adrenergic receptor function (1989) FASEB J., 3, pp. 1825-1832; Zhou, W., Flanagan, C., Ballesteros, J.A., Konvicka, K., Davidson, J.S., Weinstein, H., Millar, R.P., Sealfon, S.C.A., Reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor (1994) Mol. Pharmacol., 45, pp. 165-170; , 82. , Molecular Simulations Inc., San Diego, CA; Vogel, A.I., (1989) Vogel's Textbook of Practical Organic Chemistry, 5th Ed., , Longman: Harlow, U.K; Sam, J., Thompson, A.C., Thiaindanones. Thiophene isosters of indanone (1963) J. Pharm. Sci., 52, pp. 898-901; Nishimura, S., Nakamura, M., Suzuki, M., Imoto, E., Some reactions of 4-oxo-4,5,6,7-tetrahydrothianaphthene (1962) Nippon Kagaku Zasshi, 83, pp. 343-347; (1963) Chem. Abstr., 59, pp. 3862c; Cagniant, M.P., Cagniant, P., Contribution a l'etude des hétérocycles soufrés condensés. V. Substitution dans le noyau du tétrahydro-4-5-6-7 thionaphtène au moyen de la réaction de friedel-crafts (1953) Bull. Soc. Chim. Fr., 20, pp. 62-69; Conjat, J.P., Cagniant, P., Cagniant, D., Mirjolet, M., Syntheses dans le domaine des methoxy oxo-4 et oxo-7 tetrahydro-4,5,6,7 benzo[6]thiophenes (1975) Tetrahedron Lett., pp. 2885-2888; Protais, P., Costentin, J., Schwartz, J.C., Climbing behavior induced by apomorphine in mice: A simple test for the study of dopamine receptors in striatum (1976) Psychopharmacology, 50, pp. 1-6; Tallarida, R.J., Murray, R.B., (1987) Manual of Pharmacologic Calculations with Computer Programs, 2nd Ed., pp. 153-158. , Springer-Verlag: New York; Bradley, P.B., Engel, G., Feniuk, W., Fozard, J.R., Humphrey, P.P.A., Middlemiss, D.N., Mylecharane, E.J., Saxena, P.R., Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine (1986) Neuropharmacology, 25, pp. 563-576; Pazos, A., Cortes, R., Palacios, J.M., Quantitative autoradiographic mapping of serotonin receptors in the rat brain II. Serotonin-2 receptors (1985) Brain Res., 346, pp. 231-245; Wong, D.T., Threlkeld, P.G., Robertson, D.W., Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors (1991) Neuropsychopharmacology, 5, pp. 43-47; Fukuda, S., Su, C., Lee, T.J.F., Mechanisms of extraneuronal serotonin uptake in the rat aorta (1986) J. Pharmacol. Exp. Ther., 239, pp. 264-269; Gruetter, C.A., Lemke, S.M., Anestis, D.K., Szarek, J.L., Valentovic, M.A., Potentiation of 5-hydroxytryptamine-induced contraction in rat aorta by chlorpheniramine, citalopram and fluoxetine (1992) Eur. J. Pharmacol., 217, pp. 109-118; Cohen, M.L., Fuller, R.W., Wiley, K.S., Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle (1981) J. Pharmacol. Exp. Ther., 218, pp. 421-425","Ravina, E.; Departamento de Quimica Organica, Laboratorio de Quimica Farmaceutica, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; email: qofara@usc.es",,,,,,,,00222623,,JMCMA,"10425088","English","J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-0033614954
"Alonso A., Díaz C., Sanz F.","56228341600;57197180745;7102263897;","A matix-approach proposal for the treatment of contents to be integrated into multimedia health resources for citizens.",1999,"Studies in health technology and informatics","68",,,"3","6",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033250862&partnerID=40&md5=00e1da2bf63f789a38a76255333b5ab5","IMIM-Research Group on Medical Informatics, Barcelona, Spain.","Alonso, A., IMIM-Research Group on Medical Informatics, Barcelona, Spain.; Díaz, C., IMIM-Research Group on Medical Informatics, Barcelona, Spain.; Sanz, F., IMIM-Research Group on Medical Informatics, Barcelona, Spain.",[No abstract available],,"article; computer program; health education; human; information service; information system; Internet; Health Education; Humans; Information Management; Information Services; Internet; Software Design",,,,,,,,,,"Alonso, A.email: aalonso@imim.es",,,,,,,,09269630,,,"10724892","English","Stud Health Technol Inform",Article,"Final",,Scopus,2-s2.0-0033250862
"Domingo M., Martín-Baranera M., Sanz F., Sierra C., Uriz M.J.","57195195284;6603145514;7102263897;7006398334;7004797076;","Validating SPONGIA, an expert system for sponge identification",1999,"Expert Systems with Applications","16","4",,"379","384",,2,"10.1016/S0957-4174(99)00013-5","https://www.scopus.com/inward/record.uri?eid=2-s2.0-9344221612&doi=10.1016%2fS0957-4174%2899%2900013-5&partnerID=40&md5=abf2ebd2b1b13fef70fbd37e67f868b5","Artif. Intell. Research Institute, Span. Cncl. for Scientific Research, CSIC, 08193 Bellaterra, Barcelona, Spain; Inst. Munic. D 'Investigacio Medica, Univ. Autònoma de Barcelona, Dr Aiguader, 80, 08003 Barcelona, Spain; Ctr. d'Estudis AvanCats de Blanes, Span. Cncl. for Scientific Research, CSIC, Camí de Santa Bàrbara, 17300 Blanes, Spain","Domingo, M., Artif. Intell. Research Institute, Span. Cncl. for Scientific Research, CSIC, 08193 Bellaterra, Barcelona, Spain; Martín-Baranera, M., Inst. Munic. D 'Investigacio Medica, Univ. Autònoma de Barcelona, Dr Aiguader, 80, 08003 Barcelona, Spain; Sanz, F., Inst. Munic. D 'Investigacio Medica, Univ. Autònoma de Barcelona, Dr Aiguader, 80, 08003 Barcelona, Spain; Sierra, C., Artif. Intell. Research Institute, Span. Cncl. for Scientific Research, CSIC, 08193 Bellaterra, Barcelona, Spain; Uriz, M.J., Ctr. d'Estudis AvanCats de Blanes, Span. Cncl. for Scientific Research, CSIC, Camí de Santa Bàrbara, 17300 Blanes, Spain","In this article we present the validation of SPONGIA, an expert system to help in the identification of marine sponges. Validation was performed by using data from 82 randomly selected literature descriptions of sponge species. The data gathered by SPONGIA to identify each specimen were obtained from the bibliographical description. The set of cases, in which each case was described by the data gathered by SPONGIA, was presented to five internationally recognised experts in sponge systematics. The identifications generated by SPONGIA were compared with the identifications of these human experts by means of a cluster analysis. The similarity between SPONGIA and human identifications was assessed using four measures: Euclidean distance, City-block distance, Mahalanobis distance and Kappa index. In this article we show that SPONGIA obtains similar quality results to the experts in Porifera systematics. © 1999 Elsevier Science Ltd. All rights reserved.","Cluster analysis; Marine sponges and systematics; SPONGIA",,,,,,"Generalitat de Catalunya: FI/91-193

Comisión Interministerial de Ciencia y Tecnología: TIC91-0430","This research has been funded in part by a Generalitat de Catalunya fellowship (FI/91-193) and the CICYT project TESEU (TIC91-0430). We are especially grateful to the experts in sponge systematics that collaborated in this validation project: Nicole Boury-Esnault, Michelle Kelly-Borges, Maurizio Pansini, Jean Vacelet and Rob van Soest.",,,"Conruyt, N., Manago, M., Renard, J.L., Lévi, C., Une méthode d'acquisition de connaissances pour la classification et l'identification d'objects biologiques application au domaine des éponges marines (1993) Proceedings of the 13th International Symposium on Expert Systems and Applications, (1), pp. 485-495. , Avignon: France; Domingo, M., Evaluating the expert system approach to biological identification through application to Porifera (1994) Sponges in Time and Space, pp. 75-82. , R. van Soest & T. van Kempen & J. Braekman (Eds.), Balkema; Domingo, M., (1995) An Expert System Architecture for Taxonomic Domains. An Application in Porifera: The Development of SPONGIA, , Ph.D thesis, Universitat de Barcelona, Barcelona; Domingo, M., Uriz, M.J., Design and development of SPONGIA, an expert system for sponge identification (1998) Sci. Mar., 62 (1-2), pp. 45-57; Fieschi, M., Towards validation of expert systems as medical decision aids (1990) Int. J. Biomed. Comput., 26, pp. 93-108; Fleiss, J.L., (1981) Statistical Methods for Rates and Proportions, , New York: Wiley; Geissman, J., Schultz, R., Verification and validation of expert systems (1988) AI Expert, 3 (2), pp. 26-33; Van Gennip, E., Talmond, J., (1995) Assessment and Evaluation of Information Technologies in Medicine, , Amsterdam: IOS Press; Hernández, C., Martín-Baranera, M., Sancho, J., Sanz, F., POEMA: A computer program to compare quantitative data vectors (1994) Proceedings of the 12th International Congress of the European Federation for Medical Informatics (MIE), pp. 22-26. , Lisbon: Portugal; Hernández, C., Sancho, J., Belmonte, M., Sierra, C., Sanz, F., Validation of the medical expert system RENOIR (1994) Comput Biomed Res, 27 (6), pp. 456-471; Martín-Baranera, M., Sancho, J., Sanz, F., Simulation applied to medical expert systems validation in absence of gold standard (1996) Proceedings of Medical Informatics in Medicine, pp. 506-510. , J. Brender & J. P. Chnstensen & J. R. Scherrer & P. McNair (Eds.), Copenhagen: IOS Press; O'Keefe, R., Balci, O., Smith, E., Validating expert system performance (1987) IEEE Expert, 2 (4), pp. 81-90; Redier, H., Daures, J., Michel, C., Assessment of the severity of asthma by an expert system description and evaluation (1995) Am. J. Respir. Crit. Care Med., 151, pp. 352-354; Thonnat, M., Gandelin, M., An expert system for the automatic classification and description of Zooplanktons from monocular images (1988) Proceedings of the 9th International Conference on Pattern Recognition, pp. 114-118. , Rome; Verdaguer, A., Patak, A., Sancho, J., Sierra, C., Sanz, F., Validation of the medical expert system PNEUMONIA (1992) Comput. Biomed. Res., 25, pp. 511-526; Vogt, W., Nagel, D., Sator, H., (1987) Cluster Analysis in Clinical Chemistry: A Model, , New York: Wiley; Wooley, J., Stone, N., Application of artificial intelligence to systematics: Systex a prototype expert system for species identification (1987) Sist. Zool., 36 (3), pp. 248-267; Wyatt, J., Speigelhalter, D., Evaluating medical expert systems: What to test and how? (1990) Med. Inf. (London), 15, pp. 205-217","Sierra, C.; Artif. Intell. Research Institute, Span. Cncl. for Scientific Research, CSIC, 08193 Bellaterra, Barcelona, Spain; email: sierra@iiia.csic.es",,,"Elsevier Ltd",,,,,09574174,,ESAPE,,"English","Expert Sys Appl",Article,"Final",,Scopus,2-s2.0-9344221612
"Martin-Baranera M., Planas I., Palau J., Miralles M., Sancho J.J., Sanz F.","6603145514;6602265390;7006416471;7005000280;7201937083;7102263897;","Assessing physician's expectations and attitudes toward hospital information systems the imasis experience",1999,"M.D. Computing","16","1",,"73","76",,11,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032603136&partnerID=40&md5=3fd419d4bf2f8ed4e70cb9a97d774b2a","Department of Medical Informatics, Inst. Munic. d'Investigacio Medica, Universita Autonoma de Barcelona, Dr. Aiguader 80, E-08003, Barcelona, Spain; Dept. of Informatics, Inst. Munic. d'Assistencia Sanitaria, Barcelona, Spain; Financial Direction, Inst. Munic. d'Assistencia Sanitaria, Barcelona, Spain","Martin-Baranera, M., Department of Medical Informatics, Inst. Munic. d'Investigacio Medica, Universita Autonoma de Barcelona, Dr. Aiguader 80, E-08003, Barcelona, Spain; Planas, I., Dept. of Informatics, Inst. Munic. d'Assistencia Sanitaria, Barcelona, Spain; Palau, J., Financial Direction, Inst. Munic. d'Assistencia Sanitaria, Barcelona, Spain; Miralles, M., Department of Medical Informatics, Inst. Munic. d'Investigacio Medica, Universita Autonoma de Barcelona, Dr. Aiguader 80, E-08003, Barcelona, Spain; Sancho, J.J., Department of Medical Informatics, Inst. Munic. d'Investigacio Medica, Universita Autonoma de Barcelona, Dr. Aiguader 80, E-08003, Barcelona, Spain; Sanz, F., Department of Medical Informatics, Inst. Munic. d'Investigacio Medica, Universita Autonoma de Barcelona, Dr. Aiguader 80, E-08003, Barcelona, Spain","The methodology applied to the evaluation of the IMAS hospital information system is proposed as a systematic and practical approach to assess clinical information systems from the point of view of the medical user.",,"adult; article; attitude to computers; attitude to health; computer interface; doctor patient relation; health care quality; health personnel attitude; health survey; hospital information system; human; human computer interaction; information processing; information system; job satisfaction; medical staff; methodology; middle aged; multimedia; organization and management; physician attitude; questionnaire; Spain; standard; Adult; Attitude of Health Personnel; Attitude to Computers; Computer Literacy; Data Collection; Health Knowledge, Attitudes, Practice; Hospital Information Systems; Humans; Integrated Advanced Information Management Systems; Job Satisfaction; Medical Staff; Middle Aged; Multimedia; Physician's Role; Physician-Patient Relations; Population Surveillance; Program Evaluation; Questionnaires; Spain; User-Computer Interface",,,,,,,,,"Anderson, J.G., Aydin, C.E., Jay, S.J., (1994) Evaluating Health Care Information Systems. Methods and Applications, , Thousand Oaks, CA: SAGE; Slack, W.V., Boro, E.S., Bleich, H.L., Barriers to clinical computing: What physicians can do (1992) MD Comput, 9, pp. 278-280; Grémy, F., Scientific context and the human meaning of informatics applied to health care (1994) MD Comput, 11, pp. 149-154; Stead, W.W., A quarter-century of computer-based medical records (1989) MD Comput, 6, pp. 75-81; Forsythe, D.E., Buchanan, B.G., Osheroff, J.A., Miller, R.A., Expanding the concept of medical information: An observational study of physicians' information needs (1992) Comput Biomed Res, 25, pp. 181-200; Jelovsek, F.R., Rittwage, J., Pearse, W.H., Visscher, H.C., Information management needs of the obstetrician-gynecologist - A survey (1989) Obstet Gynecol, 73, pp. 395-399; Covell, D.G., Uman, G.C., Manning, P.R., Information needs in office practice: Are they being met? (1985) Ann Intern Med, 103, p. 596; Davidoff, F., Haynnes, B., Sackett, D., Smith, R., Evidence based medicine: A new journal to help doctors identify the information they need (1995) Br Med J, 310, pp. 1085-1086; Sackett, D.L., Richardson, W.S., Rosenberg, W., Haynes, R.B., (1997) Evidence-based Medicine. How to Practice and Teach EMB, , New York: Churchill Livingstone; Stinson, E.R., Mueller, D.A., Survey of health professionals' information habits and needs conducted through personal interviews (1980) JAMA, 243, pp. 140-143; Osheroff, J.A., Forsythe, D.E., Buchanan, B.G., Bankowitz, R.A., Blumenfeld, B.H., Miller, R.A., Physicians' information needs: Analysis of questions posed during clinical teaching (1991) Ann Intern Med, 114, p. 576; Shortliffe, E.H., Perreault, L.E., (1990) Medical Informatics: Computer Applications in Health Care, , New York: Addison-Wesley; Barfield, L., (1993) The User Interface. Concepts and Design, , New York: Addison-Wesley; Galitz, W.O., (1993) User-interface Screen Design, , Boston: QED Information Sciences; Powell, D.G., Douglas, N.M., Westlake, P.H., Physician participation in a Medical Information System (1994) MD Comput, 11, pp. 140-147; Pryor, A.T., Current state of computer-based patient record systems (1992) Aspects of the Computer-based Patient Record, (67-82). , Ball MJ, Collen MF, eds. New York: Springer-Verlag; Simpson, R.L., Clinical information systems vs. practicing physicians (1992) Nurs Manage, 23, pp. 14-16; Lumsdon, K., Pioneering protocols. Hospitals test the computer's use in patient care decision (1993) Hospitals, 67, pp. 18-21; Roderer, N.K., Clayton, P.D., IAIMS at Columbia-Presbyterian medical center: Accomplishments and challenges (1993) Yearbook of Medical Informatics, , Van Bemmel JH, McCray AT eds. Stuggart: Schattauer; Massaro, T.A., Introducing physician order entry at a major academic medical center: I. Impact on organizational culture and behavior (1993) Acad Med, 68, pp. 20-25; Rogers, M.C., Snyderman, R., Rogers, E., Cultural and organizational implications of academic managed-care networks (1994) N Engl J Med, 331, pp. 1374-1377; Mazzoleni, M.C., Baiardi, P., Giorgi, I., Franchi, G., Marconi, R., Cortesi, M., Assessing users' satisfaction through perception of usefulness and ease of use in the daily interaction with a hospital information system (1996) Proceedings of the AMIA Annual Fall Symposium, pp. 752-756. , Philadelphia: Hanley & Belfus; Wyatt, J.C., Clinical data systems, part 3: Development and evaluation (1994) Lancet, 344, pp. 1682-1688; Prokosch, H.U., Puhle, B., Dudeck, J., One-stop-information-shopping: Do we meet the information needs of the hospital staff? (1994) Proceedings of the Twelfth International Congress of the European Federation for Medical Informatics, pp. 362-365. , Barahona P, Veloso M, Bryant J, eds. Lisbon; Kraemer, K.L., (1991) The Information Systems Research Challenge: Survey Research Methods, , Boston: Harvard Business School","Martin-Baranera, M.; Department of Medical Informatics, Inst. Munic. d'Investigacio Medica, Universita Autonoma de Barcelona, Dr. Aiguader 80, E-08003, Barcelona, Spain",,,,,,,,07246811,,MDCOE,"10202428","English","M.D. Comput.",Article,"Final",,Scopus,2-s2.0-0032603136
"Nykänen P., Enning J., Talmon J., Hoyer D., Sanz F., Thayer C., Roine R., Vissers M., Eurlings F.","7003836925;7801474031;7006019325;35858336400;7102263897;7004499349;56329174600;7005196377;6507953419;","Inventory of validation approaches in selected health telematics projects",1999,"International Journal of Medical Informatics","56","1-3",,"87","96",,4,"10.1016/S1386-5056(99)00047-7","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0345072483&doi=10.1016%2fS1386-5056%2899%2900047-7&partnerID=40&md5=f6bbf7585cefabd0526f71a318be7c0e","VTT Information Technology, Info. Systems, P.O. Box 1206, 33101, Tampere, Finland; Hiscom BV, Leiden, Netherlands; Department of Medical Informatics, Maastricht University, Maastricht, Netherlands; KPMG, Unternehmungsberatung, Berlin, Germany; IMAS-IMIM, Barcelona, Spain; Ctr. National d'Equipment Hospitaux, Paris, France; Finnish Off. Hlth. Care Technol. A., Helsinki, Finland","Nykänen, P., VTT Information Technology, Info. Systems, P.O. Box 1206, 33101, Tampere, Finland; Enning, J., Hiscom BV, Leiden, Netherlands; Talmon, J., Department of Medical Informatics, Maastricht University, Maastricht, Netherlands; Hoyer, D., KPMG, Unternehmungsberatung, Berlin, Germany; Sanz, F., IMAS-IMIM, Barcelona, Spain; Thayer, C., Ctr. National d'Equipment Hospitaux, Paris, France; Roine, R., Finnish Off. Hlth. Care Technol. A., Helsinki, Finland; Vissers, M., Department of Medical Informatics, Maastricht University, Maastricht, Netherlands; Eurlings, F., Hiscom BV, Leiden, Netherlands","This paper presents the results from an inventory of validation approaches and methodologies which have been used in selected health telematics projects. The inventory was performed in the VATAM Validation of Telematic Applications in Medicine project, HC1115HC. The purpose of the inventory was to analyse the methodologies and their application assumptions in order to identify possibilities for harmonisation and consolidation. The inventory was performed using five validation dimensions: IT-development; quality; user; technology assessment and marketing. The inventory results show that possibilities exist to synthesise methodologies and to provide practical guidance and support for projects that are developing health telematics applications. All stakeholders in health telematics projects, i.e. users, health care decision-makers, developers, suppliers and IT-industries, can benefit from practical validation guidelines and support for validation when guidelines are represented in a usable, easy to access and informative way.This paper presents the results from an inventory of validation approaches and methodologies which have been used in selected health telematics projects. The inventory was performed in the VATAM Validation of Telematic Applications in Medicine project, HC1115HC. The purpose of the inventory was to analyze the methodologies and their application assumptions in order to identify possibilities for harmonization and consolidation. The inventory was performed using five validation dimensions: IT-development; quality; user; technology assessment and marketing. The inventory results show that possibilities exist to synthesize methodologies and to provide practical guidance and support for projects that are developing health telematics applications. All stakeholders in health telematics projects, i.e. users, health care decision-makers, developers, suppliers and IT-industries, can benefit from practical validation guidelines and support for validation when guidelines are represented in a usable, easy to access and informative way.","Evaluation; Health telematics; Inventory; Validation; Validation dimensions","Decision making; Economic and social effects; Information technology; Health telematics; Health care; biomedical technology assessment; health care; information science; inventory control; marketing; medical decision making; medical information; methodology; practice guideline; priority journal; quality control; review; validation process",,,,,"European Commission: HC1115","The work described in this paper is partly funded by the European Union under the contract HC1115 of Telematics Applications Programme Sector Health. The contribution of all partners and associated partners of the VATAM-project for the inventory work is gratefully acknowledged. Especially we want to acknowledge persons who have strongly contributed to this work but are not any more involved in VATAM: Elisabet van Gennip (TNO Prevention and Health), instigator of the whole work undertaken, and Martin Steegh who actively participated in the inventory while working at HISCOM.",,,"Steegh, M., Enning, J., Van Gennip, E., Marz, J., Rougier, S., Hoyer, D., Nykänen, P., Vissers, M., (1997) VATAM Inventory Report, , Deliverable D03.1; Talmon, J., (1997) Proceedings of the Inventory Workshop, , (Ed.), Deliverable D02.3; Talmon, J., Enning, J., Castadena, G., Eurlings, F., Hoyer, D., Nykänen, P., Sanz, F., Vissers, M., The VATAM Guidelines, , This issue; (1985) Assessing Medical Technologies, , Committee for Evaluating Medical Technologies, Institute of Medicine, Division of Health Sciences Policy National Academy Press, Washington DC; http://www-vatam.unimaas.nl, VATAM web-server","Nykanen, P.; VTT Information Technology, Information Systems, P.O. Box 1206, 33101 Tampere, Finland; email: pirkko.nykanen@vtt.fi",,,"Elsevier Science Ireland Ltd, Shannon",,,,,13865056,,IJMIF,"10659937","English","Int. J. Med. Inform.",Article,"Final",,Scopus,2-s2.0-0345072483
"Talmon J., Enning J., Castãneda G., Eurlings F., Hoyer D., Nykänen P., Sanz F., Thayer C., Vissers M.","7006019325;7801474031;56363481200;6507953419;35858336400;7003836925;7102263897;7004499349;7005196377;","The VATAM guidelines",1999,"International Journal of Medical Informatics","56","1-3",,"107","115",,15,"10.1016/S1386-5056(99)00035-0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033485651&doi=10.1016%2fS1386-5056%2899%2900035-0&partnerID=40&md5=6eefbf97b8f7d57822a5d7429d33f8b6","Department of Medical Informatics, Maastricht Univ., P.O. B., Maastricht, Netherlands; HISCOM BV, Leiden, Netherlands; IMAS-IMIM, Barcelona, Spain; KPMG-Unternehmungsberatung, Berlin, Germany; VTT Information Technology, Tampere, Finland; Ctr. National d'Equipment Hospitaux, Paris, France","Talmon, J., Department of Medical Informatics, Maastricht Univ., P.O. B., Maastricht, Netherlands; Enning, J., HISCOM BV, Leiden, Netherlands; Castãneda, G., IMAS-IMIM, Barcelona, Spain; Eurlings, F., HISCOM BV, Leiden, Netherlands; Hoyer, D., KPMG-Unternehmungsberatung, Berlin, Germany; Nykänen, P., VTT Information Technology, Tampere, Finland; Sanz, F., IMAS-IMIM, Barcelona, Spain; Thayer, C., Ctr. National d'Equipment Hospitaux, Paris, France; Vissers, M., Department of Medical Informatics, Maastricht Univ., P.O. B., Maastricht, Netherlands","Evaluation and assessment of the impact of information and communication technology in medicine is gaining interest. Unfortunately, till now there were no agreed upon approaches. The objective of the VATAM project is to develop guidelines that will assist assessors to set-up and execute studies. This paper describes the background of the VATAM project and provides an account of the current state of the guidelines. It concludes with an indication of the developments that will take place in the short term to further elaborate the guidelines and some considerations for consolidation of VATAM's results.Evaluation and assessment of the impact of information and communication technology in medicine is gaining interest. Unfortunately, till now there were no agreed upon approaches. The objective of the VATAM project is to develop guidelines that will assist assessors to set-up and execute studies. This paper describes the background of the VATAM project and provides an account of the current state of the guidelines. It concludes with an indication of the developments that will take place in the short term to further elaborate the guidelines and some considerations for consolidation of VATAM's results.","Assessment; Evaluation; Guidelines; Technology","Decision making; Health care; Information technology; Medical decision aids; Medical computing; behavior; biomedical technology assessment; evaluation; information science; marketing; medical information; methodology; performance; practice guideline; priority journal; review",,,,,"European Commission: HC1115","The VATAM project is partially funded by the European Union under contract HC1115 of the Health Care Sector of the Telematics Application Programme. The core partners of VATAM acknowledge the valuable contributions of the associated partners in the development of the guidelines. In particular, we thank Regis Beuscart, Jan Demaeseneer, Rolf Engelbrecht, Francesco Fedele, Bill Grimson, Ursula Hübner, Torben Jørgensen, Mohamed Makari, Rory O'Moore and Pieter Zanstra.",,,"Talmon, J.L., Knowledge based systems in medicine: Methods, applications and evaluation (1991) Lecture Notes in Medical Informatics, 47. , Fox J. Berlin: Springer-Verlag; Clarke, K., O'Moore, R., Smeets, R., Talmon, J.L., Brender, J., McNair, P., Nykänen, P., Barber, B., A methodology for evaluation of knowledge-based systems in medicine: Artificial intelligence (1994) Medicine, 6, pp. 107-121; Van Bemmel, J.H., (1997) Handbook Medical Informatics, , M.A. Musen. Heidelberg: Springer-Verlag; Laires, M.F., Ladeira, M.J., Christensen, J.P., Health in the New Communication Age (1995) Studies in Health Technology and Informatics, 24. , Amsterdam: IOS Press; Engelbrecht, R., Rector, A., Moser, W., Verification and validation (1995) Assessment and Evaluation of Information Technologies in Medicine, Studies in Health Technology and Informatics, 17, pp. 51-66. , E.M.S.J. van Gennip, Talmon J.L. Amsterdam: IOS Press; Van Gennip, E.M.S.J., Talmon, J.L., Assessment and Evaluation of Information Technologies in Medicine (1995) Studies in Health Technology and Informatics, 17. , Amsterdam: IOS Press; Buchanan, B., Verification and Validation of Knowledge Base Systems: A Representative Bibliography, , http://www.lhncbc.nlm.nih.gov/csb/projects/airheum/workshop/report.html, Appendix A of Evaluation-based systemsReport from a workshop, Lister Hill Centre, National Library of Medicine, Berthesda, MO; Talmon, J.L., Van Der Loo, R., Literature on assessment of information technology and medical KBS evaluation: Studies and methodologies (1995) Assessment and Evaluation of Information Technologies in Medicine. Studies in Health Technology and Informatics, 17, pp. 283-327. , E.M.S.J. van Gennip, & J.L. Talmon. Amsterdam: IOS Press; Jørgensen, T., Bernstein, K., Danneskiold-Samsøe, B., Lehrmann, T., Evaluation of a regional electronic health care network, consequences for general practice (1996) Medical Informatics Europe' 96. Studies in Health Technology and Informatics, 34, pp. 344-348. , J. Brender, J.P. Christensen, J.R. Scherrer, & P. Mcnair. Amsterdam: IOS Press; Engelbrecht, R., Hildebrand, C., Blecher, M., Corcoy, R., De Leiva, A., The DIABCARD feasibility study (1996) Medical Informatics Europe' 96. Studies in Health Technology and Informatics, 34, pp. 479-483. , J. Brender, J.P. Christensen, J.-R. Scherrer, & P. McNair. Amsterdam: IOS Press; Ferrara, F., The middleware-based architectural approach for opening and evolving healthcare information systems (1996) Medical Informatics Europe' 96. Studies in Health Technology and Informatics, 34, pp. 264-270. , J. Brender, J.P. Christensen, J.-R. Scherrer, & P. McNair. Amsterdam: IOS Press; Beuscart, R., Souf, N., Blassel, N., Gourdin, C., Modjeddi, B., Integration architecture: The ISAR project (1996) Medical Informatics Europe' 96. Studies in Health Technology and Informatics, 34, pp. 311-315. , J. Brender, J.P. Christensen, J.-R. Scherrer, & P. McNair. Amsterdam: IOS Press; Gordon, C., Veloso, M., The PRESTIGE project: Implementing guidelines in healthcare (1996) Medical Informatics Europe' 96. Studies in Health Technology and Informatics, 34, pp. 887-891. , J. Brender, J.P. Christensen, J.-R. Scherrer, & P. McNair. Amsterdam: IOS Press; Hübner, U., Staemmler, M., Schuier, F.J., Newell, J., Focussing on the medical department: SAMMIE (1996) Medical Informatics Europe' 96. Studies in Health Technology and Informatics, 34, pp. 321-325. , J. Brender, J.P. Christensen, J.-R. Scherrer, & P. McNair. Amsterdam: IOS Press; Grimson, J., Grimson, B., Hurlen, P., Ingram, D., Milan, J., Osseyran, A., Wilson, M., Synapses-federated healthcare record server (1996) Medical Informatics Europe' 96. Studies in Health Technology and Informatics, 34, pp. 695-699. , J. Brender, J.P. Christensen, J.-R. Scherrer, & P. McNair. Amsterdam: IOS Press; Steegh, M., Enning, J., Van Gennip, E., Marz, J., Rougier, S., Hoyer, D., Nykänen, P., Vissers, M., VATAM Inventory Report, , http://www-vatam.unimaas.nl/invrep/home.htm; Nykänen, P., Enning, J., Talmon, J., Hoyer, D., Sanz, F., Thayer, C., Roine, R., Eurlings, F., Inventory of validation approaches in health telematics projects Int. J. Biomed. Inform., , (this issue); Enning, J., Steegh, M., Van Gennip, E., Talmon, J., Vissers, M., Gonzalez, J.C., Sanz, F., Rougier, S., (1996) Draft Guidelines for Validation of Telematics Applications in Medicine, , http://www-vatam.unimaas.nl/guidelin/home.htm; Gerneth, M., FEST-framework for european services in telemedicine (1995) Health in the New Communications Age. Studies in Health Technology and Informatics, 24, pp. 417-425. , M.F. Laires, M.J. Ladeira, & J.P. Christensen. Amsterdam: IOS Press; Enning, J., F.eurlings, Talmon, J., Vissers, M., Nykänen, P., Roine, R., Hoyer, D., Coello, E., (1997) Draft Guidelines for Validation of Telematics Applications in Medicine-2nd Version, , http://www-vatam.unimaas.nl/guidel-2/home.htm; Friedman, C.P., Wyatt, J.C., (1996) Evaluation Methods in Medical Informatics, , New York: Springer-Verlag; Shortliffe, E.H., The science of biomedical computing (1984) Med. Inform., 9, pp. 185-193; (1985) Assessing Medical Technologies, , Washington, DC: National Academic Press; Brender, J., Methodology for Assessment of Medical IT-Based Systems in and Organisational Context (1997) Studies in Health Technology and Informatics, 42. , Amsterdam: IOS Press; Vissers, M.C., Talmon, J.L., Evaluationg the MACRO solution (1997) Medical Informatics Europe' 97. Studies in Health Technology and Informatics, 43. , C. Pappas, N. Maglaveras, & J.-R. Scherrer. Amsterdam: IOS Press; Hoyer, D., Marz, J., Rougier, S., Nykanen, P., Enning, J., Steegh, M., Talmon, J., Sanz, F., Inventory of Major Suppliers and Their Validation Tools, , http://www-vatam.unimaas.nl/tools/home.htm; http://www-vatam.unimaas.nl/terms","Talmon, J.; Department of Medical Informatics, Maastricht University, P.O. Box 616, 6200 Maastricht MD, Netherlands; email: talmon@mi.unimaas.nl",,,"Elsevier Science Ireland Ltd, Shannon",,,,,13865056,,IJMIF,"10659939","English","Int. J. Med. Inform.",Article,"Final",,Scopus,2-s2.0-0033485651
"Sanz F., Sil Veira C., Alonso A., Diaz C., Loza M.I., Cordero L., Fernandez-Llimós F., Tiddens L., Giorgio F., Cranz H., Mircheva J.","7102263897;55933864100;56228341600;57197180745;7003766926;7006028467;56366491700;6507831854;6506547621;6602171667;6603711833;","Telematics applications to support the role of the community pharmacists as self-medication advisors",1999,"Studies in Health Technology and Informatics","68",,,"764","767",,4,"10.3233/978-1-60750-912-7-764","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033286293&doi=10.3233%2f978-1-60750-912-7-764&partnerID=40&md5=08df578aa53a4ab814ea5f56ffe17909","R.G. on Medical Informatics, IMIM/UPF, Dr. Aiguader 80, E-08003 Barcelona, Spain; Dep. of Pharmacology, University of Santiago de Compostela, Spain; Pharmaceutical Group of the European Union, Brussels, Belgium; Association of the European Self-Medication Industry (AESGP), Brussels, Belgium","Sanz, F., R.G. on Medical Informatics, IMIM/UPF, Dr. Aiguader 80, E-08003 Barcelona, Spain; Sil Veira, C., R.G. on Medical Informatics, IMIM/UPF, Dr. Aiguader 80, E-08003 Barcelona, Spain; Alonso, A., R.G. on Medical Informatics, IMIM/UPF, Dr. Aiguader 80, E-08003 Barcelona, Spain; Diaz, C., R.G. on Medical Informatics, IMIM/UPF, Dr. Aiguader 80, E-08003 Barcelona, Spain; Loza, M.I., Dep. of Pharmacology, University of Santiago de Compostela, Spain; Cordero, L., Dep. of Pharmacology, University of Santiago de Compostela, Spain; Fernandez-Llimós, F., Dep. of Pharmacology, University of Santiago de Compostela, Spain; Tiddens, L., Pharmaceutical Group of the European Union, Brussels, Belgium; Giorgio, F., Pharmaceutical Group of the European Union, Brussels, Belgium; Cranz, H., Association of the European Self-Medication Industry (AESGP), Brussels, Belgium; Mircheva, J., Association of the European Self-Medication Industry (AESGP), Brussels, Belgium","One of the applications developed within the EU-funded projects TESEMED and TESEMED-II is a program for the information and continuous training of community pharmacists, with the aim to empower them as advisors of the citizens about self-medication topics. Several programs are being developed on the basis of ad-hoc developed protocols about minor ailments (currently, cold and flu, haemorrhoids, constipation and cough). Each program includes three modules: a hypertextual version of the protocol, an interactive scheme of it, and an educational tool called Encounter Simulator, that trains the pharmacist about the protocol by means of simulated pharmacist-customer interactions. The testing of these applications with 84 community pharmacists offers positive results in terms of expectations, program characteristics and perceived usefulness.",,"Software testing; Wireless telecommunication systems; Customer interaction; Educational tools; Haemorrhoids; Perceived usefulness; Telematics; Application programs; article; common cold; computer program; computer simulation; drug information; European Union; human; influenza; medical informatics; pharmacist; self medication; Common Cold; Computer Simulation; Drug Information Services; European Union; Humans; Influenza, Human; Medical Informatics Applications; Pharmacists; Self Medication; Software",,,,,,,,,"Bond, C.M., Bradley, C., The interface between the community pharmacist and patients (1996) BMJ, 312, pp. 758-760; (1994) Communication from the European Commission Adopted on 1 June",,,,"IOS Press","15th Congress on Medical Informatics Europe, MIE 1999","22 August 1999 through 26 August 1999","Ljubljana",,09269630,0967335515; 9780967335513,,"2000143921","English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-0033286293
"Marrugat J., Vila J., Pavesi M., Sanz F.","7006226141;7202012717;57198281309;7102263897;","Estimación del tamaño de la muestra en la investigación clínica y epidemiológica",1998,"Medicina Clinica","111","7",,"267","276",,60,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032511499&partnerID=40&md5=6aafcfb35211f4f70bf192a5fd17a4ef","U. Lipidos Y Epidemiologia C., U. de Info. Médica, Inst. Munic. de Invest. Medica, Barcelona, Spain; U. Lipidos Y Epidemiologia C., Inst. Munic. de Invest. Medica, Doctor Aiguader, 80, 08003 Barcelona, Spain","Marrugat, J., U. Lipidos Y Epidemiologia C., U. de Info. Médica, Inst. Munic. de Invest. Medica, Barcelona, Spain, U. Lipidos Y Epidemiologia C., Inst. Munic. de Invest. Medica, Doctor Aiguader, 80, 08003 Barcelona, Spain; Vila, J., U. Lipidos Y Epidemiologia C., U. de Info. Médica, Inst. Munic. de Invest. Medica, Barcelona, Spain; Pavesi, M., U. Lipidos Y Epidemiologia C., U. de Info. Médica, Inst. Munic. de Invest. Medica, Barcelona, Spain; Sanz, F., U. Lipidos Y Epidemiologia C., U. de Info. Médica, Inst. Munic. de Invest. Medica, Barcelona, Spain",[No abstract available],,"article; clinical trial; comparative study; risk; sample size; statistical model; survival rate; Clinical Trials; Models, Statistical; Risk; Sample Size; Survival Rate",,,,,,,,,"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction (1993) N Engl J Med, 329, pp. 673-682; Freiman, J.A., Chalmers, T.C., Smith, H., Kuebler, R.R., The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial (1978) N Engl J Med, 299, pp. 690-694; Moher, D., Dulberg, C.S., Wells, G.A., Statistical power, sample size, and their reporting in randomized clinical trials (1994) J Am Med Assoc, 272, pp. 122-124; Carné, X., Moreno, V., Porta Serra, M., Velilla, E., El cálculo del número de pacientes necesarios en la planificación de un estudio clinico (1989) Med Clin, 92, pp. 72-77. , Barc; Porta, M., Moreno, V., Sanz, F., Carné, X., Velilla, E., Una cuestion de poder (1989) Med Clin, 92, pp. 223-228. , Barc; Lemeshow, S., Hosmer, D.W., Klar, J., Lwanga, S.K., (1995) Adequacy of Sample Size in Health Studies, , Nueva York: John Wiley & Sons; Meinert, C.L., (1986) Clinical Trials Design, Conduct and Analysis, , Nueva York: Oxford University Press; Bland, J.M., Altman, D.G., One and two sided tests of significance (1994) Br Med J, 309, p. 248; Pease, K.E., The alternative hypothesis: One sided or two-sided? (1989) J Clin Epidemiol, 42, pp. 473-476; Pocock, S.J., (1983) Clinical Trials: A Practical Approach, , Nueva York: John Wiley & Sons; Lemeshow, S., Hosmer, D.W., Klar, J., Sample size requirements for studies estimating odds ratios or relative risks (1988) Statist Med, 7, pp. 759-764; Plasencia, A., Porta Serra, M., La calidad de la información clínica (y II): Significación estadistica (1988) Med Clin, 89, pp. 122-126. , Barc; Porta, M., Plasencia, A., Sanz, F., La calidad de la información clínica (y III) ¿Estadisticamente signiticativo o clínicamente importante? (1988) Med Clin, 90, pp. 463-468. , Barc; Lui, K.J., Cumberland, W.G., Sample size requirement for repeated measurements in continuous data (1992) Statist Med, 11, pp. 633-641; Bratcher, T.L., Moran, M.A., Zimmer, W.J., Tables of sample sizes in the analysis of variance (1970) J Quality Technology, 2, pp. 156-164; Kastenbaum, M.A., Hoel, D.G., Bowman, K.O., Sample size requirements: One-way analysis of variance (1970) Biometrika, 54, pp. 421-430; Eisenhart, C., Inverse sine transformation of proportions (1947) Selected Techniques of Statistical Analysis, pp. 395-416. , Eisenhart C. Hastay MW. vallis WA, editores. Nueva York: McGraw-Hill; Makuch, R., Simon, R., Sample size requirements for evaluating a conservative therapy (1978) Cancer Treat Rep, 62, pp. 1.037-1.040; Fleiss, J.L., (1981) Statistical Methods for Rates and Proportions, , Nueva York: Wiley & Sons; Cantor, A.B., Sample size calculations for the log rank test: A Gompertz model approach (1992) J Clin Epidemiol, 45, pp. 1.131-1.136; Collet, D., (1994) Modelling Survival Data in Medical Research, , Londres: Chapman Hall; Armitage, P., Berry, G., (1987) Statistical Methods in Medical Research, , Oxford: Blackwell Scientific Publications; Barlow, D.H., Hersen, M., (1984) Single Case Experimental Designs. Strategies for Studying Behavior Change (2.1 Ed.), , Nueva York: Pergamon; Senn, S., (1993) Cross-over Trials in Clinical Research, , Nueva York: John Wiley & Sons; Guyatt, G., Sackett, D.L., Taylor, D.W., Chong, J., Roberts, R., Pugsley, S., Determining optimal therapy -randomized trials in individual patients (1986) N Engl J Med, 314, pp. 889-892; Porta, M., The search for more clinically meaningful research designs: Single-patient randomized clinical trials (1986) J Gen Intern Med, 1, pp. 418-419; Increased mortality due to encainide or flecainide in a randomized trial of arrhythmia suppression after myocardial infarction (1989) N Engl J Med, 321, pp. 406-412; Pocock, S.J., When to stop a clinical trial (1992) Br Med J, 305, pp. 235-240; Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Design and analysis of randomized clinical trials requiring prolonged observation of each patient, I: Introduction and design (1977) Br J Cancer, 34, pp. 585-612; O'Brien, P.C., Fleming, T.R., A multiple testing procedure for clinical trials (1979) Biometrics, 35, pp. 549-556; The early termination of clinical trial: Causes, consequences and control (1994) Eur Heart J, 15, pp. 721-738; Cantor, A.B., Power estimation for rank tests using censored data: Conditional and unconditional (1991) Contr Clin Trials, 12, pp. 462-473; Campbell, M.J., Julius, S.A., Altman, D.G., Estimating sample sizes for binary, ordered categorical, and outcomes in two group comparisons (1995) Br Med J, 311, pp. 1.145-1.148; Al-Sunduqchi, M., (1990) Determinig the Appropriate Sample Size for Inferences Based on the Wilcoxon Statistics, , disertación. Laramie: University of Wyoming, PhD; Hsieh, F.Y., Sample size tables for logistic regression (1989) Statist Med, 8, pp. 795-802; Hintze, J.L., (1992) SOLO Power Analysis, , Los Angeles: BMOP Statistical Software; Bristol, D.R., Samples sizes constructing confidence intervals and testing hypothesis (1989) Statist Med, 8, pp. 803-811; Elashoff, J.D., (1995) N Query Advisor, , Los Aageles. CA: Dixon Associates; Dean, A.G., Dean, J.A., Burton, A.H., Dicker, R.C., (1990) Epilnfo, Version 5. A Word Processing, Database, and Statistics System for Epidemiology on Microcomputers, , Stone Mountain: USD, Incorporated; Alonso, J.M., Campillo, C., Castillo, C., Cotos, T., Fernández, E., Hervada, X., (1994) EPIDAT: Análisis Epidemiológico de Dates, Tabulados, , Santiago de Compostela: Xunta de Galicia","Marrugat, J.; U. Lipidos Y Epidemiologia C., Inst. Munic. de Invest. Medica, Doctor Aiguader, 80, 08003 Barcelona, Spain",,,,,,,,00257753,,MCLBA,"9789243","Spanish","Med. Clin.",Article,"Final",,Scopus,2-s2.0-0032511499
"Lozoya E., Berges M., Rodríguez J., Sanz F., Loza M.I., Moldes V.M., Masaguer C.F.","6603260860;6602787443;24773509500;7102263897;7003766926;7801671259;6701715235;","Comparison of electrostatic similarity approaches applied to a series of ketanserin analogues with 5-HT(2A) antagonistic activity",1998,"Quantitative Structure-Activity Relationships","17","3",,"199","204",,1,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031835351&partnerID=40&md5=e2abbd703d06e91c4a44066f6a88569d","Res. Grp. Med. Info. Inst. M., Univ. Autònoma de Barcelona, C/ Doctor Aiguader 80, E-08003 Barcelona, Spain; Departmento de Farmacología, Facultad de Farmacia, Univ. de Santiago de Compostela, E-15706 Santiago de Compostela, Spain; Departmento de Quim. Organ., Facultad de Farmacia, Univ. de Santiago de Compostela, E-15706 Santiago de Compostela, Spain; Departmento de Quim. Física, Univ. de Santiago de Compostela, E-15706 Santiago de Compostela, Spain","Lozoya, E.; Berges, M.; Rodríguez, J., Departmento de Quim. Física, Univ. de Santiago de Compostela, E-15706 Santiago de Compostela, Spain; Sanz, F.; Loza, M.I., Res. Grp. Med. Info. Inst. M., Univ. Autònoma de Barcelona, C/ Doctor Aiguader 80, E-08003 Barcelona, Spain, Departmento de Farmacología, Facultad de Farmacia, Univ. de Santiago de Compostela, E-15706 Santiago de Compostela, Spain; Moldes, V.M.; Masaguer, C.F., Departmento de Quim. Organ., Facultad de Farmacia, Univ. de Santiago de Compostela, E-15706 Santiago de Compostela, Spain","Similarities between the molecular electrostatic potential (MEP) distributions of a series of analogues of ketanserin were studied using the MEPSIM package with the aim of correlating MEP patterns with the binding affinities for the 5-HT(2A) receptor. This study was also used to assess different approaches that can be used in this kind of similarity studies. The best correlation between MEP distributions and biological activities was found when only negative electrostatic potentials were taken into account, while the consideration of the whole MEP distribution produced a classification of the compounds than was mainly steric and not related with their biological activities. The two structural features of the considered molecules that generated negative MEP zones and consequently that could be related with their recognition by the 5-HT(2A) receptor, were the lone pairs of a carbonyl oxygen and the π-system of an aromatic ring.","5-HT(2A) receptor; Cluster analysis; Electrostatic similarity; Ketanserin analogues; MEPCOMP; MEPSIM; Molecular electrostatic potential; Molecular similarity","ketanserin; serotonin 2a antagonist; serotonin 2a receptor; article; electric potential; priority journal; receptor affinity",,"ketanserin, 74050-98-9",,,,,,,"Dean, P.M., (1995) Molecular Similarity in Drug Design, , Chapman & Hall, London; Eriksson, L., Johansson, E., (1996) Chemometr. Intell. Lab. Sys., 34, pp. 1-19; Loza, M.I., G.-Ferreiro, T., Sanz, F., Lozoya, E., Rodríguez, J., Manaut, F., Verde, I., Raviña, E., (1993) J. Pharm. Sci., 82, pp. 513-517; Nelson, D.L., (1993) Med. Chem. Res., 3, pp. 306-316; Baxter, G., Kennett, G., Blaney, F., Blackburn, T., (1995) Trends Pharmacol. Sci., 16, pp. 105-110; Pazos, A., Hoyer, D., Palacios, J.M., (1984) Eur. J. Pharmacol., 106, pp. 531-538; Murray, J.S., Sen, K., Molecular Electrostatic Potentials: Concepts and Applications (1996) Theoretical and Computational Chemistry, 3. , Elsevier Science B.V., Amsterdam; Höltje, H.-D., (1992) Medicinal Chemistry for the 21st Century, pp. 181-189. , Wermuth, C.G., Koga, N., König, H. and Metcalf, B.W., Blackwell Scientific Publications; Sanz, F., López-de-Briñas, E., Rodríguez, J., Manaut, F., (1994) Quant. Struct.-Act. Relat., 13, pp. 281-284; Apaya, R.P., Lucchese, B., Price, S.L., Vinter, J.G., (1995) J. Comput.-Aided Mol. Design, 9, pp. 33-43; Villoutriex, B.O., Lilja, H., Pettersson, K., Lovgren, T., Teleman, O., (1996) Protein Sci., 5, pp. 836-851; Frau, J., Price, S.L., (1996) J. Comput.-Aided Mol. Design, 10, pp. 107-122; Good, A.C., Peterson, S.J., Richards, W.G., (1993) J. Med. Chem., 36, pp. 2929-2937; Nakayama, A., (1992) Quant. Struct.-Act. Relat., 11, pp. 478-485; Carrieri, A., Brasili, L., Leonetti, F., Pigini, M., Giannella, M., Bousquet, P., Carotti, A., (1997) Bioorg. Med. Chem., 5, pp. 843-856; Insight II, , Biosym/MSI, San Diego, CA, USA; GAUSSIAN94, , Gaussian Inc. Pittsburgh, PA, USA; Almaula, N., Ebersole, B.J., Zhang, D., Weinstein, H., Sealfon, S.C., (1996) J. Biol. Chem., 271, pp. 14672-14675; Luque, F.J., Sanz, F., Illas, F., Pouplana, R., Smeyers, Y.G., (1988) Eur. J. Med. Chem., 23, pp. 7-10; Manaut, F., Sanz, F., José, J., Milesi, M., (1991) J. Comput.-Aided Mol. Design, 5, pp. 371-380; Sanz, F., Manaut, F., Rodríguez, J., Lozoya, E., López-de-Briñas, E., (1993) J. Comput.-Aided Mol. Design, 7, pp. 337-347; Sanz, F., Manaut, F., José, J., Segura, J., Carbó, M., De La Torre, R., (1988) J. Mol. Struct. (Theochem), 170, pp. 171-180; Rodríguez, J., Manaut, F., Sanz, F., (1993) J. Comput. Chem., 8, pp. 922-927; Honrubia, M.A., Rodríguez, J., Domínguez, R., Lozoya, E., Manaut, F., Seijas, J.A., Villaverde, M.C., Loza, M.I., (1997) Chem. Pharm. Bull., 45, pp. 842-848; (1995) SPSS for Windows (Version 6.1.3), , SPSS Inc. Chicago; Humblet, C., Mirzadegan, T., (1992) Ann. Rev. Med. Chem., 27, pp. 291-300","Sanz, F.; Departmento Farmacologia, Facultad de Farmacia, Universidad Santiago de Compostela, E-15706 Santiago de Compostela, Spain",,,,,,,,09318771,,QSARD,,"English","Quant. Struct.-Act. Relatsh.",Article,"Final",,Scopus,2-s2.0-0031835351
"Diaz E., Villalbí J.R., Nebot M., Aubà J., Sanz F.","7102880858;7006565764;7004378913;6602542199;7102263897;","The initiation of smoking among schoolchildren: Cross-sectional and longitudinal study of the predictive factors [El inicio del consumo de tabaco en escolares: Estudio transversal y longitudinal de los factures predictivos]",1998,"Medicina Clinica","110","9",,"334","339",,32,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032515729&partnerID=40&md5=872d8ebf101d27b3688421d9a7106b50","Institut Municipal de la Salut, Ajuntament de Barcelona, Badalona, Barcelona, Spain; Inst. Univ. Salut Pub. de Catalunya, Badalona, Barcelona, Spain; Institut Català de la Salut, Badalona, Barcelona, Spain; Inst. Munic. d'Investigacio Medica, IMAS, Barcelona, Spain; Institut Municipal de la Salut, Plaza Lesseps, 1, 08023 Barcelona, Spain","Diaz, E., Institut Municipal de la Salut, Ajuntament de Barcelona, Badalona, Barcelona, Spain, Institut Municipal de la Salut, Plaza Lesseps, 1, 08023 Barcelona, Spain; Villalbí, J.R., Institut Municipal de la Salut, Ajuntament de Barcelona, Badalona, Barcelona, Spain, Inst. Univ. Salut Pub. de Catalunya, Badalona, Barcelona, Spain; Nebot, M., Institut Municipal de la Salut, Ajuntament de Barcelona, Badalona, Barcelona, Spain; Aubà, J., Institut Municipal de la Salut, Ajuntament de Barcelona, Badalona, Barcelona, Spain, Institut Català de la Salut, Badalona, Barcelona, Spain; Sanz, F., Inst. Munic. d'Investigacio Medica, IMAS, Barcelona, Spain","BACKGROUND: This study examines the evolution of tobacco use among schoolchildren in sixth and seventh grades in Barcelona (11-13 years) and identifies smoking risk factors through cross-sectional and follow-up analysis. POBLAION AND METHODS: The cohort consists of 1,003 students attendig 13 schools who served as control units for a study assessing the effects of a school-based addictive substances prevention program. Participants answered the same questionnaire in 1990 and 1991. Risk factors for the experimentation and for regular smoking are studied through cross-sectional and prospective studies. RESULST: In a year, smokers increase from 9.7% to 18.9% and regular smokers rise from 1.1% to 5.5%. The initial cross-sectional analysis finds stronger associations than the follow-up one. Some variables loose their significance in the longitudinal analysis. Among non-smokers, the strongest predictors to emerge are intention to smoke, the belief that smoking is fun, peers, siblings and mother consumption, and being male; however girls appear to consolidate the consumption more than boys among the cohort of triers. CONCLUSIONS: Tobacco use prevalences are consistent with other studies developed in our city. Social environment emerges as an important predictor; friends, siblings and mothers tobacco use and gender are the main risk factors.",,"adolescent; age; article; child; cross-sectional study; female; human; longitudinal study; male; smoking; statistical model; Adolescent; Age Factors; Child; Cross-Sectional Studies; Female; Humans; Logistic Models; Longitudinal Studies; Male; Smoking",,,,,,,,,"Via, J.M., Salleras, L., (1991) Document Marc per a l'Elaboració del Pla de Salut de Catalunya, , Barcelona: Publicacions ce la Generalitat de Catalunya; Nebot, M., Borrell, C., Ballestín, M., Villalbi, J.R., Prevalencia y caracteristicas asociadas al consumo de tabaco en población general en Barcelona entre 1983 y 1992 (1996) Rev Clin Esp, 196, pp. 359-364; Comin, E., Nebot, M., Villalbi, J.R., Exercici i consum de tabac i alcohol dels escolars de Barcelona (1989) Gac Sanit, 3, pp. 355-365; Villalbi, J.R., Nebot, M., Ballestín, M., Los adolescentes ante las sustancias adictivas: Tabaco, alcohol y drogas no institucionalizadas (1995) Med Clin, 104, pp. 784-788. , Barc; Marcus, S., Giovino, G., Pierce, J., Harel, Y., Measuring tobacco use among adolescents (1993) Public Health Reports, 108, pp. 20-24; Franzkowiak, P., Risk-taking and adolescent development. The functions of smoking and alcohol consumption in adolescence and its consequences for prevention (1987) Health Promotion, 2, pp. 51-61; Best, A., Intervention perspectives on school health promotion research (1989) Health Educ Q, 16, pp. 299-306; Glanz, K., Lewis, F., Rimer, B., (1990) Health Behavior and Health Education. Theory Research and Practice, , San Francisco: Jossey-Bass Publishers; Aubà, J., Villalbí, J.R., Prevención desde la escuela del uso de tabaco y de otras sustancias adictivas (1990) Gac Sanit, 4, pp. 70-75; Bennet, P., Hogson, R., Psychology and health promotion (1992) Health Promotion. Disciplines and Diversity, , Londres: Rouledge; Meier, K., Tobacco truths: The impact of role models on children's attitudes towards smoking (1991) Health Educ Q, 18, pp. 173-182; Bettinghaus, E., Health promotion and the knowledge-attitude-behaviour continuum (1986) Prev Med, 15, pp. 475-491; Bandura, A., (1986) Social Foundations of though and Action, , Englewood Cliffs, Nueva Jersey: Prentice-Hall Inc; Terry, D., Gallois, C., McAmish, M., (1993) The Theory of Reasoned Action: Its Application to AIDS Preventive Behaviour, , Oxford : Pergamon Press; Ariza, C., Nebot, M., Factores asociados al consumo de tabaco en una muestra de escolares de enseñanza primaria y secundaria (1995) Gac Sanit, 9, pp. 101-109; Mendoza, R., Sagrera, M.R., Batista, J.M., (1994) Conductas de los Escolares Españoles Relacionadas Con la Salud (1986-1990), , Madrid: Consejo Superior de Investigaciones Cientificas; Villalbí, J.R., Aubà, J., (1991) Disseny i Avaluació del Projecte PASE: Un Programa de Prevenció de l'Abús de Substances Addictives a l'Escola, , Barcelona: Ajuntament de Barcelona; Villalbí, J.R., Aubà, J., García, A., Resultados de un programa escolar de preventión del abuso de sustancias adictivas: Proyecto piloto PASE de Barcelona (1993) Gac Sanit, 7, pp. 70-77; Comín, E., Torrubia, R., Mor, J., Villalbi, J.R., Nebot, M., Fiabilidad de un cuestionario autoadministrado para investigar el nivel de ejercicio, de consumo de tabaco y de alcohol entre escolares (1997) Med Clin, 108, pp. 293-298. , Barc; Aluja, T., (1991) Index de Capacitat Econòmica Familiar a la Ciutat de Barcelona, , Barcelona: Ajuntament de Barcelona i Caixa de Pensions; Norussis, M., (1992) SPSS for Windows: Advanced Statistics, , Chicago: SPSS Inc; Kleinbaum, D., Una introductión al análisis de regresión logistica (1993) Revisiones en Salud Pública, 3, pp. 61-105; Kleinbaum, D., Kupper, L., Morgentern, H., (1992) Epidemiologic Research. Principles and Quantitative Methods, , Nueva York: Van Nostrand Reinhold Company Inc; Alvarez Cáceres, R., (1994) Estadística Multivariante y No Paramétrica con SPSS: Aplicación a las Ciencias de la Salud, , Madrid: Diaz de Santos; Gilpin, E., Pierce, J., Cavin, S., Berry, C., Evans, N., Johnson, M., Estimates of population smoking prevalence: Self vs proxy reports of smoking status (1994) Am J Public Health, 84, pp. 1576-1579; McDermott, R., Sarvela, P., Hoalt, P., Bajracharya, S., Marty, P., Emery, E., Multiple correlates of cigarrete use among high school students (1992) J Sch Health, 62, pp. 146-150; Adelekan, M., Gowers, S., Singh, D., Reliability and validity of the Westminster Substance Use Questionnaire among Lancashire adolescents (1994) Drug Alcohol Depend, 34, pp. 191-199; Perry, C., Murray, D., Klepp, K., Predictors of adolescent smoking and implications for prevention (1987) MMWR, 36 (4 SUPPL.), pp. 41-45; De Vries, H., Backbier, E., Dijkstra, M., Van Breukelen, G., Parcel, G., Kok, G., A Dutch social influence smoking prevention approach for vocational school students (1994) Health Education Research, 9, pp. 365-374; De Zwart, W.M., Mensik, C., Kuipers, S.B.M., (1994) Key Data: Smoking, Drinking. Drug Use and Gambling among Pupils Aged 10 Years and Older, , Utrecht: Netherlands Institute on Alcohol and Drugs; Nutbeam, D., Aaro, L., Wold, B., The lifestyle concept and health education with young people (1991) World Health Stat Q, 44, pp. 55-61; Kroohn, M., Naughton, M., Lauer, R., Adolescent cigarette use: The relationship between attitudes and behavior (1987) MMWR, 36 (4 SUPPL.), pp. 25-33; De Vries, H., Backvier, E., Kok, G., Dijkstra, M., The impact of social influences in the context of attitude, self efficacy, intention and previous behavior as predictors of smoking onset J Appl Social Psychol, , En prensa; McNeill, A.D., Jarvis, M.J., Stapleton, J.A., Russell, M.A., Eiser, J.R., Gammage, P., Prospective study of factors predicting uptake of smoking in adolescents (1988) J Epidemiol Community Health, 43, pp. 72-78; Ajzen, I., (1991) Attitudes, Personality and Behavior, , Milton Keynes: Open University Press; Sussman, S., Dent, C., Flay, B., Hansen, W., Johnson, A., Psychosocial predictors of cigarette smoking onset by white, black hispanic and asian adolescents in southern California (1987) MMWR, 36, pp. 11-16; Mittelmark, M., Murray, D., Russell, V., Luepker, R., Pechacek, T., Pirie, P., Predicting experimen-tation with cigarretes: The childhood antecedents of smoking study (1987) Am J Public Health, 77, pp. 206-208; Aubà, J., Villalbi, J.R., Tabaco y adolescentes: Influencia del entorno personal (1993) Med Clin, 100, pp. 506-509. , Barc; Swan, A.V., Creeser, R., Murray, M., When and why children first start to smoke (1990) Int J Epidemiol, 19, pp. 323-330; Hunter, S., Croft, J., Vizelberg, I., Berenson, G., Psychosocial influence on cigarette smoking among youth in a southern community: The Bogalusa Heart Study (1987) MMWR, 36, pp. 17-23; Eckhardt, L., Wooddruff, S., Elder, J., A longitudinal analysis of adolescent smoking and its correlates (1994) J Sch Health, 64, pp. 67-72; Semmer, N., Cleary, P., Dwyer, J., Fuchs, R., Lippert, P., Psychosocial predictors of adolescent smoking in two german cities: The Berlin-Bremen study (1987) MMWR, 36, pp. 3-10; Escobedo, L., Anda, R., Smith, P., Remington, P., Mast, E., Sociodemographic characteristics of cigarrette smoking initiation in the United States (1990) JAMA, 264, pp. 1550-1555; Gilpin, E., Lee, L., Evans, N., Pierce, J., Smoking initiation rates in adults and minors: United States, 1944-1988 (1994) Am J Epidemiol, 140, pp. 535-543; Clayton, S., Gender differences in psychosocial determinants of adolescent smoking (1991) J Sch Health, 61, pp. 115-120; Kok, G., Schaalma, H., De Vries, H., Parcel, G., Paulussen, T., Social psychology and health education (1996) European Review of Social Psychology, , Stroebe W, Heawstone M, editores. Chichester: Wiley","Diaz, E.; Institut Municipal de la Salut, Plaza Lesseps, 1, 08023 Barcelona, Spain",,,,,,,,00257753,,MCLBA,"9567266","Spanish","Med. Clin.",Article,"Final",,Scopus,2-s2.0-0032515729
"Sancho J.J., Planas I., Domènech D., Martín-Baranera M., Palau J., Sanz F.","7201937083;6602265390;55372301800;6603145514;7006416471;7102263897;","IMASIS. A multicenter hospital information system - Experience in barcelona",1998,"Studies in Health Technology and Informatics","56",,,"35","42",,3,"10.3233/978-1-60750-900-4-35","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032241041&doi=10.3233%2f978-1-60750-900-4-35&partnerID=40&md5=663ceec9b93e0aa592b154707f22ca1e","Dept of Lnformatics, Institut Municipal d'Assistència Sanitària (IMAS), Pg. de Gràcia 2-4, 08007 Barcelona, Spain; Dept of Medical Informatics and Education, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Dr. Aiguader 80, 08003 Barcelona, Spain; Administrative Direction, Institut Municipal d'Assistència Sanitària (IMAS), Pg. de Gràcia 2-4, 08007 Barcelona, Spain","Sancho, J.J.; Planas, I., Dept of Lnformatics, Institut Municipal d'Assistència Sanitària (IMAS), Pg. de Gràcia 2-4, 08007 Barcelona, Spain; Domènech, D., Dept of Lnformatics, Institut Municipal d'Assistència Sanitària (IMAS), Pg. de Gràcia 2-4, 08007 Barcelona, Spain; Martín-Baranera, M., Dept of Medical Informatics and Education, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Dr. Aiguader 80, 08003 Barcelona, Spain; Palau, J., Administrative Direction, Institut Municipal d'Assistència Sanitària (IMAS), Pg. de Gràcia 2-4, 08007 Barcelona, Spain; Sanz, F., Dept of Medical Informatics and Education, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Dr. Aiguader 80, 08003 Barcelona, Spain","The present study aimed to analyse physicians' attitudes towards IMASIS, and their potential influence on IMASIS medical record project. IMAS (Institut Municipal d'Assistència Sanitària) is the health care organisation of the City Council of Barcelona. IMAS hospital information system (IMASIS), which first applications were designed and implemented in 1984, is currently facing a new phase, focused on clinical information management. Our approach included a personal interview with representatives of every hospital unit, and a self-administered questionnaire distributed to every clinician. Both provided a worthy insight into the cultural patterns to be considered in the HIS implementation process. Moreover, the results helped to define the subsequent steps of IMASIS evolution. Our experience is proposed as a tool to assess clinical informations systems from a user point of view.","Hospital information systems; Technology assessment; Users' needs","Hospitals; Information systems; Information use; Surveys; Wireless telecommunication systems; City council; Clinical information; Hospital information systems; Implementation process; Medical record; Self-administered questionnaire; Technology assessments; Users' needs; Information management; adult; article; computer interface; health personnel attitude; hospital information system; human; medical record; questionnaire; Spain; Adult; Attitude of Health Personnel; Hospital Information Systems; Humans; Medical Records Systems, Computerized; Questionnaires; Spain; User-Computer Interface",,,,,,,,,"Roderer, N.K., Clayton, P.D., IAIMS at columbia-presbyterian medical center: Accomplishments and challenges (1993) Yearbook of Medical Informatics, pp. 140-149; Anderson, J.G., Jay, S.J., Evaluating health care information systems. Methods and applications (1994) SAGE Publications, , Anderson JG, Aydin CE, Jay SJ Eds. , Thousand Oaks, CA; Slack, W.V., Boro, E.S., Bleich, H.L., Barriers to clinical computing: What physicians can do (1992) MD Comput, 9, pp. 278-280; Stead, W.W., A quarter-century of computer-based medical records (1989) MD Comput, 6, pp. 75-81; Gremy, F., Scientific context and the human meaning of informatics applied to health care (1994) MD Comput, 11, pp. 149-154; Forsythe, D.E., Buchanan, B.G., Osheroff, J.A., Miller, R.A., Expanding the concept of medical information: An observational study of physicians' information needs (1992) Comput Biomed Res, 25, pp. 181-220; Jelovsek, F.R., Rittwage, J., Pearse, W.H., Visscher, H.C., Information management needs of the obstetriciangynecologist- A survey (1989) Obstet Gynecol, 73, pp. 395-399; Davidoff, F., Haynnes, B., Sackett, D., Smith, R., Evidence based medicine: A new journal to help doctors identify the information they need (1995) BMJ, 310, pp. 1085-1086; Sackett, D.L., Richardson, W.S., Rosenberg, W., Haynes, R.B., (1997) Evidence-based Medicine. How to Practice and Teach EBM, , Churchill Livingstone, New York; Covell, D.G., Uman, G.C., Manning, P.R., Information needs in office practice: Are they been met (1985) Ann Intern Med, 103, p. 596; Stinson, E.R., Mueller, D.A., Survey of health professionals' information habits and needs conducted through personal interviews (1980) JAMA, 243, pp. 140-143; Osheroff, J.A., Forsythe, D.E., Buchanan, B.G., Bankowitz, R.A., Blumenfeld, B.H., Miller, R.A., Physicians' information needs: Analysis of questions posed during clinical teaching (1991) Ann Intern Med, 114, p. 576; Shortliffe, E.H., Perreault, L.E., (1990) Medical Informatics: Computer Applications in Health Care, , Addison- Wesley; Barfield, L., (1993) The User Interface. Concepts and Design, , Addison-Wesley Publishing Company, Inc. New York; Galitz, W.O., (1993) User-interface Screen Design, , QED Information Sciences, Inc. Boston; Powell, D.G., Douglas, N.M., Westlake, P.H., Physician participation in a Medical Information System (1994) MD Comput, 11, pp. 140-147; Pryor, A.T., Current state of computer-based patient record systems (1992) Aspects of the Computer-based Patient Record, , In: Ball MJ, Collen MF Eds. Springer-Verlag, New York; Simpson, R.L., Clinical information systems vs (1992) Practicing Physicians. Nurs Manage, 23, pp. 14-16; Lumsdon, K., Pioneering protocols. Hospitals test the computer's use in patient care decision (1993) Hospitals, 67, pp. 18-21; Roderer, N.K., Clayton, P.D., IAIMS at Columbia-Presbyterian medical center: Accomplishments and challenges (1993) Yearbook of Medical Informatics, pp. 140-149; Massaro, T.A., Introducing physician order entry at a major academic medical center: I. Impact on organizational culture and behavior (1993) Acad Med, 68, pp. 20-25; Rogers, M.C., Snyderman, R., Rogers, E., Cultural and organizational implications of academic managedcare networks (1994) N Engl J Med, 331, pp. 1374-1377; Kraemer, K.L., (1991) The Information Systems Research Challenge: Survey Research Methods, , Harvard Business School, Boston; Prokosch, H.U., Puhle, B., Dudeck, J., One-stop-information-shopping: Do we meet the information needs of the hospital staff (1994) Proceedings of the Twelfth International Congress of the European Federation for Medical Informatics, pp. 362-365. , In: Barahona P, Veloso M, Bryant J eds. Lisbon; Kraemer, K.L., (1991) The Information Systems Research Challenge: Survey Research Methods, , Harvard Business School, Boston; Prokosch, H.U., Puhle, B., Dudeck, J., One-stop-information-shopping: Do we meet the information needs of the hospital staff (1994) Proceedings of the Twelfth International Congress of the European Federation for Medical Informatics, pp. 362-365. , In: Barahona P, Veloso M, Bryant J eds. Lisbon",,,"'European People's Party'","IOS Press","European Workshop on Acceptance of Health Telematics Applications and Services","12 December 1997 through 13 December 1997","Thessaloniki",,09269630,905199415X; 9789051994155,,"1999126468","English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-0032241041
"Sancho E., Vilá M.R., Sánchez-Pulido L., Lozano J.J., Paciucci R., Nadal M., Fox M., Harvey C., Bercovich B., Loukili N., Ciechanover A., Lin S.L., Sanz F., Estivill X., Valencia A., Thomson T.M.","7005895322;7103149897;6603611885;7103062769;6603574074;35453371900;7401718967;7202112966;6602380745;36966769200;7005873606;7407159107;7102263897;36047834200;16308427600;7005594330;","Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 intestinal mucosecretory cells",1998,"Molecular and Cellular Biology","18","1",,"576","589",,99,"10.1128/MCB.18.1.576","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031962188&doi=10.1128%2fMCB.18.1.576&partnerID=40&md5=70c46b80bd5f91d457a050d8f8529bea","Depto. de Biología Molecular, Inst. de Biología del Cancer, IMIM-CSIC, Barcelona, Spain; Protein Design Group, Ctro. Nac. de Biotecnologia-CSIC, Cantoblanco, Madrid, Spain; Grup de Recerca en Info. Medica, IMIM-UAB, Barcelona, Spain; Depto. de Genètica Humana, Inst. de Recerca Oncològica, Barcelona, Spain; MRC Human Biochemical Genetics Unit, University College London, London, United Kingdom; Department of Biochemistry, Faculty of Medicine, Technion-Israel Inst. of Technology, Haifa, Israel; Department of Psychiatry, UMDNJ-Robert Wood Johnson Med. Sch., Piscataway, NJ, United States; Depto. de Biología Molecular, Inst. de Biol. del Cáncer, IMIM-CSIC, Av. Doctor Aiguader 80, 08003 Barcelona, Spain; Unitat de Recerca Biomèdica, Hospital Vall d'Hebrón, Barcelona, Spain","Sancho, E., Depto. de Biología Molecular, Inst. de Biología del Cancer, IMIM-CSIC, Barcelona, Spain; Vilá, M.R., Depto. de Biología Molecular, Inst. de Biología del Cancer, IMIM-CSIC, Barcelona, Spain, Unitat de Recerca Biomèdica, Hospital Vall d'Hebrón, Barcelona, Spain; Sánchez-Pulido, L., Protein Design Group, Ctro. Nac. de Biotecnologia-CSIC, Cantoblanco, Madrid, Spain; Lozano, J.J., Grup de Recerca en Info. Medica, IMIM-UAB, Barcelona, Spain; Paciucci, R., Depto. de Biología Molecular, Inst. de Biología del Cancer, IMIM-CSIC, Barcelona, Spain; Nadal, M., Depto. de Genètica Humana, Inst. de Recerca Oncològica, Barcelona, Spain; Fox, M., MRC Human Biochemical Genetics Unit, University College London, London, United Kingdom; Harvey, C., Depto. de Biología Molecular, Inst. de Biología del Cancer, IMIM-CSIC, Barcelona, Spain, MRC Human Biochemical Genetics Unit, University College London, London, United Kingdom; Bercovich, B., Department of Biochemistry, Faculty of Medicine, Technion-Israel Inst. of Technology, Haifa, Israel; Loukili, N., Depto. de Biología Molecular, Inst. de Biología del Cancer, IMIM-CSIC, Barcelona, Spain; Ciechanover, A., Department of Biochemistry, Faculty of Medicine, Technion-Israel Inst. of Technology, Haifa, Israel; Lin, S.L., Department of Psychiatry, UMDNJ-Robert Wood Johnson Med. Sch., Piscataway, NJ, United States; Sanz, F., Grup de Recerca en Info. Medica, IMIM-UAB, Barcelona, Spain; Estivill, X., Depto. de Genètica Humana, Inst. de Recerca Oncològica, Barcelona, Spain; Valencia, A., Protein Design Group, Ctro. Nac. de Biotecnologia-CSIC, Cantoblanco, Madrid, Spain; Thomson, T.M., Depto. de Biología Molecular, Inst. de Biología del Cancer, IMIM-CSIC, Barcelona, Spain, Depto. de Biología Molecular, Inst. de Biol. del Cáncer, IMIM-CSIC, Av. Doctor Aiguader 80, 08003 Barcelona, Spain","By means of differential RNA display, we have isolated a cDNA corresponding to transcripts that are down-regulated upon differentiation of the goblet cell-like HT-29-M6 human colon carcinoma cell line. These transcripts encode proteins originally identified as CROC-1 on the basis of their capacity to activate transcription of c-fos. We show that these proteins are similar in sequence, and in predicted secondary and tertiary structure, to the ubiquitin-conjugating enzymes, also known as E2. Despite the similarities, these proteins lack a critical cysteine residue essential for the catalytic activity of E2 enzymes and, in vitro, they do not conjugate or transfer ubiquitin to protein substrates. These proteins constitute a distinct subfamily within the E2 protein family and are highly conserved in phylogeny from yeasts to mammals. Therefore, we have designated them UEV (ubiquitin-conjugating E2 enzyme variant) proteins, defined as proteins similar in sequence and structure to the E2 ubiquitin-conjugating enzymes but lacking their enzymatic activity (HW/GDB-approved gene symbol, UBE2V). At least two human genes code for UEV Proteins, and one of them, located on chromosome 20q13.2, is expressed as at least four isoforms, generated by alternative splicing. All human cell types analyzed expressed at least one of these isoforms. Constitutive expression of exogenous human UEV in HT-29-M6 cells inhibited their capacity to differentiate upon confluence and caused both the entry of a larger proportion of cells in the division cycle and an accumulation in G2-M. This was accompanied with a profound inhibition of the mitotic kinase, cdk1. These results suggest that UEV proteins are involved in the control of differentiation and could exert their effects by altering cell cycle distribution.",,"ubiquitin conjugating enzyme; article; cell cycle; cell differentiation; enzyme activity; human; human cell; intestine cell; priority journal; protein expression; protein structure; secretory cell; Mammalia","GENBANK: U49278, U97279, U97280, U97281","ubiquitin conjugating enzyme, 147154-16-3",,,,,,,"Arion, D., Meijer, L., Brizuela, L., Beach, U., cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF (1988) Cell, 55, pp. 171-378; Bailly, V., Lamb, J., Sung, P., Prakash, S., Prakash, L., Specific complex formation between yeast RAD6 and RAD18 proteins: A potential mechanism for targeting RAD6 ubiquitin-conjugating activity to DNA damage sites (1994) Genes Dev., 8, pp. 811-820; Banerjee, A., Deshaies, R.J., Chau, V., Characterization of a dominant negative mutant of the cell cycle ubiquitin-conjugating enzyme Cdc34 (1995) J. Biol. Chem., 270, pp. 26209-26215; Barila, D., Murgia, C., Nobili, F., Gaetani, S., Perozzi, G., Subtractive hybridization cloning of novel genes differentially expressed during intestinal development (1994) Eur. J. Biochem., 223, pp. 701-709; Bartz, S.R., Rogel, M.E., Emerman, M., Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control (1996) J. Virol., 70, pp. 2324-2331; Broek, D., Bartlett, R., Crawford, K., Nurse, P., Involvement of p34cdc2 in establishing the dependency of S phase in mitosis (1991) Nature, 349, pp. 388-393; Chen, P., Johnson, P., Sommer, T., Jentsch, S., Hochstrasser, M., Multiple ubiquitin-conjugating enzymes participate in the in vivo degradation of the yeast MATα2 repressor (1993) Cell, 74, pp. 357-369; Chen, X., Ko, L.J., Jayaraman, L., Prives, C., p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response to tumor cells (1996) Genes Dev., 10, pp. 2438-2451; Chomczynsky, P., Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction (1987) Anal. Biochem., 162, pp. 156-159; Ciechanover, A., The ubiquitin-proteasome proteolytic pathway (1994) Cell, 79, pp. 12-21; Cook, W.J., Jeffrey, L.C., Sullivan, M.L., Vierstra, R.D., Three-dimensional structure of a ubiquitin-conjugating enzyme (E2) (1992) J. Biol. Chem., 267, pp. 15116-15121; Cook, W.J., Jeffrey, L.C., Xu, Y., Chau, V., Tertiary structures of class I ubiquitin-conjugating enzymes are highly conserved: Crystal structure of yeast Ubc4 (1993) Biochemistry, 32, pp. 13809-13817; Cook, W.J., Martin, P.D., Edwards, B.F., Yamazaki, R.K., Chau, V., Crystal structure of a class I ubiquitin conjugating enzyme (Ubc7) from Saccharomyces cerevisiae at 2.9 angstroms resolution (1997) Biochemistry, 36, pp. 1621-1627; Diaz-Meco, M., Dominguez, I., Sanz, L., Municio, M.M., Berra, E., Cornet, M.E., De Garcia Herreros, A., Moscat, J., Phospholipase C-mediated hydrolysis of phosphatidylcholine is a target of transforming growth factor-β1 inhibitory signals (1992) Mol. Cell. Biol., 12, pp. 302-308; Fabre, M., De Garcia Herreros, A., Phorbol ester-induced scattering of HT-29 human intestinal cancer cells is associated with down-modulation of E-cadherin (1993) J. Cell Sci., 106 (2 PART), pp. 513-521; Feinberg, A.P., Vogelstein, B., A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity (1983) Anal. Biochem., 132, pp. 6-13; Felix, M.-A., Cohen, P., Karsenti, E., Cdc2 H1 kinase is negatively regulated by a type 2a phosphatase in the Xenopus early embryonic cell cycle: Evidence from the effects of okadaic acid (1990) EMBO J., 9, pp. 675-683; Gonen, H., Stancovski, I., Shkedy, D., Hadari, T., Bercovich, B., Bengal, E., Mesilati, S., Ciechanover, A., Isolation characterization, and partial purification of a novel ubiquitin-protein ligase, E3 (1996) J. Biol. Chem., 271, pp. 302-310; Gordon, J.I., Hermiston, M.L., Differentiation and self-renewal in the mouse gastrointestinal epithelium (1994) Curr. Opin. Cell Biol., 6, pp. 795-803; Gosink, M.M., Vierstra, R.D., Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes (1995) Proc. Natl. Acad Sci. USA, 92, pp. 9117-9121; Gu, Y., Rosenblatt, J., Morgan, D.O., Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15 (1992) EMBO J., 11, pp. 3995-4005; Hayles, J., Fisher, D., Woollard, A., Nurse, P., Temporal order of S phase and mitosis in fission yeast is determined by the state of the p34cdc2-mitotic B cyclin complex (1994) Cell, 78, pp. 813-822; He, J., Choe, S., Walker, R., Di Marzio, P., Morgan, D.O., Landau, N.R., Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 (1995) J. Virol., 69, pp. 6705-6711; Huet, C., Sahuquillo-Merino, C., Coudrier, E., Louvard, D., Absorptive and mucus-secreting subclones isolated from a multipotent intestinal cell line (HT-29) provide new models for cell polarity and terminal differentiation (1987) J. Cell Biol., 105, pp. 345-357; Jentsch, S., The ubiquitin-conjugation system (1992) Annu. Rev. Genet., 26, pp. 179-207; Jowett, J.B.M., Planelles, V., Poon, B., Shah, N.P., Chen, M.-L., Chen, I.S.Y., The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2-M phase of the cell cycle (1995) J. Virol., 69, pp. 6304-6313; Kaiser, P., Mandl, S., Schwiger, M., Schneider, R., Characterization of functionally independent domains in the human ubiquitin conjugating enzyme UbcH2 (1995) FEBS Lett., 377, pp. 193-196; Kitamura, H., Cho, M., Lee, B.H., Gum, J.R., Siddiki, B.B., Ho, S.B., Toribara, N.W., Kim, Y.S., Alteration in mucin gene expression and biological properties of HT-29 colon cancer cell subpopulations (1996) Eur. J. Cancer, 32 A, pp. 1788-1796; Krek, W., Nigg, E.A., Mutations of p34cdc2 phosphorylation sites induce premature mitotic events in HeLa cells: Evidence for a double block to p34cdc2 kinase activation in vertebrates (1991) EMBO J., 10, pp. 3331-3341; Koonin, E.V., Abagyan, R.A., TSG101 may be the prototype of a class of dominant negative ubiquitin regulators (1997) Nat. Genet., 16, pp. 330-331; Lee, M.P., Feinberg, A.P., Aberrant splicing but not mutations of TSG101 in human breast cancer (1997) Cancer Res., 57, pp. 3131-3134; Lesuffleur, T., Barbat, A., Luccioni, C., Beaumetin, J., Clair, M., Kornowski, A., Dussaulx, E., Zweibaum, A., Dihydrofolate reductase gene amplification-associated shift of differentiation in methotrexate-adapted HT-29 cells (1991) J. Cell Biol., 115, pp. 1409-1418; Lesuffleur, T., Porchet, N., Aubert, J.-P., Swallow, D., Gum, J.R., Kim, Y.S., Real, F.X., Zweibaum, A., Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations (1993) J. Cell Sci., 106, pp. 771-783; Li, L., Cohen, S.N., tsg101: A novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells (1996) Cell, 85, pp. 319-329; Li, L., Li, X., Francke, U., Cohen, S.N., The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer (1997) Cell, 88, pp. 143-154; Louvard, D., Kedinger, M., Hauri, H.P., The differentiating intestinal epithelial cell: Establishment and maintenance of functions through interactions between cellular structures (1992) Annu. Rev. Cell Biol., 8, pp. 157-195; Madura, K., Dohmen, R.J., Varshavsky, A., N-recognin/Ubc2 interactions in the N-end rule pathway (1993) J. Biol. Chem., 268, pp. 12046-12054; Matuschewski, K., Hauser, H.P., Treier, M., Jentsch, S., Identification of a novel family of ubiquitin-conjugating enzymes with distinct amino-terminal extensions (1996) J. Biol. Chem., 271, pp. 2789-2794; Moreno, S., Nurse, P., Regulation of progression through the G1 phase of the cell cycle by the rum1+ gene (1994) Nature, 367, pp. 236-242; Morgan, D.O., Principles of CDK regulation (1995) Nature, 374, pp. 131-134; Murray, A., Cyclin ubiquitination: The destructive end of mitosis (1995) Cell, 81, pp. 149-152; Nadal, M., Mila, M., Pritchard, M., Mur, A., Pujals, J., Blouin, J.L., Antonarakis, S.E., Extivill, X., YAC and cosmid FISH mapping of an unbalanced chromosomal translation causing partial trisomy 21 and Down syndrome (1996) Hum. Genet., 9, pp. 460-466; Nagai, Y., Kaneda, S., Nomura, K., Yasuda, H., Seno, T., Yamao, F., Ubiquitin-activating enzyme, E1, is phosphorylated in mammalian cells by the protein kinase Cdc2 (1995) J. Cell Sci., 108, pp. 2145-2152; Neutra, M., Louvard, D., Differentiation of intestinal cells in vitro (1989) Functional Epithelial Cells in Culture, pp. 363-398. , K. S. Matlin and J. D. Valentich (ed.), Alan R. Liss, Inc., New York, N.Y; Nurse, P., Ordering S phase and M phase in the cell cycle (1994) Cell, 79, pp. 547-550; Perucho, M., Welsh, J., Peinado, M.A., Ionov, Y., McClelland, M., Fingerprinting of DNA and RNA by arbitrarily primed polymerase chain reaction: Applications in cancer research (1995) Methods Enzymol., 254, pp. 275-290; Pinto, M., Appay, M.D., Simon-Assman, P., Chevalier, G., Dracopoli, N., Fogh, J., Zweibaum, A., Enterocytic differentiation of cultured human colon cancer cells by replacement of glucose by galactose in the medium (1982) Biol. Cell., 44, pp. 193-196; Pitluk, Z.W., McDonough, M., Sangan, P., Gonda, D.K., Novel CDC34 (UBC3) ubiquitin-conjugating enzyme mutants obtained by charge-to-alanine scanning mutagenesis (1995) Mol. Cell. Biol., 15, pp. 1210-1219; Ponting, C.P., Cai, Y.-D., Bork, P., The breast cancer gene product TSG101: A regulator of ubiquitination? (1997) J. Mol. Med., 75, pp. 467-469; Ptak, C., Prendergast, J.A., Hodgins, R., Kay, C.M., Chau, V., Ellison, M.J., Functional and physical characterization of the cell cycle ubiquitin-conjugating enzyme CDC34 (UBC3). Identification of a functional determinant within the tail that facilitates CDC34 self-association (1994) J. Biol. Chem., 269, pp. 26539-26545; Rehli, F.J., Krause, S.W., Andreseen, R., Kreutz, M., Molecular cloning of a 1α,25-dihydroxyvitamin D3-inducible transcript (DDVit 1) in human blood monocytes (1997) Biochem. Biophys. Res. Commun., 234, pp. 407-412; Rogel, M.E., Wu, L.I., Emerman, M., The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection (1995) J. Virol., 69, pp. 882-888; Rost, B., Sander, C., Prediction of protein secondary structure better than 70% accuracy (1993) J. Mol. Biol., 232, pp. 584-599; Rothofsky, M.L., Lin, S.L., CROC-1 encodes a protein which mediates transcriptional activation from the human FOS promoter (1997) Gene, 195, pp. 141-149; Russell, K.J., Wiens, L.W., Demers, G.W., Galloway, D.A., Plon, S.E., Groudine, M., Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells (1995) Cancer Res., 55, pp. 1639-1642; Sambrook, J., Fritsch, E.F., Maniatis, T., (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., , Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y; Scarano, F.J., Laffin, J.A., Lenman, J.M., Friedrich, T.D., Simian virus 40 prevents activation of M-phase-promoting factor during lytic infection (1994) J. Virol., 68, pp. 2355-2361; Schuler, G.D., Boguski, M.S., Stewart, E.A., Stein, L.D., Gyapay, G., A gene map of the human genome (1996) Science, 274, pp. 540-546; Simon, T.C., Gordon, J.I., Intestinal epithelial cell differentiation: New insights from mice, flies and nematodes (1995) Curr. Opin. Genet. Dev., 5, pp. 577-586; Siyanova, E.Y., Serfas, M.S., Mazo, I.A., Tyner, A.L., Tyrosine kinase gene expression in the mouse small intestine (1994) Oncogene, 9, pp. 2053-2057; Stein, G.S., Stein, J.L., Lian, J.B., Last, T.J., Owen, T., McCabe, L., Synchronization of normal dipoid and transformed mammalian cells (1994) Cell Biology. A Laboratory Handbook, pp. 282-287. , J. E. Celis (ed.), Academic Press, Inc., London, England; Suh, E., Traber, P.G., An intestine-specific homeohox gene regulates proliferation and differentiation (1996) Mol. Cell. Biol., 16, pp. 619-625; Sung, P., Prakash, S., Prakash, L., Mutation of cysteine-88 in the Saccharomyces cerevisiae RAD6 protein abolishes its ubiquitin-conjugating activity and its various biological functions (1990) Proc. Natl. Acad. Sci. USA, 87, pp. 2695-2699; Sykes, D.E., Weiser, M.M., The identification of genes specifically expressed in epithelial cells of the rat intestinal crypts (1992) Differentiation, 50, pp. 41-46; Thompson, J.D., Higgins, D.G., Gibson, T.J., CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice (1994) Nucleic Acids Res., 22, pp. 4673-4680; Towbin, H., Staehelin, T., Gordon, J., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications (1979) Proc. Natl. Acad. Sci. USA, 76, pp. 43511-44354; Usui, T., Yoshida, M., Abe, K., Osada, H., Isono, K., Beppu, T., Uncoupled cell cycle without mitosis induced hy a protein kinase inhibitor. K-252a (1991) J. Cell Biol., 115, pp. 1275-1282; Vasioukhin, V., Servas, M.S., Siyanova, E.Y., Polonskaia, M., Costigan, V.J., Liu, B., Thomason, A., Tyner, A.L., A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract (1995) Oncogene, 10, pp. 349-357; Vilá, M.R., Lloreta, J., Schüssler, M.H., Berrozpe, G., Welt, S., Real, F.X., New pancreas cancer cell lines which represent distinct stages of ductal differentiation (1995) Lab. Invest., 72, pp. 395-404; Vriend, G., WHAT IF: A molecular modeling and drug design program (1990) J. Mol. Graph., 8, pp. 52-56; Waldman, T., Lengauer, C., Kinzler, K.W., Vogelstein, B., Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 (1996) Nature, 381, pp. 713-716; Welsh, J., Chada, K., Dalal, S.S., Cheng, R., Ralph, D., McClelland, M., Arbitrarily primed PCR fingerprinting of RNA (1992) Nucleic Acids Res., 20, pp. 4965-4970; Zweibaum, A., Laburthe, M., Grasset, E., Louvard, D., Use of cultured cell lines in studies of intestinal cell differentiation and function (1991) Handbook of Physiology. The Gastrointestinal System, Vol. IV. Intestinal Absorption and Secretion, 4, pp. 223-255. , M. Field and R. A. Frizzel, (ed.), American Physiological Society, Bethesda, Md","Thomson, T.M.; Departamento de Biologia Molecular, Instituto de Biologia del Cancer, IMIM-CSIC, Av. Doctor Aiguader 80, 08003 Barcelona, Spain; email: tthomson@imim.es",,,"American Society for Microbiology",,,,,02707306,,MCEBD,"9418904","English","Mol. Cell. Biol.",Article,"Final",Open Access,Scopus,2-s2.0-0031962188
"Sanz F.","7102263897;","The videodisc for medical training. Should it be massively introduced in Spain? [El videodisco para la formación médica. Se debe introducir masivamente en España?]",1997,"Medicina clínica","109","5",,"197","198",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031589359&partnerID=40&md5=ea9eaf4ff8b44bd483ff896736bf6a80",,"Sanz, F.",[No abstract available],,"medical education; note; Spain; videorecording; Education, Medical; Spain; Video Recording",,,,,,,,,,"Sanz, F.",,,,,,,,00257753,,,"9289546","Spanish","Med Clin (Barc)",Note,"Final",,Scopus,2-s2.0-0031589359
"Sanz F., Sosa-Iudicissa M., Caston O.L.","7102263897;7801557908;55917507600;","Telematics and medicines: From rational design to rational utilisation",1997,"Studies in Health Technology and Informatics","36",,,"389","392",,1,"10.3233/978-1-60750-880-9-389","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887079094&doi=10.3233%2f978-1-60750-880-9-389&partnerID=40&md5=9e4615120df2888b704ac810be8c6670",,"Sanz, F.; Sosa-Iudicissa, M.; Caston, O.L.",[No abstract available],,"Rational design; Telematics; Wireless telecommunication systems",,,,,,,,,"Bioinformatics in the biopharmaceutical industry (1996) Trends Biotechnol, 8, pp. 261-321. , Anonymous; Kubinyi, H., From lipophilicity to 3D QSAR-The fascination of computer-aided drug design (1995) QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications, pp. 2-16. , In: Sanz F, Giraldo J, Manaut F, eds. Barcelona: Prous Science; Cambridge Structural Database System, , http://www.ccdc.cam.ac.uk; http://www.pdb.bnl.gov, Protein Data Bank. Brookhaven National Laboratory; http://swift.embl-heildelberg.de; Sanz, F., Manaut, F., Rodríguez, J., Lozoya, E., López-De- Briñas, E., MEPSIM. A computational package for analysis and comparison of molecular electrostatic potentials (1993) J Comput-Aided Mol Design, 7, pp. 337-347; Marshall, G.R., Ho, C.M.W., Head, R.D., Smythe, M.L., Oprea, T.I., Waller, C.L., Green, S.M., 3D QSAR and de novo design: Choosing the appropriate tools (1995) QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications, pp. 623-629. , In: Sanz F, Giraldo J, Manaut F, eds. Barcelona: Prous Science; Carlson, R.W., Tu, S.W., Lane, N.M., Lai, T.L., Kemper, C.A., Musen, M.A., Shortliffe, E.H., Computer-based screening of patients with HIV/AIDS for clinical-trial elegibility (1995) Online J Curr Clin Trials, , Mar 28 ; Doc No 179; Othman, R., Interactive database management (1995) Comput Methods Programs Biomed, 47, pp. 221-227; Bero, L., Rennie, D., The cochrane collaboration, preparing, maintaining, and disseminating systematic reviews on the effects of health care (1995) JAMA, 274, pp. 1962-1964; http://www.ehto.be/ht_projects/html/mansev.html; Wyatt, J., Walton, R., Computer used prescribing (1995) BMJ, 311, pp. 1181-1182; (1994) Resolution Approved by the 47th Assembly of the World Health Organisation (WHA47.12), , May; Communication from the European Commission and Proposal for an European Parliament and Council Decision, adopting a Community action on health promotion information, education and training within the framework for action in the field of public health, adopted on 1 June 1994; Sosa, M., How to support self-medication through new information technology (1996) The European Proprietary Medicines Manufacturers' Association (AESGP) 32 Nd Annual Meeting, pp. 55-57. , Self-Medication in Europe: Enlarging the Horizon, Istambul, Turkey, 29 may-1 June; Sanz, F., Loza, M.I., Ahlgrimm, E.D., Baetens, P., Sosa-Ludicissa, M., Telematics will be useful in providing information (1996) BMJ, 313, p. 116. , Over the Counter Drugs; http://www.sems.es/projects/TESEMED; http://www.pharmweb.net/; http://pharminfo.com/; Baker, D.E., Smith, G.H., Abate, M.A., Selected topics in drug information access and practice: An update (1994) Ann Pharmacother, 28, pp. 1389-1394",,,,"IOS Press",,,,,09269630,,,,"English","Stud. Health Technol. Informatics",Article,"Final",,Scopus,2-s2.0-84887079094
"Lozano J.J., López-De-Briñas E., Centeno N.B., Guigó R., Sanz F.","7103062769;7801401158;6701440183;7004339139;7102263897;","Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ",1997,"Journal of Computer-Aided Molecular Design","11","4",,"395","408",,39,"10.1023/A:1007947411145","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031181686&doi=10.1023%2fA%3a1007947411145&partnerID=40&md5=0fb31c9a720e155a26f4d3296740cdf5","Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Univ. Autònoma de Barcelona, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain","Lozano, J.J., Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Univ. Autònoma de Barcelona, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; López-De-Briñas, E., Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Univ. Autònoma de Barcelona, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Centeno, N.B., Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Univ. Autònoma de Barcelona, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Guigó, R., Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Univ. Autònoma de Barcelona, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Sanz, F., Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Univ. Autònoma de Barcelona, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain","The three-dimensional modelling of proteins is a useful tool to fill the gap between the number of sequenced proteins and the number of experimentally known 3D structures. However, when the degree of homology between the protein and the available 3D templates is low, model building becomes a difficult task and the reliability of the results depends critically on the correctness of the sequence alignment. For this reason, we have undertaken the modelling of human cytochrome P450 1A2 starting by a careful analysis of several sequence alignment strategies (multiple sequence alignments and the TOPITS threading technique). The best results were obtained using TOPITS followed by a manual refinement to avoid unlikely gaps. Because TOPITS uses secondary structure predictions, several methods that are available for this purpose (Levin, Gibrat, DPM, NnPredict, PHD, SOPM and NNSP) have also been evaluated on cytochromes P450 with known 3D structures. More reliable predictions on α-helices have been obtained with PHD, which is the method implemented in TOPITS. Thus, a 3D model for human cytochrome P450 1A2 has been built using the known crystal coordinates of P450 BM3 as the template. The model was refined using molecular mechanics computations. The model obtained shows a consistent location of the substrate recognition segments previously postulated for the CYP2 family members. The interaction of caffeine and a carcinogenic aromatic amine (MeIQ), which are characteristic P450 1A2 substrates, has been investigated. The substrates were solvated taking into account their molecular electrostatic potential distributions. The docking of the solvated substrates in the active site of the model was explored with the AUTODOCK programme, followed by molecular mechanics optimisation of the most interesting complexes. Stable complexes were obtained that could explain the oxidation of the considered substrates by cytochrome P450 1A2 and could offer an insight into the role played by water molecules.","Assessment of secondary structure prediction methods; AUTODOCK; Molecular electrostatic potential; Sequence alignment strategies; Solvation","2 amino 3,4 dimethylimidazo(4,5 f)quinoline; 2-amino-3,4-dimethylimidazo(4,5-f)quinoline; bacterial protein; Bifunctional reductase CYP102, Bacillus megaterium; caffeine; cytochrome P450; cytochrome P450 1A2; mixed function oxidase; quinoline derivative; amino acid sequence; article; binding site; chemical structure; chemistry; computer program; computer simulation; human; metabolism; molecular genetics; nucleotide sequence; protein conformation; protein secondary structure; sequence alignment; sequence homology; Amino Acid Sequence; Bacterial Proteins; Binding Sites; Caffeine; Computer Simulation; Conserved Sequence; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Humans; Mixed Function Oxygenases; Models, Molecular; Molecular Sequence Data; Protein Conformation; Protein Structure, Secondary; Quinolines; Sequence Alignment; Sequence Homology, Amino Acid; Software",,"2-amino-3,4-dimethylimidazo(4,5-f)quinoline, 77094-11-2; Bacterial Proteins; Bifunctional reductase CYP102, Bacillus megaterium, EC 1.6.2.4; Caffeine, 58-08-2; Cytochrome P-450 CYP1A2, EC 1.14.14.1; Cytochrome P-450 Enzyme System, 9035-51-2; Mixed Function Oxygenases, EC 1.-; Quinolines",,,"Comisión Interministerial de Ciencia y Tecnología: SAF93-0722-C02-02","We thank Marta Pulido, M.D., for editing the manuscript and editorial assistance. We thank Dr. A. Valencia for helpful discussions. This work was partially funded by the CICYT, grant SAF93-0722-C02-02.",,,"Black, S.D., Coon, M.J., (1987) Adv. Enzymol., 60, p. 35; Grant, D.M., Campbell, M.E., Tang, B.K., Kallow, W., (1987) Biochem. Pharmacol., 36, p. 1251; Segura, J., Roberts, D.J., Tarrús, E., (1988) J. Pharm. Pharmacol., 41, p. 129; Fuhr, V., Strobl, G., Manaut, F., Anders, E.-M., Sörgel, F., López-de-Briñas, E., Chu, D.T.W., Staib, H., (1993) Mol. Pharmacol., 43, p. 191; Wakabayashi, K., Nagao, M., Esumi, H., Sugimura, T., (1992) Cancer Res., 52 (SUPPL.), p. 2092; Shimada, T., Iwasaki, M., Martin, M.V., Guengerich, F.P., (1989) Cancer Res., 49, p. 3218; Yamashita, K., Umemoto, A., Grivas, S., Kato, S., Sato, S., Sugimura, T., (1988) Nucleic Acids Res., 19, p. 111; Poulos, T.L., Finzel, B.C., Howard, A.J., (1986) Biochemistry, 25, p. 5314; Ravichandran, K.G., Boddupalli, S.S., Hasemann, C.A., Peterson, J.A., Deisenhofer, J., (1993) Science, 261, p. 731; Hasemann, C.A., Ravichandran, K.G., Peterson, J.A., Deisenhofer, J., (1994) J. Mol. Biol., 236, p. 1169; Cupp-Vickery, J.R., Poulos, T.L., (1995) Nat. Struct. Biol., 2, p. 144; Hasemann, C.A., Kurumbail, R.G., Boddupalli, S.S., Peterson, J.A., Deisenhofer, J., (1993) Structure, 3, p. 41; Laughton, C.A., Neidle, S., Zvelebil, M.J.J.M., Sternberg, M.J.E., (1990) Biochem. Biophys. Res. Commun., 171, p. 1160; Morris, G.M., Richards, W.G., (1991) Biochem. Soc. Trans., 19, p. 793; Zvelebil, M.J.J.M., Wolf, C.R., Sternberg, M.J.E., (1991) Protein Eng., 4, p. 271; Lewis, D.F.V., Moereels, H., (1992) J. Comput.-Aided Mol. Design, 6, p. 235; Vijayakumar, S., Salerno, J.C., (1992) Biochim. Biophys. Acta, 1160, p. 281; Laughton, C.A., Zvelebil, M.J.J.M., Neidle, S., (1993) J. Steroid Biochem. Mol. Biol., 44, p. 399; Koymans, L.M.H., Vermeulen, N.P.E., Baarslag, A., Donné-Op Den Kelder, G.M., (1993) J. Comput.-Aided Mol. Design, 7, p. 281; Boscott, P.E., Grant, G.H., (1994) J. Mol. Graph., 12, p. 185; Szklarz, G.D., Ornstein, R.L., Halpert, J.R., (1994) J. Biomol. Struct. Dyn., 12, p. 61; Narhi, L.O., Fulco, A.J., (1987) J. Biol. Chem., 262, p. 6683; Nelson, D.R., Strobel, H.W., (1989) Biochemistry, 28, p. 656; Mosimann, S., Meleshko, R., James, M.N.G., (1995) Proteins Struct. Funct. Genet., 23, p. 301; Chang, Y.-T., Loew, G.H., (1996) Protein Eng., 9, p. 755; Sanz, F., López-de-Briñas, E., Rodríguez, J., Manaut, F., (1994) Quant. Struct.-Act. Relatsh., 13, p. 281; Lozano, J.J., López-de-Briñas, E., Manaut, F., Sanz, F., (1995) QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications, pp. 325-328. , Sanz, F., Giraldo, J. and Manaut, F. (Eds.) Prous Science, Barcelona, Spain; Hasemann, C.A., Kurumbail, R.G., Boddupalli, S.S., Peterson, J.A., Deisenhofer, J., (1995) Structure, 2, p. 41; Thompson, J.D., Higgins, J.D., Gibson, T.J., (1994) Nucleic Acids Res., 22, p. 4673; (1995), PILEUP, Genetics Computer Group Inc., University Research Park, Madison, WI, U.S.A; Rost, B., (1995) Proceedings of the Third International Conference on Intelligent Systems for Molecular Biology, pp. 314-321. , Rawlings, C., Clark, D., Altman, R., Hunter, L., Lengauer, T. and Wodak, S. (Eds.) AAAI Press, Menlo Park, CA, U.S.A; Rost, B., Sander, C., (1993) J. Mol. Biol., 232, p. 584; Levin, J.M., Robson, B., Garnmier, J., (1986) FEBS Lett., 205, p. 303; Gibrat, J.F., Garnier, J., Robson, B., (1987) J. Mol. Biol., 198, p. 425; Deleage, G., Roux, B., (1987) Protein Eng., 1, p. 289; Kneller, G., Cohe, F.E., Langridge, R., (1990) J. Mol. Biol., 214, p. 171; Geourjon, C., Deleage, G., (1994) Protein Eng., 7, p. 157; Salamov, A.A., Solovyev, V.V., (1995) J. Mol. Biol., 247, p. 11; Deleage, G., Clerc, F.F., Roux, B., Gautheron, D.C., (1988) Comput. Appl. Biosci., 4, p. 351; http://www.ibcp.fr, SOPM; http://www.cmpharm.ucsf.edu, NnPredict; http://www.embl-heidelberg.de, PHDsec; http://www.bcm.tcm.edu, NNSP; Kabsch, W., Sander, C., (1983) Biopolymers, 22, p. 2577; Vriend, G., (1990) J. Mol. Graph., 8, p. 52; HOMOLOGY (v. 95.0) from Biosym/MSI, San Diego, CA, U.S.A., 1995; Hobohm, U., Scharf, M., Schneider, R., Sander, C., (1992) Protein Sci., 1, p. 409; Hobohm, U., Sander, C., (1994) Protein Sci., 3, p. 522; DISCOVER (v. 2.9.5) from Biosym/MSI, San Diego, CA, U.S.A., 1995; Dauber-Osguthorpe, P., Roberst, V.A., Wolff, J., (1988) Proteins Struct. Funct. Genet., 4, p. 31; INSIGHT II (v. 95.0) from Biosym/MSI, San Diego, CA, U.S.A., 1995; Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., (1993) J. Appl. Crystallogr., 26, p. 283; Hooft, R.W.W., Vriend, G., Sander, C., Abola, E.E., (1996) Nature, 381, p. 272; GAUSSIAN 94, , Gaussian Inc., Pittsburgh, PA, U.S.A; Sanz, F., Manaut, F., José, J., Segura, J., Carbó, M., De La Torre, R., (1988) J. Mol. Struct. (THEOCHEM), 170, p. 171; Sanz, F., Manaut, F., Rodríguez, J., Lozoya, E., López-deBriñas, E., (1993) J. Comput.-Aided Mol. Design, 7, p. 337; Morris, G.M., Goodsell, D., Huey, R., Olson, A.J., (1996) J. Comput.-Aided Mol. Design, 10, p. 293; Degtyarenko, K.N., Archakov, A.I., (1993) FEBS Lett., 322, p. 1; Valencia, A., Kjeldgaard, M., Pai, E.F., Sander, C., (1991) Proc. Natl. Acad. Sci. USA, 88, p. 5443; Gotoh, O., (1992) J. Biol. Chem., 267, p. 83; Arnold, G.E., Ornstein, R.L., (1994) Proteins Struct. Funct. Genet., 18, p. 19; Guenot, J.M., Kollman, P.A., (1992) Protein Sci., 1, p. 1185; Guenot, J.M., Kollman, P.A., (1993) J. Comput. Chem., 14, p. 295; Vriend, G., Sander, C., (1993) J. Appl. Crystallogr., 26, p. 47; Furuya, H., Shimizu, T., Hirano, K., Hatano, M., Fujii-Kuriyama, Y., (1989) Biochemistry, 28, p. 6848; Shimizu, T., Sadeque, A.J.M., Sadeque, G.N., Hatano, M., Fujii-Kuriyama, Y., (1991) Biochemistry, 30, p. 1490; Tuck, F.S., Hiroya, K., Shimizu, T., Hatano, M., Ortiz De Montellano, P.R., (1993) Biochemistry, 32, p. 2548; Mayuzumi, H., Shimizu, T., Sambongi, C., Hiroya, K., Hatano, M., (1994) Arch. Biochem. Biophys., 310, p. 367; Edwards, R.J., Singleton, A.M., Murray, B.P., Murray, S., Boobis, A.R., Davies, D.S., (1991) Biochem. J., 278, p. 749; Edwards, R.J., Sesardic, D., Murray, B.P., Singleton, A.M., Davies, D.S., Boobis, A.R., (1992) Biochem. Pharmacol., 43, p. 1737; Shen, S., Strobel, H.W., (1992) Arch. Biochem. Biophys., 294, p. 83; Cvrk, T., Hodek, P., Strobel, H.W., (1996) Arch. Biochem. Biophys., 330, p. 142; Poulos, T.L., Finzel, B.C., Howard, A.J., (1987) J. Mol. Biol., 195, p. 687; Poulos, T.L., Howard, A.J., (1987) Biochemistry, 26, p. 8165; Raag, R., Li, H., Jones, B.C., Poulos, T.L., (1993) Biochemistry, 32, p. 4571; Poulos, T.L., Finzel, B.C., Gunsalus, I.C., Wagner, G.C., Kraut, J., (1985) J. Biol. Chem., 260, p. 16122; Fuhr, U., Dohmer, J., Battula, N., Wölfel, C., Kudla, C., Keita, Y., Staib, H., (1992) Biochem. Pharmacol., 43, p. 225","Sanz, F.; Res. Group on Medical Informatics, Inst. Munic. d'Investigacio Medica, Univ. Autònoma de Barcelona, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain",,,"Springer Netherlands",,,,,0920654X,,JCADE,"9334905","English","J. Comp.-Aided Mol. Des.",Article,"Final",,Scopus,2-s2.0-0031181686
"Enning J., Talmon J., Nykänen P., Marz J., Sanz F., Thayer C.","7801474031;7006019325;7003836925;6603713746;7102263897;7004499349;","VATAM: Developing consensus in validation of health telematics applications",1997,"Studies in Health Technology and Informatics","43",,,"771","775",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031313170&partnerID=40&md5=c39fdca2e8495cc473b4bfa85c9aba03",,"Enning, J.; Talmon, J.; Nykänen, P.; Marz, J.; Sanz, F.; Thayer, C.","VATAM (Validation of Telematics Applications in Medicine) is an EU supported project in the Health care sector of the Telematics Application Programme. Its objective is to assist other health telematics projects by providing a platform for discussion on validation, eventually resulting in 'guidelines for validation of telematics applications in medicine'. The VATAM work can be subdivided into three phases: the inventory phase (1996) in which information is collected on validation approaches in the Telematics Application Programme, previous efforts and expertise. The dissemination phase (1997) will be used to extend and adapt the framework developed in the inventory phase, through co-operation with other projects The experiences phase (1998) in which the projects are actually applying validation, will be used by VATAM to validate the VATAM methodology VATAM has finished the inventory phase successfully and is now working on the dissemination phase by - among others - establishing contacts with other projects, and providing information on the inventory through the World Wide Web (URL: http://www-vatam.unimaas.nl). This paper discusses the approach adopted and the proposed VATAM framework to structure the large variety of validation approaches. © 1997, The authors.",,"Healthcare sectors; Telematics; Three phasis; Validation approach; Wireless telecommunication systems; article; biomedical technology assessment; computer network; computer program; health care quality; human; medical informatics; quality control; Computer Communication Networks; Humans; Medical Informatics Applications; Quality Assurance, Health Care; Quality Control; Software Validation; Technology Assessment, Biomedical",,,,,,,,,"(1995) Studies in Health Technology and Informatics 17: Assessment and Evaluation of Information Technologies in Medicine, , eds. E.M.S.J. van Gennip and J.L. Talmon; IOS Press Amsterdam; Gordon, C., Veloso, M., The prestige project: Implementing guidelines in healthcare (1996) Studies in Health Technology and Informatics: Medical Informatics Europe '96, pp. 887-891. , eds. J. Brender, J.P. Christensen, J.-R. Scherrer, P. McNair; IOS Press Amsterdam; Engelbrecht, R., Hildebrand, C., Blecher, M., Corcoy, R., De Leiva, A., The diabcard feasibility study (1996) Studies in Health Technology and Informatics: Medical Informatics Europe '96, pp. 479-483. , eds. J. Brender, J.P. Christensen, J.-R. Scherrer, P. McNair; IOS Press Amsterdam; Hübner, U., Staemmler, M., Schuier, F.J., Newell, J., Focussing on the medical department: Sammie (1996) Studies in Health Technology and Informatics: Medical Informatics Europe '96, pp. 321-325. , eds. J. Brender, J.P. Christensen, J.-R. Scherrer, P. McNair; IOS Press Amsterdam; Beuscart, R., Integration architecture: The isar project (1996) Studies in Health Technology and Informatics: Medical Informatics Europe '96, pp. 311-315. , eds. J. Brender, J.P. Christensen, J.-R. Scherrer, P. McNair; IOS Press Amsterdam; Jørgensen, T., Bernstein, K., Danneskiold-Samsoe, B., Lehrmann, T., Evaluation of a regional electronic health care network, consequences for general practice (1996) Studies in Health Technology and Informatics: Medical Informatics Europe '96, pp. 344-348. , eds. J. Brender, J.P. Christensen, J.-R. Scherrer, P. McNair; IOS Press Amsterdam; Grimson, J., Synapses-federated healthcare record server (1996) Studies in Health Technology and Informatics: Medical Informatics Europe '96, pp. 695-699. , eds. J. Brender, J.P. Christensen, J.-R. Scherrer, P. McNair; IOS Press Amsterdam; Ferrara, F., The middleware-based architectural approach for opening and evolving healthcare information systems (1996) Studies in Health Technology and Informatics: Medical Informatics Europe '96, pp. 264-270. , eds. J. Brender, J.P. Christensen, J.-R. Scherrer, P. McNair; IOS Press Amsterdam; Enning, J., Draft Guidelines for Validation of Tlematics Applications in Medicine, , public deliverable D03.2 of the VATAM project; Van Der Loo, R., Overview of published assessment and evaluation studies (1995) Studies in Health Technology and Informatics 17: Assessment and Evaluation of Information Technologies in Medicine, pp. 261-282. , eds. E.M.S.J. Van Gennip and J.L. Talmon; IOS Press Amsterdam; 1995; European commisssion-dg xiii telecommunications, information market and exploitation of research Telematics Application Programme (1994-1998): Work Programme",,,,"IOS Press","14th Conference on Medical Informatics Europe 1997, MIE 1997","25 May 1997 through 29 May 1997","Thessaloniki",,09269630,9051993439; 9789051993431,,"1998125866","English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-0031313170
"Sancho J.J., Oliveri N., Faba G., Campos M., Clamp S., Sanz F., De Dombal F.T.","7201937083;55285046900;36839161100;7202803685;7004639003;7102263897;8075886800;","Using the internet to tackle unusual clinical cases: ELCANO",1997,"Studies in Health Technology and Informatics","36",,,"371","376",,,"10.3233/978-1-60750-880-9-371","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887029629&doi=10.3233%2f978-1-60750-880-9-371&partnerID=40&md5=c0b88189237a4f54b066e7326eafbf9c",,"Sancho, J.J.; Oliveri, N.; Faba, G.; Campos, M.; Clamp, S.; Sanz, F.; De Dombal, F.T.",[No abstract available],,,,,,,,,,,,,,,"IOS Press",,,,,09269630,,,,"English","Stud. Health Technol. Informatics",Article,"Final",,Scopus,2-s2.0-84887029629
"Honrubia M.A., Jesús R., Dominguez R., Lozoya E., Manaut F., Seijas J.A., Villaverde M.C., Calleja J.M., Cadavid M.I., Maayani S., Sanz F., Loza M.I.","7003365960;17634565600;36811440600;6603260860;6602255071;6701414266;7004236039;36832962500;6603422293;7006611853;7102263897;7003766926;","Synthesis, affinity at 5-HT(2A), 5-HT(2B) and 5-HT(2C) serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues",1997,"Chemical and Pharmaceutical Bulletin","45","5",,"842","848",,12,"10.1248/cpb.45.842","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0342981540&doi=10.1248%2fcpb.45.842&partnerID=40&md5=129aebbb4f17986406c8d22294d7d2c8","Depts. Pharmacol., Organ. Phys. C., University of Santiago, E-15706 Santiago de Compostela, Spain; Department of Medical Informatics, Inst. Munic. d'Investigacio M dica, Univ. Autènoma de Barcelona, Doctor Aiguader 80, E-08003 Barcelona, Spain; Department of Anesthesiology, Mount Sinai School of Medicine, New York, NY 10029, United States","Honrubia, M.A., Depts. Pharmacol., Organ. Phys. C., University of Santiago, E-15706 Santiago de Compostela, Spain; Jesús, R., Depts. Pharmacol., Organ. Phys. C., University of Santiago, E-15706 Santiago de Compostela, Spain; Dominguez, R., Depts. Pharmacol., Organ. Phys. C., University of Santiago, E-15706 Santiago de Compostela, Spain; Lozoya, E., Department of Medical Informatics, Inst. Munic. d'Investigacio M dica, Univ. Autènoma de Barcelona, Doctor Aiguader 80, E-08003 Barcelona, Spain; Manaut, F., Department of Medical Informatics, Inst. Munic. d'Investigacio M dica, Univ. Autènoma de Barcelona, Doctor Aiguader 80, E-08003 Barcelona, Spain; Seijas, J.A., Depts. Pharmacol., Organ. Phys. C., University of Santiago, E-15706 Santiago de Compostela, Spain; Villaverde, M.C., Depts. Pharmacol., Organ. Phys. C., University of Santiago, E-15706 Santiago de Compostela, Spain; Calleja, J.M., Depts. Pharmacol., Organ. Phys. C., University of Santiago, E-15706 Santiago de Compostela, Spain; Cadavid, M.I., Depts. Pharmacol., Organ. Phys. C., University of Santiago, E-15706 Santiago de Compostela, Spain; Maayani, S., Department of Anesthesiology, Mount Sinai School of Medicine, New York, NY 10029, United States; Sanz, F., Department of Medical Informatics, Inst. Munic. d'Investigacio M dica, Univ. Autènoma de Barcelona, Doctor Aiguader 80, E-08003 Barcelona, Spain; Loza, M.I., Depts. Pharmacol., Organ. Phys. C., University of Santiago, E-15706 Santiago de Compostela, Spain","Cyproheptadine is a drug that shows high affinity for type 2 (5-HT2) receptors. We studied a series of compounds obtained by modification of the tricyclic system of Cyp (dibenzocycloheptadiene): 2f (thioxanthene), 2g (xanthene), 2h (dihydrodibenzocycloheptadiene), 2j (diphenyl), 2i (fluorene), and 3b (phenylmethyl). Their activities at the rat cerebral cortex 5-HT(2A) receptor were (pK(i) ± S.E.M.): 8.80 ± 0.11 (Cyp), 8.60 ± 0.07 (2f), 8.40 ± 0.02 (2g), 8.05 ± 0.03 (2h), 7.87 ± 0.12 (2j), 6.70±0.02 (2i) and 6.45±0.02 (3b); those at the rat stomach fundus 5-HT(2B) receptor (pA2±S.E.M.) were: 9.14±0.25 (Cyp), 8.49±0.07 (2F), 7.58±0.58 (2g), 7.02±0.14 (2h), 6.07±0.20 (2j), and undetectable (21, 3b); and those at the pig choroidal plexus 5-HT(2C) receptor (pK(i)±S.E.M.) were: 8.71 ± 0.08 (Cyp), 8.68 ± 0.01 (20, 8.58 ± 0.20 (2g), 7.95 ± 0.05 (2h), 7.57 ± 0.04 (2j), 6.98 ± 0.04 (2i) and 6.63 ± 0.20 (3b). The slopes did not differ significantly from unity. The compounds exhibited the same order of activities at every type of receptor, and the most active molecules presented certain steric (butterfly conformation of the tricyclic system) and electrostatic (proton affinity on the top of the central rings) patterns. It is concluded that the activity of cyproheptadine derivatives at 5-HT2 receptors is related to these molecular features, which make feasible a common disposition to interact with all three 5-HT2 subtypes.","5-HT2 receptor; Cyproheptadine; Molecular feature","1 methyl 4 (9h thioxanthen 9 ylidene)piperidine; 1 methyl 4 (9h xanthen 9 ylidene)piperidine; 4 (9h fluoren 9 ylidene) 1 methylpiperidine; 4 benzhydrylidene 1 methylpiperidine; 4 methylphenylmethylene 1 methylpiperidine; cyproheptadine; drug analog; ketanserin; mesulergine; serotonin; serotonin 2 receptor; serotonin 2A receptor; serotonin 2B receptor; unclassified drug; animal tissue; article; binding site; brain cortex; chemical structure; choroid plexus; concentration response; controlled study; drug synthesis; male; molecular model; muscle contraction; nonhuman; rat; receptor affinity; stomach fundus; structure activity relation; swine",,"cyproheptadine, 129-03-3, 969-33-5; ketanserin, 74050-98-9; mesulergine, 64795-35-3, 72786-12-0; serotonin, 50-67-9",,"Sigma",,,,,"Baxter, G., Kennet, G., Blaney, F., Blackburn, T., (1995) TiPS, 16, pp. 105-110; Hoyer, D., Clarke, D.E., Fozard, J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J., Saxena, P.R., Humphrey, P.P.A., (1994) Pharmacol. Rev., 46, pp. 157-203; Pazos, A., Hoyer, D., Palacios, J.M., (1984) Eur. J. Pharmacol., 106, pp. 539-546; Foguet, M., Hoyer, D., Pardo, L.A., Parekh, A., Kluxen, F.W., Kalkman, H.O., Stuhmer, W., Lübbert, H., (1992) EMBO J., 11, pp. 3481-3487; Kursar, J.D., Nelson, D.L., Wainscott, D.B., Baez, M., (1994) Mol. Pharmacol., 46, pp. 227-234; Schmuck, K., Christoph, U., Engels, P., Lübbert, H., (1994) FEBS Lett., 342, pp. 85-90; Wang, H.Y., Eberle-Wang, K., Simansky, K.J., Friedman, E., (1993) J. Pharmacol. Exp. Ther., 267, pp. 1002-1011; Meltzer, H.Y., Nash, J.F., (1991) Pharmacol. Rev., 43, pp. 587-604; Westphal, R.S., Sanders-Bush, E., (1994) Mol. Pharmacol., 46, pp. 937-942; Barker, E.L., Westphal, R.S., Schmidt, D., Sanders-Bush, E., (1994) J. Biol. Chem., 269, pp. 11687-11690; Silver, H., Blacker, M., Weller, M.P.I., Lever, B., (1989) Biol. Psychiatry, 25, pp. 502-504; Glusa, E., Richter, M., (1993) Naunyn-Schmiedeberg's Arch. Pharmacol., 347, pp. 471-477; Kalkman, H.O., (1994) Life Sci., 54, pp. 641-644; Randall, W.C., Anderson, P.S., Cresson, E.L., Hunt, C.A., Lyon, T.F., Rittle, K.E., Remy, D.C., (1979) J. Med. Chem., 22, pp. 1222-1230; Loza, M.I., Sanz, F., Cadavid, M.I., Honrubia, M., Orallo, F., Fontenla, J.A., Calleja, J.M., Villaverde, M.C., (1993) J. Pharm. Sci., 82, pp. 1090-1093; Cid, M.M., Seijas, J.A., Villaverde, M.C., Castedo, L., (1988) Tetrahedron, 44, pp. 6197-6200; McMurry, J.E., Krepski, L.R., (1976) J. Org. Chem., 41, pp. 3929-3930; Cohen, M.F., Wittenauer, L.A., (1985) J. Pharmacol. Exp. Ther., 233, pp. 75-79; Clineschmidt, B.V., Reiss, D.R., Pettibone, D.J., Robinson, J.L., (1985) J. Pharmacol. Exp. Ther., 235, pp. 696-708; Wrigglesworth, S.J., (1985) Br. J. Pharmacol., 80, pp. 691-697; Frankhuijzen, A.L., Bonta, I.L., (1974) European J. Pharmacol., 26, pp. 220-230; Sadek, M., Craik, D.J., Hall, J.G., Andrews, P.R., (1990) J. Med. Chem., 33, pp. 1098-1107; Nagai, Y., Uno, H., (1979) Chem. Pharm. Bull., 27, pp. 2056-2064; Engelhardt, E.L., Zell, H.C., Saard, W.S., Christy, M.E., Colton, C.D., Stone, C.A., Stavorski, J.M., Ludden, C.T., (1965) J. Med. Chem., 8, pp. 829-835; Loughhead, D.G., (1988) Tetrahedron Lett., 29, pp. 5701-5702; Vane, J.R., (1957) Br. J. Pharmacol., 2, pp. 344-349; Van Rossum, J.M., (1963) Arch. Int. Pharmacodyn., 143, pp. 299-330; Arunlaksana, O., Schild, H.O., (1959) Br. J. Pharmacol., 14, pp. 48-58; Nelson, D.L., Herbert, A., Bourgoin, S., Glowinsky, J., Hamon, M., (1978) Mol. Pharmacol., 14, pp. 983-995; Tallarida, R.J., Murray, R.B., (1978) Manual of Pharmacologic Calculations with Computer Programs, , Spriger-Verlag (2nd ed.), New York; Frisch, M.J., Trucks, G.W., Head-Gordon, M., Gill, P.M.W., Wong, M.W., Foresman, J.B., Johnson, B.G., Pople, J.A., (1992) Gaussian 92, Revision A, , Gaussian, Inc., Pittsburgh PA; Sanz, F., Manaut, F., Rodriguez, J., Lozoya, E., López-de-Briñas, E., (1993) J. Comput.-Adided Mol. Design., 7, pp. 337-347","Loza, M.I.; Department of Pharmacology, University of Santiago, E-15706 Santiago de Compostela, Spain",,,"Pharmaceutical Society of Japan",,,,,00092363,,CPBTA,"9178521","English","CHEM. PHARM. BULL.",Article,"Final",Open Access,Scopus,2-s2.0-0342981540
"Garcia O., Miralles M., Sancho J., Vall O., Sanz F.","7003893972;7005000280;7201937083;6701618656;7102263897;","The micro-corner",1996,"Cardiovascular Pathobiology","1","1",,"578","583",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-1842557328&partnerID=40&md5=cc08fa1671430a5e6b5d3935bfd51aa7","Pediatric Unit, Hospital del Mar, Pg. Maritim 25-29, 08003 Barcelona, Spain","Garcia, O., Pediatric Unit, Hospital del Mar, Pg. Maritim 25-29, 08003 Barcelona, Spain; Miralles, M.; Sancho, J.; Vall, O.; Sanz, F.",[No abstract available],,,,,,,,,,,"Lynch, P.J., Jaffe, C.C., An introduction to interactive hypermedia (1990) J Biocommun, 17, pp. 2-8; Fiderio, J., A grand vision (1988) Byte, 13 (10), pp. 237-244; Chen, C.C., Hoffer, P.B., Swett, H.A., Hypermedia in radiology: Computer-assisted education (1989) J Digit Imaging, 2, pp. 48-55; Jaffe, C.C., Lynch, P.J., Hypermedia for education in the life sciences (1989) Academic Comput, 4, pp. 10-57; Jaffe, C.C., Lynch, P.J., Smeulders, A.W.M., Hypermedia techniques for diagnostic imaging instruction: Videodisk echocardiography encyclopedia (1989) Radiology, 171, pp. 475-480; Shultz, E.K., Brown, R.W., Beck, J.R., Hypermedia in pathology: The Dartmouth Interactive Medical Record Project (1989) Am J Clin Pathol, 91 (1 SUPPL.), pp. S34-8; Hennessey, J.G., Fishman, E.K., Kuhlman, J.E., Ney, D.R., Magid, D., Computer-based learning in radiology: A hypermedia application in CT (1990) AJR, 155, pp. 1317-1320; Kahn, Ch.E., A radiology hypertext system for education and clinical decision making (1991) J Digit Imaging, 4, pp. 207-212; Corvetta, A., Pomponio, G., Salvi, A., Luchetti, M.M., Teaching medicine using hypertexts: Three years of experience at the Ancona Medical School (1991) Art Intell Med, 3, pp. 203-209; Narula, I.S., Diaper, D., Third World continuing medical education with hypertext: The Liverpool Anaemia Guide System (1991) Ergonomics, 34, pp. 1147-1159; Hershey, W., Guide (1987) Byte, 12 (11), pp. 244-246; McArthur, J.R., Bolles, J.R., Fibe, J., Kidd, P., Bessis, M., Interactive computer-video modules for health sciences education (1989) Methods Inf Med, 28, pp. 360-363; Timppka, T., Introducing hypertext in primary health care: A study on the feasibility of decision support for practitioners Comput Methods Programs Biomed, 29, pp. 1-13. , 2989; Voon, F.C., Tan, C.K., Rajendran, K., The integration of knowledge through interactive computer-enhanced learning in medicine (1990) Ann Acad Med Singapore, 19, pp. 752-757; Schwartz, D.L., Wind, G.G., Hypertext and three-dimensional computer graphics in an all digital PC-based CAI workstation (1991) Proc Annu Symp Comput Appl Med Care, 15, pp. 958-960; Jackson, J., Duling, B., Hypertext across the curriculum: Implications of quizzes linked to full text course materials (1991) Proc Annu Symp Comput Appl Med Care, 15, pp. 947-949; Lyon, H.C., Healy, J.C., Bell, J.R., Significant efficiency findings while controlling for the frequent confounders of CAI research in the PlanAnalyzer project's computer-based, self-paced, case-based programs in anemia and chest pain diagnosis (1991) J Med Syst, 15, pp. 117-132; Widzinski, L., Annotated bibliography of hypertext/hypermedia in the health sciences (1992) J Biocommun, 19, pp. 9-13; Widzinski, L., How hyper are we? A look at hypermedia management in academic health sciences libraries (1993) Bull Med Libr Assoc, 81, pp. 58-61; Soula, G., Delquie, P., Moulin, G., Michel, P., Bartoli, J.M., Fieschi, M., Auto-apprentissage en radiologie: Le projet FORUM appliqué à l'IRM de l'uterus (1993) Ann Radiol Paris, 36, pp. 440-450; Halasz, F.G., Reflections on Note-Cards: Seven issues for the next generation of hypermedia systems (1988) Commun ACM, 31, pp. 836-852; Williams, G., HyperCard (1987) Byte, 12 (14), pp. 109-117; Yankelovich, N., Haan, B.J., Meyrowitz, N.K., Drucker, S.M., Intermedia: The concept and the construction of a seamless information environment (1988) Computer, 21, pp. 81-96; Guiu, E., Lizano, M., Rubio, M.J., Herramientas de autor para el desarrollo de software educativo: Autorware Professional, Course-Builder, HyperCard, Plus y Super-Card (1993) Comunicaciones del I Congreso Macintosh y Educación, pp. 7-19. , Barcelona: Seneca Software; Levy, A.H., Thrush, D.R., The implementation of a knowledge-based pathology hypertext under Hyper-Card (1989) J Med Syst, 13, pp. 321-329; Bonadonna, F., HyperShell: An expert system shell in a hypermedia environment: application in medical audiology (1990) Med Inf Lond, 15, pp. 105-114; Tan, C.K., Rajendran, K., Voon, F.C., Hypertext-based enhancement of medical and dental undergraduate learning (1990) Ann Acad Med Singapore, 19, pp. 761-767; Alper, E.J., Cardasis, C., HistoLogical: A computer atlas and drill of histology (1991) Proc Annu Symp Comput Appl Med Care, 15, pp. 935-937; Mankovich, N.J., Verma, R.C., Yue, A., Veyne, D., Ratib, O., Bennett, L.R., NMINT, introductory courseware for nuclear medicine: Database design (1991) Proc Annu Symp Comput Appl Med Care, 15, pp. 757-761; Martin, G.T., Yoon, S.S., Mott, K.E., ZOOM: A generic personal computer-based teaching program for public health and its application in schistosomiasis control (1991) Bull WHO, 69, pp. 699-706; Nixon, M.S., Fishman, E.K., Magid, D., Hennessey, J.G., Ney, D.R., The use of graphic design in an interactive computer teaching program (1991) J Med Syst, 15, pp. 155-170; Lyon, H.C., Healy, J.C., Bell, J.R., Findings from an evaluation on PlanAnalyzer's double cross-over trials on computer-based, self-paced, case-based programs in anemia and chest pain diagnosis (1991) Proc Annu Symp Comput Appl Med Care, 15, pp. 88-93; Cutts, J.H., Hazelwood, S.E., Mitchell, J.A., Bridges, A.J., Reid, J.C., GALE: A graphics assisted learning environment for computer-based interactive videodisc education (1992) Int J Biomed Comput, 31, pp. 141-150; Gurney, J.W., Pneumoconiosis assistant: A hypermedia-based classification of the pneumoconioses (1993) J Thoracic Imaging, 8, pp. 143-151; Rabushka, L.S., Fishman, E.K., Hennessey, J.G., Nixon, M.S., Development of a computer-assisted instructional tool for evaluation and treatment of renal masses: An experiment in hypermedia (1993) Invest Radiol, 28, pp. 169-174; Martens, G., Zapf, C.L., A reference system in clinical anesthesia (1993) J Clin Monit, 9, pp. 202-206; Turner, P.J., Weerakone, S., An evaluation of a hypertext system for computer-assisted learning in orthodontics (1993) Br J Orthod, 20, pp. 145-148; Cuevas, L.E., Moody, J.B., Macfarlane, S.B., Rada, R., Ghaoui, C., The use of hypertext: Demonstration of the methods for investigating an epidemic of meningitis (1993) Med Educ, 27, pp. 91-96; Theodoropoulos, G., Loumos, V., Parasitology tutoring system: A hypermedia computer-based application (1994) Comput Methods Programs Biomed, 42, pp. 113-118; Costaridou, L., Sphiris, N., Pitoura, T., Panayiotakis, G., Pallikarakis, N., An educational hypertext system supporting radiographic image quality (1993) Med Inf Lond, 18, pp. 331-338; Korpinen, L., Frey, H., Sleep Expert: An intelligent medical decision support system for sleep disorders (1993) Med Inf Lond, 18, pp. 163-170; Chavez, R.M., Cooper, G.F., Hypermedia and randomized algorithms for medical expert systems (1990) Comput Methods Programs Biomed, 32, pp. 5-16; Gunnell, C.J., McNutt, R.A., DeBliek, R., Hypermedia in medical decision analysis. HyperDecision (1991) Proc Annu Symp Comput Appl Med Care, 15, pp. 956-957; Frisse, M., From text to hypertext (1988) Byte, 13 (10), pp. 247-253; Garcia, O., Vall, O., (1994) Protocolos Práticos de Pediatria (P3), , Barcelona: Doyma; Conklin, J., Hypertext: An introduction and survey (1987) Computer, 20, pp. 17-40; Cimino, J.J., Elkin, P.L., Barnett, G.O., As we may think: The concept space and medical hypertext (1992) Comput Biomed Res, 25, pp. 238-263","Garcia, O.; Pediatric Unit, Hospital del Mar, Pg. Maritim 25-29, 08003 Barcelona, Spain",,,,,,,,10887180,,CPATF,,"English","Cardiovasc. Pathobiol.",Article,"Final",,Scopus,2-s2.0-1842557328
"Sanz F., Loza M.I., Ahlgrimm E.D., Baetens P., Sosa-Iudicissa M.","7102263897;7003766926;6602321020;16940788100;7801557908;","Over the counter drugs. Telematics will be useful in providing information.",1996,"BMJ (Clinical research ed.)","313","7049",,"116","",,7,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030582153&partnerID=40&md5=0328a856a2adcfe369dfe44f5d7360a3",,"Sanz, F.; Loza, M.I.; Ahlgrimm, E.D.; Baetens, P.; Sosa-Iudicissa, M.",[No abstract available],,"non prescription drug; human; interpersonal communication; note; telemedicine; Communication; Drugs, Non-Prescription; Humans; Telemedicine",,"Drugs, Non-Prescription",,,,,,,,"Sanz, F.",,,,,,,,09598138,,,"8688741","English","BMJ",Note,"Final",,Scopus,2-s2.0-0030582153
"Balaguer A., Argemí J., Sancho J., Patak A., Sanz F.","6701758973;6603723662;7201937083;6602985248;7102263897;","Newborn touch: A CAI program in neonatal pathology",1996,"M.D. Computing","13","4",,"351","359",,2,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030191322&partnerID=40&md5=4b7e412f2e77f20283c6104ab263a348","Dept. d'Info. Mèdica, Inst. Munic. d'Investigacio Medica, C/ Dr. Aiguader 80, E-08003, Barcelona, Spain","Balaguer, A.; Argemí, J.; Sancho, J.; Patak, A.; Sanz, F., Dept. d'Info. Mèdica, Inst. Munic. d'Investigacio Medica, C/ Dr. Aiguader 80, E-08003, Barcelona, Spain",[No abstract available],,"anamnesis; article; clinical competence; computer program; congenital malformation; education; human; medical education; methodology; neonatology; newborn; newborn intensive care; physical examination; retrospective study; teaching; Abnormalities; Clinical Competence; Computer-Assisted Instruction; Education, Medical, Graduate; Humans; Infant, Newborn; Intensive Care, Neonatal; Medical History Taking; Neonatology; Physical Examination; Retrospective Studies; Software Validation",,,,,,,,,"Physicians for the 21st century: Report of the general professional education of physicians and college preparation for medicine (1984) J Med Educ, 59, pp. 201-208; Godfrey, R., Medical education: All change? (1991) Lancet, 338, pp. 297-299; Jelovsek, F.R., Adenobojo, L., Learning principles as applied to computer-assisted instruction (1993) MD Comput, 10, pp. 165-172; Desch, L.W., Esquivel, M.T., Anderson, S.K., Comparison of a computer tutorial with other methods for teaching well-newborn care (1991) Am J Dis Child, 145, pp. 1255-1258; Santer, D.M., D'Alessandro, M.P., Huntley, J.S., Erkonen, W.E., Galvin, J.R., The multimedia textbook: A revolutionary tool for pediatric education (1994) Arch Pediatr Adolesc Med, 148, pp. 711-715; De Jong, T., Learning and instruction with computing simulations (1991) Educ Comput, 6, pp. 217-229; Bergeron, B., Iliad: A diagnostic consultant and patient simulator (1991) MD Comput, 8, pp. 46-53; Holt Jr., W.S., Mazzu, S.A., A written case simulation of osteoarthritis as a predictor of prescribing behaviour among family practitioners (1992) Acad Med, 67, pp. 414-415; Schwartz, W., Using the computer-assisted medical problem-solving system (CAMPS) to identify students' problem-solving difficulties (1992) Acad Med, 67, pp. 568-571; Lyon Jr., H.C., Healy, J.C., Bell, J.R., PlanAlyzer: An interactive computer-assisted program to teach clinical problem solving in diagnosing anemia and coronary artery disease (1992) Acad Med, 67, pp. 821-828; Volle, R.L., Standardized testing of patient management skills: A computer-based method (1990) Clin Orthop, 257, pp. 47-51; Multimedia: A visual approach to teaching medicine (1993) Syllabus, 28, pp. 2-4; Schwid, H.A., A flight simulator for anesthesia training (1987) Comput Biomed Res, 20, pp. 64-75; Caron, C.E., Sun, Y., Lucariello, R.J., Chiaramide, S.A., MacHeart: A model-based authoring system for CAI in cardiology (1993) MD Comput, 10, pp. 333-340; Schwid, H.A., Computer simulations and management of critical incidents (1994) Acad Med, 69, p. 213; Tack, G., Roselli, R.J., Overholser, K.A., Harris, T.R., The use of Microsoft Excel as a user interface for biological simulations (1995) Comput Biomed Res, 28, pp. 24-37; Saliterman, S.S., A computerized simulator for critical-care training: New technology for medical education (1990) Mayo Clin Proc, 65, pp. 968-978","Sanz, F.; Dept. d'Info. Mèdica, Inst. Munic. d'Investigacio Medica, C/ Dr. Aiguader 80, E-08003, Barcelona, Spain",,,,,,,,07246811,,MDCOE,"8754245","English","M.D. Comput.",Article,"Final",,Scopus,2-s2.0-0030191322
"Martin-Baranera M., Sancho J.J., Sanz F.","6603145514;7201937083;7102263897;","Simulation applied to medical expert systems validation in absence of gold standard",1996,"Studies in Health Technology and Informatics","34",,,"506","510",,1,"10.3233/978-1-60750-878-6-506","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887342523&doi=10.3233%2f978-1-60750-878-6-506&partnerID=40&md5=78c4b785737cfbb3b0845d3dc5498390","Dept. of Medical Informatics, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autónoma de Barcelona, Dr. Aiguader 80, 08003 Barcelona, Spain","Martin-Baranera, M., Dept. of Medical Informatics, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autónoma de Barcelona, Dr. Aiguader 80, 08003 Barcelona, Spain; Sancho, J.J., Dept. of Medical Informatics, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autónoma de Barcelona, Dr. Aiguader 80, 08003 Barcelona, Spain; Sanz, F., Dept. of Medical Informatics, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autónoma de Barcelona, Dr. Aiguader 80, 08003 Barcelona, Spain","An approach to medical experts system's validation in lack of gold standard is applied to the expert system PNEUMON-IA. Several human specialists' conclusions are compared to those proposed by the expert system on a random sample of cases. Different kinds of distances and a Kappa-like index are calculated to measure the agreement between pairs of experts. Simulation of non-experts is used as a lower limit reference to interpret the distance or concordance between human experts and the expert system. © The authors 1996.",,"Gold standards; Human expert; Lower limits; Medical expert system; Medical experts; Non-experts; Random sample; Expert systems",,,,,,,,,"Geissman, J.R., Schultz, R.D., Verification and validation of expert systems (1988) AI Expert, 3 (2), pp. 26-33; Van Gennip, E.M.S.J., Talmond, J.L., (1995) Assessment and Evaluation of Information Technologies in Medicine, , (Eds.). IOS Press, Amsterdam; Wyatt, J.C., Clinical data systems, part 3: Development and evaluation (1994) Lancet, 344, pp. 1682-1688; Slack, W.V., Boro, E.S., Bleich, H.L., Barriers to clinical computing:What physicians can do (1992) MD Comput, 9, pp. 278-280; O'Keefe, R.M., Balci, O., Smith, E.P., Validating expert system performance (1987) IEEE Expert, 2 (4), pp. 81-90; Wyatt, J., Speigelhalter, D., Evaluating medical expert systems: What to test and how'? (1990) Med Inf (Lond), 15, pp. 205-217; Hernández, C., Sancho, J.J., Belmonte, M.A., Sierra, C., Sanz, F., Validation of the medical expert system RENOIR (1994) Comput Biomed Res, 27 (6), pp. 456-471; Redier, H., Daures, J.P., Michel, C., Assessment of the severity of asthma by an expert system. Description and evaluation (1995) Am J Respir Crit Care Med, 151, pp. 345-352; Fieschi, M., Towards validation of expert systems as medical decision aids (1990) Int J Biomed Comput, 26, pp. 93-108; Verdaguer, A., Patak, A., Sancho, J.J., Sierra, C., Sanz, F., Validation of the medical expert system PNEUMON-IA (1992) Comput Biomed Res, 25, pp. 511-526; Kong, A., Barnett, O., Mosteller, F., Youtz, C., How medical professionals evaluate expressions of probability (1986) N Engl J Med, 315, pp. 740-744; Vogt, W., Nagel, D., Sator, H., (1987) Cluster Analysis in Clinical Chemistry: A Model, , John Wiley & sons",,,,"IOS Press","13th International Congress on Medical Informatics Europe, MIE 1996","19 August 1996 through 22 August 1996","Copenhagen",,09269630,9051992785; 9789051992786,,,"English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-84887342523
"Garcia O., Miralles M., Sancho J., Vall O., Sanz F.","7003893972;7005000280;7201937083;6701618656;7102263897;","Generation of hypermedia documents for medical education.",1996,"M.D. computing : computers in medical practice","13","6",,"578","583",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030280687&partnerID=40&md5=7eb4cf9248a702117fe1168e24179165","Pediatric Unit, Hospital del Mar, Barcelona, Spain","Garcia, O., Pediatric Unit, Hospital del Mar, Barcelona, Spain; Miralles, M., Pediatric Unit, Hospital del Mar, Barcelona, Spain; Sancho, J., Pediatric Unit, Hospital del Mar, Barcelona, Spain; Vall, O., Pediatric Unit, Hospital del Mar, Barcelona, Spain; Sanz, F., Pediatric Unit, Hospital del Mar, Barcelona, Spain",[No abstract available],,"article; computer program; hypermedia; medical education; Education, Medical; Hypermedia; Software Design",,,,,,,,,,"Garcia, O.",,,,,,,,07246811,,,"8973092","English","MD Comput",Article,"Final",,Scopus,2-s2.0-0030280687
"Sancho J.J., Oliveri N.C., Faba G., Campos M., Sanz F., De Dombal F.T.","7201937083;55285046900;36839161100;7202803685;7102263897;8075886800;","ELCANO: European and Latin-American countries associated for a networked database of outstanding guidelines in unusual clinical cases",1996,"Studies in Health Technology and Informatics","34",,,"103","107",,2,"10.3233/978-1-60750-878-6-103","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887351680&doi=10.3233%2f978-1-60750-878-6-103&partnerID=40&md5=7ea7f93d159618a42f6f6644ad15e687","Departament d'Informàtica Mèdica, Dr Aiguader 80, E-08003, Barcelona, Spain; FIM, Armenia, 1538/40, Buenos Aires, Argentina; Centro Nacional de Investigación y Salud, Insurgentes Sur, 1397, México, D.F., Mexico; Centro de Cómputo, Universidad Cayetano Heredia, Av Honorio Delgado, 430, Lima, Peru; Clinical Science Unit, University of Leeds, 22 Hyde Terrace, Leeds, United Kingdom","Sancho, J.J., Departament d'Informàtica Mèdica, Dr Aiguader 80, E-08003, Barcelona, Spain; Oliveri, N.C., FIM, Armenia, 1538/40, Buenos Aires, Argentina; Faba, G., Centro Nacional de Investigación y Salud, Insurgentes Sur, 1397, México, D.F., Mexico; Campos, M., Centro de Cómputo, Universidad Cayetano Heredia, Av Honorio Delgado, 430, Lima, Peru; Sanz, F., Departament d'Informàtica Mèdica, Dr Aiguader 80, E-08003, Barcelona, Spain; De Dombal, F.T., Clinical Science Unit, University of Leeds, 22 Hyde Terrace, Leeds, United Kingdom","The morbidity and mortality of unusual clinical cases ranges from five to sixfold times those of usual clinical cases. Noneless, there is an acute lack of structured information sources on the best managing practices for those cases. The general objective of ELCANO is to build and exploit a multilingual Virtual Library of outstanding clinical guidelines to manage unusual cases. This Virtual Library will be distributed across The Internet from the partners servers and accessed by specialists and specialists in training. Gastroenterology will be the initial area of the clinical practice to be addressed. The unique and innovative aspects of ELCANO are its orientation toward unusual cases, the framework embracing countries from Europe and Latin-America, the structured pre-validation of the cases and its multilingual contents as well as their indexing and codification using internationally accepted standards. An immediate benefit from ELCANO will be the availability of critical clinical information in places where there is a lack of experience coming from places where this experience is commonplace. ELCANO is to be regarded as a exploratory measure, to test the implementation of North-South and South-North collaboration in telecommunication of clinical information. When successful, a broader range of medical specialities and more countries in both regions as well as new regions are foreseen to be involved. © The authors 1996.",,"Digital libraries; Clinical guideline; Clinical information; Clinical practices; Latin americans; Medical specialities; Pre-validation; Structured information; Virtual libraries; Medical computing",,,,,,,,,"Bignall, J., Horton, R., Learning from stories-The lancet's case reports (1995) Lancet, 346, p. 1246; McAleese, P., Odling-Smee, W., The effect of complications on length of stay (1994) Ann Surg, 220 (6), p. 740; Chute, C.G., Clinical data retrieval and analysis. I've seen a case like that before (1992) Ann N y Acad Sci; Engelberg, J., Complex medical case histories as portals to medical practice and integrative, scientific thought (1992) Am J Physiol, 263 (6 PART 3), pp. S45-54; Galvin, J.R., Mp, D.A., Erkonen, W.E., Smith, W.L., El-Khoury, G.Y., Weinstein, J.N., The virtual hospital. Providing multimedia decision support tools via the internet (1995) Spine, 20 (15), pp. 1735-1738; Detmer, W.M., Shortliffe, E.H., A model of clinical query management that supports integration of biomedical information over the world wide web (1995) Proc Annu Symp Comput Appl Med Care; Bard, J.B., Davies, J.A., Development, databases and the internet (1995) Bioessays, 17 (11), pp. 999-1001; Liem, E.B., Obeid, J.S., Shareck, E.P., Sato, L., Greenes, R.A., Representation of clinical practice guidelines through an interactive world-wide-web interface (1995) Proc Annu Symp Comput Appl Med Care; Parker, J.A., Wallis, J.W., Halama, J.R., Collaboration using internet for the development of case-based teaching files: Report of the computer and instrumentation council internet focus group (1996) J Nucl Med, 37 (1), pp. 178-184; Tachinardi, U., Furuie, S.S., Bertozzo, N., Moura, L., Gutierrez, M.A., Melo, C.P., Hypermedia patient data retrieval and presentation through WWW (1995) Proc Annu Symp Comput Appl Med Care; Hohnloser, J.H., Punier, F., Kadlec, P., Coding medical concepts: A controlled experiment with a computerised coding tool (1995) Int J Clin Monit Comput, 12 (3), pp. 141-145; Lee, J.Y., Uses of clinical databases (1994) Am J Med Sci, 308 (1), pp. 58-62; De Moor, G.J., European standards development in healthcare informatics: Actual and future challenges (1995) Int J Biomed Comput, 39 (1), pp. 81-85; Zelingher, J., Internet medical publications: Publish (electronically) or perish? (1995) MD Comput, 12 (6), pp. 428-433",,,,"IOS Press","13th International Congress on Medical Informatics Europe, MIE 1996","19 August 1996 through 22 August 1996","Copenhagen",,09269630,9051992785; 9789051992786,,,"English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-84887351680
"Segura Noguera J.M., Sanz Carreras F., Bastida Bastús N., Martí Guadaño N., González Espiñeira C., Guerrero Gancedo M.","6603066752;7102263897;6505761776;6507803916;6505732247;6507706811;","Description and validation of a predictive model of the geographic distribution of chronic home-bound patients [Descripción y validación de un modelo predictivo de la distribución geográfica de los enfermos crónicos domiciliarios.]",1996,"Atencion primaria / Sociedad Española de Medicina de Familia y Comunitaria","17","4",,"292","294",,5,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030584601&partnerID=40&md5=39ae554193a791f5f8ceed917c84aee1","EAP Raval Nord, CAP Dr. Lluís Sayé, Ciutat Vella, Barcelona, Spain","Segura Noguera, J.M., EAP Raval Nord, CAP Dr. Lluís Sayé, Ciutat Vella, Barcelona, Spain; Sanz Carreras, F., EAP Raval Nord, CAP Dr. Lluís Sayé, Ciutat Vella, Barcelona, Spain; Bastida Bastús, N., EAP Raval Nord, CAP Dr. Lluís Sayé, Ciutat Vella, Barcelona, Spain; Martí Guadaño, N., EAP Raval Nord, CAP Dr. Lluís Sayé, Ciutat Vella, Barcelona, Spain; González Espiñeira, C., EAP Raval Nord, CAP Dr. Lluís Sayé, Ciutat Vella, Barcelona, Spain; Guerrero Gancedo, M., EAP Raval Nord, CAP Dr. Lluís Sayé, Ciutat Vella, Barcelona, Spain","OBJECTIVE: To find a predictive model for the geographical distribution of the homebound chronically ill in function of variables corresponding to censal areas. DESIGN: A study of an ecological type. SETTING: Raval Nord Health District, Barcelona. PATIENTS AND OTHER PARTICIPANTS: The study units are the 30 censal areas of Raval Nord. In each area researchers counted the number of homebound chronically ill recorded during the first three months of a home care programme (May 1994). MEASUREMENTS AND MAIN RESULTS: A multiple regression analysis was performed, with selection of the variables by the stepwise method of the SPSS-PC+ statistical package, taking as dependent variable ""y"" the number of homebound chronically ill per 1,000 inhabitants. The prognostic variables were taken from the 1991 municipal roll, and evaluated along with the distance in metres from each censal area to the primary care centre (PCC). The distribution of the homebound chronically ill in the different censal areas of Raval Nord was connected to 3 variables which, in order of analysis, were: distance to the PCC, the relationship with senile dependency and the index of family socio-economic capacity. CONCLUSIONS: Distance, senile dependence and economic resources are factors which condition the number and distribution of the homebound chronically ill.",,"adolescent; adult; age; aged; article; child; chronic disease; comparative study; female; home care; human; infant; male; middle aged; newborn; patient; preschool child; regression analysis; sex difference; socioeconomics; Spain; statistical model; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Child; Child, Preschool; Chronic Disease; Female; Home Care Services; Humans; Infant; Infant, Newborn; Male; Middle Aged; Models, Statistical; Patients; Regression Analysis; Sex Factors; Socioeconomic Factors; Spain",,,,,,,,,,"Segura Noguera, J.M.",,,,,,,,02126567,,,"8679867","Spanish","Aten Primaria",Article,"Final",,Scopus,2-s2.0-0030584601
"Monmany J.R., Benet T.G., Blanco F.V., Pedreño X.E., Gómez J.A.G., Roca-Cusachs A.C., Sanz F.C., Nolla J.P.","6601959245;6507054787;7102243089;6503977832;36445662300;7004601419;7102263897;7005300920;","Comparative study of the effects of antihypertensive treatment with atenolol and doxazosin on lipids, lipoproteins, apolipoproteins, and phospholipids",1996,"Topics in Catalysis","57","5",,"343","357",,,"10.1016/S0011-393X(96)80043-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84954087823&doi=10.1016%2fS0011-393X%2896%2980043-9&partnerID=40&md5=049fe8a93c37f5286e8191482285b586","Servei de Medicina Interna, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Servei de Bioquímica i Biologia Molecular, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Servicio de Bioquímica, Fundacíon Jiménez Díaz, Madrid, Spain; Departament d'Informàtica Mèdica Institut Municipal d'Investigació Mèdica, Universitat Autònoma de Barcelona, Barcelona, Spain","Monmany, J.R., Servei de Medicina Interna, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Benet, T.G., Servei de Medicina Interna, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Blanco, F.V., Servei de Bioquímica i Biologia Molecular, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Pedreño, X.E., Servei de Bioquímica i Biologia Molecular, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Gómez, J.A.G., Servicio de Bioquímica, Fundacíon Jiménez Díaz, Madrid, Spain; Roca-Cusachs, A.C., Servei de Medicina Interna, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Sanz, F.C., Departament d'Informàtica Mèdica Institut Municipal d'Investigació Mèdica, Universitat Autònoma de Barcelona, Barcelona, Spain; Nolla, J.P., Servei de Medicina Interna, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain","We conducted an open-label study to evaluate the effects on blood pressure lipids, lipoproteins, apolipoproteins, and phospholipids of two antihypertensive drugs: atenolol, a cardioselective nonsympathomimetic beta-blocker, and doxazosin, a long-acting alpha1-blocker. Sixty-four patients, 24 men and 40 women, were included in the study. Patients were randomly assigned to receive either 25 mg of atenolol or 1 mg of doxazosin. The doses of the drugs were titrated to a maximum of 100 mg for atenolol and 16 mg for doxazosin to achieve a diastolic blood pressure below 90 mm Hg. Once titration was achieved, the treatment period lasted 6 months. Low doses of atenolol (37.5 ± 13.7 mg, mean ± SD) controlled low and moderate hypertension and decreased low-density lipoprotein cholesterol (LDL-C) levels. Standard doses of doxazosin (5.4 ± 5.6 mg) were required to control blood pressure; doxazosin in these doses decreased LDL-C and apolipoprotein B levels and increased the phospholipid content of high-density lipoprotein 2. The effectiveness of doxazosin in controlling systolic blood pressure measured in the lying position was limited. We concluded that both doxazosin and atenolol slightly modified lipids, although doxazosin modified more lipid fractions than atenolol. Both drugs reduced blood pressure, but atenolol was more effective than doxazosin when patients were lying down. © 1996, All rights reserved.",,,,,,,"Pfizer","We are indebted to Pfizer Inc., Madrid, Spain, for their financial support of this study, to Dr. Jordi Ord66ez for his valuable collaboration on the data referring to quality control of lipid determinations, and to Professor Francesc Jane for his assessment in this study.",,,"Effects of treatment of morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg (1967) JAMA, 202, pp. 1028-1034; Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressures averaging 90 through 114 mm Hg (1970) JAMA, 213, pp. 1143-1152; Mittinen, TA, Huttunen, JK, Naukkarlnen, V, Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality (1985) JAMA, 254, pp. 2097-2102; Trials of the treatment of mild hypertension. An interim analysis (1982) Lancet, 1, pp. 149-156; Helgeland, A, Leren, P, Kjeldsen, S, Changes in the lipoprotein profile during antihypertensive therapy (1984) Acta Pharmacol Toxicol, 54, pp. 75-77. , Suppl 1; Langdon, CG, Doxazosin: A study in a cohort of patients with hypertension in general practice—an interim report (1991) Am Heart J, 121, pp. 268-273; Holme, I, Fauchald, P, Rugstad, HE, Stokke, HP, Preliminary results of the Norwegian doxazosin postmarketing surveillance study: A twelve-week experience (1991) Am Heart J, 121, pp. 260-267; Neusy, AJ, Lowenstein, J, Effects of prazosin, atenolol, and thiazide diuretic on plasma lipids in patients with essential hypertension (1986) Am J Med, 80, pp. 94-99. , Suppl 2A; Day, JL, Metcalfe, J, Simpson, CN, Adrenergic mechanisms in control of plasma lipid concentrations (1982) BMJ, 284, pp. 1145-1148; England, JDF, Simons, LA, Gibson, JC, Carlton, M, The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man (1980) Clin Exp Pharmacol Physiol, 7, pp. 329-333; Taylor, SH, Lee, PS, Sharma, SK, A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension (1988) Am Heart J, 116, pp. 1820-1825; Weiner, L, Rössner, S, Atenolol 50 mg or metoprolol 200 mg—a comparison of antihypertensive efficacy, side effects and lipoprotein changes (1983) Acta Med Scand, 677, pp. 153-157. , Suppl; Massey, JB, Pownall, HJ, Phosphatidylcholines in membranes and lipoproteins (1990) Curr Opin Lipidol, 1, pp. 524-528; Bielicki, JK, Johnson, WJ, Glick, JM, Rothblat, GH, Efflux of phospholipid from fibroblasts with normal and elevated levels of cholesterol (1991) Biochim Biophys Acta, 1084, pp. 7-14; Bielicki, JK, Johnson, WJ, Weinberg, RB, Efflux of lipid from fibroblasts to apolipoproteins: Dependence on elevated levels of cellular unesterified cholesterol (1992) J Lipid Res, 33, pp. 1699-1709; Kirkendall, WM, Burton, AC, Epstein, FH, Freis, ED, Subcommittee of the A.H.A. post-graduate educational committee: Recommendations for human blood pressure determination by sphygmomanometers (1967) Circulation, 36, pp. 980-988; Allain, CC, Poon, LS, Chan, CSG, Enzymatic determination of serum cholesterol (1974) Clin Chem, 20, pp. 470-471; Wiebn, DA, Bernet, JT, Influence of incomplete cholesteryl ester hydrolysis on enzymatic measurement of cholesterol (1977) Clin Chim Acta, 79, pp. 352-356; Wahlefeld, AW, Triglycerides determination after enzymatic hydrolysis (1974) Methdoden der enzymastichen Analyse, pp. 1831-1835. , HU Bergmeyer, 2nd ed, Academic Press, Weinheim, Germany; Takayama, M, Itoh, S, Nagasaki, T, Tanimizu, I, A new enzymatic method for determination of serum choline-containing phospholipids (1977) Clin Chim Acta, 79, pp. 93-96; (1982) Manual of Laboratory Operations, Lipid Research Clinic Program, Lipid Lipoprotein Analysis, , US Department of Health and Human Services, National Institutes of Health, Washington, DC; Demacker, PNM, Vos-Janssen, HF, Hijmans, AGM, Measurement of high density lipoprotein cholesterol in serum: Comparison of six isolation methods combined with enzymic cholesterol analysis (1980) Clin Chem, 26, pp. 1780-1786; Eyre, J, Hammett, F, Miller, NE, A micro-method for the rapid ultracentrifugal separation of human plasma high density lipoprotein subfractions, HDL2 and HDL3 (1981) Clin Chim Acta, 114, pp. 225-231; Babamoto, KS, Hirokawa, WT, Doxazosin: A new alpha 1-adrenergic antagonist (1992) Clin Pharm, 11, pp. 415-427; Mazzola, C, Guerrasio, E, Doxazosin versus atenolol: A randomized comparison of calculated coronary heart disease risk reduction (1988) Am Heart J, 116, pp. 1797-1801; Oliveros-Palacios, MC, Godoy-Godoy, N, Colina-Chourio, JA, Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein (1991) Am J Cardiol, 67, pp. 157-161; Lijnen, P, Fagard, R, Staessen, J, Amery, A, Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison (1990) Methods Find Exp Clin Pharmacol, 12, pp. 563-573; Monmany, J, Domingo, P, Gómez, JA, Effects of long-term treatment with metoprolol and hydrochlorothiazide on plasma lipids and lipoproteins (1989) J Intern Med, 228, pp. 323-331; Cubeddu, LX, Pool, JL, Bloomfield, R, Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension (1988) Am J Hypertens, 1, pp. 158-167; Talseth, T, Westlie, L, Daae, L, Doxazosin and atenolol as monotherapy in mild and moderate hypertension: A randomized, parallel study with a three-year follow-up (1991) Am Heart J, 121, pp. 280-285; Kaplan, N, Primary (essential) hypertension: Pathogenesis (1986) Clinical Hypertension, pp. 56-122. , N Kaplan, 4th ed, Williams & Wilkins, Baltimore, Md","Monmany, J.R.; Hospital de Sant Pau, Servei de Medicina Interna, Sant Antoni Maria Claret, Barcelona, 167-08025, Spain",,,,,,,,0011393x,,,,"English","Top. Catal.",Article,"Final",,Scopus,2-s2.0-84954087823
"Monmany J.R., Benet T.G., Blanco F.V., Pedreño X.E., Gómez J.A.G., Roca-Cusachs A.C., Sanz F.C., Nolla J.P.","6601959245;6507054787;7102243089;6503977832;36445662300;7004601419;7102263897;7005300920;","Comparative study of the effects of antihypertensive treatment with atenolol and doxazosin on lipids, lipoproteins, apolipoproteins, and phospholipids",1996,"Current Therapeutic Research - Clinical and Experimental","57","5",,"343","357",,3,"10.1016/S0011-393X(96)80043-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029891960&doi=10.1016%2fS0011-393X%2896%2980043-9&partnerID=40&md5=297818f086f7cfbb0a39b629b4d8d13f","Servei de Medicina Interna, Hospital de Sant Pau, Univ. Autònoma de Barcelona, Barcelona, Spain; Servei de Bioquim. i Biol. Molecular, Hospital de Sant Pau, Univ. Autònoma de Barcelona, Barcelona, Spain; Servicio de Bioquímica, Fund. Jiménez Díaz, Madrid, Spain; Dept. d'Info. Mèdica, Inst. Munic. d'Investigacio Medica, Univ. Autònoma de Barcelona, Barcelona, Spain; Hospital de Sant Pau, Servei de Medicina Interna, Sant Antoni Maria Claret, 167, 08025 Barcelona, Spain","Monmany, J.R., Servei de Medicina Interna, Hospital de Sant Pau, Univ. Autònoma de Barcelona, Barcelona, Spain, Hospital de Sant Pau, Servei de Medicina Interna, Sant Antoni Maria Claret, 167, 08025 Barcelona, Spain; Benet, T.G., Servei de Medicina Interna, Hospital de Sant Pau, Univ. Autònoma de Barcelona, Barcelona, Spain; Blanco, F.V., Servei de Bioquim. i Biol. Molecular, Hospital de Sant Pau, Univ. Autònoma de Barcelona, Barcelona, Spain; Pedreño, X.E., Servei de Bioquim. i Biol. Molecular, Hospital de Sant Pau, Univ. Autònoma de Barcelona, Barcelona, Spain; Gómez, J.A.G., Servicio de Bioquímica, Fund. Jiménez Díaz, Madrid, Spain; Roca-Cusachs, A.C., Servei de Medicina Interna, Hospital de Sant Pau, Univ. Autònoma de Barcelona, Barcelona, Spain; Sanz, F.C., Dept. d'Info. Mèdica, Inst. Munic. d'Investigacio Medica, Univ. Autònoma de Barcelona, Barcelona, Spain; Nolla, J.P., Servei de Medicina Interna, Hospital de Sant Pau, Univ. Autònoma de Barcelona, Barcelona, Spain","We conducted an open-label study to evaluate the effects on blood pressure, lipids, lipoproteins, apolipoproteins, and phospholipids of two antihypertensive drugs: atenolol, a cardioselective nonsympathomimetic beta- blocker, and doxazosin, a long-acting alpha1-blocker. Sixty-four patients, 24 men and 40 women, were included in the study. Patients were randomly assigned to receive either 25 mg of atenolol or 1 mg of doxazosin. The doses of the drugs were titrated to a maximum of 100 mg for atenolol and 16 mg for doxazosin to achieve a diastolic blood pressure below 90 mm Hg. Once titration was achieved, the treatment period lasted 6 months. Low doses of atenolol (37.5 ± 13.7 mg, mean ± SD) controlled low and moderate hypertension and decreased low-density lipoprotein cholesterol (LDL-C) levels. Standard doses of doxazosin (5.4 ± 5.6 mg) were required to control blood pressure; doxazosin in these doses decreased LDL-C and apolipoprotein B levels and increased the phospholipid content of high-density lipoprotein 2. The effectiveness of doxazosin in controlling systolic blood pressure measured in the lying position was limited. We concluded that both doxazosin and atenolol slightly modified lipids, although doxazosin modified more lipid fractions than atenolol. Both drugs reduced blood pressure, but atenolol was more effective than doxazosin when patients were lying down.",,"alpha 1 adrenergic receptor blocking agent; antihypertensive agent; apolipoprotein; apolipoprotein A1; apolipoprotein B; atenolol; beta adrenergic receptor blocking agent; doxazosin; high density lipoprotein; high density lipoprotein cholesterol; lipid; lipoprotein; low density lipoprotein cholesterol; phospholipid; very low density lipoprotein cholesterol; adult; aged; antihypertensive therapy; article; blood pressure regulation; bradycardia; brain hemorrhage; clinical trial; controlled clinical trial; controlled study; dose response; epigastric pain; essential hypertension; fatigue; female; heart palpitation; human; major clinical study; malaise; male; orthostatic hypotension; polyuria; practice guideline; priority journal; randomized controlled trial; somnolence; syncope; vertigo; xerostomia",,"atenolol, 29122-68-7, 93379-54-5; doxazosin, 74191-85-8; lipid, 66455-18-3",,,"Pfizer","We are indebted to Pfizer Inc., Madrid, Spain, for their financial support of this study, to Dr. Jordi Ord66ez for his valuable collaboration on the data referring to quality control of lipid determinations, and to Professor Francesc Jane for his assessment in this study.",,,"Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg (1967) JAMA, 202, pp. 1028-1034; Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressures averaging 90 through 114 mm Hg (1970) JAMA, 213, pp. 1143-1152; Mittinen, T.A., Huttunen, J.K., Naukkarlnen, V., Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality (1985) JAMA, 254, pp. 2097-2102; Trials of the treatment of mild hypertension. An interim analysis (1982) Lancet, 1, pp. 149-156; Helgeland, A., Leren, P., Kjeldsen, S., Changes in the lipoprotein profile during antihypertensive therapy (1984) Acta Pharmacol Toxicol., 54 (1 SUPPL.), pp. 75-77; Langdon, C.G., Doxazosin: A study in a cohort of patients with hypertension in general practice - An interim report (1991) Am Heart J., 121, pp. 268-273; Holme, I., Fauchald, P., Rugstad, H.E., Stokke, H.P., Preliminary results of the Norwegian doxazosin postmarketing surveillance study: A twelve-week experience (1991) Am Heart J., 121, pp. 260-267; Neusy, A.J., Lowenstein, J., Effects of prazosin, atenolol, and thiazide diuretic on plasma lipids in patients with essential hypertension (1986) Am J Med., 80 (SUPPL. 2A), pp. 94-99; Day, J.L., Metcalfe, J., Simpson, C.N., Adrenergic mechanisms in control of plasma lipid concentrations (1982) BMJ, 284, pp. 1145-1148; England, J.D.F., Simons, L.A., Gibson, J.C., Carlton, M., The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man (1980) Clin Exp Pharmacol Physiol., 7, pp. 329-333; Taylor, S.H., Lee, P.S., Sharma, S.K., A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension (1988) Am Heart J., 116, pp. 1820-1825; Weiner, L., Rössner, S., Atenolol 50 mg or metoprolol 200 mg - A comparison of antihypertensive efficacy, side effects and lipoprotein changes (1983) Acta Med Scand., 677 (SUPPL.), pp. 153-157; Massey, J.B., Pownall, H.J., Phosphatidylcholines in membranes and lipoproteins (1990) Curr Opin Lipidol., 1, pp. 524-528; Bielicki, J.K., Johnson, W.J., Glick, J.M., Rothblat, G.H., Efflux of phospholipid from fibroblasts with normal and elevated levels of cholesterol (1991) Biochim Biophys Acta, 1084, pp. 7-14; Bielicki, J.K., Johnson, W.J., Weinberg, R.B., Efflux of lipid from fibroblasts to apolipoproteins: Dependence on elevated levels of cellular unesterified cholesterol (1992) J Lipid Res., 33, pp. 1699-1709; Kirkendall, W.M., Burton, A.C., Epstein, F.H., Freis, E.D., Subcommittee of the A.H.A. post-graduate educational committee: Recommendations for human blood pressure determination by sphygmomanometers (1967) Circulation, 36, pp. 980-988; Allain, C.C., Poon, L.S., Chan, C.S.G., Enzymatic determination of serum cholesterol (1974) Clin Chem., 20, pp. 470-471; Wiebn, D.A., Bernet, J.T., Influence of incomplete cholesteryl ester hydrolysis on enzymatic measurement of cholesterol (1977) Clin Chim Acta, 79, pp. 352-356; Wahlefeld, A.W., Triglycerides determination after enzymatic hydrolysis (1974) Methdoden der Enzymastichen Analyse. 2nd Ed., pp. 1831-1835. , Bergmeyer HU, ed. Weinheim, Germany: Academic Press; Takayama, M., Itoh, S., Nagasaki, T., Tanimizu, I., A new enzymatic method for determination of serum choline-containing phospholipids (1977) Clin Chim Acta, 79, pp. 93-96; (1982) Manual of Laboratory Operations, Lipid Research Clinic Program, Lipid Lipoprotein Analysis, , Washington, DC: US Department of Health and Human Services, National Institutes of Health; Demacker, P.N.M., Vos-Janssen, H.F., Hijmans, A.G.M., Measurement of high density lipoprotein cholesterol in serum: Comparison of six isolation methods combined with enzymic cholesterol analysis (1980) Clin Chem., 26, pp. 1780-1786; Eyre, J., Hammett, F., Miller, N.E., A micro-method for the rapid ultracentrifugal separation of human plasma high density lipoprotein subfractions, HDL2 and HDL3 (1981) Clin Chim Acta, 114, pp. 225-231; Babamoto, K.S., Hirokawa, W.T., Doxazosin: A new alpha 1-adrenergic antagonist (1992) Clin Pharm., 11, pp. 415-427; Mazzola, C., Guerrasio, E., Doxazosin versus atenolol: A randomized comparison of calculated coronary heart disease risk reduction (1988) Am Heart J., 116, pp. 1797-1801; Oliveros-Palacios, M.C., Godoy-Godoy, N., Colina-Chourio, J.A., Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein (1991) Am J Cardiol., 67, pp. 157-161; Lijnen, P., Fagard, R., Staessen, J., Amery, A., Antihypertensive effect of doxazosin and atenolol in short- And long-term double-blind comparison (1990) Methods Find Exp Clin Pharmacol., 12, pp. 563-573; Monmany, J., Domingo, P., Gómez, J.A., Effects of long-term treatment with metoprolol and hydrochlorothiazide on plasma lipids and lipoproteins (1989) J Intern Med., 228, pp. 323-331; Cubeddu, L.X., Pool, J.L., Bloomfield, R., Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension (1988) Am J Hypertens, 1, pp. 158-167; Talseth, T., Westlie, L., Daae, L., Doxazosin and atenolol as monotherapy in mild and moderate hypertension: A randomized, parallel study with a three-year follow-up (1991) Am Heart J., 121, pp. 280-285; Kaplan, N., Primary (essential) hypertension: Pathogenesis (1986) Clinical Hypertension. 4th Ed., pp. 56-122. , Kaplan N, ed. Baltimore, Md: Williams & Wilkins;","Monmany, J.R.; Servei de Medicina Interna, Hospital de Sant Pau, Sant Antoni Maria Claret, 167-08025 Barcelona, Spain",,,"Excerpta Medica Inc.",,,,,0011393X,,CTCEA,,"English","CURR. THER. RES. CLIN. EXP.",Article,"Final",,Scopus,2-s2.0-0029891960
"Sanz F., Loza M.I., Ahlgrimm E.D., Baetens P., Cuypers J., Cranz H., Coronel M., Fernández-López J.L., De Mora A., Sosa-Iudicissa M.","7102263897;7003766926;6602321020;16940788100;55927570600;6602171667;57206529581;55927026800;55927801400;7801557908;","Telematics in community pharmacies to support responsible self-medication. The TESEMED project",1996,"Studies in Health Technology and Informatics","34",,,"141","145",,3,"10.3233/978-1-60750-878-6-141","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887508958&doi=10.3233%2f978-1-60750-878-6-141&partnerID=40&md5=b6c192ba083955e395e302a075569f55","IMIM, UAB, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; PGEU, Sq. Ambiorix 13, B-1040 Brussels, Belgium; AESGP, Av. Tervuren, B-1040 Brussels, Belgium; SEMA Group SAE, C/ Albarracín 25, E-28037 Madrid, Spain; European Commission - DG XIII, Av. de Beaulieu 29, 3/50. B-1160 Brussels, Belgium; Departamento de Farmacologia, Facultad de Farmacia, Universidad de Santiago, E-15706 Santiago de Compostela, Spain","Sanz, F., IMIM, UAB, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain; Loza, M.I., IMIM, UAB, C/ Dr. Aiguader 80, E-08003 Barcelona, Spain, Departamento de Farmacologia, Facultad de Farmacia, Universidad de Santiago, E-15706 Santiago de Compostela, Spain; Ahlgrimm, E.D., PGEU, Sq. Ambiorix 13, B-1040 Brussels, Belgium; Baetens, P., PGEU, Sq. Ambiorix 13, B-1040 Brussels, Belgium; Cuypers, J., PGEU, Sq. Ambiorix 13, B-1040 Brussels, Belgium; Cranz, H., AESGP, Av. Tervuren, B-1040 Brussels, Belgium; Coronel, M., AESGP, Av. Tervuren, B-1040 Brussels, Belgium; Fernández-López, J.L., SEMA Group SAE, C/ Albarracín 25, E-28037 Madrid, Spain; De Mora, A., SEMA Group SAE, C/ Albarracín 25, E-28037 Madrid, Spain; Sosa-Iudicissa, M., European Commission - DG XIII, Av. de Beaulieu 29, 3/50. B-1160 Brussels, Belgium","A project devoted to the development and testing of telematic applications to be used in community pharmacies to provide information and education on the relevant use or OTC (non-prescription) drugs is presented. Two user types are envisaged (community pharmacy professionals and customers) and, consequently. two types of systems will be considered. A comprehensive bibliographic review of the state of the art is included. © The authors 1996.",,"Bibliographic reviews; Development and testing; State of the art; Telematics; User type; Wireless telecommunication systems",,,,,,,,,"Flynn, P., The european healthcare system in 2005 (1995) Self-medication by the Year 2005: Making Wider Choices A European Reality, pp. 9-11. , In:. Richmond (UK): PJB Publications; (1986) Guidelines for the Assessment of Medicinal Products for Use in Self-medication, , European Drug Guideline Series 8. WHO. Regional Office for Europe. Copenhagen; (1994) Forty-seventh WHO Assembly: Role of the Pharmacists in Support of the WHO Revised Drug Strategy, , 10 May; Antezana, F.S., Self-medication as part of primary healthcare (1995) Self-medication by the Year 2005: Making Wider Choices A European Reality, pp. 9-11. , In:. Richmond (UK): PJB Publications; Webb, C., Addison, C., Holman, H., Saklaki, B., Wagner, A., Self-medication for elderly patients (1990) Nurs Times, 86, pp. 46-49; Johns, C., Setting standards. Steps to self-medication (1990) Nurs Times, 86, pp. 40-41; Coons, S.J., The pharmacist's role in promoting and supporting self-care (1990) Holist Nurs Pract, 4, pp. 37-44; Kelly, J.M., Implementing a patient self-medication program (1994) Rehabil Nurs, 19, pp. 87-90. , 95; Nichol, M.B., McCombs, J.S., Johnson, K.A., Spacapan, S., Sclar, D.A., The effects of consultation on over-The-counter medication purchasing decisions (1992) Hied Care, 30, pp. 989-1003; Braun, R., Schulz, M., (1994) Sclbstbchandlung, , (editors). Beratung in der Apotheke. Frankfurt; Elanjian, S., Gora, M.L., Symes, L.R., Methods used by pharmacy departments to identify drug interactions (1993) Am J Hosp Pharm, 50, pp. 2546-2549; Ausejo, M., Apecechea, C., Rodríguez, M.J., Salgado, L., Puerta, M.C., Izquierdo, M.C., Herreros De-Tejada, A., Estudio sobre automedicacion de antiinfecciosos en dos oficinas de farmacia [a study on anti-infective agent self-medication in 2 pharmacy offices] (1993) Aten Primaria, 11, pp. 41-43; Llavona-Hevia, A., Loza, M.I., Estudio de automedicación desde una oficina de farmacia [self-medication study from a community pharmacy] (1988) El Farmacéutico, 54, pp. 61-68; Llavona-Hevia, A., Dago, A.M., Zardain-Tamargo, E., Automedicación en oficinas de farmacia de asturias [selfmedication in asturian community pharmacies] (1989) El Farmacéutico, 59, pp. 75-88; Zardain-Taniargo, E., Llavona-Hevia, A., Protocolos para la atención farmacéutica de los transtornos menores [protocols for the pharmaceutical care of minor ailments] (1994) Farm Clin, 11, pp. 312-325; Eskerud, J.R., Andrew, M., Stiomnes, B., Toverud, E.L., Pharmacy personnel and fever: A study on perception, self-care and information to customers (1993) Pharm World Sci, 15, pp. 156-160; Fincham, J.E., Karnik, K.A., (1994) Patient Counseling and Dorm Therapy, , US Pharm ; 19/4: 56-57+61-66+71-78+82; Ammon, H.P.T., Moglichkeiten and grenzen der selbstmedikation mit phytopharmaka [Possibilities and limitations of selfinedication with phytotherapeutics] (1989) Z Phytother, 10 (6), pp. 167-174; Boyd, A.F., Hartzema, A.G., Computerized monitoring protocols as a pharmaceutical care practice enhancement: A conceptual illustration using diabetes mellitus (1993) Ann Pharmacother, 27, pp. 963-966; Patil, P.N., Education in pharmacy (1994) Trends Pharinacol Sci, 1, p. 177; Price, K.O., Comparison of continuing education requirements for pharmacists, physicians, ans nurses (1994) APhA Annual Meeting, 141, p. 126; Stork, M.W., Greene, R.J., Baron, A.D.J., Respond: Realistic expert simulation for pharmacists on diagnosis (1995) The Pharmaceutical Journal, 254, pp. 295-298; Segall, A., Goldstein, J., Exploring the correlates of self-provided health care behaviour (1989) Soc Sci Med, 29, pp. 153-161; Kelly, E.T., Palmer, H.A., Increasing OTC market share: Strategies for pharmacists (1993) Pharm Bus, 4, pp. 6-9; Woodruff, A.E., Hunt, C.A., Involvement in medical informatics may enable pharmacists to expand their consultation potential and improve the quality of healthcare (1992) Ann Pharmacother, 26 (1), pp. 100-104; (1992) Ann Pharmacother, 26 (4), p. 566. , Erratum appears in; (1992) Ann Pharmacother, 26 (1), pp. 99-100. , Comments appears in; Computers: Raising the value of pharmacy (1993) Computer Talk Pharm, 13, pp. 19-23. , Anonymous; Banahan, B.F., Garner, D.D., Using pharmacy computer systems for better patient care (1994) Drug Top, 138, pp. 80-88; Ray, S.L., Computers: Unlimited applications (1993) Wash Pharm, 35, pp. 16-17; Bentley, J.P., Banahan, B.F., Garner, D.D., Role of information technology in the provision of clinical community pharmacy (1994) APhA Annual Meeting, 141, p. 99; Soumerai, S.B., Lipton, H.L., Computer-based drug-utilization review-Risk, benefit, or boondoggle? (1995) N Engl J Med, 332, pp. 1641-1645; Of systems and software (1993) Am Drug, 208, pp. 46-47. , Anonymous; Banahan, B.F., What are you doing with that computer? (1993) Computer Talk Phann., 13, pp. 6-8; Dasta, J.F., Reardon, G., Survey of ACCP members regarding use of computers and information processing (1992) Pharmacotherapy, 12 (6), pp. 468-474; Van Ochten, G.J., Automation in Dutch pharmacies (1992) Pharm Weekbl, 127 (37), pp. 969-972; Milagros-Salesa, M.M., Garcia-Marco, D., Martinez-Camacho, M., Liso-Rubio, J., Computer program for the pharmacotherapeutic follow-up of patients at community pharmacies (1993) Farm Clin, 10, pp. 778-780. , 776, 782-783; Fletcher, H.J., Pharmacy keyword in Eastern European languages (1993) Int Phann J, 7, pp. 192-194; Lessel, J., Lessel, U., Computer in der Pharmazie-ein Uberblick [Computers in pharmacy-an overview] (1993) Pharr Unserer Zeit, 22, pp. 214-222; De Zegher, I., Milstein, C., Sene, B., Dhalberg, B., Harding, N., Kostrewski, B., Venot, A., (1993) Proc Annu Symp Comput Appl Mad Care, pp. 144-148; Basara, L.R., Pharmacists, patient education, and OBRA'90: Results of a national survey (1994) APhA Annual Meeting, 141, p. 97; Felkey, B.G., Pharmaceutical care: Ironing out the software dilemma (1993) Computer Talk Pharm, 13, pp. 19-25; Cataldo Jr., R., OBRA'90 and your pharmacy computer system (1992) Am Pharm, NS32 (11), pp. 39-41; Frady, J.M., Peeler, H.G., Look how tiff we've come with the help of computers (1993) South Phann J, 85, p. 12; Vincze, Z., Pandi-Torok, I., Computer programs in the teaching of pharmaceutical organisation (1989) Gyogyszereszet, 33 (3), pp. 137-141; Murphy, K.J., Plan information, pronto (1993) Computer Talk Pharm, 13, p. 26; Limburg-Mancini, B.A., Jannsen, R.K., Kaufman, J., Feldman, J.A., Evaluation of an ongoing computerized continuing education program (1993) ASHP Midyear Clinical Meeting, 28, pp. P-18; Cataldo Jr., R., On-line continuing education (1993) Am Pharm, NS33, p. 17. , 84; MacKinnon III, G.E., Pitterle, M.E., Boll, L.E., Demuth, J.E., Computer-based patient simulations: Hospital pharmacists' performance and opinions (1992) Am J Hosp Pharm, 49, pp. 2740-2745; Goodman-Snitkoff, G., Moon, D.G., Computer-assisted-learning (CAL) in an evolving pharmacy curriculum (1993) AACP Annual Meeting, 94, pp. IV-2; Ohri, L.K., Rouch, D.R., Pincus, K.T., Dougherty, J.P., Computer resources for student use at US colleges of pharmacy (1994) Ann Pharmacother, 28, p. 970; Clerc, M.A., Jolivet, J.P., Benoit, J.P., Simulation of clinical case reports on microsoft computer (1993) J Pharm Clin, 12, pp. 214-216; Tunget, C.L., Smith, G.H., Lipsy, R.J., Schumacher, R.J., Evaluation of dllearn: Interactive computer-assisted learning program for drug information (1993) Am J Pharm Educ, 57, pp. 340-343; Abate, M.A., Al, J., Shumway, J.M., Nardi, A.H., Development and evaluation of a computer-assisted instructional program to teach critical evaluation of drug studies (1993) Am J Pharm Educ, 57, pp. 416-424; Dawson, K., Fassett, W.E., Interactive multimedia role-play simulation: Building skills in pharmacist-patient communication (1993) AACP Annual Meeting, 94, pp. VII-5; Baker, D.E., Smith, G.H., Abate, M.A., Selected topics in drug information access and practice: An update (1994) Ann Pharmacother, 28, pp. 1389-1394; Poirier, T.I., Giudici, R.A., Evaluation of patient counseling microcomputer software programs (1992) Hosp Pharm, 27, pp. 411-415. , 408; Mickle, T.R., Increasing staff pharmacists' interventions with a structured program utilizing the pharmacy's existing computer system (1993) ASHP Annual Meeting, 50, pp. P-44D; Armstrong, E.P., Terry, A.K., Impact of drug use evaluation upon ambulatory pharmacy practice (1992) Ann Phannacother, 26, pp. 1546-1553; Oke, T.O., Primary health-care services with a functional ambulatory care clinical pharmacy in a low-income housing project clinic (1994) J Natl Med Assoc, 86, pp. 465-468",,,,"IOS Press","13th International Congress on Medical Informatics Europe, MIE 1996","19 August 1996 through 22 August 1996","Copenhagen",,09269630,9051992785; 9789051992786,,,"English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-84887508958
"Carbó J.M., Bayas J.M., Pi-Sunyer M.T., Sanz F., Vilella A., Sancho J.J., Martin M., Nebot X., Navarro G., Planas I., Prat A., Salleras L.I.","36820842200;7004614321;6505768446;7102263897;6604059244;7201937083;7406970850;6506491831;55432979900;6602265390;24776797300;7006233334;","EPIDO: A surveillance information system to automatically detect notifiable diseases",1996,"Studies in Health Technology and Informatics","34",,,"690","694",,,"10.3233/978-1-60750-878-6-690","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887335820&doi=10.3233%2f978-1-60750-878-6-690&partnerID=40&md5=2b8d7e7bd68a8287813b64f03182ba4b","Hospital Clinic de Barcelona, Barcelona, Spain; Institut Municipal d'Investigació Mèdica, Barcelona, Spain","Carbó, J.M., Hospital Clinic de Barcelona, Barcelona, Spain; Bayas, J.M., Hospital Clinic de Barcelona, Barcelona, Spain; Pi-Sunyer, M.T., Institut Municipal d'Investigació Mèdica, Barcelona, Spain; Sanz, F., Institut Municipal d'Investigació Mèdica, Barcelona, Spain; Vilella, A., Hospital Clinic de Barcelona, Barcelona, Spain; Sancho, J.J., Institut Municipal d'Investigació Mèdica, Barcelona, Spain; Martin, M., Institut Municipal d'Investigació Mèdica, Barcelona, Spain; Nebot, X., Hospital Clinic de Barcelona, Barcelona, Spain; Navarro, G., Hospital Clinic de Barcelona, Barcelona, Spain; Planas, I., Institut Municipal d'Investigació Mèdica, Barcelona, Spain; Prat, A., Hospital Clinic de Barcelona, Barcelona, Spain; Salleras, L.I., Hospital Clinic de Barcelona, Barcelona, Spain","Objective: Design and implementation of a surveillance information system to automate notifiable diseases episode reporting in a hospital context. Design: Development of a computer application using widespread computing and telecommunications standards. Scope: Hospital Clinic and Hospital del Mar discharge activity from 1995 onwards. Instrumentation: Relational database design and implementation techniques, distributed information systems, rule-based expert systems, natural language interpretation and computer networking facilities. Measurements: automatic detection of notifiable disease episodes from discharge data (Emergency Room and Hospital Wards) from all patients attending Hospital Clinic and Hospital del Mar of Barcelona. Validation through comparison with detection by a professional. © The authors 1996.","Epidemiology; Information systems; Notifiable diseases; Public health; Surveillance systems","Distributed database systems; Epidemiology; Expert systems; Hospitals; Information systems; Information use; Monitoring; Public health; Relational database systems; Automatic Detection; Computer networking; Design and implementations; Discharge activities; Distributed information systems; Rule based expert systems; Surveillance information; Surveillance systems; Distributed computer systems",,,,,,,,,"(1994) Addressing Emerging Infectious Disease Threats: A Prevention Strategy for the United States., , Centers for Disease Control and Prevention. Atlanta: U.S. Department of Health and Human Services, Public Health Service; Teutsch, S.M., Churchill, R.E., (1994) Principles and Practice of Public Health Surveillance., , In: Teutsch SM, Churchill RE, eds. New York: Oxford University Press; Summary of notifiable diseases (1993) MMWR, p. 42. , Centers for Disease Control and Prevention; Osterholm, M., (1993) Council of State and Territorial Epidemiologists Survey on Surveillance; Healing, T.D., The surveillance of communicable disease in the european community (1992) Commun. Dis. Rep. CDR. Rev., 2, pp. R73-R77; Desenclos, J.C., Bijkerk, H., Huisman, J., Variations in national infectious diseases surveillance in europe (1993) Lancet, 341, pp. 1003-1006; Garcia Rodriguez, J.F., De Juan-Prego, J., Vazquez Castro, J., Cuántos casos de tuberculosis no son declarados? [how many cases of tuberculosis are not reported?] (1994) Med Clin (Bare), 103, pp. 490-493; Ordre de 29 de Gener de 1982 determinant les malalties que són de declaració obligatòria en l'àmbit del territori de Catalunya (1982) DOG, pp. 571-572. , Departament de Sanitat i Seguretat Social; McCormick, A., French lessons on surveillance of communicable diseases (1987) BMJ, 294, pp. 74-75; National electronic telecommunications system for surveillance united states (1991) MMWR, 40, pp. 502-503. , Centers for Disease Control and Prevention; Fisher, I.S., Rowe, B., Bartlett, C., Gill, O.N., Salm-Net laboratory-based surveillance of human salmonella in-fections in Europe (1994) PILS Microbiology Digest, 11, pp. 181-182; Palmer, S., Henry, R., Epinet in Wales: Phls Cadwyn Cymru development of a public health information system (1992) PHLS Microbiology Digest, 9, pp. 107-109; Cimino, J.J., Data storage and knowledge representation for clinical workstations (1994) Int. J. Biomed. Comput., 34, pp. 185-194; Houtchens, B.A., Allen, A., Clemmer, T.P., Lindberg, D.A., Pedersen, S., Telemedicine protocols and standards: Development and implementation (1995) J. Med. Syst., 19, pp. 93-119; Lindberg, D.A., Humphreys, B.L., McCray, A.T., The unified medical language system (1993) Methods Inf. Med., 32, pp. 281-291; Fu, L.S., Huff, S., Bouhaddou, O., Bray, B., Warner, H., Estimating frequency of disease findings from combined hospital databases: A umis project (1991) Proc. Ann U. Symp. Comput. Appl. Med. Care, pp. 373-377; Pietrzyk, P.M., Free text analysis (1995) Int. J. Biomed. Comput., 39, pp. 139-144; Rindflesch, T.C., Aronson, A.R., Ambiguity resolution while mapping free text to the umls metathesaurus (1994) Proc. Annu. Symp. Comput. Appl. Med. Care, pp. 240-244",,,,"IOS Press","13th International Congress on Medical Informatics Europe, MIE 1996","19 August 1996 through 22 August 1996","Copenhagen",,09269630,9051992785; 9789051992786,,,"English","Stud. Health Technol. Informatics",Conference Paper,"Final",,Scopus,2-s2.0-84887335820
"Pulido M., Carles González J., Sanz F.","7006383312;6504639726;7102263897;","Errors in bibliographic references: a retrospective study in Medicina Clinica (1962-1992) [Errores en las referencias bibliográficas: un estudio retrospectivo en Medicina Clínica (1962-1992).]",1995,"Medicina clínica","104","5",,"170","174",,17,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-2542524852&partnerID=40&md5=2789105a3c000b24706b08738b989bf3","Unitat d'Edició Mèdica, Universitat Autónoma de Barcelona., Spain","Pulido, M., Unitat d'Edició Mèdica, Universitat Autónoma de Barcelona., Spain; Carles González, J., Unitat d'Edició Mèdica, Universitat Autónoma de Barcelona., Spain; Sanz, F., Unitat d'Edició Mèdica, Universitat Autónoma de Barcelona., Spain","BACKGROUND: Misspellings of transcription or the copy of references of articles published in the literature without verifying the information with the original document may be the cause of incorrect citations. The purpose of this study was to determine the accuracy of citations to journal articles in 1962 to 1992 volumes of Medicina Clínica. METHODS: A method of systematic sampling was used to choose five references for each of the 12 original articles per year selected at 5-year intervals (1962, 1967, 1972, 1977, 1982, 1987, 1992). In the final sample of 420 references, errors in the six standard bibliographic elements--authors' names, article title, journal title, year, volume number, and page numbers--were analyzed. Major errors were defined when inaccuracies prevented identification of the cited article. RESULTS: Of the total 368 references verified, 132 (35.86%) were error free and the remaining 236 (64, 13%) were inaccurate. Multiple errors were found in 45% of cases. The mean number of errors per references was 1.13. Twelve references were incorrect, 221 errors were found in the authors' name, 131 in the title of the article, 14 in the name of the journal, 5 in the year of publication, 12 in the number of the volume, and 22 in the initial or final pages of the article. Major errors were detected in 94 (22.54%) cases and minor errors in 323 (77.45%). There were no statistically significant differences in the variation of the overall percentage of errors throughout the study period. CONCLUSIONS: A high rate of citation errors has been also documented in a Spanish medical journal. The importance of reference verification should be emphasized and authors should exercise more care in preparing bibliographies of their articles.",,"article; publication; publishing; retrospective study; Bibliography; Publishing; Retrospective Studies",,,,,,,,,,"Pulido, M.",,,,,,,,00257753,,,"7877375","Spanish","Med Clin (Barc)",Article,"Final",,Scopus,2-s2.0-2542524852
"González J.C., Pulido M., Sanz F.","57195757144;7006383312;7102263897;","Evaluation of the use of statistical techniques in original articles published in the Medicina Clínica during 3 decades (1962-1992) [Evaluación del uso de procedimientos estadísticos en los artículos originales publicados en Medicina Clínica durante tres décadas (1962-1992).]",1995,"Medicina clínica","104","12",,"448","452",,12,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0039316970&partnerID=40&md5=921e54ce36feedcd92130c2d1abc6796","Departament d'Informàtica Mèdica i Docència, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain","González, J.C., Departament d'Informàtica Mèdica i Docència, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain; Pulido, M., Departament d'Informàtica Mèdica i Docència, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain; Sanz, F., Departament d'Informàtica Mèdica i Docència, Institut Municipal d'Investigació Mèdica (IMIM), Barcelona, Spain","BACKGROUND: The incorrect use of statistical techniques in medical articles may seriously compromise the validity of conclusions. This finding otherwise is relatively common. METHODS: A total of 84 original articles published in Medicina Clínica between 1962 and 1992 were reviewed with the aim of assessing the use and appropriateness of statistical techniques. The use of statistics, the quality of the analyses performed, and the inaccuracy of the statistical techniques used were evaluated. We also classified the statistical techniques most commonly used throughout the study period. RESULTS: There was a marked increase in the use of statistical analyses, from 8.3% in 1962 to 83.3% in 1992. It should be noted that a substantial part of this increase has been due to the use of inferential tests, which accounted up to 70% in the sample of articles published in 1992. This finding, however, was associated with an increase in the number of incorrect analyses. The most common statistical errors included assumption of normal distribution of data (with no mention of the test used to confirm this fact), mistake between standard deviation and standard error of the mean, inadequate inferences on the basis of the sample size, inappropriate use of the Student's t test, chi-square test, nonparametric tests or multivariate analyses as well as misunderstanding of linear regression and correlation. CONCLUSIONS: High standards in scientific research have been accompanied by a significant increase in the number of clinical studies with statistical analysis of data. However, this apparently favorable situation has been associated with an increase in the number of inaccurate analyses. It has been found that sophisticated statistical tests are rarely used in articles published in Medicina Clínica.",,"article; chi square distribution; comparative study; evaluation; multivariate analysis; publication; research; sample size; Spain; statistical model; statistics; writing; Chi-Square Distribution; Evaluation Studies; Linear Models; Multivariate Analysis; Periodicals; Research; Sample Size; Spain; Statistics; Writing",,,,,,,,,,"González, J.C.",,,,,,,,00257753,,,"7739280","Spanish","Med Clin (Barc)",Article,"Final",,Scopus,2-s2.0-0039316970
"González J.C., Roma-Millán J., Sancho J.J., Sanz F.","57195757144;6504691755;7201937083;7102263897;","Informatics in medical schools and postgraduate education centers for health professionals. Survey on the situation in Spain [La informática en las facultades de medicina y centros de formación de posgrado para profesionales sanitarios. Encuesta sobre la situación en España.]",1995,"Medicina clínica","105","15",,"570","575",,2,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029635650&partnerID=40&md5=4eac0893508d86a41541501598972dbf","Department d'Informàtica Mèdica, Universitat Autònoma de Barcelona., Spain","González, J.C., Department d'Informàtica Mèdica, Universitat Autònoma de Barcelona., Spain; Roma-Millán, J., Department d'Informàtica Mèdica, Universitat Autònoma de Barcelona., Spain; Sancho, J.J., Department d'Informàtica Mèdica, Universitat Autònoma de Barcelona., Spain; Sanz, F., Department d'Informàtica Mèdica, Universitat Autònoma de Barcelona., Spain","BACKGROUND: Informatics is acquiring an increasing relevance in the medical profession. METHODS: During the year 1993, a survey was carried out at the medical schools (MS) and postgraduate education centres (PEC) in Epidemiology, Public Health and Health Administration of Spain, on the available computer infrastructure and the teaching activities. The percentages of respondents were 81 at the MS and 100 at the PEC. RESULTS: 81% of the MS and 100% of the PEC had a computer laboratory, mainly equipped with personal computers with MS-DOS operating system. The use of general purpose applications was predominant. The number of students using the computer laboratory was very variable (5-300 per day). 48% of the MS organized courses on microcomputer applications. 66% of the MS included subjects related with informatics in the new curricula. CONCLUSIONS: Use of computers in the Spanish MS is heterogeneous. Compared with the Nord-American MS, they do not usually use applications of computer-assisted-instruction. The use of the computers at the PEC is much more generalized.",,"article; comparative study; curriculum; education; epidemiology; information processing; medical education; medical informatics; medical school; microcomputer; public health; Spain; Curriculum; Data Collection; Education, Medical, Graduate; Epidemiology; Medical Informatics; Microcomputers; Public Health; Schools, Medical; Spain",,,,,,,,,,"González, J.C.",,,,,,,,00257753,,,"7500676","Spanish","Med Clin (Barc)",Article,"Final",,Scopus,2-s2.0-0029635650
"Martín-Baranera M., Planas I., Palau J., Sanz F.","6603145514;6602265390;7006416471;7102263897;","IMASIS computer-based medical record project: dealing with the human factor.",1995,"Medinfo. MEDINFO","8 Pt 1",,,"333","",,1,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029447071&partnerID=40&md5=f51bd3910c00bfacbff68046c4891a18","Department of Medical Informatics and Education, Institut Municipal d'Investigació Mèdica (IMIM), Facultat de Medicina, Universitat Autònoma de Barcelona, Dr. Aiguader 80, Barcelona, 08003, Spain","Martín-Baranera, M., Department of Medical Informatics and Education, Institut Municipal d'Investigació Mèdica (IMIM), Facultat de Medicina, Universitat Autònoma de Barcelona, Dr. Aiguader 80, Barcelona, 08003, Spain; Planas, I., Department of Medical Informatics and Education, Institut Municipal d'Investigació Mèdica (IMIM), Facultat de Medicina, Universitat Autònoma de Barcelona, Dr. Aiguader 80, Barcelona, 08003, Spain; Palau, J., Department of Medical Informatics and Education, Institut Municipal d'Investigació Mèdica (IMIM), Facultat de Medicina, Universitat Autònoma de Barcelona, Dr. Aiguader 80, Barcelona, 08003, Spain; Sanz, F., Department of Medical Informatics and Education, Institut Municipal d'Investigació Mèdica (IMIM), Facultat de Medicina, Universitat Autònoma de Barcelona, Dr. Aiguader 80, Barcelona, 08003, Spain","The Institut Municipal d'Assistència Sanitària (IMAS) is a health care organization in Barcelona, comprising two general hospitals, a psychiatric hospital, a surgical clinic, a geriatric center, some primary care clinics, and a research institute. Since 1984, IMAS has been engaged in creating a multicenter integrated hospital information system (IMASIS). Currently, IMASIS offers the possibility to manage administrative data, laboratory results, pathology and cytology reports, radiology reports, and pharmacy inpatient orders; it also shares this information on-line among IMAS centers. IMASIS users may also work with a word processor, a spreadsheet, a database, or a statistical package and have access to MEDLINE. A second phase of IMASIS development began in December 1993 focused on clinical information management. The goal was to move towards an integrated multimedia medical record [1]. As a first step, the implementation experiences of the most advanced hospital information systems around the world were studied. Some of these experiences detected behavioral, cultural, and organizational factors [2] as the main sources of delay, or even failure, in HIS projects. A preliminary analysis to define such factors, assess their potential impact, and introduce adequate measures to deal with them seemed unavoidable before structuring of the project. In our approach to physician attitudes analysis, two survey techniques were applied. First, every hospital service head was contacted to schedule an interview, with either a service representative or a group of staff physicians and residents. The aim was to provide detailed information about project objectives and collect personal opinions, problems encountered in the current HIS, and specific needs of every medical and surgical specialty (including imaging needs). Every service head was asked to distribute a questionnaire among all clinicians, which assessed frequency of use of IMASIS current applications, user's satisfaction level, problems to be solved in utilization of the system, errors detected in the systems' database, and the personal interest in participating in the IMASIS project. The questionnaire was also intended to be a tool to monitor IMASIS evolution. Our study showed that medical staff had a lack of information about the current HIS, leading to a poor utilization of some system options. Another major characteristic, related to the above, was the feeling that the project would negatively affect the organization of work at the hospitals. A computer-based medical record was feared to degrade physician-patient relationship, introduce supplementary administrative burden in clinicians day-to-day work, unnecessarily slow history taking, and imply too-rigid patterns of work. The most frequent problems in using the current system could be classified into two groups: problems related to lack of agility and consistency in user interface design, and those derived from lack of a common patient identification number. Duplication of medical records was the most frequent error detected by physicians. Analysis of physicians' attitudes towards IMASIS revealed a lack of confidence globally. This was probably the consequence of two current features: a lack of complete information about IMASIS possibilities and problems faced when using the system. To deal with such factors, three types of measures have been planned. First, an effort is to be done to ensure that every physician is able to adequately use the current system and understands long-term benefits of the project. This task will be better accomplished by personal interaction between clinicians and a physician from the Informatics Department than through formal teaching of IMASIS. Secondly, a protocol for evaluating the HIS is being developed and will be systematically applied to detect both database errors and systemUs design pitfalls. Finally, the IMASIS project has to find a convenient point for starting, to offer short-term re",,"article; computer interface; health personnel attitude; medical record; Spain; Attitude of Health Personnel; Medical Records Systems, Computerized; Spain; User-Computer Interface",,,,,,,,,,"Martín-Baranera, M.",,,,,,,,,,,"8591191","English","Medinfo",Article,"Final",,Scopus,2-s2.0-0029447071
"Nogues R., Sitges-Serra A., Sancho J.J., Sanz F., Monne J., Girvent M., Gubern J.M.","36952739600;7007049436;7201937083;7102263897;56482092500;6602751861;6603545884;","Influence of nutrition, thyroid hormones, and rectal temperature on in-hospital mortality of elderly patients with acute illness",1995,"American Journal of Clinical Nutrition","61","3",,"597","602",,20,"10.1093/ajcn/61.3.597","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028855875&doi=10.1093%2fajcn%2f61.3.597&partnerID=40&md5=b8da3f3c673b4d015aec85f14fd36fc4","Department of Surgery, Hospital Universitari del Mar, P Marítim, 25-29, 08003 Barcelona, Spain","Nogues, R.; Sitges-Serra, A., Department of Surgery, Hospital Universitari del Mar, P Marítim, 25-29, 08003 Barcelona, Spain; Sancho, J.J.; Sanz, F.; Monne, J.; Girvent, M.; Gubern, J.M.","The present study was undertaken to investigate the interrelation of nutrition, core temperature, and thyroid function and their influence on survival of patients aged ≥70 y admitted to the hospital with acute conditions. Sixty-seven patients entered the study. Nutritional state, thyroid function, rectal temperature, and the APACHE II score were recorded at admission. The patients were followed until death or hospital discharge. Patients with a serum albumin concentration &lt;35 g/L showed a lower triiodothyronine (T3) concentration, a higher reverse triiodothyronine (rT3) concentration, and a higher death rate. Prior weight loss (≥10%) did not influence thyroid status but increased the mortality rate. Eleven patients were hypothermie (&lt;36.5 °C) and had a higher mortality, lower total T3 concentration, and higher rT3 concentration than the normothermic or hyperthermic subjects. Serum albumin, body weight, and total T3 concentration were higher in survivors (n = 51) than in nonsurvivors (n = 16). Ongoing weight loss and hypoalbuminemia at admission are highly prevalent in elderly people with acute disease, and influence their clinical outcome. Mild hypothermia was a good predictor of death. Hypoalbuminemia and hypothermia were associated with low T3 and high rT3 values.","Elderly people; Mortality; Nutrition; Temperature; Thyroid hormones","3,3',5' triiodothyronine; liothyronine; serum albumin; thyroid hormone; acute disease; aged; albumin blood level; article; controlled study; elderly care; female; human; hypoalbuminemia; hypothermia; liothyronine blood level; major clinical study; male; mortality; nutritional status; rectum temperature; thyroid function; Acute Disease; Aged; Aged, 80 and over; APACHE; Body Temperature; Comparative Study; Female; Hospital Mortality; Human; Male; Nutrition Assessment; Support, Non-U.S. Gov't; Thyroid Hormones",,"3,3',5' triiodothyronine, 5817-39-0, 70-39-3; liothyronine, 6138-47-2, 6893-02-3; serum albumin, 9048-46-8; Thyroid Hormones",,,,,,,"Barsky, A.J., The paradox of health (1988) N Engl J Med, 318, pp. 414-419; Nelson, R.C., Franzi, L.R., Nutrition and aging (1989) Med Clin North Am, 73, pp. 1531-1550; Bistrian, B.R., Blackburn, G.L., Vitale, J., Prevalence of malnutrition in general medical patients (1976) JAMA, 235, pp. 1567-1570; Kamath, S.K., Lawler, M., Smith, A.E., Kalat, T., Olson, R., Hospital malnutrition: A 33 hospital screening study (1986) J Am Diet Assoc, 86, pp. 203-206; Steffe, W.P., Malnutrition in hospitalized patients (1980) JAMA, 244, pp. 2630-2635; Reinhard, G.F., Myscofsky, J.W., Wilkans, D.B., Dobrin, P.B., Stannard, R.T., Incidence and mortality of hypoalbuminemic patients in hospitalized veterans (1980) JPEN, 4, pp. 357-359; Agarwal, N., Acevedo, F., Leighton, L.S., Cayten, C.G., Pitchumoni, C.S., Predictive ability of various nutritional variables for mortality in elderly people (1988) Am J Clin Nutr, 48, pp. 1173-1178; Bastow, M.D., Rawlings, J., Allison, S.P., Undernutrition, hypothermia, and injury in elderly women with fractured femur: An injury response to altered metabolism? (1983) Lancet, 1, pp. 143-146; Kramer, M.R., Vandijk, J., Rosin, A.J., Mortality in elderly patients with thermoregulatory failure (1989) Arch Intern Med, 149, pp. 1521-1523; Fellow, I.W., MacDonald, I.A., Bennett, T., Allison, S.P., The effect of undernutrition on thermoregulation in the elderly (1985) Clin Sci, 69, pp. 525-532; Knaus, W., Draper, E., Wagner, D., Zimmerman, J., Criteria to obtain the severity index APACHE II (1985) Crit Care Med, 10, pp. 818-829; Alastrue, A., Sitges-Serra, A., Jaurrieta, E., Sitges-Creus, A., Anthropometric assessment of our community (1982) Med Clin, 78, pp. 407-415. , (Barc) in Spanish; Moore, D.H., Evaluation of five discrimination procedures for binary variables (1973) Am J Stat, 68, pp. 399-404; White, J.V., Risk factors for poor nutritional status in older Americans (1991) Am Fam Physician, 44, pp. 2087-2097; Payette, H., Rola-Pleszczynski, M., Ghadirian, P., Nutrition factors in relation to cellular and regulatory immune variables in a free-living elderly population (1990) Am J Clin Nutr, 52, pp. 927-932; Goodwin, J.S., Garry, P.J., Lack of correlation between indices of nutritional status and immunologic function in elderly humans (1988) J Gerontol, 43, pp. 46-49; Sullivan, D.H., Walls, R.C., Lipschitz, D.A., Protein-energy undernutrition and the risk of mortality within 1 y of hospital discharge in a select population of geriatric rehabilitation patients (1991) Am J Clin Nutr, 53, pp. 599-605; Linn, B.S., Jensen, J., Malnutrition and immunocompetence in older and younger outpatients (1984) South Med J, 77, pp. 1098-1102; Manson, A., Shea, S., Malnutrition in elderly ambulatory medical patients (1991) Am J Public Health, 81, pp. 1195-1197; Patterson, B.M., Cornell, C.N., Carbone, B., Levine, B., Chapman, D., Protein depletion and metabolic stress in elderly patients who have a fracture of the hip (1992) J Bone Joint Surg [Am], 74, pp. 251-260; Tayback, M., Kumanyika, S., Chee, E., Body weight as a risk factor in the elderly (1990) Arch Intern Med, 150, pp. 1065-1072; Simons, R.J., Simon, J.M., Demers, L.M., Santen, R.J., Thyroid dysfunction in elderly hospitalized patients. Effect of age and severity of illness (1990) Arch Intern Med, 150, pp. 1249-1253; Wehmann, R.E., Gregerman, R.I., Burns, W.H., Saral, R., Santos, G.W., Suppression of thyrotropin in low thyroxine state of severe nonthyroidal illness (1985) N Engl J Med, 312, pp. 546-552; Silberman, H., Eisenberg, D., Ryan, J., The relation of thyroid indices in the critically ill patient to prognosis and nutritional factors (1988) Surg Gynecol Obstet, 166, p. 228; Gaytan, J.E., Mayoral, L.G., Gailan, E., Defective thyroidal iodine concentration in protein-caloric malnutrition (1983) J Clin Endocrinol Metab, 57, pp. 327-333; Keilson, L., Lambert, D., Fabian, D., Screening for hypothermia in the ambulatory elderly. The Maine experience (1985) JAMA, 254, pp. 1781-1784; Zweig, S., Lawhorne, L., Post, R., Factors predicting mortality in rural elderly hospitalized for pneumonia (1990) J Fam Pract, 30, pp. 153-159; Woodhouse, P., Keatinge, W.R., Coleshaw, S.R.K., Factors associated with hypothermia in patients admitted to a group of inner city hospitals (1989) Lancet, 2, pp. 1201-1204; Sitges-Serra, A., Mas, X., Sanz, F., Roquetas, F., Figueras, J., Sitges Creus, A., Mesenteric infarction. An analysis of 83 patients with prognostic studies in 44 cases undergoing a massive small bowel resection (1988) Br J Surg, 75, pp. 544-548","Sitges-Serra, A.; Department of Surgery, Hospital Universitari del Mar, P Marítim, 25-29, 08003 Barcelona, Spain",,,"American Society for Nutrition",,,,,00029165,,AJCNA,"7872226","English","Am. J. Clin. Nutr.",Article,"Final",,Scopus,2-s2.0-0028855875
"Fontenla J.A., Osuna J., Rosa E., Castro M.E., G-Ferreiro T., Loza-García I., Calleja J.M., Sanz F., Rodríguez J., Raviña E., Fueyo J., F-Masaguer C., Vidal A., de Ceballos M.L.","7004054862;7003688501;7004952752;7402292272;6505816337;15068461200;55411921400;7102263897;24773509500;56264803900;7004067667;24288587700;35835176900;7003666412;","Synthesis and Atypical Antipsychotic Profile of Some 2-(2-Piperidinoethyl)benzocycloalkanones as Analogs of Butyrophenone",1994,"Journal of Medicinal Chemistry","37","16",,"2564","2573",,43,"10.1021/jm00042a009","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028040921&doi=10.1021%2fjm00042a009&partnerID=40&md5=28c0b21b72e2f8f18748239af03c32bb","Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Department of Medical Informatics, Institut Municipal d'Investigació Mèdica (UAB), c/Doctor Aiguader, 80, 08003 Barcelona, Spain; Department of Organic Chemistry, Laboratory of Pharmaceutical Chemistry, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Department of Neuropharmacology, Cajal Institute, CSIC, 28002 Madrid, Spain","Fontenla, J.A., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Osuna, J., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Rosa, E., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Castro, M.E., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; G-Ferreiro, T., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Loza-García, I., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Calleja, J.M., Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Sanz, F., Department of Medical Informatics, Institut Municipal d'Investigació Mèdica (UAB), c/Doctor Aiguader, 80, 08003 Barcelona, Spain; Rodríguez, J., Department of Medical Informatics, Institut Municipal d'Investigació Mèdica (UAB), c/Doctor Aiguader, 80, 08003 Barcelona, Spain; Raviña, E., Department of Organic Chemistry, Laboratory of Pharmaceutical Chemistry, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Fueyo, J., Department of Organic Chemistry, Laboratory of Pharmaceutical Chemistry, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; F-Masaguer, C., Department of Organic Chemistry, Laboratory of Pharmaceutical Chemistry, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; Vidal, A., Department of Organic Chemistry, Laboratory of Pharmaceutical Chemistry, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain; de Ceballos, M.L., Department of Neuropharmacology, Cajal Institute, CSIC, 28002 Madrid, Spain","Four new 2-(2-piperidinoethyl)benzocycloalkanone derivatives, 20–23, were prepared and evaluated as potential antipsychotic agents in receptor binding assays for dopamine (DA) and 5-HT2A receptors and in functional and behavioral screens. Their affinities for D2 receptors (Ki's in the nanomolar range: 46.7–70.7) and D1 receptors (Ki's in the micromolar range: 1.09–2.81) were slightly lower than that showed by haloperidol (Ki's in the nanomolar range: 5.01 and 97.72 for D2 and for D1 receptors, respectively). The ratio of pKi's values D1/D2 showed that the new molecules are more D2-selective than haloperidol. In contrast, in the [3H]-ketanserin binding assays the new compounds had greater affinity for 5-HT2A receptors (pKi's 7.89–8.60) than haloperidol (pKi 7.70) and in functional studies, endothelium-stripped aorta rings, the pA2 values (6.75–8.12) were slightly lower than that of ketanserin (8.87) in suppresing serotonin-induced contractions. The pKi's for D2 binding (and to a lesser extent pKi's for D1 binding) tend to be greater among typical (classical) than among atypical antipsychotics, while these two classes of antipsychotics exhibit no difference with regard to pKi's for 5-HT2A receptors. The ratios of pKi's for 5-HT2A/D2 receptors may be useful for rapid screening of new compounds, and its potential induction of extrapyramidal symptoms (ratio values &gt;1.12 were predictive of an atypical antipsychotic profile). The new molecules had a ratio value in the range 1.08–1.20, while haloperidol showed a ratio of 0.93. In the behavioral screening tests, the new molecules showed antagonist activity of amphetamine-inducing hyperactivity and apomorphineinduced climbing (predictive tests for antipsychotic activity). In the catalepsy test (predictive test for induction of extrapyramidal symptoms), the values obtained were in accordance with an atypical antipsychotic drugs profile. © 1994, American Chemical Society. All rights reserved.",,"2,3,4,5 tetrahydro 7,8 dihydroxy 1 phenyl 1h 3 benzazepine; 4 (4 fluorobenzoyl) 1 [2 (1,2,3,4 tetrahydro 1 oxo 2 naphthyl)ethyl]piperidine; 8 chloro 2,3,4,5 tetrahydro 3 methyl 5 phenyl 1h 3 benzazepin 7 ol hydrogen maleate; amphetamine; apomorphine; butyrophenone derivative; carboxymethylcellulose; cycloalkanone; dopamine 1 receptor; dopamine 2 receptor; haloperidol; ketanserin; methysergide; physostigmine; qf 0303b; qf 0307b; qf 0311b; qf 0313b; serotonin 2 receptor; spiperone; sulpiride; unclassified drug; animal experiment; animal tissue; article; controlled study; dose response; drug effect; drug formulation; drug screening; drug structure; drug synthesis; extrapyramidal symptom; female; male; manic depressive psychosis; mouse; nonhuman; rat; receptor affinity; schizophrenia; Amphetamine; Animal; Antipsychotic Agents; Aorta; Apomorphine; Butyrophenones; Comparative Study; Computer Simulation; Corpus Striatum; Frontal Lobe; Haloperidol; Ketanserin; Male; Models, Molecular; Motor Activity; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists; Support, Non-U.S. Gov't",,"2,3,4,5 tetrahydro 7,8 dihydroxy 1 phenyl 1h 3 benzazepine, 67287-49-4; 8 chloro 2,3,4,5 tetrahydro 3 methyl 5 phenyl 1h 3 benzazepin 7 ol hydrogen maleate, 87134-87-0; amphetamine, 1200-47-1, 139-10-6, 156-34-3, 2706-50-5, 300-62-9, 51-62-7, 60-13-9, 60-15-1; apomorphine, 314-19-2, 58-00-4; carboxymethylcellulose, 8050-38-2, 9000-11-7, 9004-32-4, 9050-04-8; haloperidol, 52-86-8; ketanserin, 74050-98-9; methysergide, 16509-15-2, 361-37-5, 62288-72-6; physostigmine, 57-47-6, 64-47-1; spiperone, 749-02-0; sulpiride, 15676-16-1; Amphetamine, 300-62-9; Antipsychotic Agents; Apomorphine, 58-00-4; Butyrophenones; Haloperidol, 52-86-8; Ketanserin, 74050-98-9; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists","qf 0303b; qf 0307b; qf 0311b; qf 0313b; sch 23390; skf 38393","merck; sigma",,,,,"Coward, D.M., Imperato, A., Urwyler, S., White, T.G., Biochemical and behavioural properties of clozapine (1989) Psychopharmacology, 99, pp. 6-12; Fitton, A., Heel, R.C., Clozapine (1990) Drugs, 40 (5), pp. 722-747. , A review of its pharmacological properties, and therapeutic use in schizophrenia; Meltzer, H.Y., Clozapine (1990) Recent Advances in Schizophrenia, pp. 237-256. , Mechanism of action in relation to its clinical advantages Kales, A., Stefanis, D. N., Talbott, J., Eds.; Springer-Verlag: New York; Seeman, R., Grigoriades, D., Niznik, H.B., Selectivity of agonists and antagonists at D-2 dopamine receptors compared to D-1 and S-2 receptors (1986) Drug. Dev. Res., 9, pp. 63-69; Seeman, R., Chou-Wong, M., Tadesco, J., Wong, K., Antipsychotic drug doses and neuroleptic/dopamine receptors (1976) Nature, 261, pp. 717-719; Seeman, P., Lee, T., Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons (1975) Science, 188, pp. 184-189; Iorio, L.C., Barnett, A., Leitz, F.H., Houser, V.P., Korduba, C.A.J., SCH23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems (1983) J. Pharmacol. Exp. Ther., 226, pp. 462-468; Clark, D., White, F.G., Review: Di dopamine receptor-the search for a function (1987) Synapse, 1, pp. 347-388; Morelli, M., Di Chiara, G., Catalepsy induced by SCH 23390 in rats (1985) Eur. J. Pharmacol., 117, pp. 179-185; Civelli, O., Bunzow, J.R., Grandy, D.K., Zhou, Q.Y., Van Tol, H.M.M., Molecular biology of the dopamine receptors (1991) Eur. J. Pharmacol., 207, pp. 277-286; Sibley, D.R., Monsma, F.J., Jr., Molecular biology of dopamine receptors (1992) Trends Pharmacol. Sci., 13, pp. 61-69; Gingrich, J.A., Caron, M.G., Recent advances in the molecular biology of dopamine receptors (1993) Annu. Rev. Neurosci., 16, pp. 299-321; Civelli, O., Bunzow, J.R., Grandy, D.K., Molecular diversity of the dopamine receptors (1993) Annu. Rev. Pharmacol. Toxicol., 32, pp. 281-307; Meltzer, H.Y., Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia (1989) Psychopharmacology, 99, pp. 18-27; Gelders, Y.G., Thymostenic agents (1989) Br. J. Psych., 155 (5), pp. 33-36. , A novel approach in the treatment of schizophrenia; Cortizo, L., Santana, L., Ravina, E., Orallo, F., Fontenla, J.A., Castro, E., Calleja, J.M., de Ceballos, M.L., Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogues of butyrophenone (1991) J. Med. Chem., 34, pp. 2242-2247; Loza, M., Verde, I., Castro, M.E., Orallo, F., Fontenla, J.A., Calleja, J.M., Ravina, E., de Ceballos, M., 5-HT2 antagonist activity of some 3-aminomethyltetralones (1991) Bioorg. Med. Chem. Lett., 1 (12), pp. 7171-7720; Boswell, R.F., Welstead, W.J., Duncan, R.C., Funderburk, W.H., [1-[3-Phenothiazin-10-yl-propyl]-4-piperidinyl phenylmethanones, a novel class of long-acting neuroleptic agents (1978) J. Med. Chem., 21, pp. 136-139; Herndon, J.L., Ismaiel, A., Ingher, S.P., Teitler, M., Glennon, R.A., Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HTic serotonin receptor binding (1992) J. Med. Chem., 35, pp. 4903-4910; Newman, M.S., Sagar, W.C., Cochrane, C.C., A new method for introducing a two carbon acid side chain into ketones (1958) J. Org. Chem., 23, pp. 1832-1835; Cignarella, G., Barlocco, D., Landriani, L., Folloni, M., Pinna, G.A., Sala, F., Germini, M., New congeners of antihypertensive and antithrombotic 7-amino or 7-acetyl-aminosubstituted-4,4adihydro-5H-indeno[1,2-c]pyridazin-3-ones (1988) II Farmaco. Ed. Sc., 43, pp. 169-179; Bachmann, W.E., Thomas, D.G., The synthesis of analogs of the sex hormones (1941) J. Am. Chem. Soc., 63, pp. 598-602. , An analog of equilenin lacking the phenolic A ring; Bachmann, W.E., Johnson, G.D., 3-ketohydrophenantrenes and 2-ketohydro-1,2-cyclopentenonaphthalenes (1949) J. Am. Chem. Soc., 72, pp. 3463-3467; Groves, L.H., Swan, G.A., A Synthesis of 1,2,3,4,8,10-hexahydro-2-ketocyclopent[a]indene (1951) J. Chem. Soc., pp. 867-872. , Indene series; Djerassi, C., Pettit, G.R., Herald, D.L., Sanson, D.R., Arylmagnesium bromide additions to tetralone-2-acetic acid followed by catalytic hydrogenolysis: stereochemical consequences (1991) J. Org. Chem., 56, pp. 5360-5368; Cignarella, G., Grella, G., Loriga, M., Curzu, M.M., Schiatti, G., Inatessa attivita antiiflamatoria di strutture rigida derivative da 6-arilpiridazinoni antiipertensive (1978) II Farmaco. Ed. Sc., 33, pp. 866-874. , Sintesi e attivita di 4,4adiidro-5H-indeno[1,2-c]piridazin-3-oni; Loza, M., G-Ferreiro, T., Sanz, F., Lozoya, E., Rodriguez, J., Manaut, F., Verde, I., Ravina, E., Antiserotoninergic activity of 2-aminoethylbenzocyclanones in rat aorta: structure activity relationships (1993) J. Pharm. Sci., 82 (5), pp. 513-517; Meltzer, H.Y., Matsubara, S., Lee, J.C., Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pK, values (1989) J. Pharmacol. Exp. Ther., 25 (2), pp. 238-251; Meltzer, H.Y., Matsubara, S., Lee, J.C., The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs (1989) Psychopharmacol. Bull., 25 (3), pp. 390-392; Ferris, R.M., Harfenist, M., McKenzie, G.M., Cooper, B., Soroko, F.E., Maxwell, R.A., BW 234U, (cis-9-[3-(3,5-dimethyl-1-piperazinyl) propyl]carbazole dihydrochloride): a novel antipsychotic agent (1982) J. Pharm. Pharmacol., 34, pp. 388-390; Hyttel, J., Arnt, J., Berghe, M.V.D., Selective dopamine D1 and D2 receptor antagonist (1989) Clinical Pharmacology in Psychiatry, pp. 109-122. , Dahl, S. G., Gram, L. F., Eds.; Springer-Verlag: Berlin; Arnt, J., Christensen, A.V., Hyttel, J., Differential reversal by scopolamine of effects of neuroleptics in rats (1981) Neuropharmacology, 20, pp. 1331-1334. , Relevance for evaluation of therapeutic and extrapyramidal side effect potential; Bruhwyler, J., Chleide, E., Mercier, M., Clozapine: An atypical neuroleptic (1990) Neurosci. Biobehav. Rev., 14 (4), pp. 357-363; Reynols, G.P., Developments in the drug treatment of schizophrenia (1992) Trends Pharmacol. Sci., 31, pp. 116-121; Perregaard, J., Arnt, J., Bogeso, K.P., Hyttel, J., Sanchez, C., Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles (1992) J. Med. Chem., 35, pp. 1092-1101; Maitre, M., Hechler, V., Vayer, P., Gobaille, S., Cash, C.D., Schmitt, M., Bourguignon, J.J., A specific 9-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsivant properties (1990) J. Pharmacol. Exp. Ther., 225, pp. 657-663; Hardegger, B., Shatzmiller, S., Synthesis with 1,2-oxazines I. Synthesis of 4,5-dihydro-6H-1,2-oxazin-6-one derivatives (1976) Helv. Chim. Acta, 59, pp. 2499-2502; Barlocco, D., Pinna, G.A., Carboni, L., Cipolla, P., Synthesis and pharmacological study of 4,4a,5,6-tetrahydro-4a-substitutedbenzo[h]cinnolin-3(2H)ones (1989) II Farmaco, 44, pp. 967-974; Protais, P., Costentin, J., Schwartz, J.C., Climbing behavior induced by apomorphine in mice: A simple test for the study of dopamine receptors in striatum (1976) Psychopharmacology, 50, pp. 1-6; Van Rossum, J.M., Cumulative dose-response curves III. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters (1963) Arch. Int. Pharmacodyn., 143, pp. 299-330; Tallarida, R.J., Murray, R.B., (1987) Manual of Pharmacologic calculations with computer programs, , 2th ed.; Tallarida, R. J., Ed.; Springer-Verlag: New York; Cheng, Y.C., Prusoff, W., Relationship between the inhibition constant (Ki) and the concentration of inhibitor which caused 50 per cent inhibition (IC50) of an enzymatic reaction (1973) Biochem. Pharmacol., 22, pp. 3099-3108; Dawar, M.J.S., Zoebish, E.G., Healy, E.F., Stewart, J.J.P., AM1: a new general purpose quantum mechanical molecular model (1985) J. Am. Chem. Soc., 107, pp. 3902-3909; Stewart, J.J.P., MOPAC: a semiempirical molecular orbital program (1990) J. Comput.-Aided Mol. Des., 4, pp. 1-105","Fontenla, J.A.; Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain",,,,,,,,00222623,,,"7914540","English","J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-0028040921
"Pulido M., González J.C., Sanz F.","7006383312;57195757144;7102263897;","Original articles published in Medicina Clínica during 30 years (1962-1992): number of authors, interval between acceptance and publication and bibliographic references [Artículos originales publicados en Medicina Clínica durante 30 años (1962-1992): número de autores, intervalo entre la aceptación y publicación y referencias bibliográficas.]",1994,"Medicina clínica","103","20",,"770","775",,26,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028770738&partnerID=40&md5=3bfad5f4c7dd0d9395afe57c26c6255e","Unidad de Edición Médica, Universidad Autónoma de Barcelona., Spain","Pulido, M., Unidad de Edición Médica, Universidad Autónoma de Barcelona., Spain; González, J.C., Unidad de Edición Médica, Universidad Autónoma de Barcelona., Spain; Sanz, F., Unidad de Edición Médica, Universidad Autónoma de Barcelona., Spain","BACKGROUND: To study different aspects of original articles published in Medicina Clínica (Barcelona) over a 30-year period (1962-1992), with special emphasis on references. METHODS: We selected 12 articles per year at 5-year intervals (1962, 1967, 1972, 1977, 1982, 1987, 1992) using a systematic sampling procedure. The following variables were assessed: number of authors, interval between acceptance of the manuscript and publication in the journal, total number of references, language, document type, and name of the journal. RESULTS: The mean (+/- standard deviation) number of authors showed a statistically significant increase (ANOVA; F = 13.666; p = 0.0001) from 1.83 +/- 0.71 in 1962 to 6.41 +/- 1.97 in 1992. The interval between acceptance and publication decreased from 315.72 +/- 20.48 days in 1982 to 206.16 +/- 89.23 in 1992 (ANOVA, F = 6.074; p = 0.0058). A total of 1816 references were found (24.2 references per article). English was the language of publication most commonly found (76.76%) followed by Spanish (12.6%). There was a statistically significant increase in the use of references corresponding to English articles over the study period (chi 2 = 314.431; p = 0.0001). A significant change was also observed in the type of document use (chi 2 = 143.996; p = 0.0001); references from journals increased from 73.51% in 1962 to 91.40% in 1992. In addition, 50.46% of the articles were published in only 7.84% of the journals. Eight journals devoted to internal medicine (1.79% of all journals) included 23.46% of the references. CONCLUSIONS: The number of authors has shown a significant increase during the study period. The time elapsed between acceptance and publication has decreased significantly. Spanish authors acquired information mostly from the English literature. Articles published in journals are also mostly used as references. A large percentage of references consisted of articles published in core general journals. These journals accumulate a remarkable percentage of the information.",,"article; clinical medicine; comparative study; publication; publishing; Spain; writing; Authorship; Bibliography; Clinical Medicine; Periodicals; Publishing; Spain; Writing",,,,,,,,,,"Pulido, M.",,,,,,,,00257753,,,"7861835","Spanish","Med Clin (Barc)",Article,"Final",,Scopus,2-s2.0-0028770738
"Sanz F., López‐de‐Briñas E., Rodríguez J., Manaut F.","7102263897;7801401158;57199093141;6602255071;","Theoretical Study on the Metabolism of Caffeine by Cytochrome P‐450 1A2 and its Inhibition",1994,"Quantitative Structure‐Activity Relationships","13","3",,"281","284",,25,"10.1002/qsar.19940130305","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028007232&doi=10.1002%2fqsar.19940130305&partnerID=40&md5=a4038932639c6d023637ba027c1d7714","Departamento d'Informàtica Mèdica, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Barcelona, E-08003, Spain","Sanz, F., Departamento d'Informàtica Mèdica, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Barcelona, E-08003, Spain; López‐de‐Briñas, E., Departamento d'Informàtica Mèdica, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Barcelona, E-08003, Spain; Rodríguez, J., Departamento d'Informàtica Mèdica, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Barcelona, E-08003, Spain; Manaut, F., Departamento d'Informàtica Mèdica, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Barcelona, E-08003, Spain","The primary metabolism of caffeine (1,3,7‐trimethylxanthine) is catalyzed by the isozyme P‐450 1A2 which has toxicological relevance because it is involved in the activation of some chemicals to carcinogenic compounds. A theoretical model for the demethylation of caffeine is proposed by means of the study of the molecular electrostatic potential (MEP) distributions of caffeine and other xanthine derivatives that are inhibitors of this metabolic process. Negative zones of these distributions show a common triangular pattern in the xanthine plane. The model proposes that the alignment of the caffeine molecule in the active site is determined by these negative MEP zones. An interesting finding was that all the methyl groups to be removed have at least a MEP minimum at a distance of approximately 3 Å. This feature would explain the preference for the N3 demethylation leading to paraxanthine (1,7‐dimethylxanthine) because only this methyl group is placed at a distance of 3 Å from the deepest MEP minimum. Another experimental observation consistent with the proposed model is the inhibition of caffeine demethylation by several 8‐methylxanthines. Among them, 1,3,8‐trimethylxanthine, furafylline (1,8‐dimethyl‐3‐(2‐furfuryl)xanthine) and 1,8‐dimethyl‐3‐phenylxanthine were considered in the present study. The inhibition is explained by the fact that all these compounds have a methyl on C8 placed at a distance of 3 Å from the deepest MEP minimum. Copyright © 1994 WILEY‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim","Caffeine; cytochrome P‐450 1A2; furafylline; metabolism; molecular electrostatic potential (MEP); xanthine","caffeine; cytochrome p450; furafylline; paraxanthine; xanthine derivative; article; carcinogenesis; chemical structure; demethylation; electric potential; enzyme active site; metabolic inhibition; metabolism; molecular model; priority journal; toxicology",,"caffeine, 30388-07-9, 58-08-2; cytochrome P450, 9035-51-2; furafylline, 80288-49-9; paraxanthine, 611-59-6",,,,,,,"Grant, D.M., Campbell, M.E., Tang, B.K., Kallow, W., (1987) Biochem. Pharmacol., 36, pp. 1251-1260; Campbell, M.E., Grant, D.M., Inaba, T., Kalow, W., (1987) Drug Metab. Dispos., 15, pp. 237-249; Berthou, F., Flinois, J.‐P., Ratanasavanh, D., Beaune, P., Riche, C., Guillouzo, A., (1991) Drug Metab. Dispos., 19, pp. 561-567; Fuhr, U., Doehmer, J., Battula, N., Wolfel, C., Kudla, C., Keita, Y., Staib, A.H., (1992) Biochem. Pharmacol., 43, pp. 225-235; Renner, E., Wietholtz, H., Huguenin, P., Arnaud, M.J., Preisig, R., (1984) Hepatology, 4, pp. 38-46; Kalow, W., Tang, B.‐K., (1991) Clin. Pharmacol. Ther., 49, pp. 44-48; Beaune, P.H., Guengerich, P., (1988) Pharmacol. Therapeut., 37, pp. 193-211; Shimada, T., Iwasaki, M., Martin, M.V., Guengerich, F.P., (1989) Cancer Res., 49, pp. 3218-3228; Guengerich, F.P., Shimada, T., (1991) Chem. Res. Toxicol., 4, pp. 391-407; Gonzalez, F.J., (1992) Trends Pharmacol. Sci., 13, pp. 346-352; Loew, G.H., Collins, J., Luke, B., Waleh, A., Pudzianowski, A., (1986) Enzyme, 36, pp. 54-78; Collins, J.R., Loew, G.H., (1986) J. Biol. Chem., 263, pp. 3164-3170; Poulos, T.L., (1989) Nature, 339, pp. 580-581; Lewis, D.F.V., Moereels, H., (1992) J. Comp.‐Aided Mol. Design, 6, pp. 235-252; Weinstein, H., Osman, R., (1990) Neuropsychopharmacology, 3, pp. 397-409; Manaut, F., Lozoya, E., Sanz, F., (1991) Automatic Determination of Maximum Electrostatic Alignement between Methotrexate and Dihydrofolic Acid, pp. 339-342. , Silipo C., Vittoria, A., Elsevier, Amsterdam; van der Waterbeemd, H., Carrupt, P.‐A., Testa, B., Molecular electrostatic potential of orthopramides: implications for their interaction with the D-2 dopamine receptor (1986) Journal of Medicinal Chemistry, 29, pp. 600-606; Osman, R., Topiol, S., Rubenstein, L., Weinstein, H., (1987) Mol. Pharmacol., 32, pp. 699-705; Orozco, M., Canela, E.I., Franco, R., (1989) Mol. Pharmacol., 35, pp. 257-264; Richards, N.G.J., Vinter, J.G., (1991) J. Comp‐Aided Mol. Design, 5, pp. 1-3; Murray, J.S., Brinck, T., Grice, E., Politzer, P., (1992) J. Mol. Struct. (Theochem), 256, pp. 29-45; Sanz, F., Manaut, F., José, J., Segura, J., Carbö, M., Torre, R., (1988) J. Mol. Struct. (Theochem), 170, pp. 171-180. , and De la; Fuhr, U., Strobl, G., Manaut, F., Anders, E.‐M., Sörgel, F., López‐de‐Briñas, E., Chu, D.T.W., Staib, H., (1993) J. Mol. Pharmacol., 43, pp. 191-199; Segura, J., Roberts, D.J., Tarrüs, E., (1988) J. Pharm. Pharmacol., 47, pp. 129-131; Revision, H., Frisch, M.J., Head‐Gordon, M., Trucks, G.W., Foresman, J.B., Schlegel, H.B., Raghavachari, K., Pople, J.A., (1990), Gaussian 90, Gaussian, Inc., Pittsburgh PA; Sanz, F., Manaut, F., Rodríguez, J., Lozoya, E., López‐de‐Briñas, E., (1993) J. Comput.‐Aided Mol. Design, 7, pp. 337-347; Campwell, M.E., Grant, D.M., Inaba, T., Kalow, K., (1987) Drug Metab. Dispos., 15, pp. 237-249","Sanz, F.; Departamento d'Informàtica Mèdica, Institut Municipal d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, Barcelona, E-08003, Spain",,,,,,,,09318771,,,,"English","Quant. Struct.-Act. Relatsh.",Article,"Final",,Scopus,2-s2.0-0028007232
"Hernandez C., Sancho J.J., Belmonte M.A., Sierra C., Sanz F.","24294258800;7201937083;7005530979;7006398334;7102263897;","Validation of the medical expert system RENOIR",1994,"Computers and Biomedical Research","27","6",,"456","471",,14,"10.1006/cbmr.1994.1034","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028631911&doi=10.1006%2fcbmr.1994.1034&partnerID=40&md5=7c7b5bab56bc6a8da836151cd4ebc7e0","Departament d’Informàtica Mèdica, Institut Municipal d’Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Unitat de Reumatologia, Hospital General de Castelló, Castelló de la Plana, Spain; Institut d’Investigacióen Intel-ligència Artificial (IIIA-CSIC), Blanes (Girona), Spain; Departament d’Informàtica Mèdica, Institut Municipal d’Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, C/Dr. Aiguader 80, E-08003 Barcelona, Spain","Hernandez, C., Departament d’Informàtica Mèdica, Institut Municipal d’Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Sancho, J.J., Departament d’Informàtica Mèdica, Institut Municipal d’Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, C/Dr. Aiguader 80, E-08003 Barcelona, Spain; Belmonte, M.A., Unitat de Reumatologia, Hospital General de Castelló, Castelló de la Plana, Spain; Sierra, C., Institut d’Investigacióen Intel-ligència Artificial (IIIA-CSIC), Blanes (Girona), Spain; Sanz, F., Departament d’Informàtica Mèdica, Institut Municipal d’Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, C/Dr. Aiguader 80, E-08003 Barcelona, Spain, Departament d’Informàtica Mèdica, Institut Municipal d’Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona, C/Dr. Aiguader 80, E-08003 Barcelona, Spain","RENOIR is an expert system developed to assist the diagnosis of 37 diseases of connective tissue and inflammatory arthropathies. Precise diagnosis of rheumatic diseases implies great uncertainty and there is no gold standard with which to comparethe expert system output. To overcome this problem a set of clinical cases was submitted to RENOIR andits diagnoses were compared with those of clinicians. Medical records or 81 patients with rheumatic diseases were interpreted by RENOIR and by 12 clinicians at three different expertise levels in rheumatology. Distances between the likelihoods of the 37 considered diseases provided by clinicians and RENOIR were computed as a disagreement measure. Mahalanobis distance was used to correct the collinearity between the possibilities of each pair of diseases. Using the resulting matrices of distances between experts, cluster analyses were carried out to classify RENOIR among human experts. Greater differences between RENOIR and clinicians than among clinicians themselves were not found. © 1994 by Academic Press, Inc.",,"arthropathy; article; computer; connective tissue disease; controlled study; expert system; human; inflammatory disease; medical expert; medical information; priority journal; quality control; Cluster Analysis; Diagnosis, Computer-Assisted; Expert Systems; Human; Reproducibility of Results; Rheumatic Diseases; Software Validation",,,,,,,,,"Miller, P.L., Evaluation of artificial intelligence systems in medicine (1986) Comput. Methods Prog. Biomed, 22, p. 5; Nykánen, P., Chowdhury, S., Wigertz, O., Evaluation of decision support systems in medicine (1991) Comput. Methods Prog. Biomed, 34, p. 229; Indurlhya, N., Weiss, S.M., Model for measuring performance of medicai expert systems (1989) Artif. Intel. Med, 1, p. 61; Lawrence, C., Evaluation of medical expert systems: Experience with the AI/RHEUM knowledge-based consultant system in rheumatology (1988) Selected Topics in Medical Artificial Intelligence, , (P. L. Miller, Ed.). Springer-Verlag, New York; Verdaguer, A., Patak, A., Sancho, J.J., Sierra, C., Sanz, F., Validation of the medical expert system PNEUMON-IA (1992) Comput. Biomed. Res, 25, p. 511; Belmonte, M.A., (1991) RENOIR: Un sistema experto paralaayudaeneldiagnosticode colagenosis y artropatias inflamatorias, , Doctoral thesis. Universität Autònoma de Barcelona, Barcelona; Porter, J.F., Kingsland, L.C., Lindberg, D.A., The AI/RHEUM knowledge-based computer consultant system in rheumatology: Performance in the diagnosis of 59 connective tissue disease patients from Japan (1988) Arthritis Rheum, 31, p. 219; Rodriguez De La Serna, A., Blanch, J., Benito, P., (1990) Temas Actuales de Reumatologia, , ESPAXS Publicaciones Medicas, Barcelona; Szolovits, P., Patil, R.S., Schwartz, W.B., Artificial intelligence in medical diagnosis (1988) Ann. Intern. Med, 108, p. 80; Arnett, F.C., Edworthy, S.M., Bloch, D.A., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis (1988) Arthritis Rheum, 31, p. 315; Edwards, J.C.W., Diagnostic categories in rheumatology (1987) Ann. Rheum, 46, p. 259; Fries, J.F., Hunder, G.G., Bloch, D.A., The American College of Rheumatology 1990 criteria for the classification of vasculitis (1990) Arthritis Rheum, 33, p. 1035; Godo, L.L., Mantaras, L.R., Sierra, C., Verdaguer, A., Managing linguistically expressed uncertainty in MILORD application to medical diagnosis (1988) Artif. Intel. Commun, 1, p. 14; Godo, L.L., Mantaras, L.R., Sierra, C., Verdaguer, A., MILORD The architecture and management of linguistically expressed uncertainty (1989) Int. J. Intel. Sys, 4, p. 471; Engle, R.L., Flehinger, B.J., Why expert systems for medical diagnosis are not being generally used: A valedictory opinion (1987) Bull. N.Y. Acad. Med, 63, p. 193; Quaglini, S., Stefanelli, M., Barosi, G., Berzuini, A., A performance evaluation of the expert system ANEMIA (1988) Comput. Biomed. Res, 21, p. 307; Yu, V.L., Fagan, L., Bennet, S.W., Clancey, W.J., Scott, A.C., Hannigan, J.F., Buchnan, B.G., Cohen, S.N., An evaluation of MYCIN’s advice (1984) Rule-Based Expert Systems: The MYCIN Experiments of the Stanford Heuristic Programming Project, pp. 589-596. , (B. G. Buchanan and S. N. Cohen, Eds.), Addison-Wesley, Reading, MA; Aikins, J.S., Kunz, J.C., Shortliffe, E.H., Fallat, R.J., Puff: An expert system for interpretation of pulmonary function data (1983) Comput. Biomed. Res, 16, p. 199; Norusis, M.J., (1985) SPSSx Advanced Statistics Guide, , SPSS, Chicago; Vogt, W., Nagel, D., Sator, H., (1987) Cluster Analysis in Clinical Chemistry, , Wiley, New York; McLachlan, G.J., Cluster analysis and related techniques in medical research (1992) Stat. Methods Med. Res, 1, p. 27; Suttton, G.C., How accurate is computer-aided diagnosis? (1989) Lancet, 2, p. 14; Berner, E.S., Webster, G.D., Shugerman, A.A., Performance of four computer-based diagnostic systems (1994) N. Engl. J. Med, 330, p. 1792; Bernelotmoens, H.J., Van Derkorst, J.K., Computer-assisted diagnosis of rheumatic disorders (1991) Semin. Arthritis Rheum, p. 21; Bernelot Moens, H.J., Van Derkorst, J.K., Comparison of rheumatological diagnoses by Bayesian program and by physicians (1991) Methods Inf. Med, 302, p. 935",,,,,,,,,00104809,,,"7895473","English","Comput. Biomed. Res.",Article,"Final",,Scopus,2-s2.0-0028631911
"Sanz F., Manaut F., Rodríguez J., Lozoya E., López-de-Briñas E.","7102263897;6602255071;24773509500;6603260860;7801401158;","MEPSIM: A computational package for analysis and comparison of molecular electrostatic potentials",1993,"Journal of Computer-Aided Molecular Design","7","3",,"337","347",,49,"10.1007/BF00125507","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027615743&doi=10.1007%2fBF00125507&partnerID=40&md5=3bd3a23dc546df77193caa58bc407724","Facultat de Medicina (U.A.B.), Institut Municipal d'Investigació Mèdica, Passeig Marítim 25, Barcelona, E-08003, Spain; Departamento de Química Física, Facultade de Química, Universidade de Santiago, Santiago de Compostela, E-15706, Galicia, Spain","Sanz, F., Facultat de Medicina (U.A.B.), Institut Municipal d'Investigació Mèdica, Passeig Marítim 25, Barcelona, E-08003, Spain; Manaut, F., Facultat de Medicina (U.A.B.), Institut Municipal d'Investigació Mèdica, Passeig Marítim 25, Barcelona, E-08003, Spain; Rodríguez, J., Facultat de Medicina (U.A.B.), Institut Municipal d'Investigació Mèdica, Passeig Marítim 25, Barcelona, E-08003, Spain, Departamento de Química Física, Facultade de Química, Universidade de Santiago, Santiago de Compostela, E-15706, Galicia, Spain; Lozoya, E., Facultat de Medicina (U.A.B.), Institut Municipal d'Investigació Mèdica, Passeig Marítim 25, Barcelona, E-08003, Spain; López-de-Briñas, E., Facultat de Medicina (U.A.B.), Institut Municipal d'Investigació Mèdica, Passeig Marítim 25, Barcelona, E-08003, Spain","MEPSIM is a computational system which allows an integrated computation, analysis, and comparison of molecular electrostatic potential (MEP) distributions. It includes several modules. Module MEPPLA supplies MEP values for the points of a grid defined on a plane which is specified by a set of three points. The results of this program can easily be converted into MEP maps using third-parties graphical software. Module MEPMIN allows to find automatically the MEP minima of a molecular system. It supplies the cartesian coordinates of these minima, their values, and all the geometrical relationships between them (distances, angles, and dihedral angles). Module MEPCOMP computes a similarity coefficient between the MEP distributions of two molecules and finds their relative position that maximizes the similarity. Module MEPCONF performs the same process as MEPCOMP, considering not only the relative position of both molecules but also a conformational degree of freedom of one of them. The most recently developed module, MEPPAR, is another modification of MEPCOMP in order to compute the MEP similarity between two molecules, but only taking into account a particular plane. The latter module is particularly useful to compare MEP distributions generated by π systems of aromatic rings. MEPSIM can use several wavefunction computation approaches to obtain MEP distributions. MEPSIM has a menu type interface to simplify the following tasks: creation of input files from output files of external programs (GAUSSIAN and AMPAC/MOPAC), setting the parameters for the current computation, and submitting jobs to the batch queues of the computer. MEPSIM has been coded in FORTRAN and its current version runs on VMS/VAX computers. © 1993 ESCOM Science Publishers B.V.","Computational chemistry software; Molecular alignment; Molecular electrostatic potential; Molecular similarity; Spearman coefficient","article; chemical structure; comparative study; computer program; drug design; electrochemistry; Comparative Study; Drug Design; Electrochemistry; Molecular Structure; Software; Support, Non-U.S. Gov't",,,,,,,,,"Weinstein, H., Osman, R., (1989) Computer-Aided Molecular Design, pp. 105-118. , W.G., Richards, IBC Technical Services, London; Richards, N.G.J., Vinter, J.G., (1991) J. Comput.-Aided Mol. Design, 5, p. 1; Orozco, M., Canela, E.I., Franco, R., (1989) Mol. Pharmacol., 35, p. 257; Sanz, F., Manaut, F., José, J., Segura, J., Carbó, M., de la Torre, R., (1988) J. Mol. Struct. (Theochem), 170, p. 171; Manaut, F., Lozoya, E., Sanz, F., (1991) QSAR: Rational Approaches to the Design of Bioactive Compounds, pp. 339-342. , C., Silipo, A., Vitoria, Elsevier, Amsterdam; Manaut, F., Sanz, F., José, J., Milesi, M., (1991) J. Comput.-Aided Mol. Design, 5, p. 371; Sanz, F., Manaut, F., Sánchez, J.A., Lozoya, E., (1991) J. Mol. Struct. (Theochem), 230, p. 437; Sanz, F., Manaut, F., Dot, T., López de Briñas, E., (1992) J. Mol. Struct. (Theochem), 256, p. 287; Weinstein, H., Osman, R., Green, J.P., Topiol, S., (1981) Chemical Applications of Atomic and Molecular Electrostatic Potentials, pp. 309-324. , P., Politzer, D.G., Truhlar, Plenum Press, New York","Sanz, F.; Facultat de Medicina (U.A.B.), Institut Municipal d'Investigació Mèdica, Passeig Marítim 25, Barcelona, E-08003, Spain",,,"Kluwer Academic Publishers",,,,,0920654X,,JCADE,"8377028","English","J Computer-Aided Mol Des",Article,"Final",,Scopus,2-s2.0-0027615743
"Rodríguez J., Manaut F., Sanz F.","24773509500;6602255071;7102263897;","Quantitative comparison of molecular electrostatic potential distributions from several semiempirical and ab initio wave functions",1993,"Journal of Computational Chemistry","14","8",,"922","927",,29,"10.1002/jcc.540140807","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0001764290&doi=10.1002%2fjcc.540140807&partnerID=40&md5=f39380ba568ff200f2fcd25a599d323c","Medical Informatics Department, Institut Municipal d'Investigació Mèdica, Universitat Autònoma de Barcelona, Doctor Aiguader 80, Barcelona, E-08003, Spain; Departamento de Química Física, Facultade de Química, Universidade de Santiago, Santiago de Compostela, Galicia, E-15706, Spain","Rodríguez, J., Medical Informatics Department, Institut Municipal d'Investigació Mèdica, Universitat Autònoma de Barcelona, Doctor Aiguader 80, Barcelona, E-08003, Spain, Departamento de Química Física, Facultade de Química, Universidade de Santiago, Santiago de Compostela, Galicia, E-15706, Spain; Manaut, F., Medical Informatics Department, Institut Municipal d'Investigació Mèdica, Universitat Autònoma de Barcelona, Doctor Aiguader 80, Barcelona, E-08003, Spain; Sanz, F., Medical Informatics Department, Institut Municipal d'Investigació Mèdica, Universitat Autònoma de Barcelona, Doctor Aiguader 80, Barcelona, E-08003, Spain","A quantitative comparative analysis of molecular electrostatic potential (MEP) distributions generated from different wave functions was carried out. Wave functions were computed by using MNDO, AMl, STO‐3G, 3‐21G, 4‐31G, 6‐31G, 4‐31G*, 6‐31G*, and 6‐31G** methods. Ten different compounds, which include usual atoms and groups of biomolecules, such as hydroxyl, carbonyl, amine, amide, imine, double and triple bonds, and heteroaromatic rings, were studied. For each compound, MEP values in the points of a common 3‐D grid were computed; thereafter, the similarity between each pair of MEP distributions generated by different methods was assessed. Similarities were measured using the Spearman rank correlation coefficient. A similarity matrix was obtained for each compound. Similarity matrices were averaged and a hierarchical cluster analysis was carried out to classify the different quantum chemical methods. In the compounds studied, the main conclusion is the negligible difference between the pattern of MEP distributions generated from all split valence basis sets (with and without polarization functions). © 1993 John Wiley & Sons, Inc. Copyright © 1993 John Wiley & Sons, Inc.",,"Carbonyl compounds; Chemical analysis; Chemical bonds; Cluster analysis; Electrostatics; Hierarchical systems; Molecular interactions; Quantum chemistry; Comparative analysis; Hierarchical cluster analysis; Molecular electrostatic potential distributions; Polarization functions; Quantitative comparison; Quantum-chemical methods; Spearman rank correlation; Valence basis sets; Wave functions",,,,,,,,,"Weinstein, H., Osman, R., (1989) Computer‐Aided Molecular Design, pp. 105-118. , W.G. Richards, IBC Technical Services, London; Richards, N.G.J., Vinter, J.G., (1991) J. Comp Aided Mol. Design, 5, p. 1; Orozco, M., Canela, E.I., Franco, R., (1989) Mol. Pharmacol., 35, p. 257; van der Waterbeemd, H., Carrupt, P.A., Testa, B., Molecular electrostatic potential of orthopramides: implications for their interaction with the D-2 dopamine receptor (1986) Journal of Medicinal Chemistry, 29, p. 600; Luque, F.J., Sanz, F., Illas, F., Pouplana, R., Smeyers, Y.G., (1988) Eur. J. Med. Chem., 23, p. 7; Martin, M., Sanz, F., Campillo, M., Pardo, L., Pérez, J., Turmó, J., Quantum chemical study of the molecular patterns of MAO inhibitors and substrates (1983) International Journal of Quantum Chemistry, 23, p. 1627; Manaut, F., Lozoya, E., Sanz, F., (1991) QSAR: Rational Approaches to the Design of Bioactive Compounds, pp. 339-342. , C. Silipo, A. Vitoria, Elsevier, Amsterdam; Sanz, F., Manaut, F., José, J., Segura, J., Carb, M., de la Torre, R., (1988) J. Mol. Struct. (THEOCHEM), 170, p. 171. , ó, and; Manaut, F., Sanz, F., José, J., Milesi, (1991) J. Comp Aided Mol. Design, 5, p. 371; Sanz, F., Manaut, F., Sanchez, J.A., Lozoya, E., (1991) J. Mol. Struct. (THEOCHEM), 230, p. 437; Sanz, F., Manaut, F., Dot, T., López de Briñas, E., J. Mol. Struct. (THEOCHEM); Luque, F.J., Illas, F., Orozco, M., Comparative study of the molecular electrostatic potential obtained from different wavefunctions. Reliability of the semiempirical MNDO wavefunction (1990) Journal of Computational Chemistry, 11, p. 416; Dewar, M.J.S., Thiel, W., (1977) J. Am. Chem. Soc., 99, p. 4899; Dewar, M.J.S., Zoebisch, E.G., Healy, E.F., Stewart, J.J.P., (1985) J. Am. Chem. Soc., 107, p. 3902; Hehre, W.J., Stewart, R.F., Pople, J.A., (1969) J. Chem. Phys., 51, p. 2657; Binkley, J.S., Pople, J.A., Hehre, W.J., (1980) J. Am. Chem. Soc., 102, p. 939; Ditchfield, R., Hehre, W.J., Pople, J.A., Self-Consistent Molecular-Orbital Methods. IX. An Extended Gaussian-Type Basis for Molecular-Orbital Studies of Organic Molecules (1971) The Journal of Chemical Physics, 54, p. 724; Hehre, W.J., Ditchfield, R., Pople, J.A., (1972) J. Chem. Phys., 56, p. 2257; Hariharan, P.C., Pople, J.A., (1973) Theor. Chim. Acta, 28, p. 213; Stewart, J.J.P., MOPAC, QCPE 455; Frisch, M.J., Binkley, J.S., Schlegel, H.B., Raghavachari, K., Melius, C.F., Martin, R.L., Stewart, J.J.P., Pople, J.A., (1984), Gaussian 86, Carnegie‐Mellon Quantum Chemistry Publishing Unit, Pittsburgh, PA; Löwdin, P.O., (1970) J. Chem. Phys., 56, p. 365; Luque, F.J., Orozco, M., (1990) Chem. Phys. Lett., 168, p. 269; Orozco, M., Luque, F.J., On the use of AM1 and MNDO wave functions to compute accurate electrostatic charges (1990) Journal of Computational Chemistry, 11, p. 909; Giessner‐Pettre, C., Pullman, A., Molecular electrostatic potentials: Comparison of ab initio and CNDO results (1972) Theoretica Chimica Acta, 25, p. 83; Culberson, J.C., Zerner, M.C., (1985) Chem. Phys. Lett., 122, p. 436; Duben, A.J., (1981) Theor. Chim. Acta, 59, p. 81","Sanz, F.; Medical Informatics Department, Institut Municipal d'Investigació Mèdica, Universitat Autònoma de Barcelona, Doctor Aiguader 80, Barcelona, E-08003, Spain",,,,,,,,01928651,,,,"English","J. Comput. Chem.",Article,"Final",,Scopus,2-s2.0-0001764290
"SANCHO J.J., GONZÁLEZ J.C., PATAK A., SANZ F., SITGES‐SERRA A.","7201937083;57195757144;6602985248;7102263897;7007049436;","Introducing medical students to medical informatics",1993,"Medical Education","27","6",,"479","483",,11,"10.1111/j.1365-2923.1993.tb00307.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027137211&doi=10.1111%2fj.1365-2923.1993.tb00307.x&partnerID=40&md5=87642737bc2392994ac5eac66e54881d","Departament d'Informàtica Médica i Docència, Institut Municipal d'Investigació Mèdica, Facultat de Medicina, Universitat Autónoma de Barcelona; Departament de Cirurgia, Hospital Universitari del Mar, Facultat de Medicina, Universitat Autónoma de Barcelona, Spain","SANCHO, J.J., Departament d'Informàtica Médica i Docència, Institut Municipal d'Investigació Mèdica, Facultat de Medicina, Universitat Autónoma de Barcelona; GONZÁLEZ, J.C., Departament d'Informàtica Médica i Docència, Institut Municipal d'Investigació Mèdica, Facultat de Medicina, Universitat Autónoma de Barcelona; PATAK, A., Departament d'Informàtica Médica i Docència, Institut Municipal d'Investigació Mèdica, Facultat de Medicina, Universitat Autónoma de Barcelona; SANZ, F., Departament d'Informàtica Médica i Docència, Institut Municipal d'Investigació Mèdica, Facultat de Medicina, Universitat Autónoma de Barcelona; SITGES‐SERRA, A., Departament de Cirurgia, Hospital Universitari del Mar, Facultat de Medicina, Universitat Autónoma de Barcelona, Spain","Summary. Medical informatics (MI) has been introduced to medical students in several countries. Before outlining a course plan it was necessary to conduct a survey on students' computer literacy. A questionnaire was designed for students, focusing on knowledge and previous computer experience. The questions reproduced a similar questionnaire submitted to medical students from North Carolina University in Chapel Hill (NCU). From the results it is clear that although almost 80% of students used computers, less than 30% used general purpose applications, and utilization of computer‐aided search of databases or use in the laboratory was exceptional. Men reported more computer experience than women in each area investigated by our questionnaire but this did not appear to be related to academic performance, age or course. Our main objectives when planning an MI course were to give students a general overview of the medical applications of computers and instruct them in the use of computers in future medical practice. As our medical school uses both Apple Macintosh and IBM compatibles, we decided to provide students with basic knowledge of both. The programme was structured with a mix of theoretico‐practical lectures and personalized practical sessions in the computer laboratory. As well as providing a basic overview of medical informatics, the course and computer laboratory were intended to encourage other areas of medicine to incorporate the computer into their teaching programmes. 1993 Blackwell Publishing","*education, medical, undergraduate; *medical informatics; questionnaires; Spain","academic achievement; article; computer system; data base; information science; medical education; medical student; questionnaire; sex difference; teaching; united states; Computer Literacy; Curriculum; Education, Medical, Undergraduate; Female; Human; Male; Medical Informatics; Questionnaires; Spain; Students, Medical",,,,,,,,,"Clayden, G.S., Wilson, B., Computer‐assisted learning in medical education (1988) Medical Education, 22, pp. 456-457; Florey, Computer‐assisted learning in British medical schools (1988) Medical Education, 22, pp. 180-182; Greenes, R.A., Shortliffe, E.H., Medical informatics: an emerging academic discipline and institutional priority (1990) Journal of the American Medical Association, 263, pp. 1114-1120; Jones, R.A., Education in medical informatics in the undergraduate medical curriculum: a review (1990) Lecture Notes in Medical Informatics, pp. 422-429. , ed. by, O. Rienhoff, D.A.B. Lindberg, Springer‐Verlag, Berlin; Jones, R.A., Education in medical informatics in the undergraduate medical curriculum: a review (1990) Medical Informatics Europe '90, pp. 402-405. , ed. by, O. Moore, R. Bengtsson, J.R. Bryant, J.S. Bryden, Springer‐Verlag, Berlin","SANCHO, J.J.; Departament D'informàtica Mèdica I Docència, Institut Municipal D'investigació Mèdica, Dr Aigüader 80, Barcelona, 08003, Spain",,,,,,,,03080110,,,"8208154","English","Med. Educ.",Article,"Final",,Scopus,2-s2.0-0027137211
"Fuhr U., Strobl G., Manaut F., Anders E.-M., Sorgel F., Lopez-de-Brinas E., Chu D.T.W., Pernet A.G., Mahr G., Sanz F., Staib A.H.","56243453000;7004467063;6602255071;7005667753;7007170761;7801401158;7201734361;7004498378;7004620362;7102263897;7005757811;","Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2",1993,"Molecular Pharmacology","43","2",,"191","199",,92,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027452618&partnerID=40&md5=eb96f867698c475b69e5e3a16bdbdb30","Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany","Fuhr, U., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Strobl, G., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Manaut, F., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Anders, E.-M., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Sorgel, F., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Lopez-de-Brinas, E., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Chu, D.T.W., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Pernet, A.G., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Mahr, G., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Sanz, F., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany; Staib, A.H., Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany","The inhibitory effect of 44 quinolone antibacterials and derivatives (common structure, 4-oxoquinoline-3-carboxylic acid) on cytochrome P450 isoform CYP1A2 activity was tested using human liver microsomes and caffeine 3-demethylation as a specific test system for this enzyme. By direct comparison of molecules differing structurally in only one position, the following structure-activity relationships were found. 3'-Oxo derivatives had a reduced or similar activity and M1 metabolites (cleavage of piperazinyl substituent) had a greater inhibitory activity, compared with the parent molecule. Alkylation of the 7-piperazinyl substituent resulted in a reduced inhibitory potency. Naphthyridines with an unsubstituted piperazinyl group at position 7 displayed a greater inhibitory potency than did corresponding quinoline derivatives. Derivatives with a fluorine substitution at position 8 had only a minor effect. Molecular modeling studies with inhibitors and caffeine showed that it is possible to explain the potency of the quinolones to inhibit CYP1A2 on a molecular level. The keto group, the carboxylate group, and the core nitrogen at position 1 are likely to be the most important groups for binding to the active site of CYP1A2, because the molecular electrostatic potential of all inhibitors is very similar to that of caffeine in these regions. The presence of a piperazinyl substituent, however, seems to be no prerequisite for inhibitory potency. Finally, an equation to estimate the potency to inhibit CYP1A2 was developed by quantitative structure-activity relationship analysis.",,"6 cyclooctylamino 5,8 quinolinedione; 6 fluoro 1 (2 fluoroethyl) 1,4 dihydro 7 (4 methyl 1 piperazinyl) 4 oxo 3 quinolinecarboxylic acid; amifloxacin; antiinfective agent; caffeine; cinoxacin; ciprofloxacin; cytochrome p450 isoenzyme; difloxacin; enoxacin; enrofloxacin; fleroxacin; lomefloxacin; nalidixic acid; norfloxacin; ofloxacin; oxociprofloxacin; paraxanthine; pefloxacin; pipemidic acid; piromidic acid; proxyphylline; quinolone derivative; temafloxacin; antibacterial activity; article; demethylation; drug potency; enzyme activity; enzyme inhibition; human; human tissue; liver microsome; priority journal; structure activity relation; structure analysis; Anti-Infective Agents, Quinolone; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Human; In Vitro; Models, Chemical; Models, Molecular; Oxidoreductases, N-Demethylating; Protein Binding; Solubility; Structure-Activity Relationship",,"6 cyclooctylamino 5,8 quinolinedione, 35961-95-6; amifloxacin, 86393-37-5; caffeine, 30388-07-9, 58-08-2; cinoxacin, 28657-80-9; ciprofloxacin, 85721-33-1; difloxacin, 91296-86-5, 98106-17-3; enoxacin, 74011-58-8; enrofloxacin, 93106-60-6; fleroxacin, 79660-72-3; lomefloxacin, 98079-51-7; nalidixic acid, 389-08-2; norfloxacin, 70458-96-7; ofloxacin, 82419-36-1; oxociprofloxacin, 103237-52-1; paraxanthine, 611-59-6; pefloxacin, 70458-92-3; pipemidic acid, 51940-44-4; piromidic acid, 19562-30-2; proxyphylline, 603-00-9; temafloxacin, 105784-61-0, 108319-06-8; Anti-Infective Agents, Quinolone; Cytochrome P-450 CYP1A2, EC 1.14.14.1; Cytochrome P-450 Enzyme System, 9035-51-2; Oxidoreductases, N-Demethylating, EC 1.5.","am 735, kyorin pharmaceutical, Japan","abbott, United States; aldrich, United States; bayer, Germany; dainippon pharmaceutical, Japan; fluka, Switzerland; goedecke, Germany; hoechst, Germany; kyorin pharmaceutical, Japan; lilly, Germany; madaus pharmaceuticals, Germany; merck sharp and dohme, United States; rhone poulenc, France; searle, Germany; serva, Germany; winthrop, Germany",,,,,,"Fuhr, U.; Department of Clinical Pharmacology, University Hospital Frankfurt, Theodor-Stern-Kai 7, 6000 Frankfurt/Main 70, Germany",,,,,,,,0026895X,,MOPMA,"8429824","English","MOL. PHARMACOL.",Article,"Final",,Scopus,2-s2.0-0027452618
"Loza M.I., G‐Ferreiro T., Sanz F., Lozoya E., Rodriguez J., Manaut F., Verde I., Castro E., Fontenla J.A., Cadavid I., Honrubia M., Fueyo J., Raviña E.","7003766926;6505816337;7102263897;6603260860;24773509500;6602255071;55913729400;57206198202;7004054862;6603638170;7003365960;7004067667;56264803900;","Antiserotoninergic activity of 2‐aminoethylbenzocyclanones in rat aorta: Structure‐activity relationships",1993,"Journal of Pharmaceutical Sciences","82","5",,"513","517",,9,"10.1002/jps.2600820516","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027174892&doi=10.1002%2fjps.2600820516&partnerID=40&md5=cccb3b6813cc3b7158d990cc0f412b59","Department of Pharmacology, University of Santiago, Santiago de Compostela, E-15706, Spain; Department of Medical Informatics, Institut Municipal D'investigacio Mèdica, Universitat Autònoma de Barcelona, Passeig Maritim 25, Barcelona, E-08003, Spain; Department of Physical Chemistry, University of Santiago, Santiago de Compostela, E-15706, Spain; Organic Chemistry (Section of Pharmaceutical Chemistry), University of Santiago, Santiago de Compostela, E-15706, Spain","Loza, M.I., Department of Pharmacology, University of Santiago, Santiago de Compostela, E-15706, Spain; G‐Ferreiro, T., Department of Pharmacology, University of Santiago, Santiago de Compostela, E-15706, Spain; Sanz, F., Department of Medical Informatics, Institut Municipal D'investigacio Mèdica, Universitat Autònoma de Barcelona, Passeig Maritim 25, Barcelona, E-08003, Spain; Lozoya, E., Department of Medical Informatics, Institut Municipal D'investigacio Mèdica, Universitat Autònoma de Barcelona, Passeig Maritim 25, Barcelona, E-08003, Spain; Rodriguez, J., Department of Medical Informatics, Institut Municipal D'investigacio Mèdica, Universitat Autònoma de Barcelona, Passeig Maritim 25, Barcelona, E-08003, Spain, Department of Physical Chemistry, University of Santiago, Santiago de Compostela, E-15706, Spain; Manaut, F., Department of Medical Informatics, Institut Municipal D'investigacio Mèdica, Universitat Autònoma de Barcelona, Passeig Maritim 25, Barcelona, E-08003, Spain; Verde, I., Department of Pharmacology, University of Santiago, Santiago de Compostela, E-15706, Spain; Castro, E., Department of Pharmacology, University of Santiago, Santiago de Compostela, E-15706, Spain; Fontenla, J.A., Department of Pharmacology, University of Santiago, Santiago de Compostela, E-15706, Spain; Cadavid, I., Department of Pharmacology, University of Santiago, Santiago de Compostela, E-15706, Spain; Honrubia, M., Department of Pharmacology, University of Santiago, Santiago de Compostela, E-15706, Spain; Fueyo, J., Organic Chemistry (Section of Pharmaceutical Chemistry), University of Santiago, Santiago de Compostela, E-15706, Spain; Raviña, E., Organic Chemistry (Section of Pharmaceutical Chemistry), University of Santiago, Santiago de Compostela, E-15706, Spain","The antiserotoninergic activity at the serotonin receptor subtype 2 (5‐HT2) of seven new 2‐aminoethylbenzocyclanones was determined with respect to serotonin‐induced contractions in rat aorta and compared with that of ketanserine (pA2 = 8.87). Competitive antagonism was observed in six compounds (6.72 ≤ pA2 ≤ 8.12). Three‐dimensional structures and molecular electrostatic potential distributions of ketanserine and 2‐aminoethylbenzocyclanones were analyzed. Several molecular features correlated with the rank of antiserotoninergic activity. In the case of the cyclanone fragment, the rank of activity was associated with the degree of planarity of the bicyclic system. The steric and electrostatic effects due to the loss of planarity were analyzed. In the case of the amino moiety, activity was associated with a particular spatial pattern defined by the amino nitrogen, the aromatic system, and molecular electrostatic potential minima generated by the oxygen atom. Copyright © 1993 Wiley‐Liss, Inc., A Wiley Company",,"butyrophenone derivative; ethanolamine derivative; ketanserin; pirenperone; serotonin 2 receptor; setoperone; spiperone; animal tissue; aorta; article; controlled study; drug formulation; drug structure; nonhuman; priority journal; rat; serotonin release; stereochemistry; structure activity relation; Animal; Aorta, Thoracic; Butyrophenones; Comparative Study; In Vitro; Ketanserin; Ketones; Molecular Conformation; Muscle Contraction; Muscle, Smooth, Vascular; Piperidines; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Support, Non-U.S. Gov't",,"Butyrophenones; Ketanserin, 74050-98-9; Ketones; Piperidines; Serotonin Antagonists; Serotonin, 50-67-9",,,,,,,"Bradley, P.B., Engel, G., Feniuk, W., Fozard, J.R., Humphrey, P.P.A., Midlemiss, D.N., Mylecharane, E.J., Saxena, P.R., (1986) Neuropharmacol., 25, pp. 563-576; Leff, P., Martin, G.R., (1988) Med. Res. Rev., 8, pp. 187-202; Frazer, A., Maayani, S., Wolfe, B.B., (1990) Ann. Rev. Pharmacol. Toxicol., 30, pp. 307-348; Palacios, J.M., Waeber, C., Hoyer, D., Mengod, G., (1991) Ann. N.Y. Acad. Sci., 600, pp. 36-52; Watson, S., Abbott, A., (1990) Receptor Nomenclature Supplement. TiPS, , Elsevier, Cambridge, U.K; Fozard, J.R., (1987) Trends Pharmacol. Sci., 8, pp. 501-506; Cortizo, L., Santana, L., Raviña, E., Orallo, F., Fontenla, J.A., Castro, E., Calleja, J.M., Ceballos, M.L., (1991) J. Med. Chem., 34, pp. 2242-2247; Boswell, R.F., Jr., Welstead, W.J., Jr., Duncan, R.L., Jr., Johnson, D.N., Funderburk, W.H., (1978) J. Med. Chem., 21, pp. 136-139; Eirin, A., Ravina, E., Montanes, J.M., Calleja, J.M., (1976) Eur. J. Med. Chem., 11, pp. 29-32; Eirin, A., Santana, L., Raviña, E., Fernandez, F., Sanchez‐Abarca, E., Calleja, J.M., (1978) Eur. J. Med. Chem., 13, pp. 533-537; Santana, L., Raviña, E., Eirin, A., Sanchez‐Abarca, E., Calleja, J.M., (1980), p. 173. , In Proceedings of the VII International Symposium on Medicinal Chemistry; Torremolinos; Loza, M.I., Verde, I., Castro, E., Orallo, F., Fontenla, J.A., Calleja, J.M., Ravina, E., Ceballos, M.L., (1991), p. 12. , Biomed. Chem. Lett; Osman, R., Topiol, S., Rubenstein, L., Weinstein, H., (1987) Mol. Pharmacol., 32, pp. 699-705; Sleight, A.J., Peroutka, S.J., (1991) Naunyn‐Schmiedeberg's Arch Pharmacol., 343, pp. 109-116; Höltje, H.D., Briem, H., (1991) QSAR: Rational Approaches to the Design of Bioactive Compounds, pp. 245-252. , Silipo, C., Vitoria, A., Elsevier, Amsterdam; Hibert, M.F., Hoffman, K., Miller, K.C., Carr, A.A., (1990) J. Med. Chem., 33, pp. 1594-1600; Cohen, M.L., Fuller, R.W., Wiley, K.S., (1981) J. Pharmacol. Exp. Ther., 218, pp. 421-425; Fueyo, J., Raviña, E., Masaguer, C.F., Alvarez Casas, J.L., Alvarez, J., Rosa, E., Blanco, T., Calleja, J.M., (1991), p. 71. , In Proceedings of the VII Meeting of the Spanish Society of Therapeutical Chemistry; Jaca, Spain; Van Rossum, J.M., (1963) Arch. Int. Pharmacodyn., 143, pp. 299-330; Tallarida, R.J., Murray, R.B., (1987) Manual of Pharmacologic Calculations with Computer Programs, pp. 53-56. , Springer‐Verlag, New York; Dewar, M., Zoebish, E., Healy, E., Stewart, J., (1985) J. Am. Chem. Soc., 107, pp. 3902-3909; Dewar, M., Stewart, J., (1986), AMPAC program, QCPE 506; Frisch, M.J., Head‐Gordon, M., Trucks, G.W., Foresman, J.B., Schlegel, H.B., Raghavachari, K., Robb, R., Pople, J.A., (1990) GAUSSIAN 90, Revision H, , Gaussian Inc., Pittsburgh, PA; Sanz, F., Manaut, F., José, J., Segura, J., Carbó, M., De la Torre, R., (1988) J. Mol. Struct. (THEOCHEM), 170, pp. 171-180","Sanz, F.; Department of Medical Informatics, Institut Municipal D'investigacio Mèdica, Universitat Autònoma de Barcelona, Passeig Maritim 25, Barcelona, E-08003, Spain",,,,,,,,00223549,,,"8360829","English","J. Pharm. Sci.",Article,"Final",,Scopus,2-s2.0-0027174892
"Loza M.I., Sanz F., Cadavid M.I., Honrubia M., Orallo F., Fontenla J.A., Calleja J.M., Dot T., Manaut F., Cid M.M., Dominguez R., Seijas J.A., Villaverde M.C.","7003766926;7102263897;6603422293;7003365960;7003632256;7004054862;36832962500;7801649569;6602255071;7004969404;36811440600;6701414266;7004236039;","Cyproheptadine analogues: Synthesis, antiserotoninergic activity, and structure‐activity relationships",1993,"Journal of Pharmaceutical Sciences","82","11",,"1090","1093",,4,"10.1002/jps.2600821105","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027135416&doi=10.1002%2fjps.2600821105&partnerID=40&md5=f8ab34a47e100314c7c68fc58b42a7f5","Department of Farmacologiá, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Department of Quimica Organica, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Departamento de Quimica Organica, Universidad de Santiago, Lugo, E-27080, Spain; Biomedical Computer Sciences Department, Institut Municipal D'investigacio Mèdica, Facultat de Medicina(U.A.B, Passeig Maritim 25, Barcelona, B-08003, Spain","Loza, M.I., Department of Farmacologiá, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Sanz, F., Biomedical Computer Sciences Department, Institut Municipal D'investigacio Mèdica, Facultat de Medicina(U.A.B, Passeig Maritim 25, Barcelona, B-08003, Spain; Cadavid, M.I., Department of Farmacologiá, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Honrubia, M., Department of Farmacologiá, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Orallo, F., Department of Farmacologiá, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Fontenla, J.A., Department of Farmacologiá, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Calleja, J.M., Department of Farmacologiá, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Dot, T., Biomedical Computer Sciences Department, Institut Municipal D'investigacio Mèdica, Facultat de Medicina(U.A.B, Passeig Maritim 25, Barcelona, B-08003, Spain; Manaut, F., Biomedical Computer Sciences Department, Institut Municipal D'investigacio Mèdica, Facultat de Medicina(U.A.B, Passeig Maritim 25, Barcelona, B-08003, Spain; Cid, M.M., Department of Quimica Organica, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Dominguez, R., Department of Quimica Organica, Universidad de Santiago, Santiago de Compostea, E-15706, Spain; Seijas, J.A., Departamento de Quimica Organica, Universidad de Santiago, Lugo, E-27080, Spain; Villaverde, M.C., Department of Quimica Organica, Universidad de Santiago, Santiago de Compostea, E-15706, Spain","A series of cyproheptadine related compounds was synthesized and tested pharmacologically. In comparison with cyproheptadine, these compounds do not have a central ring and some contain groups other than N‐methyl. Synthesis was carried out with low‐valent titanium to generate the exocyclic double bond. The serotoninergic activity of the compounds was determined by standard determination of pA2 (‐log of the motor concentration of antagonist required to maintain a constant response when concentration of agonist is doubled) for the inhibition of serotonin‐induced contractions in rat stomach fundus. Two of the nitrogen‐containing compounds were active, but their activities were lower than that of Cyproheptadine. Structure‐activity relationships were studied by Mulliken net charges, molecular electrostatic potentials, and conformational analysis; activities are better correlated with electrostatic potentials than with net charges. The decrease in potency of the open cyproheptadine analogues may be due to “dilution” of the active conformer as the result of their conformational flexibility. Copyright © 1993 Wiley‐Liss, Inc., A Wiley Company",,"4 benzhydrylidene 1 methylpiperidine; 4 benzhydrylidene 1 methyltetrahydrothiopyranium iodide; 4 benzhydrylidenepiperidine; cyproheptadine; diphemanil methylsulfate; drug analog; serotonin; unclassified drug; animal tissue; article; drug activity; drug conformation; drug structure; drug synthesis; male; muscle contractility; nonhuman; rat; serotoninergic system; stomach muscle; structure activity relation; Animal; Cyproheptadine; Male; Molecular Conformation; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Structure-Activity Relationship",,"Cyproheptadine, 129-03-3; Serotonin Antagonists",,,,,,,"Peroutka, S.J., (1987) Psychopharmacology: The Third Generation of Progress, pp. 303-311. , Herbert, Meltzer, Raven, New York; Engelhardt, E.L., Zell, H.C., Saari, W.S., Christy, M.E., Colton, C.D., (1965) J. Med. Chem., 8, pp. 829-835; Villani, F.J., Magatti, C.V., Vashi, D., 3d., Wong, J., Popper, T.L., (1986) Arzneim‐Forsch., 36, pp. 1311-1314; Hogberg, T., Ross, S.B., Strom, P., Grunewald, G.L., Creese, M.W., Bunce, J.D., (1988) J. Med. Chem., 31, pp. 913-919; Villani, F.J., Daniels, P.J.L., Ellis, C.A., Mann, T.A., Wang, K.C., Wefer, E.A., (1972) J. Med. Chem., 15, pp. 750-754; Villani, F.J., Mann, T.A., Wefer, E.A., Hannon, J., Larca, L.L., Landon, M.J., Spivak, W., Vashi, D., (1975) J. Med. Chem., 18, pp. 1-8; Gronowitz, S., Westerlund, Ch., Hogberg, T., Ramsby, S., Hall, H., Henriklindberg, U., (1987) Acta Pharm. Suec., 24, pp. 1-14; Cohen, M.L., Colbert, W.E., (1986) J. Pharmacol. Exp. Ther., 237, pp. 713-718; Cohen, M.L., Schenck, K.W., Colbert, W., Wittenauer, L., (1985) J. Pharmacol. Exp. Ther., 232, pp. 770-774; Cohen, M.L., Wittennauer, L.A., (1985) Life Sci., 38, pp. 1-5; Cohen, M.L., (1989) The Peripheral Actions of 5‐Hydroxytryptamine, pp. 201-218. , Fozard, J. R., Oxford University, Oxford, U.K; Buchheit, K., Engel, H.G., Hagenbach, A., Hoyer, D., Kalkman, H.O., Seiler, M.P., (1986) Br. J. Pharmacol., 88, p. 367; Cohen, M.L., Wittenauer, L.A., (1987) J. Cardiovasc. Pharmacol., 10, pp. 176-181; Secrest, R.J., Schoepp, D.D., Cohen, M.L., (1989) J. Pharmacol. Exp. Ther., 250, pp. 971-978; Baez, M., Yu, L., Cohen, M.L., (1990) J. Pharmacol. Exp. Ther., 38, pp. 31-37; Kalkman, H.O., Fozard, J.R., (1991) Serotonin: Molecular Biology, Receptors and Functional Effects, pp. 153-160. , Fozard, Saxena, Birkhauser Verlag, Basel; Summer, M.J., Humphrey, P.P.A., 5-HT1D binding sites in porcine brain can be sub-divided by GR43175 (1989) British Journal of Pharmacology, 98, pp. 29-31; Martin, G.R., Maclennan, S.J., (1990) Naunyn—Schmiedeberg's Arch. Pharmacol., 342, pp. 563-576; Hilbert, M.F., Gittos, W., Middlemiss, D.N., Mir, I.A.K., Fozard, J.R., Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor (1988) Journal of Medicinal Chemistry, 31, pp. 1087-1093; Weinstein, H., Osman, R., (1990) Neuropsychopharmacology, 3, pp. 397-409; Holtje, H.D., Briem, H., (1991) QSAR: Rational Approaches to the Design of Bioactive Compounds, pp. 245-252. , Silipo, C., Vitoria, A., Elsevier, Amsterdam; Höltje, H.D., Briem, H., Theoretical Determination of the Putative Receptor-bound Conformations of 5-HT2Receptor Agonists (1991) Quantitative Structure-Activity Relationships, 10, pp. 193-197; Schmidt, A.W., Peroutka, S., (1989) J. Mol. Pharmacol., 36, pp. 505-511; Hibert, M.F., Hoffmann, R., Miller, R.C., Carr, A.A., (1990) J. Med. Chem., 33, pp. 1594-1600; Rizzi, J.P., Nagel, A.A., Rosen, T., McLean, S., Seeger, T., (1990) J. Med. Chem., 33, pp. 2721-2725; Sadek, M., Craik, D.J., Hall, J.G., Andrews, P.R., (1990) J. Med. Chem., 33, pp. 1098-1107; Schimidt, A.W., Peroutka, S.J., (1990) Mol. Pharmacol., 38 (4), pp. 511-516; Seijas, J.A., de Lera, A.R., Villaverde, M.C., Castedo, L., (1985), pp. 839-840. , J. Chem. Soc. Chem. Commun; Cid, M.M., Seijas, J.A., Villaverde, M.C., Castedo, L., (1988) Tetrahedron, 44, pp. 6197-6200; McMurry, J.E., Krepski, L.R., (1976) J. Org. Chem., 41, pp. 3929-3930; Polivka, Z., Holulek, J., Budesinsky, M., Matousova, O., Svatek, E., Metys, J., Protiva, M., Potential antihistamine agents: 4-(6,11-Dihydrodibenzo[b,e]thiepin-11-ylidene)-1-methyltetrahydrothiopyranium iodide and similar sulfonium salts derived from related tricyclic systems (1987) Collection of Czechoslovak Chemical Communications, 52, pp. 2758-2774; Tallarida, R.J., Murray, R.B., (1987) Manual of Pharmacologic Calculations with Computer Programs, pp. 53-56. , 2nd ed., Springer‐Verlag, New York; Van Rossum, J.M., (1963) Arch. Int. Pharmacodyn., 143, pp. 299-330; Glenon, R.A., Peroutka, S.J., Dukat, M., (1991) Serotonin: Molecular Biology, Receptors and Functional Effects, pp. 186-191. , Fozard, Saxena, Birkhauser Verlag, Basel; Mulliken, R.S., (1962) J. Chem. Phys., 36, p. 3428; Momany, F.A., (1987) J. Phys. Chem., 82, p. 592; Cox, S.R., Williams, D.E., Representation of the molecular electrostatic potential by a net atomic charge model (1981) Journal of Computational Chemistry, 2, p. 304; Chirlian, L.E., Franci, M.E., Atomic charges derived from electrostatic potentials: A detailed study (1987) Journal of Computational Chemistry, 8, p. 894; Orozco, M., Luque, F., On the use of AM1 and MNDO wave functions to compute accurate electrostatic charges (1990) Journal of Computational Chemistry, 11, p. 909; Luque, F.J., Sanz, F., Illas, F., Pouplana, R., Smeyers, Y.G., (1988) Eur. J. Med. Chem., 25, pp. 7-10; Van der Waterbeemd, H., Carrupt, P.A., Testa, B., Molecular electrostatic potential of orthopramides: implications for their interaction with the D-2 dopamine receptor (1986) Journal of Medicinal Chemistry, 29, pp. 600-606; Devar, M., Zoebish, E., Healy, E., Stewart, J., Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model (1985) Journal of the American Chemical Society, 107, pp. 3902-3909; Dewar, M., Stewart, J., (1986), AMPAC program, QCPE #506; Frish, M.J., Binkley, J.S., Schlegel, H.B., Raghavachari, K., Melius, C.F., Martin, R.L., Stewart, J.P., Pople, J.A., (1984), GAUSSIAN 86 program; Carnagie‐Mellon Quantum Chemistry: Pittsburgh, PA; Sanz, F., Manaut, F., José, J., Segura, J., Carbó, M., de la Torre, R., (1988) J. Mol. Struct. (THEOCHEM), 170, pp. 171-180; Barton, D.H.R., Willis, B.J., (1972), pp. 305-310. , J. Chem. Soc., Perkin Trans I; Nishikawa, Y., Shindo, T., Ishii, K., Nakamura, H., Kon, T., Uno, H., (1989) J. Med. Chem., 32, pp. 583-593; Melandri, M., Cattaneo, A.A., (1962) Boll. Chim. Farm., 101, pp. 363-375; (1963) (Chem. Abstr., 58. , 13907h; Br, J.R., (1957) J. Pharmacol., 12, pp. 344-359; Arunlaksana, O., Shild, H.O., (1959) Br. J. Pharmacol., 14, pp. 48-58; Kelly, J., Macdonald, A., (1988) J. Pharm. Pharmacol., 94, pp. 1123-1132","Loza, M.I.; Department of Farmacologiá, Universidad de Santiago, Santiago de Compostea, E-15706, Spain",,,,,,,,00223549,,,"8289119","English","J. Pharm. Sci.",Article,"Final",,Scopus,2-s2.0-0027135416
"Sanz F., Manaut F., Dot T., de Briñas E.L.","7102263897;6602255071;7801649569;24324550400;","Complete or partial comparison of molecular electrostatic potential distributions? some tests with 5-HT ligands",1992,"Journal of Molecular Structure: THEOCHEM","256","C",,"287","293",,9,"10.1016/0166-1280(92)87172-V","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0039313843&doi=10.1016%2f0166-1280%2892%2987172-V&partnerID=40&md5=6e0ee1955d7a940c17874f93eaf80b00","Departament d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.), Passeig Maritim, 25, E-8003 BarcelonaSpain","Sanz, F., Departament d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.), Passeig Maritim, 25, E-8003 BarcelonaSpain; Manaut, F., Departament d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.), Passeig Maritim, 25, E-8003 BarcelonaSpain; Dot, T., Departament d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.), Passeig Maritim, 25, E-8003 BarcelonaSpain; de Briñas, E.L., Departament d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.), Passeig Maritim, 25, E-8003 BarcelonaSpain","Two different strategies for finding the relative positions of maximum similarity between molecular electrostatic potential (MEP) distributions and for measuring their similarities were applied to several indole derivatives which are ligands of 5-hydroxytryptamine receptors. The first strategy takes into account the whole MEP distribution and allows one to discriminate between two groups of compounds according to their biological activity. In the second approach the MEP comparison is restricted to one plane which is considered relevant to receptor recognition. © 1992.",,,,,,,,,,,"Weinstein, Osman, (1989) Computer-Aided Molecular Design, pp. 105-118. , W.G. Richards, IBC Technical Services, London; Richards, Vinter, (1991) J. Comput. Aided Mol. Design, 5, pp. 1-3; Orozco, Canela, Franco, (1989) Mol. Pharmacol., 35, pp. 257-264; van der Waterbeemd, Carrupt, Testa, Molecular electrostatic potential of orthopramides: implications for their interaction with the D-2 dopamine receptor (1986) Journal of Medicinal Chemistry, 29, pp. 600-606; Luque, Fanz, Illas, Pouplana, Smeyers, (1988) Eur. J. Med. Chem., 23, pp. 7-10; Sanz, Manaut, José, Segura, Carbó, de la Torre, (1988) J. Mol Struct. (Theochem), 170, pp. 171-180; Manaut, Lozoya, Sanz, (1991) QSAR: Rational Approaches to the Design of Bioactive Compounds, pp. 339-342. , C. Silipo, A. Vitoria, Elsevier, Amsterdam; Sanz, Martín, Lapeña, Manaut, (1986) Quant. Struct.-Act. Relat., 5, pp. 54-57; Manaut, Sanz, José, Milesi, (1991) J. Comput. Aided Mol. Design, 5, pp. 371-380; Sanz, Manaut, Sánchez, Lozoya, (1991) J. Mol. Struct. (Theochem), 230, pp. 437-446; Saxena, Villalón, (1991) Trends Pharmacol. Sci., 12, pp. 223-227; Weinstein, Osman, (1990) Neuropsychopharmacology, 3, pp. 397-409; Höltje, Briem, (1991) QSAR: Rational Approaches to the Design of Bioactive Compounds, pp. 245-252. , C. Silipo, A. Vitoria, Elsevier, Amsterdam; Green, Johnson, Weinstein, Kang, Chou, (1978) The Psychopharmacology of Hallucinogens, pp. 28-60. , R.C. Stillman, R.E. Willette, Pergamon Press, New York; Reggio, Weinstein, Osman, Topiol, Molecular determinants for binding of methylenedioxytryptamines at 5-HT/LSD receptors (1981) International Journal of Quantum Chemistry, 8, pp. 373-384. , Quantum Biol. Symp; Biosym Technologies, Inc., 10065 Barnes Canyon Rd., San Diego, CA 92121; Dewar, Zoebisch, Healy, Stewart, (1985) J. Am. Chem. Soc., 107, pp. 3902-3909; Dewar, Stewart, (1986) ampac program, QCPE, (506); Frish, Binkley, Schlegel, Raghavachari, Melius, Martin, Stewart, Pople, (1984) gaussian 86, , Carnegie-Mellon Quantum Chemistry Publishing Unit, Pittsburgh, PA; Weinstein, Osman, Edwards, Green, (1978) Int. J. Quantum Chem., 5, pp. 449-461. , Quantum Biol. Symp; Weinstein, Osman, Green, Topiol, (1981) Chemical Applications of Atomic and Molecular Electrostatic Potentials, pp. 309-324. , P. Politzer, D.G. Truhlar, Plenum Press, New York; Weinstein, Chou, Kang, Johnson, Green, (1976) Int. J. Quantum Chem., 3, pp. 135-150. , Quantum Biol. Symp","Sanz, F.",,,,,,,,01661280,,THEOD,,"English","J. Mol. Struct. THEOCHEM",Article,"Final",,Scopus,2-s2.0-0039313843
"Sancho J., Sanz F.","7201937083;7102263897;","Information science and medical education [INFORMATICA Y ENSENANZA DE LA MEDICINA]",1992,"Anales Espanoles de Pediatria, Supplement","36","48",,"324","325",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026874446&partnerID=40&md5=401fb0a4e9fabc43464695aa22dbf530","Dept. d'Informatica Medica/Docencia, Unitat Docent, Facultat de Medicina, Barcelona, Spain","Sancho, J., Dept. d'Informatica Medica/Docencia, Unitat Docent, Facultat de Medicina, Barcelona, Spain; Sanz, F., Dept. d'Informatica Medica/Docencia, Unitat Docent, Facultat de Medicina, Barcelona, Spain",[No abstract available],,"conference paper; information science; medical education; article; medical informatics; Spain; teaching; Computer-Assisted Instruction; Medical Informatics Applications; Spain",,,,,,,,,,"Sancho, J.; Dept. d'Informatica Medica/Docencia, Unitat Docent, Facultat de Medicina, Barcelona, Spain",,,,,,,,02139146,,AEPED,"1637005","Spanish","AN. ESP. PEDIATR. SUPPL.",Conference Paper,"Final",,Scopus,2-s2.0-0026874446
"Balaguer A., Sancho J., Sanz F., Argemi J.","6701758973;7201937083;7102263897;6603723662;","Computer-assisted medical education: Simulation of clinical cases in neonatal pathology [ENSENANZA MEDICA ASISTIDA POR ORDENADOR: SIMULACION DE CASOS CLINICOS EN PATOLOGIA NEONATAL]",1992,"Anales Espanoles de Pediatria, Supplement","36","48",,"324","",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026870671&partnerID=40&md5=3d911369b8da8ca31def4556ac9ca509",,"Balaguer, A.; Sancho, J.; Sanz, F.; Argemi, J.",[No abstract available],,"computer program; conference paper; medical education; neonatology; article; computer simulation; education; human; neonatology; newborn; Spain; teaching; Computer Simulation; Computer-Assisted Instruction; Human; Infant, Newborn; Neonatology; Spain",,,,,,,,,,,,,,,,,,02139146,,AEPED,"1637004","Spanish","AN. ESP. PEDIATR. SUPPL.",Conference Paper,"Final",,Scopus,2-s2.0-0026870671
"Verdaguer A., Patak A., Sancho J.J., Sierra C., Sanz F.","6701656988;6602985248;7201937083;7006398334;7102263897;","Validation of the medical expert system PNEUMON-IA",1992,"Computers and Biomedical Research","25","6",,"511","526",,29,"10.1016/0010-4809(92)90006-V","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026470308&doi=10.1016%2f0010-4809%2892%2990006-V&partnerID=40&md5=2c52ebfa271814bd3526086b77421890","Department d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (Universitat Autònoma de Barcelona), Barcelona, Spain; Aliança Mataronina, Mataró, Barcelona, Spain; Centre d'Estudis Avançats de Blanes, Blanes, Barcelona, Spain","Verdaguer, A., Department d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (Universitat Autònoma de Barcelona), Barcelona, Spain, Aliança Mataronina, Mataró, Barcelona, Spain; Patak, A., Department d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (Universitat Autònoma de Barcelona), Barcelona, Spain; Sancho, J.J., Department d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (Universitat Autònoma de Barcelona), Barcelona, Spain; Sierra, C., Centre d'Estudis Avançats de Blanes, Blanes, Barcelona, Spain; Sanz, F., Department d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (Universitat Autònoma de Barcelona), Barcelona, Spain","The present study validates the expert system PNEUMON-IA. The aim of PNEUMON-IA is assessing the etiology of community-acquired pneumonias from clinical, radiological, and laboratory data obtained at the onset of the disease. Validation was performed using data from medical records of 76 patients with proven clinical diagnosis of pneumonia. The etiological diagnoses provided by PNEUMON-IA were compared to those established by five specialists unrelated to the development of the expert system. For each etiological possibility, both PNEUMON-IA and the experts provided a causal possibility, expressed as a linguistic label (i.e., ""almost impossible""). Linguistic labels were then converted to numeric values. In the majority of cases, an etiological diagnosis was unavailable to be used as a gold standard. To overcome this limitation, distances between arrays of etiological possibilities given by specialists and by PNEUMON-IA were considered as an agreement measure between diagnoses. Cluster analysis based on those distances was used to classify PNEUMON-IA among experts. Results showed the same differences between specialists and PNEUMON-IA as among the specialists themselves. The method used to validate PNEUMON-IA could prove useful to assess the performance of expert systems in fields where no gold standard is available. © 1992.",,"article; cluster analysis; diagnostic accuracy; expert system; medical record; medical specialist; pneumonia; Adolescent; Adult; Cluster Analysis; Data Collection; Diagnosis, Computer-Assisted; Expert Systems; Human; Pneumonia; Programming Languages; Reproducibility of Results; Software Validation; Support, Non-U.S. Gov't",,,,,,,,,"López de Mántaras, Cortés, Sierra, Villar, Plaza, An expert system building tool with approximate reasoning (1988) Fuzzy Logic in Knowledge Engineering, pp. 182-193. , C.V. Negoitia, H. Prade, Rheinhold Interdisciplinary System Research Serie No. 86, Verlag, Tür; Miller, Evaluation of artificial intelligence systems in medicine (1988) Selected Topics in Medical Artificial Intelligence, , P.L. Miller, Springer-Verlag, New York; Verdaguer, PNEUMON-IA: desenvolupament d'un sistema expert d'ajuda al diagnòstic mèdic (1989) Doctoral thesis, , Universitat Autònoma de Barcelona, Barcelona; Godó, López Mántaras, Sierra, Verdaguer, Managing linguistically expressed uncertainty in MILORD application to medical diagnosis (1988) Artif. Intel. Commun., 1, p. 14; Godó, López Mántaras, Sierra, Verdauger, MILORD The architecture and management of linguistically expressed uncertainty (1989) International Journal of Intelligent Systems, 4, p. 471; Yu, Fagan, Bennet, Clancey, Scott, Hannigan, Buchanan, Cohen, An evaluation of MYCIN's advice (1984) Rule-Based Expert Systems: The MYCIN Experiments of the Stanford Heuristic Programming Project, pp. 589-596. , B.G. Buchanan, S.N. Cohen, Addison-Wesley, Reading, MA; Kingsland, III, Evaluation of expert systems. Experience with the AI/Rheum knowledge-based consultant system in rheumatology (1988) Selected Topics in Medical Artificial Intelligence, , P.L. Miller, Springer-Verlag, New York; Reggia, Tabb, Price, Banko, Hebel, Computed-aided assessment of transient ischemic attacks: A clinical evaluation (1984) Arch. Neurol., 41, p. 1248; Soula, Vialettes, San Marco, Une validation multicentrique du système expert PROTIS (1987) AAVV: Proceedings, 7th International Symposium on Expert Systems and Applications, pp. 239-255. , Avignon; Quaglini, Stefanelli, Barosi, Berzuini, A performance evaluation of the expert system ANEMIA (1988) Comput. Biomed. Res., 21, pp. 307-323; Wite, Blainey, Harrison, Clarke, Causes of pneumonia presenting to a district general hospital (1981) Thorax, 36, p. 566; MacFarlane, Finch, Ward, Macrae, Hospital study of adult community-acquired pneumonia (1982) Lancet, 2, p. 255; Almirante, Pahissa, Planes, Martínez-Vázquez, Etiología de las neumonías extrahospitalarias (1985) Med. Clin. (Barcelona), 85, p. 175; Berntsson, Blomberg, Lagergard, Trollfors, Etiology of community-acquired pneumonia in patients requiring hospitalization (1985) Eur. J. Clin. Microbiol., 4, pp. 268-272; Marrie, Garyston, Wang, Kuo, Pneumonia associated with TWAR stain of Chlamydia (1987) Ann Intern. Med., 106, p. 507; Ausina, Coll, Sambeat, Puig, Condom, Luquin, Ballester, Prats, Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain (1988) Eur. J. Clin. Microbiol. Infect. Dis., 14, pp. 343-347; Norusis, (1985) SPSSx Advanced Statistics Guide, , SPSS, Chicago; Sutton, How accurate is computer-aided diagnosis? (1989) Lancet, 2, pp. 905-908; Chard, Human versus machine: A comparison of a computer ‘Expert System’ with human experts in the diagnosis of vaginal discharge (1987) Int. J. BioMed. Comput., 20, pp. 71-78; Sutton, Computer aided diagnosis: A review (1989) Br. J. Surg., 76, pp. 82-85; Baak, Artificial intelligence systems (expert systems) as diagnostic consultants for the cytologic and histologic diagnosis of cancer (1988) J. Cancer Res. Clin. Oncol., 114, pp. 325-334; Kraemer, Extension of the Kappa coefficient (1980) Biometrics, 36, pp. 207-216; Posner, Sampson, Caplan, Ward, Cheney, Measuring interrater reliability among multiple raters: An example of methods for nominal data (1990) Stat. Med., 9, pp. 1103-1115; Ahn, Mezzich, PROPOV-K: A FORTRAN program for computing a Kappa coefficient using a proportional overlap procedure (1989) Comput. Biomed. Res., 22, pp. 415-423","Sanz, F.; Department d'Informàtica Biomèdica, Institut Municipal d'Investigació Mèdica, Facultat de Medicina (Universitat Autònoma de Barcelona), Barcelona, Spain",,,,,,,,00104809,,CBMRB,"1458855","English","Comput. Biomed. Res.",Article,"Final",,Scopus,2-s2.0-0026470308
"González González J.C., Sancho Insenser J.J., Sanz Carreras F., Sitges-Serra A.","7006242416;6503937882;7102263897;7007049436;","Computer knowledge of medical students. Study in the Teaching Unit at the Hospital Universitario del Mar (Barcelona) [Conocimientos informáticos de los estudiantes de medicina. Estudio en la Unidad Docente del Hospital Universitario del Mar (Barcelona).]",1991,"Medicina Clinica","97","15",,"598","599",,3,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026414271&partnerID=40&md5=0c31b69d4dcccda645107a47964f6c3a",,"González González, J.C.; Sancho Insenser, J.J.; Sanz Carreras, F.; Sitges-Serra, A.",[No abstract available],,"education; human computer interaction; letter; medical education; medical informatics; Spain; Computer Literacy; Education, Medical; Medical Informatics; Spain",,,,,,,,,,"González González, J.C.",,,,,,,,00257753,,,"1805089","Spanish","Med Clin (Barc)",Letter,"Final",,Scopus,2-s2.0-0026414271
"Manaut F., Sanz F., José J., Milesi M.","6602255071;7102263897;16429212200;56884445700;","Automatic search for maximum similarity between molecular electrostatic potential distributions",1991,"Journal of Computer-Aided Molecular Design","5","4",,"371","380",,54,"10.1007/BF00126669","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026201884&doi=10.1007%2fBF00126669&partnerID=40&md5=fd529c80d64ee9212c599b2b8fb7c0d2","Facultat de Medicina (U.A.B), Institut Municipal d'Investigació Mèdica, P.Maritim 25-29, Barcelona, 08003, Spain","Manaut, F., Facultat de Medicina (U.A.B), Institut Municipal d'Investigació Mèdica, P.Maritim 25-29, Barcelona, 08003, Spain; Sanz, F., Facultat de Medicina (U.A.B), Institut Municipal d'Investigació Mèdica, P.Maritim 25-29, Barcelona, 08003, Spain; José, J., Facultat de Medicina (U.A.B), Institut Municipal d'Investigació Mèdica, P.Maritim 25-29, Barcelona, 08003, Spain; Milesi, M., Facultat de Medicina (U.A.B), Institut Municipal d'Investigació Mèdica, P.Maritim 25-29, Barcelona, 08003, Spain","A new computer program has been developed to automatically obtain the relative position of two molecules in which the similarity between molecular electrostatic-potential distributions is greatest. These distributions are considered in a volume around the molecules, and the similarity is measured by the Spearman rank coefficient. The program has been tested using several pairs of molecules: water vs. water; phenylethylamine and phenylpropylamine vs. benzylamine; and methotrexate vs. dihydrofolic acid. © 1991 ESCOM Science Publishers B.V.","Computational chemistry software; DHFR; Molecular electrostatic potential; Molecular similarity; Optimal relative position; Spearman coefficient","benzylamine; benzylamine derivative; cell surface receptor; dihydrofolic acid; drug; drug derivative; folic acid; methotrexate; phenethylamine derivative; article; chemistry; comparative study; computer program; electrochemistry; metabolism; quantum theory; thermodynamics; Benzylamines; Comparative Study; Electrochemistry; Folic Acid; Methotrexate; Pharmaceutical Preparations; Phenethylamines; Quantum Theory; Receptors, Cell Surface; Software; Thermodynamics",,"benzylamine, 100-46-9, 2182-52-7, 3287-99-8; dihydrofolic acid, 25512-82-7; folic acid, 59-30-3, 6484-89-5; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; benzylamine, 100-46-9; Benzylamines; dihydrofolate, 4033-27-6; Folic Acid, 59-30-3; Methotrexate, 59-05-2; Pharmaceutical Preparations; Phenethylamines; Receptors, Cell Surface",,,,,,,"Dean, P.M., (1987) Molecular Foundations of Drug-Receptor Interaction, , Cambridge University Press, Cambridge; Martin, M., Sanz, F., Campillo, M., Pardo, L., Pérez, J., Turmo, J., Quantum chemical study of the molecular patterns of MAO inhibitors and substrates (1983) International Journal of Quantum Chemistry, 23, p. 1627; Arteca, G.A., Jammal, V.B., Mezey, P.G., Yadav, J.S., Hermeier, M.A., Gund, T.M., (1988) J. Mol. Graphics, 6, p. 45; Liwo, A., Tempczyk, A., Grzonka, Z., (1989) J. Comput.-Aided Mol. Design, 3, p. 261; Sanz, F., Martin, M., Lapeña, F., Manaut, F., (1986) Quant. Struct.-Act. Relat., 5, p. 54; Kato, Y., Itai, A., Iitaka, Y., (1987) Tetrahedron, 43, p. 5229; Sanz, F., Manaut, F., José, J., Carbó, M., De la Torre, R., (1988) J. Mol. Struct. (THEOCHEM), 170, p. 171; Frish, M.J., Binkley, J.S., Schlegel, H.B., Raghavachari, K., Melius, C.F., Martin, R.L., Stewart, J.P., Pople, J.A., (1984) GAUSSIAN 86, , Carnegie-Mellon Quantum Chemistry Publishing Unit, Pittsburgh, PA; Carbó, R., Lapeña, F., Suñe, E., (1986) Afinidad, 406, p. 483; Namasivayam, S., Dean, P.M., (1986) J. Mol. Graphics, 4, p. 46; Graham, M.S., Merck Sharp & Dohme, SEA program, QCPE No. 567 (1988); Nakayama, A., Richards, W.G., A Quantum Chemical Study of Insect Juvenile Hormone Mimics: The Active Conformation and the Electrostatic Similarities (1987) Quantitative Structure-Activity Relationships, 6, p. 153; Carbó, R., Leyda, L., Arnau, M., How similar is a molecule to another? An electron density measure of similarity between two molecular structures (1980) International Journal of Quantum Chemistry, 17, p. 1185; SPSS Statistical Algorithms, SPSS Inc., Chicago, IL, 1985; Dean, P.M., Callow, P., Chau, P.-L., (1988) J. Mol. Graphics, 6, p. 28; Hazdi, D., Koller, J., Hodosek, M., (1989) QSAR: Quantitative Structure-Activity Relationships in Drug Design, pp. 259-263. , J.L., Fauchère, Alan R. Liss Inc., New York; Bolin, J.T., Filman, D.J., Matthews, D.A., Kraut, J., (1982) J. Biol. Chem., 257, p. 13663; Kuyper, L.F., (1989) Computer-Aided Drug Design, pp. 327-369. , T.J., Perun, C.L., Propst, Marcel Dekker Inc., New York","Manaut, F.; Facultat de Medicina (U.A.B), Institut Municipal d'Investigació Mèdica, P.Maritim 25-29, Barcelona, 08003, Spain",,,"Kluwer Academic Publishers",,,,,0920654X,,JCADE,"1665509","English","J Computer-Aided Mol Des",Article,"Final",,Scopus,2-s2.0-0026201884
"Sanz F., Manaut F., Sanchez J.A., Lozoya E.","7102263897;6602255071;55452633700;6603260860;","Maximum electrostatic similarity between biomolecules optimizing both relative positions and conformations",1991,"Journal of Molecular Structure: THEOCHEM","230","C",,"437","446",,16,"10.1016/0166-1280(91)85195-D","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141714668&doi=10.1016%2f0166-1280%2891%2985195-D&partnerID=40&md5=9452ea2f0e591f7508cdf6f8c3603585","Institut Municipal d'Inuestigació Médico, Facultat de Medicina (U.A.B.), Passeig Marítim 25, E-08003 BarcelonaSpain","Sanz, F., Institut Municipal d'Inuestigació Médico, Facultat de Medicina (U.A.B.), Passeig Marítim 25, E-08003 BarcelonaSpain; Manaut, F., Institut Municipal d'Inuestigació Médico, Facultat de Medicina (U.A.B.), Passeig Marítim 25, E-08003 BarcelonaSpain; Sanchez, J.A., Institut Municipal d'Inuestigació Médico, Facultat de Medicina (U.A.B.), Passeig Marítim 25, E-08003 BarcelonaSpain; Lozoya, E., Institut Municipal d'Inuestigació Médico, Facultat de Medicina (U.A.B.), Passeig Marítim 25, E-08003 BarcelonaSpain","Software was developed to find automatically the maximum electrostatic similarity between biomolecules by varying the relative positions and the conformations of one of them. This similarity is defined by means of the Spearman correlation coefficient computed over the molecular electrostatic potential (MEP) values at points of a volume around the molecules. Several tests are presented, including a comparison between 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and benzylamine (BZA), two substrates of monoamine oxidase B (MAO-B). The proposed algorithm can be useful for molecular modelling and quantitative structure-activity relationship (QSAR) studies. © 1991.",,,,,,,,,,,"Weistein, Osman, (1989) Computer-Aided Molecular Design, pp. 105-118. , W.G. Richards, IBC Technical Services, London; Dean, (1987) Molecular Foundations of Drug-Receptor Interaction, , Cambridge University Press; Martin, Sanz, Campillo, Pardo, Pérez, Turmo, Quantum chemical study of the molecular patterns of MAO inhibitors and substrates (1983) International Journal of Quantum Chemistry, 23, pp. 1627-1641; Arteca, Jammal, Mezey, Yadav, Hermsmeier, Gund, (1988) J. Mol. Graphics, 6, pp. 45-53; Liwo, Tempczyk, Grzonka, (1989) J. Computer-Aided Mol. Design, 3, pp. 261-284; Sanz, Martin, Lapeña, Manaut, (1986) Quantum Structure-Activity Relat., 5, pp. 54-57; Kato, Itai, Iitaka, (1987) Tetrahedron, 43, pp. 5229-5236; Sanz, Manaut, José, Segura, Carbó, de la Torre, (1988) J. Mol. Struct. (Theochem), 170, pp. 171-180; F. Manaut, F. Sanz, J. José and M. Milesi, J. Comput. Aided Mol. Design, accepted for publication; F. Manaut, E. Lozoya and F. Sanz, Proc. 8th Eur. Symp. QSAR, Sorrento, Elsevier, Amsterdam, in press; Kuyper, (1989) Computer-Aided Drug Design, pp. 327-369. , T.J. Perun, C.L. Propst, Marcel Dekker, New York; Frish, Binkley, Schlegel, Raghavachari, Melius, Martin, Stewart, Pople, (1984) GAUSSIAN 86, , Carnegie-Mellon Quantum Chemistry Publishing Unit, Pittsburgh PA; Dewar, Zoebish, Healy, Stewart, (1985) J. Am. Chem. Soc., 107, pp. 3902-3909; Dewar, Stewart, (1986) AMPAC program, Quantum Chemistry Program Exchange, (506); Namasivayam, Dean, (1986) J. Mol. Graphics, 4, pp. 46-50; Dean, Callow, Chau, (1988) J. Mol. Graphics, 6, pp. 28-34; Hazdi, Koller, Hodosek, (1989) QSAR: Quantitative Structure-Activity Relationships in Drug Design, pp. 259-263. , J.L. Fauchère, Alan R. Liss, New York; Marsden, (1990) Lancet, 335, pp. 948-952; Manaut, Noves eines per a la caracterització de similituds moleculars i la seva aplicacio farmacolàgica (1989) Ph.D. Thesis, , Universitat Autònoma de Barcelona, Bellaterra, Spain","Sanz, F.",,,,,,,,01661280,,THEOD,,"English","J. Mol. Struct. THEOCHEM",Article,"Final",,Scopus,2-s2.0-0141714668
"Marrugat J., Sala J., Ribalta A., Sanz F.","7006226141;7005792661;57194338806;7102263897;","Ten-year survival of a cohort of 736 patients with a first myocardial infarction. Sex-related differences? [Supervivencia a los 10 años de una cohorte de 736 pacientes con un primer infarto de miocardio. Diferencias entre sexos?]",1991,"Revista española de cardiología","44","5",,"297","305",,5,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026160706&partnerID=40&md5=0b8f0d2fc0ef171505a6729a5f1abecc","Departamento de Epidemiología y Salud Pública, Instituto Municipal de Investigación Médica, Barcelona, Spain","Marrugat, J., Departamento de Epidemiología y Salud Pública, Instituto Municipal de Investigación Médica, Barcelona, Spain; Sala, J., Departamento de Epidemiología y Salud Pública, Instituto Municipal de Investigación Médica, Barcelona, Spain; Ribalta, A., Departamento de Epidemiología y Salud Pública, Instituto Municipal de Investigación Médica, Barcelona, Spain; Sanz, F., Departamento de Epidemiología y Salud Pública, Instituto Municipal de Investigación Médica, Barcelona, Spain","The survival of a cohort of 736 patients (617 men and 119 women) with a first acute myocardial infarction is reported. All patients were admitted and diagnosed at a referral center of six areas of the province of Girona, Spain. The results of a follow-up period of 10 years are analyzed. The overall 10-year survival rate was 55% (57% in men and 43% in women). The survival curves for males and females were significantly different (p = 0.0001). In the acute phase of infarction, the mortality amongst women was higher than amongst men. Women suffered from myocardial infarction at an older age than men. When the study population was stratified by age groups, no statistically significant differences in the survival rates between men and women were observed. We conclude that age is the confounding variable that all other survival-related variables have to be adjusted for. Sex was not found to be a determinant factor for long-term survival after myocardial infarction. The worse hemodynamic condition amongst women prior to the infarction may account for the greater mortality in the acute phase observed in females.",,"age; aged; article; cohort analysis; epidemiology; female; heart infarction; human; male; middle aged; mortality; sex difference; Spain; survival rate; Age Factors; Aged; Cohort Studies; Confounding Factors (Epidemiology); Female; Humans; Male; Middle Aged; Myocardial Infarction; Sex Factors; Spain; Survival Rate",,,,,,,,,,"Marrugat, J.",,,,,,,,03008932,,,"1852958","Spanish","Rev Esp Cardiol",Article,"Final",,Scopus,2-s2.0-0026160706
"Balana Quintero C., Sole Calvo L.A., Rubio Bazan D., Sanz Carreras F., Salvador-Fernandez L.","56802274300;6603530445;6506784062;7102263897;6505844555;","Adjuvant chemotherapy with CMF in breast cancer: Results of a comparativ study in 10 years",1990,"Oncologia","13","9",,"459","466",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025614656&partnerID=40&md5=90ae9659d0e32d979d0042ede15e13bd","Hospital General de la Vall D'Hebron, Barcelona, Spain","Balana Quintero, C., Hospital General de la Vall D'Hebron, Barcelona, Spain; Sole Calvo, L.A., Hospital General de la Vall D'Hebron, Barcelona, Spain; Rubio Bazan, D., Hospital General de la Vall D'Hebron, Barcelona, Spain; Sanz Carreras, F., Hospital General de la Vall D'Hebron, Barcelona, Spain; Salvador-Fernandez, L., Hospital General de la Vall D'Hebron, Barcelona, Spain",[No abstract available],,"cyclophosphamide; fluorouracil; methotrexate; adjuvant chemotherapy; alopecia; article; breast cancer; conjunctivitis; controlled study; female; human; major clinical study; oral drug administration",,"cyclophosphamide, 50-18-0; fluorouracil, 51-21-8; methotrexate, 15475-56-6, 59-05-2, 7413-34-5",,,,,,,,,,,,,,,,03784835,,ONCIE,,"Spanish","ONCOLOGIA",Article,"Final",,Scopus,2-s2.0-0025614656
"Llorens Terol J., Sanz Carreras F.","6701729912;7102263897;","The rank of words [El rango de las palabras.]",1990,"Revista clinica espanola","186","5",,"244","245",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025391538&partnerID=40&md5=08c81a0d9f0886f3e014443e81e6b4ae",,"Llorens Terol, J.; Sanz Carreras, F.",[No abstract available],,"letter; Terminology",,,,,,,,,,"Llorens Terol, J.",,,,,,,,00142565,,,"2377782","Spanish","Rev Clin Esp",Letter,"Final",,Scopus,2-s2.0-0025391538
"MONMANY J., DOMINGO P., GOMEZ J.A., SANZ F., ROCA‐CUSACHS A., NOLLA J., JANE F.","6601959245;7102960369;36445662300;7102263897;7004601419;7005300920;7005517671;","Effects of long‐term treatment with metoprolol and hydrochlorothiazide on plasma lipids and lipoproteins",1990,"Journal of Internal Medicine","228","4",,"323","331",,4,"10.1111/j.1365-2796.1990.tb00240.x","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025163452&doi=10.1111%2fj.1365-2796.1990.tb00240.x&partnerID=40&md5=f1d4536d4d72896255981975f7e1bf46","Departments of Clinical Pharmacology, Medicine and Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Institut Municipal Investigació Mèdica, Autonomous University of Barcelona, Barcelona, Spain","MONMANY, J., Departments of Clinical Pharmacology, Medicine and Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; DOMINGO, P., Departments of Clinical Pharmacology, Medicine and Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; GOMEZ, J.A., Departments of Clinical Pharmacology, Medicine and Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; SANZ, F., Institut Municipal Investigació Mèdica, Autonomous University of Barcelona, Barcelona, Spain; ROCA‐CUSACHS, A., Departments of Clinical Pharmacology, Medicine and Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; NOLLA, J., Departments of Clinical Pharmacology, Medicine and Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; JANE, F., Departments of Clinical Pharmacology, Medicine and Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","Abstract. In order to evaluate the effects of one‐year antihypertensive treatment on plasma lipids and lipoproteins, 65 patients whose diastolic blood pressure was in the range 95‐120 mmHg were randomly allocated to groups that received either hydrochlorothiazide or metoprolol, or both drugs when the response to one of them was insufficient to control blood pressure. Blood pressure was effectively reduced in all groups. Patients on hydrochlorothiazide showed a significant increase (P < 0.01) in low‐density lipoprotein cholesterol (LDL‐C) after 3 months of treatment. A significant increase in triglycerides was observed after 6 and 12 months, together with a decrease in high‐density lipoprotein cholesterol (HDL‐C) after 12 months (P < 0.05) of treatment in patients on metoprolol. In patients treated with both hydrochlorothiazide and metoprolol, total cholesterol increased after 3 (P < 0.001) and 6 months (P < 0.05), triglycerides increased after 6 (P < 0.01) and 12 months (P< 0.01), and LDL‐C increased after 3 (P< 0.05), 6 (P < 0.001) and 12 months (P < 0.01) of treatment, respectively. In 61% of the patients, three or more lipid parameters were affected during the study period. We conclude that long‐term antihypertensive treatment with hydrochlorothiazide, metoprolol, and particularly with both drugs, can induce lipid effects that deserve recognition, because in some cases these might counteract the possible benefit of a reduction in blood pressure on the prevention of coronary heart disease. 1990 Blackwell Publishing Ltd","hydrochlorothiazide; hypertension; lipids; lipoproteins; metoprolol; therapeutic efficacy","hydrochlorothiazide; metoprolol; adult; article; cholesterol blood level; drug effect; female; high density lipoprotein cholesterol blood level; human; hypertension; lipid blood level; lipoprotein blood level; low density lipoprotein cholesterol blood level; major clinical study; male; priority journal; triacylglycerol blood level",,"hydrochlorothiazide, 58-93-5; metoprolol, 37350-58-6",,,,,,,"Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg (1967) J Am Med Assoc, 202, pp. 1028-1034; Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg (1970) J Am Med Assoc, 213, pp. 1143-1152; Five‐year findings of the hypertension detection and follow‐up program (1979) J Am Med Assoc, 242, pp. 2562-2571; Trials of the treatment of mild hypertension. An interim analysis (1982) Lancet, 1, pp. 149-156; Multiple risk factor intervention trial. Risk factor changes and mortality results (1982) J Am Med Assoc, 248, pp. 1465-1477; Antihypertensive therapy in evolution (1986) N Engl J Med, 314, pp. 1701-1702; Woolf, N., Lipids and atherosclerosis (1982) Pathology of Atherosclerosis, pp. 83-111. , Woolf N.,. London:, Butterworths & Co; Gordon, T., Castelli, P., Hjortland, MC, Kannel, WB, Dawber, TR, High density lipoprotein as a protective factor against coronary heart disease (1977) Am J Med, 62, pp. 707-714; Hamada, N., Apoprotein A and high density lipoprotein cholesterol levels in ischemic heart disease (1980) Jpn Circ J, 44, pp. 487-494; De Backer, G., Rosseneu, M., Deslypere, JP, Discriminative value of lipids and apoproteins in coronary heart disease (1982) Atherosclerosis, 42, pp. 197-203; Berg, K., Børresen, AL, Serum‐high‐density lipoprotein and atherosclerotic heart disease (1976) Lancet, 1, pp. 499-501; Kladetzky, RG, Assmann, G., Walgenbach, S., Tauchert, P., Helb, HD, Lipoprotein and apoprotein values in coronary angiography patients (1980) Artery, 7, pp. 191-205; Riesen, WF, Mordasini, R., Salzmann, C., Theler, A., Gurtner, HP, Apoproteins and lipids as discriminators of severity of coronary heart disease (1980) Atherosclerosis, 37, pp. 157-162; Epidemiology of plasma high density lipoprotein cholesterol levels. The Lipid Research Clinics Program Prevalance Study (1980) Circulation, 62, pp. 1-136. , Tyroler HA, ed. American Heart Association Monograph No. 73; Feinleib, M., Kannel, WB, Tedeschi, CE, Landau, TK, Garrison, RJ, The relation of ante‐mortem characteristics to cardiovascular findings at necropsy; ‘The Framingham Study’ (1979) Atherosclerosis, 34, pp. 145-157; Kannel, WB, Castelli, WP, Gordon, T., McNamara, PM, Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study (1971) Ann Intern Med, 74, pp. 1-12; Alaupovic, P., Structure and function of plasma lipoproteins with particular regard to hyperlipoprotinemias and atherosclerosis (1980) Ann Biol Clin, 38, pp. 83-93; Miller, GJ, High density lipoproteins and atherosclerosis (1980) Annu Rev Med, 31, pp. 97-108; Johnson, BF, The emerging problem of plasma lipid changes during antihypertensive therapy (1982) J Cardiovasc Pharmacol, 4, pp. 213-221; Lowenstein, J., Neusy, AJ, The biochemical effects of antihypertensive agents and the impact on atherosclerosis (1982) J Cardiovasc Pharmacol, 4, pp. 262-265; Sauvanet, JP, Rouffy, J., Effets des traitements hypotenseurs sur les lipides et lipoprotéines plasmatiques (1982) Sem Hôp Paris, 58, pp. 563-568; Ballantyne, D., Ballantyne, FC, Thiazides, beta‐blockers and lipoproteins (1983) Postgrad Med J, 59, pp. 483-488; Kirkendall, WM, Burton, AC, Epstein, FH, Freis, ED, Subcommittee of the A.H.A. postgraduate educational committee: recommendations for human blood pressure determination by sphygmomanometers (1967) Circulation, 36, pp. 980-988; Ames, RP, Hill, P., Improvement of glucose tolerance and lowering of glycohemoglobin and serum lipid concentrations after discontinuation of antihypertensive drug therapy (1982) Circulation, 65, pp. 899-904; Connor, DT, Grundy, SM, Preston, RA, Mitas, JA, Stone, RA, Plasma cholesterol increases during thiazide treatment of hypertension in man (1979) Clin Res, 27, p. 48A; Smith, U., Adrenergic control of lipid metabolism (1983) Acta Med Scand, pp. 41-47; Day, JL, Metcalfe, J., Simpson, N., Lowenthal, L., Adrenergic mechanisms in the control of plasma lipids in man (1984) Am J Med, 76, pp. 94-96; Avogaro, P., Cazzolato, G., Bon, Quinci, GG, High and low high‐density lipoproteins: clinical implications (1980) Nutr Metab, 24, pp. 34-44; Timolol‐induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction (1981) N Engl J Med, 304, pp. 801-807; A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results (1982) J Am Med Assoc, 247, pp. 1707-1714; Nilsson, A., Hansson, B‐G, Hökfelt, B., Effect of metoprolol on blood glycerol, free fatty acids, triglycerides and glucose in relation to plasma catecholamines in hypertensive patients at rest and following submaximal work (1978) Eur J Clin Pharmacol, 13, pp. 5-8; Bielmann, P., Leduc, G., Davignon, J., Bèta‐bloquants sélectif (métoprolol) vs non‐sélectif (propranolol): effets comparés sur la composition des lipoprotéines plasmatiques et la pression sanguine (1980) Union Med Can, 109, pp. 1734-1740; Joos, C., Kewitz, H., Reinhold‐Kourniati, D., Effects of diuretics on plasma lipoproteins in healthy men (1980) Eur J Clin Pharmacol, 17, pp. 251-257; Amery, A., Birkenhäger, W., Bulpitt, C., Influence of antihypertensive therapy on serum cholesterol in elderly hypertensive patients. Results of trial by the European Working Party on high blood pressure in the elderly (EWPHE) (1982) Acta Cardiol, 37, pp. 235-244; Bengtsson, C., Lennartsson, J., Lindquist, O., On metabolic effects of diuretics and β‐blockers. Results from a cross‐sectional and longitudinal population study of women (1982) Acta Med Scand, 212, pp. 57-64; Pittera, A., Scalisi, P., Sambataro, L., Comparison of the effects of cardioselective and non‐cardioselective beta‐blockers on serum lipids (1983) Curr Ther Res, 34, pp. 483-505; Ferrara, LA, Marotta, T., Scilla, A., Mastranzo, P., Strazzullo, P., Mancini, M., Effect of oxprenolol and metoprolol on serum lipid concentration (1984) Eur J Clin Pharmacol, 26, pp. 331-334; Lehtonen, A., The effect of acebutolol on plasma lipids, blood glucose and serum insulin levels (1984) Acta Med Scand, 216, pp. 57-60","MONMANY, J.; Servei de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Av. Sant Antoni M Claret, 167, Barcelona, 08025, Spain",,,,,,,,09546820,,,"2266340","English","J. Intern. Med. (GBR)",Article,"Final",,Scopus,2-s2.0-0025163452
"Marrugat J., Sanz F., Porta Serra M., Sancho J.","7006226141;7102263897;7102301883;7201937083;","Influence of informatics on clinical and epidemiologic investigation [La influencia de la informática en la investigación clínica y epidemiológica.]",1989,"Medicina Clinica","92","19",,"742","748",,3,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024974643&partnerID=40&md5=cd7335c140efebb0a9f887b4bb8426ab",,"Marrugat, J.; Sanz, F.; Porta Serra, M.; Sancho, J.",[No abstract available],,"epidemiology; human; medical informatics; methodology; research; review; Epidemiologic Methods; Human; Medical Informatics; Research; Research Design",,,,,,,,,,"Marrugat, J.",,,,,,,,00257753,,,"2666779","Spanish","Med Clin (Barc)",Review,"Final",,Scopus,2-s2.0-0024974643
"Porta Serra M., Moreno V., Sanz F., Carné X., Velilla E.","7102301883;7103038363;7102263897;57207555061;6602985576;","A matter of power [Una cuestión de poder.]",1989,"Medicina Clinica","92","6",,"223","228",,9,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0344860551&partnerID=40&md5=af031feb9b2d2eedae2c502727aaa5a0",,"Porta Serra, M.; Moreno, V.; Sanz, F.; Carné, X.; Velilla, E.",[No abstract available],,"clinical trial; drug therapy; human; methodology; review; Clinical Trials; Drug Therapy; Human; Research Design; Statistics",,,,,,,,,,"Porta Serra, M.",,,,,,,,00257753,,,"2651819","Spanish","Med Clin (Barc)",Review,"Final",,Scopus,2-s2.0-0344860551
"Sanz Carreras F.","7102263897;","Sobre la utilización de las urgencias hospitalarias en andalucía",1989,"Gaceta Sanitaria","3","13",,"484","",,,"10.1016/S0213-9111(89)71868-9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024695012&doi=10.1016%2fS0213-9111%2889%2971868-9&partnerID=40&md5=31a64483508b8bf1c7c228d3054ef0b6","Institut Municipal d'lnvestigació Médica, Barcelona, Spain","Sanz Carreras, F., Institut Municipal d'lnvestigació Médica, Barcelona, Spain",[No abstract available],,"emergency health service; letter; multivariate analysis; regression analysis; Spain; utilization review; Emergency Service, Hospital; Multivariate Analysis; Regression Analysis; Spain",,,,,,,,,"Estany, A., Utilización de las urgencias hospitalarias en Andalucía (1987) (1989) Gac Sanit, 10, pp. 313-319; Hanley, J., Utilizaciones adecuadas del análisis multlvariante (1989) Revisiones Salud Pública. (en prensa), 1","Sanz Carreras, F.; Institut Municipal d'lnvestigació Médica, Barcelona, Spain",,,,,,,,02139111,,,"2517752","English","Gaceta Sanit.",Letter,"Final",Open Access,Scopus,2-s2.0-0024695012
"Porta M., Sanz F.","7102301883;7102263897;","Statistical errors in software",1988,"International Journal of Epidemiology","17","4",,"931","",,,"10.1093/ije/17.4.931","https://www.scopus.com/inward/record.uri?eid=2-s2.0-17944391624&doi=10.1093%2fije%2f17.4.931&partnerID=40&md5=485d6db3263272df99f79db4d2390894","Institute of Medical Research, (IMIM), Universitat Autonomy de Barcelona, Pg Maritim 25-29, E-08003 Barcelona, Spain","Porta, M., Institute of Medical Research, (IMIM), Universitat Autonomy de Barcelona, Pg Maritim 25-29, E-08003 Barcelona, Spain; Sanz, F., Institute of Medical Research, (IMIM), Universitat Autonomy de Barcelona, Pg Maritim 25-29, E-08003 Barcelona, Spain",[No abstract available],,"computer program; epidemiology; human; letter; standard; Epidemiologic Methods; Human; Software; Statistics",,,,,,,,,"Wannamethee, G., Sharper, A.G., Men who do not drink (1988) Ini J Epidemiol, 17, pp. 307-316; Shaper, A.G., Pocock, S.J., Ashby, D., Walker, M., Whitehead, T.P., Biochemical and haematological response to alcohol intake (1985) Ann Clin BioChem., 22, pp. 50-61; Wannamethee, G., Shaper, A.G., Changes in drinking habits in middleaged British Men (1988) J Roy Coll General Proa; Pocock, S.J., Shaper, A.G., Phillips, A.N., Walker, M., Whitehead, T.P., High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men (1986) Br Med J, 292, pp. 515-579; Wilcox, A.J., Sandler, D.P., Everson, R.B., Using Father’s age to explore the Role of Germ Cell Mutation as a Cause of Human Cancer (1988) Int J Epidemiol, 17, pp. 469-471; Neutel, C.I., Buck, C.W., The Effect of Smoking during Pregnancy on the Risk of Childhood Cancer (1971) J Nat Cancer Inst, 47, pp. 59-63; Skjaerven, R., Irgens, L.M., Lie, R.T., Sex differences in neonatal survival. Relations to birthweight and gestational age. (Letter to the Editor) (1988) Int J Epidemiol, 17, pp. 687-688; Berman, S.M., Binkin, N.J., Hogue, C.J.R., Assessing sex differences in neonatal survival: A study of discordant twins (1987) Int Epidemiol, 16, pp. 436-440; Vitamin, G.E., C and plasma lipids (1976) New Engl J Med, 294, p. 559; Kothari, L.K., Jain, K., Effect of vitamin C administration on blood cholesterol level in man (1977) Acta Biol, 28, pp. 111-114; Praveen, S., Pramod, J., Sharma, P.K., Chaturvedi, S.K., Kothari, L.K., Effect of Vitamin C administration on serum and aortic lipid profile of guineapigs (1988) Ind J Med Res, 87, pp. 283-289; Kothari, L.K., Praveen, S., Aggravation of cholesterol induced hyperlipidemia by chronic vitamin C deficiency: An experimental study in guineapigs (1988) Acta Biol; Ginter, E., Cholesterol: Vitamin C controls its transformation to bile acids (1973) Science, 179, pp. 702-704; Gatenby Davies, J.D., Newson, J., Ascorbic acid and cholesterol. Levels in pastoral peoples of Kenya (1974) Am J Clin Nutr, 27, pp. 1039-1042; Acheson, R.M., Williams, D.R.R., Does consumption of fruits and vegetable protect against stroke? (1983) Lancet, 1, pp. 1191-1193; Bland, J.M., Altman, D.G., Misleading statistics: Errors in textbooks, software and manuals (1988) Int J Epidemiol, 17, pp. 245-247; (1988) SPSS-X User’s Manual, p. 436. , 3rd edition. Chicago: SPSS Inc; Everitt, B.S., (1977) The Analysis of Contingency Tables, pp. 15-20; Levy, P.S., Lemesbow, S., (1980) Sampling for Health Professionals, pp. 171-198. , Lifetime Learning Publication, Belmont, California","Porta, M.; Institute of Medical Research, (IMIM), Universitat Autonomy de Barcelona, Pg Maritim 25-29, E-08003 Barcelona, Spain",,,,,,,,03005771,,IJEPB,"3225109","English","Int. J. Epidemiol.",Letter,"Final",,Scopus,2-s2.0-17944391624
"Lopez de Mantaras R., Meseguer P., Sanz F., Sierra C., Verdaguer A.","55665410000;6701529411;7102263897;7006398334;6701656988;","Fuzzy logic approach to the management of linguistically expressed uncertainty.",1988,"Proceedings of The International Symposium on Multiple-Valued Logic",,,,"144","151",,4,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024134212&partnerID=40&md5=9b6d7b38c30f72bf1aa39b671867ea49","Cent d'Estudis Avancats de Blanes, Girona, Spain","Lopez de Mantaras, R., Cent d'Estudis Avancats de Blanes, Girona, Spain; Meseguer, P., Cent d'Estudis Avancats de Blanes, Girona, Spain; Sanz, F., Cent d'Estudis Avancats de Blanes, Girona, Spain; Sierra, C., Cent d'Estudis Avancats de Blanes, Girona, Spain; Verdaguer, A., Cent d'Estudis Avancats de Blanes, Girona, Spain","A description is given to the expert system shell called MILORD and, in particular, its management of uncertainty. This shell contains two inference engines, a rule-oriented editor, a rule compiler, and an explanation module. MILORD can be used to perform three different calculi of uncertainty, on an expert-defined set of linguistic labels, depending on three different models of the conjunction, disjunction, and implication operators. The internal representation of each linguistic label is a possibility distribution on the unit interval. The calculus performed on these labels is not closed in general, and, therefore, it is necessary to close it by means of a linguistic approximation process. This, in turn, allows the conjunction, disjunction, and implication operations to be precomputed for all the pairs of linguistic labels, storing the results in matrices. Thus, when MILORD is run on a knowledge base, the propagation and combination of uncertainty is performed accessing the precomputed matrices. The examples given correspond to an application to the diagnosis of pneumonias.",,"MATHEMATICAL TECHNIQUES -- Fuzzy Sets; CONJUNCTION, DISJUNCTION, AND IMPLICATION OPERATIONS; FUZZY LOGIC; INFERENCE ENGINES; LINGUISTICALLY EXPRESSED UNCERTAINTY; ARTIFICIAL INTELLIGENCE",,,,,,,,,,"Lopez de Mantaras, R.; Cent d'Estudis Avancats de Blanes, Girona, Spain",,"IEEE, Computer Soc, MVL Technical Committee, Los Alamitos, CA, US;Universidad de Las Islas Baleares, Spain;CSIC, Spain","Publ by IEEE, Piscataway, NJ, United States","Proceedings - Eighteenth International Symposium on Multiple-Valued Logic.",,"Palma de Mallorca, Spain",,0195623X,0818608595,PSMLD,,"English","Proc Int Symp Mult Valued Logic",Conference Paper,"Final",,Scopus,2-s2.0-0024134212
"Porta Serra M., Plasencia A., Sanz F.","7102301883;7005155812;7102263897;","The quality of clinical information (III): Statistically significant or clinically important? [La calidad de la información clínica (y III): Estadísticamente significativo o clínicamente importante?]",1988,"Medicina Clinica","90","11",,"463","468",,21,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024291610&partnerID=40&md5=29c0dbe0ee38092a7c84d8eb7f9088a0",,"Porta Serra, M.; Plasencia, A.; Sanz, F.",[No abstract available],,"human; research; review; Human; Research; Statistics",,,,,,,,,,"Porta Serra, M.",,,,,,,,00257753,,,"3290595","Spanish","Med Clin (Barc)",Review,"Final",,Scopus,2-s2.0-0024291610
"Monteis J., Fossas P., Hernández A., Sanz F.","6602904090;6603806466;57201750990;7102263897;","Duration of the apnea test in the neurological diagnosis of death [Duración de la prueba de la apnea en el diagnóstico neurológico de la muerte.]",1988,"Medicina Clinica","90","10",,"408","411",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-18744425897&partnerID=40&md5=66209874b025aa8d5d36969fa6648cb4",,"Monteis, J.; Fossas, P.; Hernández, A.; Sanz, F.",[No abstract available],,"carbon dioxide; oxygen; adult; apnea; article; blood; comparative study; death; female; human; male; neurologic examination; pH; time; Adult; Apnea; Carbon Dioxide; Comparative Study; Death; English Abstract; Female; Human; Hydrogen-Ion Concentration; Male; Middle Age; Neurologic Examination; Oxygen; Time Factors",,"carbon dioxide, 124-38-9, 58561-67-4; oxygen, 7782-44-7; Carbon Dioxide, 124-38-9; Oxygen, 7782-44-7",,,,,,,,"Monteis, J.",,,,,,,,00257753,,,"3135455","Spanish","Med Clin (Barc)",Article,"Final",,Scopus,2-s2.0-18744425897
"Castaneda G., Sanz F., Monteis J., Nogue S.","56363481200;7102263897;6602904090;7007048715;","Multivariate analysis of the predictive factors of mortality",1988,"Medicina Intensiva","12","10",,"539","542",,,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024230657&partnerID=40&md5=1f2d3388a3f7ac7fae1828d827b3f889","Departamento de Informatica Biomedica, Instituto Municipal de Investigacion Medica, Barcelona, Spain","Castaneda, G., Departamento de Informatica Biomedica, Instituto Municipal de Investigacion Medica, Barcelona, Spain; Sanz, F., Departamento de Informatica Biomedica, Instituto Municipal de Investigacion Medica, Barcelona, Spain; Monteis, J., Departamento de Informatica Biomedica, Instituto Municipal de Investigacion Medica, Barcelona, Spain; Nogue, S., Departamento de Informatica Biomedica, Instituto Municipal de Investigacion Medica, Barcelona, Spain",[No abstract available],,"fatality; forecasting; human; intensive care; intoxication; major clinical study; methodology; mortality; temperature; theoretical study",,,,,,,,,,,,,,,,,,02105691,,MDINE,,"Spanish","MED. INTENSIVA",Article,"Final",,Scopus,2-s2.0-0024230657
"Sitges‐Serra A., Mas X., Roqueta F., Figueras J., Sanz F.","7007049436;57086914300;6602125071;35603150300;7102263897;","Mesenteric infarction: an analysis of 83 patients with prognostic studies in 44 cases undergoing a massive small‐bowel resection",1988,"British Journal of Surgery","75","6",,"544","548",,62,"10.1002/bjs.1800750614","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023952515&doi=10.1002%2fbjs.1800750614&partnerID=40&md5=6a426adb5db7356389b30464ce8e2224","Department of Surgery and Institut Municipal d'Investigacions Mèdiques, Hospital de Nostra Senyora del Mar, Barcelona, Spain; Department of Surgery, Hospital de Bellvitge, Barcelona, Spain","Sitges‐Serra, A., Department of Surgery and Institut Municipal d'Investigacions Mèdiques, Hospital de Nostra Senyora del Mar, Barcelona, Spain; Mas, X., Department of Surgery and Institut Municipal d'Investigacions Mèdiques, Hospital de Nostra Senyora del Mar, Barcelona, Spain; Roqueta, F., Department of Surgery, Hospital de Bellvitge, Barcelona, Spain; Figueras, J., Department of Surgery, Hospital de Bellvitge, Barcelona, Spain; Sanz, F., Department of Surgery and Institut Municipal d'Investigacions Mèdiques, Hospital de Nostra Senyora del Mar, Barcelona, Spain","A series is presented of 83 patients surgically explored for massive bowel infarction. Old men with previous heart disease and symptoms of peripheral atherosclerosis were primarily affected. Clinical presenting features were abdominal pain (100 per cent), peritonitis (57 per cent), shock (34 per cent) and hypothermia (26 per cent). A third‐space syndrome with metabolic acidosis and uraemia was the most common physiological derangement. Age was the only factor that appeared to have influenced the surgeon's decision to perform massive bowel resection (71 years in non‐resected versus 64 years in resected patients, P < 0.006). The overall mortality rate was 71 per cent. Forty‐four patients underwent massive bowel resection (mean length of remaining small bowel 60 ± 40 cm) and twenty‐four (54 per cent) survived the procedure. Axillary temperature was higher in survivors (36.7°C versus 36.1°C, P < 0.03). Early postoperative total plasma protein and albumin concentrations were also higher in survivors (57 versus 46 g/l, P < 0.005; 27 versus 22 g/l, P < 0.02). Patients with previous symptoms of atherosclerotic disease and high pre‐operative blood urea levels also had a bad prognosis. Survivors had a mean hospital stay of 57 days and parenteral nutrition had to be maintained for a mean of 34 days. The survival rate achieved with massive resection justifies this surgical approach in selected patients with massive bowel infarction. Copyright © 1988 British Journal of Surgery Society Ltd.","Bowel resection; mesenteric infarction","adult; aged; complication; female; human; intestine resection; major clinical study; male; mesenteric artery occlusion; peritonitis; prognosis; Aged; Female; Human; Infarction; Intestine, Small; Male; Mesenteric Arteries; Mesenteric Vascular Occlusion; Middle Age; Prognosis; Risk Factors",,,,,,,,,"Ottinger, LW, The surgical management of acute occlusion of the superior mesenteric artery (1978) Ann Surg, 188, pp. 721-731; Buchardt, HJ, Korgh Christoffersen, J, Occlusive mesenteric infarction. A retrospective study of 83 cases (1976) Acta Chir Scand, 472, pp. 103-106. , (Suppl.); Krausz, MM, Manni, J, Acute superior mesenteric arterial occlusion: a plea for early diagnosis (1978) Surgery, 83, pp. 482-485; Rius, X, Escalante, JF, Llauradó, JM, Jover, J, Puig Lacalle, J, Mesenteric infarction (1979) World J Surg, 3, pp. 489-496; Andersson, R, Parsson, H, Isaksson, B, Norgren, L, Acute intestinal ischemia. A 14‐year retrospective investigation (1984) Acta Chir Scand, 150, pp. 217-221; Bergan, JJ, Dean, RH, Conn, J, Jr, Yao, JST, Revascularization in treatment of mesenteric infarction (1975) Ann Surg, 182, pp. 430-438; Boley, SJ, Feinstein, FR, Sammartano, R, Brandt, LJ, Sprayregen, S, New concepts in the management of emboli of the superior mesenteric artery (1981) Surg Gynecol Obstet, 153, pp. 561-569; Williamson, RCN, Intestinal adaptation, Structural, functional and cytokinetic changes (1978) N Engl J Med, 298, pp. 1393-1402; Scheflan, M, Galli, SJ, Perrotto, J, Fischer, JE, Intestinal adaptation after extensive resection of the small intestine and prolonged administration of parenteral nutrition (1976) Surg Gynecol Obstet, 143, pp. 757-762; Jacobson, S, Nine year's survival with short bowel syndrome after occlusion of the superior mesenteric artery in an elderly man: a study of periods of parenteral nutrition (1982) JPEN, 6, pp. 539-544; Jeejeebhoy, KN, Therapy of the short gut syndrome (1983) Lancet, 1, pp. 1427-1430; Kairaluoma, MI, Karkola, P, Heikkinen, E, Huttunen, R, Mokka, REM, Larmi, TKI, Mesenteric infarction (1973) Am J Surg, 133, pp. 188-193; Sachs, SM, Moerton, JH, Schwartz, SI, Acute mesenteric ischemia (1982) Surgery, 92, pp. 646-653; Valdivieso, A, de La Fuente, MT, Oleagoitia, JM, Ulacia, MA, Hernández Calvo, J, Isquemia mesentérica aguda (1983) Rev Clin Esp, 170, pp. 195-198; Abdu, RA, Zakhour, BJ, Dallis, DJ, Mesenteric venous thrombosis—1911 to 1984 (1987) Surgery, 101, pp. 383-388; Boley, SJ, Sprayregen, S, Siegelman, SS, Veith, FJ, Initial results from an aggressive roentgenological and surgical approach to acute mesenteric ischemia (1977) Surgery, 82, pp. 848-855; Gouttebel, MC, Saint‐Aubert, B, Astre, C, Joyeux, H, Total parenteral nutrition needs in different types of short bowel syndrome (1986) Dig Dis Sci, 31, pp. 718-723","Sitges‐Serra, A.; Servicio de Cirugía General, Hospital de Nuestra Señora del Mar, Universidad Autónoma de Barcelona, Paseo Marítimo s/n, Barcelona, 08003, Spain",,,,,,,,00071323,,,"3395820","English","Br. J. Surg.",Article,"Final",,Scopus,2-s2.0-0023952515
"Luque F.J., Sanz F., Illas F., Pouplana R., Smeyers Y.G.","23025357900;7102263897;56784420800;6602810947;7004259819;","Relationships between the activity of some H2-receptor agonists of histamine and their ab initio molecular electrostatic potential (MEP) and electron density comparison coefficients",1988,"European Journal of Medicinal Chemistry","23","1",,"7","10",,26,"10.1016/0223-5234(88)90160-2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023848399&doi=10.1016%2f0223-5234%2888%2990160-2&partnerID=40&md5=89c20c96902ab4cefae90e2f5dc86db6","Dept. Informàtica Biomédica, Institut Municipal Investigació Mèdica and Facultat de Medicina, Universitat Autònoma de Barcelona, Passeig Maritiím 25-29, 08003 BarcelonaSpain; Dept. Fisicoquímica Aplicada, Facultat de Farmacia, Universitat de Barcelona, Av. Diagonal s/n, 08028 Barcelona, Spain; Instituto de Estructura de la Materia, C.S.I.C., Serrano 119, 28006 Madrid, Spain","Luque, F.J., Dept. Informàtica Biomédica, Institut Municipal Investigació Mèdica and Facultat de Medicina, Universitat Autònoma de Barcelona, Passeig Maritiím 25-29, 08003 BarcelonaSpain; Sanz, F., Dept. Informàtica Biomédica, Institut Municipal Investigació Mèdica and Facultat de Medicina, Universitat Autònoma de Barcelona, Passeig Maritiím 25-29, 08003 BarcelonaSpain; Illas, F., Dept. Fisicoquímica Aplicada, Facultat de Farmacia, Universitat de Barcelona, Av. Diagonal s/n, 08028 Barcelona, Spain; Pouplana, R., Dept. Fisicoquímica Aplicada, Facultat de Farmacia, Universitat de Barcelona, Av. Diagonal s/n, 08028 Barcelona, Spain; Smeyers, Y.G., Instituto de Estructura de la Materia, C.S.I.C., Serrano 119, 28006 Madrid, Spain","From an analysis of the ab initio molecular electrostatic potential (MEP) maps of some H2-receptor agonists of histamine in their essential trans-trans conformations, for both neutral and cationic species, a good relationship between H2-activity data and the MEP minima located at the Nπ nitrogen atom of the imidazole ring is predicted. From these data it appears easy to define a threshold value according to which the H2-agonists may be classified as being strongly or weakly active. While the MEP values appear to be a good parameter for activity prediction, in this case, the comparison of electron densities does not give any additional useful information. © 1988.","activity prediction; histamine H2-receptor agonist; molecular electrostatic potential (MEP)","histamine; histamine derivative; nonhuman; pharmacodynamics; structure activity relation; theoretical study",,"histamine, 51-45-6, 56-92-8, 93443-21-1",,,,,,,"Ash, Schild, (1966) Br. J. Pharmacol. Chemother., 27, p. 427; Black, Duncan, Durant, Ganellin, Parsons, (1972) Nature, 236, p. 385; Schwartz, Arrang, Garbarg, (1986) Trends Pharmacol. Sci., 1, p. 24; Durant, Ganellin, Parsons, (1975) J. Med. Chem., 18, p. 905; Kier, (1968) J. Med. Chem., 11, p. 441; Ganellin, (1973) J. Med. Chem., 16, p. 620; Smeyers, Romero Sánchez, Hernández Laguna, Theoretical study of some H2-receptor agonists of histamine. The H2-essential conformation of histamine (1985) Journal of Molecular Structure: THEOCHEM, 123, p. 431; Smeyers, Romero Sánchez, Hernández Laguna, QSAR and Strategies in the Design of Bioactive Compounds (1985) Proceedings of the 5th European QSAR Symposium, pp. 374-377. , K.J Seydel, VCH, Weinheim; Weinstein, Chou, Johnson, Kang, Green, (1976) Mol. Pharmacol., 12, p. 738; Scrocco, Tomasi, (1973) Top. Curr. Chem., 42, p. 95; Carbó, Leyda, Arnau, (1980) Int. J. Quantum Chem., 17, p. 95; Ganellin, Parsons, (1982) Pharmacology of Histamine Receptors, , Wright PSG, Bristol; Martín, Sanz, Campillo, Pardo, Pérez, Turmo, Quantum chemical study of the molecular patterns of MAO inhibitors and substrates (1983) International Journal of Quantum Chemistry, 23, p. 1627","Luque, F.J.",,,,,,,,02235234,,EJMCA,,"English","Eur. J. Med. Chem.",Article,"Final",,Scopus,2-s2.0-0023848399
"Sanz F., Manaut F., José J., Segura J., Carbó M., De La Torre R.","7102263897;6602255071;16429212200;7202394545;6602710070;55418333700;","Automatic determination of MEP patterns of molecules and its application to caffeine metabolism inhibitors",1988,"Journal of Molecular Structure: THEOCHEM","170","C",,"171","180",,31,"10.1016/0166-1280(88)80060-5","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0013128555&doi=10.1016%2f0166-1280%2888%2980060-5&partnerID=40&md5=b48bc0ddfea2a8330500396bed3da8a7","Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.) Passeig Marítim, 08003 Barcelona, Spain","Sanz, F., Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.) Passeig Marítim, 08003 Barcelona, Spain; Manaut, F., Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.) Passeig Marítim, 08003 Barcelona, Spain; José, J., Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.) Passeig Marítim, 08003 Barcelona, Spain; Segura, J., Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.) Passeig Marítim, 08003 Barcelona, Spain; Carbó, M., Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.) Passeig Marítim, 08003 Barcelona, Spain; De La Torre, R., Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.) Passeig Marítim, 08003 Barcelona, Spain","Software has been developed to locate and determine accurately all the Molecular Electrostatic Potential (MEP) minima of a molecule and to plot the MEP maps corresponding to planes containing any three desired points (minima, atoms or dummy points). The minima description can be used as parameters in QSAR. Some of these techniques are used in the analysis of substances which inhibit caffeine metabolism and other similar, but inactive, compounds. The goal is to find electrostatic requirements associated with this inhibitory activity. © 1988.",,,,,,,"Comisión Asesora de Investigación Científica y Técnica, CAICYT","work has been partially funded by CAICYT",,,"Richards, (1983) Quantum Pharmacology, , Butterworths, London, Chap. 16; Liebman, Approach to modelling specificity determinants in receptor-ligand complexes: congeners of serotonin (1986) Journal of Molecular Graphics, 4, p. 61; Macchia, Balsamo, Lapucci, Martinelli, Macchia, Breschi, Fantoni, Martinotti, (1985) J. Med. Chem., 28, p. 153; Martin, Sanz, Campillo, Pardo, Pérez, Turmo, Quantum chemical study of the molecular patterns of MAO inhibitors and substrates (1983) International Journal of Quantum Chemistry, 23, p. 1627; Martin, Sanz, Campillo, Pardo, Pérez, Turmo, Aulló, Quantum chemical structure-activity relationships on ?-carbolines as natural monoamine oxidase inhibitors (1983) International Journal of Quantum Chemistry, 23, p. 1643; Luque, Sanz, Illas, Pouplana, Smeyers, (1988) Eur. J. Med. Chem., 23, p. 7; Wijnands, van Herwaarden, Vree, (1984) Lancet, 1, p. 108; Tarrús, Camí, Roberts, Spiekett, Celdran, Segura, Accumulation of caffeine in healthy volunteers treated with furafylline. (1987) British Journal of Clinical Pharmacology, 23, p. 9; Segura, de la Torre, Carbó, Badenas, Camí, (1987) Third European Congress of Biopharmaceuties and Pharmacokinetics, Freiburg; J. A. Pople, GAUSSIAN 82 program. Carnegie-Mellon University; Dewar Research Group. QCPE program. no. 506","Sanz, F.; Institut Municipal d'Investigació Mèdica, Facultat de Medicina (U.A.B.) Passeig Marítim, 08003 Barcelona, Spain",,,,,,,,01661280,,THEOD,,"English","J. Mol. Struct. THEOCHEM",Article,"Final",,Scopus,2-s2.0-0013128555
"Gil-Egea M.J., Pi-Sunyer M.T., Verdaguer A., Sanz F., Sitges-Serra A., Eleizegui L.T.","6507135650;6505768446;57198324511;7102263897;7007049436;6504737045;","Surgical wound infections: prospective study of 4,468 clean wounds.",1987,"Infection control : IC","8","7",,"277","280",,65,"10.1017/S0195941700066236","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023377062&doi=10.1017%2fS0195941700066236&partnerID=40&md5=dde75d148aec37f8875c47e40aae88d7",,"Gil-Egea, M.J.; Pi-Sunyer, M.T.; Verdaguer, A.; Sanz, F.; Sitges-Serra, A.; Eleizegui, L.T.","A prospective four-year study on the infection rate of clean operative wounds is presented. From January 1982 to June 1985, a nurse epidemiologist and a medical team assessed 4,468 operative procedures, from the day of surgery to the patients' discharge from the hospital. The infection rate was 3.2%. A higher incidence of wound infection was detected in patients requiring emergency operations (5.1%), in drained wounds (5.4%), and in patients with conditions thought to predispose to infection, such as advanced cancer, hepatic cirrhosis, diabetes, nephrotic syndrome, previous splenectomy, and treatment with immunosuppressive drugs (7.8%). Age over 65 did not influence infection rates. There were up to tenfold differences in infection indices between surgeons performing the same clean procedures. The continued monitoring of clean wound infection rates allowed the early detection and control of infection outbreaks. Providing periodic information on infection rates to the different surgical services was associated with decreasing infection rates over time.",,"age; article; computer program; cross infection; epidemic; human; immunological tolerance; prospective study; surgical infection; time; Age Factors; Cross Infection; Disease Outbreaks; Humans; Immune Tolerance; Prospective Studies; Software; Surgical Wound Infection; Time Factors",,,,,,,,,,"Gil-Egea, M.J.",,,,,,,,01959417,,,"3650204","English","Infect Control",Article,"Final",,Scopus,2-s2.0-0023377062
"Sanz F., Martiń M., Lapeña F., Manaut F.","7102263897;7406972296;6508289971;6602255071;","Quantitative Structure‐Activity Relationships on MAO Substrates by Means of Quantum Chemical Properties",1986,"Quantitative Structure‐Activity Relationships","5","2",,"54","57",,12,"10.1002/qsar.19860050204","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022608982&doi=10.1002%2fqsar.19860050204&partnerID=40&md5=21a0df1d3d810ec5eb0802e0f250e0af","Institut Municipal D'investigació Mèdica, Passeig Marítim s/n, Barcelona, 08003, Spain; Fac. Medicina, Universitat Autònoma de Barcelona, Dep. Bioestadistica, Bellaterra, Barcelona, Spain","Sanz, F., Institut Municipal D'investigació Mèdica, Passeig Marítim s/n, Barcelona, 08003, Spain, Fac. Medicina, Universitat Autònoma de Barcelona, Dep. Bioestadistica, Bellaterra, Barcelona, Spain; Martiń, M., Fac. Medicina, Universitat Autònoma de Barcelona, Dep. Bioestadistica, Bellaterra, Barcelona, Spain; Lapeña, F., Institut Municipal D'investigació Mèdica, Passeig Marítim s/n, Barcelona, 08003, Spain; Manaut, F., Institut Municipal D'investigació Mèdica, Passeig Marítim s/n, Barcelona, 08003, Spain","The structural and electrostatic requirements for the two types of monoamine oxidase (MAO) activity are quantitatively studied using similarity coefficients between the electron density and the molecular electrostatic potential (MEP) distributions of a set of substrates. For the comparison of electron density distributions, the RXY similarity coefficient is used. In the case of MEP a new similarity coefficient is defined. Correlations between these coefficients and the experimental activities are studied and the results are consistent with previous ones. This shows the interest of this two parameters in QSAR studies. Copyright © 1986 WILEY‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim","electron density; MAO; MAO substrates; molecular electrostatic potential (MEP); molecular similarity; Quantum chemical parameters","amine oxidase (flavin containing); aniline; benzylamine; dopamine; serotonin; tryptamine; tyramine; drug structure; in vitro study; nonhuman; quantum theory; structure activity relation",,"amine oxidase (flavin containing), 37255-42-8, 9001-66-5, 9059-11-4; aniline, 142-04-1, 62-53-3; benzylamine, 100-46-9, 2182-52-7, 3287-99-8; dopamine, 51-61-6, 62-31-7; serotonin, 50-67-9; tryptamine, 343-94-2, 61-54-1; tyramine, 51-67-2, 60-19-5",,,,,,,"Knoll, J., (1980) Enzyme Inhibitors as Drugs, pp. 151-171. , M. Sandler, McMillan Press, London; Fowler, C.J., (1982) Drugs of the Future, 7, pp. 501-517; Martin, M., Sanz, F., Campillo, M., Pardo, L., Pérez, J., Turmo, J., Quantum chemical study of the molecular patterns of MAO inhibitors and substrates (1983) International Journal of Quantum Chemistry, 23, pp. 1627-1641; Martin, M., Sanz, F., Campillo, M., Pardo, L., Pérez, J., Turmo, J., Aulló, J.M., Quantum chemical structure-activity relationships on ?-carbolines as natural monoamine oxidase inhibitors (1983) International Journal of Quantum Chemistry, 23, pp. 1643-1652; Sanz, F., Martin, M., Pérez, J., Turmo, J., Mitjana, A., Moreno, V., (1983) Quantitative Approaches to Drug Design, pp. 77-78. , J. C. Dearden, Elsevier, Amsterdam; Richards, W.G., (1984) Endeaviour, 8, pp. 172-178; Carbó, R., Leyda, L., Arnau, M., How similar is a molecule to another? An electron density measure of similarity between two molecular structures (1980) International Journal of Quantum Chemistry, 17, pp. 1185-1189; Tomasi, J., Scrocco, E., (1973) Top. Curr. Chem., 42, p. 95; Hopfinger, A.J., (1980) JACS, 102, pp. 7196-7206; Fowler, C.J., Oreland, L., Marcusson, J., Winblad, B., (1980) Naunyn‐Schmiedeberg's Arch. Pharmacol., 311, pp. 263-272; Tute, M.S., (1980) Physical Chemical Properties of Drugs, Medicinal Research Series, 10, pp. 141-161. , Yalkowsky, et al. (Eds.), Marcel Dekker Inc., New York","Sanz, F.; Fac. Medicina, Universitat Autònoma de Barcelona, Dep. Bioestadistica, Bellaterra, Barcelona, Spain",,,,,,,,09318771,,,,"English","Quant. Struct.-Act. Relatsh.",Article,"Final",,Scopus,2-s2.0-0022608982
"Martin M., Sanz F., Campillo M., Pardo L., Pérez J., Turmo J.","7406972296;7102263897;7007077709;57191468466;57189311628;57191467400;","Quantum chemical study of the molecular patterns of MAO inhibitors and substrates",1983,"International Journal of Quantum Chemistry","23","4",,"1627","1641",,29,"10.1002/qua.560230444","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84990723317&doi=10.1002%2fqua.560230444&partnerID=40&md5=e02ab13e27abe895d524c8aa5f769317","Department Bioestadística, Facultat Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain","Martin, M., Department Bioestadística, Facultat Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Sanz, F., Department Bioestadística, Facultat Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Campillo, M., Department Bioestadística, Facultat Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Pardo, L., Department Bioestadística, Facultat Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Pérez, J., Department Bioestadística, Facultat Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Turmo, J., Department Bioestadística, Facultat Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain","Similarities and differences between mitochondrial monoamine oxidase (MAO) substrates and inhibitors (both A and B types) are considered, studying quantitatively two molecular properties: electron density and molecular electrostatic potential (MEP). The following molecules are considered: substrates: PHEA, BZA, tele‐N‐methyl‐histamine, phenylethanolamine, phenylpropylamine, tryptamine, dopamine, phenoxylethylamine, noradrenaline, serotonin, and p‐nitro‐phenylethanolamine; inhibitors: Deprenil, Clorgyline, and Lilly 51641 (only the moiety involved in the A–B differentiation is considered). The wave functions needed to calculate the analyzed properties are of ab initio quality, and have been calculated in analogous conformations, all near the energetic minima. Electron densities distributions are qualitatively compared by means of a correlation coefficient defined over the whole space. Otherwise, patterns of the possible zones of electrostatic interactions are described by means of the distances and angles between minima, in order to differentiate MAO‐A and MAO‐B substrates. The results reproduce efficiently the experimental classification and enable us to predict the type of enzymatic action of molecules not yet experimentally classified. Copyright © 1983 John Wiley & Sons, Inc.",,,,,,,,,,,"Johnston, J.P., (1968) Biochem. Pharmacol., 17, p. 1285; Knoll, J., Ecsery, Z., Kelemen, K., Nievel, J.G., Knoll, B., (1965) Arch. Int. Pharmacodyn. Ther., 155, p. 154; Knoll, J., Magyar, K., (1972) Adv. Biochem. Psychopharmacol., 5, p. 393; (1979) Monoamine Oxidase Structure Function and Altered Functions, , P. Singer, R. W. von Korff, D. L. Murphy, Academic, New York; Severina, I.S., (1979) Monoamine Oxidase Structure Function and Altered Functions, p. 169. , P. Singer, R. W. von Korff, D. L. Murphy, Academic, New York; Knoll, J., (1980) Enzime Inhibitors as Drugs, p. 151. , M. Sandler, MacMillan, London; Tomás, F., Aulló, J.M., (1979) J. Pharm. Sci., 68, p. 772; Sabljić, A., Trinajstić, X., (1981) Acta Pharm. Yugosl., 31, p. 189; Knoll, J., (1982) Strategy in Drug Research, p. 107. , Elsevier, Amsterdam; Sufim, J.R., Dunn, D.A., Marshall, G.R., (1981) Mol. Pharm., 19, p. 307; Carbó, R., Leyda, L., Arnau, M., How similar is a molecule to another? An electron density measure of similarity between two molecular structures (1980) International Journal of Quantum Chemistry, 17, p. 1185; Scrocco, E., Tomasi, J., (1973) Topics Current Chem., 42, p. 95; Suzuki, O., Katsumata, Y., Oya, M., , p. 197. , in Ref. 3, p; Martin, M., Sanz, F., Campillo, M., Pardo, L., Perez, J., Turmo, J., Aulló, J.M., Quantum chemical structure-activity relationships on ?-carbolines as natural monoamine oxidase inhibitors (1983) International Journal of Quantum Chemistry, 23, p. 1643; Castro, J., Unzeta, M., Martin, M., Sanz, F., (1982) Afinidad, 39, p. 321","Martin, M.; Department Bioestadística, Facultat Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain",,,,,,,,00207608,,,,"English","Int J Quantum Chem",Article,"Final",,Scopus,2-s2.0-84990723317
"Martin M., Sanz F., Campillo M., Pardo L., Perez J., Turmo J., Aulló J.M.","7406972296;7102263897;7007077709;57191468466;57189311628;57191467400;6507283147;","Quantum chemical structure–activity relationships on β‐carbolines as natural monoamine oxidase inhibitors",1983,"International Journal of Quantum Chemistry","23","4",,"1643","1652",,30,"10.1002/qua.560230445","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84990735930&doi=10.1002%2fqua.560230445&partnerID=40&md5=b2089d3a1a16023a6773b1de1f4f5837","Department Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Universitat de València, Burjassot, València, Spain","Martin, M., Department Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Sanz, F., Department Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Campillo, M., Department Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Pardo, L., Department Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Perez, J., Department Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Turmo, J., Department Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain; Aulló, J.M., Universitat de València, Burjassot, València, Spain","The electron density and the molecular electrostatic potential of the β‐carbolines are studied using ab initio STO‐3G wave functions. The analysis was done from the point of view of a previous model built with monoamine oxidase substrates and irreversible inhibitors. The results confirm the usefulness of the model and make it possible to propose new precision to the molecular electrostatic potential patterns needed to have monoamine oxidase inhibitory activity. Copyright © 1983 John Wiley & Sons, Inc.",,,,,,,,,,,"Martin, M., Sanz, F., Perez, J., Turmo, J., Campillo, M., Pardo, L., Quantum chemical study of the molecular patterns of MAO inhibitors and substrates (1983) International Journal of Quantum Chemistry, 23, p. 1627. , preceding paper; Buckholtz, N., Boggan, W.O., (1977) Biochem. Pharmacol., 26, p. 1991; Tomás, F., Aulló, J.M., (1979) J. Pharm. Sci., 68, p. 772; Quantum Chemistry Program Exchange (QCPE) No. 141; Pasternak, R.A., The crystal structure of glycyl-L-tryptophan dihydrate (1956) Acta Crystallographica, 9, p. 341; Bak, B., Hansen‐Neggaarel, L., Rastmp‐Andersen, J., (1958) J. Mol. Spectrosc., 2, p. 361; Tomasi, J., Scrocco, E., (1973) Topics Current Chem., 42, p. 95; Carbó, R., Leyda, L., Arnau, M., How similar is a molecule to another? An electron density measure of similarity between two molecular structures (1980) International Journal of Quantum Chemistry, 17, p. 1185; Udenfriend, S., Witkop, B., Redfield, B.G., Weissbach, H., (1958) Biochem. Pharmacol., 1, p. 160; McIsaac, W.M., Estevez, V., (1966) Biochem. Pharmacol., 15, p. 1625","Martin, M.; Department Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain",,,,,,,,00207608,,,,"English","Int J Quantum Chem",Article,"Final",,Scopus,2-s2.0-84990735930
"Martín M., Sanz F., Andreu D.","7406973550;7102263897;7006426092;","Effect of the introduction of biostatistics into the curriculum of the study of medicine. Analysis of a decade in the periodical ""Medicina Clínica (Barcelona)"" [Efecto de la introducción de la bioestadística en el curriculum de los estudios de medicina. Análisis de una década en la revista Medicina Clínica (Barcelona).]",1982,"Medicina Clinica","79","6",,"273","276",,8,,"https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020484013&partnerID=40&md5=5dd802cda7ca8b0e18781a84bc8f5eed",,"Martín, M.; Sanz, F.; Andreu, D.",[No abstract available],,"article; curriculum; medical education; methodology; Spain; Curriculum; Education, Medical; English Abstract; Periodicals; Research Design; Spain; Statistics",,,,,,,,,,"Martín, M.",,,,,,,,00257753,,,"7144315","Spanish","Med Clin (Barc)",Article,"Final",,Scopus,2-s2.0-0020484013
"Sanz F., Bertran J.","7102263897;7006805708;","The role of solvation in redox processes",1979,"Chemical Physics Letters","62","2",,"255","258",,2,"10.1016/0009-2614(79)80170-0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-49249146734&doi=10.1016%2f0009-2614%2879%2980170-0&partnerID=40&md5=a865511a7d3771094e0071cdea9bed4c","Department de Bioestadistica, Facultat de Medicina, Universitat Autónoma de Barcelona., Bellaterra, Barcelona, Spain; Department de Quimica-Fisica, Facultat de Ciencies. Universitat Autónoma de Barcelona., Bellaterra, Barcelona, Spain","Sanz, F., Department de Bioestadistica, Facultat de Medicina, Universitat Autónoma de Barcelona., Bellaterra, Barcelona, Spain; Bertran, J., Department de Quimica-Fisica, Facultat de Ciencies. Universitat Autónoma de Barcelona., Bellaterra, Barcelona, Spain","In studying the role of solvation in redox processes we consider the influence of geometrical modifications in the discharge of monosolvated anion CN--H2O. We define as ""efficient"" those modifications whose energy cost is less than the lowering which is produced in the ionization potential. we conclude that in the above-mentioned species the redox process is enhanced by desolvation. We try to generalise the results for the ""stable"" anions and cations. © 1979.",,,,,,,,,,,"Ramuni, Salem, Solvent-Assisted Surface Crossings: A Description of Photochemical Electron Transfer Reactions (1976) Zeitschrift für Physikalische Chemie, 101, p. 123; Koopmans, (1933) Physica, 1, p. 104; Decoret, Royer, Chalvet, (1975) Tetrahedron, 31, p. 973; Minot, Trong Anh, (1975) Tetrahedron Letters, p. 3905; Forero, Bertran, Fernandez-Alonso, (1977) Progress in theorical organic chemistry, 2, p. 310. , I.G. Csizmadia, Elsevier, Amsterdam, Applications of MO theory in organic chemistry; Sanz, Bertran, (1978) Gazz. Chim. Ital., 108, p. 153; Bingham, Dewar, Lo, (1975) J. Am. Chem. Soc., 97, p. 1285; W.C. Davidon, Argonne National Laboratory Report ANL-5990 Rev., 1953; Fletcher, Powell, A Rapidly Convergent Descent Method for Minimization (1963) The Computer Journal, 6, p. 163; Fletcher, Function Minimization Without Evaluating Derivatives--a Review (1965) The Computer Journal, 8, p. 33; Davidon, (1968) Computer J., 10, p. 406; Powell, (1971) J. Inst. Math. Appl., 7, p. 21; M.J.S. Dewar, H. Metiu P.J. Student, A. Brown, R.C. Bingham, D.H. Lo, C.A. Ramsden, H. Kolimar, P. Werner and P.K. Bischof, Program no. 729, Quantum Chemistry Program Exchange, Chemistry Department, Indiana University, B loomington, Indian; J. Olivella, private communication; Epiotis, The Theory of Pericyclic Reactions (1974) Angewandte Chemie International Edition in English, 13, p. 751; Dewar, Dougherty, (1975) The PMO theory of organic chemistry, p. 57. , Plenum Press, New York; Fukui, Theory of orientation and stereoselection, p. 10. , Springer, Berlin, 1075","Sanz, F.; Department de Bioestadistica, Facultat de Medicina, Universitat Autónoma de Barcelona., Bellaterra, Barcelona, Spain",,,,,,,,00092614,,CHPLB,,"English","Chem. Phys. Lett.",Article,"Final",,Scopus,2-s2.0-49249146734
"Carbó R., Hernández J.A., Sanz F.","7006463633;24550317800;7102263897;","Unconditional convergence in SCF theory: a general level shift technique",1977,"Chemical Physics Letters","47","3",,"581","583",,24,"10.1016/0009-2614(77)85046-X","https://www.scopus.com/inward/record.uri?eid=2-s2.0-0041961441&doi=10.1016%2f0009-2614%2877%2985046-X&partnerID=40&md5=458bb6223ecc5799acdbe72e7485de37","Department of Chemistry, University of Alberta, Edmonton, Alta., Canada; Sección de Química Cuántica, Instituto Químico de Sarriá, Barcelona 17, Spain","Carbó, R., Department of Chemistry, University of Alberta, Edmonton, Alta., Canada; Hernández, J.A., Sección de Química Cuántica, Instituto Químico de Sarriá, Barcelona 17, Spain; Sanz, F., Sección de Química Cuántica, Instituto Químico de Sarriá, Barcelona 17, Spain","A level shift procedure is described in the framework of one-operator SCF formalisms. This procedure permits one to obtain in any case unconditional convergence to a stationary energy. © 1977.",,,,,,,,,,,"Sleeman, (1968) Theoret. Chim. Acta, 11, p. 135; Harrison, Henderson, Massa, Solomon, Hartree-Fock Bound States for Molecule-Ions HeC"" and Hec (1974) The Astrophysical Journal, 189, p. 605; Saunders, Hillier, A ?Level-Shifting? method for converging closed shell Hartree-Fock wave functions (1973) International Journal of Quantum Chemistry, 7, p. 699; Dement'ev, Stepanov, Yarovoi, Convergence problems in the solution of SCF equations (1974) International Journal of Quantum Chemistry, 8, p. 107; Veillard, (1975) Computational techniques in quantum chemistry and molecular physics, NATO Advanced Study Institutes Series, , Reidel, Dordrecht; Guest, Saunders, On methods for converging open-shell Hartree-Fock wave-functions (1974) Molecular Physics, 28, p. 819; Wood, Veillard, On convergence guarantees for the multi-configuration self-consistent field theory (1973) Molecular Physics, 26, p. 595; Matsuoka, Equivalence of Saunders' level-shifting method for Hartree-Fock equations and expansion method for modified Hartree-Fock equations (1975) Molecular Physics, 30, p. 1293; Grabenstetter, Grein, Improved convergence of open-shell SCF calculations (1976) Molecular Physics, 31, p. 1469; Hendeković, (1976) Theoret. Chim. Acta, 42, p. 193; Faegri, Jr., Manne, A new procedure for Roothaan's symmetry-restricted open-shell SCF method (1976) Molecular Physics, 31, p. 1037; Hsu, Davidson, Pitzer, (1976) J. Chem. Phys., 65, p. 609; Caldwell, Gordon, (1976) Chem. Phys. Letters, 43, p. 493; Hirao, Nakatsuji, (1973) J. Chem. Phys., 59, p. 1457; Hirao, (1974) J. Chem. Phys., 60, p. 3215; Caballol, Gallifa, Riera, Carbó, Generalized open shell SCF theory (1974) International Journal of Quantum Chemistry, 8, p. 373; Carbó, Gallifa, Riera, (1975) Chem. Phys. Letters, 30, p. 43; Carbó, Gallifa, Riera, (1975) Chem. Phys. Letters, 33, p. 545; Ishikawa, (1976) Chem. Phys. Letters, 37, p. 597; Huzinaga, Arnau, (1970) Phys. Rev., 1 A, p. 1285; Arnau, Carbó, Huzinaga, (1971) Afinidad, 28, p. 1147; Huzinaga, McWilliams, Cantú, (1973) Advan. Quantum Chem., 7, p. 187; CarbÃ³, Eigenspace manipulation in SCF theory: General formalism (1974) International Journal of Quantum Chemistry, 8, p. 423; Röeggen, (1973) Chem. Phys. Letters, 22, p. 140; Neilsen, (1973) Chem. Phys. Letters, 18, p. 225; Chang, (1975) Chem. Phys. Letters, 36, p. 611; Barr, Basch, (1975) Chem. Phys. Letters, 32, p. 537; Koopmans, (1934) Physica, 1, p. 104; Jungen, (1973) Chem. Phys. Letters, 21, p. 68; Cederbaum, (1974) Chem. Phys. Letters, 25, p. 562; DeKock, (1974) Chem. Phys. Letters, 27, p. 297; Doggett, Ionization energies and Koopmans' theorem (1975) Molecular Physics, 29, p. 313","Carbó, R.; Department of Chemistry, University of Alberta, Edmonton, Alta., Canada",,,,,,,,00092614,,CHPLB,,"English","Chem. Phys. Lett.",Article,"Final",,Scopus,2-s2.0-0041961441
